Trial Title,Trial Phase,Trial Status,Sponsor,Disease,Patient Segment,MeSH Term,Countries
A Phase Ib/II Open-label Study of Samuraciclib in Combination With Elacestrant in Participants With Metastatic or Locally Advanced Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Breast Cancer,I/II,Open,"Menarini Group
Carrick Therapeutics",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,France; Spain; United Kingdom; United States
"A Phase Ia/Ib, Dose-Escalation/Dose-Expansion Study of NPX267 in Subjects With Solid Tumors Known to Express HHLA-2",I,Planned,NextPoint Therapeutics,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Osteosarcoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor",(N/A); EGFR; Line of therapy N/A; Second line; Stage III; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Ewing Sarcoma; Kidney Neoplasms; Neoplasms; Osteosarcoma; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A Phase 1, Open-label Dose Escalation and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3L-001 Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors.",I,Planned,D3 Bio (Wuxi) Co.,Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Unspecified Solid Tumor,HER2 positive; Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms; Esophageal Neoplasms; Neoplasms; Stomach Neoplasms,China; United States
"A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0045 in Patients With Advanced Solid Tumors",I/II,Planned,"MD Anderson Cancer Center, University of Texas
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
(Other Hospital/Academic/Medical Center)
Zhejiang Huahai Pharmaceutical Co./Huabo Biopharm Co.","Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Synovial Sarcoma; Wilms Tumor",United States
"A Phase Ib/II Study to Evaluate the Novel Combination of Samuraciclib And Vepdegestrant, In Patients Who Have Received Prior CDK4/6i, with ER+, HER2- Metastatic Breast Cancer",I/II,Planned,"Pfizer
Arvinas",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
"A First-in-human, Multicenter, Open-label, Dose Escalation and Dose Expansion Phase I Study in Patients With Advanced Solid Tumors to Evaluate the Safety of Intravenously Administered ALG.APV-527",I/II,Open,"Alligator Bioscience
Aptevo Therapeutics","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor",Line of therapy N/A; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"An Open-label, Single-arm, Phase Ib/II  Study to Investigate the Safety, Efficacy and Pharmacokinetics of LS301-IT in Female Patients Undergoing Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for Ductal Carcinoma in Situ (DCIS) or Stage I-II Primary Invasive Breast Cancer",I/II,Open,Integro Theranostics,Oncology: Breast,Line of therapy N/A; Stage I; Stage II,"Breast Neoplasms; Carcinoma; Carcinoma, Ductal; Carcinoma, Ductal, Breast",United States
"A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the DNA Polymerase Theta Inhibitor ART6043 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors",I/II,Open,Artios Pharma,Oncology: Breast; Oncology: Unspecified Solid Tumor,HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms; Neoplasms,United States
"An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Subjects With Unresectable, Advanced and/or Metastatic Solid Tumors That Are Positive for the TP53 R175H Mutation",I,Open,AstraZeneca/Neogene Therapeutics,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",(N/A); First line; Line of therapy N/A; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck",United States
A First in Human Clinical Trial to Evaluate CRB091 for the Treatment of Colorectal and Triple-negative Breast Cancers,I,Planned,Cancer Research and Biotechnology,Oncology: Breast; Oncology: Colorectal,(N/A); HER2 negative; Line of therapy N/A; Triple receptor negative,Breast Neoplasms; Colorectal Neoplasms,United States
PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/Ib Platform Trial,I,Open,(Other Cooperative Group),Oncology: Breast; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; HER2 positive; Line of therapy N/A; Progesterone receptor positive; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma; Triple Negative Breast Neoplasms,United States
"A Multi-Regional, Open-Label, Dose Escalation and Dose Expansion Phase Ⅰ Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants With HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors",I,Planned,Hangzhou HighField Biopharmaceutical Co.,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor",(N/A); HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",China; United States
"A Phase I, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ISM3091 in Patients with Advanced Solid Tumors",I,Planned,InSilico Medicine,Oncology: Breast; Oncology: Unspecified Solid Tumor,BRCA; Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms,China; United States
"Phase I/Ib, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM54 Administered Intravenously to Patients With Selected Advanced Solid Tumors.",I,Open,PharmaMar,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",(N/A); Advanced; BRAF; Estrogen receptor positive; Fourth line or greater; Gastrointestinal; HER2 negative; HER2 positive; High-grade; Pancreas; Progesterone receptor positive; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Endometrial Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Mesothelioma; Neoplasms; Neuroendocrine Tumors; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Belgium; Spain; United States
A Phase I Clinical Study of A009 in Patients with HER2-positive breast cancer,I,Planned,Convalife,Oncology: Breast,(N/A); HER2 positive; Line of therapy N/A,Breast Neoplasms,China; United States
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) Administered Intrathecally (IT) Primed Against HER2/HER3 in Patients With Leptomeningeal Disease (LMD) From Triple-Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC),I,Open,"H. Lee Moffitt Cancer Center and Research Institute
(Other Hospital/Academic/Medical Center)",Oncology: Breast; Oncology: Metastatic Cancer,(N/A); CNS mets; Line of therapy N/A; Triple receptor negative,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Meningeal Neoplasms; Neoplasm Metastasis; Triple Negative Breast Neoplasms,United States
"Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors.",I,Open,Amgen,"Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",(N/A); First line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Mesothelioma; Pancreatic Neoplasms; Stomach Neoplasms; Uterine Cervical Neoplasms",Australia; United States
"A Multiple center, Open label, Dose Escalation Phase I Study of CycloSam For the Treatment of Metastatic Bone Cancer",I,Open,QSAM Biosciences,Oncology: Breast; Oncology: Osteosarcoma,(N/A); Line of therapy N/A; Metastatic,Breast Neoplasms; Ewing Sarcoma; Osteosarcoma,United States
"A Phase I/IIa, Multicenter, Open-Label, Non-Randomized First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1310 in Subjects With Advanced/Metastatic Solid Tumors",I/II,Open,Duality Biologics,"Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Unspecified Solid Tumor",Adenocarcinoma; EGFR; HER2 positive; Hormone refractory; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Prostatic Neoplasms",China; United States
Pilot Study of an Implantable Microdevice to Evaluate Drug Responses in Situ in Early-stage Triple-negative Breast Cancer,I,Terminated,Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute,Oncology: Breast,HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Carcinoma; Triple Negative Breast Neoplasms,United States
A Phase 1-2 Dose-escalation and Expansion Study of ST316 in Subjects With Selected Advanced Unresectable and Metastatic Solid Tumors,I/II,Open,Sapience Therapeutics,Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,(N/A); Line of therapy N/A; Locally advanced; Metastatic; MSI-H/dMMR; PD-L1 Positive; Second line; Stage III; Stage IV; Third line,Bile Duct Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Melanoma; Ovarian Neoplasms; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Synovial Sarcoma; Uterine Cervical Neoplasms,United States
"First-in-Human Study of STX-478, a Mutant-Selective PI3Kα Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor",I/II,Open,Scorpion Therapeutics,Oncology: Breast; Oncology: Cervical; Oncology: Head/Neck; Oncology: Ovarian; Oncology: Unspecified Solid Tumor; Oncology: Vaginal; Oncology: Vulvar,Estrogen receptor positive; HER2 negative; Line of therapy N/A; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms; Uterine Cervical Neoplasms; Vaginal Neoplasms; Vulvar Neoplasms,United States
"A Phase I, 2-Part, Multicenter, First-In-Human Dose-Escalation and Dose-Expansion Study of DS-1103a Combination Therapy in Subjects with Advanced Solid Tumors",I,Open,"AstraZeneca
Daiichi Sankyo","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",(N/A); Estrogen receptor positive; Line of therapy N/A; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms",United States
A Phase I/Ib Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies,I,Open,Arcus Biosciences,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Renal; Oncology: Unspecified Cancer",First line; HER2 negative; Line of therapy N/A; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms; Ovarian Neoplasms; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
Phase I/IIa Clinical Trial Evaluating the Safety and Efficacy of Rintatolimod Combined With IFNα2b (Bioferon®) to Enhance the Effectiveness of Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer,I/II,Planned,Roswell Park Cancer Institute,Oncology: Breast,First line; PD-L1 Positive; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma; Triple Negative Breast Neoplasms,United States
"A Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of NM1F as Monotherapy and in Combination With Pembrolizumab in Subjects With Locally Advanced/Metastatic Solid Tumors",I,Open,Hefei TG ImmunoPharma Co.,Oncology: Breast; Oncology: Colorectal; Oncology: Melanoma; Oncology: Ovarian,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Colorectal Neoplasms; Melanoma; Ovarian Neoplasms; Triple Negative Breast Neoplasms,China; United States
"An Open-Label, Non-randomized, Multinational, Multi-center Phase I/II Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors",I/II,Closed,Coherent Biopharma,"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Pancreas",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms",China; United States
"A Phase I/II, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Patients With Advanced Cancer",I/II,Open,Incyclix Bio,Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms; Fallopian Tube Neoplasms; Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms,Australia; United States
"A First-in-Human Study of PI3Kα Inhibitor, RLY-5836, in Combination With Targeted and Endocrine Therapies in Participants With Advanced Breast Cancer and as a Single Agent in Advanced Solid Tumors",I,Open,Relay Therapeutics,Oncology: Breast; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Clinical Study to Evaluate TCC1727 for the Treatment of Various Types of Cancers,I,Planned,Sino Biopharmaceutical/Beijing Tide Pharmaceutical Co.,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Ovarian",(N/A); Line of therapy N/A,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Ovarian Neoplasms; Small Cell Lung Carcinoma",United States
Combination Therapy of Niraparib and Irinotecan in Cancers With Mutations in DNA Repair Genes,I,Open,"GlaxoSmithKline
University of California, San Francisco",Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Ovarian; Oncology: Pancreas,Line of therapy N/A; Stage IV,Bile Duct Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms,United States
"A First-in-Human, Multicenter, Phase I, Open-Label Study of XTX301 in Patients With Advanced Solid Tumors",I,Open,Xilio Therapeutics,"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",HER2 negative; MSI-H/dMMR; MSS/pMMR; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Melanoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms",United States
"A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-Alpha Inhibitor, TOS-358, in Adult Subjects With Select Solid Tumors",I,Open,Totus Medicines,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Unspecified Solid Tumor",Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",United States
"A Multicenter, Open-label, Phase I/II Clinical Trial to Evaluate the Safety and Anti-Tumor Activity ofAB-201 in Subjects With Advanced HER2+ Solid Tumors",I/II,Planned,Artiva Biotherapeutics,Oncology: Breast; Oncology: Esophageal; Oncology: Gastric,HER2 positive; Second line; Stage III; Stage IV,Adenocarcinoma; Breast Neoplasms; Esophageal Neoplasms; Stomach Neoplasms,South Korea; United States
Phase I Study Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer,I,Open,National Institutes of Health/National Cancer Institute,Oncology: Breast,Fourth line or greater; HER2 negative; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Carcinoma; Triple Negative Breast Neoplasms,United States
Phase Ib IIT of Heat Shock Protein 90 Inhibitor TAS-116 Combined With Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib in Advanced Breast Cancer Progressing on Palbociclib & Treatment-refractory Solid Tumors With Retinoblastoma Deficiency,I,Planned,Brown University Oncology Group,"Oncology: Bladder; Oncology: Breast; Oncology: Endometrial; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Soft Tissue Sarcoma",(N/A); Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Pulmonary; Second line; Stage III; Stage IV,Breast Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neuroendocrine Tumors; Retinoblastoma; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms,United States
"A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer",I,Open,Accutar Biotechnology,Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
A Phase Ia/Ib Study of ELVN-002 for the Treatment of Patients With HER2 Mutant Non-Small Cell Lung Cancer,I,Open,Enliven Therapeutics,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",Adenocarcinoma; HER2 positive; Large Cell; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Lung Neoplasms; Stomach Neoplasms",Australia; South Korea; United States
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors,I/II,Open,IDEAYA Biosciences,Oncology: Breast; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor,BRCA; Second line; Stage III; Stage IV,Breast Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms,United States
"A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants With Advanced Solid Tumors",I,Open,Pyxis Oncology,"Oncology: Breast; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",HER2 positive; Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Wilms Tumor",United States
Phase Ib Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer,I,Open,"MD Anderson Cancer Center, University of Texas
Daiichi Sankyo",Oncology: Breast,HER2 negative; Second line; Stage IV,Breast Neoplasms,United States
"FIH Phase 1A /1B Study of AG01 Antibody Against Progranulin/GP88 in Advanced Solid Tumor Malignancies With Expansion Cohorts in Advanced Triple Negative Breast Ca, Hormone Resistant Breast Ca, Non Small Cell Lung Cancer and Mesothelioma",I,Open,"University of Maryland Greenebaum Cancer Center
A&G Pharmaceutical","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Unspecified Solid Tumor",(N/A); Estrogen receptor positive; HER2 negative; Line of therapy N/A; PD-1 Refractory; PD-L1 Positive; PD-L1 Refractory; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Neoplasms; Ovarian Neoplasms; Triple Negative Breast Neoplasms",United States
"A Phase I, Open-label, Multicenter Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors",I,Open,Bristol-Myers Squibb,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Osteosarcoma; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",HER2 negative; Line of therapy N/A; Metastatic; MSS/pMMR; Stage III; Stage IV; Triple receptor negative; Unresectable,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasms; Osteosarcoma; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Synovial Sarcoma; Wilms Tumor",Australia; Canada; Chile; France; Italy; Mexico; Spain; United States
"A Phase I/II, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (Anti VISTA) as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors",I/II,Open,"Regeneron
Sensei Biotherapeutics {Panacea Pharmaceuticals}",Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Thyroid; Oncology: Unspecified Solid Tumor,Locally advanced; Metastatic; PD-1 Naive; PD-L1 Naive; Second line; Stage III; Stage IV; Unresectable,Breast Neoplasms; Colorectal Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Melanoma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Neoplasms; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms,United States
"Phase I, Adaptive-design Trial of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Breast Cancer",I,Open,University of Pennsylvania,Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Line of therapy N/A; Progesterone receptor positive; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases,I,Planned,Daiichi Sankyo {Sankyo Co. Ltd},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate",(N/A); CNS mets; Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Pulmonary; Triple receptor negative,"Bile Duct Neoplasms; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Melanoma; Neoplasm Metastasis; Neuroendocrine Tumors; Ovarian Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
A Single Arm Phase I/II Trial of Abemaciclib + VS-6766 + Fulvestrant in Metastatic HR+/HER2- Breast Cancer,I/II,Open,"Eli Lilly
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Verastem Oncology {Verastem}",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
"Phase I Study of CodaLytic, an Intratumoral Influenza-based Oncolytic Virus, in Patients With Metastatic or Otherwise Inoperable Breast Cancer",I,Planned,Codagenix,Oncology: Breast,Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms; Neoplasm Metastasis; Neoplasms,United States
"A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors",I,Open,Zion Pharma/Suzhou Zanrong Pharmaceutical Technology Co.,Oncology: Breast; Oncology: Gastric; Oncology: Metastatic Cancer; Oncology: Unspecified Solid Tumor,CNS mets; HER2 positive; Second line; Stage III; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis; Neoplasms; Stomach Neoplasms,United States
"A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors",I,Open,Roche/Genentech,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal; Oncology: Unspecified Solid Tumor",HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Neoplasms; Melanoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
Phase I/II Study of PRO1184 in Patients With Locally Advanced and/or Metastatic Solid Tumors,I/II,Open,ProfoundBio (Suzhou) Co./ProfoundBio US Co.,"Oncology: Breast; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Primary Peritoneal",Estrogen receptor positive; HER2 negative; Line of therapy N/A; Progesterone receptor positive; Stage III; Stage IV; Triple receptor negative; Unresectable,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Fallopian Tube Neoplasms; Mesothelioma; Mesothelioma, Malignant; Ovarian Neoplasms; Peritoneal Neoplasms; Triple Negative Breast Neoplasms",China; United States
A Phase Ib Study of TBio-4101 (Autologous Selected and Expanded Tumor-Infiltrating Lymphocytes [TIL]) and Pembrolizumab in Patients With Advanced Solid Tumor Malignancies (STARLING),I,Open,Turnstone Biologics,Oncology: Breast; Oncology: Colorectal; Oncology: Melanoma; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Melanoma,United States
"TACTIVE-U: An Interventional Safety And Efficacy Phase Ib/II, Open label Umbrella Study To Investigate Tolerability, PK and Antitumor Activity Of  ARV-471 (PF-07850327), An Oral Proteolysis Targeting Chimera, In Combination with Other Anticancer treatments In Participants Aged 18 Years And With ER+ Advanced Or Metastatic Breast Cancer, Sub-Study B  (ARV-471 in combination with  Ribociclib)",I/II,Open,"Pfizer
Arvinas",Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,Canada; United States
"A Modular, Open-Label, Multi-Centre Phase I/II Dose-Finding, Optimisation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 in Patients With Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer",I/II,Open,Ellipses Pharma,Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"A Phase 1b/II, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer",I/II,Open,Menarini Group/Stemline Therapeutics,Oncology: Breast,Estrogen receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A phase I, open-label, single-center, study to investigate the absorption, metabolism, excretion, and absolute bioavailability of a single oral dose of [¹⁴C]-labeled inavolisib and IV tracer dose of [¹³C₆]-labeled inavolisib in a single cohort of healthy volunteers",I,Completed,Roche/Genentech,Oncology: Breast,(N/A); HER2 positive; Line of therapy N/A,Breast Neoplasms,United States
"TACTIVE-U: An InterventionalL Safety, And Efficacy Phase  IB/II, Open-label, Umbrella Study To Investigate Tolerability, PK, And Antitumor Activity an ARV-471 (PF-07850327), an Oral Proteolysis Targeting Chimera, in Combination With Other Anticancer Treatments In Participants Aged 18 Years And Over With ER+ Advanced Or Metastatic Breast Cancer, SUB-STUDY A (ARV-471 In Combination With Amebacicilib)",I/II,Open,"Pfizer
Arvinas",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms,Canada; United States
A Clinical Study of AB-201 in HER2-Positive Solid Tumors,I,Planned,Artiva Biotherapeutics,Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Unspecified Solid Tumor,(N/A); HER2 positive; Line of therapy N/A,Breast Neoplasms; Esophageal Neoplasms; Stomach Neoplasms,South Korea; United States
"A First-in-Human, Open-Label, Multi-Center Phase I Study of TST003 in Subjects With Locally Advanced or Metastatic Solid Tumors",I/II,Open,Transcenta Holding,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Prostatic Neoplasms; Stomach Neoplasms",China; United States
"A Phase I Open-Label, Multi-Center, Safety and Efficacy Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors",I,Open,Prelude Therapeutics,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",(N/A); Advanced; Estrogen receptor positive; HER2 negative; KRAS; Progesterone receptor positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Fibrosarcoma; Glioblastoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Mesothelioma; Mesothelioma, Malignant; Rhabdomyosarcoma; Sarcoma; Squamous Cell Carcinoma of Head and Neck; Synovial Sarcoma",United States
"First-in-human Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the Anti-CCR8 Antibody BAY 3375968 as Monotherapy and in Combination With Pembrolizumab in Participants With Selected Advanced Solid Tumors",I,Open,Bayer AG,"Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Unspecified Solid Tumor",HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Melanoma; Neoplasms",Canada; Singapore; United States
Phase I/II Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors,I/II,Open,Moderna {Moderna Therapeutics},"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Skin, Basal Cell Carcinoma",HER2 negative; MSS/pMMR; PD-1 Refractory; PD-L1 Positive; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Melanoma; Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",Australia; United States
"A Phase 1, First-in-Human, Dose-Finding and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of XmAb 808 in Combination With Pembrolizumab in Selected Advanced Solid Tumors",I,Open,Xencor,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor",HER2 negative; Hormone refractory; Line of therapy N/A; PD-1 Naive; PD-1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Ovarian Neoplasms; Prostatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"Phase I Dose-Escalation, Dose-Expansion Trial of Intratumoral HER2- and HER3-Primed Dendritic Cells Injections for the Treatment of Early-Stage TNBC and ER Low Positive Breast Cancer (DecipHER)",I,Open,H. Lee Moffitt Cancer Center and Research Institute,Oncology: Breast,HER2 negative; Neoadjuvant; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase IB/IIA Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients With Cancer",I/II,Open,Aminex Therapeutics,"Oncology: Breast; Oncology: Cervical; Oncology: CNS, Brain Stem Glioma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",(N/A); Advanced; DIPG; Locally advanced; Metastatic; Second line; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Diffuse Intrinsic Pontine Glioma; Endometrial Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Glioma; Head and Neck Neoplasms; Melanoma; Mesothelioma; Mesothelioma, Malignant; Ovarian Neoplasms; Peritoneal Neoplasms; Stomach Neoplasms; Thyroid Cancer, Papillary; Thyroid Neoplasms; Uterine Cervical Neoplasms",United States
"A Phase 1, Multicenter, Open-Label, Dose Escalation, and Dose Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors",I,Open,DynamiCure Biotechnology,"Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Renal; Oncology: Unspecified Solid Tumor",(N/A); Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Glioblastoma; Kidney Neoplasms; Liver Neoplasms; Neoplasms; Ovarian Neoplasms; Stomach Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"An Open-Label, Phase Ib-II Study of Elacestrant, in Combination With Onapristone in Patients With Estrogen Receptor-Positive, Progesterone Receptor-Positive, HER2-negative Advanced or Metastatic Breast Cancer (ELONA)",I/II,Closed,Context Therapeutics,Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung, and Other KK-LC-1 Positive Cancers",I,Open,"National Institutes of Health/National Cancer Institute
(Other Hospital/Academic/Medical Center)
T-Cure Bioscience","Oncology: Breast; Oncology: Cervical; Oncology: Gastric; Oncology: Lung, Non-Small Cell",First line; HER2 negative; Second line; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Stomach Neoplasms; Uterine Cervical Neoplasms",United States
A Phase I trial of RAD202 for HER2-positive breast cancer and Gastric Cancer,I,Planned,Radiopharm Theranostics,Oncology: Breast; Oncology: Gastric,(N/A); HER2 positive; Line of therapy N/A,Breast Neoplasms; Stomach Neoplasms,United States
"A Randomized Window of Opportunity Study of Preoperative Letrozole and Simvastatin Versus Letrozole Alone in Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer",I,Open,"National Institutes of Health/National Cancer Institute
Emory University Hospital - Atlanta",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms; Carcinoma,United States
A Phase Ib/II Basket Study To Assess The Safety And Efficacy Of AsiDNA™ In Combination With Olaparib In Participants With Recurrent Solid Tumors,I/II,Open,Onxeo,Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Prostate,Estrogen receptor positive; HER2 negative; Hormone refractory; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms,United States
"A Phase I/IIa, Multicenter, Open-Label, Non-Randomized First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1305 in Subjects With Advanced/Metastatic Solid Tumors",I/II,Open,"BioNTech
Duality Biologics","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Unspecified Solid Tumor",(N/A); HER2 positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Small Cell Lung Carcinoma",China; United States
A Phase Ib Trial of ZEN003694 (ZEN-3694) With Pembrolizumab and Nab-Paclitaxel in Patients With Metastatic Triple-Negative Breast Cancer,I,Open,National Institutes of Health/National Cancer Institute,Oncology: Breast,HER2 negative; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma; Triple Negative Breast Neoplasms,United States
"A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1)",I/II,Open,AstraZeneca,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate",BRCA; HER2 negative; Hormone refractory; Second line; Stage III; Stage IV,Breast Neoplasms; Fallopian Tube Neoplasms; Glioblastoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms,Australia; Germany; South Korea; Spain; Sweden; United Kingdom; United States
"A Phase I/II, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)",I/II,Open,Marengo Therapeutics,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer; Oncology: Ovarian; Oncology: Prostate; Oncology: Unspecified Solid Tumor",(N/A); CNS mets; HER2 negative; Hormone refractory; KRAS; MSI-H/dMMR; MSI-L; MSS/pMMR; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Colorectal Neoplasms; Neoplasm Metastasis; Neoplasms, Unknown Primary; Ovarian Neoplasms; Prostatic Neoplasms",United States
"A Phase I/IIa, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-2485 in Adult Patients With Advanced Solid Tumors",I/II,Open,Beijing Jacobio Pharmaceuticals Co.,"Oncology: Breast; Oncology: Lung, Small Cell; Oncology: Neuroendocrine",(N/A); HER2 negative; Line of therapy N/A; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Neoplasms; Neuroendocrine Tumors; Small Cell Lung Carcinoma,China; United States
"Phase I Dose-escalation Trial of OMTX705, an Anti-fibroblast Activation Protein Antibody-drug Conjugate, as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors",I,Open,Oncomatryx,"Oncology: Breast; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",(N/A); Line of therapy N/A; Pulmonary; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms",Spain; United States
"An Open-label Multicenter Phase Ib-II Study of Elacestrant in Combination With Abemaciclib in Women and Men With Brain Metastasis From Estrogen Receptor Positive, HER-2 Negative Breast Cancer",I/II,Open,Menarini Group/Stemline Therapeutics,Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Third line,Brain Diseases; Brain Neoplasms; Breast Diseases; Breast Neoplasms; Central Nervous System Diseases; Central Nervous System Neoplasms; Neoplasm Metastasis; Neoplasms; Neoplasms by Site; Nervous System Diseases; Nervous System Neoplasms,France; Germany; Italy; South Korea; Spain; United Kingdom; United States
"A Phase I/II, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors",I/II,Open,Tallac Therapeutics,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Renal; Oncology: Unspecified Solid Tumor",Line of therapy N/A; Merkel; Metastatic; PD-1 Refractory; PD-L1 Refractory; Second line; Squamous Cell; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Neoplasms; Melanoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Australia; United States
"A Phase Ib/IIa, Open-Label, Multi-Center Study of CyPep-1 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety of CyPep-1 in Patients With Advanced or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC), Melanoma, or Triple-Negative Breast Cancer (TNBC) (CATALYST)",I/II,Open,"Merck & Co./Merck Sharp & Dohme (MSD)
Cytovation",Oncology: Breast; Oncology: Head/Neck; Oncology: Melanoma,HER2 negative; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Melanoma; Squamous Cell Carcinoma of Head and Neck",France; Italy; Netherlands; Spain; United Kingdom; United States
REVERT- Breast Cancer: Phase 1b/2 Study of the Addition of STAT3 Inhibitor TTI-101 to Reverse Resistance on First- Line Palbociclib Plus Aromatase Inhibitor Therapy for Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer,I/II,Open,Tvardi Therapeutics,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
Phase I Study of Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine and Pepinemab / Trastuzumab in Patients With Metastatic HER2-Positive Breast Cancer,I,Open,"H. Lee Moffitt Cancer Center and Research Institute
Vaccinex",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 positive; Maintenance/Consolidation; Progesterone receptor positive; Second line; Stage IV; Third line,Breast Neoplasms,United States
Phase I Trial of DS-8201a (Trastuzumab Deruxtecan) in Combination With Neratinib in Solid Tumors With HER2 Alterations,I/II,Open,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Gastric; Oncology: Unspecified Solid Tumor,HER2 positive; Second line; Stage IV,"Breast Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Stomach Carcinoma; Stomach Neoplasms",United States
"An Early Phase I Study of the Pharmacodynamics of WEE1 Inhibitor, ZN-c3, in Metastatic Solid Tumors",I,Terminated,Oregon Health and Science University,Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms",United States
"A Phase Ib/II, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors With FGFR2b Overexpression (FORTITUDE-301)",I/II,Open,Amgen,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Unspecified Solid Tumor",Adenocarcinoma; FGFR; Fourth line or greater; HER2 negative; Intrahepatic; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative; Unresectable,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Uterine Cervical Neoplasms",Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Czech Republic; Denmark; Finland; France; Greece; Hungary; Israel; Italy; Japan; Mexico; Netherlands; Poland; Portugal; Romania; Russia; South Korea; Spain; Switzerland; Turkey; United Kingdom; United States
A Phase I/II Study Evaluating the Safety and Efficacy of Ivermectin in Combination With Balstilimab in Patients With Metastatic Triple Negative Breast Cancer With Expansion Cohort in PD-L1 Negative TNBC,I/II,Planned,"National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center",Oncology: Breast,HER2 negative; PD-1 Naive; PD-L1 Naive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase IB Trial Evaluating the Safety of Ribociclib, Tucatinib, and Trastuzumab in Patients With Metastatic, HER2+ Breast Cancer and a Multicenter, Randomized, Open-Label, Phase II Study of Preoperative Treatment With Ribociclib,Ttrastuzumab, Tucatinib, and Fulvestrant Versus Docetaxel, Carboplatin,Ttrastuzumab, and Pertuzumab in HR+/HER2+ Breast Cancer and Ribociclib, Trastuzumab, and Tucatinib Versus Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab in Patients With HR-/HER2+ Breast Cancer",I/II,Open,"Novartis
Jonsson Comprehensive Cancer Center, UCLA
Seagen",Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms; Carcinoma,United States
"Phase I First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 794 in Participants With Claudin 6-positive Advanced/Metastatic Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications",I,Closed,Amgen,"Oncology: Breast; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Testicular",HER2 negative; Line of therapy N/A; Metastatic; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Endometrial Neoplasms; Lung Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Testicular Neoplasms",Switzerland; United States
A Clinical Study to Evaluate JS105 in Patients with Advanced Malignant Solid Tumors including Breast Cancer,I,Planned,Shanghai Junshi Biosciences Co.,Oncology: Breast; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; Line of therapy N/A; Progesterone receptor positive; Stage III; Stage IV,"Breast Neoplasms; Neoplasms, Unknown Primary",China; United States
A Phase I/II Trial of ATI-2231 With Phase Ia in Advanced Solid Tumor Malignancies Followed by Phase Ib/II in Combination With Capecitabine in Patients With Hormone Receptor-positive and HER2 Negative Metastatic Breast Cancer,I/II,Planned,"Washington University School of Medicine
US Department of Defense
Aclaris Therapeutics",Oncology: Breast; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Neoplasms,United States
A Study of LOXO-783 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With Advanced Breast Cancer and Other Solid Tumors With a PIK3CA H1047R Mutation,I,Open,Eli Lilly/Loxo Oncology,Oncology: Breast; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; Stage III; Stage IV; Third line,"Breast Neoplasms; Neoplasms, Unknown Primary",Australia; Canada; China; France; Japan; Singapore; South Korea; Spain; United States
"First-in-Human, Escalating Oral Dose Study of RGT-419B Given Alone and With Endocrine Therapy in Subjects With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer",I,Closed,Regor Therapeutics Group,Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A First-in-Human, Open-label, Multicenter, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PYX-106 in Subjects With Advanced Solid Tumors",I,Open,Pyxis Oncology,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Renal; Oncology: Thyroid",(N/A); Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms, Unknown Primary; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Phase I First-in-human Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Malignant Tumors,I,Open,Bristol-Myers Squibb,"Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",HER2 negative; Hormone refractory; Locally advanced; Metastatic; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative; Unresectable,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Argentina; Belgium; Japan; South Korea; Spain; United States
"A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors",I,Planned,Iksuda Therapeutics,Oncology: Breast; Oncology: Gastric; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; First line; HER2 negative; HER2 positive; Line of therapy N/A; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms; Stomach Carcinoma; Stomach Neoplasms,Australia; United States
"A Phase I Open-Label Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, and Preliminary Efficacy of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors",I,Open,Orano Med {Areva Med},"Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Prostate",Estrogen receptor positive; HER2 negative; Hormone refractory; Progesterone receptor positive; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Melanoma; Prostatic Neoplasms; Uterine Cervical Neoplasms",United States
A Phase I Pilot Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA),I,Open,Mayo Clinic,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Renal; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Unspecified Solid Tumor",ALK; BRAF; EGFR; Fourth line or greater; HER2 negative; KRAS; Merkel; MSI-H/dMMR; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Adenocarcinoma; Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Renal Cancer; Skin Neoplasms; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects with Metastatic Breast Cancer,I,Open,Dantari,Oncology: Breast,BRCA; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Stage IV; Third line,Breast Neoplasms,United States
"A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CLN-418 in Subjects With Advanced Solid Tumors",I,Open,"Harbour BioMed Therapeutics
Cullinan Oncology","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Unspecified Solid Tumor",HER2 negative; Second line; Squamous Cell; Stage III; Stage IV; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",Australia; United States
RAGE Inhibition to Decrease Cancer Therapy Related Cardio Toxicity in Women With Early Breast Cancer,I/II,Open,Georgetown University,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; HER2 positive; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms; Cognitive Dysfunction,United States
"A Phase I/II, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of APS03118 in Adult Patients with Unresectable Locally Advanced or Metastatic Solid Tumors Harboring RET Mutations or Fusions (LASER)",I/II,Planned,Applied Pharmaceutical Science,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Neuroendocrine; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Line of therapy N/A; Medullary; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Thyroid Neoplasms",Australia; China; United States
Comparative Effects of Ribociclib and Palbociclib on Circulating and Tumor Infiltrating Myeloid Cells in Metastatic Breast Cancer Patients,I,Terminated,"National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center",Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage IV,Adenocarcinoma; Breast Neoplasms; Carcinoma,United States
"A Phase I, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors",I,Open,Incyte Corporation,Oncology: Breast; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma",France; Italy; Japan; Netherlands; Switzerland; United Kingdom; United States
"This is a Multicenter, Single Arm, Open-label, run-in Phase Ib / Roll-over Phase II Study of Tucatinib in Combination With Alpelisib in Subjects With PIK3CA-mutant HER2-positive Locally Advanced Unresectable or Metastatic Breast Cancer.",I/II,Open,"Novartis
Seagen {Seattle Genetics}",Oncology: Breast,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Phase I Study of SGN-PDL1V in Advanced Solid Tumors,I,Open,Seagen,"Oncology: Breast; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Unspecified Solid Tumor",HER2 negative; PD-L1 Positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Esophageal Cancer; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Melanoma; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck",Canada; France; Germany; Italy; Netherlands; Spain; United States
A Phase I Study of SGN-B7H4V in Advanced Solid Tumors,I,Open,Seagen,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Gallbladder; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Primary Peritoneal",Adenocarcinoma; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Squamous Cell; Stage III; Stage IV; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Cholangiocarcinoma; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Head and Neck Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Triple Negative Breast Neoplasms",Canada; Germany; Spain; United Kingdom; United States
"A Phase I, Open-Label, Multicenter Study of FT536 as Monotherapy and in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors",I,Closed,Fate Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas",HER2 negative; HER2 positive; MET Amplification/Alteration; PD-L1 Positive; Second line; Squamous Cell; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Phase Ib Clinical Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, as a Chemoprotection Agent in Patients With TP53-Mutated, HER2 Negative Breast Cancer Receiving Neoadjuvant or Adjuvant Chemotherapy With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)",I,Terminated,Aileron Therapeutics,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage II; Stage III; Stage IV,Breast Neoplasms,Bosnia and Herzegovina; Bulgaria; Germany; Serbia; United States
"A Phase I/II Study of GI-101 in Combination with Imfinzi (Durvalumab) and Chemotherapy for the Treatment of Small Cell Lung Cancer, Gastric/Gastroesophageal Junction Cancer, Biliary Tract Cancer and Triple-Negative Breast Cancer",I/II,Planned,"AstraZeneca
GI Innovation","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Small Cell; Oncology: Neuroendocrine",(N/A); HER2 negative; Line of therapy N/A; Pulmonary; Stage III; Stage IV; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Small Cell; Cholangiocarcinoma; Esophageal Cancer; Esophageal Neoplasms; Neuroendocrine Tumors; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms",Australia; South Korea; United States
"A Phase I Study to Assess the Safety and Efficacy of LYL797, ROR1-Targeting CAR T Cells, in Adults With Relapsed and/or Refractory Solid-Tumor Malignancies",I,Open,Lyell Immunopharma,"Oncology: Breast; Oncology: Lung, Non-Small Cell",Fourth line or greater; HER2 negative; PD-1 Refractory; PD-L1 Refractory; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Recurrence; Triple Negative Breast Neoplasms",United States
"Randomized, Non-Comparative Phase I/II Study of NUV-422 in Combination With Fulvestrant in Patients With Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative (HR+HER2-) Advanced Breast Cancer (aBC)",I/II,Terminated,Nuvation Bio,Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms; Neoplasms,United States
"A Phase I/IIa, Multicenter, Open-Label, Non-Randomized First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303 in Patients With Advanced/Metastatic Solid Tumors",I/II,Open,"BioNTech
Duality Biologics","Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Unspecified Solid Tumor; Oncology: Vaginal",HER2 negative; HER2 positive; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Neoplasms; Stomach Neoplasms; Vaginal Neoplasms",Australia; China; United States
"A Phase 1, Open-Label, Multicenter, Dose Escalation and Confirmation Study of PRT2527 in Participants With Advanced Solid Tumors",I,Closed,Prelude Therapeutics,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Estrogen receptor positive; HER2 negative; Hormone refractory; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neoplasms; Neoplasms, Unknown Primary; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Triple Negative Breast Neoplasms",United States
Phase I Trial of Alpelisib Plus Sacituzumab Govitecan In Patients With Metastatic or Locally Recurrent HER2-Negative Breast Cancer,I,Open,"Novartis
University of Kansas
Gilead Sciences",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; PD-1 Refractory; PD-L1 Refractory; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
A Phase I Dose Escalation and Dose Expansion Study of AND019 in Patients With Estrogen Receptor Positive Human Epidermal Growth Factor Receptor 2 Negative Advanced or Metastatic Breast Cancer,I,Open,Kind Pharmaceuticals,Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms,China; United States
A Clinical Study of TRS004 in Patients with Recurrent and Metastatic Breast Cancer,I,Planned,Zhejiang Teruisi Pharmaceutical Co.,Oncology: Breast,Line of therapy N/A; Stage IV,Breast Neoplasms,China; United States
A Dose-confirming Study of CFI-402257 as a Single Agent in Advanced Solid Tumors and in Combination With Fulvestrant in Patients With ER+/HER2- Advanced Breast Cancer After Disease Progression on Prior CDK4/6 and Endocrine Therapy.,I/II,Open,Treadwell Therapeutics,Oncology: Breast; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Neoplasms, Unknown Primary",United States
"A Phase Ib Dose-escalation And Imaging Study Of Ifabotuzumab In Non-CNS Solid Tumors Such As Breast, Colorectal, Lung, And Pancreatic cancer",I,Planned,Humanigen,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Pancreas",(N/A); Line of therapy N/A; Pulmonary,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Small Cell Lung Carcinoma",United States
"A Phase I/IIa Multi-center, Open-label Master Protocol to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of AZD8205 in Participants With Advanced or Metastatic Solid Malignancies",I/II,Open,AstraZeneca,Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Unspecified Solid Tumor,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Cholangiocarcinoma; Cholangiocarcinoma; Endometrial Neoplasms; Fallopian Tube Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms","Australia; Belgium; Canada; China; Japan; Netherlands; Poland; South Korea; Spain; Taiwan, China; Thailand; United Kingdom; United States"
"A Phase I, Open-Label, First in Human, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZX-4081 in Patients With Advanced Solid Tumors",I,Open,Nanjing Zenshine Pharmaceuticals Co.,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Renal",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Phase I Study of ZEN003694 in Combination With Binimetinib in Solid Tumors With RAS Pathway Alterations and Triple Negative Breast Cancer,I,Open,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Unspecified Solid Tumor,BRAF; HER2 negative; HRAS; KRAS; NRAS; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Triple Negative Breast Neoplasms",United States
"A Phase I, Open-Label Study of the Safety, Tolerability and Preliminary Clinical Activity of Allogeneic Invariant Natural Killer T (iNKT) Cells (agenT-797) as a Single Agent and in Combination With Approved Immune Checkpoint Inhibitors in Patients With Relapsed/ Refractory Solid Tumors",I,Open,Agenus/MiNK Therapeutics,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Renal; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Thymus; Oncology: Unspecified Solid Tumor",(N/A); Fourth line or greater; Line of therapy N/A; MSI-H/dMMR; PD-1 Refractory; Second line; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Cholangiocarcinoma; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Multiple Myeloma; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Neoplasms; Stomach Neoplasms; Thymus Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"Phase I Multicenter, Open-Label, First-in-Human Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors",I,Open,Orum Therapeutics,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Unspecified Solid Tumor",HER2 positive; Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Neoplasms, Unknown Primary; Ovarian Neoplasms; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Phase I, Open-label, Dose Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Modified Salmonella Typhimurium SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors",I,Open,Guangzhou Sinogen Pharmaceutical Co.,"Oncology: Breast; Oncology: Cervical; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",(N/A); Adenocarcinoma; Aggressive; Classical; Indolent; Metastatic; Nodular lymphocyte-predominant; Pulmonary; Second line; Squamous Cell; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Fibrosarcoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Liposarcoma; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Osteosarcoma; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Synovial Sarcoma; Uterine Cervical Neoplasms","Taiwan, China; United States"
A Phase I Study of TSN084 for the Treatment of Solid Tumours Including NSCLC and TNBC,I,Open,Tyligand Bioscience (Shanghai),"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",HER2 negative; Line of therapy N/A; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms, Unknown Primary",United States
PNV21-001: A Phase I Study of a Personalized Multi-Peptide Neo-Antigen Vaccine in Breast Cancer and PD1/PD-L1 Inhibitor-Refractory Melanoma,I,Open,Fred Hutchinson Cancer Research Center,Oncology: Breast; Oncology: Melanoma,BRAF; Estrogen receptor positive; HER2 negative; PD-1 Refractory; PD-L1 Refractory; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms; Carcinoma; Melanoma; Skin Neoplasms,United States
A Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies,I,Open,"H. Lee Moffitt Cancer Center and Research Institute
Precigen, Inc. {Intrexon}/Precigen","Oncology: Breast; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lymphoma, Non-Hodgkin's",Aggressive; Diffuse large B-cell lymphoma (DLBCL); HER2 negative; Mantle cell lymphoma (MCL); Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Chronic Lymphocytic Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Precursor Cell Lymphoblastic Leukemia-Lymphoma",United States
"A Multicenter, Phase IB/II Study of Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer",I/II,Open,Icahn School of Medicine at Mount Sinai {Mount Sinai School of Medicine},Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
A Pilot Study of SGT-53 With Carboplatin and Pembrolizumab in Metastatic Triple Negative Inflammatory Breast Cancer,I,Terminated,"National Institutes of Health/National Cancer Institute
Northwestern University",Oncology: Breast,HER2 negative; PD-1 Naive; PD-L1 Naive; PD-L1 Positive; Second line; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma; Inflammatory Breast Neoplasms,United States
"An Open-label, Phase I/II, Dose-escalation and Expansion Study of SBT6050 Combined With Other HER2-directed Therapies in Subjects With Pretreated Unresectable Locally Advanced and/or Metastatic HER2-expressing or HER2-amplified Cancers",I/II,Terminated,Silverback Therapeutics,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",First line; HER2 positive; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasms, Unknown Primary; Stomach Carcinoma; Stomach Neoplasms",United States
"Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib, or With Atezolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax",I,Open,"MD Anderson Cancer Center, University of Texas",Oncology: Breast; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Liver; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Renal,Line of therapy N/A; Stage III; Stage IV,"Abdominal Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Endometrial Neoplasms; Fallopian Tube Neoplasms; Genital Neoplasms, Female; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Renal Cancer; Thoracic Neoplasms; Wilms Tumor",United States
"A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of IPG7236 Administered Orally as a Single Agent in Patients With Advanced Solid Tumors",I,Open,Nanjing Immunophage Biotech Co.,Oncology: Breast; Oncology: Head/Neck; Oncology: Melanoma; Oncology: Renal; Oncology: Unspecified Solid Tumor,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Renal Cell; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms, Unknown Primary; Renal Cancer; Unspecified; Wilms Tumor",China; United States
"A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of AC682 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer",I,Open,Accutar Biotechnology,Oncology: Breast,Estrogen receptor positive; HER2 negative; Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms,United States
A Phase I/II Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer,I/II,Open,TCR2 Therapeutics,Oncology: Breast; Oncology: Colorectal; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal,(N/A); HER2 negative; Line of therapy N/A; Triple receptor negative,Breast Neoplasms; Colorectal Neoplasms; Mesothelioma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms,United States
"A Phase I, Open-Label, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of IMM2902 in Patients With HER2-Expressing Advanced Solid Tumors",I,Open,ImmuneOnco Biopharmaceuticals (Shanghai) Co.,Oncology: Breast; Oncology: Gastric; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Stomach Carcinoma; Stomach Neoplasms",United States
Phase I Study of MEM-288 Oncolytic Virus in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC),I,Completed,"H. Lee Moffitt Cancer Center and Research Institute
Duke Comprehensive Cancer Center
Memgen","Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Skin, Squamous Cell Carcinoma (cSCC)",ALK; BRAF; EGFR; Fourth line or greater; HER2 negative; KRAS; Merkel; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Lung Neoplasms; Melanoma; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Triple Negative Breast Neoplasms",United States
Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients,I/II,Open,University of Florida - Gainesville,Oncology: Breast,Line of therapy N/A; Stage 0; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
"A First-in-Human Study of Mutant-selective PI3Ka Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer",I,Open,Relay Therapeutics,"Oncology: Breast; Oncology: Cervical; Oncology: Head/Neck; Oncology: Ovarian; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Unspecified Solid Tumor",Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Uterine Cervical Neoplasms",United States
"An Open-label, Dose Escalation and Expansion, Phase Ia/Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors.",I,Open,Takeda,"Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",Adenocarcinoma; HER2 negative; Large Cell; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Mesothelioma; Neoplasms, Mesothelial; Neoplasms, Squamous Cell; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
"First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1047 in Subjects With Malignant Solid Tumors",I/II,Open,Genmab,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Renal",Fourth line or greater; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Cholangiocarcinoma; Endometrial Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Nasopharyngeal Carcinoma; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Squamous Cell Carcinoma of Head and Neck; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms; Wilms Tumor",Denmark; France; Spain; United States
"A Phase I, Open-Label, Multicenter Study of FT538 in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors",I,Closed,Fate Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Renal; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Unspecified Solid Tumor",Fourth line or greater; HER2 negative; HER2 positive; KRAS; Merkel; MSI-H/dMMR; NRAS; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A PHASE I DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTITUMOR ACTIVITY OF PF-07260437 IN ADVANCED OR METASTATIC SOLID TUMORS",I,Open,Pfizer,Oncology: Breast; Oncology: Endometrial; Oncology: Ovarian,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms",Puerto Rico; United States
Targeting Progesterone Signaling for Breast Cancer Prevention in BRCA1 Carriers: a Pilot Study,I,Terminated,"Indiana University Cancer Center
Breast Cancer Research Foundation",Oncology: Breast; Oncology: Ovarian,(N/A); BRCA; HER2 negative; Line of therapy N/A; Triple receptor negative,Breast Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Triple Negative Breast Neoplasms,United States
A Phase I Trial of Capecitabine in Combination With Cemiplimab in Patients With Hormone Receptor Positive Metastatic Breast Cancer,I,Closed,"H. Lee Moffitt Cancer Center and Research Institute
Regeneron",Oncology: Breast,Estrogen receptor positive; HER2 negative; Line of therapy N/A; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,United States
"Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM14 in Combination with Irinotecan in Pretreated Patients with Selected Advanced Solid Tumors",I/II,Open,PharmaMar,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Gastrointestinal; High-grade; Hormone refractory; Pancreas; Pulmonary; Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Cholangiocarcinoma; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Mesothelioma; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Spain; United States
Phase Ib/II Study of Grapiprant (IK-007) and Eribulin Combination Treatment for Metastatic Inflammatory Breast Cancer (mIBC),I/II,Closed,"MD Anderson Cancer Center, University of Texas",Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma; Inflammatory Breast Neoplasms,United States
"Phase I, Open-label Study to Evaluate Safety, Tolerability and Preliminary Efficacy of Modified Salmonella
 Typhimurium SGN1 in Patients With Advanced Solid Tumor",I,Open,Guangzhou Sinogen Pharmaceutical Co.,"Oncology: Breast; Oncology: Cervical; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Aggressive; Classical; Indolent; Metastatic; Nodular lymphocyte-predominant; Pulmonary; Second line; Squamous Cell; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Fibrosarcoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Uterine Cervical Neoplasms","Taiwan, China; United States"
"A Phase I First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 in Adult Subjects With Advanced Solid Tumors",I,Open,AbbVie,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",Adenocarcinoma; EGFR; Fourth line or greater; Large Cell; MET Amplification/Alteration; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line,"Adenocarcinoma; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Neoplasms, Unknown Primary; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",Japan; Puerto Rico; Spain; United States
Phase I Pilot Study With Dose Expansion of Chemotherapy in Combination With CD40 Agonist and Flt3 Ligand in Metastatic Triple Negative Breast Cancer,I,Open,"(Other Cooperative Group)
Celldex Therapeutics {AVANT Immunotherapeutics}
University of Texas Southwest Medical Center",Oncology: Breast,First line; HER2 negative; PD-1 Naive; PD-L1 Naive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies,I/II,Open,Novita Healthcare {Avexa},Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Unspecified Solid Tumor; Oncology: Vaginal; Oncology: Vulvar,HER2 negative; PD-1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Neoplasms; Uterine Cervical Neoplasms; Vaginal Neoplasms; Vulvar Neoplasms",United States
A Phase I/Ib Dose Escalation/Expansion Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors,I,Open,"Merck & Co./Merck Sharp & Dohme (MSD)
NGM Biopharmaceuticals","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal",Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A Phase I/Ib Open-label, First-in-human, Single Agent, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR443216 in Participants with Relapsed/Refractory HER2 Expressing Solid Tumors.",I,Open,Sanofi,"Oncology: Breast; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms; Neoplasms, Unknown Primary; Stomach Carcinoma; Stomach Neoplasms","South Korea; Spain; Taiwan, China; United States"
"A Phase Ia/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Subjects With Solid Malignancies",I,Open,Gilead Sciences,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Adenocarcinoma; Follicular; HER2 negative; Hormone refractory; Large Cell; Locally advanced; Metastatic; PD-1 Refractory; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative; Unresectable,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A Phase Ib, Open-label, Dose-escalation and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Inavolisib in Combination with Paclitaxel in Patients with Locally Advanced or Metastatic Solid Tumors",I,Open,Roche/Genentech,Oncology: Breast; Oncology: Fallopian Tube; Oncology: Head/Neck; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Neoplasms, Unknown Primary; Ovarian Neoplasms; Peritoneal Neoplasms",Canada; Denmark; France; South Korea; Spain; United States
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types,I/II,Open,"University of Florida - Gainesville
LG Chem/AVEO Oncology
Roche/Genentech",Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Fallopian Tube; Oncology: Gallbladder; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Vulvar,Fourth line or greater; HER2 positive; High-grade; Hormone refractory; Intermediate-grade; Low-grade; Metastatic; MSS/pMMR; Second line; Stage III; Stage IV; Third line; Unresectable,Adenocarcinoma; Bile Duct Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Cholangiocarcinoma; Fallopian Tube Neoplasms; Fibrosarcoma; Gallbladder Neoplasms; Leiomyosarcoma; Liposarcoma; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Vulvar Neoplasms,United States
"A Phase Ib/IIa, Open-label Platform Study to Evaluate Mirdametinib as Monotherapy or in Combination With Other Anticancer Agents in Patients With Advanced Solid Cancers Harboring MAPK-activating Mutations.",I/II,Closed,"Memorial Sloan-Kettering Cancer Center
SpringWorks Therapeutics",Oncology: Breast; Oncology: Unspecified Solid Tumor,BRAF; EGFR; Estrogen receptor positive; HER2 negative; HRAS; KRAS; Progesterone receptor positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms, Unknown Primary",United States
A Phase l Study of TAS2940 in Patients With Locally Advanced or Metastatic Solid Tumors With EGFR and / or HER2 Aberrations,I,Open,Otsuka Holdings/Taiho Pharmaceutical,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",EGFR; HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Glioblastoma; Neoplasms, Unknown Primary",France; United States
"A Phase I/II Study To Evaluate The Safety, Pharmacokinetics, And Efficacy Of BLU-222 As A Single Agent And In Combination Therapy For Patients With Advanced Solid Tumors.",I/II,Open,Blueprint Medicines,Oncology: Breast; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Ovarian; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinosarcoma; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Mixed Tumor, Mullerian; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
A Phase  I/II  Open-label Trial of KVA12123 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors,I/II,Open,Kineta,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms, Unknown Primary; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Neoplasms; Thyroid Neoplasms; Wilms Tumor",United States
"A Phase I, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 as Monotherapy in Patients With Selected Advanced Solid Tumors",I,Open,ADC Therapeutics {Auven Therapeutics/ADC Therapeutics},Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Fallopian Tube; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor,HER2 negative; Other; Second line; Stage III; Stage IV; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Renal Cell; Cholangiocarcinoma; Fallopian Tube Neoplasms; Kidney Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Wilms Tumor",Spain; United States
A Clinical Study of ATG-101 for the Treatment of Advanced/ Metastatic Solid Tumors and B-cell Non-Hodgkin Lymphoma (B-NHL),I,Open,Antengene Corporation Limited/Antengene Corporation Co.,"Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Unspecified Solid Tumor",(N/A); Aggressive; Diffuse large B-cell lymphoma (DLBCL); Extranodal marginal zone B-cell lymphoma (MALT); Follicular lymphoma (FL); HER2 negative; Indolent; Lymphoblastic lymphoma (LBL); Mantle cell lymphoma (MCL); Other subtype; Second line; Small lymphocytic lymphoma (SLL); Stage III; Stage IV; Third line; Triple receptor negative; Waldenstrom's macroglobulinemia (WM),"Breast Neoplasms; Esophageal Neoplasms; Glioblastoma; Head and Neck Neoplasms; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Neoplasms, Unknown Primary; Stomach Neoplasms; Uterine Cervical Neoplasms; Waldenstrom Macroglobulinemia",China; United States
A Phase I/Ib Dose Escalation/Expansion Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors,I,Open,NGM Biopharmaceuticals,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A Phase I Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors",I,Open,Cullinan Oncology,"Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",(N/A); Fourth line or greater; Line of therapy N/A; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Thyroid Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Australia; Poland; Spain; United States
Open-Label Phase Ib/II Study of Sacituzumab Govitecan-Hziy Plus Chemoimmunotherapy for the Treatment of Subjects With Advanced Triple-Negative Breast Cancer After Prior Therapy,I/II,Terminated,NantWorks/ImmunityBio,Oncology: Breast,Fourth line or greater; HER2 negative; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase Ib/II Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination With Systemic Anti-cancer Agents in Patients With ER Positive Breast Cancer or Advanced Solid Tumors.",I/II,Open,Ascentage Pharma Group,Oncology: Breast; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; Second line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms, Unknown Primary",China; United States
"A Phase Ib/II, Multicenter, Single Arm Study of RBN-2397 in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung (SCCL)",I/II,Closed,Ribon Therapeutics,"Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell",(N/A); HER2 positive; PD-1 Refractory; PD-L1 Refractory; Second line; Squamous Cell; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Head and Neck Neoplasms; Small Cell Lung Carcinoma",Israel; Spain; United Kingdom; United States
Phase I/II Study of Stereotactic Radiation and Abemaciclib in the Management of Hormone Receptor Positive HER2 Negative Breast Cancer Brain Metastases,I/II,Open,"Eli Lilly
H. Lee Moffitt Cancer Center and Research Institute",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Estrogen receptor positive; HER2 negative; Line of therapy N/A; Progesterone receptor positive; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
A Phase I/II Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies,I/II,Open,"Merck & Co./Merck Sharp & Dohme (MSD)
NGM Biopharmaceuticals","Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal",Adenocarcinoma; Fourth line or greater; Second line; Squamous Cell; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor","South Korea; Taiwan, China; United States"
"A Phase Ib/II, Multicenter, Open-label Study of S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors",I/II,Open,Shionogi,"Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal; Oncology: Unspecified Solid Tumor",HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Japan; United States
"A Phase I/II Study of Tucatinib With Chemotherapy and Trastuzumab in Patients With Previously Treated, Advanced Her-2-Neu Overexpressing Breast Cancer",I/II,Terminated,"Providence Cancer Center at Providence Portland Medical Center
Seagen",Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
"Phase Ib Study of Neoadjuvant DPX-Survivac, Aromatase Inhibition, and With/Without Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer",I,Open,"(Other Cooperative Group)
IMV Inc. {IImmunovaccine {ImmunoVaccine Technologies}}",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
A First-in-Human Phase I Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas,I,Open,Antengene Corporation Limited/Antengene Corporation Co.,"Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Unspecified Solid Tumor",(N/A); Aggressive; Diffuse large B-cell lymphoma (DLBCL); Extranodal marginal zone B-cell lymphoma (MALT); Follicular lymphoma (FL); HER2 negative; Indolent; Lymphoblastic lymphoma (LBL); Mantle cell lymphoma (MCL); Other subtype; Second line; Small lymphocytic lymphoma (SLL); Stage II; Stage III; Stage IV; Triple receptor negative; Waldenstrom's macroglobulinemia (WM),"Breast Neoplasms; Esophageal Neoplasms; Glioblastoma; Head and Neck Neoplasms; Hematologic Neoplasms; Lymphoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Neoplasms; Neoplasms, Unknown Primary; Stomach Neoplasms; Uterine Cervical Neoplasms; Waldenstrom Macroglobulinemia",Australia; United States
"An Open-label, Two-part Dose escalation and Expansion Study to Evaluate Safety, Pharmacokinetics, and Preliminary Activity of JBI-778 in Solid Tumors Patients with Stable Brain Metastasis",I/II,Planned,Jubilant Life Sciences,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer; Oncology: Myelodysplastic Syndrome; Oncology: Unspecified Solid Tumor",(N/A); CNS mets; HER2 negative; Line of therapy N/A; RA/RARS; RCMD; Second line; Triple receptor negative,"Acute Myelocytic Leukemia; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Glioblastoma; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Neoplasm Metastasis",United States
"An Open Label, Phase I Dose Escalation Trial, With Dose Confirmation and Expansion, of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations",I,Open,Boehringer Ingelheim,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Renal; Oncology: Small Intestine; Oncology: Unspecified Solid Tumor",(N/A); ALK; BRAF; EGFR; Fourth line or greater; HER2 positive; Line of therapy N/A; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Intestinal Neoplasms; Kidney Neoplasms; Neoplasm Metastasis; Neoplasms, Unknown Primary; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor","Australia; Austria; Belgium; China; France; Germany; Hong Kong, S.A.R., China; Israel; Italy; Japan; Netherlands; Portugal; Singapore; South Korea; Spain; Sweden; United Kingdom; United States"
"A Phase I-II Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents in Subjects With Advanced Malignancies",I/II,Open,OncoResponse,"Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Cancer; Oncology: Unspecified Solid Tumor",ALK; EGFR; First line; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Squamous Cell Carcinoma of Head and Neck; Synovial Sarcoma; Triple Negative Breast Neoplasms",United States
"To Evaluate TROP2-TRACTr in an Initial Proof of Concept Clinical Trial in Triple Receptor Negative Breast Cancer, Urothelial Cancer and Non Small Cell Lung Cancer Patients",I,Planned,Janux Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Renal",(N/A); HER2 negative; Line of therapy N/A; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Kidney Neoplasms; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"An Open-label, Phase I, Dose-escalation Study to Evaluate the Safety and Preliminary Antitumor Activity of TAK-676 With Pembrolizumab Following Radiation Therapy in the Treatment of Non-small-cell Lung Cancer, Triple-negative Breast Cancer, or Squamous-cell Carcinoma of the Head and Neck That Has Progressed on Checkpoint Inhibitors.",I,Open,Takeda,"Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell",HER2 negative; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms",United States
"A Phase I/II a, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas",I/II,Open,Immunitas Therapeutics,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Small Intestine; Oncology: Unspecified Solid Tumor",Aggressive; BRAF; BRCA; Classical; Cutaneous T-cell lymphoma (CTCL); Diffuse large B-cell lymphoma (DLBCL); Estrogen receptor positive; Fourth line or greater; HER2 negative; Indolent; Line of therapy N/A; MSI-H/dMMR; MSS/pMMR; Nodular lymphocyte-predominant; Other subtype; PD-1 Refractory; PD-L1 Refractory; Peripheral T-cell lymphoma (PTCL); Progesterone receptor positive; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Hodgkin Disease; Intestinal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Neoplasms",United States
"A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS5001, an Anti-ROR1 Antibody Drug Conjugate, in Patients With Advanced Solid Tumors and Lymphomas",I,Open,"CStone Pharmaceuticals
United Biotechnology (Zhuhai Hengqin) Co.","Oncology: Breast; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Unspecified Solid Tumor",Aggressive; Classical; Diffuse large B-cell lymphoma (DLBCL); Extranodal marginal zone B-cell lymphoma (MALT); Follicular lymphoma (FL); HER2 negative; Indolent; Lymphoblastic lymphoma (LBL); Mantle cell lymphoma (MCL); Nodular lymphocyte-predominant; Other subtype; Second line; Small lymphocytic lymphoma (SLL); Stage III; Stage IV; Third line; Triple receptor negative; Waldenstrom's macroglobulinemia (WM),"Breast Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Neoplasms, Unknown Primary; Waldenstrom Macroglobulinemia",Australia; China; United States
"ctDNA-guided Adaptive Therapy Escalation in ER+ MBC: A Phase Ib Study With Letrozole, Palbociclib and Onapristone ER",I,Terminated,"Memorial Sloan-Kettering Cancer Center
Context Therapeutics",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRa Overexpressing Tumors",I/II,Open,Elucida Oncology,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Unspecified Cancer",Distal; Fourth line or greater; HER2 negative; Hilar; Intrahepatic; Second line; Stage III; Stage IV; Triple receptor negative,"Adenocarcinoma; Adenocarcinoma, Clear Cell; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinosarcoma; Cholangiocarcinoma; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Klatskin Tumor; Neoplasm Metastasis; Neoplasms; Ovarian Cancer; Ovarian Diseases; Ovarian Neoplasms; Peritoneal Neoplasms; Rectal Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Diseases",United States
"A Phase I/II, Open-Label, Dose-Escalation and Expansion Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Subjects With Advanced Solid Tumors Associated With Nectin-4 Expression",I/II,Terminated,Silverback Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Renal; Oncology: Unspecified Solid Tumor",Estrogen receptor positive; HER2 negative; HER2 positive; Line of therapy N/A; Progesterone receptor positive; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms, Unknown Primary; Renal Cancer; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Phase Ib/III Study to Evaluate the Efficacy and Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer Who Failed Standard of Care Therapies,I,Completed,Laekna Therapeutics Shanghai Co./Laekna Limited,Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,China; United States
"A Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the DNA Polymerase Theta Inhibitor ART4215 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors",I/II,Open,Artios Pharma,Oncology: Breast; Oncology: Ovarian; Oncology: Prostate; Oncology: Unspecified Solid Tumor,Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Neoplasm Metastasis; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms",United States
"A Multicentre, Open-label, Non-randomized, Phase Ia/Ib Study of NG-641, a Tumour-selective and Transgene-expressing Adenoviral Vector, in Combination With Nivolumab in Patients With Metastatic or Advanced Epithelial Tumours (NEBULA)",I,Open,"Bristol-Myers Squibb
Akamis Bio {PsiOxus Therapeutics}","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Renal; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Unspecified Cancer; Oncology: Unspecified Solid Tumor",(N/A); Distal; HER2 negative; Hilar; Intrahepatic; Line of therapy N/A; MSI-H/dMMR; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Cholangiocarcinoma; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasm Metastasis; Neoplasms; Neoplasms, Glandular and Epithelial; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Spain; United Kingdom; United States
"A Multicenter, Open-label, Phase Ia Study of HC-5404-FU in Subjects With Selected, Advanced Solid Tumors",I,Open,HiberCell {Biothera Pharmaceuticals},"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Renal",Fourth line or greater; HER2 positive; Pulmonary; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Kidney Neoplasms; Neuroendocrine Tumors; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",United States
"A Phase I, Open-Label, Multicenter, Dose Escalation Study of PRT1419 in Patients With Advanced Solid Tumors",I,Completed,Prelude Therapeutics,"Oncology: Breast; Oncology: Cervical; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Soft Tissue Sarcoma",Extensive; Fourth line or greater; HER2 negative; Metastatic; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative; Unresectable,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neuroendocrine Tumors; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Uterine Cervical Neoplasms",United States
A Phase I/II Study of RTX-224 for the Treatment of Patients With Advanced Solid Tumors,I/II,Terminated,Rubius Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma",HER2 negative; PD-1 Refractory; PD-L1 Positive; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Melanoma; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS- BREAST CANCER)",I/II,Open,Roche {F. Hoffmann-La Roche},Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,Australia; Israel; South Korea; Spain; United States
"A 6-Week, Randomized, Double-Blind, Sponsor-Open Study To Assess The Effect Of Repeated Subcutaneous Administration Of Pf-06946860 On Appetite In Participants With Advanced Cancer And Anorexia, Followed By An 18-Week Open-Label Treatment Period",I,Completed,Pfizer,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Supportive Care",Cachexia; Stage III; Stage IV; Third line,"Anorexia; Breast Neoplasms; Cachexia; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fatigue; Ovarian Cancer; Ovarian Neoplasms; Palliative Care; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Wasting Syndrome",Canada; United States
Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test,I/II,Open,"Novartis
MD Anderson Cancer Center, University of Texas
Puma Biotechnology
Celcuity",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms; Inflammatory Breast Neoplasms,United States
"A Phase I/II, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors",I/II,Open,NextCure,"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Unspecified Solid Tumor",Second line; Squamous Cell; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Liver Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms",United States
"An Open Label, Phase I, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants With Advanced Solid Tumors",I/II,Terminated,IDEAYA Biosciences,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Pancreas; Oncology: Renal; Oncology: Thymus; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV; Thymic carcinoma,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Thymus Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
Focused Ultrasound With Low-Dose Gemcitabine to Augment Immune Control of Early Stage Breast Cancer,I,Open,University of Virginia,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; HER2 positive; Progesterone receptor positive; Stage 0; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
Multicenter Open Label Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer,I/II,Open,(Other Industry Sponsor),Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Third line,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
Phase I/II Trial of BINTRAFUSP ALFA (M7824) and Pimasertib for Treatment of Intracranial Metastases,I/II,Closed,"MD Anderson Cancer Center, University of Texas","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Unspecified Solid Tumor",CNS mets; Estrogen receptor positive; Fourth line or greater; HER2 negative; PD-1 Naive; PD-1 Refractory; Progesterone receptor positive; Second line; Stage IV; Third line; Triple receptor negative,"Brain Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Lung Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Unknown Primary; Skin Neoplasms",United States
"A Phase Ia Open-Label, Dose-Escalation, and a Phase II Study to Investigate the Safety, PK, PD, and Clinical Activity of ST-067 Administered Subcutaneously as Monotherapy in Patients with Relapsed or Refractory Solid Tumors",I/II,Open,"Merck & Co./Merck Sharp & Dohme (MSD)
Simcha IL-18","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Renal; Oncology: Unspecified Solid Tumor",HER2 negative; Merkel; MSI-H/dMMR; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
A Clinical Study of Oraxol in Patients with Metastatic Breast Cancer,I,Terminated,Athenex {Kinex Pharmaceuticals},Oncology: Breast,Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase I, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FRα Antibody-drug Conjugate) in Adult Patients With Recurrent Endometrial Cancer and Recurrent, High-Grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers",I,Open,ImmunoGen,"Oncology: Breast; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Primary Peritoneal",(N/A); Fourth line or greater; HER2 negative; Line of therapy N/A; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Fallopian Tube Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms",United States
"A Phase IB, Open-Label, Dose-Escalation Study of the Safety of and Antigen-specific Immune Responses Elicited by VB10.NEO in Combination With Atezolizumab in Patients With Locally Advanced and Metastatic Tumors",I,Open,"Roche/Genentech
Nykode Therapeutics {Vaccibody}","Oncology: Anal; Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal; Oncology: Unspecified Solid Tumor",HER2 negative; Maintenance/Consolidation; MSI-H/dMMR; Stage III; Stage IV; Triple receptor negative,"Anus Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Germany; Spain; United States
LCI-BRE-MTN-NIR-001: A Phase I Study of Niraparib in Combination With Standard Chemotherapy in Metastatic Triple-Negative Breast Cancer,I,Terminated,GlaxoSmithKline/Tesaro,Oncology: Breast,HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
"A Phase Ia, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase Ib Expansion in Select Tumor Types",I,Open,Nurix Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Aggressive; Diffuse large B-cell lymphoma (DLBCL); HER2 negative; Hormone refractory; MSS/pMMR; Second line; Stage III; Stage IV; Third line; Triple receptor negative; Unresectable,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Chronic Lymphocytic Leukemia; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Mesothelioma; Mesothelioma, Malignant; Neoplasms; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Renal Cancer; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United Kingdom; United States
"REINA: A Phase I Study of Radiation Enhanced IL 12-Necrosis Attraction in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients",I,Terminated,"MD Anderson Cancer Center, University of Texas",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Third line,Adenocarcinoma; Breast Neoplasms,United States
"A Phase I/II, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CYC140, an Oral PLK1 Inhibitor, in Subjects With Advanced Solid Tumors and Lymphoma",I/II,Open,Cyclacel,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",Aggressive; Cutaneous T-cell lymphoma (CTCL); Diffuse large B-cell lymphoma (DLBCL); Extranodal marginal zone B-cell lymphoma (MALT); Follicular lymphoma (FL); HER2 negative; Indolent; KRAS; Mantle cell lymphoma (MCL); Peripheral T-cell lymphoma (PTCL); Pulmonary; Second line; Small lymphocytic lymphoma (SLL); Stage III; Stage IV; Triple receptor negative; Waldenstrom's macroglobulinemia (WM),"Acute Myelocytic Leukemia; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cholangiocarcinoma; Chronic Lymphocytic Leukemia; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Leukemia, Myeloid, Acute; Liver Cancer; Liver Neoplasms; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Myelodysplastic Syndromes; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Waldenstrom Macroglobulinemia",United States
"Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of ON 123300 Capsules Administered Orally as Escalating Daily Doses in Patients With Advanced Cancer Relapsed or Refractory to at Least One (1) Prior Line of Therapy",I,Open,Onconova Therapeutics,Oncology: Breast; Oncology: Unspecified Cancer,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms; Neoplasms; Unspecified,United States
"A Phase I, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants With Advanced/Recurrent Solid Tumors That Express HER2",I,Temporarily Closed,Mersana Therapeutics,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
"A Phase I, First-in-human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants With Solid Tumors",I,Open,Mersana Therapeutics,Oncology: Breast; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Fallopian Tube Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Triple Negative Breast Neoplasms",United States
A Phase I/II Study Investigating Safety and Efficacy of Autologous TAC T Cells Targeting HER2 in Relapsed or Refractory Solid Tumors.,I/II,Open,"Merck & Co.
Triumvira Immunologics","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",HER2 positive; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Gallbladder Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",Canada; United States
"A Phase I/Ib, Open-Label, Multicenter, Dose-Escalation Study of RMC 5552 Monotherapy in Adult Subjects With Relapsed/Refractory Solid Tumors",I,Open,Revolution Medicines,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Neoplasms; Pancreatic Neoplasms",United States
A Phase I Safety and Window-of-opportunity Study of Preoperative Intratumoral Injection of OX40-ligand Expressing Oncolytic Adenovirus (DNX-2440) in Patients With Resectable Liver Metastasis,I,Open,"H. Lee Moffitt Cancer Center and Research Institute
DNAtrix {VectorLogics}","Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: GIST; Oncology: Liver; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Osteosarcoma; Oncology: Pancreas; Oncology: Renal; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Soft Tissue Sarcoma",Liver mets; Neoadjuvant; Resectable; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Gastrointestinal Stromal Tumors; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms, Second Primary; Osteosarcoma; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Wilms Tumor",United States
Phase I/II Study of Stereotactic Radiosurgery With Concurrent Administration of DNA Damage Response (DDR) Inhibitor (OLAparib) Followed by Adjuvant Combination of DuRvalumab (MEDI4736) and Physician's Choice Systemic Therapy in Subjects With BreAst Cancer Brain Metastases,I/II,Open,"AstraZeneca
University of North Carolina",Oncology: Breast; Oncology: Metastatic Cancer,Adjuvant; BRCA; CNS mets; HER2 negative; PD-1 Naive; PD-L1 Naive; Stage IV; Triple receptor negative,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
Phase I/I B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial),I,Open,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Unspecified Solid Tumor,HER2 positive; Second line; Stage III; Stage IV,"Adenocarcinoma; Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasm Metastasis; Neoplasms; Neoplasms, Unknown Primary; Salivary Gland Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
"A Phase I Dose-Escalation Trial of Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer",I,Open,"Pfizer
University of Michigan Comprehensive Cancer Center
Aurobindo Pharma/Acrotech Biopharma",Oncology: Breast; Oncology: Ovarian; Oncology: Prostate,Estrogen receptor positive; HER2 negative; Hormone refractory; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms; Neoplasm Metastasis; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms,United States
Neratinib and Tepotinib Combination in Advanced Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal Her2 and C-met Pathway Activity as Measured by the Celsignia Signaling Pathway Activity Test,I/II,Planned,"MD Anderson Cancer Center, University of Texas
City of Hope Comprehensive Cancer Center
Ohio State University",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
Phase I/II Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors,I/II,Open,Nuvation Bio,Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Unspecified Solid Tumor,BRCA; HER2 negative; Hormone refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Acute Myelocytic Leukemia; Breast Neoplasms; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Triple Negative Breast Neoplasms",United States
A Phase I Dose Escalation and Expanded Cohort Study of P-MUC1C-ALLO1 in Adult Subjects With Advanced or Metastatic Solid Tumors,I,Open,Poseida Therapeutics,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",(N/A); Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",United States
"A Phase 1b Trial of ARV-471 in Combination With Everolimus in Patients With ER+, HER2- Advanced or Metastatic Breast Cancer",I,Open,"Pfizer
Arvinas",Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage IV; Third line,Breast Neoplasms,Spain; United States
Phase I Trial of Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Patients With Non-Metastatic Triple-Negative Breast Cancer at High Risk of Recurrence,I,Open,(Other Hospital/Academic/Medical Center),Oncology: Breast,Adjuvant; HER2 negative; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase I, Open Label, Crossover Study to Establish Bioequivalence Between the Proposed Soft Gel Talazoparib Capsule Formulation and the Current Talazoparib Commercial Formulation and to Estimate the Food Effect on Pharmacokinetics of the Proposed Talazoparib Soft Gel Capsule Formulation in Participants with Advanced Solid Tumors",I,Completed,Pfizer,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor",BRCA; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms",Australia; United States
"Phase IB Trial of Niraparib and TSR-042 in Patients With BRCA-Mutated Breast, Pancreas or Ovary Cancer",I,Open,"GlaxoSmithKline
University of Washington",Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal,BRCA; Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms",United States
"A Phase I, First in Human, Study to Evaluate the Safety and Tolerability of AdAPT-001 in Subjects With Refractory Solid Tumors",I,Open,EpicentRx {RadioRx},Oncology: Breast; Oncology: Colorectal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Melanoma; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,"Breast Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Rhabdomyosarcoma; Sarcoma; Stomach Neoplasms; Synovial Sarcoma",United States
A Phase I Study of SGN-STNV in Advanced Solid Tumors,I,Open,Seagen,"Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas",HER2 negative; Second line; Stage III; Stage IV,"Adenocarcinoma; Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Pseudomyxoma Peritonei; Stomach Carcinoma; Stomach Neoplasms; Uterine Cervical Neoplasms",Canada; France; Italy; Spain; United Kingdom; United States
A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XL102 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors,I,Open,Exelixis,Oncology: Breast; Oncology: Ovarian; Oncology: Prostate; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; Hormone refractory; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Ovarian Epithelial; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Triple Negative Breast Neoplasms",Belgium; Italy; Spain; United States
Evaluation of Variations pharmacokinEtics and phArmacogeNOmics of Ribociclib in rAce-based Cohorts: The LEANORA Study,I,Open,"(Other Hospital/Academic/Medical Center)
Breast Cancer Research Foundation",Oncology: Breast,Estrogen receptor positive; HER2 negative; Line of therapy N/A; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,United States
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors,I,Open,Exelixis,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor",Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Renal Cancer; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A Phase Ib/II, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer",I/II,Open,Zymeworks,Oncology: Breast; Oncology: Unspecified Solid Tumor,HER2 positive; Stage III; Stage IV; Third line,"Breast Neoplasms; Neoplasms, Unknown Primary; Unspecified",United States
"EMBER-2: A Phase I, Open-Label, Preoperative Window Study Evaluating the Biological Effects of LY3484356 in Post-menopausal Women With Stage I-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer",I,Completed,Eli Lilly,Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,Belgium; France; Germany; Spain; United Kingdom; United States
Phase Ib Expansion Study of CX-5461 in Patients With Solid Tumours and BRCA2 and/or PALB2 Mutation,I,Open,Senhwa Biosciences,Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Unspecified Solid Tumor,BRCA; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Fallopian Tube Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms",Canada; United States
"A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies",I/II,Open,AstraZeneca,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",BRCA; Fourth line or greater; HER2 negative; Hormone refractory; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Lung Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",Australia; Canada; China; Czech Republic; Hungary; Italy; Japan; Poland; Russia; South Korea; Spain; United Kingdom; United States
"A Phase 1b Open-Label Multicenter Study of OP-1250 in Combination With the CDK4/6 Inhibitor Ribociclib or With the PI3K Inhibitor Alpelisib in Adult Subjects With Advanced and/or Metastatic HR Positive, HER2 Negative Breast Cancer",I,Open,"Novartis
Olema Oncology",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,Australia; United States
A Phase I Study in High-Risk Women with Early Stage Triple Receptor Negative (TNBC) Breast Cancer who are Receiving Standard of Care,I,Open,"US Department of Defense
(Other Hospital/Academic/Medical Center)
Anixa Biosciences",Oncology: Breast,HER2 negative; Line of therapy N/A; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
ATTAMAGE-A1.: Phase I/II Study of Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity MAGE-A1-Specific T-Cell Receptor (TCR) Combined With Atezolizumab in Patients With Metastatic MAGE-A1 Expressing Cancer.,I/II,Terminated,"Fred Hutchinson Cancer Research Center
SignalOne Bio","Oncology: Bladder; Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Renal",HER2 negative; PD-1 Refractory; PD-L1 Refractory; Second line; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Kidney Neoplasms; Lung Neoplasms; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase I/II Trial of EMB-02, a Bi-specific Antibody Against PD-1 and LAG-3, in Patients With Advanced Solid Tumors",I/II,Open,EpimAb Biotherapeutics,"Oncology: Anal; Oncology: Breast; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Unspecified Solid Tumor",BRAF; HER2 negative; PD-1 Refractory; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,"Anus Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms",Australia; China; United States
"A Phase I Study of In Situ Immunomodulation With CDX-301, Radiotherapy, CDX-1140, and Poly-ICLC in Patients With Unresectable and Metastatic Solid Tumors With Injectable Palpable Disease",I,Open,Roswell Park Cancer Institute,Oncology: Breast; Oncology: Melanoma,HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms; Carcinoma; Melanoma,United States
"A Phase I/II, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination With Cemiplimab in Patients With Advanced Cancers",I/II,Open,Palleon Pharmaceuticals,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",MSI-H/dMMR; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase I, First in Human, Open-label, Dose Escalation and Dose Expansion Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors",I,Open,Transcenta Holding {Mabspace Biosciences Co.},"Oncology: Anal; Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Penile; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor; Oncology: Vaginal; Oncology: Vulvar",PD-1 Refractory; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Third line,"Anus Neoplasms; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Penile Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Vaginal Neoplasms; Vulvar Neoplasms; Wilms Tumor",China; United States
A Phase I/II Trial of ATI-450 in Combination With Paclitaxel or Capecitabine in Patients With Hormone Receptor-positive and HER2 Negative Metastatic Breast Cancer With Bone Metastasis,I/II,Terminated,"Washington University School of Medicine
US Department of Defense
Aclaris Therapeutics",Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms; Neoplasm Metastasis,United States
"An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Amivantamab, a Human Bispecific EGFR and cMet Antibody for the Treatment of Advanced Solid Malignancies.",I,Open,Johnson & Johnson/Janssen R&D {Johnson & Johnson/J&JPRD {Johnson & Johnson/Janssen-Cilag/Janssen Research Foundation}},"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Renal; Oncology: Thyroid",EGFR; Fourth line or greater; Medullary; Metastatic; Second line; Stage III; Stage IV; Third line; Unresectable,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms; Wilms Tumor",Canada; South Korea; United Kingdom; United States
"A Phase I Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Anti-tumor Activity of PF-07248144 in Participants With Advanced or Metastatic Solid Tumors.",I,Open,Pfizer,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Prostate",Estrogen receptor positive; Fourth line or greater; HER2 negative; Hormone refractory; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Prostatic Neoplasms",China; Japan; South Korea; United States
ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib Trial,I,Terminated,"(Other Cooperative Group)
Byondis {Synthon}
ALX Oncology {Alexo Therapeutics}",Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Ovarian; Oncology: Renal,Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoid Tumor; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Kidney Neoplasms; Neoplasm Metastasis; Neoplasms; Neoplasms, Second Primary; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
Phase I/II Study of Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in the Management of HER2+ Breast Leptomeningeal Disease,I/II,Open,"H. Lee Moffitt Cancer Center and Research Institute
Roche/Genentech",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Fourth line or greater; HER2 positive; Second line; Stage IV; Third line,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Meningeal Neoplasms; Neoplasm Metastasis,United States
"A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors, With Emphasis on Squamous Cell Carcinoma of the Head and Neck, Triple Negative Breast Cancer, Anaplastic Thyroid Carcinoma, and Cutaneous Squamous Cell Carcinoma",I/II,Completed,Codiak BioSciences,"Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Renal; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Soft Tissue Sarcoma; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Advanced; Anaplastic; HER2 negative; Metastatic; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Unknown Primary; Rhabdomyosarcoma; Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United Kingdom; United States
"Open Label, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of CYH33, an Oral a-specific PI3K Inhibitor in Combination With Olaparib, an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.",I,Open,"Haihe Biopharma Co.
Haihe Biopharma Co./Shanghai Haihe Pharmaceutical Research and Development Co.",Oncology: Breast; Oncology: Endometrial; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Unspecified Solid Tumor,BRCA; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms",Australia; China; United States
A Phase I Study of TAS0612 in Patients With Locally Advanced or Metastatic Solid Tumors,I,Open,Otsuka Holdings/Taiho Pharmaceutical,Oncology: Breast; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; KRAS; Progesterone receptor positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms; Neoplasms, Unknown Primary",France; Spain; United States
Evaluation of Radiosurgery With Concurrent Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Brain Metastases,I,Terminated,"National Institutes of Health/National Cancer Institute
Winship Cancer Institute of Emory University",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Estrogen receptor positive; HER2 negative; Line of therapy N/A; Progesterone receptor positive; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis; Neoplasms,United States
"A Phase Ib, Open-Label, Multicohort Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Patients With Triple-Negative Breast Cancer",I/II,Completed,Roche,Oncology: Breast,First line; HER2 negative; PD-L1 Positive; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,"Australia; Brazil; Germany; Italy; Russia; South Korea; Spain; Taiwan, China; United States"
"A Phase I, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors",I,Closed,Incyte Corporation,"Oncology: Anal; Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate; Oncology: Unspecified Solid Tumor",Adjuvant; HER2 negative; Hormone refractory; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,"Anus Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",Belgium; France; Italy; Spain; United Kingdom; United States
"An Open-Label, Phase Ib/2 Study to Evaluate the Safety and Efficacy of Fruquintinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors",I/II,Open,"Hutchmed {Hutchison MediPharma}
BeiGene",Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Unspecified Solid Tumor,HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Colorectal Neoplasms; Endometrial Neoplasms; Triple Negative Breast Neoplasms",United States
"Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta “Trap“/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)",I/II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Head/Neck; Oncology: Pancreas; Oncology: Unspecified Solid Tumor,HER2 negative; PD-1 Refractory; PD-L1 Positive; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Head and Neck Neoplasms; Neoplasm Metastasis; Neoplasms, Unknown Primary; Pancreatic Neoplasms",United States
"A Safety, Tolerability, and Pharmacokinetics Phase I Clinical Trial Of ON 123300 in Relapsed/Refractory, Advanced Cancer Including Patients with HR+ HER 2- Metastatic Breast Cancer with Resistance to Approved Second-Generation CDK4/6 Inhibitors and Non-Hodgkin’s Lymphoma with a special interest in Mantle Cell Lymphoma",I,Planned,"Onconova Therapeutics
Hanx Biopharmaceutical Co.","Oncology: Breast; Oncology: Lymphoma, Non-Hodgkin's",Aggressive; Estrogen receptor positive; HER2 negative; Mantle cell lymphoma (MCL); Progesterone receptor positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin",United States
"A Phase I, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO-100 in Adult Patients With Advanced Solid Tumors",I,Open,CSPC Pharmaceutical Group Co./Conjupro Biotherapeutics,"Oncology: Breast; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate; Oncology: Unspecified Solid Tumor",First line; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
"A Phase I Study to Determine Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of SCO-120 in Hormone Receptor Positive, HER-2 Negative Advanced Breast Cancer Patients",I,Terminated,Sun Pharma Advanced Research,Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,India; United States
"A Phase Ib Multicentre, Open-Label, Modular, Dose-Finding And Dose-Expansion Study To Explore The Safety, Tolerability, Pharmacokinetics And Anti-Tumour Activity Of Trastuzumab Deruxtecan (T-Dxd) In Combination With Other Anti-Cancer Agents In Patients With Metastatic HER2-Low Breast Cancer (DESTINY-Breast08)",I,Closed,"AstraZeneca
Daiichi Sankyo",Oncology: Breast,Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Third line,Breast Neoplasms,"Australia; Belgium; Brazil; Canada; France; Mexico; Russia; South Korea; Taiwan, China; United States"
"A Phase I/IIa Study Evaluating The Safety, Tolerability, Pharamcokinetics, Pharmacodynamics, And Anti-Tumor Activity Of PF-07220060 As A Single Agent And as Part of Combination Therapy In Participants With Advanced Solid Tumors",I,Open,Pfizer,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Untreated,"Adenocarcinoma of Lung; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neoplasms, Unknown Primary; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
"Phase I/IIa Dose Escalation, Finding and Expansion Study Evaluating Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti Tumor Activity of PF-07104091 as a Single Agent and in Combination Therapy",I/II,Open,Pfizer,"Oncology: Breast; Oncology: Fallopian Tube; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Primary Peritoneal",(N/A); Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Fallopian Tube Neoplasms; Lung Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms",Argentina; Bulgaria; China; Japan; Mexico; Ukraine; United States
A Phase I Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors,I,Completed,"I-Mab Biopharma Co. {Tasgen (Genexine, Shanghai Tasly Pharmaceutical Co., and C-Bridge Capital joint venture)}",Oncology: Breast; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Neoplasm Metastasis; Neoplasms, Unknown Primary",United States
"Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients with Nectin-4 Expressing Advanced Malignancies",I/II,Open,Bicycle Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",First line; Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor","Belgium; Canada; France; Germany; Hong Kong, S.A.R., China; Italy; Netherlands; South Korea; Spain; United Kingdom; United States"
"Phase I/II Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors",I/II,Terminated,Nuvation Bio,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Metastatic Cancer; Oncology: Prostate; Oncology: Unspecified Solid Tumor",(N/A); CNS mets; Estrogen receptor positive; Fourth line or greater; HER2 negative; Hormone refractory; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,"Brain Neoplasms; Breast Neoplasms; Carcinoma; Central Nervous System Neoplasms; Glioblastoma; Glioma; Neoplasm Metastasis; Neoplasms; Neoplasms, Unknown Primary; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant",United States
"A Phase Ib/II Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With HER2-positive Metastatic Breast Cancer (DESTINY-Breast07)",I/II,Closed,"AstraZeneca
Daiichi Sankyo",Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,"Australia; Brazil; Canada; France; Germany; India; Italy; Poland; Russia; South Korea; Spain; Taiwan, China; Turkey; United Kingdom; United States"
A Phase I Open Label First in Human Dose Escalation and Expansion Study of the Bispecific Anti-Mucin 1 - Epidermal Growth Factor Receptor Antibody Drug Conjugate M1231 as a Single Agent in Participants With Advanced Solid Tumors,I,Completed,"Merck KGaA/EMD Serono {EMD Pharmaceuticals}
Sutro Biopharma","Oncology: Breast; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Unspecified Solid Tumor",EGFR; MSI-H/dMMR; PD-1 Refractory; PD-L1 Refractory; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms",Canada; United States
"A Phase Ib Dose-escalation Study of the Safety and Pharmacokinetics of Fixed-dose PCS6422 With Escalating Doses of Capecitabine Administered Orally to Patients With Advanced, Refractory Gastrointestinal Tract Tumors",I,Open,Processa Pharmaceuticals,Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Gastric; Oncology: Liver; Oncology: Pancreas,Second line; Stage III; Stage IV; Unresectable,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gallbladder Neoplasms; Liver Cancer; Liver Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
"A First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors.",I/II,Open,Relay Therapeutics,Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Endometrial; Oncology: Gastric; Oncology: Liver; Oncology: Unspecified Solid Tumor,FGFR; First line; Fourth line or greater; Intrahepatic; Second line; Stage III; Stage IV; Third line; Unresectable,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Cholangiocarcinoma; Cholangiocarcinoma; Endometrial Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms, Unknown Primary; Stomach Carcinoma; Stomach Neoplasms","Australia; Canada; France; Germany; Hong Kong, S.A.R., China; Italy; Netherlands; Singapore; South Korea; Spain; Sweden; Taiwan, China; United Kingdom; United States"
Phase I Trial of Intratumoral Administration of a Measles Virus Derivative Expressing the Helicobacter Pylori Neutrophil-Activating Protein (NAP) (MV-s-NAP) in Patients With Metastatic Breast Cancer,I,Open,Mayo Clinic,Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma,United States
A Phase Ib/II Clinical Study of Intratumoral Administration of V937 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors,I/II,Closed,Merck & Co./Merck Sharp & Dohme (MSD),"Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Metastatic Cancer; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Unspecified Solid Tumor",HER2 negative; HER2 positive; Liver mets; PD-1 Naive; PD-L1 Naive; PD-L1 Positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasm Metastasis; Neoplasms, Unknown Primary; Stomach Carcinoma; Stomach Neoplasms","Brazil; Canada; Colombia; France; Germany; Hungary; Israel; Italy; Japan; Norway; Peru; Poland; Portugal; Singapore; South Korea; Spain; Switzerland; Taiwan, China; United Kingdom; United States"
Clinical and Immunologic Activity of Nemvaleukin Alfa With Less Frequent IV Dosing Schedule as Monotherapy and in Combination With Pembrolizumab and Impact on Tumor Microenvironment in Solid Tumor Patients - ARTISTRY-3,I/II,Open,Alkermes,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Renal; Oncology: Unspecified Solid Tumor",(N/A); Fourth line or greater; HER2 negative; Intrahepatic; MSI-H/dMMR; MSS/pMMR; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Stomach Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Spain; United States
"A Phase I First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Selected Advanced Solid Tumors",I,Open,"GlaxoSmithKline
Surface Oncology","Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Renal; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Wilms Tumor",Canada; Japan; Spain; United States
Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV Infection,I,Open,National Institutes of Health/National Cancer Institute,"Infectious Disease: HIV; Oncology: Bladder; Oncology: Breast; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Extensive; First line; Follicular; HER2 negative; HIV-related cancer; Hormone refractory; Limited; Locally advanced; Medullary; Metastatic; Papillary; PD-1 Naive; PD-L1 Naive; Pulmonary; Recurrent; Second line; Stage III; Stage IV; Triple receptor negative; Untreated,"Acquired Immunodeficiency Syndrome; Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Medullary; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Transitional Cell; Head and Neck Neoplasms; HIV Infections; HIV Seropositivity; Infections; Kaposi Sarcoma; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Melanoma; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Sarcoma; Sarcoma, Kaposi; Skin Neoplasms; Small Cell Lung Carcinoma; Thyroid Diseases; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase Ib Study of ZN-c5 in Combination With Abemaciclib in Patients With Estrogen-Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Advanced Breast Cancer",I,Completed,Zentalis/Zeno Alpha,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Stage III; Stage IV,Breast Neoplasms,Bosnia and Herzegovina; Poland; United States
"TOPAZ: Single Arm, Open Label Phase Ib/II Study of Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Women With HER2-Positive Breast Cancer Brain Metastases",I/II,Terminated,"Cedars-Sinai Medical Center
Merck & Co./Merck Sharp & Dohme (MSD)
Seagen",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; First line; HER2 positive; Second line; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Diseases; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
"A Phase I, Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of DZD1516 in Combination With Trastuzumab and Capecitabine,or DZD1516 in Combination With T-DM1, in Patients with Metastatic HER2 Positive (HER2+) Breast Cancer",I,Completed,Dizal (Jiangsu) Pharmaceutical Co. (AstraZeneca and SDIC Fund Management Company joint venture),Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,China; United States
"A Phase I/II, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of AMXI-5001 in Patients With Advanced Malignancies",I/II,Open,AtlasMedx,Oncology: Breast; Oncology: Ovarian,Second line; Stage III; Stage IV,Breast Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms,United States
"A Phase IB Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer",I,Terminated,"National Institutes of Health/National Cancer Institute
Stanford University Medical Center
Breast Cancer Research Foundation
BridgeBio Pharma/QED Therapeutics",Oncology: Breast,Estrogen receptor positive; FGFR; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase I First-in-Human Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD8701 Administered Intravenously as Monotherapy and in Combination With Durvaluamb (MEDI4736) in Participants With Advanced Solid Tumours.",I/II,Closed,AstraZeneca,"Oncology: Breast; Oncology: Cervical; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Renal; Oncology: Unspecified Solid Tumor",HER2 negative; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Lung Neoplasms; Melanoma; Neoplasms, Squamous Cell; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Canada; France; Spain; United States
"Phase I Trial of Abexinostat Combined With Palbociclib and Fulvestrant in Patients With Antiestrogen Refractory ER+, HER2- Breast Cancer and Gynecological Metastatic Tumors",I,Terminated,"Pfizer
University of California, San Francisco
Xynomic Pharmaceuticals",Oncology: Breast; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal,Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Endometrial Neoplasms; Fallopian Tube Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms",United States
"Phase 1/2a Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-3500 Alone or in Combination With Talazoparib or Gemcitabine in Advanced Solid Tumors With ATR Inhibitor Sensitizing Mutations (TRESR Study)",I/II,Open,"Roche
Repare Therapeutics",Oncology: Breast; Oncology: Head/Neck; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor,BRCA; Fourth line or greater; Second line; Stage III; Stage IV,"Breast Neoplasms; Head and Neck Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms",Canada; Denmark; United Kingdom; United States
"A Phase I Dose Escalation and Dose Expansion and Phase II Monotherapy Open-label, First-in-Human, Multicenter Study of OP-1250 in Adult Subjects With Advanced and/or Metastatic Hormone Receptor (HR)-Positive, HER2-negative Breast Cancer",I/II,Open,Olema Oncology,Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,Australia; United States
A Phase I Trial of the ATR Inhibitor BAY 1895344 in Combination With Cisplatin and With Cisplatin Plus Gemcitabine in Advanced Solid Tumors With an Emphasis on Urothelial Carcinoma,I,Open,National Institutes of Health/National Cancer Institute,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Penile; Oncology: Renal",Advanced; HER2 negative; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Cholangiocarcinoma; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Neoplasms, Mesothelial; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Penile Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A Phase I/II, FIH, Two-part, Open-label Clinical Trial of Intravenous (IV) Administration of CTL-002 Given as Monotherapy and/or in Combination With an Anti-PD-1 Checkpoint Inhibitor in Subjects With Advanced-stage, Relapsed/Refractory Solid Tumors (The “GDFATHER“-Trial: GDF-15 Antibody-mediaTed Human Effector Cell Relocation)",I/II,Open,CatalYm,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Unspecified Solid Tumor",Fourth line or greater; MSS/pMMR; Neoadjuvant; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",Germany; Spain; Switzerland; United States
"A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors",I,Open,"Zion Pharma/Suzhou Zanrong Pharmaceutical Technology Co.
Zion Pharma",Oncology: Breast; Oncology: Metastatic Cancer; Oncology: Unspecified Solid Tumor,CNS mets; HER2 positive; Second line; Stage III; Stage IV; Third line,"Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis; Neoplasms; Neoplasms, Unknown Primary",China; United States
"A Phase I/II, Dose Escalation and Expansion Study of the Safety, Tolerability, and Anti-tumor Activity of BND-22 Administered Alone and in Combination With Pembrolizumab or With Cetuximab in Patients With Advanced Solid Tumors",I/II,Open,Biond Biologics,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV; Unresectable,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gallbladder Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms, Unknown Primary; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Israel; United States
A Phase I Study of Abemaciclib and Niraparib as Neoadjuvant Therapy in Hormone Receptor Positive (HR+) HER2 Negative (HER2-) Breast Cancer,I,Closed,"Eli Lilly
GlaxoSmithKline
OHSU Cancer Institute
Oregon Health and Science University",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Adenocarcinoma; Breast Neoplasms; Carcinoma,United States
"A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, as Monotherapy and in Combination With Pembrolizumab or Cetuximab in Patients With Advanced Solid Refractory/Resistant Malignancies",I,Closed,Tizona Therapeutics,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",HER2 negative; Second line; Squamous Cell; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Neoplasms; Neoplasms, Unknown Primary",United States
"This Study is a Phase I/II Clinical Evaluation of a New Investigational Agent, Lutetium-177-PEG-αvβ3-IAC (HurlutinTM Lu-177) to Treat Patients With Unresectable Angiogenic Breast Cancer.",I/II,Planned,"Department of Veterans Affairs
(Other Hospital/Academic/Medical Center)
All India Institute of Medical Sciences (AIIMS)
University of Witwatersrand, South Africa
PositronPharma
Advanced Imaging Projects",Oncology: Breast; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms, Unknown Primary",Chile; India; Italy; South Africa; Switzerland; United States
"A Multi-Center Open Label Dose Escalation and Dose Expansion Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and GEJ Cancer",I/II,Open,Precirix {Camel-IDS},Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Metastatic Cancer,CNS mets; Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Disease Progression; Esophageal Cancer; Esophageal Neoplasms; Neoplasm Metastasis; Stomach Carcinoma; Stomach Neoplasms,Canada; United States
"Phase I/II, First-in-human, Open-label Dose Escalation and Cohort Expansion Study of KB-0742 in Patients with Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma",I/II,Open,Kronos Bio,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",(N/A); Aggressive; HER2 negative; Indolent; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
Preoperative Use of Radiation Boost to Enhance Effectiveness of Immune Checkpoint Blockade Therapy in Operable Breast Cancer,I/II,Open,University of Pennsylvania,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage II; Triple receptor negative,Breast Neoplasms,United States
"A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation",I,Open,Roche/Genentech,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",Fourth line or greater; KRAS; Second line; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Pancreatic Neoplasms; Stomach Neoplasms",Australia; Belgium; Brazil; Canada; France; Germany; Hungary; Israel; Italy; Kenya; Netherlands; New Zealand; Norway; Poland; Russia; South Korea; Spain; Switzerland; United Kingdom; United States
A Phase I/II Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors,I/II,Open,Regeneron,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Unspecified Solid Tumor",BRAF; HER2 negative; Line of therapy N/A; MSS/pMMR; PD-1 Naive; PD-L1 Naive; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Neoplasms; Neoplasms, Unknown Primary",Japan; United States
"A Phase I Multi-Country, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1811 in HER2 Expressing or Mutated Advanced Malignant Solid Tumor Subjects",I,Open,"Jiangsu Hengrui Pharmaceuticals Co. {Jiangsu Hengrui Medicine}/Shanghai Hengrui Pharmaceutical {Shanghai Hengrui Pharmaceutical (Jiangsu Hengrui Medicine, HKG Science & Tech. JV)}
Jiangsu Hengrui Pharmaceuticals Co. {Jiangsu Hengrui Medicine Co.}/Atridia
Jiangsu Hengrui Pharmaceuticals Co. {Jiangsu Hengrui Medicine Co.}/Suzhou Suncadia Biopharmaceuticals Co.","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Renal; Oncology: Unspecified Solid Tumor",Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor","Australia; China; South Korea; Taiwan, China; United States"
"An Open-Label, Multicenter, Phase Ib/II Study to Establish Safety, Tolerability, and Optimal Dosing Strategy of GLR2007 in Subjects With Advanced Solid Tumors",I/II,Completed,Gan & Lee Pharmaceuticals,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer; Oncology: Unspecified Solid Tumor",ALK; BRAF; CNS mets; EGFR; Other mets; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Glioblastoma; Neoplasm Metastasis; Neoplasms, Unknown Primary",United States
A Phase I/II Open-Label Study to Evaluate Safety and Efficacy of SEL120 in Patients with Relapsed/refractory Metastatic or Advanced Solid Tumors,I/II,Open,Ryvu Therapeutics {Selvita},Oncology: Breast; Oncology: Unspecified Solid Tumor,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Neoplasms, Unknown Primary; Recurrence",Australia; China; Czech Republic; France; Netherlands; Poland; Russia; Spain; United States
"Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT7480 in Patients With Nectin-4 Associated Advanced Malignancies",I/II,Open,Bicycle Therapeutics,"Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Renal; Oncology: Unspecified Solid Tumor",Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",United States
"A Phase I/II Multicenter, Open-label, Dose-escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of Q901 Administered Via Intravenous Infusion in Adult Patients With Selected Advanced Solid Tumors With a Cohort Expansion at the Recommended Phase II Dose",I/II,Open,Qurient,"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor",(N/A); Estrogen receptor positive; HER2 negative; Hormone refractory; Progesterone receptor positive; Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma",United States
BRE-03: Window of Opportunity Trial of Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC),I,Open,University of Illinois at Chicago Health Sciences Center,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Stage I; Stage II; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"First-in-Human, Phase I/Ib, Open-label, Multicenter Study of Bifunctional EGFR/TGFß Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors",I,Open,"Merck & Co./Merck Sharp & Dohme (MSD)
Biocon/Bicara Therapeutics","Oncology: Anal; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Anaplastic; EGFR; First line; Fourth line or greater; HER2 negative; KRAS; PD-1 Refractory; PD-L1 High; PD-L1 Positive; PD-L1 Refractory; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Anus Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Squamous Cell; Colorectal Neoplasms; Glioblastoma; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Melanoma; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Thyroid Neoplasms",Canada; United States
"First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1044 in Subjects With Malignant Solid Tumors",I/II,Terminated,"Genmab
AbbVie","Oncology: Bladder; Oncology: Breast; Oncology: Endometrial; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Prostate",Adenocarcinoma; HER2 negative; Large Cell; Second line; Squamous Cell; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Prostatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Neoplasms",Belgium; Denmark; France; Israel; Netherlands; South Korea; Spain; United States
Phase I Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies,I,Closed,Curis,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Unspecified Solid Tumor",HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Neoplasms, Unknown Primary",Australia; United States
A Phase Ib Clinical Study of DPV-001 with BMS-986178 and Nivolumab in Patients with Advanced Triple Negative Breast Cancer,I,Open,"Bristol-Myers Squibb
UbiVac",Oncology: Breast,First line; HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,Poland; United States
"A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications",I/II,Open,Dragonfly Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Skin, Squamous Cell Carcinoma (cSCC)",BRAF; Extensive; Fourth line or greater; HER2 negative; Merkel; Metastatic; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Australia; France; Spain; United States
A Phase I/II Study of the SV-BR-1-GM Regimen in HLA Matched Metastatic Breast Cancer Patients in Combination With Pembrolizumab,I/II,Terminated,"Kimmel Cancer Center-Thomas Jefferson University - Philadelphia, PA",Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma,United States
"A First-In-Human, Phase I/II Study Of CFI-402411, a Hematopoietic Progenitor Kinase-1 (HPK1) Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Malignancies.",I/II,Open,"Treadwell Therapeutics
TIO Discovery","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Renal; Oncology: Unspecified Solid Tumor",HER2 negative; Metastatic; MSI-H/dMMR; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor","Canada; Hong Kong, S.A.R., China; Singapore; United States"
"A Phase I/IIa, Open-Label, Multi-Center Study Evaluating the Safety and Anti-Tumor Activity of Ex Vivo Expanded, Autologous Natural Killer Cells (SNK01) in Combination With Trastuzumab or Cetuximab in Subjects With Advanced/Metastatic HER2- or EGFR-Expressing Cancers",I/II,Terminated,NKGen Biotech,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",EGFR; HER2 negative; HER2 positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative; Unresectable,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Lung Neoplasms; Neoplasm Metastasis; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",United States
"A Phase I, First-In-Human, Multicenter, Open-Label, Study of GQ1001, a HER2 Targeted Antibody-Drug Conjugate, Administered Intravenously, in Adult Patients With HER2-Positive Advanced Solid Tumors",I,Open,"GeneQuantum Healthcare (Suzhou) Co.
Conjugate Light (Australia)",Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Unspecified Solid Tumor,Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Esophageal Cancer; Esophageal Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",Australia; China; United States
"Phase I Study of X-PACT (X-ray Psoralen Activated Cancer Therapy) for Intra-tumoral Injection of Superficial Tumors in Patients With Advanced Head and Neck Cancer, Breast Cancer, Soft Tissue Sarcoma or Melanoma",I,Open,Immunolight,Oncology: Breast; Oncology: Head/Neck; Oncology: Melanoma; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV,Breast Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma,United States
A Phase I/II Study of CBX-12 in Subjects with Advanced or Metastatic Refractory Solid Tumors,I/II,Open,"Exelixis
Cybrexa Therapeutics","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",Pulmonary; Second line; Stage III; Stage IV,"Appendiceal Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Kidney Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Sarcoma; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Phase I Study of SGN-B6A in Advanced Solid Tumors,I,Open,Seagen {Seattle Genetics},"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Skin, Squamous Cell Carcinoma (cSCC)",Adenocarcinoma; HER2 negative; Second line; Squamous Cell; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Esophageal Cancer; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Neoplasms; Neoplasms, Squamous Cell; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",France; Spain; Switzerland; United Kingdom; United States
"Phase I/Ib, Open-label, Multiple Ascending Dose, First-in-Human Study, to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of INT-1B3 in Patients With Advanced Solid Tumors",I,Open,InteRNA Technologies,Oncology: Breast; Oncology: Liver; Oncology: Unspecified Solid Tumor,HER2 negative; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Liver Cancer; Liver Neoplasms; Neoplasms; Neoplasms, Unknown Primary",Belgium; Netherlands; United States
Clinical Onboard Utilization of Image Guided Radiation Therapy With Magnetic Resonance (CONFIRM): A Master Protocol,I/II,Open,Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute,"Oncology: Bladder; Oncology: Breast; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lymphoma, Non-Hodgkin's",(N/A); Aggressive; Line of therapy N/A; Mantle cell lymphoma (MCL),"Breast Carcinoma In Situ; Breast Neoplasms; Head and Neck Neoplasms; Laryngeal Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
Phase Ib Study of INO-5401 Alone or INO-5401 in Combination With INO-9012 Followed by Electroporation in Adult Cancer and Non-Cancer Patients With BRCA1 or BRCA2 Mutations,I,Open,"University of Pennsylvania
Inovio Pharmaceuticals {Inovio Biomedical}",Oncology: Breast; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate,(N/A); BRCA; Line of therapy N/A,Breast Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Unspecified,United States
"Phase II Trial of Abemaciclib and T-DM1 in Women and Men With HER2-Positive Advanced or Metastatic Breast Cancer Who Progressed on Treatment With a Taxane, Trastuzumab and Pertuzumab",I/II,Terminated,"National Institutes of Health/National Cancer Institute
Academic and Community Cancer Research United",Oncology: Breast,Estrogen receptor positive; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms; Carcinoma,United States
"A Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers",I,Open,"National Institutes of Health/National Cancer Institute
(Other Hospital/Academic/Medical Center)
T-Cure Bioscience","Oncology: Breast; Oncology: Cervical; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Cancer",HER2 negative; Second line; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Liver Cancer; Liver Neoplasms; Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Uterine Cervical Neoplasms",United States
A Phase I/II Trial Evaluating the Safety and Efficacy of Eribulin in Combination With Copanlisib in Patients With Metastatic Triple Negative Breast Cancer,I/II,Open,National Institutes of Health/National Cancer Institute,Oncology: Breast,Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Carcinoma; Triple Negative Breast Neoplasms,United States
"Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors",I/II,Open,BioNTech,"Oncology: Breast; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Renal; Oncology: Unspecified Solid Tumor",HER2 negative; Second line; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Renal Cancer; Wilms Tumor",Spain; United Kingdom; United States
"A First In Human, Open Label, Dose Escalation Phase I Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Clinical Activity Profile Of Single Agent RO7119929 (TLR7 Agonist) Administered Orally To Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases",I,Completed,Roche {F. Hoffmann-La Roche},Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Gallbladder; Oncology: Gastric; Oncology: Liver; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor,Distal; Fourth line or greater; HER2 negative; Hilar; Intrahepatic; Liver mets; Second line; Stage III; Stage IV; Third line; Triple receptor negative; Unresectable,"Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Gallbladder Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor","Canada; Denmark; Hong Kong, S.A.R., China; South Korea; Spain; Taiwan, China; United States"
"A Dose Finding Phase I of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)",I/II,Closed,"National Institutes of Health/National Cancer Institute
University of Florida - Gainesville",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Second line; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Phase Ib/II Study to Evaluate Safety and Tolerability of Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer,I/II,Completed,"Bristol-Myers Squibb
Washington University School of Medicine",Oncology: Breast,HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase I, Open Label, Dose Escalation Study of ACE1702 Cell Immunotherapy in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors",I,Open,Acepodia,Oncology: Breast; Oncology: Gastric; Oncology: Unspecified Solid Tumor,HER2 positive; Line of therapy N/A; Stage III; Stage IV,"Breast Neoplasms; Neoplasm Metastasis; Neoplasms; Neoplasms, Unknown Primary; Stomach Carcinoma; Stomach Neoplasms","Taiwan, China; United States"
Hydroxychloroquine (HCQ) in Combination With Abemaciclib and Endocrine Therapy in HR+/Her 2- Advanced Breast Cancer After a Lead in Dose Escalation Cohort of HCQ and Abemaciclib in Advanced Solid Tumors,I,Terminated,Medical College of Wisconsin Cancer Center,Oncology: Breast; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms, Unknown Primary",United States
"A Phase I/II Open-Label, Multicenter Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors.",I/II,Open,UCB,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Prostate",Line of therapy N/A; Stage I; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United Kingdom; United States
A Phase I/Ib Trial of the CDK4/6 Antagonist Ribociclib And The HDAC Inhibitor Belinostat In Patients With Metastatic Triple Negative Breast Cancer And Recurrent Ovarian Cancer With Response Prediction By Genomics (CHARGE).,I,Open,"Novartis
University of Utah
Aurobindo Pharma/Acrotech Biopharma",Oncology: Breast; Oncology: Ovarian,HER2 negative; Line of therapy N/A; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Ovarian Cancer; Ovarian Neoplasms,United States
A Phase I/II Trial of Intracerebroventricular 177Lu DTPA Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors,I/II,Terminated,Y-mAbs Therapeutics,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer",CNS mets; Line of therapy N/A; Stage IV,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Melanoma; Meningeal Carcinomatosis; Neoplasm Metastasis",United States
"A Phase I, Multicenter, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of hSTC810 Monotherapy in Subjects With Advanced Solid Tumors",I,Open,STCube,"Oncology: Anal; Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Thymus; Oncology: Unspecified Solid Tumor",Advanced; First line; Line of therapy N/A; MSI-H/dMMR; Stage III; Stage IV,"Anus Neoplasms; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Neoplasms; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Synovial Sarcoma; Thymus Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",South Korea; United States
"A Phase I/IIa, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered Alone and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors",I/II,Closed,"Takeda
Turnstone Biologics","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Renal; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Unspecified Solid Tumor",(N/A); Distal; HER2 negative; Hilar; Intrahepatic; Line of therapy N/A; MSS/pMMR; PD-1 Refractory; PD-L1 Positive; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative; Unresectable,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Cholangiocarcinoma; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Mesothelioma; Mesothelioma, Malignant; Neoplasms, Unknown Primary; Oropharyngeal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Uterine Cervical Neoplasms; Wilms Tumor",Canada; South Korea; United States
"A Phase I/II Study to Evaluate Safety, Efficacy of Bria-OTS in Patients with Advanced Breast Cancer",I/II,Planned,BriaCell,Oncology: Breast,Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase lb/ll, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer",I/II,Terminated,Roche {F. Hoffmann-La Roche},Oncology: Breast,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,Australia; Hungary; South Korea; Spain; United States
"A First-in-Human, Multicenter, Phase I/II, Open-Label Study of XTX101 in Patients With Advanced Solid Tumors",I/II,Open,Xilio Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Fourth line or greater; MSI-H/dMMR; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
Pilot Study of DS-8201a Pharmacodynamics in Patients With HER2-Expressing Advanced Solid Tumors,I,Open,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Unspecified Solid Tumor,HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms; Neoplasms, Unknown Primary",United States
"Phase l, First in Human, Multi-centre, Open-label, Clinical Trial of MPT0B640 in Subject With Locally Advanced or Metastatic Solid Malignancies.",I,Planned,J Ints Bio {Joseah Bio},"Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor",HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms",South Korea; United States
"A Phase I, Multicenter, Open-label, Dose-Exploration and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 650 in Subjects With Advanced Solid Tumors",I,Completed,Amgen,Oncology: Breast; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Unspecified Solid Tumor,Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Fallopian Tube Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms","Australia; Belgium; Canada; Italy; Japan; Spain; Taiwan, China; United States"
An Open-Label Multicenter Phase Ib Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive HER2-Negative Breast Cancer,I,Closed,Eisai,Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United Kingdom; United States
"A Phase Ib Study of Venetoclax and Capecitabine In Subjects With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Experienced Disease Progression During or After CDK4/6 Inhibitor Therapy",I,Terminated,AbbVie,Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms; Disease Progression,Germany; Puerto Rico; United States
A Phase I Study of Cancer Peptides Plus GM-CSF and Adjuvant Following Completion of Prescribed Systemic Therapy of Estrogen Receptor Positive Breast Cancer,I,Open,Duke University Medical Center,Oncology: Breast,Adjuvant; Estrogen receptor positive; Stage II; Stage III,Breast Neoplasms,United States
Pilot Clinical Trial of Treatment With Bortezomib to Inhibit Homologous Recombination (HR) Followed by Pembrolizumab and Cisplatin in Patients With Chemotherapy-Pretreated Metastatic Triple Negative Breast Cancer,I,Open,Baylor Research Institute,Oncology: Breast; Oncology: Metastatic Cancer,HER2 negative; Liver mets; Other mets; Second line; Stage IV; Triple receptor negative,Breast Neoplasms; Liver Neoplasms; Neoplasm Metastasis,United States
DNA Damage Repair (DDR) Inhibitor-Based Basket of Baskets Phase I/II Trial in Patients With Advanced Solid Tumors Harboring Aberrations in DDR Genes (D-BoB),I/II,Open,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast; Oncology: Colorectal; Oncology: Prostate; Oncology: Unspecified Solid Tumor,(N/A); BRCA; Hormone refractory; Line of therapy N/A; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV,"Breast Neoplasms; Colorectal Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Prostatic Neoplasms",United States
Phase I/II Study of IMC-F106C in Advance PRAME-Positive Cancers,I/II,Open,Immunocore,"Oncology: Bladder; Oncology: Breast; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Renal; Oncology: Unspecified Solid Tumor",Adjuvant; HER2 negative; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Endometrial Neoplasms; Ewing Sarcoma; Fallopian Tube Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United Kingdom; United States
"A Phase I Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of GS-1811, an Afucosylated Anti-CCR8 Monoclonal Antibody, as Monotherapy and in Combination With an Anti-PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors",I,Open,Gilead Sciences,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Estrogen receptor positive; First line; HER2 negative; HER2 positive; Large Cell; MSS/pMMR; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Positive; PD-L1 Refractory; Progesterone receptor positive; Second line; Squamous Cell; Stage II; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Stomach Neoplasms","Australia; Taiwan, China; United States"
A Phase I Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies.,I,Open,Seagen {Seattle Genetics},"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Ovarian; Oncology: Unspecified Solid Tumor",(N/A); Aggressive; Classical; Diffuse large B-cell lymphoma (DLBCL); Fourth line or greater; HER2 negative; PD-1 Naive; PD-L1 Naive; Peripheral T-cell lymphoma (PTCL); Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",France; Italy; Spain; United Kingdom; United States
"A First-in-human, Open Label, Multiple Dose, Dose Escalation and Cohort Expansion Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors",I,Closed,Bliss Biopharmaceutical (Hangzhou) Co.,Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Gastric; Oncology: Ovarian; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gallbladder Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",China; United States
Predicting Response of Metastatic Triple Negative Breast Cancer to Immunotherapy Based on Patients Cytokine Profile,I/II,Temporarily Closed,Texas Tech University Health Sciences Center,Oncology: Breast,HER2 negative; Line of therapy N/A; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Phase I Study of GNX102 in Patients With Advanced Solid Tumors,I,Open,GlycoNex,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",United States
"A Phase I Open-Label Study to Evaluate the Safety and Antitumor Activity of FS120, an OX40/CD137 Bispecific Antibody, Alone and in Combination With Pembrolizumab, in Subjects With Advanced Malignancies",I,Open,Sino Biopharmaceutical/invoX Pharma/F-star Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Neoplasm Metastasis; Neoplasms, Unknown Primary; Urethral Neoplasms; Urinary Bladder Neoplasms",Spain; United States
Cryoablation and Anti-PD-L1 Immunotherapy for Triple Negative Breast Cancer (TNBC),I,Terminated,"National Institutes of Health/National Cancer Institute
Mayo Clinic",Oncology: Breast,HER2 negative; PD-1 Naive; PD-L1 Naive; PD-L1 Positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma; Triple Negative Breast Neoplasms,United States
Phase I Trial of Intravenous Administration of TAEK-VAC-HerBy Vaccine Alone and in Combination With HER2 Antibodies in Patients With Advanced Cancer,I/II,Open,Bavarian Nordic,"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",Fourth line or greater; HER2 positive; Merkel; Pulmonary; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chordoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Liver Cancer; Liver Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms",United States
"A Phase Ib Trial of Sequential Combinations of BN-Brachyury, Entinostat, Ado-trastuzuamb Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)",I,Terminated,National Institutes of Health/National Cancer Institute,Oncology: Breast,First line; HER2 negative; HER2 positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Phase I Study of CAR T-cell therapy as Monotherapy and in Combination with OncoSec's TAVO (IL-12) in Patients with Triple-negative Breast Cancer (TNBC),I,Planned,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
OncoSec Medical",Oncology: Breast; Oncology: Unspecified Solid Tumor,(N/A); HER2 negative; Line of therapy N/A; Triple receptor negative,"Breast Neoplasms; Neoplasms, Unknown Primary",United States
A Phase Ib/II Study of SDX-7320 in Combination with Alpelisib and Fulvestrant to Assess Safety in Patients with Metastatic Breast Cancer with the PIK3CA Mutation,I/II,Open,SynDevRx,Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase Ia/Ib Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY159 as a Single Agent and In Combination With Pembrolizumab in Subjects With Advanced Solid Tumors",I,Closed,Pionyr Immunotherapeutics,"Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Thyroid; Oncology: Unspecified Solid Tumor; Oncology: Vaginal; Oncology: Vulvar",Adenocarcinoma; Estrogen receptor positive; HER2 negative; MSI-H/dMMR; MSI-L; PD-1 Refractory; PD-L1 Refractory; Progesterone receptor positive; Second line; Squamous Cell; Stage III; Stage IV; Triple receptor negative,"Adenocarcinoma; Adenocarcinoma of Lung; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms; Uterine Cervical Neoplasms; Vaginal Neoplasms; Vulvar Neoplasms",United States
"A Phase Ia/Ib Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY314 as a Single Agent and In Combination With Pembrolizumab in Subjects With Advanced Solid Tumors",I,Closed,"Gilead Sciences
Pionyr Immunotherapeutics","Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Renal; Oncology: Unspecified Solid Tumor; Oncology: Vaginal; Oncology: Vulvar",Estrogen receptor positive; HER2 negative; PD-1 Refractory; PD-L1 Refractory; Progesterone receptor positive; Second line; Squamous Cell; Stage III; Stage IV; Triple receptor negative,"Adenocarcinoma of Lung; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Kidney Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms; Vaginal Neoplasms; Vulvar Neoplasms; Wilms Tumor",United States
"First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors.",I,Open,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Pancreas; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,"Breast Neoplasms; Colorectal Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Nerve Sheath Neoplasms; Neurofibrosarcoma; Pancreatic Cancer; Pancreatic Neoplasms",United States
A Phase Ib/II Study of the Safety and Pharmacology of Nilotinib to Prevent Paclitaxel-Induced Peripheral Neuropathy in Patients With Breast Cancer,I/II,Open,"National Institutes of Health/National Cancer Institute
Ohio State University",Oncology: Breast; Oncology: Supportive Care,Line of therapy N/A; Neurotoxicity; Stage I; Stage II; Stage III,Breast Neoplasms; Palliative Care; Peripheral Nervous System Diseases,United States
Pilot Trial of Acute Effect of Lorcaserin to Reduce Patient-Reported Symptoms of Taxane and Oxaliplatin-Induced Peripheral Neuropathy,I,Terminated,"National Institutes of Health/National Cancer Institute
Ohio State University",CNS: Pain (neuropathic); Oncology: Breast; Oncology: Gastric; Oncology: Supportive Care,Cancers-related; Chronic pain; Line of therapy N/A; Neurotoxicity; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms; Cancer pain; Cancer Pain; Neuralgia; Palliative Care; Peripheral Nervous System Diseases; Stomach Carcinoma; Stomach Neoplasms,United States
A Phase I Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients with Advanced Malignancies.,I,Completed,Celldex Therapeutics {AVANT Immunotherapeutics},"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A Phase I, Open-Label, Dose Escalation and Expansion Study of TH1902 in Patients With Advanced Solid Tumors",I,Open,"Theratechnologies
Windtree Therapeutics","Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",(N/A); Estrogen receptor positive; HER2 negative; Locally advanced; Metastatic; Progesterone receptor positive; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Endometrial Neoplasms; Melanoma; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Thyroid Neoplasms; Triple Negative Breast Neoplasms",United States
An Open-label Phase Ib/IIa Study of NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Advanced Solid Tumors,I/II,Open,Genexine/NeoImmuneTech,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",ALK; BRAF; BRCA; EGFR; First line; Fourth line or greater; HER2 negative; MSS/pMMR; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative; Untreated,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Lung Neoplasms; Melanoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms",United States
Phase I Sequential Trial of Agents Against DNA Repair (STAR),I,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Ovarian; Oncology: Prostate; Oncology: Unspecified Solid Tumor,BRCA; Estrogen receptor positive; Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Colorectal Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Neoplasms; Prostatic Neoplasms; Stomach Neoplasms",United States
A Phase I/Ib Study of BP1001-A (a Liposomal Grb2 Antisense Oligonucleotide) in Patients With Advanced or Recurrent Solid Tumors,I,Open,Bio-Path Holdings,Oncology: Breast; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Unspecified Solid Tumor,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Endometrial Neoplasms; Fallopian Tube Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms",United States
EMBER: A Phase Ia/Ib Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers,I,Completed,Eli Lilly/Loxo Oncology,Oncology: Breast; Oncology: Endometrial,Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; HER2 positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms","Australia; Belgium; France; Japan; South Korea; Spain; Taiwan, China; United States"
"Open-Label, Phase I Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer",I,Open,Spectrum Pharmaceuticals,Oncology: Breast; Oncology: Supportive Care,First line; Neutropenia; Stage I; Stage II; Stage III,Breast Neoplasms; Neutropenia; Palliative Care,United States
"A Phase I Study of Ipilumumab, Nivolumab and Talimogene Laherparepvec Preoperative Treatment of Localized Breast Cancer-deleted",I,Closed,"Jonsson Comprehensive Cancer Center, UCLA
National Institutes of Health/National Cancer Institute",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage 0; Stage I; Stage II; Triple receptor negative,"Breast Carcinoma In Situ; Breast Neoplasms; Carcinoma; Carcinoma, Ductal",United States
A Phase I Dose Escalation Study of NMS-03305293 in Adult Patients With Selected Advanced/Metastatic Solid Tumors,I,Open,Nerviano Medical Sciences,Oncology: Breast; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate,BRCA; Estrogen receptor positive; Fourth line or greater; HER2 negative; Hormone refractory; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms,China; Italy; United States
"A Phase I Open-Label, Multicenter Study to Evaluate Biomarkers for ZN-c5 in Subjects With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer",I,Completed,Zentalis/Zeno Alpha,Oncology: Breast,(N/A); Estrogen receptor positive; HER2 negative; Line of therapy N/A,Breast Neoplasms,"Australia; Bosnia and Herzegovina; Bulgaria; Hong Kong, S.A.R., China; Serbia; United States"
Phase I/II Study of BDC-1001 as a Single Agent and in Combination With Nivolumab in Patients With Advanced HER2-Expressing Solid Tumors,I/II,Open,"Bristol-Myers Squibb
Bolt Biotherapeutics","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",South Korea; Spain; United States
A Pilot Study of FES Imaging to Optimize Tamoxifen Dose for Metastatic Breast Cancer Patients With ESR1 Mutations,I,Open,University of Wisconsin,Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Estrogen receptor positive; HER2 negative; Second line; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
"Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients With Advanced Malignancies Associated With EphA2 Expression.",I/II,Open,Bicycle Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",HER2 negative; PD-1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Cancer; Esophageal Neoplasms; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Belgium; South Korea; Spain; United Kingdom; United States
"A Phase I, First-in-Human Study of Intratumoral Administration of CF33-hNIS-antiPDL1, A Novel Chimeric Oncolytic Poxvirus Encoding Human Sodium Iodide Symporter (HNIS) in Patients With Metastatic Triple Negative Breast Cancer",I,Open,"National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center
Imugene {Biolife Science}",Oncology: Breast,Fourth line or greater; HER2 negative; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Phase Ia/Ib Open Label Dose-escalation and Expansion Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors,I,Open,Tempest Therapeutics,"Oncology: Anal; Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Fourth line or greater; HER2 negative; MSS/pMMR; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Adenocarcinoma; Anus Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A Phase Ib Dose Escalation and Expansion Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 as Monotherapy and in Combination With Other Anticancer Agents in Adults With Advanced Solid Malignancies",I,Open,Atreca,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Primary Peritoneal",BRAF; Fourth line or greater; HER2 negative; MSI-H/dMMR; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Squamous Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"An Open-Label, Dose-Escalation Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Modakafusp Alfa (TAK-573) as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors",I/II,Open,Takeda,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor",BRAF; HER2 negative; MSI-H/dMMR; MSS/pMMR; PD-1 Naive; PD-1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Melanoma; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms",Australia; United States
A Phase I Study of ZN-c3 as a Single Agent in Subjects With Solid Tumors,I,Open,"Zentalis/Zeno Pharmaceuticals
Zentalis/K-Group Beta","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Renal; Oncology: Unspecified Solid Tumor",Extensive; Fourth line or greater; HER2 negative; Limited; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Kidney Neoplasms; Lung Neoplasms; Melanoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase Ib/II, Multicenter, Open-Label Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, in Patients With Advanced Solid Tumors",I/II,Open,TransThera Biosciences Co.,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Gallbladder; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Estrogen receptor positive; HER2 negative; Line of therapy N/A; Metastatic; Progesterone receptor positive; Pulmonary; Stage III; Stage IV; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Small Cell; Cholangiocarcinoma; Cholangiocarcinoma; Fibrosarcoma; Gallbladder Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Phase I-II, First-in-Human Study of SKB264 in Patients With Locally Advanced/Unresectable/Metastatic Solid Tumors Who Are Refractory to Available Standard Therapies.",I/II,Open,"Sichuan Kelun Pharmaceutical Co./Klus Pharma
Sichuan Kelun Pharmaceutical Co./Sichuan Kelun Botai Biopharmaceutical Co.","Oncology: Bladder; Oncology: Breast; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal",Extensive; HER2 negative; MSI-H/dMMR; MSS/pMMR; PD-1 Refractory; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Small Cell; Endometrial Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Lung Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",China; United States
A Phase I Multicenter Global First in Human Study of the CD73 Inhibitor LY3475070 as Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies,I,Completed,"Eli Lilly
Merck & Co./Merck Sharp & Dohme (MSD)","Oncology: Breast; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Fourth line or greater; HER2 negative; Large Cell; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Wilms Tumor",Australia; United Kingdom; United States
SHARON: Study of Metastatic Cancers in Patients With a Defect in a Homologous Recombination Gene Using Autologous Stems Cells and Potentiated Redox Cycling to Overcome Drug Resistance to Nitrogen Mustard Derivatives,I,Open,"Myriad Genetics
General Oncology, Inc.",Oncology: Breast; Oncology: Pancreas,BRCA; HER2 negative; Line of therapy N/A; Stage IV,"Adenocarcinoma; Breast Neoplasms; Carcinoma, Acinar Cell; Pancreatic Cancer; Pancreatic Neoplasms",United States
"A Phase I Open-label, First-in-human, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of Thorium-227 Labeled Antibody-chelator Conjugate BAY2701439, in Participants With Advanced HER2-expressing Tumors",I,Terminated,Bayer AG,Oncology: Breast; Oncology: Esophageal; Oncology: Gastric,HER2 negative; HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Unspecified,United Kingdom; United States
"A Phase Ib/IIa, Randomized, Placebo-Controlled Trial of the Synthetic Cannabinoid ART27.13 in Patients with Cancer Anorexia and Weight Loss",I/II,Open,Artelo Biosciences,Oncology: Breast; Oncology: Colorectal; Oncology: Prostate; Oncology: Supportive Care; Oncology: Unspecified Cancer,(N/A); Cachexia; Line of therapy N/A,Breast Neoplasms; Cachexia; Colorectal Neoplasms; Neoplasms; Palliative Care; Prostatic Neoplasms,Australia; Canada; Ireland; Norway; United Kingdom; United States
"An Open-Label, Multicenter Phase I/Ib Study of Intratumorally Administered STING Agonist E7766 in Subjects With Advanced Solid Tumors or Lymphomas - INSTAL-101",I,Completed,"Eisai
H3 Biomedicine","Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Unspecified Solid Tumor",Aggressive; Classical; Indolent; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV,"Breast Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms, Unknown Primary",France; South Korea; Spain; United Kingdom; United States
Window of Opportunity Study of Parsaclisib in Subjects With Newly Diagnosed Stage I-IIIC Triple-Negative or HER2-Positive Breast Cancer,I,Terminated,"UNC Lineberger Comprehensive Cancer Center
Incyte Corporation",Oncology: Breast,First line; HER2 negative; HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications",I/II,Open,Dragonfly Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Renal; Oncology: Unspecified Solid Tumor",HER2 positive; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Neoplasms; Kidney Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Renal Cancer; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Belgium; Denmark; France; Netherlands; United States
A Phase I/II Dose Escalation Study of AP-002 In Patients With Advanced or Recurrent Solid Tumors,I/II,Terminated,BetterLife Pharma/MedMelior {Altum Pharmaceuticals},"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms; Neoplasms, Unknown Primary; Prostatic Neoplasms",United States
"Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)",I/II,Open,"National Institutes of Health/National Cancer Institute
OncoC4","Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",(N/A); ALK; EGFR; First line; Fourth line or greater; HER2 negative; Merkel; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Positive; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative; Untreated,"Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fallopian Tube Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Melanoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Uterine Cervical Neoplasms; Wilms Tumor",Australia; United States
A Pilot Trial of Preoperative Oral Microbiota-based Investigational New Drug RBX7455 to Target Immune Response in Patients With Operable Stage I-III Breast Cancer,I,Closed,"National Institutes of Health/National Cancer Institute
Mayo Clinic
Ferring/Rebiotix",Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Carcinoma,United States
A Phase I Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer,I,Open,"Otsuka Holdings/Otsuka Pharmaceutical/Astex Pharmaceuticals {SuperGen}
Pfizer
Van Andel Research Institute",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Phase I Study of BBI-3000 in Patients with Breast Cancer,I,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
"A Phase I Multi-Targeted Study to Promote Anti-Tumor Immunity in ER Positive, HER2 Negative Advanced Breast Cancer",I,Completed,Bristol-Myers Squibb,Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"A Phase I Dose Escalation With Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMV564 Alone and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors.",I,Closed,Amphivena Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Small Intestine; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Fourth line or greater; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Intestinal Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Phase I/II Clinical Trial of FlowVax(TM) Peptide Vaccine in Breast Cancer Patients.,I/II,Planned,Flow Pharma,Oncology: Breast; Oncology: Cervical,(N/A); Line of therapy N/A,Breast Neoplasms; Uterine Cervical Neoplasms,China; United States
A Phase I Dose Escalation Trial of Alpha-Tocopheryloxyacetic Acid (a-TEA) in Patients With Treatment Refractory HER2+ Metastatic Breast Cancer,I,Open,"University of Washington
Veana Therapeutics",Oncology: Breast,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms; Carcinoma,United States
"Phase I/IIa, Non-Randomised, Open-Label Dose Escalation and Expansion Trial With Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Metastatic or Unresectable, Locally Advanced Malignant Solid Tumors.",I/II,Open,"Baylor Research Institute
Buzzard Pharmaceuticals",Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Prostate; Oncology: Unspecified Solid Tumor,Fourth line or greater; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Prostatic Neoplasms",United States
Pilot Evaluation of Focused Ultrasound Ablation and Focused Ultrasound Ablation Plus PD-1 Antibody Blockade in Advanced Solid Tumors,I,Closed,"(Other Hospital/Academic/Medical Center)
Theraclion","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Renal",Extensive; Merkel; Metastatic; PD-1 Refractory; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Esophageal Cancer; Esophageal Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Melanoma; Microsatellite Instability; Neoplasms, Squamous Cell; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy",I,Closed,Fate Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",Aggressive; Classical; EGFR; HER2 positive; Indolent; Merkel; Nodular lymphocyte-predominant; Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Microsatellite Instability; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
Phase Ib/II Trial of Copanlisib in Combination With Trastuzumab and Pertuzumab After Induction Treatment of HER2 Positive (HER2+) Metastatic Breast Cancer (MBC) With PIK3CA Mutation or PTEN Mutation,I/II,Open,National Institutes of Health/National Cancer Institute,Oncology: Breast,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms; Carcinoma,United States
"MasterKey-01: A Phase I/II, Open-label, Two-part, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics & Antitumor Activity of BDTX-189, an Inhibitor of Allosteric ErbB Mutations, in Patients w/ Advanced Solid Malignancies.",I/II,Terminated,Black Diamond Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Unspecified Solid Tumor",EGFR; HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms",Canada; Denmark; France; Germany; Israel; Italy; Netherlands; Poland; Portugal; Spain; United Kingdom; United States
"A Multicenter Phase I, Open-Label Study of SQ3370 in Patients With Advanced Solid Tumors.",I,Open,Shasqi,Oncology: Breast; Oncology: Head/Neck; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,First line; Fourth line or greater; HER2 negative; Locally advanced; Merkel; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified",Australia; United States
An Open Label Phase Ia/b Study of MTL-CEBPA in Combination With a PD-1 Inhibitor (Pembrolizumab) in Adult Patients With Advanced Solid Tumours,I,Closed,MiNA Therapeutics,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Thymus; Oncology: Unspecified Solid Tumor",(N/A); HER2 negative; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Thymic carcinoma; Triple receptor negative; Unspecified,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Liver Cancer; Liver Neoplasms; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Thymus Neoplasms",United Kingdom; United States
A Phase Ia/Ib Study of LY3435151 Administered to Patients With Advanced Solid Tumors,I,Terminated,Eli Lilly,Oncology: Breast; Oncology: Cervical; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Fibrosarcoma; Head and Neck Neoplasms; Histiocytoma, Malignant Fibrous; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms",Canada; Japan; United States
"A Multicenter, Non-randomized, Open-label Phase 1b Study to Determine the Maximum Tolerated and Recommended Phase 2 Dose of the ATR Inhibitor Elimusertib in Combination With Pembrolizumab and to Characterize Its Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Participants With Advanced Solid Tumors",I,Completed,Bayer AG,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor",Fourth line or greater; HER2 negative; Hormone refractory; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",Germany; Spain; Switzerland; United Kingdom; United States
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous Zotatifin (eFT226) in Subjects With Selected Advanced Solid Tumor Malignancies,I/II,Open,eFFECTOR Therapeutics,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",Estrogen receptor positive; FGFR; Fourth line or greater; HER2 negative; HER2 positive; KRAS; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
"A Pilot Neoadjuvant Clinical Trial of Combination Therapy With Abemaciclib, Durvalumab (MEDI4736), and an Aromatase Inhibitor in Locally Advanced Hormone Receptor Positive Breast Cancer",I,Terminated,"AstraZeneca
Eli Lilly",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms; Neoplasms,United States
"A Phase I/II Safety, Tolerability and Efficacy Study of ST101 In Adult Patients with Unresectable and Metastatic, Advanced HR Positive Breast Cancer, Glioblastoma, Melanoma and Castration-Resistant Prostate Cancer.",I/II,Open,Sapience Therapeutics,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Esophageal; Oncology: Liver; Oncology: Melanoma; Oncology: Prostate; Oncology: Small Intestine; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",(N/A); BRAF; Estrogen receptor positive; Fourth line or greater; HER2 positive; Hormone refractory; Line of therapy N/A; Metastatic; PD-1 Refractory; PD-L1 Refractory; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Esophageal Neoplasms; Fibrosarcoma; Glioblastoma; Intestinal Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Neoplasms; Melanoma; Neoplasms, Unknown Primary; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United Kingdom; United States
Phase I Clinical Trial Assessing the Combination of Chemokine Modulation With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer,I,Completed,Roswell Park Cancer Institute,Oncology: Breast,HER2 negative; Neoadjuvant; Stage 0; Stage I; Stage II; Stage III; Triple receptor negative,Breast Carcinoma In Situ; Breast Neoplasms; Carcinoma; Triple Negative Breast Neoplasms,United States
"An Open-label, Phase I, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics and Tumor Response Profile of the Aryl Hydrocarbon Receptor Inhibitor (AhRi) BAY 2416964 in Participants With Advanced Solid Tumors",I,Open,"MD Anderson Cancer Center, University of Texas
Royal Marsden NHS Trust
Bayer AG
Prisma Health","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",Fourth line or greater; MSS/pMMR; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Neoplasms; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Canada; China; Germany; Spain; United Kingdom; United States
"A First-in-human, Two-part Clinical Study to Assess the Safety, Tolerability and Activity of IV Doses of ICT01 as Monotherapy and in Combination With a Checkpoint Inhibitor, in Patients With Advanced-stage, Relapsed/Refractory Cancer.

EValuation of ICT01 in Immuno-ONcology (EVICTION).",I/II,Open,ImCheck Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Hematological Cancer; Oncology: Unspecified Solid Tumor",Aggressive; Diffuse large B-cell lymphoma (DLBCL); Follicular lymphoma (FL); Indolent; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV,"Acute Myelocytic Leukemia; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",Belgium; France; Germany; Spain; United Kingdom; United States
"A Phase I, Open-label, Dose Finding Study to Assess the Safety, Tolerability, PK, and Preliminary Efficacy of OBT076, a CD205-directed ADC, in Recurrent and/or Metastatic CD205+ Solid Tumors and CD205+ HER2-negative Metastatic Breast Cancer",I,Open,Oxford BioTherapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Renal; Oncology: Thymus; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Estrogen receptor positive; HER2 negative; Locally advanced; Metastatic; PD-L1 Positive; Progesterone receptor positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Kidney Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Thymus Neoplasms; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Belgium; France; Greece; United States
"A Phase I/II First-in-Human, Open-label, Dose Escalation Study of GB1275 Monotherapy and in Combination With an Anti-PD-1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma, Followed by Basket Expansion of GB1275 With Standard of Care or in Combination With an Anti-PD-1 Antibody in Patients With Specified Metastatic Solid Tumors",I/II,Terminated,"Merck & Co./Merck Sharp & Dohme (MSD)
Gossamer Bio","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal",First line; Fourth line or greater; HER2 negative; Hormone refractory; MSS/pMMR; PD-1 Refractory; PD-L1 Positive; PD-L1 Refractory; Pulmonary; Stage III; Stage IV; Triple receptor negative; Untreated,"Adenocarcinoma; Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United Kingdom; United States
A Phase I/Ib Study of Enhancement of Immune Reconstitution and Vaccine Responses With Administration of Recombinant Human IL-7-hyFc (NT-I7) in Older Subjects Following Chemotherapy,I,Closed,"National Institutes of Health/National Cancer Institute
Genexine/NeoImmuneTech",Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Prostate,Adjuvant; Estrogen receptor positive; HER2 positive; Maintenance/Consolidation; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms; Carcinoma; Colorectal Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms,United States
"A Phase 1b Study of M6620 in Combination with Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer.",I,Closed,National Institutes of Health/National Cancer Institute,Oncology: Breast,HER2 negative; Line of therapy N/A; Stage 0; Stage I; Stage II; Triple receptor negative,Breast Neoplasms; Carcinoma,United States
"A Phase 1-2 Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Dose-Expansion in Patients With Non-Small Cell Lung Cancer Harboring c-MET Dysregulation",I/II,Open,Abion,"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Locally advanced; MET Amplification/Alteration; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms, Unknown Primary; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",Australia; South Korea; United States
"A Phase I, First-in-human Study of the Safety, Single- and Multiple-Dose Pharmacokinetics, and Preliminary Activity of Escalating Doses of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors",I,Open,Ribon Therapeutics,"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",(N/A); Aggressive; Estrogen receptor positive; HER2 negative; Mantle cell lymphoma (MCL); PD-1 Refractory; PD-L1 Refractory; Progesterone receptor positive; Pulmonary; Second line; Squamous Cell; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Small Cell Lung Carcinoma",Spain; United States
A Compassionate Use Study of Leronlimab (PRO 140) in Combination With Treatment of Physician's Choice in Patients With CCR5+ Metastatic Triple Negative Breast Cancer (mTNBC),I/II,Completed,CytoDyn,Oncology: Breast,HER2 negative; PD-1 Refractory; PD-L1 Refractory; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,United States
A Phase I Study of StemVacs-V in Patients with Metastatic Breast Cancer,I,Planned,Therapeutic Solutions International,Oncology: Breast,Line of therapy N/A; Stage IV,Breast Neoplasms,United States
"A Phase I Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Ovarian and Cervical Carcinoma, Sarcomas, and Neuroendocrine Tumors Including Small Cell Lung Cancer and Merkel Cell Carcinoma",I,Open,Fujifilm Corporation/Fujifilm Pharmaceuticals U.S.A.,"Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Merkel; Metastatic; Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Small Cell; Endometrial Neoplasms; Ewing Sarcoma; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Uterine Cervical Neoplasms",United States
A Phase I Study of SGN-CD228A in Select Advanced Solid Tumors,I,Terminated,Seagen {Seattle Genetics},"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",Estrogen receptor positive; Fourth line or greater; HER2 negative; PD-1 Refractory; PD-L1 Refractory; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Unresectable,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms",France; Italy; Spain; United Kingdom; United States
Pre-Surgical Window Pilot Investigation of the Effect of PARP Inhibition on the Cellular and Molecular Changes in Primary Ovarian and Breast Cancer,I,Completed,University of Texas Southwest Medical Center,Oncology: Breast; Oncology: Ovarian,(N/A); BRCA; First line; HER2 negative; Triple receptor negative,Breast Neoplasms; Ovarian Cancer; Ovarian Neoplasms,United States
Phase I/II Study to Evaluate Antibody-Drug Conjugate Sacituzumab Govitecan in Combination With PARP Inhibitor Talazoparib in Patients With Metastatic Breast Cancer,I/II,Open,"Pfizer
Massachusetts General Hospital",Oncology: Breast,Fourth line or greater; HER2 negative; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
A Phase Ib/II Study of Onvansertib in Combination With Paclitaxel in Triple-negative Metastatic Breast Cancer Patients,I/II,Open,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Cardiff Oncology {Trovagene}",Oncology: Breast,First line; HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"A Phase I, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 in Adult Patients With Advanced Solid Tumors",I,Open,Beijing Jacobio Pharmaceuticals Co.,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Pancreas",BRAF; BRCA; First line; KRAS; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Ductal; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck",United States
"A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33- hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination with Pembrolizumab in Adult Patients with Metastatic or Advanced Solid Tumours (MAST)",I,Open,Imugene {Biolife Science},"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal; Oncology: Unspecified Solid Tumor",HER2 negative; PD-1 Refractory; PD-L1 Refractory; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Australia; United States
"A Phase I Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients With Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma",I,Terminated,Gilead Sciences/Kite Pharma {Tmunity Therapeutics},"Oncology: Breast; Oncology: Fallopian Tube; Oncology: Lung, Non-Small Cell; Oncology: Multiple Myeloma; Oncology: Ovarian; Oncology: Pancreas",Fourth line or greater; HER2 negative; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Multiple Myeloma; Neoplasms, Plasma Cell; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Triple Negative Breast Neoplasms",United States
A Multicenter Open-label Phase I/Ib Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced/Metastatic Solid Tumors,I,Open,Sotio,"Oncology: Anal; Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Renal; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Thymus; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Fourth line or greater; HER2 negative; Merkel; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Anus Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Melanoma; Mesothelioma; Mesothelioma, Malignant; Microsatellite Instability; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Thymus Neoplasms; Thyroid Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Czech Republic; France; Spain; United States
Phase I/IIA Safety and Efficacy Study of IMSA101 in Patients With Advanced Treatment-Refractory Malignancies,I/II,Open,ImmuneSensor Therapeutics,"Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal",HER2 negative; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",United States
"An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors.",I/II,Open,Sanofi/Synthorx,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Large Cell; PD-1 Naive; PD-1 Refractory; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Australia; Austria; Singapore; Spain; United Kingdom; United States
"A Phase I, Open Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Initial Therapeutic Activity of AVA6000, a Novel FAP-activated Doxorubicin Prodrug Administered Intravenously in Patients With Locally Advanced or Metastatic Selected Solid Tumours",I,Open,Avacta,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Metastatic; Second line; Stage III; Stage IV; Unresectable,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United Kingdom; United States
Open-Label Phase I Study of PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers,I,Closed,NantWorks/ImmunityBio {NantKwest {Conkwest {ZelleRX}}},"Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Glioblastoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Unknown Primary; Osteosarcoma; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Phase I/II, Open-Label, Dose-Escalation Study of CRX100 in Patients With Advanced Solid Tumors",I/II,Open,BioEclipse Therapeutics,Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Unspecified Solid Tumor,(N/A); HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Ewing Sarcoma; Liver Cancer; Liver Neoplasms; Neoplasms, Unknown Primary; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms",United States
"A Multi-Center, Open Label Phase I/II Study of CYT-0851, an Oral RAD51 Inhibitor, in Patients with Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors",I/II,Closed,Cyteir Therapeutics,"Oncology: Breast; Oncology: Head/Neck; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",Aggressive; Diffuse large B-cell lymphoma (DLBCL); Estrogen receptor positive; Follicular lymphoma (FL); HER2 negative; HER2 positive; Indolent; Mantle cell lymphoma (MCL); Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Small Cell; Chronic Lymphocytic Leukemia; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Leukemia, Lymphocytic, Chronic, B-Cell; Liposarcoma; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Squamous Cell Carcinoma of Head and Neck; Synovial Sarcoma; Triple Negative Breast Neoplasms",United States
"A Phase 0, Investigator Initiated Study to Determine the Bioavailability of Sacituzumab Govitecan in Breast Brain Metastasis and Glioblastoma",I,Completed,"Gilead Sciences/Immunomedics
University of Texas Health Science Center at San Antonio","Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Metastatic Cancer",(N/A); Adjuvant; CNS mets; Neoadjuvant; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Glioblastoma; Neoplasm Metastasis,United States
"A Phase I/Ib Safety, Tolerability, Pharmacokinetics and Efficacy Study of PMD-026 In Women with Advanced Breast Cancer and a Sub-Group of Women with Triple Negative Breast Cancer",I,Closed,Phoenix Molecular Designs,Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Phase IB Pilot Study of Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer,I,Terminated,"Washington University School of Medicine
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 positive; Maintenance/Consolidation; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"A ""Window Trial"" on Curcumin, the Active Compound in Turmeric, for Invasive Breast Cancer Primary Tumors",I,Closed,Medical University of South Carolina,Oncology: Breast,Line of therapy N/A; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Phase Ia/Ib, Open-label First-in-human Study of the Safety, Tolerability and Feasibility of Gene-edited Autologous NeoTCR-T Cells (NeoTCR-P1) Administered as a Single Agent or in Combination With Anti-PD-1 to Patients With Locally Advanced or Metastatic Solid Tumors",I,Completed,PACT Pharma,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal",Estrogen receptor positive; MSS/pMMR; Progesterone receptor positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
TALAVE: A Pilot Trial of Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer,I/II,Closed,"Pfizer
Georgetown University Medical Center",Oncology: Breast,Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms,United States
A Pilot and Feasibility Neoadjuvant Study of a 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer,I,Temporarily Closed,Vanderbilt-Ingram Cancer Center,Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Concurrent Capecitabine and Radiotherapy in the Adjuvant Treatment of Resistant Breast Cancer: A Prospective Feasibility Trial,I,Closed,Vanderbilt-Ingram Cancer Center,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
"Clinical Trial to Evaluate Safety and Anti-tumor Activity of AKT Inhibitor, Ipatasertib, With Endocrine Therapy With/Without CDK 4/6 Inhibitor for Patients With Metastatic Hormone Receptor Positive Breast Cancer (TAKTIC)",I,Closed,"Massachusetts General Hospital
Roche/Genentech",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
A Phase I Study of BMS-986301 Monotherapy and Combination Therapy With Nivolumab and Ipilimumab in Participants With Advanced Solid Cancers,I,Closed,Bristol-Myers Squibb,"Oncology: Bladder; Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal",HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Renal Cancer; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Canada; United States
A Phase I Study of SGN-CD47M in Patients With Advanced Solid Tumors,I,Terminated,Seagen {Seattle Genetics},"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma",United States
A Phase Ib Study of Aurora A Kinase Inhibitor LY3295668 Erbumine in Monotherapy and Combination Therapy in Patients With Metastatic Breast Cancer Post CDK4/6 Inhibitor and Endocrine Therapy,I,Completed,Eli Lilly,Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,Belgium; France; Italy; Spain; United States
"A Phase I, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of CPI-200 Via Intravenous Infusion in Patients With Advanced Solid Tumors",I,Completed,Coordination Pharmaceuticals,Oncology: Breast; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Neoplasms, Unknown Primary; Unspecified",United States
A Pilot Trial of Hyperthermia in Combination With Olaparib in Breast Cancer Patients With Chest Wall Recurrences,I,Closed,"AstraZeneca
Kimmel Cancer Center-Thomas Jefferson University - Philadelphia, PA",Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms; Hyperthermia; Neoplasms; Recurrence,United States
Phase I Study of FCN-437c in Patients with Advanced Solid Tumors,I,Completed,Shanghai Fosun Pharmaceutical (Group) Co./Fochon Pharmaceuticals,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",ALK; EGFR; Estrogen receptor positive; HER2 negative; HER2 positive; KRAS; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms; Neoplasms, Unknown Primary",United States
"A Phase I/II, Open Label, Dose-Escalation and Expansion Study of Oral ORIN1001 With and Without Chemotherapy in the Treatment of Subjects With Solid Tumors.",I/II,Closed,Shanghai Fosun Pharmaceutical (Group) Co./Fosun Orinove (Suzhou) PharmaTech,"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor",Estrogen receptor positive; Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Mesothelioma; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Wilms Tumor",United States
"A First-in-Human, Phase I/II Study of NBE-002, an Anti-ROR1 Antibody Drug Conjugate, in Patients With Advanced Solid Tumors",I/II,Closed,"Boehringer Ingelheim
Boehringer Ingelheim/NBE-Therapeutics","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Aggressive; Fourth line or greater; HER2 negative; Indolent; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Ewing Sarcoma; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms, Unknown Primary; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Triple Negative Breast Neoplasms",United States
A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients (UNITY),I,Completed,"Massachusetts General Hospital
GlaxoSmithKline/Tesaro",Oncology: Breast,Adjuvant; HER2 negative; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Prevention of Paclitaxel-Associated Neuropathy With Fingolimod: a Pilot Trial,I,Completed,"National Institutes of Health/National Cancer Institute
Mayo Clinic",Oncology: Breast; Oncology: Supportive Care,(N/A); Adjuvant; Neoadjuvant; Neurotoxicity,Breast Neoplasms; Palliative Care,United States
"A Randomized Phase I/II Trial of Fulvestrant and Abemaciclib in Combination With Copanlisib (FAC) Versus Fulvestrant and Abemaciclib Alone (FA) for Endocrine-Resistant, Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer (FAC vs FA)",I/II,Terminated,National Institutes of Health/National Cancer Institute,Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms; Carcinoma,United States
"A First-in-human, Open-label Dose Escalation Followed by Dose Expansion Phase I/IIa Trial to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of Intratumoral CyPep-1 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Cancers.",I/II,Open,"Merck & Co.
Cytovation",Oncology: Breast; Oncology: Head/Neck; Oncology: Melanoma,HER2 negative; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Head and Neck Neoplasms; Melanoma; Neoplasms,France; Germany; Netherlands; Spain; United Kingdom; United States
"A Phase 1 Study of LY3434172, a Bispecific Antibody Monotherapy in Advanced Solid Tumors",I,Completed,Eli Lilly,"Oncology: Anal; Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Advanced; Locally advanced; Merkel; Metastatic; PD-1 Refractory; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV,"Anus Neoplasms; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Australia; Belgium; France; South Korea; United States
A Phase I Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma,I/II,Closed,"AbbVie
I-Mab Biopharma Co. {Tasgen (Genexine, Shanghai Tasly Pharmaceutical Co., and C-Bridge Capital joint venture)}","Oncology: Bladder; Oncology: Breast; Oncology: Fallopian Tube; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Unspecified Solid Tumor",Aggressive; Classical; Cutaneous T-cell lymphoma (CTCL); Diffuse large B-cell lymphoma (DLBCL); Estrogen receptor positive; Extranodal marginal zone B-cell lymphoma (MALT); Follicular lymphoma (FL); Fourth line or greater; HER2 negative; HER2 positive; Indolent; Nodular lymphocyte-predominant; Other subtype; PD-1 Naive; PD-L1 Naive; Peripheral T-cell lymphoma (PTCL); Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative; Waldenstrom's macroglobulinemia (WM),"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Waldenstrom Macroglobulinemia",China; United States
A Phase I Study of OKI-179 as a Single Agent in Patients With Advanced Solid Tumors,I,Completed,"University of Colorado
OnKure","Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms",United States
An Open-label Phase Ib Study of ORIC-101 in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors,I,Terminated,Oric Pharmaceuticals,"Oncology: Breast; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Testicular; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Estrogen receptor positive; Fourth line or greater; HER2 negative; Large Cell; Progesterone receptor positive; Pulmonary; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Testicular Cancer; Testicular Neoplasms; Unspecified",United States
"Adoptive Immunotherapy for Advanced MUC1* Positive Breast Cancer With Autologous T Cells Engineered to Express a Chimeric Antigen Receptor, huMNC2-CAR44 Specific for a Cleaved Form of MUC1 (MUC1*)",I/II,Open,"Fred Hutchinson Cancer Research Center
City of Hope Comprehensive Cancer Center
Minerva Biotechnologies",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Progesterone receptor positive; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
"A Phase 1 Open-label, Multicenter Dose Escalation and Expansion Study of MT-5111 in Subjects With Previously Treated Advanced HER2-positive Solid Tumors",I/II,Terminated,Molecular Templates,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Thyroid",(N/A); Adenocarcinoma; Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gallbladder Neoplasms; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Medulloblastoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Australia; New Zealand; United States
"First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors",I/II,Open,"Genmab
BioNTech","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",Fourth line or greater; HER2 negative; PD-L1 Positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Belgium; Czech Republic; Germany; Hungary; Israel; Italy; Japan; Poland; Spain; United States
"A Phase Ib, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-0482 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors.",I,Closed,Merck & Co./Merck Sharp & Dohme (MSD),"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Adenocarcinoma; First line; HER2 negative; Large Cell; Locally advanced; Maintenance/Consolidation; Metastatic; PD-1 Naive; PD-L1 Naive; PD-L1 Positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Fibrosarcoma; Glioblastoma; Leiomyosarcoma; Liposarcoma; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified",Australia; Canada; Chile; Israel; Italy; South Korea; Spain; United States
"A Phase I, Multicenter, Open-Label Preoperative, Short-Term Window Study of GDC-9545 in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer",I,Completed,Roche/Genentech,Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,Australia; Belgium; France; Germany; Spain; United Kingdom; United States
"A Phase Ib, Single and Multiple Dose, Open-Label Trial of Intravenous GMI-1359 in HR+ Metastatic Breast Cancer Subjects",I,Terminated,"Duke Comprehensive Cancer Center
GlycoMimetics",Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; Estrogen receptor positive; Line of therapy N/A; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms; Neoplasm Metastasis,United States
Window of Opportunity Trial to Evaluate Change in PD-L1 Expression in Triple Negative Breast Tumors in Response to the PARP Inhibitor Rucaparib,I,Closed,University of Arizona,Oncology: Breast,First line; HER2 negative; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
"Phase II Trial With Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers.",I/II,Closed,"Pfizer
University of Wisconsin",Oncology: Breast,BRCA; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase I/IIa, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD7648 Monotherapy or in Combination With Either Cytotoxic Chemotherapies or Novel Anti-Cancer Agents in Patients With Advanced Malignancies",I/II,Terminated,AstraZeneca,Oncology: Breast; Oncology: Ovarian; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms","France; Germany; South Korea; Spain; Taiwan, China; United Kingdom; United States"
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation,I/II,Open,Eli Lilly/Loxo Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Renal; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",(N/A); Fourth line or greater; Medullary; Papillary; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Thyroid Cancer, Papillary; Thyroid Diseases; Thyroid Neoplasms; Wilms Tumor","Australia; France; Germany; Hong Kong, S.A.R., China; Israel; Italy; Japan; Netherlands; New Zealand; Poland; Singapore; South Korea; Spain; Switzerland; United States"
"A Phase I Study of SY 5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients With Select Advanced Solid Tumors",I,Closed,Syros Pharmaceuticals,"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Pulmonary; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Small Cell Lung Carcinoma",United States
Phase I/II Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors.,I/II,Completed,Salarius Pharmaceuticals,Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A Phase I, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects With Locally Advanced or Metastatic Solid Tumors",I,Closed,AbbVie,"Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",HER2 negative; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Triple Negative Breast Neoplasms","Australia; France; Israel; Spain; Taiwan, China; United States"
"A Phase I/Ib, Open-label, Multi-center, Study of DKY709 as a Single Agent and in Combination With PDR001 in Patients With Advanced Solid Tumors",I,Closed,Novartis,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Unspecified Solid Tumor",HER2 negative; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Melanoma; Nasopharyngeal Carcinoma; Neoplasms, Unknown Primary; Triple Negative Breast Neoplasms","Germany; Hong Kong, S.A.R., China; Japan; Spain; Taiwan, China; United States"
"An Open-label Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MEDI5395 in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors",I,Terminated,AstraZeneca {MedImmune},"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal; Oncology: Unspecified Solid Tumor",Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Renal Cancer; Wilms Tumor",Spain; United Kingdom; United States
"A Phase I, Open-Label Study of ABSK021 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Solid Tumor",I,Open,Abbisko Therapeutics Co.,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Tenosynovial Giant Cell Tumor; Oncology: Thymus; Oncology: Unspecified Solid Tumor",Diffuse; Extensive; HER2 negative; Localized; Pulmonary; Second line; Stage III; Stage IV; Thymoma; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Fibrosarcoma; Giant Cell Tumor of Tendon Sheath; Leiomyosarcoma; Liposarcoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Synovial Sarcoma; Synovitis, Pigmented Villonodular; Thymoma; Thymus Neoplasms; Unspecified",Australia; China; United States
"A Dose-optimization, Exploratory Phase Ib/II Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143, When Given in Combination With the Anti-PD-1 Antibody Nivolumab in Patients With Specific Solid Tumors Who Have Progressed During or Immediately After Anti-PD-1/PD-L1 Treatment",I/II,Completed,"Merck KGaA
Debiopharm","Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal",BRCA; Extensive; Limited; MSI-H/dMMR; PD-1 Refractory; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Uterine Cervical Neoplasms",France; Spain; United States
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial,I,Closed,"(Other Cooperative Group)
National Institutes of Health/National Cancer Institute
OHSU Cancer Institute
Oregon Health and Science University","Oncology: Breast; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome; Oncology: Myeloproliferative Neoplasms; Oncology: Pancreas; Oncology: Prostate",(N/A); Aggressive; Classical; First line; HER2 negative; HER2 positive; Indolent; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV; Triple receptor negative,"Acute Myelocytic Leukemia; Adenocarcinoma; Blast Crisis; Breast Neoplasms; Carcinoma; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Hematologic Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Acute; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Leukemia, Myeloid, Chronic-Phase; Leukemia, Myelomonocytic, Chronic; Leukemia, Myelomonocytic, Juvenile; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Multiple Myeloma; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Myeloproliferative Disorders; Neoplasms; Neoplasms, Plasma Cell; Pancreatic Cancer; Pancreatic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Preleukemia; Primary Myelofibrosis; Prostatic Neoplasms; Syndrome; Thrombocytosis",United States
"A Phase I/II Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors

The ABILITY (A Beta-only IL-2 ImmunoTherapY) study",I/II,Open,Medicenna Therapeutics,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",(N/A); Adenocarcinoma; Fourth line or greater; HER2 negative; Large Cell; Line of therapy N/A; Merkel; Metastatic; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative; Unresectable,"Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Cholangiocarcinoma; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Fibrosarcoma; Gallbladder Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Neoplasms; Lung Neoplasms; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Basal Cell; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms; Wilms Tumor",Australia; Canada; United Kingdom; United States
"A Phase Ib/II Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor CB-839 in Combination With the PARP Inhibitor Talazoparib in Patients With Advanced or Metastatic Solid Tumors",I/II,Terminated,"Pfizer
Calithera Biosciences",Oncology: Breast; Oncology: Colorectal; Oncology: Renal; Oncology: Unspecified Solid Tumor,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Neoplasms, Unknown Primary; Renal Cancer; Triple Negative Breast Neoplasms; Wilms Tumor",United States
Phase I Study Proxalutamide in Triple Negative Breast Cancer Patients in United States,I,Terminated,Kintor Pharmaceutical,Oncology: Breast,(N/A); HER2 negative; Line of therapy N/A; Triple receptor negative,Breast Neoplasms,United States
"A PhaseI/IB, Open-Label, Dose Escalation and Expansion Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced Solid Tumors Expressing HER2",I,Closed,Silverback Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gallbladder; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Renal; Oncology: Unspecified Cancer; Oncology: Unspecified Solid Tumor",Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Australia; South Korea; United States
"Open Label, Multicenter, Phase I Study to Evaluate the Maximum Tolerated Dose of Orally Administered CB-03-10 With Dose Expansion Phase, in Subjects With Advanced Solid Tumors",I,Open,Cosmo Pharmaceuticals,Oncology: Breast; Oncology: Colorectal; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor,HER2 negative; Hormone refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Colorectal Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms",United States
"A Phase I/II, Open-Label, Dose-Escalation Study of ISB 1302 in Subjects With HER2-Positive Metastatic Breast Cancer",I/II,Terminated,"Glenmark
Ichnos Sciences",Oncology: Breast,Fourth line or greater; HER2 positive; Second line; Stage IV; Third line,Breast Neoplasms,Germany; United States
'ADVANCE' (A Pilot Trial) ADjuVANt Chemotherapy in the Elderly: Developing and Evaluating Lower-Toxicity Chemotherapy Options for Older Patients With Breast Cancer,I,Completed,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Mayo Clinic",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
"A Phase I/IB Study of Ipatasertib in Combination with Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Patients with Metastatic Triple Negative Breast Cancer.",I,Completed,"National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center
Roche/Genentech",Oncology: Breast,First line; HER2 negative; Second line; Stage I; Stage II; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Phase I Trial of Palbociclib and Bosutinib With Fulvestrant in Patients With Metastatic Hormone Receptor Positive and HER2 Negative (HR+ HER2-) Breast Cancer Refractory to an Aromatase Inhibitor and a CDK4/6 Inhibitor(ASPIRE - WI231696),I,Completed,"Pfizer
Georgetown University Medical Center",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"Phase I Study of KN026 in HER2 Expressing Breast Cancer, Astric/Gastroesophageal Junction Cancer and Other Locally Advanced/Metastatic Solid Tumors",I,Closed,Suzhou Alphamab Co./Alphamab Oncology {Jiangsu Alphamab Biopharmaceuticals Co.},Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Unspecified Solid Tumor,HER2 positive; Stage III; Stage IV; Third line,"Breast Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Neoplasms, Unknown Primary; Stomach Carcinoma; Stomach Neoplasms",United States
"Phase IB, Open-Label, Dose Escalation and Cohort Expansions Trial of Naptumomab Estafenatox (NAP, ABR-217620) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced or Metastatic Solid Tumors.",I/II,Closed,"AstraZeneca
NeoTX Therapeutics","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Advanced; Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Israel; United States
Phase Ib Trial of Tucatinib in Combination With Abemaciclib and Trastuzumab for Patients With HER2-Positive Metastatic Breast Cancer,I,Terminated,"Eli Lilly
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute",Oncology: Breast,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
"A Phase I/IIa Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Whole-body Distribution, Radiation Dosimetry and Anti-tumor Activity of [177Lu]-NeoB Administered in Patients With Advanced Solid Tumors Known to Overexpress Gastrin-releasing Peptide Receptor (GRPR)",I/II,Open,Novartis/Advanced Accelerator Applications,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: GIST; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Stromal Tumors; Glioblastoma; Neoplasms, Unknown Primary; Prostatic Neoplasms; Unspecified",Austria; Germany; Netherlands; Spain; United Kingdom; United States
"A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combination With Rucaparib in Patients With Advanced Breast, Ovarian, or Prostate Cancer",I/II,Completed,Roche {F. Hoffmann-La Roche},Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Prostate,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms",Australia; Italy; South Korea; Spain; United States
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors,I,Open,Exelixis,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Renal",Estrogen receptor positive; HER2 negative; HER2 positive; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Progesterone receptor positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Neoplasms; Prostatic Neoplasms; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Australia; Czech Republic; France; Spain; United Kingdom; United States
A Phase I Study Of Oral Endoxifen In Patient With Pre-Menopausal Estrogen-Receptor Positive (ER+) Breast Cancer,I,Completed,Atossa Therapeutics {Atossa Genetics},Oncology: Breast,(N/A); Adjuvant; Estrogen receptor positive; First line,Breast Neoplasms,United States
"A Phase I/II, Open-Label, Multicenter, Non-Randomized, Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) In Subjects With Previously Treated Advanced HER2-Positive Solid Tumors",I/II,Terminated,Bellicum Pharmaceuticals,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Ovarian; Oncology: Unspecified Solid Tumor",HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Colorectal Neoplasms; Endometrial Neoplasms; Glioblastoma; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
Assessing the Immunogenicity of pING-hHER3FL in Patients With Resected Malignancies,I,Open,Duke University Medical Center,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",United States
"A Phase I/Ib Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination With Systemic Anti-Cancer Therapies in Subjects With Advanced Solid Tumors",I,Completed,Tempest Therapeutics,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",First line; Fourth line or greater; HER2 negative; Hormone refractory; MSS/pMMR; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase I First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors",I,Open,AbbVie,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",Fourth line or greater; HER2 negative; MSS/pMMR; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor","Australia; Belgium; Canada; France; Israel; Japan; Puerto Rico; South Korea; Spain; Taiwan, China; United States"
"A Phase I, Open-label, Dose-escalation and Expansion Study of MEDI1191 Administered Intratumorally as Monotherapy and in Combination With Durvalumab in Subjects With Advanced Solid Tumors",I,Terminated,AstraZeneca {MedImmune},"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",(N/A); Fourth line or greater; Line of therapy N/A; PD-1 Refractory; PD-L1 Positive; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Pancreatic Neoplasms; Stomach Neoplasms",France; Netherlands; Spain; United States
Phase I/II Study of RTX-240 Monotherapy and in Combination With Pembrolizumab,I/II,Terminated,Rubius Therapeutics,"Oncology: Anal; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Leukemia, Acute Myelogenous; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Merkel; PD-1 Refractory; PD-L1 Refractory; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Acute Myelocytic Leukemia; Anus Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Colorectal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Leukemia, Myeloid, Acute; Liposarcoma; Melanoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Unspecified; Wilms Tumor",United States
"A Phase I/IIa Open Label, Multicenter Study to Access the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AFM24 in Patients With Advanced Solid Tumors",I/II,Open,Affimed {Affimed Therapeutics AG},"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal",BRAF; EGFR; Fourth line or greater; KRAS; MSS/pMMR; NRAS; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Germany; South Korea; Spain; United Kingdom; United States
A Phase Ia/Ib Dose-escalation Study of Intravenously Administered SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors,I/II,Open,"Roche
Sino Biopharmaceutical/invoX Pharma/F-star Therapeutics {Spring Bank Pharmaceuticals}","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",BRAF; HER2 negative; Merkel; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"An Open-Label, Multicenter, Phase I Study of RP3 as a Single Agent and in Combination With PD-1 Blockade in Patients With Solid Tumors.",I,Open,"Bristol-Myers Squibb
Replimune","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",Liver mets; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",France; Spain; United Kingdom; United States
Phase Ib Study of Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases,I,Completed,"Bristol-Myers Squibb
H. Lee Moffitt Cancer Center and Research Institute",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Second line; Stage IV; Third line; Triple receptor negative,"Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis; Neoplasms, Second Primary",United States
tGLI1 as a Therapeutic Target in Brain Metastases: A Window of Opportunity Study in Breast Cancer Brain Metastases and Primary Gliomas,I,Open,"National Institutes of Health/National Cancer Institute
(Other Hospital/Academic/Medical Center)","Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Other; Oncology: Metastatic Cancer",CNS mets; Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage IV; Triple receptor negative,Astrocytoma; Brain Neoplasms; Breast Neoplasms; Carcinoma; Central Nervous System Neoplasms; Glioblastoma; Glioma; Neoplasm Metastasis; Oligodendroglioma,United States
A Phase IB Trial of Neoadjuvant Multi-Epitope HER2 Peptide Vaccine in Patients With HER2-Expressing DCIS,I/II,Open,"National Institutes of Health/National Cancer Institute
Mayo Clinic",Oncology: Breast,HER2 positive; Neoadjuvant; Stage 0,"Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Unspecified",United States
An Open-Label Multicenter Phase Ib Study of AN0025 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors,I,Open,"Merck & Co./Merck Sharp & Dohme (MSD)
Adlai Nortye Biopharma Co.","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Fourth line or greater; HER2 negative; Large Cell; MSS/pMMR; Other subtype; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Positive; PD-L1 Refractory; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasms, Unknown Primary; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",France; United States
"A Phase I/IIa Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients with Advanced Cancers Associated with Mesothelin Expression who Have Failed Standard Available Therapy",I/II,Completed,Harpoon Therapeutics,"Oncology: Breast; Oncology: Fallopian Tube; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal",Advanced; HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms",United States
"In Situ Vaccination With Flt3L, Radiation, and Poly-ICLC Combined With Pembrolizumab in Patients With Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, and Head and Neck Squamous Cell Carcinoma",I/II,Open,"Icahn School of Medicine at Mount Sinai {Mount Sinai School of Medicine}
Celldex Therapeutics {AVANT Immunotherapeutics {Medarex/Celldex Therapeutics {Alteris Therapeutics}}}
Merck & Co./Merck Sharp & Dohme (MSD)","Oncology: Breast; Oncology: Head/Neck; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lymphoma, Non-Hodgkin's",Aggressive; Cutaneous T-cell lymphoma (CTCL); Extranodal marginal zone B-cell lymphoma (MALT); First line; Follicular lymphoma (FL); Indolent; Mantle cell lymphoma (MCL); Other subtype; Second line; Small lymphocytic lymphoma (SLL); Stage IV; Waldenstrom's macroglobulinemia (WM),"Breast Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Chronic Lymphocytic Leukemia; Head and Neck Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Squamous Cell Carcinoma of Head and Neck; Waldenstrom Macroglobulinemia",United States
A Phase I Dose-Escalation Study of TJ004309 in Combination With Atezolizumab (Tecentriq) in Patients With Advanced or Metastatic Cancer,I,Closed,"Tracon Pharmaceuticals
I-Mab Biopharma Co. {Tasgen (Genexine, Shanghai Tasly Pharmaceutical Co., and C-Bridge Capital joint venture)}","Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Skin, Basal Cell Carcinoma; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",(N/A); First line; Fourth line or greater; Pulmonary; Second line; Stage III; Stage IV; Third line; Untreated,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Basal Cell; Neoplasms, Second Primary; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Uterine Cervical Neoplasms",United States
"A Multicentre, Open-Label Phase I/II Study to Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)",I/II,Terminated,Ipsen,"Oncology: Breast; Oncology: Lung, Small Cell; Oncology: Neuroendocrine",BRCA; Estrogen receptor positive; Extensive; HER2 negative; Limited; Maintenance/Consolidation; Progesterone receptor positive; Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Small Cell; Neoplasm Metastasis; Neuroendocrine Tumors; Small Cell Lung Carcinoma",Austria; Belgium; France; Germany; Switzerland; United Kingdom; United States
A Phase Ia/Ib Study of LY3405105 Administered to Patients with Advanced Solid Tumors,I,Terminated,Eli Lilly,Oncology: Bladder; Oncology: Breast; Oncology: Endometrial; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms","Canada; France; Italy; Spain; Taiwan, China; United Kingdom; United States"
"A Phase I Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors.",I,Completed,Incyte Corporation,"Oncology: Anal; Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gallbladder; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Penile; Oncology: Prostate; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor; Oncology: Vaginal",(N/A); Advanced; Extensive; First line; Fourth line or greater; Hormone refractory; Locally advanced; Merkel; MSI-H/dMMR; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Positive; Pulmonary; Second line; Stage III; Stage IV; Third line,"Anus Neoplasms; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Fibrosarcoma; Gallbladder Neoplasms; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Neoplasms; Pancreatic Neoplasms; Penile Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Vaginal Neoplasms; Wilms Tumor",Belgium; France; Italy; United Kingdom; United States
"A Phase I Cohort Dose-Escalation Trial of AVID200, a Transforming Growth Factor ß (TGFß) Inhibitor, in Patients With Advanced or Metastatic Solid Tumor Malignancies",I,Completed,Bristol-Myers Squibb {Forbius {Formation Biologics}},Oncology: Breast; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms; Neoplasms, Unknown Primary",Canada; United States
"A Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study of ONCR-177, an Oncolytic Herpes Simplex Virus for Intratumoral Injection, Alone and in Combination with PD-1 Blockade in Adult Subjects with Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or with Liver Metastases of Solid Tumors",I,Terminated,"Merck & Co./Merck Sharp & Dohme (MSD)
Oncorus",Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Unspecified Solid Tumor,HER2 negative; Liver mets; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Colorectal Neoplasms; Head and Neck Neoplasms; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Unknown Primary; Skin Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms",Canada; United States
"A Phase I/Ib, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination With Capecitabine, Given Orally on a Daily Schedule in Patients With Advanced Solid Tumors or Lymphoma

Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or Lymphoma (GEN602)",I,Completed,Genzada Pharmaceuticals,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Aggressive; Classical; Cutaneous T-cell lymphoma (CTCL); Indolent; Nodular lymphocyte-predominant; Peripheral T-cell lymphoma (PTCL); Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Liposarcoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma",United States
"A Phase I/IIa, Multicenter, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics of ICP-192 in Patients With Advanced Solid Malignancies",I/II,Open,Beijing InnoCare Pharma Tech Co.,Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Head/Neck; Oncology: Ovarian; Oncology: Unspecified Solid Tumor,FGFR; First line; Second line; Stage III; Stage IV; Unresectable,"Bile Duct Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Head and Neck Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms",China; United States
Phase I/II Study of AP-002 in Patients with Solid Tumors with Bone Metastases or at Risk of Bone Metastases,I/II,Terminated,BetterLife Pharma,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer; Oncology: Prostate",Bone mets; Line of therapy N/A; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Prostatic Neoplasms",United States
A Phase Ib/II Study of Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ Metastatic Triple Negative Breast Cancer (mTNBC),I/II,Closed,CytoDyn,Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; First line; HER2 negative; Liver mets; Other mets; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Positive; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Liver Neoplasms; Neoplasm Metastasis; Triple Negative Breast Neoplasms,United States
"Phase I/II First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumor Malignancies",I/II,Closed,Jounce Therapeutics,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Renal; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Distal; FGFR; First line; Fourth line or greater; HER2 negative; Hilar; Intrahepatic; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Positive; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Cholangiocarcinoma; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified; Wilms Tumor",United States
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase I),I,Completed,Fate Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Renal; Oncology: Unspecified Solid Tumor",Aggressive; Classical; EGFR; Extensive; Fourth line or greater; HER2 positive; Indolent; Merkel; Nodular lymphocyte-predominant; PD-1 Refractory; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Mesothelioma; Microsatellite Instability; Neoplasms; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
A First in Human Phase I Trial of Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR T Cells in Patients With Advanced HER2 Positive Solid Tumors,I,Open,"Baylor College of Medicine
(Other Hospital/Academic/Medical Center)
Tessa Therapeutics {FF CanVac}","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Salivary Gland Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Phase IB/II, 2-stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer",I/II,Open,AstraZeneca,Oncology: Breast,First line; HER2 negative; PD-L1 Positive; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Neoplasms; Triple Negative Breast Neoplasms,"Canada; Poland; South Korea; Taiwan, China; United Kingdom; United States"
Multicenter Phase I/Ib Trial of Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer,I,Open,"AstraZeneca
(Other Hospital/Academic/Medical Center)",Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
"A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Immunotherapy Combinations in Adult Patients With Triple-negative Breast Cancer",I,Terminated,Novartis,Oncology: Breast,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,"Australia; Hong Kong, S.A.R., China; Israel; Italy; Japan; Netherlands; Singapore; Spain; United States"
"A Phase I/II, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGC936 (Anti-ADAM9 Antibody Drug Conjugate) in Patients With Advanced Solid Tumors",I/II,Open,"ImmunoGen
MacroGenics","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",Adenocarcinoma; HER2 negative; Large Cell; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",Italy; Spain; United States
"Phase I/II, Two-Part, Multicenter First-in-Human Study of DS-7300a in Subjects With Advanced Solid Malignant Tumors.",I/II,Open,Daiichi Sankyo,"Oncology: Bladder; Oncology: Breast; Oncology: Endometrial; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",(N/A); Adenocarcinoma; Hormone refractory; Metastatic; Pulmonary; Second line; Squamous Cell; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Osteosarcoma; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",Japan; United States
"A Phase I/II, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid Tumors",I/II,Terminated,MacroGenics,"Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Prostate; Oncology: Unspecified Solid Tumor",Fourth line or greater; HER2 negative; Hormone refractory; PD-L1 Positive; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Head and Neck Neoplasms; Melanoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Prostatic Neoplasms; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms",Australia; Germany; Hungary; Poland; Spain; United Kingdom; United States
A Phase Ib Study of ALRN-6924 in Combination With Paclitaxel in Wild-Type TP53 Advanced or Metastatic Solid Tumors Including Estrogen-Receptor Positive Breast Cancer,I,Terminated,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms; Neoplasms, Unknown Primary",United States
"A Phase I Study With Expansion Cohorts to Assess the Safety, Tolerability, and Activity of Eribulin ORA in Subjects With Solid Tumors",I,Terminated,Athenex {Kinex Pharmaceuticals},Oncology: Breast; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV; Unresectable; Untreated,"Breast Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neoplasms; Neoplasms, Unknown Primary; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
"A Phase I, Multi-center, Open-label, and Dose-finding Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors",I,Open,"Calithera Biosciences
Antengene Corporation Limited","Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Unspecified Hematological Cancer; Oncology: Unspecified Solid Tumor",Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Hematologic Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Unspecified",Australia; China; United States
A Phase I/Ib Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast and Gynecologic Malignancies,I,Completed,"Infinity Pharmaceuticals
Arcus Biosciences",Oncology: Breast; Oncology: Ovarian,First line; Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Triple Negative Breast Neoplasms,Australia; New Zealand; United States
Phase IB Study of Avelumab With Radiotherapy in Patients With Leptomeningeal Disease,I,Completed,"Pfizer
H. Lee Moffitt Cancer Center and Research Institute","Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer; Oncology: Ovarian; Oncology: Pancreas; Oncology: Unspecified Cancer",(N/A); CNS mets; HER2 negative; Line of therapy N/A; Second line; Stage IV; Triple receptor negative,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Head and Neck Neoplasms; Melanoma; Meningeal Neoplasms; Neoplasm Metastasis; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms",United States
"An Open Label, Multicenter, Phase Ib/II Study of Rebastinib (DCC-2036) in Combination With Carboplatin to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid Tumors",I/II,Terminated,Deciphera Pharmaceuticals,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Testicular; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Pancreas; Progesterone receptor positive; Second line; Squamous Cell; Stage III; Stage IV; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Testicular Cancer; Testicular Neoplasms",United States
"A Phase I, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients With Advanced Solid Tumors",I,Completed,Sumitomo Dainippon Pharma/Sumitomo Dainippon Pharma Oncology {Tolero Pharmaceuticals},"Oncology: Breast; Oncology: Colorectal; Oncology: Pancreas; Oncology: Skin, Basal Cell Carcinoma; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Soft Tissue Sarcoma; Oncology: Testicular",Fourth line or greater; Metastatic; Second line; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Colorectal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neoplasms; Neoplasms, Basal Cell; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms",United States
"An Open-Label, Multicenter, First-in-Human, Phase I Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas",I,Open,Inhibrx,Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Mesothelioma; Oncology: Osteosarcoma; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; HER2 positive; Locally advanced; Metastatic; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Adenocarcinoma; Breast Neoplasms; Chondrosarcoma; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Mesothelioma; Mesothelioma, Malignant; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Osteosarcoma; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma",United States
DAPHNe: De-escalation to Adjuvant Antibodies Post-pCR to Neoadjuvant THP (Paclitaxel/Trastuzumab/Pertuzumab)-a Pilot Study in HER2-positive Breast Cancer,I,Completed,"(Other Cooperative Group)
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}
Breast Cancer Research Foundation",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; HER2 positive; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
"A Phase I/IIa Study of Intra-tumoral BT-001 (TG6030) Administered Alone and in Combination With Pembrolizumab in Patients With Cutaneous or, Subcutaneous Lesions or Easily Injectable Lymph Nodes of Metastatic/Advanced Solid Tumors.",I/II,Open,"Transgene
Merck & Co./Merck Sharp & Dohme (MSD)
BioInvent","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Aggressive; HER2 negative; Indolent; Locally advanced; Merkel; Metastatic; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Ewing Sarcoma; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasm Metastasis; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Osteosarcoma; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Triple Negative Breast Neoplasms",Belgium; France; United States
"Phase I/IIa Open-label Clinical Study of BI-1607, an Fc-Engineered Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors",I/II,Open,BioInvent,Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Unspecified Solid Tumor,HER2 positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Neoplasms, Unknown Primary; Stomach Carcinoma; Stomach Neoplasms",Germany; Spain; United Kingdom; United States
A Phase I/II Trial of Leflunomide in Women With Previously Treated Metastatic Triple Negative Cancers,I/II,Open,Icahn School of Medicine at Mount Sinai {Mount Sinai School of Medicine},Oncology: Breast,HER2 negative; Second line; Stage IV; Triple receptor negative,Breast Diseases; Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"An Open Label, Multicenter, Dose Escalation and Expansion, Phase I Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Patients With Advanced and/or Metastatic Solid Tumors",I,Closed,Roche {F. Hoffmann-La Roche},"Oncology: Breast; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Unspecified Solid Tumor",(N/A); First line; PD-L1 High; PD-L1 Positive; Pulmonary; Second line; Stage III; Stage IV; Third line; Untreated,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Esophageal Cancer; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Melanoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Small Cell Lung Carcinoma",Denmark; France; New Zealand; South Korea; Spain; United States
"A Phase I/II Study of Palbociclib, Letrozole and T-DM1 in Trastuzumab Refractory Estrogen Receptor Positive (ER+) and HER2 Positive Metastatic Breast Cancer",I/II,Completed,"Pfizer
University of Kansas",Oncology: Breast,Estrogen receptor positive; HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
"A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-601 in Patients With Advanced Solid Tumors",I,Terminated,ADC Therapeutics {Auven Therapeutics/ADC Therapeutics},"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",Adenocarcinoma; Fourth line or greater; HER2 negative; Large Cell; Second line; Squamous Cell; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma",United States
A Phase I Cellular Immunotherapy Study of Intraventricularly Administered Autologous HER2-Targeted Chimeric Antigen Receptor (HER2-CAR) T Cells in Patients With Brain and/or Leptomeningeal Metastases From HER2 Positive Cancers,I,Open,"National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center
California Institute for Regenerative Medicine (CIRM)",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; HER2 positive; Line of therapy N/A; Stage IV,"Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis; Neoplasms; Neoplasms, Second Primary",United States
Phase I/II Safety and Efficacy Study of Autophagy Inhibition With Hydroxychloroquine to Augment the Antiproliferative and Biological Effects of Pre-Operative Palbociclib Plus Letrozole for Estrogen Receptor-Positive and HER2-Negative Breast Cancer,I/II,Closed,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase I Dose Escalation and Expansion Study Evaluating Safety, Tolerability And Pharmacokinetics Of PF-06952229 In Adult Patients With Advanced Solid Tumors",I,Terminated,Pfizer,Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; HER2 positive; Hormone refractory; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Neoplasms, Squamous Cell; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Wilms Tumor",United States
"Harnessing Olaparib, Palbociclib and Endocrine Therapy: A Phase I/II Trial of Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer (HOPE).",I/II,Open,Abramson Cancer Center at  University of Pennsylvania Medical Center,Oncology: Breast,BRCA; Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
Immunotherapy for Peritoneal Carcinomatosis (IPC) - A Phase I Study of the Safety and Efficacy of Anti-CEA CAR-T Cell Intraperitoneal Infusions for Treatment of CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites,I,Terminated,Sorrento Therapeutics/Scilex Pharmaceuticals {Scilex Holding {SCILEX Pharmaceuticals}},Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Metastatic Cancer; Oncology: Pancreas,Peritoneal mets; Second line; Stage IV,Adenocarcinoma; Ascites; Breast Neoplasms; Carcinoma; Colorectal Neoplasms; Neoplasm Metastasis; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Stomach Carcinoma; Stomach Neoplasms,United States
"A Phase I/II, Open-Label Study to Investigate the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of GSK3145095 Administered Alone and in Combination With Anticancer Agents Including Pembrolizumab in Adult Participants With Selected Advanced Solid Tumors",I/II,Terminated,GlaxoSmithKline,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas",HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Pancreatic Cancer; Pancreatic Neoplasms",United States
"A Phase Ib, Multicenter, Two-Part, Open-Label Study of Trastuzumab Deruxtecan (DS-8201a), An Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), In Combination With Pembrolizumab, An Anti-PD-1 Antibody, For Subjects With Locally Advanced/Metastatic Breast Or Non-Small Cell Lung Cancer (NSCLC).",I,Open,"AstraZeneca
Merck & Co./Merck Sharp & Dohme (MSD)
Daiichi Sankyo","Oncology: Breast; Oncology: Lung, Non-Small Cell",ALK; BRAF; EGFR; Estrogen receptor positive; First line; HER2 positive; PD-1 Naive; PD-L1 Naive; Progesterone receptor positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms",France; Spain; United Kingdom; United States
A Phase I Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer,I,Completed,"National Institutes of Health/National Cancer Institute
Bavarian Nordic","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal",ALK; BRAF; EGFR; Estrogen receptor positive; HER2 negative; HER2 positive; Hormone refractory; Metastatic; PD-1 Refractory; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasm Metastasis; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase I Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of Escalating Doses Of and Treatment Intensification A Vaccine-based Immunotherapy Regimen-2 (VBIRr-2) (PF-06936308) For Advanced Non-small Cell Lung Cancer And Metastatic Triple-negative Breast Cancer",I,Terminated,Pfizer,"Oncology: Breast; Oncology: Lung, Non-Small Cell",HER2 negative; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Triple Negative Breast Neoplasms",United States
"A Phase I/II, Open Label, Dose Escalation, and Cohort Expansion Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-471 Alone and in Combination with Palbociclib (IBRANCE) in Patients with Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer, who Have Received Prior Hormonal Therapy and Chemotherapy in the Locally Advanced/Metastatic Setting",I/II,Open,"Pfizer
Arvinas",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
Phase Ia First-in-Human Study of Safety and Tolerability of ASV AGEN2017 With QS-21 Stimulon Adjuvant as a Single Agent in Subjects With Solid Tumor at Risk of Relapse Undergoing Observation as SOC Following Complete Surgical Resection,I,Completed,Agenus {Antigenics},"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal; Oncology: Soft Tissue Sarcoma",(N/A); Adjuvant; Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer",I,Completed,Roche {F. Hoffmann-La Roche},Oncology: Breast,First line; HER2 negative; Neoadjuvant; PD-L1 Positive; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Australia; France; Spain; United Kingdom; United States
"A Phase I/II, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors",I/II,Completed,NextCure,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian",Fourth line or greater; HER2 negative; PD-L1 Positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck",United States
A Phase I Study of Anti-CD3 x Anti-Her2/Neu (Her2Bi) Armed Activated T Cells (ATC) in Patients With Breast Cancer Leptomeningeal Metastases,I,Terminated,University of Virginia,Oncology: Breast; Oncology: Metastatic Cancer,(N/A); CNS mets; Estrogen receptor positive; HER2 negative; HER2 positive; Line of therapy N/A; Progesterone receptor positive,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Meningeal Carcinomatosis; Neoplasm Metastasis,United States
Phase I/II Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Participants With Advanced Solid Tumors,I/II,Completed,Bristol-Myers Squibb,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",First line; HER2 negative; MSI-H/dMMR; Second line; Squamous Cell; Stage II; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Belgium; Canada; Israel; Italy; United States
"A Phase I, First-In-Human, Multicenter, Open-Label Study of TT-00420, Administered Orally in Adult Patients With Advanced Solid Tumors and Triple Negative Breast Cancers",I,Completed,"Nanjing Pharmaceutical Factory Co.
TransThera Biosciences Co.","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Testicular; Oncology: Unspecified Solid Tumor",Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage II; Stage III; Stage IV; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Neoplasms, Unknown Primary; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",China; United States
A Phase I/IIa Study of SI-001 in Patients with Advanced Solid Tumor,I/II,Completed,Calidi Biotherapeutics,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Leukemia, Acute Myelogenous; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",First line; Stage III; Stage IV,"Acute Myelocytic Leukemia; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Leukemia, Myeloid, Acute; Liver Cancer; Liver Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Thyroid Neoplasms",United States
A Phase Ib/II Study of Olaparib With Sapacitabine in BRCA Mutant Breast Cancer,I/II,Terminated,"AstraZeneca
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Cyclacel",Oncology: Breast,BRCA; Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms,United States
"A Phase Ib Clinical Trial Evaluating DCVax-Direct, Autologous Activated Dendritic Cells for Intratumoral Injection, in Patients With Unresectable Brain Metastases From Breast- or Non-Small Cell Lung Cancer",I,Planned,"Northwest Biotherapeutics
Mayo Clinic","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer",CNS mets; Estrogen receptor positive; First line; HER2 negative; HER2 positive; Progesterone receptor positive; Stage IV; Triple receptor negative,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Neoplasms; Neoplasms, Second Primary",United States
Phase I Study of Autologous T Lymphocytes Expressing GD2-specific Chimeric Antigen and Constitutively Active IL-7 Receptors for the Treatment of Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Solid Cancers(GAIL-N),I,Open,"Baylor College of Medicine
(Other Hospital/Academic/Medical Center)",Oncology: Breast; Oncology: Melanoma; Oncology: Neuroblastoma; Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,Fourth line or greater; HER2 positive; Pediatric or Adolescent; Second line; Stage IV; Third line,"Breast Neoplasms; Ewing Sarcoma; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms, Unknown Primary; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
"A Phase Ib, Open-Label, Dose Escalation Study of PRS-343 in Combination With Atezolizumab in Patients With HER2-Positive Advanced or Metastatic Solid Tumors",I,Closed,Pieris Pharmaceuticals {Pieris AG},"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas",Fourth line or greater; HER2 positive; PD-L1 Positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Liver Cancer; Liver Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",United States
RANKL Inhibition and Breast Tissue Biomarkers in Premenopausal Women With Dense Breasts,I,Completed,Washington University School of Medicine,Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
A Phase I Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies,I,Completed,Arcus Biosciences,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor",First line; Fourth line or greater; Hormone refractory; Merkel; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Australia; United States
"A Phase Ib, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (ADCT-301) as Monotherapy or in Combination in Patients With Selected Advanced Solid Tumors.",I,Terminated,ADC Therapeutics {Auven Therapeutics/ADC Therapeutics},"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal",Fourth line or greater; HER2 negative; MSI-H/dMMR; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Belgium; United Kingdom; United States
A Pilot Single Arm Open Label Trial Evaluating M7824 (Anti-PD-L1/TGF-Beta TRAP) in a Window Setting in Patients With Stage II-III HER2/Neu Positive (HER2+) Breast Cancer (BC),I,Closed,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast,HER2 positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
"A Phase I Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Women With ER-positive, HER2-negative Advanced Breast Cancer (SERENA-1)",I,Open,AstraZeneca,Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,Spain; United Kingdom; United States
Study of Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients,I/II,Terminated,"University of Florida - Gainesville
Prana Therapeutics",Oncology: Breast,First line; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
A Safety Lead-In/Randomized Phase II Study of BMX-001 as a Therapeutic Agent for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy,I/II,Open,"National Institutes of Health/National Cancer Institute
Duke Comprehensive Cancer Center
BioMimetix JV","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Renal",CNS mets; Line of therapy N/A; Stage IV,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Kidney Neoplasms; Melanoma; Neoplasm Metastasis; Renal Cancer; Wilms Tumor",United States
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors,I/II,Terminated,"Merck KGaA
Pfizer
Leap Therapeutics/Macrocure",Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Fallopian Tube Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Triple Negative Breast Neoplasms",United States
Pilot Open Label Clinical Trial Evaluating the Safety and Efficacy of Chemokine Modulation to Enhance the Effectiveness of Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer,I,Completed,"National Institutes of Health/National Cancer Institute
Roswell Park Cancer Institute
AIM ImmunoTech {Hemispherx Biopharma}",Oncology: Breast,HER2 negative; PD-1 Positive; Second line; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies",I/II,Completed,Sichuan Kelun Pharmaceutical Co./Klus Pharma,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Unspecified Solid Tumor",Fourth line or greater; HER2 positive; Pulmonary; Second line; Stage III; Stage IV; Third line,"Adenocarcinoma, Mucinous; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Mucoepidermoid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Cholangiocarcinoma; Colorectal Neoplasms; Cystadenocarcinoma; Head and Neck Neoplasms; Kidney Neoplasms; Laryngeal Neoplasms; Lip Neoplasms; Liver Cancer; Liver Neoplasms; Mouth Neoplasms; Neoplasms; Neoplasms, Basal Cell; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rare Diseases; Rectal Neoplasms; Renal Cancer; Salivary Gland Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Tongue Neoplasms; Tonsillar Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
A Phase I First-in-Human Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors,I,Closed,AbbVie,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Unspecified Solid Tumor",ALK; BRAF; EGFR; Estrogen receptor positive; Fourth line or greater; HER2 negative; PD-1 Refractory; PD-L1 Positive; PD-L1 Refractory; Progesterone receptor positive; Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Small Cell Lung Carcinoma","Australia; Canada; Israel; Japan; Netherlands; Puerto Rico; South Korea; Spain; Taiwan, China; United States"
A Pilot Trial of Topical Calcipotriene Treatment for Breast Cancer Immunoprevention,I,Open,Massachusetts General Hospital,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Stage 0; Stage I; Stage II; Triple receptor negative,Breast Neoplasms,United States
"An Open-label, Phase I, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Tumor Response Profile of the Anti-CEACAM6 Antibody BAY1834942 in Patients With Advanced Solid Tumors",I,Completed,Bayer AG/Bayer Pharmaceuticals,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Pancreas",Adenocarcinoma; Line of therapy N/A; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",Canada; Singapore; United States
"A Phase I/II, Open-label, Multi-Center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies",I/II,Open,Sanofi/Kymab,"Oncology: Breast; Oncology: Cervical; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",Adenocarcinoma; First line; Fourth line or greater; HER2 negative; Large Cell; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor","Germany; Hungary; Italy; Poland; Spain; Taiwan, China; United Kingdom; United States"
A Phase Ib Trial of M7824 and Eribulin in Patients With Metastatic Triple Negative Breast Cancer (TNBC),I,Terminated,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast,Fourth line or greater; HER2 negative; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Phase I/II Safety and Feasibility Study of Personalized Immunotherapy in Adults With Advanced Cancers,I/II,Closed,University of California San Diego,Oncology: Breast; Oncology: Gastric; Oncology: Head/Neck; Oncology: Pancreas; Oncology: Unspecified Solid Tumor,Adjuvant; Stage III; Stage IV,"Breast Neoplasms; Head and Neck Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
"A Phase I Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab for Participants With Advanced Solid Tumors",I,Open,Merck & Co./Merck Sharp & Dohme (MSD),"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Renal; Oncology: Unspecified Solid Tumor",Adenocarcinoma; First line; Fourth line or greater; HER2 negative; Large Cell; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Positive; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Mesothelioma; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Wilms Tumor",Australia; Canada; Greece; Israel; Poland; South Africa; South Korea; Spain; United States
Examining Oncolytic Poliovirus Bioactivity in Tumor Tissue After Intratumoral Administration of PVSRIPO in Women With Invasive Breast Cancer,I,Open,"Duke University Medical Center
US Department of Defense
Istari Oncology",Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"A Phase Ib Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors",I,Completed,"Merck & Co./Merck Sharp & Dohme (MSD)
Astellas Pharma","Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor",ALK; EGFR; Hormone refractory; PD-L1 High; PD-L1 Positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms","Canada; Italy; Japan; Portugal; South Korea; Spain; Taiwan, China; United Kingdom; United States"
"A Phase I, Open-Label, Multicenter Study of FT516 in Combination With Monoclonal Antibodies in participants With Advanced Solid Tumors",I,Completed,"Fate Therapeutics
California Institute for Regenerative Medicine (CIRM)","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Unspecified Solid Tumor",PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Hematologic Neoplasms; Lymphoma, Non-Hodgkin; Melanoma; Multiple Myeloma; Neoplasms; Neoplasms, Unknown Primary",United States
"A Phase I/II Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of ZN-c5 Alone and in Combination With Palbociclib in Subjects With Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Advanced Breast Cancer.",I/II,Completed,Zentalis/Zeno Alpha,Oncology: Breast,Estrogen receptor positive; HER2 negative; Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms,Belarus; Belgium; Bosnia and Herzegovina; Bulgaria; Croatia; Czech Republic; Georgia; Hungary; Lebanon; Lithuania; Moldova Republic; Russia; Serbia; Turkey; Ukraine; United Kingdom; United States
A Pilot Trial of Atorvastatin in p53-Mutant and p53 Wild-Type Malignancies,I,Open,University of Kansas,"Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Leukemia, Acute Myelogenous; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Myelodysplastic Syndrome; Oncology: Ovarian; Oncology: Unspecified Cancer; Oncology: Unspecified Hematological Cancer; Oncology: Unspecified Solid Tumor",(N/A); First line; Neoadjuvant; Second line; Untreated,"Acute Myelocytic Leukemia; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Glioblastoma; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Melanoma; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma",I,Open,VM Oncology,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Cervical; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Leukemia, Acute Myelogenous; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Thymus; Oncology: Unspecified Solid Tumor",Aggressive; Classical; HER2 negative; Indolent; Nodular lymphocyte-predominant; Second line; Squamous Cell; Stage III; Stage IV; Thymic carcinoma; Thymoma; Triple receptor negative,"Acute Myelocytic Leukemia; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cholangiocarcinoma; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Mesothelioma; Mesothelioma, Malignant; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Thymoma; Thymus Neoplasms; Uterine Cervical Neoplasms",United States
QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.,I,Closed,NantWorks/NantBioScience,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",Adjuvant; Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Stage I; Stage II; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck",United States
"A Phase Ib Study of Talimogene Laherparepvec (T-VEC) in Combination With Chemotherapy or Endocrine Therapy in Patients With Metastatic, Unresectable, or Locoregionally Recurrent HER2-negative Breast Cancer",I,Closed,"Amgen
University of California, San Francisco",Oncology: Breast,Estrogen receptor positive; HER2 negative; Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms; Carcinoma,United States
"A Phase I Open-label Study of EDP1503 Alone and in Combination With Pembrolizumab in Patients With Advanced Metastatic Colorectal Carcinoma, Triple-negative Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors",I,Terminated,"Merck & Co./Merck Sharp & Dohme (MSD)
Evelo Biosciences","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal; Oncology: Small Intestine",Adenocarcinoma; HER2 negative; Large Cell; MSS/pMMR; PD-1 Refractory; PD-L1 Refractory; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Intestinal Neoplasms; Kidney Neoplasms; Melanoma; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Canada; United States
"A Phase I/II Open Label, Safety And Preliminary Efficacy Study of MRx0518 In Combination With Pembrolizumab In Patients With Advanced Malignancies Who Have Progressed On PD-1/PD-L1 Inhibitors",I/II,Terminated,"Merck & Co./Merck Sharp & Dohme (MSD)
4D Pharma","Oncology: Bladder; Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal; Oncology: Unspecified Solid Tumor",EGFR; Fourth line or greater; HER2 negative; MSI-H/dMMR; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase I/Ib, Open-label, Multi-center, Study of NZV930 as a Single Agent and in Combination With PDR001 and/or NIR178 in Patients With Advanced Malignancies",I,Terminated,Novartis,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Myeloproliferative Neoplasms; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Cancer",Fourth line or greater; HER2 negative; MSS/pMMR; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Myeloproliferative Disorders; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Triple Negative Breast Neoplasms; Wilms Tumor",Australia; Canada; Israel; Japan; Singapore; Spain; United Kingdom; United States
"SEASTAR: A Phase Ib/II, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor",I/II,Terminated,"Gilead Sciences/Immunomedics
Clovis Oncology","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor",BRCA; Fourth line or greater; HER2 negative; Hormone refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Kidney Neoplasms; Mesothelioma; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Phase I Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers,I,Closed,Zymeworks,Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Unspecified Cancer; Oncology: Unspecified Solid Tumor,HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Stomach Carcinoma; Stomach Neoplasms; Unspecified",Australia; Canada; South Korea; United States
A Pilot Study of Olaparib and Durvalumab in Patients With Metastatic Triple Negative Breast Cancer,I,Completed,"(Other Cooperative Group)
OHSU Cancer Institute
Oregon Health and Science University","Oncology: Breast; Oncology: Cervical; Oncology: Skin, Squamous Cell Carcinoma (cSCC)",First line; HER2 negative; Progesterone receptor positive; Second line; Stage 0; Stage I; Stage II; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Squamous Cell; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms",United States
A Phase I Study of Rucaparib Administered Concurrently With Postoperative Radiotherapy in Patients With Triple Negative Breast Cancer With an Incomplete Pathologic Response Following Neoadjuvant Chemotherapy,I,Closed,"Memorial Sloan-Kettering Cancer Center
Clovis Oncology",Oncology: Breast,HER2 negative; Maintenance/Consolidation; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase I Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants With Select Advanced Malignancies",I,Completed,Incyte Corporation,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Renal",Aggressive; Diffuse large B-cell lymphoma (DLBCL); Fourth line or greater; HER2 negative; Merkel; MSI-H/dMMR; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Mesothelioma; Microsatellite Instability; Neoplasms, Mesothelial; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A Phase I Study of an Autologous ACTR T Cell Product in Combination With Trastuzumab, a Monoclonal Antibody, in Subjects With HER2-Positive Advanced Malignancies",I,Terminated,Cogent Biosciences {Unum Therapeutics},Oncology: Breast; Oncology: Gastric; Oncology: Unspecified Solid Tumor,HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms, Unknown Primary; Stomach Carcinoma; Stomach Neoplasms; Unspecified",United States
"RACHEL1: A Phase I Radiation and Checkpoint blockade Trial in Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer",I,Completed,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute
Merck KGaA/EMD Serono {EMD Pharmaceuticals}",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Third line,Breast Neoplasms,United States
A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies,I,Open,Incyte Corporation,"Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Leukemia, Acute Myelogenous; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",(N/A); HER2 negative; Metastatic; MSI-H/dMMR; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Acute Myelocytic Leukemia; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Leukemia, Myeloid, Acute; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase I, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies",I,Completed,Incyte Corporation,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Renal; Oncology: Unspecified Cancer",HER2 negative; Merkel; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
A Phase I Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4),I,Completed,Xencor,"Oncology: Anal; Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Penile; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor; Oncology: Vulvar",(N/A); HER2 negative; Intrahepatic; MSI-H/dMMR; PD-1 Naive; PD-1 Refractory; PD-L1 High; PD-L1 Naive; Pulmonary; Second line; Squamous Cell; Stage III; Stage IV; Triple receptor negative,"Anus Neoplasms; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cholangiocarcinoma; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Melanoma; Nasopharyngeal Carcinoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Penile Neoplasms; Prostatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Vulvar Neoplasms; Wilms Tumor",United States
Defining the Molecular Profile of Breast Cancer in Uganda and Its Clinical Implications,I,Completed,"GlaxoSmithKline
Fred Hutchinson Cancer Research Center",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; HER2 positive; Progesterone receptor positive; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,Uganda; United States
"Phase I/IIa Dose Escalation And Expansion Study Evaluating Safety, Tolerability, Pharmacokinetic, Pharmacodynamics And Anti-tumor Activity Of Pf-06873600 As A Single Agent And In Combination With Endocrine Therapy",I/II,Terminated,Pfizer,Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal,Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Breast Neoplasms, Male; Fallopian Tube Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Triple Negative Breast Neoplasms",Bulgaria; Canada; Japan; Russia; Ukraine; United States
"A Phase I/II Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-ROR2-ADC, Alone and in Combination With a PD-1 Inhibitor, in Patients With Advanced Solid Tumors (Ph1) and Melanoma and NSCLC Patients (Ph2)",I/II,Open,BioAtla,"Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",HER2 negative; Locally advanced; Metastatic; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative; Unresectable,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms, Unknown Primary; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Triple Negative Breast Neoplasms","France; Germany; Greece; Hong Kong, S.A.R., China; Italy; Poland; Spain; Taiwan, China; United States"
"Open-label, Multicentre, Phase Ib Dose-escalation Study of MEN1611, a PI3K Inhibitor Combined With Trastuzumab With or Without Fulvestrant, in Subjects With PIK3CA Mutated HER2 Positive Locally Recurrent Unresectable (Advanced) or Metastatic (a/m) Breast Cancer Progressed to Anti-HER2 Based Therapy",I,Closed,Menarini Group,Oncology: Breast,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Stage III; Stage IV; Third line,Breast Neoplasms,Belgium; France; Italy; Netherlands; Spain; United Kingdom; United States
"An Open-Label, Multicenter, Phase Ib/II Study of Rebastinib (DCC-2036) in Combination With Paclitaxel to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid Tumors",I/II,Terminated,Deciphera Pharmaceuticals,Oncology: Breast; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Soft Tissue Sarcoma,Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage II; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Fallopian Tube Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
Phase I Open-Label Dose Escalation Study of BDB001 as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors,I,Closed,"Seven and Eight BioPharmaceuticals/Birdie Biopharmaceuticals HK
Seven and Eight BioPharmaceuticals","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Ovarian; Oncology: Renal; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Aggressive; Classical; First line; Fourth line or greater; HER2 negative; Indolent; Large Cell; Nodular lymphocyte-predominant; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Unspecified; Wilms Tumor",United States
A Phase I/II Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas,I/II,Open,MorphoSys/Constellation Pharmaceuticals,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Hematological Cancer; Oncology: Unspecified Solid Tumor",Aggressive; Classical; Diffuse large B-cell lymphoma (DLBCL); Fourth line or greater; Hormone refractory; Indolent; Metastatic; MSI-H/dMMR; Nodular lymphocyte-predominant; PD-1 Refractory; Peripheral T-cell lymphoma (PTCL); Pulmonary; Second line; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Renal Cell; Carcinoma, Small Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Hematologic Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Peripheral; Melanoma; Mesothelioma; Mesothelioma, Malignant; Neoplasms; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",France; Italy; Poland; Spain; United Kingdom; United States
"A Phase I, Open-Label Study of D-0502 Single Agent and D-0502 in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer",I,Completed,InventisBio,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,China; United States
A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy,I,Completed,"University of Virginia
Syndax",Oncology: Breast,Adjuvant; Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Progesterone receptor positive; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
Pilot Study of the Antibody-drug Conjugate Glembatumumab Vedotin (CDX-011) Following Doxorubicin (Adriamycin) and Cytoxan as Neo-adjuvant Therapy in Glycoprotein NMB-expressing High Risk Triple Negative Breast Cancer,I,Terminated,"University of Virginia
Celldex Therapeutics {AVANT Immunotherapeutics}",Oncology: Breast,HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase I, Open-Label Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Escalating Doses of DHES0815A in Patients With HER2-Positive Breast Cancer",I,Completed,Roche/Genentech {Genentech},Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,South Korea; United States
"A Phase I Open-Label, Dose-Escalation Study of Para-toluenesulfonamide Injection (PTS) Administered Intratumorally and Locally to Patients With Solid Tumors",I,Terminated,(Other Industry Sponsor),Oncology: Breast; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms, Unknown Primary; Unspecified",United States
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients.,I/II,Open,"Weill Medical College of Cornell University
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast; Oncology: Metastatic Cancer,Adjuvant; CNS mets; Neoadjuvant; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
"A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study of BI 907828 in Patients With Advanced or Metastatic Solid Tumors",I,Open,Boehringer Ingelheim,"Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: GIST; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer; Oncology: Osteosarcoma; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Adenocarcinoma; CNS mets; Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; HER2 positive; Large Cell; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Ewing Sarcoma; Fibrosarcoma; Gastrointestinal Stromal Tumors; Glioblastoma; Leiomyosarcoma; Liposarcoma; Neoplasm Metastasis; Neoplasms, Unknown Primary; Osteosarcoma; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms",Belgium; Canada; Germany; Japan; Poland; Spain; Sweden; United States
"A Phase Ia/Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Runimotamab Administered Intravenously as a Single Agent and in Combination With Trastuzumab in Patients With Locally Advanced or Metastatic HER2-Expressing Cancers",I,Open,Roche/Genentech {Genentech},Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Unspecified Solid Tumor,HER2 negative; HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Neoplasms, Unknown Primary; Stomach Carcinoma; Stomach Neoplasms; Unspecified","Australia; Belgium; Canada; Denmark; France; Italy; Japan; Netherlands; Singapore; South Korea; Spain; Taiwan, China; United Kingdom; United States"
A Phase I/II First-in-Human Study of BMS-986258 Alone and in Combination With Nivolumab in Advanced Malignant Tumors,I/II,Completed,"Bristol-Myers Squibb
Ono Pharmaceutical","Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Renal; Oncology: Unspecified Solid Tumor",Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms, Unknown Primary; Renal Cancer; Unspecified; Wilms Tumor",Australia; Canada; Japan; United States
A Phase Ib Investigation of Pembrolizumab in Combination With Intratumoral Injection of Clostridium Novyi-NT in Patients With Treatment-Refractory Solid Tumors,I,Open,"MD Anderson Cancer Center, University of Texas
Merck & Co./Merck Sharp & Dohme (MSD)
BioMed Valley Discoveries","Oncology: Anal; Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Testicular; Oncology: Thyroid",Advanced; Metastatic; Second line; Stage III; Stage IV,"Anus Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Eye Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Genital Neoplasms, Female; Genital Neoplasms, Male; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Lip Neoplasms; Liposarcoma; Liver Cancer; Liver Neoplasms; Medulloblastoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
Pilot Safety and Feasibility Study of an In Vivo Sensitivity Screen Using a Direct Tumor Microinjection Technique and FDG-PET,I,Temporarily Closed,"National Institutes of Health/National Cancer Institute
Mayo Clinic","Oncology: Breast; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's",Classical; Cutaneous T-cell lymphoma (CTCL); Extranodal marginal zone B-cell lymphoma (MALT); Indolent; Nodular lymphocyte-predominant; Second line; Stage IV,"Breast Neoplasms; Carcinoma; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Mycoses; Mycosis Fungoides",United States
A Phase Ib Study Evaluating the Safety and Tolerability of Durvalumab (MEDI4736) (Anti-PDL1) in Combination With Eribulin in Patients With HER2-Negative Metastatic Breast Cancer and Recurrent Ovarian Cancer,I,Completed,"AstraZeneca
Eisai
Icahn School of Medicine at Mount Sinai {Mount Sinai School of Medicine}",Oncology: Breast; Oncology: Ovarian,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Ovarian Epithelial; Ovarian Cancer; Ovarian Neoplasms",United States
A Phase I Study of TAK-228 (MLN0128) in Combination With Carboplatin Plus Paclitaxel in Patients With Advanced Malignancies,I,Completed,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,"Acute Myelocytic Leukemia; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Leukemia, Myeloid, Acute; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Testicular Cancer; Testicular Neoplasms; Thyroid Neoplasms",United States
Platform Phase I Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) With Immuno-oncology Agents for the Treatment of Multiple Metastases in Advanced Solid Tumors,I,Completed,"Bristol-Myers Squibb
University of Chicago Medical Center","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; PD-1 Refractory; PD-L1 Positive; PD-L1 Refractory; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms, Unknown Primary; Unspecified",United States
"A Phase I/IIa Study in 3 Parts (Phase Ia and Phase Ib - Dose Escalations and Phase IIa Expansion Cohorts) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of MIV-818 in Patients with Liver Cancer Manifestations",I/II,Open,Medivir,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",Fourth line or greater; Intrahepatic; Liver mets; Second line; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Cholangiocarcinoma; Colorectal Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",Belgium; South Korea; Spain; United Kingdom; United States
Initial safety and production efficiency of an autologous tumor lysate-loaded yeast cell wall particle vaccine,I,Completed,(Other Hospital/Academic/Medical Center),"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal",Line of therapy N/A; Stage I; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Kidney Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Wilms Tumor",United States
A Phase I/II Study of OBI-3424 in Subjects With Advanced Solid Tumors,I/II,Open,OBI Pharma,"Oncology: Breast; Oncology: Colorectal; Oncology: Leukemia, Acute Lymphocytic; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor",(N/A); Fourth line or greater; Hormone refractory; Second line; Stage III; Stage IV; T-cell; Third line,"Adenocarcinoma; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms, Unknown Primary; Ovarian Neoplasms; Pancreatic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms",United States
A Phase I/II Study Using the Administration of Autologous T-Cells Engineered Using the Sleeping Beauty Transposon/Transposase System to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients With Metastatic Cancer,I/II,Open,National Institutes of Health/National Cancer Institute,"Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: GIST; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Large Cell; Second line; Squamous Cell; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Glioblastoma; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Urogenital Neoplasms",United States
"A Phase I/II, Open Label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of TAS0728, an Oral Covalent Binding Inhibitor of HER2, in Subjects With Advanced Solid Tumors With HER2 or HER3 Abnormalities",I/II,Terminated,Otsuka Holdings/Taiho Pharmaceutical,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Renal; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Fourth line or greater; HER2 positive; Large Cell; Second line; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Congenital Abnormalities; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gallbladder Neoplasms; Kidney Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Australia; France; Spain; United Kingdom; United States
"A Multicenter, Open-Label Phase I/II Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRa)-Targeting Antibody-drug Conjugate (ADC) in Subjects With Selected Tumor Types",I/II,Open,"Bristol-Myers Squibb
Eisai/Morphotek","Oncology: Breast; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Primary Peritoneal",Adenocarcinoma; Fourth line or greater; HER2 negative; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Fallopian Tube Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Unspecified",United Kingdom; United States
"A Phase I/II, Open-Label, Dose Escalation and Cohort Expansion Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.",I/II,Terminated,OBI Pharma,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms","Taiwan, China; United States"
A Phase I Study of CPI-1205 With Ipilimumab in Patients With Advanced Solid Tumors Followed by a Phase II Basket Study of CPI-1205 With Ipilimumab in Selected Tumor Types Previously Treated With PD-1 or PD-L1 Inhibitors,I,Terminated,MorphoSys/Constellation Pharmaceuticals,"Oncology: Bladder; Oncology: Breast; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor",CNS mets; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Unknown Primary; Prostatic Neoplasms; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase Ib/II Trial of Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer (""GLACIER"")",I/II,Terminated,"(Other Cooperative Group)
Pfizer
Abramson Cancer Center at  University of Pennsylvania Medical Center
Breast Cancer Research Foundation",Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Second line; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
"A Phase I First-in-Human Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR441000 Administered Intratumorally as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors.",I/II,Completed,"Sanofi {Sanofi-Aventis}
BioNTech","Oncology: Breast; Oncology: Head/Neck; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Skin, Basal Cell Carcinoma; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Unspecified Solid Tumor",First line; Merkel; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Ewing Sarcoma; Head and Neck Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms, Basal Cell; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Osteosarcoma",Belgium; France; Germany; Netherlands; Spain; United States
A Phase I Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors,I,Closed,Merck & Co./Merck Sharp & Dohme (MSD),"Oncology: Breast; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",Adenocarcinoma; First line; HER2 negative; Large Cell; PD-1 Naive; PD-L1 Naive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Neoplasms, Unknown Primary; Triple Negative Breast Neoplasms","Chile; Israel; Netherlands; South Korea; Spain; Taiwan, China; United States"
"A Phase Ia/Ib Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors",I,Completed,Amgen/Five Prime Therapeutics,Oncology: Breast; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Head/Neck; Oncology: Liver; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; Fourth line or greater; HER2 negative; PD-1 Naive; PD-L1 Naive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Endometrial Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Urinary Bladder Neoplasms",South Korea; United States
A Phase Ib/IIa Multicenter Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors,I/II,Terminated,Noxopharm,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Unspecified Solid Tumor",Fourth line or greater; Hormone refractory; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Neoplasms, Unknown Primary; Prostatic Neoplasms",Australia; France; Hungary; United States
A Pilot Study Utilizing a HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+ Breast Cancer,I,Closed,"H. Lee Moffitt Cancer Center and Research Institute
US Department of Defense",Oncology: Breast,Adjuvant; HER2 positive; Neoadjuvant; Stage II; Stage III,"Breast Neoplasms; Breast Neoplasms, Male",United States
NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.,I/II,Completed,NantWorks/ImmunityBio {NantCell},Oncology: Breast,Fourth line or greater; HER2 negative; Maintenance/Consolidation; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Phase I Clinical Study To Test The Safety And Efficacy of CARMA in Patients With Recurrent Ovarian Cancer And in Patients With HER2-overexpressing Malignancies Through A Basket Trial Approach.,I,Open,"MD Anderson Cancer Center, University of Texas
Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}
Abramson Cancer Center at  University of Pennsylvania Medical Center
University of North Carolina
Carisma Therapeutics {CARMA Therapeutics}","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Testicular; Oncology: Unspecified Solid Tumor",Adenocarcinoma; EGFR; Fourth line or greater; HER2 positive; Pulmonary; Second line; Squamous Cell; Stage IV; Third line,"Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Ductal; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gallbladder Neoplasms; Head and Neck Neoplasms; Inflammatory Breast Neoplasms; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Testicular Cancer; Testicular Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",United States
Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer,I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Unspecified Solid Tumor",ALK; EGFR; HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Colorectal Neoplasms; Neoplasms, Unknown Primary; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
Phase I/II Dose-Escalation and Expansion Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer,I/II,Open,"Merck & Co./Merck Sharp & Dohme (MSD)
RAPT Therapeutics {FLX Bio {Flexus Biosciences}}","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Ovarian; Oncology: Renal",Adenocarcinoma; Aggressive; Classical; Fourth line or greater; HER2 negative; Other subtype; PD-L1 High; PD-L1 Positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor","Australia; Georgia; Hong Kong, S.A.R., China; South Korea; Taiwan, China; Thailand; United States"
"A Phase Ib/IIa, Open-Label, Dose-Escalation/Dose-Expansion Safety, Tolerability and Pharmacokinetic Study of IMX-110 in Patients with Advanced Solid Tumors",I/II,Open,Immix Biopharma,Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,"Breast Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",Australia; United States
"A Phase I/II, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination With Bempegaldesleukin (NKTR-214) With or Without Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies",I/II,Terminated,Nektar Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",BRAF; First line; HER2 negative; Merkel; Other; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Squamous Cell Carcinoma of Head and Neck; Synovial Sarcoma; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
Phase I/II Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer,I/II,Closed,"AbbVie/Pharmacyclics
US Oncology Research",Oncology: Breast,Second line; Stage IV; Third line,Breast Neoplasms; Neoplasms,United States
Phase Ib/II Study of Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer,I/II,Closed,"Memorial Sloan-Kettering Cancer Center
Puma Biotechnology",Oncology: Breast,Fourth line or greater; HER2 positive; Second line; Stage IV; Third line,Breast Neoplasms,United States
A Phase I Study of AG-270 in the Treatment of Subjects With Advanced Solid Tumors or Lymphoma With Homozygous Deletion of MTAP,I,Terminated,"Bristol-Myers Squibb/Celgene
Servier","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Mesothelioma; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",Aggressive; Classical; Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Indolent; Nodular lymphocyte-predominant; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Mesothelioma; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms",France; Spain; United States
"Phase I, Two-part, Multicenter, Open-label, Multiple Dose, First-in-human Study of DS-1062a in Subjects With Advanced Solid Tumors (TROPION-PanTumor01)",I,Open,"AstraZeneca
Daiichi Sankyo","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal",Adenocarcinoma; ALK; EGFR; Estrogen receptor positive; Extensive; Fourth line or greater; HER2 negative; Hormone refractory; Large Cell; PD-1 Refractory; PD-L1 Refractory; Progesterone receptor positive; Pulmonary; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Japan; United States
"An Open-Labeled, Phase I Study to Evaluate the Safety and Tolerability of Apatinib With Nivolumab in Patients With Unresectable or Metastatic Cancer",I,Completed,Elevar Therapeutics {LSK BioPharma {LSK BioPartners}},"Oncology: Breast; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Line of therapy N/A; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasm Metastasis; Neoplasms, Unknown Primary; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Wilms Tumor",United States
"An Open-Label, Multicenter, Phase I/II Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors.",I/II,Open,"Bristol-Myers Squibb
Replimune","Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Skin, Basal Cell Carcinoma; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",BRAF; First line; Locally advanced; Merkel; Metastatic; MSI-H/dMMR; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Positive; PD-L1 Refractory; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Non-Hodgkin; Melanoma; Microsatellite Instability; Neoplasms, Basal Cell; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Skin Neoplasms; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",Australia; France; Germany; Spain; United Kingdom; United States
A Phase I Trial to Evaluate Safety and Tolerance of Intravenous 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Adult Subjects With Cancer Involving the CNS,I,Completed,"National Institutes of Health/National Cancer Institute
Dekk-Tec","Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Ewing Sarcoma; Fibrosarcoma; Glioblastoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Medulloblastoma; Melanoma; Neoplasm Metastasis; Osteosarcoma; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified; Wilms Tumor",United States
A Phase Ib/II Study of the PARP Inhibitor Niraparib in Combination With Trastuzumab in Patients With Metastatic HER2+ Breast Cancer,I/II,Open,"(Other Cooperative Group)
University of Alabama, Birmingham
Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}
(Other Hospital/Academic/Medical Center)
GlaxoSmithKline/Tesaro",Oncology: Breast,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Phase I/II First-in-Human Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors,I/II,Closed,Bristol-Myers Squibb,Oncology: Breast; Oncology: Liver; Oncology: Melanoma; Oncology: Prostate; Oncology: Unspecified Solid Tumor,First line; HER2 negative; Hormone refractory; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms, Unknown Primary; Prostatic Neoplasms; Unspecified",Argentina; Australia; Canada; Chile; Finland; Germany; Italy; Netherlands; Poland; Romania; Spain; Switzerland; United States
Phase I Trial of 5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in Patients With Advanced Solid Tumors,I,Open,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Colorectal; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,"Breast Neoplasms; Colorectal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
Preoperative Combination of Pembrolizumab and Radiation Therapy in Patients With Operable Breast Cancer,I/II,Completed,"Cedars-Sinai Medical Center
US Department of Defense",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
Phase I/IIa First in Human Study of BMS-986277 Administered Alone and in Combination With Nivolumab in Advanced Epithelial Tumors,I/II,Terminated,Bristol-Myers Squibb,Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Australia; Canada; Spain; United States
A Phase IB Dose Escalation Trial of Human Anti 4 1BB Agonistic Antibody Utomilumab (PF 05082566) in Combination With Ado Trastuzumab Emtansine or Trastuzumab in Patients With HER2 Postive Advanced Breast Cancer,I,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,First line; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms; Carcinoma,United States
"A Phase I Study Evaluating the Safety, Pharmacology, and Preliminary Activity of VT1021 in Patients With Advanced Solid Tumors",I/II,Completed,Vigeo Therapeutics,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Thymus; Oncology: Unspecified Solid Tumor",BRCA; Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Thymoma; Triple receptor negative,"Breast Neoplasms; Fallopian Tube Neoplasms; Glioblastoma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Thymoma; Thymus Neoplasms",United States
"An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination, in Patients With Advanced Solid/Metastatic Tumours.",I/II,Open,CellCentric,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Unspecified Solid Tumor",Hormone refractory; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms, Unknown Primary; Prostatic Neoplasms",France; Germany; Netherlands; Spain; Sweden; United Kingdom; United States
"A Non-randomized, Non-comparative, Open-label, Window Trial of Entinostat Given With or Without Exemestane in Patients With Newly Diagnosed, Stage I-IIIC, Hormone Receptor - Positive (HR+) or Triple Negative Breast Cancer (TNBC)",I,Terminated,"National Institutes of Health/National Cancer Institute
UNC Lineberger Comprehensive Cancer Center
Syndax",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Phase Ib Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination With Pembrolizumab in HLA-A2+ Patients With Metastatic Triple Negative Breast Cancer (TNBC).,I,Closed,"Massachusetts General Hospital
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Modular, Multipart, Multiarm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies",I/II,Completed,Carrick Therapeutics,"Oncology: Breast; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate; Oncology: Unspecified Solid Tumor",Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Small Cell; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma",United Kingdom; United States
An Open-label Phase I Trial to Evaluate the Safety and Tolerability of a Modified Vaccinia Ankara (MVA) Priming Followed by Fowlpox Booster Vaccines Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-BN-Brachyury/FPV-Brachyury),I,Completed,"National Institutes of Health/National Cancer Institute
Bavarian Nordic","Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Thyroid",(N/A); EGFR; Estrogen receptor positive; First line; Fourth line or greater; HER2 positive; Maintenance/Consolidation; Merkel; Progesterone receptor positive; Pulmonary; Second line; Stage III; Stage IV; Third line; Untreated,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Fowlpox; Liver Cancer; Liver Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Thyroid Neoplasms; Unspecified; Vaccinia",United States
"A Phase I Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of APG-1387 as A Single Agent or in Combination With Systemic Anti-Cancer Agents in Patients With Advanced Solid Tumors or Hematologic Malignancies",I/II,Completed,Ascentage Pharma Group,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Unspecified Hematological Cancer; Oncology: Unspecified Solid Tumor",Estrogen receptor positive; Fourth line or greater; HER2 negative; MSS/pMMR; PD-1 Naive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Hematologic Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms",China; United States
A Phase Ia/Ib Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination With Anti- PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors,I,Terminated,Eli Lilly,"Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Renal; Oncology: Unspecified Solid Tumor",HER2 negative; Line of therapy N/A; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms, Unknown Primary; Renal Cancer; Triple Negative Breast Neoplasms; Wilms Tumor",Belgium; Denmark; France; Italy; Spain; United States
A Phase Ib/II Study of Debio 1347 Plus Fulvestrant in Patients With FGFR-Amplified Endocrine Receptor Positive Metastatic Breast Cancer,I/II,Completed,"Memorial Sloan-Kettering Cancer Center
Debiopharm",Oncology: Breast,Estrogen receptor positive; FGFR; HER2 negative; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
"A Phase I, Open-Label, Dose-Escalation, Safety, Tolerability, and Preliminary Efficacy Study of MCLA-145 in Participants With Advanced or Metastatic Malignancies",I,Open,"Merus
Incyte Corporation","Oncology: Bladder; Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Unspecified Solid Tumor",Aggressive; Diffuse large B-cell lymphoma (DLBCL); Extranodal marginal zone B-cell lymphoma (MALT); Follicular lymphoma (FL); HER2 negative; Indolent; Mantle cell lymphoma (MCL); MSI-H/dMMR; PD-1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Urethral Neoplasms; Urinary Bladder Neoplasms",Belgium; Netherlands; Spain; United States
"AIPAC-002 (Active Immunotherapy Paclitaxel-002): A Multicentre, Phase Ib Study to Test a New Schedule of Eftilagimod Alpha (a Soluble LAG-3 Protein) as Adjunctive to Weekly Paclitaxel in Hormone Receptor-positive Metastatic Breast Carcinoma Patients",I,Terminated,Immutep {Prima BioMed},Oncology: Breast,Estrogen receptor positive; First line; Maintenance/Consolidation; Progesterone receptor positive; Stage IV,Breast Neoplasms,United States
A Phase Ia/Ib Study of COM701 as Monotherapy and In Combination With an Anti-PD-1 Antibody in Subjects With Advanced Solid Tumors,I,Closed,"Bristol-Myers Squibb
Compugen","Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Renal",Adenocarcinoma; BRAF; BRCA; EGFR; Fourth line or greater; HER2 negative; KRAS; MSS/pMMR; PD-1 Refractory; PD-L1 Positive; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A Phase I/Ib Multicenter Study To Evaluate The Humanized Anti-CD73 Antibody, CPI-006, As A Single Agent Or In Combination With Ciforadenant, With Pembrolizumab, And With Ciforadenant Plus Pembrolizumab In Adult Subjects With Advanced Cancers",I,Closed,Corvus Pharmaceuticals,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Aggressive; Fourth line or greater; HER2 negative; Hormone refractory; Indolent; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Squamous Cell Carcinoma of Head and Neck; Synovial Sarcoma; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Australia; Canada; United States
"A Phase Ia/Ib, Multicenter, Open-Label, Dose Escalation, Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-9545 Alone or in Combination With Palbociclib and/or LHRH Agonist in Patients With Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer",I,Closed,Roche/Genentech,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,Australia; South Korea; Spain; United Kingdom; United States
A Phase Ib/II Study To Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors,I/II,Terminated,Pfizer,"Oncology: Bladder; Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor",BRCA; Estrogen receptor positive; HER2 negative; Hormone refractory; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Kidney Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Australia; Belgium; Canada; Czech Republic; Denmark; Hungary; New Zealand; Russia; South Korea; Spain; United Kingdom; United States
"An Open-Label, Single-arm Pilot Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Localized, HER2-negative, BRCA-mutant Breast Cancer Patients",I,Completed,GlaxoSmithKline/Tesaro,Oncology: Breast,BRCA; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
A Phase I/II Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination With Retifanlimab,I/II,Open,"Incyte Corporation
BriaCell",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
Phase Ib/II Clinical Trial of Glembatumumab Vedotin and Nivolumab in Advanced Solid Tumors,I/II,Terminated,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Melanoma; Oncology: Unspecified Solid Tumor,HER2 negative; Line of therapy N/A; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Triple Negative Breast Neoplasms; Uveal Neoplasms",United States
A Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer,I,Terminated,National Institutes of Health/National Cancer Institute,Oncology: Breast,BRCA; Line of therapy N/A; Stage 0; Stage I; Stage II; Stage III; Stage IV,"Breast Carcinoma In Situ; Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Hyperplasia",United States
BRE 17107: A Phase Ib/II Trial of Atezolizumab (an Anti-PD-L1 Monoclonal Antibody) With Cobimetinib (a MEK1/2 Inhibitor) or Idasanutlin (an MDM2 Antagonist) in Metastatic ER+ Breast Cancer.,I/II,Terminated,"(Other Industry Sponsor)
Vanderbilt-Ingram Cancer Center
Roche/Genentech",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Stage IV; Third line,Breast Neoplasms,United States
"An Open Label, Multicenter, Dose-Finding Clinical Phase I Study of ASN004 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy in Patients With Advanced Malignant Solid Tumors",I,Open,Asana BioSciences,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV,"Adenocarcinoma; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Colonic Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms",United States
"A Phase I/II, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Fadraciclib (CYC065), an Oral CDK 2/9 Inhibitor, in Subjects with Advanced Solid Tumors and Lymphoma",I/II,Open,Cyclacel,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Liver; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",(N/A); Aggressive; Classical; Cutaneous T-cell lymphoma (CTCL); HER2 negative; Indolent; KRAS; Line of therapy N/A; Nodular lymphocyte-predominant; Peripheral T-cell lymphoma (PTCL); Second line; Stage III; Stage IV; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Liver Cancer; Liver Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Neoplasms",South Korea; Spain; United States
"A Phase I, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors",I,Closed,Biosplice Therapeutics {Samumed},"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate; Oncology: Unspecified Solid Tumor",Fourth line or greater; HER2 negative; Hormone refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Neoplasms; Prostatic Neoplasms",United States
Phase I Trial of Endoxifen Gel Versus Placebo Gel in Women Undergoing Breast Surgery,I,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Neoadjuvant; Stage 0; Stage I; Stage II; Stage III,"Breast Carcinoma In Situ; Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular",United States
Combination Therapy of Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair,I,Completed,"University of California, San Francisco
Clovis Oncology",Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal; Oncology: Small Intestine; Oncology: Testicular,BRCA; Fourth line or greater; HER2 negative; Other; Pancreas; Stage III; Stage IV; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Cholangiocarcinoma; Head and Neck Neoplasms; Intestinal Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Testicular Cancer; Testicular Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC),I,Terminated,AbbVie,Oncology: Breast,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase 1, First-in-Human, Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors",I,Completed,CicloMed,Oncology: Bladder; Oncology: Breast; Oncology: Fallopian Tube; Oncology: Prostate; Oncology: Unspecified Solid Tumor,Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Fallopian Tube Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Prostatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Pilot Study of AZD5363 for Patients With Advanced Solid Tumors Harboring Mutations in AKT1, AKT2, or AKT3",I,Completed,Memorial Sloan-Kettering Cancer Center,Oncology: Breast; Oncology: Prostate,Estrogen receptor positive; First line; Second line; Stage III; Stage IV,Breast Neoplasms; Neoplasms; Prostatic Neoplasms,United States
"Single Arm, Open Label Phase Ib/II Study of SGN-LIV1A in Combination With Pembrolizumab for First-Line Treatment of Patients With Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer.",I/II,Closed,"Seagen {Seattle Genetics}
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,First line; HER2 negative; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,France; Germany; Italy; South Korea; Spain; United States
"Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer",I,Completed,GlaxoSmithKline/Tesaro,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal",Adenocarcinoma; Fourth line or greater; Large Cell; Pulmonary; Second line; Stage I; Stage II; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Multicenter, Phase I/II Trial of Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast Cancer",I/II,Closed,"Herbert Irving Comprehensive Cancer Center at Columbia University
Icahn School of Medicine at Mount Sinai {Mount Sinai School of Medicine}
Weill Medical College of Cornell University
NYU Langone Health",Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Stage IV,Breast Diseases; Breast Neoplasms,United States
A Phase I Dose Escalation / Dose Expansion Study of NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy,I,Open,Nanobiotix,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Neuroendocrine; Oncology: Renal; Oncology: Thyroid; Oncology: Unspecified Cancer",(N/A); Anaplastic; Fourth line or greater; HER2 negative; Liver mets; Merkel; MSI-H/dMMR; Other mets; PD-1 Naive; PD-1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Disease; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Microsatellite Instability; Neoplasm Metastasis; Neoplasms; Neoplasms, Second Primary; Neuroendocrine Tumors; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Combination With the PD-1 Inhibitor PDR001 in Patients With Metastatic Hormone Receptor-positive Breast Cancer and Metastatic Ovarian Cancer,I,Terminated,"Novartis
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute",Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal,Estrogen receptor positive; Fourth line or greater; HER2 negative; PD-1 Naive; PD-L1 Naive; Progesterone receptor positive; Second line; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms",United States
"Open Label, Dose Finding and Expansion Phase IB Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (Pd L1 Antibody) in Pateints With Advanced Ovarian Cancer or Triple Negative Breast Cancer",I,Terminated,Roche {F. Hoffmann-La Roche},Oncology: Breast; Oncology: Ovarian,HER2 negative; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Ovarian Epithelial; Ovarian Cancer; Ovarian Neoplasms; Triple Negative Breast Neoplasms",Australia; Canada; Denmark; United Kingdom; United States
An Exploratory Phase IB Study to Assess the Effects of Merestinib on Bone Metastases in Subjects With Breast Cancer,I,Terminated,"Eli Lilly
Huntsman Cancer Institute
University of Utah",Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; Second line; Stage IV,Bone Marrow Diseases; Bone Neoplasms; Breast Neoplasms; Neoplasm Metastasis,United States
"A Phase Ia/Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors",I,Closed,"Roche/Genentech
BioNTech","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal",First line; Fourth line or greater; HER2 negative; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Positive; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Belgium; Canada; Germany; Netherlands; Spain; Sweden; United Kingdom; United States
"Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM14 Administered Intravenously to Patients With Advanced Solid Tumors",I,Open,PharmaMar,Oncology: Breast; Oncology: Colorectal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,BRCA; Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma",France; Spain; United States
"A Phase I/II, Open-Label, Multicenter, Dose Escalation and Efficacy Study of mRNA 2416, a Lipid Nanoparticle Encapsulated mRNA Encoding Human OX40L, for Intratumoral Injection Alone or in Combination With Durvalumab for Patients With Advanced Malignancies",I/II,Terminated,Moderna {Moderna Therapeutics},"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroblastoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Aggressive; BRCA; Classical; Indolent; Merkel; Nodular lymphocyte-predominant; PD-L1 Positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroblastoma; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
"Phase I Study of MCS110 Combined With Neoadjuvant Dose-Dense Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer",I,Terminated,"Novartis
Washington University School of Medicine",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,United States
A Phase I Dose Escalation Study Evaluating The Safety And Tolerability Of PF-06804103 In Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Solid Tumors,I,Terminated,Pfizer,Oncology: Breast; Oncology: Esophageal; Oncology: Gastric,(N/A); HER2 negative; HER2 positive; Second line,Breast Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Stomach Carcinoma; Stomach Neoplasms,Australia; Italy; Russia; South Korea; Spain; United States
"A Phase I/II Study for the Safety, Efficacy, Pharmacokinetic and Pharmacodynamics Evaluation of SAR439859, Administered Orally as Monotherapy, Then in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor-positive Advanced Breast Cancer (AMEERA-1).",I/II,Terminated,Sanofi {Sanofi-Aventis},Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,Belgium; Canada; Czech Republic; France; Italy; Poland; Portugal; Spain; United Kingdom; United States
A Phase Ib/IIa Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab,I/II,Closed,"Pfizer
Merck KGaA/EMD Serono {EMD Pharmaceuticals}
Promontory Therapeutics {Phosplatin Therapeutics}","Oncology: Bladder; Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Fourth line or greater; Large Cell; PD-1 Refractory; PD-L1 Positive; PD-L1 Refractory; Second line; Squamous Cell; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms, Unknown Primary; Prostatic Neoplasms; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Switzerland; United States
"A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Hormone Receptor-Positive HER2-Negative Breast Cancer (MORPHEUS-HR+ Breast Cancer)",I/II,Closed,Roche {F. Hoffmann-La Roche},Oncology: Breast,Estrogen receptor positive; HER2 negative; PD-L1 Positive; Progesterone receptor positive; Second line; Stage II; Stage III; Stage IV; Third line,Breast Neoplasms,Israel; South Korea; United States
"A Phase I/II Open-Label, Three-Part, Dose-Finding and Separate Cohort Expansion Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Repeated Doses of CLEVER-1 Antibody FP-1305, in Subjects With Advanced Solid Tumours.


MATINS (Macrophage Antibody To INhibit immune Suppression)

TIETALC (Tumour Immunity Enabling Technology Against Live Cancer) 
MATINS (Macrophage Antibody To INhibit immune Suppression)",I/II,Closed,Faron Pharmaceuticals,Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Gastric; Oncology: Liver; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Thyroid,Anaplastic; Distal; Estrogen receptor positive; Fourth line or greater; Hilar; Intrahepatic; PD-1 Refractory; PD-L1 Positive; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gallbladder Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms; Unspecified",Finland; France; Germany; Netherlands; Spain; United Kingdom; United States
A Phase I/II Safety and Efficacy Study of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies,I/II,Terminated,Incyte Corporation,Oncology: Bladder; Oncology: Breast; Oncology: Melanoma; Oncology: Renal; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Kidney Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Phase I/II Study of Anti-CD3 x Anti-HER2/Neu (HER2Bi) Armed Activated T Cells (ATC) and Pembrolizumab Combination Therapy in Women With Metastatic Breast Cancer,I/II,Open,"University of Virginia
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"A Phase Ib, Multicenter, Two-Part, Open-Label Study of Trastuzumab Deruxtecan, an Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), in Combination With Nivolumab, an Anti-PD-1 Antibody, for Subjects With HER2-expressing Advanced Breast and Urothelial Cancer",I/II,Closed,"AstraZeneca
Bristol-Myers Squibb
Daiichi Sankyo",Oncology: Bladder; Oncology: Breast,Fourth line or greater; HER2 positive; PD-1 Naive; PD-L1 Naive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Transitional Cell; Urethral Neoplasms; Urinary Bladder Neoplasms",France; Germany; Italy; Spain; United Kingdom; United States
"A Phase Ib Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors",I,Completed,"Merck & Co./Merck Sharp & Dohme (MSD)
Astellas Pharma
Astellas Pharma/Potenza Therapeutics","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",ALK; Classical; EGFR; Hormone refractory; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor","Canada; Italy; Japan; Portugal; South Korea; Spain; Taiwan, China; United Kingdom; United States"
"A Phase I, Multicenter, Open-label, Multiple Dose-escalation and Expansion Study of ARX788, as Monotherapy in Advanced Solid Tumors With HER2 Expression",I,Closed,Ambrx,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Renal; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Australia; United States
"A Phase I-II Multicenter, Open Label Trial of H3B-6545, a Covalent Antagonist of Estrogen Receptor Alpha, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer.",I/II,Closed,Eisai,Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,France; United Kingdom; United States
"A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anticancer Activity of Fruquintinib in Patients With Advanced Solid Tumors",I,Completed,Hutchmed {Hutchison MediPharma},"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Testicular; Oncology: Thyroid",Adenocarcinoma; Anaplastic; Estrogen receptor positive; Fourth line or greater; HER2 negative; Large Cell; Locally advanced; Metastatic; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gastrointestinal Stromal Tumors; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Medulloblastoma; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Testicular Cancer; Testicular Neoplasms; Thyroid Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A Phase I Open-label, Multicenter Study of MK-2118 Administered by Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab or by Subcutaneous Injection in Combination With Pembrolizumab for Patients With Advanced/Metastatic Solid Tumors or Lymphomas",I,Completed,Merck & Co./Merck Sharp & Dohme (MSD),"Oncology: Breast; Oncology: Head/Neck; Oncology: Liver; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Unspecified Solid Tumor",Aggressive; Classical; Cutaneous T-cell lymphoma (CTCL); Indolent; Liver mets; Nodular lymphocyte-predominant; Peripheral T-cell lymphoma (PTCL); Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Liver Cancer; Liver Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Melanoma; Neoplasm Metastasis; Neoplasms, Unknown Primary",Israel; United States
"A Phase I, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 Alone and in Combination With Palbociclib in Women With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer",I,Completed,G1 Therapeutics,Oncology: Breast,Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Ductal; Carcinoma, Ductal, Breast",Belgium; Bulgaria; Georgia; Moldova Republic; Netherlands; Ukraine; United States
An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer,I,Completed,Indiana University Cancer Center,Oncology: Breast,HER2 negative; Second line; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Phase Ib Study of Poziotinib in Combination With T-DM1 in Women With Advanced or Metastatic HER2-Positive Breast Cancer,I,Terminated,Spectrum Pharmaceuticals,Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase Ib Trial of Fulvestrant, Palbociclib (CDK4/6 Inhibitor) and Erdafitinib (JNJ- 42756493,Pan-FGFR Tyrosine Kinase Inhibitor) in ER+/HER2-/FGFR-Amplified Metastatic Breast Cancer (MBC)",I,Completed,"National Institutes of Health/National Cancer Institute
Vanderbilt-Ingram Cancer Center",Oncology: Breast,Estrogen receptor positive; FGFR; First line; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Third line,Breast Neoplasms,United States
"A Phase I Study Evaluating the Safety, Pharmacokinetics, And Anti-tumor Activity of ABBV-321 In Subjects With Advanced Solid Tumors Associated With Overexpression Of The Epidermal Growth Factor Receptor (EGFR) Or Its Ligands",I,Completed,AbbVie,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",EGFR; Second line; Squamous Cell; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Australia; Israel; United States
Phase I/Ia First-in-Human Study of EOS100850 as a Single Agent and in Combination With Pembrolizumab and/or Chemotherapy in Participants With Advanced Cancers,I/II,Closed,"Merck & Co./Merck Sharp & Dohme (MSD)
iTeos Therapeutics","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Fourth line or greater; HER2 negative; NRAS; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",Belgium; United Kingdom; United States
"A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Triple-Negative Breast Cancer (Morpheus-TNBC)",I/II,Closed,"Merck & Co.
Seagen {Seattle Genetics}
Gilead Sciences/Immunomedics
Roche {F. Hoffmann-La Roche}",Oncology: Breast,First line; HER2 negative; PD-L1 Naive; PD-L1 Positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Australia; France; Germany; Israel; South Korea; Spain; United Kingdom; United States
"A Phase I Study of AZD8186 in Combination With Docetaxel in Patients With PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel",I,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Prostate; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Neoplasms; Neoplasms, Unknown Primary; Prostatic Neoplasms",United States
"A Phase I, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms",I,Completed,"MacroGenics
Zai Lab","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Unspecified Hematological Cancer; Oncology: Unspecified Solid Tumor",Aggressive; Diffuse large B-cell lymphoma (DLBCL); Fourth line or greater; HER2 negative; HER2 positive; PD-1 High; PD-1 Positive; PD-L1 Positive; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative; Unresectable,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cholangiocarcinoma; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Hematologic Neoplasms; Lung Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Mesothelioma; Neoplasm Metastasis; Neoplasms; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",Australia; Bulgaria; China; Poland; Spain; Thailand; Ukraine; United States
Focused Ultrasound Therapy to Augment Antigen Presentation and Immune-Specificity of Checkpoint Inhibitor Therapy With Pembrolizumab in Metastatic Breast Cancer,I,Terminated,University of Virginia,Oncology: Breast,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Phase I/II Study of the TRK Inhibitor Selitrectinib in Adult and Pediatric Subjects With Previously Treated NTRK Fusion Cancers,I/II,Completed,"Bayer AG
Eli Lilly/Loxo Oncology","Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: GIST; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Pediatric or Adolescent; Second line; Stage III; Stage IV,"Astrocytoma; Bile Duct Neoplasms; Biliary Tract Neoplasms; Brain Neoplasms; Breast Neoplasms; Bronchial Neoplasms; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Bronchogenic; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Central Nervous System Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Glioblastoma; Head and Neck Neoplasms; Intestinal Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Melanoma; Neoplasms; Neoplasms, Basal Cell; Neoplasms, Nerve Tissue; Nephroma, Mesoblastic; Nerve Sheath Neoplasms; Nervous System Neoplasms; Neurofibrosarcoma; Nevi and Melanomas; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Respiratory Tract Neoplasms; Rhabdomyosarcoma; Salivary Gland Neoplasms; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Squamous Cell Carcinoma of Head and Neck; Synovial Sarcoma; Thoracic Neoplasms; Thyroid Diseases; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Neoplasms; Wilms Tumor","Australia; Belgium; Canada; China; Denmark; France; Germany; Hong Kong, S.A.R., China; Ireland; Italy; Singapore; South Korea; Spain; United Kingdom; United States"
A Phase I Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies,I,Closed,"Gilead Sciences
Arcus Biosciences","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Renal",Fourth line or greater; HER2 negative; Merkel; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Australia; United States
"A Phase 1/2, Open-Label, Study to Evaluate the Safety and Anti-Tumor Activity of FS118, a LAG-3/PD-L1 Bispecific Antibody, as a Monotherapy and in Combination With Paclitaxel, in Patients With Advanced Malignancies",I/II,Closed,"Merck KGaA
Sino Biopharmaceutical/invoX Pharma/F-star Therapeutics","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Advanced; Anaplastic; Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Locally advanced; Metastatic; PD-1 Refractory; PD-L1 Refractory; Progesterone receptor positive; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Neoplasms; Lymphoma, Non-Hodgkin; Melanoma; Mesothelioma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Squamous Cell Carcinoma of Head and Neck; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",United States
Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies,I,Open,"Oregon Health and Science University
Georgetown University Medical Center
GlaxoSmithKline/Tesaro","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV; Unspecified,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A Phase I, Multicenter Dose-Escalation Study to Assess the Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of AZD5153 in Patients With Relapsed/Refractory Malignant Solid Tumors, Including Lymphomas",I,Completed,AstraZeneca,"Oncology: Breast; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate",(N/A); Aggressive; Classical; HER2 negative; Indolent; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms",Canada; United States
Phase Ib Study of BYL719 (Alpelisib) in Combination With Androgen Receptor Inhibitor (Enzalutamide) in Patients With Androgen Receptor (AR)-Positive and PTEN Positive Metastatic Breast Cancer,I,Closed,"Novartis
MD Anderson Cancer Center, University of Texas
Astellas Pharma",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma,United States
Phase I Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy,I,Completed,TTC Oncology,Oncology: Breast,Estrogen receptor positive; Stage IV; Third line,Breast Neoplasms,United States
"First-in-Human, Dose Finding, Open Label Phase IA-IB Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies",I,Completed,Novita Healthcare {Avexa},"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",Aggressive; Classical; Indolent; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms",United States
A Randomized Phase I Trial of Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy,I,Closed,"National Institutes of Health/National Cancer Institute
Washington University School of Medicine
AstraZeneca {MedImmune}",Oncology: Breast,First line; HER2 negative; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"Phase I Study of TTI-101, an Oral Inhibitor of Signal Transducer and Activator of Transcription (STAT) 3, in Patients With Advanced Cancers",I,Completed,"MD Anderson Cancer Center, University of Texas
Tvardi Therapeutics","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Testicular; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms; Thyroid Neoplasms; Wilms Tumor",United States
"A Phase I/Ib First-in-human Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR439459 Administered Intravenously as Monotherapy and in Combination With Cemiplimab in Adult Patients With Advanced Solid Tumors",I,Terminated,Sanofi {Sanofi-Aventis}/Sanofi Genzyme {Genzyme},"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Multiple Myeloma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor",Fourth line or greater; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Multiple Myeloma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor","Australia; Belgium; Canada; Estonia; France; Germany; Italy; Netherlands; South Korea; Spain; Taiwan, China; United Kingdom; United States"
"A Phase I, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36, for Intratumoral Injection Alone and in Combination With Immune Checkpoint Blockade",I,Open,"AstraZeneca
Moderna {Moderna Therapeutics}","Oncology: Bladder; Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Unspecified Solid Tumor",Aggressive; Classical; Diffuse large B-cell lymphoma (DLBCL); Fourth line or greater; HER2 negative; Indolent; Nodular lymphocyte-predominant; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Positive; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",Australia; Israel; Italy; United States
Phase I/II Study of T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery,I/II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Metastatic Cancer,Adjuvant; CNS mets; HER2 positive; Stage IV,"Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis; Neoplasms, Second Primary",United States
"An Open-label, First-in-human, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose and / or Recommended Phase II Dose of the ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas",I/II,Open,Bayer AG/Bayer Pharmaceuticals,"Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Prostate",Adenocarcinoma; Aggressive; Diffuse large B-cell lymphoma (DLBCL); Estrogen receptor positive; Fourth line or greater; HER2 negative; Hormone refractory; Indolent; Mantle cell lymphoma (MCL); Progesterone receptor positive; Pulmonary; Second line; Squamous Cell; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Uterine Cervical Neoplasms",Canada; China; France; Germany; Japan; Singapore; Switzerland; United Kingdom; United States
"An Open-label Phase I Dose Finding Trial With BI 891065 Alone and in Combination With BI 754091 to Characterise Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Advanced and/or Metastatic Malignancies",I,Terminated,Boehringer Ingelheim,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Unknown Primary; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Phase Ib Study of PU-H71 With Nab-paclitaxel (Abraxane) in Patients With HER2-Negative Metastatic Breast Cancer,I,Completed,"Memorial Sloan-Kettering Cancer Center
Samus Therapeutics",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
"Evaluation of the Combination of Selumetinib and Olaparib in Endometrial, Ovarian and Other Solid Tumors With Ras Pathway Alterations, and Ovarian Tumors With PARP Resistance",I,Closed,"AstraZeneca
MD Anderson Cancer Center, University of Texas",Oncology: Breast; Oncology: Endometrial; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Thyroid; Oncology: Unspecified Solid Tumor,BRAF; Fourth line or greater; HRAS; KRAS; NRAS; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Genital Neoplasms, Female; Genital Neoplasms, Male; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Thyroid Neoplasms",United States
A Phase 1 Evaluation of the Safety and Tolerability of Niraparib in Combination With Everolimus in Advanced Gynecologic Malignancies and Breast Cancer,I,Closed,(Other Hospital/Academic/Medical Center),Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Ovarian,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Uterine Cervical Neoplasms",United States
A Phase I Evaluation of the Safety and Tolerability of TAK-228 in Combination With TAK-117 and Paclitaxel in Advanced Solid Tumors.,I,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast; Oncology: Endometrial; Oncology: Ovarian; Oncology: Unspecified Solid Tumor,Fourth line or greater; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms",United States
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors,I,Completed,Fate Therapeutics,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",EGFR; HER2 positive; Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",United States
"A Phase Ib Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors",I/II,Completed,"Myrexis {Myriad Pharmaceuticals {Myriad Genetics}}
BeiGene/BeiGene USA","Oncology: Breast; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Adenocarcinoma; BRCA; Extensive; First line; Fourth line or greater; HER2 negative; Hormone refractory; Large Cell; Pulmonary; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative; Untreated,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma",Australia; Spain; United Kingdom; United States
"A Phase Ib, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas",I,Terminated,"Novartis
Chinook Therapeutics {Aduro BioTech {Anza Therapeutics}}","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Prostate; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Aggressive; Classical; First line; Fourth line or greater; HER2 negative; Indolent; Merkel; MSS/pMMR; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Squamous Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Liposarcoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma",Australia; Canada; Germany; Japan; Netherlands; Spain; Switzerland; United States
"A Phase I Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)",I,Terminated,AbbVie,Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Renal,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Renal Cancer; Unspecified; Wilms Tumor",Australia; Denmark; Spain; United States
Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy,I,Completed,Spectrum Pharmaceuticals,Oncology: Breast,First line; Stage I; Stage II; Stage III,Breast Neoplasms,United States
A Phase I Multi-Center Trial of Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab,I,Completed,University of Michigan Comprehensive Cancer Center,Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
Phase I/II Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss,I/II,Closed,"GlaxoSmithKline
MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute
Merck & Co./Merck Sharp & Dohme (MSD)","Oncology: Breast; Oncology: Endometrial; Oncology: Melanoma; Oncology: Prostate; Oncology: Skin, Basal Cell Carcinoma; Oncology: Skin, Squamous Cell Carcinoma (cSCC)",Fourth line or greater; HER2 negative; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Endometrioid; Carcinoma, Squamous Cell; Endometrial Neoplasms; Melanoma; Neoplasms; Neoplasms, Basal Cell; Prostatic Neoplasms; Skin Neoplasms",United States
"A Pilot Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab [MEDI4736]) Plus Anti-CTLA-4 Antibody (Tremelimumab) in Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer",I,Terminated,"AstraZeneca
MD Anderson Cancer Center, University of Texas",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,United States
"Ph I/IB Evaluation of the Safety, Pharmacokinetics and Efficacy of GRN-300, a Salt-inducible Kinase Inhibitor, Alone and in Combination With Paclitaxel, in Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers",I,Closed,Arrien Pharmaceuticals,"Oncology: Breast; Oncology: Fallopian Tube; Oncology: Leukemia, Acute Myelogenous; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Unspecified Solid Tumor",(N/A); Aggressive; Diffuse large B-cell lymphoma (DLBCL); HER2 negative; Second line; Stage IV; Third line; Triple receptor negative,"Acute Myelocytic Leukemia; Breast Neoplasms; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms",United States
"A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelide Capsules Given Daily for 21 Days Followed by 7 Days Off Schedule in Patients With Advanced Solid Tumors",I,Open,Minneamrita Therapeutics,Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Cancer; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Colorectal Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
A Phase I Study to Evaluate the Safety and Tolerability of IACS-010759 in Subjects With Advanced Solid Tumors and Lymphoma,I,Completed,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute","Oncology: Breast; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",Aggressive; Classical; HER2 negative; Indolent; Maintenance/Consolidation; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms",United States
"A Phase Ib Trial Evaluating the Safety of Copanlisib, Letrozole, and Palbociclib in Metastatic Breast Cancer and Phase II Trial Comparing the Molecular Effects of Neoadjuvant Copanlisib in Combination With Palbociclib and Letrozole, vs. Copanlisib With Letrozole, vs. Palbociclib With Letrozole for Patients With Hormone Receptor Positive, HER2 Normal Breast Cancer",I/II,Terminated,"(Other Cooperative Group)
Jonsson Comprehensive Cancer Center, UCLA
Bayer AG/Bayer Pharmaceuticals",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms; Carcinoma,United States
"A Phase I/II Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies",I/II,Completed,Incyte Corporation,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Renal; Oncology: Unspecified Solid Tumor",(N/A); Adenocarcinoma; First line; HER2 negative; HER2 positive; Merkel; MSI-H/dMMR; MSI-L; MSS/pMMR; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Pulmonary; Second line; Squamous Cell; Stage III; Stage IV; Triple receptor negative; Untreated,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Australia; Belgium; Italy; Spain; United States
"A Phase I Study of HMBD-002-V4C26 (HMBD-002), a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Malignancies.",I/II,Open,Hummingbird Bioscience,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",HER2 negative; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms; Neoplasms, Unknown Primary; Triple Negative Breast Neoplasms",United States
"First-in-human, Open-Label, Dose-Escalation Trial with Expansion Cohorts to Evaluate Safety of GEN1029 in Patients with Malignant Solid Tumors",I/II,Terminated,Genmab,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Kidney Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",France; Spain; United Kingdom; United States
"A Phase I-II Study of Interferon-gamma Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients With HER-2 Positive Breast Cancer",I/II,Completed,"H. Lee Moffitt Cancer Center and Research Institute
Horizon Therapeutics {Horizon Pharma}",Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Second line; Stage 0; Stage I; Stage II; Stage III; Stage IV,"Breast Neoplasms; Breast Neoplasms, Male",United States
"Phase Ib Clinical Study of CBP501, Cisplatin and Nivolumab Administered Every 3 Weeks in Patients With Advanced Refractory Tumors",I,Completed,CanBas,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Fourth line or greater; MSS/pMMR; PD-1 Refractory; PD-L1 Positive; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Gallbladder Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Mesothelioma; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression",I,Terminated,ADC Therapeutics {Auven Therapeutics/ADC Therapeutics},"Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell",HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Cancer; Esophageal Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",Belgium; United States
Phase I/II Trial of Pembrolizumab in Combination With Binimetinib in Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer,I/II,Completed,"National Institutes of Health/National Cancer Institute
Mayo Clinic",Oncology: Breast,First line; Fourth line or greater; HER2 negative; PD-1 Naive; PD-L1 Naive; PD-L1 Positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Phase Ib Multi-Indication Study of Anetumab Ravtansine (BAY94-9343) in Patients With Mesothelin Expressing Advanced or Recurrent Malignancies,I,Completed,"National Institutes of Health/National Cancer Institute
Bayer AG/Bayer Pharmaceuticals
ImmunoGen
MorphoSys","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Thymus; Oncology: Unspecified Solid Tumor",Adenocarcinoma; HER2 negative; Second line; Stage III; Stage IV; Thymic carcinoma; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Esophageal Cancer; Esophageal Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Thymus Neoplasms; Unspecified",Australia; Belgium; Canada; France; Germany; Italy; Netherlands; Singapore; South Korea; Spain; Switzerland; United Kingdom; United States
"Phase I/II Dose-Rising, Safety, Tolerability and Efficacy Study of Topical SOR007 for Cutaneous Metastases",I/II,Completed,"Nanology (DFB Pharmaceuticals, CritiTech, and US Biotest joint venture)","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Testicular",Line of therapy N/A; Metastatic; Other mets; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Neoplasm Metastasis; Neoplasms, Second Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Skin Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Testicular Cancer; Testicular Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",United States
"A Phase 1b Study of Neratinib, Pertuzumab, and Trastuzumab With Taxol (3HT) in Primary Metastatic and Locally Advanced Breast Cancer, and Phase II Study of 3HT Followed by AC in HER2 + Primary IBC, and Neratinib With Taxol (NT) Followed by AC in HR+ /HER2- Primary IBC",I/II,Closed,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms; Carcinoma; Inflammatory Breast Neoplasms,United States
"A Phase I, Open-Label, Multicentre Dose-Escalation Study to Investigate the Safety and Pharmacokinetics of AZD4785 in Patients With Advanced Solid Tumours Where KRAS May Be an Important Driver of Tumour Survival",I/II,Completed,AstraZeneca,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Estrogen receptor positive; First line; HER2 negative; HER2 positive; KRAS; Large Cell; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United Kingdom; United States
Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response,I,Completed,University of Wisconsin,Oncology: Breast,Neoadjuvant; Stage 0; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"Phase Ia/IIa Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin",I/II,Terminated,Forbius {Formation Biologics},"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",HER2 negative; Second line; Squamous Cell; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",Canada; United States
"Pilot Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in ER+, Metastatic Breast Cancer Patients Receiving Endocrine Therapy",I,Terminated,Medical University of South Carolina,Oncology: Breast,Estrogen receptor positive; Line of therapy N/A; Stage IV,Breast Neoplasms,United States
"A Phase I/II, Single Arm, Non-randomized Study of Ribociclib (LEE011), a CDK 4/6 Inhibitor, in Combination With Bicalutamide, an Androgen Receptor (AR) Inhibitor, in Advanced AR+ Triple-negative Breast Cancer: Big Ten Cancer Research Consortium BRE15-024.",I/II,Open,"Novartis
(Other Academic Cancer Center)",Oncology: Breast,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Phase I Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies,I,Completed,"Celldex Therapeutics {AVANT Immunotherapeutics}
Merck & Co./Merck Sharp & Dohme (MSD)","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Renal; Oncology: Unspecified Solid Tumor",Aggressive; Diffuse large B-cell lymphoma (DLBCL); Extranodal marginal zone B-cell lymphoma (MALT); Follicular lymphoma (FL); Indolent; Mantle cell lymphoma (MCL); PD-1 Refractory; PD-L1 Refractory; Second line; Small lymphocytic lymphoma (SLL); Stage III; Stage IV; Waldenstrom's macroglobulinemia (WM),"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Waldenstrom Macroglobulinemia; Wilms Tumor",United States
"A Phase I/II Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination With AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical).",I/II,Completed,"(Other Industry Sponsor)
Agenus {Antigenics}","Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: GIST; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Soft Tissue Sarcoma",Adenocarcinoma; Advanced; HER2 negative; PD-L1 Positive; Second line; Squamous Cell; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Glioblastoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Liposarcoma; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Uterine Cervical Neoplasms",Australia; Brazil; Georgia; Hungary; Moldova Republic; Poland; Spain; Ukraine; United States
"A Multicenter, Phase I, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors",I,Completed,AbbVie,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Renal; Oncology: Unspecified Solid Tumor",(N/A); HER2 negative; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Cholangiocarcinoma; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor","France; Japan; Puerto Rico; Spain; Taiwan, China; United States"
"A Phase-I Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients With Solid Tumors",I,Terminated,Merrimack Pharmaceuticals,"Oncology: Bladder; Oncology: Breast; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",HER2 negative; Pulmonary; Second line; Stage IV; Triple receptor negative,"Adenocarcinoma; Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Lung Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Multicenter Phase I/II, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor",I/II,Open,Deciphera Pharmaceuticals,"Oncology: Breast; Oncology: Gastric; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lung, Non-Small Cell; Oncology: Myelodysplastic Syndrome; Oncology: Ovarian; Oncology: Prostate; Oncology: Tenosynovial Giant Cell Tumor",(N/A); Diffuse; Maintenance/Consolidation; Second line; Stage III; Stage IV,"Acute Myelocytic Leukemia; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Chronic Lymphocytic Leukemia; Giant Cell Tumor of Tendon Sheath; Giant Cell Tumors; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Synovitis; Synovitis, Pigmented Villonodular",Australia; Canada; France; Italy; Netherlands; Poland; Spain; United Kingdom; United States
"A Phase I, Open-Label, Dose Escalation Study of PRS-343 in Patients With HER2-Positive Advanced or Metastatic Solid Tumors",I,Completed,Pieris Pharmaceuticals {Pieris AG},Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Liver; Oncology: Pancreas; Oncology: Unspecified Solid Tumor,HER2 positive; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
A Phase Ib Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors.,I/II,Closed,"Exelixis
Takeda
Ipsen","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Thyroid",Adenocarcinoma; EGFR; First line; Follicular; HER2 negative; Hormone refractory; Large Cell; Papillary; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Positive; PD-L1 Refractory; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative; Untreated,"Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Australia; Belgium; France; Germany; Italy; Netherlands; Spain; United Kingdom; United States
"A Phase I, First-in-Human, Multi-Part Study of RAD140 in Postmenopausal Women With Hormone Receptor Positive Breast Cancer",I,Completed,"Radius Health {Radius}
Ellipses Pharma",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms; Neoplasms,United States
"Phase I Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib, or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation",I,Closed,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast; Oncology: Head/Neck; Oncology: Ovarian; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid; Oncology: Unspecified Solid Tumor,EGFR; HER2 negative; HER2 positive; KRAS; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Wilms Tumor",United States
Clinical Trial of Autologous cMET Redirected T Cells Administered Intravenously in Patients With Melanoma & Breast Carcinoma,I,Terminated,University of Pennsylvania,Oncology: Breast; Oncology: Melanoma,HER2 negative; PD-1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Melanoma,United States
A First-in-Human Clinical Study of ASLAN002 in Patients with Cancer,I,Completed,"Bristol-Myers Squibb
Aslan Pharmaceuticals","Metabolic/Endocrinology: Osteoporosis; Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer; Oncology: Prostate; Oncology: Renal; Oncology: Thyroid",(N/A); Bone mets; Chemotherapy-induced bone loss; Line of therapy N/A,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Kidney Neoplasms; Neoplasm Metastasis; Osteoporosis; Prostatic Neoplasms; Renal Cancer; Thyroid Neoplasms; Wilms Tumor",United States
Phase IB/II Open-label Single Arm Study to Evaluate Safety and Efficacy of Tucatinib in Combination With Palbociclib and Letrozole in Subjects With Hormone Receptor Positive and HER2-positive Metastatic Breast Cancer,I/II,Closed,"(Other Cooperative Group)
Pfizer
Seagen {Seattle Genetics/Cascadian Therapeutics {Oncothyreon {Biomira {OncoTherapeutics}}}}
University of Colorado",Oncology: Breast,Estrogen receptor positive; First line; Fourth line or greater; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"Pilot Study of Mirvetuximab Soravtansine (IMGN853) in Folate Receptor Alpha (FRa)-Expressing, Triple Negative Breast Cancer (TNBC) With Residual Disease Post Standard Neoadjuvant Chemotherapy",I,Terminated,"Duke University Medical Center
National Comprehensive Cancer Network",Oncology: Breast,HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
"A Phase I/IIA, Multi-Centre, Open-Label, Dose-Escalation Study with Expansion Arms to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CB-103 Administered Orally in Adult Patients with Locally Advanced or Metastatic Solid Tumours and Haematological Malignancies Characterised by Alterations of the NOTCH Signalling Pathway",I/II,Terminated,"Sotio
Cellestia Biotech
Glatt GmbH/Glatt Pharmaceutical Services","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Leukemia, Acute Lymphocytic; Oncology: Liver; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma",(N/A); Aggressive; Classical; Diffuse large B-cell lymphoma (DLBCL); Estrogen receptor positive; Extranodal marginal zone B-cell lymphoma (MALT); Follicular lymphoma (FL); Fourth line or greater; HER2 negative; HER2 positive; Indolent; Mantle cell lymphoma (MCL); Metastatic; Nodular lymphocyte-predominant; Other subtype; Peripheral T-cell lymphoma (PTCL); Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative; Unresectable,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Glioblastoma; Glomus Tumor; Head and Neck Neoplasms; Hematologic Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral; Melanoma; Multiple Myeloma; Neoplasms; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Uterine Cervical Neoplasms","China; France; Germany; Netherlands; South Korea; Spain; Switzerland; Taiwan, China; United Kingdom; United States"
A Phase Ib Study Of Pembrolizumab In Combination With Trastuzumab-DM1 In Metastatic HER2-Positive Breast Cancer,I,Completed,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,Estrogen receptor positive; HER2 positive; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Progesterone receptor positive; Second line; Stage I; Stage II; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"A Phase I/II Study With Open-Label, Dose Escalation Phase Followed by Single-Arm Expansion at the Maximum Tolerated Dose to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of NT219 Injection Alone and in Combination With ERBITUX (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer",I/II,Open,Purple Biotech {Kitov Pharma},Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Mesothelioma; Oncology: Pancreas; Oncology: Thyroid; Oncology: Unspecified Solid Tumor,Fourth line or greater; Metastatic; Papillary; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Mesothelioma; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms",Canada; Israel; United States
Phase I Study of TAK-228 (MLN0128) in Combination With Metformin in Patients With Advanced Cancers,I,Completed,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Fourth line or greater; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
Phase I/II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined With Daratumumab in Participants With Advanced or Metastatic Solid Tumors,I/II,Terminated,"Bristol-Myers Squibb
Johnson & Johnson/Janssen Biotech","Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",Adenocarcinoma; HER2 negative; Large Cell; PD-1 Naive; PD-L1 Naive; Second line; Squamous Cell; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Triple Negative Breast Neoplasms",Australia; Canada; France; Germany; Italy; Puerto Rico; Spain; Switzerland; United States
A Phase I Study of PD-1 Inhibition With Pembrolizumab Combined With JAK2 Inhibition in Triple Negative Breast Cancer,I,Closed,"National Institutes of Health/National Cancer Institute
Mayo Clinic",Oncology: Breast,Estrogen receptor positive; HER2 negative; PD-1 Naive; PD-L1 Naive; Second line; Stage IV; Triple receptor negative,Breast Neoplasms; Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase 1, Dose Escalation Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)",I,Completed,ALX Oncology {Alexo Therapeutics},"Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Aggressive; Diffuse large B-cell lymphoma (DLBCL); Extranodal marginal zone B-cell lymphoma (MALT); First line; Follicular lymphoma (FL); Fourth line or greater; HER2 positive; Indolent; Mantle cell lymphoma (MCL); PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Positive; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",South Korea; United States
"Phase I Open Label, Multicenter Study of MK-1454 Administered by Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab for Patients With Advanced/Metastatic Solid Tumors or Lymphomas",I,Completed,Merck & Co./Merck Sharp & Dohme (MSD),"Oncology: Breast; Oncology: Head/Neck; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Metastatic Cancer; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Aggressive; Anaplastic; Classical; Cutaneous T-cell lymphoma (CTCL); FGFR; First line; HER2 negative; Indolent; Liver mets; Nodular lymphocyte-predominant; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Peripheral T-cell lymphoma (PTCL); Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Liver Cancer; Liver Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Neoplasm Metastasis; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Thyroid Neoplasms",France; Israel; South Korea; United Kingdom; United States
"A Phase I, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Inavolisib as a Single Agent in Patients With Locally Advanced or Metastatic PIK3CA-Mutant Solid Tumors and in Combination With Endocrine and Targeted Therapies in Patients With Locally Advanced or Metastatic PIK3CA-Mutant Breast Cancer",I,Open,Roche/Genentech,Oncology: Breast; Oncology: Colorectal; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Colorectal Neoplasms; Neoplasms, Unknown Primary",Canada; France; Spain; United Kingdom; United States
A Presurgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist Darolutamide (ODM-201),I,Completed,"Bayer AG/Bayer Pharmaceuticals
Organisation for Oncology and Translational Research",Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,Canada; Germany; United States
"A Phase I, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (Anti-LAG-3 mAb) Administered Alone or in Combination With REGN2810 (Anti-PD-1 mAb) in Patients With Advanced Malignancies",I/II,Closed,"Regeneron
Sanofi {Sanofi-Aventis}","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid; Oncology: Unspecified Hematological Cancer; Oncology: Unspecified Solid Tumor",Aggressive; BRAF; Classical; First line; Indolent; Nodular lymphocyte-predominant; PD-1 Naive; PD-1 Refractory; PD-L1 High; PD-L1 Naive; PD-L1 Positive; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Untreated,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Glioblastoma; Head and Neck Neoplasms; Hematologic Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Medulloblastoma; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Ireland; South Korea; United Kingdom; United States
"A Multicenter, Phase I, Open-Label, Dose-Escalation Study of ABBV-181 as Monotherapy and in Combination With Another Anti-Cancer Therapy in Subjects With Advanced Solid Tumors",I,Completed,AbbVie,"Oncology: Anal; Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Mesothelioma; Oncology: Neuroblastoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Penile; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Extensive; First line; Fourth line or greater; Limited; PD-1 Naive; PD-1 Positive; PD-1 Refractory; PD-L1 Naive; PD-L1 Positive; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Third line; Untreated,"Anus Neoplasms; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Neuroblastoma; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Penile Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor","Australia; Austria; Belgium; Canada; Finland; France; Japan; Spain; Taiwan, China; United States"
A Pilot Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer.,I,Completed,Merck & Co./Merck Sharp & Dohme (MSD),Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Phase I Dose-Escalation Safety and Tolerability Study of MirvetuximabSoravtansine (IMGN853) and Gemcitabine in Patients With FRa-positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial Cancer, or Triple Negative Breast Cancer (TNBC).",I,Closed,"National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center",Oncology: Breast; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal,(N/A); Fourth line or greater; HER2 negative; Second line; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Endometrial Neoplasms; Fallopian Tube Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Triple Negative Breast Neoplasms",United States
"A Phase I Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients With Advanced Solid Tumors",I,Terminated,Syros Pharmaceuticals,"Oncology: Breast; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Unspecified Solid Tumor",BRCA; Estrogen receptor positive; Fourth line or greater; HER2 negative; Maintenance/Consolidation; Progesterone receptor positive; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Small Cell; Endometrial Neoplasms; Fallopian Tube Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Small Cell Lung Carcinoma; Unspecified",Canada; France; United States
"A Multicenter, Phase I, Open-Label, Dose-Escalation Study of ABBV-927 and ABBV-181, an Immunotherapy, in Subjects With Advanced Solid Tumors",I,Closed,AbbVie,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",PD-L1 Refractory; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Glioblastoma; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms",Australia; Canada; France; South Korea; Spain; United States
Expanded Access Protocol With ABT-888 (Veliparib) in Patients With Metastatic BRCA-Mutation Associated or Triple Negative Breast Cancer,I,Completed,"University of Washington
AbbVie",Oncology: Breast,BRCA; HER2 negative; Maintenance/Consolidation; Second line; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"Phase I/II Safety, Pharmacokinetic, and Antitumor Activity Study of G1T38 in Combination With Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer After Endocrine Failure",I/II,Closed,G1 Therapeutics,Oncology: Breast,Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Ductal; Carcinoma, Ductal, Breast",Bulgaria; Czech Republic; Georgia; Moldova Republic; Romania; United Kingdom; United States
"A Phase Ib/II Study of GS-5829 in Combination With Fulvestrant or Exemestane in Subjects With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer",I,Terminated,Gilead Sciences,Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms,Belgium; France; Italy; Spain; United Kingdom; United States
Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer With and Without Intra-operative RT: a Window of Opportunity Study,I,Open,Merck & Co./Merck Sharp & Dohme (MSD),Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase I Study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination With Temozolomide and Irinotecan",I,Completed,"National Institutes of Health/National Cancer Institute
Children’s Oncology Group","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: CNS, Brain Stem Glioma; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",(N/A); Pediatric or Adolescent; Second line,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Glioblastoma; Glioma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Medulloblastoma; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Nervous System Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A Phase I, Multi-Center, Open-Label, Dose Escalation, Multiple Ascending Dose, Efficacy, Safety and Tolerability Study of SRF-231 in Patients with Advanced Solid tumours and Hematological Malignancies",I,Completed,Surface Oncology,"Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Leukemia, Acute Myelogenous; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Hematological Cancer; Oncology: Unspecified Solid Tumor",(N/A); Aggressive; Cutaneous T-cell lymphoma (CTCL); Follicular lymphoma (FL); Indolent; Line of therapy N/A; Peripheral T-cell lymphoma (PTCL); Stage III; Stage IV,"Acute Myelocytic Leukemia; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Hematologic Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Leukemia, Myeloid, Acute; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Follicular; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Uterine Cervical Neoplasms; Wilms Tumor",Canada; United States
"A Phase I, Dose Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of TAS-116 in Patients with Advanced Solid Tumors.",I,Completed,Otsuka Holdings/Taiho Pharmaceutical,"Oncology: Breast; Oncology: Gastric; Oncology: GIST; Oncology: Lung, Non-Small Cell; Oncology: Thymus; Oncology: Unspecified Solid Tumor",(N/A); ALK; EGFR; HER2 positive; Second line; Stage III; Stage IV; Thymic carcinoma,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Stromal Tumors; Neoplasms; Neoplasms, Unknown Primary; Stomach Carcinoma; Stomach Neoplasms; Thymus Neoplasms",Italy; Japan; United Kingdom; United States
"A Phase I/II Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive/HER2-negative (HR+/HER2-) Advanced or Metastatic Breast Cancer",I/II,Completed,GlaxoSmithKline,Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,Australia; Canada; France; South Korea; Spain; United Kingdom; United States
A Phase I Trial of MK-7684 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors.,I,Closed,Merck & Co./Merck Sharp & Dohme (MSD),"Oncology: Breast; Oncology: Cervical; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal; Oncology: Unspecified Solid Tumor",Adenocarcinoma; BRCA; HER2 negative; Large Cell; PD-1 Naive; PD-L1 Naive; PD-L1 Positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Lung Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Australia; China; Israel; Japan; South Korea; United States
"A Phase I/II, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second Line Cervical Cancer.",I/II,Completed,Agenus {Antigenics},Oncology: Breast; Oncology: Cervical; Oncology: Ovarian; Oncology: Unspecified Solid Tumor,Adenocarcinoma; Fourth line or greater; PD-1 Positive; Second line; Squamous Cell; Stage III; Stage IV; Third line,"Breast Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Uterine Cervical Neoplasms",Australia; Belgium; Brazil; Chile; Estonia; France; Georgia; Lithuania; Moldova Republic; Poland; Romania; Spain; Ukraine; United States
A Phase Ib/II Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer,I/II,Completed,"Gilead Sciences/Forty Seven
California Institute for Regenerative Medicine (CIRM)",Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Ovarian; Oncology: Pancreas; Oncology: Unspecified Solid Tumor,Fourth line or greater; KRAS; Maintenance/Consolidation; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms",United States
"An Open-label, Phase I Trial to Determine the Maximum-tolerated Dose and Investigate Safety, Pharmacokinetics, and Efficacy of BI 754091 in Patients With Advanced Solid Tumours",I,Completed,Boehringer Ingelheim,"Oncology: Bladder; Oncology: Breast; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Renal; Oncology: Unspecified Solid Tumor",HER2 negative; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Kidney Neoplasms; Melanoma; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Canada; United Kingdom; United States
"A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGN-2FF in Patients With Advanced Solid Tumors",I,Terminated,Seagen {Seattle Genetics},"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Renal; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV,"Adenocarcinoma; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Colorectal Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Renal Cancer; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase Ib Study to Assess the Safety, Tolerability and Immunologic Activity of Preoperative IRX 2 In Early Stage Breast Cancer",I,Completed,"Providence Cancer Center at Providence Portland Medical Center
Eterna Therapeutics {Brooklyn ImmunoTherapeutics {IRX Therapeutics}}",Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,"Breast Neoplasms; Breast Neoplasms, Male; Neoplasms; Triple Negative Breast Neoplasms",United States
Escalation Study of BTP-114 in Patients With Advanced Solid Tumors and BRCA or DNA Repair Mutation,I,Completed,Placon Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",BRCA; Fourth line or greater; HER2 negative; Hormone refractory; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase I/Ib, Open-label, Multi-center Dose Escalation Study of NIS793 in Combination With PDR001 in Adult Patients With Advanced Malignancies",I,Completed,Novartis,"Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",HER2 negative; MSS/pMMR; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Wilms Tumor","Austria; Canada; Germany; Hong Kong, S.A.R., China; Italy; Japan; Singapore; South Korea; Switzerland; Taiwan, China; United States"
A Combined Phase I/II Efficacy Study of a Carbohydrate Mimotope-based Vaccine With MONTANIDE ISA 51 VG STERILE Combined With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer,I/II,Completed,University of Arkansas,Oncology: Breast,Adjuvant; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-115 in Patients With Advanced Solid Tumors or Lymphomas",I,Completed,Ascentage Pharma Group,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: GIST; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Aggressive; Classical; First line; Fourth line or greater; Indolent; Nodular lymphocyte-predominant; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Gastrointestinal Stromal Tumors; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms, Unknown Primary; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
"Comparison in the Change of Proliferation Index Between Fulvestrant and Tamoxifen in Cyclin D1 +, Estrogen Receptor + Breast Cancer",I,Terminated,"AstraZeneca
Icahn School of Medicine at Mount Sinai {Mount Sinai School of Medicine}",Oncology: Breast,(N/A); Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive,Breast Neoplasms,United States
"Phase I/II, Multicenter, Open-label, Multiple-Dose First-in-human Study of U3-1402, in Subjects With HER3 Positive Metastatic Breast Cancer",I/II,Closed,Daiichi Sankyo,Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,Japan; United States
"An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of a Single 100mg Oral Dose of Lapatinib in Healthy Subjects and in Subjects with Hepatic Impairment",I,Completed,GlaxoSmithKline,Oncology: Breast; Oncology: Unspecified Cancer,(N/A); Line of therapy N/A,"Breast Neoplasms; Carcinoma, Hepatocellular; Liver Cancer; Liver Neoplasms; Neoplasms",United States
"A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients With Advanced Solid Malignancies and Expansion in Select Malignancies",I/II,Open,Inspirna {Rgenix},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Aggressive; Classical; Extensive; First line; Fourth line or greater; HER2 negative; High-grade; Indolent; Large Cell; Limited; Nodular lymphocyte-predominant; PD-L1 Positive; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative; Unspecified; Untreated,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"Phase I Trial of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta (VSV-IFNß-NIS) Monotherapy and in Combination With Avelumab, in Patients With Refractory Solid Tumors.",I,Completed,Vyriad {Omnis Pharmaceuticals},"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Fourth line or greater; Other; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
"A Phase I/II, Open-label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab, and Other Anti-Cancer Therapies in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies

Doublet Combination Trial Of NKTR-214 With Anti-PD-1 And Anti-CTLA-4 Agents",I/II,Completed,"Bristol-Myers Squibb
Nektar Therapeutics","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Renal; Oncology: Unspecified Solid Tumor",(N/A); Adenocarcinoma; ALK; BRAF; First line; HER2 negative; Large Cell; PD-L1 Positive; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative; Untreated,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor","Australia; Belgium; Canada; Denmark; France; Hong Kong, S.A.R., China; Italy; Poland; Spain; Sweden; Ukraine; United Kingdom; United States"
A Phase Ib Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors (ILLUMINATE-101),I,Completed,"(Other Cooperative Group)
Aceragen {Idera Pharmaceuticals {Hybridon}}","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: GIST; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",Fourth line or greater; Second line; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Gastrointestinal Stromal Tumors; Leiomyosarcoma; Liposarcoma; Melanoma; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",Israel; United States
A Phase I Trial of Lenvatinib (Multi-kinase Inhibitor) and Capecitabine (Anti-metabolite) in Patients With Advanced Malignancies,I,Terminated,"MD Anderson Cancer Center, University of Texas
Eisai","Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Liver; Oncology: Mesothelioma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Testicular; Oncology: Thyroid",Advanced; Metastatic; Second line; Stage III; Stage IV,"Bone Neoplasms; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Cartilage Diseases; Central Nervous System Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Eye Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Genital Neoplasms, Female; Genital Neoplasms, Male; Glioblastoma; Head and Neck Neoplasms; Leiomyosarcoma; Lip Neoplasms; Liposarcoma; Liver Cancer; Liver Neoplasms; Medulloblastoma; Mesothelioma; Neoplasms; Neoplasms, Basal Cell; Neoplasms, Fibrous Tissue; Neoplasms, Mesothelial; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms",United States
Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib: A Randomized Pilot Trial With ESR1 Mutation Tested in Circulating Tumor DNA.,I,Closed,University of Pittsburgh,Oncology: Breast,Estrogen receptor positive; First line; Fourth line or greater; Second line; Stage IV; Third line,Breast Neoplasms,United States
"A Phase I Study of OTS167PO, a MELK Inhibitor, to Evaluate Safety, Tolerability and Pharmacokinetics in Patients With Advanced Breast Cancer and Dose-Expansion Study in Patients With Triple Negative Breast Cancer",I,Open,OncoTherapy Science,Oncology: Breast,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Japan; United States
"A Phase I, Randomized, Open-Label, Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors (SNDX-275-0141, MK3475-460/KEYNOTE-460)",I,Completed,"Merck & Co./Merck Sharp & Dohme (MSD)
Syndax","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV,"Breast Diseases; Breast Neoplasms; Bronchial Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Digestive System Neoplasms; Endocrine Gland Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Lung Diseases; Lung Neoplasms; Neoplasms; Neoplasms by Histologic Type; Neoplasms, Glandular and Epithelial; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Respiratory Tract Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Thoracic Neoplasms; Wilms Tumor",United States
Pre-surgical Evaluation of Denosumab in Patients With Operable Invasive Breast Cancer,I,Completed,NYU Langone Health,Oncology: Breast,Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
A Phase I Study of Palbociclib in Combination With Cisplatin or Carboplatin in Advanced Solid Malignancies,I,Closed,"Pfizer
(Other Hospital/Academic/Medical Center)","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gallbladder; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",First line; Squamous Cell; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Fibrosarcoma; Gallbladder Neoplasms; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
A Phase I Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors,I,Completed,Syndax,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Renal",Second line; Stage III; Stage IV,"Breast Diseases; Breast Neoplasms; Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Digestive System Neoplasms; Endocrine Gland Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gastrointestinal Neoplasms; Kidney Neoplasms; Lung Diseases; Lung Neoplasms; Neoplasms; Neoplasms by Histologic Type; Neoplasms, Glandular and Epithelial; Renal Cancer; Respiratory Tract Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Thoracic Neoplasms; Wilms Tumor",United States
"A Phase I Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors With Expansion in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer.",I,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Unspecified Solid Tumor,Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Adenocarcinoma; Breast Neoplasms; Carcinoma; Cystadenocarcinoma, Serous; Fallopian Tube Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Triple Negative Breast Neoplasms",United States
"Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With LCL161, Everolimus (RAD001) or Panobinostat (LBH589)",I,Completed,Novartis,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Renal",Adenocarcinoma; HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Renal Cancer; Triple Negative Breast Neoplasms; Wilms Tumor","Germany; Netherlands; South Korea; Spain; Taiwan, China; United Kingdom; United States"
A Novel Phase I/IIa Open Label Study of IMM 101 in Combination With Selected Standard of Care (SOC) Regimens in Patients With Metastatic Cancer or Unresectable Cancer at Study Entry,I/II,Terminated,Immodulon Therapeutics,"Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",Maintenance/Consolidation; Metastatic; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Second Primary; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",France; United Kingdom; United States
A Phase I Trial to Evaluate Safety and Tolerance of Intravenous 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Adolescent and Young Adults (AYA) Subjects With Cancers,I,Completed,Dekk-Tec,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Leukemia, Acute Lymphocytic; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Unspecified Cancer",Aggressive; Indolent; Pediatric or Adolescent; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Glioblastoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Medulloblastoma; Melanoma; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma",United States
"Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib)",I,Completed,Novartis,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell",Adenocarcinoma; HER2 negative; MSS/pMMR; Second line; Stage III; Stage IV; Triple receptor negative,"Adenocarcinoma; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Triple Negative Breast Neoplasms","Belgium; Canada; France; Israel; Italy; Singapore; South Korea; Spain; Taiwan, China; United States"
Phase Ib 9cUAB30 in Early Stage Breast Cancer to Evaluate Biologic Effect,I,Closed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Stage I; Stage II,"Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating",United States
Phase I Adoptive Cellular Therapy Trial With Endogenous CD8+ T Cells (ACTolog® IMA101) Alone or in Combination With Atezolizumab in Patients With Relapsed and/or Refractory Solid Cancers,I,Completed,"MD Anderson Cancer Center, University of Texas
Roche
immatics biotechnologies",Oncology: Anal; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Melanoma; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,"Anus Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified",United States
Phase I Trial of ZW25 in Patients With Locally Advanced (Unresectable) and/or Metastatic HER2-expressing Cancers.,I,Closed,"BeiGene
Zymeworks","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Distal; First line; Fourth line or greater; HER2 positive; Hilar; Intrahepatic; Second line; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Gallbladder Neoplasms; Leiomyosarcoma; Liposarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Unspecified; Uterine Cervical Neoplasms",Canada; South Korea; United States
Testing the Ability of Pembrolizumab to Alter the Tumor Immune MicroEnvironment (TIME) of High Risk DCIS,I,Open,"(Other Hospital/Academic/Medical Center)
Merck & Co./Merck Sharp & Dohme (MSD)
Moderna {Moderna Therapeutics}",Oncology: Breast,HER2 positive; Neoadjuvant; Stage 0,"Breast Neoplasms; Carcinoma; Carcinoma, Intraductal, Noninfiltrating",United States
A Phase I Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides,I,Terminated,Pfizer {Trillium Therapeutics {Stem Cell Therapeutics/Trillium Therapeutics}},"Oncology: Breast; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Multiple Myeloma; Oncology: Neuroendocrine; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Aggressive; Cutaneous T-cell lymphoma (CTCL); First line; Fourth line or greater; Indolent; Maintenance/Consolidation; Merkel; Peripheral T-cell lymphoma (PTCL); Second line; Stage I; Stage II; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma; Carcinoma, Merkel Cell; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Melanoma; Multiple Myeloma; Mycoses; Mycosis Fungoides; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
"Phase I/II Study Evaluating Safety and Effects of Preoperative High-Dose Vitamin D on the Receptors, Biomarkers and Pathological Characteristics of High Grade DCIS or Invasive Breast Cancer.",I/II,Terminated,University of Miami School of Medicine,Oncology: Breast,Neoadjuvant; Stage 0; Stage I; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Intraductal, Noninfiltrating",United States
"A Phase Ib/II Study of ARRY-382 in Combination With Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients With Advanced Solid Tumors",I/II,Terminated,Pfizer {Array BioPharma},"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Unspecified Solid Tumor",ALK; EGFR; First line; Fourth line or greater; HER2 negative; PD-1 Naive; PD-1 Refractory; PD-L1 High; PD-L1 Naive; PD-L1 Positive; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
A Phase I Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb20717 in Subjects With Selected Advanced Solid Tumors,I,Completed,Xencor,"Oncology: Anal; Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Penile; Oncology: Prostate; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Thymus; Oncology: Vulvar",Fourth line or greater; HER2 negative; Hormone refractory; MSI-H/dMMR; PD-1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Third line; Thymic carcinoma; Thymoma; Triple receptor negative,"Anus Neoplasms; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cholangiocarcinoma; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Melanoma; Mesothelioma; Mesothelioma, Malignant; Nasopharyngeal Carcinoma; Neoplasms, Basal Cell; Neoplasms, Mesothelial; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Penile Neoplasms; Prostatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Thymoma; Thymus Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Vulvar Neoplasms; Wilms Tumor",United States
A Phase I Trial of CV301 in Combination With Anti- PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer,I,Completed,Bavarian Nordic,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",Adenocarcinoma; ALK; EGFR; Fourth line or greater; HER2 positive; Hormone refractory; KRAS; Large Cell; Maintenance/Consolidation; PD-L1 High; PD-L1 Positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Lung Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",United States
Phase I/II Clinical Trial Of TERTiNT (4-1BB-based Adoptive T-Cell Therapy) To Treat  Cancer Patients,I/II,Open,(Other Hospital/Academic/Medical Center),"Oncology: Breast; Oncology: Lung, Non-Small Cell",(N/A); Second line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung",United States
A Phase Ib Study to Evaluate TAK-659 in Combination With Nivolumab in Patients With Advanced Solid Tumors.,I,Terminated,Takeda/Takeda Oncology {Millennium},"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",ALK; EGFR; First line; Fourth line or greater; HER2 negative; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Triple Negative Breast Neoplasms",Italy; Spain; United Kingdom; United States
"An Open Label, Phase Ib, Dose-escalation Study Evaluating the Safety and Tolerability of Xentuzumab and Abemaciclib in Patients With Locally Advanced or Metastatic Solid Tumours and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-positive, HER2-, Breast Cancer, Followed by Expansion Cohorts.",I,Closed,Boehringer Ingelheim,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",ALK; EGFR; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms; Neoplasms, Unknown Primary",Denmark; Finland; France; Japan; Spain; United States
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to Patients With CD70-Expressing Cancers,I/II,Open,"National Institutes of Health/National Cancer Institute
Center for Cancer Research",Oncology: Breast; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Kidney Neoplasms; Melanoma; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Wilms Tumor",United States
"A Phase I/II, Open-label, Multi-center Study of the Safety and Efficacy of BLZ945 as Single Agent and in Combination With PDR001 in Adults Patients With Advanced Solid Tumors",I/II,Terminated,Novartis,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",HER2 negative; Second line; Stage III; Stage IV,"Breast Neoplasms; Glioblastoma; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms","Australia; Israel; Italy; Japan; Singapore; Spain; Switzerland; Taiwan, China; United States"
CAREFOR Study: Precision Nutrition Caloric Restriction for Oncology Research: Precision Medicine Driving Precision Nutrition During Neoadjuvant Chemotherapy for Breast Cancer,I,Completed,"Kimmel Cancer Center-Thomas Jefferson University - Philadelphia, PA",Oncology: Breast,Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
A Phase Ib Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination With Durvalumab in Human Leukocyte Antigen (HLA)-A2+ Subjects Following Standard Treatment of Stage II or III Triple Negative Breast Cancer,I,Completed,"AstraZeneca
Massachusetts General Hospital
OncoPep",Oncology: Breast,First line; HER2 negative; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"An Open Label, Phase I Study to Assess the Effect of Itraconazole (CYP3A4 and P-gp Inhibitor) on the Pharmacokinetics of Anetumab Ravtansine and to Assess the ECG Effects, Safety and Immunogenicity of Anetumab Ravtansine Given as a Single Agent and Together With Itraconazole in Subjects With Mesothelin-expressing Advanced Solid Cancers",I,Completed,Bayer AG/Bayer Pharmaceuticals,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Thymus",Adenocarcinoma; Advanced; HER2 negative; Second line; Stage III; Stage IV; Thymic carcinoma; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Thymus Neoplasms",Australia; Belgium; France; Netherlands; Spain; United Kingdom; United States
"A Phase I, Two-Cohort, Open-Label, Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women with Locally Recurrent or Metastatic ER+ Breast Cancer",I,Completed,Syndax,Oncology: Breast,Estrogen receptor positive; Second line; Stage IV,Breast Neoplasms,United States
"A Multi-Center, Randomized, Double Blind, Placebo-Controlled, Phase IIA Study to Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid With Adjuvant Chemotherapy in Patients With Triple Negative Breast Cancer (TNBC) After Surgery",I/II,Planned,BioLite,Oncology: Breast,Adjuvant; HER2 negative; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,"Taiwan, China; United States"
"A Phase Ib/II, Open Label, Multicenter Study Of MCS110 In Combination With PDR001 In Patients With Advanced Malignancies",I/II,Completed,Novartis,Oncology: Breast; Oncology: Endometrial; Oncology: Melanoma; Oncology: Pancreas; Oncology: Unspecified Solid Tumor,HER2 negative; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Endometrial Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Triple Negative Breast Neoplasms","Belgium; Finland; France; Germany; Hong Kong, S.A.R., China; Italy; Japan; South Korea; Spain; Switzerland; United States"
"A Phase Ia/Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Patients With Locally Advanced or Metastatic Tumors",I,Closed,Roche/Genentech,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Renal; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Estrogen receptor positive; HER2 negative; HER2 positive; PD-L1 Positive; Progesterone receptor positive; Second line; Squamous Cell; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Australia; Canada; France; Italy; Japan; South Korea; Spain; United States
A Phase I Clinical Trial to Evaluate the Safety and Tolerability of Mesothelin-Specific Chimeric Antigen Receptor-Positive T Cells in Patients With Metastatic Mesothelin-Expressing Breast Cancer,I,Closed,"Memorial Sloan-Kettering Cancer Center
US Department of Defense",Oncology: Breast,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
A Phase Ia/Ib Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination with Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT),I,Completed,Eli Lilly,"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Small Intestine; Oncology: Unspecified Solid Tumor",Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; MSI-H/dMMR; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Intestinal Neoplasms; Melanoma; Microsatellite Instability; Neoplasms; Neoplasms, Unknown Primary; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms","Belgium; Canada; France; South Korea; Spain; Taiwan, China; United States"
A Phase Ib Study of LY3039478 in Combination With Other Anticancer Agents in Patients With Advanced or Metastatic Solid Tumors,I,Completed,Eli Lilly,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Aggressive; Classical; HER2 negative; Indolent; Locally advanced; Metastatic; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Cholangiocarcinoma; Colorectal Neoplasms; Fibrosarcoma; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms, Unknown Primary; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",Denmark; France; Spain; United States
"A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma",I,Closed,GlaxoSmithKline,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Renal; Oncology: Unspecified Solid Tumor",Aggressive; Estrogen receptor positive; HER2 negative; Indolent; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms, Unknown Primary; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Canada; France; Netherlands; United States
Pilot Clinical Trial of Short-Term Bisphosphonate Administration as Chemoprevention For Breast Cancer Via Engagement of Gamma delta T Cells,I,Terminated,"University of Wisconsin
(Other Hospital/Academic/Medical Center)",Oncology: Breast,(N/A); BRCA; Neoadjuvant,Breast Neoplasms,United States
"A Phase I-II, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors (PROCLAIM-CX-2009)",I/II,Completed,CytomX Therapeutics,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate",Adenocarcinoma; BRCA; Estrogen receptor positive; Fourth line or greater; HER2 negative; Hormone refractory; PD-1 Refractory; PD-L1 Refractory; Progesterone receptor positive; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Cholangiocarcinoma; Endometrial Neoplasms; Head and Neck Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms",Germany; Netherlands; Spain; United Kingdom; United States
A Phase I Study to Evaluate the Pharmacokinetic and Safety Profile of AZD9496 Following Single Dose Administration of Different Forms and Formulations in Healthy Subjects,I,Completed,AstraZeneca,Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
"Phase I/II Study of the Combination of Pembrolizumab, Letrozole, and Palbociclib in Postmenopausal Patients With Newly Diagnosed Metastatic Estrogen Receptor Positive Breast Cancer",I/II,Temporarily Closed,"National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center",Oncology: Breast,Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; PD-1 Naive; PD-L1 Naive; PD-L1 Positive; Progesterone receptor positive; Second line; Stage IV; Third line,Breast Neoplasms,United States
"A Phase Ib Study of Abemaciclib in Combination With Pembrolizumab for Patients With Stage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast Cancer",I,Completed,"Eli Lilly
Merck & Co./Merck Sharp & Dohme (MSD)","Oncology: Breast; Oncology: Lung, Non-Small Cell",Adenocarcinoma; Estrogen receptor positive; First line; HER2 negative; KRAS; Large Cell; PD-1 Naive; PD-L1 High; PD-L1 Naive; PD-L1 Positive; Progesterone receptor positive; Second line; Squamous Cell; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms","Belgium; France; Italy; Spain; Taiwan, China; Turkey; United States"
A Phase I/II Study of Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer,I/II,Completed,"Amgen
H. Lee Moffitt Cancer Center and Research Institute",Oncology: Breast,HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Ductal; Carcinoma, Ductal, Breast; Triple Negative Breast Neoplasms",United States
"A Phase Ib Pilot Clinical Trial of Cirmtuzumab, an Anti-ROR1 Monoclonal Antibody, in Combination With Paclitaxel for the Treatment of Patients With Metastatic, or Locally Advanced, Unresectable Breast Cancer",I,Completed,"(Other Hospital/Academic/Medical Center)
Oncternal Therapeutics {Tokalas}",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"An Open-Label, Multicenter, Dose-Escalation Phase Ib Study With Expansion Phase to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Therapeutic Activity of Emactuzumab and RO7009789 Administered in Combination in Patients With Advanced Solid Tumors",I,Completed,Roche {F. Hoffmann-La Roche},Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas,Advanced; HER2 negative; Line of therapy N/A; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Colorectal Neoplasms; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Unspecified",Belgium; France; United States
"Phase I/II Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone and in Combination With Nivolumab, Ipilimumab, or Pembrolizumab in Adult Subjects With Advanced and/or Refractory Solid Tumor Malignancies",I/II,Completed,Jounce Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative; Unspecified,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"Phase I Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Low-Expressing (IHC 1+/2+) Breast Cancer",I,Completed,NantWorks/NantBioScience,Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A Multinational, Open-Label, Dose Escalation Phase I/II Study To Assess The Safety And Clinical Activity Of Multiple Administrations Of NKR-2 In Patients With Different Metastatic Tumor Types

THerapeutic Immunotherapy with NKR-2 (THINK)",I/II,Terminated,Celyad Oncology {Celyad {Cardio3 BioSciences}},"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Fallopian Tube; Oncology: Leukemia, Acute Myelogenous; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome; Oncology: Ovarian; Oncology: Pancreas",HER2 negative; Maintenance/Consolidation; RAEB; Second line; Stage III; Stage IV; Triple receptor negative,"Acute Myelocytic Leukemia; Breast Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms, Plasma Cell; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",Belgium; United States
"Phase I/II Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3ß) Inhibitor, as a Single Agent and Combined With Chemotherapy, in Patients With Refractory Hematologic Malignancies or Solid Tumors.",I/II,Open,"(Other Hospital/Academic/Medical Center)
Actuate Therapeutics","Oncology: Bladder; Oncology: Breast; Oncology: CNS, Astrocytoma; Oncology: CNS, Glioblastoma; Oncology: CNS, Oligodendroglioma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Head/Neck; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Hematological Cancer",Advanced; Aggressive; BRAF; EGFR; Fourth line or greater; Grade 2; Grade 3; Indolent; Merkel; Metastatic; PD-1 Refractory; PD-L1 Positive; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Third line,"Acute Myelocytic Leukemia; Astrocytoma; Bone Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Colorectal Neoplasms; Endometrial Neoplasms; Ewing Sarcoma; Fibrosarcoma; Glioblastoma; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, T-Cell; Liposarcoma; Lung Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasm Metastasis; Neoplasms; Neuroendocrine Tumors; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Denmark; France; Germany; Netherlands; Spain; United Kingdom; United States
A Phase I/IIa Study of BMS-986178 Administered Alone or in Combination With Nivolumab and/or Ipilimumab in Subjects With Advanced Solid Tumors,I/II,Completed,Bristol-Myers Squibb,"Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal",ALK; BRAF; EGFR; First line; HER2 negative; KRAS; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative; Untreated,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Uterine Cervical Neoplasms; Wilms Tumor",Australia; Belgium; Canada; France; Germany; Israel; Italy; Netherlands; Spain; Switzerland; United Kingdom; United States
"A Pilot and Phase II Study to Assess the Safety, Tolerability and Efficacy of Pembrolizumab Plus Chemotherapy in Metastatic Triple Negative Breast Cancer Patients",I/II,Completed,"Earle A. Chiles Research Institute - EACRI
(Other Hospital/Academic/Medical Center)
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,First line; HER2 negative; Second line; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase I/Ib, Open Label Study of LSZ102 Single Agent and LSZ102 in Combination With Either LEE011 (LSZ102 + LEE011) or BYL719 (LSZ102 + BYL719) in Patients With Advanced or Metastatic ER+ Breast Cancer Who Have Progressed After Endocrine Therapy",I,Terminated,Novartis,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Stage III; Stage IV,Breast Neoplasms,Belgium; Canada; France; Germany; Italy; Japan; Singapore; Spain; United States
"A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor",I/II,Completed,Novartis,Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"A Phase I/II Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)",I/II,Open,"Eli Lilly
Eli Lilly/Loxo Oncology","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Small Intestine; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Anaplastic; First line; Follicular; Fourth line or greater; Large Cell; Medullary; Other; Papillary; Second line; Squamous Cell; Stage I; Stage II; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Fibrosarcoma; Intestinal Neoplasms; Leiomyosarcoma; Liposarcoma; Lung Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Diseases; Thyroid Neoplasms","Australia; Canada; Denmark; France; Germany; Hong Kong, S.A.R., China; Israel; Italy; Japan; Netherlands; Poland; Singapore; South Korea; Spain; Switzerland; Taiwan, China; United Kingdom; United States"
"A Phase I, Multi-center, Open-label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Pediatric Subjects With Advanced Non Central Nervous System Tumors That Are Amenable to Direct Injection",I,Completed,Amgen,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor",Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Australia; Belgium; Canada; France; Italy; Spain; Sweden; Switzerland; United States
"Phase I Study of Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors",I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Unspecified",United States
"Phase I, Open Label, Study Of Pgv001 A Multi-Peptide Therapeutic Vaccine Platform For Use In The Treatment Of Malignancies In The Adjuvant Setting",I,Completed,Icahn School of Medicine at Mount Sinai {Mount Sinai School of Medicine},"Oncology: Bladder; Oncology: Breast; Oncology: Fallopian Tube; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Multiple Myeloma; Oncology: Ovarian; Oncology: Renal; Oncology: Skin, Squamous Cell Carcinoma (cSCC)",Adjuvant; Maintenance/Consolidation; Other subtype; Squamous Cell; Stage III,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Multiple Myeloma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase Ib Study of the Combination of MLN0128 (Dual TORC1/2 Inhibitor) and MLN8237 (Aurora A Inhibitor, Alisertib) in Patients With Advanced Solid Tumors With an Expansion Cohort in Metastatic Triple-negative Breast Cancer (TNBC)",I,Completed,University of Colorado,Oncology: Breast; Oncology: Colorectal; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor,Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Triple Negative Breast Neoplasms; Wilms Tumor",United States
A Phase I Trial of MK-4280 as Monotherapy and in Combination With Pembrolizumab With or Without Chemotherapy or Lenvatinib (E7080/MK-7902) in Subjects With Advanced Solid Tumors,I/II,Closed,Merck & Co./Merck Sharp & Dohme (MSD),"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Renal; Oncology: Unspecified Solid Tumor",ALK; EGFR; Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; MSS/pMMR; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms, Unknown Primary; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Wilms Tumor",Canada; China; Germany; Israel; Japan; Poland; South Korea; Spain; United States
A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Olaparib (PARP Inhibitor) in Patients with Advanced Solid Tumors.,I/II,Completed,AstraZeneca,"Oncology: Breast; Oncology: Gastric; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate",BRCA; Extensive; First line; Fourth line or greater; HER2 negative; HER2 positive; PD-L1 Positive; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative; Untreated,"Breast Neoplasms; Carcinoma, Small Cell; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms",France; Israel; Netherlands; South Korea; Switzerland; United Kingdom; United States
"A Phase I/II, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies",I/II,Terminated,Incyte Corporation,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Fallopian Tube; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome; Oncology: Myeloproliferative Neoplasms; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Hematological Cancer; Oncology: Unspecified Solid Tumor",Advanced; Aggressive; Classical; High risk; Hormone refractory; Indolent; Nodular lymphocyte-predominant; Primary Myelofibrosis; Second line; Stage III; Stage IV,"Acute Myelocytic Leukemia; Bile Duct Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Fallopian Tube Neoplasms; Fibrosarcoma; Glioblastoma; Hematologic Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Leukemia, Myeloid, Acute; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Multiple Myeloma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",Belgium; France; United States
A Phase I Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb23104 in Subjects With Selected Advanced Solid Tumor,I,Open,Xencor,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",(N/A); Adenocarcinoma; HER2 negative; Large Cell; MSI-H/dMMR; MSS/pMMR; PD-1 Refractory; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Histiocytoma, Malignant Fibrous; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Melanoma; Nasopharyngeal Carcinoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A Phase I Study of Safety, Tolerability, and Feasibility of AutoSynVax Vaccine as a Single Agent in Subjects With Advanced Cancer",I,Terminated,Agenus {Antigenics},Oncology: Breast; Oncology: Liver; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
"A Phase I, Open Label, Dose Escalation Study of The Safety and Pharmacokinetics of Anti-PD-L1 Monoclonal Antibody KN035 Administered in Subcutaneous Injection as A Single Agent to Subjects With Locally Advanced or Metastatic Solid Tumors",I,Completed,"Suzhou Alphamab Co.
3D Medicines Inc./Sichuan 3DMed-Alphamab Co. {3D Medicines (Sichuan) Co.}","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Prostate; Oncology: Unspecified Solid Tumor",MSI-H/dMMR; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",United States
"A Phase IB Dose Exploration Trial With MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Advanced Solid Tumors",I,Terminated,Merck & Co./Merck Sharp & Dohme (MSD),"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Prostate",HER2 negative; Hormone refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Prostatic Neoplasms; Triple Negative Breast Neoplasms",Belgium; Canada; France; Spain; Switzerland; United States
"Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884) in Subjects With Advanced or Refractory Cancer and in Subjects Who Have Progressed During Treatment With a PD 1/PD-L1 Inhibitor as Their Most Recent Therapy",I/II,Completed,"Agenus {Antigenics}
Recepta Biopharma","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Liver; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Aggressive; Classical; Fourth line or greater; Indolent; Nodular lymphocyte-predominant; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Cholangiocarcinoma; Fibrosarcoma; Glioblastoma; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms, Unknown Primary; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified",United States
"Effects of Multiple Doses of Abemaciclib on the Pharmacokinetics of Cytochrome P450 (CYP) 1A2, CYP2C9, CYP2D6, and CYP3A Substrates (Caffeine, Warfarin, Dextromethorphan, and Midazolam) in Cancer Patients",I,Completed,Eli Lilly,Oncology: Breast; Oncology: Unspecified Cancer,Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms; Neoplasm Metastasis; Neoplasms,United States
"A Phase Ib Dose Escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX51107 in Subjects With Advanced Malignancies",I/II,Terminated,Daiichi Sankyo/Plexxikon,"Oncology: Breast; Oncology: Leukemia, Acute Myelogenous; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Myelodysplastic Syndrome; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",(N/A); Aggressive; Classical; High risk; Indolent; Int-2 risk; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV,"Acute Myelocytic Leukemia; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Fibrosarcoma; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Myelodysplastic Syndromes; Neoplasms, Unknown Primary; Preleukemia; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
"Phase Ib Study To Assess The Safety, Tolerability, And Clinical Activity Of Gedatolisib In Combination With Palbociclib And Either Letrozole Or Fulvestrant In Women With Metastatic Or Locally Advanced/Recurrent Breast Cancer (MBC)",I,Completed,Celcuity,Oncology: Breast,Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"A Phase Ib, First-in-Human, Dose Escalation and Expansion Study of XMT-1522 in Patients With Advanced Breast Cancer and Other Advanced Tumors Expressing HER2",I,Terminated,Mersana Therapeutics,"Oncology: Breast; Oncology: Gastric; Oncology: Lung, Non-Small Cell",HER2 negative; HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Stomach Carcinoma; Stomach Neoplasms",United States
A Phase Ib Trial of LY2157299 (TGFBetaR1 Kinase Inhibitor) With Paclitaxel in Patients With Triple Negative Metastatic Breast Cancer,I,Completed,"National Institutes of Health/National Cancer Institute
Vanderbilt-Ingram Cancer Center",Oncology: Breast,HER2 negative; Second line; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma,United States
A Phase Ib Study of ARQ 751 as a Single Agent or in Combination With Other Anti-Cancer Agents in Adult Subjects With Advanced Solid Tumors With PIK3CA / AKT / PTEN Mutations,I,Terminated,Merck & Co. {ArQule},Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Ovarian; Oncology: Prostate; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Colorectal Neoplasms; Endometrial Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Uterine Cervical Neoplasms",United States
"An Open-Label, Multicenter, Dose Escalation Phase Ib Study With Expansion Cohorts to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Therapeutic Activity of RO7009789 (CD40 Agonistic Monoclonal Antibody) in Combination With Vanucizumab (Anti-Ang2 and Anti-VEGF Bi-Specific Monoclonal Antibody, Part I) or Bevacizumab (Anti-VEGF Monoclonal Antibody, Part II) in Patients With Metastatic Solid Tumors",I,Completed,Roche {F. Hoffmann-La Roche},"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Adenocarcinoma; HER2 negative; Large Cell; Medullary; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",Belgium; Canada; Denmark; Italy; Netherlands; Spain; United States
"A Phase I/IIa Multicenter, Open-Label Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer",I/II,Completed,"Bristol-Myers Squibb/Celgene
Lycera","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Fourth line or greater; Pulmonary; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasm Metastasis; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase I/II Trial of CDX-1401 (a Vaccine Consisting of a Human Monoclonal Antibody Specific for DEC-205, Fused to Full-length Tumor Antigen NY-ESO-1) in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients",I/II,Terminated,Case Western Reserve University,"Oncology: Bladder; Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine",Advanced; HER2 negative; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Lung Neoplasms; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Neuroendocrine Tumors; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Phase I/Ib, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Participants With Advanced Solid Tumors",I,Completed,"Myrexis {Myriad Pharmaceuticals {Myriad Genetics}}
BeiGene","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor",BRCA; Extensive; Fourth line or greater; HER2 negative; Hormone refractory; MSI-H/dMMR; PD-1 Naive; PD-L1 Naive; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Kidney Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Australia; France; New Zealand; Spain; United Kingdom; United States
A Phase I Dose Escalation Study Evaluating The Safety And Tolerability Of Pf-06671008 In Patients With Advanced Solid Tumors,I,Terminated,Pfizer,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor",HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
A Phase I Study of CB1 for the Treatment of Breast Cancer,I,Terminated,Tiziana Life Sciences,Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
A Phase I/II Study to Evaluate the Safety and Efficacy of Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer,I/II,Terminated,"Sylvester Cancer Center, University of Miami
Roche/Genentech",Oncology: Breast,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Phase Ib Study to Evaluate the Safety and Tolerability of Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Patients With Advanced Solid Tumors.,I,Completed,AstraZeneca,"Oncology: Breast; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas",First line; HER2 negative; Pulmonary; Stage III; Stage IV; Triple receptor negative; Untreated,"Breast Neoplasms; Carcinoma; Carcinoma, Pancreatic Ductal; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Esophageal Cancer; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms",Japan; South Korea; United States
"A Phase I Dose Escalaton and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors.",I/II,Closed,GlaxoSmithKline/Tesaro,"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: GIST; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Renal; Oncology: Small Intestine; Oncology: Unspecified Solid Tumor",ALK; EGFR; Fourth line or greater; MSI-H/dMMR; MSS/pMMR; PD-1 Naive; PD-L1 High; PD-L1 Naive; PD-L1 Positive; Second line; Stage I; Stage II; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gastrointestinal Stromal Tumors; Intestinal Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",Canada; Czech Republic; Denmark; France; Italy; Poland; Spain; United Kingdom; United States
"An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.",I/II,Completed,"Novartis
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute",Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"Phase IB Study Investigating the Tolerability, Immunomodulatory Impacts and, Therapeutic Correlates of the Novel Toll-like Receptor 8 Agonist Motolimod (MOTO) Plus Cyclophosphamide (CTX) Treatment of Advanced Solid Tumors",I,Terminated,"National Institutes of Health/National Cancer Institute
Mayo Clinic","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",Second line; Stage IV,"Adenocarcinoma; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Lung Neoplasms; Melanoma; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Wilms Tumor",United States
Phase I Study of Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases,I,Completed,"Memorial Sloan-Kettering Cancer Center
(Other Hospital/Academic/Medical Center)",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; HER2 positive; Second line; Stage III; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
MK-3475 (Pembrolizumab) in Combination With an Anthracycline or Anti-estrogen Therapy in Patients With Triple Negative and Hormone Receptor Positive (HR+ HER2-) Metastatic Breast Cancer,I/II,Terminated,"National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; PD-L1 Positive; Progesterone receptor positive; Second line; Stage I; Stage II; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
Evaluation of an Alternative Schedule for CRLX101 Alone in Combination With Bevacizumab and in Combination With mFOLFOX6 in Subjects With Advanced Solid Tumor Malignancies,I,Terminated,"Lumos Pharma {NewLink Genetics}
Dare Bioscience {Cerulean Pharma}","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",HER2 negative; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Renal Cell; Carcinoma, Small Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Kidney Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Pembrolizumab + INCB Combinations in Advanced Solid Tumors",I/II,Completed,Incyte Corporation,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",HER2 negative; KRAS; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Pilot Study of a Rapid Access Platform for Investigational Drugs (RAPID) in Advanced Cancers,I,Completed,"National Institutes of Health/National Cancer Institute
Mayo Clinic",Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal,Second line; Squamous Cell; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Endometrial Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Recurrence; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms; Wilms Tumor",United States
"A Phase I/II Study of In Situ Vaccination With Tremelimumab and IV Durvalumab (MEDI4736) Plus the Toll-like Receptor Agonist PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers",I/II,Completed,"(Other Academic Cancer Center)
AstraZeneca {MedImmune}
Ludwig Institute for Cancer Research","Oncology: Bladder; Oncology: Breast; Oncology: Head/Neck; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Cancer",Cutaneous T-cell lymphoma (CTCL); Indolent; Merkel; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma; Carcinoma, Merkel Cell; Carcinoma, Renal Cell; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Melanoma; Neoplasms; Neuroendocrine Tumors; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Squamous Cell Carcinoma of Head and Neck; Synovial Sarcoma; Testicular Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Phase Ib/IIa Study of Palbociclib in Combination With Everolimus and Exemestane in Postmenopausal Women With Estrogen Receptor Positive and HER2 Negative Metastatic Breast Cancer,I/II,Completed,"Pfizer
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
"A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 in Patients With Advanced Solid Tumors",I,Closed,"MacroGenics
Catalent {Catalent Pharma Solutions}
Incyte Corporation
Zai Lab","Oncology: Anal; Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",Adenocarcinoma; Fourth line or greater; MSI-H/dMMR; PD-1 Naive; PD-L1 Naive; PD-L1 Positive; Second line; Stage III; Stage IV; Third line,"Anus Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",Australia; Belgium; Bulgaria; China; Finland; France; Germany; Italy; Latvia; Lithuania; New Zealand; Poland; Spain; Ukraine; United Kingdom; United States
"Phase I Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers",I,Closed,Abramson Cancer Center at  University of Pennsylvania Medical Center,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas",Second line; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Pancreatic Cancer; Pancreatic Neoplasms",United States
"A Phase I Trial of SL-801, a Novel Inhibitor of XPO1 Nuclear Export, in Patients With Advanced Solid Tumors",I,Terminated,Menarini Group/Stemline Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Fourth line or greater; Metastatic; Pulmonary; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
A Phase I/II Study of the Oral TRK Inhibitor Larotrectinib in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors.,I/II,Closed,"Bayer AG/Bayer Yakuhin
Eli Lilly/Loxo Oncology
PCI Pharma Services","Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Other; Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Fourth line or greater; Papillary; Pediatric or Adolescent; Second line; Stage III; Stage IV; Third line,Breast Neoplasms; Central Nervous System Neoplasms; Ewing Sarcoma; Fibrosarcoma; Glioblastoma; Leiomyosarcoma; Liposarcoma; Neoplasms; Osteosarcoma; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms,Australia; Canada; China; Czech Republic; Denmark; France; Germany; Ireland; Israel; Italy; Japan; Netherlands; Poland; Russia; South Korea; Spain; Sweden; Switzerland; Turkey; Ukraine; United Kingdom; United States
Phase I/II With Expansion Cohorts in a Study of NEO-201 in Adults With Chemo-Resistant Solid Tumors,I/II,Open,"National Institutes of Health/National Cancer Institute
Precision Biologics {Neogenix}","Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer; Oncology: Pancreas",BRAF; MSI-H/dMMR; MSS/pMMR; Other mets; PD-1 Refractory; PD-L1 Positive; PD-L1 Refractory; Second line; Squamous Cell; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Neoplasm Metastasis; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Uterine Cervical Neoplasms; Uterine Neoplasms",United States
"An Open-label, Multicenter Phase I Dose Escalation Study to Characterize Safety, Tolerability, Preliminary Anti-tumor Activity, Pharmacokinetics and Maximum Tolerated Dose of VIP152 (BAY 1251152) as Monotherapy or Combination Therapy in Subjects With Advanced Cancer.",I,Open,Bayer AG/Bayer Pharmaceuticals,"Oncology: Breast; Oncology: Colorectal; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor",Aggressive; Diffuse large B-cell lymphoma (DLBCL); Follicular lymphoma (FL); Fourth line or greater; HER2 negative; Mantle cell lymphoma (MCL); Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Colorectal Neoplasms; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Unspecified",Chile; Spain; United States
"A Clinical Study on Efficacy of Liposomal Doxorubicin, Bevacizumab and the mTOR Inhibitors Temsirolimus or Everolimus for the Treatment of Mesenchymal Triple-Negative Breast Cancer (TNBC)",I,Completed,"MD Anderson Cancer Center, University of Texas",Oncology: Breast,HER2 negative; HER2 positive; Line of therapy N/A; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
Multi-center Phase IB Trial of ACY-1215 (Ricolinostat) Combined With Nab-paclitaxel in Unresectable or Metastatic Breast Cancer,I,Completed,"National Institutes of Health/National Cancer Institute
Columbia University Medical Center
Acetylon",Oncology: Breast,First line; Fourth line or greater; HER2 negative; HER2 positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
A Phase Ib/IIa Three-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer,I/II,Open,Esperas Pharma,Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Triple Negative Breast Neoplasms",Canada; United States
"A Phase I Study of PARP Inhibitor BMN 673 and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors With Expansion in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer",I,Terminated,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Adenocarcinoma; Breast Neoplasms; Carcinoma; Cystadenocarcinoma, Serous; Fallopian Tube Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Triple Negative Breast Neoplasms",United States
"A Phase I Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab in Adults With Advanced Solid Tumors",I,Completed,Leap Therapeutics {HealthCare Pharmaceuticals {Dekkun}},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Esophageal Cancer; Esophageal Neoplasms; Gallbladder Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
Phase I Dose-Escalation Study of Combination of Gedatolisib (a Dual Inhibitor of PI3-K and mTOR) With Palbociclib and Faslodex in the Neoadjuvant Setting in Previously Untreated Patients With ER+/HER2- Breast Cancer,I,Closed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
"An Open-Label, Multicenter, Dose-Escalation, Phase Ia/Ib Study to Evaluate Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281, an Immunocytokine Consisting of Interleukin 2 Variant (IL-2v) Targeting Fibroblast Activation Protein-alpha (FAP), as a Single Agent (Part A) or in Combination with Trastuzumab or Cetuximab (Part B or C)",I,Completed,Roche {F. Hoffmann-La Roche},Oncology: Breast; Oncology: Head/Neck; Oncology: Melanoma; Oncology: Unspecified Solid Tumor,HER2 positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Head and Neck Neoplasms; Melanoma; Neoplasms, Unknown Primary",Belgium; Canada; Denmark; France; Italy; Netherlands; Spain; United Kingdom; United States
"A Phase I, Open-Label Study to Evaluate the Effect of GDC-0810 on the Pharmacokinetics of Pravastatin in Healthy Female Subjects of Non-Childbearing Potential",I,Completed,Roche/Genentech,Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms; Unspecified,United States
"A Phase Ib, Open-label Study of Alpelisib (BYL719) in Combination With Cisplatin in Patients With HPV+ Solid Tumor Malignancies",I,Terminated,"University of California, San Francisco",Oncology: Anal; Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Neuroendocrine; Oncology: Penile; Oncology: Prostate; Oncology: Unspecified Solid Tumor,Fourth line or greater; Other; Second line; Stage III; Stage IV; Third line,"Anus Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Penile Neoplasms; Prostatic Neoplasms; Uterine Cervical Neoplasms",United States
Phase Ib Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer,I,Terminated,Dartmouth-Hitchcock Medical Center,Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase I Study Assessing the Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) in Combination With MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours",I,Completed,AstraZeneca,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Renal",Adenocarcinoma; Extensive; Fourth line or greater; HER2 negative; Large Cell; Pulmonary; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
Combination Immunotherapy With Interferon-gamma and Nivolumab for Patients With Advanced Solid Tumors: A Phase I Study,I,Completed,"Fox Chase Cancer Center
Horizon Therapeutics {Horizon Pharma}","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",HER2 negative; HER2 positive; MSI-H/dMMR; PD-1 Positive; PD-1 Refractory; PD-L1 Refractory; Pulmonary; Second line; Squamous Cell; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"An Open-Label, Dose-Finding and Proof of Concept Study of the PD-L1 Probody Therapeutic , CX-072, as Monotherapy and in Combination With Yervoy (Ipilimumab) or With Zelboraf (Vemurafenib) in Subjects With Advanced or Recurrent Solid Tumors or Lymphomas PROCLAIM-CX-072: PRObody CLinical Assessment In Man CX-072 clinical trial

Probody Clinical Assessment In Man (PROCLAIM-072)",I/II,Completed,CytomX Therapeutics,"Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Small Intestine; Oncology: Soft Tissue Sarcoma; Oncology: Testicular; Oncology: Thymus; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Aggressive; BRAF; Classical; Estrogen receptor positive; Fourth line or greater; HER2 negative; Hormone refractory; Indolent; Merkel; Nodular lymphocyte-predominant; Other; PD-1 Naive; PD-L1 High; PD-L1 Naive; Progesterone receptor positive; Pulmonary; Second line; Stage III; Stage IV; Third line; Thymic carcinoma; Thymoma; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Glioblastoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Intestinal Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms; Thymoma; Thymus Neoplasms; Thyroid Neoplasms; Uterine Cervical Neoplasms",France; Germany; Hungary; Netherlands; Poland; Spain; Ukraine; United Kingdom; United States
A Pharmacokinetic and Pharmacodynamic Study of LA-EP2006 in Healthy Subjects,I,Completed,Novartis/Sandoz,Oncology: Breast; Oncology: Supportive Care,(N/A); Line of therapy N/A; Neutropenia,Breast Neoplasms; Neutropenia; Palliative Care,United States
"A Phase I Open-Label, Multicenter, Dose-Escalation Study of PRN1371, a FGFR 1-4 Kinase Inhibitor, in Adult Patients With Advanced Solid Tumors, Followed by an Expansion Cohort in Patients With Metastatic Urothelial Carcinoma With FGFR I, II, III, or IV Genetic Alterations",I,Terminated,Sanofi/Principia Biopharma,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Renal; Oncology: Unspecified Solid Tumor",FGFR; PD-1 Refractory; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Kidney Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Renal Cancer; Small Cell Lung Carcinoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Spain; United States
Phase I-Ib/II Open-label Multi-center Study of the Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies,I/II,Terminated,Novartis,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thymus; Oncology: Unspecified Solid Tumor",Extensive; First line; Metastatic; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Positive; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Thymoma,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thymoma; Thymus Neoplasms; Wilms Tumor","Australia; Canada; Germany; Italy; Japan; Netherlands; Singapore; South Korea; Switzerland; Taiwan, China; United States"
"Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors",I/II,Completed,"Calithera Biosciences
Incyte Corporation","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Fourth line or greater; Large Cell; MSI-H/dMMR; MSI-L; MSS/pMMR; PD-1 Refractory; PD-L1 Refractory; Second line; Squamous Cell; Stage III; Stage IV; Third line,"Acute Myelocytic Leukemia; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Leukemia, Myeloid, Acute; Liposarcoma; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Italy; Netherlands; Spain; United States
A Phase I-II Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors,I/II,Completed,eFFECTOR Therapeutics,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: GIST; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Fourth line or greater; PD-1 Refractory; PD-L1 Refractory; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
Phase I/II Trial of Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC),I/II,Closed,"Memorial Sloan-Kettering Cancer Center
Pfizer",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage I; Stage II; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
"A Phase Ib, Open-Label Study Evaluating the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Trastuzumab Emtansine or With Trastuzumab and Pertuzumab (With and Without Docetaxel) in Patients With HER2-Positive Breast Cancer and Atezolizumab With Doxorubicin and Cyclophosphamide in HER2-Negative Breast Cancer",I,Completed,Roche {F. Hoffmann-La Roche},Oncology: Breast,Adjuvant; HER2 negative; HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
Phase I Study of Adoptive Immunotherapy for Advanced ROR1+ Malignancies With Defined Subsets of Autologous T Cells Engineered to Express a ROR1-Specific Chimeric Antigen Receptor,I,Terminated,"National Institutes of Health/National Cancer Institute
Fred Hutchinson Cancer Research Center
Bristol-Myers Squibb/Celgene/Juno Therapeutics","Oncology: Breast; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's",Aggressive; ALK; EGFR; HER2 negative; Mantle cell lymphoma (MCL); Remission; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Chronic Lymphocytic Leukemia; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Lung Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma",United States
"A Phase I/II Multicenter Study of the Combination of AZD2014 and Palbociclib on a Background of Hormonal Therapy in Patients With Locally Advanced/Metastatic Estrogen Receptor Positive Breast Cancer Comprising a Safety, Pharmacokinetic and Preliminary Efficacy Evaluation Followed by a Randomized, Double-Blind, Placebo-controlled, Parallel Group Extension",I/II,Completed,AstraZeneca,Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms,United Kingdom; United States
"A Phase I/IIa Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy of BMS-986156 Administered Alone and in Combination With Nivolumab (BMS-936558, Anti PD-1 Monoclonal Antibody) in Advanced Solid Tumors",I/II,Completed,Bristol-Myers Squibb,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal",Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Australia; Belgium; Canada; France; Germany; Italy; Netherlands; Spain; Switzerland; United Kingdom; United States
A Phase I Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer,I,Completed,Abramson Cancer Center at  University of Pennsylvania Medical Center,Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,United States
Phase I Dose Escalation Trial of Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis,I,Terminated,Duke University Medical Center,Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; First line; HER2 positive; Stage IV,"Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis; Neoplasms, Second Primary",United States
A Phase I/II Safety Study of Intratumorally Administered INT230-6 in Adult Subjects with Advanced Refractory Cancers.,I/II,Completed,"Bristol-Myers Squibb
University of Southern California
Merck & Co./Merck Sharp & Dohme (MSD)
University Health Network, Toronto
Intensity Therapeutics","Oncology: Anal; Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Aggressive; Classical; First line; Fourth line or greater; Indolent; MSS/pMMR; Nodular lymphocyte-predominant; PD-1 Refractory; PD-L1 Refractory; Stage III; Stage IV; Third line,"Anus Neoplasms; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Cholangiocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Glioblastoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Canada; United States
A Phase I Study of APX3330 in Patients With Advanced Solid Tumors.,I/II,Completed,Apexian Pharmaceuticals {ApeX Therapeutics},"CNS: Pain (neuropathic); Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Endometrial; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Supportive Care; Oncology: Unspecified Solid Tumor",Cancers-related; Neurotoxicity; Second line; Stage III; Stage IV,"Breast Neoplasms; Cancer pain; Cancer Pain; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Glioblastoma; Liver Cancer; Liver Neoplasms; Medulloblastoma; Melanoma; Neoplasms, Unknown Primary; Neuralgia; Ovarian Cancer; Ovarian Neoplasms; Palliative Care; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
A Phase I/II Clinical Trial of Pritumumab in Patients With Metastatic Lung Cancer and Metastatic Breast Cancer,I/II,Terminated,Nascent Biotech,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer",CNS mets; Line of therapy N/A; Stage IV,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Neoplasm Metastasis",United States
A Bioequivalence Study of EIR-101 for Metastatic Breast Cancer in Postmenopausal Women,I,Completed,OPKO Health/EirGen Pharma,Oncology: Breast,Line of therapy N/A; Stage IV,Breast Neoplasms,United States
"A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Preliminary Anti-tumour Activity of Ascending Doses of Selumetinib (AZD6244 Hyd-sulfate) in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours",I,Completed,AstraZeneca,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas",MSI-L; MSS/pMMR; Second line; Stage III; Stage IV,"Adenocarcinoma; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",Czech Republic; Germany; United States
The TEEL Study: A Phase I Trial of Tamoxifen With Ribociclib (LEE011) in Adult Patients With Advanced ER+ (HER2 Negative) Breast Cancer,I,Terminated,"Novartis
H. Lee Moffitt Cancer Center and Research Institute",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"A Phase I/II Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Immunogencity, and Antitumor Activity of MEDI4276 in Subjects With Select HER2-expressing Advanced Solid Tumors",I/II,Completed,AstraZeneca {MedImmune},Oncology: Breast; Oncology: Esophageal; Oncology: Gastric,Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Stomach Carcinoma; Stomach Neoplasms,Belgium; France; South Korea; Spain; United States
Phase I Trial of Super-Selective Intra-Arterial Cerebral Infusion of Trastuzumab After Blood-Brain Barrier Disruption for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer,I,Terminated,(Other Hospital/Academic/Medical Center),Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; HER2 positive; Second line; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
"Phase I, Two-Part, Multicenter, Non-randomized, Open-label, Multiple Dose First-In-Human Study Of DS-8201A, In Subjects With Advanced Solid Malignant Tumors.",I,Completed,"AstraZeneca
Daiichi Sankyo","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",Estrogen receptor positive; Fourth line or greater; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gallbladder Neoplasms; Head and Neck Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Stomach Carcinoma; Stomach Neoplasms",Japan; United States
"A Multicenter, Phase I, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors",I,Completed,AbbVie,"Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Osteosarcoma; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Histiocytoma, Malignant Fibrous; Leiomyosarcoma; Liposarcoma; Neoplasms, Unknown Primary; Osteosarcoma; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Squamous Cell Carcinoma of Head and Neck; Synovial Sarcoma",France; Spain; United States
A Pilot Study of Brain Irradiation and Tremelimumab in Metastatic Breast Cancer,I,Completed,"Memorial Sloan-Kettering Cancer Center
AstraZeneca {MedImmune}",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; HER2 negative; HER2 positive; Second line; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
Phase I/II Study of CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors,I/II,Completed,Corcept Therapeutics,Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Fallopian Tube; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor; Oncology: Vulvar,Fourth line or greater; HER2 negative; Stage III; Stage IV; Third line; Triple receptor negative; Unspecified,"Bile Duct Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Fallopian Tube Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Vulvar Neoplasms",United States
"A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety, Tolerability and Efficacy of Olaparib in Combination With Carboplatin: Part A: Dose Escalation of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer; Followed by Part B: an Expansion Phase of Olaparib in Combination With Carboplatin in the Neoadjuvant Treatment of HER-2 Negative Breast Cancer Patients With Germline BRCA1/2 Mutations",I,Terminated,AstraZeneca,Oncology: Breast,BRCA; Estrogen receptor positive; First line; HER2 negative; Neoadjuvant; Progesterone receptor positive; Second line; Stage II; Stage III; Stage IV; Third line,Breast Neoplasms,Israel; Spain; United States
"A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment and Efficacy of INCB Combinations in Advanced Solid Tumors",I,Terminated,Incyte Corporation,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",ALK; BRAF; EGFR; HER2 negative; HER2 positive; PD-1 Naive; PD-1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"Phase I, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms",I,Terminated,MacroGenics,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Advanced; Fourth line or greater; HER2 negative; Locally advanced; Metastatic; PD-1 Refractory; PD-L1 Refractory; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative; Unresectable,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Squamous Cell Carcinoma of Head and Neck; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Australia; Canada; United States
"A Phase I/Ib First-In-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Monotherapy and in Combination With Nivolumab in Subjects With Advanced Solid Tumors",I,Completed,"Bristol-Myers Squibb
Infinity Pharmaceuticals","Oncology: Breast; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Unspecified Solid Tumor",ALK; EGFR; Fourth line or greater; HER2 negative; MSI-H/dMMR; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Stage III; Stage IV; Triple receptor negative,"Adrenocortical Carcinoma; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Mesothelioma; Mesothelioma, Malignant; Neoplasms, Mesothelial; Neoplasms, Squamous Cell; Neoplasms, Unknown Primary; Triple Negative Breast Neoplasms",United States
"A Phase Ib/II Open-label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (msb0010718c) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies",I/II,Terminated,Pfizer,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Tenosynovial Giant Cell Tumor; Oncology: Unspecified Solid Tumor",ALK; Diffuse; EGFR; Extensive; First line; Fourth line or greater; HER2 negative; Metastatic; MSI-H/dMMR; MSS/pMMR; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Positive; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative; Untreated,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Giant Cell Tumor of Tendon Sheath; Head and Neck Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Synovitis, Pigmented Villonodular; Urethral Neoplasms; Urinary Bladder Neoplasms","Australia; Canada; France; Germany; Japan; Netherlands; Poland; Taiwan, China; United Kingdom; United States"
"A Phase Ib Study of the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors",I,Completed,"Bristol-Myers Squibb/Celgene
Acetylon","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Cervical; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Prostate",Second line; Stage II; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Uterine Cervical Neoplasms",United States
"A Phase I, First-in-man, Multicenter, Open-label, Dose-escalation Study of Single-agent GBR 1302 in Subjects With HER2 Positive Cancers",I,Terminated,Glenmark,Oncology: Bladder; Oncology: Breast; Oncology: Gastric,(N/A); HER2 positive; Line of therapy N/A,"Breast Neoplasms; Neoplasms, Unknown Primary; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms",Germany; Spain; United States
A Phase 1b Dose-Escalation Study of the AKT Inhibitor MK-2206 (NSC# 749607) Plus Lapatinib (NSC# 727989) Administered in Patients With HER2 Positive Metastatic Breast Cancer,I,Terminated,National Institutes of Health/National Cancer Institute,Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
Phase I Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer,I,Terminated,HUYABIO International {HUYA Bioscience},Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase Ib Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma",I,Terminated,Forte Biosciences {Tocagen},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Adjuvant; Aggressive; BRCA; Classical; CNS mets; FGFR; Fourth line or greater; HER2 negative; Indolent; Intrahepatic; KRAS; Liver mets; Neoadjuvant; Nodular lymphocyte-predominant; NRAS; Other mets; Stage II; Stage III; Stage IV; Triple receptor negative,"Bile Duct Neoplasms; Brain Neoplasms; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasm Metastasis; Neoplasms, Basal Cell; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
An Open-Label Multicenter Phase I Study of E7046 in Subjects With Selected Advanced Malignancies,I,Terminated,Eisai,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal",Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",France; United States
"Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors",I,Completed,PharmaMar {Zeltia/PharmaMar},"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: GIST; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Testicular",First line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Testicular Cancer; Testicular Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",Spain; United States
"A Randomized, Placebo-controlled, Double-blind, Multicenter Phase II Study of Atezolizumab With or Without Entinostat in Patients With Advanced Triple Negative Breast Cancer, With a Phase Ib Lead in Phase",I/II,Completed,"Syndax
Roche/Genentech",Oncology: Breast,Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,Georgia; United States
A Phase I Trial of Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies,I,Completed,"MD Anderson Cancer Center, University of Texas
Mologen",Oncology: Breast; Oncology: Cervical; Oncology: Liver; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Unspecified Solid Tumor,Fourth line or greater; High-grade; Pancreas; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Peritoneal Neoplasms; Prostatic Neoplasms; Uterine Cervical Neoplasms",United States
Evaluation of Pharmacodynamic Effects of Intratumoral Delivery of Plasmid IL-12 Electroporation in Patients With Triple Negative Breast Cancer,I,Completed,"Stanford University Medical Center
OncoSec Medical",Oncology: Breast,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase I, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection to Patients With Advanced/Metastatic Solid Tumors or Lymphomas",I,Terminated,"Novartis
Chinook Therapeutics {Aduro BioTech {Anza Therapeutics}}","Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Unspecified Solid Tumor",Aggressive; Classical; Estrogen receptor positive; HER2 negative; HER2 positive; Indolent; Line of therapy N/A; Merkel; Nodular lymphocyte-predominant; Other; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms",United States
"A Phase I, Open-Label Study of GSK3174998 Administered Alone and in Combination With Anticancer Agents Including Pembrolizumab in Subjects With Selected Advanced Solid Tumors",I,Completed,"GlaxoSmithKline
Merck & Co./Merck Sharp & Dohme (MSD)","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Fourth line or greater; HER2 negative; Locally advanced; Metastatic; MSI-H/dMMR; PD-1 Naive; PD-1 Refractory; PD-L1 Low; PD-L1 Naive; PD-L1 Positive; PD-L1 Refractory; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Canada; France; Netherlands; United States
A Phase I Study of the Safety and Tolerability of Single Agent MSI-1436C in Metastatic Breast Cancer Patients,I,Terminated,"(Other Hospital/Academic/Medical Center)
DepYmed (Ohr Pharmaceutical and Cold Spring Harbor Laboratory joint venture)",Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
"A Phase I/II Study of Preoperative (Neoadjuvant) Combination of Letrozole (Femara), Everolimus (Afinitor), and TRC105 in Postmenopausal Women With Newly Diagnosed Local or Locally Advanced Potentially Resectable Hormone-Receptor Positive and Her2 Negative Breast Cancer",I/II,Closed,"Novartis
University of Alabama, Birmingham
Tracon Pharmaceuticals",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,United States
"A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications.",I,Terminated,"GlaxoSmithKline
National Institutes of Health/National Cancer Institute
Merck KGaA/EMD Serono {EMD Pharmaceuticals}","Oncology: Anal; Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",Adenocarcinoma; BRAF; First line; Fourth line or greater; HER2 negative; Large Cell; PD-1 Naive; PD-1 Refractory; PD-L1 High; PD-L1 Naive; PD-L1 Positive; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative; Unspecified,"Anus Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Glioblastoma; Head and Neck Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Uterine Cervical Neoplasms","Australia; Belgium; Canada; France; Germany; Italy; Japan; South Korea; Spain; Taiwan, China; United Kingdom; United States"
"A Phase I/II Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer.",I/II,Open,Takeda,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer; Oncology: Unspecified Solid Tumor",CNS mets; EGFR; First line; Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Cholangiocarcinoma; Esophageal Cancer; Esophageal Neoplasms; Gallbladder Neoplasms; Head and Neck Neoplasms; Neoplasm Metastasis; Neoplasms, Unknown Primary; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms","China; France; Germany; Italy; Japan; South Korea; Spain; Taiwan, China; United Kingdom; United States"
"A Randomized, Open-label, Multicenter, Phase Ib/II Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)",I/II,Terminated,"Eisai
Halozyme Therapeutics",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Maintenance/Consolidation; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
Phase I Study of Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children With Relapsed and Refractory Solid Tumors and Leukemias,I,Open,"Amgen {Onyx Pharmaceuticals}
(Other Hospital/Academic/Medical Center)","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Neuroendocrine; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",(N/A); Aggressive; Classical; Indolent; Nodular lymphocyte-predominant; Pediatric or Adolescent; Pulmonary; Second line,"Acute Myelocytic Leukemia; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Phase Ib Study of AZD1775 and Olaparib in Patients With Refractory Solid Tumours.,I/II,Completed,AstraZeneca,"Oncology: Breast; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian",Extensive; First line; HER2 negative; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative; Untreated,"Breast Neoplasms; Carcinoma, Small Cell; Lung Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Small Cell Lung Carcinoma",Canada; United States
"A Phase IB/II, Multicenter, Open-label, Basket Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab in Phase 1b and to Evaluate the Efficacy and Safety of Intratumoral Talimogene Laherparepvec in Combination With Systemic Pembrolizumab to Treat Subjects With Advanced Solid Tumors in Phase 2 (MASTERKEY-318)",I/II,Completed,"Amgen
Merck & Co./Merck Sharp & Dohme (MSD)","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Skin, Squamous Cell Carcinoma (cSCC)",Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; HER2 positive; Liver mets; Progesterone receptor positive; Second line; Stage I; Stage II; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms, Basal Cell; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",Australia; Austria; Belgium; Germany; Poland; South Korea; Spain; Switzerland; United States
A Phase I Trial of the Combination of the Heat Shock Protein-90 (HSP90) Inhibitor Onalespib (AT13387) and the Cyclin-Dependent Kinase (CDK) Inhibitor AT7519M in Patients With Advanced Solid Tumors,I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: GIST; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Uterine Cervical Neoplasms",United States
"A Phase I, Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CA-170 in Patients With Advanced Tumors and Lymphomas",I,Completed,Curis,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Renal; Oncology: Unspecified Solid Tumor",(N/A); Adenocarcinoma; Classical; First line; Fourth line or greater; HER2 negative; Large Cell; Nodular lymphocyte-predominant; Pulmonary; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative; Untreated,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Lymphoma; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Serbia; South Korea; Spain; United Kingdom; United States
A Phase I/IIa Study of SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer Patients,I/II,Completed,BriaCell,Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; PD-L1 Positive; Progesterone receptor positive; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
"A Two-part Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Pyrotinib in Patients With HER2-positive Solid Tumors Whose Disease Progressed on Prior HER2 Targeted Therapy",I,Completed,Jiangsu Hengrui Pharmaceuticals Co. {Jiangsu Hengrui Medicine}/HengRui USA {Hengrui Therapeutics},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Endometrial; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas",Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Endometrial Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
A Phase I/II Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-1.,I/II,Closed,Alkermes,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",(N/A); Classical; First line; Fourth line or greater; HER2 negative; MSI-H/dMMR; Nodular lymphocyte-predominant; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Positive; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative; Untreated,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Australia; Belgium; Canada; Hungary; Poland; South Korea; Spain; United States
Single Arm Neoadjuvant Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) Concomitant With Weekly Nab-paclitaxel and Dose-dense Doxorubicin/Cyclophosphamide (ddAC) Chemotherapy for Clinical Stage I-III Triple Negative Breast Cancer,I/II,Completed,"AstraZeneca
Yale University",Oncology: Breast,HER2 negative; Neoadjuvant; PD-L1 Positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase I/Ib, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers",I/II,Completed,"Roche/Genentech {Genentech}
Corvus Pharmaceuticals","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Prostate; Oncology: Renal",Adenocarcinoma; Fourth line or greater; HER2 negative; Hormone refractory; Large Cell; MSI-H/dMMR; Other subtype; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Prostatic Neoplasms; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Australia; Canada; United States
"A Phase I/II Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor in Small Cell Cancers",I/II,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Anal; Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Gallbladder; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate",(N/A); ALK; EGFR; First line; Pulmonary; Second line; Stage III; Stage IV; Unspecified; Untreated,"Anus Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Gallbladder Neoplasms; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",United States
A Comparison Study to Assess the Value of Naturopathic Medicine Given Immediately and Continuously or Delayed Until Cycle 3 in Combination With Neo-Adjuvant Chemotherapy for Breast Cancer,I/II,Terminated,Midwestern Regional Medical Center,Oncology: Breast,Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms; Unspecified,United States
"Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers",I/II,Open,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",ALK; BRAF; BRCA; EGFR; Fourth line or greater; HER2 negative; Hormone refractory; PD-1 High; PD-1 Naive; PD-L1 Naive; PD-L1 Positive; Pulmonary; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Uterine Cervical Neoplasms",United States
Dose Optimization of Rosuvastatin in Early Stage and Metastatic Estrogen Receptor Positive Breast Cancer Patients on Endocrine Therapy,I,Terminated,Duke University Medical Center,Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage IV,Breast Neoplasms,United States
"A Phase Ib, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours",I/II,Completed,AstraZeneca,"Oncology: Breast; Oncology: Fallopian Tube; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal",BRCA; Fourth line or greater; HER2 negative; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Small Cell; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Small Cell Lung Carcinoma",Canada; United States
Pilot Trial of a Type I-Polarized Autologous Dendritic Cell Vaccine Incorporating Tumor Blood Vessel Antigen-Derived Peptides in Patients With Metastatic Breast Cancer,I,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
An Open-label Phase Ib Study of ARQ 092 in Combination With Other Antineoplastic Agents in Subjects With Selected Solid Tumors,I,Terminated,Merck & Co. {ArQule},Oncology: Breast; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; First line; Fourth line or greater; Second line; Stage III; Stage IV; Third line; Unspecified,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
"A Phase I, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab and in Combination With MGA012 in Patients With Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and Other Cancers",I,Completed,MacroGenics,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Adenocarcinoma; HER2 negative; Hormone refractory; Large Cell; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Second line; Squamous Cell; Stage III; Stage IV; Triple receptor negative; Unresectable,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Lung Neoplasms; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"Phase Ib Study of HSP90 Inhibitor, AT13387 (Onalespib) in Combination With Paclitaxel in Patients With Advanced, Triple Negative Breast Cancer",I,Terminated,National Institutes of Health/National Cancer Institute,Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma; Triple Negative Breast Neoplasms,United States
"An Open-Label, Multicenter, Dose Escalation And Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumor Malignancies",I/II,Completed,Nektar Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Renal; Oncology: Unspecified Solid Tumor",Adenocarcinoma; BRAF; HER2 negative; PD-1 Naive; PD-1 Positive; PD-L1 Naive; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Ewing Sarcoma; Kidney Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Osteosarcoma; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Phase I/Ib Trial of MK-1966 in Combination With SD-101 in Subjects With Advanced Malignancies,I,Terminated,Merck & Co./Merck Sharp & Dohme (MSD),"Oncology: Breast; Oncology: Head/Neck; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma",BRAF; Extranodal marginal zone B-cell lymphoma (MALT); Follicular lymphoma (FL); Indolent; PD-1 Refractory; Second line; Small lymphocytic lymphoma (SLL); Stage III; Stage IV,"Breast Neoplasms; Head and Neck Neoplasms; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms, Unknown Primary; Unspecified",United States
"A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies",I/II,Completed,Novartis,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Renal; Oncology: Unspecified Solid Tumor",ALK; BRAF; EGFR; HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor","Australia; Belgium; Canada; France; Germany; Hong Kong, S.A.R., China; Italy; Japan; Singapore; Spain; Taiwan, China; United States"
A Phase Ib Study of Talimogene Laherparepvec in Combination With Atezolizumab in Subjects With Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases,I,Completed,"Amgen
Roche/Genentech",Oncology: Breast; Oncology: Colorectal; Oncology: Metastatic Cancer,HER2 negative; Liver mets; Second line; Stage IV; Triple receptor negative,Breast Neoplasms; Colorectal Neoplasms; Liver Neoplasms; Neoplasm Metastasis; Triple Negative Breast Neoplasms,Australia; Austria; Belgium; France; Germany; Greece; Italy; Netherlands; Poland; Portugal; Spain; Sweden; Switzerland; United Kingdom; United States
Phase I/II Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer,I/II,Completed,"(Other Industry Sponsor)
Merck & Co./Merck Sharp & Dohme (MSD)
GlaxoSmithKline/Tesaro",Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal,BRCA; Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Triple Negative Breast Neoplasms",United States
"A Phase Ib/II Trial of Taselisib (GDC-0032), a PI3K Inhibitor, in Combination With Enzalutamide in Patients With Androgen Receptor Positive Triple Negative Metastatic Breast Cancer",I/II,Terminated,"(Other Cooperative Group)
National Institutes of Health/National Cancer Institute
Vanderbilt-Ingram Cancer Center
Roche/Genentech",Oncology: Breast,Estrogen receptor positive; FGFR; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"A Phase I Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab With or Without Ipilimumab in Advanced Solid Tumors.",I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor; Oncology: Vaginal; Oncology: Vulvar",(N/A); First line; Fourth line or greater; HER2 negative; PD-1 Positive; PD-L1 Positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Ewing Sarcoma; Fallopian Tube Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasms; Neoplasms, Unknown Primary; Osteosarcoma; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Stomach Neoplasms; Synovial Sarcoma; Uterine Cervical Neoplasms; Vaginal Neoplasms; Vulvar Neoplasms",United States
"A Phase I Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers",I,Closed,Cyclacel,"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Aggressive; Classical; First line; Indolent; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified",United States
"A Phase I/II Study to Investigate the Safety, Pharmacokinetics and Efficacy of EDO-S101, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Patients With Advanced Solid Tumors",I/II,Completed,Mundipharma EDO,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: GIST; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Extensive; Fourth line or greater; HER2 negative; Limited; Locally advanced; Metastatic; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative; Unresectable,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Small Cell; Endometrial Neoplasms; Fallopian Tube Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Glioblastoma; Leiomyosarcoma; Liposarcoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Triple Negative Breast Neoplasms",Canada; Italy; Netherlands; Spain; United States
A Phase Ib/II Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer,I/II,Completed,"Pfizer
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
Phase I/IIa Study of Double-Immune Suppression Blockade By Combining a CSF1R Inhibitor (PLX3397) With An Anti-PD-1 Antibody (Pembrolizumab) To Treat Advanced Melanoma And Other Solid Tumors,I/II,Terminated,"Merck & Co./Merck Sharp & Dohme (MSD)
Daiichi Sankyo/Plexxikon","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Adenocarcinoma; HER2 negative; Large Cell; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
A Phase I Study of a p53MVA Vaccine in Combination With Pembrolizumab,I,Completed,"National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma",HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative; Unresectable,"Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Squamous Cell Carcinoma of Head and Neck; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients with Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy,I,Terminated,"Washington University School of Medicine
Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}",Oncology: Breast,HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase I/IIa Trial with BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination with Nivolumab in Subjects With Selected Advanced Solid Tumors or Hematologic Malignancies.",I/II,Completed,Bristol-Myers Squibb,"Oncology: Breast; Oncology: Fallopian Tube; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Aggressive; Diffuse large B-cell lymphoma (DLBCL); HER2 negative; Hormone refractory; Other; Other subtype; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Fallopian Tube Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified; Wilms Tumor",Australia; Belgium; Canada; France; Netherlands; Spain; United Kingdom; United States
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies,I,Closed,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute
Karyopharm Therapeutics","Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal; Oncology: Thymus; Oncology: Unspecified Solid Tumor; Oncology: Vaginal",Adenocarcinoma; First line; Fourth line or greater; HER2 negative; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Second line; Squamous Cell; Stage III; Stage IV; Third line; Thymoma; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Kidney Neoplasms; Lung Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Renal Cancer; Skin Neoplasms; Thymoma; Thymus Neoplasms; Uterine Cervical Neoplasms; Vaginal Neoplasms; Wilms Tumor",United States
"A Phase I Trial of the Safety and Immunogenicity of a DNA Plasmid Based Vaccine (WOKVAC) Encoding Epitopes Derived from Three Breast Cancer Antigens (IGFBP-2, HER2, and IGF-1R) in Patients With Breast Cancer",I,Completed,"National Institutes of Health/National Cancer Institute
University of Washington
University of Wisconsin",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
"A Phase I/II Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects With Advanced Breast Cancer

CYP17 Lyase and Androgen Receptor Inhibitor Treatment with Seviteronel (CLARITY)",I/II,Completed,"Memorial Sloan-Kettering Cancer Center
Innocrin Pharmaceuticals",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Second line; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Breast Neoplasms, Male; Triple Negative Breast Neoplasms",United States
Phase Ib/II Study of Hydroxychloroquine in Metastatic ER-Positive Breast Cancer Progressing on Hormonal Therapy,I/II,Terminated,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; Second line; Stage IV,Breast Neoplasms,United States
A Phase I/II Clinical Trial of Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin,I/II,Closed,"Memorial Sloan-Kettering Cancer Center
US Department of Defense
Bellicum Pharmaceuticals
Atara Biotherapeutics","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Metastatic Cancer",Fourth line or greater; Other mets; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Mesothelioma; Neoplasm Metastasis; Neoplasms, Mesothelial; Pleural Diseases",United States
"A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors",I,Completed,Roche/Genentech,"Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Fourth line or greater; HER2 negative; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Australia; Belgium; Canada; France; South Korea; Spain; United States
Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies,I/II,Completed,Novartis,"Oncology: Anal; Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Soft Tissue Sarcoma; Oncology: Testicular; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",(N/A); Adenocarcinoma; ALK; Anaplastic; BRAF; First line; Fourth line or greater; HER2 negative; Merkel; Metastatic; PD-1 Positive; PD-L1 High; PD-L1 Positive; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative; Untreated,"Anus Neoplasms; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor","Canada; France; Germany; Hungary; Italy; Lebanon; Netherlands; Norway; Poland; Spain; Taiwan, China; Thailand; Turkey; United States"
"A Phase Ia/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 in Advanced Solid Tumors and in Combination With FOLFIRI for Patients With Previously Treated Metastatic Colorectal Cancer",I,Terminated,"Bristol-Myers Squibb/Celgene
Mereo BioPharma/OncoMed","Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: GIST; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Unspecified Solid Tumor",Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Small Cell; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms",United States
"A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) as a Monotherapy in Subjects With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Subjects With Estrogen Receptor Positive Breast Cancer",I,Completed,Gilead Sciences,"Oncology: Breast; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Unspecified Solid Tumor",Aggressive; Diffuse large B-cell lymphoma (DLBCL); Estrogen receptor positive; Peripheral T-cell lymphoma (PTCL); Second line; Stage III; Stage IV,"Breast Neoplasms; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral; Neoplasms, Unknown Primary",United States
"A Phase I/II, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies - (FIGHT-101)",I/II,Completed,Incyte Corporation,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Multiple Myeloma; Oncology: Myeloproliferative Neoplasms; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",FGFR; First line; Fourth line or greater; Second line; Squamous Cell; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Multiple Myeloma; Myeloproliferative Disorders; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Denmark; United States
Phase I/II Study of Cisplatin Plus Romidepsin and Nivolumab in Metastatic Triple Negative Breast Cancer or BRCA Mutation-Associated Locally Recurrent or Metastatic Breast Cancer,I/II,Completed,"Bristol-Myers Squibb
Bristol-Myers Squibb/Celgene",Oncology: Breast,BRCA; First line; Fourth line or greater; HER2 negative; PD-L1 Positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer",I,Terminated,"Celldex Therapeutics {AVANT Immunotherapeutics}
Roche/Genentech","Oncology: Bladder; Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal",HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Head and Neck Neoplasms; Kidney Diseases; Kidney Neoplasms; Melanoma; Neoplasms; Neoplasms by Histologic Type; Renal Cancer; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Urogenital Neoplasms; Urologic Diseases; Urologic Neoplasms; Wilms Tumor",United States
"A Phase I, Multi-center, Open-Label Dose Escalation Study of SYN004 in Patients With Solid Tumors to Evaluate the Safety, Immunogenicity and Pharmacokinetics of SYN004 Following Administration of Eight Intravenous Doses",I,Completed,Synermore Biologics,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",EGFR; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
A Phase I Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer,I,Completed,AbbVie,"Oncology: Breast; Oncology: Head/Neck; Oncology: Leukemia, Acute Myelogenous; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor",Aggressive; Fourth line or greater; Indolent; KRAS; Pulmonary; Second line; Stage III; Stage IV; Third line,"Acute Myelocytic Leukemia; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Head and Neck Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma",United States
Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer,I,Closed,"Roche/Genentech {Genentech}
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute",Oncology: Breast,Estrogen receptor positive; HER2 positive; Stage III; Stage IV; Third line,Breast Neoplasms,United States
Phase I Study of the Combination of MLN9708 and Fulvestrant in Patients With Advanced Estrogen Receptor Positive Breast Cancer,I,Terminated,Dartmouth-Hitchcock Medical Center,Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"An Open-Label, Dose-Escalation/Expansion Phase 1 Study of ASP4132 Given Orally to Patients With Advanced Refractory Solid Tumors and Lymphoma",I,Completed,Astellas Pharma,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Ovarian; Oncology: Prostate; Oncology: Unspecified Solid Tumor",Aggressive; Classical; Fourth line or greater; HER2 negative; Hormone refractory; Indolent; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms",United States
A Pilot Study of Short-term Fasting on Neoadjuvant Chemotherapy in Patients With Newly Diagnosed Breast Cancer (STEFNE Study),I/II,Terminated,Midwestern Regional Medical Center,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
Phase I Trial of the Combination of Nilotinib and Paclitaxel in Adults and Pediatric Patients With Refractory Solid Tumors,I,Open,National Institutes of Health/National Cancer Institute,"Oncology: Anal; Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Small Intestine; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Metastatic; Second line; Stage III; Stage IV,"Anus Neoplasms; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Ewing Sarcoma; Fibrosarcoma; Intestinal Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Osteosarcoma; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Phase I, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers",I,Completed,MacroGenics,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Fourth line or greater; HER2 negative; Hormone refractory; PD-1 Refractory; PD-L1 Refractory; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative; Unresectable,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Lung Neoplasms; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
Phase I/II Study of BYL719 and Nab-Paclitaxel in Subjects With Locally Recurrent or Metastatic HER-2 Negative Breast Cancer,I/II,Completed,"Novartis
University of Kansas",Oncology: Breast,First line; HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"An Open-Label, Single-Arm Multicenter Phase Ib/II Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)",I/II,Completed,"Eisai
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; PD-L1 Positive; Progesterone receptor positive; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Single-arm, Open-label Study of Ad-RTS-hIL-12 + Veledimex Following First-, Second-, or Third-Line Standard Treatment in Subjects With Locally Advanced or Metastatic Breast Cancer",I/II,Completed,Alaunos Therapeutics {Ziopharm Oncology},Oncology: Breast,Fourth line or greater; HER2 negative; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"An Open-label,Phase I, Dose-escalation Trial to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetic, and Pharmacodynamics of the Anti-FGFR2 Antibody Drug Conjugate BAY1187982 in Subjects With Advanced Solid Tumors Known to Express FGFR2",I,Terminated,Bayer AG/Bayer Pharmaceuticals,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas",FGFR; Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Uterine Cervical Neoplasms",Singapore; South Korea; United States
"An Open-label Randomized Two-arm Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of Oral BAY 1217389 in Combination With Weekly Intravenous Paclitaxel Given in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies",I,Completed,Bayer AG/Bayer Pharmaceuticals,Oncology: Breast; Oncology: Unspecified Solid Tumor,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Neoplasms; Neoplasms, Unknown Primary",Canada; Netherlands; United States
A Phase I Study of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor,I,Terminated,AbbVie,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",EGFR; HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Glioblastoma; Head and Neck Neoplasms; Neoplasms, Unknown Primary; Triple Negative Breast Neoplasms","Spain; Taiwan, China; United States"
"A Phase I, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies",I,Terminated,"Seagen {Seattle Genetics}
Merck & Co./Merck Sharp & Dohme (MSD)","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Small Intestine; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Advanced; Aggressive; Classical; Diffuse large B-cell lymphoma (DLBCL); First line; Follicular lymphoma (FL); Fourth line or greater; Indolent; PD-1 Naive; PD-L1 Naive; Second line; Squamous Cell; Stage III; Stage IV; Third line; Unresectable,"Breast Neoplasms; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Intestinal Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Mesothelioma; Neoplasm Metastasis; Neoplasms; Neoplasms, Basal Cell; Neoplasms, Mesothelial; Neoplasms, Squamous Cell; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A Phase I/II, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies",I/II,Terminated,Incyte Corporation,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor",Aggressive; Classical; Diffuse large B-cell lymphoma (DLBCL); Hormone refractory; Indolent; Nodular lymphocyte-predominant; Other subtype; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms",United States
"A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination with Other Anti-Cancer Therapies in Patients with Advanced Malignancies",I,Completed,"Regeneron
Sanofi {Sanofi-Aventis}","Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Skin, Basal Cell Carcinoma; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Unspecified Solid Tumor",Adenocarcinoma; ALK; EGFR; Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; HER2 positive; Large Cell; PD-1 Naive; PD-L1 High; PD-L1 Naive; PD-L1 Positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Endometrial Neoplasms; Glioblastoma; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Neoplasms, Basal Cell; Neoplasms, Unknown Primary; Prostatic Neoplasms; Uterine Cervical Neoplasms",Australia; Spain; United States
"Phase I Study to Evaluate the Tolerability, Safety and Efficacy of BMN-673 in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumor Malignancies That Have BRCA Mutations or Triple Negative Metastatic Breast Cancer",I,Completed,"University of California, San Francisco
(Other Hospital/Academic/Medical Center)",Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Head/Neck; Oncology: Liver; Oncology: Ovarian; Oncology: Prostate; Oncology: Unspecified Solid Tumor,BRCA; HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Cholangiocarcinoma; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
A Pre-surgical Clinical Trial of Therapy With S-equol in Women With Triple Negative Breast Cancer.,I,Completed,"University of Texas Health Science Center at San Antonio
Ausio Pharmaceuticals",Oncology: Breast,HER2 negative; Neoadjuvant; Stage 0; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase I Pivotal, Double Blind, Randomized, Pharmacodynamics, Pharmacokinetics, Safety, Immunogenicity, 2-Way Cross Over, Bioequivalence Study of Biosimilar Filgrastim and Neupogen in Healthy Volunteers.",I,Completed,Novartis/Sandoz,Oncology: Breast; Oncology: Supportive Care,(N/A); Line of therapy N/A; Neutropenia,Breast Neoplasms; Neutropenia; Palliative Care,United States
A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy,I,Completed,"Washington University School of Medicine
Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}",Oncology: Breast,First line; HER2 negative; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies",I,Open,Microbio Group/Microbio/Oneness Biotech,"Oncology: Breast; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Liver Cancer; Liver Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Prostatic Neoplasms","Taiwan, China; United States"
"A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0919 Administered With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors",I,Completed,"Lumos Pharma {NewLink Genetics}
Roche/Genentech","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor",(N/A); BRAF; Fourth line or greater; HER2 negative; Merkel; PD-L1 High; PD-L1 Positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",France; South Korea; Spain; United States
"A Phase Ib, Open-Label, Multi-Center, Dose Escalation Study of the Safety, Pharmacokinetics, and Therapeutic Activity of Cergutuzumab Amunaleukin, an Immunocytokine, Which Consists of a Variant of Interleukin 2 (IL 2v), That Targets Carcinoembryonic Antigen (CEA), and Atezolizumab, an Antibody That Targets Programmed Death-Ligand 1 (PD-L1), Administered Intravenously, in Patients With Locally Advanced and/or Metastatic Solid Tumors",I,Completed,Roche {F. Hoffmann-La Roche},Oncology: Breast; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Neoplasms; Neoplasms, Unknown Primary",Canada; Denmark; Netherlands; Spain; Switzerland; United States
"A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer",I,Completed,Radius Health {Radius},Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy)",I/II,Open,"(Other Industry Sponsor)
(Other Hospital/Academic/Medical Center)
Merus","Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Fourth line or greater; HER2 positive; Large Cell; Second line; Squamous Cell; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Wilms Tumor","Austria; Belgium; Canada; Denmark; France; Germany; Israel; Italy; Japan; Netherlands; Norway; Portugal; Singapore; South Korea; Spain; Sweden; Taiwan, China; United Kingdom; United States"
A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS,I/II,Terminated,H. Lee Moffitt Cancer Center and Research Institute,Oncology: Breast,Estrogen receptor positive; HER2 positive; Maintenance/Consolidation; Stage 0,Breast Neoplasms,United States
A Phase Ib/II Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus),I/II,Terminated,(Other Hospital/Academic/Medical Center),"Oncology: Breast; Oncology: Cervical; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Estrogen receptor positive; Extensive; First line; HER2 negative; PD-1 Naive; PD-1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative; Untreated,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Uterine Cervical Neoplasms",United States
"Phase I/II Clinical Trial of the Combination of Carboplatin, Eribulin Mesylate, and E7449 in Patients With BRCA-Related Cancers",I/II,Terminated,University of Texas Health Science Center at San Antonio,Oncology: Breast; Oncology: Ovarian,BRCA; First line; HER2 negative; Second line; Stage IV; Triple receptor negative,Breast Neoplasms; Ovarian Cancer; Ovarian Neoplasms,United States
A Phase Ib Study of an adjuvant GM-CSF-Secreting Breast Cancer Vaccine,I,Completed,Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute,Oncology: Breast,Adjuvant; Stage II; Stage III,Breast Neoplasms,United States
A Phase Ib/II Study of Pembrolizumab and Monoclonal Antibody Therapy in Patients With Advanced Cancer (PembroMab,I/II,Terminated,Midwestern Regional Medical Center,Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Unspecified Solid Tumor,HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Stomach Carcinoma; Stomach Neoplasms",United States
A Phase I Study of Talazoparib (BMN 673) in Combination with Carboplatin and Paclitaxel in Patients with Advanced Solid Tumors.,I,Completed,National Institutes of Health/National Cancer Institute,Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor,BRCA; First line; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"An Open-Label, Multicenter, Dose-Escalation Phase I Study to Evaluate the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688, A Novel T-cell Bispecific Antibody That Targets the Human Carcinoembryonic Antigen (CEA) on Tumor Cells and CD3 on T Cells, Administered Intravenously in Patients With Locally Advanced and/or Metastatic CEA(+) Solid Tumors",I,Completed,Roche {F. Hoffmann-La Roche},"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Pancreas",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",Canada; Denmark; France; Italy; Netherlands; Spain; United States
"A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of TAS-119 in Patients With Advanced Solid Tumors",I,Terminated,Otsuka Holdings/Taiho Pharmaceutical,"Oncology: Breast; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Unspecified Solid Tumor",HER2 negative; Pulmonary; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Small Cell; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Small Cell Lung Carcinoma; Unspecified",Canada; Italy; Netherlands; Spain; United Kingdom; United States
"An Open-Label, Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer",I,Terminated,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Vanderbilt-Ingram Cancer Center
Roche/Genentech {Seragon Pharmaceuticals}",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,Spain; United States
"Open-Label, Multicenter, Dose Escalation Phase Ib Study With Expansion Phase to Evaluate the Safety, Pharmacokinetics, and Activity of RO5509554 (Emactuzumab) and MPDL3280A (Atezolizumab) Administered in Combination in Patients With Advanced Solid Tumors",I,Completed,Roche {F. Hoffmann-La Roche},Oncology: Bladder; Oncology: Breast; Oncology: Gastric; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma,HER2 negative; Locally advanced; Metastatic; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Ovarian Cancer; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms,Belgium; France; Spain; United States
RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers.,I,Completed,"Merck & Co.
National Institutes of Health/National Cancer Institute
Abramson Cancer Center at  University of Pennsylvania Medical Center","Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",First line; Fourth line or greater; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Second Primary; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Wilms Tumor",United States
A Phase I Trial of MK-3475 Plus Ziv-Aflibercept in Patients with Advanced Solid Tumors,I,Closed,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Colorectal; Oncology: GIST; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,HER2 negative; Locally advanced; Metastatic; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Skin Neoplasms; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",Canada; United States
Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics,I/II,Terminated,New York University,Oncology: Breast,Adjuvant; HER2 negative; HER2 positive; Stage II; Stage III,Breast Neoplasms,United States
Omega-3 Fatty Acids and ERPR(-) and HER-2/Neu(+/-) Breast Cancer Prevention,I,Closed,"National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center
Ohio State University",Oncology: Breast,First line; HER2 negative; HER2 positive; Second line; Stage 0; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
"Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors",I,Completed,"Bristol-Myers Squibb
F-star Alpha",Oncology: Breast; Oncology: Esophageal; Oncology: Gastric,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Neoplasms; Stomach Carcinoma; Stomach Neoplasms,Canada; United States
"A Multi-Center Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Durvalumab (MEDI4736), in Subjects With Relapsed or Refractory Solid Tumors",I/II,Completed,AbbVie/Pharmacyclics,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Pancreas",Adenocarcinoma; Fourth line or greater; HER2 negative; HER2 positive; PD-L1 High; PD-L1 Low; PD-L1 Positive; Second line; Squamous Cell; Stage II; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms",United States
A Phase I Dose Escalation and Expansion Study of OMP-305B83 in Subjects With Solid Tumors,I,Completed,"Bristol-Myers Squibb/Celgene
Mereo BioPharma/OncoMed",Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
"A Phase I/II Study of the Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects with Advanced and/or Metastatic Solid Tumors",I/II,Completed,"Memorial Sloan-Kettering Cancer Center
Kyowa Kirin {Kyowa Hakko Kirin}","Oncology: Breast; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms; Neoplasms, Unknown Primary; Stomach Carcinoma; Stomach Neoplasms",United States
Pilot Biomarker Modulation Study of Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer,I,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Maintenance/Consolidation; Stage 0; Stage I; Stage II; Stage III,Breast Carcinoma In Situ; Breast Neoplasms; Carcinoma,United States
A Phase Ib/IIa Dose Escalation Study of PTX-100 in Combination with Docetaxel in Patients with Metastatic Breast Cancer,I/II,Terminated,Prescient Therapeutics {Virax},Oncology: Breast,Line of therapy N/A; Stage IV,Breast Neoplasms,United States
"Phase I Study to Identify the Immunomodulatory Activity of LY3022855 (IMC-CS4) in Patients with Advanced, Refractory Breast or Prostate Cancer",I,Completed,Eli Lilly,Oncology: Breast; Oncology: Prostate,Hormone refractory; Second line; Stage III; Stage IV,Breast Neoplasms; Neoplasm Metastasis; Neoplasms; Prostatic Neoplasms,United States
"A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ceralasertib in Combination With Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients With Advanced Solid Malignancies.",I,Open,AstraZeneca,"Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate",Adenocarcinoma; BRCA; HER2 negative; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Adenocarcinoma; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Uterine Cervical Neoplasms",Australia; Canada; France; South Korea; Spain; United Kingdom; United States
"A Phase I/II, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies",I/II,Terminated,"Vanderbilt University Medical Center
Incyte Corporation","Oncology: Bladder; Oncology: Breast; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome; Oncology: Myeloproliferative Neoplasms; Oncology: Pancreas; Oncology: Unspecified Cancer",(N/A); Aggressive; Classical; Diffuse large B-cell lymphoma (DLBCL); First line; HER2 negative; High risk; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Acute Myelocytic Leukemia; Breast Neoplasms; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Hodgkin Disease; Hodgkin Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Multiple Myeloma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A phase I, open-label, multicentre, dose-escalation study to investigate the safety and pharmacokinetics of AZD8835 in patients with advanced solid tumours",I,Terminated,AstraZeneca,Oncology: Breast; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; Second line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms, Unknown Primary",United Kingdom; United States
A Safety and Efficacy Study of dCellVax in Patients with Advanced Metastatic Breast Cancer,I/II,Planned,Regen BioPharma,Oncology: Breast,Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase IB Trial With OTX015/MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors",I/II,Completed,Merck & Co. {OncoEthix},"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Prostate",ALK; First line; HER2 negative; Hormone refractory; KRAS; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Triple Negative Breast Neoplasms",Belgium; Canada; France; Spain; Switzerland; United States
"Phase I Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered CUDC-907, an HDAC and PI3K Inhibitor, in Subjects With Advanced/Relapsed Solid Tumors",I,Completed,Curis,Oncology: Breast; Oncology: Ovarian; Oncology: Unspecified Solid Tumor,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Triple Negative Breast Neoplasms",United States
"A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy.",I,Completed,Eli Lilly,Oncology: Breast; Oncology: Renal; Oncology: Soft Tissue Sarcoma,Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",United States
"A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies",I,Completed,Athenex {Kinex Pharmaceuticals},Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Ovarian; Oncology: Pancreas; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Colorectal Neoplasms; Endometrial Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms",United States
"Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD9496 in Women With Estrogen Receptor Positive HER-2 Negative Advanced Breast Cancer",I,Completed,AstraZeneca,Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,France; South Korea; United Kingdom; United States
A Phase Ib/II Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer,I/II,Completed,"National Surgical Adjuvant Breast and Bowel Project (NSABP)
Puma Biotechnology",Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
"A Phase I, Open-Label, Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CB-5083 in Subjects With Advanced Solid Tumors",I,Completed,Cleave Therapeutics {Cleave Biosciences},"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",KRAS; NRAS; PD-1 Refractory; PD-L1 Refractory; Second line; Stage II; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Neoplasms; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Combined Phase I/II Feasibility-and-Efficacy Study of a Carbohydrate Mimotope-based Vaccine With MONTANIDE ISA 51 VG Combined With Neoadjuvant Chemotherapy,I/II,Completed,University of Arkansas,Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Phase I, Open-label, Multicenter, Randomized, 2-Period, Crossover Study to Evaluate the Bioequivalence and Food Effect Bioavailability of CC-486 (Oral Azacitidine) Tablets in Adult Cancer Subjects",I,Completed,Bristol-Myers Squibb/Celgene,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Leukemia, Acute Myelogenous; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome; Oncology: Osteosarcoma; Oncology: Renal; Oncology: Thyroid",(N/A); Aggressive; Classical; First line; Indolent; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV,"Acute Myelocytic Leukemia; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Ewing Sarcoma; Glioblastoma; Hematologic Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leukemia; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Osteosarcoma; Preleukemia; Renal Cancer; Small Cell Lung Carcinoma; Thyroid Neoplasms; Wilms Tumor",Canada; United States
"A First-in-human Phase I, Dose Escalation, Safety and Pharmacokinetic Study of PF-06647020 in Adult Patients with Advanced Solid Tumors",I,Completed,Pfizer,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Unspecified Solid Tumor",First line; Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms",Spain; United States
"A Phase I Study of LY3164530, a Bispecific Antibody Targeting MET and EGFR, in Patients With Advanced or Metastatic Cancer",I,Completed,Eli Lilly,Oncology: Breast; Oncology: Prostate; Oncology: Unspecified Cancer,Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms; Neoplasm Metastasis; Neoplasms; Prostatic Neoplasms,United States
"A Phase I, Open-Label, Multicenter, Safety Study Of Nivolumab (BMS-936558) In Combination With Nab-Paclitaxel Plus Or Minus Gemcitabine In Pancreatic Cancer, Nab-Paclitaxel / Carboplatin In Stage IIIB/IV Non-Small Cell Lung Cancer Or Nab-Paclitaxel In Metastatic Breast Cancer",I/II,Completed,Bristol-Myers Squibb/Celgene,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Pancreas",Adenocarcinoma; First line; HER2 negative; Large Cell; Other subtype; PD-L1 Positive; Second line; Squamous Cell; Stage II; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms",United States
A Phase I Trial to Evaluate the Safety of the Addition of Alisertib to Fulvestrant in Women With Advanced Hormone Receptor Positive (HR+) Breast Cancer,I,Completed,"National Institutes of Health/National Cancer Institute
Mayo Clinic",Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
A First-in-Human Phase I Dose Escalation Trial of Hu5F9-G4 in Patients With Advanced Solid Malignancies,I,Completed,Gilead Sciences/Forty Seven,"Oncology: Breast; Oncology: Colorectal; Oncology: Fallopian Tube; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Pancreas; Oncology: Thyroid",Aggressive; Classical; Diffuse large B-cell lymphoma (DLBCL); Follicular; Indolent; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Thyroid Neoplasms; Unspecified",United States
L-glutamine Supplementation to Alleviate Symptoms of Taxane-Induced Neuropathy in Patients With Breast Cancer,I,Terminated,"(Other Industry Sponsor)
(Other Hospital/Academic/Medical Center)",Oncology: Breast; Oncology: Supportive Care,(N/A); Neurotoxicity; Second line,Breast Neoplasms; Palliative Care; Peripheral Nervous System Diseases,United States
"Effect of CTAP101 Capsules on Serum Calcium, Plasma Intact Parathyroid Hormone and Vitamin D Metabolites in Patients With Advanced Breast or Prostate Carcinomas With Metastases to Bone and Receiving Ongoing Therapy With Denosumab or Zoledronic Acid",I,Completed,OPKO Health/OPKO Renal {Cytochroma},Oncology: Breast; Oncology: Metastatic Cancer; Oncology: Prostate,Bone mets; Second line; Stage III; Stage IV,"Bone Neoplasms; Breast Neoplasms; Hyperparathyroidism; Hyperparathyroidism, Secondary; Hypocalcemia; Neoplasm Metastasis; Prostatic Neoplasms",United States
"A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 +Dabrafenib Under Adaptable Dosing Schedules in Patients With Advanced Solid Tumors That Are Metastatic or Cannot be Removed by Surgery",I/II,Completed,(Other Cooperative Group),Oncology: Breast; Oncology: Endometrial; Oncology: Melanoma; Oncology: Ovarian,BRAF; Estrogen receptor positive; First line; HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms",France; Germany; Russia; Ukraine; United States
"A Phase Ib Study of the Oral PARP Inhibitor Olaparib with the Oral mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial, Triple Negative Breast, and Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.",I/II,Closed,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal,BRCA; First line; Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Adenocarcinoma; Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Fallopian Tube Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms",United States
"A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies",I,Completed,Novartis,Oncology: Breast; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,First line; HER2 negative; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Chordoma; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neoplasms, Unknown Primary; Rhabdomyosarcoma; Sarcoma; Sarcoma, Alveolar Soft Part; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Triple Negative Breast Neoplasms","Canada; France; Germany; Israel; Italy; Japan; Singapore; Spain; Taiwan, China; United States"
"A Phase Ib Clinical Trial to Evaluate the Safety and Immune Response to a Mammaglobin-A DNA Vaccine in ER+, HER2- Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy or Chemotherapy",I,Closed,"Washington University School of Medicine
US Department of Defense
(Other Hospital/Academic/Medical Center)",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage II; Stage III,Breast Neoplasms; Neoplasms,United States
"A Phase I Dose-escalation Study of Radio- Labeled Antibody, FF-21101(90Y) for the Treatment of Advanced Cancer",I,Completed,"Fujifilm Corporation/Fujifilm Pharmaceuticals U.S.A.
Strategia Therapeutics {Boston Strategics}",Oncology: Anal; Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Fallopian Tube; Oncology: Head/Neck; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Small Intestine; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid; Oncology: Vaginal,First line; Fourth line or greater; HER2 negative; Pancreas; Papillary; Second line; Stage III; Stage IV; Third line; Triple receptor negative; Unspecified,Anus Neoplasms; Bile Duct Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Fallopian Tube Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Intestinal Neoplasms; Leiomyosarcoma; Liposarcoma; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Unspecified; Vaginal Neoplasms,United States
"A Phase I/IIa, Dose-escalation Study of FF-10502-01 for the Treatment of Advanced Solid Tumors and Lymphomas",I/II,Completed,Fujifilm Corporation/Fujifilm Pharmaceuticals U.S.A.,"Oncology: Anal; Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Head/Neck; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Aggressive; Classical; Fourth line or greater; Gastrointestinal; Indolent; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV; Third line,"Anus Neoplasms; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Gallbladder Neoplasms; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
(STM-03) Phase I Study of Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1,I,Completed,"(Other Hospital/Academic/Medical Center)
Vanquish Oncology","Oncology: Bladder; Oncology: Breast; Oncology: CNS, Astrocytoma; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Testicular; Oncology: Unspecified Solid Tumor",(N/A); Aggressive; Classical; Grade 3; Indolent; Nodular lymphocyte-predominant; Pancreas; Second line; Stage III; Stage IV; Unspecified,"Astrocytoma; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Glioblastoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase I Multi-center, Open-label Dose Escalation and Expansion Study of PCA062 Administered Intravenously in Adult Patients With p-CAD Positive Tumors",I,Completed,Novartis,"Oncology: Breast; Oncology: Cervical; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell",(N/A); HER2 negative; Second line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms","France; Italy; Japan; Singapore; South Korea; Spain; Taiwan, China; United States"
"A Phase I/II Multicenter, Open-label Study of CLR457, Administered Orally in Adult Patients With Advanced Solid Malignancies.",I/II,Terminated,Novartis,"Oncology: Breast; Oncology: Endometrial; Oncology: Lung, Non-Small Cell",EGFR; Estrogen receptor positive; First line; Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Neoplasms","Australia; Austria; Canada; France; Germany; Hong Kong, S.A.R., China; Israel; Italy; Japan; Singapore; Spain; United States"
A Phase I Study of TPI 287 Concurrent With Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases From Advanced Breast and Non-Small Cell Lung (NSCL) Cancer,I,Terminated,"H. Lee Moffitt Cancer Center and Research Institute
Cortice Biosciences {Archer Biosciences}","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer",CNS mets; Second line; Stage III; Stage IV,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Neoplasm Metastasis; Neoplasms",United States
"A First-in-Human Study for the Evaluation of the Safety, Pharmacokinetics and Antitumor Activity of SAR408701 in Patients With Advanced Solid Tumors",I/II,Completed,Sanofi {Sanofi-Aventis},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas",(N/A); Adenocarcinoma; First line; Fourth line or greater; KRAS; Large Cell; PD-1 Refractory; PD-L1 Refractory; Pulmonary; Second line; Squamous Cell; Stage II; Stage III; Stage IV; Third line; Untreated,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",Canada; France; South Korea; Spain; United States
An Open Label Phase I Study to Evaluate the Safety and Tolerability of a Modified Vaccinia Ankara (MVA) Based Vaccine Modified to Express Brachyury and T-Cell Costimulatory Molecules (MVA Brachyury-TRICOM),I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",Adenocarcinoma; EGFR; Estrogen receptor positive; HER2 positive; Merkel; Pulmonary; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Liver Cancer; Liver Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Vaccinia",United States
"A Phase Ib/II, Multi-center, Uncontrolled, Open-label, Dose Escalation Study of Refametinib  (BAY86-9766) in Combination With Regorafenib (BAY73-4506) in Patients With Advanced or Metastatic  Cancer",I/II,Terminated,Bayer AG/Bayer Pharmaceuticals,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell",First line; HER2 negative; KRAS; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasm Metastasis",France; Germany; Israel; Italy; Netherlands; Russia; United States
"A Phase I, Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer.",I,Completed,"Novartis
Memorial Sloan-Kettering Cancer Center
MorphoSys",Oncology: Breast,First line; HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
Phase I Study of MLN0128 (TAK-228) (NSC# 768435) in Combination With Ziv-Aflibercept (NSC# 724770) in Patients With Advanced Cancers,I,Closed,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; HER2 positive; Pancreas; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms",United States
First-in-Human Dose-Escalation Study of Vactosertib (TEW-7197) Monotherapy in Subjects With Advanced Stage Solid Tumors,I,Completed,"(Other government agency)
MedPacto","Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",First line; Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Glioblastoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
A Phase I Trial of the Safety and Immunogenicity of a Multiple Antigen Vaccine (STEMVAC) in HER2 Negative Advanced Stage Breast Cancer Patients,I,Completed,"(Other Cooperative Group)
University of Washington",Oncology: Breast,Estrogen receptor positive; HER2 negative; Line of therapy N/A; Progesterone receptor positive; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma,United States
"A Phase I Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole for the Treatment of HR+, HER2-negative Post-menopausal Women With Locally Advanced or Metastatic Breast Cancer.",I,Terminated,Novartis,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,Spain; United States
"Combination Treatment With Everolimus, Letrozole and Trastuzumab in Hormone Receptor and HER2/Neu-positive Patients With Advanced Metastatic Breast Cancer and Other Solid Tumors: Evaluating Synergy and Overcoming Resistance",I,Completed,"Novartis
MD Anderson Cancer Center, University of Texas",Oncology: Breast; Oncology: Cervical; Oncology: Esophageal; Oncology: Gastric; Oncology: Ovarian; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; Fourth line or greater; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma; Esophageal Cancer; Esophageal Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Uterine Cervical Neoplasms",United States
"A Phase Ib, Study of ONT 10 and Varlilumab in Patients With Advanced Ovarian Cancer or Breast Cancer.",I,Terminated,"Seagen {Seattle Genetics/Cascadian Therapeutics {Oncothyreon {Biomira}}}
Celldex Therapeutics {CuraGen}",Oncology: Breast; Oncology: Ovarian,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Ovarian Epithelial; Ovarian Cancer; Ovarian Neoplasms",United States
A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors,I,Terminated,(Other Hospital/Academic/Medical Center),"Oncology: Breast; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Renal",Aggressive; Classical; Indolent; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms; Renal Cancer; Wilms Tumor",United States
"A Phase I Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients With Advanced Solid Tumors",I,Completed,Amgen/Five Prime Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Pancreas",Aggressive; FGFR; Fourth line or greater; Indolent; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms","South Korea; Taiwan, China; United States"
Ad-sig-hMUC-1/ecdCD40L Vector Vaccine for Immunotherapy of Epithelial Cancers,I,Completed,"(Other Hospital/Academic/Medical Center)
MicroVAX","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate",Second line; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Lung Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms",Singapore; United States
"An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of Oral BAY1161909 in Combination With Weekly Intravenous Paclitaxel Given in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies",I,Terminated,Bayer AG/Bayer Pharmaceuticals,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Fourth line or greater; HER2 negative; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer,I/II,Completed,"H. Lee Moffitt Cancer Center and Research Institute
Roche/Genentech",Oncology: Breast,Fourth line or greater; HER2 positive; Stage IV; Third line,Breast Neoplasms,United States
"A Phase I/II Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)",I/II,Completed,"AstraZeneca {MedImmune}
Incyte Corporation","Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal",BRAF; EGFR; First line; HER2 negative; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Positive; PD-L1 Refractory; Second line; Squamous Cell; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
Bioavailability Study of SPARC1210 and Reference1210 in Subjects With Metastatic Breast Cancer,I,Terminated,Sun Pharma Advanced Research,Oncology: Breast,Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms,India; United States
"An Open-label Phase I Dose-escalation Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Pharmacodynamics of the Anti-C4.4a Antibody Drug Conjugate BAY1129980 in Subjects with Advanced Solid Tumors Known to Express C4.4a",I,Terminated,Bayer AG/Bayer Pharmaceuticals,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate",First line; HER2 negative; Hormone refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Unspecified",United States
"A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic  Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors",I,Terminated,Otsuka Holdings/Taiho Pharmaceutical,Oncology: Breast; Oncology: Colorectal; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Pancreas; Oncology: Unspecified Solid Tumor,Fourth line or greater; Stage III; Stage IV,"Breast Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms",United States
A Phase I Dose Escalation Study Evaluating The Safety And Tolerability Of PF-06650808 In Patients With Advanced Solid Tumors,I,Terminated,Pfizer,Oncology: Breast; Oncology: Unspecified Solid Tumor,First line; HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Neoplasms, Unknown Primary",United States
A Phase Ib Trial of LY2606368 in Combination With Chemotherapy or Targeted Agents in Advanced and/or Metastatic Tumors,I,Completed,Eli Lilly,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Unspecified Cancer",HER2 negative; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Small Cell; Cholangiocarcinoma; Colorectal Neoplasms; Head and Neck Neoplasms; Neoplasm Metastasis; Neoplasms; Neuroendocrine Tumors; Small Cell Lung Carcinoma",United States
"A Phase I, Dose Escalation Study Of PF-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors",I,Terminated,Pfizer,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Ovarian",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms; Ovarian Cancer; Ovarian Neoplasms",United States
Phase I/IB Trial of Eribulin and Everolimus in Patients with Triple Negative Metastatic Breast Cancer.,I,Completed,"National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center",Oncology: Breast,First line; HER2 negative; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"A Phase I, Dose-Escalation, Safety and Tolerability Study of COH29 in Patients With Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy Exists",I,Completed,"National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center
Novonco Therapeutics","Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
A Phase I/II Study of the Treatment of Metastatic Cancer That Expresses MAGE-A3 Using Lymphodepleting Conditioning Followed by Infusion of HLA-DP0401/0402 Restricted Anti-MAGE-A3 TCR-Gene Engineered Lymphocytes and Aldesleukin,I/II,Completed,"National Institutes of Health/National Cancer Institute
Gilead Sciences/Kite Pharma",Oncology: Breast; Oncology: Cervical; Oncology: Esophageal; Oncology: Melanoma; Oncology: Renal; Oncology: Soft Tissue Sarcoma,Second line; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasm Metastasis; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Uterine Cervical Neoplasms; Wilms Tumor",Belgium; United States
"A Phase I open-label study to investigate the pharmacodynamics, metabolomics and pharmacokinetics of CUDC-101 in subjects with HER2 positive invasive breast cancer",I,Terminated,Curis,Oncology: Breast,First line; HER2 positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients With Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma",I,Terminated,Novo Nordisk/Dicerna Pharmaceuticals,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",Aggressive; Indolent; Intermediate-grade; Low-grade; Metastatic; Pancreas; Pulmonary; Second line; Stage I; Stage III; Stage IV,"Adenoma, Islet Cell; Breast Neoplasms; Carcinoid Tumor; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms; Neoplasms, Plasma Cell; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Multicenter, Phase I/Ib, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors",I,Closed,AbbVie,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian",Adenocarcinoma; EGFR; First line; Fourth line or greater; Large Cell; MET Amplification/Alteration; PD-1 Refractory; PD-L1 Refractory; Second line; Squamous Cell; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Stomach Carcinoma; Stomach Neoplasms","Belgium; Finland; France; Italy; Japan; South Korea; Taiwan, China; United States"
"A Phase I, Open-Label Study Evaluating The Safety And Tolerability Of Escalating Doses Of DLYE5953A In Patients With Refractory Solid Tumors",I,Completed,Roche/Genentech,"Oncology: Breast; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas",Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Unspecified",United States
A Multi-center Study of hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Post Definitive Surgery and Standard Therapy,I,Completed,"Barbara Ann Karmanos Cancer Institute
University of Pennsylvania
Mayo Clinic
University of Pittsburgh
University of North Carolina
(Other Hospital/Academic/Medical Center)
Kimmel Cancer Center-Thomas Jefferson University - Philadelphia, PA
Inovio Pharmaceuticals {Inovio Biomedical}","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal",Adenocarcinoma; Estrogen receptor positive; First line; HER2 negative; HER2 positive; Squamous Cell; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms, Squamous Cell; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Recurrence; Stomach Carcinoma; Stomach Neoplasms",United States
"A Phase Ib/II Study of LEE011 in Combination With Fulvestrant and BYL719 or BKM120 in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Recurrent or Advanced Metastatic Breast Cancer",I,Completed,Bracco/Blue Earth Therapeutics,Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,"Austria; Brazil; Canada; Czech Republic; France; Hungary; Israel; Italy; Poland; Singapore; South Korea; Spain; Switzerland; Taiwan, China; Thailand; United Kingdom; United States"
Clinical Phase Ib/II Trial of L-NMMA Plus Taxane Chemotherapy in the Treatment of Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients,I/II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase Ia/Ib trial of chemotherapy followed by infusions of activated T cells armed with OKT3 x trastuzumab bispecific antibody, IL-2 and GM-CSF for stage II/ III, Her2+ or Her2- high risk breast cancer (> 10+ nodes)",I,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Line of therapy N/A; Stage II; Stage III,Breast Neoplasms,United States
A Pivotal Bioequivalence Study of DOXIL/CAELYX Manufactured at a New Site in Subjects With Advanced or Refractory Solid Malignancies Including Subjects With Ovarian Cancer,I,Completed,Johnson & Johnson/Janssen R&D {Johnson & Johnson/J&JPRD {Johnson & Johnson/Janssen-Cilag/Janssen Research Foundation}},Oncology: Breast; Oncology: Ovarian,Second line; Stage III; Stage IV,Breast Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms,Belgium; Canada; Spain; United States
"A First-in-human Phase I, Dose Escalation, Safety And Pharmacokinetic Study Of Pf-06647263 In Adult Patients With Advanced Solid Tumors",I,Terminated,Pfizer,Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Unspecified Solid Tumor,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Fallopian Tube Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Triple Negative Breast Neoplasms",United States
"A Phase Ib Dose-finding Study of BYL719 Plus Everolimus and BYL719 Plus Everolimus Plus Exemestane in Patients With Advanced Solid Tumors, With Dose-expansion Cohorts in Renal Cell Cancer (RCC), Pancreatic Neuroendocrine Tumors (pNETs), and Advanced Breast Cancer (BC) Patients.",I,Completed,Novartis,Oncology: Breast; Oncology: Neuroendocrine; Oncology: Renal; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; Pancreas; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Renal Cell; Kidney Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Renal Cancer; Wilms Tumor","France; Germany; Hong Kong, S.A.R., China; Hungary; Italy; Netherlands; Spain; United Kingdom; United States"
A diagnostic feasibility trial of a [14C]oxaliplatin microdosing assay for prediction of chemoresistance to oxaliplatin chemotherapy,I,Completed,"National Institutes of Health/National Cancer Institute
University of California Davis",Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"A Phase I, Multicenter, Open-Label Study of Oral Entrectinib (RXDX-101) in Adult Patients with Locally Advanced or Metastatic Cancer Confirmed to be Positive for NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations",I,Completed,Roche {F. Hoffmann-La Roche},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Neuroblastoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Thyroid",Adenocarcinoma; ALK; First line; Fourth line or greater; Large Cell; Locally advanced; Metastatic; Papillary; Second line; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasm Metastasis; Neuroblastoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Thyroid Neoplasms; Wilms Tumor",France; Italy; South Korea; Spain; United Kingdom; United States
A Phase Ib Study of Crizotinib (XALKORI) and Sunitinib (SUTENT) in Metastatic Breast Cancer,I,Terminated,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
Phase Ib Trial of Trastuzumab Emtansine in Combination with Lapatinib Plus Abraxane in Metastatic Her 2 neu Over-Expressed Breast Cancer Patients,I,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; First line; Fourth line or greater; HER2 positive; Progesterone receptor positive; Second line; Stage IV; Third line,Breast Neoplasms,United States
A Phase I/II Study of Ado-Trastuzumab Emtansine(T-DM1) + ABT-737 in Treating Patients With HER2(+) Breast Cancer,I/II,Terminated,"National Institutes of Health/National Cancer Institute
(Other Hospital/Academic/Medical Center)
Breast Cancer Research Foundation",Oncology: Breast,First line; HER2 positive; Second line; Stage IV,Breast Neoplasms,Ukraine; United States
Assessment of HER2 Receptors in Breast Carcinoma by Positron Emission Tomography (PET) Using 89 Zr-Trastuzumab,I,Completed,"National Institutes of Health/National Cancer Institute
Washington University School of Medicine",Oncology: Breast,HER2 negative; HER2 positive; Line of therapy N/A; Stage IV,Breast Neoplasms,United States
Pilot Phase I HER-2 Pulsed DC Vaccine to Prevent Recurrence for Patients with HER-2 Driven High Risk Invasive Breast Cancer,I,Completed,"H. Lee Moffitt Cancer Center and Research Institute
Abramson Cancer Center at  University of Pennsylvania Medical Center",Oncology: Breast,HER2 positive; Line of therapy N/A; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms; Recurrence,United States
"A Phase I Clinical Trial of Ganetespib (Heat Shock Protein 90 Inhibitor) in Combination With Paclitaxel, Trastuzumab and Pertuzumab in Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Metastatic Breast Cancer",I,Completed,"Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute
Madrigal Pharmaceuticals {Synta Pharmaceuticals}
(Other Hospital/Academic/Medical Center)",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 positive; Progesterone receptor positive; Stage III; Stage IV; Third line,"Breast Neoplasms; Breast Neoplasms, Male",United States
Pilot Phase I HER-2 Pulsed DC Vaccine to Prevent Recurrence for Patients With HER-2 Driven High Risk Invasive Breast Cancer Post Neoadjuvant Chemotherapy,I,Completed,"H. Lee Moffitt Cancer Center and Research Institute
Abramson Cancer Center at  University of Pennsylvania Medical Center",Oncology: Breast,First line; HER2 positive; Stage I; Stage II; Stage III,Breast Neoplasms; Recurrence,United States
A Phase I Study of Twice Weekly and Radical Re-irradiation Using Helical Tomotherapy for Aggressive Chest Wall Recurrences of Breast Cancer,I,Terminated,University of Kentucky,Oncology: Breast,(N/A); First line; Second line,Breast Neoplasms,United States
A Phase Ib Study of Abemaciclib in Combination With Therapies for Patients With Metastatic Breast Cancer,I,Completed,Eli Lilly,Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"A Phase I/II Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers (ECHO-202/KEYNOTE-037)",I/II,Completed,"Merck & Co./Merck Sharp & Dohme (MSD)
Incyte Corporation","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal",Adenocarcinoma; Aggressive; ALK; BRAF; BRCA; Diffuse large B-cell lymphoma (DLBCL); EGFR; First line; Fourth line or greater; HER2 negative; KRAS; MSI-H/dMMR; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Second line; Squamous Cell; Stage I; Stage II; Stage III; Stage IV; Third line; Triple receptor negative; Untreated,"Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Microsatellite Instability; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Phase Ib Dose Escalation Study of ADXS31-164 in Subjects with HER2 Expressing Solid Tumors,I,Completed,Ayala Pharmaceuticals {Advaxis},Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Osteosarcoma,HER2 positive; Metastatic; Second line; Stage III; Stage IV,Breast Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Neoplasms; Osteosarcoma; Stomach Carcinoma; Stomach Neoplasms,United States
Phase IB Study of Pembrolizumab (MK-3475) in Subjects With Select Advanced Solid Tumors,I,Completed,Merck & Co./Merck Sharp & Dohme (MSD),"Oncology: Anal; Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Small Cell; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Advanced; Estrogen receptor positive; Extensive; First line; Follicular; Fourth line or greater; Gastrointestinal; HER2 negative; Hilar; Intrahepatic; Locally advanced; Metastatic; Pancreas; Papillary; PD-1 Naive; PD-L1 Naive; PD-L1 Positive; Pulmonary; Second line; Squamous Cell; Stage III; Stage IV; Third line; Unresectable; Unspecified; Untreated,"Anus Neoplasms; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Small Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Gallbladder Neoplasms; Glioblastoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Uterine Cervical Neoplasms","Canada; France; Italy; Japan; Netherlands; South Korea; Spain; Taiwan, China; United Kingdom; United States"
Phase I/II Study of TAS-120 in Patients With Advanced Solid Tumors Harboring FGF/FGFR Aberrations.,I/II,Completed,Otsuka Holdings/Taiho Pharmaceutical,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Multiple Myeloma; Oncology: Neuroblastoma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Distal; FGFR; First line; Fourth line or greater; HER2 negative; HER2 positive; Hilar; Intrahepatic; Second line; Stage III; Stage IV; Third line; Triple receptor negative; Unspecified,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Cholangiocarcinoma; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Mesothelioma; Multiple Myeloma; Neoplasms; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Neuroblastoma; Neuroendocrine Tumors; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor","Australia; Canada; France; Germany; Hong Kong, S.A.R., China; Italy; Japan; Netherlands; Portugal; Slovakia; South Korea; Spain; Taiwan, China; United Kingdom; United States"
A Phase Ib Open Label Dose Finding Study of BYL719 in Combination With Paclitaxel in Advanced Solid Tumors Followed by Two Expansion Phases in Locally Advanced/Metastatic Chemotherapy Naive HER2 Negative Breast Cancer Patients (HER2- mBC) and in Recurrent and Metastatic Head-and-neck Squamous Cell Carcinoma Patients (HNSCC) Pre-treated With Platinum Based Therapy,I,Terminated,Novartis,Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck,First line; HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms,"Australia; Belgium; Denmark; Finland; France; Germany; Israel; Italy; Norway; Russia; Spain; Sweden; Switzerland; Taiwan, China; Thailand; United Kingdom; United States"
A Phase Ib/II Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination with Exemestane or Fulvestrant Therapy in Postmenopausal Women with ER+/HER2- Advanced or Metastatic Breast Cancer that has Progressed on Treatment with Everolimus in Combination with Exemestane or Fulvestrant,I/II,Completed,Takeda/Takeda Oncology {Millennium},Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage I; Stage II; Stage III; Stage IV; Third line,Breast Neoplasms,Belgium; France; United States
Fusion Cell Vaccination of Patients with Metastatic Breast and Renal Cancer Induces Immunological and Clinical Responses,I,Completed,Sanofi {Sanofi-Aventis}/Sanofi Genzyme {Genzyme},Oncology: Breast; Oncology: Renal,First line; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Kidney Neoplasms; Renal Cancer; Wilms Tumor",United States
"Carboplatin, Gemcitabine, and Mifepristone for Advanced Breast Cancer and Recurrent or Persistent Epithelial Ovarian Cancer",I,Completed,"National Institutes of Health/National Cancer Institute
University of Chicago Cancer Research Center",Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal,Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Breast Neoplasms, Male; Fallopian Tube Neoplasms; Neoplasms, Glandular and Epithelial; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms",United States
STM-02: Phase I Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing Insulin-like Growth Factor Receptor 1 (IGF-1R),I,Completed,"University of Illinois at Chicago Health Sciences Center
IGF Oncology","Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Liver; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal",(N/A); Indolent; Second line; Stage III; Stage IV; Waldenstrom's macroglobulinemia (WM),"Acute Myelocytic Leukemia; Brain Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gastrointestinal Neoplasms; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Multiple Myeloma; Myelodysplastic Syndromes; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Urogenital Neoplasms; Waldenstrom Macroglobulinemia; Wilms Tumor",United States
"Phase l Open-Label, Dose Escalation, Multi-Center Study of ACT-PFK-158, 2HCl in Patients With Advanced Solid Malignancies",I,Completed,Advanced Cancer Therapeutics,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas",Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Melanoma; Pancreatic Cancer; Pancreatic Neoplasms; Unspecified",United States
"A Phase I, Open-Label, Multicentre Dose-Escalation Study to Investigate the Safety and Pharmacokinetics of AZD5312 in Patients With Advanced Solid Tumours Where the Androgen Receptor Pathway is a Potential Factor",I/II,Completed,"AstraZeneca
Ionis Pharmaceuticals {Isis Pharmaceuticals}",Oncology: Bladder; Oncology: Breast; Oncology: Gastric; Oncology: Head/Neck; Oncology: Ovarian; Oncology: Prostate,Hormone refractory; Second line; Stage III; Stage IV,Breast Neoplasms; Head and Neck Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms,United Kingdom; United States
Phase II Study of Combination Ruxolitinib (INCB018242) With Preoperative Chemotherapy for Triple Negative Inflammatory Breast Cancer Following Completion of a Phase I Combination Study in Recurrent/Metastatic Breast Cancer,I/II,Completed,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Incyte Corporation",Oncology: Breast,HER2 negative; Neoadjuvant; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors,I,Completed,"Sanofi {Sanofi-Aventis {Aventis}}
Genta","Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms",United States
A Phase I Study of BYL719 and Trastuzumab-MCC-DM1 in HER2-Positive Metastatic Breast Cancer Patients With Progression on Prior Trastuzumab and Taxane-Based Therapy,I,Completed,"Novartis
National Institutes of Health/National Cancer Institute
Northwestern University",Oncology: Breast,Estrogen receptor positive; First line; Fourth line or greater; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
An Extension Study to Evaluate the Safety of Veliparib as Single Agent Therapy or in Combination With Chemotherapy in Subjects With Solid Tumors,I,Completed,AbbVie,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Ovarian",BRCA; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Stomach Carcinoma; Stomach Neoplasms",Netherlands; Spain; United States
"A Phase I, Open-label Study to Evaluate the Mass Balance of Orally Administered FTD and TPI as Components of TAS-102 in Patients with Advanced Solid Tumors",I,Completed,Otsuka Holdings/Taiho Pharmaceutical,Oncology: Breast; Oncology: Unspecified Solid Tumor,First line; Second line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms; Neoplasms, Unknown Primary",United States
"Phase I, Double Blind, Randomized, Parallel-Group, Single-Dose, 3-Arm, Comparative Pharmacokinetic Study Of PF-06439535 And Bevacizumab Sourced From US And EU Administered To Healthy Male Volunteers",I,Completed,Pfizer,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Multiple Myeloma; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma",(N/A); Line of therapy N/A,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Chronic Lymphocytic Leukemia; Colorectal Neoplasms; Fibrosarcoma; Glioblastoma; Kidney Neoplasms; Leiomyosarcoma; Leukemia, Lymphocytic, Chronic, B-Cell; Liposarcoma; Liver Cancer; Liver Neoplasms; Medulloblastoma; Melanoma; Multiple Myeloma; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified; Wilms Tumor",United States
Phase Ib Study of Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Patients With Metastatic Breast Cancer,I,Terminated,"Albert Einstein Medical College
Montefiore Medical Center
Deciphera Pharmaceuticals",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms; Carcinoma,United States
Phase I/II Trial of Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer,I/II,Completed,"National Institutes of Health/National Cancer Institute
Herbert Irving Comprehensive Cancer Center at Columbia University
Incyte Corporation",Oncology: Breast,Fourth line or greater; HER2 positive; Stage IV,Breast Neoplasms,United States
"A Phase Ib, Open-label Study to Assess the Safety and Tolerability of Tucatinib (ONT-380) Combined With Capecitabine and Trastuzumab, Alone and in Combination in HER2+ Metastatic Breast Cancer",I,Completed,"Seagen {Seattle Genetics/Cascadian Therapeutics {Oncothyreon {Biomira}}}
Pfizer {Array BioPharma}",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Fourth line or greater; HER2 positive; Stage IV; Third line,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
"In-Situ Cancer Vaccine: Phase I/IIb, Open-Label Study to Assess Safety of Allostim in Combination With Cryoablation in Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine",I/II,Terminated,Immunovative Therapies,Oncology: Breast,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage IV; Third line,Breast Neoplasms,United States
"Pilot Safety Trial of Preoperative Chemotherapy Combined With Dendritic Cell Vaccine in Patients With Locally Advanced, Triple-Negative Breast Cancer or ER-Positive, Her2-Negative Breast Cancer",I/II,Completed,Baylor Research Institute,Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage III; Triple receptor negative,Breast Neoplasms,United States
A Phase I Study of Trametinib in Combination With Radiation Therapy for Brain Metastases,I,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Melanoma; Oncology: Metastatic Cancer,(N/A); BRAF; CNS mets; HRAS; KRAS; Line of therapy N/A; NRAS,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms,United States
"Phase I, Double-Blind, Randomized, Parallel-Group, Single-Dose, 2-Arm, Safety Study Of PF-05280014 And Trastuzumab Sourced From The US Administered To Healthy Male Volunteers.",I,Completed,Pfizer,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell",(N/A); Line of therapy N/A,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Glioblastoma; Medulloblastoma; Stomach Carcinoma; Stomach Neoplasms; Unspecified",United States
"A Phase I Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer",I,Completed,Merck & Co. {Immune Design},"Oncology: Bladder; Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Renal; Oncology: Soft Tissue Sarcoma",First line; Metastatic; Second line; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Ewing Sarcoma; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasm Metastasis; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"Part I and Part II A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Alone or With Chemotherapy",I,Completed,Celldex Therapeutics {Kolltan},"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Testicular; Oncology: Thyroid",BRAF; Fourth line or greater; HER2 positive; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Testicular Cancer; Testicular Neoplasms; Thyroid Neoplasms; Unspecified",United States
A Phase I Study of LY3009120 in Patients With Advanced or Metastatic Cancer,I,Completed,Eli Lilly,"Oncology: Breast; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Pancreas",BRAF; KRAS; NRAS; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasm Metastasis; Neoplasms; Neoplasms, Mesothelial; Pancreatic Cancer; Pancreatic Neoplasms",Australia; France; Spain; United States
"A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers",I/II,Completed,GlaxoSmithKline,"Oncology: Breast; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Multiple Myeloma; Oncology: Neuroblastoma; Oncology: Neuroendocrine; Oncology: Prostate; Oncology: Unspecified Solid Tumor",Estrogen receptor positive; First line; HER2 negative; Hormone refractory; Pediatric or Adolescent; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative; Untreated,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Multiple Myeloma; Neoplasms, Unknown Primary; Neuroblastoma; Neuroendocrine Tumors; Prostatic Neoplasms; Small Cell Lung Carcinoma",Australia; France; Netherlands; South Korea; Spain; United Kingdom; United States
Oral ONC201 in Treating Patients With Advanced Solid Tumors,I,Completed,"National Institutes of Health/National Cancer Institute
(Other Hospital/Academic/Medical Center)","Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Prostate",(N/A); Fourth line or greater; HER2 negative; Hormone refractory; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Glioblastoma; Neoplasms; Prostatic Neoplasms; Triple Negative Breast Neoplasms",United States
"Phase I Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer.",I/II,Completed,Corcept Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Fallopian Tube; Oncology: Lung, Non-Small Cell; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Fourth line or greater; HER2 negative; HER2 positive; Locally advanced; Metastatic; Second line; Stage III; Stage IV; Third line; Triple receptor negative; Unresectable,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Ewing Sarcoma; Fallopian Tube Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasms, Glandular and Epithelial; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Randomized, Placebo-Controlled Crossover Study to Evaluate the Effect of Veliparib (ABT-888) on Cardiac Repolarization in Subjects With Relapsed or Refractory Solid Tumors",I,Completed,AbbVie,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Ovarian",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Colorectal Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Stomach Carcinoma; Stomach Neoplasms",Netherlands; Spain; United States
A Phase I Study of GDC-0919 for Adult Patients With Recurrent Advanced Solid Tumors,I,Terminated,"Lumos Pharma {NewLink Genetics}
Roche/Genentech","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Testicular",First line; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Lung Neoplasms; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Phase I Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Advanced or Recurrent Malignancies,I/II,Completed,"MD Anderson Cancer Center, University of Texas
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
NorthWestern Memorial Hospital
Cotinga Pharmaceuticals {Critical Outcome Technologies}","Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Unspecified Solid Tumor",Fourth line or greater; HER2 negative; Pulmonary; Squamous Cell; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Small Cell Lung Carcinoma; Uterine Cervical Neoplasms",United States
A Phase I Study of Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion,I,Completed,"University of Pennsylvania
Candel Therapeutics {Advantagene}","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian",(N/A); Line of therapy N/A; Pulmonary,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Mesothelioma; Neoplasms, Mesothelial; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pleural Effusion; Pleural Effusion, Malignant; Small Cell Lung Carcinoma",United States
"A Phase I, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, Preliminary Clinical Activity and Pharmacokinetics of AM0010 in Patients with Advanced Solid Tumors",I,Completed,Eli Lilly/ARMO BioSciences,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal",Adenocarcinoma; Cutaneous T-cell lymphoma (CTCL); Fourth line or greater; HER2 negative; Hormone refractory; Indolent; Large Cell; PD-L1 High; PD-L1 Positive; Peripheral T-cell lymphoma (PTCL); Second line; Squamous Cell; Stage II; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Wilms Tumor",United States
"PhI Study of the Safety, PK, and PDn of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a Single Agent and in Combination With Standard Chemotherapy in Patients With Advanced and/or Treatment-Refractory Solid Tumors",I,Completed,Calithera Biosciences,"Oncology: Breast; Oncology: Colorectal; Oncology: GIST; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Advanced; EGFR; First line; Fourth line or greater; HER2 negative; KRAS; Locally advanced; Metastatic; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative; Untreated,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Triple Negative Breast Neoplasms; Wilms Tumor",United States
A Pilot & Feasibility Study of the Imaging Potential of EC17 in Subjects Undergoing Surgery Presenting Breast Cancer,I,Completed,University of Pennsylvania,Oncology: Breast,Neoadjuvant; Stage 0; Stage I; Stage II,Breast Neoplasms,United States
"Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients with Advanced Solid Tumors and Deleterious BRCA Mutations",I/II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Gastric; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Unspecified Solid Tumor,BRCA; Fourth line or greater; HER2 positive; Hormone refractory; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
"A Phase Ib, Open-label Study to Assess the Safety and Tolerability of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (Trastuzumab Emtansine;T-DM1)",I,Completed,"Seagen {Seattle Genetics/Cascadian Therapeutics {Oncothyreon {Biomira}}}
Pfizer {Array BioPharma}",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Estrogen receptor positive; Fourth line or greater; HER2 positive; Second line; Stage IV; Third line,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,Canada; United States
"A Two-Part, Phase I, Multicenter, Open-Label Study of RO6870810/TEN-010 Given Subcutaneously: Part A: A Dose-Escalation Study in Patients With Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Selected Malignancies",I,Completed,Roche {Tensha Therapeutics},"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: GIST; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Aggressive; Diffuse large B-cell lymphoma (DLBCL); First line; Fourth line or greater; Second line; Squamous Cell; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
Treatment of Solid Tumors with Intratumoral Hiltonol (Poly-ICLC): A Phase II Clinical Study,I/II,Terminated,Oncovir,Oncology: Breast; Oncology: Head/Neck; Oncology: Melanoma; Oncology: Soft Tissue Sarcoma,Maintenance/Consolidation; Second line; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms, Basal Cell; Rhabdomyosarcoma; Sarcoma; Skin Neoplasms; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
"Pre-Surgical ""Window of Opportunity"" Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer",I,Completed,Columbia University Medical Center,Oncology: Breast,Neoadjuvant; Stage 0; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Phase I Trial of Intratumoral Administration of a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck or Metastatic Breast Cancer,I,Completed,"National Institutes of Health/National Cancer Institute
Mayo Clinic",Oncology: Breast; Oncology: Head/Neck,Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck",United States
"An Open Label, Non-randomized, Phase I Dose Escalation Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY1163877 in Subjects with Refractory, Locally Advanced or Metastatic Solid Tumors",I,Completed,Bayer AG/Bayer Pharmaceuticals,"Oncology: Bladder; Oncology: Breast; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Adenocarcinoma; FGFR; Second line; Squamous Cell; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasms, Unknown Primary; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms",France; Germany; Singapore; South Korea; Spain; Switzerland; United States
A Phase I A/B Study of the Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors,I,Terminated,Novartis/Endocyte,"Oncology: Breast; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian",Adenocarcinoma; ALK; BRCA; EGFR; HER2 negative; Large Cell; PD-1 Refractory; PD-L1 Refractory; Pulmonary; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Mesothelioma; Neoplasms, Mesothelial; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms",United States
"A Phase I Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination with Tremelimumab in Subjects with Advanced Solid Tumors",I,Completed,"(Other Academic Cancer Center)
AstraZeneca {MedImmune}
Ludwig Institute for Cancer Research","Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Renal",Extensive; Fourth line or greater; HER2 negative; Pulmonary; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Uterine Cervical Neoplasms; Wilms Tumor",Canada; France; Germany; Israel; Netherlands; South Korea; Spain; United Kingdom; United States
Phase IB Study of PD-0332991 in Combination with T-DM1 in the Treatment of Patients with Advanced HER2 (Human Epidermal Growth Factor Receptor 2)-Positive Breast Cancer,I,Completed,"Pfizer
University of Pennsylvania
University of Texas Southwest Medical Center",Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies",I,Completed,Merck KGaA/EMD Serono {EMD Pharmaceuticals},"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Unspecified Solid Tumor",Aggressive; Classical; Estrogen receptor positive; HER2 negative; HER2 positive; Indolent; Nodular lymphocyte-predominant; Progesterone receptor positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Glioblastoma; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms, Unknown Primary; Unspecified",United States
"A Phase I, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors",I,Completed,Sagimet Biosciences {3-V Biosciences},"Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Aggressive; Diffuse large B-cell lymphoma (DLBCL); HER2 negative; KRAS; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Liver Cancer; Liver Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Uterine Cervical Neoplasms",United Kingdom; United States
"A Phase I, First Time in Human, Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Anti-Her3 Monoclonal Antibody GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors",I,Completed,GlaxoSmithKline,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",BRAF; First line; HER2 positive; Hormone refractory; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms",Australia; Netherlands; United States
"A Phase I Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced or Refractory Solid Tumors or Lymphoma",I,Completed,Johnson & Johnson/Janssen Pharmaceuticals {Janssen Pharmaceutica},"Oncology: Bladder; Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Neuroendocrine",Aggressive; Classical; FGFR; Indolent; Nodular lymphocyte-predominant; Pulmonary; Second line; Stage III; Stage IV,"Adenocarcinoma; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neuroendocrine Tumors; Small Cell Lung Carcinoma; Urethral Neoplasms; Urinary Bladder Neoplasms","France; Japan; South Korea; Spain; Taiwan, China; United States"
A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors,I,Completed,Sihuan Pharmaceutical Holdings Group,"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",EGFR; HER2 positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Unspecified",United States
"Phase I, Open-label Study Assessing the Pharmacokinetics, Immunogenicity and Safety/Tolerability of Process 2 Patritumab in Patients with Advanced, Refractory Solid Tumors",I,Completed,Daiichi Sankyo,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",Hormone refractory; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",United States
"A Phase I Study of [ 14 C]-Ixazomib to Assess Mass Balance, Pharmacokinetics, and Metabolism in Patients With Advanced Solid Tumors or Lymphoma",I,Completed,Takeda/Takeda Oncology {Millennium},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Pancreas",Aggressive; Classical; Indolent; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
Phase I Study of VISA-Claudin4-BikDD Therapy in Advanced Breast Cancer,I,Terminated,"MD Anderson Cancer Center, University of Texas",Oncology: Breast,Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase I First-in-Man, Open-label, Dose-escalating, Clinical and Pharmacokinetic, Safety Study of PM060184 in Advanced Malignant Solid Tumors",I,Completed,PharmaMar {Zeltia/PharmaMar},"Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: GIST; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Thymus",Fourth line or greater; Second line; Stage III; Stage IV; Third line; Thymic carcinoma,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Thymus Neoplasms; Uterine Cervical Neoplasms",France; Spain; United States
Phase I Trial of ADI-PEG 20 Plus Doxorubicin in Patients With HER2 Negative Metastatic Breast Cancer or Advanced Solid Tumor.,I,Completed,Polaris Group {Polaris Pharmaceuticals},Oncology: Breast; Oncology: Unspecified Solid Tumor,HER2 negative; Second line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms, Unknown Primary",United States
"A Multicenter, Phase I/Ib, Open-Label, Dose-Escalation Study of ABT-165, a Dual Variable Domain Immunoglobulin in Subjects With Advanced Solid Tumors",I,Completed,AbbVie,Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Ovarian; Oncology: Renal; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Kidney Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Wilms Tumor",United States
A Phase I/II Study of Romidepsin in Combination With Abraxane in Patients With Metastatic Inflammatory Breast Cancer,I/II,Terminated,"Bristol-Myers Squibb/Celgene
Kimmel Cancer Center-Thomas Jefferson University - Philadelphia, PA",Oncology: Breast,First line; HER2 negative; Second line; Stage IV; Third line,"Breast Neoplasms; Breast Neoplasms, Male; Inflammatory Breast Neoplasms",United States
"An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY1143572 Given in a Once-daily or an Intermittent Dosing Schedule in Subjects With Advanced Malignancies",I,Terminated,Bayer AG/Bayer Pharmaceuticals,"Oncology: Breast; Oncology: Gastric; Oncology: Lymphoma, Non-Hodgkin's",Aggressive; Diffuse large B-cell lymphoma (DLBCL); HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Stomach Carcinoma; Stomach Neoplasms; Unspecified","Singapore; South Korea; Taiwan, China; United States"
"A Phase I, Gene Alteration-based, Open Label, Multicenter Study of Oral Debio 1347 (CH5183284) in Patients With Advanced Solid Malignancies, Whose Tumours Have an Alteration of the FGFR 1, 2 or 3 Genes",I,Terminated,"(Other Industry Sponsor)
Roche/Chugai Pharmaceutical
Debiopharm","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell",FGFR; Fourth line or greater; Second line; Squamous Cell; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Glioblastoma; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms","Singapore; South Korea; Spain; Taiwan, China; United States"
Randomized Phase II Study of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy in Women with Early Stage Breast Cancer (PBI 3.0).,I/II,Open,(Other Hospital/Academic/Medical Center),Oncology: Breast,Adjuvant; Estrogen receptor positive; Stage I; Stage II,Breast Neoplasms,United States
"A Phase Ib, Open-label Study of Oral BGJ398 in Combination With Oral BYL719 in Adult Patients With Select Advanced Solid Tumors",I,Completed,Novartis,Oncology: Anal; Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Melanoma; Oncology: Renal,FGFR; Fourth line or greater; Stage III; Stage IV,"Anus Neoplasms; Breast Neoplasms; Carcinoma, Renal Cell; Esophageal Cancer; Esophageal Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor","Australia; Belgium; Canada; France; Germany; Hong Kong, S.A.R., China; Italy; Netherlands; Singapore; South Korea; Spain; Sweden; Switzerland; Taiwan, China; United Kingdom; United States"
"A Phase I/II, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors.",I/II,Completed,Bristol-Myers Squibb,"Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal",HER2 negative; Metastatic; MSI-H/dMMR; PD-L1 Positive; Pulmonary; Second line; Stage II; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Renal Cell; Carcinoma, Small Cell; Esophageal Cancer; Esophageal Neoplasms; Kidney Neoplasms; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Canada; Denmark; Finland; Germany; Italy; Spain; United Kingdom; United States
A Phase I/II Study of Onapristone in Patients with Progesterone Receptor Expressing Cancers,I/II,Completed,"Arno Therapeutics
Invivis",Oncology: Breast; Oncology: Endometrial; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma,First line; Metastatic; Progesterone receptor positive; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Ovarian Cancer; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified",France; United States
A Phase Ib Open-label Three-arm Multi-center Study To Assess The Safety And Tolerability Of Pf-05212384 (pi3k/Mtor Inhibitor) In Combination With Other Anti-tumor Agents,I,Completed,Pfizer,"Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal",EGFR; First line; Fourth line or greater; HER2 negative; HER2 positive; Hormone refractory; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Canada; Italy; Spain; United Kingdom; United States
A Phase I Study of BikDD Therapy in Advanced Breast Cancer,I,Terminated,"MD Anderson Cancer Center, University of Texas",Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer,I/II,Terminated,"National Institutes of Health/National Cancer Institute
Vanderbilt-Ingram Cancer Center
Roche/Genentech",Oncology: Breast,First line; HER2 negative; Second line; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase I, Multi-center, Non-randomized, Open-label, Dose Escalation Design Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY 1125976 in Subjects with Advanced Solid Tumors",I,Completed,Bayer AG/Bayer Pharmaceuticals,Oncology: Breast; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms, Unknown Primary; Unspecified",France; Germany; Switzerland; United States
A Phase I Pharmacokinetic Study of Oral IXAZOMIB (MLN9708) in Patients With Advanced Solid Tumors or Hematologic Malignancies With Varying Degrees of Liver Dysfunction,I,Completed,Takeda/Takeda Oncology {Millennium},"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Testicular",Aggressive; Classical; Hormone refractory; Indolent; Nodular lymphocyte-predominant; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Chronic Lymphocytic Leukemia; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Testicular Cancer; Testicular Neoplasms; Wilms Tumor",United States
"An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970/M6620 in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors",I/II,Completed,"Merck KGaA
Merck KGaA/EMD Serono {EMD Pharmaceuticals}
Vertex Pharmaceuticals","Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: GIST; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",HER2 negative; Other; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Uterine Cervical Neoplasms; Wilms Tumor",United Kingdom; United States
"A Phase I, Dose Escalation Study Of Pf-06263507 In Patients With Advanced Solid Tumors",I,Terminated,Pfizer,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Ovarian",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms; Ovarian Cancer; Ovarian Neoplasms",Canada; United States
"Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies.",I,Completed,Eli Lilly,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Wilms Tumor",Netherlands; United States
A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors.,I,Completed,"Sanofi {Sanofi-Aventis {Aventis}}
Astellas Pharma {OSI Pharmaceuticals}","Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",(N/A); Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Neuroendocrine Tumors; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Wilms Tumor",United States
"A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumour Activity of AZD8186 in Patients with Advanced Castration-resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients with Known PTEN-deficient/mutated or PIK3CB mutated/ amplified Advanced Solid Malignancies as Monotherapy and in Combination with Abiraterone Acetate or AZD2014",I,Completed,AstraZeneca,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Unspecified Solid Tumor",HER2 negative; Hormone refractory; Second line; Squamous Cell; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Lung Neoplasms; Neoplasms, Unknown Primary; Prostatic Neoplasms; Triple Negative Breast Neoplasms",Canada; Spain; United Kingdom; United States
Pilot Study of Anti-oxidant Supplementation With N-Acetyl Cysteine in Stage 0/I Breast Cancer,I,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Neoadjuvant; Stage 0; Stage I,Breast Neoplasms,United States
"Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib",I,Completed,"GlaxoSmithKline
Novartis
UNC Lineberger Comprehensive Cancer Center
Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}
Roche/Genentech",Oncology: Breast,FGFR; HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
Phase Ib Study of Docetaxel + PF-03084014 In Metastatic or Locally Recurrent/Advanced Triple Negative Breast Cancer,I,Terminated,Pfizer,Oncology: Breast,First line; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,Belgium; Italy; Spain; United States
"A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 With Letrozole in Adult Patients With Advanced ER+ Breast Cancer",I/II,Closed,Novartis,Oncology: Breast,Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Canada; Czech Republic; France; Germany; Hong Kong, S.A.R., China; Israel; Italy; Lebanon; Netherlands; Singapore; South Korea; Spain; Sweden; Switzerland; Taiwan, China; United Kingdom; United States"
A Phase I Trial of BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer,I,Completed,"Novartis
Memorial Sloan-Kettering Cancer Center",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
A Phase Ib Dose Escalation Study of Vantictumab (OMP-18R5) in Combination with Paclitaxel in Patients with Locally Recurrent or Metastatic Breast Cancer,I,Completed,"Bayer AG
Mereo BioPharma/OncoMed",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
"A Phase Ib, Open-Label, Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Patients With Solid Tumors",I,Completed,Takeda/Takeda Oncology {Millennium},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma",Adenocarcinoma; Fourth line or greater; Large Cell; Maintenance/Consolidation; Second line; Squamous Cell; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Phase Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0032 in Combination With Either Docetaxel or Paclitaxel in Patients With HER2-Negative, Locally Advanced or Metastatic Breast Cancer or Non-Small Cell Lung Cancer",I,Completed,Roche/Genentech,"Oncology: Breast; Oncology: Lung, Non-Small Cell",HER2 negative; Line of therapy N/A; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms",Belgium; Canada; Spain; United States
Single-Dose Fasting Bioequivalence Study of Anastrozole Tablets (1 mg; Genpharm) and ArimidexTablets (1 mg; AstraZeneca) in Healthy Male and Female (Not of Childbearing Potential) Volunteers.,I,Completed,Viatris {Mylan/Mylan Pharmaceuticals {Genpharm}},Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
Single-Dose Fasting Bioequivalence Study of Anastrozole Tablets (1 mg; Mylan) and Arimidex Tablets (1 mg; AstraZeneca) in Healthy Female (Not of Childbearing Potential) Volunteers,I,Completed,Viatris {Mylan/Mylan Pharmaceuticals},Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
"Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Unresectable Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC)",I,Completed,PharmaMar {Zeltia/PharmaMar},Oncology: Breast; Oncology: Colorectal; Oncology: Pancreas,BRCA; Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Colorectal Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms,Belgium; Spain; United States
"A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer",I,Completed,Novartis,Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,"Belgium; France; Hong Kong, S.A.R., China; Spain; United States"
"A Phase I Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib Extended Release Formulations in Subjects With Solid Tumors",I,Completed,AbbVie,Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal,Second line; Stage III; Stage IV,Breast Neoplasms; Fallopian Tube Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms,United States
A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors,I,Completed,Merck & Co./Merck Sharp & Dohme (MSD),Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Renal,First line; Fourth line or greater; HER2 negative; PD-L1 High; PD-L1 Positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Renal Cell; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor","Belgium; Israel; Japan; South Korea; Spain; Taiwan, China; United States"
"A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With Metastatic Breast Cancer.",I,Completed,"Merck & Co.
Seagen {Seattle Genetics}",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; PD-L1 Positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Neoplasms; Triple Negative Breast Neoplasms,United States
"A Single Arm, Phase I/II Study of SNX-5422 in Subjects With Selected HER2 Positive Cancers.",I/II,Terminated,Esanex,"Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Renal",HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Cancer; Esophageal Neoplasms; Kidney Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
Evaluation of the Safety and Immunogenicity of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies (Mel59),I,Completed,University of Virginia,"Oncology: Breast; Oncology: Colorectal; Oncology: Fallopian Tube; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian",First line; HER2 negative; HER2 positive; Second line; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fallopian Tube Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Unspecified",United States
"An Open-Label Study to Investigate the Pharmacokinetics (Absorption, Distribution, Metabolism, and Excretion) of Omacetaxine Mepesuccinate Following Subcutaneous Administration of [14C]Omacetaxine Mepesuccinate in Patients With Relapsed and/or Refractory Hematologic Malignancies or Advanced Solid Tumors",I,Completed,Teva,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Myelodysplastic Syndrome; Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma",(N/A); APL/M3; Localized; Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Acute Myelocytic Leukemia; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Chronic Myeloid Leukemia; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Liposarcoma; Melanoma; Myelodysplastic Syndromes; Neoplasms; Osteosarcoma; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",Netherlands; United States
"A Phase I, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB047986 in Subjects With Advanced Malignancies",I,Terminated,Incyte Corporation,"Oncology: Bladder; Oncology: Breast; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Pancreas; Oncology: Renal",Aggressive; Classical; First line; HER2 negative; Indolent; Nodular lymphocyte-predominant; Second line; Stage II; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Renal Cell; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasm Metastasis; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
Clinical Trial of Autologous cMet Redirected T Cells Administered Intratumorally in Patients With Breast Cancer,I,Completed,University of Pennsylvania,Oncology: Breast,Adjuvant; First line; HER2 negative; Neoadjuvant; Second line; Stage I; Stage II; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase I Dose Escalation Study of POL6326 With Eribulin in Patients With Relapsed, Triple Negative and Hormone Refractory ER Positive Metastatic Breast Cancer",I,Completed,Spexis {Polyphor},Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,Spain; United States
"Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Weekly Paclitaxel, With or Without Bevacizumab, in Patients With Selected Advanced Solid Tumors",I,Completed,PharmaMar {Zeltia/PharmaMar},"Oncology: Breast; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian",Adenocarcinoma; Extensive; First line; Large Cell; Pulmonary; Second line; Stage III; Stage IV; Untreated,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Endometrial Neoplasms; Head and Neck Neoplasms; Lung Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Small Cell Lung Carcinoma",Spain; Switzerland; United States
"A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection",I,Terminated,"(Other Hospital/Academic/Medical Center)
Synlogic {Mirna Therapeutics}","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: GIST; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Multiple Myeloma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Aggressive; Classical; Fourth line or greater; HER2 negative; Indolent; Liver mets; Nodular lymphocyte-predominant; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative; Unspecified,"Acute Myelocytic Leukemia; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Cholangiocarcinoma; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Leukemia, Myeloid, Acute; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Metastasis; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",South Korea; United States
Phase Ib Trial of Two Folate Binding Protein (FBP) Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients,I,Completed,"MD Anderson Cancer Center, University of Texas
(Other Hospital/Academic/Medical Center)",Oncology: Breast; Oncology: Ovarian,(N/A); Second line,"Breast Neoplasms; Carcinoma, Ovarian Epithelial; Ovarian Cancer; Ovarian Neoplasms",United States
A Phase Ib Study of the Safety and Tolerability of Ruxolitinib in Combination With Gemcitabine With or Without Nab-Paclitaxel in Subjects With Advanced Solid Tumors,I,Terminated,Incyte Corporation,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas",Second line; Stage II; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms",United States
A Pivotal Bioequivalence Study of DOXIL/CAELYX Manufactured at a New Site in Subjects With Advanced or Refractory Solid Malignancies Including Subjects With Ovarian Cancer.,I,Completed,Johnson & Johnson/Janssen Pharmaceuticals {Janssen Pharmaceutica},Oncology: Breast; Oncology: Ovarian,Second line; Stage III; Stage IV,Breast Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms,Belgium; Canada; Spain; United Kingdom; United States
Thrombokinetic Studies of Ado-trastuzumab Emtansine,I,Completed,"National Institutes of Health/National Cancer Institute
University of Washington",Oncology: Breast,First line; HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
A First-in-human Study of the Novel Metabolism-based Anti-cancer Agent SM-88 in Subjects with Advanced Metastatic Cancer,I,Completed,Syros Pharmaceuticals {Tyme Technologies {Luminant Biosciences}},"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer; Oncology: Pancreas; Oncology: Prostate; Oncology: Thyroid",Bone mets; CNS mets; Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; HER2 positive; Liver mets; Other mets; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Colorectal Neoplasms; Glioblastoma; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasm Metastasis; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Thyroid Neoplasms",United States
A Phase Ib Study of TAK-700 in Postmenopausal Women with Hormone-receptor Positive Metastatic Breast Cancer,I,Completed,"Takeda/Takeda Oncology {Millennium}
University of Wisconsin",Oncology: Breast,Estrogen receptor positive; First line; Fourth line or greater; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors",I,Completed,Gilead Sciences,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor",Adenocarcinoma; BRAF; First line; HER2 negative; Hormone refractory; Second line; Squamous Cell; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
Pilot Safety and Blood Immune Cell Transcriptional Profiling Study of Anakinra Plus the Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients,I,Completed,Baylor Research Institute,Oncology: Breast,Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
A Phase I Dose Escalation Study of Eribulin in Combination With Weekly Carboplatin for the Treatment of Metastatic Breast Cancer,I,Completed,"H. Lee Moffitt Cancer Center and Research Institute
Eisai",Oncology: Breast,Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"An Open-label, Phase Ia/Ib/IIa Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or an LHRH Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer",I/II,Terminated,Roche/Genentech {Seragon Pharmaceuticals},Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,Netherlands; South Korea; Spain; United States
A Double Blind Prospective Study of Metformin vs. Placebo in Overweight or Obese Post-menopausal Women at Elevated Risk for Breast Cancer,I,Completed,"National Institutes of Health/National Cancer Institute
Indiana University School of Medicine",Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms; Overweight,United States
A Phase Ib Trial of BYL719 (an alpha-Specific PI3K Inhibitor) in Combination With Endocrine Therapy in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer,I,Completed,"Novartis
National Institutes of Health/National Cancer Institute
Vanderbilt-Ingram Cancer Center",Oncology: Breast,Estrogen receptor positive; FGFR; Fourth line or greater; HER2 negative; KRAS; Progesterone receptor positive; Second line; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Ductal, Breast",United States
"Phase Ib/II Single-arm Trial Evaluating the Combination of Lapatinib, Everolimus and Capecitabine for the Treatment of Patients With HER2-positive Metastatic Breast Cancer With CNS Progression After Trastuzumab",I/II,Completed,"Jonsson Comprehensive Cancer Center, UCLA",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; First line; HER2 positive; Stage IV,"Brain Neoplasms; Breast Neoplasms; Breast Neoplasms, Male; Central Nervous System Neoplasms; Neoplasm Metastasis",United States
"A Phase I Study of VS-4718, a Focal Adhesion Kinase Inhibitor, in Subjects With Metastatic Non-Hematologic Malignancies",I,Terminated,Verastem Oncology {Verastem},Oncology: Breast; Oncology: Mesothelioma,Advanced; Line of therapy N/A; Stage IV,"Breast Neoplasms; Mesothelioma; Neoplasm Metastasis; Neoplasms, Mesothelial",United States
A Phase I Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors.,I,Completed,"GlaxoSmithKline
Mereo BioPharma/OncoMed","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Pancreas",HER2 negative; Pulmonary; Second line; Stage II; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Small Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Neoplasms; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms",United States
"A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications.",I,Completed,"National Institutes of Health/National Cancer Institute
Merck KGaA/EMD Serono {EMD Pharmaceuticals}","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal; Oncology: Thymus; Oncology: Unspecified Solid Tumor",Adenocarcinoma; ALK; BRCA; EGFR; Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; HER2 positive; Hormone refractory; KRAS; Large Cell; Maintenance/Consolidation; Other subtype; PD-L1 High; PD-L1 Positive; Progesterone receptor positive; Second line; Squamous Cell; Stage III; Stage IV; Third line; Thymic carcinoma; Thymoma; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Thymoma; Thymus Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor","Belgium; Czech Republic; France; Germany; Hungary; Poland; South Korea; Taiwan, China; United Kingdom; United States"
"A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment",I,Completed,"Merrimack Pharmaceuticals
Ipsen","Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Small Intestine; Oncology: Unspecified Solid Tumor",Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Intestinal Neoplasms; Mesothelioma; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms",United States
A Pilot Study of Systemically Administered Bevacizumab in Patients With Neoplastic Meningitis (NM),I/II,Completed,"MD Anderson Cancer Center, University of Texas
Roche/Genentech","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer",Adenocarcinoma; CNS mets; Large Cell; Second line; Squamous Cell; Stage IV,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Melanoma; Meningeal Carcinomatosis; Meningitis; Meningococcal Infections; Neoplasm Metastasis",United States
SU2C Phase Ib Trial of Dual PI3K/ mTOR Inhibitor BEZ235 with Letrozole in ER+/HER2- Metastatic Breast Cancer (MBC),I,Completed,"Novartis
(Other Hospital/Academic/Medical Center)",Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage IV,Breast Neoplasms,United States
Phase I/II Randomized Study of Combination Immunotherapy With or Without Polysaccharide Krestin (PSK) Concurrently With a HER2 ICD Peptide-Based Vaccine in Patients With Stage IV Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy,I/II,Completed,"National Institutes of Health/National Cancer Institute
National Institutes of Health/National Center for Complementary and Alternative Medicine
University of Washington",Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
"A Phase I Study of the Safety, Tolerability, and PK of MORAb-066, a Humanized Monoclonal Antibody to Human TF, in Patients With Advanced or Metastatic Breast, Pancreatic, Colorectal, or NSCLC (Adenocarcinoma) Malignancies",I,Completed,Eisai/Morphotek,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Pancreas",Adenocarcinoma; Second line; Stage II; Stage III; Stage IV,"Adenocarcinoma; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms",United States
A Pilot Study of Broccoli Sprout Extract in Patients With Breast Cancer,I,Completed,"National Institutes of Health/National Cancer Institute
Roswell Park Cancer Institute",Oncology: Breast,Estrogen receptor positive; Line of therapy N/A; Stage I; Stage II,"Breast Carcinoma In Situ; Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular",United States
"A Phase I/II Study of ARQ 087	 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations, Including Intrahepatic Cholangiocarcinoma With FGFR2 Gene Fusion",I/II,Completed,"Merck & Co. {ArQule}
Basilea Pharmaceutica","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Advanced; FGFR; First line; Fourth line or greater; Intrahepatic; Locally advanced; Metastatic; Second line; Squamous Cell; Stage I; Stage II; Stage III; Stage IV; Third line; Unresectable; Unspecified,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Ewing Sarcoma; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Neuroendocrine Tumors; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Italy; United States
A Phase I Trial of Dasatinib in Combination With Crizotinib in Patients With Advanced Malignancies,I,Completed,"MD Anderson Cancer Center, University of Texas
Pfizer","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Small Intestine; Oncology: Soft Tissue Sarcoma; Oncology: Thymus",(N/A); Adenocarcinoma; Aggressive; BRAF; Classical; Fourth line or greater; Hormone refractory; Indolent; MET Amplification/Alteration; Metastatic; Nodular lymphocyte-predominant; Second line; Stage IV; Third line; Thymic carcinoma; Unresectable,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fallopian Tube Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Glioblastoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Intestinal Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thymus Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A Phase I Study of Single-Agent AZD1775 (MK-1775), A Wee1 Inhibitor, In Patients With Advanced Refractory Solid Tumors.",I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Aggressive; BRCA; Classical; Fourth line or greater; Indolent; Nodular lymphocyte-predominant; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Ewing Sarcoma; Fallopian Tube Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms; Neoplasms, Unknown Primary; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Uterine Cervical Neoplasms",United States
A Phase I Study of MM-141 in Patients With Advanced Solid Tumors,I,Completed,Merrimack Pharmaceuticals,Oncology: Breast; Oncology: Head/Neck; Oncology: Liver; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",France; United States
A Phase I Study of an Adenoviral Transduced Autologous Dendritic Cell Vaccine Expressing Human HER2/Neu ECTM in Adults With Tumors With 1-3+ HER2/Neu Expression,I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor",Estrogen receptor positive; First line; Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1082439 Given Once Daily Continuously or in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies",I,Completed,Bayer AG/Bayer Pharmaceuticals,"Oncology: Breast; Oncology: Endometrial; Oncology: Lymphoma, Non-Hodgkin's",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Unspecified","Singapore; South Korea; Taiwan, China; United States"
Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM): A Phase I Study,I,Completed,"Memorial Sloan-Kettering Cancer Center
Bayer AG/Bayer Pharmaceuticals
Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; First line; HER2 negative; HER2 positive; Second line; Stage IV; Triple receptor negative,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
"A Phase I First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors or Multiple Myeloma",I,Completed,Amgen,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Multiple Myeloma; Oncology: Soft Tissue Sarcoma",Estrogen receptor positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Fibrosarcoma; Glioblastoma; Leiomyosarcoma; Liposarcoma; Multiple Myeloma; Neoplasms; Neoplasms, Plasma Cell; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",France; Netherlands; United States
"A Phase I, Open-Label, Non-randomized, Dose-Escalating Safety, Tolerability, and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors",I,Completed,Otsuka Holdings/Taiho Pharmaceutical,Oncology: Breast; Oncology: Colorectal; Oncology: Gallbladder; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,"Breast Neoplasms; Colorectal Neoplasms; Gallbladder Neoplasms; Neoplasms, Unknown Primary; Unspecified",United States
"A Phase I, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once Daily OPB-111077 in Subjects With Advanced Cancer",I,Completed,Otsuka Holdings/Otsuka Pharmaceutical/Otsuka Pharmaceutical Development & Commercialization {Otsuka/Otsuka Maryland Research Institute},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Neuroblastoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Aggressive; Diffuse large B-cell lymphoma (DLBCL); Hormone refractory; KRAS; Second line; Stage III; Stage IV; Unspecified,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neuroblastoma; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Unspecified; Uterine Cervical Neoplasms; Wilms Tumor",South Korea; United States
A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors,I/II,Terminated,"Amgen
Novartis
NantWorks/ImmunityBio {NantCell}",Oncology: Breast; Oncology: Ovarian; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms",Belgium; Canada; Spain; United States
A Phase I Study of MK-2206 in Combination With Trastuzumab and Lapatinib in HER2-Positive Breast and Gastric Cancer,I,Terminated,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Esophageal; Oncology: Gastric,First line; HER2 positive; Second line; Stage III; Stage IV,"Adenocarcinoma; Breast Neoplasms; Breast Neoplasms, Male; Esophageal Cancer; Esophageal Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
Dose Finding and Tolerability Study of Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Peripheral Neuropathy,I/II,Completed,Northwestern University,Oncology: Breast; Oncology: Ovarian; Oncology: Supportive Care,Estrogen receptor positive; First line; HER2 negative; HER2 positive; Neurotoxicity; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Palliative Care; Peripheral Nervous System Diseases,United States
A Phase I-II Study of PTX-200 (TCN-PM) Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients With Metastatic and Locally Advanced Breast Cancer,I/II,Terminated,"National Institutes of Health/National Cancer Institute
Prescient Therapeutics {Virax}
Cahaba Pharmaceuticals",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Neoadjuvant; Second line; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas",I/II,Terminated,GlaxoSmithKline/Tesaro,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Aggressive; ALK; Classical; First line; Indolent; Locally advanced; Metastatic; Nodular lymphocyte-predominant; Papillary; Second line; Stage II; Stage III; Stage IV; Unspecified,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Liposarcoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neuroendocrine Tumors; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms","Poland; Spain; Taiwan, China; United Kingdom; United States"
A Phase I Study of LY3039478 in Patients With Advanced or Metastatic Cancer,I,Completed,Eli Lilly,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: GIST; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Liver; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",Aggressive; Classical; Estrogen receptor positive; First line; HER2 negative; Hormone refractory; Indolent; Locally advanced; Lymphoblastic lymphoma (LBL); Metastatic; Nodular lymphocyte-predominant; Peripheral T-cell lymphoma (PTCL); Progesterone receptor positive; Second line; Small lymphocytic lymphoma (SLL); Stage III; Stage IV; Third line; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Cholangiocarcinoma; Chronic Lymphocytic Leukemia; Fibrosarcoma; Gastrointestinal Stromal Tumors; Glioblastoma; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Leukemia, Lymphocytic, Chronic, B-Cell; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral; Neoplasm Metastasis; Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",Denmark; France; Germany; Spain; United Kingdom; United States
"A Phase I/II Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumors.",I/II,Completed,AstraZeneca {MedImmune},"Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Adenocarcinoma; ALK; EGFR; Extensive; First line; Fourth line or greater; HER2 negative; Large Cell; MSI-H/dMMR; PD-1 Naive; PD-L1 Naive; PD-L1 Positive; Pulmonary; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative; Untreated,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor","Australia; Belgium; Canada; Czech Republic; Denmark; France; Germany; Hungary; Italy; Netherlands; New Zealand; Poland; South Korea; Spain; Taiwan, China; United Kingdom; United States"
"A Phase l Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects with Advanced or Refractory Solid Tumors or Lymphoma",I,Completed,Johnson & Johnson/Janssen-Cilag,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Aggressive; Classical; FGFR; Fourth line or greater; Indolent; Nodular lymphocyte-predominant; Pulmonary; Second line; Squamous Cell; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Glioblastoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neuroendocrine Tumors; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",France; Spain; United States
Calcium and Magnesium Infusion for the Prevention of Taxane Induced Neuropathy in Earlier Stage Breast Cancer,I,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast; Oncology: Supportive Care,Adjuvant; Neoadjuvant; Neurotoxicity; Stage I; Stage II; Stage III,Breast Neoplasms; Palliative Care; Peripheral Nervous System Diseases,United States
A Phase Ib Trial of the Cyclin-dependent Kinase Inhibitor Dinaciclib in Combination With Pembrolizumab in Patients With Advanced Breast Cancer and Assessment of MYC Oncogene Overexpression,I,Completed,"University of California, San Francisco
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast; Oncology: Unspecified Solid Tumor,HER2 negative; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Neoplasms, Unknown Primary; Triple Negative Breast Neoplasms",United States
A Phase I Dose-Escalation Study of Cisplatin and Radiation Therapy for Patients With Triple Negative Breast Cancer,I,Completed,Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute,Oncology: Breast,HER2 negative; Second line; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Study of hTERT/Survivin Multi-Peptide Vaccination With Basiliximab And Prevnar For Patients With Metastatic Breast Cancer,I,Completed,Abramson Cancer Center at  University of Pennsylvania Medical Center,Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
"A Phase I, Open-Label, Dose-Ranging, Safety and Pharmacokinetic Study to Determine the Maximum Tolerated Dose of RX-3117 Administered Orally as a Single-Agent to Subjects With Advanced Malignancies",I/II,Completed,Ocuphire Pharma {Rexahn Pharmaceuticals},"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",FGFR; Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Mesothelioma; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",United States
A Phase I First-in-Human Dose Study of LY3023414 in Patients With Advanced Cancer,I,Completed,Eli Lilly,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Mesothelioma; Oncology: Unspecified Cancer",Estrogen receptor positive; Extranodal marginal zone B-cell lymphoma (MALT); First line; Follicular lymphoma (FL); Fourth line or greater; HER2 negative; Indolent; Other subtype; Progesterone receptor positive; Small lymphocytic lymphoma (SLL); Squamous Cell; Stage III; Stage IV; Untreated; Waldenstrom's macroglobulinemia (WM),"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Mesothelioma; Mesothelioma, Malignant; Neoplasms; Neoplasms, Mesothelial; Waldenstrom Macroglobulinemia",Italy; Puerto Rico; United States
"A Phase Ib Ascending Multi-arm, Dose Escalation Study of BMS-906024 Combined with Several Chemotherapy Regimens in Subjects with Advanced or Metastatic Tumors",I,Completed,Bristol-Myers Squibb,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",HER2 negative; Line of therapy N/A; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms, Unknown Primary; Unspecified",Belgium; Canada; Hungary; United States
Phase I Study of Erlotinib and Metformin in Triple Negative Breast Cancer,I,Completed,"Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}
Columbia University Medical Center
Astellas Pharma",Oncology: Breast,HER2 negative; Second line; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Phase I Study of Anti-TGFßRII Monoclonal Antibody IMC-TR1 (LY3022859) in Patients With Advanced Solid Tumors That Have Failed Standard Therapy or for Which No Standard is Available,I,Completed,Eli Lilly {ImClone},Oncology: Breast; Oncology: Colorectal; Oncology: Pancreas,Second line; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms,United States
Phase I/II Study of Stereotactic Body Radiation Therapy to Metastatic Lesions in the Liver or Lung in Combination With Monoclonal Antibody to OX40 (MEDI6469) in Patients With Progressive Metastatic Breast Cancer After Systemic Therapy.,I/II,Completed,"AstraZeneca {MedImmune}
Earle A. Chiles Research Institute - EACRI
(Other Hospital/Academic/Medical Center)
Providence Cancer Center at Providence Portland Medical Center
(Other government agency)",Oncology: Breast; Oncology: Metastatic Cancer,Estrogen receptor positive; Liver mets; Other mets; Progesterone receptor positive; Second line; Stage IV,"Breast Neoplasms; Liver Neoplasms; Neoplasm Metastasis; Neoplasms, Second Primary",United States
Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors,I,Completed,"Bayer AG/Bayer Pharmaceuticals
Yale University",Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Pancreas,First line; Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Digestive System Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gastrointestinal Neoplasms; Liver Cancer; Liver Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination with Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy in Solid Tumors,I,Completed,"Takeda/Takeda Oncology {Millennium}
University of Illinois at Chicago Health Sciences Center","Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Pancreas; Oncology: Unspecified Hematological Cancer",Advanced; Fourth line or greater; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Colorectal Neoplasms; Digestive System Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gastrointestinal Neoplasms; Glioblastoma; Head and Neck Neoplasms; Hematologic Neoplasms; Liver Cancer; Liver Neoplasms; Medulloblastoma; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Thoracic Neoplasms; Urogenital Neoplasms",United States
"A Phase I and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction",I,Terminated,"National Institutes of Health/National Cancer Institute
Bristol-Myers Squibb/Celgene","Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Aggressive; Classical; Cutaneous T-cell lymphoma (CTCL); Elderly; Indolent; Nodular lymphocyte-predominant; Other subtype; Peripheral T-cell lymphoma (PTCL); Second line; Stage III; Stage IV; Unspecified,"Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Chronic Lymphocytic Leukemia; Colorectal Neoplasms; Fibrosarcoma; Glioblastoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Liposarcoma; Liver Cancer; Liver Diseases; Liver Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Melanoma; Neoplasms; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Skin Neoplasms; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Canada; United States
A Phase I Dose-Escalation Trial of Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors,I,Completed,"University of Texas Health Science Center at San Antonio
VG Life Sciences {Viral Genetics}","Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas",Adenocarcinoma; HER2 negative; Second line; Stage II; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms",United States
A Phase Ib Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered With Bevacizumab and/or Chemotherapy in Patients With Advanced Solid Tumors,I,Completed,Roche/Genentech,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor",Adenocarcinoma; First line; Fourth line or greater; HER2 negative; Hormone refractory; MSI-H/dMMR; PD-1 Naive; PD-L1 Naive; PD-L1 Positive; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fallopian Tube Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients with Epithelial Cancers,I/II,Completed,"Seagen {Seattle Genetics}
Gilead Sciences/Immunomedics","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Thyroid",(N/A); Adenocarcinoma; Estrogen receptor positive; Extensive; Follicular; Fourth line or greater; HER2 negative; Hormone refractory; KRAS; PD-1 Refractory; PD-L1 Refractory; Progesterone receptor positive; Pulmonary; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A Multi-Center, Dose Finding, Open Label, Phase I Study of RX-5902 in Subjects With Advanced or Metastatic Solid Tumors",I/II,Terminated,Ocuphire Pharma {Rexahn Pharmaceuticals},"Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Testicular",Estrogen receptor positive; Fourth line or greater; HER2 negative; Other; Progesterone receptor positive; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
A Phase I Study With Dose Expansion of Dinaciclib (SCH 727965) in Combination With Epirubicin in Patients With Metastatic Triple Negative Breast Cancer,I,Terminated,National Institutes of Health/National Cancer Institute,Oncology: Breast,First line; HER2 negative; Second line; Stage IV; Triple receptor negative,"Breast Neoplasms; Breast Neoplasms, Male; Carcinoma; Triple Negative Breast Neoplasms",United States
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer,I,Completed,"AstraZeneca
Novartis
(Other Cooperative Group)
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute",Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal,BRCA; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Triple Negative Breast Neoplasms",United States
Pre-Operative PARPi and Irradiation (POPI) in Women With an Incomplete Response to Neo-Adjuvant Chemotherapy for Breast Cancer,I,Terminated,Indiana University School of Medicine,Oncology: Breast,HER2 negative; Neoadjuvant; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"Phase I, Double Blind, Randomized, Parallel-Group, Single-Dose, 3-Arm, Comparative Pharmacokinetic Study Of PF-05280014 And Trastuzumab Sourced From US And EU Administered To Healthy Male Volunteers",I,Completed,Pfizer,Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms; Unspecified,United States
"A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors",I,Completed,Otsuka Holdings/Taiho Pharmaceutical,"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gallbladder; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Neuroendocrine; Oncology: Pancreas",Fourth line or greater; Pancreas; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Gallbladder Neoplasms; Neoplasms; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Unspecified",Belgium; France; Italy; Japan; Switzerland; United States
A Phase I Trial of the Safety and Immunogenicity of a Multi-epitope Folate Receptor Alpha Peptide Vaccine Used in Combination With Cyclophosphamide in Subjects Previously Treated for Breast or Ovarian Cancer,I,Completed,"Mayo Clinic
GemVax & KAEL {KAEL-GemVax {VaxOnco}}",Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms",United States
"A Phase I Study of LJM716 in Patients With Squamous Cell Carcinoma of Head and Neck, or HER2 Overexpressing Metastatic Breast Cancer or Gastric Cancer",I,Completed,Novartis,Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck,Fourth line or greater; HER2 positive; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Esophageal Cancer; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Neoplasms, Squamous Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms","Canada; South Korea; Spain; Taiwan, China; United States"
"A Phase I, Open-label, Multicentre, Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered Orally in Combination With Intramuscular (IM) Fulvestrant to Patients With Estrogen Receptor Positive (ER+) Advanced, Metastatic Breast Cancer",I,Completed,AstraZeneca,Oncology: Breast,Estrogen receptor positive; Fourth line or greater; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
A Phase I Study to Assess the Food Effect on the Pharmacokinetics of Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic ER+ Breast Cancer and Men and Women With Progressive Non-Small Cell Lung Cancer,I,Completed,Syndax,"Oncology: Breast; Oncology: Lung, Non-Small Cell",Estrogen receptor positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms",United States
EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery: A Phase I Clinical Trial.,I,Open,"(Other Cooperative Group)
MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute
(Other Hospital/Academic/Medical Center)",Oncology: Breast; Oncology: Ovarian; Oncology: Prostate; Oncology: Unspecified Solid Tumor,Line of therapy N/A; Stage III; Stage IV,"Breast Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms",United States
"A Phase I, Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects with Advanced Solid Tumors or Lymphomas",I,Completed,Daiichi Sankyo,"Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Advanced; Aggressive; Classical; Hormone refractory; Indolent; Locally advanced; Metastatic; Nodular lymphocyte-predominant; Second line; Squamous Cell; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Mesothelioma; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Uterine Cervical Neoplasms; Wilms Tumor",United Kingdom; United States
"A Phase I Open-Label, Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Enzalutamide (Formerly MDV3100) in Patients With Incurable Breast Cancer",I,Completed,"Astellas Pharma
Pfizer {Medivation}",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Progesterone receptor positive; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
A Phase I Study of BKM120 With mFOLFOX6 in Patients With Advanced Solid Tumors With Expansion Cohort in Metastatic Pancreatic Cancers.,I,Completed,UNC Lineberger Comprehensive Cancer Center,Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Melanoma; Oncology: Pancreas,First line; Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
"A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of GDC-0973 and GDC-0068 in Patients With Locally Advanced or Metastatic Solid Tumors",I,Completed,"Pfizer {Array BioPharma}
Roche/Genentech",Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Ovarian,HER2 negative; KRAS; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Unspecified; Uterine Cervical Neoplasms",Spain; United States
A Phase Ib/II Study of Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies,I/II,Completed,"Eisai
University of California, San Francisco",Oncology: Breast; Oncology: Unspecified Solid Tumor,Fourth line or greater; HER2 negative; HER2 positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Neoplasms, Unknown Primary",United States
"A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications",I,Closed,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Autoimmune/Inflammation: Castleman Disease; Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid; Oncology: Unspecified Solid Tumor,(N/A); Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Castleman Disease; Colorectal Neoplasms; Erdheim-Chester Disease; Fibrosarcoma; Genital Neoplasms, Female; Genital Neoplasms, Male; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphangioleiomyomatosis; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Neurofibromatoses; Neurofibromatosis 2; Ovarian Cancer; Ovarian Neoplasms; Pharyngeal Neoplasms; Recurrence; Respiratory Tract Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thoracic Neoplasms; Thyroid Diseases; Thyroid Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms",United States
"A Two Steps Phase I Trial of Pazopanib or Pemetrexed in Combination With Crizotinib Followed by the Triplet, Crizotinib Plus Pazopanib Plus Pemetrexed in Patients With Advanced Malignancies",I,Terminated,"MD Anderson Cancer Center, University of Texas",Oncology: Breast; Oncology: Unspecified Cancer,ALK; MET Amplification/Alteration; Second line; Stage IV,Breast Neoplasms; Neoplasms,United States
"A Phase I Trial of AMG 386 and Temsirolimus in Advanced Solid Tumors with an Expansion Cohort in Uterine Cancer, Renal Cell Carcinoma and Carcinoid Tumors",I,Terminated,"National Institutes of Health/National Cancer Institute
University Health Network, Toronto",Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid,Estrogen receptor positive; Fourth line or greater; HER2 negative; Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV; Third line; Unresectable; Unspecified,"Apudoma; Breast Neoplasms; Carcinoid Tumor; Carcinoma, Endometrioid; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Wilms Tumor",Canada; United States
"Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers.",I,Completed,University of Pittsburgh Cancer Institute,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Aggressive; Classical; Indolent; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
Phase I Dose Escalation Study of ON 01910.Na by 3-day Continuous Infusion in Patients With Advanced Cancer,I,Completed,Onconova Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Neoplasms; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
A Pilot Study of the Immunogenicity of a 9-Peptide Breast Cancer Vaccine Plus Poly-ICLC in Stage I-IV Breast Cancer,I,Terminated,University of Virginia,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; HER2 positive; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"A Phase I/II Study to Evaluate the Antitumor Activity and Safety of Etbx-021, an Adenoviral Vector Encoding the Her2 Extracellular Domain and Transmembrane Region, in Patients with Locally Advanced or Metastatic Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Cancers Including Breast Cancer",I/II,Completed,NantWorks/Etubics,Oncology: Breast; Oncology: Unspecified Cancer,HER2 positive; Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms; Neoplasms,United States
"A Phase I Study To Evaluate The Antitumor Activity And Safety Of DUKE-002-VRP(HUHER2-ECD+TM), An Alphaviral Vector Encoding The HER2 Extracellular Domain And Transmembrane Region, In Patient With Locally Advanced Or Metastatic Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Cancers Including Breast Cancer",I,Completed,"Duke University Medical Center
Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}
US Department of Defense
AlphaVax",Oncology: Breast; Oncology: Esophageal; Oncology: Gastric,First line; Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Unspecified,United States
A Phase Ib Study to Assess the Safety of PLX3397 and Paclitaxel in Patients with Advanced Solid Tumors,I,Completed,Daiichi Sankyo/Plexxikon,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Soft Tissue Sarcoma",Fourth line or greater; Pulmonary; Second line; Stage III; Stage IV; Third line; Unspecified,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Fallopian Tube Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
A Phase I Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced Anti-tumor Immunity in Patients With NY-ESO-1 Expressing Solid Tumors,I,Completed,"National Institutes of Health/National Cancer Institute
Roswell Park Cancer Institute","Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Estrogen receptor positive; First line; Hormone refractory; Second line; Stage I; Stage II; Stage III; Stage IV,"Astrocytoma; Brain Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Glioblastoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Melanoma; Oligodendroglioma; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Neoplasms; Wilms Tumor",United States
"Phase I Study of Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma",I,Completed,"Memorial Sloan-Kettering Cancer Center
Genelux Corporation","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Metastatic Cancer; Oncology: Unspecified Solid Tumor",First line; Other mets; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Mesothelioma; Neoplasm Metastasis; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Pleural Effusion; Pleural Effusion, Malignant; Vaccinia",United States
"A Phase I, Open Label, Parallel Group, Pharmacokinetic Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function",I,Completed,Roche {F. Hoffmann-La Roche},Oncology: Breast,First line; Fourth line or greater; HER2 positive; Second line; Stage IV; Third line,Breast Neoplasms,Canada; France; Italy; Spain; United States
"An Open Label Phase I Study to Evaluate the Safety and Tolerability of GI-6301 Vaccine Consisting of Whole, Heat-Killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express Brachyury Protein in Adults With Solid Tumors",I,Completed,"(Other Cooperative Group)
National Institutes of Health/National Cancer Institute
GlobeImmune
(Other government agency)","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",Estrogen receptor positive; Second line; Stage III; Stage IV,"Adenocarcinoma; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Colorectal Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
A Phase I and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors,I,Completed,Merrimack Pharmaceuticals,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Pancreas",EGFR; HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Triple Negative Breast Neoplasms",United States
A Phase I Trial of CBL0137 in Patients with Metastatic or Unresectable Advanced Solid Neoplasm,I,Completed,Incuron (Cleveland BioLabs and Bioprocess Capital Ventures joint venture),"Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Testicular; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Aggressive; Classical; Indolent; Nodular lymphocyte-predominant; Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Glioblastoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Medulloblastoma; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms; Thyroid Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
A Phase I Dose Escalation and Pharmacodynamic Study of ARQ 761 (Beta-Lapachone) in Adult Patients with Advanced Solid Tumors,I,Completed,"Merck & Co. {ArQule}
University of Texas Southwest Medical Center","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor",First line; Fourth line or greater; Hormone refractory; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Pilot Study of Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer",I,Completed,"Bristol-Myers Squibb
(Other Cooperative Group)
Memorial Sloan-Kettering Cancer Center",Oncology: Breast,HER2 negative; HER2 positive; Neoadjuvant; Stage I; Stage II; Triple receptor negative,Adenocarcinoma; Breast Neoplasms,United States
"Phase I Study of ONT-10, a Liposomal MUC1 Cancer Vaccine, in Patients With Solid Tumors",I,Completed,Seagen {Seattle Genetics/Cascadian Therapeutics {Oncothyreon {Biomira}}},"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal; Oncology: Small Intestine",Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Intestinal Neoplasms; Kidney Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
Phase Ib Pilot Study to Evaluate Reparixin in Combination With Chemotherapy With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC),I,Completed,Dompe,Oncology: Breast,HER2 negative; Second line; Stage IV,Breast Neoplasms,United States
"A Dose-finding Phase Ib Study Followed by an Open-label, Randomized Phase II Study of BEZ235 Plus Paclitaxel in Patients With HER2 Negative, Inoperable Locally Advanced or Metastatic Breast Cancer",I/II,Terminated,Novartis,Oncology: Breast,HER2 negative; Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms,"Argentina; Australia; Belgium; Brazil; France; Germany; Hong Kong, S.A.R., China; Italy; Russia; Singapore; South Korea; Spain; Taiwan, China; Thailand; Turkey; United Kingdom; United States"
"A Randomized Phase I Trial of Nanoparticle Albumin Bound Paclitaxel (Nab-paclitaxel, Abraxane) With or Without Mifepristone for Advanced Breast Cancer",I,Completed,University of Chicago Medical Center,Oncology: Breast,Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Breast Neoplasms, Male",United States
"Open-label, Multicenter, Dose Escalation Phase Ia/Ib Study With Expansion Phase to Evaluate Safety, Pharmacokinetics and Activity of RO5509554, Administered as an Intravenous Infusion as Monotherapy and in Combination With Paclitaxel in Patients With Advanced Solid Tumors",I/II,Completed,Roche {F. Hoffmann-La Roche},Oncology: Breast; Oncology: Endometrial; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Tenosynovial Giant Cell Tumor; Oncology: Unspecified Solid Tumor,Diffuse; First line; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Giant Cell Tumor of Tendon Sheath; Mesothelioma; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Synovitis, Pigmented Villonodular; Unspecified",France; United States
A Phase I/II Trial of TKI258 (Dovitinib) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer,I/II,Terminated,"Novartis
Georgetown University Medical Center",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"An Open-label, Multi-center Phase I Dose-finding Study of RAD001 (Everolimus, Afinitor) in Combination With BEZ235 in Patients With Advanced Solid Tumors",I,Terminated,Novartis,Oncology: Breast; Oncology: Renal,Estrogen receptor positive; HER2 negative; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Renal Cell; Kidney Neoplasms; Renal Cancer; Wilms Tumor",Belgium; France; Italy; New Zealand; South Korea; Spain; United Kingdom; United States
A Phase I Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors and Determination of Tumor Receptor Occupancy by U3-1287,I,Terminated,Washington University School of Medicine,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",Hormone refractory; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",United States
"Phase I/II Study of Trastuzumab in Combination With AMG 479, A Fully Human Monoclonal Antibody Against Insulin-Like Growth Factor Type 1 Receptor (IGF-1R), in Patients With HER-2 Overexpressing Metastatic Breast Cancer Progressing on Trastuzumab-Based or Lapatinib-based Therapy",I/II,Terminated,"Amgen
MD Anderson Cancer Center, University of Texas",Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
"An Open-Label, Two Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination With the AKT Inhibitor GSK2110183 in Subjects With Solid Tumors and Multiple Myeloma",I/II,Completed,GlaxoSmithKline,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Multiple Myeloma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal",HER2 negative; KRAS; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Multiple Myeloma; Neoplasms, Plasma Cell; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United Kingdom; United States
A Phase I Study of Veliparib Administered Concurrently With Chest Wall and Nodal Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer,I,Completed,"University of Michigan Comprehensive Cancer Center
Johns Hopkins University
Breast Cancer Research Foundation",Oncology: Breast,Adjuvant; Stage III; Stage IV,Breast Neoplasms,United States
A Phase Ib/Randomized Phase II Study of BEZ235 and Trastuzumab Versus Lapatinib and Capecitabine in Patients With HER2-positive Locally Advanced or Metastatic Breast Cancer Who Failed Prior to Trastuzumab,I/II,Completed,Novartis,Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,"Argentina; Australia; Belgium; Brazil; Canada; China; Czech Republic; France; Germany; Hong Kong, S.A.R., China; Hungary; Italy; Japan; Netherlands; Russia; Singapore; South Korea; Spain; Taiwan, China; Thailand; Turkey; United Kingdom; United States"
"A Multi-Center, Phase I/Ib, Open-Label, Dose Escalation Study of ABT-700, a Monoclonal Antibody in Subjects With Advanced Solid Tumors",I,Completed,AbbVie {Abbott},"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Renal",First line; Fourth line or greater; HER2 negative; MET Amplification/Alteration; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor","Australia; South Korea; Taiwan, China; United States"
A Phase I Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma,I,Completed,"National Institutes of Health/National Cancer Institute
Merck & Co. {ArQule}
Daiichi Sankyo","Oncology: Bladder; Oncology: Breast; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Aggressive; Classical; Follicular lymphoma (FL); Hormone refractory; Indolent; Localized; Locally advanced; Metastatic; Nodular lymphocyte-predominant; Second line; Small lymphocytic lymphoma (SLL); Stage III; Stage IV; Unspecified,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Chronic Lymphocytic Leukemia; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Leukemia, Lymphocytic, Chronic, B-Cell; Liposarcoma; Lymphoma; Lymphoma, Follicular; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies,I,Completed,"Novartis
Winship Cancer Institute of Emory University","Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma; Oncology: Thymus; Oncology: Thyroid",Second line; Stage III; Stage IV; Thymic carcinoma,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Glioblastoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Lung Neoplasms; Medulloblastoma; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thymus Neoplasms; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,I,Completed,"GlaxoSmithKline
National Institutes of Health/National Cancer Institute
UNC Lineberger Comprehensive Cancer Center
Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}",Oncology: Breast,HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase I Study of LY3007113, a p38 MAPK Inhibitor, in Patients With Advanced Cancer",I,Terminated,Eli Lilly,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor",Aggressive; Classical; Indolent; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasm Metastasis; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase I/IIa, First Time in Human, Open-label Dose-escalation Study of GSK2636771 in Subjects With Advanced Solid Tumors With PTEN Deficiency",I/II,Terminated,GlaxoSmithKline,"Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Prostate",Fourth line or greater; HER2 negative; Hormone refractory; PD-1 Naive; PD-L1 Naive; Second line; Stage II; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Glioblastoma; Head and Neck Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Uterine Cervical Neoplasms",South Korea; United Kingdom; United States
Phase I Study of Pemetrexed and Sorafenib in Advanced Malignancy.,I,Completed,"National Institutes of Health/National Cancer Institute
Virginia Commonwealth University",Oncology: Breast; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms, Unknown Primary; Unspecified",United States
A Phase I Study of MM-121 in Combination With Cetuximab and Irinotecan in Patients With Advanced Cancers,I,Completed,"Merrimack Pharmaceuticals
Sanofi {Sanofi-Aventis}","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell",EGFR; HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Head and Neck Neoplasms; Lung Neoplasms; Triple Negative Breast Neoplasms",United States
Phase I/II Study of XL184 in Combination with Trastuzumab in Patients with HER2/neu Amplified Metastatic Breast Cancer Patients,I/II,Terminated,Southwest Oncology Group,Oncology: Breast,HER2 positive; Line of therapy N/A; Stage IV,Breast Neoplasms,United States
"A Phase Ib Open-label, Multi-center, Dose Escalation and Expansion Study of Orally Administered MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors",I,Completed,"Novartis
Pfizer {Array BioPharma}","Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Leukemia, Acute Myelogenous; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Myelodysplastic Syndrome; Oncology: Ovarian; Oncology: Pancreas",BRAF; Fourth line or greater; HER2 negative; High risk; KRAS; NRAS; Second line; Stage II; Stage III; Stage IV; Third line; Triple receptor negative,"Acute Myelocytic Leukemia; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Leukemia, Myeloid, Acute; Melanoma; Myelodysplastic Syndromes; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms",Australia; Canada; France; Italy; Spain; Switzerland; United Kingdom; United States
"Two-Part, Open-Label, Multi-Center Phase I Study of Monoclonal Antibody CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors",I,Terminated,"Teva {Cephalon}
Kyowa Kirin {Kyowa Hakko Kirin}","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Aggressive; Classical; Indolent; Locally advanced; Metastatic; Nodular lymphocyte-predominant; Second line; Stage II; Stage III; Stage IV; Unresectable,"Adenocarcinoma; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design.",I,Completed,"Bristol-Myers Squibb
Barbara Ann Karmanos Cancer Institute","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",United States
"A Phase I, Open Label, Dose Escalation Study of the VEGF-C Human Monoclonal Antibody VGX-100 Administered by Intravenous Infusion Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced or Metastatic Solid Tumors",I,Completed,Opthea {Circadian Technologies/Ceres Oncology {Circadian Technologies/Vegenics}},"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal",Adenocarcinoma; HER2 negative; Large Cell; Other subtype; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Wilms Tumor",United States
Phase I Trial of ECI301 in Combination With Radiation in Patients With Advanced or Metastatic Cancer,I,Terminated,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Prostate",Line of therapy N/A; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Neoplasm Metastasis; Neoplasms; Neoplasms, Second Primary; Prostatic Neoplasms",United States
Prospective Evaluation of Clinical Safety of Combining Metformin With Anticancer Chemotherapy,I,Completed,Tufts Medical Center {Tufts-New England Medical Center},Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver,(N/A); First line,"Breast Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Liver Cancer; Liver Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Unspecified",United States
A Phase Ib/IIa Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer,I/II,Terminated,Sanofi/Kadmon Holdings {Kadmon Corporation},Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Estrogen receptor positive; Fourth line or greater; HER2 positive; Second line; Stage IV; Third line,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis; Neoplasms,United States
Phase I Trial of ABT-888 and SCH727965 in Patients With Advanced Solid Tumors,I,Closed,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Prostate; Oncology: Thymus; Oncology: Unspecified Solid Tumor,BRCA; HER2 negative; Second line; Stage III; Stage IV; Thymic carcinoma; Triple receptor negative,"Breast Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Prostatic Neoplasms; Thymus Neoplasms",United States
"Phase I and Phase II Trastuzumab Cohort Study of Entinostat, Lapatinib and Trastuzumab in Patients With HER2-Positive Metastatic Breast Cancer in Whom Trastuzumab Has Failed",I/II,Completed,"GlaxoSmithKline
Novartis
MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms; Carcinoma,United States
"An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose of the Anti-mesothelin Antibody Drug Conjugate BAY94-9343 in Subjects With Advanced Solid Tumors.",I,Completed,Bayer AG/Bayer Pharmaceuticals,Oncology: Breast; Oncology: Fallopian Tube; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal,Advanced; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Fallopian Tube Neoplasms; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms",United States
A Phase Ib/II Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC),I/II,Completed,AstraZeneca {MedImmune},Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms; Hypersensitivity,Belgium; Canada; France; Germany; Hungary; Israel; Poland; Spain; United Kingdom; United States
"Phase I/II, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer",I/II,Completed,Xcovery,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Unspecified Solid Tumor",(N/A); ALK; First line; Fourth line or greater; Pulmonary; Second line; Stage III; Stage IV; Third line; Untreated,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Lung Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Small Cell Lung Carcinoma",United States
"A Phase I Dose-Escalation First-In-Human Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral MEK Inhibitor MSC2015103B Administered With Two Different Treatment Schedules in Subjects With Advanced Solid Tumors",I,Terminated,Merck KGaA/EMD Serono {EMD Pharmaceuticals},"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Thyroid",Locally advanced; Metastatic; Recurrent; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Thyroid Neoplasms; Wilms Tumor",United States
Breast Cancer Prevention Using Synergistic Prostaglandin Inhibitors (The Vitamin D/Celecoxib Study),I/II,Completed,"(Other Cooperative Group)
US Department of Defense
(Other Hospital/Academic/Medical Center)",Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
A Phase I Dose-Escalation Study Evaluating the Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer.,I,Completed,"National Surgical Adjuvant Breast and Bowel Project (NSABP)
Pfizer
Puma Biotechnology",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"A Phase Ia/Ib, Multi Center, Open-Label, Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Pleiotropic Pathway Modifier CC-122 Administered Orally to Subjects with Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma",I,Closed,Bristol-Myers Squibb/Celgene,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Liver; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Aggressive; Diffuse large B-cell lymphoma (DLBCL); Fourth line or greater; Locally advanced; Mantle cell lymphoma (MCL); Metastatic; Other subtype; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Hepatocellular; Fibrosarcoma; Glioblastoma; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms, Plasma Cell; Neoplasms, Unknown Primary; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",Belgium; France; Italy; Spain; United States
"Phase I/II Study of TLR7 Agonist Imiquimod, Cyclophosphamide, and Radiotherapy in Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases",I/II,Completed,"National Institutes of Health/National Cancer Institute
New York University",Oncology: Breast; Oncology: Metastatic Cancer,First line; Other mets; Second line; Stage IV,Breast Neoplasms; Neoplasm Metastasis,United States
A Phase I Trial of the Safety and Immunogenicity of a Multi-epitope HER-2/Neu Peptide Vaccine in Subjects Previously Treated for HER-2 Positive Breast Cancer,I,Completed,"Mayo Clinic
Marker Therapeutics {TapImmune {GeneMax}}",Oncology: Breast,Adjuvant; First line; HER2 positive; Stage II; Stage III,"Breast Neoplasms; Breast Neoplasms, Male",United States
"An Open-label, Phase I, Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0575 Administered Alone and in Combination with Gemcitabine in Patients with Refractory Solid Tumors or Lymphoma",I,Completed,"Pfizer {Array BioPharma}
Roche/Genentech","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Aggressive; Classical; HER2 negative; Indolent; Nodular lymphocyte-predominant; Pulmonary; Second line; Squamous Cell; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Fibrosarcoma; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Liposarcoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",France; United States
A Phase I Study of BAY80-6946 (Phosphatidylinositol 3-Kinase Inhibitor) in Combination with Paclitaxel in Subjects with Advanced Solid Malignancy,I,Completed,Bayer AG/Bayer Pharmaceuticals,Oncology: Breast; Oncology: Unspecified Solid Tumor,First line; HER2 negative; HER2 positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Neoplasms, Unknown Primary; Unspecified",United States
"A Phase I Dose Escalation Study of Hepatic Intra-Arterial Administration of TKM 080301 (Lipid Nanoparticles Containing siRNA Against the PLK1 Gene Product) in Patients with Colorectal, Pancreas, Gastric, Breast, Ovarian and Esophageal Cancers with Hepatic metastasis",I,Terminated,"National Institutes of Health/National Cancer Institute
Arbutus Biopharma {Tekmira Pharmaceuticals}",Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Metastatic Cancer; Oncology: Ovarian; Oncology: Pancreas,Liver mets; Second line; Stage IV; Unresectable,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasm Metastasis; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
Phase I Study of Pazopanib in Combination With Weekly Paclitaxel and Carboplatin to Assess the Safety and Tolerability in Patients With Advanced Solid Tumors,I,Terminated,"GlaxoSmithKline
Novartis
National Institutes of Health/National Cancer Institute
(Other Hospital/Academic/Medical Center)","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms; Neoplasms, Unknown Primary",United States
Phase I Trial of Intratumoral Bi-functional shRNA Stathmin 1-knockdown Lipoplex in Patients With Advanced and/or Metastatic Cancer,I,Completed,Gradalis,Oncology: Breast; Oncology: Colorectal; Oncology: Melanoma; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma,Locally advanced; Metastatic; Second line; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Colorectal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Second Primary; Ovarian Cancer; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
"A Phase I, Dose Escalation Study of MLN1117 in Subjects With Advanced Solid Malignancies Followed by Expansion in Subjects With Measurable Disease",I,Completed,Takeda/Takeda Oncology {Millennium {Intellikine}},Oncology: Breast; Oncology: Gastric,Second line; Stage III; Stage IV,Breast Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Unspecified,Spain; United Kingdom; United States
"Dose Escalation, Safety, Pharmacokinetic and Pharmacodynamic, First in Man Study, of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors",I,Completed,Sanofi {Sanofi-Aventis},"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian",Adenocarcinoma; MET Amplification/Alteration; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms",France; Italy; Spain; United States
"Phase I Study of the Hsp90 Inhibitor, PU-H71, in Patients With Refractory Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma",I,Completed,"Memorial Sloan-Kettering Cancer Center
Samus Therapeutics","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Esophageal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Myeloproliferative Neoplasms; Oncology: Ovarian; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",Aggressive; Classical; Estrogen receptor positive; Extranodal marginal zone B-cell lymphoma (MALT); HER2 negative; HER2 positive; Indolent; Mantle cell lymphoma (MCL); Nodular lymphocyte-predominant; Second line; Squamous Cell; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Liver Cancer; Liver Neoplasms; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melanoma; Myeloproliferative Disorders; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",United States
A Phase I Dose Escalation Study of MGA271 in Refractory Cancer,I,Completed,"Servier
MacroGenics","Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Prostate; Oncology: Renal",(N/A); Fourth line or greater; HER2 negative; PD-1 Refractory; PD-L1 Refractory; Second line; Squamous Cell; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Prostatic Neoplasms; Renal Cancer; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients With gBRCA Mutation Ovarian Cancer or Other Solid Tumor",I/II,Completed,"(Other Industry Sponsor)
Clovis Oncology","Oncology: Breast; Oncology: Fallopian Tube; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Unspecified Solid Tumor",Aggressive; BRCA; Classical; Fourth line or greater; Indolent; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms",Canada; Israel; Spain; United Kingdom; United States
A Phase I Study of an Oral p38 MAPK Inhibitor in Patients With Advanced Cancer,I,Completed,Eli Lilly,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Aggressive; Classical; HER2 positive; Indolent; Metastatic; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",United States
Vaccination of High Risk Breast Cancer Patients,I,Completed,"University of Arkansas
US Department of Defense",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"Phase I/II Study of Neoadjuvant Carboplatin, Eribulin Mesylate and Trastuzumab (ECH) for Operable HER2 Positive Breast Cancer",I/II,Terminated,Eisai,Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
Phase I Trial of Escalating Doses of CT-011 in Combination With p53 Vaccine in Adults With Advanced Solid Tumors,I,Terminated,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Colorectal; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma,Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV,Breast Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma,United States
Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2,I,Completed,Stanford University Medical Center,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Lung, Non-Small Cell; Oncology: Pancreas",Line of therapy N/A; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Glioblastoma; Pancreatic Cancer; Pancreatic Neoplasms",United States
"A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors",I,Completed,Novartis,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Pancreas",Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage II; Stage III; Stage IV; Triple receptor negative,Adenocarcinoma; Breast Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Glioblastoma; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms,Australia; Belgium; Canada; Germany; Italy; Spain; United Kingdom; United States
Phase I Dose Escalation Trial of MEK1/2 Inhibitor MSC1936369B Combined With Temsirolimus in Subjects With Advanced Solid Tumors,I,Terminated,Merck KGaA/EMD Serono {EMD Pharmaceuticals},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",BRAF; EGFR; Hormone refractory; KRAS; Locally advanced; Metastatic; Recurrent; Second line; Stage II; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Atezolizumab (MPDL3280A) Administered Intravenously as a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies",I,Completed,Roche/Genentech,"Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Multiple Myeloma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Hematological Cancer; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Advanced; Aggressive; Classical; Extensive; Fourth line or greater; HER2 negative; Hormone refractory; Indolent; Large Cell; Localized; Locally advanced; Metastatic; MSI-H/dMMR; MSS/pMMR; Nodular lymphocyte-predominant; PD-1 Naive; PD-L1 Naive; PD-L1 Positive; Pulmonary; Second line; Squamous Cell; Stage II; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Glioblastoma; Head and Neck Neoplasms; Hematologic Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Multiple Myeloma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",France; Spain; United Kingdom; United States
Phase I Active Immunotherapy Trial with a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like) Human Epidermal Growth Factor Receptor 2 (HER-2) B Cell Peptide Vaccine Emulsified in ISA 720 and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors,I/II,Open,"National Institutes of Health/National Cancer Institute
Ohio State University",Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: GIST; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,EGFR; Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Leiomyosarcoma; Liposarcoma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Uterine Cervical Neoplasms",United States
"An Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Cross-Over, Single-Dose, Comparative Oral Bioavailability Study Of Letrozole 2.5 mg Tablets (Test) of Dr.Reddy's Laboratories Ltd And Femara 2.5 mg Tablets (Reference) of Novartis Pharmaceuticals Corporation, USA In Healthy, Post Menopausal Women Subjects Under Fasting Conditions",I,Completed,Dr. Reddys Laboratories,Genitourinary: Infertility; Oncology: Breast; Oncology: Endometrial,"(N/A); Infertility, female; Line of therapy N/A","Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Female Infertility; Infertility; Male Infertility; Unspecified",United States
"Randomized Open-label Phase Ib Study of Doxorubicin-based Chemotherapy Regimens, with and Without Sildenafil, with Exploratory Analysis of Intermediate Cardiac Markers",I,Completed,Virginia Commonwealth University,Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Testicular; Oncology: Unspecified Cancer,(N/A); Line of therapy N/A,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Ewing Sarcoma; Fibrosarcoma; Gastrointestinal Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasms; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Urogenital Neoplasms; Wilms Tumor",United States
"An Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Cross-Over, Single-Dose, Comparative Oral Bioavailability Study Of Letrozole 2.5 mg Tablets (Test) Of Dr.Reddy's Laboratories Ltd And Femara 2.5 mg Tablets (Reference) Of Novartis Pharmaceuticals Corporation, USA In Healthy, Post Menopausal Women Subjects Under Fed Conditions",I,Completed,Dr. Reddys Laboratories,Genitourinary: Endometriosis; Genitourinary: Menopausal Symptoms; Oncology: Breast; Oncology: Endometrial,(N/A); Line of therapy N/A,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Endometriosis; Menopause; Unspecified",United States
A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of AGS-22M6E or ASG-22CE Given as Monotherapy Followed by Expansion Cohorts in Subjects With Malignant Solid Tumors That Express Nectin-4,I,Completed,"Seagen {Seattle Genetics}
Astellas Pharma {Agensys}","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Thyroid",Second line; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Canada; United States
"A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors",I,Completed,Pfizer {Array BioPharma},"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",BRAF; EGFR; HER2 negative; KRAS; NRAS; Second line; Stage II; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms",Canada; Germany; Netherlands; Singapore; Spain; Switzerland; United States
An Early Phase I Study of ABT-888 in Combination with Carboplatin and Paclitaxel in Patients with Hepatic or Renal Dysfunction and Solid Tumors,I,Completed,"National Institutes of Health/National Cancer Institute
Abbott","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Testicular; Oncology: Unspecified Solid Tumor",Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Failure; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
A Phase I/II Trial of BIIB022 (a Human Monoclonal Antibody Against Human Type I Insulin-Like Growth Factor Receptor) in Combination with Everolimus (an Oral mTor Inhibitor-RAD0001) in Patients with ER and/or PR Positive Metastatic Breast Cancer,I/II,Completed,University of Alabama at Birmingham Comprehensive Cancer Center,Oncology: Breast,Estrogen receptor positive; Line of therapy N/A; Progesterone receptor positive; Stage IV,Breast Neoplasms,United States
"A Phase Ib, Open-label, Dose-escalation Study of the Safety and Pharmacology of Ipatasertib (GDC-0068) in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors",I,Completed,"Pfizer {Array BioPharma}
Roche/Genentech","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; HER2 positive; Hormone refractory; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Mesothelioma; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",France; Spain; United Kingdom; United States
"A Phase I/II, Multi-center, Open-label Study, to Evaluate the Efficacy of AUY922 in Combination With Lapatinib With Letrozole in Postmenopausal Patients With Locally Advanced or Metastatic ER+ , HER2 + Breast Cancer.",I/II,Terminated,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; First line; Fourth line or greater; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors.",I,Completed,Novartis,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Osteosarcoma; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Line of therapy N/A; Locally advanced; Metastatic; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Osteosarcoma; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",Spain; United States
"An Open-Label, Phase I, Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma",I,Completed,"Tennessee Oncology Center
Yale University
Roche/Genentech","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma",Aggressive; Classical; HER2 negative; Indolent; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms",France; United States
"Open-Label Multicenter 2-Arm Phase I Study of RO5429083 With Dose-Escalation and Extension Cohorts, and Imaging Cohorts With RO5429083 and 89Zr-labeled RO5429083, in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors",I,Terminated,Roche {F. Hoffmann-La Roche},"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Melanoma; Oncology: Pancreas; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Soft Tissue Sarcoma",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Endometrioid; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Neoplasms, Basal Cell; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Wilms Tumor",France; Netherlands; United States
Phase I-II Study of HER2 Vaccination With Poly(I)* Poly(C12U) (Ampligen) as an Adjuvant in Optimally Treated Breast Cancer Patients,I/II,Completed,"National Institutes of Health/National Cancer Institute
University of Washington
AIM ImmunoTech {Hemispherx Biopharma}",Oncology: Breast,Adjuvant; HER2 positive; Stage II; Stage III; Stage IV,"Breast Neoplasms; Breast Neoplasms, Male",United States
"A Phase Ia/b, Multicenter, Open Label, Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Dual DNA-PK and TOR Kinase Inhibitor, CC-115, Administered Orally to Subjects With Advanced Solid Tumors, and Hematologic Malignancies.",I,Completed,Bristol-Myers Squibb/Celgene,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Multiple Myeloma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",HER2 negative; Hormone refractory; Indolent; Second line; Small lymphocytic lymphoma (SLL); Stage II; Stage III; Stage IV; Triple receptor negative; Unspecified,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Chronic Lymphocytic Leukemia; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Glioblastoma; Head and Neck Neoplasms; Hematologic Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Leukemia, Lymphocytic, Chronic, B-Cell; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Multiple Myeloma; Neoplasm Metastasis; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Squamous Cell Carcinoma of Head and Neck; Synovial Sarcoma; Thyroid Neoplasms; Wilms Tumor",France; Germany; Spain; United States
Phase I Trial of Low-Dose Cyclophosphamide in Combination With Veliparib (ABT-888) in HER2/Neu-Negative Metastatic Breast Cancer,I,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,BRCA; Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms; Carcinoma,United States
"A Phase I, Open Label, Dose Escalation Study of Oral Administration of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies",I,Completed,Takeda/Takeda Oncology {Millennium {Intellikine}},"Oncology: Breast; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine",Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Endometrial Neoplasms; Neoplasms; Neuroendocrine Tumors; Small Cell Lung Carcinoma",United States
"A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands.",I,Completed,Novartis,"Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas",BRAF; HER2 negative; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Second line; Stage II; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Melanoma; Neoplasms, Squamous Cell; Pancreatic Cancer; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms",Canada; France; Germany; Italy; Netherlands; Spain; United States
Phase I/II Trial of Motesanib in Combination With Ixabepilone and Capecitabine in Women With Locally Recurrent or Metastatic Breast Cancer,I/II,Terminated,"Amgen
Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}
Kimmel Cancer Center-Thomas Jefferson University - Philadelphia, PA",Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase I Trial of MK-2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole Plus Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive Metastatic Breast Cancer",I,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Estrogen receptor positive; First line; Second line; Stage IV,Breast Neoplasms; Carcinoma,United States
A Phase I PK/PD Study of the PI3 Kinase/mTOR Inhibitor BEZ235 Given Twice Daily for the Treatment of Patients With Advanced Solid Tumors,I,Completed,Novartis,"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Pancreas",Extensive; Metastatic; Pulmonary; Second line; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Head and Neck Neoplasms; Melanoma; Neoplasms; Neuroendocrine Tumors; Osteosarcoma; Pancreatic Cancer; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms",United Kingdom; United States
A Phase Ia Dose Escalation Study of OMP-18R5 in Subjects with Solid Tumors,I,Completed,Mereo BioPharma/OncoMed,Oncology: Breast; Oncology: Colorectal; Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma,Second line; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neoplasms; Osteosarcoma; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma,United States
"A phase I/II study to evaluate TCN-P in combination with tipifarnib, doxorubicin (Dox) and cyclophosphamide (AC) in stage IIB-IIIC breast cancer patients",I/II,Terminated,"National Institutes of Health/National Cancer Institute
Cahaba Pharmaceuticals",Oncology: Breast,Line of therapy N/A; Stage II; Stage III,Breast Neoplasms,United States
"A Phase I Trial of BKM 120, a Novel Oral Selective Phosphatidylinositol-3-kinase (PI3K) Inhibitor, in Combination With Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive Metastatic Breast Cancer.",I,Completed,"National Institutes of Health/National Cancer Institute
Washington University School of Medicine",Oncology: Breast,Estrogen receptor positive; First line; Fourth line or greater; Second line; Stage IV; Third line,Breast Neoplasms,United States
"A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BEZ235 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors",I/II,Terminated,"Novartis
Pfizer {Array BioPharma}","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas",BRAF; EGFR; HER2 negative; KRAS; NRAS; Second line; Stage 0; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Melanoma; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms",Australia; Canada; France; Germany; Spain; United States
A Phase I With Dose Expansion to Determine the Maximum Tolerated Dose of Liposomal Doxorubicin in Combination With Seliciclib for the Treatment of Patients With Metastatic Triple Negative Breast Cancer,I,Terminated,"MD Anderson Cancer Center, University of Texas
National Institutes of Health",Oncology: Breast,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase Ib, Open Label, Dose Escalation Study of the Safety and Pharmacology of GDC-0980 in Combination with a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients with Advanced Solid Tumors",I,Completed,Roche/Genentech,Oncology: Anal; Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck,HER2 negative; KRAS; Second line; Stage III; Stage IV; Triple receptor negative,Anus Neoplasms; Bile Duct Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Head and Neck Neoplasms; Unspecified,Spain; United States
"An Open-Label Randomized Phase II Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Phase I Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin",I/II,Terminated,Piramal Healthcare {Nicholas Piramal India Ltd},Oncology: Breast,HER2 negative; Second line; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Phase I Study of Z-Endoxifen as a Hormonal Therapy for Breast Cancer,I,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Estrogen receptor positive; HER2 positive; KRAS; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
Phase I Open Label Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 as a Single Agent in Patients With Refractory Solid Tumors,I,Completed,"Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}
MEI Pharma {Marshall Edwards {Novogen/Marshall Edwards}}","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",Pulmonary; Second line; Stage III; Stage IV; Unspecified,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",United States
An Open Label Phase IB Dose-Finding Study of TRC105 in Combination with Capecitabine for Progressive or Recurrent Metastatic Breast Cancer,I/II,Completed,"Roswell Park Cancer Institute
US Department of Defense
Tracon Pharmaceuticals",Oncology: Breast; Oncology: Colorectal,Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line,Breast Neoplasms; Colorectal Neoplasms,United States
A Phase I Open-label Dose Escalation Study with Expansion to assess the Safety and Tolerability of INC280 in Patients with c-MET Dependent Advanced Solid Tumors,I,Completed,Novartis,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Renal; Oncology: Unspecified Solid Tumor",Fourth line or greater; HER2 negative; MET Amplification/Alteration; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor","Australia; Canada; France; Germany; Hong Kong, S.A.R., China; Israel; Italy; Netherlands; Norway; Singapore; South Korea; Spain; Taiwan, China; United States"
A Phase Ib/II Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies,I/II,Terminated,Sumitomo Dainippon Pharma {Dainippon Sumitomo}/Sumitomo Dainippon Pharma Oncology {Boston Biomedical},"Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Thymus; Oncology: Unspecified Solid Tumor",Adenocarcinoma; ALK; BRAF; EGFR; Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Large Cell; Progesterone receptor positive; Second line; Squamous Cell; Stage III; Stage IV; Third line; Thymic carcinoma; Thymoma; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Glioblastoma; Head and Neck Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Thymoma; Thymus Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",Canada; United States
Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer,I/II,Completed,Northwestern University,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: Colorectal; Oncology: Metastatic Cancer",(N/A); CNS mets; HER2 positive; Second line; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Colorectal Neoplasms; Glioblastoma; Medulloblastoma; Neoplasm Metastasis,United States
A Phase I Trial of PD0332991 and Paclitaxel in Patients With Rb-Expressing Advanced Breast Cancer,I,Completed,Abramson Cancer Center at  University of Pennsylvania Medical Center,Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
A Phase I Study of Tesetaxel Administered in Combination With Capecitabine to Subjects With Solid Tumors,I,Completed,Genta,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",First line; Second line; Stage II; Stage III; Stage IV; Untreated,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
An Open-Label Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 when Administered as a Single Agent in Patients with Advanced or Metastatic Solid Tumors,I/II,Terminated,Teva {Cephalon},Oncology: Breast; Oncology: Gastric; Oncology: Prostate,Second line; Stage III; Stage IV,Breast Neoplasms; Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms,United States
"A Phase I, Multi-Center, Open-Label, Dose-Escalation, Safety, and Pharmacokinetic Clinical Study of Intravenously Administered MM-302 Monotherapy and in Combination With Trastuzumab With or Without Cyclophosphamide in Patients With Advanced HER2 Positive Breast Cancer",I,Completed,Merrimack Pharmaceuticals,Oncology: Breast,Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"A Phase I Pharmacokinetic (PK), Safety, and Tolerability Study of SPARC1028 Administered Weekly in Subjects With Advanced Solid Malignancies in US Population",I,Completed,Sun Pharma Advanced Research,Oncology: Bladder; Oncology: Breast; Oncology: Ovarian; Oncology: Renal,First line; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Renal Cell; Kidney Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination With Doxorubicin in Non-heavily Pretreated Patients With Selected Advanced Solid Tumors",I,Completed,PharmaMar {Zeltia/PharmaMar},"Oncology: Bladder; Oncology: Breast; Oncology: Endometrial; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma",Extensive; Gastrointestinal; Locally advanced; Metastatic; Pancreas; Pulmonary; Second line; Stage III; Stage IV; Third line,"Adenocarcinoma; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Small Cell; Endometrial Neoplasms; Ewing Sarcoma; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Neuroendocrine Tumors; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",Spain; United Kingdom; United States
A Phase I and Pharmacologic Study of MM-111 in Combination With Multiple Treatment Regimens in Patients With Advanced HER2 Positive Solid Tumors,I,Completed,"Merrimack Pharmaceuticals
US Oncology Research",Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Ovarian; Oncology: Prostate,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms,United States
"A Four Part, Phase I Dose-Escalation Study of the Combinations of Concurrent BKM120 and Capecitabine, or Concurrent BYL719 and Capecitabine, or Concurrent BKM120 and Capecitabine and Trastuzumab, or Concurrent BKM120 and Capecitabine and Lapatinib in Patients With Metastatic Breast Cancer",I,Completed,"Novartis
UNC Lineberger Comprehensive Cancer Center",Oncology: Breast,Fourth line or greater; HER2 negative; HER2 positive; Second line; Stage IV; Third line,Breast Neoplasms,United States
"An Open-Label, Phase I/II, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer",I/II,Terminated,"Roche/Chugai Pharmaceutical
Roche/Genentech","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Unspecified Solid Tumor",Aggressive; Diffuse large B-cell lymphoma (DLBCL); EGFR; Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Indolent; KRAS; NRAS; Progesterone receptor positive; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",Canada; France; Japan; Spain; United States
"Phase I, First in Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of X-82 in Patients With Advanced Solid Tumors",I,Completed,Xcovery/Tyrogenex,"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: GIST; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor",Hormone refractory; Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastrointestinal Stromal Tumors; Kidney Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Wilms Tumor",United States
Phase I Parallel Protocol of MK-8669 (Ridaforolimus) + MK-2206 and MK-8669 (Ridaforolimus) + MK-0752 Doublets (MK-MK) in Patients With Advanced Cancer,I,Completed,Merck & Co./Merck Sharp & Dohme (MSD),"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Prostate",Aggressive; Estrogen receptor positive; Fourth line or greater; Hormone refractory; Indolent; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Glioblastoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms",France; Norway; Spain; United States
"Phase I Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BMS-906024 in Subjects With Advanced Solid Tumors",I,Completed,Bristol-Myers Squibb,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas",HER2 negative; Second line; Squamous Cell; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Unspecified",Australia; Canada; United States
"Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM060184 Administered Intravenously Over 10 Minutes on Days 1 and 8 Every 21 Days to Patients With Advanced Solid Tumors",I,Completed,PharmaMar {Zeltia/PharmaMar},"Oncology: Breast; Oncology: Colorectal; Oncology: GIST; Oncology: Lung, Non-Small Cell",Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Neoplasms",France; Spain; United States
Phase I Study of the Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available,I,Completed,Eli Lilly {ImClone},"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Renal",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Renal Cancer; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
Phase I-II Study of Concurrent Adjuvant Systemic Therapy and Accelerated Radiotherapy (Over 3 Weeks),I/II,Completed,NYU Langone Health,Oncology: Breast,Adjuvant; HER2 negative; Stage I; Stage II; Triple receptor negative,Breast Neoplasms,United States
"A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors",I,Completed,(Other Hospital/Academic/Medical Center),"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma",(N/A); Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",United States
"A Phase Ib Multi-center, Open-label, 4-arm Dose-escalation Study of Oral BEZ235 and BKM120 in Combination with Weekly Paclitaxel in Patients With Advanced Solid Tumors and Weekly Paclitaxel/Trastuzumab in Patients With HER2+ Metastatic Breast Cancer",I,Completed,Novartis,"Oncology: Anal; Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Penile; Oncology: Soft Tissue Sarcoma; Oncology: Vulvar",First line; Fourth line or greater; HER2 positive; Large Cell; Second line; Stage I; Stage II; Stage III; Stage IV; Third line,"Anus Neoplasms; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Penile Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Unspecified; Uterine Cervical Neoplasms; Vulvar Neoplasms",Belgium; Germany; Netherlands; Spain; Switzerland; United States
"A Phase I, Multi-center, Open Label Dose Escalation Study of LDK378, Administered Orally in Adult Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)",I,Completed,Novartis,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Soft Tissue Sarcoma",ALK; First line; Fourth line or greater; Locally advanced; Metastatic; Second line; Stage III; Stage IV; Third line; Untreated,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Congenital Abnormalities; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",Australia; Belgium; Canada; China; Germany; Italy; Japan; Netherlands; New Zealand; Singapore; South Korea; Spain; Thailand; United Kingdom; United States
"A Phase I, Multicenter, Open-Label, Dose Escalation Study of ASP3026 in Subjects With Advanced Malignancies",I,Completed,Astellas Pharma,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Soft Tissue Sarcoma",Adenocarcinoma; Aggressive; ALK; Diffuse large B-cell lymphoma (DLBCL); Extranodal marginal zone B-cell lymphoma (MALT); Follicular lymphoma (FL); Indolent; Lymphoblastic lymphoma (LBL); Mantle cell lymphoma (MCL); Other subtype; Second line; Small lymphocytic lymphoma (SLL); Stage III; Stage IV; Waldenstrom's macroglobulinemia (WM),"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Lymphoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Waldenstrom Macroglobulinemia",United States
Omega 3 Fatty Acids and Breast Cancer Prevention: Protective Benefits of Increased Fish Consumption,I,Completed,Ohio State University,Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
Phase I Trial of Intraperitoneal ²¹²Pb-TCMC-Trastuzumab for HER-2 Expressing Malignancy,I,Completed,"National Institutes of Health
(Other Hospital/Academic/Medical Center)
Orano Med {Areva Med}",Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Ovarian; Oncology: Pancreas,HER2 positive; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Colorectal Neoplasms; Endometrial Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
A Phase I Study of ABT-888 (Veliparib) in Combination With Weekly Carboplatin and Paclitaxel in Advanced Solid Tumors,I,Completed,"(Other Cooperative Group)
National Institutes of Health/National Cancer Institute
AbbVie {Abbott}","Oncology: Breast; Oncology: Cervical; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate",Estrogen receptor positive; Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Breast Neoplasms, Male; Carcinoma; Carcinoma, Non-Small-Cell Lung; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms",United States
A Phase I Trial of Weekly Paclitaxel in Combination With Bavituximab in Patients With Her-2 Negative Metastatic Breast Cancer,I,Completed,"National Institutes of Health/National Cancer Institute
Peregrine Pharmaceuticals
University of Arizona",Oncology: Breast,First line; HER2 negative; Second line; Stage IV; Triple receptor negative,"Breast Neoplasms; Breast Neoplasms, Male",United States
"A Phase I, Open Label, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetic Properties of the Combination of Cilengitide and Paclitaxel in Patients with Advanced Solid Malignancies",I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Thyroid",First line; HER2 negative; Locally advanced; Metastatic; Second line; Stage III; Stage IV; Triple receptor negative; Unresectable,"Breast Neoplasms; Breast Neoplasms, Male; Carcinoma; Carcinoma, Non-Small-Cell Lung; Esophageal Cancer; Esophageal Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Phase lb, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Daily Oral Doses of ZSTK474 in Subjects With Advanced Solid Malignancies",I,Completed,Zenyaku Kogyo {Zenoaq},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",Second line; Stage III; Stage IV; Unresectable,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified",United States
A Phase I Study of REGN910 Administered Every 2 Weeks in Patients with Advanced Solid Malignancies,I,Completed,"Regeneron
Sanofi {Sanofi-Aventis}","Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Renal; Oncology: Thyroid",Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Thyroid Neoplasms; Unspecified; Wilms Tumor",Canada; United States
"Phase I Trial of Z-Endoxifen in Adults With Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or Other Hormone Receptor-Positive Solid Tumors",I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Estrogen receptor positive; HER2 positive; Hormone refractory; Progesterone receptor positive; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Fibromatosis, Aggressive; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
"A Phase Ib/II, Multi-center, Open-label Study to Evaluate the Efficacy of AUY922 in Combination With Trastuzumab in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer, That Has Progressed After or During at Least One Trastuzumab-containing Regimen",I/II,Completed,Novartis,Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,France; Germany; Italy; Netherlands; Singapore; Spain; Sweden; United Kingdom; United States
A Phase I Dose Escalation Study of OMP-59R5 in Subjects with Solid Tumors,I,Completed,Mereo BioPharma/OncoMed,Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Cancer,Second line; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms,United States
A Phase I Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer,I,Completed,"Geron
Indiana University Cancer Center
Breast Cancer Research Foundation",Oncology: Breast,First line; Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
Phase Ib Dose Escalation and Biomarker Study of MK-2206 in Combination With Standard Doses of Weekly Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors With an Expansion in Advanced Breast Cancer,I,Completed,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Melanoma; Oncology: Ovarian,First line; Fourth line or greater; Second line; Stage III; Stage IV; Third line,Breast Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms,United States
"An Open-Label, Phase Ib Dose Escalation Trial of Oral Combination Therapy With MSC1936369B and SAR245409 in Subjects With Locally Advanced or Metastatic Solid Tumors",I,Completed,"Merck KGaA/EMD Serono {EMD Pharmaceuticals}
Sanofi {Sanofi-Aventis}","Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Thyroid",BRAF; EGFR; HER2 negative; KRAS; Locally advanced; Metastatic; Recurrent; Second line; Stage II; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Thyroid Neoplasms; Wilms Tumor",Italy; Spain; United States
A Phase I Dose Escalation Study of Combination Therapy With Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors,I,Completed,Sanofi {Sanofi-Aventis},"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Thyroid",Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Thyroid Neoplasms; Wilms Tumor",United States
"A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer",I,Completed,Novartis,Oncology: Breast; Oncology: Prostate,First line; Hormone refractory; Second line; Stage III; Stage IV,Breast Neoplasms; Leiomyoma; Myofibroma; Prostatic Neoplasms,Belgium; Italy; Spain; United States
Phase Ib Trial of Combination Immunotherapy with HER2/neu Peptide GP2 + GM-CSF Vaccine and Trastuzumab in Breast Cancer Patients,I,Completed,"MD Anderson Cancer Center, University of Texas
(Other Hospital/Academic/Medical Center)",Oncology: Breast,(N/A); Adjuvant; Estrogen receptor positive; HER2 positive; Progesterone receptor positive,Breast Neoplasms,United States
"A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel with or without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer",I,Completed,Roche/Genentech,Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,Belgium; United States
A Phase I/II Study to Assess the Safety and Therapeutic Effect of INCB007839 in Combination With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer.,I/II,Terminated,Incyte Corporation,Oncology: Breast,First line; HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Phase I Dose-Escalation Study of ABT-888 (Veliparib) in Combination With Carboplatin in HER2 Negative Metastatic Breast Cancer,I,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,BRCA; Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Carcinoma; Triple Negative Breast Neoplasms,United States
"A Phase I, First-In-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 337 in Adult Subjects With Advanced Solid Tumors",I,Completed,"Amgen
NantWorks/NantPharma","Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",Hormone refractory; MET Amplification/Alteration; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Glioblastoma; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Medulloblastoma; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous Infusion of VX15/2503 in Adult Patients With Advanced Solid Tumors.",I,Completed,Vaccinex,Oncology: Breast; Oncology: Colorectal; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid,Hormone refractory; Papillary; Second line; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms,United States
A Phase I Study of Paclitaxel and Carboplatin in Solid Tumors (With Focus on Upper Aerodigestive Cancers) in Persons With HIV Infection,I,Terminated,"National Institutes of Health/National Cancer Institute
AIDS Associated Malignancies Clinical Trials Consortium
University of Arkansas","Infectious Disease: HIV; Oncology: Anal; Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian",Second line; Stage III; Stage IV; Treatment experienced,"Acquired Immunodeficiency Syndrome; Anus Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Squamous Cell; Carcinoma, Verrucous; Communicable Diseases; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; HIV Infections; HIV Seropositivity; Infection; Laryngeal Diseases; Laryngeal Neoplasms; Lung Neoplasms; Nasopharyngeal Carcinoma; Oropharyngeal Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Paranasal Sinus Neoplasms; Salivary Gland Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
A Phase Ib Trial of BKM120 (a PI3K Inhibitor) or BEZ235 (a PI3K/mTOR Inhibitor) in Combination With Endocrine Therapy in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer,I,Completed,Vanderbilt-Ingram Cancer Center,Oncology: Breast,Estrogen receptor positive; FGFR; HER2 positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
"Open-label, Phase I Trial to Evaluate the Safety and Pharmacokinetic Parameters of a 2-day Pulse of Intravenous (IV) AC480 (AC480IV) Administered as Monotherapy and in Combination With Docetaxel in Patients With Advanced Solid Tumors",I,Terminated,Daiichi Sankyo/Ambit Biosciences,"Oncology: Breast; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Neoplasms",United States
A Phase I Study of MK-2206 in Combination With Lapatinib in Refractory Solid Tumors Followed by Dose-Expansion in Advanced HER2+ Breast Cancer,I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell",HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Breast Neoplasms, Male; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasms",United States
A Phase Ib Trial of MK-2206 (an AKT Inhibitor) in Combination With Endocrine Therapy in Patients With Hormone Receptor Positive Breast Cancer,I,Terminated,Vanderbilt-Ingram Cancer Center,Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
"Phase I Parallel Arm Study of MK-0646 (Dalotuzumab) + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 (Ridaforolimus) Doublets (MK-MK Doublets) in Patients With Advanced Cancer",I,Terminated,Merck & Co.,"Oncology: Breast; Oncology: Colorectal; Oncology: Fallopian Tube; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Fourth line or greater; Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Ewing Sarcoma; Fallopian Tube Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",Canada; Israel; South Korea; United States
"An Early Phase I Study of IPdR Absorption, Metabolism, and Safety in Patients With Advanced Solid Tumors and Lymphomas",I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Thyroid",Aggressive; Classical; Indolent; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Liver Cancer; Liver Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Phase I Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.",I,Terminated,GlaxoSmithKline,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Small Intestine",HER2 negative; KRAS; Second line; Stage II; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Intestinal Neoplasms; Kidney Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Canada; Italy; United States
A Phase Ib Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors,I,Completed,Novartis,Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal,Second line; Stage III; Stage IV,Breast Neoplasms; Fallopian Tube Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms,Canada; Italy; Spain; United States
"A Phase Ib, Open-Label, Dose-Escalating Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda) in Subjects With Advanced Solid Tumors",I,Completed,"Astellas Pharma
LG Chem/AVEO Oncology",Oncology: Breast; Oncology: Colorectal; Oncology: Prostate,First line; Hormone refractory; Second line; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Neoplasms; Prostatic Neoplasms,United States
A Phase I Study of NK012 in Combination With Carboplatin in Patients With Advanced Solid Tumors Followed by a Dose Expansion Phase in Patients With Triple Negative Metastatic Breast Cancer,I,Completed,Nippon Kayaku,Oncology: Breast; Oncology: Unspecified Solid Tumor,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Triple Negative Breast Neoplasms",United States
A Phase Ib Dose-escalation Trial of the AKT Inhibitor MK2206 in Combination With Weekly Paclitaxel With or Without Trastuzumab,I,Completed,"Merck & Co.
University of California, San Francisco
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast; Oncology: Esophageal; Oncology: Gastric,First line; Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Neoplasms; Stomach Carcinoma; Stomach Neoplasms,United States
A Phase I Study of Neoadjuvant Chemotherapy With The Gamma Secretase Inhibitor RO4929097 in Combination With Paclitaxel And Carboplatin In Patients With Clinical Stage II-III Triple Negative Breast Cancer,I,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase I Multi-center, Open Label, Dose-escalation Study of Oral LEE011 in Patients With Advanced Solid Tumors or Lymphoma",I,Completed,"Novartis
Otsuka Holdings/Otsuka Pharmaceutical/Astex Pharmaceuticals {Astex Therapeutics}","Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Head/Neck; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroblastoma; Oncology: Soft Tissue Sarcoma",Aggressive; Classical; Estrogen receptor positive; HER2 negative; Locally advanced; Mantle cell lymphoma (MCL); Metastatic; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV,"Breast Neoplasms; Central Nervous System Neoplasms; Fibrosarcoma; Glioblastoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Liposarcoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Medulloblastoma; Melanoma; Neuroblastoma; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",France; Netherlands; United States
A Pharmacokinetic/Pharmacodynamic Study With a Phase I Run-In With a PARP Inhibitor (Olaparib) in Combination With Carboplatin for Refractory or Recurrent Women's Cancers,I,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Soft Tissue Sarcoma,BRCA; Fourth line or greater; HER2 negative; Metastatic; Second line; Stage III; Stage IV; Third line; Triple receptor negative; Unresectable,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Fallopian Tube Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Uterine Cervical Neoplasms",United States
A Phase I Study of Therapeutic Cancer Vaccine IMF-001 in Patients With Malignancies Expressing NY-ESO-1,I,Completed,ImmunoFrontier,Oncology: Breast; Oncology: Endometrial; Oncology: Esophageal; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma,Hormone refractory; Metastatic; Second line; Stage I; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Renal Cell; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified; Wilms Tumor",United States
GCC 0927 A Pilot and Phase II Study of Entinostat and Anastrozole/Tamoxifen in Women With Triple Negative Breast Cancer to Evaluate Biomarkers and Surrogates for Response,I/II,Terminated,"National Institutes of Health/National Cancer Institute
University of Maryland Greenebaum Cancer Center
Syndax",Oncology: Breast,HER2 negative; Neoadjuvant; Second line; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Phase I Study of ABT-888 in Combination with Oxaliplatin and Capecitabine in Advanced Solid Tumors,I,Terminated,National Institutes of Health/National Cancer Institute,Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas,BRCA; First line; Second line; Stage I; Stage II; Stage III; Stage IV; Unspecified,"Adenocarcinoma; Bile Duct Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Cystadenocarcinoma; Cystadenocarcinoma, Mucinous; Germinoma; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neoplasms, Glandular and Epithelial; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rectal Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
"A Phase I, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors",I/II,Completed,"Pfizer {Medivation}
BioMarin","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",BRCA; Fourth line or greater; Hormone refractory; Locally advanced; Metastatic; Pulmonary; Second line; Stage II; Stage III; Stage IV; Third line; Unresectable,"Breast Neoplasms; Carcinoma, Small Cell; Colorectal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Lung Neoplasms; Neoplasms, Glandular and Epithelial; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United Kingdom; United States
A Phase I Dose-Escalation Study of LY2940680 in Patients With Advanced Cancer,I,Completed,"Eli Lilly
Roche/Ignyta","Oncology: Breast; Oncology: CNS, Medulloblastoma; Oncology: Liver; Oncology: Prostate; Oncology: Skin, Basal Cell Carcinoma; Oncology: Unspecified Cancer",Hormone refractory; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Liver Cancer; Liver Neoplasms; Medulloblastoma; Neoplasms; Neoplasms, Basal Cell; Prostatic Neoplasms",United States
"An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered Daily in Patients With Refractory Solid Tumors or Lymphoma",I,Completed,Roche/Genentech,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate",(N/A); Extranodal marginal zone B-cell lymphoma (MALT); Indolent; Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Small Cell; Colorectal Neoplasms; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Unspecified",United States
A Phase I Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors,I,Completed,Novartis,Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Pancreas,Second line; Stage II; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms,United States
"A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Patients With Advanced Solid Malignancies",I,Completed,AstraZeneca,"Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate; Oncology: Unspecified Solid Tumor",(N/A); Adenocarcinoma; Estrogen receptor positive; Fourth line or greater; HER2 positive; Hormone refractory; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Uterine Cervical Neoplasms",Canada; Denmark; France; Germany; Italy; Japan; Netherlands; Singapore; Spain; Sweden; United Kingdom; United States
A Clinical Trial to Qualify the Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer,I,Completed,Merck & Co./Merck Sharp & Dohme (MSD),Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Stage I; Stage II; Stage III,Breast Neoplasms,Brazil; Israel; South Korea; Spain; United States
Phase I Study of Adoptive T-Cell Therapy With HER-2/Neu (HER-2)-Specific Memory CD8+ T Lymphocytes Obtained Following In Vivo Priming With a Peptide Vaccine in Patients With Advanced Stage HER-2-Positive Breast Cancer,I,Terminated,"National Institutes of Health/National Cancer Institute
Fred Hutchinson Cancer Research Center
University of Washington/Seattle Cancer Care Alliance
(Other Hospital/Academic/Medical Center)",Oncology: Breast,HER2 positive; Second line; Stage IV,"Breast Neoplasms; Breast Neoplasms, Male",United States
"Two Phase I Studies in Patients With Brain Metastases From Any Primary Histology, Followed by a Randomized Phase II Study of RO4929097 Combined With CNS Radiotherapy in Patients With Brain Metastases From Breast Cancer Whose Tumors Are Estrogen Receptor Negative",I,Terminated,"National Institutes of Health/National Cancer Institute
Roche {F. Hoffmann-La Roche}","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Neuroendocrine; Oncology: Unspecified Cancer",(N/A); CNS mets; First line; HER2 negative; HER2 positive; Pulmonary; Second line; Stage IV; Untreated,"Brain Neoplasms; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Central Nervous System Neoplasms; Lung Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Neuroendocrine Tumors; Small Cell Lung Carcinoma",United States
"A Phase I Clinical Trial of Hepatic Arterial Infusion of Oxaliplatin, Oral Capecitabine, With or Without Systemic Bevacizumab for Patients With Advanced Cancer Metastatic to the Liver.",I,Completed,"MD Anderson Cancer Center, University of Texas",Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Metastatic Cancer; Oncology: Pancreas; Oncology: Unspecified Cancer,Fourth line or greater; Liver mets; Second line; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasm Metastasis; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms",United States
"A Phase I/IIa trial of TVAX Immunotherapy for Breast, GI, Lung, Melanoma, Ovarian and Prostate cancer.",I/II,Completed,TVAX Biomedical,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Prostate",(N/A); Line of therapy N/A,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms",United States
"A Phase I Study of LY2874455 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Advanced Cancer",I,Completed,Eli Lilly,"Oncology: Breast; Oncology: Gastric; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Prostate",Aggressive; Classical; FGFR; Fourth line or greater; Hormone refractory; Indolent; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Chronic Lymphocytic Leukemia; Hodgkin Disease; Hodgkin Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",Australia; South Korea; United States
"A Phase I, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers",I,Completed,"Merrimack Pharmaceuticals
Sanofi {Sanofi-Aventis}",Oncology: Breast; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal,HER2 negative; Line of therapy N/A; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Fallopian Tube Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms",United States
A Phase Ib Neoadjuvant Study of the Gamma Secretase Inhibitor (RO4929097) in Combination With the Aromatase Inhibitor Letrozole in Post-Menopausal Women With Stage II/III Hormone Receptor-Positive Breast Cancer,I,Terminated,National Institutes of Health/National Cancer Institute,Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,United States
"A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MEHD7945A Administered Intravenously to Patients With Locally Advanced or Metastatic Epithelial Tumors",I,Completed,Roche/Genentech,"Oncology: Anal; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas",Fourth line or greater; HER2 negative; KRAS; Second line; Stage II; Stage III; Stage IV; Third line; Triple receptor negative,"Anus Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms, Glandular and Epithelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms",Spain; United States
A Phase I Clinical Trial of Sequential Pralatrexate Followed by a 48-hour Infusion of 5- Fluorouracil Given Every Other Week in Adult Patients With Solid Tumors,I,Completed,"National Institutes of Health/National Cancer Institute
University of Nebraska Medical Center
National Comprehensive Cancer Network","Oncology: Breast; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",(N/A); Hormone refractory; Second line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
"An Open-label, Multicenter, Phase Ib Study of CNTO 888 (an Anti-CCL 2 Monoclonal Antibody) in Combination With Chemotherapies for the Treatment of Subjects With Solid Tumors",I,Completed,Johnson & Johnson/Janssen Biotech {{Centocor Ortho Biotech {J&J/Centocor}},"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Thyroid",First line; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms; Unspecified",Spain; United States
"A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of KW-2450 in Combination With Lapatinib and Letrozole in Subjects With Advanced or Metastatic Breast Cancer Whose Tumors Overexpress HER2",I/II,Terminated,Kyowa Kirin {Kyowa Hakko Kirin},Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance,I,Completed,"MD Anderson Cancer Center, University of Texas",Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Ovarian,Estrogen receptor positive; FGFR; First line; Fourth line or greater; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Uterine Cervical Neoplasms",United States
Phase I/II Trial of Tamoxifen Following Epigenetic Regeneration of Estrogen Receptor Using Decitabine and LBH 589 in Patients with Triple Negative Metastatic Breast Cancer,I/II,Terminated,"Novartis
Winship Cancer Institute of Emory University
Eisai",Oncology: Breast,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Neoplasms; Triple Negative Breast Neoplasms,United States
Study of GSK2302024A Antigen-Specific Cancer Immunotherapeutic Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer,I/II,Terminated,GlaxoSmithKline,Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,Belgium; Canada; Denmark; France; Germany; Italy; Russia; United Kingdom; United States
HER2 dendritic cell vaccines.,I,Completed,Duke Comprehensive Cancer Center,Oncology: Breast; Oncology: Unspecified Cancer,HER2 positive; Line of therapy N/A; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms; Neoplasms,United States
A Phase II Open-Label Study of TPI 287 in Patients With Breast Cancer Metastatic to the Brain,I/II,Completed,"MD Anderson Cancer Center, University of Texas
Cortice Biosciences {Archer Biosciences}",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Second line; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
A Phase I/II Study of 1-Methyl-D-tryptophan (NSC-721782; IND # 78060) in Combination with Docetaxel in Metastatic Solid Tumors,I/II,Completed,"National Institutes of Health/National Cancer Institute
Lumos Pharma {NewLink Genetics}","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Thymus",Estrogen receptor positive; First line; HER2 negative; HER2 positive; Metastatic; Progesterone receptor positive; Stage IV; Thymic carcinoma; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thymus Neoplasms",Poland; United States
"Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer.",I,Closed,"MD Anderson Cancer Center, University of Texas","Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",HER2 negative; Hormone refractory; Second line; Squamous Cell; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.",I/II,Completed,BBB Therapeutics {to-BBB},"Oncology: Breast; Oncology: CNS, Astrocytoma; Oncology: CNS, Glioblastoma; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer",(N/A); CNS mets; Extensive; Fourth line or greater; Grade 3; HER2 positive; Second line; Stage IV; Third line,"Astrocytoma; Brain Neoplasms; Breast Neoplasms; Carcinoma, Small Cell; Central Nervous System Neoplasms; Glioblastoma; Glioma; Melanoma; Neoplasm Metastasis; Neoplasms, Second Primary; Small Cell Lung Carcinoma",Belgium; France; Netherlands; United States
"A Phase I Study of Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) in Patients With Advanced Cancers",I,Completed,"MD Anderson Cancer Center, University of Texas
Bristol-Myers Squibb/Celgene","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Soft Tissue Sarcoma; Oncology: Testicular; Oncology: Thymus",Fourth line or greater; Hormone refractory; Locally advanced; Merkel; Metastatic; Second line; Stage III; Stage IV; Third line; Thymic carcinoma; Thymoma; Unspecified,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Neoplasms, Basal Cell; Neuroendocrine Tumors; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms; Thymoma; Thymus Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase I, Open-Label, Dose-Escalation Study of Orally Administered TAK-960, a Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Nonhematologic Malignancies",I,Terminated,Takeda/Takeda Oncology {Millennium},Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Thyroid,Second line; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms,United States
"A Phase I, Pharmacokinetic Study of STA-9090 in Combination With Docetaxel in Subjects With Advanced Solid Tumor Malignancies.",I,Completed,Madrigal Pharmaceuticals {Synta Pharmaceuticals},"Oncology: Breast; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Prostate",(N/A); First line; Pulmonary; Second line; Stage III; Stage IV; Untreated,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Neoplasms; Neuroendocrine Tumors; Prostatic Neoplasms; Small Cell Lung Carcinoma",United States
"A Phase IB/IIA, Open-label, Non-randomized, Multi-arm Study of TL32711 in Combination With Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors.",I/II,Completed,TetraLogic Pharmaceuticals,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas",(N/A); Aggressive; Classical; First line; Fourth line or greater; Indolent; Nodular lymphocyte-predominant; Pulmonary; Second line; Stage III; Stage IV; Third line; Untreated,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Unspecified",United States
"A Phase I, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of INCB024360 in Patients With Advanced Malignancies",I/II,Completed,Incyte Corporation,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Distal; Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
Phase I/II Study of the Insulin-like Growth Factor Receptor Inhibitor MK-0646 in Combination with Paclitaxel and Bevacizumab in Metastatic Breast Cancer.,I/II,Terminated,North Central Cancer Treatment Group (NCCTG),Oncology: Breast,Line of therapy N/A; Stage IV,Breast Neoplasms,United States
"A Phase I/II, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma",I/II,Completed,Bristol-Myers Squibb/Celgene,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Aggressive; Diffuse large B-cell lymphoma (DLBCL); Fourth line or greater; Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV; Third line; Unspecified,"Breast Neoplasms; Carcinoid Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms, Plasma Cell; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",France; Spain; United Kingdom; United States
Phase I Clinical Trial of Ixabepilone and Pemetrexed in Advanced Solid Tumors,I,Terminated,USC/Norris Comprehensive Cancer Center and Hospital,"Oncology: Breast; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Prostate",Advanced; Second line; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms",United States
"A Phase I Study To Assess The Tolerability, Pharmacokinetics and Clinical Activity of Rigosertib Administered Orally as Escalating Multiple Doses Twice or Three Times a Day up to 21 Days of a 21-Day Cycle in Patients With Advanced Cancer",I,Completed,Onconova Therapeutics,Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: GIST; Oncology: Head/Neck; Oncology: Liver; Oncology: Melanoma; Oncology: Ovarian; Oncology: Renal,Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Unspecified; Wilms Tumor",United States
A Phase I/II Clinical Study of BBI608 in Adult Patients With Advanced Malignancies.,I,Completed,Sumitomo Dainippon Pharma {Dainippon Sumitomo}/Sumitomo Dainippon Pharma Oncology {Boston Biomedical},"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Multiple Myeloma; Oncology: Ovarian; Oncology: Unspecified Solid Tumor",Aggressive; Indolent; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Multiple Myeloma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Stomach Carcinoma; Stomach Neoplasms",Canada; United States
A Phase I Safety and Immunogenicity Trial of MVA-BN-HER2 Vaccine in Locally Advanced and Advanced HER2+ Breast Cancer (GENE TRANSFER PROTOCOL).,I,Terminated,"Stanford University Medical Center
Bavarian Nordic/BN ImmunoTherapeutics",Oncology: Breast,HER2 positive; Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms,United States
A Phase I Study of RO4929097 (NSC749225) in Combination With Capecitabine in Refractory Solid Tumors.,I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Colorectal; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's",Aggressive; Classical; HER2 negative; Indolent; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV,"Breast Neoplasms; Breast Neoplasms, Male; Burkitt Lymphoma; Colonic Neoplasms; Colorectal Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Immunoblastic Lymphadenopathy; Intraocular Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, T-Cell; Leukemia-Lymphoma, Adult T-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphomatoid Granulomatosis; Lymphoproliferative Disorders; Mycoses; Mycosis Fungoides; Neoplasms; Rectal Neoplasms; Sezary Syndrome; Syndrome; Waldenstrom Macroglobulinemia",Canada; United States
"Dose Escalation, Safety and Pharmacokinetic, First in Man Study, of SAR566658 Administered as a Single Agent by Intravenous Infusion in Adult Patients With CA6-Positive and Refractory Solid Tumors",I,Completed,Sanofi {Sanofi-Aventis},"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas",(N/A); Second line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",France; Spain; United States
"A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Anastrozole 1 mg Tablets Under Fed Conditions",I,Completed,Hikma Pharmaceuticals {Hikma Labs {Boehringer Ingelheim/Roxane Laboratories}},Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
Phase I Clinical Trial of Temsirolimus and Vinorelbine in Advanced Solid Tumors.,I,Completed,"University of Southern California
Pfizer {Wyeth}","Oncology: Bladder; Oncology: Breast; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal",Second line; Stage III; Stage IV,"Breast Neoplasms; Breast Neoplasms, Male; Carcinoid Tumor; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Islet Cell; Carcinoma, Medullary; Carcinoma, Merkel Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carotid Body Tumor; Endometrial Neoplasms; Gastrointestinal Neoplasms; Germinoma; Kidney Neoplasms; Lung Neoplasms; Malignant Carcinoid Syndrome; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neoplasms, Glandular and Epithelial; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Paraganglioma; Pheochromocytoma; Prostatic Neoplasms; Renal Cancer; Sarcoma; Skin Neoplasms; Small Cell Lung Carcinoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Anastrozole 1 mg Tablets Under Fasting Conditions",I,Completed,Hikma Pharmaceuticals {Hikma Labs {Boehringer Ingelheim/Roxane Laboratories}},Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
Phase I Study of ABT-888 in Combination With Gemcitabine in Patients With Advanced Malignancies,I,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Prostate,BRCA; First line; Hormone refractory; Second line; Stage III; Stage IV,Breast Neoplasms; Prostatic Neoplasms; Unspecified,United States
A Phase I Study of Bendamustine and Bevacizumab for Patients With Advanced Cancers.,I,Completed,"MD Anderson Cancer Center, University of Texas
Teva {Cephalon}
National Comprehensive Cancer Network","Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Cancer",Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Neoplasms",United States
"A Phase I Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Given by Intravenous Infusion to Patients With Advanced or Metastatic Cancer",I,Completed,"(Other Hospital/Academic/Medical Center)
Pfizer {BIND Therapeutics {BIND Biosciences}}","Oncology: Anal; Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Vulvar",Fourth line or greater; Hormone refractory; Pulmonary; Second line; Stage II; Stage III; Stage IV; Third line,"Anus Neoplasms; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gallbladder Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasm Metastasis; Neoplasms; Neoplasms, Mesothelial; Neoplasms, Second Primary; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Vulvar Neoplasms; Wilms Tumor",United States
A Phase I Dose Escalation Trial of RO4929097 Administered in Combination With Exemestane in Pre- and Postmenopausal Patients With ER + Metastatic Breast Cancer,I/II,Terminated,National Institutes of Health/National Cancer Institute,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Breast Neoplasms, Male; Carcinoma",United States
Phase II Trial of Single Agent ABT-888 With Post-Progression Therapy of ABT-888 in Combination With Carboplatin in Patients With Stage IV BRCA-Associated Breast Cancer,I/II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,BRCA; Estrogen receptor positive; Fourth line or greater; HER2 positive; Progesterone receptor positive; Second line; Stage IV; Third line,Breast Neoplasms; Carcinoma,Canada; United States
"Phase I Study of ABT-888, PARP Inhibitor, and Pegylated Liposomal Doxorubicin (PLD) in Recurrent Gynecologic Cancer and Breast Cancer",I,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal,BRCA; HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Breast Neoplasms, Male; Carcinoma; Fallopian Tube Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Triple Negative Breast Neoplasms",United States
"A Phase Ib, Open-label, Multi-center, Dose-escalation Study of Oral BKM120 in Combination With Oral GSK1120212 in Adult Patients With Selected Advanced Solid Tumors",I,Completed,"GlaxoSmithKline
Novartis","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas",BRAF; First line; HER2 negative; KRAS; Second line; Stage II; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms",Belgium; Canada; Spain; Switzerland; United States
"A Phase IA, Multicenter, Open-label Dose Escalation Study of Oral BYL719, in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene",I,Completed,Novartis,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",Estrogen receptor positive; HER2 negative; HER2 positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Germany; Netherlands; Spain; United Kingdom; United States
A Phase I Study of LY2624587 in Patients With Advanced Cancer.,I,Completed,Eli Lilly,"Oncology: Breast; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Prostate",Aggressive; Classical; Hormone refractory; Indolent; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV,"Breast Neoplasms; Chronic Lymphocytic Leukemia; Hodgkin Disease; Hodgkin Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasm Metastasis; Prostatic Neoplasms",United States
Phase I evaluation of an 18-day outpatient IL-2 infusion following AC+t adjuvant chemotherapy of loco-regionally advanced breast cancer (BrCA).,I,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Adjuvant; Maintenance/Consolidation; Stage IV,Breast Neoplasms,United States
"A Phase I, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 780 in Adult Subjects With Advanced Solid Tumors",I,Terminated,Amgen,Oncology: Breast; Oncology: Prostate,Hormone refractory; Second line; Stage III; Stage IV,Breast Neoplasms; Neoplasms; Prostatic Neoplasms,United States
"Phase I Study of the Hsp90 Inhibitor, AT13387, in Adults With Refractory Solid Tumors.",I,Completed,"National Institutes of Health/National Cancer Institute
Otsuka Holdings/Otsuka Pharmaceutical/Astex Pharmaceuticals {Astex Therapeutics}",Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Soft Tissue Sarcoma,Metastatic; Second line; Stage III; Stage IV; Unresectable,Breast Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma,United States
A Phase I Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination,I,Completed,Sun Pharma Advanced Research,Oncology: Anal; Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Testicular,Merkel; Second line; Stage II; Stage III; Stage IV,"Anus Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Neuroendocrine Tumors; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",United States
"A Phase I, Open-label, Dose Escalation Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors",I,Completed,Amgen {Onyx Pharmaceuticals},"Oncology: Breast; Oncology: CNS, Medulloblastoma; Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",(N/A); Locally advanced; Merkel; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Medulloblastoma; Melanoma; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Wilms Tumor",United States
A Phase I/II Study of Intravenous Rexin-G and Reximmune-C For Cancer Immunotherapy: The GeneVieve Protocol.,I/II,Completed,Epeius Biotechnologies,"Oncology: Breast; Oncology: Colorectal; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Aggressive; First line; Indolent; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",Philippines; United States
Phase I Study of the Poly (ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors.,I,Completed,Eisai,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Melanoma; Oncology: Ovarian; Oncology: Renal",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Wilms Tumor",United States
A Phase I Dose-escalation Study of NKTR-102 in Combination with Infusional 5-FU and Leucovorin in Patients with Gastrointestinal Cancers and Other Solid Tumors,I,Completed,Nektar Therapeutics,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma",United States
Phase I Study of mTOR Inhibitor RAD001 in Combination With IGF-1R Inhibitor AMG479 for Patients With Advanced Solid Tumors,I,Completed,"Amgen
Novartis
Indiana University School of Medicine","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian",Metastatic; Second line; Stage IV; Unspecified,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasm Metastasis; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms",United States
"A Phase I Open-Label, Dose-Escalation Study of Veliparib in Combination With Bimonthly FOLFIRI in Subjects With Advanced Solid Tumors",I,Completed,AbbVie {Abbott},Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Ovarian; Oncology: Pancreas,Second line; Stage II; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms,South Korea; United States
"A Phase I Study of anti-OX40 in Patients with Advanced Solid Tumors (e.g. Breast cancer, Colon cancer, Melanoma, Prostate cancer) Refractory to Standard Treatments.",I,Completed,National Institutes of Health,Oncology: Breast; Oncology: Colorectal; Oncology: Melanoma; Oncology: Prostate,Second line; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Melanoma; Prostatic Neoplasms,United States
"A Phase I, Open-label, Non-randomized, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors.",I,Completed,Otsuka Holdings/Otsuka Pharmaceutical/Otsuka Beijing Research Institute,"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas",EGFR; Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Melanoma; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Unspecified",China; Japan; Singapore; United States
"Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer",I/II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal,BRCA; Fourth line or greater; HER2 negative; Second line; Stage IV; Third line; Triple receptor negative,"Adenocarcinoma; Adenocarcinoma, Papillary; Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Fallopian Tube Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Triple Negative Breast Neoplasms",United States
"A Phase Ib Open Label, Expansion Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver Tumors and Non-Small Cell Lung Cancer.",I,Completed,Curis,"Oncology: Breast; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell",First line; Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
A Study to Evaluate Fully Serotype 3 Oncolytic Adenovirus Ad3-hTERT-E1A in the Treatment of Advanced Solid Tumors,I,Completed,Circio {Targovax {Oncos Therapeutics}},"Oncology: Bladder; Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",Finland; Germany; Switzerland; United States
"A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795",I,Completed,GlaxoSmithKline,"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Thyroid",BRAF; HER2 negative; KRAS; Recurrent; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Thyroid Neoplasms; Unspecified",United States
A Phase I/II Trial of Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer,I/II,Completed,"Pfizer
Puma Biotechnology",Oncology: Breast,First line; Fourth line or greater; HER2 negative; HER2 positive; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,"Denmark; France; Hong Kong, S.A.R., China; Spain; United Kingdom; United States"
Enhancing Efficacy of Chemotherapy in Triple Negative/Basal-Like Breast Cancer by Targeting Macrophages: A Multicenter Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer,I/II,Completed,"University of California, San Francisco
Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}
Daiichi Sankyo/Plexxikon",Oncology: Breast,HER2 negative; HER2 positive; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,United States
Phase I Study of ABT-888 in Combination with Cisplatin and Vinorelbine for Patients with Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer,I,Completed,"National Institutes of Health/National Cancer Institute
University of Washington",Oncology: Breast,BRCA; First line; Fourth line or greater; HER2 negative; Second line; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Breast Neoplasms, Male; Ovarian Neoplasms; Triple Negative Breast Neoplasms",United States
"A Phase I, Dose-finding Study of Single Agent EPO906 (Epothilone B) Administered Weekly to
Adult Patients with Advanced Solid Tumors",I,Completed,Novartis,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Ovarian",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Ovarian Cancer; Ovarian Neoplasms",Canada; United States
A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Induced Hypertension,I,Terminated,"National Institutes of Health/National Cancer Institute
Vanderbilt-Ingram Cancer Center","Oncology: Breast; Oncology: Colorectal; Oncology: Fallopian Tube; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Primary Peritoneal",First line; Stage I; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Lung Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms",United States
"MM-111-02-12-02: A Phase I Study of MM-111 in Combination With Herceptin in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Breast Cancer",I/II,Completed,Merrimack Pharmaceuticals,Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase I, Open label, Oral, Single-dose, Escalating, Randomized, Parallel study to Evaluate Safety, Tolerability and Pharmacokinetics of Endoxifen and Tamoxifen in Healthy Adult Human Male and Female Subjects Under Fasting Conditions.",I,Completed,"(Other Industry Sponsor)
Intas Pharmaceuticals/Jina Pharmaceuticals",Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,India; United States
"A Phase I, Dose Escalation Study of MGAH22 in Patients With Refractory HER2 Positive Breast Cancer and Patients With Other HER2 Positive Carcinomas for Whom No Standard Therapy Is Available",I,Completed,"National Institutes of Health/National Cancer Institute
MacroGenics
GC Biopharma Corp. {GC Pharma {Green Cross Corp.}}","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",HER2 positive; Hormone refractory; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",South Korea; United States
"Randomized Phase II Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase I Portion in Patients With Ovarian or Breast Cancer",I/II,Completed,Takeda/Takeda Oncology {Millennium},Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal,Fourth line or greater; Second line; Stage III; Stage IV; Third line,Breast Neoplasms; Carcinoma; Fallopian Tube Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms,France; Poland; United States
A Phase I Trial of Sirolimus or Everolimus or Temsirolimus (mTOR Inhibitor) and Vorinostat (Histone Deacetylase Inhibitor) in Patients With Advanced Cancer,I,Closed,"MD Anderson Cancer Center, University of Texas","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid; Oncology: Unspecified Cancer",Classical; Fourth line or greater; Locally advanced; Metastatic; Pediatric or Adolescent; Second line; Stage III; Stage IV; Third line; Unspecified,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A Phase I/II trial of Lu-AMBA in patients with Hormone Resistant Prostate cancer, Metastatic Breast Cancer and Non-Small Cell Lung Cancer.",I/II,Terminated,Marillion Pharmaceuticals,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Prostate",Line of therapy N/A; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Prostatic Neoplasms",United States
Phase I Trial of Ixabepilone and Vorinostat in Metastatic Breast Cancer,I,Completed,City of Hope Comprehensive Cancer Center,Oncology: Breast,Fourth line or greater; HER2 positive; Second line; Stage IV; Third line,"Breast Neoplasms; Breast Neoplasms, Male",United States
A Phase I/II Dose-Escalation Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Hormone Receptor-Positive and HER2-Negative Breast Cancer Refractory to a Nonsteroidal Aromatase Inhibitor,I/II,Completed,"Exelixis
Sanofi {Sanofi-Aventis}",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,France; Spain; United States
"A Phase I Study of Anti-CD3 x Cetuximab-Armed Activated T Cells, Low Dose IL-2, and GM-CSF for EGFR-Positive, Advanced Solid Tumors",I,Terminated,Roger Williams Medical Center,Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal,Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasm Metastasis; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",United States
A Phase l Study of LY2606368 in Patients with Advanced Cancer,I,Completed,Eli Lilly,"Oncology: Anal; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate",Fourth line or greater; Hormone refractory; Second line; Squamous Cell; Stage III; Stage IV; Third line,"Anus Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms",United States
Phase I Dose-Finding Trial of Letrozole in Postmenopausal Women at High Risk for Breast Cancer,I,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,(N/A); Line of therapy N/A,"Breast Neoplasms; Carcinoma in Situ; Carcinoma, Lobular",United States
A Phase I Study of the Hedgehog Smoothened Antagonist GDC-0449 (NSC # 747691) Plus Pan-Notch Inhibitor RO4929097 (NSC # 749225) Administered in Patients With Advanced Breast Cancer,I,Terminated,National Institutes of Health/National Cancer Institute,Oncology: Breast,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma,United States
"A Double-blind Randomised, Parallel Phase I/IIb Study to Evaluate Initial Safety and Efficacy, Comparative Pharmacokinetics and Immunogenicity for CT-P6 and Herceptin in Metastatic Breast Cancer.",I/II,Completed,Celltrion,Oncology: Breast,First line; HER2 positive; Stage IV,Breast Neoplasms,"Bulgaria; Latvia; Lithuania; Philippines; Russia; Serbia; South Korea; Taiwan, China; Ukraine; United Kingdom; United States"
"Plasma and Cerebrospinal Fluid Pharmacokinetics of Topotecan in a Phase I Trial of Topotecan, Tamoxifen, and Carboplatin, in the Treatment of Recurrent or Refractory Brain or Spinal Cord Tumors",I,Completed,GlaxoSmithKline {SmithKline Beecham},"Oncology: Breast; Oncology: CNS, Astrocytoma; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine",(N/A); Grade 3; Pulmonary; Second line; Stage IV,"Astrocytoma; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Glioblastoma; Medulloblastoma; Neuroendocrine Tumors; Small Cell Lung Carcinoma",United States
"A Phase I, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of ABC294640 in Patients With Advanced Solid Tumors",I,Completed,"National Institutes of Health/National Cancer Institute
FDA Office of Orphan Products Development
Medical University of South Carolina
RedHill Biopharma
Apogee Biotechnology","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal",Second line; Stage II; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Phase I/II Study of an Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancers,I/II,Completed,"Hadassah Medical Organization
Immunovative Therapies","Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Aggressive; Classical; First line; Indolent; Nodular lymphocyte-predominant; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Wilms Tumor",Israel; United States
A Phase I Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors,I,Completed,AbbVie {Abbott},"Oncology: Breast; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate; Oncology: Skin, Basal Cell Carcinoma",BRCA; First line; Fourth line or greater; Maintenance/Consolidation; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Liver Cancer; Liver Neoplasms; Neoplasms; Neoplasms, Basal Cell; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms",United States
Phase I Trial of Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer,I,Completed,Gradalis,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gallbladder; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Extensive; First line; Locally advanced; Metastatic; Pediatric or Adolescent; Pulmonary; Second line; Stage III; Stage IV; Third line; Unresectable; Untreated,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cholangiocarcinoma; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Gallbladder Neoplasms; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Phase I, Single-institution Open Label, Dose-escalation Trial With an Expansion Trial Cohort Evaluating the Safety and Tolerability of AZD6244 and IMCA12 in Subjects With Advanced Solid Malignancies",I,Completed,"AstraZeneca
National Institutes of Health/National Cancer Institute","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Osteosarcoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Skin, Basal Cell Carcinoma; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",BRAF; Hormone refractory; Locally advanced; Metastatic; Recurrent; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Basal Cell; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neoplasms, Basal Cell; Osteosarcoma; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
Phase I Study of Pazopanib in Combination with Vinorelbine in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) and Breast Cancer,I,Terminated,"Robert H. Lurie Comprehensive Cancer Center at Northwestern University
Northwestern University","Oncology: Breast; Oncology: Lung, Non-Small Cell",First line; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms",United States
A Phase I Study of Hepatic Arterial Infusion (HAI) of Abraxane in Combination With Gemcitabine and Bevacizumab for Patients With Advanced Cancers Metastatic to the Liver.,I,Completed,"MD Anderson Cancer Center, University of Texas",Oncology: Breast; Oncology: Metastatic Cancer; Oncology: Pancreas; Oncology: Unspecified Cancer,Fourth line or greater; Liver mets; Second line; Stage IV; Third line,Breast Neoplasms; Liver Neoplasms; Neoplasm Metastasis; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms,United States
"Evaluation of the Safety, Pharmacokinetics and Efficacy of Four Doses of YN968D1 in Subjects With Solid Tumors",I/II,Completed,"Bukwang Pharmaceutical
Elevar Therapeutics {LSK BioPharma {LSK BioPartners}}","Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: GIST; Oncology: Lung, Non-Small Cell; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Renal; Oncology: Soft Tissue Sarcoma",(N/A); HER2 negative; Second line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Ewing Sarcoma; Fibrosarcoma; Gastrointestinal Stromal Tumors; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Unspecified; Wilms Tumor",South Korea; United States
A Phase IB Combination Study of MEK Inhibitor GSK1120212 With Gemcitabine in Subjects With Solid Tumors,I,Completed,GlaxoSmithKline,"Oncology: Bladder; Oncology: Breast; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas",(N/A); First line; HER2 negative; Metastatic; Pulmonary; Second line; Stage II; Stage III; Stage IV; Triple receptor negative; Untreated,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Endometrial Neoplasms; Head and Neck Neoplasms; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Liver Cancer; Liver Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
A Protocol for the Safety and Tolerance of Intravenous 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer,I,Completed,"National Institutes of Health/National Cancer Institute
Dekk-Tec","Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma",Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Glioblastoma; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Medulloblastoma; Melanoma; Neoplasms; Osteosarcoma; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",France; United States
Clinical Study of Limonene in Women With a Recent Diagnosis of Early Stage Breast Cancer Electing to Undergo Excision Surgery,I,Completed,"National Institutes of Health/National Cancer Institute
University of Arizona",Oncology: Breast,Estrogen receptor positive; Neoadjuvant; Stage 0; Stage I; Stage II,Breast Neoplasms,United States
"A Phase I Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematological Malignancies, Followed by a Phase II of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies",I/II,Completed,Takeda/Takeda Oncology {Millennium},"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",Estrogen receptor positive; Extensive; First line; HER2 negative; HER2 positive; Locally advanced; Metastatic; Progesterone receptor positive; Pulmonary; Second line; Squamous Cell; Stage II; Stage III; Stage IV; Third line; Triple receptor negative; Untreated,"Adenocarcinoma; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Lung Neoplasms; Neoplasms; Neuroendocrine Tumors; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma",Czech Republic; France; Poland; United States
A Phase I/II Study of XL147 (SAR245408) Administered in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-Based Regimen.,I/II,Terminated,Sanofi {Sanofi-Aventis},Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,France; Spain; United States
A Phase l/ll Study of Ad.p53 DC Vaccine in Combination With 1-methyl-D-tryptophan in Metastatic Solid Tumors and Invasive Breast Cancer,I/II,Completed,"National Institutes of Health/National Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
Lumos Pharma {NewLink Genetics}","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; Metastatic; Second line; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Breast Neoplasms, Male; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma",United States
A Phase I Study Of A CDK 4/6 Dual Inhibitor In Patients With Advanced Cancer,I,Completed,Eli Lilly,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Ovarian",Aggressive; Classical; Estrogen receptor positive; Fourth line or greater; HER2 positive; Indolent; KRAS; Nodular lymphocyte-predominant; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Glioblastoma; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms",United States
"A Phase Ib/II, Open Label, Multi-center Study Evaluating the Safety and Efficacy of BKM120 in Combination With Trastuzumab in Patients With Relapsing HER2 Overexpressing Breast Cancer Who Have Previously Failed Trastuzumab",I/II,Terminated,Novartis,Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,Belgium; Canada; France; Italy; Spain; Switzerland; United Kingdom; United States
Phase I/II Trial of Amrubicin as Second- or Third-Line Treatment for Patients With HER2-Negative Metastatic Breast Cancer,I/II,Completed,Bristol-Myers Squibb/Celgene,Oncology: Breast,HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
"A Phase Ib/II Study of Cisplatin, Paclitaxel, and RAD001 in Patients With Metastatic Breast Cancer",I/II,Completed,"National Institutes of Health/National Cancer Institute
Vanderbilt-Ingram Cancer Center",Oncology: Breast,Fourth line or greater; HER2 negative; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
"A Phase I, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered ATI-1123, a Liposomal Docetaxel Formulation, on an Every 3 Week Schedule, in Patients With Advanced Solid Tumors.",I,Completed,Plus Therapeutics {Cytori Therapeutics {Azaya Therapeutics}},"Oncology: Bladder; Oncology: Breast; Oncology: Endometrial; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Thyroid",Hormone refractory; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Phase I Study of Two Different Doses of the Subcutaneous Administration of an Immunotherapeutic Vaccine, DPX-0907 in Advanced Stage Patients with Ovarian, Breast or Prostate Cancer",I,Completed,IMV Inc. {IImmunovaccine {ImmunoVaccine Technologies}},Oncology: Breast; Oncology: Ovarian; Oncology: Prostate,Hormone refractory; Second line; Stage III; Stage IV,Breast Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms,United States
Preventing Invasive Breast Neoplasia With Chloroquine (PINC) Trial,I/II,Completed,"(Other Cooperative Group)
University of Pittsburgh
US Department of Defense
(Other Hospital/Academic/Medical Center)
U.S. Army Medical Research and Materiel Command
(Other government agency)",Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage 0,"Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Intraductal, Noninfiltrating",United States
"Tanespimycin pharmacokinetics: Results of a randomized
dose-escalation crossover phase 1 study of two formulations.",I,Completed,Bristol-Myers Squibb,"Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell",(N/A); Line of therapy N/A,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms",United States
"Phase I Trial of Intratumoral Administration of HF10, A Replication Competent Herpes Simplex Virus Type 1, in Patients with Refractory Head and Neck Cancer or Solid Tumors with Cutaneous and/or Superficial Lesions",I,Completed,Takara Bio,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Skin, Basal Cell Carcinoma; Oncology: Soft Tissue Sarcoma",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms, Basal Cell; Osteosarcoma; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",Japan; United States
"A Phase I, Open-label, Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of INCB028060 in Subjects With Advanced Malignancies",I/II,Completed,"Novartis
Incyte Corporation","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasm Metastasis; Neoplasms; Neoplasms, Unknown Primary; Prostatic Neoplasms",United States
ABT-888 as Monotherapy and in Combination With Mitomycin C in Patients With Solid Tumors With Deficiency in Homologous Recombination Repair,I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate; Oncology: Small Intestine; Oncology: Thymus",BRCA; Distal; Extensive; Hormone refractory; Pulmonary; Second line; Stage III; Stage IV; Thymoma,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Intestinal Neoplasms; Neoplasms; Neoplasms, Second Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Recurrence; Small Cell Lung Carcinoma; Thymoma; Thymus Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
A Phase I-II Study of Gemcitabine and Vinorelbine in Metastatic Breast Cancer Patients Who are Heavily Pretreated with Chemotherapy,I/II,Completed,"MD Anderson Cancer Center, University of Texas",Oncology: Breast,Estrogen receptor positive; Second line; Stage IV,Breast Neoplasms,United States
Phase I Study of Pazopanib and Ixabepilone in Patients With Solid Tumors,I,Completed,"GlaxoSmithKline
University of Minnesota Cancer Center","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Soft Tissue Sarcoma",Extensive; Fourth line or greater; Localized; Metastatic; Pulmonary; Second line; Stage II; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Gallbladder Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Neoplasms; Neoplasms, Basal Cell; Neuroendocrine Tumors; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",United States
"A Phase I Dose Ranging, Pharmacokinetic Study of Tesetaxel for the Treatment of Cancer.",I,Completed,Genta,Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Prostate; Oncology: Renal,Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",United States
"A Phase I/II Trial of ABT-888, an Inhibitor of Poly(ADP-Ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase I) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase II) After Prior Platinum Containing First-Line Chemotherapy",I/II,Completed,"National Institutes of Health/National Cancer Institute
Mayo Clinic Cancer Center",Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Unspecified Solid Tumor,BRCA; First line; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma; Fallopian Tube Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms",Canada; United States
"Molecular Signature of Valproic Acid in Breast Cancer With Functional Imaging Assessment - a Pilot

Valproic Acid Signature Trial (VAST)",I,Terminated,University of Utah,Oncology: Breast,HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
Phase I/II Study of PX-866 and Docetaxel in Patients with  Solid Tumors,I/II,Completed,Seagen {Seattle Genetics/Cascadian Therapeutics {Oncothyreon {Biomira}}},"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",Fourth line or greater; Hormone refractory; KRAS; Pulmonary; Second line; Stage II; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Melanoma; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",Canada; Russia; United States
Phase I/II Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer,I/II,Terminated,"Memorial Sloan-Kettering Cancer Center
Alaunos Therapeutics {Ziopharm Oncology}",Oncology: Breast,Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,Spain; United States
"A Parallel Arms Phase l Safety, Pharmacokinetic And Pharmacodynamic Study Of The Intravenous Poly (ADP-Ribose) Polymerase (PARP) Inhibitor PF-01367338 (AG-014699) In Combination With Several Chemotherapeutic Regimens In Adult Patients With Advanced Solid Tumor",I,Completed,"Pfizer
Clovis Oncology","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Ovarian",First line; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Ovarian Cancer; Ovarian Neoplasms; Unspecified",France; Ireland; Italy; United Kingdom; United States
A Phase I/II Trial of Short Course Pre-Operative Ritonavir To Determine Akt Inhibition in Breast Cancer,I/II,Completed,"University of Minnesota Cancer Center
Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}",Oncology: Breast,(N/A); Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Triple receptor negative,Breast Neoplasms,United States
A Phase I Study of LY2801653 in Patients with Advanced Cancer,I,Completed,Eli Lilly,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Prostate; Oncology: Unspecified Solid Tumor",Aggressive; Distal; First line; Hilar; Hormone refractory; Indolent; Intrahepatic; Second line; Squamous Cell; Stage II; Stage III; Stage IV; Unresectable,"Bile Duct Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms, Unknown Primary; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Uterine Cervical Neoplasms",United States
"A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies",I,Completed,Novartis,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Renal",FGFR; Second line; Squamous Cell; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Kidney Neoplasms; Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor","Australia; Austria; Belgium; Canada; France; Germany; Israel; Italy; Netherlands; Singapore; South Korea; Spain; Taiwan, China; Thailand; Turkey; United States"
"Phase I Study of Combined Temosirolimus, Erlotinib and Cisplatin in Advanced Solid Tumors",I,Completed,"National Institutes of Health
Columbia University Medical Center
Pfizer {Wyeth}
Roche/Genentech",Oncology: Breast,Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients with Triple Negative Metastatic Breast Cancer,I/II,Completed,"National Institutes of Health/National Cancer Institute
Cancer Trials Support Unit - CTSU/NCI
Alliance for Clinical Trials in Oncology",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"An Open-label, Randomized, Adaptive Design, Two-period Crossover Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib Compared to the Commercial Tablet",I,Completed,GlaxoSmithKline,Oncology: Breast; Oncology: Unspecified Solid Tumor,HER2 negative; HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms, Unknown Primary",United States
A Phase I Study of PKI-179 Administered Orally to Subjects With Solid Tumors,I,Terminated,Pfizer {Wyeth},"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Ovarian",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Glioblastoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms",United States
Pilot Study Evaluating the Expression of ERB-B4 After Treatment with HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer.,I,Terminated,"Novartis
Tulane Cancer Center
(Other government agency)",Oncology: Breast,Estrogen receptor positive; Line of therapy N/A; Stage IV,Breast Neoplasms,United States
Pre-Surgical Trial of Metformin in Patients With Operable Breast Cancer,I,Terminated,"National Institutes of Health/National Cancer Institute
Vanderbilt-Ingram Cancer Center",Oncology: Breast,Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Phase I, Open-label, Study of the Safety and Tolerability of Cyclosporine A (CsA) in Combination With Nab-paclitaxel in Patients With Metastatic Breast Cancer.",I,Completed,"(Other Cooperative Group)
Northwestern University",Oncology: Breast,First line; Second line; Stage IV,Breast Neoplasms,United States
A Multi-arm Phase I Trial of Hepatic Arterial Infusion of Irinotecan with 1) Systemic Bevacizumab 2) Systemic Bevacizumab and Oxaliplatin 3) Systemic Bevacizumab and Cetuximab in Patients with Advanced Cancers Metastatic to the Liver,I,Completed,"MD Anderson Cancer Center, University of Texas","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer; Oncology: Neuroendocrine; Oncology: Pancreas",Fourth line or greater; Liver mets; Metastatic; Second line; Stage IV; Third line; Unspecified,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Liver Neoplasms; Neoplasm Metastasis; Neoplasms; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms",United States
"A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD4547 in Patients With Advanced Solid Malignancies",I,Terminated,AstraZeneca,"Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Prostate",Adenocarcinoma; FGFR; Hormone refractory; Second line; Squamous Cell; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Cancer; Esophageal Neoplasms; Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",France; Germany; Italy; Netherlands; Spain; United Kingdom; United States
Phase I Safety and Tolerability Study of Figitumumab Combined with Pegvisomant in Patients with Advanced Solid Tumors,I,Terminated,Pfizer,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",Pediatric or Adolescent; Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Lung Neoplasms; Neoplasms; Neuroendocrine Tumors; Osteosarcoma; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",Canada; Finland; Germany; United States
"Phase I Randomized, Placebo-Controlled, Cross-Over, Dose-Finding Pharmacokinetic Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer",I,Completed,Columbia University Medical Center,Oncology: Breast,Adjuvant; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Phase I Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX3397 in Patients with Advanced, Incurable, Solid Tumors in which the Target Kinases Are Linked to Disease Pathophysiology",I,Completed,Daiichi Sankyo/Plexxikon,"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: GIST; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Tenosynovial Giant Cell Tumor; Oncology: Thyroid",Anaplastic; Classical; Diffuse; Hormone refractory; Locally advanced; Metastatic; Nodular lymphocyte-predominant; Recurrent; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Ewing Sarcoma; Fibrosarcoma; Gastrointestinal Stromal Tumors; Giant Cell Tumor of Tendon Sheath; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Liposarcoma; Neoplasms; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Synovitis, Pigmented Villonodular; Thyroid Neoplasms",United States
"An Open Label, Single-Arm, Dose-Escalation Phase I Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors",I,Completed,Inspyr Therapeutics {GenSpera},"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal",First line; Hormone refractory; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Pilot Study of Androgen Receptor as a Target for the Treatment of ER-/PR-/AR + Breast Cancer,I,Terminated,"Barbara Ann Karmanos Cancer Institute
National Institutes of Health/National Cancer Institute",Oncology: Breast,HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
"A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK2126458 in Subjects with Solid Tumors or Lymphoma.",I,Completed,GlaxoSmithKline,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Pancreas; Oncology: Renal",(N/A); Aggressive; Classical; Indolent; Nodular lymphocyte-predominant; Second line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Netherlands; United States
177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Nonprostate Metastatic Solid Tumors: A Pilot Study,I,Completed,Weill Medical College of Cornell University,"Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase I Investigation of the Combination of MK2206, Trastuzumab and Lapatinib in HER2+ Solid Tumors",I,Terminated,Merck & Co./Merck Sharp & Dohme (MSD),Oncology: Breast; Oncology: Esophageal; Oncology: Gastric,Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Stomach Carcinoma; Stomach Neoplasms,United States
"An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Maximum Tolerated Dose and Biomarker Response After Intravenous Administration of Weekly BAY80-6946 to Patients With Advanced Cancer",I,Completed,Bayer AG/Bayer Pharmaceuticals,"Oncology: Bladder; Oncology: Breast; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Aggressive; Diffuse large B-cell lymphoma (DLBCL); Follicular lymphoma (FL); Fourth line or greater; HER2 negative; Indolent; KRAS; Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase I/II, Open-label Study of Bosutinib Administered in Combination with Capecitabine in Subjects with Solid Tumor and ErbB2 Negative Locally Advanced or Metastatic Breast Cancer",I/II,Terminated,Pfizer {Wyeth},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Pancreas",Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line,Bile Duct Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Cholangiocarcinoma; Colorectal Neoplasms; Glioblastoma; Pancreatic Cancer; Pancreatic Neoplasms,"Australia; Belgium; France; Hong Kong, S.A.R., China; Hungary; Spain; United Kingdom; United States"
"A Phase I, Open-label, Dose Escalation, Non-randomized Study to Assess the Pharmacokinetics, Dose Limiting Toxicity, and Maximum Tolerated Dose of OPB-31121 in Subjects With Advanced Solid Tumors",I,Completed,"MD Anderson Cancer Center, University of Texas
Otsuka Holdings/Otsuka Pharmaceutical/Otsuka Pharmaceutical Development & Commercialization {Otsuka/Otsuka Maryland Research Institute}",Oncology: Breast; Oncology: Colorectal; Oncology: Thyroid,Second line; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Neoplasms; Thyroid Neoplasms,United States
"An Open-Label, Dose-Escalation, Phase IB/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination With Oral Everolimus in Subjects With Solid Tumors",I/II,Completed,GlaxoSmithKline,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas",First line; KRAS; Second line; Squamous Cell; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Melanoma; Pancreatic Cancer; Pancreatic Neoplasms; Unspecified",Germany; Spain; United States
"A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of MNRP1685A, a Human IgG1 Antibody, in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors",I,Completed,Roche/Genentech,Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid,Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV; Third line,Breast Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Unspecified,United States
A Dose-Escalation Study to Evaluate the Safety and Tolerability of SCH 717454 in Combination With Different Treatment Regimens in Subjects With Advanced Solid Tumors (Phase 1B/II; Protocol No. P04722),I/II,Terminated,Merck & Co./Merck Sharp & Dohme (MSD),"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Renal",HER2 positive; Line of therapy N/A; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",Austria; Netherlands; Norway; United Kingdom; United States
"A Monocentric, Open-label Phase I/II Study to Assess dHER2+AS15 Cancer Immunotherapeutic Given in Combination With Lapatinib to Patients With ErbB2 Overexpressing Metastatic Breast Cancer Refractory to Trastuzumab",I/II,Completed,"GlaxoSmithKline
Duke University Medical Center
US Department of Defense",Oncology: Breast,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
A Molecular Pharmacodynamic Dose-titration Trial of Conjugated Linoleic Acid (CLA; Clarinol) in Patients with Advanced Solid Tumors,I,Terminated,"National Institutes of Health/National Cancer Institute
Dartmouth-Hitchcock Medical Center",Oncology: Breast; Oncology: Colorectal; Oncology: Melanoma,Second line; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Melanoma; Neoplasms,United States
"A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of PI3-Kinase Inhibitor GDC-0941 (Pictilisib) in Combination with Paclitaxel, with and Without Bevacizumab or Trastuzumab, and with Letrozole in Patients with Locally Recurrent Or Metastatic Breast Cancer",I,Completed,Roche/Genentech,Oncology: Breast,Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,Belgium; Italy; United States
"A Phase Ib, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors",I,Terminated,"Exelixis
Roche/Genentech","Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: GIST; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",BRAF; KRAS; Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gastrointestinal Stromal Tumors; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms",United States
"A Phase Ib-IIa, Open-label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of Trastuzumab Emtansine, Paclitaxel and Pertuzumab Administered Intravenously to Patients With Her2-positive, Locally Advanced or Metastatic Breast Cancer",I/II,Completed,Roche/Genentech,Oncology: Breast,Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"Phase I Trial of Everolimus, Gemcitabine, and Cisplatin for Patients With Solid Tumors Refractory to Standard Therapy",I,Completed,"Novartis
National Institutes of Health/National Cancer Institute
Mayo Clinic",Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Gallbladder; Oncology: Pancreas; Oncology: Primary Peritoneal,Distal; First line; Second line; Stage III; Stage IV; Unresectable,Bile Duct Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Cholangiocarcinoma; Gallbladder Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms,United States
Green Tea Supplement in Women with Incident Breast Cancer,I,Completed,"(Other Cooperative Group)
USC/Norris Comprehensive Cancer Center and Hospital",Oncology: Breast,Adjuvant; Neoadjuvant; Stage 0; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase I/II, Open-Label, Dose-Escalation Study of CDX-1401 in Patients with Advanced Malignancies Known to Express NY-ESO-1",I/II,Completed,Celldex Therapeutics {AVANT Immunotherapeutics {Medarex/Celldex Therapeutics {Alteris Therapeutics}}},"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Multiple Myeloma; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Cancer",Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Melanoma; Multiple Myeloma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Phase I, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Advanced Malignant Solid Tumors",I,Completed,Sanofi {Sanofi-Aventis}/Sanofi Genzyme {Genzyme},"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Prostate",(N/A); Hormone refractory; Pulmonary; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Neoplasms; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma",United States
A Phase I Study Of PF-05212384 (Also Known as PKI-587) Administered As An Intravenous Infusion To Subjects With Solid Tumors.,I,Completed,"(Other Cooperative Group)
Pfizer
(Other Hospital/Academic/Medical Center)
(Other government agency)","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Small Intestine; Oncology: Soft Tissue Sarcoma",Localized; Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Glioblastoma; Head and Neck Neoplasms; Intestinal Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Spain; United Kingdom; United States
A Phase I Study of AZD2171 and WBRT in Patients With Brain Metastases,I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Renal",CNS mets; Second line; Stage IV,"Brain Neoplasms; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Kidney Neoplasms; Lung Neoplasms; Melanoma; Neoplasm Metastasis; Rectal Neoplasms; Renal Cancer; Wilms Tumor",United States
Phase I study of prolonged-infusion gemcitabine combined with cyclophosphamide in patients with metastatic carcinoma of the breast: tolerability of an optimal dose schedule.,I,Completed,"MD Anderson Cancer Center, University of Texas",Oncology: Breast,Line of therapy N/A; Stage IV,Breast Neoplasms,United States
Short-Term Fasting Prior To Platinum-based Chemotherapy: Feasibility and Impact on Toxicity,I/II,Closed,University of Southern California,"Oncology: Bladder; Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Renal; Oncology: Unspecified Solid Tumor",Adjuvant; Neoadjuvant; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Kidney Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"An Open-label, Multi-center Study of the Safety and Tolerability of the Combination of Trastuzumab-MCC-DM1 (T-DM1) With Docetaxel, and Potentially Pertuzumab, for Treatment for Patients With Advanced Breast Cancer",I/II,Completed,Roche {F. Hoffmann-La Roche},Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III; Stage IV,Breast Neoplasms,France; Spain; United Kingdom; United States
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Advanced or Metastatic Breast Cancer. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG),I/II,Terminated,"Novartis
National Institutes of Health/National Cancer Institute
(Other Hospital/Academic/Medical Center)",Oncology: Breast,First line; HER2 negative; Stage III; Stage IV,Breast Neoplasms,United States
The Impact of Obesity and Obesity Treatments on Breast Cancer: A Phase I/II Trial of Exemestane With Metformin and Rosiglitazone for Postmenopausal Obese Women With ER+ Metastatic Breast Cancer,I/II,Completed,"MD Anderson Cancer Center, University of Texas
Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
"Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial",I,Completed,"Novartis
New York University
US Department of Defense
U.S. Army Medical Research and Materiel Command","Oncology: Breast; Oncology: Skin, Basal Cell Carcinoma",(N/A); Line of therapy N/A,"Breast Neoplasms; Carcinoma in Situ; Carcinoma, Basal Cell; Carcinoma, Lobular; Hyperplasia; Neoplasms, Basal Cell",United States
"Phase I, Open Label, Dose-Escalation, Safety, Pharmacokinetic And Pharmacodynamic Study Of Single Agent PF-03758309, An Oral PAK4 Inhibitor, In Patients With Advanced Solid Tumors.",I,Terminated,Pfizer,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Osteosarcoma; Oncology: Pancreas",Metastatic; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Ewing Sarcoma; Neoplasms; Osteosarcoma; Pancreatic Cancer; Pancreatic Neoplasms",Australia; United States
A Phase Ib study of S-222611 Her2/EGFR dual inhibitor (Oral) in malignant tumors.,I,Completed,Shionogi,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal",EGFR; HER2 positive; Hormone refractory; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",United Kingdom; United States
"Phase I Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer",I,Terminated,"Bristol-Myers Squibb/Celgene
University of Utah",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
Phase I/II Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer.,I/II,Completed,Bristol-Myers Squibb,Oncology: Breast,HER2 negative; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"A Phase Ib, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer.",I,Completed,"National Institutes of Health/National Cancer Institute
Roche/Genentech",Oncology: Breast; Oncology: Unspecified Solid Tumor,HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms, Unknown Primary; Unspecified",United States
"A Phase Ib, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Activity of Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy",I,Completed,Roche/Genentech,Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase I, Open-Label, Dose-Escalation Study To Evaluate Safety, Pharmacokinetics, And Pharmacodynamics Of The PI3K/MTOR Inhibitor PF-04691502 In Adult Patients With Advanced Malignant Solid Tumors",I,Completed,Pfizer,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Small Intestine; Oncology: Soft Tissue Sarcoma",HER2 positive; Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Intestinal Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Unspecified; Wilms Tumor",United States
"A Dose-Escalation Study Of The Safety, Tolerability, And Pharmacokinetics Of Cabazitaxel In Combination With Cisplatin Administered Every 3 Weeks In Subjects With Advanced Solid Malignancies",I,Completed,Sanofi {Sanofi-Aventis},"Oncology: Breast; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",Hormone refractory; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Liver Cancer; Liver Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Unspecified",United States
A Randomized Trial of HER-2/Neu Pulsed DC1 Vaccine for Patients With DCIS,I/II,Completed,"(Other Cooperative Group)
National Institutes of Health/National Cancer Institute
University of Pennsylvania",Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Stage 0,Breast Neoplasms,United States
"A Phase I, Open-Label, Two-Stage Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oral AKT Inhibitor GSK2141795 in Subjects With Solid Tumors or Lymphomas.",I,Completed,GlaxoSmithKline,"Oncology: Anal; Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Thyroid",Aggressive; Classical; Hormone refractory; Indolent; Locally advanced; Metastatic; Nodular lymphocyte-predominant; Second line; Stage II; Stage III; Stage IV,"Anus Neoplasms; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Thyroid Neoplasms; Unspecified",Canada; United States
"A Phase I and Pharmacologic Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers",I,Completed,Merrimack Pharmaceuticals,Oncology: Breast; Oncology: Gastric,Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms; Stomach Carcinoma; Stomach Neoplasms,United States
A Phase I Study of Oral MK2206 in Combination With Oral AZD6244 in Patients With Locally Advanced or Metastatic Solid Tumors.,I,Completed,"AstraZeneca
Merck & Co./Merck Sharp & Dohme (MSD)","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",BRAF; KRAS; Locally advanced; Metastatic; Recurrent; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms",United Kingdom; United States
"A Phase I Open Label, Single Site, Safety and Efficacy Study of the Effects of Autologous Natural Killer and Natural Killer T Cell Immunotherapy on Malignant Disease.",I,Completed,(Other Hospital/Academic/Medical Center),"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Prostate",Second line; Squamous Cell; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Glioblastoma; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms",United States
"Phase I trial of weekly docetaxel, weekly doxorubicin, daily oral cyclophosphamide, and G-CSF (ConTAC Regimen)in advanced malignancies.",I,Completed,Cleveland Clinic Taussig Cancer Center,"Oncology: Breast; Oncology: Lung, Non-Small Cell",Line of therapy N/A; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung",United States
"A Phase I Dose-Escalation Study of LY2495655, an Anti-Myostatin Monoclonal Antibody, in Patients with Advanced Cancer",I,Completed,Eli Lilly,Oncology: Breast; Oncology: Prostate; Oncology: Supportive Care; Oncology: Unspecified Cancer,Cachexia; Second line; Stage III; Stage IV,Breast Neoplasms; Cachexia; Neoplasms; Palliative Care; Prostatic Neoplasms,United States
A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients,I/II,Terminated,Cornerstone Pharmaceuticals {Rafael Pharmaceuticals {Cornerstone Pharmaceuticals}},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Thyroid",First line; Fourth line or greater; Second line; Stage II; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gallbladder Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
Metabotropic Glutamate Receptor-1 (mGluR1): Validation of a Serendipitously Discovered Molecular Target for Breast Cancer Treatment.,I,Terminated,"Barbara Ann Karmanos Cancer Institute
National Institutes of Health/National Cancer Institute",Oncology: Breast,Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Study of Resistance Mechanisms Against Lapatinib in Patients With ErbB-2-Positive Breast Cancers.,I,Terminated,"National Institutes of Health/National Cancer Institute
Case Western Reserve University",Oncology: Breast,HER2 positive; Line of therapy N/A; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
A Phase I Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors.,I,Completed,Cyclacel,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",BRCA; HER2 negative; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
"A Phase I-II, Randomization, Open-Label Clinical Trial of Fulvestrant Versus the Combination of Fulvestrant, MK-0646, and Dasatinib as First-Line Therapy for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer",I/II,Terminated,"Bristol-Myers Squibb
(Other Cooperative Group)
MD Anderson Cancer Center, University of Texas
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,First line; HER2 negative; Stage IV,Breast Neoplasms,United States
"A Phase I Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Acetamide) in Adult Patients With Advanced or Recurrent Solid Tumors or Lymphoma, for Which No Standard Therapy Is Available",I,Completed,Arno Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Aggressive; Classical; First line; Indolent; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United Kingdom; United States
The Effect of Enalapril on Doxorubicin Exposure in Adjuvant Breast Cancer Treatment,I,Completed,University of Minnesota Cancer Center,Oncology: Breast,(N/A); Adjuvant,Breast Neoplasms,United States
Evaluation of CD8+ T Cell Activation and Infiltration Into Primary Breast Tumors Following Administration of a Peptide Vaccine,I,Completed,"National Institutes of Health
University of Virginia",Oncology: Breast,Line of therapy N/A; Stage I; Stage II,Breast Neoplasms,United States
"A Phase I Study of Chronically-Dosed, Single-Agent ABT-888 in Patients With Either BRCA 1/2 -Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer",I,Completed,"(Other Cooperative Group)
National Institutes of Health/National Cancer Institute
AbbVie {Abbott}",Oncology: Breast; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal,BRCA; HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Endometrial Neoplasms; Fallopian Tube Neoplasms; Hereditary Breast and Ovarian Cancer Syndrome; Kidney Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Renal Cancer; Triple Negative Breast Neoplasms; Wilms Tumor",United States
A Phase I Study of R-(-)-Gossypol (Ascenta's AT-101) in Combination With Paclitaxel and Carboplatin in Solid Tumors,I,Terminated,National Institutes of Health/National Cancer Institute,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Prostate",Aggressive; First line; Indolent; Second line; Stage IV,"Breast Neoplasms; Burkitt Lymphoma; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Peripheral; Lymphomatoid Granulomatosis; Melanoma; Neoplasms; Prostatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Waldenstrom Macroglobulinemia",United States
Administration of Her2 Chimeric Receptor and TGFbeta Dominant Negative Receptor (DNR) Expressing EBV Specific Lymphocytes for Subjects With Advanced Her2 Positive Malignancy (HERCREEM),I,Completed,"Baylor College of Medicine
(Other Hospital/Academic/Medical Center)","Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Prostate",HER2 positive; Pediatric or Adolescent; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Glioblastoma; Head and Neck Neoplasms; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
"A Phase IA, Multicenter, Open-label, Dose Escalation Study of BKM120, Administered Orally in Adult Patients With Advanced Solid Malignancies.",I,Completed,"Novartis
Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}","Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Small Intestine; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Estrogen receptor positive; Fourth line or greater; HER2 negative; Hormone refractory; KRAS; Locally advanced; Metastatic; Recurrent; Stage II; Stage III; Stage IV; Triple receptor negative; Unresectable,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Glioblastoma; Head and Neck Neoplasms; Intestinal Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Wilms Tumor",Canada; Netherlands; Spain; United States
Phase I/II Trial of Neoadjuvant Sunitinib Administered With Weekly Paclitaxel/Carboplatin in Patients With Locally Advanced Triple-Negative Breast Cancer,I/II,Completed,"(Other Cooperative Group)
Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}
Pfizer",Oncology: Breast,HER2 negative; Maintenance/Consolidation; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Phase I Safety and Pharmacokinetic Study of ABT-263 in Combination with Taxotere (Docetaxel) in the Treatment of Subjects with Solid Tumors,I,Completed,"AbbVie {Abbott}
Roche/Genentech","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Thymus",(N/A); Second line; Thymoma,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thymoma; Thymus Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms",Netherlands; United Kingdom; United States
"A Phase I, Multi-center, Open-label, Dose-escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of EP-100 Given Intravenously 3 Out of 4 Weeks in Subjects With Advanced Solid Tumors.",I,Completed,Esperance Pharmaceuticals,Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate,Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Colorectal Neoplasms; Endometrial Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms",United States
A Phase I Study of Single Agent LY2584702 in Patients with Advanced or Metastatic Cancer.,I,Terminated,Eli Lilly,Oncology: Breast; Oncology: Prostate,Second line; Stage III; Stage IV,Breast Neoplasms; Neoplasms; Prostatic Neoplasms,United States
"A Phase Ib Study of Autologous Vaccination With Lethally Irradiated, Autologous Breast Cancer Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete GM-CSF Following Preoperative Chemotherapy in Women With Operable Breast Cancer",I,Completed,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Brigham and Womens Hospital",Oncology: Breast,HER2 positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
"A Phase I, Multicenter, Open-Label, Dose-Escalation Study of Oral LDE225 in Patients With Advanced Solid Tumors.",I,Completed,Novartis,"Oncology: Breast; Oncology: CNS, Medulloblastoma; Oncology: Lung, Non-Small Cell; Oncology: Osteosarcoma; Oncology: Pancreas; Oncology: Skin, Basal Cell Carcinoma",Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung; Ewing Sarcoma; Medulloblastoma; Neoplasms, Basal Cell; Osteosarcoma; Pancreatic Cancer; Pancreatic Neoplasms",Spain; Switzerland; United Kingdom; United States
Phase I Study of Bendamustine With Concurrent Whole Brain Radiation Therapy in Patients With Brain Metastases From Solid Tumors,I,Terminated,"H. Lee Moffitt Cancer Center and Research Institute
Teva {Cephalon}
National Comprehensive Cancer Network","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer",CNS mets; Line of therapy N/A; Stage IV,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Melanoma; Neoplasm Metastasis",United States
A Phase I Trial of Panobinostat (LBH589) and Epirubicin in Patients With Solid Tumor Malignancies.,I,Completed,"Novartis
National Institutes of Health/National Cancer Institute
University of California, San Francisco","Oncology: Breast; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Testicular",First line; Fourth line or greater; Second line; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Colorectal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms",United States
Phase I Trial of the Combination of GDC-0449 and Erlotinib + or - Gemcitabine,I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Thymus",First line; Second line; Stage III; Stage IV; Thymoma,"Breast Neoplasms; Carcinoma; Carcinoma, Acinar Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Liver Cancer; Liver Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Thymoma; Thymus Neoplasms",United States
A Phase I Dose Escalation Study of ARQ 197 Administered in Combination With Gemcitabine in Adult Patients With Advanced Solid Tumors,I,Completed,Merck & Co. {ArQule},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Endometrial; Oncology: Gallbladder; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas",Adenocarcinoma; First line; Fourth line or greater; Second line; Squamous Cell; Stage II; Stage III; Stage IV; Third line; Unresectable; Untreated,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Endometrial Neoplasms; Gallbladder Neoplasms; Head and Neck Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms",United States
Phase I Study of MCP-3100 in Patients With Refractory or Relapsed Cancer.,I,Completed,Myrexis {Myriad Pharmaceuticals {Myriad Genetics}},"Oncology: Breast; Oncology: Colorectal; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Liver; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",Aggressive; Classical; First line; Fourth line or greater; Indolent; Metastatic; Nodular lymphocyte-predominant; Second line; Stage IV; Third line,"Acute Myelocytic Leukemia; Breast Neoplasms; Carcinoma, Hepatocellular; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Colorectal Neoplasms; Fibrosarcoma; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified",United States
"A Phase I study of SQ LY2510924 in Patients with Solid Tumors, Lymphomas and Chronic Leukemia Lymphocytic Leukemia",I,Completed,Eli Lilly,"Oncology: Bladder; Oncology: Breast; Oncology: CNS, Medulloblastoma; Oncology: Colorectal; Oncology: Endometrial; Oncology: GIST; Oncology: Head/Neck; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Mesothelioma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Aggressive; Classical; Hormone refractory; Indolent; Locally advanced; Metastatic; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Chronic Lymphocytic Leukemia; Colorectal Neoplasms; Endometrial Neoplasms; Ewing Sarcoma; Fibrosarcoma; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Leukemia, Lymphocytic, Chronic, B-Cell; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Medulloblastoma; Mesothelioma; Neoplasms, Mesothelial; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Phase I Trial Of PF-03084014 In Patients With Advanced Solid Tumor Malignancy And T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma,I,Terminated,Pfizer,"Oncology: Breast; Oncology: Colorectal; Oncology: Leukemia, Acute Lymphocytic; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Aggressive; First line; HER2 negative; Lymphoblastic lymphoma (LBL); Second line; Stage III; Stage IV; T-cell; Triple receptor negative; Untreated,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Leukemia; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms by Histologic Type; Pancreatic Cancer; Pancreatic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Wilms Tumor",Italy; United States
"Open Label Phase I Study to Evaluate the Safety and Tolerability of Vaccine (GI-6207) Consisting of Whole, Heat-Killed Recombinant Saccharomyces Cerevisiae Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-Expressing Carcinoma",I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Thyroid",Second line; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Prostatic Neoplasms; Thyroid Neoplasms",United States
A Phase I Dose-Escalation Study of the Safety and Clinical Effects of ON 01910.Na in Combination With Either Irinotecan or Oxaliplatin in Patients With Advanced Solid Tumors.,I,Completed,Onconova Therapeutics,Oncology: Breast; Oncology: Colorectal; Oncology: Ovarian; Oncology: Renal,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Unspecified; Wilms Tumor",United States
"A Phase I , Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612, NSC 281612) in Advanced Malignancies",I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Prostate; Oncology: Renal",Aggressive; Classical; Indolent; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Colonic Neoplasms; Colorectal Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Prostatic Neoplasms; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
Dose Escalating Study of Yttrium 90 Microspheres (TheraSphere) With Capecitabine (Xeloda) for Intrahepatic Cholangiocarcinoma or Metastatic Disease to the Liver,I,Completed,"Northwestern University
Serb Specialty Pharmaceuticals/BTG Specialty Pharmaceuticals {Boston Scientific/BTG {Biocompatibles}}",Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Metastatic Cancer,First line; Intrahepatic; Liver mets; Second line; Stage IV,Bile Duct Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Cholangiocarcinoma; Colorectal Neoplasms; Liver Neoplasms; Neoplasm Metastasis,United States
Phase I/II Study of a Therapeutic Cancer Vacccine Created In-situ in Patients With Refractory or Metastatic Cancer,I/II,Completed,Immunovative Therapies,"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal",Aggressive; Classical; Indolent; Nodular lymphocyte-predominant; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Second Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",United States
Phase Ib Trial of HER2/Neu Peptide (E75) Vaccine in Node Negative Breast Cancer Patients.,I/II,Completed,"(Other Academic Cancer Center)
(Other Hospital/Academic/Medical Center)
Walter Reed Army Institute of Research - WRAIR
SELLAS Life Sciences Group {Galena Biopharma {RXi Pharmaceuticals {Apthera}}}",Oncology: Breast,First line; HER2 positive; Stage I; Stage II,Breast Neoplasms,United States
"A Phase I, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects With Advanced Solid Tumors.",I,Completed,Amgen,"Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Soft Tissue Sarcoma; Oncology: Testicular; Oncology: Unspecified Solid Tumor",HER2 negative; Hormone refractory; Locally advanced; Metastatic; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fallopian Tube Neoplasms; Fibrosarcoma; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Medulloblastoma; Melanoma; Neoplasms; Neoplasms, Basal Cell; Neoplasms, Unknown Primary; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Australia; United States
"An Open-label, Phase I, Dose-escalation Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors and Non-hodgkin's Lymphoma",I,Completed,Roche/Genentech,"Oncology: Breast; Oncology: Colorectal; Oncology: GIST; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Advanced; Aggressive; Indolent; Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",France; Italy; United Kingdom; United States
"A Phase I, Multi-Center, Open-Label, Dose Escalation Study of I-131-CLR1404 in Subjects With Relapsed or Refractory Advanced Solid Malignancies",I,Completed,Cellectar Biosciences {Novelos {Cellectar}},"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",HER2 negative; Hormone refractory; Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Glioblastoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Medulloblastoma; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Unspecified; Wilms Tumor",United States
"A Phase I, Multi-Center, Open-Label, Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors Who Have Failed Standard Therapy or for Whom No Standard Therapy Exists",I,Completed,Cellectar Biosciences {Novelos {Cellectar}},"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Glioblastoma; Kidney Neoplasms; Medulloblastoma; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Wilms Tumor",United States
"A Targeted Ph I/II Trial of ZD6474 (Vandetanib; CAPRELSA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Ca (MTC)",I/II,Terminated,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",First line; Hormone refractory; Locally advanced; Medullary; Metastatic; Recurrent; Second line; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Neuroendocrine Tumors; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Diseases; Thyroid Neoplasms; Wilms Tumor",United States
Phase I Trial of Adenoviral Vector Delivery of the Human Interleukin-12 cDNA by Intratumoral Injection in Patents With Metastatic Breast Cancer,I,Completed,Icahn School of Medicine at Mount Sinai {Mount Sinai School of Medicine},Oncology: Breast,First line; Second line; Stage IV,Breast Neoplasms,United States
"An Open-Label, Two-Part, Single Sequence Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2",I,Completed,GlaxoSmithKline,Oncology: Breast,First line; HER2 positive; Second line; Stage IV,Breast Neoplasms,South Korea; Spain; United States
A Phase I/II Safety and Immunogenicity Trial of MVA-BN-HER2 Vaccine in HER-2-Positive Breast Cancer Patients Following Adjuvant Therapy,I/II,Completed,Bavarian Nordic/BN ImmunoTherapeutics,Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
A Phase I Dose Escalation Study of MK-2206 in Combination With Standard Doses of Selected Chemotherapies or Targeted Agents in Patients With Locally Advanced or Metastatic Solid Tumors,I,Completed,Merck & Co./Merck Sharp & Dohme (MSD),"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",(N/A); Advanced; Hormone refractory; Locally advanced; Metastatic; Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Neuroendocrine Tumors; Osteosarcoma; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Canada; United Kingdom; United States
A Phase I and Pharmacokinetic Study of a Novel Oral Taxane BAY 59-8862 in Solid Tumors,I,Completed,"Spectrum Pharmaceuticals
Bayer AG",Oncology: Breast; Oncology: Colorectal; Oncology: Pancreas; Oncology: Renal,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Wilms Tumor",Canada; United States
"A Phase I Open Label, First-in-Human, Pharmacokinetic (PK), Combination After Single Agent (CASA) Dose-Escalation Study of EZN-3042 in Patients with Solid Tumors and Lymphomas.",I,Completed,Enzon,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Mesothelioma; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Thymus; Oncology: Unspecified Cancer",Advanced; Aggressive; Classical; Fourth line or greater; Indolent; Locally advanced; Metastatic; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV; Third line; Thymic carcinoma,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fibrosarcoma; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thymus Neoplasms",United States
"A Phase I, Open Label, Dose Escalation Study Evaluating the Safety and Pharmacokinetics of Enteric Coated D-3263 Hydrochloride in Subjects With Advanced Solid Tumors",I,Completed,Dendreon {Bausch Health Companies {Valeant Pharmaceuticals {Dendreon}}},"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
A Phase I/Randomized Phase II Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer,I/II,Completed,Eli Lilly,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Aggressive; First line; Indolent; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Mesothelioma; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Germany; Italy; Netherlands; Poland; Romania; Spain; United States
Pharmacodynamic Study of Axitinib in Patients With Advanced Solid Malignancies,I,Completed,"Pfizer
University of Wisconsin","Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",United States
Phase I Study of Bendamustine and Fractionated Stereotactic Radiotherapy of Patients With 1- 4 Brain Metastases From Solid Malignancies,I,Completed,National Comprehensive Cancer Network,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer",CNS mets; First line; Second line; Stage IV,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Melanoma; Neoplasm Metastasis",United States
A Phase I Study Of Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors,I,Completed,"Pfizer {Wyeth}
Puma Biotechnology","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Thymus; Oncology: Vulvar",First line; Fourth line or greater; HER2 positive; Second line; Stage II; Stage III; Stage IV; Third line; Thymoma,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Kidney Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Thymoma; Thymus Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Vulvar Neoplasms; Wilms Tumor",France; United States
Phase I/II Study of Bendamustine and Erlotinib for Metastatic or Locally Advanced Triple Negative Breast Cancer.,I/II,Terminated,"National Institutes of Health/National Cancer Institute
(Other Hospital/Academic/Medical Center)
National Comprehensive Cancer Network
Roche/Genentech",Oncology: Breast,First line; HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Phase I/II Vinorelbine and Sorafenib as Salvage Therapy in Metastatic Breast Cancer,I/II,Completed,"National Institutes of Health/National Cancer Institute
Bayer AG/Bayer Pharmaceuticals
City of Hope Comprehensive Cancer Center",Oncology: Breast,First line; Second line; Stage IV; Third line,Breast Neoplasms,United States
A Phase I Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors,I,Completed,"Merck & Co. {ArQule}
Daiichi Sankyo","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Prostate; Oncology: Renal",Advanced; First line; Localized; MET Amplification/Alteration; NRAS; Second line; Stage II; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Prostatic Neoplasms; Renal Cancer; Wilms Tumor",Italy; United States
Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer (MBC),I/II,Completed,"Bristol-Myers Squibb
Bayer AG/Bayer Pharmaceuticals",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage IV; Triple receptor negative,Breast Neoplasms,United States
An Open Label Study to Examine the Effects of Low-Fat and High-Fat Meals on the Pharmacokinetics of Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients,I,Completed,GlaxoSmithKline,Oncology: Breast,HER2 positive; Line of therapy N/A; Stage IV,Breast Neoplasms,Canada; Netherlands; United States
A Phase I-II Study of Dasatinib in Combination With Weekly Paclitaxel for Patients With Metastatic Breast Carcinoma,I/II,Terminated,"Bristol-Myers Squibb
Memorial Sloan-Kettering Cancer Center",Oncology: Breast,Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
Phase I Study of Vaccination With CpG 7909 and Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-Derived Peptides or the NY-ESO-1 Protein in Patients With NY-ESO-1-Expressing Tumors.,I,Completed,"National Institutes of Health/National Cancer Institute
University of Pittsburgh","Oncology: Bladder; Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Multiple Myeloma; Oncology: Ovarian; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",Estrogen receptor positive; Hormone refractory; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Multiple Myeloma; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Phase Ib/II Open Label, Dose Escalation Study of AMG 655 in Combination With AMG 479 in Subjects With Advanced, Refractory Solid Tumors",I/II,Terminated,"Amgen
NantWorks/ImmunityBio {NantCell}","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",Adenocarcinoma; Large Cell; Locally advanced; Metastatic; Second line; Squamous Cell; Stage II; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neoplasm Metastasis; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",Spain; United States
A Phase I Study of an Autologous GM-CSF-secreting Breast Cancer Vaccine.,I,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Line of therapy N/A; Stage IV,Breast Neoplasms,United States
"A Phase I, Multicenter, Open-label, Single-arm, Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573, a Fully Human Monoclonal Antibody Directed Against Insulin-like Growth Factors I and II, in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy Exists.",I,Completed,AstraZeneca {MedImmune},"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A Phase I, Multicenter, Open-label, Single-arm, Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, a Fully Human Monoclonal Antibody Directed Against Platelet-derived Growth Factor Receptor Alpha (PDGFRa), in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy Exists",I,Completed,AstraZeneca {MedImmune},"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",Fourth line or greater; Hormone refractory; Locally advanced; Metastatic; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Glioblastoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified",United States
"A Phase I, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients with Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma",I,Completed,Cylene Pharmaceuticals,"Autoimmune/Inflammation: Castleman Disease; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: GIST; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Multiple Myeloma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Testicular; Oncology: Thyroid",(N/A); Hormone refractory; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Castleman Disease; Colorectal Neoplasms; Endometrial Neoplasms; Gastrointestinal Stromal Tumors; Giant Lymph Node Hyperplasia; Head and Neck Neoplasms; Inflammatory Breast Neoplasms; Kidney Neoplasms; Melanoma; Multiple Myeloma; Neoplasms, Plasma Cell; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Testicular Cancer; Testicular Neoplasms; Thyroid Neoplasms; Wilms Tumor",United States
"A Phase I, First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 208 in Adult Subjects With Advanced Solid Tumors",I,Completed,Amgen,Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal,Hormone refractory; MET Amplification/Alteration; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",United States
Phase Ib Study To Evaluate The Safety Of Combining IGF-1R Antagonist R1507 With Multiple Standard Chemotherapy Drug Treatments In Patients With Advanced Malignancies.,I,Terminated,Roche {F. Hoffmann-La Roche},"Oncology: Breast; Oncology: Colorectal; Oncology: GIST; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma",First line; Fourth line or greater; Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Melanoma; Unspecified",United States
A Phase I Pharmacokinetic and Randomized Phase II Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer,I/II,Completed,"AstraZeneca
(Other Cooperative Group)
National Institutes of Health/National Cancer Institute
Stanford University Medical Center
Sylvester Cancer Center, University of Miami
National Institutes of Health",Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Second line; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
A Phase I Trial of Weekly and Every Three Weeks Ixabepilone and Sunitinib in Solid Tumor Patients.,I,Completed,"Bristol-Myers Squibb
Pfizer
Sylvester Cancer Center, University of Miami",Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Liver; Oncology: Osteosarcoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma,First line; Fourth line or greater; Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Neoplasms; Osteosarcoma; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Phase I Study of ABT-888 in Combination with Metronomic Cyclophosphamide in Adults With Refractory Solid Tumors and Lymphomas,I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Colorectal; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",(N/A); Aggressive; BRCA; Classical; HER2 negative; Indolent; Nodular lymphocyte-predominant; Second line; Triple receptor negative,"Breast Neoplasms; Chronic Lymphocytic Leukemia; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Liposarcoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
A Phase I Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies,I,Completed,Merck & Co. {ArQule},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",Aggressive; APL/M3; Blast phase; Classical; First line; Indolent; Metastatic; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV; Third line,"Acute Myelocytic Leukemia; Bile Duct Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Colorectal Neoplasms; Fibrosarcoma; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
A Phase Ib Study of AMG 479 With Biologics or Chemotherapy in Adult Subjects With Advanced Solid Tumors,I,Completed,Amgen,"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Prostate",Fourth line or greater; Hormone refractory; KRAS; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Prostatic Neoplasms",United States
An Open-Label Study of AMG 386 in Combination With Either Paclitaxel and Trastuzumab or Capecitabine and Lapatinib in Subjects With HER2-positive Locally Recurrent or Metastatic Breast Cancer,I,Completed,Amgen,Oncology: Breast,First line; HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms; Neoplasm Metastasis,Belgium; France; United States
A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Mammaglobin-A DNA Vaccine in Breast Cancer Patients with Metastatic Disease,I,Completed,"National Institutes of Health/National Cancer Institute
Washington University School of Medicine
US Department of Defense
(Other Hospital/Academic/Medical Center)",Oncology: Breast,Second line; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
Phase I/II Study of Metastatic Cancer That Expresses Her-2 Using Lymphodepleting Conditioning Followed by Infusion of Anti-Her-2 Gene Engineered Lymphocytes,I/II,Terminated,"National Institutes of Health/National Cancer Institute
Center for Cancer Research",Oncology: Breast; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage IV,"Breast Neoplasms; Neoplasm Metastasis; Neoplasms; Neoplasms, Second Primary; Neoplasms, Unknown Primary",United States
A Pilot Trial of Itraconazole Pharmacokinetics in Patients With Metastatic Breast Cancer,I,Completed,Indiana University School of Medicine,Oncology: Breast,HER2 positive; Line of therapy N/A; Stage IV,Breast Neoplasms; Neoplasm Metastasis; Neoplasms,United States
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors,I,Completed,Novartis,Oncology: Breast; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms, Unknown Primary",Canada; Netherlands; South Korea; Spain; United States
"A Phase I, Open-Label Study of MEDI-547 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Biologic Activity of Intravenous Administration in Subjects With Relapsed or Refractory Solid Tumors Associated With EphA2 Expression",I,Terminated,"National Institutes of Health/National Cancer Institute
AstraZeneca {MedImmune}","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Kidney Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Multicenter, Open-Label, Dose Escalation Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematologic Malignancies",I,Completed,Takeda/Takeda Oncology {Millennium},Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma,Advanced; Localized; Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
Clinical Study to Assess Entry of Chemotherapeutic Agents Into Brain Metastases in Women With Breast Cancer,I,Completed,"(Other Academic Cancer Center)
National Institutes of Health/National Cancer Institute
US Department of Defense",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; HER2 negative; HER2 positive; Second line; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
A Phase I/II Study of Aflibercept Administered in Combination with Pemetrexed and Cisplatin in Patients with Advanced Carcinoma,I/II,Terminated,"Regeneron
Sanofi {Sanofi-Aventis}","Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid; Oncology: Unspecified Cancer",Adenocarcinoma; Advanced; First line; Large Cell; Locally advanced; Maintenance/Consolidation; Metastatic; Second line; Stage II; Stage III; Stage IV; Untreated,"Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Wilms Tumor",Canada; United States
Phase I/II Study of Adoptive T Cell Therapy Following In Vivo Priming With a HER-2/Neu (HER2) Intracellular Domain (ICD) Peptide-Based Vaccine in Patients With Advanced Stage HER2 Overexpressing Breast Cancer,I/II,Completed,"National Institutes of Health/National Cancer Institute
Fred Hutchinson Cancer Research Center
University of Washington/Seattle Cancer Care Alliance
(Other Hospital/Academic/Medical Center)",Oncology: Breast,HER2 positive; Second line; Stage IV,"Breast Neoplasms; Breast Neoplasms, Male",United States
"A Phase Ib, Open-Label, Two Arm Study of i.v. and Oral Panobinostat (LBH589) in Combination With i.v. Trastuzumab (Herceptin) and i.v. Paclitaxel as Treatment for Adult Female Patients With HER2 Overexpressing Metastatic Breast Cancer (MBC)",I,Terminated,Novartis,Oncology: Breast,HER2 positive; Second line; Stage IV; Third line,Breast Neoplasms,Australia; Belgium; Italy; Netherlands; Russia; Sweden; United States
A Window Trial of Vorinostat in Patients With Ductal Carcinoma in Situ (DCIS) of the Breast,I,Completed,"Merck & Co.
National Institutes of Health/National Cancer Institute
University of California, San Francisco",Oncology: Breast,Neoadjuvant; Stage 0,"Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Intraductal, Noninfiltrating",United States
"Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas",I,Completed,PharmaMar {Zeltia/PharmaMar},"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",Aggressive; Classical; Nodular lymphocyte-predominant; Other subtype; Peripheral T-cell lymphoma (PTCL); Second line; Stage III; Stage IV,"Breast Neoplasms; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Liposarcoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",France; Italy; Spain; United States
"A Phase I, Open-Label, Dose Escalation Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of PF-04554878 in Patients with Advanced Non-Hematologic Malignancies.",I,Completed,Pfizer,"Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas",Fourth line or greater; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms",Canada; United States
"A Phase I Open Label, Multi Centre Study of AZD2281 Administered Orally in Combination With Cisplatin, to Assess the Safety and Tolerability in Patients With Advanced Solid Tumours",I,Completed,AstraZeneca,Oncology: Breast; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal,Fourth line or greater; Second line; Stage III; Stage IV; Third line,Breast Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms,Spain; United States
Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma,I,Completed,(Other Cooperative Group),"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Osteosarcoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Aggressive; Classical; First line; Indolent; Nodular lymphocyte-predominant; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Osteosarcoma; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Wilms Tumor",United States
Phase I Study of Erbitux (Cetuximab) in Patients with Advanced Cancer: Single Dose Effects on Epidermal Growth Factor Receptor (EGFR) in Normal Skin and Tumor Tissue Followed by Repeated Weekly Dosing and Safety Assessments.,I,Completed,Bristol-Myers Squibb,"Oncology: Anal; Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Small Intestine",Maintenance/Consolidation; Second line; Stage III; Stage IV,"Anus Neoplasms; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Intestinal Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
"Phase I Study of Erbitux (Cetuximab) in Patients with Advanced Cancer: A Detailed Characterization of Serum Pharmacokinetics, Safety, and Immunogenicity Following Single Doses and Repeated Weekly Administration.",I,Completed,Bristol-Myers Squibb,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate",Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cholangiocarcinoma; Colorectal Neoplasms; Head and Neck Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms",United States
A Phase I Study of Dasatinib in Combination With Bevacizumab in Advanced Solid Tumors,I,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: GIST; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Thyroid; Oncology: Unspecified Solid Tumor,Fourth line or greater; HER2 positive; Medullary; Metastatic; Pancreas; Second line; Stage II; Stage III; Stage IV; Third line; Unresectable,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Renal Cell; Endometrial Neoplasms; Gastrointestinal Stromal Tumors; Kidney Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Thyroid Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms; Wilms Tumor",United States
A Phase I/II Study of MGCD265 in Combination With Erlotinib or Docetaxel in Subjects With Advanced Malignancies and in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC),I/II,Terminated,Mirati Therapeutics {MethylGene},"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Thyroid",EGFR; Papillary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Medulloblastoma; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms; Wilms Tumor",United States
"A Phase Ib/II, Open-label Study of the Safety, Tolerability, and Efficacy of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab",I/II,Completed,Roche/Genentech,Oncology: Breast,First line; Fourth line or greater; HER2 positive; Stage III; Stage IV,Breast Neoplasms,Belgium; Canada; France; Germany; Italy; Spain; Switzerland; United States
"A Phase I, First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 820 in Adult Patients With Advanced Solid Tumors",I,Completed,LifeMax Healthcare International/AmMax Bio,Oncology: Anal; Oncology: Bladder; Oncology: Breast; Oncology: Neuroendocrine; Oncology: Prostate,First line; Hormone refractory; Other; Second line; Stage III; Stage IV,Anus Neoplasms; Breast Neoplasms; Neoplasms; Neuroendocrine Tumors; Prostatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms,United States
Phase I/II Study of Ixabepilone in Combination With the Autophagy Inhibitor Hydroxychloroquine for the Treatment of Patients With Metastatic Breast Cancer.,I/II,Terminated,"National Institutes of Health/National Cancer Institute
Cancer Institute of New Jersey",Oncology: Breast,HER2 negative; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,United States
Quantitative Real Time PCR in Formalin Fixed Breast Tissue From Biopsy and Re-Excision Specimens: An Ancillary Protocol to a Chemoprevention Trial of Celecoxib.,I,Completed,University of Kansas,Oncology: Breast,First line; Stage I; Stage II,Breast Neoplasms,United States
A Study to Establish Proof-of-Biology for MK0646 in Breast Cancer.,I,Completed,Merck & Co.,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,Belgium; Spain; United States
A Pilot Study of MK-0752 in Combination With Tamoxifen or Letrozole in Patients With Early Stage Breast Cancer Prior to Surgery.,I,Completed,"Merck & Co.
(Other Cooperative Group)
Loyola University",Oncology: Breast,Estrogen receptor positive; Neoadjuvant; Stage 0; Stage I; Stage II,Breast Neoplasms,United States
"A Phase I Investigation of the Safety, Tolerability and Immunogenicity of V934/V935 hTERT Vaccination in Cancer Patients with Selected Solid Tumors",I,Completed,Merck & Co./Merck Sharp & Dohme (MSD),"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal",First line; Second line; Stage I; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Phase I Study of MK-4827 in Patients With Advanced Solid Tumors or Hematologic Malignancies.,I,Completed,"Merck & Co./Merck Sharp & Dohme (MSD)
GlaxoSmithKline/Tesaro","Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",BRCA; Estrogen receptor positive; Fourth line or greater; HER2 negative; Hormone refractory; Locally advanced; Metastatic; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Chronic Lymphocytic Leukemia; Colorectal Neoplasms; Endometrial Neoplasms; Ewing Sarcoma; Fallopian Tube Neoplasms; Fibrosarcoma; Leiomyosarcoma; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Leukemia, Prolymphocytic; Leukemia, Prolymphocytic, T-Cell; Liposarcoma; Melanoma; Neoplasms; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United Kingdom; United States
A Phase I/II Clinical Trial of the Hypomethylating Agent Azacitidine (Vidaza) With the Nanoparticle Albumin Bound Paclitaxel (Abraxane) in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer,I/II,Completed,"Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}}
University of Utah","Oncology: Bladder; Oncology: Breast; Oncology: Endometrial; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",Aggressive; Classical; Diffuse large B-cell lymphoma (DLBCL); First line; Fourth line or greater; HER2 negative; Indolent; Locally advanced; Metastatic; Nodular lymphocyte-predominant; Small lymphocytic lymphoma (SLL); Stage II; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Chronic Lymphocytic Leukemia; Endometrial Neoplasms; Ewing Sarcoma; Fibrosarcoma; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Leukemia, Lymphocytic, Chronic, B-Cell; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
Phase I Dose-escalation Trial of ARRY-380 in Combination With Trastuzumab in Participants With Brain Metastases From HER2+ Breast Cancer.,I,Completed,"Seagen {Seattle Genetics/Cascadian Therapeutics {Oncothyreon {Biomira}}}
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Pfizer {Array BioPharma}
Breast Cancer Research Foundation",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; HER2 positive; Stage IV; Third line,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
"A Phase I Trial of Doxil, Bevacizumab and Temsirolimus",I,Completed,"MD Anderson Cancer Center, University of Texas",Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Ovarian; Oncology: Prostate; Oncology: Thymus; Oncology: Unspecified Solid Tumor,Adenocarcinoma; First line; Fourth line or greater; Second line; Squamous Cell; Stage III; Stage IV; Third line; Thymoma,"Breast Neoplasms; Carcinoma, Endometrioid; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Thymoma; Thymus Neoplasms; Unspecified; Uterine Cervical Neoplasms",United States
Phase I Study of Rubitecan and Gemcitabine in Patients with Advanced Malignancies.,I,Completed,"Otsuka Holdings/Otsuka Pharmaceutical/Astex Pharmaceuticals {SuperGen}
American Cancer Society","Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",United States
"A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of MNRP1685A, a Human IgG1 Antibody, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors",I,Completed,Roche/Genentech {Genentech},"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Small Intestine; Oncology: Soft Tissue Sarcoma",Advanced; Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Intestinal Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Unspecified; Wilms Tumor",United States
The Effect of Aromatase Inhibition on the Cognitive Function of Older Patients With Breast Cancer,I,Completed,"National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center",Oncology: Breast,Adjuvant; Estrogen receptor positive; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
A Phase I/II Study of the Combination of RDEA119 and Sorafenib in Patients With Advanced Cancer.,I/II,Completed,AstraZeneca/Ardea Biosciences {IntraBiotics},"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Small Intestine; Oncology: Thyroid",BRAF; KRAS; Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Intestinal Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Thyroid Neoplasms; Wilms Tumor",Canada; United States
Phase I Study of Disulfiram and Copper Gluconate for the Treatment of Refractory Solid Tumors Involving the Liver,I,Completed,University of Utah,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Pancreas; Oncology: Prostate",Fourth line or greater; Liver mets; Second line; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Unspecified",United States
A Phase I Dose Escalation Study of Oral SB939 When Administered Thrice Weekly (Every Other Day) for 3 Weeks in a 4-week Cycle in Patients With Advanced Malignancies,I,Completed,SBIO (The Singapore Economic Development Board Investments and Chiron joint venture),"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Liver; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome; Oncology: Myeloproliferative Neoplasms; Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Aggressive; Classical; Diffuse large B-cell lymphoma (DLBCL); First line; Fourth line or greater; High risk; Indolent; Int-1 risk; Int-2 risk; Locally advanced; Lymphoblastic lymphoma (LBL); Mantle cell lymphoma (MCL); Metastatic; Nodular lymphocyte-predominant; Other subtype; Peripheral T-cell lymphoma (PTCL); Post-transplant/ineligible; Primary Myelofibrosis; Second line; Stage III; Stage IV; Third line,"Acute Myelocytic Leukemia; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Colorectal Neoplasms; Endometrial Neoplasms; Ewing Sarcoma; Fibrosarcoma; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral; Multiple Myeloma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasms; Osteosarcoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Preleukemia; Primary Myelofibrosis; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Syndrome; Synovial Sarcoma; Thyroid Neoplasms",Singapore; United States
"Carboplatin (AUC 5) with oral vinorelbine (VNR) d 1,8 at 50 mg/m2 (level 1, L1) or 60 mg/m2 (level 2, L2) every 3 weeks: A Phase I Study in Patients with metastatic solid tumors.",I,Completed,New York University,Oncology: Breast; Oncology: Endometrial; Oncology: Prostate,Fourth line or greater; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Prostatic Neoplasms",United States
"A Phase I/II, Open-Label Study of Neratinib (HKI-272) in Combination with Capecitabine in Subjects with Solid Tumors and ErbB-2 Positive Metastatic or Locally Advanced Breast Cancer.",I/II,Completed,"(Other Industry Sponsor)
Pfizer {Wyeth}
Puma Biotechnology
Excella GmbH","Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Renal",First line; HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor","Australia; Brazil; China; Croatia; Hong Kong, S.A.R., China; Hungary; Russia; Singapore; South Korea; Spain; United States"
A Phase I Study of ABT-888 in Combination With Cyclophosphamide in Solid Tumors or Non-Hodgkin Lymphoma,I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Prostate; Oncology: Unspecified Solid Tumor",Aggressive; BRCA; Cutaneous T-cell lymphoma (CTCL); Diffuse large B-cell lymphoma (DLBCL); Estrogen receptor positive; Extranodal marginal zone B-cell lymphoma (MALT); Follicular lymphoma (FL); HER2 negative; HER2 positive; Hormone refractory; Indolent; Mantle cell lymphoma (MCL); Other subtype; Peripheral T-cell lymphoma (PTCL); Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative; Waldenstrom's macroglobulinemia (WM),"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Liver Cancer; Liver Neoplasms; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Waldenstrom Macroglobulinemia",United States
"A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer",I,Terminated,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
A Phase I Study of 1-methyl-D-tryptophan (D-1MT) in Patients With Relapsed or Refractory Solid Tumors,I,Completed,Lumos Pharma {NewLink Genetics},"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas",(N/A); Second line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms",United States
A Phase I Dose-escalation Study of OSI-906 and Erlotinib (Tarceva) in Patients With Advanced Solid Tumors.,I,Completed,Astellas Pharma {OSI Pharmaceuticals},"Oncology: Anal; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",Second line; Stage III; Stage IV,"Anus Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Unspecified",United Kingdom; United States
Phase I Trial of Hepatic Arterial Infusion of Abraxane With a Pharmacokinetic Study in Advanced Solid Cancer Patients With Predominant Hepatic Metastases,I,Completed,"MD Anderson Cancer Center, University of Texas
National Comprehensive Cancer Network",Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Liver; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma,First line; Hormone refractory; Liver mets; Metastatic; Second line; Stage IV; Unspecified,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Neuroendocrine Tumors; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Uterine Cervical Neoplasms",United States
"A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6918 Administered Daily as a Single Agent and in Combination Treatment in Adult Patients With Refractory Solid Malignancies",I,Terminated,AstraZeneca,"Oncology: Breast; Oncology: Colorectal; Oncology: Melanoma; Oncology: Skin, Basal Cell Carcinoma; Oncology: Soft Tissue Sarcoma",Metastatic; Second line; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Carcinoma, Basal Cell; Colorectal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Neoplasms, Basal Cell; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
"A Phase I Open-label Study of the Safety, Tolerability, and Pharmacokinetics of Two Schedules of Oral Topotecan in Combination With Pazopanib in Subjects With Advanced Solid Tumors",I,Completed,GlaxoSmithKline,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasms; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",Netherlands; South Korea; United States
A Phase I and Pharmocologic Study of MM-121 in Patients With Refractory Advanced Solid Tumors,I,Completed,"Merrimack Pharmaceuticals
Sanofi {Sanofi-Aventis}","Oncology: Breast; Oncology: Colorectal; Oncology: Fallopian Tube; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Primary Peritoneal",Estrogen receptor positive; HER2 negative; Maintenance/Consolidation; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fallopian Tube Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms",United States
"A Phase I, Open-Label, Dose-Finding Study to Assess the Safety and Tolerability of U3-1287 (AMG 888), a Human Monoclonal Antibody Targeting HER3 in Patients With Advanced Solid Tumors.",I,Completed,Daiichi Sankyo {U3 Pharma},"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",Fourth line or greater; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
A Phase I Study of Ridaforolimus (MK8669) and MK0646 in Patients With Advanced Cancer,I,Completed,"Takeda {Ariad}
Merck & Co./Merck Sharp & Dohme (MSD)","Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Cancer",Estrogen receptor positive; HER2 negative; HER2 positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified",Spain; United States
A phase I and pharmacokinetic study of the quinoxaline anti tumor Agent R(+)XK469 in patients with advanced solid tumours.,I,Completed,University of Chicago Cancer Research Center,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase I, Multidose Study of BMS-936559 (MDX-1105) Administered Every 14 Days in Subjects With Selected Advanced or Recurrent Solid Tumors",I,Completed,Bristol-Myers Squibb/Medarex,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal",Adenocarcinoma; Large Cell; Second line; Squamous Cell; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Wilms Tumor",United States
"Phase I Targeted Combination Trial of PF-00299804 And CP-751,871 in Patients with Advanced Solid Tumors",I,Completed,Pfizer,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasm Metastasis; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",France; Spain; United States
Phase Ib Study of Indibulin in Combination With Capecitabine in Advanced Solid Tumors.,I,Completed,Alaunos Therapeutics {Ziopharm Oncology},Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Prostate,Fourth line or greater; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Neoplasms; Prostatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms,United States
"Evaluation of the Use of Trastuzumab to Induce Increased ER Expression in ER-Negative/Low, Her-2/Neu Positive Breast Cancer.",I/II,Terminated,University of Michigan Comprehensive Cancer Center,Oncology: Breast,HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Phase I Study of AV-299 (Formerly SCH 900105) Administered by IV Infusion as Monotherapy in Advanced Solid Tumors, Lymphomas, or Multiple Myeloma or in Combination With Erlotinib in Advanced Solid Tumors",I,Completed,"Merck & Co. {Schering-Plough}
LG Chem/AVEO Oncology","Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Mesothelioma; Oncology: Multiple Myeloma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",(N/A); Aggressive; Classical; Indolent; Metastatic; Nodular lymphocyte-predominant; Post-transplant/ineligible; Stage I; Stage II; Stage III; Stage IV; Third line; Unresectable,"Breast Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Glioblastoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Mesothelioma; Multiple Myeloma; Neoplasms; Neoplasms, Mesothelial; Neoplasms, Plasma Cell; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Phase I Open-Label, Multiple Dose, Sequential Dose Escalation Study to Investigate the Safety and Pharmacokinetics of Intravenous CUDC-101 in Subjects with Advanced and Refractory Solid Tumors.",I,Completed,Curis,"Oncology: Breast; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Prostate",Fourth line or greater; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
"A Phase I, Dose Escalation Study of the Safety and Pharmacokinetics of ALB 109564(a) Administered Intravenously Every 3 weeks to Subjects with Advanced Solid Tumors.",I,Terminated,"Curia {AMRI {Albany Molecular Research}}
Westat","Oncology: Anal; Oncology: Breast; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV,"Anus Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Colorectal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Unspecified",United States
"Phase I/II, Open-label, Randomized Study Of The Safety, Efficacy, And Pharmacokinetics Of Letrozole Plus Pd 0332991 (Oral Cdk 4/6 Inhibitor) And Letrozole Single Agent For The First-line Treatment Of Er Positive, Her2 Negative Advanced Breast Cancer In Postmenopausal Women",I/II,Completed,Pfizer,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Stage III; Stage IV,Breast Neoplasms,Canada; France; Germany; Hungary; Ireland; Italy; Russia; South Africa; South Korea; Spain; Ukraine; United States
"A Dose-escalating and Phase II Clinical Trial of the Histone Deacetylase (HDAC) Inhibitor Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA, ZolinzaTM) in Combination With Capecitabine (XelodaTM) Using a New Weekly Dose Regimen for Advanced Breast Cancer",I,Completed,"Merck & Co.
Yale University",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
A Phase I Study of Ixabepilone Combined With Dasatinib in Patients With Solid Tumors.,I,Completed,"Bristol-Myers Squibb
Washington Hospital Center",Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Pancreas; Oncology: Renal,Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",United States
"A Multi-Center Phase I Evaluation of the Doublet MHC Class I and II HER2/neu Peptide Vaccines (GP2 and AE37, respectively) in HLA-A2+ or HLA-A3+ Patients with Intermediate- to High-Risk Breast or Ovarian Cancer",I,Completed,"(Other Hospital/Academic/Medical Center)
Generex Biotechnology/NuGenerex Immuno-Oncology {Antigen Express}",Oncology: Breast; Oncology: Ovarian,HER2 positive; Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms; Ovarian Cancer; Ovarian Neoplasms,United States
"A Phase Ib/IIa, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer.",I/II,Completed,LG Chem/AVEO Oncology,Oncology: Breast,First line; Fourth line or greater; HER2 negative; HER2 positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,Germany; United States
A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors.,I,Completed,ImmunoGen,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",First line; Metastatic; Second line; Stage IV; Unresectable,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Translational Breast Cancer Prevention Trial of Mushroom Powder in Postmenopausal Breast Cancer Survivors.,I,Completed,"National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center",Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
Phase I Dose Escalating Study of TAS-106 In Combination with Carboplatin in Patients with Solid Tumors,I,Completed,"MD Anderson Cancer Center, University of Texas
Otsuka Holdings/Taiho Pharmaceutical","Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Skin, Basal Cell Carcinoma",Fourth line or greater; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Neoplasms, Basal Cell; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Unspecified",United States
A Single Arm Open-Label Phase I Study of An Injectable Replication-Incompetent Adenoviral Vector Vaccine Used to Produce An Immune Response to MUC-1 Positive Epithelial Cancer Cells in Metastatic Breast Cancer.,I,Terminated,"National Institutes of Health/National Cancer Institute
University of California Los Angeles",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
"A Phase Ib Study to Assess the Safety Profile, Pharmacokinetics, and Anti-VEGF Activity of PTC299 in Patients With Advanced Cancer",I,Terminated,PTC Therapeutics,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Prostate; Oncology: Skin, Basal Cell Carcinoma; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",(N/A); Aggressive; Classical; First line; Fourth line or greater; Hormone refractory; Indolent; Locally advanced; Metastatic; Nodular lymphocyte-predominant; Papillary; Pulmonary; Recurrent; Second line; Stage III; Stage IV; Third line; Untreated,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Small Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Neoplasms, Basal Cell; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Prostatic Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms",United States
"A Phase I Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Lipotecan (TLC388 HCl for Injection) when Administered to Patients with Advanced Solid Tumors",I,Completed,Taiwan Liposome Company,Oncology: Anal; Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Thymus; Oncology: Vaginal,Second line; Stage II; Stage III; Stage IV; Thymoma,"Anus Neoplasms; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gallbladder Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Thymoma; Thymus Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Vaginal Neoplasms; Wilms Tumor","Taiwan, China; United States"
Phase I Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Resistant Solid Malignancies.,I,Completed,Washington University School of Medicine,Oncology: Breast; Oncology: Liver,Second line; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Liver Cancer; Liver Neoplasms; Neoplasms",United States
"Phase I Study of Sorafenib, Pemetrexed, and Cisplatin for the Treatment of Advanced Solid Tumors.",I,Completed,"University of Minnesota Cancer Center
Bayer AG/Bayer Pharmaceuticals","Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",(N/A); Adenocarcinoma; Advanced; First line; Large Cell; Locally advanced; Metastatic; Pulmonary; Second line; Stage III; Stage IV; Untreated,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Mesothelioma; Neoplasms, Mesothelial; Neuroendocrine Tumors; Osteosarcoma; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
Phase I clinical trial of i.v. ascorbic acid in advanced malignancy.,I,Completed,(Other Hospital/Academic/Medical Center),"Oncology: Breast; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Cutaneous T-cell lymphoma (CTCL); Follicular lymphoma (FL); Indolent; Peripheral T-cell lymphoma (PTCL); Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Follicular; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",Canada; United States
A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of XL147 (SAR245408) in Combination With Paclitaxel and Carboplatin in Subjects With Solid Tumors,I/II,Completed,"Exelixis
Sanofi {Sanofi-Aventis}","Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Vulvar",Merkel; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Melanoma; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Uterine Cervical Neoplasms; Vulvar Neoplasms",United States
"A Phase l Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL647 and XL147 Administered in Combination Daily to Subjects with Solid Tumors.",I,Terminated,Exelixis,"Oncology: Breast; Oncology: Lung, Non-Small Cell",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung",United States
"A Phase I Study to Evaluate the Safety and Tolerability of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours",I,Completed,Chroma Therapeutics,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",Advanced; Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",Netherlands; United Kingdom; United States
A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus weekly gemcitabine (Gem) in patients with advanced solid tumors: preliminary results.,I,Completed,"Regeneron
Sanofi {Sanofi-Aventis}",Oncology: Breast; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma,Second line; Stage III; Stage IV,Breast Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma,United States
"Phase I Dose Escalation Study with Irinotecan, Capecitabine, epirubicin and Granulocyte Colony-Stimulating Factor Support for Patients with Solid Malignancies.",I,Completed,Baylor College of Medicine,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell",Adenocarcinoma; Second line; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
"A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK1059615 in Patients With Solid Tumors or Lymphoma.",I,Terminated,GlaxoSmithKline,"Oncology: Breast; Oncology: Endometrial; Oncology: Lymphoma, Non-Hodgkin's",Aggressive; Indolent; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms",United States
"Phase I/II Clinical and Pharmacokinetic Study of BMS-247550, a Novel Derivative of Epothilone B, in Solid Tumors",I/II,Completed,Bristol-Myers Squibb,"Oncology: Breast; Oncology: Colorectal; Oncology: Fallopian Tube; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Vulvar",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fallopian Tube Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Vulvar Neoplasms",United States
"A Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Cyclin-Dependent Kinase (CDK) Inhibitor SCH 727965 Administered Every 3 Weeks in Subjects With Advanced Malignancies.",I,Completed,Merck & Co. {Schering-Plough},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Multiple Myeloma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Thymus; Oncology: Thyroid",Aggressive; Indolent; Second line; Stage III; Stage IV; Thymic carcinoma,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Multiple Myeloma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thymus Neoplasms; Thyroid Neoplasms",United States
"A Phase I, Open-Label, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of FP-1039 in Subjects With Metastatic or Locally Advanced Unresectable Solid Tumors.",I,Completed,"GlaxoSmithKline {Human Genome Sciences}
Amgen/Five Prime Therapeutics","Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Prostate; Oncology: Small Intestine; Oncology: Soft Tissue Sarcoma",FGFR; Locally advanced; Metastatic; Second line; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Intestinal Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified",United States
Phase I Trial of TGFB2-Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine for Advanced Cancer,I,Terminated,"(Other Hospital/Academic/Medical Center)
Gradalis","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Hormone refractory; Locally advanced; Metastatic; Stage III; Stage IV; Third line; Unspecified,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
A Feasibility Trial of Partial Breast Irradiation With Various Concurrent Chemotherapy Regimens (PBIC),I/II,Completed,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}
Breast Cancer Research Foundation",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Stage I; Stage II,Breast Neoplasms,United States
Phase I/II Clinical Trial of 1alpha-Hydroxyvitamin D(5) as a Chemotherapeutic and Possibly Chemopreventive Agent in Advanced Breast Cancer Patients,I/II,Terminated,Marillion Pharmaceuticals,Oncology: Breast,Line of therapy N/A; Stage 0; Stage III; Stage IV,Breast Neoplasms,United States
Phase I Clinical Trial of Trametes Versicolor in Women With Breast Cancer.,I,Completed,"National Institutes of Health/National Cancer Institute
University of Minnesota Cancer Center
National Institutes of Health/National Center for Complementary and Alternative Medicine",Oncology: Breast,Second line; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Phase I Study of Cisplatin, Paclitaxel, and RAD001 Patients With Metastatic Breast Cancer.",I,Completed,"National Institutes of Health/National Cancer Institute
Vanderbilt-Ingram Cancer Center",Oncology: Breast,Fourth line or greater; HER2 negative; HER2 positive; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy.",I,Completed,Bristol-Myers Squibb,Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Ovarian,Second line; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; Ovarian Cancer; Ovarian Neoplasms,Belgium; United States
Phase Ia/Ib Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer,I,Temporarily Closed,"Roger Williams Medical Center
US Department of Defense",Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Phase I/II Study Of HKI-272 In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer.,I/II,Completed,"Pfizer {Wyeth}
Puma Biotechnology",Oncology: Breast; Oncology: Gastric,First line; Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms; Stomach Carcinoma; Stomach Neoplasms,"Belgium; China; France; Hong Kong, S.A.R., China; Netherlands; Poland; Spain; Sweden; Taiwan, China; United Kingdom; United States"
A Pharmacokinetic Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients with Advanced Solid and Hematologic Tumors.,I,Completed,Teva {Cephalon/ChemGenex},"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Myelodysplastic Syndrome; Oncology: Soft Tissue Sarcoma",(N/A); APL/M3; Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Acute Myelocytic Leukemia; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Chronic Myeloid Leukemia; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Liposarcoma; Melanoma; Myelodysplastic Syndromes; Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
"A Phase I, Multicenter, Open-Label, Dose Escalation Trial of PDL192 in Subjects With Advanced Solid Tumors",I,Completed,"PDL BioPharma {Protein Design Labs}
AbbVie {Abbott/Facet Biotech}",Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Liver; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Thyroid,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Thyroid Neoplasms; Unspecified",United States
A Phase I Dose Escalation Study of Oral MK2206 in Patients with Locally Advanced or Metastatic Solid Tumors.,I,Completed,Merck & Co./Merck Sharp & Dohme (MSD),"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: GIST; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Estrogen receptor positive; HER2 negative; HER2 positive; Hormone refractory; KRAS; Locally advanced; Metastatic; Other; Pancreas; Second line; Stage II; Stage III; Stage IV; Third line; Triple receptor negative; Unresectable,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United Kingdom; United States
Evaluation of the Aromatase Inhibition Potential of Standardized Grape Extract,I,Completed,"National Institutes of Health/National Cancer Institute
Mayo Clinic",Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
The Effect of Antidepressants and Gabapentin on Tamoxifen Pharmacokinetics: A Prospective Study,I,Completed,"National Institutes of Health/National Cancer Institute
Mayo Clinic",Oncology: Breast,Estrogen receptor positive; Line of therapy N/A; Stage 0; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms; Depression; Hot Flashes,United States
A Phase I Study of Rapamycin (Sirolimus) with Bevacizumab in Patients with Advanced Malignancies,I,Completed,"Roche/Genentech {Genentech}
University of Chicago Cancer Research Center",Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid,Locally advanced; Metastatic; Second line; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasm Metastasis; Neoplasms; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
8-Cl-Ado-clinical trial in breast cancer,I,Terminated,"MD Anderson Cancer Center, University of Texas",Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
A Phase I/II Study of CR011-vcMMAE in Patients With Locally Advanced or Metastatic Breast Cancer,I/II,Completed,Celldex Therapeutics {CuraGen},Oncology: Breast,Fourth line or greater; HER2 negative; HER2 positive; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
Phase I Study to Evaluate GFB-204 as a Potential Cancer Therapeutic in Patients with Variety of Solid Tumors,I,Terminated,Kirax Corporation {Tigris Pharmaceuticals},"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal",(N/A); Line of therapy N/A,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Kidney Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Wilms Tumor",United States
A Phase I Study of Bortezomib and Concurrent External Beam Radiation in Patients with Advanced Solid Malignancies.,I,Completed,University of Colorado Cancer Center at University of Colorado Health Sciences Center,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Wilms Tumor",United States
Pre-Surgical Trial of Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer (Spore).,I,Terminated,"National Institutes of Health/National Cancer Institute
Vanderbilt-Ingram Cancer Center",Oncology: Breast,Estrogen receptor positive; FGFR; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"An Open-Label, Two-Part, Single Sequence Study to Examine the Effects of Lapatinib on the Pharmacokinetics of Orally Administered Digoxin in Subjects with Metastatic ErbB2 Positive Breast Cancer.",I,Completed,GlaxoSmithKline,Oncology: Breast,First line; HER2 positive; Second line; Stage IV,Breast Neoplasms,Canada; South Korea; United States
"A Phase I Dose Escalation Study Evaluating MK1775 in Both Monotherapy and in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adult Subjects With Advanced Solid Tumors",I,Completed,Merck & Co./Merck Sharp & Dohme (MSD),"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Skin, Basal Cell Carcinoma; Oncology: Soft Tissue Sarcoma",First line; Fourth line or greater; Hormone refractory; Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Neoplasms, Basal Cell; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",Canada; Netherlands; United States
"A Phase I Study Evaluating the Safety, Tolerability and Pharmacokinetics of ABT-888 in Combination With Whole Brain Radiation Therapy in Subjects With Brain Metastases",I,Completed,AbbVie {Abbott},"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Renal",CNS mets; First line; Second line; Stage IV,"Brain Diseases; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Diseases; Central Nervous System Neoplasms; Colorectal Neoplasms; Kidney Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Second Primary; Nervous System Diseases; Nervous System Neoplasms; Renal Cancer; Wilms Tumor",Canada; Puerto Rico; United States
Phase I/II Trial Of MK-0752 Followed By Docetaxel In Locally Advanced or Metastatic Breast Cancer: A Study By The Stem Cell Clinical Consortium,I/II,Completed,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
University of Michigan Comprehensive Cancer Center
Baylor College of Medicine
Weill Medical College of Cornell University
Ohio State University
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,United States
MUC1/HER-2/Neu Peptide Based Immunotherapeutic Vaccines for Breast Adenocarcinomas,I,Completed,"National Institutes of Health/National Cancer Institute
Mayo Clinic",Oncology: Breast,HER2 negative; HER2 positive; Second line; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer,I,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Line of therapy N/A; Stage 0,"Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Hyperplasia",United States
A Phase I Study of DAVANAT in combination with 5-FU to treat Breast Cancer.,I,Terminated,Galectin Therapeutics {Pro-Pharmaceuticals},Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
A Phase I Study of PNT2258 in Patients With Advanced Solid Tumors.,I,Completed,GlaxoSmithKline/Sierra Oncology {ProNAi Therapeutics},"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",Second line; Squamous Cell; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
A Phase I Study With an Expansion Cohort of the PARP Inhibitor AZD2281 (KU-0059436) Combined With Carboplatin in Breast and Ovarian Cancer in BRCA1/2 Mutation Carriers (Familial Breast and Ovarian Cancer) and Sporadic Triple Negative Breast Cancer and Ovarian Cancer,I/II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal,BRCA; Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms",United States
"A Phase I Pharmacodynamic Study of CP-751,871 as Neoadjuvant Treatment for Early Breast Cancer.",I,Terminated,"National Institutes of Health/National Cancer Institute
Pfizer",Oncology: Breast,Neoadjuvant; Stage I; Stage II,Breast Neoplasms,United States
Phase I Study of MKC-1 in Patients with Advanced or Metastatic Solid Malignancies.,I,Completed,CASI Pharmaceuticals {EntreMed},Oncology: Breast; Oncology: Head/Neck; Oncology: Renal,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms; Renal Cancer; Wilms Tumor",United States
Parallel Phase I Study of Ixabepilone Plus Lapatinib and Ixabepilone Plus Lapatinib Plus Capecitabine in Subjects With HER2 Positive Locally Advanced or Metastatic Breast Cancer.,I,Terminated,"Bristol-Myers Squibb
GlaxoSmithKline",Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,Australia; Italy; United States
A Phase I Study of LBH589 in Combination With Capecitabine + or - Lapatinib.,I,Completed,Novartis,Oncology: Breast,Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"A Phase I/II, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed in Patients with Advanced Solid Tumors.",I/II,Completed,Molecular Templates {Threshold Pharmaceuticals},"Oncology: Anal; Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: GIST; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",First line; Hormone refractory; Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV; Unresectable,"Anus Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
Phase I/II Trial of Letrozole (Femara) and Sorafenib (Nexavar) in Postmenopausal Women With Hormone-Receptor Positive Locally Advanced or Metastatic Breast Cancer.,I/II,Completed,"Novartis
National Institutes of Health/National Cancer Institute
Bayer AG/Bayer Pharmaceuticals
Cancer Institute of New Jersey
(Other Hospital/Academic/Medical Center)",Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,United States
Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12,I/II,Terminated,"National Institutes of Health/National Cancer Institute
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Beth Israel Deaconess Medical Center
US Department of Defense
Harvard Medical School
Brigham and Womens Hospital",Oncology: Breast,First line; Second line; Stage IV,Breast Neoplasms,United States
Phase I Study of Bortezomib and Gemcitabine in Elderly Patients With Solid Tumors (X05227).,I,Completed,University of Minnesota Cancer Center,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",First line; Fourth line or greater; Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Lung Neoplasms; Melanoma; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
A Phase I Study of Pazopanib in Combination With Either Erlotinib or Pemetrexed in Patients With Advanced Solid Tumors,I,Completed,GlaxoSmithKline,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Thyroid",Advanced; Locally advanced; Metastatic; Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Small Cell Lung Carcinoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",Italy; United States
"A Phase I, Dosage-Finding and Pharmacokinetic Study of Intravenous Topotecan and Oral Erlotinib in Adults With Refractory Solid Tumors.",I,Completed,"Roche/Genentech {Genentech}
GlaxoSmithKline
(Other Cooperative Group)","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",(N/A); First line; Fourth line or greater; Pulmonary; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
Phase I/II Safety Trial of the Combination of Samarium Sm-153 Lexidronam (QUADRAMET) and Albumin-Bound Paclitaxel (Abraxane) in the Treatment of Patients with Metastatic Breast Carcinoma,I/II,Completed,Jazz Pharmaceuticals {Jazz Pharmaceuticals/EUSA Pharma {Cytogen}},Oncology: Breast,Line of therapy N/A; Stage IV,Breast Neoplasms,United States
A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of HGS1029 (AEG40826-2HCl) in Patients With Advanced Solid Tumors,I,Completed,"GlaxoSmithKline {Human Genome Sciences}
Pharmascience {Aegera}","Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Prostate",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms",United States
"A Phase I Study of Oral Palifosfamide Tris in Advanced, Refractory, Solid Tumors",I,Terminated,Alaunos Therapeutics {Ziopharm Oncology},Oncology: Breast; Oncology: Colorectal; Oncology: Ovarian; Oncology: Prostate,Second line; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Unspecified,United States
A Phase I Open-label Dose Escalation Study of AT13387 in Patients With Metastatic Solid Tumors,I,Completed,"National Institutes of Health/National Cancer Institute
Otsuka Holdings/Otsuka Pharmaceutical/Astex Pharmaceuticals {Astex Therapeutics}","Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Esophageal; Oncology: GIST; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",(N/A); Aggressive; Classical; EGFR; Follicular; HER2 positive; Hormone refractory; Indolent; Locally advanced; Metastatic; Nodular lymphocyte-predominant; Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Glioblastoma; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Multi-Center, Open-Label, Single-Arm, Phase I, Dose Escalation Study of ASONEP (Sonepcizumab/LT1009) Administered as a Single Agent Weekly to Subjects with Refractory Advanced Solid Tumors",I,Completed,"Merck KGaA/Merck Serono {Serono}
Premiere Oncology
Lpath",Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Melanoma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Wilms Tumor",United States
"A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) When Given in Combination With Standard Doses of Selected Chemotherapies to Patients With Advanced Solid Tumors",I,Completed,AstraZeneca,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal",BRAF; Fourth line or greater; NRAS; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colonic Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms; Renal Cancer; Wilms Tumor",United States
"A Phase I/II, Multi-Center, Open-Label Study of BGT226, Administered Orally in Adult Patients with Advanced Solid Malignancies Including Patients with Advanced Breast Cancer.",I/II,Terminated,Novartis,Oncology: Breast; Oncology: Unspecified Solid Tumor,HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Hamartoma Syndrome, Multiple; Neoplasms, Unknown Primary; Syndrome",Canada; Spain; United States
A Phase I/II Study of GRN163L in Combination With Paclitaxel and Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer.,I/II,Completed,Geron,Oncology: Breast,First line; HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase 1, Multicenter, Open-Label Dose Escalation Study Evaluating the Safety and Tolerability of Multiple Hematide Injections in Subjects With Refractory Non-Small Cell Lung Cancer, Breast Cancer, or Prostate Cancer Who Are Anemic and Receiving Cytotoxic Chemotherapy",I,Terminated,"Takeda
Affymax","Metabolic/Endocrinology: Anemia; Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Supportive Care",Anemia; Cancer-related; Second line,"Anemia; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Palliative Care; Prostatic Neoplasms; Unspecified",United States
A Phase I Study of Concurrent Sorafenib (BAY 43-9006) and Palliative Radiation Therapy in Adult Patients with Advanced Solid Tumors.,I,Completed,Nevada Cancer Center,Oncology: Breast; Oncology: Prostate,Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms; Prostatic Neoplasms,United States
"A Pharmacodynamic Study of the P-glycoprotein (Pgp) Antagonist, CBT-1, Evaluating Pgp Inhibition in Tumors and Normal Tissues.",I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Multiple Myeloma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate",(N/A); Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Multiple Myeloma; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Unspecified",United States
"An Open-Label, Phase I, Dose-Escalation Study Evaluating Two Dosing Schedules of PI3-Kinase Inhibitor (GDC-0941) in Patients with Locally Advanced or Metastatic Solid Tumors for which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable",I,Completed,Roche/Genentech {Genentech},"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Skin, Basal Cell Carcinoma; Oncology: Small Intestine; Oncology: Soft Tissue Sarcoma",Advanced; Estrogen receptor positive; HER2 negative; Localized; Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Intestinal Neoplasms; Leiomyosarcoma; Liposarcoma; Mesothelioma; Neoplasms, Basal Cell; Neoplasms, Mesothelial; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified",United States
"An Open-Label, Dose-Escalation, Safety, and Pharmacokinetic Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer",I,Completed,CASI Pharmaceuticals {EntreMed},Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Thyroid,Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Thyroid Neoplasms; Wilms Tumor",United States
Effects of Therapeutic Agents on Estrogens in the Breast,I,Completed,"National Institutes of Health/National Cancer Institute
University of Nebraska Medical Center",Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Stage 0; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
An Open Label Phase I Dose Finding Study of TRC105 in Patients with Advanced or Metastatic Solid Cancer for Whom Curative Therapy is Unavailable.,I,Completed,Tracon Pharmaceuticals,"Oncology: Anal; Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Hormone refractory; Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV,"Anus Neoplasms; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Ewing Sarcoma; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Neoplasm Metastasis; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Wilms Tumor",United States
A Phase I Dose Escalation Study of Daily Oral OSI-930 and Erlotinib (Tarceva) in Patients With Advanced Solid Tumors.,I,Completed,Astellas Pharma {OSI Pharmaceuticals},"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Melanoma; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Wilms Tumor",United Kingdom; United States
"Phase I trial of a HER2/neu-derived peptide (GP2) vaccine in disease-free, node-negative breast cancer patients.",I,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
A Phase I Dose-Escalation Trial Of Vvdd-CDSR (Double-Deleted Vaccinia Virus Plus CD/ SMR) Administered By Intratumoral Injection Or Intravenous Injection,I,Completed,Sillajen Biotherapeutics {SillaJen}/Jennerex,Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Melanoma; Oncology: Pancreas,Second line; Stage III; Stage IV,"Adenocarcinoma; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms, Squamous Cell; Pancreatic Cancer; Pancreatic Neoplasms; Vaccinia",United States
"A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients With Advanced Solid Tumors",I,Closed,National Institutes of Health/National Cancer Institute,"Oncology: Anal; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor",Aggressive; BRCA; Classical; Fourth line or greater; HER2 negative; Indolent; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Anus Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Colonic Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Lung Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms",United States
Phase I-II Trial of Vorinostat Plus Weekly Paclitaxel (+/- Trastuzumab) Followed by Doxorubicin-cyclophosphamide in Patients With Locally Advanced Breast Cancer,I/II,Completed,"Merck & Co./Merck Sharp & Dohme (MSD)
Albert Einstein Medical College",Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
A Study of hTERT/Survivin Multi-Peptide Vaccine With Daclizumab and Prevnar for Patients With Metastatic Breast Cancer.,I,Completed,University of Pennsylvania,Oncology: Breast,Second line; Stage IV,"Breast Neoplasms; Carcinoma, Ductal",United States
A Phase Ib/IIa Trial of Panobinostat in Combination With Trastuzumab in Adult Female Patients With HER2 Positive Metastatic Breast Cancer Whose Disease Has Progressed During or Following Therapy With Trastuzumab,I/II,Terminated,Novartis,Oncology: Breast,HER2 positive; Second line; Stage IV; Third line,Breast Neoplasms,Australia; Canada; France; Germany; Italy; Spain; United Kingdom; United States
Phase I/II Study of Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis,I/II,Completed,"Bristol-Myers Squibb
MD Anderson Cancer Center, University of Texas",Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; Estrogen receptor positive; First line; HER2 negative; Stage IV,"Bone Marrow Diseases; Bone Neoplasms; Breast Neoplasms; Neoplasm Metastasis; Neoplasms, Second Primary",United States
A Phase I Study to Evaluate the Safety/Tolerability and Immunogenicity of V930/V932 in Patients With Cancers Expressing HER-2 and/or CEA.,I,Completed,Merck & Co.,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian",(N/A); HER2 positive; Pulmonary; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Small Cell Lung Carcinoma; Unspecified",United States
A Phase I Pharmacokinetic and Pharmacodynamic Study Of PF-03446962 In Patients with Advanced Solid Tumors.,I,Completed,Pfizer,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: GIST; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thymus; Oncology: Thyroid",Advanced; First line; Fourth line or greater; Locally advanced; Metastatic; Second line; Stage III; Stage IV; Third line; Thymic carcinoma,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Gastrointestinal Stromal Tumors; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thymus Neoplasms; Thyroid Neoplasms; Wilms Tumor",Italy; South Korea; United States
A Phase I Pharmacokinetic and Pharmacodynamic Study Of PF-03732010 In Patients with Advanced Solid Tumors.,I,Completed,Pfizer,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Thyroid",Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms",Australia; South Korea; United States
"A Phase I/II, Multicenter, Open-Label Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination with Weekly Paclitaxel in Patients with Advanced Breast Cancer.",I/II,Terminated,Pharmascience {Aegera},Oncology: Breast,First line; Second line; Stage IV,Breast Neoplasms,United States
A Phase I Study of LBH589 in Combination with Paclitaxel and Carboplatin +/- Bevacizumab the Treatment of Solid Tumors.,I,Completed,"Novartis
Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}","Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian",First line; Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms",United States
Neoadjuvant Trial of Lapatinib for the Treatment of Women with DCIS Breast Cancer,I/II,Completed,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute
(Other Hospital/Academic/Medical Center)
Breast Cancer Research Foundation",Oncology: Breast,HER2 positive; Neoadjuvant; Stage 0,"Breast Carcinoma In Situ; Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating",United States
"A Phase I Study of the HSP90 Inhibitor, STA-9090, Administered Twice-Weekly in Patients with Solid  Tumors",I,Completed,Madrigal Pharmaceuticals {Synta Pharmaceuticals},"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas",HER2 negative; Second line; Stage II; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Melanoma; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms",United States
An Open Label Phase I Trial of PBI-05204 in Advanced Cancer Patients.,I,Completed,"MD Anderson Cancer Center, University of Texas",Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate,Second line; Stage II; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms,United States
"A Phase I Study to Determine the Safety, Pharmacology, and Pharmacodynamics of JNJ26854165 in Subjects with Advanced Stage and/or Refractory Solid Tumors",I,Completed,"Johnson & Johnson/Janssen Biotech {Centocor Ortho Biotech {J&J/Ortho Biotech}}
Johnson & Johnson/Janssen R&D {Johnson & Johnson/J&JPRD}",Oncology: Breast; Oncology: Colorectal; Oncology: Melanoma; Oncology: Renal; Oncology: Soft Tissue Sarcoma,Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",Belgium; Spain; United States
Phase I/II Trial of IMC-A12 in Combination With Temsirolimus in Patients With Metastatic Breast Cancer,I/II,Completed,"National Institutes of Health/National Cancer Institute
Cancer Trials Support Unit - CTSU/NCI
Alliance for Clinical Trials in Oncology",Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Second line; Stage IV; Third line,"Breast Neoplasms; Breast Neoplasms, Male; Carcinoma",United States
Phase I Study of IMC-A12 (NSC# 742460) in Combination With Temsirolimus CCI-779 (NSC# 683864) in Patients With Advanced Cancers,I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",(N/A); Aggressive; Classical; First line; Fourth line or greater; Indolent; Locally advanced; Metastatic; Nodular lymphocyte-predominant; Pulmonary; Second line; Stage III; Stage IV; Third line; Untreated,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma",United States
Increase of CD4(+)CD25(+) regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4(+)CD25(+) T lymphocytes.,I,Completed,(Other Academic Cancer Center),"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Renal",(N/A); Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Prostatic Neoplasms; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",France; United Kingdom; United States
"A Phase I Study of Gemcitabine, Capecitabine and ZD6474 (ZACTIMA) in Patients With Advanced Solid Tumors With an Expanded Cohort of Patients With Biliary or Pancreatic Malignancies.",I,Completed,"AstraZeneca
University of Colorado","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gallbladder; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Thymus",First line; Second line; Stage II; Stage III; Stage IV; Thymic carcinoma,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Gallbladder Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Thymus Neoplasms",United States
"A Phase I, Multicenter, Open-Label, Dose Escalation Study Evaluating the Safety and Tolerability of EZN-2968, Administered as a Daily 2-Hour Intravenous Infusion x 5 Days Every 4 Weeks in Adult Patients with Advanced Solid Tumors or Lymphoma",I,Completed,Enzon,"Oncology: Breast; Oncology: Colorectal; Oncology: GIST; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Aggressive; Classical; Indolent; Locally advanced; Metastatic; Nodular lymphocyte-predominant; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",United States
A Phase I Study of LBH589 in Combination with Gemcitabine in the Treatment of Solid Tumors,I,Terminated,"Novartis
Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}","Oncology: Bladder; Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian",Aggressive; Classical; Fourth line or greater; Indolent; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Phase I/II, Ascending Multiple-Dose Study to Evaluate the Safety, Efficacy and Pharmacokinetics of BMS-753493 in Subjects With Advanced Cancer (Schedule 2)",I/II,Terminated,Bristol-Myers Squibb,Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Renal,Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Renal Cell; Fallopian Tube Neoplasms; Kidney Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Renal Cancer; Unspecified; Wilms Tumor",Canada; United Kingdom; United States
"A Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Cyclin-Dependent Kinase (CDK) Inhibitor SCH 727965 Administered Weekly in Subjects With Advanced Malignancies.",I,Completed,Merck & Co. {Schering-Plough},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: GIST; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Multiple Myeloma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Vulvar",Aggressive; Hormone refractory; Indolent; Locally advanced; Metastatic; Second line; Small lymphocytic lymphoma (SLL); Stage II; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Chronic Lymphocytic Leukemia; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Gastrointestinal Stromal Tumors; Leiomyosarcoma; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Multiple Myeloma; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Vulvar Neoplasms",United States
"A Phase I/II, Ascending Multiple-Dose Study to Evaluate the Safety, Efficacy and Pharmacokinetics of BMS-753493 in Subjects With Advanced Cancer (Schedule 1).",I/II,Terminated,Bristol-Myers Squibb,Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Renal,Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Renal Cell; Fallopian Tube Neoplasms; Kidney Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Renal Cancer; Unspecified; Wilms Tumor",Netherlands; United States
A Phase I Open Label Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors,I,Completed,Boehringer Ingelheim,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal",EGFR; HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Unspecified; Wilms Tumor",United States
A Phase I Dose Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy With Biomarker Analysis in Patients With HER2-Overexpressing Breast Cancer,I,Completed,"National Institutes of Health/National Cancer Institute
University of California, San Francisco",Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms; Neoplasm Metastasis,United States
Phase I Study of the Pharmacokinetics and Pharmacodynamics of ZD6474 in Combination With Docetaxel in Advanced Solid Tumors.,I,Terminated,"Southwest Oncology Group
National Institutes of Health/National Cancer Institute","Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Prostate",Hormone refractory; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Lung Neoplasms; Prostatic Neoplasms",United States
Phase I Pharmacokinetic Study of Dasatinib (BMS-354825) (NSC-732517; IND-73969) in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction,I,Completed,"Southwest Oncology Group
National Institutes of Health/National Cancer Institute","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Testicular",(N/A); Aggressive; Classical; Cutaneous T-cell lymphoma (CTCL); Extensive; Extranodal marginal zone B-cell lymphoma (MALT); Follicular lymphoma (FL); Indolent; Locally advanced; Mantle cell lymphoma (MCL); Metastatic; Nodular lymphocyte-predominant; Peripheral T-cell lymphoma (PTCL); Pulmonary; Remission; Second line; Small lymphocytic lymphoma (SLL); Stage II; Stage III; Stage IV; Unresectable; Waldenstrom's macroglobulinemia (WM),"Breast Neoplasms; Burkitt Lymphoma; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Chronic Lymphocytic Leukemia; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Immunoblastic Lymphadenopathy; Intraocular Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Leukemia, Hairy Cell; Leukemia, Large Granular Lymphocytic; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Leukemia, T-Cell; Leukemia-Lymphoma, Adult T-Cell; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Lymphomatoid Granulomatosis; Melanoma; Mycoses; Mycosis Fungoides; Neuroendocrine Tumors; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Sezary Syndrome; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Syndrome; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Waldenstrom Macroglobulinemia; Wilms Tumor",United States
"A Phase I Study of Bevacizumab in Combination With 1) Sunitinib, 2) Sorafenib, 3) Erlotinib and Cetuximab, 4) Trastuzumab and Lapatinib.",I,Completed,"MD Anderson Cancer Center, University of Texas","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gallbladder; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Follicular; Fourth line or greater; HER2 positive; Locally advanced; Medullary; Metastatic; Papillary; Recurrent; Stage II; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Fibrosarcoma; Gallbladder Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase I/II, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer.",I/II,Completed,AngioChem,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas",(N/A); Bone mets; CNS mets; Fourth line or greater; HER2 negative; HER2 positive; Liver mets; Other mets; Pulmonary; Stage III; Stage IV,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Small Cell Lung Carcinoma",France; United States
Phase I study of weekly docetaxel and topotecan in the treatment of advanced solid tumors.,I,Completed,Siteman Cancer Center,"Oncology: Bladder; Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine",(N/A); Fourth line or greater; Pulmonary; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Neuroendocrine Tumors; Small Cell Lung Carcinoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
A Phase I/II Study of Lapatinib in Combination with Oxaliplatin and Capecitabine in Subjects with Advanced or Metastatic Colorectal Cancer,I/II,Terminated,GlaxoSmithKline,Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Pancreas,First line; HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Liver Cancer; Liver Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
A Phase I Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Advanced Solid Malignancies,I,Completed,"(Other Cooperative Group)
National Institutes of Health/National Cancer Institute
AbbVie {Abbott}","Oncology: Bladder; Oncology: Breast; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Renal",BRCA; First line; HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Head and Neck Neoplasms; Hereditary Breast and Ovarian Cancer Syndrome; Kidney Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Multicenter, Open-Label, Noncomparative Phase I Clinical and Pharmacokinetic Study of Oral TAK-285 in Patients With Advanced Cancer",I,Completed,Takeda/Takeda Oncology {Millennium},"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Soft Tissue Sarcoma",Advanced; HER2 positive; Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Mesothelioma; Neoplasms, Basal Cell; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
An international multicenter Phase 1b/2 clinical trial to evaluate the safety and efficacy of Xcytrin in cancer patients receiving radiation therapy for treatment of tumors which have spread to the brain,I/II,Completed,AbbVie/Pharmacyclics,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Neuroendocrine",CNS mets; First line; Pulmonary; Stage IV; Untreated,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Central Nervous System Neoplasms; Melanoma; Neoplasm Metastasis; Neuroendocrine Tumors; Small Cell Lung Carcinoma",France; United States
Phase I/II Study of SU11248 (Sutent) in Combination With Metronomic Dosing of Cyclophosphamide and Methotrexate in Patients With Metastatic Breast Cancer.,I/II,Terminated,"National Institutes of Health/National Cancer Institute
Pfizer
University of California, San Francisco",Oncology: Breast,Fourth line or greater; HER2 positive; Second line; Stage IV; Third line,Breast Neoplasms,United States
Concurrent whole brain radiotherapy and bortezomib for brain metastasis,I,Completed,"Takeda/Takeda Oncology {Millennium}
National Institutes of Health","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Renal",CNS mets; First line; HER2 negative; Stage IV,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Kidney Neoplasms; Melanoma; Neoplasm Metastasis; Renal Cancer; Wilms Tumor",United States
"A Multi-Center Phase I, Dose-Escalation Trial to Determine the Safety and  Pharmacokinetics/Pharmacodynamics of RDEA119, A MEK Inhibitor, in Advanced Cancer Patients.",I,Completed,"Bayer AG
AstraZeneca/Ardea Biosciences {IntraBiotics}","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Gastric; Oncology: GIST; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",BRAF; KRAS; Papillary; Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Gallbladder Neoplasms; Gastrointestinal Stromal Tumors; Glioblastoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Basal Cell; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Wilms Tumor",United States
A Phase I/II Study of Active Immunotherapy With CEA(6D)VRP Vaccine(AVX701) in Patients With Advanced or Metastatic Malignancies Expressing CEA or Stage III Colon Cancer.,I/II,Completed,"Duke University Medical Center
AlphaVax","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Pancreas",Fourth line or greater; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms",United States
Phase I/II trial of sequential azacitidine and valproic acid plus carboplatin in the treatment of patients with advanced malignancies and platinum resistant epithelial ovarian cancer,I/II,Completed,"MD Anderson Cancer Center, University of Texas
Bristol-Myers Squibb/Celgene {Pharmion}","Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Uterine Cervical Neoplasms",United States
"Phase I Study of SU011248 in Combination with Pemetrexed, Pemetrexed/Cisplatin and Pemetrexed/ Carboplatin In Patients with Advanced Solid Malignancies.",I,Completed,Pfizer,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Thymus",(N/A); Advanced; Aggressive; Indolent; Locally advanced; Metastatic; Pulmonary; Second line; Stage II; Stage III; Stage IV; Thymoma; Unresectable,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thymoma; Thymus Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms",Canada; United States
"A Phase I Dose Escalation, Multi-Center, Open-Label Study of AUY922 Administered IV on a Once weekly Schedule in Adult Patients with Advanced Solid Malignancies Including Phase II Expansion Arms in Patients with Either HER2 Positive or ER Positive Locally Advanced or Metastatic Breast Cancer.",I/II,Terminated,"Novartis
Ligand Pharmaceuticals {Vernalis}","Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: GIST; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",Estrogen receptor positive; Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Hematologic Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",Netherlands; Switzerland; United Kingdom; United States
"A Phase I, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of PRLX 93936 Administered Intravenously Daily for Five Days Followed by a 23-Day Rest Period in Patients With Advanced Solid Tumors",I,Completed,Prolexys,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Pancreas",Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Liver Cancer; Liver Neoplasms; Mesothelioma; Neoplasms, Mesothelial; Pancreatic Cancer; Pancreatic Neoplasms; Unspecified",United States
A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer,I,Completed,Savara {Mast Therapeutics {ADVENTRX}},"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Unspecified Cancer",Hormone refractory; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms; Prostatic Neoplasms",Argentina; Estonia; United States
A Phase I Study of DHEA in Combination With Letrozole in ER- Breast Cancer.,I,Terminated,"National Institutes of Health/National Cancer Institute
OHSU Cancer Institute",Oncology: Breast,Line of therapy N/A; Stage IV,Breast Neoplasms,United States
"Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women With a History of Hormone Receptor-Negative Breast Cancer",I,Completed,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute
National Institutes of Health",Oncology: Breast,First line; Second line; Stage I; Stage II; Stage III,Breast Neoplasms,United States
A Phase I study of INOC-009 in solid tumors.,I,Terminated,Acuvax {{Avantogen}/Avantogen Oncology {Innovate Oncology}},Oncology: Breast; Oncology: Unspecified Solid Tumor,(N/A); Line of therapy N/A,"Breast Neoplasms; Neoplasms, Unknown Primary",United States
A Study of ARRY-380 in Patients With Advanced HER2+ Cancer,I,Completed,"Seagen {Seattle Genetics}
Pfizer {Array BioPharma}","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate",Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms",Canada; United States
"A Phase I, Multicenter, Open-Label, Dose-Escalation Study Evaluating the Safety and Tolerability of Intravenous EZN-2208 (PEG-SN38) Administered Every 3 Weeks in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-01)",I,Completed,Enzon,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gallbladder; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Thyroid",(N/A); Aggressive; Classical; Fourth line or greater; Indolent; KRAS; Nodular lymphocyte-predominant; Pulmonary; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Liver Cancer; Liver Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms",United States
"A Phase I, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors.",I,Completed,Eisai,Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: GIST; Oncology: Liver; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Prostate; Oncology: Small Intestine; Oncology: Testicular; Oncology: Thyroid,BRAF; Gastrointestinal; Line of therapy N/A; Papillary; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gastrointestinal Stromal Tumors; Intestinal Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Testicular Cancer; Testicular Neoplasms; Thyroid Neoplasms",United States
"A Phase I, Open-Label, Dose-Escalation, First Time in Human Study to Evaluate the Safety Profile, Pharmacokinetics, and Pharmacodynamics of GSK923295 in Subjects With Refractory Cancers",I,Completed,GlaxoSmithKline,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas",Aggressive; Indolent; Pulmonary; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chronic Lymphocytic Leukemia; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Phase IB, Study to Investigate the Effect of Ketoconazole, a CYP3A4 Inhibitor, on Oral LBH589 and to Assess the Efficacy and Safety of Oral LBH589 in Patients with Advanced Solid Tumors.",I,Completed,Novartis,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Pancreas; Oncology: Prostate; Oncology: Thyroid",Aggressive; Indolent; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Thyroid Neoplasms",Netherlands; United States
"Phase I/II Study of Weekly Vinorelbine (Navelbine, GlaxoWellcome) and Docetaxel (Taxotere, Aventis) in Chemotherapy-Naive Patients with Metastatic Breast Cancer.",I/II,Completed,Cancer Institute of New Jersey,Oncology: Breast,First line; Stage III; Stage IV,Breast Neoplasms,United States
A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors.,I,Completed,(Other Hospital/Academic/Medical Center),"Oncology: Bladder; Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Renal",Line of therapy N/A; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Head and Neck Neoplasms; Kidney Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
Sequential Administration of Cryoablation and Cyclophosphamide for Advanced Solid Epithelial Cancer.,I,Terminated,"National Institutes of Health/National Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}","Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Line of therapy N/A; Locally advanced; Metastatic; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Osteosarcoma; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified; Wilms Tumor",United States
"A Randomized, Partially-Blind, Placebo-Controlled, 2-Period Crossover Study to Assess the Effects of a Single Dose of Vorinostat on the QTc Interval in Patients with Advanced Cancer.",I,Completed,Merck & Co./Merck Sharp & Dohme (MSD),"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Advanced; Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms",Belgium; United States
Phase I and Pharmacokinetic Study of Vorinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction,I,Completed,"Merck & Co.
National Institutes of Health/National Cancer Institute
University of Pittsburgh","Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Liver; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Thymus; Oncology: Thyroid",Aggressive; Classical; First line; Indolent; Nodular lymphocyte-predominant; Papillary; Second line; Stage III; Stage IV; Thymoma; Unresectable,"Breast Neoplasms; Burkitt Lymphoma; Carcinoma, Hepatocellular; Colorectal Neoplasms; Glioblastoma; Hodgkin Disease; Hodgkin Lymphoma; Immunoblastic Lymphadenopathy; Intraocular Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, T-Cell; Leukemia-Lymphoma, Adult T-Cell; Liver Cancer; Liver Neoplasms; Lymphoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphomatoid Granulomatosis; Melanoma; Mycoses; Mycosis Fungoides; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Sezary Syndrome; Syndrome; Thymoma; Thymus Neoplasms; Thyroid Neoplasms; Waldenstrom Macroglobulinemia",United States
"A Phase I, Open-Label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Endothelin B Agonist, SPI-1620, in Patients with Recurrent or Progressive Carcinoma",I,Completed,Spectrum Pharmaceuticals,Oncology: Breast; Oncology: Gastric; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate,(N/A); Second line,Breast Neoplasms; Carcinoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms,United States
A Phase I Study of ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer.,I,Completed,"AstraZeneca
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Massachusetts General Hospital
Brigham and Womens Hospital",Oncology: Breast,Line of therapy N/A; Stage IV,Breast Neoplasms,United States
Use of TheraSphere Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors,I/II,Completed,(Other Hospital/Academic/Medical Center),"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer",Liver mets; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Stomach Carcinoma; Stomach Neoplasms",United States
Extended phase I trial of the oral pan-BCL-2 inhibitor AT-101 by multiple dosing schedules in patients with advanced cancers.,I,Completed,Ascenta Therapeutics,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Aggressive; Classical; First line; Indolent; Locally advanced; Metastatic; Nodular lymphocyte-predominant; Pulmonary; Second line; Small lymphocytic lymphoma (SLL); Stage III; Stage IV; Unspecified; Untreated,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Cholangiocarcinoma; Chronic Lymphocytic Leukemia; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Leukemia, Lymphocytic, Chronic, B-Cell; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
Open Label Phase I Dose Finding Study of TRC102 in Combination With Pemetrexed in Patients With Advanced or Metastatic Solid Cancer for Whom Curative Therapy is Unavailable.,I,Completed,Tracon Pharmaceuticals,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",Hormone refractory; Second line; Stage II; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
A Phase I Study of Methoxyamine and Temozolomide in Patients with Advanced Solid Tumors,I,Completed,"National Institutes of Health/National Cancer Institute
Case Western Reserve University
Tracon Pharmaceuticals","Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Thymus",Gastrointestinal; Locally advanced; Metastatic; Pancreas; Second line; Stage II; Stage III; Stage IV; Thymic carcinoma,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Glioblastoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Medulloblastoma; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thymus Neoplasms",United States
"A Combined Rising Single-Dose (RSD) and Rising Multiple-Dose (RMD) Phase I Study to Evaluate Safety, Tolerability and Pharmacokinetics of KX2-391 in Patients With Advanced Malignancies That Are Refractory to Conventional Therapies",I,Completed,"Roswell Park Cancer Institute
Athenex {Kinex Pharmaceuticals}","Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Thyroid",Aggressive; Classical; Hormone refractory; Indolent; Locally advanced; Metastatic; Nodular lymphocyte-predominant; Papillary; Recurrent; Second line; Stage II; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Thyroid Neoplasms; Unspecified",United States
A Phase I Study Evaluating A Second Generation Antisense Oligonucleotide (OGX 427) That Inhibits Heat Shock Protein 27 (Hsp27).,I,Completed,Achieve Life Sciences {OncoGenex Pharmaceuticals},"Oncology: Bladder; Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate",First line; Fourth line or greater; Hormone refractory; Second line; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms",Canada; United States
A Phase I Dose Escalation Study of Intermittent Oral OSI-906 Dosing in Patients With Advanced Solid Tumors.,I,Completed,Astellas Pharma {OSI Pharmaceuticals},"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Thyroid",(N/A); Advanced; Locally advanced; Metastatic; Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Ewing Sarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Neuroendocrine Tumors; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms; Unspecified; Wilms Tumor",United Kingdom; United States
"A Phase I Trial of Epirubicin, Carboplatin and Capecitabine in Adult Cancer Patients",I,Completed,"National Institutes of Health/National Cancer Institute
University of Nebraska Medical Center","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gallbladder; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Testicular",First line; Second line; Stage III; Stage IV; Untreated,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Gallbladder Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Testicular Cancer; Testicular Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Phase I Study of Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine With Filgrastim Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer,I,Completed,"Amgen
University of Chicago Cancer Research Center",Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,United States
"Phase I Study of Imatinib, Gemcitabine and Capecitabine in Patients with Solid Tumors",I,Completed,"National Institutes of Health/National Cancer Institute
University of Nebraska Medical Center","Oncology: Breast; Oncology: CNS, Other; Oncology: Esophageal; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal",(N/A); Fourth line or greater; Pulmonary; Second line; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Renal Cell; Carcinoma, Small Cell; Central Nervous System Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Wilms Tumor",United States
"A Phase I, Open-Label Study to Determine the Maximum Tolerated Dose (MTD) and to Evaluate the Safety Profile of CC-4047 in Subjects With Advanced Solid Tumors",I,Completed,"National Institutes of Health/National Cancer Institute
Case Western Reserve University","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Fourth line or greater; Hormone refractory; Locally advanced; Metastatic; Recurrent; Second line; Stage II; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Wilms Tumor",United States
Phase I/II Evaluation of Safety and Efficacy of Pathotropic Nanoparticles Bearing a Dominant Negative Cyclin G1 Construct (Rexin-G) as Intervention for Recurrent or Metastatic Breast Cancer.,I/II,Completed,Epeius Biotechnologies,Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
A Phase Ib Study of IPI-504 and Docetaxel in Patients with Advanced Solid Tumors.,I,Completed,"AstraZeneca {MedImmune}
Infinity Pharmaceuticals","Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",(N/A); Metastatic; Pulmonary; Second line; Stage II; Stage III; Stage IV; Third line; Unresectable,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasms; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
A phase I/II study of imatinib and docetaxel as neoadjuvant therapy in locally advanced breast cancer.,I/II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
Phase I Study Of Trastuzumab-DM1 In Patients Who Have Progressed After Herceptin With HER2 Positive Metastatic Breast Cancer,I,Completed,Roche/Genentech {Genentech},Oncology: Breast,Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
A phase I study (CA180021-Segment 2) of dasatinib in patients with advanced solid tumors.,I,Completed,Bristol-Myers Squibb,Oncology: Breast; Oncology: Colorectal; Oncology: Melanoma,Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Melanoma,United States
"A Phase I, Open-Label, Dose-Escalation Study Of The Safety And Pharmacokinetics Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies Or Non-Hodgkin's Lymphoma",I,Terminated,Pfizer {Serenex},"Oncology: Breast; Oncology: Colorectal; Oncology: GIST; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Prostate",Aggressive; Gastrointestinal; HER2 positive; Indolent; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Neuroendocrine Tumors; Prostatic Neoplasms",United States
Phase I Clinical and Pharmacodynamic Evaluation of Oral CI-1033 in Patients with Refractory Cancer.,I,Completed,Pfizer,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Renal; Oncology: Thymus",Second line; Stage III; Stage IV; Thymic carcinoma,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Thymus Neoplasms; Wilms Tumor",United States
A Study of the Proper Dosage of Lovastatin and Docetaxel for Patients with Cancer.,I,Terminated,Holden Comprehensive Cancer Center at University of Iowa,Oncology: Breast; Oncology: Unspecified Solid Tumor,Second line; Stage IV,"Breast Neoplasms; Neoplasms, Unknown Primary",United States
"A Phase I/II Study Evaluating the Maximum Tolerated Dose, Bioequivalence/Pharmacokinetics, Safety, and Efficacy of Hyperthermia and ThermoDox (Lyso-Thermosensitive Liposomal Doxorubucin) in Patients With Local-Regional Recurrent Breast Cancer.",I/II,Completed,Imunon {Celsion},Oncology: Breast,Fourth line or greater; HER2 negative; HER2 positive; Stage IV; Triple receptor negative,Breast Neoplasms; Fever,United States
A Phase I Pilot Study of the Oral mTOR Inhibitor RAD001 in Combination With Capecitabine for Metastatic Breast Cancer.,I,Terminated,"Novartis
Stanford University Medical Center",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Third line,Breast Neoplasms,United States
A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of XL765 Administered Orally Daily to Subjects with Solid Tumors,I,Completed,"Exelixis
Sanofi {Sanofi-Aventis}","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: GIST; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Small Intestine; Oncology: Soft Tissue Sarcoma; Oncology: Testicular",Advanced; Aggressive; Classical; Diffuse large B-cell lymphoma (DLBCL); Follicular lymphoma (FL); Fourth line or greater; Indolent; Locally advanced; Mantle cell lymphoma (MCL); Metastatic; Nodular lymphocyte-predominant; Second line; Stage II; Stage III; Stage IV; Third line; Unresectable,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Gastrointestinal Stromal Tumors; Hodgkin Disease; Hodgkin Lymphoma; Intestinal Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melanoma; Mesothelioma; Neoplasms, Basal Cell; Neoplasms, Mesothelial; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Spain; United States
"A Phase I, Multi-Center, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors",I/II,Completed,Molecular Templates {Threshold Pharmaceuticals},"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",(N/A); Hormone refractory; Locally advanced; Metastatic; Pulmonary; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Neuroendocrine Tumors; Osteosarcoma; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
"A Phase I, Open-Label, Multi-Center, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 Administered Twice a Week in Adult Patients with Advanced Solid Malignancies Including Lymphoma.",I,Terminated,AstraZeneca,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Liver; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Prostate",Aggressive; Indolent; Pulmonary; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Liver Cancer; Liver Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
A Phase I/II Study of ALIMTA Plus Oxaliplatin Administered Every Other Week in the Treatment of Patients With Metastatic Cancer.,I/II,Completed,"Eli Lilly
National Institutes of Health/National Cancer Institute
Vanderbilt-Ingram Cancer Center","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Soft Tissue Sarcoma",Aggressive; Indolent; Locally advanced; Second line; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma",United States
Phase I Evaluation of J591 as a Vascular Targeting Agent in Progressive Solid Tumors.,I,Completed,(Other Hospital/Academic/Medical Center),Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Melanoma; Oncology: Renal,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
Oral Administration of the GnRH Antagonist Acyline in Normal Men.,I,Completed,"National Institutes of Health/Eunice Kennedy Shriver National Institute of Child Health and Human Development
University of Washington
Merrion Pharmaceuticals",Genitourinary: Benign Prostatic Hyperplasia; Genitourinary: Contraception; Genitourinary: Infertility; Oncology: Breast; Oncology: Prostate,(N/A); Line of therapy N/A; Men,Breast Neoplasms; Contraception; Female Infertility; Infertility; Male Infertility; Prostatic Hyperplasia; Prostatic Neoplasms; Unspecified,United States
"A Phase I-II Study of R115777 (Tipifarnib, Zarnestra) Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients With Stage IIB-IIIC Breast Cancer",I/II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III; Triple receptor negative,"Breast Neoplasms; Breast Neoplasms, Male",United States
A Phase I Study of Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer.,I,Completed,"GlaxoSmithKline
Brigham and Womens Hospital
Breast Cancer Research Foundation",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; First line; HER2 positive; Second line; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
Phase I/II Trial of Abraxane (ABI-007) and Alimta (Pemetrexed) in Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer (NSCLC) and Breast Cancer.,I/II,Terminated,"(Other Industry Sponsor)
Eli Lilly
Bristol-Myers Squibb/Celgene
University of California Davis","Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate",Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Lung Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms",Canada; United States
"A Phase I, Multicenter, Open-Label, Dose-Escalation Study Evaluating the Safety and Tolerability of Intravenous EZN-2208 PEG-SN38) Administered Weekly for 3 Weeks in 4-Week Cycles in Patients With Advanced Solid Tumors or Lmphoma (EZN-2208-02)",I,Completed,Enzon,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",Aggressive; Classical; Fourth line or greater; Indolent; Locally advanced; Metastatic; Nodular lymphocyte-predominant; Second line; Stage II; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Liposarcoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
Phase I pharmacokinetic interaction and safety study of DN-101/docetaxel in patients with advanced solid tumors.,I,Completed,Paratek Pharmaceuticals {Transcept Pharmaceuticals {Novacea}},"Oncology: Bladder; Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Prostate",Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies.",I,Completed,Otsuka Holdings/Otsuka Pharmaceutical/Astex Pharmaceuticals {SuperGen},"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Neuroendocrine; Oncology: Prostate; Oncology: Renal; Oncology: Small Intestine; Oncology: Soft Tissue Sarcoma",Aggressive; Classical; Fourth line or greater; Gastrointestinal; Indolent; Locally advanced; Metastatic; Nodular lymphocyte-predominant; Pulmonary; Second line; Stage III; Stage IV; Third line; Unresectable,"Breast Neoplasms; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Intestinal Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms; Neuroendocrine Tumors; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Phase I Trial of LY573636 Administered as an Intravenous 2 hour Infusion on Day 1 of a 21-Day Cycle in Patients with Refractory Solid Tumors,I,Completed,Eli Lilly,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thymus; Oncology: Thyroid",Locally advanced; Medullary; Metastatic; Second line; Stage II; Stage III; Stage IV; Thymoma,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thymoma; Thymus Neoplasms; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
Phase I/II Study of Stereotactic Radiation Therapy and Concurrent and Adjuvant Sutent (SU11248) as Treatment for Oligometastatic Disease,I/II,Completed,"Pfizer
Icahn School of Medicine at Mount Sinai {Mount Sinai School of Medicine}","Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Adjuvant; Bone mets; First line; Fourth line or greater; Liver mets; Maintenance/Consolidation; Metastatic; Other mets; Second line; Stage IV; Third line; Untreated,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified; Wilms Tumor",United States
"An Open-Label, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102 with AMG 706 and AMG 102 with Bevacizumab in Adult Subjects With Advanced Solid Tumors.",I,Completed,Amgen,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Small Intestine",First line; Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Intestinal Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
A Phase I Study of Sunitinib Malate and Standard Infusion Gemcitabine in Solid Tumors,I,Completed,"(Other Academic Cancer Center)
National Institutes of Health/National Cancer Institute
National Institutes of Health",Oncology: Breast; Oncology: Liver; Oncology: Mesothelioma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Testicular; Oncology: Thymus; Oncology: Thyroid,First line; Second line; Stage IV; Thymic carcinoma,"Adenocarcinoma; Breast Neoplasms; Carcinoma, Hepatocellular; Ewing Sarcoma; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms; Thymus Neoplasms; Thyroid Neoplasms",United States
"A Phase Ib Study to Assess the Safety, Feasibility, Pharmacokinetics, and Activity of PTC299 Monotherapy or Combination Therapy with Hormonal Agents in Patients with Metastatic Breast Cancer.",I,Completed,"US Department of Defense
PTC Therapeutics",Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
A Phase I Study of ABT-888 in Combination with Temozolomide (TMZ) in Subjects with Non-Hematologic Malignancies (NHM) and Metastatic Melanoma (MM).,I,Completed,AbbVie {Abbott},Oncology: Breast; Oncology: Fallopian Tube; Oncology: Liver; Oncology: Melanoma; Oncology: Ovarian; Oncology: Primary Peritoneal,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Fallopian Tube Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms",United States
"Phase I Clinical Trial Evaluating the Toxicity, Pharmacokinetics and Biological Effect of Intravenous Bevacizumab (Avastin) in Combination with Escalating Doses of Oral AZD2171 for Patients with Advanced Malignancies",I,Completed,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute","Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Soft Tissue Sarcoma",Aggressive; Classical; Indolent; Locally advanced; Mantle cell lymphoma (MCL); Metastatic; Nodular lymphocyte-predominant; Peripheral T-cell lymphoma (PTCL); Second line; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Burkitt Lymphoma; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Fibrosarcoma; Glioblastoma; Hodgkin Disease; Hodgkin Lymphoma; Immunoblastic Lymphadenopathy; Intraocular Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Leukemia, Hairy Cell; Leukemia, Large Granular Lymphocytic; Leukemia, T-Cell; Leukemia-Lymphoma, Adult T-Cell; Liposarcoma; Lymphoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Peripheral; Lymphomatoid Granulomatosis; Mycoses; Mycosis Fungoides; Neoplasms; Neoplasms, Basal Cell; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Sezary Syndrome; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Syndrome; Synovial Sarcoma; Waldenstrom Macroglobulinemia; Wilms Tumor",United States
Phase I/II Cellular Immunotherapy Study With Autologous Dendritic Cells Loaded With Oncofetal Antigen/iLRP in Patients With Metastatic Breast Cancer,I/II,Completed,"(Other Hospital/Academic/Medical Center)
Quantum Immunologics",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
A Brief Dose Escalation Followed by a Phase II Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer.,I/II,Completed,"Novartis
National Institutes of Health/National Cancer Institute
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Beth Israel Deaconess Medical Center",Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
"A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors.",I,Completed,Mersana Therapeutics,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Skin, Basal Cell Carcinoma; Oncology: Soft Tissue Sarcoma",(N/A); Hormone refractory; Pulmonary; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Neoplasms, Basal Cell; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma",United States
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer,I,Completed,"National Institutes of Health/National Cancer Institute
University of Kansas",Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Stage 0; Stage I; Stage II,Breast Neoplasms,United States
Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Advanced Breast Cancer,I,Completed,Bristol-Myers Squibb,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,Italy; Spain; United States
"Pilot Study of GW786034 (Pazopanib), a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Operable Breast Cancer",I,Terminated,National Institutes of Health/National Cancer Institute,Oncology: Breast,Neoadjuvant; Stage I; Stage II; Stage III,"Breast Neoplasms; Breast Neoplasms, Male; Carcinoma",United States
An Open-Label Study to Determine the Maximum Tolerated Oral Dose of the Kinase Inhibitor CEP-11981 in Patients With Advanced Cancer.,I,Completed,Teva {Cephalon},"Oncology: Bladder; Oncology: Breast; Oncology: CNS, Medulloblastoma; Oncology: Colorectal; Oncology: Endometrial; Oncology: GIST; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Small Intestine; Oncology: Soft Tissue Sarcoma",Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Ewing Sarcoma; Fibrosarcoma; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Intestinal Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Medulloblastoma; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Phase I/II Trial of ABI-008 (Nab-Docetaxel) in Patients With Metastatic Breast Cancer.,I/II,Completed,Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}},Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
"A Phase I, Open-Label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of MGCD0103 (MG-0103) in Combination With Docetaxel (Taxotere) in Subjects With Advanced Solid Malignancies.",I,Terminated,"Bristol-Myers Squibb/Celgene
Mirati Therapeutics {MethylGene}","Oncology: Breast; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Prostate",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Lung Neoplasms; Melanoma; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of XL147 Administered Orally Daily to Subjects With Solid Tumors or Lymphoma.,I,Completed,"Exelixis
Sanofi {Sanofi-Aventis}","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Mesothelioma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Soft Tissue Sarcoma",Aggressive; Classical; Cutaneous T-cell lymphoma (CTCL); Diffuse large B-cell lymphoma (DLBCL); Extranodal marginal zone B-cell lymphoma (MALT); Follicular lymphoma (FL); Fourth line or greater; Hormone refractory; Indolent; Locally advanced; Metastatic; Nodular lymphocyte-predominant; Other subtype; Peripheral T-cell lymphoma (PTCL); Second line; Small lymphocytic lymphoma (SLL); Stage II; Stage III; Stage IV; Third line; Unresectable; Waldenstrom's macroglobulinemia (WM),"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Mesothelioma; Neoplasms, Basal Cell; Neoplasms, Mesothelial; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Waldenstrom Macroglobulinemia; Wilms Tumor",France; Spain; United States
"Phase I Study of Pemetrexed (P) and Pegylated Liposomal Doxorubicin (PLD) in Patients with Refractory Breast, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.",I,Completed,Eli Lilly,Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal,Second line; Stage III; Stage IV,Breast Neoplasms; Fallopian Tube Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms,United States
Phase I study of NKTR-102 (PEG-irinotecan) to treat patients with refractory solid tumors.,I,Completed,Nektar Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Neuroendocrine; Oncology: Ovarian",(N/A); Classical; HER2 negative; Nodular lymphocyte-predominant; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Small Cell Lung Carcinoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",United States
A Phase I/II Study of HKI-272 in Combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer,I/II,Completed,"(Other Industry Sponsor)
Pfizer {Wyeth/Wyeth Research}
Puma Biotechnology",Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal,First line; Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Uterine Cervical Neoplasms","Belgium; Canada; China; Hong Kong, S.A.R., China; India; Poland; South Korea; Ukraine; United States"
Phase I Trial Using a CD80-Modified Allogeneic Breast Cancer Cell Line to Vaccinate HLA-A2-Positive Women With Breast Cancer.,I,Completed,"Earle A. Chiles Research Institute - EACRI
Providence Cancer Center at Providence Portland Medical Center",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
"A Phase I/II Study in Metastatic Breast Cancer Patients Infused With Stromagen and Isolated, Mobilized, Autologous Peripheral Blood CD34+ Progenitor Cells After High-Dose Chemotherapy.",I/II,Completed,"National Institutes of Health/National Cancer Institute
Roswell Park Cancer Institute
Smith & Nephew/Osiris Therapeutics",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
Phase I Study of T Cells Modified With Chimeric AntiCEA Immunoglobulin-T Cell Receptors (IgTCR) in Adenocarcinoma.,I,Completed,Beth Israel Deaconess Medical Center,Oncology: Breast; Oncology: Colorectal; Oncology: Pancreas,Second line; Stage IV,Adenocarcinoma; Breast Neoplasms; Colorectal Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms,United States
Phase I Study of Paclitaxel (Taxol) and Bortezomib (Velcade) in Patients With Refractory Solid Tumor Malignancies Involving an Activated MAPK Pathway,I,Completed,"National Institutes of Health/National Cancer Institute
Takeda/Takeda Oncology {Millennium}
Cancer Institute of New Jersey","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Thyroid",Papillary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Lung Neoplasms; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Thyroid Neoplasms",United States
Pharmacokinetic/Dosimetry/MTNTD Study of 111In/90Y-2IT-BAD-m170 for Therapy in Metastatic Breast Cancer Patients With Post Therapy Support of Autologous Pretherapy Apheresed Peripheral Blood Stem Cells and Cyclosporin A Given for Suppression of HAMA Response.,I,Completed,University of California Davis,Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
Pilot Study of p53 Intralesional Gene Therapy With Chemotherapy in Breast Cancer.,I,Completed,"National Institutes of Health/National Cancer Institute
Fox Chase Cancer Center",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
A Phase I Trial of Bizelesin (NSC 615291) Using a Single Bolus Infusion Given Every Twenty-Eight (28) Days in Patients With Advanced Cancer.,I,Completed,"National Institutes of Health/National Cancer Institute
University of Texas","Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal",(N/A); Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Wilms Tumor",United States
A Phase I Trial of Suramin With Sequential Doxorubicin in Patients With Advanced Solid Tumors.,I,Completed,"National Institutes of Health/National Cancer Institute
Mayo Clinic Cancer Center",Oncology: Breast; Oncology: Colorectal; Oncology: Prostate,Second line; Stage III; Stage IV,Adrenocortical Carcinoma; Breast Neoplasms; Carcinoma; Colorectal Neoplasms; Neoplasms; Prostatic Neoplasms,United States
Vaccination of High Risk Breast Cancer Patients Lacking Identifiable Disease With GM2-KLH Conjugate Plus the Immunological Adjuvant QS21.,I,Completed,"Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute",Oncology: Breast,Second line; Stage I; Stage II; Stage III,Breast Neoplasms,United States
A Phase I Study of a HER-2/Neu Peptide Based Vaccine With GM-CSF as an Adjuvant in Patients With Advanced Stage HER-2/Neu Expressing Cancers.,I,Completed,University of Washington,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Ovarian",HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Ovarian Cancer; Ovarian Neoplasms",United States
A Phase I Study of Batracylin (NSC 320846) in Subjects with Solid Tumors and Lymphomas.,I,Terminated,National Institutes of Health/National Cancer Institute,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Advanced; Extranodal marginal zone B-cell lymphoma (MALT); Follicular lymphoma (FL); Hormone refractory; Indolent; Locally advanced; Metastatic; Second line; Small lymphocytic lymphoma (SLL); Stage II; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
Autotransplantation and Her 2 Neu Antibody Immunotherapy in Advanced Breast Cancer.,I/II,Terminated,Beth Israel Deaconess Medical Center,Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
Dose Finding and Efficacy Evaluation of DOXIL (Doxorubicin HCL Liposome Injection) in Combination With Abraxane (Abraxane) in Patients With Metastatic Breast Cancer (MBC) [Phase I and II].,I/II,Completed,"Johnson & Johnson/Janssen Biotech {Centocor Ortho Biotech {J&J/Ortho Biotech}}
West Virginia University",Oncology: Breast,First line; HER2 negative; Second line; Stage IV,Breast Neoplasms,United States
A Phase I Dose Escalation Study of Continuous Oral OSI-906 Dosing in Patients With Advanced Solid Tumors.,I,Completed,Astellas Pharma {OSI Pharmaceuticals},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Testicular; Oncology: Thymus",Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV; Thymic carcinoma,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms; Thymus Neoplasms; Unspecified; Wilms Tumor",United Kingdom; United States
"A Phase I Dose Escalation Trial To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of Epothilone D In Patients With Advanced Solid Tumor",I,Completed,"Bristol-Myers Squibb
Jonsson Comprehensive Cancer Center, UCLA
National Institutes of Health/National Cancer Institute","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified",United States
Multiple Daily Dose Phase I Safety And Pharmacokinetic Clinical Study Of Indole-3-Carbinol,I,Completed,"National Institutes of Health/National Cancer Institute
University of Kansas",Oncology: Breast,First line; Stage 0,Breast Neoplasms,United States
"A Dose Escalation Study of Sorafenib (BAY 43-9006, NSC 724772) in Normotensive Patients With Advanced Malignancies",I,Terminated,"National Institutes of Health/National Cancer Institute
Bayer AG/Bayer Pharmaceuticals","Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Osteosarcoma; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Testicular; Oncology: Thyroid",Localized; Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Osteosarcoma; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms; Thyroid Neoplasms; Unspecified; Wilms Tumor",United States
Protocol EC-0225-01: A Phase 1 Study of EC0225 Administered Weeks 1 and 3 of a 4-Week Cycle,I,Completed,Novartis/Endocyte,Oncology: Breast; Oncology: Colorectal; Oncology: Mesothelioma; Oncology: Prostate; Oncology: Soft Tissue Sarcoma,Second line; Stage IV,"Breast Neoplasms; Colorectal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Mesothelioma; Neoplasms, Mesothelial; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified",United States
Immunotherapy With Subcutaneous Il-2 and Stem Cell Factor (SCF) for Patients With Lymphoma or Breast Cancer After Autologous Transplantation,I,Completed,"National Institutes of Health/National Cancer Institute
University of Minnesota","Oncology: Breast; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's",Aggressive; Classical; Indolent; Line of therapy N/A; Nodular lymphocyte-predominant; Stage III; Stage IV,"Breast Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin",United States
"Phase I Multiple Dose Clinical Study of Soy Isoflavones in Healthy, Post-Menopausal Women.",I,Completed,"National Institutes of Health/National Cancer Institute
UNC Lineberger Comprehensive Cancer Center",Oncology: Breast; Oncology: Endometrial,(N/A); Line of therapy N/A,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms",United States
Safety and pharmacokinetics of AMG 706 in combination with gemcitabine for the treatment of patients with solid tumors.,I,Completed,Amgen,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Aggressive; First line; Fourth line or greater; Indolent; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Australia; United States
"Phase I safety, pharmacokinetic and pharmacodynamic study of 2-methoxyestradiol alone in patients with locally recurrent or metastatic breast cancer.",I,Completed,CASI Pharmaceuticals {EntreMed},Oncology: Breast,Fourth line or greater; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
Phase I/II Trial of High-Dose Radioimmunotherapy With a 90Y-Humanized MN-14 Anti-Carcinoembryonic Antigen (CEA) Antibody for the Treatment of Stage IV Breast Cancer.,I/II,Completed,"National Institutes of Health/National Cancer Institute
Garden State Cancer Center",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
"A pilot trial of interleukin-2 with G-CSF as priming therapy for peripheral blood stem cell harvesting in patients with advanced breast cancer: stamp V high dose chemotherapy, stem cell infusion and post-infusion G-CSF and interleukin-2.",I,Completed,"Amgen
(Other Academic Cancer Center)
Loyola University
University of Illinois at Chicago Health Sciences Center",Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,United States
Phase I Study of Combination Therapy With Oral 9-Nitrocamptothecin and Oral Etoposide.,I,Completed,"National Institutes of Health/National Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute","Oncology: Anal; Oncology: Breast; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Pancreas; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Soft Tissue Sarcoma",Advanced; Aggressive; Classical; Fourth line or greater; Indolent; Metastatic; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV; Third line,"Anus Neoplasms; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Fibrosarcoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Mesothelioma; Neoplasms, Basal Cell; Neoplasms, Mesothelial; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Unspecified; Wilms Tumor",United States
Phase I/II Study of Samarium 153 as Part of a Double (Sequential) Autologous Bone Marrow Transplant (ABMT) for Patients With Stage IV Breast Cancer,I/II,Terminated,Louisiana State University Health Sciences Center,Oncology: Breast,First line; Stage IV,Breast Neoplasms,United States
"Phase I/II Study of Dose-Intensive Doxorubicin, Paclitaxel, and Cyclophosphamide With Peripheral Blood Stem Cell and G-CSF Support for Metastatic Breast Cancer",I/II,Completed,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast,First line; Stage IV,Breast Neoplasms,United States
Infusion Of Activated T Cells And Low Dose Interleukin 2 Combined With Peripheral Blood Stem Cell Transplantation For The Treatment Of Women With Metastatic Breast Cancer: Phase I/II,I/II,Completed,St. Lukes Medical Center,Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,United States
Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients,I/II,Completed,"(Other Cooperative Group)
(Other Hospital/Academic/Medical Center)
Generex Biotechnology/NuGenerex Immuno-Oncology {Antigen Express}
Greenwich LifeSciences {Norwell}",Oncology: Breast,Adjuvant; HER2 negative; HER2 positive; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,Germany; Greece; United States
"A Phase I Trial of The Histone Deacetylase (HDAC) Inhibitor MS-275 in Patients with Advanced, Refractory Solid Malignancies and Lymphomas.",I,Completed,Bayer AG/Bayer Pharmaceuticals {Bayer HealthCare {Bayer Schering Pharma {Schering AG}}},"Oncology: Breast; Oncology: Colorectal; Oncology: GIST; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Aggressive; Indolent; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",United States
Phase I Open-Labeled Trial of Gemcitabine and Dasatinib in Advanced Solid Tumors.,I,Completed,"Bristol-Myers Squibb
MD Anderson Cancer Center, University of Texas",Oncology: Anal; Oncology: Breast; Oncology: Pancreas; Oncology: Thymus,Fourth line or greater; HER2 negative; Second line; Stage II; Stage III; Stage IV; Third line; Thymoma; Triple receptor negative,Anus Neoplasms; Breast Neoplasms; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Thymoma; Thymus Neoplasms,United States
A Phase I Trial of Bevacizumab and Bortezomib in Patients With Advanced Malignancy.,I,Completed,"MD Anderson Cancer Center, University of Texas","Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",(N/A); Aggressive; First line; Fourth line or greater; Indolent; Locally advanced; Metastatic; Pulmonary; Second line; Stage III; Stage IV; Third line; Untreated,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Uterine Cervical Neoplasms; Wilms Tumor",United States
"Safety, tolerability, and maximum tolerated dose of an intravenously administered human-engineered monoclonal antibody, ING-1(heMAb), in patients with advanced adenocarcinomas.",I,Completed,XOMA,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",Hormone refractory; Second line; Stage II; Stage III,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms",United States
Phase I Trial of Gemzar Administered as a 96 Hour Infusion in Patients with Relapsed/Refractory Lymphoma and Other Solid Tumors.,I,Completed,Albert Einstein Cancer Center (AECC),"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Neuroendocrine",(N/A); Aggressive; Indolent; Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neuroendocrine Tumors; Small Cell Lung Carcinoma",United States
"A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.",I,Completed,"Pfizer
Merck & Co./MSD K.K. {Banyu Pharmaceuticals}
PTC Therapeutics",Oncology: Bladder; Oncology: Breast; Oncology: Colorectal,Second line; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms,United States
"A Phase Ib, Multicenter, Open-Label, Dose-Finding Study of Patupilone Administered Intravenously Every 3 Weeks in Combination with Carboplatin AUC 6 in Adult Patients with Advanced Solid Tumors.",I,Completed,Novartis,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Prostate; Oncology: Renal; Oncology: Thymus",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms; Prostatic Neoplasms; Renal Cancer; Thymus Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",France; United States
A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer.,I/II,Completed,Novartis,Oncology: Breast,First line; Fourth line or greater; HER2 positive; Second line; Stage IV; Third line,Breast Neoplasms,Belgium; France; Netherlands; Spain; United States
"A Stratified, Randomized, Open-Label, Multi-Center Comparative 2-Arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-Month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year.",I,Completed,Novartis,Oncology: Breast; Oncology: Metastatic Cancer; Oncology: Multiple Myeloma,Bone mets; Second line; Stage I; Stage II; Stage III; Stage IV,"Breast Neoplasms; Multiple Myeloma; Neoplasm Metastasis; Neoplasms, Plasma Cell",United States
A Phase I Safety Evaluation of Oral Enzastaurin in Combination with Bevacizumab in Patients with Advanced/Metastatic Cancer,I,Completed,"Eli Lilly
National Institutes of Health/National Cancer Institute","Oncology: Bladder; Oncology: Breast; Oncology: Endometrial; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Neoplasm Metastasis; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Phase Ib Study Investigating the Combination of Everolimus With Trastuzumab and Vinorelbine in Patients With HER2-Overexpressing Metastatic Breast Cancer,I,Completed,Novartis,Oncology: Breast,First line; Fourth line or greater; HER2 positive; Second line; Stage IV; Third line,Breast Neoplasms; Neoplasm Metastasis; Neoplasms,Belgium; France; Italy; Poland; Sweden; United States
Phase I Study of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP) in Patients With Solid Tumors,I,Completed,"National Institutes of Health/National Cancer Institute
Vion Pharmaceuticals","Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Unspecified; Wilms Tumor",United States
Phase I Study of Melphalan and Thiotepa with Bone Marrow or Stem Cell Rescue in Patients with Responsive or Refractory Solid Tumors.,I,Completed,"National Institutes of Health/National Cancer Institute
Fred Hutchinson Cancer Research Center",Oncology: Breast,Second line; Stage IV,Breast Neoplasms; Unspecified,United States
A Phase I and Pharmacokinetic Study of Sequences of NSC 655649 (Rebeccamycin Analogue) and Cisplatin Without and With Granulocyte Colony-Stimulating Factor Support Every 21 Days,I,Completed,"National Institutes of Health/National Cancer Institute
University of Texas","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas",Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Lymphoma; Melanoma; Pancreatic Cancer; Pancreatic Neoplasms",United States
Phase I Study of Doxorubicin HCl Liposome (Doxil) and PSC 833 in Patients with AIDS-Related Kaposi's Sarcoma and Other Advanced Malignancies.,I,Completed,"National Institutes of Health/National Cancer Institute
Washington University School of Medicine",Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Renal; Oncology: Soft Tissue Sarcoma,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Sarcoma, Kaposi; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",United States
Phase I Study of Ro 31-7453 in Patients With Locally Advanced or Metastatic Solid Tumors,I,Completed,"Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute
Roche {F. Hoffmann-La Roche}","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"Use of Weekly One Hour Paclitaxel Infusion With Dose Escalation for Recurrent and Resistant Cancers, Using Amifostine as a Cytoprotector.",I/II,Completed,"Johnson & Johnson/ALZA
(Other Hospital/Academic/Medical Center)","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Prostate",(N/A); Pulmonary; Second line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Unspecified",United States
Phase I Study of UCN-01 in Patients With Advanced Solid Tumors or Chronic Lymphoproliferative Disorders.,I,Completed,"National Institutes of Health/National Cancer Institute
Johns Hopkins University","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Aggressive; Extranodal marginal zone B-cell lymphoma (MALT); Follicular lymphoma (FL); Fourth line or greater; Indolent; Mantle cell lymphoma (MCL); Second line; Small lymphocytic lymphoma (SLL); Stage III; Stage IV; Third line; Waldenstrom's macroglobulinemia (WM),"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Chronic Lymphocytic Leukemia; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Leukemia, Lymphocytic, Chronic, B-Cell; Liposarcoma; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Waldenstrom Macroglobulinemia; Wilms Tumor",United States
Phase I Study of LY231514 With Irinotecan in Patients With Metastatic Cancer.,I,Completed,"Eli Lilly
San Antonio Cancer Institute","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Pancreas",Advanced; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Liver Cancer; Liver Neoplasms; Mesothelioma; Neoplasms, Mesothelial; Pancreatic Cancer; Pancreatic Neoplasms; Unspecified",United States
A Phase I Study of High-Dose IV Vitamin C Treatment in Patients With Solid Tumors,I,Completed,"(Other Cooperative Group)
Midwestern Regional Medical Center","Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Pancreatic Cancer; Pancreatic Neoplasms; Unspecified",United States
A Pilot Study of Low-Dose Interleukin-2 Plus Recombinant Human Anti-HER2 Monoclonal Antibody in Solid Tumors.,I,Completed,"Cancer and Leukemia Group B (CALGB)
National Institutes of Health/National Cancer Institute","Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian",Fourth line or greater; HER2 positive; Second line; Third line,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
Phase I Pharmacokinetic and Pharmacodynamic Trial of Irinotecan in Combination With Tomudex in Patients With Refractory Solid Malignancies.,I,Completed,"National Institutes of Health/National Cancer Institute
Fox Chase Cancer Center",Oncology: Breast; Oncology: Colorectal; Oncology: Prostate,Second line; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Prostatic Neoplasms; Unspecified,United States
A phase I study of perillyl alcohol in patients with refractory malignancies. (NSC #641066),I,Completed,"National Institutes of Health/National Cancer Institute
Yale University","Oncology: Breast; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",(N/A); Second line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma",United States
A Phase I Clinical and Pharmacologic Evaluation of Phenylbutyrate in Patients With Refractory Solid Tumors: Study of Continuous Exposure oral Phenylbutyrate on a Three Times Daily Schedule.,I,Completed,"National Institutes of Health/National Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}",Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Prostate; Oncology: Renal; Oncology: Thyroid,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Lymphoma; Neoplasms; Prostatic Neoplasms; Renal Cancer; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase I Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of BMS-690514 in Combination with Paclitaxel and Carboplatin for Patients with Advanced or Metastatic Solid Tumors",I,Completed,Bristol-Myers Squibb,"Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian",First line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Esophageal Cancer; Esophageal Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms",Canada; United Kingdom; United States
Phase I/II Open-Label Trial of Sutent (Sunitinib Malate) And Aromasin(Exemestane) in the First-Line Treatment of Hormone Receptor-Positive Metastatic Breast Cancer.,I/II,Terminated,Pfizer,Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,Canada; United States
Phase IB Study of Biomarker Modulation by Celecoxib vs. Placebo in Women With Newly-Diagnosed Breast Cancer,I,Completed,"Pfizer
University of Kansas
Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}",Oncology: Breast,First line; Stage 0; Stage I,Breast Neoplasms,United States
A Phase I/II Trial of a Fixed Dose of MVA-BN-HER2 Following 1st- or 2nd-Line Chemotherapy for HER-2-Positive Metastatic Breast Cancer,I/II,Completed,Bavarian Nordic/BN ImmunoTherapeutics,Oncology: Breast,First line; HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
"Phase I, pharmacokinetic, and biological study of erlotinib in combination with Paclitaxel and Carboplatin in patients with advanced solid tumors.",I,Completed,Astellas Pharma {OSI Pharmaceuticals},"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Thyroid",First line; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
A Phase I Dose-Escalation Study to Examine the Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients with Cancer,I,Completed,Eli Lilly,"Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Small Intestine",Fourth line or greater; Second line; Stage II; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Intestinal Neoplasms; Kidney Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Uterine Cervical Neoplasms; Wilms Tumor",United States
A Phase I Study of Halichondrin B Analog (E7389) in Combination with Cisplatin in Advanced Solid Tumors,I,Completed,"National Institutes of Health/National Cancer Institute
California Cancer Consortium","Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Pancreas",Second line; Stage II; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer",I/II,Completed,Novartis,"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: GIST; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Skin, Basal Cell Carcinoma; Oncology: Soft Tissue Sarcoma",Aggressive; Classical; First line; HER2 negative; HER2 positive; Hormone refractory; Indolent; Locally advanced; Metastatic; Nodular lymphocyte-predominant; Second line; Stage I; Stage II; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Hamartoma Syndrome, Multiple; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms, Basal Cell; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",Germany; Netherlands; Spain; United Kingdom; United States
"An Open-label, Multi-center, 2-arm Phase I/II trial of LBY135 Alone and in Combination with Capecitabine in Advanced Solid Tumors.",I/II,Terminated,Novartis,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Cancer",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma",Netherlands; United States
"A Phase I, Open Label, Multi-Center, Accelerated Dose-Escalation, Pharmacokinetic and Pharmacodynamic Trial of The Oral Single Agent Aurora Kinase Inhibitor PF-03814735 In Patients with Advanced Solid Tumors for Whom No Standard Therapy is Available",I,Completed,Pfizer,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Renal",Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Belgium; United States
"A Phase I Open-Label,Dose-Escalation,Safety,PK & PD Study of CNF2024 as a Single-Agent Treatment in Subjects w/HER2- Adv Breast Cancer or in Combo w/Trastuzumab in Subjects w/HER2+ Advanced Breast Cancer",I,Completed,Biogen {Biogen Idec},Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
Phase I/II Trial of HER2/Neu Peptide (E75) Vaccine in Breast Cancer Patients at Risk for Recurrence After Surgical and Medical Therapies,I/II,Completed,"Walter Reed Army Institute of Research - WRAIR
SELLAS Life Sciences Group {Galena Biopharma {RXi Pharmaceuticals {Apthera}}}",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Stage I; Stage II,Breast Neoplasms,United States
"A Phase I Open Label Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of SF1126, A PI3 Kinase (PI3K) Inhibitor, Given Twice Weekly By IV Infusion To Patients With Advanced or Metastatic Tumors",I,Completed,"Semafore Pharmaceuticals
SignalRx","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: GIST; Oncology: Head/Neck; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Aggressive; Cutaneous T-cell lymphoma (CTCL); Diffuse large B-cell lymphoma (DLBCL); Extranodal marginal zone B-cell lymphoma (MALT); Follicular lymphoma (FL); Hormone refractory; Indolent; Locally advanced; Lymphoblastic lymphoma (LBL); Mantle cell lymphoma (MCL); Metastatic; Other subtype; Second line; Small lymphocytic lymphoma (SLL); Stage III; Stage IV; Waldenstrom's macroglobulinemia (WM),"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Chronic Lymphocytic Leukemia; Colorectal Neoplasms; Endometrial Neoplasms; Ewing Sarcoma; Fibrosarcoma; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Leukemia, Lymphocytic, Chronic, B-Cell; Liposarcoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Multiple Myeloma; Neoplasms; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Waldenstrom Macroglobulinemia; Wilms Tumor",United States
Phase I Study Of Anti-Platelet Derived Growth Factor Receptor Alpha (PDGFR&#945;) Monoclonal Antibody IMC-3G3 In Patients With Advanced Solid Tumors Who No Longer Respond To Standard Therapy Or For Whom No Standard Therapy Is Available.,I,Completed,Eli Lilly {ImClone},"Oncology: Bladder; Oncology: Breast; Oncology: Endometrial; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Prostate",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Small Cell; Endometrial Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
Phase I Dose Escalation Trial of Biweekly Alimta (With Vitamin Supplementation) in Combination With Taxotere in Advanced Solid Tumor Patients.,I,Completed,"Eli Lilly
National Institutes of Health/National Cancer Institute
University of Arizona","Oncology: Bladder; Oncology: Breast; Oncology: CNS, Other; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thymus",First line; Locally advanced; Metastatic; Second line; Stage III; Stage IV; Thymoma; Untreated,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thymoma; Thymus Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase I, Multicenter, Open Label, Clinical Trial of Immune Response, Safety and Tolerability of DNA Vector pPRA-PSM With Synthetic Peptides E-PRA and E-PSM in Subjects With Advanced Solid Malignancies.",I,Completed,MannKind,Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Testicular,Second line; Stage III; Stage IV,"Anus Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Sarcoma; Small Cell Lung Carcinoma; Stomach Neoplasms; Testicular Cancer; Testicular Neoplasms; Thyroid Neoplasms; Wilms Tumor",United States
A Phase I Trial of the Combination of Sirolimus and SU11248 (Sutent) in Patients With Advanced Solid Tumors That Are Non-Curable With Standard Therapy.,I,Terminated,"Pfizer
Yale University","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal; Oncology: Soft Tissue Sarcoma",First line; Fourth line or greater; Second line; Squamous Cell; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",United States
An Open-Label Phase I Study of the Safety of Perifosine in Combination With Sorafenib for Patients With Advanced Cancers.,I,Completed,Akebia Therapeutics {Keryx Biopharmaceuticals {Access Oncology/AOI Pharmaceuticals}},Oncology: Breast; Oncology: Liver; Oncology: Prostate; Oncology: Renal,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Prostatic Neoplasms; Renal Cancer; Wilms Tumor",United States
A Phase I/II Study of HKI-272 in Combination With Trastuzumab (Herceptin) in Subjects with Advanced Breast Cancer.,I/II,Completed,"(Other Industry Sponsor)
Pfizer {Wyeth}
Puma Biotechnology
Excella GmbH",Oncology: Breast,First line; HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,China; France; South Africa; Spain; Switzerland; United States
"A Phase I/II Pilot Study of Patients With Brain Metastasis Secondary to Breast Cancer Treated With Methotrexate and Carboplatin in Conjunction With Blood-Brain Barrier Disruption, With Concurrent Trastuzumab in HER-2 Positive Patients.",I/II,Terminated,"National Institutes of Health/National Cancer Institute
OHSU Cancer Institute",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; HER2 negative; HER2 positive; Second line; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis; Nervous System Neoplasms,United States
"Phase I Study Of ABT869, A Multiple Receptor Tyrosine Kinase Inhibitor in Patients with Refractory Solid Malignancies",I,Completed,"AbbVie {Abbott}
National Medical Research Council of Singapore","Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",Singapore; United States
Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and Immunogenicity,I,Completed,Memorial Sloan-Kettering Cancer Center,Oncology: Breast,HER2 positive; Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms,United States
A Phase I/II Clinical Trial Assessing Safety and Efficacy of BZL101 For Metastatic Breast Cancer,I/II,Completed,Bionovo,Oncology: Breast,Estrogen receptor positive; Fourth line or greater; Progesterone receptor positive; Stage III; Stage IV; Third line,Breast Neoplasms,United States
A Phase I Open-Label Safety and Pharmacokinetic Study of Escalating Doses of SGT-53 for Infusion in Subjects With Advanced Solid Tumors,I,Completed,"National Institutes of Health
SynerGene Therapeutics","Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",Metastatic; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Glioblastoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Medulloblastoma; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"An Open-Label, Randomized, 2-Period Crossover, Drug Interaction Study to Evaluate the Potential Pharmacokinetic Interaction Between Multiple Doses of Ketoconazole and a Single Dose of HKI-272 Administered Orally to Healthy Subjects",I,Completed,Pfizer {Wyeth},Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms; Unspecified,United States
"A Phase I Study of Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic Fluorouracil, Leucovorin and Avastin for Patients with Advanced Solid Tumors Metastatic to the Liver",I,Completed,"MD Anderson Cancer Center, University of Texas",Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Ovarian,Fourth line or greater; Liver mets; Second line; Stage IV; Third line,Bile Duct Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Ovarian Cancer; Ovarian Neoplasms; Stomach Carcinoma; Stomach Neoplasms,United States
"A Phase I, Open-Label, Study of the Safety, Tolerability and Pharmacokinetics of Pazopanib in Combination With Paclitaxel on a Weekly Schedule for 3 Consecutive Wks, Paclitaxel & Carboplatin on an Every 21 Days Schedule and Lapatinib & Paclitaxel on a Weekly Schedule for 3 Consecutive Weeks",I,Completed,GlaxoSmithKline,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Lung, Non-Small Cell",Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms",United States
A Phase I Study of AVE1642 in Combination With Taxotere for The Treatment of Advanced Solid tumors.,I,Terminated,"ImmunoGen
Sanofi {Sanofi-Aventis}",Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Melanoma; Oncology: Soft Tissue Sarcoma,Second line; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Melanoma; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma,France; United States
"A First In Man Phase I Study Of EPC2407, A Microtubule Inhibitor Anti-Cancer Drug With Tumor Vascular Endothelial Disrupting Activity: Intravenous Administration Daily For Three Days In Patients With Advanced Solid Tumors And Lymphomas.",I,Completed,Immune Pharmaceuticals {EpiCept},"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Small Intestine; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Aggressive; Anaplastic; Indolent; Peripheral T-cell lymphoma (PTCL); Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Intestinal Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms",United States
Phase I study of docetaxel and topotecan in patients with advanced malignancies.,I,Completed,GlaxoSmithKline {SmithKline Beecham},"Oncology: Breast; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Prostate",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
Phase I Radiosensitization Study of GW572016 With Biologic Correlates in Locoregionally Recurrent Breast Cancer.,I,Completed,"National Institutes of Health/National Cancer Institute
UNC Lineberger Comprehensive Cancer Center",Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase I Injection Study of Intratumoral Injection with Telomerase-Specific Replication-Competent Oncolytic Adenovirus, Telomelysin (OBP-301) for Various Solid Tumors",I,Completed,"Medigen Biotechnology
Oncolys BioPharma","Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Skin, Basal Cell Carcinoma; Oncology: Soft Tissue Sarcoma",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms, Basal Cell; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
A Phase I Imaging and Safety Study of Intravenous 131-I-TM-601 Labeled Chlorotoxin in Patients With Recurrent or Refractory Somatic and/or Cerebral Metastatic Solid Tumors,I,Completed,TransMolecular,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Thyroid",(N/A); CNS mets; Hormone refractory; Medullary; Pulmonary; Second line; Stage IV,"Adenocarcinoma; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Glioblastoma; Melanoma; Neoplasm Metastasis; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Thyroid Neoplasms",United States
A Phase I/II Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors,I,Completed,Bristol-Myers Squibb/Celgene {Gloucester Pharmaceuticals},"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Pancreas",Aggressive; Indolent; Line of therapy N/A; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms",United States
A Phase I Study to Assess the Safety of ARRY-334543 With Capecitabine in Patients With Advanced Cancer,I,Completed,Pfizer {Array BioPharma},Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Ovarian; Oncology: Unspecified Cancer,HER2 positive; Second line; Stage III; Stage IV,Bile Duct Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms,Canada; United States
Phase I/II trial of huanglian and Taxol administered concurrently to women with stage IV breast cancer that have progressed after anthracycline,I/II,Terminated,Memorial Sloan-Kettering Cancer Center,Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
A Phase I/II Study of a Combination of Suberoylanilide Hydroxamic Acid (Vorinostat) Plus Paclitaxel and Bevacizumab in Patients With Advanced Metastatic and/or Local Chest Wall Recurrent Breast Cancer.,I/II,Completed,"Merck & Co.
National Institutes of Health/National Cancer Institute
Albert Einstein Medical College",Oncology: Breast,First line; Stage III; Stage IV,"Breast Neoplasms; Breast Neoplasms, Male","Australia; Hong Kong, S.A.R., China; Singapore; South Korea; United States"
"A Phase I Dose Escalation Study of the Safety and Tolerability of Lapatinib in Combination With Carboplatin, Paclitaxel, and Herceptin in Patients With Metastatic Breast Cancer.",I,Completed,GlaxoSmithKline,Oncology: Breast,First line; HER2 negative; HER2 positive; Stage III; Stage IV,Breast Neoplasms,Germany; United States
Pharmacokinetic and Pharmacodynamic Study of the Effect of Imatinib on  Vascularity and on Gemcitabine uptake using Non-invasive Dynamic Contrast Enhanced Magnetic Resonance Imaging and Spectroscopy -Study BUS228.,I,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast; Oncology: Ovarian; Oncology: Pancreas,(N/A); Second line,Breast Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms,United States
Phase I and Pharmacokinetic Study of weekly Docosahexaenoic acid-paclitaxel (Taxoprexin) in Resistant Solid Tumor Malignancies.,I,Completed,"(Other Cooperative Group)
Daiichi Sankyo/American Regent {Luitpold}","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma",(N/A); Second line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Melanoma",United States
A Phase I Study of Pegylated Liposomal Doxorubicin (PLD) and Irinotecan (I) in Patients with Solid Tumors,I,Completed,Johnson & Johnson/Janssen Therapeutics {J&J/Centocor Ortho Biotech/Tibotec Therapeutics {J&J/Ortho Biotech/Tibotec}},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gallbladder; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal",Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Gallbladder Neoplasms; Kidney Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
Phase I trial of Ixabepilone given weekly in patients with advanced malignancies,I,Completed,Bristol-Myers Squibb,Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Ovarian,Second line; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; Ovarian Cancer; Ovarian Neoplasms,United States
A Multicenter Phase I Dose Escalation Study of SN2310 Injectable Emulsion in Patients with Advanced Solid Tumors.,I,Completed,Achieve Life Sciences {OncoGenex Pharmaceuticals {Sonus Pharmaceuticals}},"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Lung Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Pelvic Neoplasms",United States
"An Open-Label, Dose Escalation Phase Ib Trial of MK0646 Given as a One to Two Hour Every Other Week Infusion in Patients With Relapsed or Refractory Locally Advanced or Metastatic Cancers",I,Completed,Merck & Co./Merck Sharp & Dohme (MSD),Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma,Second line; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms,Puerto Rico; United States
Transplantation of Umbilical Cord Blood From Unrelated Donors in Patients With Hematological Diseases Using a Non-Myeloablative Preparative Regimen.,I/II,Completed,"National Institutes of Health/National Cancer Institute
University of Minnesota","Oncology: Breast; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome; Oncology: Renal",Accelerated phase; Blast phase; Chronic phase; Classical; Cutaneous T-cell lymphoma (CTCL); del(5q); Extranodal marginal zone B-cell lymphoma (MALT); Follicular lymphoma (FL); High risk; Indolent; Nodular lymphocyte-predominant; Other subtype; Peripheral T-cell lymphoma (PTCL); Poor-risk; RA/RARS; RAEB; RAEB-t; RCMD; Remission; Second line; Small lymphocytic lymphoma (SLL); Stage III; Stage IV; Waldenstrom's macroglobulinemia (WM),"Acute Myelocytic Leukemia; Breast Neoplasms; Carcinoma, Renal Cell; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms, Plasma Cell; Plasmacytoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Preleukemia; Renal Cancer; Syndrome; Waldenstrom Macroglobulinemia; Wilms Tumor",United States
"Open Label, Dose Escalation Trial of Oral PXD101 in Patients with Advanced Solid Tumors.",I,Completed,"Celldex Therapeutics {CuraGen}
Onxeo {TopoTarget}","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Aggressive; Classical; Cutaneous T-cell lymphoma (CTCL); Diffuse large B-cell lymphoma (DLBCL); Extranodal marginal zone B-cell lymphoma (MALT); Follicular lymphoma (FL); Hormone refractory; Indolent; Lymphoblastic lymphoma (LBL); Mantle cell lymphoma (MCL); Nodular lymphocyte-predominant; Other subtype; Peripheral T-cell lymphoma (PTCL); Second line; Small lymphocytic lymphoma (SLL); Stage III; Stage IV; Waldenstrom's macroglobulinemia (WM),"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Mesothelioma; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Waldenstrom Macroglobulinemia; Wilms Tumor",Denmark; United Kingdom; United States
"A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Daily Oral Administration of AV-412 in Patients With Refractory or Relapsed Solid Tumor Malignancies.",I,Terminated,LG Chem/AVEO Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",EGFR; Fourth line or greater; Hormone refractory; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms",Argentina; Spain; United States
A Phase I Study to Characterize the Pharmacokinetics of Topotecan at 4 Mg/m2 Administered Weekly as a 30-Minute Intravenous Infusion in Patients with Cancer.,I,Completed,GlaxoSmithKline,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Small Intestine",Second line; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Intestinal Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Unspecified; Wilms Tumor",United States
Phase I study of vaccine (Ad-sig-TAA/ecdCD40L vector prime) in patients with breast cancer.,I,Completed,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}
Breast Cancer Research Foundation",Oncology: Breast,(N/A); Second line,Breast Neoplasms,United States
"A Phase Ib, Open-Label, Dose Escalation Study Evaluating the Safety of BSI-201 in Combination with Chemotherapeutic Regimens in Subjects with Advanced Solid Tumors",I,Completed,Sanofi {Sanofi-Aventis/BiPar},"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma",BRCA; Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Ewing Sarcoma; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasms; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",United States
Phase I Trial of O6-BENZYLGUANINE and BCNU: a Biochemical Modulation Trial Based Upon Depletion of O6-ALKYLGUANINE DNA Alkyltransferase Directed DNA Repair,I,Completed,"National Institutes of Health/National Cancer Institute
Case Western Reserve University","Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Renal",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Wilms Tumor",United States
Phase I Study Evaluating MK6592 in Combination With Docetaxel in Adult Patients With Relapsed or Refractory Advanced Solid Tumors,I,Terminated,"Merck & Co.
Vertex Pharmaceuticals","Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Medulloblastoma; Melanoma; Neoplasms; Neoplasms, Basal Cell; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
Phase I Study of Two Different Schedules of Lapatinib (GW572016) in Combination With Vinorelbine in Advanced Solid Tumors.,I,Completed,"GlaxoSmithKline
National Institutes of Health/National Cancer Institute
University of California Davis","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Prostate",HER2 positive; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms; Prostatic Neoplasms",United States
A Phase I Study of Bevacizumab in Combination With SU11248,I,Completed,"National Institutes of Health/National Cancer Institute
Pfizer
Case Western Reserve University","Oncology: Bladder; Oncology: Breast; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Small Intestine; Oncology: Soft Tissue Sarcoma; Oncology: Testicular; Oncology: Thyroid",First line; Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Fibrosarcoma; Intestinal Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms; Thyroid Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase I/II Clinical Trial Evaluating DCVax-Direct, Autologous Activated Dendritic Cells For Intratumoral Injection In Patients With Solid Tumors",I/II,Closed,Northwest Biotherapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",Fourth line or greater; PD-L1 Positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
Phase I Study of Aprotinin in Advanced Breast Cancer.,I,Terminated,"Bayer AG/Bayer Pharmaceuticals
Dartmouth-Hitchcock Medical Center",Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,United States
Phase I-II Study of Denileukin Diftitox (ONTAK) in Patients with Advanced Refractory Breast Cancer,I/II,Completed,"National Institutes of Health/National Cancer Institute
Fred Hutchinson Cancer Research Center
University of Washington",Oncology: Breast,Fourth line or greater; HER2 negative; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Breast Neoplasms, Male",United States
Phase I Study of Bryostatin 1 and Gemcitabine in Patients With Advanced Refractory Cancer.,I,Completed,"Barbara Ann Karmanos Cancer Institute
National Institutes of Health/National Cancer Institute","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Renal; Oncology: Small Intestine; Oncology: Soft Tissue Sarcoma",Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Intestinal Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Unspecified; Wilms Tumor",United States
A Phase I Trial of 5-Fluorouracil Given With 776C85 (GW776) and Low-Dose Leucovorin in Adult Patients With Solid Tumors,I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Pancreas",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Liver Cancer; Liver Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Unspecified",United States
A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833.,I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Aggressive; Indolent; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",United States
"A Phase I Open-Label Study of S-Trans, Trans-Farnesylthiosalicylic Acid (FTS) Administered on Days 1 to 21 of a 28-Day Cycle in Patients with Solid Malignancies.",I,Completed,Advanz Pharma {Concordia Healthcare Corp. {Concordia Pharmaceuticals}},"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Multiple Myeloma; Oncology: Pancreas; Oncology: Renal; Oncology: Thyroid",Aggressive; Cutaneous T-cell lymphoma (CTCL); Fourth line or greater; Indolent; Nodular lymphocyte-predominant; Peripheral T-cell lymphoma (PTCL); Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Melanoma; Multiple Myeloma; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Thyroid Neoplasms; Wilms Tumor",United States
A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast Cancer,I,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,First line; Stage 0; Stage I,Breast Neoplasms,United States
Phase I Study of Intrathecal Topotecan,I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Leukemia, Acute Lymphocytic; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Soft Tissue Sarcoma",(N/A); Aggressive; Classical; Indolent; Nodular lymphocyte-predominant; Pediatric or Adolescent; Second line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Fibrosarcoma; Glioblastoma; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Medulloblastoma; Meningeal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
Phase I Study of Bortezomib (Velcade) and Cetuximab (Erbitux) for Patients with Solid Tumors Expressing EGFR.,I,Completed,"National Institutes of Health/National Cancer Institute
Takeda/Takeda Oncology {Millennium}
University of Minnesota","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma",EGFR; First line; Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Lung Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Poland; United States
Phase I/II study of AA102 in the treatment of metastatic breast cancer.,I/II,Terminated,Bionovo,Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms,I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Prostate",Aggressive; ALK; Indolent; Second line,"Breast Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms; Prostatic Neoplasms",Canada; Japan; United States
A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833.,I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Renal",Aggressive; Indolent; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Kidney Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasm Metastasis; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Wilms Tumor",United States
Pharmacokinetics of Etoposide in Patients With Breast Cancer Receiving High-Dose Etoposide.,I,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
A Phase I Trial of PS-341 in Combination With Topotecan in Advanced Solid Tumor Malignancies.,I,Completed,"National Institutes of Health/National Cancer Institute
Beckman Research Institute","Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian",First line; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
Phase I dose-escalating study of Pemetrexed (Alimta) and Gemcitabine(Gemzar) given every 14 days in patients with an advanced malignancy or Ovarian Cancer.,I,Completed,Eli Lilly,"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Wilms Tumor",United States
"Breast Cancer Chemoprevention Phase I Evaluation of Biomarker Modulation by Arzoxifene, a Third Generation Selective Estrogen Receptor Modulator",I,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,First line; Stage 0; Stage I; Stage II,Breast Neoplasms,United States
A Phase I Study and Pharmacological Trial of Once weekly Aminoflavone Prodrug (AFP464) Administered 3 out of Every 4 weeks in Solid Tumor Patients,I,Completed,"National Institutes of Health/National Cancer Institute
Mayo Clinic
Kirax Corporation {Tigris Pharmaceuticals}",Oncology: Breast; Oncology: Ovarian; Oncology: Renal,HER2 negative; Second line; Stage IV; Triple receptor negative,"Breast Neoplasms; Breast Neoplasms, Male; Carcinoma, Renal Cell; Kidney Neoplasms; Neoplasms; Neoplasms, Glandular and Epithelial; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Renal Cancer; Wilms Tumor",United States
Pilot study of regional hepatic intra-arterial (HIA) paclitaxel in patients with breast carcinoma metastatic to the liver.,I/II,Completed,"MD Anderson Cancer Center, University of Texas",Oncology: Breast; Oncology: Metastatic Cancer,Fourth line or greater; HER2 negative; HER2 positive; Liver mets; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Liver Neoplasms; Neoplasm Metastasis,United States
"A Phase I, Open Label, Non-Randomized, Dose Escalation Study To Evaluate the Safety of CP-675,206 in Combination with Exemestane in Second Line Treatment For Post-Menopausal Women with Metastatic or Locally Advanced Breast Cancer.",I,Completed,Pfizer,Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,Canada; United States
A Multiple Ascending Dose (MAD) Study of R547 Administered as an Intravenous Infusion on a Weekly Schedule in Patients with Advanced Solid Tumors.,I,Completed,Roche {F. Hoffmann-La Roche},"Oncology: Breast; Oncology: Colorectal; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Neuroendocrine; Oncology: Prostate",(N/A); Aggressive; First line; Fourth line or greater; Indolent; Pulmonary; Second line; Stage III; Stage IV; Third line; Untreated,"Breast Neoplasms; Carcinoma, Small Cell; Chronic Lymphocytic Leukemia; Colorectal Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neuroendocrine Tumors; Prostatic Neoplasms; Small Cell Lung Carcinoma; Unspecified",United States
"A Phase Ib, Multi-Center, Open-Label, Dose Escalation Trial of Intravenous PR-104 Given in Combination With Docetaxel or Gemcitabine in Subjects With Solid Tumors.",I,Completed,Proacta,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",First line; Fourth line or greater; Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma",New Zealand; United States
"A Phase I, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CNF2024 Administered Orally Twice Weekly for Three Weeks of a Four Week Course or Twice Weekly for Four Weeks of a Four Week Course to Patients With Advanced Solid Tumors.",I,Completed,Biogen {Biogen Idec {Conforma Therapeutics}},"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: GIST; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Aggressive; Indolent; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",United Kingdom; United States
A phase I study of oral navelbine in patients with advanced solid tumors.,I,Completed,(Other Hospital/Academic/Medical Center),"Oncology: Breast; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Renal",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Endometrial Neoplasms; Kidney Neoplasms; Prostatic Neoplasms; Renal Cancer; Wilms Tumor",United States
Combination therapy with gefitinib and capecitabine in metastatic breast cancer (MBC): A phase I trial.,I,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage IV; Third line,Breast Neoplasms,United States
Phase I Combination Study of Trabectedin (T) and Capecitabine (C) in Patients with Advanced Malignancies.,I,Completed,"Johnson & Johnson/Janssen R&D {Johnson & Johnson/J&JPRD}
PharmaMar {Zeltia/PharmaMar}","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma",Second line; Stage III; Stage IV; Unresectable,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Melanoma; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma",United States
"A Phase l, Open Label Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2171 and Selected Chemotherapy Regimens When Given in Combination to Patients With Advanced Solid Tumors",I,Completed,AstraZeneca,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",(N/A); First line; Fourth line or greater; Locally advanced; Metastatic; Pulmonary; Second line; Stage II; Stage III; Stage IV; Third line; Untreated,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Phase I Study of AFP464 (Aminoflavone Prodrug) in Patients With Advanced Solid Tumors.,I,Completed,"National Institutes of Health/National Cancer Institute
Kirax Corporation {Tigris Pharmaceuticals}","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Renal",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Kidney Neoplasms; Neoplasms; Prostatic Neoplasms; Renal Cancer; Wilms Tumor",United States
Phase I Trial of Liposomal Doxorubicin (Doxil) and ZD1839 (Iressa) in Patients with Refractory Gynecological Malignancies or Metastatic Breast Cancer,I,Completed,Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute,Oncology: Breast; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal,HER2 negative; HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Fallopian Tube Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms",United States
"A Phase I Study of the mTOR Inhibitor  (Rapamune, Sirolimus) in Combination With Abraxane (Paclitaxel Protein-Bound Particles) in Advanced Solid Cancers.",I,Completed,"Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}}
Yale University","Oncology: Breast; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma",First line; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified",United States
A phase I study of LP-261-01 in patients with advanced solid malignancies,I,Completed,Ansaris {Locus Pharmaceuticals},"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",(N/A); Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase I/II Dose-Escalation Trial of Intratumoral Injection with a Replication-Deficient Adenovirus Vector, Ad-mda7 (INGN 241), in Combination with Radiation Therapy in Patients with Locally Recurrent Breast Cancer.",I/II,Terminated,Introgen Therapeutics,Oncology: Breast,Second line; Stage III,Breast Neoplasms,United States
A Phase I Study of ILX-651 Administered Intravenously Daily For Five Days Every Three Weeks in Patients with Advanced Solid Tumors.,I,Completed,Sanofi {Sanofi-Aventis}/Sanofi Genzyme {Genzyme {ILEX Oncology}},"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A phase I clinical trial of ILX651, a dolastatin-15 analog, administered as a 30-minute intravenous infusion every other day x 3 doses every 21 days in patients with advanced solid tumors.",I,Completed,Sanofi {Sanofi-Aventis}/Sanofi Genzyme {Genzyme {ILEX Oncology}},"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Wilms Tumor",United States
"Phase I Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab with or without Paclitaxel.",I/II,Terminated,Bristol-Myers Squibb {Kosan Biosciences},Oncology: Breast; Oncology: Ovarian,First line; Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms; Ovarian Cancer; Ovarian Neoplasms,United States
Nanoparticle albumin-bound (Nab) paclitaxel (P) in combination with bevacizumab (B) with and without gemcitabine (G): Early experience at the Braman Family Breast Cancer Institute.,I,Completed,"Sylvester Cancer Center, University of Miami",Oncology: Breast,Fourth line or greater; HER2 negative; Stage IV; Third line,Breast Neoplasms,United States
A Phase I Trial of PXD101 in Combination With 13-cis-Retinoic Acid in Advanced Solid Tumor Malignancies,I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Pancreas; Oncology: Renal",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Wilms Tumor",United States
"A Phase I Clinical Trial of Repeated Dose Intrapleural Adenoviral-Mediated Interferon-Beta (BG00001, Ad.hIFN-ß)  for pleural Malignancies.",I,Completed,"National Institutes of Health/National Cancer Institute
University of Pennsylvania
Biogen","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma",Advanced; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Mesothelioma; Neoplasms, Mesothelial; Pleural Effusion",United States
"Phase I Trial of Vorinostat (NSC-701852, Suberoylanilide Hydroxamic Acid) and Doxorubicin (NSC-123127, Adriamycin).",I,Completed,"Merck & Co.
National Institutes of Health/National Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",(N/A); Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
Phase I - II Study of Doxil In Combination With Daily Oral Cyclophosphamide and Herceptin for Patients With HER-2/Neu Positive Disease In Patients With Metastatic Breast Cancer,I/II,Completed,"National Institutes of Health/National Cancer Institute
Fred Hutchinson Cancer Research Center
University of Washington/Seattle Cancer Care Alliance",Oncology: Breast,HER2 positive; Second line; Stage IV,"Breast Neoplasms; Breast Neoplasms, Male",United States
A Phase I Trial of Escalating Treosulfan in Combination with High-Dose Melphalan and Dacarbazine (TMD) with Peripheral Blood Progenitor Cell Transplant (PBPCT) in Recurrent Metastatic Ovarian and Breast Cancer.,I,Completed,Barbara Ann Karmanos Cancer Institute,Oncology: Breast; Oncology: Ovarian,Fourth line or greater; Second line; Stage IV; Third line,Breast Neoplasms; Ovarian Cancer; Ovarian Neoplasms,United States
"A Phase I Dose-Escalation Trial of Intravenous Infusion With An E1B-Attenuated Adenovirus, Onyx-015 In Combination With Enbrel Into Patients With Advanced Carcinoma.",I,Completed,(Other Hospital/Academic/Medical Center),"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Ovarian",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Ovarian Cancer; Ovarian Neoplasms",United States
"A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.",I,Completed,Amgen,Oncology: Breast; Oncology: Metastatic Cancer; Oncology: Multiple Myeloma,(N/A); Bone mets; Line of therapy N/A; Stage IV,Breast Neoplasms; Multiple Myeloma; Neoplasm Metastasis,Belgium; France; United Kingdom; United States
"A Dose-Escalating, Multicenter, Single Arm, Open-Label Study of XRP9881 in Combination With Capecitabine (Xeloda), in Metastatic Breast Cancer Patients With Disease Progressing After Anthracycline and Taxane Therapy",I/II,Completed,Sanofi {Sanofi-Aventis},Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,France; United States
A Phase I Study of Herceptin/CCI-779 in HER2-Positive Metastatic Breast Cancer,I,Completed,"National Institutes of Health/National Cancer Institute
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute",Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
Phase I Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma,I,Completed,Triphase Accelerator {Triphase Research {Nereus}},"Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Ovarian; Oncology: Renal",Aggressive; Classical; Indolent; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Colorectal Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
Phase 1 Study of Weekly Anti-Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1) Monoclonal Antibody IMC-18F1 in Patients With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or For Whom No Standard Therapy is Available,I,Completed,Eli Lilly {ImClone},"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Thyroid",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Thyroid Neoplasms",United States
"An Open-Label, Dose-Finding Study to Evaluate the Safety of AMG 706 in Combination With Paclitaxel or Docetaxel as Treatment for Locally Recurrent or Metastatic Breast Cancer.",I,Completed,"Amgen
Takeda",Oncology: Breast,First line; Second line; Stage III; Stage IV,Breast Neoplasms,Australia; United States
A Two Arm Phase I Dose Escalation Trial of Vinflunine With Erlotinib or Pemetrexed in Refractory Solid Tumors.,I,Terminated,"Bristol-Myers Squibb
Eli Lilly
Roche/Genentech {Genentech}
National Institutes of Health/National Cancer Institute
UNC Lineberger Comprehensive Cancer Center","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",Metastatic; Second line; Stage III; Stage IV; Unresectable,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma",United States
"A Phase I Trial of Vaccination with Autologous, Lethally Irradiated Breast Cancer Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Colony Stimulating Factor in Metastatic Breast Cancer Patients.",I,Completed,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Brigham and Womens Hospital",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 positive; Progesterone receptor positive; Second line; Stage IV; Third line,Breast Neoplasms,United States
"A Phase I, Dose-escalation, Sequential-cohort Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous AVE0005 (VEGF Trap) in Combination with Intravenous Docetaxel/Cisplatin/5-Fluorouracil Administered Every 3 Weeks In Subjects with Advanced Solid Malignancies.",I,Completed,Sanofi {Sanofi-Aventis},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Thyroid",(N/A); Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Esophageal Cancer; Esophageal Neoplasms; Liver Cancer; Liver Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms",France; United States
Phase I Study of carbohydrate-targeting vaccine to prevent the recurrence of breast cancer,I,Terminated,University of Arkansas,Oncology: Breast,(N/A); Second line,Breast Neoplasms,United States
"Phase I-II Study of Trastuzumab in Combination With RAD001 in Patients With HER-2 Overexpressing, PTEN-Deficient Metastatic Breast Cancer Progressing on Trastuzumab-Based Therapy",I/II,Completed,"Novartis
MD Anderson Cancer Center, University of Texas",Oncology: Breast,HER2 positive; Second line; Stage IV; Third line,Breast Neoplasms; Neoplasm Metastasis,United States
"A Phase I, Open-Label, Non-Randomized, Dose-Finding, Safety, Tolerance, and Pharmacokinetic Study of Orally Administered S-1 in Combination with Gemcitabine in Patients with Advanced Solid Tumors",I,Completed,(Other Hospital/Academic/Medical Center),"Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas",Line of therapy N/A; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
A Phase Ib Study with Biologic Endpoints Of Paclitaxel and 2-Methoxyestradiol (Panzem Nanocrystal Colloidal Dispersion) In Metastatic Breast Cancer,I,Completed,"Duke Comprehensive Cancer Center
CASI Pharmaceuticals {EntreMed}
Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}",Oncology: Breast,First line; HER2 positive; Stage III; Stage IV,Breast Neoplasms,United States
"Phase I Clinical Evaluation of Weekly Administration of the Novel Vascular-Targeting Agent, ZD6126, in Patients With Solid Tumors.",I,Completed,AstraZeneca,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Renal",(N/A); Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Kidney Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Wilms Tumor",Netherlands; United States
"Use of Mouse Renal Adenocarcinoma Cell-containing Agarose-agarose Macrobeads in the Treatment of Patients With End-stage, Treatment-resistant Epithelial-derived Cancer",I,Completed,(Other Hospital/Academic/Medical Center),"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal",Extranodal marginal zone B-cell lymphoma (MALT); Indolent; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Wilms Tumor",United States
Phase I/II Lapatinib Plus Carboplatin and Paclitaxel in Stage III or IV Relapsed Ovarian or Stage IV Breast Cancer Patients.,I/II,Completed,"GlaxoSmithKline
Swedish Cancer Institute",Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal,Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Fallopian Tube Neoplasms; Neoplasms, Glandular and Epithelial; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms",United States
"Phase I study of BMS-247550, an epothilone B analog, administered weekly for 3 weeks followed by a one-week break in patients with advanced malignancies.",I,Completed,University of Texas Health Science Center at San Antonio,"Oncology: Breast; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Prostate",(N/A); Fourth line or greater; Hormone refractory; Pulmonary; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Small Cell; Neuroendocrine Tumors; Prostatic Neoplasms; Small Cell Lung Carcinoma",United States
"A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer.",I,Completed,Merck & Co.,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Testicular; Oncology: Unspecified Hematological Cancer",Advanced; Aggressive; Classical; Fourth line or greater; Indolent; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Hematologic Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Mesothelioma; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Testicular Cancer; Testicular Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase I, Open-Label Study of the Safety, Tolerability and Pharmacokinetics of Lapatinib in Combination With Liposomal Doxorubicin in Patients With Metastatic Breast Cancer.",I,Completed,"GlaxoSmithKline
National Institutes of Health/National Cancer Institute
Robert H. Lurie Comprehensive Cancer Center at Northwestern University",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
A Phase I Dose Escalation Study of a 2 Day Oral Lapatinib Chemosensitization Pulse Given Prior To Weekly Intravenous Abraxane in Patients With Advanced Solid Tumors.,I,Completed,"National Institutes of Health/National Cancer Institute
University of California, San Francisco","Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",Advanced; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Lung Neoplasms; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neoplasms, Mesothelial; Nervous System Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
A Phase I Study of Hydralazine as a Demethylating Agent in Operable Breast Cancer.,I,Completed,University of Arkansas,Oncology: Breast,Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Phase I Study Evaluating the Combination of Lapatinib (GW572016; NSC-727989) and Everolimus (RAD001) in Patients with Advanced Solid Tumors.,I,Completed,"Southwest Oncology Group
National Institutes of Health/National Cancer Institute","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Advanced; Aggressive; Follicular lymphoma (FL); Hormone refractory; Indolent; Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma; Lymphoma, Follicular; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
Allogeneic Peripheral Blood Progenitor Cell Transplantation in Patients With Incurable Solid Tumors: A Phase I Study,I,Terminated,"National Institutes of Health/National Cancer Institute
Northwestern University","Oncology: Breast; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Renal; Oncology: Testicular",Extensive; Pulmonary; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Carcinoma, Small Cell; Kidney Neoplasms; Melanoma; Neoplasms, Germ Cell and Embryonal; Neuroendocrine Tumors; Renal Cancer; Small Cell Lung Carcinoma; Testicular Cancer; Testicular Neoplasms; Wilms Tumor",United States
"A Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Hepatocellular Carcinoma Not Amenable to Resection or Transplant",I,Closed,Provectus Biopharmaceuticals,"Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Ovarian; Oncology: Pancreas; Oncology: Small Intestine",First line; Liver mets; Other mets; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Intestinal Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms",United States
Protocol EC-FV-01: A Phase I Study of EC145 Administered Weeks 1 and 3 of a 4 -Week Cycle.,I,Completed,Novartis/Endocyte,"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate",Hormone refractory; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Unspecified",United States
A Phase I Surrogate Endpoint Trial of Human Recombinant Endostatin in Patients With Advanced Solid Tumors Amenable to Biopsy,I,Completed,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute","Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",First line; Fourth line or greater; Medullary; Metastatic; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Wilms Tumor",United States
"A Phase I Study of Vinorelbine Liposomes Injection (VLI) for Treatment in Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease.",I,Completed,"Arbutus Biopharma {Tekmira Pharmaceuticals {Inex Pharmaceuticals}}
Spectrum Pharmaceuticals/Talon Therapeutics {Hana Biosciences}","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's",Aggressive; Classical; Indolent; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin",Canada; United States
Evaluation of the Safety and Immunogenicity of Vaccination With Multiple Synthetic Peptides in Participants With Advanced Breast Cancer.,I,Completed,"National Institutes of Health/National Cancer Institute
University of Virginia",Oncology: Breast,Estrogen receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"Phase I Pilot Study of Tumor-Derived, Ex Vivo Expanded and Costimulated Allogeneic T-Lymphocyte Infusion In An Individual Patient With Pulmonary Metastases Secondary to Breast Cancer Who Has Received Prior Allogeneic Hematopoietic Stem Cell Transplantation.",I,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms; Neoplasm Metastasis,United States
A Phase I/Ib Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid Tumors,I,Completed,Sanofi {Sanofi-Aventis/BiPar},Oncology: Breast; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; HER2 positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Neoplasms, Unknown Primary; Unspecified",United States
A Phase I Study Using Vaccination With NY-ESO-1 Recombinant Protein Mixed With CpG 7909 and Montanide ISA-51 VG in Patients With Cancers That Often Express NY-ESO-1,I,Completed,"NYU School of Medicines Kaplan Comprehensive Cancer Center
Ludwig Institute for Cancer Research","Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",(N/A); Line of therapy N/A,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
A phase I pharmacokinetic (PK)/food effect and safety study of satraplatin.,I,Completed,"Agennix {GPC Biotech}
Spectrum Pharmaceuticals",Oncology: Breast; Oncology: Head/Neck; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Prostate; Oncology: Soft Tissue Sarcoma,(N/A); Fourth line or greater; Hormone refractory; Second line; Third line,"Breast Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Mesothelioma; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
Phase I Study of the Vascular Disrupting Agent NPI-2358 Administered Via Intravenous Infusion in Patients with Advanced Solid Tumor Malignancies or Lymphoma.,I,Completed,Triphase Accelerator {Triphase Research {Nereus}},"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Aggressive; Indolent; Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Wilms Tumor",United States
Phase I Trial of Adenoviral Vector Delivery of the Human Interleukin-12 cDNA by Intratumoral Injection in Patients With Metastatic Breast Cancer to the Liver,I,Terminated,"Icahn School of Medicine at Mount Sinai {Mount Sinai School of Medicine}
U.S. Army Medical Research and Materiel Command",Oncology: Breast; Oncology: Metastatic Cancer,Liver mets; Second line; Stage IV,Breast Neoplasms; Liver Neoplasms; Neoplasm Metastasis,United States
"A Phase I, Open-label, Dose Escalation Study of the Humanized Monoclonal Antibody, TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors",I,Completed,"Amgen {Micromet {CancerVax Corporation}}
Tracon Pharmaceuticals","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate",Fourth line or greater; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasm Metastasis; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
A phase I study of SU6668 in patients with refractory solid tumors,I,Completed,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}
Pfizer {Sugen}","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Prostate; Oncology: Renal",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Kidney Neoplasms; Prostatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Wilms Tumor",United States
A Phase I Study of a Prolonged Infusion of Triapine in Combination with a Fixed Dose Rate of Gemcitabine in Patients with Advanced Solid Tumors and Lymphomas,I,Completed,"National Institutes of Health/National Cancer Institute
Richard J. Solove Research Institute
Arthur G. James Cancer Hospital
Vion Pharmaceuticals","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: GIST; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Pancreas",First line; Fourth line or greater; Second line; Stage II; Stage III; Stage IV; Third line,"Breast Neoplasms; Burkitt Lymphoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gastrointestinal Stromal Tumors; Hodgkin Disease; Immunoblastic Lymphadenopathy; Intraocular Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, T-Cell; Leukemia-Lymphoma, Adult T-Cell; Liver Cancer; Liver Neoplasms; Lymphoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Mycoses; Mycosis Fungoides; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Sezary Syndrome; Stomach Carcinoma; Stomach Neoplasms; Syndrome; Urethral Neoplasms; Urinary Bladder Neoplasms; Waldenstrom Macroglobulinemia",United States
A Phase I Trial of TNF-Bound Colloidal Gold (CYT-6091) by Intravenous Administration in Subjects with Advanced Solid Organ Malignancies,I,Completed,"National Institutes of Health/National Cancer Institute
CytImmune Sciences","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",First line; Locally advanced; Metastatic; Second line; Stage III; Stage IV; Untreated,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Melanoma; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified",United States
"A Phase I/II, Open-Label, Dose Escalation Study To Assess The Safety, Tolerability, and Pharmacokinetics of INCB007839 Following Multiple Oral Doses in Patients With Solid Tumors",I/II,Completed,Incyte Corporation,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Prostate",(N/A); HER2 positive; Hormone refractory; Second line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Neoplasms; Prostatic Neoplasms",United States
"Phase I, Open-Label, Multi-Center, Accelerated Dose Escalation Study Of The Anti-Angiogenesis Agent PF-00337210 In Patients With Advanced Solid Tumors",I,Completed,"Pfizer
University of Wisconsin Comprehensive Cancer Center","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma",(N/A); Locally advanced; Metastatic; Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neuroendocrine Tumors; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase I Dose-Finding Study Of The Anti-Angiogenesis Agent, AG-013736, In Combinations Of Paclitaxel/Carboplatin, Weekly Paclitaxel, Docetaxel, Capecitabine, Gemcitabine/Cisplatin and Pemetrexed/Cisplatin In Patients With Advanced Solid Tumors.",I,Completed,Pfizer,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Thyroid",(N/A); First line; Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms; Unspecified; Wilms Tumor",Poland; Spain; United States
"A Phase IB, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination with Doxorubicin",I,Completed,"Takeda {Ariad}
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast; Oncology: Endometrial; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Ovarian Cancer; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
A Phase I Study of the Safety and Tolerability of Four Doses of Cetuximab (C225) in Patients With Advanced Solid Tumors.,I,Completed,"Bristol-Myers Squibb
Eli Lilly {ImClone}
University of California Davis Cancer Center","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Pancreas",EGFR; First line; Second line; Stage II; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"Phase I/II Study of Two Different Schedules of Pemetrexed (ALIMTA) and Erlotinib (TARCEVA) in Advanced Solid Tumors, With Emphasis on Non-Small Cell Lung Cancer (NSCLC).",I/II,Completed,"National Institutes of Health/National Cancer Institute
University of California Davis Cancer Center","Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Lung Neoplasms; Neoplasms",Canada; United States
"Phase I/II Study of Two Different Schedules of Bortezomib (VELCADE, PS-341) and Pemetrexed (ALIMTA) in Advanced Solid Tumors, With Emphasis on Non-Small Cell Lung Cancer (NSCLC).",I/II,Completed,University of California Davis,"Oncology: Breast; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Thymus",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Lung Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thymus Neoplasms",United States
"A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Trastuzumab-MCC-DM1 (PRO132365) Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen",I,Completed,Roche/Genentech {Genentech},Oncology: Breast,Fourth line or greater; HER2 positive; Second line; Stage IV; Third line,Breast Neoplasms,United States
A Phase I Study of the Raf Kinase/VEGFR Inhibitor BAY 43-9006 in Combination With the Proteasome Inhibitor PS-341 in Patients With Advanced Malignancies.,I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Multiple Myeloma; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Hematological Cancer",Advanced; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Chronic Lymphocytic Leukemia; Hematologic Neoplasms; Kidney Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Melanoma; Multiple Myeloma; Neoplasms, Plasma Cell; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Wilms Tumor",United States
A Phase I Study Assessing the Feasibility and Safety of Intraductal Administration of Pegylated Liposomal Doxorubicin (Doxil) in Women with Breast Cancer.,I,Completed,"National Institutes of Health/National Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}",Oncology: Breast,Neoadjuvant; Stage 0; Stage I; Stage II; Stage III,Breast Neoplasms,United States
A Phase 1 Dose Escalation Study of ARQ 197 in Adult Patients with Metastatic Solid Tumors.,I,Completed,Merck & Co. {ArQule},"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Metastatic; Peritoneal mets; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasm Metastasis; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Wilms Tumor",United States
A Continuation Study of CPG 7909 Injection in Patients With Metastatic or Recurrent Malignancies Who Have Stable Disease or Who Have Responded to CPG 7909 Injection Therapy.,I/II,Completed,"Pfizer
Pfizer {Coley Pharmaceutical Group}","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Renal",Aggressive; Cutaneous T-cell lymphoma (CTCL); Indolent; Peripheral T-cell lymphoma (PTCL); Second line; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Kidney Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Melanoma; Renal Cancer; Wilms Tumor",Germany; United States
Phase I/II Partial Breast Irradiation With Concurrent Chemotherapy.,I/II,Completed,"National Institutes of Health/National Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}
Breast Cancer Research Foundation",Oncology: Breast,Adjuvant; Estrogen receptor positive; Stage I; Stage II,Breast Neoplasms,United States
"A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Apomab Administered Intravenously to Subjects with Advanced or Metastatic Solid Malignancies, or Non-Hodgkin's Lymphoma.",I,Completed,Roche/Genentech {Genentech},"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Ovarian",Aggressive; First line; Fourth line or greater; Indolent; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Colorectal Neoplasms; Glioblastoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Ovarian Cancer; Ovarian Neoplasms",United States
"Phase I Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of KOS-1584 Administered Using Two Schedules: Weekly for 2 Weeks every 3 Weeks and Weekly for 3 Weeks every 4 Weeks in Patients With Advanced Solid Tumors.",I,Completed,"Bristol-Myers Squibb {Kosan Biosciences}
Roche {F. Hoffmann-La Roche}","Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal",(N/A); Fourth line or greater; Pulmonary; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Wilms Tumor",United States
A Phase I Dose-Escalation Study of Intravenous MST-997 Formulated in Polysorbate 80 Diluent Administered Weekly in Subjects With Advanced Malignant Solid Tumors.,I,Terminated,Pfizer {Wyeth},"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",Netherlands; Poland; United States
"A Phase I, Open-Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of PF-00562271 In Patients With Advanced Non-Hematologic Malignancies",I,Completed,Pfizer,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Fourth line or greater; Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasms; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Wilms Tumor",Australia; Canada; United States
"A Phase I, Multi-Center, Open Label, Dose Escalation Trial of the Safety and Pharmacokinetics of Intravenous PR-104 Given Every 3 Weeks in Patients With Solid Tumors.",I,Completed,"Jonsson Comprehensive Cancer Center, UCLA
National Institutes of Health/National Cancer Institute
Proacta","Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma",Australia; New Zealand; United States
"Phase I and Pharmacokinetic Study of LU79553 (Elinafide), a DNA Intercalating Bisnaphthalimide, in Patients With Solid Malignancies.",I,Completed,"National Institutes of Health/National Cancer Institute
Sanofi {Sanofi-Aventis}/Sanofi Genzyme {Genzyme {ILEX Oncology}}","Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Advanced; Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Mesothelioma; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",United States
Phase I Dose-Escalation Study of LY2157299 Monotherapy and in Combination With Lomustine in Patients With Recurrent Malignant Glioma,I,Completed,"Eli Lilly
Vall d Hebron University Hospital","Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Oligodendroglioma; Oncology: Colorectal; Oncology: GIST; Oncology: Liver; Oncology: Melanoma; Oncology: Prostate",(N/A); Grade 3; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Glioblastoma; Glioma; Liver Cancer; Liver Neoplasms; Melanoma; Prostatic Neoplasms",Spain; United Kingdom; United States
"A Phase I, Open Label, Dose Escalation Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CE-245,677, an Oral TIE2 Kinase Inhibitor, in Patients with Advanced Solid Tumors.",I,Terminated,Pfizer,Oncology: Breast; Oncology: Colorectal; Oncology: Liver,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Liver Cancer; Liver Neoplasms",United States
"A Phase I, Open-Label, Dose Finding Study Evaluating the Safety and Pharmacokinetics of AMG 479 in Subjects with Advanced Solid Tumors",I,Completed,"Amgen
National Institutes of Health/National Cancer Institute","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Thymus",Aggressive; Fourth line or greater; Indolent; Second line; Stage III; Stage IV; Third line; Thymoma,"Breast Neoplasms; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Neuroendocrine Tumors; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thymoma; Thymus Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"Phase I Study of Interferon Alfa-1b in Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma",I,Completed,The Cleveland Clinic Foundation,"Oncology: Breast; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Multiple Myeloma; Oncology: Renal",Aggressive; Indolent; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Kidney Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Multiple Myeloma; Renal Cancer; Wilms Tumor",United States
A Phase I Pharmacokinetic and Pharmacodynamic Study of Temsirolimus (CCI-779) in Patients With Advanced Malignancies and Normal and Impaired Liver Function: An NCI Organ Dysfunction Working Group Study.,I,Completed,"National Institutes of Health/National Cancer Institute
Cancer Therapy & Research Center San Antonio, Texas
Pfizer {Wyeth}","Oncology: Breast; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Unspecified Solid Tumor",Aggressive; Classical; Indolent; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV,"Breast Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms, Unknown Primary",United States
A Phase I Dose-Escalation Study of NK012 Administered Intravenously as a Single Dose every Three weeks in Patients with Refractory Solid Tumors.,I,Completed,Nippon Kayaku,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Testicular",(N/A); Pulmonary; Second line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Testicular Cancer; Testicular Neoplasms; Unspecified",United States
A Phase I Prevention Trial of ACTIVIN Grape Seed Extract as an Aromatase Inhibitor In Healthy Postmenopausal Women at Risk for Breast Cancer.,I,Completed,"National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center
(Other government agency)",Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
A Phase I Study of CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer.,I,Completed,"MD Anderson Cancer Center, University of Texas
CTI BioPharma {Cell Therapeutics}",Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
A Phase I Trial of Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Recurrent or Refractory Gynecological Cancer Patients.,I,Completed,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Massachusetts General Hospital
Brigham and Womens Hospital",Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian,Second line; Stage IV,Breast Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Uterine Cervical Neoplasms,United States
"A Phase Ib Open-Label, Two-Arm, Dose-Finding Study of E7389 in Combination with Carboplatin in Patients with Solid Tumors.",I/II,Completed,Eisai,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",First line; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms",Austria; India; United States
A phase I dose escalation trial of gemcitabine with radiotherapy for breast cancer in the treatment of chest wall recurrences.,I,Completed,University of Michigan Comprehensive Cancer Center,Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,United States
Phase I Study of ABT-510 in Combination With Bevacizumab in Advanced Solid Tumors.,I,Completed,"Roche/Genentech {Genentech}
National Institutes of Health/National Cancer Institute
AbbVie {Abbott}
Duke University Medical Center","Oncology: Breast; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Unspecified; Wilms Tumor",United States
"A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer.",I,Completed,"Novartis
The Cleveland Clinic Foundation","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer; Oncology: Prostate",Bone mets; First line; Second line; Stage IV,"Bone Marrow Diseases; Bone Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Neoplasm Metastasis; Neoplasms, Second Primary; Prostatic Neoplasms",United States
"A Phase I study to evaluate the safety/tolerability and immunogenicity of V-930 in patients with cancers expressing HER-2 and/or CEA

V930 First in Man (FIM) Study.",I,Completed,Merck & Co./Merck Sharp & Dohme (MSD),"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Ovarian",First line; HER2 positive; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Unspecified",Italy; United States
The Impact of Platelet Function Inhibition on Circulating Cancer Cells in Metastatic Breast Cancer Patients,I/II,Completed,"(Other Cooperative Group)
Washington University School of Medicine",Oncology: Breast,Line of therapy N/A; Stage IV,Breast Neoplasms,United States
"A Phase I Study of Brevarex, a Murine Monoclonal Antibody Directed at the MUC1 Antigen, in Patients with Advanced Solid Tumors.",I,Completed,"United Therapeutics {Unither Pharmaceuticals}
Endo International {Paladin Labs {ViRexx {AltaRex}}}",Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid,Follicular; Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms",United States
Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients.,I,Completed,"Amgen {Onyx Pharmaceuticals}
Bayer AG","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Mesothelioma; Oncology: Osteosarcoma; Oncology: Prostate; Oncology: Renal; Oncology: Thyroid",Advanced; Aggressive; Indolent; Papillary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Ewing Sarcoma; Kidney Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Mesothelioma; Neoplasms, Mesothelial; Osteosarcoma; Prostatic Neoplasms; Renal Cancer; Thyroid Neoplasms; Unspecified; Wilms Tumor",United States
"Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors",I,Completed,AstraZeneca,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Prostate; Oncology: Renal",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Prostatic Neoplasms; Renal Cancer; Wilms Tumor",Australia; United States
Phase I of Fixed-Dose-Rate Gemcitabine in Combination with Bortezomib in Patients with Advanced Solid Tumors.,I,Completed,"National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Testicular",(N/A); First line; Fourth line or greater; Locally advanced; Metastatic; Pulmonary; Second line; Stage III; Stage IV; Third line; Untreated,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"Phase I Study of PS-341, Leucovorin Calcium, and Fluorouracil in Patients With Advanced Solid Tumors",I,Completed,"National Institutes of Health/National Cancer Institute
Beckman Research Institute
California Cancer Consortium",Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Pancreas,First line; Fourth line or greater; Second line; Stage III; Stage IV; Third line,Breast Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms,United States
A Phase I/II Suberoylanilide Hydroxamic Acid (SAHA) in Combination with Trastuzumab (Herceptin) in Patients with Advanced Metastatic and/or Local Chest Wall Recurrent Her-2 Amplified Breast Cancer.,I/II,Terminated,"Merck & Co.
Eastern Cooperative Oncology Group (ECOG)
National Institutes of Health/National Cancer Institute",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Breast Neoplasms, Male",United States
Phase II Study of the Antiproteolytic Targeting Therapy: Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination with Capecitabine in Advanced Malignancies,I,Terminated,"Heidelberg Pharma {WILEX}
US Department of Defense",Oncology: Breast; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms, Unknown Primary",United States
"A Phase 1, Open-Label, Q21 Day Dose Escalation, Multi-Center Study of TPI 287 in Patients With Advanced Malignancies.",I,Completed,Tapestry Pharmaceuticals,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas",Fourth line or greater; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Hodgkin Disease; Lymphoma; Lymphoma, Non-Hodgkin; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",Israel; United States
A Phase I/II Study of NB1011 Administered Intravenously by Continuous Infusion in an Every Second Week Regimen With Open-Label Continuation in Cancers That Overexpress the Enzyme Thymidylate Synthase,I/II,Completed,"Jonsson Comprehensive Cancer Center, UCLA
National Institutes of Health/National Cancer Institute
Sanofi {Kiadis Pharma {Celmed Biosciences}}","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms",Canada; United States
"Phase I, Pharmacokinetic and Pharmacodynamic Study of BAY 43-9006 (Sorafenib) in Combination With CCI-779 (Temsirolimus) in Advanced Solid Malignancies.",I,Completed,"National Institutes of Health/National Cancer Institute
Cancer Therapy & Research Center San Antonio, Texas","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Aggressive; First line; Indolent; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase I Dose Escalation Trial of BIBW 2992 Administration for 20, 13 or 6 Days in Combination With Docetaxel Every 21 Days",I,Completed,Boehringer Ingelheim,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Thyroid",EGFR; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Kidney Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
LCCC 0412: A Phase I Trial of Abraxane and Carboplatin in Patients With Solid Tumors.,I,Completed,"National Institutes of Health/National Cancer Institute
UNC Lineberger Comprehensive Cancer Center
Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}}","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",(N/A); Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Phase I, Dose Escalation and Pharmacokinetics Study of Temperature Sensitive Liposome Encapsulated Doxorubicin (ThermoDox) and Hyperthermia in Patients With Local-Regionally Recurrent Breast Cancer.",I,Completed,"National Institutes of Health/National Cancer Institute
Imunon {Celsion}
Duke University Medical Center",Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A 2-Part Phase 1 Study Evaluating the Safety and Anti-Tumor Activity of ADH300004 (Eniluracil) Administered With 5-Fluorouracil (5-FU), and the Pharmacokinetics of 5-FU Given as: 5.0 mg ADH300004 With Escalating Doses of 5-FU Administered Orally 3 Weeks Out of 4 in Subjects With Refractory Solid Tumors (Part 1); or 5.0 mg ADH300004 With 5 FU Administered Orally as a Split Dose for 3 Weeks Out of 4 in Subjects With Hepatocellular Carcinoma, Non-Small Cell Lung Carcinoma, Gastric Cancer, Cervical Cancer, Prostate Cancer, or Breast Cancer (Part 2) (Adherex Protocol Number AHX-03-104).",I,Terminated,Fennec Pharmaceuticals {Adherex Technologies},"Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Renal",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
GSK - Doublet: A Phase I Study of Pegylated Liposomal Doxorubicin (Doxil) and Weekly Intravenous Topotecan in P	atients With Advanced Solid Tumors.,I,Completed,"GlaxoSmithKline
Johnson & Johnson/Janssen R&D {Johnson & Johnson/J&JPRD}
(Other Hospital/Academic/Medical Center)",Oncology: Breast; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Neoplasms; Synovial Sarcoma; Wilms Tumor",United States
Phase I Study of Paclitaxel Administered by Hepatic Artery Infusion to Patients With Advanced Cancer And Dominant Liver Involvement.,I,Completed,"MD Anderson Cancer Center, University of Texas","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Ovarian; Oncology: Prostate; Oncology: Thyroid",(N/A); First line; Fourth line or greater; Liver mets; Second line; Stage IV; Third line; Untreated,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Small Cell; Cholangiocarcinoma; Colorectal Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"Phase I Open-Label Multicenter, Dose-Escalating, Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of SNS-314, a Novel Aurora Kinase Inhibitor, Administered to Patients With Advanced Solid Tumors.",I,Completed,Viracta Therapeutics {Sunesis},"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
"An Open-Label, Multicenter, Phase Ib/II Dose Escalation Study of Oral GW572016 in Combination with Docetaxel (Taxotere) Plus Trastuzumab (Herceptin) in Subjects Previously Untreated for ErbB2-Overexpressing Metastatic Breast Cancer.",I/II,Terminated,"GlaxoSmithKline
Novartis",Oncology: Breast,First line; HER2 positive; Stage III; Stage IV,Breast Neoplasms,France; Ireland; United States
"Phase I/II Open Label, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of the Combination RAD001 Plus Docetaxel in Patients with Metastatic Breast Cancer",I/II,Terminated,"Novartis
MD Anderson Cancer Center, University of Texas",Oncology: Breast,Fourth line or greater; Second line; Stage IV; Third line,Breast Neoplasms,United States
Phase I Study of Low-Dose Hypomethylating Agent Azacitidine Combined With the Histone Deacetylase Inhibitor Valproic Acid in Patients With Advanced Cancers,I,Completed,"MD Anderson Cancer Center, University of Texas
Bristol-Myers Squibb/Celgene {Pharmion}","Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thymus; Oncology: Thyroid",Medullary; Papillary; Pediatric or Adolescent; Second line; Stage III; Stage IV; Thymic carcinoma,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thymus Neoplasms; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Phase I Study Of The Chinese Herb Huanglian (Coptis Chinesis) In Patients With Advanced Solid Tumors.,I,Completed,"Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute",Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Renal; Oncology: Soft Tissue Sarcoma,Fourth line or greater; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",United States
"Phase I Trial of Combination Pegylated Liposomal Doxorubicin (Doxil), Vinorelbine, and Gemcitabine.",I,Completed,"Johnson & Johnson/Janssen Biotech {Centocor Ortho Biotech {J&J/Ortho Biotech}}
National Institutes of Health/National Cancer Institute
Ireland Cancer Center","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Thymus; Oncology: Thyroid",Second line; Stage III; Stage IV; Thymoma,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Thymoma; Thymus Neoplasms; Thyroid Neoplasms; Unspecified",United States
"Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumors.",I,Completed,"Pfizer {Pharmacia}
Pfizer {Sugen}","Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Testicular; Oncology: Thymus; Oncology: Thyroid",Line of therapy N/A; Locally advanced; Metastatic; Stage III; Stage IV; Thymic carcinoma,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms; Thymus Neoplasms; Thyroid Neoplasms; Wilms Tumor",United States
"A dose-escalation, Phase I study of a depot formulation of paclitaxel administered intralesionally in end-stage cancer patients with solid malignant tumors.",I,Completed,Serb Specialty Pharmaceuticals/BTG Specialty Pharmaceuticals {Boston Scientific/BTG {Protherics {MacroMed}}},"Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Thyroid",(N/A); Aggressive; Classical; Indolent; Line of therapy N/A; Nodular lymphocyte-predominant; Pulmonary; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neuroendocrine Tumors; Small Cell Lung Carcinoma; Thyroid Neoplasms",United States
Phase IB Sulindac Study for Women at High Risk for Breast Cancer.,I,Completed,"National Institutes of Health/National Cancer Institute
University of Arizona",Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
Phase I Study of Tipifarnib (R115777) and Sorafenib (BAY 43-9006) in Patients With Biopsiable Advanced Cancers,I,Completed,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute","Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thymus; Oncology: Thyroid",Anaplastic; BRAF; First line; Follicular; Localized; Locally advanced; Medullary; Metastatic; Papillary; Second line; Stage II; Stage III; Stage IV; Thymic carcinoma; Untreated,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Neuroendocrine Tumors; Osteosarcoma; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thymus Neoplasms; Thyroid Neoplasms; Wilms Tumor",United States
A Phase I/II Safety And Efficacy Study Of Imoxine (Hyb2055 For Injection) In Combination With First-Line Gemzar And Carboplatin Treatments In Patients With solid tumors and non-small cell lung cancer (NSCLC),I/II,Completed,Aceragen {Idera Pharmaceuticals {Hybridon}},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma",First line; Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma",United States
Phase I trial of Electroporation-based SECTA therapy in Conjunction with Intralesionally Injected Bleomycin in Patients with Locally Recurrent or Metastatic Breast Carcinoma after Partial Mastectomy (lumptectomy) or Cutaneous or Sub-cutaneous Recurrent or Metastatic Carcinoma of the Breast or Chest Wall Following Mastectomy.,I/II,Completed,Inovio Pharmaceuticals {Inovio Biomedical},Oncology: Breast,Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms,United States
"Phase I trial Amplimexon (Imexon, Inj) plus Taxotere (Docetaxel) in previously treated inoperable stage III & stage IV non-small cell lung cancer (NSCLC), locally advanced or metastatic previously treated Breast cancer or hormone refractory prostate cancer.",I,Completed,AmpliMed,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Prostate",Fourth line or greater; Hormone refractory; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Prostatic Neoplasms",United States
"A Phase I and Pharmacokinetic Study of TAS-108 in Postmenopausal Female Patients with Locally Advanced, Locally Recurrent Inoperable, or Progressive Metastatic Breast Cancer.",I,Completed,Otsuka Holdings/Taiho Pharmaceutical,Oncology: Breast,Estrogen receptor positive; Fourth line or greater; Progesterone receptor positive; Stage III; Stage IV; Third line,Breast Neoplasms,United States
A Multicenter Phase I/II Study of Every Other Week Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model.,I/II,Completed,"Roche/Genentech {Genentech}
Memorial Sloan-Kettering Cancer Center",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"A Phase I, Open Label Study of the Safety, Pharmacokinetics and Pharmacodynamics of GW572016 in Once Daily Versus Twice Daily Dosing Regimens in Patients With Treatment- Naive Breast Cancer",I,Completed,GlaxoSmithKline,Oncology: Breast,First line; HER2 positive; Stage II; Stage III; Stage IV,Breast Neoplasms,Israel; United States
Phase I Study to Determine the Maximum Tolerated Dose of ET-743 (Yondelis) and Capecitabine Administered to Patients with Advanced Breast Cancer.,I,Completed,"Johnson & Johnson/Janssen R&D {Johnson & Johnson/J&JPRD}
PharmaMar {Zeltia/PharmaMar}",Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Phase 1 Open-Label Study of the Safety and Feasibility of ZYC300 Administration With Cyclophosphamide Pre-Dosing.,I/II,Completed,Eisai {MGI Pharma},Oncology: Breast; Oncology: Colorectal; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal,Hormone refractory; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Wilms Tumor",United States
A phase I trial of the combination of perifosine and docetaxel with or without prednisone.,I,Completed,Akebia Therapeutics {Keryx Biopharmaceuticals {Access Oncology/AOI Pharmaceuticals}},"Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",(N/A); Second line; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Unspecified",United States
A Phase I Study of Infusion of HER-2/Neu Specific T-cells in Patients With Advanced Stage HER-2/Neu Expressing Cancers Who Have Received a HER-2/Neu Vaccine,I,Completed,"National Institutes of Health/National Cancer Institute
University of Washington","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Ovarian",HER2 positive; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Germinoma; Lung Neoplasms; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neoplasms, Glandular and Epithelial; Ovarian Cancer; Ovarian Neoplasms",United States
"A Phase I Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of 2 Dosing Schedules of PF-00299804 in Patients with Advanced Malignant Solid Tumors.",I,Completed,"Jonsson Comprehensive Cancer Center, UCLA
National Institutes of Health/National Cancer Institute
Pfizer","Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal",EGFR; First line; Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Wilms Tumor",Netherlands; United States
A Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With Bortezomib in Patients With Advanced Malignancies.,I,Completed,"Merck & Co.
National Institutes of Health/National Cancer Institute","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Thymus",Advanced; Metastatic; Second line; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Mesothelioma; Neoplasms, Mesothelial; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thymus Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"An Open Label, Dose Escalation Study of Paricalcitol (Zemplar) [19-NOR-1 ALPHA, 25-(OH) D] in Combination With Gemcitabine [2', 2' -Difluorodeoxycytidine] in Patients With Advanced Malignancies",I,Completed,"Roswell Park Cancer Institute
AbbVie {Abbott}","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Prostate",First line; Hormone refractory; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Liver Cancer; Liver Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
A Phase I/II Trial of BAY-43-9006 (Sorafenib) in Combination With Anastrozole in Patients With Metastatic Breast Cancer.,I/II,Completed,"National Institutes of Health/National Cancer Institute
Lombardi Cancer Center at Georgetown University Medical Center",Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Second line; Stage IV; Third line,Breast Neoplasms,United States
Phase I & biological study of Etanercept & weekly Docetaxel in patients with advanced solid tumors,I,Completed,"Amgen {Immunex}
Ohio State University","Oncology: Breast; Oncology: Lung, Non-Small Cell",Line of therapy N/A; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms",United States
Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer.,I,Completed,Bristol-Myers Squibb,Oncology: Breast; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms, Unknown Primary; Unspecified",United States
Safety and Immunological Evaluation of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Given by Particle-Mediated Epidermal Delivery (PMED) in Patients with Tumor Type Known to Express NY-ESO-1 or LAGE-1 Antigen,I,Completed,"MD Anderson Cancer Center, University of Texas
Memorial Sloan-Kettering Cancer Center
New York Presbyterian Hospital
Ludwig Institute for Cancer Research","Oncology: Bladder; Oncology: Breast; Oncology: CNS, Other; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Ovarian; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Central Nervous System Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
Phase I/II Study of Combination Immunotherapy for the Generation of HER-2/Neu (HER2) Specific Cytotoxic T Cells (CTL) in Vivo,I/II,Completed,"National Institutes of Health/National Cancer Institute
University of Washington
Cancer Treatment Research Foundation (CTRF)",Oncology: Breast; Oncology: Ovarian,HER2 positive; Maintenance/Consolidation; Stage IV,"Breast Neoplasms; Carcinoma, Ovarian Epithelial; Ovarian Cancer; Ovarian Neoplasms",United States
A Phase I Study of a DNA Plasmid Based Vaccine Encoding the HER-2/Neu Intracellular Domain in Subjects with HER-2/Neu (HER2) Overexpressing Tumors.,I,Completed,"National Institutes of Health/National Cancer Institute
Fred Hutchinson Cancer Research Center
University of Washington/Seattle Cancer Care Alliance
(Other Hospital/Academic/Medical Center)",Oncology: Breast; Oncology: Ovarian,HER2 positive; Line of therapy N/A; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Ovarian Epithelial; Germinoma; Neoplasms, Germ Cell and Embryonal; Ovarian Cancer; Ovarian Neoplasms",United States
A Phase I/II Study of BMS-247550 and Pegylated Liposomal Doxorubicin (Doxil) in Patients With Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer Who Have Been Previously Treated With a Platinum and a Taxane,I/II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal,Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Fallopian Tube Neoplasms; Neoplasms, Glandular and Epithelial; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms",United States
Phase I Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere).,I,Completed,"USC/Norris Comprehensive Cancer Center and Hospital
Johnson & Johnson/Janssen Therapeutics {J&J/Centocor Ortho Biotech/Tibotec Therapeutics {J&J/Ortho Biotech/Tibotec}}","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Renal; Oncology: Thyroid",(N/A); Pulmonary; Recurrent; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms; Unspecified; Wilms Tumor",United States
A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a.,I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",Locally advanced; Metastatic; Second line; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"Selection of CD34+THY-1 Positive Cells From Peripheral Blood Cells Procured for Autologous Hematopoietic Support Following High Dose Treatment with BCNU, Cyclophosphamide & Cisplatin for Stage IV Breast Cancer & Limited Prior Treatment.",I/II,Completed,Stanford University Medical Center,Oncology: Breast,First line; Second line; Stage IV,Breast Neoplasms,United States
A Phase I Study of Paclitaxel In Combination with SU011248 For Patients with Breast Cancer As First-Line Treatment In the Advanced Disease Setting.,I,Completed,Pfizer,Oncology: Breast,First line; HER2 positive; Stage III; Stage IV,Breast Neoplasms,United States
"An Open Label, Phase 1b Rollover Study to Assess the Long-Term Safety Profile of Lapatinib (GW572016) in Cancer Patients.",I,Completed,GlaxoSmithKline,Oncology: Breast; Oncology: Unspecified Solid Tumor,Line of therapy N/A; Stage III; Stage IV,"Breast Neoplasms; Neoplasms, Unknown Primary",Canada; Israel; United States
Phase I Study of a Novel Schedule of Capecitabine and Docetaxel in Patients with Advanced Solid Tumors.,I,Completed,"Roche {F. Hoffmann-La Roche}
Dartmouth-Hitchcock Medical Center",Oncology: Breast; Oncology: Pancreas,Line of therapy N/A; Stage IV,Breast Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms,United States
"A Phase I/II Trial of an Oral mTOR Protein Kinase Inhibitor (Everolimus, RAD001) in Combination With an Oral EGFR Tyrosine Kinase Inhibitor (Erlotinib, Tarceva) in Patients With Metastatic Breast Cancer",I/II,Terminated,"Roche/Genentech {Genentech}
Novartis
National Institutes of Health/National Cancer Institute
Vanderbilt University Medical Center",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"A Phase I Multicenter, Open-Label, Dose Escalation Trial of AS703569 Given Orally to Subjects With Solid Tumours.",I,Completed,"Merck KGaA/Merck Serono {Serono}
Rigel","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Prostate",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasms; Prostatic Neoplasms",United States
A Phase I Study of the effects of Hepatic Impairment on the Pharmacokinetics and Safety of Satraplatin in Patients with Refractory Non-hematologic Cancer.,I,Completed,Agennix {GPC Biotech},"Oncology: Anal; Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",(N/A); Fourth line or greater; Second line; Stage IV; Third line,"Anus Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Small Cell; Colorectal Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma",United States
A Phase I Study of the Effects of Renal Impairment on the Pharmacokinetics and Safety of Satraplatin in Patients with Refractory Non-Hematologic Cancer,I,Completed,Agennix {GPC Biotech},Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Prostate; Oncology: Renal,Hormone refractory; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Prostatic Neoplasms; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
Phase I Study of Ixabepilone Administered as a 24-Hour Infusion in Patients With Advanced Solid Malignancies,I,Completed,Bristol-Myers Squibb,"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
Phase I study of OSI-211 in combination with liposomal doxorubicin every 3 weeks in patients with advanced solid tumors; final analysis suggests benefit in refractory ovarian cancer.,I,Completed,Astellas Pharma {OSI Pharmaceuticals},"Oncology: Breast; Oncology: Endometrial; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian",(N/A); Pulmonary; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Endometrial Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms",United States
"Pharmacokinetics of edotecarin (J-107088), a topoisomerase I inhibitor, in patients with metastatic breast cancer or glioblastoma multiforme.",I,Completed,Pfizer,"Oncology: Breast; Oncology: CNS, Glioblastoma",(N/A); Line of therapy N/A; Stage IV,Breast Neoplasms; Glioblastoma,United States
A Phase I Study of Oral Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer.,I,Completed,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Massachusetts General Hospital
Brigham and Womens Hospital",Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,United States
A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors.,I/II,Completed,"Novartis {Chiron}
Cleveland Clinic Taussig Cancer Center
Alnylam {Merck & Co./Sirna Therapeutics {Ribozyme}}","Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",(N/A); Gastrointestinal; Medullary; Second line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Wilms Tumor",United States
Phase I trial of irinotecan and epirubicin in patients with advanced solid tumors.,I,Completed,(Other Academic Cancer Center),"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas",(N/A); Fourth line or greater; Pulmonary; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Melanoma; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms",United States
Effects of cytochrome P450 polymorphisms on tamoxifen metabolism.,I,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Line of therapy N/A; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,Canada; United States
"Effect of genetic variants in CYP2C8, CYP3A4, CYP3A5, and ABCB1 on paclitaxel pharmacokinetics.",I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Bladder; Oncology: Breast; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Renal",(N/A); Line of therapy N/A; Pulmonary,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Head and Neck Neoplasms; Kidney Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Netherlands; Sweden; United States
An Open-Label Phase I/II Study of Weekly ABI-007 and Vinorelbine With or Without G-CSF in Patients With Stage IV (Metastatic) Breast Cancer,I/II,Terminated,Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}},Oncology: Breast,First line; HER2 positive; Stage IV,Breast Neoplasms,United States
"A tolerability study of a cremophor - free, nanoparticle albumin bound paclitaxel intravenously administered in Chinese patients with advanced solid tumor.",I,Completed,Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}},"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Soft Tissue Sarcoma",Line of therapy N/A; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma",China; United States
"A Phase I Clinical, Pharmacokinetic, And Pharmacodynamic Evaluation Of 2 Schedules Of Oral PD 0332991, A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer",I,Completed,Pfizer,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma",Aggressive; Diffuse large B-cell lymphoma (DLBCL); Follicular lymphoma (FL); Indolent; Second line; Stage III; Stage IV,"Breast Neoplasms; Colorectal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
Phase I/II Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin.,I/II,Completed,"Bristol-Myers Squibb {Kosan Biosciences}
Triphase Accelerator {Triphase Research {Nereus}}",Oncology: Breast; Oncology: Colorectal; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Thymus,First line; Fourth line or greater; HER2 positive; Second line; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Thymus Neoplasms; Wilms Tumor",United States
"Paclitaxel, bevacizumab, and Quadramet for the treatment of metastatic breast cancer.",I/II,Terminated,Jazz Pharmaceuticals {Jazz Pharmaceuticals/EUSA Pharma {Cytogen}},Oncology: Breast,Line of therapy N/A; Stage IV,Breast Neoplasms,United States
"A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant (Montanide ISA-51) as Consolidation Following Optimal Debulking and Systemic Chemotherapy for Women With Advanced Stage Ovarian, Tubal, or Peritoneal Cancer.",I,Completed,"(Other Cooperative Group)
Duke University Medical Center
Immunotope",Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal,Maintenance/Consolidation; Stage III; Stage IV,Breast Neoplasms; Fallopian Tube Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms,United States
Phase I study of anti-insulin-like growth factor-I receptor (IGF-IR) monoclonal antibody IMC-A12 administered every other week in patients with advanced solid tumors who no longer respond to standard therapy or for whom no standard therapy is available,I,Completed,Eli Lilly {ImClone},Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Liver; Oncology: Pancreas; Oncology: Prostate,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Colorectal Neoplasms; Endometrial Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"Phase  I/IIa Evaluation of Sodium Stibogluconate in Combination With Interferon a-2b for Solid Tumors, Lymphoma or Myeloma.",I/II,Terminated,"National Institutes of Health
Cleveland Clinic Taussig Cancer Center
Case Western Reserve University
VioQuest Pharmaceuticals","Oncology: Breast; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Multiple Myeloma; Oncology: Osteosarcoma; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Adenocarcinoma; Aggressive; Classical; Indolent; Nodular lymphocyte-predominant; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Multiple Myeloma; Osteosarcoma; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified; Wilms Tumor",United States
"A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days.",I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",(N/A); Second line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Cholangiocarcinoma; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Mesothelioma; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",United States
A Phase I Study of Regulatory T Cell Depletion With Denileukin Diftitox Followed by Active Immunotherapy With Autologous Dendritic Cells Infected With CEA-6D Expressing Fowlpox-Tricom in Patients With Advanced or Metastatic Malignancies Expressing CEA.,I,Completed,"National Institutes of Health/National Cancer Institute
Duke Comprehensive Cancer Center","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Pancreas",(N/A); HER2 positive; Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Lung Neoplasms; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Small Cell Lung Carcinoma",United States
"A Phase I, Open-Label, Dose Escalation Study Evaluating High-Dose Gefitinib (IRESSA) on Weekly and Twice Weekly Schedules in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic.",I,Terminated,AstraZeneca,"Oncology: Breast; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Prostate",Advanced; Hormone refractory; Localized; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Mesothelioma; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Unspecified",United States
A Phase I Study of SU5416 in Combination With Gemcitabine/Cisplatin in Patients With Advanced Solid Tumors,I,Terminated,"Jonsson Comprehensive Cancer Center, UCLA
National Institutes of Health/National Cancer Institute
Pfizer {Sugen}","Oncology: Bladder; Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Advanced; Extensive; Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Netherlands; United States
"A Phase I, Open-Label, Multiple Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of ARRY-334543 Given on a Daily Oral Regimen in Patients with Advanced Cancer.",I,Completed,Pfizer {Array BioPharma},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Head/Neck; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Thymus",Aggressive; HER2 positive; Indolent; Second line; Stage III; Stage IV; Thymic carcinoma,"Acute Myelocytic Leukemia; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Gallbladder Neoplasms; Glioblastoma; Head and Neck Neoplasms; Leiomyosarcoma; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thymus Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",Canada; United States
A Phase I study of TST10088 in patients with advanced incurable solid tumors.,I,Completed,Emergent BioSolutions {Cangene {Twinstrand Therapeutics}},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",(N/A); First line; Hormone refractory; Second line; Stage III; Stage IV; Untreated,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cholangiocarcinoma; Colorectal Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma",Canada; United States
"A Phase I, Pharmacokinetic and Biological Evaluation of a Small Molecule Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP-1), KU-0059436, in Patients With Advanced Tumours.",I,Completed,AstraZeneca {KuDOS Pharmaceuticals},"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Advanced; BRCA; Fourth line or greater; Hormone refractory; Locally advanced; Metastatic; Pulmonary; Second line; Stage II; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Ewing Sarcoma; Fallopian Tube Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Neuroendocrine Tumors; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",Belgium; Netherlands; Poland; United Kingdom; United States
"A Phase I, Two-Arm, Open-Label Study of E7974 Administered on Days 1, 8, and 15 of a 28-Day Cycle and Days 1 and 8 of a 21-Day Cycle in Patients With Solid Malignancies.",I,Completed,Eisai,Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Prostate,Second line; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms,United States
"A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma",I,Completed,Eisai,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Aggressive; BRAF; Classical; Indolent; Locally advanced; Metastatic; Nodular lymphocyte-predominant; NRAS; Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Wilms Tumor",United States
Phase I Study of Rx-0201 in Patients with Advanced or Metastatic Solid Tumors.,I,Completed,Ocuphire Pharma {Rexahn Pharmaceuticals},"Oncology: Breast; Oncology: Gastric; Oncology: GIST; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Skin, Basal Cell Carcinoma",Locally advanced; Metastatic; Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Small Cell; Gastrointestinal Stromal Tumors; Neoplasms, Basal Cell; Neuroendocrine Tumors; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms",United States
An Open-Labeled Non-Randomized Phase I Study of 17-N-Allylamino-17-Demethoxy Geldanamycin (17AGG) Administered With Irinotecan (CPT) in Patients With Advanced Solid Tumors.,I,Completed,"Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute",Oncology: Breast; Oncology: Pancreas,Second line; Stage III; Stage IV,Breast Neoplasms; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms,United States
"A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Tolerability of Ispinesib in Combination With Capecitabine on an Every 21-Day Schedule in Subjects With Advanced Solid Tumors",I,Completed,"GlaxoSmithKline
National Institutes of Health/National Cancer Institute
Cytokinetics","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Thyroid",Fourth line or greater; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
Phase I Trial of Motexafin Gadolinium (MGd) and Docetaxel Chemotherapy in the Treatment of Advanced Solid Tumors,I,Completed,"AbbVie/Pharmacyclics
University of Pittsburgh","Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate",(N/A); Fourth line or greater; Pulmonary; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Digestive System Neoplasms; Gastrointestinal Neoplasms; Glioblastoma; Head and Neck Neoplasms; Lung Neoplasms; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
A dose escalation study of CT-2106 administered for three consecutive weeks on a 4-week cycle for patients with solid tumors.,I,Completed,CTI BioPharma {Cell Therapeutics},"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",Fourth line or greater; Second line; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Melanoma; Osteosarcoma; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
"Redosing With CP-870,893 in Patients With Clinical Benefit After a Single Infusion of CP-870,893 From A Phase I, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors",I,Completed,"National Institutes of Health/National Cancer Institute
Pfizer
Abramson Cancer Center at  University of Pennsylvania Medical Center","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Ewing Sarcoma; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Osteosarcoma; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms",United States
Phase I trial of liposomal encapsulated doxorubicin (MyocetTM; D-99) and weekly docetaxel in advanced breast cancer patients.,I,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; HER2 positive; Line of therapy N/A; Progesterone receptor positive; Stage IV,Breast Neoplasms,United States
Phase I/II feasibility trial of adjuvant dose-dense (DD) docetaxel/epirubicin/cyclophosphamide (TEC) in stage II/III breast cancer.,I/II,Completed,Sanofi {Sanofi-Aventis {Aventis}},Oncology: Breast,Adjuvant; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
"Phase I Pharmacokinetic and Pharmacodynamic, Open-Label, Dose Escalation Study of Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Subjects With Metastatic Cancer Which Have Activated Akt Demonstrated by Immunohistochemistry.",I/II,Terminated,"H. Lee Moffitt Cancer Center and Research Institute
VioQuest Pharmaceuticals",Oncology: Breast; Oncology: Colorectal; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas,Second line; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Melanoma; Neoplasm Metastasis; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms,United States
Pharmacogenetic analysis of paclitaxel in breast cancer.,I,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Line of therapy N/A; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
"A phase I dose escalation and pharmacokinetic study of E7389, a microtubule-binding drug in patients with advanced solid tumors.",I,Completed,Eisai,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",Aggressive; Indolent; Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies,I/II,Completed,"National Institutes of Health/National Cancer Institute
Pfizer
H. Lee Moffitt Cancer Center and Research Institute","Oncology: Breast; Oncology: Cervical; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Soft Tissue Sarcoma",(N/A); First line; Fourth line or greater; Locally advanced; Metastatic; Pulmonary; Second line; Stage III; Stage IV; Third line; Untreated,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Neuroendocrine Tumors; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Uterine Cervical Neoplasms",United States
A Phase I Safety And Pharmacokinetic Study Of SU011248 And Capecitabine In Patients With Advanced Solid Tumors.,I,Completed,Pfizer,Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: GIST; Oncology: Liver; Oncology: Pancreas; Oncology: Renal; Oncology: Thyroid,Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gastrointestinal Stromal Tumors; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Phase Ib study with Tumor Molecular Pharmacodynamic evaluation of Dose and Schedule of the Oral mTOR-inhibitor Everolimus (RAD001) in Patients with Advanced Solid Tumors.,I,Completed,Novartis,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Soft Tissue Sarcoma",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms, Basal Cell; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",Spain; United Kingdom; United States
"An Open-Label, Multi-Dose, Phase I, Dose-Escalating Study of a Subcutaneously Administered Human-Engineered Monoclonal Antibody, ING-1(heMAb), in Subjects With Advanced Adenocarcinomas",I,Completed,XOMA,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",Extensive; Hormone refractory; Second line; Stage III; Stage IV,"Adenocarcinoma; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma",United States
A Phase I clinical and pharmacokinetic (PK) study of oral CI-1033 + docetaxel in the treatment of patients with advanced solid tumors.,I,Completed,Pfizer,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Renal; Oncology: Small Intestine",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Intestinal Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of XL184 Administered Orally to Subjects With Advanced Malignancies,I,Completed,"Bristol-Myers Squibb
(Other Cooperative Group)
National Institutes of Health/National Cancer Institute
Pfizer
Exelixis
National Institutes of Health","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Advanced; Aggressive; Follicular; Fourth line or greater; Indolent; Medullary; Second line; Stage II; Stage III; Stage IV; Third line; Unresectable,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Wilms Tumor",United States
Phase I Study of Bexarotene and Rosiglitazone in Patients with Refractory Cancers.,I,Completed,"Washington University School of Medicine
Ligand Pharmaceuticals","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",(N/A); First line; Fourth line or greater; Second line; Stage II; Stage III; Stage IV; Third line; Untreated,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Mesothelioma; Neoplasms, Mesothelial; Neuroendocrine Tumors; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Wilms Tumor",United States
"A Phase I, Open-Label, Multi-Center, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetic Properties of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients with Advanced Malignancies.",I,Completed,Ascenta Therapeutics,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",Aggressive; Classical; Indolent; Locally advanced; Metastatic; Nodular lymphocyte-predominant; Second line; Small lymphocytic lymphoma (SLL); Stage II; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Chronic Lymphocytic Leukemia; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Leukemia, Lymphocytic, Chronic, B-Cell; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Phase 1 Study of Vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in Combination With Decitabine in Patients With Advanced Solid Tumors, Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia in Blast Crisis",I,Completed,"Merck & Co.
National Institutes of Health/National Cancer Institute
University Health Network, Toronto/Princess Margaret Cancer Centre {Princess Margaret Hospital}","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Pancreas; Oncology: Small Intestine; Oncology: Soft Tissue Sarcoma",Aggressive; APL/M3; Blast phase; First line; Fourth line or greater; Indolent; Locally advanced; Metastatic; Second line; Stage III; Stage IV; Third line; Untreated,"Acute Myelocytic Leukemia; Bile Duct Neoplasms; Blast Crisis; Breast Neoplasms; Burkitt Lymphoma; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Chronic Myeloid Leukemia; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Intestinal Neoplasms; Leiomyosarcoma; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Liposarcoma; Lymphoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Pancreatic Cancer; Pancreatic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma",Canada; United States
A Pilot Study of Flavopiridol in Patients With Advanced Solid Tumors.,I,Completed,"National Institutes of Health/National Cancer Institute
Richard J. Solove Research Institute
Arthur G. James Cancer Hospital",Oncology: Breast; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms; Neoplasms, Unknown Primary",United States
"Phase I, First in Human, Open-label, Sequential Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 102 in Patients with Advanced Solid Tumors.",I,Completed,"Amgen
Premiere Oncology","Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
Phase I Study of BMS-188797 in Patients With Advanced Malignancies.,I,Completed,"Bristol-Myers Squibb
National Institutes of Health/National Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gallbladder; Oncology: GIST; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Hormone refractory; Locally advanced; Metastatic; Pulmonary; Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Gallbladder Neoplasms; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Neuroendocrine Tumors; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Unspecified; Wilms Tumor",United States
"A Phase I, Open-Label, Dose-escalation Study to Assess the Safety and Tolerability of AT7519M, a Selective Small Molecule Inhibitor of Cyclin-Dependent Kinases, in Patients with Advanced Solid Malignancies",I,Terminated,Otsuka Holdings/Otsuka Pharmaceutical/Astex Pharmaceuticals {Astex Therapeutics},"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: GIST; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Pancreas",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gastrointestinal Stromal Tumors; Liver Cancer; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United Kingdom; United States
"Phase I Study To Determine The Safety, Tolerance And Preliminary Antineoplastic Activity Of Combined EGFR (erbB1) And HER2 (erbB2) Blockade, With OSI-774 And Trastuzumab, In Combination With Weekly Paclitaxel",I,Completed,"National Institutes of Health/National Cancer Institute
Astellas Pharma {OSI Pharmaceuticals}
Institute for Drug Development
Cancer Therapy & Research Center San Antonio, Texas",Oncology: Breast; Oncology: Colorectal; Oncology: Ovarian,First line; HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Unspecified,United States
Phase I Trial of ZIO-101 in Patients With Solid Tumors.,I,Completed,"MD Anderson Cancer Center, University of Texas
Alaunos Therapeutics {Ziopharm Oncology}","Oncology: Breast; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",(N/A); Fourth line or greater; Pulmonary; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",United States
Phase I Study of Bevacizumab in Combination With Everolimus and Erlotinib in Advanced Cancer,I,Completed,"Roche/Genentech {Genentech}
Novartis
National Institutes of Health/National Cancer Institute
Duke Comprehensive Cancer Center","Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: GIST; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",First line; Locally advanced; Medullary; Metastatic; Second line; Stage II; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Ewing Sarcoma; Fibrosarcoma; Gastrointestinal Stromal Tumors; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Unspecified; Wilms Tumor",United States
"Phase I Open-Label, Multicenter, Dose-Escalation Clinical Study of the Safety and Tolerability of SNS-032, a Novel Cyclin-Dependent Kinase Inhibitor, Administered to Patients With Select Advanced Solid Tumors.",I/II,Terminated,Viracta Therapeutics {Sunesis},"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Melanoma",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Neoplasms",United States
A Phase I Trial of ABI-007 Administered Weekly for Three Doses Every 4 Weeks in Patients With Advanced Non-Hematologic Malignancies.,I,Completed,Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}},"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal",Extensive; First line; Hormone refractory; Pulmonary; Second line; Stage III; Stage IV; Untreated,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Kidney Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Wilms Tumor",United States
"A Phase 1, Dose Escalation, Sequential Cohort Study of the Safety, Tolerability and Pharmacokinetics of Intravenous AVE0005A (VEGF-trap) in Combination with Intravenous Oxaliplatin/5-Fluorouracil/ Leucovorin Administered Every 2 Weeks in Subjects with Advanced Solid Malignancies.",I,Completed,"Regeneron
Sanofi {Sanofi-Aventis}",Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Ovarian; Oncology: Pancreas,Fourth line or greater; Second line; Stage III; Stage IV; Third line,Bile Duct Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms,United States
"A Phase Ia, Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of PRO1762 Administered Intravenously to Subjects with Advanced or Metastatic Solid Malignancies, or Non-Hodgkins Lymphoma.",I,Completed,"Roche/Genentech {Genentech}
Amgen {Immunex}
Premiere Oncology","Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",(N/A); Aggressive; Indolent; Liver mets; Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasm Metastasis; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",United Kingdom; United States
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of XL820 Administered Orally to Subjects With Solid Tumors,I,Completed,Exelixis,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: GIST; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Distal; Locally advanced; Metastatic; Pulmonary; Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Cholangiocarcinoma; Colorectal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Unspecified; Wilms Tumor",United States
Clinical Trial of a HER2/neu (E75) Vaccine to Prevent Recurrence in High-Risk Breast Cancer Patients.,I/II,Completed,Walter Reed Army Institute of Research - WRAIR,Oncology: Breast,(N/A); Adjuvant,Breast Neoplasms,United States
"A Phase I/IIa, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability and Maximum Tolerated Dose of AP23573 when Administered Orally in Patients with Refractory or Advanced Malignancies.",I/II,Completed,"Merck & Co.
Takeda {Ariad}","Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",(N/A); Locally advanced; Metastatic; Pulmonary; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Wilms Tumor",United States
KOS-862 (epothilone D): A comparison of two schedules in patients with advanced malignancies,I,Completed,"Roche
Bristol-Myers Squibb {Kosan Biosciences}",Oncology: Breast; Oncology: Colorectal; Oncology: Ovarian; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Testicular,Second line; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms,United States
"A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine",I,Completed,Pfizer,Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: GIST; Oncology: Liver; Oncology: Mesothelioma; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Mesothelioma; Neoplasms, Mesothelial; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
A Phase I clinical trial of CHP-HER2 vaccine (LUD01-016) for HLA-A2402-positive patients with HER2-expressing refractory cancers.,I,Completed,Ludwig Institute for Cancer Research,"Oncology: Bladder; Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Pancreas",HER2 positive; Second line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",Australia; Japan; United States
A Phase I Dose-Escalation Study of PHA-739358 Administered as a 24-Hour Infusion in a 14-Day Cycle in Patients with Advanced/Metastatic Solid Tumors,I,Completed,Nerviano Medical Sciences,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Thyroid",Extensive; Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms; Wilms Tumor",United States
"Phase I and Pharmacokinetics (PK) of DJ-927, an oral taxane, in patients with advanced cancers.",I,Completed,Daiichi Sankyo {Daiichi Pharmaceutical},"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Mesothelioma; Neoplasms, Mesothelial; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Canada; United States
"A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms",I,Completed,"Case Western Reserve University
Cancer Therapy & Research Center San Antonio, Texas","Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Advanced; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Fibrosarcoma; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase I Study Dose Escalation Clinical Study Of Hepatic Intraarterial Cisplatin, In Combination With Systemic Intravenous Liposomal Doxorubicin Administered Every Four Weeks to Patients With Advanced Cancer And Dominant Liver Involvement",I,Completed,"MD Anderson Cancer Center, University of Texas","Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",Aggressive; Classical; Fourth line or greater; Indolent; Liver mets; Locally advanced; Metastatic; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Liposarcoma; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasm Metastasis; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma",United States
"Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies",I,Completed,University of Colorado Cancer Center at University of Colorado Health Sciences Center,"Oncology: Breast; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma",Aggressive; Fourth line or greater; Indolent; Stage III; Stage IV,"Breast Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Ovarian Cancer; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
Phase I clinical trial of systemic delivery of REOLYSIN as a treatment for patients with advanced or metastatic solid tumours.,I,Completed,Oncolytics Biotech,Oncology: Breast; Oncology: Colorectal; Oncology: Ovarian,Fourth line or greater; Second line; Stage III; Stage IV; Third line,Breast Neoplasms; Colorectal Neoplasms; Ovarian Cancer; Ovarian Neoplasms,United States
A Phase I Trial of Perifosine on a Loading Dose/Maintenance Dose Schedule in Patients With Advanced Cancer,I,Completed,"National Institutes of Health/National Cancer Institute
University of Wisconsin Comprehensive Cancer Center","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Locally advanced; Maintenance/Consolidation; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified; Wilms Tumor",United States
A HER-2/Neu Pulsed DC1 Vaccine for Patients With DCIS.,I,Completed,"National Institutes of Health/National Cancer Institute
Abramson Cancer Center at  University of Pennsylvania Medical Center",Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Stage 0,"Breast Neoplasms; Carcinoma in Situ; Carcinoma, Intraductal, Noninfiltrating",United States
An Open-Label Study to Assess the Effect of Omeprazole Administration on the Pharmacokinetics of VELCADE in Subjects with Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma,I,Completed,"Jonsson Comprehensive Cancer Center, UCLA
National Institutes of Health/National Cancer Institute
Johnson & Johnson/Janssen R&D {Johnson & Johnson/J&JPRD}
Takeda/Takeda Oncology {Millennium}","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",Aggressive; Indolent; Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms",United States
"Phase I Clinical Trial with Weekly Irinotecan and Oral Capecitabine, Both Administered for Two Weeks of a Three Week Cycle, in Patients with Advanced Solid Malignancies",I,Completed,Albert Einstein Cancer Center (AECC),Oncology: Breast; Oncology: Colorectal; Oncology: Ovarian,Second line; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Ovarian Cancer; Ovarian Neoplasms,United States
Phase I dose-escalating clinical trial of HGS-ETR2 (TRAIL-R2 mAb) in patients with advanced tumours.,I,Completed,GlaxoSmithKline {Human Genome Sciences},"Oncology: Breast; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thymus; Oncology: Thyroid",Aggressive; Cutaneous T-cell lymphoma (CTCL); Indolent; Locally advanced; Metastatic; Peripheral T-cell lymphoma (PTCL); Second line; Stage III; Stage IV; Thymic carcinoma,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Melanoma; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thymus Neoplasms; Thyroid Neoplasms; Wilms Tumor",United States
Phase I Study of Carboplatin and Cyclophosphamide with Amifostine for Cytoprotection in Patients with Advanced Malignancies.,I,Completed,"Amgen {Immunex}
Cleveland Clinic Foundation Hospital","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Soft Tissue Sarcoma; Oncology: Supportive Care; Oncology: Unspecified Cancer",Extensive; First line; Neutropenia; Pulmonary; Second line; Stage III; Stage IV; Untreated,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Lymphoma; Melanoma; Multiple Myeloma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasms; Neoplasms, Plasma Cell; Neuroendocrine Tumors; Neutropenia; Palliative Care; Plasmacytoma; Precancerous Conditions; Preleukemia; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Syndrome; Synovial Sarcoma",United States
A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80,I/II,Terminated,"Novartis
Walther Cancer Institute",Oncology: Breast,First line; HER2 positive; Stage III; Stage IV,Breast Neoplasms,United States
A Phase I Study of OSI-461 in Combination with Mitoxantrone (Novantrone) in Patients with Advanced Solid Tumors Potentially Responsive to Mitoxantrone,I,Terminated,Astellas Pharma {OSI Pharmaceuticals},Oncology: Bladder; Oncology: Breast; Oncology: Prostate; Oncology: Testicular,First line; Second line; Stage III; Stage IV,Breast Neoplasms; Prostatic Neoplasms; Testicular Cancer; Testicular Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms,United States
"A Phase I Study of MK0752, a Notch Inhibitor, in Patients With Metastatic or Locally Advanced Breast Cancer and Other Solid Tumors.",I,Completed,Merck & Co./Merck Sharp & Dohme (MSD),"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Endometrial; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Central Nervous System Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Glioblastoma; Leiomyosarcoma; Liposarcoma; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",Canada; United States
A phase I clinical trial of an Ii-Key/HER2/neu MHC class II peptide-based vaccine in breast cancer patients.,I,Completed,"Walter Reed Army Institute of Research - WRAIR
Generex Biotechnology/NuGenerex Immuno-Oncology {Antigen Express}",Oncology: Breast,Line of therapy N/A; Stage II; Stage III,Breast Neoplasms,United States
A Phase I Open Label Dose Escalation Study of Once-Daily Oral Treatment with BIBW 2992 for 21 Days in Patients with Advanced Solid Tumors.,I,Completed,Boehringer Ingelheim,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Thyroid",EGFR; HER2 positive; Hormone refractory; Metastatic; Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Mesothelioma; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Thyroid Neoplasms; Unspecified",United States
A Phase I Study to Determine the Maximum Tolerated Dose of Yondelis (ET-743)and Doxil Administered to Subjects with Advanced Malignancies.,I,Completed,"Johnson & Johnson/Janssen R&D {Johnson & Johnson/J&JPRD}
PharmaMar {Zeltia/PharmaMar}","Oncology: Bladder; Oncology: Breast; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Soft Tissue Sarcoma",First line; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Phase I Study of Doxorubicin, Docetaxel and Gemcitabine Combination (TAG) in Patients with Solid Tumors.",I,Completed,University of Maryland Greenebaum Cancer Center,"Oncology: Bladder; Oncology: Breast; Oncology: Endometrial; Oncology: Lung, Small Cell; Oncology: Mesothelioma; Oncology: Neuroendocrine",(N/A); First line; Pulmonary; Second line; Untreated,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Small Cell; Endometrial Neoplasms; Mesothelioma; Neoplasms, Mesothelial; Neuroendocrine Tumors; Small Cell Lung Carcinoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
Phase I and Pharmacokinetic study of Sequential Paclitaxel followed by Trabectedin (ET-743) in 24-h Every 2 weeks in Patients with Advanced or Metastatic Cancer,I,Completed,PharmaMar {Zeltia/PharmaMar},"Oncology: Breast; Oncology: CNS, Medulloblastoma; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma",First line; Fourth line or greater; Metastatic; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Medulloblastoma; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",Netherlands; United States
"A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer.",I,Completed,(Other Academic Cancer Center),"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Renal",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Wilms Tumor",Ireland; United States
"An Open-Label, Dose Escalation Phase I/II Trial of a KSP Inhibitor Given as a Constant 24 Hour Infusion in Patients with Advanced Solid Tumors.",I/II,Completed,Merck & Co./Merck Sharp & Dohme (MSD),"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",(N/A); Fourth line or greater; Locally advanced; Metastatic; Pulmonary; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"An investigator-sponsored Phase I Trial of STR(TM), NeoRx's investigational bone-targeted radiotherapeutic, in patients with advanced breast cancer",I,Completed,"MD Anderson Cancer Center, University of Texas",Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; Line of therapy N/A; Stage IV,Breast Neoplasms; Neoplasm Metastasis,United States
"A Phase 1 Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of AMG 386 in Adult Patients With Advanced Solid Tumors.",I,Completed,Amgen,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",First line; Locally advanced; Metastatic; Second line; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Wilms Tumor",United States
"A Phase I, Open-Label, Dose-Escalation Study of the Safety and Tolerability of SB-715992 in Combination with Carboplatin on an Every 21-Day Schedule in Subjects with Advanced Solid Tumors.",I,Completed,"GlaxoSmithKline
Cytokinetics","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Prostate",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms; Prostatic Neoplasms",United Kingdom; United States
A phase I study of the anti-microtubule agent T138067-sodium administered daily x 5 every 3 weeks.,I,Completed,Amgen {Tularik},"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Prostate; Oncology: Renal",(N/A); Aggressive; Classical; Indolent; Nodular lymphocyte-predominant; Second line,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",United States
A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors,I,Completed,"GlaxoSmithKline
Exelixis",Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Melanoma; Oncology: Ovarian; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid,Medullary; Metastatic; Papillary; Recurrent; Second line; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"An Open-Label, Dose-Finding Study to Evaluate the Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Subjects with Advanced Cancer",I,Terminated,Amgen,"Oncology: Breast; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas",First line; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Cancer; Esophageal Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms",United States
"Phase I dose-ranging study of anti-cancer agent AEZS-108 in ovarian, endometrial or breast cancer.",I,Completed,Aeterna Zentaris,Oncology: Breast; Oncology: Endometrial; Oncology: Ovarian,(N/A); First line; Second line; Untreated,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Ovarian Cancer; Ovarian Neoplasms",Bulgaria; Germany; United States
A Phase I Trial of the Combination of Perifosine and Paclitaxel Given Either Weekly or Every 3 Weeks.,I,Completed,Akebia Therapeutics {Keryx Biopharmaceuticals {Access Oncology/AOI Pharmaceuticals}},"Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Thyroid",Fourth line or greater; Second line; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Thyroid Neoplasms; Unspecified; Uterine Cervical Neoplasms",United States
"Phase I/II Study of Ifosfamide, Carboplatin, and Docetaxel Followed by Autologous Stem Cell Rescue in Patients With Refractory Malignancies.",I/II,Completed,Midwestern Regional Medical Center,"Oncology: Breast; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Testicular; Oncology: Unspecified Cancer",Aggressive; Classical; Diffuse large B-cell lymphoma (DLBCL); Lymphoblastic lymphoma (LBL); Mantle cell lymphoma (MCL); Nodular lymphocyte-predominant; Other subtype; Peripheral T-cell lymphoma (PTCL); Second line; Stage IV,"Breast Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral; Multiple Myeloma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasms; Neoplasms, Plasma Cell; Ovarian Cancer; Ovarian Neoplasms; Plasmacytoma; Precancerous Conditions; Preleukemia; Syndrome; Testicular Cancer; Testicular Neoplasms",United States
Phase I/II Study of High Dose Melphalan with Autologous Peripheral Blood Stem Cell Support and Amifostine Cytoprotection in Cancer Patients,I/II,Completed,"Johnson & Johnson/ALZA
National Institutes of Health
University of Kentucky","Oncology: Breast; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma",Aggressive; Classical; Cutaneous T-cell lymphoma (CTCL); Diffuse large B-cell lymphoma (DLBCL); Extranodal marginal zone B-cell lymphoma (MALT); Follicular lymphoma (FL); Fourth line or greater; Indolent; Lymphoblastic lymphoma (LBL); Mantle cell lymphoma (MCL); Nodular lymphocyte-predominant; Other subtype; Peripheral T-cell lymphoma (PTCL); Second line; Small lymphocytic lymphoma (SLL); Third line; Waldenstrom's macroglobulinemia (WM),"Acute Myelocytic Leukemia; Breast Neoplasms; Fibrosarcoma; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Leukemia, Myeloid, Acute; Liposarcoma; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Multiple Myeloma; Neuroblastoma; Ovarian Cancer; Ovarian Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Waldenstrom Macroglobulinemia",United States
"A phase I/II study of neoadjuvant Evacet, Paclitaxel and hyperthermia in locally advanced breast cancer patients.",I/II,Completed,"National Institutes of Health
Duke University Medical Center",Oncology: Breast,Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
Gemcitabine and R115777 Combination Therapy for Metastatic Breast Cancer,I/II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,First line; Second line; Stage IV,Breast Neoplasms,United States
Phase I Study Of Weekly Anti-Vascular Endothelial Growth Factor Receptor 2(Vegfr-2) Monoclonal Antibody Imc-1121b In Patients With Advanced Solid Tumors Who Have Not Responded To Standard Therapy,I,Completed,Eli Lilly {ImClone},Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms",United States
Phase I study of intensive course immunization with NY-ESO-1 derived peptides presented by MHC class 1 molecules alone and combined with GM-CSF in patients with advanced NY-ESO-1 or LAGE expressing cancers.,I,Completed,Ludwig Institute for Cancer Research,"Oncology: Breast; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",First line; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",Germany; Switzerland; United States
A Phase I Dose-Escalation Study of BMS-354825 in Patients With Refractory Solid Tumors,I,Completed,Bristol-Myers Squibb,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: GIST; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Soft Tissue Sarcoma",Metastatic; Second line; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Leiomyosarcoma; Liposarcoma; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Unspecified",United Kingdom; United States
"A Phase I, Open-Label Study of the Safety, Tolerability and Pharmacokinetics of GW572016 in Combination with Letrozole (Femara) in Cancer Subjects.",I,Completed,GlaxoSmithKline,Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Ovarian,Estrogen receptor positive; First line; Fourth line or greater; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",United Kingdom; United States
A Phase I Safety and Pharmacokinetic Study of SU011248 in Combination with Docetaxel in Patients with Advanced Solid Tumors,I,Completed,Pfizer,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Renal",(N/A); Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Kidney Neoplasms; Lung Neoplasms; Neuroendocrine Tumors; Renal Cancer; Small Cell Lung Carcinoma; Wilms Tumor",United States
Phase I combination Trial of Irofulven and Gemcitabine in Patients with Advanced Cancers.,I,Completed,Eisai {MGI Pharma},Oncology: Breast; Oncology: Colorectal; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma,Line of therapy N/A; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",United States
Primary Hormonal Therapy for Ductal Carcinoma in Situ: Exploration of a Novel Approach to the Clinical Management of Noninvasive Breast Cancer.,I/II,Completed,"Novartis
University of California, San Francisco",Oncology: Breast,Estrogen receptor positive; Neoadjuvant; Stage 0,"Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Intraductal, Noninfiltrating",United States
"A Phase I, Open-Label, Dose-Escalation, Multidose Study of CDX-1307, a Mannose Receptor-Targeted hCG-ß Vaccine, in Patients With Incurable Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder and Ovarian Cancer",I,Completed,Celldex Therapeutics {AVANT Immunotherapeutics {Medarex/Celldex Therapeutics {Alteris Therapeutics}}},Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Ovarian; Oncology: Pancreas,HER2 positive; Second line; Stage II; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms,United States
Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies.,I,Completed,PharmaMar {Zeltia/PharmaMar},Oncology: Breast; Oncology: Melanoma; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma,Second line; Stage III; Stage IV,Breast Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma,United States
"Phase I Open-Label, Dose Escalating, Multiple Dose Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, And Pharmacokinetics of MPC-6827 Administered IV Weekly x 3, Repeated Every 28 Days, in Subjects with Refractory Solid Tumors",I,Completed,Myrexis {Myriad Pharmaceuticals {Myriad Genetics}},Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Thymus,Fourth line or greater; Second line; Stage III; Stage IV; Third line; Thymoma,"Breast Neoplasms; Carcinoma, Endometrioid; Colorectal Neoplasms; Endometrial Neoplasms; Neoplasms; Thymoma; Thymus Neoplasms",United States
"A Phase I, Open-Label, Dose Escalation, Multi-Center Study of TPI 287 in Patients with Advanced Malignancies.",I,Completed,Tapestry Pharmaceuticals,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Soft Tissue Sarcoma; Oncology: Thymus; Oncology: Thyroid",(N/A); Fourth line or greater; Pulmonary; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Glioblastoma; Head and Neck Neoplasms; Hodgkin Disease; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Neoplasms, Basal Cell; Neuroendocrine Tumors; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thymus Neoplasms; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A Phase I/II, Multicenter, Randomized Dose-Escalation Study of Oral AEE788 on Intermittent Dosing Schedules in Adult Patients With Advanced Cancer (Effective Amendment 5) Previously Entitled A Phase IA, Multicenter, Dose-Escalating Study of Oral AEE788 on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Cancer",I/II,Terminated,Novartis,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",First line; Fourth line or greater; HER2 positive; Locally advanced; Medullary; Metastatic; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Australia; Belgium; Spain; United States
Phase I Study to Determine the Maximum Tolerated Dose of LErafAON in Combination With Radiotherapy in Patients With Advanced Malignancies,I,Completed,"Insys Therapeutics {NeoPharm, Inc.}
Georgetown University Medical Center","Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Pancreas",Classical; Cutaneous T-cell lymphoma (CTCL); Indolent; Large Cell; Nodular lymphocyte-predominant; Other subtype; Peripheral T-cell lymphoma (PTCL); Second line; Squamous Cell; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms",United States
"A Phase I, Multi-Dose Study of RAV12 (ANTI-RAAG12 MAB) in Patients With Metastatic or Recurrent Adenocarcinoma",I/II,Completed,MacroGenics {Raven biotechnologies},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",Fourth line or greater; Second line; Stage IV; Third line,"Adenocarcinoma; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Liver Cancer; Liver Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Phase Ib, Single-Center, Open-Label, Dose Escalation, Safety and Pharmacokinetic Study of Panzem Nanocrystal Colloidal Dispersion Administered Orally to patients with Advanced Cancer.",I,Completed,CASI Pharmaceuticals {EntreMed},"Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
A Phase I-II Study for Stage IV Breast and HER2/Neu Positive Cancers to Evaluate the Safety and Efficacy of a Vaccine Using Whole Cells From the SVBR- 1-GM Cell Line Genetically Engineered To Produce Granulocyte- Macrophage Colony Stimulating Factor,I/II,Terminated,BriaCell,"Oncology: Bladder; Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",First line; HER2 negative; HER2 positive; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
Phase I Dose-Escalation Study of Oral SKI-606 in Subjects with Advanced Malignant Solid Tumors.,I,Completed,Pfizer {Wyeth/Wyeth Research},"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",United States
"A Multicenter, Open-Label, Noncomparative Phase 1-2 Clinical And Pharmacokinetic Study Of Oral PD 0325901 In Patients With Advanced Cancer.",I/II,Terminated,Pfizer,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma",BRAF; First line; Fourth line or greater; KRAS; NRAS; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Colorectal Neoplasms; Melanoma; Neoplasms",United States
"A Phase 1 Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL999 Administered Intravenously to Subjects with Solid Tumors",I,Completed,Exelixis,Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: GIST; Oncology: Liver; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid,Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Unspecified; Wilms Tumor",United States
A Phase I Trial of BAY 43-9006 (Sorafenib) and Bevacizumab in Refractory Solid Tumors with Biologic and Proteomic Analysis.,I,Completed,"National Institutes of Health/National Cancer Institute
Center for Cancer Research
Warren G Magnuson Clinical Center
National Institutes of Health","Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Follicular; Fourth line or greater; HER2 negative; Metastatic; Second line; Stage III; Stage IV; Third line; Unresectable,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Endometrioid; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Mesothelioma; Neoplasms, Basal Cell; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Unspecified; Uterine Cervical Neoplasms; Wilms Tumor",United States
"First in Human Phase I Trial of 852A, a Novel Systemic Toll-like Receptor 7 Agonist, to Activate Innate Immune Responses in Patients with Advanced Cancer.",I,Completed,"Pfizer {Coley Pharmaceutical Group}
Bausch Health Companies {Valeant Pharmaceuticals {Medicis {Graceway Pharmaceuticals {3M Pharmaceuticals}}}}","Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Renal",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Unspecified; Wilms Tumor",United States
An open-label 2-cycle trial of 168-hour infusion of YM155 in patients with advanced solid tumors or or non-Hodgkin’s lymphoma,I,Completed,Astellas Pharma {Yamanouchi Pharmaceutical},"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Aggressive; Diffuse large B-cell lymphoma (DLBCL); Follicular lymphoma (FL); Fourth line or greater; Hormone refractory; Indolent; Peripheral T-cell lymphoma (PTCL); Small lymphocytic lymphoma (SLL); Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Wilms Tumor",United States
"A Phase I/II Dose-Escalation Study of the Safety, Efficacy and Pharmacokinetics of Glufosfamide in Combination with Gemcitabine in Advanced Solid Tumors and Pancreatic Adenocarcinoma.",I/II,Completed,Molecular Templates {Threshold Pharmaceuticals},Oncology: Breast; Oncology: Gastric; Oncology: Liver; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma,First line; Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Wilms Tumor",Brazil; United States
Phase I Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) Alone and in Combination with Docetaxel in Subjects with Advanced Solid Malignancies.,I,Completed,Molecular Templates {Threshold Pharmaceuticals},"Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Head and Neck Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Stomach Neoplasms",United States
A Phase I Study of MGCD0103 Given as a Three-Times Weekly Oral Dose in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma.,I,Completed,"Mirati Therapeutics {MethylGene}
Bristol-Myers Squibb/Celgene {Pharmion}","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma",First line; Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Neoplasms; Neoplasms, Basal Cell; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",Canada; United States
Phase I study of Xyotax (CT-2103) and carboplatin in patients with solid tumors,I,Completed,CTI BioPharma {Cell Therapeutics},"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Thyroid",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Thyroid Neoplasms; Wilms Tumor",United States
Phase I/II Study of Maitake Extract in Breast Cancer Patients.,I/II,Completed,"Memorial Sloan-Kettering Cancer Center
New York Presbyterian Hospital - Cornell Campus",Oncology: Breast,Line of therapy N/A; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"EKB-569, an irreversible inhibitor of the epidermal growth factor receptor: Phase I trial results in patients with advanced solid tumors",I,Completed,"Mayo Clinic Cancer Center
Pfizer {Wyeth/Wyeth Research}
Cancer Therapy & Research Center San Antonio, Texas","Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Renal",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Renal Cancer; Wilms Tumor",United States
Phase I Study Of Capecitabine In Combination With Temozolomide In The Treatment Of Patients With Brain Metastases From Breast Carcinoma,I,Completed,Merck & Co. {Schering-Plough},Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Estrogen receptor positive; Progesterone receptor positive; Second line; Stage IV; Third line,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
"Phase I Open-Label, Multicenter, Dose-Escalation Clinical Study of the Safety and Pharmacokinetic Profiles of Weekly Intravenous Administrations of SNS-595 in Patients With Advanced Malignancies.",I,Completed,Viracta Therapeutics {Sunesis},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma",(N/A); Advanced; Locally advanced; Metastatic; Pulmonary; Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Renal Cell; Carcinoma, Small Cell; Cholangiocarcinoma; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified; Wilms Tumor",United States
A prospective study of concurrent cyclophosphamide/methotrexate/5-fluorouracil and reduced-dose radiotherapy in patients with early-stage breast carcinoma.,I,Completed,Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute,Oncology: Breast,Adjuvant; Stage I; Stage II,Breast Neoplasms,United States
A Phase I Vaccine Safety and Chemotherapy Dose-Finding Trial of an Allogeneic GM-CSF-Secreting Breast Cancer Vaccine Given in a Specifically Timed Sequence With Immunomodulatory Doses of Cyclophosphamide and Doxorubicin,I,Completed,"National Institutes of Health/National Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}",Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
"A Multicenter, Open-Label Safety and Pharmacokinetics Study of Chimeric Anti-Phosphatidylserine Monoclonal Antibody (Bavituximab) in Patients with Refractory Advanced Solid Tumor Malignancies.",I,Completed,"Peregrine Pharmaceuticals
Premiere Oncology",Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Pancreas; Oncology: Prostate,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms",United States
"To investigate the tolerability, pharmacokinetics, and antitumor activity of the oral, selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 in patients with solid malignant tumors.",I,Completed,AstraZeneca,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Advanced; EGFR; First line; Second line; Stage III; Stage IV; Untreated,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Mesothelioma; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",United Kingdom; United States
"A Phase I, Open-Label, Multicenter, Dose-Escalation Study of the Safety and Pharmacokinetics of a Recombinant Humanized Antibody to Her2 (rhuMAb 2C4) Administered Every 3 Weeks to Subjects with Advanced Solid Malignancies",I,Completed,Roche/Genentech {Genentech},"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",HER2 negative; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Unspecified",United States
"A Phase I, Open-Label, Dose-Escalation Study of SB-715992 Administered Weekly for Three Consecutive Weeks of 28-Day Cycle in Patients with Solid Tumors.",I,Completed,"GlaxoSmithKline
Cytokinetics","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal",First line; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Mesothelioma; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"Phase I, Open-Label, Dose-Escalation Study to Assess the Safety and Tolerability of AZD0530 in Patients With Advanced Solid Malignancies That Have Activated c-Src Kinase.",I,Completed,AstraZeneca,Oncology: Breast; Oncology: Colorectal; Oncology: Pancreas,Fourth line or greater; Second line; Stage III; Stage IV; Third line,Breast Neoplasms; Colorectal Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms,Netherlands; Spain; United Kingdom; United States
"Phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of a single intravenous dose of rhIGFBP-3.",I,Completed,Insmed,Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
"A Phase I, Open-Label, Dose-Escalation Study of AQ4N Administered Intravenously in Patients with Advanced Malignancies.",I,Completed,Paratek Pharmaceuticals {Transcept Pharmaceuticals {Novacea}},"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Aggressive; Indolent; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",United States
"An Open-Label, Phase Ib Study of CYC682 in Patients with Refractory Solid Tumors or Lymphomas (IND#53,748).",I,Completed,Cyclacel,"Oncology: Breast; Oncology: Colorectal; Oncology: GIST; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian",Aggressive; Fourth line or greater; Indolent; Locally advanced; Metastatic; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Ovarian Cancer; Ovarian Neoplasms",United States
"An Ascending Single and Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HKI-272 Administered Orally to Subjects with HER-2/NEU or HER-1/EGFR-Positive Tumors.",I,Completed,Puma Biotechnology,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Cancer",EGFR; Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Glioblastoma; Kidney Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Wilms Tumor",United States
"An Open Label, Dose Escalation Study to Determine the Maximum Tolerated Dose and to Evaluate the Safety Profile of CC-5013 with Weekly Docetaxel (Taxotere ®)",I,Completed,Bristol-Myers Squibb/Celgene,"Oncology: Breast; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Prostate",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Cancer; Esophageal Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms",United States
"A Phase I/II Study of an Antitumor Vaccination Using Alpha(1,3)Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Relapsed or Refractory Breast Cancer",I/II,Terminated,Lumos Pharma {NewLink Genetics},Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,United States
"Phase I Study of Fenretinide, Paclitaxel, and Cisplatin in Patients With Advanced Solid Tumors.",I,Completed,"National Institutes of Health/National Cancer Institute
Ireland Cancer Center",Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Melanoma,Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Melanoma; Stomach Carcinoma; Stomach Neoplasms; Unspecified,United States
A phase I clinical and pharmacokinetic study of ro 31-7453 given as a 7 or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors.,I,Completed,"Cancer Research UK
Roche {F. Hoffmann-La Roche}","Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Prostate; Oncology: Renal",(N/A); First line; Fourth line or greater; Pulmonary; Second line; Stage III; Stage IV; Third line; Untreated,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Neuroendocrine Tumors; Prostatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Wilms Tumor",United Kingdom; United States
"Phase I/II Randomized Study of Adjuvant Doxorubicin and Cyclophosphamide With or Without Chinese Herbal Therapy for Symptom Management in Women With Stage I, II, or Early Stage III Breast Cancer.",I/II,Completed,"National Institutes of Health/National Cancer Institute
University of California, San Francisco",Oncology: Breast,Adjuvant; Second line; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Multi-Center, Open-Label, Dose-Escalation Phase Ib Study to Evaluate the Safety and Tolerability of TRM-1 (Fully-Human Monoclonal Antibody to Trail-R1) in Combination with Paclitaxel and Carboplatin in Subjects with Advanced Solid Malignancies",I,Completed,GlaxoSmithKline {Human Genome Sciences},"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",First line; Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
"Phase I, open-label, dose escalation, study of the combination of cisplatin and OSI-7904L  in patients who have advanced solid tumors.",I,Completed,Astellas Pharma {OSI Pharmaceuticals},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Small Intestine",Advanced; First line; Fourth line or greater; Hormone refractory; Second line; Stage III; Stage IV; Third line; Untreated,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Intestinal Neoplasms; Kidney Neoplasms; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",United States
A Phase I Evaluation of the Combination of Pegylated Liposomal Doxorubicin (Doxil) with PS-341 in Patients with Refractory Hematologic and Solid Malignancies.,I/II,Completed,"(Other Cooperative Group)
National Institutes of Health/National Cancer Institute
UNC Lineberger Comprehensive Cancer Center
Takeda/Takeda Oncology {Millennium}
National Institutes of Health","Oncology: Breast; Oncology: Head/Neck; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome; Oncology: Ovarian",Aggressive; Classical; Fourth line or greater; Indolent; Nodular lymphocyte-predominant; RAEB; Second line; Stage IV; Third line,"Acute Myelocytic Leukemia; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Chronic Lymphocytic Leukemia; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms, Plasma Cell; Ovarian Cancer; Ovarian Neoplasms; Plasmacytoma",United States
Phase I Trial of Oral Cyclophosphamide in Combination with Celecoxib in Patients with Advanced Malignancies.,I,Completed,"National Institutes of Health/National Cancer Institute
Beckman Research Institute","Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Unspecified Cancer",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Unspecified; Uterine Cervical Neoplasms",United States
Phase I Trial of Oral Etoposide in Combination with Celecoxib in Patients with Advanced Malignancies.,I,Completed,"National Institutes of Health/National Cancer Institute
Beckman Research Institute","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate; Oncology: Thyroid",(N/A); Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Thyroid Neoplasms; Unspecified",United States
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor.,I/II,Completed,"Roche/Genentech {Genentech}
(Other Cooperative Group)
Jonsson Comprehensive Cancer Center, UCLA
National Institutes of Health/National Cancer Institute
Translational Oncology Research International",Oncology: Breast,First line; HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"Phase I, Open Label, Dose-Escalation, Multidose Study of MDX-1307, a Mannose Receptor-Targeted hCG-B Vaccine, in Patients with Incurable Colorectal, Pancreatic or Bladder Cancer",I,Completed,"National Institutes of Health/National Cancer Institute
Duke University Medical Center
Celldex Therapeutics {AVANT Immunotherapeutics {Medarex/Celldex Therapeutics {Alteris Therapeutics}}}",Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Ovarian; Oncology: Pancreas,Second line; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms,United States
"An Open-Label, Single Arm, Phase I Study of Troxatyl (Troxacitabine) Administrated by Continuous Infusion in Subjects with Advanced Solid Malignancy.",I,Terminated,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}
Takeda/Shire
Eli Lilly {SGX Pharmaceuticals {Structural GenomiX}}",Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Pancreas; Oncology: Renal,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Unspecified; Wilms Tumor",United States
Phase I Study of Continuous Weekly Dosing of Dimethyl Benzoylphenylurea (BPU) in Patients With Solid Tumors Not Responding to Conventional Therapy,I,Completed,"National Institutes of Health/National Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Wilms Tumor",United States
"Phase I Study Of 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (17-DMAG, NSC #707545) In Patients With Solid Tumors.",I,Completed,"Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute",Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Melanoma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal,Hormone refractory; Second line; Stage III; Stage IV,"Breast Neoplasms; Breast Neoplasms, Male; Carcinoma; Carcinoma, Adenoid Cystic; Carcinoma, Basal Cell; Carcinoma, Mucoepidermoid; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Verrucous; Colonic Neoplasms; Colorectal Neoplasms; Esthesioneuroblastoma, Olfactory; Granuloma; Head and Neck Neoplasms; Kidney Neoplasms; Laryngeal Diseases; Laryngeal Neoplasms; Melanoma; Nasopharyngeal Neoplasms; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Unknown Primary; Oropharyngeal Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Papilloma; Papilloma, Inverted; Paranasal Sinus Neoplasms; Prostatic Neoplasms; Renal Cancer; Salivary Gland Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",United States
Phase 1 Trial of the Combination of Perifosine and Gemcitabine.,I,Completed,Akebia Therapeutics {Keryx Biopharmaceuticals {Access Oncology/AOI Pharmaceuticals}},"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma",(N/A); Fourth line or greater; Second line; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified; Wilms Tumor",United States
A Phase 1 Dose-Escalation Study of Intravenous MST-997 Formulated in Intralipid 20% Administered Weekly in Subjects with Advanced Malignant Solid Tumors.,I,Terminated,Pfizer {Wyeth/Wyeth Research},"Oncology: Bladder; Oncology: Breast; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"Phase I/II pharmacokinetic, pharmacogenomic trial of weekly amonafide in patients (pts) with solid tumors.",I/II,Completed,Teva {Cephalon/ChemGenex},"Oncology: Breast; Oncology: Colorectal; Oncology: GIST; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate",Hormone refractory; Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms",United States
An Open Label Pilot Study to Evaluate the Safety and Tolerability of PANVAC-V (Vaccinia) and PANVAC-F (Fowlpox) in Combination With Sargramostim in Adults With Metastatic Carcinoma,I,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Ovarian,Second line; Stage IV,"Adenocarcinoma; Breast Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Liver Cancer; Liver Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
"Phase I trial of a potent novel taxane, TL00139 (MAC-321), in patients with advanced malignant solid tumors.",I,Completed,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}
Pfizer {Wyeth/Wyeth Research}
Taxolog","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Advanced; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Mesothelioma; Neoplasms, Mesothelial; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",United States
Phase I Study of Soblidotin and Gemcitabine in Patients With Locally Advanced or Metastatic Solid Tumors.,I,Terminated,Daiichi Sankyo {Daiichi Pharmaceutical},"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Ovarian",Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Small Cell Lung Carcinoma",United States
A Phase I Trial of STA-4783 in Patients Receiving Paclitaxel for Treatment of Solid Tumors.,I,Completed,Madrigal Pharmaceuticals {Synta Pharmaceuticals},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Unspecified",United States
"Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies.",I,Completed,Samyang Holdings Corporation/Samyang Holdings Biopharmaceuticals {Samyang Research},"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Renal",Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Kidney Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Wilms Tumor",South Korea; United States
Phase I study of XYOTAX (CT-2103) administered weekly for patients with advanced solid tumors.,I,Completed,CTI BioPharma {Cell Therapeutics},"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal",(N/A); Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",Mexico; United States
A Phase I Trial Of UCN-01 And Prednisone In Patients With Refractory Solid Tumors And Lymphomas,I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal",Aggressive; Classical; Hormone refractory; Indolent; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",United States
A Prospective Study Of The Effect Of Tamoxifen On Breast Density In Premenopausal Women,I,Completed,"National Institutes of Health/National Cancer Institute
Robert H. Lurie Comprehensive Cancer Center at Northwestern University",Oncology: Breast,Line of therapy N/A; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Phase I Study of 17- Allylamino-17 Demethoxygeldanamycin (17-AAG) in Combination With Paclitaxel in Advanced Solid Malignancies.,I,Completed,"National Institutes of Health/National Cancer Institute
Bristol-Myers Squibb {Kosan Biosciences}
University of Pittsburgh","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Ovarian; Oncology: Prostate",Second line; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gallbladder Neoplasms; Head and Neck Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Unspecified",United States
"Phase I/II Trial of ZD1839 (Iressa), Trastuzumab (Herceptin), and Docetaxel (Taxotere) in Patients with erbB-2 (HER-2) Overexpressing, Stage IV Breast Carcinoma.",I/II,Terminated,"AstraZeneca
National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center",Oncology: Breast,First line; HER2 positive; Stage IV,Breast Neoplasms,United States
Phase 1 study of TLK286 (Telcyta) administered weekly in advanced malignancies.,I,Completed,"Jonsson Comprehensive Cancer Center, UCLA
Mabvax Therapeutics {Telik}","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Advanced; Fourth line or greater; Metastatic; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Mesothelioma; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
Single Center Open-Label Non-Comparative Phase I Dose Finding Study Of Weekly Flavopiridol In Combination With Weekly Docetaxel In Patients With Advanced Solid Tumors.,I,Completed,"Sanofi {Sanofi-Aventis {Aventis}}
Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",First line; Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma",United States
"An Open-Label, Phase I, Dose-Escalation Study of Tumor Necrosis Factor-alpha (TNFerade™ Biologic) Gene Therapy with Radiation Therapy for Locally Advanced, Recurrent, or Metastatic Solid Tumors",I,Completed,"Precigen, Inc. {Intrexon {GenVec}}",Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Melanoma; Oncology: Pancreas,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Pancreatic Cancer; Pancreatic Neoplasms",United States
Phase I Trial of Daily Imatinib Mesylate and Weekly Paclitaxel in Patients with Advanced Refractory Solid Tumors.,I,Completed,Novartis,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Soft Tissue Sarcoma",Fourth line or greater; Locally advanced; Metastatic; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
A Phase I Single Centre 2-part Open Study to Assess the Safety and Tolerability of AZD2171 Following Single and Multiple Oral Doses in Patients With Advanced Solid Malignant Tumors and Liver Metastases,I,Completed,AstraZeneca,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Metastatic Cancer; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Small Intestine; Oncology: Soft Tissue Sarcoma",Extensive; Liver mets; Locally advanced; Metastatic; Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Intestinal Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Neoplasms; Neoplasm Metastasis; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Wilms Tumor",Germany; United Kingdom; United States
"Phase I Open-Label, Multicenter, Dose Escalation Clinical Study of the Initial Safety and Pharmacokinetic Profiles of IV Administration of SNS-595 in Patients With Advanced Malignancies.",I,Completed,Viracta Therapeutics {Sunesis},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase I Study of STA-4783, an Inducer of Heat Shock Protein 70, Combined With Paclitaxel in Patients With Advanced Solid Tumors.",I,Completed,Madrigal Pharmaceuticals {Synta Pharmaceuticals},Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Melanoma; Oncology: Soft Tissue Sarcoma,Second line; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Gallbladder Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms,United States
A Phase I and Pharmacokinetic Study of ILX651 Administered Intravenously Weekly for 3 Weeks Every 4 Weeks in Patients with Advanced Solid Tumors.,I,Completed,Sanofi {Sanofi-Aventis}/Sanofi Genzyme {Genzyme {ILEX Oncology}},"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal",Advanced; Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Wilms Tumor",United States
"Phase I/II study of carboplatin, vinorelbine and capecitabine in metastatic breast cancer.",I/II,Completed,University of New Mexico Cancer Research and Treatment Center,Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Stage IV; Third line,Breast Neoplasms,United States
"A Phase I, Pharmacokinetic (PK), and Pharmacodynamic (PD) Study of the Farnesyl Transferase Inhibitor (FTI) R115777 in Combination with Weekly Paclitaxel in Patients with Advanced Solid Cancers.",I,Completed,Johnson & Johnson/Janssen R&D {Johnson & Johnson/J&JPRD},"Oncology: Breast; Oncology: Pancreas; Oncology: Skin, Basal Cell Carcinoma",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Basal Cell; Neoplasms, Basal Cell; Pancreatic Cancer; Pancreatic Neoplasms",United States
"A phase I trial of the farnesyltransferase (FT) inhibitor, BMS-214662 (B) in combination with paclitaxel (P) and carboplatin (C) in patients with advanced cancer",I,Completed,Bristol-Myers Squibb,"Oncology: Breast; Oncology: Endometrial; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",First line; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",United States
"Phase I study of 17-allylamino-17 demethoxygeldanamycin (17-AAG), gemcitabine (Gem) and/or cisplatin (CDDP) in solid tumor patients",I,Completed,"National Institutes of Health/National Cancer Institute
Bristol-Myers Squibb {Kosan Biosciences}
Mayo Clinic","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Locally advanced; Metastatic; Second line; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
An Open-Label Phase I Dose Escalation Trial To Evaluate The Safety And Pharmacokinetics Of Motexafin Gadolinium And Doxorubicin Chemotherapy In The Treatment Of Advanced Malignancies.,I,Completed,"National Institutes of Health/National Cancer Institute
AbbVie/Pharmacyclics
University of Wisconsin","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Intestinal Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Leukemia; Liposarcoma; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Lymphoma; Multiple Myeloma; Myelodysplastic-Myeloproliferative Diseases; Myeloproliferative Disorders; Neoplasms, Plasma Cell; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Wilms Tumor",United States
"A Phase I and pharmacokinetic study of HMN-214, a novel oral polo-like kinase inhibitor, in patients with advanced solid tumors",I,Completed,Nippon Shinyaku/NS Pharma,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Melanoma; Oncology: Primary Peritoneal; Oncology: Soft Tissue Sarcoma",Classical; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Liposarcoma; Melanoma; Peritoneal Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
"A phase I study of thalidomide, capecitabine and temozolomide (TCT) in advanced cancer.",I,Completed,Bristol-Myers Squibb/Celgene,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A phase I and pharmacokinetic study of DE-310 administered as a 3 hour infusion every 4 weeks (wks) to patients (pts) with advanced solid tumors or lymphomas,I,Terminated,Daiichi Sankyo {Daiichi Pharmaceutical},"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Thymus",Line of therapy N/A; Stage III; Stage IV; Thymoma,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Liver Cancer; Liver Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Thymoma; Thymus Neoplasms",Canada; United States
"A Phase I study of The Partaject* formulation of busulfan in patients  with neoplastic meningitis  (with the primary tumor being skin, breast, or lung cancer).",I,Completed,Otsuka Holdings/Otsuka Pharmaceutical/Astex Pharmaceuticals {SuperGen},"Oncology: Breast; Oncology: CNS, Other; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine",(N/A); Line of therapy N/A; Pulmonary,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Central Nervous System Neoplasms; Neuroendocrine Tumors; Small Cell Lung Carcinoma",United States
Phase 1/2a open-label clinical trial of ZYCOS 300 in late-stage metastatic cancer patients,I/II,Completed,Eisai {MGI Pharma {ZYCOS}},Oncology: Breast; Oncology: Colorectal; Oncology: Ovarian; Oncology: Prostate,Hormone refractory; Second line; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms,United States
"A Phase I clinical, biology & pharmacokinetic study of the combination of GW 572016 and capecitabine in patients with advanced solid tumors.",I,Terminated,GlaxoSmithKline,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell",HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
Phase I Study Of Capecitabine in Combination With Cisplatin and Irinotecan in Patients With Advanced Malignancies,I,Completed,University of New Mexico Cancer Research and Treatment Center,"Oncology: Breast; Oncology: Cervical; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell",Second line; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Unspecified; Uterine Cervical Neoplasms",United States
Phase I study of PS-341 (bortezomib) with 5-fluorouracil/leucovorin (5-FU/LV) in advanced solid tumors: A California Cancer Consortium study.,I,Completed,California Cancer Consortium,Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Pancreas,First line; Fourth line or greater; Second line; Stage III; Stage IV; Third line,Breast Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms,United States
Phase I Study of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) Formulation in Patients with Advanced Cancer.,I,Completed,"Insys Therapeutics {NeoPharm, Inc.}",Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma,Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
A Phase I Study of Intravenous (IV) Calcitriol in Combination With ZD1839 (IRESSA) in Refractory Solid Tumors,I,Completed,"AstraZeneca
National Institutes of Health/National Cancer Institute
Roswell Park Cancer Institute","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: GIST; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
"Phase I Study of GTI-2040, Oxaliplatin, and Capecitabine in Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors.",I,Completed,"National Institutes of Health/National Cancer Institute
California Cancer Consortium","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Colorectal Neoplasms; Neoplasms; Rectal Neoplasms",United States
Phase I trial of hu3S193 in patients with advanced epithelial cancers which express the Lewis-y antigen.,I,Completed,"National Institutes of Health/National Cancer Institute
Ludwig Institute for Cancer Research","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell",Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms",Australia; United States
"A Phase I, Open-Label Study of the Safety, Tolerability and Pharmacokinetics of GW572016 in Combination with Trastuzumab [Herceptin].",I,Completed,"GlaxoSmithKline
Jonsson Comprehensive Cancer Center, UCLA
National Institutes of Health/National Cancer Institute",Oncology: Breast,First line; HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
Adenovirus p53 Infected DC Vaccine For Breast Cancer,I/II,Completed,"National Institutes of Health/National Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
(Other Hospital/Academic/Medical Center)",Oncology: Breast,Adjuvant; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
Phase I clinical trial of Triapine combined with the anticancer agent gemcitabine in patients with treatment-refractory advanced or metastatic solid tumors.,I,Completed,Vion Pharmaceuticals,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms",United States
Phase I Clinical and Pharmacological Study of Suberoylanilide Hydroxamic Acid- SAHA (MSK390) in Patients With Advanced Solid Tumors,I,Completed,"Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute
Merck & Co. {Aton Pharma}","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal",Aggressive; Classical; Cutaneous T-cell lymphoma (CTCL); Diffuse large B-cell lymphoma (DLBCL); Extranodal marginal zone B-cell lymphoma (MALT); Follicular lymphoma (FL); Indolent; Lymphoblastic lymphoma (LBL); Mantle cell lymphoma (MCL); Nodular lymphocyte-predominant; Other subtype; Peripheral T-cell lymphoma (PTCL); Post-transplant/ineligible; Second line; Small lymphocytic lymphoma (SLL); Stage III; Stage IV; Waldenstrom's macroglobulinemia (WM),"Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Multiple Myeloma; Neoplasms; Neoplasms, Plasma Cell; Ovarian Cancer; Ovarian Neoplasms; Plasmacytoma; Prostatic Neoplasms; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Waldenstrom Macroglobulinemia; Wilms Tumor",United States
A Phase I Trial of Daily Bolus Flavopiridol for Five Consecutive Days in Patients With Refractory Neoplasms.,I,Completed,"Sanofi {Sanofi-Aventis {Aventis}}
National Institutes of Health/National Cancer Institute","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Prostate; Oncology: Renal",Aggressive; Classical; Hormone refractory; Indolent; Mantle cell lymphoma (MCL); Nodular lymphocyte-predominant; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melanoma; Prostatic Neoplasms; Renal Cancer; Wilms Tumor",United States
"A Phase Ib Multicenter Trial To Determine The Safety, Tolerance And Preliminary Antineoplastic Activity Of Gemcitabine Administered In Combination With Escalating Oral Doses Of OSI-774 To Patient Cohorts With Recently Diagnosed, Gemcitabine-Naive, Advanced Pancreatic Carcinoma Or Other Potentially Responsive Malignancies",I,Completed,Astellas Pharma {OSI Pharmaceuticals},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Thyroid",(N/A); Pulmonary; Second line; Stage II; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Cholangiocarcinoma; Colorectal Neoplasms; Kidney Neoplasms; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Weekly Administration of AP23573, an mTOR Inhibitor, in Patients with Refractory or Advanced Malignancies",I,Completed,Takeda {Ariad},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Multiple Myeloma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Locally advanced; Medullary; Metastatic; Second line; Stage III; Stage IV; Unresectable,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Mesothelioma; Multiple Myeloma; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase I, Open-Label, Multiple Dose Study to Assess the Tolerability, Pharmacokinetics and Pharmacodynamics of ARRY-142886 Given on a Daily Oral Regime in Subjects with Advanced Solid Malignancies",I,Completed,"AstraZeneca
Pfizer {Array BioPharma}","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thymus; Oncology: Thyroid",KRAS; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thymus Neoplasms; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
Phase I Study of the Antiproteolytic Targeting Therapy: Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination with Capecitabine in Advanced Malignancies.,I,Completed,"Heidelberg Pharma {WILEX}
US Department of Defense",Oncology: Breast; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms; Neoplasms, Unknown Primary",United States
Phase I Study of CL-F-ARA-A in Solid and Hematologic Malignancies,I,Completed,"National Institutes of Health/National Cancer Institute
FDA Office of Orphan Products Development
Sanofi {Sanofi-Aventis}/Sanofi Genzyme {Genzyme {Bioenvision}}","Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine",(N/A); Pulmonary; Second line,"Acute Myelocytic Leukemia; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Colorectal Neoplasms; Hematologic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Lymphoproliferative Disorders; Neuroendocrine Tumors; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms",United States
Phase I/II open-label dose-escalation study of MDX-214 as a single agent given to patients with EGFR-expressing malignancies,I/II,Completed,Bristol-Myers Squibb/Medarex,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Thyroid",Medullary; Other; Pancreas; Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms, Basal Cell; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Thyroid Neoplasms; Wilms Tumor",United States
"A Clinical Trial of the P-Glycoprotein Antagonist, XR9576, in Combination with Vinorelbine in Patients with Cancer: Analysis of the Interaction Between XR9576 and Vinorelbine",I,Completed,"National Institutes of Health/National Cancer Institute
Celtic Pharma {Xenova}",Oncology: Breast; Oncology: Renal,First line; Fourth line or greater; Second line; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Renal Cell; Kidney Neoplasms; Ovarian Neoplasms; Renal Cancer; Wilms Tumor",Netherlands; United Kingdom; United States
Pilot Study of Autologous T Cells and/or IL-2 for the Enhancement of Immune Reconstitution after Dose-Intensive Chemotherapy for Breast Cancer,I,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,First line; Stage II; Stage III; Stage IV,Breast Neoplasms; Neoplasm Metastasis; Neoplasms,United States
"Phase I Pilot Study Of Sequential High Dose Cycles Of Cisplatin, Cyclophosphamide, Etoposide And Ifosfamide, Carboplatin And Taxol With Autologous Stem Cell Support",I,Completed,"National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center",Oncology: Breast; Oncology: Soft Tissue Sarcoma,Fourth line or greater; Second line; Stage II; Stage III; Stage IV; Third line,Breast Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified,United States
Phase I Study of Intraperitoneal Aminocamptothecin Colloidal Dispersion in Patients with Cancer Predominantly Confined to the Peritoneal Cavity,I,Completed,"National Institutes of Health/National Cancer Institute
Kaplan Cancer Center",Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Metastatic Cancer; Oncology: Ovarian; Oncology: Pancreas,Peritoneal mets; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasm Metastasis; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Unspecified",United States
A Multicenter Phase I Open-Label Dose-Escalation Vaccine Trial of dHER2 Protein with AS15 Adjuvant in HER2-Overexpressing Patients With High-Risk Breast Cancer.,I,Completed,GlaxoSmithKline {Corixa},Oncology: Breast,Adjuvant; HER2 negative; Second line; Stage II; Stage III,Breast Neoplasms,Australia; Belgium; France; Italy; United States
Pilot Study to Evaluate the Influence of Garlic on the Pharmacokinetics of Docetaxel in Patients With Locally Advanced or Metastatic Breast Cancer,I,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms,United States
"A Pilot Study of Active Immunotherapy With HER2/Neu Intracellular Domain (ICD) Protein-Pulsed, Autologous, Cultured Dendritic Cells in Patients With No Evidence of Disease After Standard Treatment for HER2/Neu Expressing Malignancies.",I,Completed,"National Institutes of Health/National Cancer Institute
Duke Comprehensive Cancer Center",Oncology: Breast; Oncology: Gastric; Oncology: Ovarian,HER2 positive; Line of therapy N/A; Stage II; Stage III; Stage IV,Breast Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Stomach Carcinoma; Stomach Neoplasms,United States
A Phase I Open-Label Study To Evaluate The Safety and Tolerability Of Escalating Doses Of DAVANAT (A Galactomannan Derivative) In the Presence and Absence Of 5-Fluorouracil (5-FU) In Subjects with Advanced Solid Tumors,I,Completed,Galectin Therapeutics {Pro-Pharmaceuticals},Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms",United States
A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu.,I,Completed,Dendreon {Bausch Health Companies {Valeant Pharmaceuticals {Dendreon}}},Oncology: Breast,Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
Phase I Trial of Motexafin Gadolinium (MGd) and Docetaxel Administered at 3-Week Intervals for Advanced Solid Tumors.,I,Completed,AbbVie/Pharmacyclics,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate",Fourth line or greater; Hormone refractory; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms",United States
Vaccination Against High Risk Breast Cancer with Autologous Tumor-derived Heat Shock Protein 70-peptide Complexes (HSP70),I/II,Completed,University of Connecticut Health Center,Oncology: Breast,Second line; Stage II; Stage IV,Breast Neoplasms,United States
A Phase I/II Trial of Docetaxel Followed by Infusional Flavopiridol Over 72 Hours in Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer.,I/II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,First line; Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Phase I/II Trial Of Temozolomide And Vinorelbine For Patients With Recurrent Brain Metastases.,I/II,Completed,"Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute
NorthWestern Memorial Hospital","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Metastatic Cancer; Oncology: Neuroendocrine; Oncology: Renal",(N/A); CNS mets; Pulmonary; Second line; Stage IV,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasm Metastasis; Neuroendocrine Tumors; Renal Cancer; Small Cell Lung Carcinoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase I/II Single Dose Trial to Determine The Safety, Tolerance, Pharmacokinetic Profile, and Preliminary Activity of Intrahepatic Delivery (via Hepatic Artery Catheterization) of Doxorubicin Hydrochloride Adsorbed to Magnetic Targeted Carriers ( MTC-DOX) in Patients With Metastatic Cancer to the Liver.",I/II,Completed,"UCSF Comprehensive Cancer Center
FeRx","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",First line; Metastatic; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Digestive System Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Gastrointestinal Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma",Germany; United States
"Phase I-II study to evaluate safety, efficacy and pharmacokinetic interactions between capecitabine (XELODA) and exisulind (APTOSYN) in patients with metastatic breast cancer.",I/II,Completed,"MD Anderson Cancer Center, University of Texas
Roche
Astellas Pharma {OSI Pharmaceuticals {Cell Pathways}}",Oncology: Breast,Second line; Stage IV,Breast Neoplasms; Neoplasm Metastasis; Neoplasms,United States
"Phase I Study of LMB-9, a Recombinant Disulfide Stabilized Immunotoxin for Advanced Carcinomas that Express Lewis Y Antigen",I,Completed,"National Institutes of Health/National Cancer Institute
Teva {IVAX}","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Phase l/II Trial Of Tipifarnib (R15777, ZARNESTRA) In Combination With Tamoxifen In Subjects With Metastatic Breast Cancer",I/II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Estrogen receptor positive; Fourth line or greater; Progesterone receptor positive; Stage III; Stage IV; Third line,Breast Neoplasms,United States
Phase I Study of Yttrium 90-labeled Monoclonal Antibody B3 with Autologous Stem Cell Support for Metastatic Breast Cancer,I,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
"A Phase I/II Open Label, Multi-Center, Dose Escalation, Non-Randomized, 2 Step Study for the Evaluation of the Combination of CpG7909 and Herceptin in Patients with Breast Cancer, Refractory to Herceptin Plus Chemotherapy",I/II,Completed,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Pfizer {Coley Pharmaceutical Group}",Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
"Combined Modality Radioimmunotherapy For Metastatic Breast Adenocarcinoma With Two Cycles Of Escalating Dose 90Y-DOTA-Peptide-m170 and Fixed, Low Dose Paclitaxel With Blood Stem Cell Support And Cyclosporine For HAMA Suppression",I,Terminated,University of California Davis Cancer Center,Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
A Phase I Trial of Tamoxifen and 9-cis-Retinoic Acid in Breast Cancer Patients,I,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Pilot Study to Evaluate Epidermal Growth Factor Receptor Signaling after Treatment with Oral OSI-774 in Patients with Locally Advanced or Metastatic Breast Cancer,I/II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase I/II Study of Active Immunotherapy With Carcinoembryonic Antigen RNA-Pulsed, Autologous Cultured Dendritic Cells for Patients With Breast Cancer Who Achieve a Complete Response After High Dose Chemotherapy and Stem Cell Support",I/II,Terminated,"National Institutes of Health/National Cancer Institute
Duke Comprehensive Cancer Center",Oncology: Breast,Line of therapy N/A; Stage IV,Breast Neoplasms,United States
Phase I Study of Docetaxel in Patients With Advanced Solid Tumors and Varying Degrees of Abnormal Liver Function.,I,Completed,"National Institutes of Health/National Cancer Institute
Beckman Research Institute","Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Lung Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
A Phase I Study Of SU006668 Via Twice Daily Oral Administration Under Fed Conditions In Patients With Advanced Malignancies,I,Completed,"Jonsson Comprehensive Cancer Center, UCLA
National Institutes of Health/National Cancer Institute
Pfizer","Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Multiple Myeloma; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Thyroid",Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Lung Neoplasms; Multiple Myeloma; Neoplasms, Plasma Cell; Pancreatic Cancer; Pancreatic Neoplasms; Plasmacytoma; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms; Wilms Tumor",United States
"Phase I Study of Intravenous Interleukin-4 PE38KDEL Cytotoxin in Patients With Recurrent or Unresponsive, Metastatic Renal Cell, Non-Small Cell Lung, or Breast Cancer That Overexpresses Interleukin-4 Receptors",I,Completed,Neurocrine Biosciences,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Renal",First line; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Kidney Neoplasms; Lung Neoplasms; Renal Cancer; Wilms Tumor",United States
Phase I Study of HER-2 Protein AutoVac in Women With Breast Cancer.,I,Completed,"National Institutes of Health/National Cancer Institute
Ireland Cancer Center",Oncology: Breast,First line; HER2 positive; Second line; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
Phase Ib Trial of Active Specific Immunotherapy With MVF-HER-2(628-647) and CRL1005 Copolymer Adjuvant in Patients With Metastatic Cancer.,I,Terminated,"National Institutes of Health/National Cancer Institute
University of Alabama at Birmingham Comprehensive Cancer Center","Oncology: Breast; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Ovarian",Second line; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
"A Phase I/II Clinical Trial of Immunotherapy with Humanized MN-14 IgG in Recurrent, Metastatic, Unresectable Colorectal and Breast Carcinomas",I/II,Completed,Gilead Sciences/Immunomedics,Oncology: Breast; Oncology: Colorectal,Second line; Stage IV,Breast Neoplasms; Carcinoma; Colonic Neoplasms; Colorectal Neoplasms; Neoplasms; Rectal Neoplasms,United States
"A Phase I/II Trial of Xeloda, Every Three Week Taxol and Herceptin in Metastatic Breast Cancer",I/II,Completed,"National Institutes of Health/National Cancer Institute
UNC Lineberger Comprehensive Cancer Center",Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Stage IV,Breast Neoplasms,United States
A Phase I Trial of Recombinant Vaccinia Virus That Expresses DF3/MUC1 in Patients With Metastatic Adenocarcinoma of the Breast,I,Completed,"National Institutes of Health/National Cancer Institute
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute",Oncology: Breast,First line; Second line; Stage IV,Breast Neoplasms,United States
Phase I Vaccine Study of HER-2/neu Peptides Incorporated into Polyactide-co-glycolide (PLG) Microspheres in Patients With Advanced Stage HER-2/neu Expressing Cancers,I,Completed,"National Institutes of Health/National Cancer Institute
University of Washington/Seattle Cancer Care Alliance","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Ovarian",HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Ovarian Cancer; Ovarian Neoplasms",United States
Herceptin and Paclitaxel in Locally Advanced Breast Cancer With Her-2 Overexpression,I,Completed,"Roche/Genentech {Genentech}
National Institutes of Health/National Cancer Institute
New York University",Oncology: Breast,Adjuvant; HER2 positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
"Phase I Study of High Dose Paclitaxel, Cyclophosphamide, and Thiotepa Followed By Autologous Peripheral Blood Stem Cell Rescue and Radiotherapy in Patients with Advanced Breast Cancer.",I,Completed,"National Institutes of Health/National Cancer Institute
Robert H. Lurie Comprehensive Cancer Center at Northwestern University",Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,United States
Phase I Clinical Trial Of Vinorelbine (Navelbine) And Trastuzumab (Herceptin) In Patients with Carcinoma Of The Breast Or Non-Small Cell Lung Cancer And HER-2/NEU Overexpression,I,Completed,"National Institutes of Health/National Cancer Institute
Dartmouth-Hitchcock Norris Cotton Cancer Center
GlaxoSmithKline {Glaxo Wellcome}","Oncology: Breast; Oncology: Lung, Non-Small Cell",HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung",United States
Phase I/II Study of TLC D-99 Plus Herceptin as First or Second Line Therapy for Patients With Locally Advanced Inflammatory or Metastatic Breast Cancer,I/II,Completed,"Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute
Perrigo Company {Elan}}
Teva {Cephalon}",Oncology: Breast,First line; HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,Canada; United States
Phase I/II Study of Annamycin Liposomal in Patients With Anthracycline-Resistant Locally Advanced or Metastatic Breast Cancer,I/II,Completed,"National Institutes of Health/National Cancer Institute
Kaplan Cancer Center",Oncology: Breast,Stage III; Stage IV; Third line,Breast Neoplasms,United States
Phase I Clinical Trial of Oral Suberoylanilide Hydroxamic Acid - SAHA (MSK390) in Patients With Advanced Solid Tumors and Hematologic Malignancies,I,Completed,"Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute
Merck & Co. {Aton Pharma}","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Head/Neck; Oncology: Leukemia, Acute Myelogenous; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Thyroid",(N/A); Advanced; Aggressive; Classical; Cutaneous T-cell lymphoma (CTCL); Diffuse large B-cell lymphoma (DLBCL); Follicular lymphoma (FL); Hormone refractory; Indolent; Mantle cell lymphoma (MCL); Metastatic; Nodular lymphocyte-predominant; Papillary; Peripheral T-cell lymphoma (PTCL); Post-transplant/ineligible; Second line; Small lymphocytic lymphoma (SLL); Stage III; Stage IV,"Acute Myelocytic Leukemia; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Melanoma; Mesothelioma; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Thyroid Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
Phase I Study of R115777 and Trastuzumab (Herceptin) in Patients With Advanced or Metastatic Adenocarcinoma,I,Completed,"National Institutes of Health/National Cancer Institute
University of Texas","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell",HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Unspecified",United States
"Phase I Study of LMB-9, a Recombinant Disulfide Stabilized Anti-Lewis Y Immunotoxin Admistered by Continuous Infusion",I,Completed,"National Institutes of Health/National Cancer Institute
University of Maryland Greenebaum Cancer Center","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Lung Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"An Open-Label, Long-Term, Safety and Tolerability Study of VEGF Trap Administered Intravenously in Patients With Advanced Solid Tumors or Lymphoma",I,Completed,"Sanofi {Sanofi-Aventis {Aventis}}
Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute
Regeneron","Oncology: Breast; Oncology: Head/Neck; Oncology: Liver; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Aggressive; Fourth line or greater; Indolent; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",United States
Phase I Study of Irinotecan Followed by Capecitabine in Patients With Advanced Breast Carcinoma.,I,Completed,"National Institutes of Health/National Cancer Institute
Roswell Park Cancer Institute",Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,United States
Allogeneic Breast Protocol 2: Phase I Trial Of T Cell Exchange With Th2/Tc2 Cells For Allogeneic Stem Cell Transplantation After Reduced Intensity Conditioning For Metastatic Breast Cancer.,I,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factor.,I,Completed,Kaplan Cancer Center,Oncology: Breast; Oncology: Unspecified Cancer,Line of therapy N/A; Stage IV,Breast Neoplasms; Neoplasms,United States
"Phase I Study of Oxaliplatin, Fluorouracil, and Gemcitabine in Patients With Metastatic or Unresectable Solid Tumors",I,Completed,"Eli Lilly
National Institutes of Health/National Cancer Institute
Albert Einstein Cancer Center (AECC)
Sanofi {Sanofi-Aventis {Sanofi-Synthelabo}}",Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",United States
Phase I Study of Oxaliplatin and Docetaxel in Patients With Metastatic or Recurrent Solid Tumors,I,Completed,"National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center",Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Liver; Oncology: Melanoma; Oncology: Ovarian; Oncology: Thyroid,Metastatic; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Thyroid Neoplasms",United States
A Phase I Study of Oxaliplatin in Combination With Capecitabine in Metastatic/Recurrent Solid Tumors,I,Completed,"National Institutes of Health/National Cancer Institute
Beckman Research Institute","Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Small Intestine",First line; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Intestinal Neoplasms; Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
"An Open-Labeled, Non-Randomized Phase I Study of Alvocidib (Flavopiridol) Administered With Irinotecan (CPT-11) and Fluorouracil/Leucovorin in Patients With Advanced Solid Tumors.",I,Completed,"Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute",Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Small Intestine; Oncology: Soft Tissue Sarcoma; Oncology: Thymus,Fourth line or greater; Second line; Stage III; Stage IV; Third line; Thymic carcinoma,"Breast Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Intestinal Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thymus Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
Phase I and Pharmacokinetic Study of Intravenous Irinotecan in Refractory Solid Tumor Patients with Hepatic Dysfunction.,I,Completed,Pfizer {Pharmacia},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Pancreas",(N/A); Second line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Liver Cancer; Liver Diseases; Liver Neoplasms; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",Canada; United States
Phase I Trial of OSI-774 and CPT-11 in Patients With Advanced Solid Tumors,I,Completed,"National Institutes of Health/National Cancer Institute
Mayo Clinic Cancer Center","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas",EGFR; Fourth line or greater; Pulmonary; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Small Cell Lung Carcinoma",United States
"An Open-Labeled, Non-Randomized Phase I Study Of Flavopiridol Administered With Irinotecan (CPT-11) In Patients With Advanced Solid Tumors",I,Completed,"Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute",Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Pancreas,Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
Phase I Clinical Study of Every Three Week Irinotecan With Oral Capecitabine Given Twice Daily for Two Weeks Out of Three in Patients With Gastrointestinal and Other Solid Malignancies,I,Completed,Albert Einstein Cancer Center (AECC),Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Pancreas,Second line; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Unspecified,United States
"A Phase I And Pharmacogenetic Study Of CPT-11, Oxaliplatin, And Capecitabine In Patients With Solid Tumors.",I,Completed,"National Institutes of Health/National Cancer Institute
Mayo Clinic Cancer Center",Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Liver; Oncology: Ovarian; Oncology: Pancreas,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms",United States
Phase I/II Study of BMS-247550 and Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With a Taxane and an Anthracycline.,I/II,Completed,"Bristol-Myers Squibb
National Institutes of Health/National Cancer Institute
R-Pharm",Oncology: Breast,Fourth line or greater; HER2 negative; Stage IV; Triple receptor negative,Breast Neoplasms,United States
A Phase I Scientific Exploratory Study of Epothilone B Analog in Patients With Solid Tumors and Gynecological Malignancies,I/II,Completed,"Bristol-Myers Squibb
National Institutes of Health/National Cancer Institute
Albert Einstein Cancer Center (AECC)",Oncology: Breast; Oncology: Endometrial; Oncology: Ovarian,First line; Fourth line or greater; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Ovarian Cancer; Ovarian Neoplasms",United States
"An Open-Label, Safety, Pharmacokinetic and Pharmacodynamic Study of Multiple Doses of GW572016 to examine the Inhibition of ErbB1 (EGFR)/ErbB2 Phosphorylation in Cancer Patients with Solid Tumors.",I,Completed,GlaxoSmithKline,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian",EGFR; HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Ovarian Cancer; Ovarian Neoplasms",United States
"Phase I Open Label Multiple Dose, Dose Escalation Study of GW572016 in Patients with Solid Tumors.",I,Completed,GlaxoSmithKline,"Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Soft Tissue Sarcoma",EGFR; Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Mesothelioma; Neoplasms, Basal Cell; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Uterine Cervical Neoplasms; Wilms Tumor",United States
"Phase I and pharmacokinetic (PK) study of oral GW572016, a potent reversible dual inhibitor of both erbB1 and erbB2 tyrosine kinase (TK), administered in combination with capecitabine.",I,Completed,"GlaxoSmithKline
Institute for Drug Development",Oncology: Breast; Oncology: Colorectal; Oncology: Gastric,(N/A); Line of therapy N/A,Breast Neoplasms; Colorectal Neoplasms; Stomach Carcinoma; Stomach Neoplasms,United States
Phase I/II Dose-Escalating Study of Biweekly Alimta and Gemcitabine in Patients with Advanced Cancer.,I/II,Completed,Eli Lilly,"Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas",Advanced; First line; Second line; Stage III; Stage IV; Untreated,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Lung Neoplasms; Mesothelioma; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms",United States
"Phase I Study of Bortezomib, Carboplatin, and Etoposide in Patients With Advanced Solid Tumors Refractory to Standard Therapy",I,Completed,"National Institutes of Health/National Cancer Institute
University of Colorado Cancer Center at University of Colorado Health Sciences Center","Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma",First line; Second line; Stage III; Stage IV; Untreated,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Wilms Tumor",United States
"A Phase I, Open-Label, Dose-Esclation Study of the Safety, Tolerability, and Pharmacokinetics of GW572016 in Combination with Paclitaxel in Patients with Solid Tumors.",I,Completed,GlaxoSmithKline,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Renal; Oncology: Thyroid",First line; Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Mesothelioma; Neoplasms, Mesothelial; Renal Cancer; Thyroid Neoplasms; Wilms Tumor",United States
"An Open Labeled, Non-Randomized Phase I Study of Alvocidib (Flavopiridol) Administered With Oxaliplatin and Fluorouracil/Leucovorin in Patients With Advanced Solid Tumors.",I,Completed,"Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute",Oncology: Anal; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Pancreas; Oncology: Renal,Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Anus Neoplasms; Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",United States
"A Phase I Study Of Weekly Taxotere (Docetaxel) And Gleevec (STI571, Imatinib Mesylate, CGP 57148B) In Locally Advanced Or Metastatic Breast Cancer.",I,Completed,"National Institutes of Health/National Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}",Oncology: Breast,First line; Fourth line or greater; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial.",I/II,Terminated,"Amgen
Bristol-Myers Squibb
GlaxoSmithKline",Oncology: Breast,First line; HER2 negative; HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
"A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer.",I,Completed,"Bristol-Myers Squibb
Lombardi Cancer Center at Georgetown University Medical Center","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Cancer",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasms",United States
Phase I Dose-escalating and Pharmacokinetic Trial of OSI-461 in Patients with Advanced Solid Tumours.,I,Completed,Astellas Pharma {OSI Pharmaceuticals},"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: GIST; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Thymus",Line of therapy N/A; Stage III; Stage IV; Thymoma,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Thymoma; Thymus Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase I, Open Label, Multiple Dose, Dose Escalation Study of GW786034 In Patients With Solid Tumors.",I,Completed,"GlaxoSmithKline
National Institutes of Health/National Cancer Institute
Case Western Reserve University","Oncology: Breast; Oncology: Colorectal; Oncology: GIST; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Adenocarcinoma; Follicular; Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Wilms Tumor",United States
Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination with Gemcitabine and Cisplatin in Advanced Cancer.,I,Terminated,Merck & Co. {Schering-Plough},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thymus",(N/A); First line; Fourth line or greater; Second line; Stage III; Stage IV; Third line; Thymic carcinoma; Thymoma,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thymoma; Thymus Neoplasms; Unspecified; Wilms Tumor",United States
"A Single-Center, Open-Label, Between-Patient, Dose-Escalation Phase 1 Study of CDC-501 In Patients With Solid Tumors",I,Completed,Bristol-Myers Squibb/Celgene,"Oncology: Breast; Oncology: Colorectal; Oncology: GIST; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Renal",Second line; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Unspecified; Wilms Tumor",United States
Phase I Study of Interleukin-12 and Trastuzumab (Herceptin) in Patients With HER2-Neu Overexpressing Malignancies,I,Completed,"National Institutes of Health/National Cancer Institute
Richard J. Solove Research Institute",Oncology: Breast; Oncology: Cervical; Oncology: Pancreas,HER2 positive; Maintenance/Consolidation; Second line; Stage IV,"Adenocarcinoma; Adenocarcinoma, Follicular; Adrenocortical Carcinoma; Anus Neoplasms; Appendiceal Neoplasms; Bile Duct Neoplasms; Breast Neoplasms; Breast Neoplasms, Male; Carcinoid Tumor; Carcinoma; Carcinoma, Adenoid Cystic; Carcinoma, Islet Cell; Carcinoma, Medullary; Carcinoma, Mucoepidermoid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colonic Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Gastrinoma; Gastrointestinal Neoplasms; Glucagonoma; Inflammatory Breast Neoplasms; Insulinoma; Kidney Neoplasms; Laryngeal Diseases; Laryngeal Neoplasms; Liver Neoplasms; Lung Neoplasms; Malignant Carcinoid Syndrome; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neoplasms, Glandular and Epithelial; Neoplasms, Unknown Primary; Oropharyngeal Neoplasms; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Pericardial Effusion; Peritoneal Neoplasms; Pleural Effusion; Pleural Effusion, Malignant; Prostatic Neoplasms; Rectal Neoplasms; Salivary Gland Neoplasms; Somatostatinoma; Stomach Neoplasms; Testicular Neoplasms; Thyroid Diseases; Thyroid Neoplasms; Ureteral Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Vaginal Neoplasms; Vulvar Neoplasms",United States
"Phase I Study of Post Transplant rhIL-12 High Dose Cyclophosphamide, Thiotepa, and Carboplatin in the Treatment of Metastatic Breast Carcinoma.",I,Completed,"National Institutes of Health/National Cancer Institute
Beth Israel Deaconess Medical Center",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
A Phase I Pharmacodynamic Trial of SU5416 (NSC 696819),I,Terminated,"National Institutes of Health/National Cancer Institute
Ireland Cancer Center",Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Renal; Oncology: Soft Tissue Sarcoma,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified; Wilms Tumor",United States
"Phase I Pharmacokinetic, Pharmacodynamic, and Clinical Study of the Combination of the Angiogenesis Inhibitor SU5416 and Doxorubicin in Inflammatory Breast Cancer.",I,Completed,"National Institutes of Health/National Cancer Institute
Ireland Cancer Center",Oncology: Breast,Estrogen receptor positive; Neoadjuvant; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms; Inflammatory Breast Neoplasms,United States
"A Phase I Open-label, Dose escalation Study of GCS-100 up to 80 mg/m2 For Advanced Solid Tumours",I,Completed,GlycoGenesys,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",United States
A Phase I Trial Of ZD1839 With Capecitabine In Patients With Advanced Solid Tumors (Formerly a Phase I Trial of ZD1839 With Capecitabine and Celecoxib).,I,Completed,"National Institutes of Health/National Cancer Institute
University of Colorado Cancer Center at University of Colorado Health Sciences Center","Oncology: Breast; Oncology: Colorectal; Oncology: Gallbladder; Oncology: Lung, Non-Small Cell; Oncology: Pancreas",First line; Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Gallbladder Neoplasms; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms",United States
"A Phase I, Pharmacologic and Biologic Study of Col-3 (NSC683551) Administered on a 28-Day Oral Dosing Schedule in Patients With Advanced Solid Tumors",I,Completed,"National Institutes of Health/National Cancer Institute
University of Texas Health Science Center at San Antonio","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Testicular; Oncology: Thyroid",Advanced; Classical; Locally advanced; Metastatic; Nodular lymphocyte-predominant; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms; Thyroid Neoplasms; Wilms Tumor",United States
A Phase I Study of 2- Methoxyestradiol (2ME2) plus Docetaxel in Patients with Metastatic Breast Cancer,I,Completed,CASI Pharmaceuticals {EntreMed},Oncology: Breast,First line; Second line; Stage III; Stage IV,Breast Neoplasms,United States
Phase I study of Panzem (2ME2)  in patients with advanced refractory metastatic breast cancer.,I,Completed,CASI Pharmaceuticals {EntreMed},Oncology: Breast,Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"A phase 1 trial of CI-1033, a pan-erbB tyrosine kinase inhibitor, given daily for 14 days every 3 weeks, in patients with advanced solid tumors",I,Completed,Pfizer,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Pancreas",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
"Phase Ib combination clinical trial of anti-tumor vascular targeting agent, Combretastatin A4 Prodrug (CA4P) with Carboplatin for injection.",I,Terminated,Oncotelic Therapeutics {Mateon Therapeutics {OXiGENE}},Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Mesothelioma; Oncology: Pancreas; Oncology: Renal; Oncology: Thyroid,Anaplastic; First line; Fourth line or greater; Locally advanced; Metastatic; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Renal Cell; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Mesothelioma; Neoplasms, Mesothelial; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms; Wilms Tumor",United States
A Phase I Trial of IV CI-1033 Three Times Per Week in Patients with Advanced Nonhematologic Malignancies,I,Completed,"Pfizer
H. Lee Moffitt Cancer Center and Research Institute","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Advanced; Extensive; Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Neuroendocrine Tumors; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies.,I,Completed,TBG Diagnostics {Progen Pharmaceuticals},Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Melanoma; Oncology: Ovarian,First line; Second line; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Stomach Carcinoma; Stomach Neoplasms,Australia; Canada; United States
"A Phase I Trial Of 2-Methoxyestradiol (2ME2), (NSC-659853) An Angiogenesis Inhibitor, In Patients With Solid Tumors",I,Completed,"National Institutes of Health/National Cancer Institute
CASI Pharmaceuticals {EntreMed}",Oncology: Breast; Oncology: Colorectal; Oncology: Melanoma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma,Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",United States
Phase I/II Study of Augmerosen With Docetaxel in Patients With Androgen Independent Prostate Cancer or Other Advanced Solid Tumors.,I/II,Completed,"Memorial Sloan-Kettering Cancer Center
Genta","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal",Hormone refractory; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Lung Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Phase I Dose Escalation Study With Oral LY317615 in Combination With Capecitabine in Advanced Cancer Patients.,I,Completed,"Eli Lilly
Jonsson Comprehensive Cancer Center, UCLA
National Institutes of Health/National Cancer Institute","Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",First line; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified",United States
A Phase I Study of Antisense Bcl-2 Oligonucleotide (G3139) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumors,I,Completed,"National Institutes of Health/National Cancer Institute
University of Wisconsin Comprehensive Cancer Center","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Metastatic; Second line; Stage III; Stage IV; Unresectable,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
Phase I Study of Combretastatin A4 Phosphate in Patients With Advanced Solid Tumors.,I,Completed,"National Institutes of Health/National Cancer Institute
Ireland Cancer Center
Oncotelic Therapeutics {Mateon Therapeutics {OXiGENE}}","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Unspecified; Wilms Tumor",United States
Phase I/II clinical trial for advanced colon and pancreatic cancer using Rexin-G.,I/II,Completed,Epeius Biotechnologies,Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Melanoma; Oncology: Pancreas,Second line; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; Melanoma; Pancreatic Cancer; Pancreatic Neoplasms,Philippines; United States
Phase I clinical trial of Angiostatin combined with radiation therapy in advanced cancer,I,Completed,"CASI Pharmaceuticals {EntreMed}
Alchemgen Therapeutics","Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Prostate",Extensive; Line of therapy N/A; Pulmonary; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Head and Neck Neoplasms; Neuroendocrine Tumors; Prostatic Neoplasms; Small Cell Lung Carcinoma",United States
"Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers.",I,Completed,"(Other Academic Cancer Center)
Wellstat Biologics","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Advanced; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
Phase I study of INGN-241 in patients with advanced solid tumour,I,Completed,Introgen Therapeutics,Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Melanoma; Oncology: Renal,Line of therapy N/A; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Lymphoma, Non-Hodgkin; Melanoma; Renal Cancer; Wilms Tumor",United States
Study to Determine the Maximum Tolerated Dose of Liposome-Encapsulated C-RAF Antisense Oligodeoxynucleotide (LErafAON) in Patients With Advanced Solid Tumors,I,Completed,"Insys Therapeutics {NeoPharm, Inc.}","Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Extensive; First line; Fourth line or greater; Locally advanced; Metastatic; Pulmonary; Second line; Stage III; Stage IV; Third line; Untreated,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Unspecified; Uterine Cervical Neoplasms; Wilms Tumor",United States
"Phase I clinical study of M200, a direct anti-endothelial cell antibody targeting the alpha 5 beta 1 integrin in advanced cancer.",I,Completed,PDL BioPharma {Protein Design Labs},"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Thyroid",Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Thyroid Neoplasms; Wilms Tumor",United States
"A Phase I, Open-Label, Dose Escalating, Multiple Dose Study to Determine the Safety, Tolerability, Maximum Tolerated Dose and Pharmacokinetics of Oral TAK-165 Administered Once Daily to Subjects with Tumors Known to Express HER2.",I,Terminated,Takeda,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal",Extensive; HER2 positive; Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Kidney Neoplasms; Lung Neoplasms; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Wilms Tumor",Japan; United States
A phase 1/2 trial of GEM-231 in combination with irinotecan (Camptosar).,I/II,Completed,"National Institutes of Health
Aceragen {Idera Pharmaceuticals {Hybridon}}","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Ovarian; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",(N/A); Line of therapy N/A,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial.,I/II,Completed,Velindre NHS Trust,Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
"A Phase I Clinical, Pharmacokinetic Study of ARQ 501 in Subjects with Advanced Solid Tumors.",I,Completed,"Merck & Co. {ArQule}
Roche {F. Hoffmann-La Roche}","Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Metastatic; Papillary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Unspecified",United States
Phase I and pharmacokinetic trial of weekly docetaxel and gossypol in patients with metastatic breast cancer in the adjuvant  setting.,I,Completed,University of Michigan Comprehensive Cancer Center,Oncology: Breast,Adjuvant; Stage IV,Breast Neoplasms,United States
Phase I Study of E7389 in Patients With Advanced Solid Tumors ; A California Cancer Consortium trial,I,Completed,"National Institutes of Health/National Cancer Institute
Eisai
California Cancer Consortium","Oncology: Bladder; Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Thyroid",Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Phase I Trial of 17-N-Allylamino-17-Demethoxy Geldanamycin (17-AAG, NSC #330507) Daily X 5 in Patients With Advanced Cancer Therapeutic Protocol.",I,Completed,"Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute","Oncology: Bladder; Oncology: Breast; Oncology: Head/Neck; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Prostate; Oncology: Renal; Oncology: Thyroid",First line; Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Chronic Myeloid Leukemia; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Neoplasms; Melanoma; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Neoplasms; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A phase I study of a second-generation immunomodulatory oligonucleotide (HYB2055) in patients with advanced solid malignancies.,I,Completed,"Lombardi Cancer Center at Georgetown University Medical Center
Aceragen {Idera Pharmaceuticals {Hybridon}}","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",United States
Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers.,I,Completed,University of Washington/Seattle Cancer Care Alliance,Oncology: Breast; Oncology: Ovarian,HER2 positive; Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms; Ovarian Cancer; Ovarian Neoplasms,United States
A Phase I Study Of HER-2/NEU (HER2) Peptide-Based Vaccines For The Generation Of HER2 Specific Immunity In Patients With HER2 Overexpressing Cancers.,I,Completed,University of Washington/Seattle Cancer Care Alliance,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Ovarian",Adenocarcinoma; HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Ovarian Cancer; Ovarian Neoplasms",United States
Phase I  study of ATN-161 in patients with advanced solid tumors that have not responded to treatments with traditional therapies,I,Completed,Attenuon,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",First line; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Wilms Tumor",United States
"Phase Ib trial of drug AVI-4126, a NeuGene antisense cancer drug that targets the oncogene c-myc, in patients with cancer.",I,Completed,Sarepta Therapeutics {AVI BioPharma},Oncology: Breast; Oncology: Prostate,(N/A); Line of therapy N/A,Breast Neoplasms; Prostatic Neoplasms,United States
"Phase I clinical trial to determine the safety, dosage and efficacy of Dendreon's APC8024, a vaccine composed of autologous antigen presenting cells (APC) pulsed with an engineered Her-2/neu (Her500)/GM-CSF fusion protein (BA7072), for the treatment of cancer.",I,Completed,"Dendreon {Bausch Health Companies {Valeant Pharmaceuticals {Dendreon}}}
University of California, San Francisco",Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Ovarian,First line; Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Colorectal Neoplasms; Endometrial Neoplasms; Ovarian Cancer; Ovarian Neoplasms",United States
"Phase I study of AmplimexonTM (imexon, inj.) in patients with advanced solid tumors and lymphomas.",I,Completed,AmpliMed,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Follicular lymphoma (FL); Indolent; Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Follicular; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",United States
Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: A phase I trial,I,Completed,Memorial Sloan-Kettering Cancer Center,Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
"Phase I, Open-Label, Dose Escalation Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Continuous Daily Oral-dosing of CP-868,596, a Tyrosine Kinase Inhibitor of PGDFr in Patients with Advanced Solid Tumors.",I,Completed,"Pfizer
Astellas Pharma {OSI Pharmaceuticals}","Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Soft Tissue Sarcoma",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
Phase I trial of OPT-22,I,Completed,Merck & Co. {Cubist {Optimer Pharmaceuticals}},Oncology: Breast; Oncology: Prostate,(N/A); Line of therapy N/A,Breast Neoplasms; Prostatic Neoplasms,United States
Phase I clinical trial for the breast cancer vaccine HER-2VAX.,I,Completed,Aixlie Pharmaceuticals,Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
LUD00-014: Phase I study of recombinant vaccinia-NY-ESO-1 (rV-NY-ESO-1) and recombinant fowlpox-NY-ESO-1 (rF-NY-ESO-1) in patients with NY-ESO-1 or LAGE positive cancers.,I,Completed,"Ludwig Institute for Cancer Research
Therion Biologics",Oncology: Bladder; Oncology: Breast; Oncology: Melanoma; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma,Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms,Germany; United States
A Phase I Trial of Oral Penclomedine.,I,Completed,"National Institutes of Health/National Cancer Institute
University of Wisconsin","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Wilms Tumor",United States
Phase I Study of Recombinant Fowlpox-CEA-B7.1/ICAM-1/LFA-3 Vaccine Alone or in Combination With Recombinant Vaccinia-CEA-B7.1/ICAM-1/LFA-3 Vaccine With or Without Sargramostim (GM-CSF) in Patients With CEA-Expressing Tumors.,I,Completed,"National Institutes of Health/National Cancer Institute
Lombardi Cancer Center at Georgetown University Medical Center
Therion Biologics","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Thyroid",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Thyroid Neoplasms; Unspecified",United States
Phase I Feasibility Study of Ytrium-90 (Y-90) Chimeric T84.66 (cT84.66) Anti-CEA Antibody in Combination with Gemcitabine and Cisplatin Chemotherapy Followed by Peripheral Blood Progenitor Cell Rescue (PBPC) in Patients with Stage IV CEA-Producing Breast Carcinoma.,I,Completed,City of Hope Comprehensive Cancer Center,Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
"A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors.",I,Completed,Novartis,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Advanced; Cutaneous T-cell lymphoma (CTCL); Extensive; Indolent; Peripheral T-cell lymphoma (PTCL); Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Wilms Tumor",United Kingdom; United States
An Open Label Phase I Study of Humanized Human Milk Fat Globule-1 (huHMFG1) Antibody in Patients With Locally Advanced or Metastatic Breast Cancer (TOPCAT),I,Completed,"Jonsson Comprehensive Cancer Center, UCLA
National Institutes of Health/National Cancer Institute
Antisoma
Roche {F. Hoffmann-La Roche}",Oncology: Breast,Fourth line or greater; HER2 negative; HER2 positive; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"A Phase Ib, Open-Label, Proof-of-Concept Trial to Evaluate the Safety,Tolerability and Immunogenicity of Multiple Doses of an Anti-idiotype Vaccine for Lewis Y (IGN301) Administered by Subcutaneous Injection to Subjects with Proven Adenocarcinomas.",I,Completed,"Aphton {igeneon}
Cleveland Clinic Taussig Cancer Center","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Ovarian; Oncology: Prostate",Hormone refractory; Second line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma",United States
A Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine in Advanced Malignancies,I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine",(N/A); Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Neuroendocrine Tumors; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Unspecified",United States
Phase I Study to Determine the Safety and Pharmacokinetics of Oral Administration of TAS-102 on a Twice Daily Schedule for Five Days a Week Followed by Two Days Rest for Two Weeks Every Fours Weeks in Patients with Solid Tumors.,I,Completed,Otsuka Holdings/Taiho Pharmaceutical,Oncology: Breast,Fourth line or greater; Stage III; Stage IV,Breast Neoplasms,United States
Phase I study of intensive course immunization with NY-ESO-1 peptides in HLA-A2+ patients with NY-ESO-1+ cancer,I,Completed,Ludwig Institute for Cancer Research,"Oncology: Breast; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate",Extensive; Line of therapy N/A; Metastatic; Pulmonary; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Esophageal Cancer; Esophageal Neoplasms; Melanoma; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma",United States
Liposome Encapsulated SN38 (LE-SN38) in Patients with Advanced Cancer.,I,Completed,"Insys Therapeutics {NeoPharm, Inc.}","Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Renal; Oncology: Thyroid",Extensive; Fourth line or greater; Locally advanced; Metastatic; Pulmonary; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Kidney Neoplasms; Melanoma; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms; Unspecified; Wilms Tumor",United States
A Phase I Study of Oral ILX23-7553 in Patients With Solid Tumors,I,Terminated,"Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute
Sanofi {Sanofi-Aventis}/Sanofi Genzyme {Genzyme {ILEX Oncology}}","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Thyroid",Aggressive; Indolent; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A Phase I, First in Human, Open-Label, Dose Finding Study Evaluating the Safety and Pharmacokinetics of AMG 706 in Subjects with Advanced Solid Tumors.",I,Completed,"Amgen
MD Anderson Cancer Center, University of Texas","Oncology: Bladder; Oncology: Breast; Oncology: Gastric; Oncology: GIST; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Extensive; Locally advanced; Metastatic; Pulmonary; Recurrent; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Fibrosarcoma; Gastrointestinal Stromal Tumors; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasms; Neuroendocrine Tumors; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"Phase I clinical and pharmacokinetic study of NSC 655649, a rebeccamycin analogue, given in both single-dose and multiple-dose formats.",I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",(N/A); Pulmonary; Second line,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Wilms Tumor",United States
Phase I Study of Telomerase: 540-548 Peptide Vaccine Emulsified in Montanide ISA-51 and Sargramostim (GM-CSF) in Patients With HLA-A2-Expressing Stage IV Breast Cancer.,I,Completed,"National Institutes of Health/National Cancer Institute
Abramson Cancer Center at  University of Pennsylvania Medical Center",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
A Phase I Study of Weekly Administration of Oral Navelbine in Combination With the COX-2 Inhibitor Celebrex in Relapsed and/or Metastatic Breast Cancer.,I,Terminated,"GlaxoSmithKline
Ireland Cancer Center",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
A Pharmacokinetic Interaction Study Of Docetaxel (Taxotere) 75 mg/mIV On The Combination Therapy Doxorubicin (50 mg/m) And Cyclophosphamide (50 mg/m) In The Treatment Of Advanced Breast Cancer,I,Terminated,"National Institutes of Health/National Cancer Institute
(Other Hospital/Academic/Medical Center)",Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase I Trial of an Admixture of Recombinant Vaccinia Virus That Express DF3/MUC1 and rV-TRICOM (B7.ICAM-1, and LFA-3) in Patients With Metastatic Adenocarcinoma of the Breast.",I,Terminated,National Institutes of Health/National Cancer Institute,Oncology: Breast,Second line; Stage IV,"Breast Neoplasms; Breast Neoplasms, Male",United States
"A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Novel Flavopiridol in Patients With Refractory Solid Tumors and Hematologic Malignancies",I,Terminated,"National Institutes of Health/National Cancer Institute
Sanofi {Sanofi-Aventis}","Oncology: Breast; Oncology: GIST; Oncology: Head/Neck; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Multiple Myeloma; Oncology: Renal",Advanced; Aggressive; Classical; Extensive; HER2 positive; Indolent; Limited; Mantle cell lymphoma (MCL); Nodular lymphocyte-predominant; Second line; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Carcinoma, Renal Cell; Carcinoma, Small Cell; Chronic Lymphocytic Leukemia; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melanoma; Mesothelioma; Multiple Myeloma; Neoplasms; Neoplasms, Mesothelial; Renal Cancer; Small Cell Lung Carcinoma; Wilms Tumor",United States
A Study of COX-2 Inhibition and Aromatase Activity in Breast Cancer,I,Completed,"Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute",Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
An Open Label Phase I/II Study of Humanized Human Milk Fat Globule-1 (THEREX) in Patients With Locally Advanced or Metastatic Breast Cancer Following Prior Anthracycline and Taxane Therapy,I/II,Completed,"Jonsson Comprehensive Cancer Center, UCLA
National Institutes of Health/National Cancer Institute
Roche
Antisoma",Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Phase I/II Study of Bcl-2 Antisense Oligonucleotide (Genasense) in Combination With Doxorubicin and Docetaxel in Metastatic and Locally Advanced Breast Cancer.,I/II,Completed,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast,First line; Neoadjuvant; Second line; Stage III; Stage IV,"Breast Neoplasms; Breast Neoplasms, Male",United States
CTLA-4 Blockade With MDX-010 To Induce Graft - Versus - Malignancy Effects Following Allogeneic Hematopoietic Stem Cell Transplantation.,I,Completed,"National Institutes of Health/National Cancer Institute
Bristol-Myers Squibb/Medarex
University of California San Diego","Oncology: Breast; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Renal",Aggressive; Classical; Diffuse large B-cell lymphoma (DLBCL); Lymphoblastic lymphoma (LBL); Mantle cell lymphoma (MCL); Nodular lymphocyte-predominant; Peripheral T-cell lymphoma (PTCL); Post-transplant/ineligible; Remission; Second line; Stage II; Stage III; Stage IV,"Acute Myelocytic Leukemia; Breast Neoplasms; Burkitt Lymphoma; Carcinoma; Carcinoma, Embryonal; Carcinoma, Renal Cell; Choriocarcinoma; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Dermoid Cyst; Endodermal Sinus Tumor; Germinoma; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neoplasms, Glandular and Epithelial; Neoplasms, Plasma Cell; Neuroblastoma; Ovarian Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Preleukemia; Renal Cancer; Seminoma; Syndrome; Teratoma; Testicular Neoplasms; Wilms Tumor",United States
"A 24-Week Blinded Study Conducted at Multiple Centers, Evaluating the Safety and Effectiveness of Various Doses of the Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) When Randomly Assigned to Patients With Breast Cancer That Has Metastasized to Bone",I/II,Completed,"National Institutes of Health/National Cancer Institute
Ireland Cancer Center
Roche/Chugai Pharmaceutical",CNS: Pain (nociceptive); Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; Cancer-related; First line; Second line; Stage IV,Breast Neoplasms; Cancer pain; Cancer Pain; Hypercalcemia; Neoplasm Metastasis; Neoplasms; Nociceptive Pain; Paraneoplastic Syndromes,United States
"A Phase I Safety and Pharmacokinetic/Pharmacodynamic Study of CP-724, 714 In Patients With Metastatic HER2-Overexpressing Breast Cancer.",I,Completed,"Jonsson Comprehensive Cancer Center, UCLA
National Institutes of Health/National Cancer Institute
Pfizer",Oncology: Bladder; Oncology: Breast; Oncology: Colorectal,Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms; Colorectal Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms,Canada; United States
A Phase I/II Study of Suramin in Combination With Paclitaxel in Advanced (Stage IIIB or IV) Metastatic Breast Cancer,I/II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; First line; HER2 negative; Liver mets; Other mets; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Liver Neoplasms; Neoplasm Metastasis,United States
"A Phase I Study Of The Effect Of Mistletoe Extract, A Complementary Medicine Botanical, On Pharmacokinetics, Pharmacodynamics And Safety Of Gemcitabine In Patients With Advanced Solid Tumors",I,Completed,"National Institutes of Health/National Cancer Institute
National Institutes of Health/National Center for Complementary and Alternative Medicine","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Pancreas",First line; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Lung Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms",United States
A Phase II Study Of Tipifarnib (Zarnestra) Plus Doxorubicin And Cyclophosphamide In Patients With Locally Advanced Breast Cancer.,I/II,Completed,"National Institutes of Health/National Cancer Institute
Albert Einstein Cancer Center (AECC)",Oncology: Breast,Estrogen receptor positive; First line; Neoadjuvant; Progesterone receptor positive; Second line; Stage II; Stage III; Stage IV,Breast Neoplasms; Inflammatory Breast Neoplasms,United States
A Phase I Study Of Medi 522 In Patients With Advanced Tumors,I,Completed,"National Institutes of Health/National Cancer Institute
University of Wisconsin Comprehensive Cancer Center
AstraZeneca {MedImmune}","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Aggressive; Indolent; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Intestinal Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",United States
A Phase I Study of Herceptin/Flavopiridol in HER-2 Positive Metastatic Breast Cancer,I,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,HER2 positive; Second line; Stage IV,"Breast Neoplasms; Breast Neoplasms, Male",United States
"Phase I/II Open Label, Multi-Center Dose-Escalation Study of s.c. CpG 7909 plus Herceptin in Patients with Metastatic Breast Cancer",I/II,Completed,Pfizer {Coley Pharmaceutical Group},Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
Phase I/II Study Of Herceptin Combined With OSI-774 In The First-Line Treatment Of Metastatic Breast Cancer Associated With HER2/Neu Overexpression.,I/II,Terminated,"Roche/Genentech {Genentech}
Jonsson Comprehensive Cancer Center, UCLA
National Institutes of Health/National Cancer Institute",Oncology: Breast,First line; HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
"A Phase I Study Of UCN-01 In Combination With Irinotecan In Resistant Solid Tumor Malignancies (Part I) and in Triple Negative (ER-negative, PgR-negative, HER-2 Not Amplified) Recurrent Breast Cancers (Part II).",I,Completed,"National Institutes of Health/National Cancer Institute
Siteman Cancer Center
Washington University
University of Virginia","Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",Fourth line or greater; HER2 negative; Metastatic; Second line; Stage III; Stage IV; Third line; Triple receptor negative; Unresectable,"Adenocarcinoma; Anus Neoplasms; Appendiceal Neoplasms; Bile Duct Neoplasms; Breast Neoplasms; Carcinoid Tumor; Carcinoma; Carcinoma, Adenoid Cystic; Carcinoma, Basal Cell; Carcinoma, Endometrioid; Carcinoma, Mucoepidermoid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Verrucous; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Esthesioneuroblastoma, Olfactory; Ewing Sarcoma; Gallbladder Neoplasms; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Germinoma; Granuloma; Head and Neck Neoplasms; Laryngeal Diseases; Laryngeal Neoplasms; Leiomyosarcoma; Liver Neoplasms; Lung Neoplasms; Malignant Carcinoid Syndrome; Nasopharyngeal Neoplasms; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neoplasms, Glandular and Epithelial; Neoplasms, Unknown Primary; Oropharyngeal Neoplasms; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Papilloma; Papilloma, Inverted; Paranasal Sinus Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Salivary Gland Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms",United States
Vaccination Of High Risk Breast Cancer Patients With Heptavalent Antigen - Keyhole Limpet Hemocyanin Conjugate Plus The Immunological Adjuvant QS21,I,Completed,"Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute
Seagen {Seattle Genetics/Cascadian Therapeutics {Oncothyreon {Biomira}}}",Oncology: Breast,Second line; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase I Study Of The Toxicities, Biologic And Clinical Effects Of Daily 5 Aza 2'Deoxycytidine (DAC), NSC 127716 (IND 50733) For Four Weeks In Patients With Advanced Malignancies.",I,Completed,"National Institutes of Health/National Cancer Institute
USC/Norris Comprehensive Cancer Center and Hospital",Oncology: Bladder; Oncology: Breast; Oncology: Melanoma,Second line; Stage III; Stage IV,"Breast Neoplasms; Breast Neoplasms, Male; Melanoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
Phase I Study of Erlotinib in Patients With Solid Tumors and Hepatic or Renal Dysfunction,I,Completed,"Cancer and Leukemia Group B (CALGB)
National Institutes of Health/National Cancer Institute","Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal",Advanced; Second line; Stage III; Stage IV,"Anus Neoplasms; Astrocytoma; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma; Carcinoma, Adenoid Cystic; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Mucoepidermoid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Verrucous; Central Nervous System Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Ependymoma; Esophageal Cancer; Esophageal Neoplasms; Esthesioneuroblastoma, Olfactory; Glioblastoma; Glioma; Glioma, Subependymal; Gliosarcoma; Granuloma; Head and Neck Neoplasms; Kidney Neoplasms; Laryngeal Diseases; Laryngeal Neoplasms; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Mesothelioma; Nasopharyngeal Neoplasms; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Oligodendroglioma; Oropharyngeal Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Papilloma; Papilloma, Inverted; Paranasal Sinus Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Renal Cancer; Salivary Gland Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
Phase I/II Pilot Study of Herba Scutellaria Barbatae (Chinese Herbal Extract) in Women With Metastatic Breast Cancer.,I/II,Completed,"National Institutes of Health/National Cancer Institute
UCSF Comprehensive Cancer Center
Bionovo",Oncology: Breast,First line; Fourth line or greater; Second line; Stage IV; Third line,Breast Neoplasms,United States
Phase I Trial of Interleukin-12 in Combination With Paclitaxel Plus Herceptin in Patients With Her2-Positive Malignancies,I,Completed,"National Institutes of Health/National Cancer Institute
Richard J. Solove Research Institute
Arthur G. James Cancer Hospital",Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Pancreas; Oncology: Thyroid,First line; HER2 positive; Metastatic; Second line; Stage IV,"Breast Neoplasms; Breast Neoplasms, Male; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Lung Neoplasms; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms",United States
"Treatment of Stage IV Breast Cancer With OKT3 x Herceptin Armed Activated T Cells, Low Dose IL-2, And GM-CSF (Phase I Only as of 4-22-09 as Per IRB Approval Date)
Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients",I/II,Completed,"Barbara Ann Karmanos Cancer Institute
National Institutes of Health/National Cancer Institute",Oncology: Breast; Oncology: Prostate,First line; HER2 positive; Hormone refractory; Second line; Stage IV,Breast Neoplasms; Prostatic Neoplasms,United States
A Phase I Study Of Active Immunotherapy With Autologous Dendritic Cells Infected With CEA-6D Expressing Fowlpox -Tricom In Patients With Advanced Or Metastatic Malignancies Expressing CEA,I,Completed,"National Institutes of Health/National Cancer Institute
Duke Comprehensive Cancer Center
Therion Biologics",Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Ovarian; Oncology: Pancreas,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Gallbladder Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms, Germ Cell and Embryonal; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Testicular Neoplasms",United States
Phase I Trial of PC 4-PDT (NSC 676418) for Cutaneous Malignancies.,I,Terminated,"National Institutes of Health/National Cancer Institute
Ireland Cancer Center","Oncology: Breast; Oncology: Head/Neck; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Skin, Basal Cell Carcinoma",Cutaneous T-cell lymphoma (CTCL); Indolent; Peripheral T-cell lymphoma (PTCL); Second line; Stage I; Stage II; Stage IV,"Breast Neoplasms; Carcinoma, Basal Cell; Head and Neck Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Neoplasm Metastasis; Neoplasms, Basal Cell; Sarcoma; Skin Neoplasms",United States
"Combination of Chemotherapy With Taxol, Adriamycin, and Cytoxan (TAC), Multiple Infusions of Activated T Cells (ATC), Interleukin-2 (IL-2) and GM-CSF for High Risk Breast Cancer With and Without Her2/Neu Overexpression. (Phase I/II).",I/II,Completed,Roger Williams Medical Center,Oncology: Breast,HER2 negative; HER2 positive; Second line; Stage II; Stage III,Breast Neoplasms,United States
"A Phase I Study of an Oral Histone Deacetylase Inhibitor, MS-275, in Refractory Solid Tumors and Lymphomas.",I,Completed,"National Institutes of Health/National Cancer Institute
Bayer AG/Bayer Pharmaceuticals {Bayer HealthCare {Bayer Schering Pharma {Schering AG/Berlex}}}","Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Prostate; Oncology: Renal; Oncology: Small Intestine; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Aggressive; Indolent; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Intestinal Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A Dose-Escalation Trial Of The Combination Of Docetaxel, Gemcitabine And Filgrastim (NEUPOGEN) For The Treatment Of Patients With Advanced Solid Tumors.",I,Completed,"Amgen
National Institutes of Health/National Cancer Institute
Dartmouth-Hitchcock Norris Cotton Cancer Center","Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",Line of therapy N/A; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Lung Neoplasms; Melanoma; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"Phase I Study of Yttrium Y 90 Labeled, Humanized Monoclonal Antibody BrE-3 and Indium In 111 Labeled, Humanized Monoclonal Antibody BrE-3 Followed by Autologous Bone Marrow or Peripheral Blood Stem Cell Transplantation in Patients With Metastatic Breast Cancer",I,Completed,"Seagen {Seattle Genetics/Cascadian Therapeutics {Oncothyreon {Biomira}}}
Cancer Research Institute of Contra Costa",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
A Safety Study Of Doxil And Herceptin In Patients With Advanced Her-2 Overexpressing Breast Cancer,I/II,Completed,"National Institutes of Health/National Cancer Institute
NYU School of Medicines Kaplan Comprehensive Cancer Center
Johnson & Johnson/ALZA",Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Phase I Investigation of IL-12/Pulse IL-2 in Adults with Advanced Solid Tumors.,I,Terminated,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Renal; Oncology: Soft Tissue Sarcoma",(N/A); Line of therapy N/A; Pulmonary; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Neoplasms; Neuroendocrine Tumors; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",United States
Phase I Study of Isolated Lung Perfusion With Paclitaxel and Moderate Hyperthermia in Patients With Unresectable Pulmonary Malignancies,I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Soft Tissue Sarcoma",Second line; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Lung Neoplasms; Melanoma; Neoplasm Metastasis; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
A Phase I Trial of Oral Perifosine With Different Loading Schedules in Patients With Refractory Neoplasms.,I,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Myelodysplastic Syndrome; Oncology: Prostate",(N/A); Aggressive; Classical; Hormone refractory; Indolent; Maintenance/Consolidation; Nodular lymphocyte-predominant; Second line; Stage IV,"Breast Neoplasms; Chronic Lymphocytic Leukemia; Hodgkin Disease; Hodgkin Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Myeloproliferative Disorders; Neoplasms; Preleukemia; Prostatic Neoplasms",United States
A Multi-Center Study of Paclitaxel/Cyclophosphamide and High Dose Melphalan/Etoposide With Autologous Progenitor Cell Transplantation for the Treatment of Inflammatory Breast Cancer,I/II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,First line; Stage III; Stage IV,Breast Neoplasms; Inflammatory Breast Neoplasms; Neoplasm Metastasis; Neoplasms,New Zealand; United States
Phase IB trial of ABT-510 in patients with different types of cancer.,I,Completed,AbbVie {Abbott},"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Testicular; Oncology: Unspecified Cancer",(N/A); Line of therapy N/A,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"Phase I, Open-Label, Multicenter, Dose-Escalation Study Of The Tyrosine Kinase Inhibitor Of VEGFR-2, AG013736, In Patients With Advanced Solid Tumors",I,Completed,Pfizer,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Renal; Oncology: Thyroid",Extensive; Locally advanced; Metastatic; Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Kidney Neoplasms; Neoplasms; Neuroendocrine Tumors; Renal Cancer; Small Cell Lung Carcinoma; Thyroid Neoplasms; Wilms Tumor",United States
Phase I study of the Raf-1 kinase inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.,I,Completed,"Bayer AG/Bayer Pharmaceuticals
Amgen {Onyx Pharmaceuticals}",Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Uterine Cervical Neoplasms; Wilms Tumor",Canada; United States
"Randomized, Placebo-Controlled, Double-Blind, Phase II Study of AG-013736 in Combination with Docetaxel versus Docetaxel Alone in Patients with Metastatic Breast Cancer Preceded by a Phase I Evaluation of the Combination.",I/II,Completed,"Pfizer
National Health Service (NHS) - UK",Oncology: Breast,First line; Stage IV,Breast Neoplasms,Canada; Czech Republic; Germany; India; Italy; Spain; United Kingdom; United States
"Phase Ib/II Neoadjuvant Trial Of The Farnesyltransferase Inhibitor, R115777 With Docetaxel And Capecitabine For Patients With Stage IIIA Or IIIB Breast Cancer.",I/II,Completed,"National Institutes of Health/National Cancer Institute
Mayo Clinic Cancer Center",Oncology: Breast; Oncology: Unspecified Solid Tumor,Neoadjuvant; Stage III; Stage IV,"Breast Neoplasms; Breast Neoplasms, Male; Carcinoma; Inflammatory Breast Neoplasms; Neoplasms, Unknown Primary",United States
Vaccine Therapy With Tumor Specific p53 Peptides in Adult Patients With Adenocarcinoma of the Breast or Ovary,I/II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Ovarian,Second line; Stage IV,Breast Neoplasms; Ovarian Cancer; Ovarian Neoplasms,United States
A Multicenter Phase I-II Study of Tumor Vaccine Following Chemotherapy in Patients With Metastatic Breast Cancer Untreated With Chemo/Radiation in the Previous 18 Months: Vaccine-Induced Bias of T-Cell Repertoire Reconstitution After T-Cell Re-Infusion.,I/II,Terminated,"National Institutes of Health/National Cancer Institute
National Institutes of Health",Oncology: Breast,First line; Stage IV,Breast Neoplasms; Neoplasm Metastasis; Neoplasms,United States
Phase I/II Trial of Doxil and Hyperthermia for Breast Cancer Patients with Chest Wall Recurrence or Stage IV Disease with Locally Advanced Breast Cancer.,I/II,Completed,National Center for Research Resources,Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase I/II Trial of Herceptin and ZD1839 (Iressa, NSC #715055, IND#61187) in Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu (erbB-2)",I/II,Terminated,"Eastern Cooperative Oncology Group (ECOG)
National Institutes of Health/National Cancer Institute",Oncology: Breast,EGFR; Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Second line; Stage IV,"Breast Neoplasms; Breast Neoplasms, Male",Peru; United States
Phase II Randomized Study of Sequential Vaccination With Vaccinia-Carcinoembryonic Antigen (CEA) Vaccine and ALVAC-CEA Vaccine With the Addition of Interleukin-2 and Sargramostim (GM-CSF) in Patients With CEA Expressing Tumors (Summary Last Modified 08/2001),I/II,Completed,"National Institutes of Health/National Cancer Institute
Lombardi Cancer Center at Georgetown University Medical Center
Therion Biologics
Sanofi {Sanofi-Aventis}","Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Pancreas",Second line; Stage I; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Cancer; Esophageal Neoplasms; Lung Neoplasms; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
Phase I Randomized Study of MAGE-12 Peptide Vaccine in Patients With Refractory Metastatic Cancer Expressing MAGE-12 Antigen,I,Terminated,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma",Second line; Stage III; Stage IV,"Bone Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Ewing Sarcoma; Eye Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasm Metastasis; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
Phase I/II Study of Gemcitabine and Doxil Combination Chemotherapy in Patients With Advanced Solid Tumors (Phase I)/Breast Cancer (Phase II),I/II,Completed,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast,First line; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"High-Dose Infusional Taxol, Amifostine, Doxorubicin, and Cyclophosphamide Followed by Stem Cell Rescue for High Risk Primary and Responsive Metastatic Breast Cancer",I,Completed,"National Institutes of Health/National Cancer Institute
Beckman Research Institute
Johnson & Johnson/ALZA",Oncology: Breast; Oncology: Supportive Care,First line; Neurotoxicity; Second line; Stage II; Stage III; Stage IV,Breast Neoplasms; Palliative Care,United States
A Phase I-II Trial of Mild Whole-Body Hyperthermia Combined With Liposomal Doxorubicin/5-Fluorouracil in Patients With Advanced Malignancy,I/II,Completed,University of Texas,Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Ovarian,Second line; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Fever; Ovarian Cancer; Ovarian Neoplasms; Uterine Cervical Neoplasms",United States
BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer,II,Planned,"Washington University School of Medicine
BioVica AB",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
RETENTION: An Open-Label Phase II Trial of InteRlEukin (5) InhibiTion for the prEveNTION of Alpelisib Rash in Metastatic PIK3CA-mutant Hormone-Receptor Positive Breast Cancer,II,Open,"AstraZeneca
Novartis
Memorial Sloan-Kettering Cancer Center",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
"An Open-label, Interventional, Multicenter, Randomized, Phase II Study of Fulvestrant With or Without Samuraciclib in Participants With Metastatic or Locally Advanced Hormone Receptor (HR) Positive and Human Epidermal Growth Factor Receptor (HER)2-Negative Breast Cancer (BC)",II,Open,"Pfizer
Carrick Therapeutics",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"Phase II, Multi-Center, Randomized, Open-Label Trial of BDC-1001 as a Single Agent and in Combination With Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab Deruxtecan",II,Planned,"Roche {F. Hoffmann-La Roche}
Bolt Biotherapeutics",Oncology: Breast,Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,South Korea; United States
OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple Negative Breast Cancer,II,Planned,(Other Hospital/Academic/Medical Center),Oncology: Breast,(N/A); Adjuvant; First line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Phase IIA Trial of Acolbifene (20 mg) vs Low Dose Tamoxifen (5 mg) in Pre-Menopausal Women at High Risk for Development of Breast Cancer,II,Planned,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Ovarian,(N/A); Line of therapy N/A,"Breast Carcinoma In Situ; Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Hyperplasia; Ovarian Neoplasms",United States
Genetically-informed Therapy for ER+ Breast Cancer in a Post-CDK4/6 Inhibitor Setting: a Phase II Umbrella Study (GERTRUDE),II,Planned,Dartmouth-Hitchcock Medical Center,Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms,United States
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers,II,Planned,"National Institutes of Health/National Cancer Institute
Vanderbilt-Ingram Cancer Center
Puma Biotechnology",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Lobular",United States
Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults,II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Adjuvant; HER2 negative; HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer",III,Open,Roche {F. Hoffmann-La Roche},Oncology: Breast,HER2 positive; Maintenance/Consolidation; Second line; Stage III; Stage IV,Breast Neoplasms,Argentina; South Korea; United States
Window of Opportunity Analysis of Pre-Operative Tucatinib for Surgically Resected HER2+ Brain Metastases: Understanding Mechanisms of Resistance,II,Open,"Memorial Sloan-Kettering Cancer Center
Seagen","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer",CNS mets; First line; HER2 positive; MET Amplification/Alteration; Neoadjuvant; Second line; Stage IV,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Colorectal Neoplasms; Esophageal Neoplasms; Neoplasm Metastasis; Stomach Neoplasms",United States
A Study of the Natural History of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients,IV,Open,Mayo Clinic,Oncology: Breast,Adjuvant; HER2 positive; Second line; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab,IV,Planned,"National Institutes of Health/National Cancer Institute
(Other Hospital/Academic/Medical Center)",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"A Phase II, Multicenter, Randomized, Double-Blind Study of RO7247669 Combined With Nab-Paclitaxel Compared With Pembrolizumab Combined With Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer",II,Open,Roche {F. Hoffmann-La Roche},Oncology: Breast,First line; HER2 negative; PD-L1 Positive; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Phase II Trial of Carboplatin +/- Tocilizumab as Initial Therapy for Metastatic Triple Negative and ER-low Breast Cancers,II,Planned,"Indiana University Cancer Center
Roche/Genentech",Oncology: Breast,First line; HER2 negative; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Randomized, Open-label, Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH-]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy",III,Open,Gilead Sciences,Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"NeoTAILOR: A Phase II Biomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer",II,Planned,Washington University School of Medicine,Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
A Pivotal Phase III Monotherapy Clinical Trial Of OP-1250 In Second- And Third Line Setting in Patients with ER+/HER2- Metastatic Breast Cancer,III,Planned,Olema Oncology,Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage IV; Third line,Breast Neoplasms,Australia; United States
"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer: A Phase II  Randomized, Open-Label Study",II,Open,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; HER2 negative; Line of therapy N/A; Stage IV,Breast Neoplasms,United States
OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy,III,Open,"National Institutes of Health/National Cancer Institute
Alliance for Clinical Trials in Oncology",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy,II,Open,Fox Chase Cancer Center,Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Prostate; Oncology: Renal; Oncology: Supportive Care,(N/A); Anemia; Neoadjuvant,"Anemia; Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Palliative Care; Prostatic Neoplasms; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"TRUDI: A Phase II Study of Neoadjuvant Trastuzumab Deruxtecan and Durvalumab for Stage III, HER2-expressing Inflammatory Breast Cancer",II,Open,"AstraZeneca
Daiichi Sankyo",Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage III,Adenocarcinoma; Breast Neoplasms; Inflammatory Breast Neoplasms,United States
"A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer",III,Open,"AstraZeneca
Thermo Fisher Scientific/Patheon",Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage I; Stage II; Stage III,Breast Neoplasms,Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Czech Republic; France; Georgia; Germany; Hungary; India; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; Peru; Philippines; Poland; Portugal; Romania; Serbia; Singapore; South Africa; South Korea; Spain; Thailand; Turkey; United Kingdom; United States; Vietnam
A Randomized Clinical Trial Comparing ctDNA-Directed Therapy Change With Standard of Care in Patients With Metastatic Triple Negative Breast Cancer,II,Planned,"National Institutes of Health/National Cancer Institute
Vanderbilt-Ingram Cancer Center",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma,United States
Neoadjuvant tamoxifen therapy reactivates tumor suppressor protein p53 in luminal breast cancer patients: Results from a window-of-opportunity clinical trial,IV,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; First line; Neoadjuvant,Breast Neoplasms,United States
A real-world study on the efficacy and safety of pyrotinib in the treatment of HER-2 positive breast cancer patients with brain metastases,IV,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; HER2 positive; Second line; Stage III; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,China; United States
"Nab-Paclitaxel Followed By Dose-Dense Epirubicin/Cyclophosphamide In Neoadjuvant Chemotherapy For Triple-Negative Breast Cancer: An Open-Label, Single-Arm Phase Ii Study.",II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Neoadjuvant; Stage II; Triple receptor negative,Breast Neoplasms,China; United States
Prognostic relevance of PD-L1 expression on circulating tumor cells in metastatic breast cancer patients treated with anti-PD-1 immunotherapy.,Other,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,PD-L1 High; PD-L1 Positive; Second line; Stage IV,Breast Neoplasms,China; United States
An Early Phase and Phase II Clinical Trial to Evaluate Ganglioside-Monosialic Acid (GM1) for Preventing Paclitaxel-Associated Neuropathy,II,Open,"National Institutes of Health/National Cancer Institute
Alliance for Clinical Trials in Oncology",CNS: Pain (neuropathic); Oncology: Breast; Oncology: Supportive Care,Cancers-related; Neurotoxicity; Second line; Stage IV,Breast Neoplasms; Cancer pain; Cancer Pain; Neuralgia; Palliative Care; Peripheral Nervous System Diseases,United States
"Efficacy of Neoadjuvant Endocrine Therapy Compared with Neoadjuvant Chemotherapy in Pre-Menopausal Patients with Hormone-Responsive and Her2-Negative, Lymph Node negative Breast Cancer.",II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,(N/A); Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive,Breast Neoplasms,United States
Breast Cancer Microenvironment Change After Neoadjuvant Endocrine Treatment,IV,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; PD-L1 Positive,Breast Neoplasms,United States
Gain of HER2 Amplification in Patients with HR+/HER2- and Triple Negative Early Breast Cancer Treated with Neoadjuvant Chemotherapy.,IV,Completed,Memorial Sloan-Kettering Cancer Center,Oncology: Breast,(N/A); Estrogen receptor positive; HER2 negative; Neoadjuvant; Second line; Triple receptor negative,Breast Neoplasms,United States
Immune-related adverse events (irAEs) and pathological complete response (pCR) rates in patients receiving neoadjuvant chemotherapy (CHT) and pembrolizumab (PEM) for early triple-negative breast cancer (eTNBC),IV,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,(N/A); Neoadjuvant; Second line; Triple receptor negative,Breast Neoplasms,Austria; United States
An Evaluation of FACIT-Fatigue in Patients with Locally Advanced or Metastatic Breast Cancer receiving Treatment with Taxane-based Chemotherapy,IV,Open,(Other Hospital/Academic/Medical Center),Oncology: Breast,Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms,Italy; United States
Impact of Beta-2 Adrenergic Blockade With Checkpoint Inhibition in Checkpoint Inhibitor Refractory Metastatic Triple Negative Breast Cancer,II,Planned,Roswell Park Cancer Institute,Oncology: Breast,First line; HER2 negative; PD-1 Refractory; PD-L1 Refractory; Second line; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma; Triple Negative Breast Neoplasms,United States
Tumor microenvironment subtype influence the response of neoadjuvant chemotherapy in breast cancer,Other,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,HER2 negative; HER2 positive; Neoadjuvant; Stage III,Breast Neoplasms,South Korea; United States
Trastuzumab-Induced Tumor Microenvironment Changes in Early HER2+ Breast Cancer,Other,Completed,University of Washington,Oncology: Breast,Estrogen receptor positive; HER2 positive; Second line; Stage I; Stage II; Stage III,Breast Neoplasms,United States
The STOP-HER2 Trial: A Phase II Study of Stopping Trastuzumab - Outcomes in Patients With HER2+ Metastatic Breast Cancer,II,Open,"(Other Academic Cancer Center)
National Institutes of Health/National Cancer Institute
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Johns Hopkins University
Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}",Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Stage IV,Breast Neoplasms,United States
Phase II Study of Estradiol Therapy to Target ER-Mutant and ER-Wild-Type ER+ Metastatic or Advanced Breast Cancer,II,Open,Dartmouth-Hitchcock Medical Center,Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO),III,Open,"Eastern Cooperative Oncology Group (ECOG)
Southwest Oncology Group
National Institutes of Health/National Cancer Institute
Alliance for Clinical Trials in Oncology
NRG Oncology",Oncology: Breast,(N/A); Adjuvant; HER2 positive,Breast Neoplasms,United States
Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET),II,Planned,"MD Anderson Cancer Center, University of Texas","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Metastatic Cancer; Oncology: Neuroendocrine",(N/A); CNS mets; HER2 negative; PD-L1 Positive; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Neoplasm Metastasis; Neuroendocrine Tumors; Small Cell Lung Carcinoma",United States
An Observational Study of Women With Breast Cancer Examining the Effect of Endocrine Therapy on Aging,IV,Open,(Other Hospital/Academic/Medical Center),Oncology: Breast,Line of therapy N/A; Stage I; Stage II; Stage III,Arthralgia; Breast Neoplasms,United States
Integrating Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort (INSIGHT),II,Open,"Vanderbilt-Ingram Cancer Center
Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}
Agendia",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
"Phase 2, Single Center, Single Arm Study to Evaluate the Decrease in CIPN With the Addition of Hydroxychloroquine to Chemotherapy in Patients With Early Stage (1-3) Breast Cancer and Gynecological Cancers Treated With Curative Intent",II,Planned,University of Arizona,Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal,(N/A); First line; Line of therapy N/A; Stage I; Stage II; Stage III,Breast Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Ovarian Neoplasms; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Uterine Cervical Neoplasms,United States
"Definitive Local Consolidative Therapy for Oligometastatic Solid Tumors: Results from the Lead-In Phase of the Randomized Basket Trial EXTEND

EXTernal beam radiation to Eliminate Nominal metastatic disease",II,Open,University of Texas,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Line of therapy N/A; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Synovial Sarcoma; Uterine Cervical Neoplasms; Wilms Tumor",United States
A Two Arm Pilot Study Utilizing Molecular Profiling to Find Potential Targets and Influence Treatments for Patients With Metastatic Breast Cancer or Advanced Gynecological Malignancies,II,Terminated,(Other Hospital/Academic/Medical Center),Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC),II,Open,"MD Anderson Cancer Center, University of Texas
Gilead Sciences",Oncology: Breast,HER2 negative; Neoadjuvant; Stage I; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB),II,Open,"MD Anderson Cancer Center, University of Texas
Roche/Genentech
Seagen",Oncology: Breast; Oncology: Gastric; Oncology: Metastatic Cancer,CNS mets; HER2 positive; Second line; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis; Stomach Neoplasms,United States
Phase II Trial of Alpelisib With iNOS Inhibitor and Nab-paclitaxel in Patients With HER2 Negative Metastatic or Locally Advanced Metaplastic Breast Cancer (MpBC),II,Open,"Novartis
(Other Hospital/Academic/Medical Center)",Oncology: Breast,First line; HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A phase III trial comparing ARV-471 (PF-07850327) with fulvestrant in subjects with estrogen receptor-positive, HER2-negative advanced breast cancer who had progressed on prior endocrine-based therapy for advanced disease , randomized, open, multicenter trial (VERITAC-2)",III,Open,"Pfizer
Arvinas",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms,"Australia; Austria; Belgium; Brazil; Bulgaria; Canada; China; Czech Republic; Finland; France; Germany; Greece; Hungary; India; Israel; Italy; Japan; Mexico; Norway; Poland; Puerto Rico; Slovakia; South Africa; South Korea; Spain; Sweden; Switzerland; Taiwan, China; Turkey; United Kingdom; United States"
"A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Who Progressed During or After CDK4/6 Inhibitor and Endocrine Combination Therapy",III,Open,Roche {F. Hoffmann-La Roche {Memory Pharmaceuticals}},Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,"Argentina; Mexico; Taiwan, China; Turkey; United States"
"Open-label, Safety Extension Study for Subjects With HR+, HER2-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer OVELIA Study",III,Open,Tolmar Pharmaceuticals,Oncology: Breast,(N/A); Estrogen receptor positive; HER2 negative; Line of therapy N/A; Progesterone receptor positive,Breast Neoplasms,United States
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC,II,Open,University of Kansas,Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy",III,Open,"Gilead Sciences
Alliance for Clinical Trials in Oncology",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Japan; United States
"A Phase III Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)",III,Open,"AstraZeneca
Southwest Oncology Group
Daiichi Sankyo",Oncology: Breast,HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,"Belgium; Brazil; Canada; China; Denmark; France; Germany; Greece; Italy; Japan; Poland; South Korea; Spain; Sweden; Taiwan, China; Turkey; United Kingdom; United States"
A Randomized Phase II Non-inferiority Trial of (Z)-Endoxifen and Exemestane + Goserelin as Neoadjuvant Treatment in Premenopausal Women With ER+/HER2- Breast Cancer,II,Open,"(Other Cooperative Group)
Atossa Therapeutics {Atossa Genetics}",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage II,Breast Neoplasms,United States
"ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer: An Open-Label Multicenter Phase 2 Study (ELCIN)",II,Open,Menarini Group/Stemline Therapeutics,Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A Multi-center, Multi-country Prospective Observational Study of Patients Initiating T-DXd in the First or Second Treatment Line for HER2+ Unresectable and/or Metastatic Breast Cancer",IV,Open,AstraZeneca,Oncology: Breast,First line; HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,Brazil; United States
A ComboMATCH Treatment Trial EAY191-N2: Phase II Trial of Fulvestrant and Binimetinib in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With a Frameshift or Nonsense Mutation or Genomic Deletion in NF1,II,Open,"National Institutes of Health/National Cancer Institute
NRG Oncology",Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms; Carcinoma,United States
Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage,II,Open,"Northwestern University
NorthWestern Memorial Hospital
(Other Hospital/Academic/Medical Center)",Cardiovascular: Hemostasis/Hemophilia; Oncology: Breast,(N/A); Line of therapy N/A; Surgical patients (other),Blood Coagulation Disorders; Breast Neoplasms; Hemostatic Disorders,United States
"An Open-label, Randomized, Non-comparative Phase II Study of ARV-471 or Anastrozole in Post-menopausal Women With ER+/HER2- Breast Cancer in the Neoadjuvant Setting",II,Open,"Pfizer
Arvinas",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,Georgia; Germany; Spain; United States
A Phase I/II Study of Intratumorally Injected Autologous Dendritic Cells (DCs) in PD-L1-Negative Treatment Naïve and in Refractory Metastatic Triple Negative Breast Cancer Patients,II,Planned,Roswell Park Cancer Institute,Oncology: Breast,First line; HER2 negative; PD-L1 Naive; PD-L1 Positive; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma; Triple Negative Breast Neoplasms,United States
"Phase II, Open-Labeled, Single-Armed Combination Treatment With Anastrozole, Fulvestrant and Abemaciclib for Hormone Receptor Positive, HER2(-) Metastatic Breast Cancer",II,Open,"University of California Medical Center, Irvine",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Maintenance/Consolidation; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation",III,Open,Sermonix Pharmaceuticals,Oncology: Breast,Estrogen receptor positive; HER2 negative; Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms,Israel; Japan; United States
"EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence",III,Open,Eli Lilly,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Second line; Stage I; Stage II; Stage III,Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Brazil; Canada; China; Czech Republic; Finland; France; Germany; Greece; Hong Kong, S.A.R., China; Hungary; India; Ireland; Israel; Italy; Japan; Mexico; Netherlands; Poland; Portugal; Romania; Singapore; Slovakia; South Korea; Spain; Taiwan, China; Turkey; United Kingdom; United States"
ETHAN: A Phase II Study Comparing Different Endocrine Therapies for male Breast cancer,II,Planned,"Eli Lilly
(Other Cooperative Group)
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,"Breast Neoplasms; Breast Neoplasms, Male",United States
"A Phase II, Multicentre, Open-Label Study to Assess the Efficacy and Safety of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination as Neoadjuvant Therapy in Patients With BRCA Mutations and Early Stage HER2-Negative Breast Cancer",II,Open,AstraZeneca,Oncology: Breast,HER2 negative; Neoadjuvant; Stage III,Breast Neoplasms,Australia; Austria; Belgium; France; Germany; Israel; Italy; Spain; United Kingdom; United States
Comparison of Adjuvant Monotherapy With Endocrine Therapy or Accelerated Partial Breast Irradiation Following Lumpectomy for Low Risk Breast Cancer Patients Over 65 (CAMERAN),II,Open,UNC Lineberger Comprehensive Cancer Center,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Stage I,Breast Neoplasms,United States
"A Phase II Study of Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer",II,Open,"Novartis
Hoosier Cancer Research Network {Hoosier Oncology Group}",Oncology: Breast,(N/A); Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line,Breast Neoplasms; Recurrence,United States
"A Phase II Study of the Safety, Tolerability and Antitumor Activity of Tucatinib in Combination With Eribulin and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer",II,Open,(Other Cooperative Group),Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase II Trial of The Immunogenicity of a DNA Plasmid Based Vaccine (STEMVAC) Encoding Th1 Selective Epitopes From Five Antigens Associated With Breast Cancer Stem Cells (MDM2, YB1, SOX2, CDC25B, CD105) in Participants With Early Stage Triple Negative Breast Cancer",II,Open,"National Institutes of Health/National Cancer Institute
University of Washington
University of Wisconsin",Oncology: Breast,HER2 negative; Line of therapy N/A; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase II, Multicenter, Open-Label Basket Study of Navicixizumab Monotherapy or in Combination With Paclitaxel or Irinotecan in Patients With Select Advanced Solid Tumors",II,Open,OncXerna Therapeutics {Oncologie},Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Unspecified Solid Tumor,Fourth line or greater; HER2 negative; PD-1 Refractory; PD-L1 Positive; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Colorectal Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms,United States
Comprehensive Single-Cell Transcriptional Analysis of Aromatase Inhibitor-Resistant Breast Cancer,II,Open,Mayo Clinic,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage I; Stage II,Breast Neoplasms; Carcinoma,United States
Pilot Study to Evaluate 64Cu-DOTA-Trastuzumab Imaging in Patients With HER2+ Breast Cancer With Brain Metastatsis Treated With Fam-Trastuzumab Deruxtecan,IV,Open,"National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; HER2 positive; Second line; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis; Neoplasms,United States
"A Randomized, Open-label, Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1",III,Open,Gilead Sciences,Oncology: Breast,First line; HER2 negative; PD-L1 Positive; PD-L1 Refractory; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; Czech Republic; France; Germany; Hungary; Israel; Italy; Japan; Mexico; Netherlands; Peru; Poland; Puerto Rico; Romania; Russia; Slovakia; South Africa; Spain; Switzerland; Turkey; Ukraine; United Kingdom; United States
"An Open-Labeled, Single Arm Phase II Efficacy and Safety Study of REM-001 Photodynamic Therapy (PDT) for Treatment of Cutaneous Metastatic Breast Cancer (CMBC) That is Refractory or Not Eligible for Radiotherapy or Surgery",II,Planned,Kintara Therapeutics,Oncology: Breast,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
"Phase II Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients With Molecularly-Selected Solid Tumors (ComBET)",II,Open,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor,(N/A); BRCA; First line; KRAS; Line of therapy N/A; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Ovarian Epithelial; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms",United States
"A Phase II Study of Human Epidermal Growth Factor Receptor 2 (HER-2) Directed Dendritic Cell (DC1) Vaccine Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients With HER-2 Positive Breast Cancer",II,Open,"H. Lee Moffitt Cancer Center and Research Institute
ImmunoRestoration",Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Secondary Brain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 In Patients With Advanced Human Epidermal Growth Factor Receptor 2+ Breast Cancer with The Addition of Tucatinib,II,Open,Seagen,Oncology: Breast,Adjuvant; First line; HER2 positive; Second line; Stage III; Stage IV,"Brain Neoplasms; Breast Neoplasms; Neoplasm Metastasis; Neoplasms, Second Primary",United States
"Phase II Trial of Fulvestrant Plus Abemaciclib With or Without Run-in of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer After Failure of a CDK4/6 Inhibitor In Combination With an Aromatase Inhibitor",II,Open,"Eli Lilly
(Other Hospital/Academic/Medical Center)",Oncology: Breast,HER2 negative; Second line; Stage IV,Breast Neoplasms,United States
"A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Patients With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer",III,Open,Roche/Genentech,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Second line; Stage II; Stage III; Stage IV,Breast Neoplasms,Japan; Spain; United Kingdom; United States
A Phase IIa Study Assessing QBS72S For Treating Brain Metastases of Triple Negative Breast Cancer,II,Open,(Other Hospital/Academic/Medical Center),Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; HER2 negative; Second line; Stage I; Stage II; Triple receptor negative,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis; Triple Negative Breast Neoplasms,United States
"A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Giredestrant in Combination With Phesgo Versus Phesgo After Induction Therapy With Phesgo + Taxane in Patients With Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally-Advanced or Metastatic Breast Cancer",III,Open,Roche {F. Hoffmann-La Roche},Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Maintenance/Consolidation; Stage III; Stage IV,Breast Neoplasms,"Argentina; Belgium; Brazil; China; Colombia; Germany; Hungary; India; Italy; Kenya; Mexico; Poland; Portugal; Russia; South Korea; Spain; Taiwan, China; Thailand; Turkey; Uganda; Ukraine; United Kingdom; United States"
A Study of Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer,II/III,Open,University of Virginia,Oncology: Breast,Adjuvant; HER2 negative; HER2 positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Phase II study of THIO and a Checkpoint Inhibitor in Patients with Colorectal, Hepatocellular, Small Cell Lung Cancer",II,Planned,MAIA Biotechnology,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate; Oncology: Unspecified Solid Tumor",(N/A); Line of therapy N/A; Pulmonary,Breast Neoplasms; Colorectal Neoplasms; Liver Neoplasms; Neuroendocrine Tumors; Ovarian Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Stomach Neoplasms,United States
Diffusion Weighted MR Imaging Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: A Sub-study of the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And MoLecular Analysis),II,Completed,"(Other Cooperative Group)
National Institutes of Health/National Cancer Institute",Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage III,Breast Neoplasms,United States
A Registration Study of  Bria-IMT™ in Combination with retifanlimab in Patients with Third line Advanced Breast Cancer,III,Planned,BriaCell,Oncology: Breast,Stage III; Stage IV; Third line,Breast Neoplasms; Neoplasms,United States
Surveillance Markers of Utility for Recurrence After Neoadjuvant Chemotherapy for Breast Cancer,II,Completed,Abramson Cancer Center at  University of Pennsylvania Medical Center,Oncology: Breast,(N/A); Neoadjuvant,Breast Neoplasms,United States
"A phase I B/2, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of PF-07220060 in combination with PF-07104091 plus endocrine therapy in participants with advanced solid tumors",II,Open,Pfizer,Oncology: Breast; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms, Unknown Primary",Argentina; Brazil; Bulgaria; China; Czech Republic; Mexico; South Africa; Spain; United States
Phase II Study of the Combination of Liposomal Irinotecan (Nal-IRI) and Pembrolizumab for Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM),II,Terminated,Washington University School of Medicine,Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; First line; Fourth line or greater; HER2 negative; Second line; Stage IV; Third line; Triple receptor negative,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis; Triple Negative Breast Neoplasms,United States
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment (ACT),II,Planned,"Oregon Health and Science University
Roche/Genentech",Oncology: Breast; Oncology: Ovarian; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Ovarian Epithelial; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms",United States
Phase II Study of Radiotherapy in Combination With Chemotherapy and Immunotherapy in Patients With PD-L1-Positive Metastatic Triple-Negative Breast Cancer,II,Terminated,"(Other Hospital/Academic/Medical Center)
University of Colorado",Oncology: Breast,HER2 negative; PD-L1 Positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior,Other,Open,"National Institutes of Health/National Cancer Institute
UNC Lineberger Comprehensive Cancer Center",Oncology: Breast,Adjuvant; First line; Neoadjuvant; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
"AIPAC-003 (Active Immunotherapy and PAClitaxel): A Randomized, Double-blind, Placebo-controlled Phase III Trial Testing Eftilagimod Alpha (Soluble LAG-3) in HER2-neg/Low Metastatic Breast Cancer Patients Receiving Paclitaxel, Following an Open-label Dose Optimization",II/III,Open,Immutep {Prima Biomed/Immutep},Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,Belgium; Bulgaria; Czech Republic; Germany; Italy; Netherlands; Poland; Romania; Spain; United States
Phase II of Neoadjuvant Olaparib in Combination With Pembrolizumab in Patients With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer and Germline Mutations in DNA Damage Repair Genes,II,Open,"Memorial Sloan-Kettering Cancer Center
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Association of HSD3B1 Genotype With Response to Preoperative Letrozole Therapy Among Postmenopausal Women With Estrogen-Receptor Positive (ER+) HER2/Neu-Negative (HER2-) Invasive Carcinomas of the Breast,IV,Temporarily Closed,"National Institutes of Health/National Cancer Institute
University of Washington",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms; Carcinoma,United States
Phase IV Single-arm Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Breast Cancer,IV,Open,University of Michigan Comprehensive Cancer Center,Oncology: Breast,Line of therapy N/A; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Human Pilot Studies To Evaluate Fulvestrant For the Treatment of HR+/HER- Advanced Breast Cancer,II,Planned,Eagle Pharmaceuticals,Oncology: Breast,Estrogen receptor positive; HER2 negative; Line of therapy N/A; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,United States
Enhancing Immunotherapy by Targeting the EGFR Pathway in Inflammatory Breast Cancer: A Phase II Study of Panitumumab (PmAb) and Pembrolizumab (Pembro) in Combination With Neoadjuvant Chemotherapy (NAC) in Patients With Newly Diagnosed Triple Negative Inflammatory Breast Cancer (TN-IBC),II,Open,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast,HER2 negative; Neoadjuvant; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma; Inflammatory Breast Neoplasms,United States
"A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02)",III,Open,"AstraZeneca
Daiichi Sankyo",Oncology: Breast,First line; HER2 negative; PD-L1 Positive; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,"Argentina; Belgium; Brazil; Canada; China; France; Germany; Hungary; India; Italy; Japan; Mexico; Philippines; Poland; Russia; Singapore; South Africa; South Korea; Spain; Taiwan, China; Thailand; Turkey; United Kingdom; United States"
"postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase lll Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy",III,Open,Eli Lilly,Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms; Neoplasm Metastasis; Neoplasms,"Argentina; Australia; Belgium; China; Czech Republic; Denmark; France; Greece; Hungary; Israel; Italy; Mexico; Poland; Russia; South Korea; Spain; Sweden; Taiwan, China; Turkey; United States"
A Post-trial Access Roll-over Study to Allow Access to Ribociclib (LEE011) for Patients Who Are on Ribociclib Treatment in Novartis-sponsored Study,IV,Open,Novartis,Oncology: Breast,HER2 negative; Line of therapy N/A; Stage IV,Breast Neoplasms,"Australia; Brazil; Colombia; France; Germany; Greece; Hong Kong, S.A.R., China; Italy; Japan; Mexico; Poland; Portugal; Singapore; South Africa; South Korea; Spain; Taiwan, China; Thailand; Turkey; United States; Vietnam"
"Phase II Study of Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer",II,Open,University of Kentucky,Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage I; Stage II,Breast Neoplasms,United States
Phase II Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of PD-(L)1 Resistant Solid Tumors,II,Open,Rapa Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Unspecified Cancer; Oncology: Unspecified Solid Tumor",ALK; BRAF; BRCA; EGFR; HER2 negative; Pulmonary; Second line; Third line; Triple receptor negative,"Adenocarcinoma; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Esophageal Cancer; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Melanoma; Nasopharyngeal Carcinoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"Effectiveness of RaproCell in Alleviating the Side Effects of Chemotherapeutic Agents, Without Adversely Impacting the Overall Success of the Agents on Cancer Cells.",II,Completed,(Other Hospital/Academic/Medical Center),"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Prostate",(N/A); Line of therapy N/A,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Prostatic Neoplasms",United States
Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in a Celcuity-Sponsored Clinical Study (B2151009),III,Open,Celcuity,Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms; Neoplasms,United States
"A Randomized, Double-blind, Phase III Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05).",III,Open,"Merck & Co./Merck Sharp & Dohme (MSD)
Seagen",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Estrogen receptor positive; First line; HER2 positive; Maintenance/Consolidation; Progesterone receptor positive; Stage III; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,"Australia; Austria; Belgium; Brazil; Canada; China; Czech Republic; Finland; France; Germany; Greece; Italy; Japan; Poland; Portugal; Russia; South Korea; Spain; Switzerland; Taiwan, China; United Kingdom; United States"
"Phase III, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor Therapy",III,Open,Celcuity,Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; China; Czech Republic; France; Greece; Hungary; India; Mexico; Poland; Romania; Singapore; South Korea; Spain; Taiwan, China; United States"
"EMERGE-201: A Phase II, Multicenter, Open-label Study of Lurbinectedin Efficacy and Safety in Participants With Advanced or Metastatic Solid Tumors",II,Closed,Jazz Pharmaceuticals,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Neuroendocrine; Oncology: Pancreas",Estrogen receptor positive; HER2 negative; High-grade; Large Cell; Metastatic; PD-1 Refractory; PD-L1 Refractory; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Lung Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Phase II, Open-Label, Single-Arm Study of Single-Dose Lead-In and Neoadjuvant Trilaciclib and Chemotherapy in Patients With Early-Stage Triple Negative Breast Cancer (TNBC)",II,Completed,G1 Therapeutics,Oncology: Breast,HER2 negative; Neoadjuvant; PD-L1 Positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Phase III Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd Followed by THP Compared to ddAC-THP in Participants With High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11),III,Closed,"AstraZeneca
Daiichi Sankyo",Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage 0; Stage I; Stage II; Stage III,Breast Neoplasms,"Austria; Brazil; Bulgaria; Canada; China; Germany; India; Italy; Japan; Peru; Philippines; Poland; Russia; Saudi Arabia; South Korea; Spain; Taiwan, China; Thailand; United States"
"Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting",II,Closed,G1 Therapeutics,Oncology: Breast,BRCA; Fourth line or greater; HER2 negative; PD-L1 Positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase-III, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)",III,Closed,"AstraZeneca
Daiichi Sankyo",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,"Argentina; Belgium; Brazil; Canada; China; France; Germany; Hungary; India; Italy; Japan; Mexico; Netherlands; Poland; Russia; South Africa; South Korea; Spain; Taiwan, China; United Kingdom; United States"
A Phase II Multi-center Open-label Basket Trial of ABI-009 (Nab Sirolimus) for Adult and Adolescent Patients With Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes,II,Open,Aadi Bioscience,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",(N/A); Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Unknown Primary; Ovarian Neoplasms; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Puerto Rico; United States
"An Umbrella, Randomized, Controlled, Pre-Operative Trial Testing Integrative Subtype-Targeted Therapeutics in Hormone Receptor-Positive, HER2-Negative Breast Cancer",II,Open,"Stanford University Medical Center
(Other government agency)",Oncology: Breast,(N/A); Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive,Breast Neoplasms,United States
"A Randomized, Open-label, Phase III Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1",III,Open,"Gilead Sciences
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,First line; HER2 negative; PD-L1 Positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; Czech Republic; France; Germany; Hong Kong, S.A.R., China; Hungary; Israel; Italy; Japan; Mexico; Netherlands; Peru; Poland; Puerto Rico; South Africa; South Korea; Spain; Switzerland; Taiwan, China; Turkey; United Kingdom; United States"
A Phase II Study to Evaluate the Safety and Efficacy of Lerociclib in Participants With Advanced Breast Cancer,II,Closed,EQRx,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,Belgium; Georgia; Italy; Mexico; Moldova Republic; Ukraine; United States
"Phase II Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations",II,Open,"MD Anderson Cancer Center, University of Texas
Bayer AG",Oncology: Breast; Oncology: Endometrial; Oncology: Ovarian,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage I; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Ovarian Cancer; Ovarian Neoplasms",United States
Phase 2 Randomized Control Trial of Evexomostat (SDX-7320) in Combination With Eribulin for Patients With Metastatic Triple-Negative Breast Cancer and Metabolic Dysfunction: The ARETHA Study,II,Open,"Memorial Sloan-Kettering Cancer Center
SynDevRx",Oncology: Breast,(N/A); HER2 negative; Second line; Third line; Triple receptor negative,Breast Neoplasms,United States
"P2 Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on a Nonsteroidal Aromatase Inhibitor, Fulvestrant and CDK 4/6 Inhibitor",II,Terminated,Veru,Oncology: Breast,Estrogen receptor positive; HER2 negative; Stage IV; Third line,Breast Neoplasms,United States
A Phase II Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy for Post and Pre-menopausal Patients With Early Stage Hormone Receptor Positive and Her-2/Neu Negative Breast Cancer,II,Open,University of Nebraska Medical Center,Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,United States
"Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases",II,Open,"Eisai
(Other Hospital/Academic/Medical Center)","Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer; Oncology: Renal",CNS mets; HER2 negative; Line of therapy N/A; Stage IV; Triple receptor negative,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Kidney Neoplasms; Neoplasm Metastasis; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",United States
"An International, Randomized, Phase III, Multicenter, Open-Label Study of Kisqali (ribociclib) versus Ibrance (palbociclib), both in combination with Endocrine Therapy, in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-negative (HR+/HER2-) Advanced or Metastatic Breast Cancer with a HER2-enriched (HER2E) intrinsic subtype",III,Open,"Novartis
(Other Cooperative Group)",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,Portugal; Spain; United States
A Global Phase II Study to Evaluate the Efficacy and Safety of ARX788 for Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors,II,Terminated,Ambrx,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Unspecified Solid Tumor",HER2 positive; Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms",United States
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors,IV,Open,VastBiome,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal",HER2 negative; Line of therapy N/A; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Kidney Neoplasms; Melanoma; Renal Cancer; Triple Negative Breast Neoplasms; Wilms Tumor",United States
A Phase II Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC),II,Open,"MD Anderson Cancer Center, University of Texas
Zymeworks",Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Stage I; Stage II,Breast Neoplasms,United States
"Time Restricted Eating And Metformin (TEAM) in Invasive Breast Cancer (IBC) or Ductal Carcinoma in Situ (DCIS). A Randomized, Phase IIb, Window of Opportunity Presurgical Trial.",II,Open,National Cancer Research Institute,Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage 0; Stage I; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating",Italy; United States
"Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer",II,Open,"Novartis
(Other Hospital/Academic/Medical Center)",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation,II,Open,"Ipsen
Ipsen {Epizyme}
Prisma Health/Prisma Health-Upstate","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Liver Cancer; Liver Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms",United States
A Phase II Trial to Correlate Early Clinical Response to Pathologic Outcome With Neoadjuvant Systemic Therapy in Patients With Early Stage Breast Cancer,II,Open,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Neoplasms; Triple Negative Breast Neoplasms,United States
"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study To Assess The Efficacy And Safety Of Oral Reparixin In Cancer Related Fatigue In Patients With Locally Advanced Or Metastatic Breast Cancer Undergoing Taxane-Based Chemotherapy.",II,Terminated,Dompe,Oncology: Breast; Oncology: Supportive Care,Cachexia; HER2 negative; Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms; Cachexia; Fatigue; Palliative Care,Germany; Italy; Poland; United States
A Phase II Clinical Study of TJ004309 in Combination with Atezolizumab (TECENTRIQ) in Patients with Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid Tumors,II,Closed,"I-Mab Biopharma Co. {Tasgen (Genexine, Shanghai Tasly Pharmaceutical Co., and C-Bridge Capital joint venture)}","Oncology: Breast; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Unspecified Solid Tumor",HER2 negative; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Positive; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms",United States
A Phase II Study of Palliative Radiation in Combination With Pembrolizumab in Subjects With Unresectable Metastatic Stage IV Breast Cancer: Twisted Pink,II,Open,"University of Louisville
(Other Hospital/Academic/Medical Center)",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
Genomically Guided Phase II Study to Evaluate the Clinical Benefit of Niraparib in Tumors Metastatic to the CNS,II,Open,"GlaxoSmithKline
Massachusetts General Hospital",Oncology: Breast; Oncology: Metastatic Cancer; Oncology: Ovarian; Oncology: Unspecified Solid Tumor,BRCA; CNS mets; HER2 negative; Second line; Stage IV; Triple receptor negative,"Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis; Neoplasms, Unknown Primary; Nervous System Neoplasms; Ovarian Cancer; Ovarian Neoplasms",United States
"A Multicenter, Open-label, Phase II Basket Study of MK-7684A, a Co-formation of Vibostolimab (MK-7684) With Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors",II,Open,Merck & Co./Merck Sharp & Dohme (MSD),Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Ovarian,Adenocarcinoma; First line; HER2 negative; Intrahepatic; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative; Unresectable; Untreated,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Cholangiocarcinoma; Cholangiocarcinoma; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gallbladder Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms","Canada; Chile; Colombia; France; Germany; Israel; Italy; Japan; Netherlands; Poland; South Korea; Spain; Taiwan, China; Turkey; United States"
"A Phase III, Randomized, Open-label, Multicenter Study of Arv-471(PF-07850327) plus Palbociclib Versus Letrozole plus Palbociclib for the Treatment of Participants with Estrogen Receptor-positive, Her2-negative Breast Cancer Who Have Not Received Any Prior Systemic Anti-cancer Treatment for Advanced Disease (VERITAC-3)",III,Open,"Pfizer
Arvinas",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Stage III; Stage IV,Breast Neoplasms,United States
An Open-Label Phase II Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling,II,Open,University of Rochester,Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Estrogen receptor positive; HER2 negative; Second line; Stage IV; Triple receptor negative,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
"A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole)+ CDK4/6 Inhibitor in HR+/HER2-MBC Patients With Detectable ESR1Mutation Without Disease Progression During 1L Treatment With Aromatase Inhibitor+ CDK4/6 Inhibitor- A ctDNA Guided Early Switch Study",III,Open,AstraZeneca,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage IV,Breast Neoplasms; Disease Progression,"Australia; Austria; Belgium; Bulgaria; Canada; France; Germany; Hungary; Italy; Japan; Norway; Poland; Portugal; Russia; Slovakia; South Korea; Spain; Switzerland; Taiwan, China; Turkey; United Kingdom; United States"
"A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Patients With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer",III,Open,Roche {F. Hoffmann-La Roche},Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Stage I; Stage II; Stage III,Breast Neoplasms,"Argentina; Australia; Austria; Azerbaijan; Belarus; Belgium; Bosnia and Herzegovina; Brazil; Bulgaria; Canada; Chile; China; Colombia; Costa Rica; Croatia; Czech Republic; Egypt; Finland; France; Georgia; Germany; Greece; Guatemala; Hong Kong, S.A.R., China; Hungary; India; Ireland; Israel; Italy; Japan; Kenya; Latvia; Macedonia; Malaysia; Mexico; Netherlands; Pakistan; Peru; Philippines; Poland; Portugal; Romania; Russia; Serbia; Slovakia; Slovenia; South Africa; South Korea; Spain; Sweden; Switzerland; Taiwan, China; Thailand; Turkey; Uganda; Ukraine; United Kingdom; United States; Vietnam"
"A Phase II Study of Magrolimab Combination Therapy in Patients With Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer",II,Open,Gilead Sciences,Oncology: Breast; Oncology: Unspecified Solid Tumor,First line; HER2 negative; PD-1 Refractory; PD-L1 Positive; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Neoplasms, Unknown Primary; Triple Negative Breast Neoplasms","Australia; Hong Kong, S.A.R., China; United Kingdom; United States"
"A Multicenter, Open-label, Phase II Study of Imprime PGG and Pembrolizumab in Patients With Metastatic Breast Cancer (mBCA) Who Have Progressed Through Prior Hormonal Therapy.",II,Completed,"Merck & Co./Merck Sharp & Dohme (MSD)
HiberCell {Biothera Pharmaceuticals}",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage II; Stage IV; Third line,Breast Neoplasms; Neoplasms,United States
Systemic Assessment of CIPN Risk Using Molecular Aging Trajectories,IV,Open,"University of Alabama, Birmingham
University of North Carolina
Sapere Bio",Oncology: Breast; Oncology: Supportive Care,Adjuvant; Neoadjuvant; Neurotoxicity; Stage I; Stage II; Stage III,Breast Neoplasms; Palliative Care; Peripheral Nervous System Diseases,United States
P3 Efficacy Evaluation of Enobosarm in Combo With Abemaciclib Compared to Estrogen Blocking Agent for 2nd Line Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on an Estrogen Blocking Agent Plus Palbociclib.,III,Open,Veru,Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage IV,Breast Neoplasms,United States
"EMBER-3: A Phase III, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy",III,Open,Eli Lilly,Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms; Neoplasm Metastasis; Neoplasms,"Argentina; Australia; Austria; Belgium; Brazil; China; Czech Republic; France; Germany; Greece; India; Italy; Japan; Mexico; Netherlands; Russia; South Korea; Spain; Taiwan, China; Turkey; Ukraine; United States"
A Randomized Phase III Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo in Participants With Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer With Molecular Disease Based on Presence of Circulating Tumor DNA After Definitive Therapy (ZEST),III,Closed,"GlaxoSmithKline
Takeda",Oncology: Breast,BRCA; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; Colombia; Finland; France; Germany; Hungary; Ireland; Israel; Italy; Japan; Mexico; Netherlands; New Zealand; Norway; Poland; Portugal; Romania; Russia; South Africa; Spain; Sweden; Switzerland; United Kingdom; United States
"A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer",II,Open,Regeneron/Checkmate Pharmaceuticals,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Neuroendocrine; Oncology: Skin, Squamous Cell Carcinoma (cSCC)",First line; HER2 negative; Merkel; PD-L1 High; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Neoplasm Metastasis; Neoplasms; Neoplasms, Second Primary; Neuroendocrine Tumors; Triple Negative Breast Neoplasms",United States
"Phase III,Single Arm,Open-Label Study Evaluating Ovarian Suppression Following 3 Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination With Endocrine Therapy in Premenopausal Subjects With Hormone-Receptor-Positive (HR+),Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer",III,Open,Tolmar Pharmaceuticals,Oncology: Breast,Estrogen receptor positive; HER2 negative; Line of therapy N/A; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,Puerto Rico; United States
"A Double-blind, Phase II Randomized Study of Brain-directed Stereotactic Radiation With or Without AGuIX Gadolinium-based Nanoparticles in the Management of Brain Metastases at Higher Risk of Local Recurrence With Radiation Alone",II,Open,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
NH TherAguix","Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Unspecified Solid Tumor",CNS mets; First line; HER2 positive; Other mets; Stage IV,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Colorectal Neoplasms; Gastrointestinal Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms, Second Primary; Neoplasms, Unknown Primary; Stomach Carcinoma; Stomach Neoplasms",United States
"An Open-Label Phase II Trial of Fulvestrant And Neratinib in Previously Treated HRPositive, HER2-Negative Metastatic Breast Cancer Subjects Assessed With a Test Measuring Live Cell HER2 Signaling Function",II,Terminated,"Massachusetts General Hospital
Puma Biotechnology
Celcuity",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Third line,Breast Neoplasms,United States
"A Phase II Study to Evaluate the Efficacy and Safety of an Adjuvant Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With HER2 Low Breast Cancer (Cornerstone-001)",II,Open,Aston Sci.,Oncology: Breast,Adjuvant; HER2 positive; Stage I; Stage II; Stage III,Breast Neoplasms,"Australia; Taiwan, China; United States"
"EPIK-B4: A Phase II, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin During Treatment With Alpelisib (BYL719) in Combination With Fulvestrant in Participants With HR+, HER2-, Advanced Breast Cancer With a PIK3CA Mutation Following Progression on/After Endocrine-based Therapy.",II,Terminated,Novartis,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,"Argentina; Hong Kong, S.A.R., China; India; Malaysia; Philippines; Russia; Saudi Arabia; Singapore; United States"
A Randomized Phase II Trial of Adjuvant Trastuzumab Emtansine (T-DM1) Followed by Subcutaneous Trastuzumab Versus Paclitaxel in Combination With Subcutaneous Trastuzumab for Stage I HER2-positive Breast Cancer (ATEMPT 2.0),II,Open,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Roche/Genentech",Oncology: Breast,Adjuvant; First line; HER2 negative; HER2 positive; Stage I,Breast Neoplasms,United States
"A Randomized, Double-blind, Placebo-controlled, Phase III Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer (KEYNOTE-B49)",III,Open,Merck & Co./Merck Sharp & Dohme (MSD),Oncology: Breast,Estrogen receptor positive; HER2 negative; PD-1 Naive; PD-L1 Naive; PD-L1 Positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,Argentina; Australia; Austria; Brazil; Canada; Chile; China; France; Germany; Greece; Guatemala; Hungary; Ireland; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; Philippines; Poland; Portugal; Russia; South Korea; Spain; Sweden; Turkey; United Kingdom; United States
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer.,II,Open,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
"An Open Label, Phase II Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in Triple Positive Breast Cancers Hoosier Cancer Research Network BRE17-141",II,Open,"University of Rochester
Puma Biotechnology",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
A Phase II Basket Study of Milademetan in Advanced/Metastatic Solid Tumors (MANTRA-2),II,Closed,Rain Oncology {Rain Therapeutics},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Gallbladder; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Fibrosarcoma; Gallbladder Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Stomach Neoplasms; Synovial Sarcoma",United States
"A Phase Ib/III Randomised Study of Capivasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer",III,Open,AstraZeneca,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,Australia; Belgium; Canada; China; Denmark; France; India; Japan; Poland; Spain; Sweden; Thailand; United States
"A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer",III,Open,"National Institutes of Health/National Cancer Institute
NRG Oncology",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Stage I,Breast Neoplasms; Recurrence,Canada; Lebanon; United States
"A Phase II Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer (PERSEVERE)",II,Open,"Pfizer
Indiana University Cancer Center
(Other Hospital/Academic/Medical Center)
Roche/Genentech
Roche/Foundation Medicine
Epic Sciences",Oncology: Breast,Adjuvant; HER2 negative; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Precision Performance Status Assessment in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy,Other,Open,"MD Anderson Cancer Center, University of Texas",Oncology: Breast,HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Phase II Trial of Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer (PALAVY),II,Open,"(Other Cooperative Group)
Pfizer
Johns Hopkins University
Abramson Cancer Center at  University of Pennsylvania Medical Center
Breast Cancer Research Foundation",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
"A Phase II Study of NirAparib, Dostarlimab and Radiotherapy in Metastatic, PD-L1 Negative or Immunotherapy-Refractory Triple-Negative Breast Cancer (NADiR)",II,Open,"Johns Hopkins University
Duke University Medical Center
University of Pennsylvania
Massachusetts General Hospital
(Other Hospital/Academic/Medical Center)",Oncology: Breast,Estrogen receptor positive; HER2 negative; PD-1 Refractory; PD-L1 Refractory; Progesterone receptor positive; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Global, Phase II Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd",II,Closed,Ambrx,Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,"Australia; Belgium; Brazil; Canada; Czech Republic; France; Germany; Hong Kong, S.A.R., China; Italy; Portugal; South Korea; Spain; Taiwan, China; United States"
"A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Her2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy",III,Open,Roche {F. Hoffmann-La Roche},Oncology: Breast,Adjuvant; HER2 positive; PD-L1 Positive; Stage I; Stage II; Stage III,Breast Neoplasms; Recurrence,"Australia; Austria; Belgium; Brazil; Bulgaria; China; Czech Republic; Denmark; France; Germany; Greece; Hong Kong, S.A.R., China; Hungary; India; Italy; Kenya; Mexico; New Zealand; Poland; Portugal; Romania; Russia; Singapore; South Korea; Spain; Taiwan, China; Thailand; Turkey; Uganda; Ukraine; United Kingdom; United States"
Phase II Study of Avapritinib in Patients With CKIT or PDGFRA Mutation-Positive Malignant Solid Tumors,II,Open,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute","Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV,"Adenocarcinoma; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Glioblastoma; Leiomyosarcoma; Liposarcoma; Lung Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Nervous System Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma",United States
Phase II Trial of Circulating Tumor DNA Monitoring During Adjuvant Capecitabine in Patients With Triple-negative Breast Cancer and Residual Disease Following Standard Neoadjuvant Chemotherapy,II,Open,Stanford University Medical Center,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Second line; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase II, Single Arm, Non-randomized Study of Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer",II,Open,"Novartis
University of Wisconsin",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
A Phase II Clinical Trial of Talazoparib Monotherapy for PALB2 Mutation Associated Advanced Breast Cancer,II,Open,"Pfizer
(Other Hospital/Academic/Medical Center)",Oncology: Breast,First line; Fourth line or greater; HER2 negative; Second line; Stage IV; Third line,Breast Neoplasms,United States
"eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase III Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy.",III,Closed,Eli Lilly,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Brazil; China; Finland; France; Germany; Greece; Hungary; Israel; Italy; Japan; Mexico; Puerto Rico; Romania; Russia; South Korea; Spain; Sweden; Switzerland; Taiwan, China; United Kingdom; United States"
"An Open-Label, Multinational, Multicenter, Phase IIIb/IV Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously Treated Advanced/Metastatic HER2-Positive Breast Cancer (DESTINY-Breast12)",III/IV,Closed,"AstraZeneca
Daiichi Sankyo",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; First line; HER2 positive; Second line; Stage III; Stage IV; Third line,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,Australia; Belgium; Canada; Denmark; Finland; Germany; Ireland; Italy; Japan; Netherlands; Norway; Poland; Portugal; Russia; Spain; Sweden; Switzerland; United Kingdom; United States
"A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Study of the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo in Patients With HER2-Positive and PD-L1-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab- (+/- Pertuzumab) and Taxane-Based Therapy (KATE3).",III,Open,Roche {F. Hoffmann-La Roche},Oncology: Breast,HER2 positive; PD-L1 Positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,Australia; Brazil; Canada; China; Colombia; Croatia; Egypt; Finland; France; Germany; Greece; Hungary; Italy; Mexico; Norway; Philippines; Poland; Portugal; Russia; Slovenia; South Korea; Spain; Turkey; United Kingdom; United States
Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer Response to Neoadjuvant Treatment,IV,Terminated,"Pfizer
(Other Hospital/Academic/Medical Center)
American Cancer Society",Oncology: Breast,(N/A); Neoadjuvant,Breast Neoplasms; Insulin Resistance,United States
OASIS: Phase II Trial of OrAl SM-88 in Patients With Metastatic Hormone Receptor-posItive HER2-negative (HR+/HER2-) breast Cancer,II,Closed,"(Other Hospital/Academic/Medical Center)
Syros Pharmaceuticals {Tyme Technologies}",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) Plus Palbociclib Versus Anastrozole Plus Palbociclib for the Treatment of Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease.",III,Open,AstraZeneca,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Stage III; Stage IV,Breast Neoplasms,"Austria; Belgium; Bulgaria; Canada; Chile; China; Czech Republic; Finland; France; Germany; Hungary; India; Italy; Japan; Malaysia; Mexico; Norway; Poland; Portugal; Russia; Slovakia; South Korea; Spain; Switzerland; Taiwan, China; Turkey; United Kingdom; United States"
Expasnion Study of ARV-471 in ER+/HER2- Metastatic Breast Cancer,II,Planned,Arvinas,Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage IV; Third line,Breast Neoplasms,United States
A Phase II Study of U3-1402 in Patients With Metastatic Breast Cancer,II,Open,Daiichi Sankyo,Oncology: Breast,BRCA; Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
"A Multi-institutional Phase II Study to Evaluate Efficacy and Safety of TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer",II,Completed,"Pfizer
Emory University Hospital - Atlanta
Roche/Genentech",Oncology: Breast,Fourth line or greater; HER2 negative; PD-L1 Positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Phase II Clinical Efficacy and Safety Study of Sabizabulin (VERU-111) Monotherapy and Sacituzumab Govitecan-hziy/Sabizabulin Combination Therapy for the Treatment of Metastatic Triple Negative Breast Cancer,II,Terminated,Veru,Oncology: Breast,HER2 negative; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"Randomized Crossover Ph3 to Evaluate Efficacy/Safety of Enobosarm Monotherapy vs Active Control for Treatment of AR+/ER+/HER2- MBC With AR Staining =40% Previously Treated w/Nonsteroidal Aromatase Inhibitor, SERD & CDK 4/6 Inhibitor",III,Closed,Veru,Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; Estrogen receptor positive; HER2 negative; Second line; Stage III; Stage IV; Third line,Breast Neoplasms; Neoplasm Metastasis,Poland; Spain; Ukraine; United States
"Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)",III,Open,"AstraZeneca
Baxter International
Daiichi Sankyo",Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Brazil; Canada; China; Denmark; France; Germany; Hungary; India; Israel; Italy; Japan; Mexico; Peru; Philippines; Romania; Russia; Saudi Arabia; South Africa; South Korea; Spain; Sweden; Taiwan, China; Turkey; United Kingdom; United States"
Phase II Study of Pembrolizumab and Ablative Radiotherapy With or Without Olaparib in Metastatic Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancers : Initial Test Cohorts of a Platform Trial to Sequentially Investigate Immunotherapy Combinations for the Augmentation of Immune Responses,II,Open,Memorial Sloan-Kettering Cancer Center,Oncology: Breast,HER2 negative; PD-1 Refractory; PD-L1 Refractory; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients Receiving Neoadjuvant Chemotherapy for Operable Triple Negative Breast Cancer,II,Open,"National Institutes of Health/National Cancer Institute
(Other Hospital/Academic/Medical Center)",Oncology: Breast,(N/A); HER2 negative; Neoadjuvant; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms; Vitamin D Deficiency,United States
"Open-label, Multi-cohort, Phase II Trial, Evaluating the Efficacy and Safety of Tusamitamab Ravtansine (SAR408701) Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors",II,Open,Sanofi,Oncology: Breast; Oncology: Pancreas,Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms,"Argentina; Chile; France; Hungary; Netherlands; Russia; South Korea; Spain; Taiwan, China; Turkey; United States"
A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases,II,Open,"Southwest Oncology Group
National Institutes of Health/National Cancer Institute
Gilead Sciences/Immunomedics",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Triple receptor negative,Brain Neoplasms; Breast Neoplasms; Carcinoma; Central Nervous System Neoplasms; Neoplasm Metastasis; Neoplasms,United States
"An Open-Label, Multicenter, Long-term Treatment Extension Study in Subjects Who Have Completed a Prior GlaxoSmithKline/TESARO-Sponsored Niraparib Study and Are Judged by the Investigator to Benefit From Continued Treatment With Niraparib",II,Closed,GlaxoSmithKline,Oncology: Breast; Oncology: Ovarian,(N/A); Line of therapy N/A,Breast Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms,Austria; Belgium; Canada; Denmark; France; Germany; Israel; Italy; Spain; Sweden; United Kingdom; United States
"ARGONAUT: Development and Analysis of a Blood and Stool Sample Bank for Cancer Patients, Enabling the Systematic Study of the Effect of Gut Microbiomes on Response to Treatment",IV,Open,"Johnson & Johnson/Janssen R&D {Johnson & Johnson/J&JPRD {Johnson & Johnson/Janssen-Cilag/Janssen Research Foundation}}
Persephone Biosciences","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Pancreas",First line; HER2 negative; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Triple Negative Breast Neoplasms",United States
"A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Unresectable and/or Metastatic Solid Tumors Harboring HER2 Activating Mutations Regardless of Tumor Histology",II,Completed,"AstraZeneca
Daiichi Sankyo",Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor,HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Belgium; Canada; Denmark; France; Italy; Japan; South Korea; Spain; United States
MyTACTIC: An Open-Label Phase II Study Evaluating Targeted Therapies in Patients Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response,II,Closed,Roche/Genentech,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Neuroendocrine; Oncology: Prostate; Oncology: Unspecified Solid Tumor",ALK; EGFR; First line; Fourth line or greater; HER2 negative; HER2 positive; Metastatic; MSI-H/dMMR; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Prostatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib and Letrozole in Hormone Receptor Positive Breast Cancer,II,Open,"Eli Lilly
University of Texas Southwest Medical Center
(Other government agency)",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Phase III, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Participants With High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy (DESTINY-Breast05)",III,Open,"AstraZeneca
National Surgical Adjuvant Breast and Bowel Project (NSABP)
Spanish Breast Cancer Research Group
Baxter International/Baxter Oncology {ASTA Medica Oncology}
German Breast Group
Daiichi Sankyo",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,"Argentina; Australia; Belgium; Brazil; Canada; Chile; China; Czech Republic; Denmark; France; Germany; Greece; Hong Kong, S.A.R., China; Ireland; Israel; Italy; Japan; Mexico; Netherlands; Peru; Poland; Portugal; Romania; Russia; Singapore; South Korea; Spain; Taiwan, China; Turkey; United Kingdom; United States"
"A Randomized, Multicenter, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects With Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01).",III,Open,Greenwich LifeSciences,Oncology: Breast,Adjuvant; HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms; Unspecified,France; Germany; Spain; United States
Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS With Brain Metastasis Velocity > or = 4 Brain Metastases/Year,III,Open,"National Institutes of Health/National Cancer Institute
NRG Oncology","Oncology: Breast; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Renal",CNS mets; Second line; Stage IV; Third line,"Brain Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Kidney Neoplasms; Lung Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",United States
A Phase II Study of Niraparib With Dostarlimab Therapy as Neoadjuvant Treatment for Patients With BRCA-mutated Breast Cancer,II,Open,"GlaxoSmithKline
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Johns Hopkins University
Breast Cancer Research Foundation",Oncology: Breast,BRCA; Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
"A Phase II Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations",II,Closed,Seagen {Seattle Genetics},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Gallbladder; Oncology: Lung, Non-Small Cell; Oncology: Renal; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Estrogen receptor positive; HER2 negative; HER2 positive; Large Cell; Progesterone receptor positive; Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Endometrial Neoplasms; Gallbladder Neoplasms; Kidney Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms; Wilms Tumor",Belgium; France; Germany; Italy; Japan; Netherlands; Poland; South Korea; Spain; United Kingdom; United States
"A Phase II, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Compared With Physician's Choice of Endocrine Monotherapy in Patients With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer",II,Completed,Roche,Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,"Argentina; Australia; Brazil; China; Germany; Israel; Poland; Russia; Serbia; Singapore; South Africa; South Korea; Taiwan, China; Thailand; Turkey; Ukraine; United Kingdom; United States"
"A Single Arm Phase II Study of Adjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (ADEPT)",II,Open,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Roche/Genentech",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Stage I,Breast Neoplasms; Neoplasm Micrometastasis,United States
A Phase IIB Randomized Trial of Oral Tamoxifen vs. Topical 4-hydroxytamoxifen Gel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ,II/III,Open,(Other Cooperative Group),Oncology: Breast,(N/A); Line of therapy N/A,"Breast Carcinoma In Situ; Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Lobular; Hyperplasia",United States
Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI),II,Open,Dartmouth-Hitchcock Medical Center,Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Randomized Phase II Trial of Circulating Tumor DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer",II,Open,(Other Industry Sponsor),Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage II; Stage III,Breast Neoplasms,United States
CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer,II,Open,Weill Medical College of Cornell University,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage IV,Breast Neoplasms,United States
"A Phase II, Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of Trastuzumab Deruxtecan (DS-8201a) With or Without Anastrozole for HER2 Low Hormone Receptor Positive (HR+) Breast Cancer in the Neoadjuvant Setting",II,Open,"Jonsson Comprehensive Cancer Center, UCLA
Organisation for Oncology and Translational Research
Daiichi Sankyo",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response",II,Open,National Institutes of Health/National Cancer Institute,Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Gastric; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor,BRCA; Fourth line or greater; HER2 positive; Hormone refractory; Second line; Stage II; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Cholangiocarcinoma; Kidney Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",United States
"A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer",III,Closed,Roche {F. Hoffmann-La Roche},Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Stage III; Stage IV,Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Brazil; Canada; China; Denmark; France; Germany; Greece; Hong Kong, S.A.R., China; Hungary; Israel; Italy; Japan; Mexico; New Zealand; Peru; Poland; Portugal; Russia; South Africa; South Korea; Spain; Switzerland; Taiwan, China; Thailand; Turkey; Ukraine; United Kingdom; United States"
"A Single Arm, Open Label Phase II Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer",II,Closed,Seagen {Seattle Genetics},Oncology: Breast,Fourth line or greater; HER2 positive; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"A Phase II Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib for Patients Whose Tumors Harbor Pathogenic Alterations in BRAF, RAF1, MEK1/2, ERK1/2, and NF1",II,Open,"Eli Lilly
(Other Hospital/Academic/Medical Center)","Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",BRAF; Line of therapy N/A; Metastatic; Second line; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Neoplasms, Unknown Primary; Pancreatic Neoplasms; Thyroid Neoplasms; Unspecified",United States
A Phase II Pilot Study of (Lutetium (177Lu)-DOTATATE in Patients With Metastatic Breast Cancer,II,Planned,"OHSU Cancer Institute
Oregon Health and Science University
Novartis/Advanced Accelerator Applications",Oncology: Breast,Second line; Stage IV; Third line,Breast Neoplasms; Carcinoma,United States
"A Phase II Pilot Trial of ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer Patients (""ABBY"")",II,Open,Abramson Cancer Center at  University of Pennsylvania Medical Center,Oncology: Breast,Second line; Stage I; Stage II; Stage III; Stage IV,"Breast Neoplasms; Neoplasm, Residual",United States
"A Phase II, Open-Label Study to Evaluate the Safety and Antitumor Activity of Praluzatamab Ravtansine (CX-2009) in Advanced HR-Positive/HER2-Negative Breast Cancer and of Praluzatamab Ravtansine as Monotherapy and in Combination With Pacmilimab (CX-072) in Advanced Triple-Negative Breast Cancer (CTMX-2009-002)",II,Terminated,CytomX Therapeutics,Oncology: Breast,Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; PD-L1 Positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Neoplasms; Triple Negative Breast Neoplasms,South Korea; Spain; United States
"A Phase II, Open-Label, Multi-Center Study to Evaluate Efficacy, Safety and Tolerability of KN026 in Combination With KN046 in Patients With Locally Advanced Unresectable or Metastatic HER2-positive Solid Tumors",II,Closed,"Peking Union Medical College Hospital, CAMS
Shanghai JinManTe Biotechnology Co.
Suzhou Alphamab Co./Alphamab Oncology {Jiangsu Alphamab Biopharmaceuticals Co.}","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Metastatic Cancer; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal",(N/A); First line; HER2 positive; Liver mets; Pulmonary; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gallbladder Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasm Metastasis; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",China; United States
An Expanded Access Program with Plinabulin for Patients Suffering from Chemotherapy-induced Neutropenia,IV,Open,BeyondSpring Pharmaceuticals,Oncology: Breast; Oncology: Supportive Care,(N/A); Line of therapy N/A; Neutropenia,Breast Neoplasms; Neutropenia; Palliative Care,United States
"A Phase III, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)",III,Closed,"AstraZeneca
Baxter International/Baxter Oncology {ASTA Medica Oncology}
Daiichi Sankyo",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Brazil; Canada; China; Denmark; France; Germany; Hungary; India; Israel; Italy; Japan; Mexico; Netherlands; Poland; Portugal; Russia; Saudi Arabia; Singapore; South Korea; Spain; Sweden; Taiwan, China; United Kingdom; United States"
A Phase II Study of VLS-101 in Patients With Solid Tumors,II,Closed,Merck & Co. {VelosBio},"Oncology: Breast; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Estrogen receptor positive; HER2 negative; HER2 positive; Large Cell; Line of therapy N/A; Progesterone receptor positive; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms",Canada; United States
"The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib.",III,Open,"National Institutes of Health/National Cancer Institute
Alliance for Clinical Trials in Oncology
Seagen",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage I; Stage II; Stage III,Brain Neoplasms; Breast Neoplasms; Carcinoma; Central Nervous System Neoplasms; Neoplasm Metastasis,Canada; United States
IRENE Study: Phase II Study of INCMGA00012 and the Oncolytic Virus Pelareorep in Metastatic Triple Negative Breast Cancer,II,Open,"National Institutes of Health/National Cancer Institute
Oncolytics Biotech
(Other Hospital/Academic/Medical Center)
Incyte Corporation",Oncology: Breast,HER2 negative; PD-1 Refractory; PD-L1 Positive; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Carcinoma; Triple Negative Breast Neoplasms,United States
"P-RAD: A Randomized Study of Preoperative Chemotherapy, Pembrolizumab and No, Low or High Dose RADiation in Node-Positive, HER2-Negative Breast Cancer",II,Open,"(Other Cooperative Group)
Merck & Co./Merck Sharp & Dohme (MSD)
Breast Cancer Research Foundation",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
MATCH Treatment Subprotocol Y: AZD5363 in Patients With Tumors With AKT Mutations,II,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Unspecified Solid Tumor",Aggressive; Classical; Estrogen receptor positive; HER2 negative; Indolent; Line of therapy N/A; Nodular lymphocyte-predominant; Progesterone receptor positive; Stage III; Stage IV,"Breast Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms; Neoplasms, Plasma Cell; Neoplasms, Unknown Primary",United States
"MATCH Treatment Subprotocol N: Phase II Study of PI3K Beta Specific Inhibitor, GSK2636771, in Patients With Tumors With PTEN Mutation or Deletion, With PTEN Expression on IHC",II,Closed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Aggressive; Classical; Indolent; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Liposarcoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms; Neoplasms, Plasma Cell; Neoplasms, Unknown Primary; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
"MATCH Treatment Subprotocol P: Phase II Study of PI3K Beta Specific Inhibitor, GSK2636771, in Patients With Tumors With PTEN Loss by IHC",II,Closed,National Institutes of Health/National Cancer Institute,"Oncology: Anal; Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Prostate; Oncology: Unspecified Solid Tumor",Aggressive; Classical; Indolent; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV,"Anus Neoplasms; Bile Duct Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms; Neoplasms, Plasma Cell; Neoplasms, Unknown Primary; Prostatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"MATCH Treatment Subprotocol Z1B: Phase II Study of Palbociclib (PD-0332991) in Patients With Tumors With CCND1, 2, 3 Amplification",II,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Unspecified Cancer",Aggressive; Classical; Indolent; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV,"Breast Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms",United States
MATCH Treatment Subprotocol Z1D: Nivolumab in Patients With Tumors With Mismatch Repair Deficiency,II,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Cancer",Aggressive; Classical; Indolent; MSI-H/dMMR; Nodular lymphocyte-predominant; PD-1 Naive; PD-L1 Naive; Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Cholangiocarcinoma; Endometrial Neoplasms; Esophageal Neoplasms; Fibrosarcoma; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Liposarcoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms; Neoplasms, Plasma Cell; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Neoplasms; Synovial Sarcoma",United States
MATCH Treatment Subprotocol Z1I: Phase II Study of AZD1775 in Patients With Tumors Containing BRCA1 and BRCA2 Mutations,II,Closed,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Ovarian,BRCA; HER2 negative; Second line; Stage IV,"Breast Neoplasms; Lymphoma; Multiple Myeloma; Neoplasms; Neoplasms, Plasma Cell; Ovarian Cancer; Ovarian Neoplasms",United States
"A Randomized, Multicenter, Open-Label, Two-Arm, Phase II, Neoadjuvant Study Evaluating the Efficacy, Safety, and Pharmacokinetics of GDC-9545 Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer",II,Completed,Roche {F. Hoffmann-La Roche},Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,"Australia; Brazil; China; Germany; Hungary; Poland; Russia; South Korea; Spain; Taiwan, China; Ukraine; United States"
"A Phase II Trial of Surgery and Stereotactic Radiosurgery With Neoadjuvant Nivolumab and Ipilimumab in Patients With Surgically-resectable, Solid Tumor Brain Metastases",II,Terminated,"Bristol-Myers Squibb
Duke University Medical Center","Oncology: Bladder; Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Ovarian; Oncology: Renal",(N/A); Adenocarcinoma; CNS mets; HER2 negative; Large Cell; Neoadjuvant; PD-L1 Positive; Squamous Cell; Triple receptor negative,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Kidney Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms, Second Primary; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"An Open-label, Multicenter Study Evaluating the Safety of Lasofoxifene in Combination With Abemaciclib for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer and Have an ESR1 Mutation ( ELAINEII )",II,Closed,Sermonix Pharmaceuticals,Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
A Single Arm Phase II Trial of Atezolizumab With Sacituzumab Govitecan to Prevent Recurrence in Triple Negative Breast Cancer (ASPRIA),II,Closed,"(Other Cooperative Group)
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Roche/Genentech",Oncology: Breast,HER2 negative; PD-L1 Positive; Second line; Stage I; Stage II; Stage III; Triple receptor negative,"Breast Neoplasms; Neoplasm, Residual; Recurrence; Triple Negative Breast Neoplasms",United States
"A Randomized, Multicenter, Double-blind Phase III Study of Amcenestrant (SAR439859) Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease",III,Terminated,"Thermo Fisher Scientific/Patheon
Sanofi
Creapharm
Thermo Fisher Scientific/Patheon {Fisher Clinical Services}",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Stage III; Stage IV,Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Czech Republic; Denmark; Estonia; Finland; France; Georgia; Germany; Hungary; India; Italy; Japan; Mexico; Netherlands; Poland; Portugal; Puerto Rico; Romania; Russia; Singapore; South Africa; South Korea; Spain; Taiwan, China; Turkey; Ukraine; United Kingdom; United States"
Margetuximab or Trastuzumab (MARGOT): A Phase II Study Comparing Neoadjuvant Paclitaxel/Margetuximab/Pertuzumab to Paclitaxel/Trastuzumab/Pertuzumab in Patients With Stage II-III HER2-positive Breast Cancer,II,Open,"(Other Cooperative Group)
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
MacroGenics",Oncology: Breast,Adjuvant; HER2 positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
Roll Over Study for Patients Who Have Completed a Previous Oncology Study With Olaparib and Are Judged by the Investigator to Clinically Benefit From Continued Treatment,III,Open,AstraZeneca,Oncology: Breast; Oncology: Endometrial; Oncology: Ovarian,BRCA; HER2 negative; Line of therapy N/A; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Unspecified","Belgium; Bulgaria; Canada; Czech Republic; Denmark; Finland; France; Germany; Hungary; Israel; Italy; Netherlands; Norway; Poland; Portugal; Russia; Slovenia; South Korea; Spain; Sweden; Taiwan, China; Turkey; United Kingdom; United States"
A Feasibility Study of De-escalation of Chemotherapy in Patients With Early-Stage HER2 Positive Breast Cancer,II,Planned,University of Rochester,Oncology: Breast,Adjuvant; HER2 positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
Saci-IO HR+: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in Hormone Receptor-positive (HR+) / HER2- Metastatic Breast Cancer (MBC),II,Open,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Gilead Sciences/Immunomedics
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; PD-1 Naive; PD-L1 Naive; PD-L1 Positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
Saci-IO TNBC: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-negative Metastatic Triple Negative Breast Cancer (TNBC),II,Open,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Gilead Sciences/Immunomedics
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,First line; HER2 negative; PD-1 Naive; PD-L1 Naive; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"Coala-T-CBD Study: A Study of the Effect of Hemp-CBD on the Severity and Duration of Chemotherapy-Induced Peripheral Neuropathy in Patients Receiving Neurotoxic Chemotherapy for Non-Metastatic Breast, Uterine, Pancreatic, and Colorectal Cancer and All Stages of Ovarian Cancer",III,Closed,"(Other Hospital/Academic/Medical Center)
Ananda Hemp",CNS: Pain (neuropathic); Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Ovarian; Oncology: Pancreas; Oncology: Supportive Care,Adjuvant; Cancers-related; Neoadjuvant; Neurotoxicity; Second line; Stage II; Stage III,Breast Neoplasms; Cancer pain; Cancer Pain; Colorectal Neoplasms; Endometrial Neoplasms; Neuralgia; Ovarian Cancer; Ovarian Neoplasms; Palliative Care; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Uterine Neoplasms,United States
"An Expanded Access, Single-Arm, Multicenter Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic",III,Completed,Roche/Genentech {Genentech},Oncology: Breast,HER2 positive; Maintenance/Consolidation; Second line; Stage 0; Stage I; Stage II; Stage IV,Breast Neoplasms; COVID-19,United States
CRESTONE: A Phase II Study of Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors,II,Closed,Elevation Oncology,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Fourth line or greater; Maintenance/Consolidation; Second line; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Gallbladder Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasms; Neoplasms, Unknown Primary; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Neoplasms; Wilms Tumor",Australia; Canada; South Korea; United States
Induction Immunotherapy to Promote Immunologic Priming and Enhanced Response to Neoadjuvant Pembrolizumab + Chemotherapy in Triple Negative Breast Cancer (TNBC),II,Closed,"Providence Cancer Center at Providence Portland Medical Center
Merck & Co./Merck Sharp & Dohme (MSD)
Eterna Therapeutics {Brooklyn ImmunoTherapeutics {IRX Therapeutics}}",Oncology: Breast,HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Genomic/Molecular Profiling of Residual Disease After Neoadjuvant Chemotherapy in Hispanic/ Latino Women With Triple-negative Breast Cancer,II,Open,Texas Tech University Health Sciences Center,Oncology: Breast,HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Evaluation of the Effects of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer,II,Closed,Duke University Medical Center,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Phase IIa Study of Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab in Patients With Asymptomatic Brain Metastasis From Triple Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC),II,Open,"Roswell Park Cancer Institute
US Department of Defense",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; HER2 negative; HER2 positive; Maintenance/Consolidation; Stage IV; Triple receptor negative,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis; Neoplasms; Triple Negative Breast Neoplasms,United States
"A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma",II,Closed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Liver; Oncology: Skin, Basal Cell Carcinoma; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Cancer",(N/A); Adjuvant; Fourth line or greater; Locally advanced; Metastatic; PD-1 Naive; PD-L1 Naive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Basal Cell; Fibrosarcoma; Hemangiosarcoma; Leiomyosarcoma; Liposarcoma; Liver Neoplasms; Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",Guam; United States
An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and Pertuzumab in Early Stage HER2-Negative Breast Cancer Patients Selected With a Test Measuring Live Cell HER2 Signaling Transduction (FACT 1),II,Open,"National Surgical Adjuvant Breast and Bowel Project (NSABP)
Roche/Genentech
Celcuity",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage 0; Stage I; Stage II,Breast Neoplasms,United States
A Phase II Study of Concurrent WOKVAC Vaccination With Neoadjuvant Chemotherapy and HER2-Targeted Monoclonal Antibody Therapy,II,Open,"National Institutes of Health/National Cancer Institute
University of Washington
US Department of Defense",Oncology: Breast,HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
A Phase II Open Label Trial of Neo-Adjuvant Abemaciclib With Fulvestrant in Patients Who Develop Localized Recurrence While on Adjuvant Endocrine Therapy With Molecular Evidence of Endocrine Resistance,II,Terminated,"Eli Lilly
University of California Medical Center, Irvine",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
"A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer Following Recurrence or Progression On or After Treatment With an Aromatase Inhibitor",III,Completed,AstraZeneca,Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,"Argentina; Australia; Belgium; Canada; China; France; Germany; Hungary; Israel; Italy; Japan; Peru; Poland; Russia; South Korea; Spain; Taiwan, China; United Kingdom; United States"
A Phase IIA Trial Assessing the Tolerability of Abemaciclib in Combination With Endocrine Therapy in Patients Age 70 and Older With Hormone Receptor Positive Metastatic Breast Cancer Who Have Progressed on or After Prior CDK 4/6 Inhibition,II,Open,"National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms; Carcinoma,United States
"A Randomized, Double-Blind, International Multi-Centre, Phase III Clinical Study to Evaluate Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)",III,Temporarily Closed,Shanghai Henlius Biotech/Henlix Biotech,Oncology: Breast,Adjuvant; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Brazil; China; Hungary; Mexico; Russia; Spain; Turkey; Ukraine; United States
Pharmacodynamic Study of Estrogen Suppression Threshold-Directed Therapy (ESTDT) of Anastrozole as Adjuvant Therapy for Early Stage Breast Cancer,II,Completed,"National Institutes of Health/National Cancer Institute
Mayo Clinic",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Second line; Stage I; Stage II; Stage III,Breast Neoplasms; Carcinoma,United States
A Phase II Single Arm Trial Evaluating the Safety and Efficacy of Anhydrous Enol-Oxaloacetate on Improving Cognitive Complaints in Breast Cancer Survivors,II,Open,"Jonsson Comprehensive Cancer Center, UCLA
Breast Cancer Research Foundation
MetVital",Oncology: Breast; Oncology: Supportive Care,Neurotoxicity; Second line; Stage 0; Stage I; Stage II; Stage III,Breast Carcinoma In Situ; Breast Neoplasms; Palliative Care,United States
A Study on Marrow-Infiltrating Lymphocytes (MILs) in Patients with Breast Cancer and Solid Tumors,II,Completed,"Earle A. Chiles Research Institute - EACRI
(Other Hospital/Academic/Medical Center)
WindMIL Therapeutics","Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Prostate",(N/A); Line of therapy N/A; Squamous Cell,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Glioblastoma; Head and Neck Neoplasms; Prostatic Neoplasms",United States
Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors,II,Completed,CytoDyn,"Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Testicular; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Glioblastoma; Head and Neck Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Testicular Cancer; Testicular Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
Pre-Operative Window of Adjuvant Endocrine Therapy to Inform Radiation Therapy Decisions In Older Women With Early-Stage Breast Cancer,II,Open,University of Virginia,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I,Breast Neoplasms,United States
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response,II,Open,"National Institutes of Health/National Cancer Institute
ECOG-ACRIN Cancer Research Group",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,Puerto Rico; United States
INTERACT- Integrated Evaluation of Resistance and Actionability Using Circulating Tumor DNA in HR Positive Metastatic Breast Cancers,II,Open,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Stage IV,Breast Neoplasms,United States
Phase II Trial of Rifaximin in Patients With Early Stage HER2 Positive Breast Cancer With Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy,II,Closed,"National Institutes of Health/National Cancer Institute
Mayo Clinic
Bausch Health Companies/Salix",Oncology: Breast,HER2 positive; Line of therapy N/A; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Factors associated with decreased relative dose intensity in older adults with early-stage breast cancer receiving chemotherapy,IV,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
Phase II Study of PD-1 Inhibition With Cemiplimab in Locally Advanced Hormone Receptor (HR) Positive HER2 Negative or Triple-Negative Breast Cancer Patients Undergoing Standard Neoadjuvant Chemotherapy,II,Open,Medical College of Wisconsin Cancer Center,Oncology: Breast,Estrogen receptor positive; HER2 negative; Line of therapy N/A; PD-L1 Positive; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Peripheral T cell clonality and exhaustion as novel biomarkers for anti-PD-1 (pembrolizumab) maintenance therapy in patients with metastatic inflammatory breast cancer (mIBC) and non-IBC triple negative breast cancer (mTNBC),II,Completed,"MD Anderson Cancer Center, University of Texas",Oncology: Breast,HER2 negative; Maintenance/Consolidation; Stage IV; Triple receptor negative,Breast Neoplasms,United States
The incidence of febrile neutropenia (FN) for chemotherapy patients receiving pegfilgrastim by an on-body injector (pegfilgrastim OBI) versus other FN prophylaxis strategies,IV,Open,(Other Hospital/Academic/Medical Center),"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Neuroendocrine; Oncology: Prostate; Oncology: Supportive Care",Adjuvant; Aggressive; First line; Indolent; Neoadjuvant; Neutropenia; Pulmonary; Stage III; Stage IV; Untreated,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neuroendocrine Tumors; Neutropenia; Palliative Care; Prostatic Neoplasms; Small Cell Lung Carcinoma",United States
Characterization of the tumor immune microenvironment (TME) in early stage HR-positive HER2-positive breast cancer,IV,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Neoadjuvant; Progesterone receptor positive,Breast Neoplasms,United States
Prospective genomic and PD-L1 profiling of patients with residual triple negative breast cancer after neoadjuvant chemotherapy,IV,Closed,(Other Hospital/Academic/Medical Center),Oncology: Breast,HER2 negative; Neoadjuvant; PD-L1 Positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
A Phase II Study of Response-guided Neoadjuvant Sacituzumab Govitecan (IMMU-132) in Patients With Localized Triple-Negative Breast Cancer (NeoSTAR),II,Open,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Gilead Sciences/Immunomedics
Massachusetts General Hospital",Oncology: Breast,Adjuvant; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)",II,Closed,"Seagen {Seattle Genetics}
Astellas Pharma","Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell",Adenocarcinoma; ALK; BRAF; EGFR; Estrogen receptor positive; HER2 negative; HER2 positive; Large Cell; PD-1 Positive; PD-L1 Positive; Progesterone receptor positive; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Neoplasms; Stomach Carcinoma; Stomach Neoplasms",Canada; Japan; Lebanon; United States
"A Multicenter, Open-label, Treatment Protocol of Tucatinib in Combination With Capecitabine and Trastuzumab in Patients With Previously Treated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma",III,Completed,Seagen {Seattle Genetics},Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer,II,Terminated,Weill Medical College of Cornell University,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage IV,Breast Neoplasms,United States
Impact of Chemotherapy (Chemo) on Peripheral T-cell Diversity And Implications for Subsequent Immunotherapy Response in Breast Cancer.,II,Completed,"Earle A. Chiles Research Institute - EACRI
Providence Cancer Center at Providence Portland Medical Center
Adaptive Biotechnologies",Oncology: Breast,(N/A); Second line,Breast Neoplasms,United States
"A Phase-II, Two-Cohort Trial of Neoadjuvant Nab-Paclitaxel and Alpelisib in Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations",II,Closed,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast,HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Carcinoma; Triple Negative Breast Neoplasms,United States
"SERENA-2: A Randomised, Open-Label, Parallel-Group, Multicentre Phase II Study Comparing the Efficacy and Safety of Oral AZD9833 Versus Fulvestrant in Women With Advanced ER-Positive HER2-Negative Breast Cancer",II,Completed,AstraZeneca,Oncology: Breast,BRCA; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,Belgium; Canada; France; Georgia; Germany; Hungary; Israel; Italy; Mexico; Peru; Poland; Portugal; Russia; South Korea; Spain; Ukraine; United Kingdom; United States
"EPIK-B2: A Two Part, Phase III, Multicenter, Randomized (1:1), Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation",III,Terminated,Novartis,Oncology: Breast,HER2 positive; Maintenance/Consolidation; Second line; Stage III; Stage IV,Breast Neoplasms,"Argentina; Austria; Belgium; Brazil; Bulgaria; Canada; China; Colombia; Czech Republic; Finland; France; Germany; Greece; Hungary; Israel; Italy; Lebanon; Malaysia; Netherlands; Poland; Romania; Russia; Singapore; Slovakia; Spain; Sweden; Taiwan, China; Thailand; Turkey; United Kingdom; United States"
Phase II Trial to Evaluate Immune-Related Biomarkers for Pathological Response in Stage II-III HER2-Positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Subsequent Randomization to Multi-Epitope HER2 Vaccine vs. Placebo in Patients With Residual Disease Post-Neoadjuvant Chemotherapy,II,Open,"National Institutes of Health/National Cancer Institute
Mayo Clinic
Academic and Community Cancer Research United",Oncology: Breast,HER2 positive; Maintenance/Consolidation; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab,II,Completed,National Institutes of Health,Oncology: Breast,Line of therapy N/A; Stage IV,Breast Neoplasms; Unspecified,United States
Epigenetic Priming for Immune Therapy in ER-Positive Breast Cancer in Biomarker Select Population,II,Terminated,"University of California, San Francisco
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,Estrogen receptor positive; Line of therapy N/A; Stage IV,Breast Neoplasms,United States
"Phase II Window Study of Two Dose Levels of Amcenestrant [SAR439859] (SERD) Versus Letrozole in Newly Diagnosed Pre-operative Post-menopausal Patients With ER Positive, HER2 Negative Primary Breast Cancer",II,Terminated,Sanofi {Sanofi-Aventis},Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,Belgium; France; Italy; Japan; Puerto Rico; Russia; South Korea; Spain; United States
"A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib  Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer",II/III,Open,Roche {F. Hoffmann-La Roche},Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,"Australia; Austria; Belgium; Canada; China; Denmark; France; Georgia; Germany; Greece; Hong Kong, S.A.R., China; Hungary; Italy; Malaysia; New Zealand; Poland; Portugal; Russia; Singapore; South Korea; Spain; Taiwan, China; Thailand; Turkey; Ukraine; United Kingdom; United States"
A Phase II Study of Futibatinib in Patients With Specific FGFR Aberrations,II,Closed,Otsuka Holdings/Taiho Pharmaceutical,"Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome; Oncology: Myeloproliferative Neoplasms; Oncology: Unspecified Solid Tumor",(N/A); Aggressive; Classical; FGFR; Indolent; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV; Third line,"Acute Myelocytic Leukemia; Breast Neoplasms; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Esophageal Cancer; Esophageal Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Multiple Myeloma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasms; Neoplasms, Unknown Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Stomach Carcinoma; Stomach Neoplasms","Belgium; Denmark; France; Germany; Hong Kong, S.A.R., China; Italy; Japan; Netherlands; Portugal; Singapore; South Korea; Spain; Sweden; Turkey; United Kingdom; United States"
Self-Reported Pain and Nadir White Blood Cell/Absolute Neutrophil Count in Women 45 and Under Compared to Older Women Receiving Pegfilgrastim (or Biosimilar Substitution) While Undergoing Chemotherapy for Non-Metastatic Breast Cancer,III,Open,"(Other Cooperative Group)
(Other Hospital/Academic/Medical Center)
Atrium Health",Oncology: Breast; Oncology: Supportive Care,Adjuvant; Neoadjuvant; Neutropenia; Other; Stage I; Stage II; Stage III,Breast Neoplasms; Neutropenia; Palliative Care; Unspecified,United States
A Phase II Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies,II,Terminated,Spectrum Pharmaceuticals,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",EGFR; Estrogen receptor positive; HER2 negative; HER2 positive; MSI-H/dMMR; PD-1 Refractory; PD-L1 Refractory; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Glioblastoma; Neoplasms, Unknown Primary",United States
"A Phase II Basket Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPP), Administered in Combination With Pembrolizumab in Patients With Advanced Solid Cancers",II,Closed,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute","Oncology: Breast; Oncology: CNS, Astrocytoma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Melanoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Skin, Basal Cell Carcinoma; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Grade 3; HER2 negative; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Astrocytoma; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Endometrioid; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Neoplasms, Basal Cell; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
"Phase III Postneoadjuvant Study Evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in Primary HER2-negative Breast Cancer Patients With High Relapse Risk After Standard Neoadjuvant Treatment - SASCIA",III,Open,"Gilead Sciences/Immunomedics
Cancer Trials Ireland {Irish Clinical Oncology Research Group}
Austrian Breast & Colorectal Cancer Study Group
Spanish Breast Cancer Research Group
German Breast Group",Oncology: Breast,Adjuvant; BRCA; Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Australia; Austria; Belgium; France; Germany; Ireland; Italy; South Korea; Spain; Switzerland; United States
Tumour-infiltrating lymphocytes and BRCA-like status in stage III breast cancer patients treated with intensified carboplatin-based chemotherapy,IV,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Adjuvant; HER2 negative; Stage III; Triple receptor negative,Breast Neoplasms,Austria; Belgium; Netherlands; United States
Longitudinal Changes in Cell-free Dna (CfDNA) Methylation Levels Identify Early Non-responders to Treatment in Advanced Solid Tumours,II,Completed,(Other Hospital/Academic/Medical Center),"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",Line of therapy N/A; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms, Unknown Primary",United States
"A Phase III, Double-blind, Placebo-controlled, Randomized Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer.",III,Completed,"Roche/Chugai Pharmaceutical
Roche {F. Hoffmann-La Roche}",Oncology: Breast,First line; HER2 negative; PD-L1 Positive; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,"Andorra; Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; China; Colombia; Costa Rica; Czech Republic; Denmark; Finland; France; Germany; Greece; Hong Kong, S.A.R., China; Hungary; India; Ireland; Israel; Italy; Japan; Mexico; New Zealand; Peru; Poland; Portugal; Romania; Russia; Serbia; Singapore; South Africa; South Korea; Spain; Switzerland; Taiwan, China; Thailand; Turkey; Ukraine; United Kingdom; United States"
The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer,II,Completed,"Johns Hopkins University
Agendia",Oncology: Breast,Estrogen receptor positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"An Open-label, Randomized, Phase II/III Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC) (KEYLYNK-009).",II/III,Closed,Merck & Co./Merck Sharp & Dohme (MSD),Oncology: Breast,First line; HER2 negative; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,"Canada; Chile; Colombia; France; Germany; Hungary; Ireland; Japan; Poland; South Korea; Spain; Taiwan, China; Ukraine; United Kingdom; United States"
"A Phase II Study of Sitravatinib in Metastatic, Pre-treated, Triple Negative Breast Cancer",II,Terminated,"Mirati Therapeutics {MethylGene}
(Other Hospital/Academic/Medical Center)",Oncology: Breast,HER2 negative; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase II Study of Olaparib in Combination With Pembrolizumab in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer",II,Closed,Merck & Co./Merck Sharp & Dohme (MSD),"Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate; Oncology: Unspecified Solid Tumor",BRCA; PD-1 Naive; PD-L1 Naive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Unspecified; Uterine Cervical Neoplasms",Argentina; Australia; Canada; Colombia; France; Germany; Guatemala; Israel; Italy; Japan; Latvia; Mexico; Peru; Poland; Puerto Rico; Romania; South Africa; South Korea; Spain; Sweden; Turkey; Ukraine; United States
"A Phase II Safety Study to Assess the Combination of Apristor and Fulvestrant in Patients With Advanced Breast Cancer Who Have ER+,PR+, and HER2- tumors and Received Prior Antiestrogen (aromatase inhibitor) Plus CDK4/6 Inhibitor Treatment.",II,Closed,"Medical College of Wisconsin Cancer Center
Context Therapeutics",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
Alleviation by NIAGEN of Persistent Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors,II,Open,"(Other Academic Cancer Center)
University of Iowa","CNS: Pain (neuropathic); Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Supportive Care",(N/A); Cancers-related; First line; Neurotoxicity; Pulmonary; Second line; Untreated,"Breast Neoplasms; Cancer pain; Cancer Pain; Carcinoma, Endometrioid; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Neuralgia; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Palliative Care; Peripheral Nervous System Diseases; Small Cell Lung Carcinoma",United States
A Phase II Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Pretreated Metastatic Triple Negative Breast Cancer,II,Closed,"Yale University
Iovance Biotherapeutics {Lion Biotechnologies}",Oncology: Breast,Fourth line or greater; HER2 negative; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase III, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)",III,Closed,"Thermo Fisher Scientific/Patheon
G1 Therapeutics
Simcere Pharmaceutical Group {Jiangsu Simcere Pharmaceutical Co.}",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Positive; PD-L1 Refractory; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Australia; Bulgaria; China; France; Georgia; Moldova Republic; Poland; Russia; Serbia; Spain; Turkey; Ukraine; United States
"A Randomized, Multicenter, Double-blind, Placebo-controlled Phase III Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer",III,Closed,Bristol-Myers Squibb,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant; PD-L1 Positive; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Colombia; Czech Republic; Denmark; Finland; France; Germany; Hong Kong, S.A.R., China; Ireland; Italy; Mexico; Netherlands; New Zealand; Poland; Portugal; Puerto Rico; Romania; Russia; Singapore; South Korea; Spain; Switzerland; Taiwan, China; Turkey; United Kingdom; United States"
Phase II Study of Docetaxel Chemotherapy With Pembrolizumab and Interleukin-12 Gene Therapy in Patients With Anthracycline- Refractory Triple Negative Breast Cancer (INTEGRAL),II,Open,"(Other Hospital/Academic/Medical Center)
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,HER2 negative; Neoadjuvant; Stage 0; Stage I; Stage II; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients With Bone Metastatic Breast Cancer,II,Open,"National Institutes of Health/National Cancer Institute
University Health Network, Toronto/Princess Margaret Cancer Centre {Princess Margaret Hospital}",Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma; Neoplasm Metastasis; Neoplasms,United States
Overcoming PARP Inhibitor Resistance in BRCA Germline Mutation Positive Advanced Breast Cancer,II,Open,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast,BRCA; Estrogen receptor positive; HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma,United States
BRE-01: Phase II Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel Followed by Doxorubicin and Cyclophosphamide in Triple Negative Breast Cancer,II,Closed,University of Illinois at Chicago Health Sciences Center,Oncology: Breast,HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Phase II Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations.,II,Closed,Johnson & Johnson/Janssen R&D,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: CNS, Astrocytoma; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Small Intestine; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Estrogen receptor positive; FGFR; Fourth line or greater; Grade 1; Grade 2; Grade 3; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,"Astrocytoma; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Glioblastoma; Intestinal Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms","Argentina; Australia; Belgium; Brazil; China; Denmark; France; Germany; Italy; Japan; Poland; South Korea; Spain; Sweden; Taiwan, China; United Kingdom; United States"
"Randomized, Non-comparative Neoadjuvant Phase II Study in Patients With ER+/HER2- Breast Cancer > or = 2 cm With Safety Run-in, Assessing Nivolumab + Palbociclib + Anastrozole",II,Completed,Bristol-Myers Squibb,Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage II; Stage III; Stage IV,Breast Neoplasms,Argentina; Australia; Belgium; Canada; France; Germany; Puerto Rico; Spain; United States
Randomized Clinical Trial of RANKL Inhibition With Denosumab on Mammographic Density in Premenopausal Women With Dense Breasts (TRIDENT).,II,Open,"Washington University School of Medicine
National Institutes of Health",Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms; Unspecified,United States
A Phase IB/III Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer,III,Closed,Roche {F. Hoffmann-La Roche},Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,Australia; Brazil; Canada; Japan; South Korea; Spain; United Kingdom; United States
"An Open Label Randomized Phase II Trial of Amcenestrant (SAR439859), Versus Endocrine Monotherapy as Per Physician's Choice in Patients With Estrogen Receptor-positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer With Prior Exposure to Hormonal Therapies",II,Completed,Sanofi {Sanofi-Aventis},Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,"Argentina; Australia; Belgium; Brazil; Canada; China; Czech Republic; France; Greece; Israel; Italy; Japan; Latvia; Mexico; Poland; Puerto Rico; Russia; South Korea; Spain; Sweden; Taiwan, China; Turkey; Ukraine; United States"
"COX Inhibition and Biomarkers of Response During Neoadjuvant Chemoendocrine Therapy for Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Stage I-III Breast Cancer",II,Terminated,University of Virginia,Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Pilot Clinical Trial of Treatment With LY3023414 and Prexasertib to Inhibit Homologous Recombination (HR) in Patients With Chemotherapy-Pretreated Metastatic Triple Negative Breast Cancer (Amendment 1),II,Closed,"Eli Lilly
Baylor Research Institute",Oncology: Breast,HER2 negative; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases",IV,Terminated,Eli Lilly,Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,Puerto Rico; United States
A Phase II Study of TAS-120 in Metastatic Breast Cancers Harboring Fibroblast Growth Factor Receptor (FGFR) Amplifications,II,Closed,Otsuka Holdings/Taiho Pharmaceutical,Oncology: Breast,Estrogen receptor positive; FGFR; Fourth line or greater; HER2 negative; PD-1 Refractory; PD-L1 Refractory; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,Canada; France; Italy; Portugal; Spain; United Kingdom; United States
Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neuropathy in African American Women,II,Closed,"National Institutes of Health/National Cancer Institute
ECOG-ACRIN Cancer Research Group",Oncology: Breast; Oncology: Supportive Care,Adjuvant; HER2 negative; Neoadjuvant; Neurotoxicity; Stage I; Stage II; Stage III,Breast Neoplasms; Palliative Care; Peripheral Nervous System Diseases,United States
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study,II,Completed,"(Other Cooperative Group)
Pfizer
Oncolytics Biotech",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Pilot Study of PD-L1 and IRF-1 expression on CTC (Circulating tumor cell),II,Open,"Fred Hutchinson Cancer Research Center
University of Washington
RareCyte","Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",Line of therapy N/A; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Neoplasms, Unknown Primary",United States
"Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial.",II,Open,"Pfizer
Massachusetts General Hospital",Oncology: Breast,BRCA; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"A Single-Arm, Global, Phase IV Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors",IV,Terminated,Eli Lilly,Oncology: Breast,Estrogen receptor positive; HER2 negative; Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms,"Argentina; Austria; Belgium; Brazil; Germany; Italy; Puerto Rico; Taiwan, China; United States"
A Single Center Pilot Study Evaluating the Use of Mathematical Modeling to Predict Response to Neoadjuvant Anthracycline / Taxane Based Chemotherapy in Women With HER2 Negative Stage II and III Breast Cancer,II,Completed,(Other Cooperative Group),Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
"A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple negative Breast Cancer.",III,Closed,AstraZeneca,Oncology: Breast,First line; HER2 negative; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,"Argentina; Brazil; Canada; China; Colombia; Czech Republic; France; Greece; Hungary; India; Japan; Malaysia; Mexico; Peru; Philippines; Poland; Portugal; Russia; Saudi Arabia; Slovakia; South Africa; South Korea; Spain; Sweden; Taiwan, China; Thailand; Turkey; United Kingdom; United States; Vietnam"
"Window Trial of Abemaciclib for Surgically Resectable, Chemotherapy-Resistant, Triple Negative Breast Cancer (a BEAUTY Study)",II,Open,"National Institutes of Health/National Cancer Institute
Mayo Clinic",Oncology: Breast,HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,"Breast Carcinoma In Situ; Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Fibrocystic Breast Disease; Triple Negative Breast Neoplasms",United States
A Phase II Study of Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Who Have Had Prior Treatment With a PD-1 Inhibitor,II,Closed,Roche/Genentech,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Renal; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Fourth line or greater; HER2 negative; Large Cell; MSI-H/dMMR; PD-1 Refractory; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Kidney Neoplasms; Melanoma; Neoplasms, Unknown Primary; Renal Cancer; Small Cell Lung Carcinoma; Wilms Tumor",United States
"Randomized, Double-blind, Phase III Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)",III,Completed,"Merck & Co.
Seagen {Seattle Genetics}
CordenPharma
Almac Group/Almac Clinical Services",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; HER2 positive; Second line; Stage III; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,"Australia; Austria; Belgium; Canada; China; Denmark; France; Germany; Israel; Italy; Japan; Netherlands; Singapore; South Korea; Spain; Sweden; Switzerland; Taiwan, China; United Kingdom; United States"
"Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study.",II,Open,"(Other Cooperative Group)
Pfizer
Johns Hopkins University
Pfizer {Array BioPharma}
Breast Cancer Research Foundation",Oncology: Breast,First line; HER2 negative; PD-L1 Positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Carcinoma; Triple Negative Breast Neoplasms,United States
"A Phase II, Multi-center, Open-label, Single Arm Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer",II,Closed,Ayala Pharmaceuticals,Oncology: Breast,Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Belgium; France; Israel; Netherlands; Spain; United Kingdom; United States
Genomically-Guided Treatment Trial in Brain Metastases,II,Open,"National Institutes of Health/National Cancer Institute
Kazia Therapeutics {Novogen}
Roche/Genentech
Alliance for Clinical Trials in Oncology","Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Unspecified Solid Tumor",BRAF; CNS mets; Estrogen receptor positive; HER2 negative; HER2 positive; PD-1 Refractory; PD-L1 Refractory; Progesterone receptor positive; Second line; Stage IV; Triple receptor negative,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Glioblastoma; Melanoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Unknown Primary",United States
Therapeutic Targeting of ER Beta in Triple Negative Breast Cancer,II,Open,"National Institutes of Health/National Cancer Institute
Mayo Clinic",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Carcinoma,United States
"A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With HMGA2-expressing Triple Negative Breast Cancer",II,Terminated,Merck KGaA/EMD Serono {EMD Pharmaceuticals},Oncology: Breast,(N/A); HER2 negative; Second line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Belgium; France; Italy; Russia; Spain; United States
A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients,III,Closed,"Southwest Oncology Group
National Institutes of Health/National Cancer Institute","Oncology: Breast; Oncology: Fallopian Tube; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Supportive Care",Line of therapy N/A; Neurotoxicity; Stage I; Stage II; Stage III,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Lung Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Palliative Care; Peripheral Nervous System Diseases; Peritoneal Neoplasms",Chile; United States
"A Phase III Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer",III,Open,Amgen,"Oncology: Breast; Oncology: Fallopian Tube; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer; Oncology: Ovarian; Oncology: Supportive Care; Oncology: Unspecified Cancer",Fourth line or greater; PD-1 Refractory; PD-L1 Refractory; Peritoneal mets; Second line; Stage I; Stage II; Stage III; Stage IV; Third line; Thrombocytopenia,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Palliative Care; Peritoneal Neoplasms; Thrombocytopenia",Argentina; Austria; Brazil; Bulgaria; Canada; Chile; Colombia; Greece; Hungary; Mexico; Peru; Poland; Portugal; Romania; Russia; Spain; Turkey; Ukraine; United States
A Phase II Open Label Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients Receiving Chemotherapy Treatment for Non-Myeloid Malignancies,II,Completed,"AstraZeneca
FibroGen","Metabolic/Endocrinology: Anemia; Oncology: Anal; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Small Intestine; Oncology: Supportive Care",(N/A); Anemia; Cancer-related; Line of therapy N/A,"Anemia; Anus Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Intestinal Neoplasms; Ovarian Neoplasms; Palliative Care; Pancreatic Neoplasms; Stomach Neoplasms",United States
Evaluation of the Effects of Endocrine Therapies on Immune Cell Repertoire and Function in Early Stage Estrogen Receptor Positive Breast Cancer Patients,II,Closed,"Duke University Medical Center
US Department of Defense",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Stage I; Stage II; Stage III,Breast Neoplasms,United States
DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination With Chemotherapy in Patients With Advanced Solid Tumors,II,Open,National Institutes of Health/National Cancer Institute,Oncology: Anal; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor,Fourth line or greater; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line,"Anus Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms",United States
"A Multicenter, Phase II Study of Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Metastatic TNBC and Tesetaxel Monotherapy in Elderly Patients With HER2 Negative MBC",II,Terminated,Odonate Therapeutics,Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; CNS mets; Estrogen receptor positive; First line; HER2 negative; PD-L1 Positive; Progesterone receptor positive; Stage III; Stage IV; Triple receptor negative,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,"Australia; Belgium; Canada; France; Germany; Poland; Russia; Singapore; South Korea; Spain; Taiwan, China; Ukraine; United States"
"A Phase III, Randomized, Open-Label Study Investigating the Addition of Durvalumab to an Anthracycline-Taxane based Chemotherapy in Early-Stage Triple-Negative Breast Cancer",III,Completed,"AstraZeneca
German Breast Group",Oncology: Breast,Adjuvant; HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,Australia; Brazil; Canada; China; France; Germany; India; Japan; South Africa; South Korea; Spain; United States
Phase III Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in Subjects With Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) Who Have Failed at Least Two Prior Chemotherapy Regimens,III,Completed,Gilead Sciences/Immunomedics,Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Third line,Breast Neoplasms,"Belgium; Canada; France; Germany; Hong Kong, S.A.R., China; Italy; Netherlands; South Korea; Spain; United Kingdom; United States"
"A Phase II, Multi-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of IPI-549 Administered in Combination With Front-line Treatment Regimens in Patients With Locally Advanced and/or Metastatic Triple-Negative Breast Cancer or Renal Cell Carcinoma",II,Closed,"Infinity Pharmaceuticals
Roche/Genentech",Oncology: Breast; Oncology: Renal,First line; HER2 negative; PD-1 Naive; PD-L1 Naive; PD-L1 Positive; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Renal Cell; Kidney Neoplasms; Renal Cancer; Triple Negative Breast Neoplasms; Wilms Tumor",United States
"An Expanded Access Programme of Oral Endoxifen In Pre-menopausal, Estrogen-Receptor Positive (ER+) Breast cancer",II,Closed,Atossa Therapeutics {Atossa Genetics},Oncology: Breast,(N/A); Estrogen receptor positive; Neoadjuvant,Breast Neoplasms,United States
A Phase II Trial With Safety Run-in of Neoadjuvant Therapy With an Aromatase Inhibitor in Combination With Durvalumab (MEDI4736) in Postmenopausal Patients With Hormone-Receptor-Positive Breast Cancer,II,Terminated,"AstraZeneca
H. Lee Moffitt Cancer Center and Research Institute",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,United States
"Atorvastatin in Triple-Negative Breast Cancer (TNBC) Patients Who Did Not Achieve a Pathologic Complete Response (pCR) After Receiving Neoadjuvant Chemotherapy, a Multicenter Pilot Study",II,Closed,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast,First line; HER2 negative; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Carcinoma; Inflammatory Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Randomized Phase II Study Evaluating Pathologic Response Rates Following Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab (MEDI4736) +/- RAdiation Therapy (RT) in Triple Negative Breast Cancer (TNBC): The PANDoRA Study.",II,Terminated,"AstraZeneca
Cedars-Sinai Medical Center",Oncology: Breast,Adjuvant; HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"Multinational, Multicenter, Phase II Study of Tesetaxel Plus a Reduced Dose of Capecitabine in Patients With HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane",II,Terminated,Odonate Therapeutics,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,"Australia; Canada; South Korea; Spain; Taiwan, China; Ukraine; United States"
"A Pivotal Randomized, Blinded Two-arm Phase III Study to Evaluate Efficacy and Safety of Nelipepimut-S in Combination With Trastuzumab in Triple Negative Breast Cancer in the Adjuvant Setting After Standard Treatment",III,Terminated,SELLAS Life Sciences Group,Oncology: Breast,(N/A); Adjuvant; HER2 negative; Maintenance/Consolidation; Triple receptor negative,Breast Neoplasms,United States
"A Phase II Basket Study of the Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects With Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3",II,Terminated,"Debiopharm
(Other Hospital/Academic/Medical Center)
Caris Life Sciences","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",ALK; BRAF; EGFR; Estrogen receptor positive; FGFR; HER2 positive; PD-1 Refractory; PD-L1 Refractory; Progesterone receptor positive; Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Head and Neck Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Prostatic Neoplasms; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms","Australia; Austria; Brazil; Bulgaria; Canada; Croatia; Czech Republic; Denmark; Finland; France; Germany; Greece; Mexico; Netherlands; Norway; Philippines; Poland; Romania; Russia; Singapore; South Korea; Spain; Taiwan, China; Thailand; Turkey; Ukraine; United Kingdom; United States"
"A Phase II, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)",II,Terminated,Incyte Corporation,Oncology: Bladder; Oncology: Breast; Oncology: Unspecified Solid Tumor,FGFR; Second line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Urethral Neoplasms; Urinary Bladder Neoplasms",Denmark; France; Germany; Israel; Italy; Japan; South Korea; Spain; Switzerland; United Kingdom; United States
"A Phase II, Multicenter, Randomized, Open-label Study to Evaluate the Safety and Efficacy of 400 mg of Ribociclib in Combination With Non-steroidal Aromatase Inhibitors for the Treatment of Pre- and Postmenopausal Women With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease",II,Completed,Novartis,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,Argentina; Austria; Belgium; Brazil; Bulgaria; Canada; Colombia; Costa Rica; Czech Republic; Finland; France; Germany; Hungary; India; Jordan; Lithuania; Peru; Portugal; Russia; Saudi Arabia; South Africa; Sweden; Switzerland; Thailand; United States
Multicenter Phase II Trial of Durvalumab (MEDI4736) With Trastuzumab and Pertuzumab Combination in HER2-Enriched and HER2-Amplified Breast Cancer (DTP Trial),II,Open,"AstraZeneca
(Other Hospital/Academic/Medical Center)",Oncology: Breast,HER2 positive; Line of therapy N/A; Stage I; Stage II,Breast Neoplasms,United States
Phase II Trial Evaluating the Efficacy and Safety of Neoadjuvant Neratinib and Chemotherapy in Early Stage Triple-Negative Breast Cancer Patients Who Exhibit Enhanced HER2 Signaling by Live Cell HER2 Signaling Transduction Analysis (FACT-2),II,Open,"(Other Hospital/Academic/Medical Center)
Puma Biotechnology
Celcuity",Oncology: Breast,HER2 negative; HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
PROMISE-005: A Phase II Randomized Study Assessing the Efficacy of Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Breast or Lung Cancer,II,Open,Memorial Sloan-Kettering Cancer Center,"Oncology: Breast; Oncology: Lung, Non-Small Cell",ALK; EGFR; Estrogen receptor positive; First line; HER2 negative; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Triple Negative Breast Neoplasms",United States
A Phase II Study of Copanlisib (BAY 80-6946) in Combination With Fulvestrant in Patients With Metastatic Breast Cancer Progressing After Aromatase Inhibitor Plus CDK 4/6 Inhibitor,II,Terminated,National Institutes of Health/National Cancer Institute,Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage IV; Third line,Breast Neoplasms; Neoplasms,United States
Converting HR+ Breast Cancer Into an Individualized Vaccine,II,Open,"Weill Medical College of Cornell University
US Department of Defense
Celldex Therapeutics {AVANT Immunotherapeutics}
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Phase II, Open-Label, Study of Olaparib in Combination With Either Durvalumab (MEDI4736), Selumetinib or Capivasertib, or Ceralasertib Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer",II,Open,"AstraZeneca
Oregon Health and Science University",Oncology: Breast,HER2 negative; PD-1 Naive; PD-L1 Naive; PD-L1 Positive; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Multicenter, Open-label Phase II Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects With Selected Solid Tumors (LEAP-005)",II,Closed,"Eisai
Merck & Co./Merck Sharp & Dohme (MSD)","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Fallopian Tube; Oncology: Gallbladder; Oncology: Gastric; Oncology: Liver; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Unspecified Solid Tumor",Distal; Fourth line or greater; HER2 negative; Hilar; Intrahepatic; MSS/pMMR; PD-L1 Positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative; Unresectable,"Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Cholangiocarcinoma; Colorectal Neoplasms; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Glioblastoma; Liver Cancer; Liver Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms","Argentina; Australia; Canada; Chile; Colombia; France; Germany; Israel; Italy; Russia; South Korea; Spain; Switzerland; Taiwan, China; Thailand; United Kingdom; United States"
NIMBUS: A Phase II Study of Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer,II,Completed,"Bristol-Myers Squibb
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute",Oncology: Breast,Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; PD-1 Naive; PD-L1 Naive; Progesterone receptor positive; Second line; Stage IV; Third line,Breast Neoplasms,United States
A Phase III Randomized Pivotal Study of LiPlaCis in Advanced or Metastatic Breast Cancer,III,Planned,Allarity Therapeutics,Oncology: Breast,Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms,United States
A Single Arm Phase II Pilot Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma,II,Terminated,(Other Hospital/Academic/Medical Center),Oncology: Breast,Line of therapy N/A; Stage IV,Breast Neoplasms,United States
The Effect of Dispensed Cannabis on Taxane Induced Peripheral Neuropathy,II,Terminated,New York State Psychiatric Institute,CNS: Pain (neuropathic); Oncology: Breast; Oncology: Supportive Care,(N/A); Cancers-related; Line of therapy N/A; Neurotoxicity,Breast Neoplasms; Cancer pain; Cancer Pain; Neuralgia; Palliative Care; Peripheral Nervous System Diseases,United States
A Phase IIB Study of ZEN003694 in Combination With Talazoparib in Patients With Triple-Negative Breast Cancer,II,Open,"Pfizer
Zenith Epigenetics
Newsoara Biopharma Co.",Oncology: Breast,Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Belgium; China; Spain; United States
"An Open Label, Multicenter Extension Study In Patients Previously Enrolled In A Genentech And/Or  F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study",IV,Open,"Roche/Chugai Pharmaceutical
Roche {F. Hoffmann-La Roche}","Oncology: Bladder; Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Renal; Oncology: Unspecified Solid Tumor",(N/A); HER2 negative; Line of therapy N/A; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms, Unknown Primary; Renal Cancer; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor","Belgium; Brazil; Bulgaria; Canada; Chile; Czech Republic; Denmark; France; Germany; Greece; Guatemala; Hong Kong, S.A.R., China; Hungary; Israel; Italy; Japan; Latvia; Malaysia; Mexico; Netherlands; Norway; Poland; Portugal; Romania; Russia; Singapore; Slovakia; Slovenia; South Korea; Spain; Switzerland; Taiwan, China; Thailand; Turkey; Ukraine; United Kingdom; United States"
Phase II Trial of GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases,II,Open,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Kazia Therapeutics {Novogen}",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; HER2 positive; Neoadjuvant; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
Pre-Surgical Trial of Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer,II,Closed,"(Other Academic Cancer Center)
University of Texas Southwest Medical Center",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Neoadjuvant HER2-Targeted Therapy and Immunotherapy with Pembrolizumab (neoHIP),II,Open,"University of Texas
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
An Open-Label Extension Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib,II,Terminated,Spectrum Pharmaceuticals,"Oncology: Breast; Oncology: Lung, Non-Small Cell",(N/A); Line of therapy N/A,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Unspecified",Italy; Netherlands; United States
"A Phase II Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer",II,Open,"AstraZeneca
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast; Oncology: Unspecified Solid Tumor,BRCA; Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Neoplasms, Unknown Primary; Unspecified",Argentina; Australia; Canada; Colombia; Denmark; France; Guatemala; Ireland; Israel; Italy; Japan; Mexico; New Zealand; Peru; Romania; Russia; South Korea; Spain; Switzerland; Turkey; United Kingdom; United States
Phase II Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC),II,Completed,NYU Langone Health,Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Inflammatory Breast Neoplasms,United States
"A Phase III, Multicenter, Randomized, Open-label, Active Controlled Trial of DS-8201a, an Anti-HER2-antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice for HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects",III,Completed,"AstraZeneca
Daiichi Sankyo",Oncology: Breast,Estrogen receptor positive; FGFR; Progesterone receptor positive; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,"Austria; Belgium; Canada; China; France; Germany; Greece; Hungary; Israel; Italy; Japan; Portugal; Russia; South Korea; Spain; Sweden; Switzerland; Taiwan, China; United Kingdom; United States"
"A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early HER2-Positive Breast Cancer.",III,Completed,"Roche/Chugai Pharmaceutical
Roche {F. Hoffmann-La Roche}",Oncology: Breast,Adjuvant; HER2 positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,"Australia; Brazil; Canada; China; Czech Republic; Germany; Italy; Japan; Poland; Russia; South Korea; Spain; Taiwan, China; United States"
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer,IV,Completed,Roche/Genentech,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,United States
"A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (KEYNOTE-756)",III,Completed,Merck & Co./Merck Sharp & Dohme (MSD),Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage 0; Stage I; Stage II,Breast Neoplasms,"Australia; Belgium; Brazil; Canada; China; Colombia; Costa Rica; France; Germany; Hungary; Ireland; Israel; Japan; New Zealand; Poland; Portugal; Puerto Rico; Russia; South Korea; Spain; Taiwan, China; Ukraine; United Kingdom; United States"
"A Pilot Trial of Ifetroban, A Thromboxane A2 Receptor Antagonist, in Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence",II,Open,"Vanderbilt-Ingram Cancer Center
Cumberland Pharmaceuticals","Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Pancreas",HER2 negative; Limited; Pulmonary; Second line; Stage I; Stage II; Stage III; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Esophageal Cancer; Esophageal Neoplasms; Neoplasms; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Recurrence; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms",United States
"A Phase II Multi-Institutional Study of Concurrent Radiotherapy, Palbociclib, and Hormone Therapy for Treatment of Bone Metastasis in Breast Cancer Patients",II,Closed,"National Institutes of Health/National Cancer Institute
Pfizer
Emory University Hospital - Atlanta",Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms; Neoplasm Metastasis; Neoplasms,United States
"A Randomized, Multicenter, Open-Label Cross-Over Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Patients With HER2-Positive Early Breast Cancer",II,Completed,Roche {F. Hoffmann-La Roche},Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,"Argentina; Brazil; Chile; Cuba; Finland; Hong Kong, S.A.R., China; Jordan; Lebanon; Mexico; Panama; Portugal; Qatar; Saudi Arabia; Serbia; Spain; Sweden; United Kingdom; United States"
"A Randomized, Open-Label, Phase II Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)",II,Closed,Bristol-Myers Squibb,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Small Intestine; Oncology: Unspecified Solid Tumor",(N/A); First line; Fourth line or greater; PD-L1 Positive; Pulmonary; Second line; Stage III; Stage IV; Third line; Unresectable; Untreated,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Small Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Intestinal Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Small Cell Lung Carcinoma",Argentina; Australia; Belgium; Brazil; Canada; Chile; Denmark; France; Germany; Italy; Netherlands; Norway; Peru; Poland; Puerto Rico; Romania; Singapore; Spain; United Kingdom; United States
"XENERA-1: A Multi-centre, Double-blind, Placebo-controlled, Randomised Phase II Trial to Compare Efficacy of Xentuzumab in Combination With Everolimus and Exemestane Versus Everolimus and Exemestane in Post-menopausal Women With HR+ / HER2- Metastatic Breast Cancer and Non-visceral Disease",II,Completed,Boehringer Ingelheim,Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,Australia; Belgium; Canada; France; Germany; Greece; Greenland; Ireland; Italy; Portugal; Spain; United Kingdom; United States
A Phase II Study of Nivolumab Combined With Bicalutamide and Ipilimumab in Metastatic HER2-negative Breast Cancer,II,Closed,"Bristol-Myers Squibb
(Other Cooperative Group)
Memorial Sloan-Kettering Cancer Center
Earle A. Chiles Research Institute - EACRI",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
A Phase II Trial Evaluating Safety and Efficacy of Pembrolizumab and Cisplatin in Patients With Advanced Triple Negative Breast Cancer,II,Terminated,"University of Washington
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,First line; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Nicotinamide Riboside (NR) in Paclitaxel-induced Peripheral Neuropathy,II,Terminated,"National Institutes of Health/National Cancer Institute
University of Iowa
ChromaDex",Oncology: Breast; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Head/Neck; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Supportive Care,Neurotoxicity; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Palliative Care; Peripheral Nervous System Diseases; Peritoneal Neoplasms",United States
Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer,II,Completed,"(Other Hospital/Academic/Medical Center)
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Phase II Randomized Study to Evaluate the Immunologic and Antitumor Activity of Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Advanced HER2-overexpressing Breast Cancer,II,Closed,"Duke University Medical Center
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,First line; HER2 positive; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase II Trial Assessing the Tolerability of Palbociclib in Combination With Letrozole or Fulvestrant in Patients Aged 70 and Older With Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer",II,Completed,"National Institutes of Health/National Cancer Institute
Alliance for Clinical Trials in Oncology",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms,United States
Immune Response Surveillance and Potential Booster Vaccines for Patients Who Have Received HER2-pulsed DC1 Vaccine,II,Terminated,"H. Lee Moffitt Cancer Center and Research Institute
(Other Hospital/Academic/Medical Center)",Oncology: Breast,HER2 positive; Maintenance/Consolidation; Second line; Stage 0; Stage I; Stage II; Stage III; Stage IV,"Breast Neoplasms; Breast Neoplasms, Male",United States
An Assessment of the Biological and Clinical Effects of Palbociclib (PD 0332991) With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Patients With Premenopausal Estrogen-Receptor Positive/HER2-Negative Primary Breast Cancer,II,Completed,"National Surgical Adjuvant Breast and Bowel Project (NSABP)
Pfizer
Exact Sciences {Genomic Health}",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II,Breast Neoplasms,Canada; United States
Randomized Phase II Clinical Trial of Nab-Paclitaxel + MEDI4736 (Durvalumab) + Tremelimumab + Neoantigen Vaccine Vs. Nab-Paclitaxel + MEDI4736 (Durvalumab) + Tremelimumab in Patients With Metastatic Triple Negative Breast Cancer,II,Open,National Institutes of Health/National Cancer Institute,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma; Triple Negative Breast Neoplasms,United States
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer,II,Open,National Institutes of Health/National Cancer Institute,Oncology: Breast,First line; HER2 positive; Second line; Stage III,Breast Neoplasms; Inflammatory Breast Neoplasms,Canada; Puerto Rico; United States
"A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)",III,Completed,Novartis,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Brazil; Canada; China; France; Germany; Hungary; Ireland; Italy; Peru; Poland; Romania; Russia; South Korea; Spain; Taiwan, China; United Kingdom; United States"
Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer,IV,Open,"(Other Hospital/Academic/Medical Center)
Breast Cancer Research Foundation",Oncology: Breast,(N/A); First line; HER2 negative; Neoadjuvant; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase II, Multicenter, Randomized Study To Compare The Efficacy Of Venetoclax Plus Fulvestrant Versus Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy",II,Terminated,Roche {F. Hoffmann-La Roche},Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage III; Stage IV; Third line,Breast Neoplasms; Recurrence,Australia; Canada; Germany; United Kingdom; United States
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant,II,Closed,Zymeworks,Oncology: Breast,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,Canada; Spain; United States
"A Pilot Study of IMMUNe mOdulation in Early Stage Estrogen Receptor Positive Breast Cancer Treated With Neoadjuvant Avelumab, Palbociclib, and Endocrine Therapy: The ImmunoADAPT Study",II,Closed,"Pfizer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}
National Institutes of Health",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
Monitoring Response to Neoadjuvant Chemotherapy (NAC) in HER2 Negative Breast Cancer (HNBC) Using High-speed MR Spectroscopic Imaging (MRSI),II,Open,(Other Cooperative Group),Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,United States
Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy,II,Open,(Other Hospital/Academic/Medical Center),CNS: Pain (neuropathic); Oncology: Breast; Oncology: Supportive Care,Cancers-related; Line of therapy N/A; Neurotoxicity; Stage 0; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms; Cancer pain; Cancer Pain; Neuralgia; Palliative Care; Peripheral Nervous System Diseases,United States
"BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase III Study to Determine the Preventive Effect of Denosumab on Breast Cancer in Women Carrying a BRCA1 Germline Mutation",III,Open,"National Institutes of Health/National Cancer Institute
Austrian Breast & Colorectal Cancer Study Group
Alliance for Clinical Trials in Oncology",Oncology: Breast,BRCA; HER2 negative; Line of therapy N/A; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Diseases; Breast Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms,Australia; Austria; Germany; Israel; Spain; United Kingdom; United States
A Phase II Study To Evaluate Safety And Anti-tumor Activity of Avelumab In Combination With Talazoparib In Patients With BRCA or ATM Mutant Tumors JAVELIN BRCA/ATM,II,Completed,Pfizer,Oncology: Breast; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor,BRCA; Estrogen receptor positive; HER2 negative; Hormone refractory; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Liver Cancer; Liver Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Unspecified",Argentina; Belgium; Denmark; France; Israel; Italy; Japan; Netherlands; Spain; United Kingdom; United States
"A Global, Multicenter, Three Arms, Open-Label Randomized Study To Evaluate The Efficacy And Safety Of Nanosomal Docetaxel Lipid Suspension Compared To Taxotere (Docetaxel Injection Concentrate) In Triple-Negative Breast Cancer Patients With Locally Advanced Or Metastatic Breast Cancer After Failure To Prior Chemotherapy",III/IV,Open,Intas Pharmaceuticals/Jina Pharmaceuticals,Oncology: Breast,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,India; Russia; United States
An Open-Label Randomized Phase II Trial Of The NANT NEOADJUVANT Triple-Negative Breast Cancer (TNBC) VACCINE VS Standard-Of-Care For The Neoadjuvant Treatment Of Subjects With TNBC,II,Terminated,NantWorks/ImmunityBio {NantKwest {Conkwest {ZelleRX}}},Oncology: Breast,HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Single Arm Phase II Study of Peri-Operative Ipilimumab, Nivolumab and Cryoablation in Women With Hormone Receptor-Negative, HER2-Negative Early Stage/Resectable Breast Cancer.",II,Open,"Memorial Sloan-Kettering Cancer Center
University of Texas Southwest Medical Center",Oncology: Breast,Adjuvant; HER2 negative; Neoadjuvant; Stage I; Stage II; Triple receptor negative,Breast Neoplasms,United States
Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery,II,Open,"Pfizer
Georgetown University Medical Center",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage 0; Stage I; Triple receptor negative,"Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating",United States
Ketogenic Diet and Chemotherapy to Affect Recurrence of Breast Cancer (The KETO-CARE Study),II,Completed,Ohio State University,Oncology: Breast,First line; Stage IV,Breast Neoplasms; Recurrence,United States
A Single Arm Phase II Study to Evaluate Efficacy of T-DM1 With Palbociclib in the Treatment of Patients With Metastatic HER2 Positive Breast Cancer,II,Completed,"Pfizer
University of Arizona",Oncology: Breast,HER2 positive; Second line; Stage IV; Third line,Breast Neoplasms,Canada; United States
"Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase III Randomized, Open-label, Active-controlled, Multicenter Trial",III,Completed,"Menarini Group
Radius Health {Radius}",Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,Argentina; Australia; Austria; Belgium; Canada; Denmark; France; Germany; Greece; Hungary; Ireland; Israel; Italy; Portugal; South Korea; Spain; United Kingdom; United States
A Phase II Non-randomized Study to Assess the Safety and Efficacy of the Combination of Tucatinib and Trastuzumab and Capecitabine for Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer,II,Completed,"Seagen {Seattle Genetics/Cascadian Therapeutics {Oncothyreon {Biomira}}}
University of Alabama, Birmingham
Johns Hopkins University
(Other Hospital/Academic/Medical Center)",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; First line; HER2 positive; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
"A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti PD-L1 Antibody) in Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone in Patients With Operable Triple Negative Breast Cancer.",III,Closed,"(Other Cooperative Group)
Breast International Group
Roche/Chugai Pharmaceutical
(Other Hospital/Academic/Medical Center)
Roche {F. Hoffmann-La Roche}",Oncology: Breast,Adjuvant; HER2 negative; Maintenance/Consolidation; PD-L1 Positive; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Brazil; China; Costa Rica; Czech Republic; Denmark; France; Germany; Guatemala; Hong Kong, S.A.R., China; Hungary; Ireland; Israel; Italy; Japan; Mexico; Peru; Poland; Romania; Russia; Singapore; South Korea; Spain; Switzerland; Taiwan, China; Thailand; Turkey; Ukraine; United Kingdom; United States"
"A Phase II, Non-randomized, Open Label, Single Arm, Multi-center Study Of Talazoparib For Neoadjuvant Treatment Of Germline Brca1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2  negative Breast Cancer.",II,Terminated,Pfizer,Oncology: Breast,BRCA; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
"A Phase II Open-label, Randomized, Three-arm, Multicenter Study of LAG525 Given in Combination With Spartalizumab (PDR001), or With Spartalizumab and Carboplatin, or With Carboplatin, as First or Second Line Therapy in Patients With Advanced Triple-negative Breast Cancer",II,Completed,Novartis,Oncology: Breast,First line; HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,"Argentina; Australia; Belgium; Canada; France; Germany; Hungary; Israel; Italy; Japan; Lebanon; Singapore; South Korea; Spain; Taiwan, China; Thailand; United Kingdom; United States"
"A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer",III,Completed,"Roche/Chugai Pharmaceutical
Roche {F. Hoffmann-La Roche}",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,"Argentina; Belgium; Brazil; Canada; Czech Republic; France; Germany; Hungary; Italy; Japan; Mexico; Poland; Russia; South Korea; Spain; Taiwan, China; Thailand; Turkey; Ukraine; United Kingdom; United States"
"OXEL: A Pilot Study of Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for Triple Negative Breast Cancer With Residual Disease Following Neoadjuvant Chemotherapy

OXEL (Opdivo® -XELoda ®)",II,Completed,"Bristol-Myers Squibb
(Other Hospital/Academic/Medical Center)",Oncology: Breast,Adjuvant; HER2 negative; Stage I; Stage II; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Phase II Study of Atezolizumab in Combination With Stereotactic Radiation for Patients With Triple-negative Breast Cancer and Brain Metastasis,II,Closed,"Roche/Genentech {Genentech}
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; HER2 negative; PD-1 Naive; PD-L1 Naive; Second line; Stage IV; Triple receptor negative,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis; Triple Negative Breast Neoplasms,United States
A Phase IIA Trial Assessing the Tolerability of Ribociclib in Combination With an Aromatase Inhibitor in Patients Aged 70 and Older With Hormone Receptor Positive Metastatic Breast Cancer,II,Completed,"National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
"An International, Phase III, Multicenter, Randomized, Open- Label Trial Comparing Balixafortide in Combination With Eribulin Versus Eribulin Alone in Patients With HER2 Negative, Locally Recurrent or Metastatic Breast Cancer.",III,Completed,Spexis {Polyphor},Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,"Argentina; Belgium; Brazil; Czech Republic; France; Germany; Italy; Russia; South Korea; Spain; Taiwan, China; Ukraine; United Kingdom; United States"
The Effect of Statins on Markers of Breast Cancer Proliferation and Apoptosis in Women With Early Stage Breast Cancer,II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Line of therapy N/A; Progesterone receptor positive; Stage 0; Stage I; Stage II; Triple receptor negative,Breast Neoplasms,United States
Essential Oils Effect on Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer: A Mixed Methods Study,II,Completed,"(Other Industry Sponsor)
(Other Cooperative Group)
(Other Hospital/Academic/Medical Center)",CNS: Pain (neuropathic); Oncology: Breast; Oncology: Supportive Care,(N/A); Cancers-related; Line of therapy N/A; Neurotoxicity,Breast Neoplasms; Cancer pain; Cancer Pain; Neuralgia; Palliative Care; Peripheral Nervous System Diseases,United States
A Multicentre Observational Study for the Long Term Follow Up of Subjects that have been Treated with Enadenotucirev during Interventional Clinical Trial,II,Completed,Akamis Bio {PsiOxus Therapeutics},Oncology: Breast; Oncology: Colorectal; Oncology: Ovarian,Line of therapy N/A; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Ovarian Cancer; Ovarian Neoplasms,Belgium; Spain; United Kingdom; United States
Prospective Evaluation of Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor in Hormone Receptor (HR) Positive Metastatic Breast Cancer (MBC),II,Open,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center},Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,United States
A Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic Instability,II,Open,"National Institutes of Health/National Cancer Institute
(Other Hospital/Academic/Medical Center)",Oncology: Breast; Oncology: Ovarian; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Ovarian Epithelial; Genomic Instability; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms",United States
Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer,II,Completed,Seagen {Seattle Genetics},Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms; Unspecified,United States
A Phase II Study of Atezolizumab in Combination With Pertuzumab Plus High-dose Trastuzumab for the Treatment of Central Nervous System Metastases in Patients With Her2-positive Breast Cancer,II,Closed,Roche/Genentech,Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; HER2 positive; Line of therapy N/A; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
"A Randomized, Phase II Study Comparing Trastuzumab and Vinorelbine in Combination With Avelumab or Avelumab and Utomilumab (41BB/CD137 Agonist), in Patients With HER2-positive Metastatic Breast Cancer Who Have Progressed on Prior Trastuzumab and Pertuzumab",II,Closed,"Pfizer
Johns Hopkins University
Breast Cancer Research Foundation",Oncology: Breast,First line; HER2 positive; PD-1 Naive; PD-L1 Naive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Randomized Phase II Trial of Carboplatin With or Without Nivolumab in First-line Metastatic Triple-negative Breast Cancer.,II,Completed,"Bristol-Myers Squibb
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute",Oncology: Breast,First line; HER2 negative; PD-1 Naive; PD-L1 Naive; PD-L1 Positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients with Metastatic Cancer,II,Open,National Institutes of Health/National Cancer Institute,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Multiple Myeloma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Testicular; Oncology: Unspecified Solid Tumor",HER2 negative; HER2 positive; Pulmonary; Second line; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Endocrine Gland Neoplasms; Kidney Neoplasms; Multiple Myeloma; Neoplasm Metastasis; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Testicular Cancer; Testicular Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Urogenital Neoplasms; Wilms Tumor",United States
"A Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled, Parallel Group Phase 3b Study to Assess the Safety and to Describe the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination (IV NEPA FDC) Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination (Akynzeo) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Initial and Repeated Cycles of Anthracycline-cyclophosphamide (AC) Chemotherapy in Women With Breast Cancer",III,Completed,"(Other Cooperative Group)
Helsinn Healthcare",Oncology: Breast; Oncology: Supportive Care,Emesis; First line; Stage IV,Breast Neoplasms; Nausea; Palliative Care; Vomiting,Georgia; Russia; Switzerland; Ukraine; United States
"A Phase II Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients: Big Ten Cancer Research Consortium BTCRC-BRE16-042.",II,Completed,"(Other Hospital/Academic/Medical Center)
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage I; Stage II; Stage III; Stage IV; Third line,Breast Neoplasms,United States
Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy,IV,Open,"National Institutes of Health/National Cancer Institute
University of Wisconsin Comprehensive Cancer Center",Oncology: Breast,Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms,United States
A Multicenter Phase II Study of Vaccines to Prevent Recurrence in Patients With HER-2 Positive Breast.,II,Closed,"H. Lee Moffitt Cancer Center and Research Institute
(Other government agency)",Oncology: Breast,Adjuvant; HER2 positive; Second line; Stage I; Stage II; Stage III,"Breast Neoplasms; Breast Neoplasms, Male; Recurrence",United States
"A Phase III, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201a (Trastuzumab Deruxtecan), an Anti-HER2 Antibody Drug Conjugate (ADC), Versus Ado Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane.",III,Completed,"AstraZeneca
Baxter International/Baxter Oncology {ASTA Medica Oncology}
Daiichi Sankyo
Thermo Fisher Scientific/Patheon {Fisher Clinical Services}",Oncology: Breast,Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,"Australia; Belgium; Brazil; Canada; China; France; Germany; Hong Kong, S.A.R., China; Italy; Japan; South Korea; Spain; Taiwan, China; United Kingdom; United States"
"A Phase III, Multicenter, Randomized, Open-label, Active-controlled Study of Trastuzumab Deruxtecan (DS-8201a), an Anti-HER2-antibody Drug Conjugate, Versus Treatment of Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1",III,Completed,"AstraZeneca
Daiichi Sankyo",Oncology: Breast,HER2 positive; Second line; Stage I; Stage II; Stage III; Stage IV; Third line,Breast Neoplasms,Australia; Belgium; Brazil; Czech Republic; France; Germany; Greece; Israel; Italy; Japan; South Korea; Spain; Turkey; United Kingdom; United States
"A Randomized Phase II Trial of Fulvestrant and Palbociclib in Combination With Copanlisib (FPC) Versus Fulvestrant and Palbociclib Alone (FP) for Endocrine Resistant, Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer (FPC vs FP)",II,Terminated,National Institutes of Health/National Cancer Institute,Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
"A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study Of The Efficacy And Safety Of Atezolizumab Plus Chemotherapy For Patients With Early Relapsing Recurrent (Inoperable Locally Advanced Or Metastatic) Triple-Negative Breast Cancer",III,Open,Roche {F. Hoffmann-La Roche},Oncology: Breast,First line; HER2 negative; PD-L1 Positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,"Algeria; Argentina; Bosnia and Herzegovina; Brazil; Chile; China; Cuba; Egypt; Finland; France; Germany; Hong Kong, S.A.R., China; Hungary; Italy; Kazakhstan; Mexico; Montenegro; Morocco; Panama; Peru; Portugal; Russia; Serbia; Singapore; South Africa; South Korea; Spain; Turkey; United Kingdom; United States"
Treatment of Refractory Nausea,III,Open,"National Institutes of Health/National Cancer Institute
University of Rochester",Oncology: Breast; Oncology: Supportive Care,(N/A); Emesis; First line,Breast Neoplasms; Palliative Care; Vomiting,United States
A Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma,II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Endometrial,Estrogen receptor positive; Fourth line or greater; HER2 negative; PD-1 Refractory; PD-L1 Refractory; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Triple Negative Breast Neoplasms",United States
A Phase II Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients With Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded),II,Open,"AstraZeneca
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Johns Hopkins University",Oncology: Breast,BRCA; Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
"Phase II Study of Combination of Nivolumab and Ipilimumab in (1) Neoadjuvant Setting in Previously Untreated Breast Cancer Patients, (2) Platinum-Resistant/Refractory Advanced Ovarian Cancer Patients; and (3) Advanced Gastric Cancer Patients",II,Terminated,(Other Industry Sponsor),Oncology: Breast; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Ovarian; Oncology: Primary Peritoneal,First line; Fourth line or greater; Neoadjuvant; Second line; Stage II; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Ovarian Epithelial; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
A Phase II Randomized Trial Evaluating Neoadjuvant Dose-Dense Doxorubicin/Cyclophosphamide Followed by Paclitaxel/Trastuzumab/Pertuzumab (AC THP) and Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) For Early Her2Neu Positive Breast Cancer,II,Terminated,Icahn School of Medicine at Mount Sinai {Mount Sinai School of Medicine},Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination With Olaparib Versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-Related Genes (Including BRCA1/2) (VIOLETTE)",II,Terminated,AstraZeneca,Oncology: Breast,BRCA; FGFR; HER2 negative; KRAS; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,"Belgium; Canada; Czech Republic; Denmark; France; Germany; Ireland; Italy; Netherlands; Poland; Portugal; South Korea; Spain; Taiwan, China; United Kingdom; United States"
"A Multinational, Multicenter, Randomized, Phase III Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane",III,Completed,Odonate Therapeutics,Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,"Australia; Austria; Belgium; Canada; Czech Republic; France; Germany; Hungary; Israel; Italy; Netherlands; Poland; Russia; Singapore; South Korea; Spain; Taiwan, China; Thailand; Ukraine; United Kingdom; United States"
A Phase II Single Arm Trial of Adding Simvastatin to Dual Anti-HER2 Therapy in Patients With HER2-Positive Metastatic Breast Cancer,II,Open,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
Phase II Study of MCLA-128-based Combinations in Metastatic Breast Cancer (MBC): MCLA-128/Trastuzumab/Chemotherapy in HER2-positive MBC and MCLA-128/Endocrine Therapy in Estrogen Receptor Positive and Low HER2 Expression MBC,II,Completed,"(Other Cooperative Group)
Merus",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,Belgium; France; Netherlands; Portugal; Spain; United Kingdom; United States
A Pharmacodynamic Study of Oral eFT508 in Subjects With Advanced Triple Negative Breast Cancer and Hepatocellular Carcinoma,II,Terminated,eFFECTOR Therapeutics,Oncology: Breast; Oncology: Liver,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Liver Cancer; Liver Neoplasms; Triple Negative Breast Neoplasms",United States
A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer,II,Completed,"Bristol-Myers Squibb
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Exelixis",Oncology: Breast,First line; Fourth line or greater; HER2 negative; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Randomized, Double-blind, Parallel Group, Phase III Trial to Compare the Efficacy, Safety, and Immunogenicity of TX05 With Herceptin in Subjects With HER2 Positive Early Breast Cancer",III,Completed,Tanvex BioPharma,Oncology: Breast,Adjuvant; HER2 positive; Stage II; Stage III,Breast Neoplasms,Belarus; Brazil; Bulgaria; Chile; Georgia; Hungary; India; Italy; Mexico; Peru; Philippines; Poland; Romania; Russia; Slovakia; South Korea; Thailand; Ukraine; United States
A Phase II Trial to Evaluate the Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer,II,Terminated,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas,Second line; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gastrointestinal Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
"A Phase II Study of Neoadjuvant Carboplatin/Paclitaxel Followed by Dose-Dense Doxorubicin/Cyclophosphamide in Patients With Hormone Receptor Negative, HER2 Receptor Negative Breast Cancer",II,Terminated,University of Wisconsin,Oncology: Breast,HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Multi-center, Open-label, Phase II Clinical Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DHP107 (Liporaxel, Oral Paclitaxel) Compared to IV Paclitaxel in Patients With Recurrent or Metastatic Breast Cancer (OPERA)",II,Completed,Daehwa Pharmaceutical,Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,Czech Republic; United States
"A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer",III,Completed,"Roche/Chugai Pharmaceutical
Pfizer {Array BioPharma}
Roche {F. Hoffmann-La Roche}",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,"Argentina; Australia; Belgium; Brazil; Canada; Chile; China; Costa Rica; Czech Republic; France; Germany; Greece; Hungary; India; Italy; Japan; Macedonia; Mexico; Peru; Poland; Romania; Russia; Singapore; Slovenia; South Africa; South Korea; Spain; Taiwan, China; Turkey; Ukraine; United Kingdom; United States"
"A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients With Germline or Somatic BRCA1/2 Mutations.",III,Completed,AstraZeneca,Oncology: Breast,BRCA; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,"Australia; Bulgaria; Canada; China; France; Germany; Hungary; Italy; Japan; Poland; Russia; South Korea; Spain; Taiwan, China; Turkey; United Kingdom; United States"
"Phase II Study of CDK 4/6 Inhibitor, LEE011 (Ribociclib), in Combination With Adjuvant Endocrine Therapy at Varying Duration for ER-positive Breast Cancer (LEADER).",II,Open,"Novartis
Massachusetts General Hospital",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
"Prospective Study to Evaluate the Role of Tumor Sequencing in Women Receiving Palbociclib for Advanced Hormone Receptor (HR)-Positive, Breast Cancer (PROMISE)",IV,Closed,"National Institutes of Health/National Cancer Institute
Mayo Clinic Cancer Center",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms; Carcinoma,United States
POLARIS: Palbociclib In Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study,IV,Completed,Pfizer,Oncology: Breast,Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,Canada; United States
"A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo",III,Closed,"National Surgical Adjuvant Breast and Bowel Project (NSABP)
Roche {F. Hoffmann-La Roche}
German Breast Group
Roche/Genentech",Oncology: Breast,Adjuvant; HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Belgium; Bulgaria; Canada; Czech Republic; Germany; Slovakia; Spain; Turkey; United States
Chemotherapy Induced Peripheral Neuropathy (CIPN): A Pilot Study of Intraneural Facilitation for Managing Chemotherapy-Induced Peripheral Neuropathy,II,Completed,Loma Linda University,Oncology: Breast; Oncology: Cervical; Oncology: Ovarian; Oncology: Supportive Care,(N/A); Estrogen receptor positive; First line; HER2 positive; Neurotoxicity; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms; Ovarian Neoplasms; Palliative Care; Peripheral Nervous System Diseases; Uterine Cervical Neoplasms,United States
Evaluating Immune Checkpoint Inhibition In Solid Tumor Patients With Homologous Recombination Repair Deficiency,II,Completed,"(Other Hospital/Academic/Medical Center)
Merck & Co./Merck Sharp & Dohme (MSD)","Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Small Intestine; Oncology: Thymus; Oncology: Vaginal",(N/A); First line; Fourth line or greater; Gastrointestinal; PD-1 Naive; PD-L1 Naive; Pulmonary; Second line; Stage IV; Third line; Thymic carcinoma; Untreated,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Intestinal Neoplasms; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Thymus Neoplasms; Uterine Cervical Neoplasms; Vaginal Neoplasms",United States
"A Multi-centre, Open-label, Randomized Clinical Trial Comparing the Efficacy and Safety of the Antibody-drug Conjugate SYD985 to Physician's Choice in Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer.",III,Completed,Byondis {Synthon},Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,Belgium; Canada; Denmark; France; Italy; Netherlands; Singapore; Spain; Sweden; United Kingdom; United States
"A Phase II Study of AZD1775, a Wee1 Inhibitor, in Patients With CCNE1 Amplification",II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Melanoma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Renal Cell; Cholangiocarcinoma; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Gallbladder Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase III, Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta Active-Controlled Clinical Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy",III,Completed,Evive Biotech {Generon (Shanghai)},Oncology: Breast; Oncology: Supportive Care,Adjuvant; Neoadjuvant; Neutropenia; Stage I; Stage II; Stage III,Breast Neoplasms; Neutropenia; Palliative Care,Bulgaria; China; Hungary; Latvia; Romania; Russia; Ukraine; United States
Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer,II,Open,(Other Hospital/Academic/Medical Center),Oncology: Breast,HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
An Investigator Initiated Registry of Simple Oral Therapy for Low Risk Breast Cancer (SOLR),IV,Terminated,"National Institutes of Health/National Cancer Institute
Fred Hutchinson Cancer Research Center",Oncology: Breast,Estrogen receptor positive; HER2 negative; Line of therapy N/A; Progesterone receptor positive; Stage 0; Stage I,Breast Carcinoma In Situ; Breast Neoplasms,United States
"A Pivotal, Multi Arm Phase III Study to Evaluate Rubraca + Opdivo, Rubraca, Opdivo and Chemotherapy as First-line Maintenance Treatment in Patients with Stage IV or Recurrent locally Advanced Inoperable Triple-Negative Breast Cancer Associated with a Homologous Recombination Deficiency",III,Terminated,Bristol-Myers Squibb,Oncology: Breast,First line; HER2 negative; Maintenance/Consolidation; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
A Phase II Randomized Study to Evaluate the Safety and Efficacy of AE37 plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer,II,Closed,"National Surgical Adjuvant Breast and Bowel Project (NSABP)
Merck & Co./Merck Sharp & Dohme (MSD)
Generex Biotechnology/NuGenerex Immuno-Oncology {Antigen Express}",Oncology: Breast,HER2 negative; Second line; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Phase II Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer,II,Closed,"Merck & Co.
University of Chicago Cancer Research Center",Oncology: Breast,Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; PD-1 Naive; PD-L1 Naive; PD-L1 Positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive HER2-Negative Node-Negative Breast Cancer Patients to Assess Responses and Mechanisms of Endocrine Resistance,II,Completed,"(Other Cooperative Group)
Medical College of Wisconsin Cancer Center",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II,Breast Neoplasms,United States
"I-CURE-1: A Phase II, Single Arm Study of Pembrolizumab Combined With Carboplatin in Patients With Circulating Tumor Cells (CTCs) Positive Her-2 Negative Metastatic Breast Cancer (MBC)",II,Open,"National Institutes of Health/National Cancer Institute
Northwestern University
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Neoplastic Cells, Circulating",United States
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase II Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex,II,Completed,"National Institutes of Health/National Cancer Institute
Children’s Oncology Group","Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Multiple Myeloma; Oncology: Neuroblastoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Testicular; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Aggressive; Classical; Indolent; Low-grade; Nodular lymphocyte-predominant; Pediatric or Adolescent; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Ependymoma; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Glioblastoma; Glioma; Hepatoblastoma; Histiocytosis; Histiocytosis, Langerhans-Cell; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Medulloblastoma; Melanoma; Multiple Myeloma; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neoplasms, Unknown Primary; Nervous System Neoplasms; Neuroblastoma; Neuroectodermal Tumors; Neuroectodermal Tumors, Primitive; Neuroectodermal Tumors, Primitive, Peripheral; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdoid Tumor; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms; Thyroid Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Puerto Rico; United States
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase II Subprotocol of LY3023414 in Patients With Solid Tumors,II,Closed,National Institutes of Health/National Cancer Institute,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroblastoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Aggressive; Indolent; Pediatric or Adolescent; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Ependymoma; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Glioblastoma; Glioma; Head and Neck Neoplasms; Hepatoblastoma; Histiocytosis; Histiocytosis, Langerhans-Cell; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Medulloblastoma; Melanoma; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neoplasms, Unknown Primary; Nervous System Neoplasms; Neuroblastoma; Neuroectodermal Tumors; Neuroectodermal Tumors, Primitive; Neuroectodermal Tumors, Primitive, Peripheral; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdoid Tumor; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Puerto Rico; United States
"A Phase II, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma",II,Terminated,Novartis,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal",Aggressive; BRAF; Diffuse large B-cell lymphoma (DLBCL); EGFR; Fourth line or greater; HER2 negative; Hormone refractory; MSS/pMMR; PD-1 Naive; PD-L1 Naive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor","Argentina; Australia; Austria; Belgium; Canada; Czech Republic; France; Germany; Italy; Japan; Netherlands; Singapore; South Korea; Spain; Switzerland; Taiwan, China; United Kingdom; United States"
A Phase II Trial of Atezolizumab (Anti-PDL1) With Carboplatin in Patients With Metastatic Triple Negative Breast Cancer,II,Closed,"Roche/Genentech {Genentech}
National Institutes of Health/National Cancer Institute
Vanderbilt-Ingram Cancer Center",Oncology: Breast,First line; HER2 negative; Second line; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response (DDR) Pathway Deficient Neoplasms (UF-STO-ETI-001)",II,Completed,"University of Florida - Gainesville
GlaxoSmithKline/Tesaro","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Soft Tissue Sarcoma; Oncology: Testicular",(N/A); Second line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Cholangiocarcinoma; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Ewing Sarcoma; Fibrosarcoma; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Medulloblastoma; Melanoma; Mesothelioma; Mesothelioma, Malignant; Neoplasms; Neoplasms, Basal Cell; Neoplasms, Mesothelial; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
A Phase II Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) or Atezolizumab + Eribulin (AE) in Patients With Recurrent/Metastatic Inflammatory Breast Cancer,II,Closed,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute
Roche/Genentech",Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; PD-L1 Positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms; Carcinoma; Inflammatory Breast Neoplasms,United States
"A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer.",III,Closed,"National Institutes of Health/National Cancer Institute
NRG Oncology",Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Stage III; Stage IV,Adenocarcinoma; Breast Neoplasms; Carcinoma,Canada; United States
A Phase III Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Neoadjuvant Anthracycline/Nab-Paclitaxel-Based Chemotherapy Compared With Placebo and Chemotherapy in Patients With Primary Invasive Triple-Negative Breast Cancer,III,Completed,Roche {F. Hoffmann-La Roche},Oncology: Breast,Adjuvant; HER2 negative; Neoadjuvant; PD-L1 Positive; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,"Australia; Belgium; Brazil; Canada; Germany; Italy; Japan; Poland; South Korea; Spain; Taiwan, China; United Kingdom; United States"
Phase II Clinical Trial of Treatment With TAK-228 and TAK-117 to Inhibit Homologous Recombination (HR) Followed by Cisplatin and Nab Paclitaxel in Patients With Chemotherapy-pretreated Metastatic Triple Negative Breast Cancer,II,Completed,"Takeda
Baylor Research Institute",Oncology: Breast,HER2 negative; Second line; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Evaluation of Antiangiogenic Therapy With Bevacizumab in Addition to Neoadjuvant Chemotherapy in the Treatment of Locally Advanced Breast Cancer.,II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
A Phase II Study of Alpelisib (BYL-719) and T-DM1 in HER2-Positive Metastatic Breast Cancer,II,Terminated,Northwestern University,Oncology: Breast,HER2 positive; Line of therapy N/A; Stage IV,Breast Neoplasms,United States
"A Phase II, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1",II,Completed,"AstraZeneca
Daiichi Sankyo",Oncology: Breast,First line; Fourth line or greater; HER2 positive; Second line; Stage IV; Third line,Breast Neoplasms,Belgium; Canada; France; Germany; Italy; Japan; South Korea; Spain; United Kingdom; United States
"Phase II Trial to Evaluate the Efficacy of the FASN Inhibitor, TVB-2640, in Combination With Trastuzumab Plus Paclitaxel or Endocrine Therapy in Patients With HER2+ Metastatic Breast Cancer Resistant to Trastuzumab-Based Therapy",II,Open,"National Institutes of Health/National Cancer Institute
Mayo Clinic",Oncology: Breast,Estrogen receptor positive; First line; Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms; Carcinoma,United States
"An Observational Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Herceptin, Perjeta in Combination With Herceptin, or Kadcyla During Pregnancy or Within 7 Months Prior to Conception",IV,Completed,Roche/Genentech,Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
Phase II Multicenter Study of Durvalumab and Olaparib in Platinum Treated Advanced Triple Negative Breast Cancer,II,Completed,"AstraZeneca
(Other Hospital/Academic/Medical Center)
Asan Medical Center",Oncology: Breast,HER2 negative; Maintenance/Consolidation; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Singapore; South Korea; United States
"A Phase III, Randomized Study to Evaluate Plinabulin Versus Pegfilgrastim in the Prevention of Severe Neutropenia in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) (Protective 2).",III,Completed,"(Other Industry Sponsor)
BeyondSpring Pharmaceuticals
Dalian Wanchunbulin Pharmaceuticals",Oncology: Breast; Oncology: Supportive Care,Adjuvant; First line; HER2 negative; Neoadjuvant; Neutropenia; Second line; Stage I; Stage II; Stage III,Breast Neoplasms; Neutropenia; Palliative Care,Australia; China; Israel; Russia; Ukraine; United States
LCCC 1642: Plasma Circulating Tumor DNA (ctDNA) Analyses in ER+ Metastatic Breast Cancer,IV,Terminated,UNC Lineberger Comprehensive Cancer Center,Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Second line; Stage IV; Third line,Breast Neoplasms,United States
"A Randomized, Open-Label, Phase III Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer",III,Completed,"Eli Lilly
(Other Cooperative Group)",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage 0; Stage I; Stage II; Stage III,Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Czech Republic; Denmark; Finland; France; Germany; Greece; Hong Kong, S.A.R., China; Hungary; India; Israel; Italy; Japan; Mexico; Netherlands; New Zealand; Norway; Poland; Portugal; Puerto Rico; Romania; Russia; Saudi Arabia; Singapore; Slovakia; South Africa; South Korea; Spain; Sweden; Taiwan, China; Turkey; Ukraine; United Kingdom; United States"
"Palbociclib After CDK and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer",II,Completed,"Pfizer
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"A Phase III, Randomized, Multicenter, Double-blind Study to Compare Efficacy and Safety of EG12014 With Herceptin as Neoadjuvant Treatment in Combination With Anthracycline/Paclitaxel-based Systemic Therapy in Patients With HER2 Positive Early Breast Cancer",III,Completed,EirGenix,Oncology: Breast,Adjuvant; HER2 positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,"Belarus; Chile; China; Colombia; Georgia; India; Lithuania; Moldova Republic; Russia; South Africa; South Korea; Taiwan, China; Ukraine; United States"
"A Phase II Study of Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer",II,Terminated,"Eli Lilly
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute",Oncology: Breast,Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Retinoblastoma,United States
"A Phase III, Multicenter, Randomised, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-Pd-L1 Antibody) in Combination With Paclitaxel Compared With Placebo With Paclitaxel for Patients With Previously Untreated Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer.",III,Completed,Roche {F. Hoffmann-La Roche},Oncology: Breast,First line; HER2 negative; PD-L1 Positive; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Algeria; Argentina; Brazil; Canada; China; Croatia; Czech Republic; Egypt; France; Germany; Greece; India; Israel; Italy; Japan; Morocco; Romania; Russia; Saudi Arabia; Slovakia; South Africa; Spain; Turkey; United Kingdom; United States; Vietnam
"Single Arm, Phase IIA Clinical Trial Assessing The Safety And Efficacy of Atezolizumab in Combination With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer",II,Closed,"Roche/Genentech {Genentech}
Fox Chase Cancer Center",Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Stage IV,Breast Neoplasms,United States
"Women's Triple-Negative First-Line Study: A Phase II Trial of Mirvetuximab Soravtansine in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy (NACT), Including a Lead-in Cohort to Establish Activity in Patients With Metastatic TNBC",II,Completed,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast,First line; HER2 negative; Neoadjuvant; Second line; Stage I; Stage II; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Pivotal Phase III Study to Evaluate Reolysin in Combination with Paclitaxel in Patients with HR Positive/HER2 Negative Metastatic Breast Cancer,III,Planned,Oncolytics Biotech,Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Third line,Breast Neoplasms,United States
An Open Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With HER2+ Breast Cancer Treated With Neratinib With or Without Trastuzumab,II,Completed,"University of California, San Francisco
Puma Biotechnology",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms; Diarrhea,United States
"A Randomized Phase II Study of Pembrolizumab, an Anti-Programmed Cell Death (PD)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease",II,Open,"(Other Cooperative Group)
Johns Hopkins University
Massachusetts General Hospital
University of California, San Francisco
Mayo Clinic
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; PD-1 Refractory; PD-L1 Positive; PD-L1 Refractory; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
Tumor Associated Antigen (TAA) Specific Cytotoxic T Lymphocytes Administered in Patients With Breast Cancer,II,Completed,"National Institutes of Health/National Cancer Institute
Baylor College of Medicine
(Other Hospital/Academic/Medical Center)",Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
Pembrolizumab in Patients With Leptomeningeal Disease,II,Terminated,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}
Merck & Co./Merck Sharp & Dohme (MSD)","Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer; Oncology: Skin, Squamous Cell Carcinoma (cSCC)",CNS mets; Estrogen receptor positive; First line; HER2 positive; PD-1 Naive; PD-L1 Naive; Progesterone receptor positive; Second line; Stage III; Stage IV,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Central Nervous System Neoplasms; Glioblastoma; Head and Neck Neoplasms; Meningeal Neoplasms; Neoplasm Metastasis",United States
A Phase II Study of HER2/neu-targeted T-cell Vaccine in Women with HER2/neu Positive Ductal Carcinoma In Situ (DCIS) Breast Cancer,II,Completed,"Mayo Clinic
US Department of Defense
Marker Therapeutics {TapImmune {GeneMax}}",Oncology: Breast,HER2 positive; Neoadjuvant; Stage 0,Breast Neoplasms,United States
"An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE)",II,Completed,Sermonix Pharmaceuticals,Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms,Canada; Czech Republic; Israel; Lithuania; United States
"A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, Intermediate Risk Early Breast Cancer",III,Terminated,Novartis,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,Germany; United States
"A Phase II, Multi Centre Study of BGB324 in Combination With Pembrolizumab in Patients With Previously Treated, Locally Advanced and Unresectable or Metastatic Triple Negative Breast Cancer (TNBC) or Triple Negative Inflammatory Breast Cancer (TN-IBC)",II,Completed,"Merck & Co./Merck Sharp & Dohme (MSD)
BerGenBio",Oncology: Breast,HER2 negative; PD-1 Positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Inflammatory Breast Neoplasms; Triple Negative Breast Neoplasms,Norway; Spain; United Kingdom; United States
"BREAKOUT -International Breast Cancer Biomarker, Standard of Care and Real World Outcomes Study",IV,Completed,AstraZeneca,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage IV,Breast Neoplasms,"Australia; Bulgaria; Canada; China; France; Hungary; Italy; Japan; Poland; Russia; South Korea; Spain; Sweden; Taiwan, China; Turkey; United Kingdom; United States"
"An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer",II,Completed,Novartis,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Czech Republic; Denmark; France; Germany; Greece; Hong Kong, S.A.R., China; Hungary; India; Ireland; Israel; Italy; Lebanon; Mexico; Netherlands; Poland; Romania; Russia; Saudi Arabia; Singapore; South Korea; Spain; Sweden; Switzerland; Taiwan, China; Thailand; Turkey; United Arab Emirates; United Kingdom; United States"
"Randomized Phase II Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastatic Breast Cancer (Merrimack Pharmaceuticals Inc.)",II,Terminated,Merrimack Pharmaceuticals,Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Stage IV; Third line,Breast Neoplasms,Belgium; Canada; Spain; United States
"A Phase II, Open Label Study to Evaluate Denosumab in Patients With ER and/or PR-Positive, HER2-Negative Metastatic Breast Cancer (MBC) With Bone Metastases and Detectable Circulating Tumor Cells (CTCs)",II,Terminated,"Amgen
National Institutes of Health/National Cancer Institute
Northwestern University",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage IV,"Breast Neoplasms; Neoplastic Cells, Circulating",United States
"A Randomized, Double-Blind, Placebo-Controlled Study of 4-hydroxytamoxifen Topical Gel in Women With Mammographically Dense Breast",II,Closed,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms; Unspecified,United States
A Multicenter Phase II Study of the Glutaminase Inhibitor CB-839 in Combination With Paclitaxel in Patients With Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry,II,Completed,Calithera Biosciences,Oncology: Breast,First line; Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase II, Multicenter, Open-label, Three-cohort, Non- Comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After Prior Treatments",II,Completed,Novartis,Oncology: Breast,EGFR; Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,"Argentina; Austria; Belgium; Bulgaria; Canada; Chile; Denmark; France; Germany; Greece; India; Israel; Italy; Japan; Mexico; Netherlands; Russia; Saudi Arabia; Singapore; South Korea; Spain; Switzerland; Taiwan, China; United Arab Emirates; United Kingdom; United States"
A Randomized Phase II Study of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer,II,Completed,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,Estrogen receptor positive; HER2 negative; PD-1 Naive; PD-L1 Naive; PD-L1 Positive; Progesterone receptor positive; Second line; Stage IV; Third line,Breast Neoplasms,United States
A Phase II Study Of Pembrolizumab In Combination With Palliative Radiotherapy For Metastatic Hormone Receptor Positive Breast Cancer,II,Terminated,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; PD-1 Naive; PD-L1 Naive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
Phase II Study of Pembrolizumab and Capecitabine for Advanced Triple Negative and Hormone-Refractory Breast Cancer,II,Completed,"National Institutes of Health/National Cancer Institute
Northwestern University
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma,United States
A Phase III Study of Regional Radiation Therapy in Early Breast Cancer,III,Completed,"(Other Cooperative Group)
Canadian Cancer Trials Group {NCIC Clinical Trials Group}
North Central Cancer Treatment Group (NCCTG)
Radiation Therapy Oncology Group (RTOG)
Southwest Oncology Group
National Institutes of Health/National Cancer Institute",Oncology: Breast,Adjuvant; Estrogen receptor positive; First line; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II,Breast Neoplasms,Australia; Canada; United States
"A Phase II Study of Neratinib With or Without Fulvestrant in HER2-Positive, ER-Positive Metastatic Breast Cancer",II,Terminated,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Puma Biotechnology",Oncology: Breast,Estrogen receptor positive; HER2 positive; Line of therapy N/A; Progesterone receptor positive; Stage IV,Breast Neoplasms,United States
"A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC).",III,Completed,Merck & Co./Merck Sharp & Dohme (MSD),Oncology: Breast,Adjuvant; HER2 negative; Neoadjuvant; PD-L1 Positive; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,"Australia; Brazil; Canada; Colombia; France; Germany; Ireland; Israel; Italy; Japan; Poland; Portugal; Russia; Singapore; South Korea; Spain; Sweden; Taiwan, China; Turkey; United Kingdom; United States"
"CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer",II,Closed,Abramson Cancer Center at  University of Pennsylvania Medical Center,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage II,Breast Neoplasms,United States
"Phase II Clinical Trial on the Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients With Homologous Recombination Deficiency",II,Terminated,University of Texas Health Science Center at San Antonio,Oncology: Breast; Oncology: Ovarian,Second line; Stage III; Stage IV,Breast Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Unspecified,United States
Hyperthermic Pleural Lavage for Pleural Metastases,IV,Completed,(Other Hospital/Academic/Medical Center),Oncology: Anal; Oncology: Breast; Oncology: Colorectal; Oncology: Metastatic Cancer; Oncology: Renal; Oncology: Thymus,Line of therapy N/A; Other mets; Stage IV; Thymic carcinoma,"Anus Neoplasms; Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Neoplasm Metastasis; Renal Cancer; Thymus Neoplasms; Wilms Tumor",United States
"Open Label, Phase II Pilot Study of Immune Checkpoint Inhibition With Pembrolizumab in Combination With PARP Inhibition With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancers",II,Open,"Cedars-Sinai Medical Center
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,BRCA; Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
LCI-BRE-H2N-PEPP-001: A Pilot Study of Paclitaxel Plus Pembrolizumab in Patients With Metastatic HER2-Negative Breast Cancer (The PePPy Trial),II,Completed,"(Other Hospital/Academic/Medical Center)
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,Estrogen receptor positive; HER2 negative; PD-1 Naive; PD-L1 Naive; PD-L1 Positive; Progesterone receptor positive; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Breast Neoplasms, Male",United States
"A Managed Access Program Of Neratinib in Patients with Early Stage HER2-Positive Breast Cancer (Extended Adjuvant Setting), HER-2 positive Metastatic Breast Cancer, and HER2-Mutated Solid Tumors",III,Open,Puma Biotechnology,Oncology: Breast; Oncology: Unspecified Solid Tumor,Adjuvant; HER2 positive; Stage I; Stage IV,"Breast Neoplasms; Neoplasms, Unknown Primary",United States
"Double Blind, Parallel Groups, Controlled, Randomized Phase II Trial to Evaluate Vaccination With Folate Receptor Alpha Peptide Vaccine With GM-CSF as Vaccine Adjuvant Following Oral Cyclophosphamide Versus GM-CSF/Placebo to Prevent Recurrence in Patients With Triple Negative Breast Cancer",II,Completed,"National Institutes of Health/National Cancer Institute
Academic and Community Cancer Research United",Oncology: Breast,HER2 negative; Second line; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma; Inflammatory Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Phase II Study of Cisplatin + AZD1775 in Metastatic Triple-negative Breast Cancer and Evaluation of pCDC2 as a Biomarker of Target Response,II,Completed,"AstraZeneca
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute",Oncology: Breast,HER2 negative; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,United States
A Phase II Clinical Trial Assessing the Safety of an Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer,II,Completed,"Pfizer
Washington University School of Medicine",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms; Neoplasms,United States
A Phase II Clinical Study of Elenagen in Ovarian and Breast Cancer Patients,II,Planned,CureLab Oncology,Oncology: Breast; Oncology: Ovarian,HER2 negative; Line of therapy N/A; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Renal Cell; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms",United States
Phase II Window of Opportunity Trial of Stereotactic Body Radiation Therapy and In Situ Oncolytic Virus Therapy in Metastatic Triple Negative Breast Cancer and Metastatic Non-Small Cell Lung Cancer Followed by Pembrolizumab,II,Completed,"(Other Hospital/Academic/Medical Center)
Merck & Co./Merck Sharp & Dohme (MSD)","Oncology: Breast; Oncology: Lung, Non-Small Cell",ALK; EGFR; First line; HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Triple Negative Breast Neoplasms",United States
A Biomarker Study of Virexxa in Patients with Triple Negative Breast Cancer,II,Terminated,Xenetic Biosciences {Lipoxen},Oncology: Breast,(N/A); HER2 negative; Line of therapy N/A; Triple receptor negative,Breast Neoplasms,United States
Phase IIB Trial of Neoadjuvant Oral Tamoxifen Versus Transdermal 4-hydroxytamoxifen in Women With DCIS of the Breast,II,Open,"National Institutes of Health/National Cancer Institute
Northwestern University
BHR Pharma",Oncology: Breast,(N/A); Estrogen receptor positive; First line; Neoadjuvant; Second line,"Breast Carcinoma In Situ; Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating",United States
"Open Label, Phase II Trial of Neoadjuvant TAK-228 Plus Tamoxifen in Patients With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer",II,Completed,"Takeda/Takeda Oncology {Millennium}
(Other Hospital/Academic/Medical Center)",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Immune Characterization Of Inflammatory Breast Cancer And Correlation To Pathological Complete Response,Other,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Adjuvant; HER2 negative; HER2 positive; Neoadjuvant; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
Pertuzumab And Trastuzumab In Combination With Weekly Paclitaxel Delivers High PCR Rates With Favourable Toxicity Profile In Neo-Adjuvant Treatment Of Her-2 Positive Breast Cancer,II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Weekly doxorubicin and daily oral cyclophosphamide followed by nab-paclitaxel for adjuvant therapy of high-risk localized breast cancer,II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Stage I; Triple receptor negative,Breast Neoplasms,United States
"Pilot Study of Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer",II,Completed,"Merck & Co.
Case Western Reserve University",Oncology: Breast,HER2 negative; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"Phase II Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy",II,Completed,G1 Therapeutics,Oncology: Breast,First line; HER2 negative; PD-L1 Positive; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Neoplasms; Triple Negative Breast Neoplasms,Belgium; Bulgaria; Croatia; Macedonia; Serbia; Slovakia; Slovenia; United States
Genomic Profiling of Residual ER+ Breast Cancers Treated with Prolonged Neoadjuvant Letrozole Reveals Novel Alterations in Clinically Resistant Tumors,Other,Completed,Roche/Genentech,Oncology: Breast,(N/A); Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant,Breast Neoplasms,Spain; United States
Differential effect of chemotherapy on immune gene expression signatures based on molecular subtype of breast cancer,Other,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,(N/A); Neoadjuvant,Breast Neoplasms,Belgium; United States
A Phase II Study of Anti-PD-1 (Pembrolizumab) in Combination With Hormonal Therapy During or After Radiation in Patients With Hormone Receptor (HR)-Positive Localized Inflammatory Breast Cancer (IBC) Who Did Not Achieve a Pathological Complete Response (pCR) to Neoadjuvant Chemotherapy,II,Closed,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms; Inflammatory Breast Neoplasms,United States
A Phase II Clinical Trial of the Combination of Pembrolizumab and Selective Androgen Receptor Modulator (SARM) GTX-024 in Patients With Metastatic Androgen Receptor (AR) Positive Triple Negative Breast Cancer (TNBC),II,Completed,"National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center",Oncology: Breast,First line; Fourth line or greater; HER2 negative; Second line; Stage I; Stage II; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Open-label Phase II Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer,II,Terminated,Sanofi {Sanofi-Aventis},Oncology: Breast,HER2 negative; Second line; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Belgium; Czech Republic; France; Italy; Netherlands; Spain; United States
T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced HER2-Negative Breast Cancer - A Phase II Neoadjuvant Window Trial of Pembrolizumab and Decitabine Followed by Standard Neoadjuvant Chemotherapy,II,Closed,"National Institutes of Health/National Cancer Institute
Virginia Commonwealth University
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Carcinoma,United States
Randomized Phase II Trial of Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer,II,Completed,"US Department of Defense
University of Colorado",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
"An Open-Label, Multicenter, Rollover Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib",II,Closed,Incyte Corporation,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Pancreas",(N/A); Line of therapy N/A,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms",United States
Phase II Trial of Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer,II,Completed,"US Department of Defense
University of Colorado",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
To Evaluate the Effects of a Low-Methionine Diet in Newly Diagnosed Triple-Negative Breast Cancer Patients,II,Terminated,"(Other Cooperative Group)
University of Wisconsin",Oncology: Breast,First line; HER2 negative; Triple receptor negative,Breast Neoplasms,United States
"Randomized, OpEn-Label, Active-ContrOl Trial of SPI-2012 (Eflapegrastim) Versus Pegfilgrastim in the Management of Chemotherapy-Induced Neutropenia in Early-Stage BReast Cancer Patients Receiving Docetaxel and Cyclophosphamide (RECOVER)",III,Completed,Spectrum Pharmaceuticals,Oncology: Breast; Oncology: Supportive Care,Adjuvant; Neoadjuvant; Neutropenia; Stage I; Stage II; Stage III,Breast Neoplasms; Neutropenia; Palliative Care,Canada; Hungary; India; Poland; South Korea; United States
Th1 Epitopes As Potential Biomarkers For Ipilimumab Treatment.,Other,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast; Oncology: Colorectal; Oncology: Multiple Myeloma; Oncology: Ovarian; Oncology: Pancreas,First line; HER2 negative; Stage IV; Triple receptor negative,Breast Neoplasms; Colorectal Neoplasms; Multiple Myeloma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms,Mexico; United States
ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer,II,Terminated,"(Other Cooperative Group)
University of Wisconsin",Oncology: Breast,HER2 negative; Second line; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer",III,Closed,"(Other Cooperative Group)
Pfizer
(Other Hospital/Academic/Medical Center)
German Breast Group",Oncology: Breast,Estrogen receptor positive; HER2 positive; Maintenance/Consolidation; Progesterone receptor positive; Stage IV,Breast Neoplasms,Australia; France; Germany; Italy; New Zealand; Portugal; Spain; United States
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy,II,Completed,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast,HER2 negative; HER2 positive; Neoadjuvant; Stage I; Stage II; Triple receptor negative,Breast Neoplasms; Carcinoma,United States
"Pilot Trial of Anastrozole and Palbociclib as First-Line Therapy and as Maintenance Therapy After First Line Chemotherapy in Hormone Receptor Positive, HER2-Negative Postmenopausal Metastatic Breast Cancer",II,Closed,"Pfizer
(Other Hospital/Academic/Medical Center)",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Maintenance/Consolidation; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,United States
"COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease",III,Completed,Novartis,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,"Argentina; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; Colombia; Costa Rica; Czech Republic; Denmark; Egypt; Finland; France; Greece; Hong Kong, S.A.R., China; Hungary; India; Israel; Italy; Jordan; Lebanon; Luxembourg; Malaysia; Mexico; Netherlands; Norway; Oman; Panama; Philippines; Poland; Portugal; Romania; Russia; Saudi Arabia; Singapore; Slovakia; Slovenia; Spain; Sweden; Taiwan, China; Thailand; United Arab Emirates; United Kingdom; United States"
Phase II Trial of Ipilimumab and Nivolumab in Leptomeningeal Metastases.,II,Completed,"Bristol-Myers Squibb
Massachusetts General Hospital","Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Unspecified Solid Tumor",(N/A); Adenocarcinoma; BRAF; CNS mets; EGFR; Estrogen receptor positive; HER2 negative; HER2 positive; Line of therapy N/A; Progesterone receptor positive; Pulmonary; Triple receptor negative,"Brain Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Central Nervous System Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Glioblastoma; Hodgkin Disease; Hodgkin Lymphoma; Melanoma; Meningeal Carcinomatosis; Neoplasm Metastasis; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
An Exploratory Pilot Study of Vitamin D Supplementation in Women With DCIS and/or LCIS,II,Terminated,(Other Hospital/Academic/Medical Center),Oncology: Breast,Line of therapy N/A; Stage 0,Breast Neoplasms; Unspecified,United States
"A Phase II Multi-Cohort, Open-Label Study of Intratumoral Tavokinogene Telseplasmid Plus Electroporation in Combination With Pembrolizumab +/- Chemotherapy in Patients With Inoperable Locally Advanced/Metastatic Triple-Negative Breast Cancer",II,Closed,"Merck & Co./Merck Sharp & Dohme (MSD)
OncoSec Medical",Oncology: Breast,Fourth line or greater; HER2 negative; PD-L1 Positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Australia; United States
TBCRC 042 - A Randomized Phase II Window-of-Opportunity Trial of Ruxolitinib in Patients With High Risk and Premalignant Breast Conditions,II,Open,"(Other Cooperative Group)
Incyte Corporation",Oncology: Breast,Neoadjuvant; Stage 0,"Breast Carcinoma In Situ; Breast Diseases; Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Hyperplasia; Precancerous Conditions",United States
A Phase II Study of Merestinib in Non-Small Cell Lung Cancers Harboring MET Exon 14 Mutations and Solid Tumors With NTRK Rearrangements,II,Completed,"Eli Lilly
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute","Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",ALK; EGFR; MET Amplification/Alteration; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Melanoma; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Wilms Tumor",United States
A Phase II Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN),II,Terminated,"(Other Cooperative Group)
Pfizer
Washington University School of Medicine
Siteman Cancer Center",Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
A Phase II Study of Palbociclib in Progressive Brain Metastases Harboring Alterations in the CDK Pathway,II,Completed,"Pfizer
Massachusetts General Hospital","Oncology: Breast; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Unspecified Solid Tumor",CNS mets; Second line; Stage IV,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Unknown Primary",United States
"Chemotherapy Effect on Brain Structure, Neurophysiology and Psychomotor Behavior in Breast Cancer Patients",Other,Completed,(Other Cooperative Group),Oncology: Breast,Adjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
A Phase II Window of Opportunity Trial of Ipilimumab and Nivolumab in Metastatic Recurrent HER2- Inflammatory Breast Cancer (IBC) The Win Trial,II,Terminated,"Bristol-Myers Squibb
National Institutes of Health/National Cancer Institute
Northwestern University",Oncology: Breast,First line; HER2 negative; Second line; Stage IV,Breast Neoplasms; Carcinoma; Inflammatory Breast Neoplasms,United States
Phase II Trial of Pembrolizumab in Central Nervous System Metastases From Multiple Histologies.,II,Closed,"Massachusetts General Hospital
Merck & Co./Merck Sharp & Dohme (MSD)","Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Cancer; Oncology: Unspecified Solid Tumor",CNS mets; First line; HER2 negative; HER2 positive; Second line; Stage IV; Triple receptor negative,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Second Primary; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",United States
"Randomized Phase II Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, With or Without Atezolizumab in Triple Negative Breast Cancer (TNBC)",II,Closed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Adjuvant; HER2 negative; Neoadjuvant; PD-L1 Positive; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Carcinoma; Triple Negative Breast Neoplasms,United States
A Randomized Phase II Study of Neoadjuvant Carboplatin/Paclitaxel (CT) Versus Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen for Newly Diagnosed Primary Triple-Negative Inflammatory Breast Cancer,II,Closed,"Amgen
MD Anderson Cancer Center, University of Texas",Oncology: Breast,(N/A); HER2 negative; Neoadjuvant; Triple receptor negative,Breast Neoplasms; Carcinoma; Erythema; Inflammatory Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Phase II Study Of Combination Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer,II,Closed,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Incyte Corporation",Oncology: Breast,(N/A); HER2 negative; Neoadjuvant; Triple receptor negative,Breast Neoplasms; Inflammatory Breast Neoplasms,United States
"A Phase II Study of Metformin in Combination With Doxycycline in Patients With Localized Breast, and Uterine, and Cervical Cancer.",II,Completed,"Kimmel Cancer Center-Thomas Jefferson University - Philadelphia, PA",Oncology: Breast; Oncology: Cervical; Oncology: Endometrial,First line; Stage III; Untreated,"Adenocarcinoma; Adenocarcinoma, Clear Cell; Breast Neoplasms; Carcinoma, Endometrioid; Carcinosarcoma; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Mixed Tumor, Mullerian; Uterine Cervical Neoplasms",United States
"A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy",III,Completed,Evive Biotech {Generon (Shanghai)},Oncology: Breast; Oncology: Supportive Care,Line of therapy N/A; Neutropenia; Stage II; Stage III; Stage IV,Breast Neoplasms; Neutropenia; Palliative Care,Hungary; Russia; Ukraine; United States
"Randomized Phase II Trial to Evaluate Alisertib Alone or Combined With Fulvestrant for Women With Advanced, Endocrine-resistant Breast Cancer",II,Completed,"National Institutes of Health/National Cancer Institute
Mayo Clinic",Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination With Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer",II,Closed,National Institutes of Health/National Cancer Institute,Oncology: Breast,BRCA; HER2 negative; PD-1 Naive; PD-L1 Naive; Second line; Stage III; Stage IV,Breast Neoplasms; Carcinoma,United States
IIT2015-11-Giuliano: Safety and Efficacy of Omission of Sentinel Node Biopsy for Breast Cancer Patients Who Plan to Have Adjuvant Chemotherapy,II,Terminated,Cedars-Sinai Medical Center,Oncology: Breast,Adjuvant; Stage I; Stage II,Breast Neoplasms,United States
"A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane Based Therapy",II,Completed,Roche {F. Hoffmann-La Roche},Oncology: Breast,First line; HER2 positive; PD-L1 Positive; Second line; Stage III; Stage IV,Breast Neoplasms,"Australia; Canada; Germany; Italy; South Korea; Spain; Taiwan, China; United Kingdom; United States"
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors,II,Closed,National Institutes of Health/National Cancer Institute,"Oncology: Anal; Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gallbladder; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Penile; Oncology: Prostate; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Small Intestine; Oncology: Soft Tissue Sarcoma; Oncology: Testicular; Oncology: Thyroid; Oncology: Unspecified Cancer; Oncology: Vaginal; Oncology: Vulvar",Adenocarcinoma; Advanced; Distal; Follicular; HER2 negative; Hilar; Intrahepatic; Metastatic; MSS/pMMR; Other; Other subtype; PD-1 Naive; PD-L1 High; PD-L1 Naive; PD-L1 Positive; Pulmonary; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative; Unspecified,"Adenocarcinoma; Adenocarcinoma of Lung; Adenocarcinoma, Bronchiolo-Alveolar; Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Adrenocortical Carcinoma; Anus Neoplasms; Bile Duct Neoplasms; Breast Neoplasms; Carcinoid Tumor; Carcinoma; Carcinoma, Acinar Cell; Carcinoma, Adenoid Cystic; Carcinoma, Basal Cell; Carcinoma, Endometrioid; Carcinoma, Giant Cell; Carcinoma, Hepatocellular; Carcinoma, Islet Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Cholangiocarcinoma; Chordoma; Choriocarcinoma; Colorectal Neoplasms; Cystadenocarcinoma; Cystadenocarcinoma, Mucinous; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Fibroma; Fibromatosis, Aggressive; Fibrosarcoma; Gallbladder Neoplasms; Gastrointestinal Stromal Tumors; Gestational Trophoblastic Disease; Head and Neck Neoplasms; Hemangiosarcoma; Intestinal Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Mesothelioma; Mixed Tumor, Mullerian; Nasopharyngeal Carcinoma; Neoplasms; Neoplasms, Basal Cell; Neoplasms, Germ Cell and Embryonal; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Nerve Sheath Neoplasms; Neuroendocrine Tumors; Neurofibrosarcoma; Ovarian Cancer; Ovarian Neoplasms; Paget Disease, Extramammary; Pancreatic Cancer; Pancreatic Neoplasms; Paraganglioma; Penile Neoplasms; Pheochromocytoma; Prostatic Neoplasms; Pseudomyxoma Peritonei; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Seminoma; Sex Cord-Gonadal Stromal Tumors; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Teratoma; Testicular Cancer; Testicular Neoplasms; Thyroid Neoplasms; Trophoblastic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Vaginal Neoplasms; Vulvar Neoplasms; Wilms Tumor",Guam; United States
"A Pilot Study of Pre-Operative, Single-Dose Ipilimumab, Nivolumab and Cryoablation in Early Stage/Resectable Breast Cancer",II,Completed,"Bristol-Myers Squibb
Memorial Sloan-Kettering Cancer Center",Oncology: Breast,HER2 negative; HER2 positive; Neoadjuvant; Stage I; Stage II,Breast Neoplasms,United States
Use of 64Cu-DOTA-Trastuzumab PET Imaging and Molecular Markers for Prediction of Response to Trastuzumab and Pertuzumab-Based Neoadjuvant Therapy,II,Completed,"National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center",Oncology: Breast,HER2 positive; Neoadjuvant; Stage III,Breast Neoplasms,United States
A Pilot Study Utilizing Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers,Other,Completed,(Other Hospital/Academic/Medical Center),"Oncology: Breast; Oncology: Colorectal; Oncology: GIST; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian",Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Liver Cancer; Liver Neoplasms; Ovarian Cancer; Ovarian Neoplasms",United States
"A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - (KEYNOTE-355)",III,Completed,Merck & Co./Merck Sharp & Dohme (MSD),Oncology: Breast,First line; HER2 negative; PD-1 Naive; PD-L1 Naive; PD-L1 Positive; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; Colombia; Czech Republic; Denmark; Finland; France; Germany; Hong Kong, S.A.R., China; Hungary; Ireland; Italy; Japan; Malaysia; Mexico; Netherlands; New Zealand; Poland; Russia; South Korea; Spain; Taiwan, China; Turkey; Ukraine; United Kingdom; United States"
"A Phase III Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine",III,Completed,"Nektar Therapeutics
Daiichi Sankyo",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage IV; Third line; Triple receptor negative,"Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis; Neoplasms, Second Primary",Australia; Austria; Belgium; Canada; Czech Republic; France; Germany; Hungary; Ireland; Israel; Italy; Netherlands; New Zealand; Poland; Portugal; Spain; Switzerland; United Kingdom; United States
"An Open-Label, Multi-Center Expanded Access Program of Abemaciclib for the Treatment of Hormone Receptor Positive, HER2 Negative Advanced or Metastatic Breast Cancer in Patients With Disease Progression on Prior Therapies",III,Completed,Eli Lilly,Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer Defined as Primary Tumor That is Her2-neu and Low (< 10%) ER/PR Nuclear Staining,II,Completed,Marker Therapeutics {TapImmune {GeneMax}},Oncology: Breast,HER2 negative; Maintenance/Consolidation; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Efficacy of Carboplatin and Paclitaxel With Trastuzumab and Pertuzumab (wPCbTP) and Switching to an Anthracycline-based Regimen (AC) in Non-responding Patients in Clinical Stage I-III HER2-positive Breast Cancer,II,Completed,"Rhode Island Hospital
(Other Hospital/Academic/Medical Center)
Women and Infants Hospital of Rhode Island",Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Randomized, Placebo-Controlled, Double-Blind, Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel (Nab-Paclitaxel, Abraxane) With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer",II,Completed,"National Institutes of Health/National Cancer Institute
University of Chicago Cancer Research Center
Bristol-Myers Squibb/Celgene",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase II Study of Lenvatinib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma",II,Completed,"Memorial Sloan-Kettering Cancer Center
Eisai","Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",Fourth line or greater; Second line; Stage IV; Third line,"Breast Neoplasms; Carcinoma; Carcinoma, Adenoid Cystic; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Neoplasms, Unknown Primary",United States
A Phase II Single Arm Study of Palbociclib in Patients With Metastatic HER2-Positive and Triple Negative Breast Cancer With Brain Metastasis,II,Terminated,"National Institutes of Health/National Cancer Institute
Pfizer
Northwestern University",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; HER2 negative; HER2 positive; Stage IV; Third line; Triple receptor negative,Brain Neoplasms; Breast Neoplasms; Carcinoma; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
Phase II Study of Single-dose Cyclophosphamide +Pembrolizumab In Patients with Metastatic Triple Negative Breast Cancer.,II,Completed,"UNC Lineberger Comprehensive Cancer Center
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,Fourth line or greater; HER2 negative; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS): A Randomized Phase II Study of Palbociclib With Letrozole Versus Letrozole Alone for Invasive Lobular Carcinoma and Invasive Ductal Carcinoma,II,Closed,"Pfizer
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Phase II Trial of Primary Endocrine Therapy With Combination of Fulvestrant and Palbociclib in Elderly Patients With Hormone Responsive Breast Cancer Who Have Inoperable Tumor Or Operable Tumor But Cannot Undergo Surgery Due to Frailty Or Who Refuse Surgery,II,Open,"Pfizer
Ohio State University",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
An Open-Label Phase II Study of MLN0128 (A TORC1/2 Inhibitor) in Combination With Fulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic Breast Cancer That Has Progressed During or After Aromatase Inhibitor Therapy,II,Terminated,Takeda/Takeda Oncology {Millennium},Oncology: Breast,Estrogen receptor positive; HER2 negative; Stage III; Stage IV; Third line,Breast Neoplasms,Spain; United States
A Randomized Phase II Clinical Trial Assessing the Efficacy and Safety of MK-3475 (Pembrolizumab) in Combination With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer,II,Closed,"Fox Chase Cancer Center
University of Wisconsin",Oncology: Breast,HER2 negative; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer,II,Completed,NYU Langone Health,Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
"A Phase III, Multicenter, Randomized, Double Blind, Study to Evaluate Duration of Severe Neutropenia With Plinabulin Versus Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (PROTECTIVE 1).",III,Completed,"BeyondSpring Pharmaceuticals
Dalian Wanchunbulin Pharmaceuticals
Pharmaceutics International","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Supportive Care",Fourth line or greater; Hormone refractory; Neutropenia; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neutropenia; Palliative Care; Prostatic Neoplasms",China; Russia; Ukraine; United States
Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR(+) Triple Negative Breast Cancer.,II,Completed,"Memorial Sloan-Kettering Cancer Center
Astellas Pharma
Pfizer {Medivation}",Oncology: Breast,Adjuvant; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"Histology-Independent Study of the Multikinase Inhibitor Lucitanib (E3810) in Patients With Advanced Cancer and Fibroblast Growth Factor Receptor (FGFR), Vascular Endothelial Growth Factor Receptors (VEGFR), or Platelet Derived Growth Factor Receptor (PDGFR) Pathway Aberrations",II,Terminated,Clovis Oncology,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Unspecified Cancer",FGFR; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms; Prostatic Neoplasms",United States
"A Randomized, Open-Label, Phase II Study of Abemaciclib Plus Tamoxifen or Abemaciclib Alone, in Women With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer",II,Completed,Eli Lilly,Oncology: Breast,Estrogen receptor positive; FGFR; HER2 negative; Progesterone receptor positive; Stage IV; Third line,Breast Neoplasms,"Argentina; Austria; Belgium; Brazil; Canada; Czech Republic; France; Germany; Italy; Mexico; Russia; Spain; Taiwan, China; Turkey; United States"
"A Multicenter, Open-label, Phase II Study of Imprime PGG and Pembrolizumab in Subjects With Advanced Melanoma Failing Front-line Treatment With Checkpoint Inhibitors (CPI) or TNBC Failing Front-line Chemotherapy for Metastatic Disease",II,Completed,"Merck & Co./Merck Sharp & Dohme (MSD)
HiberCell {Biothera Pharmaceuticals}",Oncology: Breast; Oncology: Melanoma,Estrogen receptor positive; HER2 negative; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Positive; PD-L1 Refractory; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Melanoma; Triple Negative Breast Neoplasms,United States
"Phase II Trial of Palbociclib With Fulvestrant in Individuals With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Who Have Progressed on Treatment With Palbociclib and an Aromatase Inhibitor",II,Closed,"National Institutes of Health/National Cancer Institute
Pfizer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as a Prophylaxis for Patients Receiving Chemotherapy With Intermediate Risk for Febrile Neutropenia - Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER),III,Completed,"Southwest Oncology Group
National Institutes of Health/National Cancer Institute
(Other Hospital/Academic/Medical Center)","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Supportive Care",First line; Neutropenia; Second line; Stage 0; Stage I; Stage II; Stage III; Stage IV,"Breast Carcinoma In Situ; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Febrile Neutropenia; Fever; Hyperthermia; Lung Neoplasms; Neutropenia; Palliative Care",Puerto Rico; United States
A Single Arm Phase II Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients,II,Completed,"Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute
Cedars-Sinai Medical Center
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,First line; Fourth line or greater; HER2 negative; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Pilot Study of Durvalumab (MEDI4736) in Combination With Vigil in Advanced Women's Cancers,II,Completed,"AstraZeneca
(Other Hospital/Academic/Medical Center)
Gradalis",Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal,First line; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Positive; PD-L1 Refractory; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Fallopian Tube Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms",United States
Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer,II,Terminated,"(Other Hospital/Academic/Medical Center)
Roche/Genentech",Oncology: Breast,First line; Neoadjuvant,Breast Neoplasms,United States
Window of Opportunity Study of Dasatinib in Operable Triple Negative Breast Cancers With Nuclear Epidermal Growth Factor Receptor,II,Terminated,"National Institutes of Health/National Cancer Institute
University of Wisconsin",Oncology: Breast,HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Neoplasms; Triple Negative Breast Neoplasms,United States
A Clinical Study on Genetic Predictors of Exemestane Pharmacokinetics and Pharmacodynamics in Healthy Human Volunteers,Other,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
"Femara (Letrozole) Plus Ribociclib (LEE011) or Placebo as Neo-adjuvant Endocrine Therapy for Women With ER-positive, HER2-negative Early Breast Cancer",II,Completed,Novartis,Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
An Observational Cohort Study Of Treatment Patterns And Outcomes In Patients With HER2 Positive (Her2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).,IV,Completed,Roche/Genentech,Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Stage IV,Breast Neoplasms,United States
Feasibility and Safety of Avoiding Granulocyte Colony-stimulating Factor Prophylaxis During the Paclitaxel Portion of Dose Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen,II,Completed,Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute,Oncology: Breast,Line of therapy N/A; Stage I; Stage II; Stage III,Breast Neoplasms,United States
A Phase II Randomized-double Blinded Placebo Controlled Window of Opportunity Trial Comparing Conjugated Estrogens/Bazedoxifene to Placebo in Women Undergoing Surgical Therapy for Ductal Carcinoma in Situ (DCIS),II,Open,"National Institutes of Health/National Cancer Institute
Pfizer
University of Chicago Cancer Research Center
Northwestern University
University of California, San Francisco",Oncology: Breast,Estrogen receptor positive; Neoadjuvant; Stage 0,"Breast Carcinoma In Situ; Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating",United States
Targeted Agent and Profiling Utilization Registry (TAPUR) Study,II,Open,"AstraZeneca
Bristol-Myers Squibb
Eli Lilly
(Other Cooperative Group)
Pfizer
Seagen {Seattle Genetics}
Bayer AG/Bayer Pharmaceuticals
Otsuka Holdings/Taiho Pharmaceutical
Merck & Co./Merck Sharp & Dohme (MSD)
Roche/Genentech","Oncology: Anal; Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Multiple Myeloma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid; Oncology: Unspecified Solid Tumor; Oncology: Vaginal",(N/A); Advanced; Aggressive; Anaplastic; BRAF; BRCA; Diffuse large B-cell lymphoma (DLBCL); Extranodal marginal zone B-cell lymphoma (MALT); FGFR; First line; Follicular lymphoma (FL); Fourth line or greater; Indolent; Lymphoblastic lymphoma (LBL); Mantle cell lymphoma (MCL); MET Amplification/Alteration; MSI-L; MSS/pMMR; Other subtype; Second line; Small lymphocytic lymphoma (SLL); Stage III; Stage IV; Third line; Unspecified; Waldenstrom's macroglobulinemia (WM),"Anus Neoplasms; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Fibrosarcoma; Gallbladder Neoplasms; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Neoplasms; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melanoma; Mesothelioma; Multiple Myeloma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Uterine Cervical Neoplasms; Vaginal Neoplasms; Waldenstrom Macroglobulinemia; Wilms Tumor",United States
A Phase IIB Study of Neoadjuvant ZT Regimen (Enzalutamide) Therapy in Combination With Weekly Paclitaxel) for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer,II,Open,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute
Astellas Pharma",Oncology: Breast,First line; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Carcinoma; Triple Negative Breast Neoplasms,United States
A Phase II Study of NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab (NEOADAPT),II,Terminated,Midwestern Regional Medical Center,Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II,Breast Neoplasms,United States
A Phase II Study to Determine the Pathological Complete Response Rate and Immunomodulatory Effects of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer,II,Terminated,Peregrine Pharmaceuticals,Oncology: Breast,HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Neoplasms; Triple Negative Breast Neoplasms,United States
Phase II Study of Neratinib in Patients 60 and Older With HER2 Positive Metastatic Breast Cancer,II,Completed,"National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center
Puma Biotechnology",Oncology: Breast,Fourth line or greater; HER2 negative; HER2 positive; Second line; Stage IV; Third line,Breast Neoplasms,United States
"monarcHER: A Phase II, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib plus Trastuzumab with or without Fulvestrant to Standard-of-Care Chemotherapy of Physician's Choice plus Trastuzumab in Women with HR+, HER2+ Locally Advanced or Metastatic Breast Cancer",II,Completed,Eli Lilly,Oncology: Breast,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,Argentina; Australia; Belgium; Brazil; Canada; France; Germany; Greece; Italy; Mexico; South Korea; Spain; United Kingdom; United States
A Phase II Study of MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors,II,Terminated,"AstraZeneca
Washington University School of Medicine","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",CNS mets; Other subtype; Second line; Stage IV,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Kidney Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Phase II Study Using Talimogene Laherparepvec for Inflammatory Breast Cancer (IBC) or Non-IBC Patients With Inoperable Local Recurrence,II,Terminated,"Amgen
MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma; Inflammatory Breast Neoplasms,United States
"A Phase III, Randomized, International Study Comparing the Efficacy and Safety of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer",III,Terminated,"Astellas Pharma
Pfizer {Medivation}",Oncology: Breast,First line; HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Argentina; Australia; Brazil; Canada; Japan; South Korea; Thailand; United States
"A Phase II Study of Adjuvant Therapy Using a Regimen of Cyclophosphamide, Paclitaxel With Trastuzumab in Stage I-II HER2/Neu Positive Breast Cancer Patients",II,Closed,"National Institutes of Health/National Cancer Institute
University of Nebraska Medical Center",Oncology: Breast,Adjuvant; First line; HER2 positive; Maintenance/Consolidation; Stage I; Stage II,Breast Neoplasms,United States
Phase II Safety Study of Palbociclib in Combination With Letrozole or Fulvestrant in African American Women With Hormone Receptor Positive HER2 Negative Advanced Breast Cancer,II,Completed,"Pfizer
(Other Hospital/Academic/Medical Center)
Kimmel Cancer Center-Thomas Jefferson University - Philadelphia, PA",Oncology: Breast,Estrogen receptor positive; HER2 negative; Line of therapy N/A; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,United States
A Single Arm Phase II Study of Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-016.,II,Closed,Pfizer,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Neoplasms,United States
Phase II Trial of Eribulin and Lenvatinib in Advanced Solid Tumors (CTMS# 15-2139),II,Closed,"Eisai
University of Texas Health Science Center at San Antonio","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Soft Tissue Sarcoma",Second line; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer,II,Terminated,University of Chicago Medical Center,Oncology: Breast,HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Prospective, Pilot Study on Characterization Of Circulating Myeloid Derived Suppressor Cells And Cytokines In Patients Undergoing Neo-Adjuvant Chemotherapy For Breast Cancer",IV,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
"A Randomized Phase II Trial of Fulvestrant With or Without Ribociclib After Progression on Aromatase Inhibition Plus Cyclin-dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer",II,Closed,"Novartis
Columbia University Medical Center",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
Phase II Study of Pemetrexed and Sorafenib for Treatment of Recurrent or Metastatic Triple Negative Breast Cancer,II,Terminated,"Eli Lilly
(Other Cooperative Group)
Bayer AG
Virginia Commonwealth University",Oncology: Breast,HER2 negative; Second line; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Prospective Study on TIMP-4 Expression Correlates with Disease Progression among HER2-positive Breast Cancers,Other,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,HER2 positive; Line of therapy N/A; Stage I; Stage II; Stage III,Breast Neoplasms,United States
A Phase II Study of Eribulin Followed by Doxorubicin and Cyclophosphamide as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer,II,Completed,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Eisai",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage III; Triple receptor negative,"Breast Neoplasms; Inflammatory Breast Neoplasms; Lymphoma, Non-Hodgkin",United States
Alternative Dosing of Exemestane in Postmenopausal Women With Stage 0-II ER-Positive Breast Cancer: A Randomized Presurgical Trial,II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Estrogen receptor positive; Neoadjuvant; Stage 0; Stage I; Stage II,Breast Carcinoma In Situ; Breast Neoplasms,Italy; United States
TME Neoadjuvant Breast Registry (The NEAT Registry),IV,Completed,(Other Academic Cancer Center),Oncology: Breast,Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
"Pilot ""Window of Opportunity"" Neoadjuvant Study of Propranolol in Breast Cancer",II,Terminated,University of Texas Health Science Center at San Antonio,Oncology: Breast,Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.",II,Closed,University of Kansas,Oncology: Breast; Oncology: Gastric,HER2 negative; HER2 positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gastrointestinal Neoplasms; Neoplasm Metastasis; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms,United States
Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy.,II,Completed,Indiana University School of Medicine,Oncology: Breast,HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
"Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxel (PaCT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy",II,Open,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast,HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate,II,Terminated,(Other Hospital/Academic/Medical Center),Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage IV; Third line; Triple receptor negative,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
"An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments",III,Completed,"Seagen {Seattle Genetics}
Gilead Sciences/Immunomedics",Oncology: Breast,BRCA; Fourth line or greater; HER2 negative; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Belgium; Canada; France; Germany; Ireland; Italy; Spain; United Kingdom; United States
"An Open-Label, Multicenter, Global Phase II Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Studies of Tumor Alterations Responsive to Targeting Receptor Kinases (STARTRK-2)",II,Closed,"Roche {F. Hoffmann-La Roche}
Mayne Pharma {Halcygen {Hospira/Mayne Pharma}}","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Neuroblastoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Penile; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Aggressive; ALK; Anaplastic; BRAF; CNS mets; First line; KRAS; NRAS; Peripheral T-cell lymphoma (PTCL); Second line; Stage III; Stage IV; Unspecified,"Bile Duct Neoplasms; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Cholangiocarcinoma; Cholangiocarcinoma; Colorectal Neoplasms; Fibrosarcoma; Glioblastoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral; Medulloblastoma; Melanoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Unknown Primary; Neuroblastoma; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Penile Neoplasms; Renal Cancer; Rhabdomyosarcoma; Salivary Gland Neoplasms; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Cancer, Papillary; Thyroid Neoplasms","Australia; Belgium; China; Denmark; Finland; France; Germany; Hong Kong, S.A.R., China; Ireland; Israel; Italy; Japan; Netherlands; Norway; Poland; Romania; Singapore; South Korea; Spain; Sweden; Switzerland; Taiwan, China; Thailand; United Kingdom; United States"
"A Phase II Multi-center, Single-Blind, Double Arm, Randomized, Controlled Study of NeuVax (nelipepimut-S) in Combination with Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus GM-CSF Alone in Patients with Ductal Carcinoma in Situ

VADIS Trial: Phase II Trial of Nelipepimut-S Peptide Vaccine in Women With DCIS of the Breast",II,Completed,"National Institutes of Health/National Cancer Institute
SELLAS Life Sciences Group {Galena Biopharma {RXi Pharmaceuticals {Apthera}}}",Oncology: Breast,Adjuvant; HER2 negative; HER2 positive; Neoadjuvant; Stage 0,"Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating",United States
A Phase II Study of Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Patients With Percutaneously Accessible Lesions With Advanced Melanoma Refractory to Pembrolizumab,II,Open,Lytix Biopharma,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Renal",BRAF; Fourth line or greater; HER2 negative; Merkel; MSI-H/dMMR; PD-1 Refractory; PD-L1 Positive; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neuroendocrine Tumors; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",France; Norway; Spain; United States
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial,III,Completed,"National Institutes of Health/National Cancer Institute
Bayer AG/Bayer Pharmaceuticals
US Department of Defense
Alliance for Clinical Trials in Oncology",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,Canada; Guam; Puerto Rico; United States
A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab Versus Single Agent Chemotherapy Per Physician's Choice for Metastatic Triple Negative Breast Cancer (mTNBC) - (KEYNOTE-119),III,Completed,Merck & Co./Merck Sharp & Dohme (MSD),Oncology: Breast,HER2 negative; PD-1 Naive; PD-L1 High; PD-L1 Naive; PD-L1 Positive; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,"Argentina; Australia; Belgium; Brazil; Colombia; Denmark; France; Germany; Guatemala; Hong Kong, S.A.R., China; Ireland; Italy; Japan; Malaysia; Mexico; Netherlands; New Zealand; Peru; Philippines; Poland; Russia; Singapore; South Africa; South Korea; Spain; Sweden; Switzerland; Taiwan, China; Thailand; Turkey; United Kingdom; United States"
"A Phase II, Double-Blind, Randomized, Multi-Center, Placebo-Controlled Study to Evaluate the Efficacy of TPIV-200 in Prolonging Disease-Free Survival in Women With Advanced Triple Negative Breast Cancer",II,Open,"Mayo Clinic
US Department of Defense
Marker Therapeutics {TapImmune {GeneMax}}",Oncology: Breast,HER2 negative; Second line; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"CADENCE: Carboplatin and Docetaxel in Neoadjuvant Treatment of ER-Negative, HER2-Negative Breast Cancer: A Co-Clinical Trial With Genoproteomic Discovery.",II,Completed,Baylor College of Medicine,Oncology: Breast,HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Triple receptor negative,Breast Neoplasms,United States
"An Open Label, Phase II Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal Fulvestrant in Women With Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy",II,Terminated,Atossa Therapeutics {Atossa Genetics},Oncology: Breast,Estrogen receptor positive; Neoadjuvant; Stage 0; Stage I; Stage II,"Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Intraductal, Noninfiltrating",United States
"15xxGCC: Phase II Trial of The EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors",II,Terminated,University of Maryland Greenebaum Cancer Center,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Unspecified Solid Tumor",Line of therapy N/A; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms, Unknown Primary; Prostatic Neoplasms",United States
LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer,II,Terminated,"University of California Los Angeles
Weill Medical College of Cornell University",Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
A Single Arm Phase II Study Evaluating the Efficacy and Safety of MEDI4736 in Combination With Tremelimumab in Patients With Metastatic Her2 Negative Breast Cancer,II,Completed,"(Other Cooperative Group)
National Institutes of Health/National Cancer Institute
Northwestern University
AstraZeneca {MedImmune}",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Second line; Stage IV,Breast Neoplasms,United States
"An Open-Label, Single-Arm, Phase II Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Central Nervous System Progression Post-Radiotherapy in Patients With HER2-Positive Metastatic Breast Cancer (PATRICIA)",II,Completed,Roche/Genentech,Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; First line; HER2 positive; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
A Multi-Centered Randomized Phase II Study Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer,II,Closed,"Novartis
Icahn School of Medicine at Mount Sinai {Mount Sinai School of Medicine}",Oncology: Breast,Fourth line or greater; HER2 negative; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A, a Pdl-1 Inhibitor in Patients With Triple Negative Breast Cancer",II,Completed,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast,Adjuvant; First line; HER2 negative; Neoadjuvant; Second line; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Carcinoma; Triple Negative Breast Neoplasms,United States
"A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients With Advanced Solid Tumors",II,Completed,AstraZeneca,Oncology: Bladder; Oncology: Breast; Oncology: Pancreas,Fourth line or greater; HER2 negative; PD-1 Naive; PD-L1 High; PD-L1 Naive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Adenocarcinoma; Breast Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms,Belgium; Netherlands; Poland; South Korea; United States
A Phase II Basket Study of the Oral TRK Inhibitor Larotrectinib in Subjects With NTRK Fusion-positive Tumors.,II,Open,"Bayer AG
Eli Lilly/Loxo Oncology
PCI Pharma Services
Bayer AG/Bayer China","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Anaplastic; Estrogen receptor positive; Follicular; Fourth line or greater; HER2 negative; MSI-H/dMMR; Papillary; Pediatric or Adolescent; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Fibrosarcoma; Gallbladder Neoplasms; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Medulloblastoma; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Wilms Tumor","Argentina; Australia; Belgium; Brazil; China; Colombia; Czech Republic; Denmark; France; Germany; Greece; Hungary; India; Ireland; Italy; Japan; New Zealand; Norway; Poland; Portugal; Russia; Singapore; Slovakia; South Korea; Spain; Sweden; Taiwan, China; Turkey; United Kingdom; United States"
Multicenter Study Investigating Utilization of Pharmacokinetic(PK)-Guided Docetaxel in Senior Adult Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy,IV,Terminated,H. Lee Moffitt Cancer Center and Research Institute,Oncology: Breast,Line of therapy N/A; Stage III,Breast Neoplasms,United States
"A Phase Ib/II, Open-Label, Multicentre Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck",II,Terminated,"Ionis Pharmaceuticals {Isis Pharmaceuticals}
AstraZeneca {MedImmune}",Oncology: Breast; Oncology: Head/Neck; Oncology: Prostate; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; First line; HER2 positive; Hormone refractory; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Positive; PD-L1 Refractory; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Neoplasms, Unknown Primary; Prostatic Neoplasms; Squamous Cell Carcinoma of Head and Neck",Belgium; Canada; Germany; Italy; Spain; United Kingdom; United States
PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer.,III,Terminated,"(Other Cooperative Group)
Breast International Group
National Surgical Adjuvant Breast and Bowel Project (NSABP)
Pfizer
Austrian Breast & Colorectal Cancer Study Group
Alliance for Clinical Trials in Oncology",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,"Australia; Austria; Bahrain; Belgium; Canada; China; France; Germany; Greece; Hong Kong, S.A.R., China; Hungary; Ireland; Israel; Italy; Japan; Mexico; Netherlands; Poland; Portugal; Singapore; South Korea; Spain; Sweden; Switzerland; Taiwan, China; United Kingdom; United States"
A Phase II Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors.,II,Closed,"AstraZeneca
National Institutes of Health/National Cancer Institute
(Other Hospital/Academic/Medical Center)","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Pancreas",Adenocarcinoma; ALK; BRCA; EGFR; Extensive; Fourth line or greater; HER2 negative; Large Cell; Limited; PD-1 Refractory; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Adenocarcinoma; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Small Cell Lung Carcinoma",Canada; United States
"Phase II Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis",II,Terminated,"Memorial Sloan-Kettering Cancer Center
Boehringer Ingelheim","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Supportive Care; Oncology: Thymus",(N/A); Aggressive; Classical; First line; Indolent; Nodular lymphocyte-predominant; Other; Pulmonary; Stage II; Thymoma; Untreated,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Mesothelioma; Neoplasms, Mesothelial; Neuroendocrine Tumors; Palliative Care; Pneumonia; Radiation Pneumonitis; Small Cell Lung Carcinoma; Thymoma; Thymus Neoplasms",United States
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases,II,Terminated,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute
Roche/Genentech
Alliance for Clinical Trials in Oncology","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer; Oncology: Unspecified Solid Tumor",Adjuvant; CNS mets; Second line; Stage IV,"Brain Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Neoplasms; Neoplasms, Second Primary; Neoplasms, Unknown Primary",Canada; United States
Randomized Pilot Trial of Omega-3 Fatty Acids or Placebo in Peri- or Post-Menopausal Women at High Risk for Breast Cancer Undergoing a Weight Loss Intervention,II,Completed,DSM Nutritional Products,Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms; Weight Loss,United States
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer,III,Open,"National Institutes of Health/National Cancer Institute
NRG Oncology",Oncology: Breast,Adjuvant; HER2 negative; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,Canada; United States
To Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly for Subjects With HER2 Negative Metastatic Breast Cancer,II,Completed,Eisai,Oncology: Breast,Fourth line or greater; HER2 negative; Stage IV; Third line,Breast Neoplasms,United States
Endocrine Treatment Alone as Primary Treatment for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score,II,Open,"Washington University School of Medicine
Exact Sciences {Genomic Health}",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage I; Stage II,Breast Neoplasms; Recurrence,United States
A Phase II Pilot Study Using Metformin to Reduce Cardiac Toxicity in Breast Cancer Patients,II,Terminated,(Other Hospital/Academic/Medical Center),Oncology: Breast,(N/A); Adjuvant; Neoadjuvant,Breast Neoplasms; Cardiotoxicity,United States
Phase II Study of Chemo-Radiation-Induced Abscopal Effect in Metastatic Breast Cancer and in Other Metastatic Sites of Solid Tumors,II,Completed,New York University,Oncology: Breast; Oncology: Thymus; Oncology: Unspecified Solid Tumor,Line of therapy N/A; Stage IV; Thymic carcinoma,"Breast Neoplasms; Neoplasms, Unknown Primary; Thymus Neoplasms",United States
Phase II Window of Opportunity Study of Short-term Preoperative Treatment With Enzalutamide (Alone or in Combination With Exemestane) in Patients With Primary Breast Cancer,II,Terminated,"(Other Hospital/Academic/Medical Center)
Astellas Pharma",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,Germany; Ireland; Spain; United Kingdom; United States
Molecular Analysis for Therapy Choice (MATCH).,II,Closed,"National Institutes of Health/National Cancer Institute
Roche/Genentech
ECOG-ACRIN Cancer Research Group","Oncology: Anal; Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: CNS, Oligodendroglioma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gallbladder; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Multiple Myeloma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Small Intestine; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",(N/A); Adenocarcinoma; Aggressive; BRAF; BRCA; Classical; EGFR; FGFR; Fourth line or greater; Grade 2; HER2 positive; HRAS; Indolent; Large Cell; Line of therapy N/A; MET Amplification/Alteration; MSI-H/dMMR; MSI-L; MSS/pMMR; Nodular lymphocyte-predominant; NRAS; PD-1 Positive; Pulmonary; Second line; Squamous Cell; Stage III; Stage IV; Third line; Unspecified,"Acute Myelocytic Leukemia; Anus Neoplasms; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Small Cell; Cholangiocarcinoma; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Glioblastoma; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Intestinal Neoplasms; Kidney Neoplasms; Leukemia, Myeloid, Acute; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Medulloblastoma; Melanoma; Multiple Myeloma; Neoplasms; Neoplasms, Basal Cell; Neoplasms, Plasma Cell; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Renal Cancer; Skin Neoplasms; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Testicular Cancer; Testicular Neoplasms; Thyroid Diseases; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms; Wilms Tumor",Guam; Puerto Rico; United States
"An Open-Label, Randomized, Phase II/III Trial of Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer",II/III,Terminated,Peregrine Pharmaceuticals,Oncology: Breast,HER2 negative; Line of therapy N/A; Stage II; Stage III; Stage IV,Breast Neoplasms,Germany; Spain; United States
"An Open-Label, Multicohort, Phase II Study of Atezolizumab in Advanced Solid Tumors",II,Completed,Roche {F. Hoffmann-La Roche},"Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: GIST; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Small Cell; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Thyroid",EGFR; Estrogen receptor positive; Follicular; Papillary; Pulmonary; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Mesothelioma; Neoplasms, Mesothelial; Neuroendocrine Tumors; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms; Unspecified; Uterine Cervical Neoplasms",Austria; Brazil; Canada; Denmark; Finland; France; Germany; Ireland; Italy; Netherlands; Norway; Poland; Russia; Spain; Switzerland; Turkey; United Kingdom; United States
"Phase II Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)",II,Completed,Seagen {Seattle Genetics/Cascadian Therapeutics {Oncothyreon {Biomira}}},Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,Australia; Austria; Belgium; Canada; Czech Republic; Denmark; France; Germany; Israel; Italy; Portugal; Spain; Switzerland; United Kingdom; United States
Tissue Procurement Protocol for Patients Undergoing Treatment for Early-Stage Breast Cancer,Other,Terminated,(Other Hospital/Academic/Medical Center),Oncology: Breast,Adjuvant; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization (QTc Duration) in Patients With Selected Solid Tumors,II,Completed,PharmaMar {Zeltia/PharmaMar},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Unspecified Solid Tumor",(N/A); Line of therapy N/A; Pulmonary; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Small Cell; Cholangiocarcinoma; Endometrial Neoplasms; Head and Neck Neoplasms; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Small Cell Lung Carcinoma",Spain; United States
Investigation of Circulating Tumor Cells From Cancer Patients Undergoing Radiation Therapy,IV,Completed,UNC Lineberger Comprehensive Cancer Center,"Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer; Oncology: Prostate; Oncology: Unspecified Solid Tumor",Neoadjuvant; Other mets; Stage I; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Neoplasm Metastasis; Neoplasms, Unknown Primary; Neoplastic Cells, Circulating; Prostatic Neoplasms; Uterine Cervical Neoplasms",United States
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy.,III,Terminated,"National Institutes of Health/National Cancer Institute
ECOG-ACRIN Cancer Research Group",Oncology: Breast,Adjuvant; HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Carcinoma,South Africa; United States
"neoMONARCH: A Phase II Neoadjuvant Trial Comparing the Biological Effects of 2 Weeks of Abemaciclib (LY2835219) in Combination With Anastrozole to Those of Abemaciclib Monotherapy and Anastrozole Monotherapy and Evaluating the Clinical Activity and Safety of a Subsequent 14 Weeks of Therapy With Abemaciclib in Combination With Anastrozole in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer",II,Completed,Eli Lilly,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,"Austria; Belgium; Canada; Germany; Italy; Netherlands; South Korea; Spain; Taiwan, China; United States"
"A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination with Fulvestrant for Men and Postmenopausal Women with Hormone Receptor Positive, HER2-negative Advanced Breast Cancer which Progressed on or after Aromatase Inhibitor Treatment",III,Completed,Novartis,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Czech Republic; Denmark; France; Germany; Greece; Hong Kong, S.A.R., China; Hungary; India; Israel; Italy; Japan; Lebanon; Mexico; Netherlands; Norway; Peru; Portugal; Romania; Russia; Singapore; South Africa; South Korea; Spain; Sweden; Taiwan, China; Thailand; Turkey; United Arab Emirates; United Kingdom; United States"
A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors,II,Completed,PharmaMar {Zeltia/PharmaMar},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma; Oncology: Testicular",BRCA; Fourth line or greater; HER2 negative; HER2 positive; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative; Unspecified,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Small Cell; Cholangiocarcinoma; Endometrial Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms",Belgium; France; Germany; Italy; Spain; Sweden; Switzerland; United Kingdom; United States
A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting,II,Closed,"University of California Medical Center, Irvine",Oncology: Breast,HER2 negative; HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
A Randomized Phase II Study of MCS110 Combined With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC),II,Terminated,Novartis,Oncology: Breast,First line; HER2 negative; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,"Australia; Austria; Belgium; France; Germany; Hong Kong, S.A.R., China; Italy; South Korea; Spain; Taiwan, China; Turkey; United States"
"A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer",III,Completed,"Roche/Chugai Pharmaceutical
Roche {F. Hoffmann-La Roche}",Oncology: Breast,BRCA; First line; HER2 negative; PD-L1 Positive; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Bosnia and Herzegovina; Brazil; Canada; Chile; Colombia; Costa Rica; Czech Republic; Denmark; Estonia; Finland; France; Germany; Greece; Guatemala; Hong Kong, S.A.R., China; Hungary; Italy; Japan; Latvia; Mexico; Norway; Panama; Poland; Portugal; Romania; Russia; Serbia; Singapore; Slovenia; South Korea; Spain; Sweden; Switzerland; Taiwan, China; Thailand; Turkey; Ukraine; United Kingdom; United States"
"A Randomized Double-blind, Placebo-controlled Study of Ribociclib in Combination With Fulvestrant for the Treatment of Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer Who Have Received no or Only One Line of Prior Endocrine Treatment",III,Completed,Novartis,Oncology: Breast,Estrogen receptor positive; FGFR; First line; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Bulgaria; Canada; China; Colombia; Czech Republic; Denmark; France; Germany; Hong Kong, S.A.R., China; Hungary; Israel; Italy; Jordan; Lebanon; Malaysia; Mexico; Netherlands; Norway; Poland; Portugal; Russia; Saudi Arabia; Singapore; South Africa; South Korea; Spain; Sweden; Switzerland; Taiwan, China; Thailand; Turkey; United Kingdom; United States"
A Phase II Trial of Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy,II,Completed,"Memorial Sloan-Kettering Cancer Center
Cedars-Sinai Medical Center",Oncology: Breast,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Traditional Incision and Drainage of Cutaneous Abscess Vs. Minimally Invasive Incision and Drainage With Vessel Loop: A Randomized Controlled Trail,II,Open,"Comprehensive Cancer Center of Wake Forest University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; First line; HER2 negative; HER2 positive; Second line; Stage IV; Third line; Triple receptor negative,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
ATOP Trial: Adjuvant Ado-Trastuzumab Emtansine (T-DM1) for Older Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,II,Closed,"National Institutes of Health/National Cancer Institute
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Randomized Open Label Phase II Trial of Neoadjuvant Carboplatin Plus Docetaxel or Carboplatin Plus Paclitaxel Followed by Doxorubicin Plus Cyclophosphamide in Stage I-III Triple-negative Breast Cancer,II,Completed,University of Kansas,Oncology: Breast,HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Phase II Study of Anti-PD-1 (MK-3475) Therapy in Patients With Metastatic Inflammatory Breast Cancer (IBC) or Non-IBC Triple Negative Breast Cancer (TNBC) Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy,II,Closed,"MD Anderson Cancer Center, University of Texas
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,HER2 negative; Maintenance/Consolidation; Second line; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma; Erythema; Inflammatory Breast Neoplasms; Triple Negative Breast Neoplasms,United States
[18F]Fluoroestradiol (FES) PET/CT Imaging to Evaluate in Vivo ER in Endocrine Refractory Metastatic Breast Cancer,II,Closed,University of Pennsylvania,Oncology: Breast,Estrogen receptor positive; Second line; Stage IV,Breast Neoplasms,United States
Investigator-Initiated Phase 2 Clinical Trial of Selinexor (KPT-330) for the Treatment of Metastatic Triple Negative Breast Cancer,II,Terminated,"H. Lee Moffitt Cancer Center and Research Institute
Karyopharm Therapeutics",Oncology: Breast,Fourth line or greater; HER2 negative; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Depressed anti-HER2 CD4 Th1 responses correlate with residual disease following neoadjuvant therapy in HER2+ breast cancer patients and can be restored by dendritic cell vaccination,II,Completed,University of Pennsylvania,Oncology: Breast,(N/A); Adjuvant; First line; HER2 positive; Neoadjuvant,Breast Neoplasms,United States
"A Phase II Clinical Trial of the PARP Inhibitor Talazoparib in BRCA1 and BRCA2 Wild Type Patients With Advanced Triple Negative Breast Cancer and Homologous Recombination Deficiency or Advanced HER2 Negative Breast Cancer or Other Solid Tumors With a Mutation in Homologous Recombination Pathway Genes

Talazoparib Beyond BRCA (TBB) Trial",II,Completed,"Pfizer
Stanford University Medical Center
BioMarin",Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Pancreas; Oncology: Testicular,Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Testicular Cancer; Testicular Neoplasms; Triple Negative Breast Neoplasms",United States
The IDEA Study (Individualized Decisions for Endocrine Therapy Alone),II,Closed,"Memorial Sloan-Kettering Cancer Center
Stanford University Medical Center
Loyola University
Medical College of Wisconsin Cancer Center
University of Michigan Comprehensive Cancer Center
Johns Hopkins University
University of Pennsylvania
(Other Hospital/Academic/Medical Center)
Yale University
Ohio State University
Harvard University Medical Center
University of Texas Southwest Medical Center",Oncology: Breast,Estrogen receptor positive; HER2 negative; Line of therapy N/A; Progesterone receptor positive; Stage I,Breast Neoplasms,United States
"Reversing Therapy Resistance With Epigenetic-immune Modification: Phase II Trial of Vorinostat, Tamoxifen and Pembrolizumab in Hormone Receptor Expressing Advanced Breast Cancer",II,Terminated,"(Other Cooperative Group)
University of California, San Francisco
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 positive; PD-1 High; PD-L1 Low; Second line; Stage IV; Third line,Breast Neoplasms,United States
A Phase II Study of BIBF1120 (Nintedanib) for Patients With Metastatic HER2-Negative Inflammatory Breast Cancer (IBC),II,Terminated,"MD Anderson Cancer Center, University of Texas
Boehringer Ingelheim",Oncology: Breast,HER2 negative; Second line; Stage IV,Breast Neoplasms; Inflammatory Breast Neoplasms,United States
An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide,II,Completed,Puma Biotechnology,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms; Diarrhea,Australia; Austria; Canada; France; Germany; Spain; United Kingdom; United States
Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer Previously Exposed to Inhibitors of the PI3K Pathway: A Phase II Study With Pharmacodynamics Markers,II,Completed,"University of California, San Francisco",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
A Phase II Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer (MBC) Who Have Received Prior HER2 Regimens for MBC,II,Completed,Spectrum Pharmaceuticals,Oncology: Breast,Fourth line or greater; HER2 positive; Second line; Stage IV; Third line,Breast Neoplasms,United States
Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.,II,Completed,"Bristol-Myers Squibb
Roche/Genentech {Genentech}",Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase II, Randomized, Open-Label, Two-arm Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination with Fulvestrant in Postmenopausal Women with ER+, HER2- Metastatic Breast Cancer Who Have Progressed on an Aromatase Inhibitor",II,Terminated,Bristol-Myers Squibb/Celgene,Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage IV,Breast Neoplasms,Belgium; France; Germany; Italy; Spain; United States
"A Randomized, Double-blind, Placebo-controlled Phase II Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)",II,Completed,Dompe,Oncology: Breast,First line; HER2 negative; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Belgium; Czech Republic; France; Italy; Poland; Spain; United States
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer,II/III,Closed,"National Institutes of Health/National Cancer Institute
NRG Oncology",Oncology: Breast,First line; HER2 negative; HER2 positive; Stage IV; Triple receptor negative,"Breast Neoplasms; Neoplasms; Neoplasms, Second Primary",Canada; Saudi Arabia; South Korea; United States
Phase II Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer,II,Completed,"MD Anderson Cancer Center, University of Texas
Bayer AG/Bayer Pharmaceuticals",Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; Estrogen receptor positive; First line; Fourth line or greater; Other mets; Progesterone receptor positive; Second line; Stage IV; Third line,Breast Neoplasms; Neoplasm Metastasis,United States
"Atavistic Chemotherapy and Immunotherapy in Advanced, Metastatic, and Otherwise Incurable and Lethal Cancers Under Conventional Treatments",II,Open,(Other Hospital/Academic/Medical Center),"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",First line; Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Glioblastoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified",Mexico; United States
Metformin for Reduction of Paclitaxel Treatment-Related Neuropathy in Patients With Breast Cancer: A Randomized Pilot Study,II,Terminated,"MD Anderson Cancer Center, University of Texas",Oncology: Breast; Oncology: Supportive Care,Line of therapy N/A; Neurotoxicity; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms; Palliative Care,United States
"Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.",II,Completed,"Sanofi {Sanofi-Aventis {Aventis}}
University of California Los Angeles",Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Taxotere, Trastuzumab and Pertuzumab) in Patients With HER2-positive and ER-Positive Breast Cancer (NeoHTTP Study)",II,Terminated,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
"A Randomized, Multicenter, Open Label Study of MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in Anthracycline Naive Patients With Locally Advanced/Metastatic HER2-Positive Breast Cancer",II/III,Terminated,Merrimack Pharmaceuticals,Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,Austria; Belgium; Canada; Czech Republic; France; Germany; Italy; Russia; Spain; United States
"The Methods and Compositions for Treating / Preventing Various Types of Cancer Which Comprise Administered an Effective Amount of Glyco-Polypeptides, Such as Comosain, Bromelainases, Ananase, and a Mixture Thereof. By Way of (a) MMAPKinase (Major Mitogen Activiting Protein Kinase), (B) TPKinase (Tryosine Phosphorylation Kinase) Inhibitors Which Induce Cascade Production of Interleukin II B, 6, 8 & TNFs Through TCRs/ CD-2, TCRs/ CD-3 of WBC",II,Completed,(Other Cooperative Group),"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Ovarian; Oncology: Prostate",Aggressive; Classical; Indolent; Nodular lymphocyte-predominant; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",United States
Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer Patients,IV,Completed,University of Michigan Comprehensive Cancer Center,Oncology: Breast,Adjuvant; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"Association of Baseline Pro-Inflammatory (IL-6, CRP) and Coagulation (D-dimer) Markers with Baseline Functional Status in Women with Breast Cancer (BC) undergoing Chemotherapy.",Other,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Line of therapy N/A; Stage I; Stage II; Stage III,Breast Neoplasms,United States
p16INK4a Expression and Chemotherapy Toxicity in Women with Early Stage Breast Cancer,Other,Open,(Other Hospital/Academic/Medical Center),Oncology: Breast,Adjuvant; HER2 negative; HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
A Phase II Study of Neoadjuvant Goserelin and Letrozole for Premenopausal Women with Estrogen Receptor Positive HER2 Negative Stage II and III Breast Cancer,II,Completed,"Washington University School of Medicine
(Other Hospital/Academic/Medical Center)",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,Brazil; United States
Molecular Profiling of Stage II and III Breast Cancer in Latin American Women Receiving Standard-of-Care Treatment,IV,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,HER2 negative; HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,Argentina; Brazil; Chile; Mexico; United States; Uruguay
The Impact of HER2 Heterogeneity on the Treatment of Early-stage HER2-positive Breast Cancer: a Phase II Study of T-DM1 in Combination with Pertuzumab in the Preoperative Setting,II,Completed,"Roche/Genentech {Genentech}
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute",Oncology: Breast,Estrogen receptor positive; HER2 positive; Maintenance/Consolidation; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Phase II, Open-Label, Randomized Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic ER+ /HER2- Breast Cancer Resistant to Aromatase Inhibitor Therapy",II,Terminated,Roche/Genentech {Seragon Pharmaceuticals},Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms,Australia; Germany; South Korea; Spain; United Kingdom; United States
Low dose capecitabine is effective and relatively nontoxic in breast cancer treatment.,II,Completed,"University of Alabama, Birmingham",Oncology: Breast,Adjuvant; Neoadjuvant; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
"A Multistage, Phase II Study Evaluating the Safety and Efficacy of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as First-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer",II,Terminated,"Exelixis
Roche {F. Hoffmann-La Roche}",Oncology: Breast,First line; HER2 negative; PD-L1 Positive; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,"Australia; Belgium; Czech Republic; France; Israel; Italy; Latvia; Lithuania; Romania; South Africa; South Korea; Spain; Taiwan, China; United Kingdom; United States"
A Single-arm Open-label Multi-centre Extension study of Pertuzumab Administered as a Single Agent or  in Combination with Other Anti-cancer Therapies in Patients Previously Enrolled in a Hoffmann-la  Roche-sponsored Pertuzumab study,III,Closed,Roche {F. Hoffmann-La Roche},Oncology: Breast; Oncology: Ovarian; Oncology: Unspecified Solid Tumor,HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Unspecified",Brazil; China; Costa Rica; France; Germany; Italy; Japan; Mexico; Peru; Poland; Portugal; South Korea; Spain; Ukraine; United Kingdom; United States
"A Pilot Study of Sirolimus (Rapamycin, Rapamune[Registered Trademark]) in Subjects With Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN",II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Renal; Oncology: Thyroid,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage II,"Breast Neoplasms; Carcinoma, Renal Cell; Hamartoma; Hamartoma Syndrome, Multiple; Kidney Neoplasms; Renal Cancer; Syndrome; Thyroid Neoplasms; Wilms Tumor",United States
Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk,II,Completed,"National Institutes of Health/National Cancer Institute
University of Arizona",Metabolic/Endocrinology: Obesity; Oncology: Breast,(N/A); Line of therapy N/A; Obese; Obese with other comorbidities; Overweight,Breast Neoplasms; Obesity,United States
Phase II Randomized Trial of Mugard Compared With Best Supportive Care for Prevention and Treatment of Stomatitis in Women With Hormone Receptor Positive Breast Cancer Initiating Treatment With Everolimus-based Endocrine Therapy.,II,Completed,"Jonsson Comprehensive Cancer Center, UCLA
Translational Oncology Research International",Oncology: Breast; Oncology: Supportive Care,Estrogen receptor positive; HER2 negative; Mucositis; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms; Mucositis; Palliative Care; Stomatitis,United States
"Testing for Atypia in Random Periareolar Fine Needle Aspiration (RPFNA) Cytology After 12 Months Metformin (1, 1-Dimethylbiguanide Hydrochloride) Chemoprevention Versus Placebo Control in Premenopausal Women",III,Closed,"National Institutes of Health/National Cancer Institute
Alliance for Clinical Trials in Oncology",Oncology: Breast,(N/A); BRCA; Line of therapy N/A,"Breast Carcinoma In Situ; Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Hyperplasia",United States
SAFE-HEaRt: A Pilot Study Assessing the Cardiac SAFEty of HER2 Targeted Therapy in Patients With HER2 Positive Breast Cancer and Reduced Left Ventricular Function,II,Completed,"Washington Hospital Center
(Other Hospital/Academic/Medical Center)
Roche/Genentech",Oncology: Breast,HER2 positive; Line of therapy N/A; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase II Trial of Liposomal Doxorubicin and Carboplatin in Patients with ER, PR, HER2 Negative Breast Cancer (TNBC)",II,Completed,"National Institutes of Health/National Cancer Institute
Cancer Institute of New Jersey",Oncology: Breast,Adjuvant; HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Intra-mammary Distribution of Transdermal Telapristone versus Oral Telapristone: A Randomized Window Trial in Women Undergoing Mastectomy,II,Completed,"National Institutes of Health/National Cancer Institute
Northwestern University",Oncology: Breast,BRCA; Line of therapy N/A; Stage 0; Stage I; Stage II,"Breast Carcinoma In Situ; Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular",United States
A Phase II Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy for Metastatic Triple-Negative Breast Cancer (mTNBC) - (KEYNOTE-086),II,Completed,Merck & Co./Merck Sharp & Dohme (MSD),Oncology: Breast,First line; Fourth line or greater; HER2 negative; PD-1 Naive; PD-L1 High; PD-L1 Naive; PD-L1 Positive; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Argentina; Australia; Belgium; Brazil; Canada; Colombia; France; Germany; Israel; Italy; Japan; Mexico; New Zealand; Puerto Rico; Russia; Singapore; South Africa; Spain; Turkey; United Kingdom; United States
A Phase IV Long-term Follow-up Study to Define the Safety Profile of Radium-223 Dichloride,IV,Closed,Bayer AG/Bayer Pharmaceuticals,Oncology: Breast; Oncology: Metastatic Cancer; Oncology: Prostate,Bone mets; Hormone refractory; Second line; Stage IV,Breast Neoplasms; Neoplasm Metastasis; Prostatic Neoplasms,"Australia; Belgium; Brazil; Canada; Chile; Czech Republic; Finland; France; Germany; Israel; Italy; Japan; Netherlands; Norway; Poland; Russia; Singapore; South Korea; Spain; Sweden; Taiwan, China; United Kingdom; United States"
"A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women with  Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer",II,Completed,"National Institutes of Health/National Cancer Institute
Alliance for Clinical Trials in Oncology",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Phase II Study of Etirinotecan Pegol (NKTR 102) in Patients With Refractory Brain Metastases and Advanced Lung Cancer or Metastatic Breast Cancer (MBC),II,Completed,"Stanford University Medical Center
Nektar Therapeutics","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Metastatic Cancer; Oncology: Neuroendocrine",CNS mets; EGFR; Extensive; First line; KRAS; NRAS; Pulmonary; Second line; Stage IV; Untreated,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Central Nervous System Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Neuroendocrine Tumors; Small Cell Lung Carcinoma",United States
"A Phase III, Double-Blind, Placebo-Controlled, Randomized Study of Taselisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy",III,Terminated,Roche {F. Hoffmann-La Roche},Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms; Recurrence,"Australia; Austria; Bosnia and Herzegovina; Bulgaria; Canada; China; Colombia; Czech Republic; Finland; France; Germany; Greece; Italy; Japan; Mexico; Netherlands; Peru; Poland; Portugal; Romania; Russia; Serbia; South Korea; Spain; Sweden; Taiwan, China; Thailand; Turkey; United States"
"A Phase II Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)",II,Terminated,Oncternal Therapeutics {GTx},Oncology: Breast,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Australia; Bulgaria; Czech Republic; Hungary; Lithuania; Romania; Ukraine; United Kingdom; United States
"A Phase II Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of 	GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women",II,Completed,Oncternal Therapeutics {GTx},Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms,Australia; Bulgaria; Czech Republic; Hungary; Lithuania; Romania; Ukraine; United Kingdom; United States
"A Phase III, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment",III,Completed,"MacroGenics
GC Biopharma Corp. {GC Pharma {Green Cross Corp.}}
Zai Lab",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms; Neoplasm Metastasis,Austria; Belgium; Canada; Czech Republic; Denmark; Finland; France; Germany; Israel; Italy; Netherlands; Poland; Portugal; Puerto Rico; South Korea; Spain; Switzerland; United Kingdom; United States
"A Phase II Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma",II,Completed,Eli Lilly,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer",CNS mets; Estrogen receptor positive; First line; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage IV,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Lung Neoplasms; Melanoma; Neoplasm Metastasis",Australia; Austria; Belgium; Canada; France; Israel; Italy; Spain; United States
"A Phase II Randomized, Double-Blind, Study of Ipatasertib (GDC-0068), an Inhibitor to AKT, in Combination With Paclitaxel as Neoadjuvant Treatment for Patients With Early Stage Triple Negative Breast Cancer",II,Completed,"(Other Cooperative Group)
Roche/Genentech",Oncology: Breast,HER2 negative; Neoadjuvant; PD-L1 Positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Portugal; Spain; United States
Phase II Study of Single-agent Pf-03084014 in Patients with Advanced Triple-negative Breast Cancer with or without Genomic Alterations in Notch Receptors,II,Terminated,Pfizer,Oncology: Breast,First line; HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Belgium; France; Germany; Hungary; Italy; Poland; Spain; United Kingdom; United States
"Pilot Clinical Trial Evaluating the Utility of Minocycline as an Agent to Decrease Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Paclitaxel-Induced Acute Pain Syndrome (P-APS): A Randomized Placebo-Controlled, Double Blind Trial",II,Completed,"National Institutes of Health/National Cancer Institute
Academic and Community Cancer Research United",CNS: Pain (neuropathic); CNS: Pain (nociceptive); Oncology: Breast; Oncology: Supportive Care,(N/A); Acute Pain; Adjuvant; Cancer-related; Cancers-related; Neoadjuvant; Neurotoxicity,Acute Pain; Breast Neoplasms; Cancer pain; Cancer Pain; Neuralgia; Nociceptive Pain; Palliative Care; Peripheral Nervous System Diseases,United States
A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer,II,Completed,"(Other Cooperative Group)
National Surgical Adjuvant Breast and Bowel Project (NSABP)
Pfizer
Royal Marsden NHS Trust
Cancer Research UK
Institute of Cancer Research - UK",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage I; Stage II,Breast Neoplasms,Canada; United Kingdom; United States
Phase II Open Label Study of Everolimus in Combination With Anti-estrogen Therapy in Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer,II,Completed,Novartis,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"Detection of Tumor DNA in Blood Samples From Patients With Late Stage Cancer and ""Healthy Controls""",IV,Completed,(Other Industry Sponsor),"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",First line; Metastatic; Second line; Stage II; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
The Eradication of Malignant Carcinoma in the Breast Tissue using an ATP (Adenosine-5'-Triphosphate) Inhibitor,II/III,Completed,(Other Cooperative Group),Oncology: Breast,(N/A); First line,Breast Neoplasms,United States
"A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy",III,Closed,"Southwest Oncology Group
National Institutes of Health/National Cancer Institute",Oncology: Breast,Adjuvant; HER2 negative; PD-L1 Positive; Stage 0; Stage I; Stage II; Stage III; Triple receptor negative,Breast Carcinoma In Situ; Breast Neoplasms; Carcinoma,Canada; Puerto Rico; United States
A Pilot Study of Talazoparib as a Neoadjuvant Study in Patients With a Diagnosis of Invasive Breast Cancer and a Deleterious BRCA Mutation,II,Completed,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute
Pfizer {Medivation}
BioMarin",Oncology: Breast,BRCA; Estrogen receptor positive; First line; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"Response, Resistance and Metastasis of Locally Advanced Breast Cancer (LABC, Stage 2B-3C) in a Multiethnic Cohort: A Phase II International Multicentric Study of Concurrent Paclitaxel and Radiation",II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,First line; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase III Randomized, Double-blind, Placebo-controlled Study of LEE011 or Placebo in Combination With Tamoxifen and Goserelin or a Non-steroidal Aromatase Inhibitor (NSAI) and Goserelin for the Treatment of Premenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer.",III,Completed,Novartis,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,"Argentina; Australia; Belgium; Brazil; Bulgaria; Canada; Colombia; France; Germany; Greece; Hong Kong, S.A.R., China; Hungary; India; Italy; Lebanon; Malaysia; Mexico; Poland; Portugal; Russia; Saudi Arabia; Singapore; South Korea; Spain; Switzerland; Taiwan, China; Thailand; Turkey; United Arab Emirates; United States"
ARTEMIS: A Robust TNBC Evaluation FraMework to Improve Survival,II,Open,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute
National Comprehensive Cancer Network",Oncology: Breast,HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Carcinoma,United States
"Phase II Evaluation of Real-Time, Pharmacokinetically Guided Everolimus in Patients With Hormone Receptor Positive Breast Cancer, Pancreatic Neuroendocrine Tumors (PNET), and Renal Cell Carcinoma",II,Terminated,"Novartis
Winship Cancer Institute of Emory University
Emory University Hospital - Atlanta",Oncology: Breast; Oncology: Neuroendocrine; Oncology: Renal,Estrogen receptor positive; HER2 negative; Metastatic; Pancreas; Progesterone receptor positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Islet Cell; Carcinoma, Renal Cell; Gastrinoma; Glucagonoma; Insulinoma; Kidney Neoplasms; Mucositis; Neuroendocrine Tumors; Pancreatic Neoplasms; Renal Cancer; Somatostatinoma; Wilms Tumor",United States
"Phase II Study of Everolimus Beyond Progression in Postmenopausal Women With Advanced, Hormone Receptor Positive Breast Cancer",II,Terminated,"Novartis
Winship Cancer Institute of Emory University",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Phase II Study of Cabozantinib Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases,II,Completed,"Roche/Genentech {Genentech}
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Exelixis",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; HER2 positive; MET Amplification/Alteration; Progesterone receptor positive; Second line; Stage IV; Third line; Triple receptor negative,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
"A Phase II Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride versus Placebo when administered to Metastatic HER2 Negative Hormone Receptor Positive Breast Cancer Subjects with Bone Metastases treated with Hormonal Treatment Background Therapy",II,Terminated,Bayer AG/Bayer Pharmaceuticals,Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Third line,Breast Neoplasms; Neoplasm Metastasis,"Austria; Canada; China; Czech Republic; Denmark; Finland; France; Germany; Hong Kong, S.A.R., China; Ireland; Israel; Netherlands; Norway; Poland; Singapore; South Korea; Spain; Switzerland; Taiwan, China; United Kingdom; United States"
"A Phase II Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus When Administered to Metastatic HER2 Negative Hormone Receptor Positive Breast Cancer Subjects With Bone Metastases",II,Completed,"Bayer AG/Bayer Pharmaceuticals
1st Biotherapeutics",Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms; Neoplasm Metastasis,"Austria; Belgium; Canada; China; Czech Republic; France; Germany; Hong Kong, S.A.R., China; Israel; Italy; Japan; Netherlands; Norway; Poland; Singapore; South Korea; Spain; Switzerland; Taiwan, China; United Kingdom; United States"
"Phase II Study of Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab- or Pertuzumab-Based Therapy",II,Completed,"Memorial Sloan-Kettering Cancer Center
(Other Hospital/Academic/Medical Center)
Roche {F. Hoffmann-La Roche}
Roche/Genentech",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 positive; Progesterone receptor positive; Second line; Stage IV; Third line,Breast Neoplasms,United States
Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer,IV,Completed,"(Other Industry Sponsor)
Icahn School of Medicine at Mount Sinai {Mount Sinai School of Medicine}",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Neoadjuvant Phase II Trial of Aromatase Inhibitors in Combination With Everolimus in Postmenopausal Women With Hormone Receptor Positive/HER2 Negative Breast Cancers With Low and Intermediate Risk (< 25) Oncotype Dx Recurrence Scores,II,Terminated,"Novartis
Yale University",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,United States
Randomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) (ADVANCE),III,Completed,Spectrum Pharmaceuticals,Oncology: Breast; Oncology: Supportive Care,Adjuvant; Neoadjuvant; Neutropenia; Stage I; Stage II; Stage III,Breast Neoplasms; Neutropenia; Palliative Care,Canada; South Korea; United States
Evaluation of Miracle Mouthwash (MMW) Plus Hydrocortisone and Prednisolone Mouth Rinse as Prophylaxis for Everolimus-Associated Stomatitis,II,Completed,"Novartis
US Oncology Research",Oncology: Breast; Oncology: Supportive Care,Estrogen receptor positive; Mucositis; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms; Mucositis; Neoplasms; Palliative Care; Stomatitis,United States
"Randomized Phase II Trial of Chemotherapy of Physician's Choice Plus Trastuzumab Versus Chemotherapy of Physician's Choice Plus Trastuzumab Plus Pertuzumab In Women With Pretreated, HER2-Overexpressing Metastatic Breast Cancer (MBC)",II,Terminated,"US Oncology Research
Roche/Genentech",Oncology: Breast,Fourth line or greater; HER2 positive; Second line; Stage IV; Third line,Breast Neoplasms; Neoplasms,United States
A Pilot Study of 64Cu-DOTA-trastuzumab Positron Emission Tomography in Treatment of Advanced HER2 Positive Breast Cancer With the Antibody Drug Conjugate Ado-trastuzumab Emtansine,II,Completed,"National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center",Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; HER2 positive; Liver mets; Other mets; Second line; Stage IV,"Breast Neoplasms; Liver Neoplasms; Neoplasm Metastasis; Neoplasms, Second Primary",United States
"A Pilot Study Evaluating the Effect of 'R' (Electro-Kinetically Altered Beverage) on Insomnia, Fatigue and Depression in Breast Cancer Patients Receiving Adjuvant Chemotherapy",II,Terminated,"(Other Cooperative Group)
Revalesio",Oncology: Breast,Adjuvant; Stage I; Stage II,Breast Neoplasms; Depression; Fatigue; Sleep Initiation and Maintenance Disorders,United States
"An Open-Label, Phase II, Study to Evaluate Biomarkers Associated with Response to Subsequent Therapies in Subjects with HER2-Positive Metastatic Breast Cancer Receiving Treatment with Trastuzumab in Combination with Lapatinib or Chemotherapy (EGF117165)",II,Terminated,"GlaxoSmithKline
Novartis",Oncology: Breast,HER2 positive; Maintenance/Consolidation; Second line; Stage IV,Breast Neoplasms,"Argentina; Austria; Brazil; Canada; China; Hong Kong, S.A.R., China; Ireland; Italy; Mexico; Netherlands; Peru; Philippines; Portugal; Russia; Spain; Thailand; United States"
A Trial of Endocrine Response in Women With Invasive Lobular Breast Cancer.,Other,Open,"AstraZeneca
(Other Cooperative Group)
University of Pittsburgh",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"The GLORIA Study: A Phase III, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With High Risk, Early Stage Globo H-Positive Triple Negative Breast Cancer",III,Open,OBI Pharma,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage 0; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,"Argentina; Australia; Brazil; China; France; Germany; Hong Kong, S.A.R., China; Mexico; Peru; Poland; Russia; South Africa; South Korea; Spain; Taiwan, China; Ukraine; United States"
Phase II Pre-emptive OsciLLation of ER activitY Levels Through Alternation of Estradiol/Anti-estrogen Therapies Prior to Disease Progression in ER+/HER2- Metastatic or Advanced Breast Cancer,II,Closed,Dartmouth-Hitchcock Medical Center,Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms,United States
Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 8 - LEE011 for Patients with CDK4/6 Pathway Activated Tumors,II,Completed,Novartis,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Renal; Oncology: Soft Tissue Sarcoma",(N/A); Adenocarcinoma; Aggressive; Classical; Cutaneous T-cell lymphoma (CTCL); Diffuse large B-cell lymphoma (DLBCL); Extranodal marginal zone B-cell lymphoma (MALT); First line; Follicular lymphoma (FL); Fourth line or greater; HER2 negative; Indolent; Lymphoblastic lymphoma (LBL); Nodular lymphocyte-predominant; Other subtype; Peripheral T-cell lymphoma (PTCL); Second line; Small lymphocytic lymphoma (SLL); Stage III; Stage IV; Third line; Triple receptor negative; Waldenstrom's macroglobulinemia (WM),"Acute Myelocytic Leukemia; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Waldenstrom Macroglobulinemia; Wilms Tumor",United States
"Safety, Feasibility and Efficacy of Vitamin D Supplementation in Women With Metastatic Breast Cancer (SAFE-D)",II,Completed,Loyola University,Oncology: Breast,Estrogen receptor positive; Line of therapy N/A; Stage IV,Breast Neoplasms,United States
"A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination with Paclitaxel vs. Paclitaxel alone in Patients with Metastatic or Locally Recurrent Breast Cancer",II,Completed,"Takeda/Takeda Oncology {Millennium}
US Oncology Research",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Neoplasms,United States
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module - 7 Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1,II,Terminated,Novartis,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Skin, Basal Cell Carcinoma; Oncology: Soft Tissue Sarcoma",Aggressive; Classical; Diffuse large B-cell lymphoma (DLBCL); Follicular lymphoma (FL); Gastrointestinal; Indolent; Mantle cell lymphoma (MCL); Nodular lymphocyte-predominant; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Glioblastoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Medulloblastoma; Melanoma; Neoplasms; Neoplasms, Basal Cell; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",United States
"A Randomized, Double-blind Pharmacokinetic Study Of Pf-05280014 Plus Taxotere (Registered) And Carboplatin Versus Herceptin (Registered) Plus Taxotere (Registered) And Carboplatin For The Neoadjuvant Treatment Of Patients With Operable Her2-positive Breast Cancer",III,Completed,Pfizer,Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II,Breast Neoplasms,Belarus; Croatia; Czech Republic; Hungary; Italy; Poland; Puerto Rico; Russia; Serbia; Slovakia; Spain; Ukraine; United States
"A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer with no Prior Systemic Therapy in this Disease Setting",III,Completed,Eli Lilly,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,"Australia; Austria; Belgium; Canada; France; Germany; Greece; Israel; Italy; Japan; Mexico; Netherlands; New Zealand; Puerto Rico; Russia; Slovakia; South Korea; Spain; Sweden; Taiwan, China; Turkey; United Kingdom; United States"
Phase lll Efficacy and Safety Study of CT-P6 and Herceptin as Neoadjuvant and Adjuvant Treatment in Patients With Her2-positive Early Breast Cancer,III,Completed,"Nippon Kayaku
Celltrion",Oncology: Breast,Adjuvant; HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,"Argentina; Belarus; Bosnia and Herzegovina; Brazil; Bulgaria; Chile; Croatia; Ecuador; France; Georgia; Greece; Hungary; India; Italy; Japan; Latvia; Mexico; Montenegro; Netherlands; Peru; Philippines; Poland; Portugal; Romania; Russia; Serbia; South Africa; South Korea; Spain; Taiwan, China; Thailand; Turkey; Ukraine; United States"
"A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer",II,Completed,"Pfizer {Array BioPharma}
Roche/Genentech",Oncology: Breast,First line; HER2 negative; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,"Belgium; France; Italy; Singapore; South Korea; Spain; Taiwan, China; United States"
Randomized Phase II Study of IMMU-132 alone or in Combination with Carboplatin in Patients with Relapsed/Refractory Triple-Negative Breast Cancer,II,Terminated,Gilead Sciences/Immunomedics,Oncology: Breast,Fourth line or greater; HER2 negative; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"An Open Label, Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer",II,Completed,"GlaxoSmithKline
University of Alabama, Birmingham
Breast Cancer Research Foundation
AbbVie",Oncology: Breast,First line; HER2 negative; Second line; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Management of stomatitis associated with mTOR inhibitor in hormone receptor positive/ HER- negative advance breast cancer,II,Terminated,(Other Hospital/Academic/Medical Center),Oncology: Breast; Oncology: Supportive Care,Estrogen receptor positive; HER2 negative; Line of therapy N/A; Mucositis; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms; Mucositis; Palliative Care,United States
"A Phase II Randomized, Double-Blind Study of Neoadjuvant Letrozole Plus GDC-0032 Versus Letrozole Plus Placebo in Postmenopausal Women With ER-positive/HER2-negative, Early Stage Breast Cancer",II,Completed,"(Other Cooperative Group)
Breast International Group
Austrian Breast & Colorectal Cancer Study Group
EORTC Breast Cancer Group
Roche/Genentech",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,Australia; Austria; Belgium; Brazil; Chile; Czech Republic; El Salvador; France; Germany; Guatemala; Hungary; Italy; Mexico; Panama; Peru; Poland; Portugal; Russia; South Korea; Spain; Switzerland; Ukraine; United Kingdom; United States
Randomized Study Evaluating Molecular Profiling and Targeted Agents in Metastatic Cancer: Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II),II,Open,"MD Anderson Cancer Center, University of Texas
(Other Hospital/Academic/Medical Center)","Oncology: Breast; Oncology: Melanoma; Oncology: Skin, Basal Cell Carcinoma; Oncology: Unspecified Cancer",KRAS; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Basal Cell; Melanoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Basal Cell; Recurrence",United States
Serial [F-18] Fluoroestradiol (FES) PET Imaging to Evaluate Endocrine-Targeted Therapy,II,Terminated,"National Institutes of Health/National Cancer Institute
University of Washington",Oncology: Breast,Estrogen receptor positive; Line of therapy N/A; Stage IV,Breast Neoplasms,United States
Phase II study of Anti-HER3 antibody Patritumab in Breast Cancer,II,Completed,Daiichi Sankyo {U3 Pharma},Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
"An Expanded Access Study Of Palbociclib In Combination With Letrozole As Treatment Of Post-menopausal Women With Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate",III,Completed,Pfizer,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,Canada; United States
Predictive value of  circulating tumor cells (CTCs) biomarkers status in patients with metastatic breast cancer (MBC) receiving anti-HER2 therapy,Other,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; HER2 positive; Line of therapy N/A; Progesterone receptor positive; Stage IV,Breast Neoplasms,China; United States
"Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases",II,Completed,"Southwest Oncology Group
National Institutes of Health/National Cancer Institute",Oncology: Breast; Oncology: Metastatic Cancer,BRCA; CNS mets; First line; HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Brain Neoplasms; Breast Neoplasms; Carcinoma; Central Nervous System Neoplasms; Neoplasm Metastasis; Neoplasms,Puerto Rico; United States
"A Multicenter, Multinational, Phase II Study to Evaluate Pertuzumab in Combination with Trastuzumab and Standard Neoadjuvant Anthracycline-based Chemotherapy in Patients with HER2-Positive, Locally Advanced, Inflammatory, or Early-Stage Breast Cancer",II,Completed,"Roche {F. Hoffmann-La Roche}
Roche/Genentech",Oncology: Breast,Adjuvant; HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,Brazil; Canada; Costa Rica; Denmark; Dominican Republic; El Salvador; France; Germany; Guatemala; Italy; Mexico; Norway; Poland; Portugal; Spain; United Kingdom; United States
Phase II Trial of Combination Immunotherapy with Nelipepimut-S + GM-CSF (NeuVax) and Trastuzumab in High-risk HER2+ Breast Cancer Patients,II,Completed,"MD Anderson Cancer Center, University of Texas
US Department of Defense
SELLAS Life Sciences Group {Galena Biopharma {RXi Pharmaceuticals {Apthera}}}
Roche/Genentech",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Maintenance/Consolidation; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
A Co-clinical Trial in Triple Negative Breast Cancer Patients with Genoproteomic Discovery,II,Terminated,"National Institutes of Health/National Cancer Institute
Washington University School of Medicine
Breast Cancer Research Foundation
Genexine/NeoImmuneTech",Oncology: Breast,HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer",II,Terminated,Incyte Corporation,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,France; Italy; Portugal; Spain; United Kingdom; United States
Prospective Observational Study of Breast Cancer Patients Starting Therapy With an AI to Evaluate Mechanisms Underlying Development of Aromatase Inhibitor Associated Musculoskeletal Symptoms,IV,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; Line of therapy N/A; Progesterone receptor positive; Stage I; Stage II; Stage III,Arthralgia; Breast Neoplasms,United States
"A Phase II Open-Label Study to Evaluate the Efficacy and Safety of VT-464 in Patients With Metastatic Castration Resistant Prostate Cancer Who Have Previously Been Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer",II,Completed,"National Institutes of Health/National Cancer Institute
Innocrin Pharmaceuticals",Oncology: Breast; Oncology: Prostate,Estrogen receptor positive; First line; HER2 negative; Hormone refractory; Second line; Stage IV; Triple receptor negative,Breast Neoplasms; Prostatic Neoplasms; Triple Negative Breast Neoplasms,United States
Registry to Demonstrate the Clinical Utility of CELLSEARCH Circulating Tumor Cell (CTC) Test in Medicare-Eligible Metastatic Breast Cancer Patients,IV,Terminated,"Johnson & Johnson/Janssen R&D {Johnson & Johnson/J&JPRD}
The Cleveland Clinic Foundation",Oncology: Breast,Line of therapy N/A; Stage IV,Breast Neoplasms,United States
"A Phase II, Randomized, Double-Blind, Multicenter Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer (ENCORE 305)",II,Terminated,Syndax,Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer",III,Completed,Eli Lilly,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,"Australia; Belgium; Canada; Denmark; Finland; France; Germany; Greece; Italy; Japan; Mexico; Poland; Puerto Rico; Romania; Russia; South Korea; Spain; Switzerland; Taiwan, China; United States"
"A Phase II Study Of LY2835219 For Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer.",II,Completed,Eli Lilly,Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,Belgium; France; Italy; Spain; United States
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158.,II,Completed,"(Other Cooperative Group)
Indiana University Cancer Center
Walther Cancer Institute",Oncology: Breast,First line; HER2 negative; Stage 0; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Neoplasms; Triple Negative Breast Neoplasms,United States
GCC 1366: A Prospective Study of Neoadjuvant Non-Steroidal Aromatase Inhibitors to Evaluate Anti-Proliferative Response in Obese and Overweight Patients,II,Open,University of Maryland Greenebaum Cancer Center,Oncology: Breast,HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms; Overweight,United States
"A Phase II, Multicenter, Open-label Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Subjects With HER2+ AR+ Metastatic or Locally Advanced Breast Cancer",II,Completed,"Astellas Pharma
Pfizer {Medivation}",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 positive; Progesterone receptor positive; Second line; Stage 0; Stage I; Stage II; Stage III; Stage IV; Third line,Breast Neoplasms,Belgium; Canada; Italy; Spain; United Kingdom; United States
"My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents",II,Completed,Roche/Genentech,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Metastatic Cancer; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",ALK; BRAF; BRCA; EGFR; Fourth line or greater; HER2 negative; HER2 positive; KRAS; PD-1 Naive; PD-L1 Naive; Peritoneal mets; Progesterone receptor positive; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gallbladder Neoplasms; Head and Neck Neoplasms; Neoplasm Metastasis; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia.,II,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Anal; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Supportive Care",(N/A); Cachexia; Pulmonary; Second line,"Anus Neoplasms; Breast Neoplasms; Cachexia; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Chronic Lymphocytic Leukemia; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Leukemia, Lymphocytic, Chronic, B-Cell; Liposarcoma; Liver Cancer; Liver Neoplasms; Multiple Myeloma; Myelodysplastic Syndromes; Neuroendocrine Tumors; Palliative Care; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Wilms Tumor",United States
A Phase II Clinical Trial of TPIV110 Vaccine (Her2neu Vaccine Conjugate) in Combination with Trastuzumab in Women with HER2 Positive (NER2/neu) Breast Cancer,II,Completed,"Mayo Clinic
US Department of Defense
Marker Therapeutics {TapImmune {GeneMax}}",Oncology: Breast,(N/A); HER2 positive; Line of therapy N/A,Breast Neoplasms,United States
A Phase III Study Of Paclitaxel Injection Concentrate For Nanodispersion In Metastatic Breast Cancer Patients,III,Terminated,Sun Pharma Advanced Research,Oncology: Breast,Line of therapy N/A; Stage IV,Breast Neoplasms,United States
"A Phase II, Single Arm Study of the Use of Steroid-based Mouthwash to Prevent Stomatitis in Postmenopausal Women With Advanced or Metastatic Hormone Receptor Positive Breast Cancer Being Treated With Everolimus Plus Exemestane",II,Completed,Novartis,Oncology: Breast; Oncology: Supportive Care,Estrogen receptor positive; First line; HER2 negative; HER2 positive; Mucositis; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms; Mucositis; Palliative Care; Stomatitis,United States
Real Time Contrast Enhanced Ultrasound and Ultrasound-Based Elastography: Novel Techniques in Assessment of Treatment Response to Neoadjuvant Chemotherapy for Breast Cancer,II,Terminated,"(Other Cooperative Group)
National Institutes of Health/National Cancer Institute
University of Southern California",Oncology: Breast,(N/A); Neoadjuvant,Breast Neoplasms,United States
Randomized Open Label PhII Trial of Neoadjuvant Trastuzumab Emtansine (Te) in Combination w/Lapatinib (L) Followed by Abraxane (A) Compared w/Trastuzumab Plus Pertuzumab Followed by Paclitaxel in Her 2 Neu Over-Expressed Breast Cancer Patients,II,Completed,"Novartis
Bristol-Myers Squibb/Celgene
(Other Hospital/Academic/Medical Center)",Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Pilot Study of Hydroxytyrosol, a Component of Olive Oil for Breast Cancer Prevention In Women At High Risk Of Breast Cancer",II/III,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,BRCA; Line of therapy N/A; Stage 0,Breast Neoplasms,United States
"Prospective Study To Validate The Predictive Value Of Mammostrat Score, DDR Score And TLE3 Gene When A Taxane-Based Chemo Agents Or Anthracycline-Based Chemo Agent Is Used In The Neo-Adjuvant Setting.",II,Terminated,"GE Healthcare
(Other Hospital/Academic/Medical Center)",Oncology: Breast,HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
"A Randomized Open-label Phase II Study of Letrozole Plus Afatinib Versus Letrozole Alone in First-line Treatment of Advanced ER+, HER2- Postmenopausal Breast Cancer With Low ER Expression",II,Completed,"Boehringer Ingelheim
Translational Oncology Research International",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Stage III; Stage IV,Breast Neoplasms,Bosnia and Herzegovina; Romania; Spain; United States
A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS).,II,Completed,"National Institutes of Health/National Cancer Institute
ECOG-ACRIN Cancer Research Group",Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Phase II Study to Evaluate the Efficacy, Safety, and Central Nervous System (CNS) Pharmacokinetics of the HER Family Inhibitor Dacomitinib in Progressive Brain Metastases",II,Terminated,"Pfizer
University of California San Diego","Oncology: Breast; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer",CNS mets; HER2 positive; Second line; Stage IV,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Melanoma; Neoplasm Metastasis; Stomach Carcinoma; Stomach Neoplasms",United States
A Randomized Phase II/III Study of Eryaspase in Combination With Gemcitabine and Carboplatin Chemotherapy Versus Chemotherapy Alone for the Treatment of Patients With Metastatic or Locally Recurrent Triple-Negative Breast Cancer,II/III,Completed,ERYtech Pharma,Oncology: Breast,First line; HER2 negative; Second line; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Belgium; France; Hungary; Netherlands; Spain; United Kingdom; United States
A Phase II Pilot Feasibility Study of Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive Invasive Breast Carcinoma,II,Completed,"Pfizer
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,United States
A Phase II Trial: Safety and Tolerance of Intravenous 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Malignancies Involving the Central Nervous System,II,Completed,"National Institutes of Health/National Cancer Institute
Tulane Cancer Center
Icahn School of Medicine at Mount Sinai {Mount Sinai School of Medicine}
University of Texas- Houston Medical School
(Other Hospital/Academic/Medical Center)
Dekk-Tec","Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer",CNS mets; Second line; Stage III; Stage IV,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Glioblastoma; Liver Cancer; Liver Neoplasms; Medulloblastoma; Melanoma; Neoplasm Metastasis; Neoplasms",United States
A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer.,III,Completed,"National Institutes of Health/National Cancer Institute
Eisai
Academic and Community Cancer Research United",Oncology: Breast,First line; HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms,Canada; United States
"A Phase II, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673) Administered to Germline BRCA Mutation Subjects With Locally Advanced and/or Metastatic Breast Cancer",II,Completed,"Myrexis {Myriad Pharmaceuticals {Myriad Genetics}}
Pfizer {Medivation}",Oncology: Breast,BRCA; Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,France; Germany; Spain; United Kingdom; United States
"A Randomized, Placebo-Controlled, Double-Blind, Phase III Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer (TNBC)",III,Completed,"(Other Cooperative Group)
Grupo Espanol de investigacion del Cancer de Mama
National Surgical Adjuvant Breast and Bowel Project (NSABP)
Austrian Breast & Colorectal Cancer Study Group
Spanish Breast Cancer Research Group
US Oncology Research
German Breast Group
AbbVie
Alliance for Clinical Trials in Oncology",Oncology: Breast,BRCA; HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,"Australia; Austria; Belgium; Canada; Czech Republic; France; Germany; Hungary; Israel; Italy; Netherlands; Poland; Russia; South Korea; Spain; Sweden; Taiwan, China; United Kingdom; United States"
The Role of FLT PET Early Assessment of Response to Endocrine Therapy for Early Stage Breast Cancer,Other,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage I; Stage II,Breast Neoplasms,United States
Evaluation of Response to Two Schedules of Capecitabine in Patients With Metastatic Breast Cancer,IV,Completed,"(Other Cooperative Group)
Breast Cancer Research Foundation",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,Argentina; Mexico; Peru; United States
Two-week change in optical tomography predicts residual cancer burden score in women treated with neoadjuvant chemotherapy,II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,HER2 negative; HER2 positive; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
Breast Cancer Genome Guided Therapy Study (BEAUTY),Other,Closed,Mayo Clinic,Oncology: Breast,BRCA; Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
A Pilot Study of Beta-Blockers in Patients With Advanced Cancer,II,Completed,(Other Academic Cancer Center),Oncology: Breast; Oncology: Liver; Oncology: Melanoma; Oncology: Ovarian; Oncology: Unspecified Solid Tumor,First line; Second line; Stage III; Stage IV,"Breast Neoplasms; Breast Neoplasms, Male; Carcinoma, Hepatocellular; Carcinoma, Ovarian Epithelial; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms",United States
Presurgical Treatment with Letrozole in Patients with Early-stage Breast Cancer,Other,Completed,Dartmouth-Hitchcock Medical Center,Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Study of Circulating Myeloid Derived Suppressor Cells (MDSC) in Patients with Breast Cancer Undergoing Neo-Adjuvant Chemotherapy.,Other,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Triple receptor negative,Breast Neoplasms,United States
"A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) with or without Estrogen Deprivation",III,Completed,"Roche/Genentech {Genentech}
National Surgical Adjuvant Breast and Bowel Project (NSABP)
National Institutes of Health/National Cancer Institute
NRG Oncology",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Neoadjuvant; PD-1 Positive; PD-L1 Positive; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms; Carcinoma,Canada; Puerto Rico; United States
Phase II Multicenter Single-arm Study of BKM120 Plus Capecitabine for Breast Cancer Patients With Brain Metastases,II,Completed,"Novartis
US Oncology Research",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Estrogen receptor positive; HER2 negative; HER2 positive; Second line; Stage IV; Triple receptor negative,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
Phase II Study of Trastuzumab and Pertuzumab Alone and in Combination With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over With HER2/Neu Overexpressed Locally Advanced and/or Metastatic Breast Carcinoma,II,Terminated,Roche/Genentech,Oncology: Breast,First line; Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety of Enzalutamide in Combination with Exemestane in Patients with Advanced Breast Cancer that is Estrogen or Progesterone Receptor Positive and HER2-Normal",II,Completed,"Astellas Pharma
Pfizer {Medivation}",Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,Belgium; Canada; Ireland; Italy; Spain; United Kingdom; United States
"A Phase III, Open Label, Randomized, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutations",III,Completed,"AstraZeneca
Myrexis {Myriad Pharmaceuticals {Myriad Genetics}}",Oncology: Breast,BRCA; Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,"Bulgaria; China; Czech Republic; France; Hungary; Italy; Japan; Mexico; Peru; Poland; Romania; Russia; South Korea; Spain; Switzerland; Taiwan, China; Turkey; United Kingdom; United States"
18F-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET/CT) for the Evaluation of Response to Therapy in Bone-dominant Metastatic Breast Cancer,IV,Closed,Abramson Cancer Center at  University of Pennsylvania Medical Center,Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; Estrogen receptor positive; First line; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms; Neoplasm Metastasis,United States
A Single Arm Phase II Trial to Assess Association of BRCA1 Protein Expression with Overall Response Rate in Patients with Metastatic Breast Cancer on Pegylated Liposomal Doxorubicin,II,Terminated,University of Arizona,Oncology: Breast,Line of therapy N/A; Stage IV,Breast Neoplasms,United States
A Phase II Study With Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR),II,Completed,Takeda/Takeda Oncology {Millennium},Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
"A Phase II, Randomized, Open-label, Multicenter, Safety and Efficacy Study of Oral Lucitanib in Patients With FGF Aberrant Metastatic Breast Cancer",II,Terminated,Clovis Oncology,Oncology: Breast,Estrogen receptor positive; FGFR; HER2 negative; HER2 positive; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,United States
A Randomized Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Patients With Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker,II,Completed,"(Other Cooperative Group)
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Myrexis {Myriad Pharmaceuticals {Myriad Genetics}}",Oncology: Breast,BRCA; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase III Randomized, Double-blind Study Of Pf-05280014 Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel For The First-line Treatment Of Patients With Her2-positive Metastatic Breast Cancer",III,Completed,Pfizer,Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Stage IV,Breast Neoplasms,"Argentina; Australia; Brazil; Canada; Chile; Croatia; Czech Republic; Georgia; Greece; Hong Kong, S.A.R., China; Hungary; India; Italy; Japan; Latvia; Mexico; Peru; Philippines; Poland; Portugal; Puerto Rico; Romania; Russia; Serbia; Slovakia; South Africa; South Korea; Spain; Thailand; Turkey; Ukraine; United States"
"Nanoemulsion Curcumin for Obesity, Inflammation and Breast Cancer Prevention - a Pilot Trial",II,Completed,Ohio State University,Oncology: Breast,Second line; Stage 0,"Breast Carcinoma In Situ; Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Hyperplasia",United States
Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes,II,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: CNS, Other; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Meningioma; Neoplasms, Unknown Primary; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
"A Phase II, Open-Label, Multi-Center Study of ANG1005 in  Breast Cancer Patients With Recurrent Brain  Metastases",II,Completed,"Merck & Co. {Schering-Plough/Integrated Therapeutics}
AngioChem",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; HER2 negative; HER2 positive; Line of therapy N/A; Stage IV; Triple receptor negative,"Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis; Neoplasms, Second Primary",United States
"A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer",II,Completed,"GlaxoSmithKline
National Institutes of Health/National Cancer Institute",Oncology: Breast,Fourth line or greater; HER2 negative; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Carcinoma; Triple Negative Breast Neoplasms,United States
"A Randomized, Multicenter, Open-label, Phase III Trial Comparing Trastuzumab Plus Pertuzumab Plus a Taxane following Anthracyclines Versus Trastuzumab Emtansine Plus Pertuzumab Following Anthracyclines as Adjuvant Therapy in Patients with Operable HER 2 Positive Primary Breast Cancer",III,Completed,"Roche/Chugai Pharmaceutical
Roche {F. Hoffmann-La Roche}",Oncology: Breast,Adjuvant; HER2 positive; Stage I; Stage II,Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Bosnia and Herzegovina; Brazil; Bulgaria; Canada; Chile; Colombia; Croatia; Czech Republic; Denmark; El Salvador; France; Georgia; Germany; Guatemala; Hong Kong, S.A.R., China; Hungary; Ireland; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; New Zealand; Norway; Panama; Peru; Philippines; Poland; Portugal; Romania; Russia; Serbia; Singapore; Slovenia; South Africa; South Korea; Spain; Sweden; Switzerland; Taiwan, China; Thailand; Turkey; Ukraine; United Kingdom; United States; Uruguay"
Phase II Trial of Exemestane With Immunomodulatory Cyclophosphamide in ER and/or PR-positive and HER2/Neu Negative Metastatic Breast Cancer,II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Third line,Breast Neoplasms,United States
Next Generation Sequencing to Evaluate Breast Cancer Subtypes and Genomic Predictors of Response to Therapy in the Preoperative Setting for Stage II-III Breast Cancer,II,Completed,"National Institutes of Health/National Cancer Institute
(Other Hospital/Academic/Medical Center)",Oncology: Breast,HER2 negative; HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Randomized Double-blind, Placebo-controlled Study of LEE011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease",III,Completed,Novartis,Oncology: Breast,Estrogen receptor positive; FGFR; First line; HER2 negative; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Brazil; Canada; Czech Republic; Denmark; Finland; France; Germany; Hungary; Ireland; Israel; Italy; Lebanon; Netherlands; Norway; Russia; Singapore; South Africa; South Korea; Spain; Sweden; Taiwan, China; Thailand; Turkey; United Kingdom; United States"
Neoadjuvant Phase II Trial of Paclitaxel in Combination With BKM120 in Endocrine Resistant Clinical Stage II or III Estrogen Receptor-Positive and HER2 Negative Breast Cancer,II,Terminated,Washington University School of Medicine,Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study,III,Closed,"National Institutes of Health/National Cancer Institute
Alliance for Clinical Trials in Oncology",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,"Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Carcinoma, Lobular",Puerto Rico; United States
Phase II Study of Denosumab to Define the Role of Bone Related Biomarkers in Breast Cancer Bone Metastasis,II,Terminated,"Amgen
MD Anderson Cancer Center, University of Texas",Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; Estrogen receptor positive; First line; Second line; Stage IV,Breast Neoplasms; Neoplasm Metastasis,United States
"A Multicentre, Randomized Study of Trastuzumab Combined With Chemotherapy or Endocrine Therapy as the First Line Treatment for Patients With Metastatic Luminal B2 Breast Cancer Subtype",III,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Stage IV,Breast Neoplasms,China; United States
"Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Of Fulvestrant (Faslodex) With Or Without PD-0332991 (palbociclib) + or - Goserelin In Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Whose Disease Progressed After Prior Endocrine Therapy.",III,Completed,"AstraZeneca
Pfizer",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; KRAS; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,"Australia; Belgium; Canada; France; Germany; Ireland; Italy; Japan; Mexico; Netherlands; Portugal; Romania; Russia; South Korea; Switzerland; Taiwan, China; Turkey; Ukraine; United Kingdom; United States"
"Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer.",II,Terminated,"Sanofi {Sanofi-Aventis {Aventis}}
Memorial Sloan-Kettering Cancer Center
Pfizer",Oncology: Breast,Adjuvant; HER2 positive; Stage II; Stage III,Breast Neoplasms,United States
A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases,II,Terminated,"University of California Medical Center, Irvine",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; First line; Second line; Stage IV,"Brain Neoplasms; Breast Neoplasms; Breast Neoplasms, Male; Central Nervous System Neoplasms; Neoplasm Metastasis",United States
A Phase II Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) with Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients with Primary Operable HER2-Positive Breast Cancer,II,Completed,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center},Oncology: Breast,First line; HER2 positive; Neoadjuvant; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
"Pilot Study of Hepatic Arterial Infusion (HAI) With Oxaliplatin, Folinic Acid and 5 Fluorouracil (FOLFOX) in Heavily Pre-Treated Patients With Liver-Predominant Metastasis From Breast Cancer",II,Terminated,Midwestern Regional Medical Center,Oncology: Breast; Oncology: Metastatic Cancer,Liver mets; Second line; Stage III; Stage IV,Breast Neoplasms; Liver Neoplasms; Neoplasm Metastasis,United States
A Pilot Study of Immunochemotherapy + or - Hypofractionated Radiation for Complete Response in Solid Tumors (I-CREST),II,Terminated,(Other Hospital/Academic/Medical Center),"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell",ALK; EGFR; HER2 negative; Second line; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Triple Negative Breast Neoplasms",United States
"A Randomized, Double-Blind, Placebo-Controlled Trial Investigating the Effect of Vandetanib on Cellular Markers of Proliferation and Apoptosis in Invasive Breast Cancer",II,Terminated,"AstraZeneca
University of Iowa",Oncology: Breast,Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Phase II Study With Lead-in Safety Cohort of Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases.,II,Terminated,"GlaxoSmithKline
Novartis
Sanofi {Sanofi-Aventis}",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; First line; HER2 positive; Second line; Stage IV,"Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis; Neoplasms, Second Primary",United States
"Imaging Early Response of ER+, HER2- Breast Cancer to Aromatase Inhibitor (AI) + or - Ovarian Suppression (OS) Therapy with [18F]Fluorothymidine (FLT) PET",Other,Completed,"National Institutes of Health/National Cancer Institute
University of Washington",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III,"Breast Neoplasms; Breast Neoplasms, Male",United States
Quantitative Dynamic PET and MRI and Breast Cancer Therapy.,II,Completed,"National Institutes of Health/National Cancer Institute
Washington University",Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Stage II; Stage III,"Breast Neoplasms; Breast Neoplasms, Male",United States
Neoadjuvant Phase II Study Of Everolimus Plus Cisplatin In Triple Negative Breast Cancer Patients With Residual Disease After Standard Chemotherapy,II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,(N/A); HER2 negative; Neoadjuvant; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Phase II Study of Stereotactic Radiosurgery Plus HER-2 Directed Therapy in HER2-positive Breast Cancer with Brain Metastasis,II,Terminated,University of Maryland School of Medicine,Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; HER2 positive; Neoadjuvant; Stage IV,"Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis; Neoplasms, Second Primary",United States
"A Phase II Randomized, Double-Blind Placebo Controlled, Study Of Letrozole With Or Without BYL719 Or Buparlisib, For The Neoadjuvant Treatment Of Postmenopausal Women With Hormone Receptor-Positive HER2-Negative Breast Cancer",II,Completed,Novartis,Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,"Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Colombia; Czech Republic; Germany; Hong Kong, S.A.R., China; Israel; Italy; Japan; Lebanon; Netherlands; Spain; United States"
A Randomized Pre-surgical Pharmacodynamics Study to Assess the Biological Activity of LEE011 Plus Letrozole Versus Single Agent Letrozole in Primary Breast Cancer,II,Terminated,Novartis,Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II,Breast Neoplasms,Belgium; France; Italy; Netherlands; Singapore; Spain; United States
"An Open-Label, Phase II Basket Study of Neratinib in Patients With Solid Tumors With Somatic Activating HER Mutations.",II,Completed,Puma Biotechnology,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Distal; EGFR; Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; HER2 positive; Hilar; Intrahepatic; PD-1 Refractory; PD-L1 Refractory; Progesterone receptor positive; Second line; Stage I; Stage II; Stage III; Stage IV; Third line; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Gallbladder Neoplasms; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Australia; Belgium; Canada; Denmark; Finland; France; Ireland; Israel; Italy; Serbia; South Korea; Spain; United Kingdom; United States
"An Open-label, Randomized, Multi-center, Single-Dose, 2-Sequence, 2-Period, Crossover, Comparative Bioequivalence Study of IG-001 (Cb-paclitaxel) 260 mg/m2 Versus Nab-paclitaxel 260 mg/m2 Administered Intravenously With an Open-Label Extension of IG-001 in Patients With Metastatic or Locally Recurrent Breast Cancer  

TRIal designed to evaluate BioEquivalence between Cynviloq and Abraxane (TRIBECA)",III,Completed,Sorrento Therapeutics/Scilex Pharmaceuticals {Scilex Holding {SCILEX Pharmaceuticals}},Oncology: Breast,Second line; Stage IV,Breast Neoplasms,Bulgaria; Georgia; Hungary; Moldova Republic; Romania; Serbia; Singapore; Ukraine; United States
"A Phase II Study of Eribulin Mesylate in Combination with Trastuzumab and Pertuzumab in Women with Metastatic, Unresectable Locally Advanced, or Locally Recurrent Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer",II,Terminated,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Eisai
Roche/Genentech",Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
Phase II Trial of Metronomic Eribulin (Halaven) In Pretreated Metastatic Breast Cancer (MBC),II,Completed,"National Institutes of Health/National Cancer Institute
University of Washington",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
Prospective Tissue Collection in Breast Cancer Patients Receiving Preoperative Systemic Therapy,Other,Closed,"National Institutes of Health/National Cancer Institute
Albert Einstein Medical College",Oncology: Breast,HER2 negative; HER2 positive; Neoadjuvant; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
"A Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study To Assess The Efficacy And Safety Of Olaparib Versus Placebo As Adjuvant Treatment In Patients With gBRCA1/2 Mutations And High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment And Neoadjuvant Or Adjuvant Chemotherapy",III,Completed,"AstraZeneca
(Other Cooperative Group)
Breast International Group
National Surgical Adjuvant Breast and Bowel Project (NSABP)
National Institutes of Health/National Cancer Institute
Cancer Research UK
EORTC Breast Cancer Group
Myrexis {Myriad Pharmaceuticals {Myriad Genetics}}
Merck & Co./Merck Sharp & Dohme (MSD)
Alliance for Clinical Trials in Oncology
NRG Oncology",Oncology: Breast,Adjuvant; BRCA; Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Czech Republic; Denmark; Finland; France; Germany; Hungary; Iceland; Israel; Italy; Japan; Netherlands; Poland; Portugal; Puerto Rico; South Korea; Spain; Sweden; Switzerland; Taiwan, China; United Kingdom; United States"
"A Randomized, Open-Label, Parallel Group, Multicentre Phase III Study to Assess the Impact on Pathological Complete Response Rate of Adding Olaparib To Paclitaxel in The Neoadjuvant Setting In Patients With BRCA-m Triple-Negative Breast Cancer",III,Terminated,"AstraZeneca
(Other Cooperative Group)
Breast International Group
German Breast Group",Oncology: Breast,BRCA; HER2 negative; Neoadjuvant; Second line; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,Canada; Germany; United States
Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients with Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy,II,Completed,"National Institutes of Health/National Cancer Institute
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute",Oncology: Breast,HER2 negative; Neoadjuvant; Stage 0; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms; Carcinoma; Inflammatory Breast Neoplasms,United States
Metronomic Capecitabine With Digoxin for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment,II,Terminated,Midwestern Regional Medical Center,Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
"A Phase II, Single-arm, Open-label, Multicenter Study Of The Clinical Activity And Safety Of Enzalutamide In Patients With Advanced, Androgen Receptor-positive, Triple-negative Breast Cancer",II,Completed,"Astellas Pharma
Pfizer {Medivation}",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Belgium; Canada; Ireland; Italy; Spain; United Kingdom; United States
N-telopeptide of type I collagen (NTX) dynamics over one year of determinations in patients with breast cancer (BC) with bone metastases (BM): Predictive factors of outcome.,Other,Completed,Grunenthal/Thar Pharmaceuticals,Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; Line of therapy N/A; Stage IV,Breast Neoplasms; Neoplasm Metastasis,Portugal; United States
Window of Opportunity Study Targeting the Inflammatory Milieu of Pregnancy Associated Breast Cancer,Other,Completed,University of Colorado Cancer Center at University of Colorado Health Sciences Center,Oncology: Breast,Neoadjuvant; Stage 0; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase II/III, Multi-Center, Open-Label, Randomized Study of Weekly Nab-Paclitaxel in Combination With Gemcitabine or Carboplatin, Compared to Gemcitabine/Carboplatin, as First Line Treatment in Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer

tnAcity (triple-negative Albumin-bound paclitaxel combination international treatment study)",II/III,Terminated,Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}},Oncology: Breast,First line; HER2 negative; Stage 0; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Argentina; Australia; Austria; Brazil; Canada; Finland; France; Germany; Greece; Italy; Japan; Portugal; Spain; Sweden; United Kingdom; United States
"Women's Triple-Negative First-Line Study: A Phase II Trial of Liposomal Doxorubicin, Bevacizumab and Everolimus (DAE) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy
ARTEMIS: A Randomized, TNBC-Enrolling trial to confirm Molecular profiling Improves Survival",II,Completed,"Novartis
Southwest Oncology Group
MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast,HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma,United States
Investigation of the pharmacogenetic influences of carbonyl reductase on doxorubicin and doxorubicinol in breast cancer patients,Other,Completed,"Roswell Park Cancer Institute
National Institutes of Health",Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
Phase II Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab With or Without Paclitaxel in Her2+ Metastatic Breast Cancer (MBC),II,Terminated,Southwest Oncology Group,Oncology: Breast,HER2 positive; Line of therapy N/A; Stage IV,Breast Neoplasms,United States
"Fulvestrant Alone Versus Fulvestrant and Everolimus Versus Fulvestrant, Everolimus and Anastrozole: A Phase III Randomized Placebo-Controlled Trial in Postmenopausal Patients",III,Terminated,"AstraZeneca
Novartis
Southwest Oncology Group",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage IV,Breast Neoplasms,United States
Phase II Trial of Metronomic Capecitabine and Cyclophosphamide With Lapatinib and Ttrastuzumab in Patients With HER2 Positive Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-Based Regimen,II,Terminated,"National Institutes of Health/National Cancer Institute
USC/Norris Comprehensive Cancer Center and Hospital",Oncology: Breast,First line; HER2 positive; Second line; Stage IV; Third line,Breast Neoplasms,United States
"A Randomized, Placebo-Controlled Phase II Clinical Trial of Omega-3 PUFA Dietary Supplementation in Patients With Stage I-III Breast Carcinoma",II,Completed,"National Institutes of Health/National Cancer Institute
Comprehensive Cancer Center of Wake Forest University",Oncology: Breast,First line; Stage I; Stage II; Stage III,"Breast Carcinoma In Situ; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular",United States
"A Phase III, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of Talazoparib (BMN 673) Versus Physician's Choice in Germline BRCA Mutation Subjects With Locally Advanced and/or Metastatic Breast Cancer, Who Have Received Prior Chemotherapy Regimens for Metastatic Disease.",III,Completed,"(Other Cooperative Group)
US Oncology Research
Myrexis {Myriad Pharmaceuticals {Myriad Genetics}}
Pfizer {Medivation}",Oncology: Breast,BRCA; Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,"Australia; Belgium; Brazil; Canada; France; Germany; Ireland; Israel; Italy; Poland; Russia; South Korea; Spain; Taiwan, China; Ukraine; United Kingdom; United States"
Phase II Study to Investigate Concurrent Lapatinib and Radiotherapy in Locally Advanced or Locally Recurrent Breast Cancer and the Impact on Breast Cancer Stem Cells,II,Terminated,"National Institutes of Health/National Cancer Institute
Stanford University Medical Center",Oncology: Breast,Second line; Stage III,"Breast Neoplasms; Breast Neoplasms, Male",United States
"Phase III Study Evaluating Palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in Patients With Hormone-receptor-positive, HER2-normal Primary Breast Cancer With High Relapse Risk After Neoadjuvant Chemotherapy ""PENELOPEB""",III,Completed,"(Other Cooperative Group)
Breast International Group
Pfizer
AGO-Study Group Ovarian Cancer
German Breast Group",Oncology: Breast,Adjuvant; Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,Australia; Austria; Belgium; Brazil; Canada; France; Germany; Ireland; Israel; Italy; Japan; South Korea; Spain; United Kingdom; United States
"A Pilot, Nonrandomized, Open-label Study on the Impact Of UGT2B17 Genetic Polymorphisms On The Disposition Of Exemestane In Healthy Volunteers",Other,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
"A Single Arm, Preoperative, Pilot Study to Evaluate the Safety and Biological Effects of Orally Administered Reparixin in Early Breast Cancer Patients Who Are Candidates for Surgery",II,Terminated,Dompe,Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Triple receptor negative,Breast Neoplasms,United States
"Single Arm, Neoadjuvant, Phase II Trial of Pertuzumab and Trastuzumab Administered Concomitantly With Weekly Paclitaxel and FEC for Clinical Stage I-II HER2-Positive Breast Cancer",II,Completed,"Roche/Genentech {Genentech}
Yale University",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Phase II, Randomized, Double-blind, Parallel Group, Pivotal, Efficacy Study of Netupitant in combination with Palonosetron for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy (HEC).",II,Completed,Helsinn Healthcare,"Oncology: Bladder; Oncology: Breast; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Renal; Oncology: Supportive Care",(N/A); Emesis; First line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Head and Neck Neoplasms; Kidney Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Palliative Care; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Vomiting; Wilms Tumor",Germany; Russia; Switzerland; Ukraine; United States
"Topical Menthol for Chemotherapy Induced Peripheral Neuropathy (CIPN): A Randomized, Placebo Controlled Phase II Trial",II,Terminated,Columbia University Medical Center,CNS: Pain (neuropathic); Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gallbladder; Oncology: Gastric; Oncology: Ovarian; Oncology: Small Intestine; Oncology: Supportive Care; Oncology: Vaginal; Oncology: Vulvar,Cancers-related; Neurotoxicity; Second line; Stage I; Stage II; Stage III,Breast Neoplasms; Cancer pain; Cancer Pain; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Intestinal Neoplasms; Neuralgia; Ovarian Neoplasms; Palliative Care; Stomach Neoplasms; Uterine Cervical Neoplasms; Vaginal Neoplasms; Vulvar Neoplasms,United States
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial),II,Completed,Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Stage I,Breast Neoplasms,United States
"A Multicenter Phase II Study Of Docosahexaenoic Acid (DHA) In Patients With A History Of Breast Cancer, Premalignant Lesions, Or Benign Breast Disease",II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Second line; Stage I; Stage II; Stage III,"Breast Carcinoma In Situ; Breast Diseases; Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Paget's Disease, Mammary",United States
NSABP Biospecimen Discovery Project,Other,Completed,"National Surgical Adjuvant Breast and Bowel Project (NSABP)
Washington University School of Medicine
Breast Cancer Research Foundation",Oncology: Breast,HER2 positive; Neoadjuvant; Stage III,Breast Neoplasms,United States
A Phase II Study of the Beta-blocker Propranolol Alone and With Chemotherapy in Patients Receiving Neoadjuvant Treatment for Newly Diagnosed Breast Cancer,II,Completed,Columbia University Medical Center,Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms; Neoplasms,United States
"A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, Her2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients",III,Terminated,"(Other Cooperative Group)
Breast International Group
Grupo Espanol de investigacion del Cancer de Mama
Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}
International Breast Cancer Study Group
Hellenic Oncology Research Group
EORTC Breast Cancer Group
US Oncology Research
Myrexis {Myriad Pharmaceuticals {Myriad Genetics}}
GlaxoSmithKline/Tesaro",Oncology: Breast,BRCA; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms; Carcinoma; Neoplasms; Ovarian Neoplasms,Belgium; Canada; France; Greece; Hungary; Iceland; Israel; Italy; Netherlands; Poland; Portugal; Spain; United Kingdom; United States
Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors. A Phase II Study to Identify Molecular Predictors for Hormone Responsiveness and/or Resistance,II,Completed,University of Colorado,Oncology: Breast,Estrogen receptor positive; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,United States
"A randomized Phase III Clinical trial evaluating pathologic complete response in Patients with Palpable and Operable, Triple negative breast cancer treated with Docetaxel and cyclophosphamide followed by Gemcitabine and carboplatin with or without the PARP 1 inhibitor BSI-201",III,Terminated,National Surgical Adjuvant Breast and Bowel Project (NSABP),Oncology: Breast,HER2 negative; Neoadjuvant; Stage I; Stage II; Triple receptor negative,Breast Neoplasms,United States
"A Phase II Study of Eribulin in Patients With HER2-Negative, Metastatic Breast Cancer: Evaluation of Efficacy, Toxicity and Patient-Reported Outcomes",II,Terminated,Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
Molecular Profiling-Based Assignment of Cancer Therapy for Patients with Advanced Solid Tumors,II,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Metastatic Cancer; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor",ALK; Bone mets; BRAF; BRCA; CNS mets; EGFR; Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasm Metastasis; Neoplasms; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
The Feasibility of Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer,II,Terminated,"GlaxoSmithKline
Memorial Sloan-Kettering Cancer Center",Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Stage 0; Stage I; Stage II,Breast Neoplasms,United States
Pilot Clinical Trial of COGNUTRIN in Breast Cancer Survivors,II,Completed,H. Lee Moffitt Cancer Center and Research Institute,Oncology: Breast; Oncology: Supportive Care,Line of therapy N/A; Neurotoxicity; Stage II; Stage III,Breast Neoplasms; Palliative Care,United States
"A Pilot Randomized, Placebo Controlled, Double Blind Study of Omega-3 Fatty Acids to Prevent Paclitaxel Associated Acute Pain Syndrome",II,Completed,"(Other Cooperative Group)
(Other Hospital/Academic/Medical Center)",CNS: Pain (neuropathic); CNS: Pain (nociceptive); Oncology: Breast; Oncology: Ovarian; Oncology: Supportive Care,(N/A); Acute Pain; Cancers-related; Line of therapy N/A; Neurotoxicity,Breast Neoplasms; Cancer pain; Cancer Pain; Neuralgia; Nociceptive Pain; Ovarian Neoplasms; Palliative Care,United States
"A Single Arm, Open-Label, Phase II Study of MGAH22 (Fc-optimized Chimeric Anti-HER2 Monoclonal Antibody) in Patients With Relapsed or Refractory Advanced Breast Cancer Whose Tumors Express HER2 at the 2+ Level by Immunohistochemistry and Lack Evidence of HER2 Gene Amplification by FISH",II,Completed,MacroGenics,Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Phase II Trial Of Ixabepilone and Stereotactic Body Radiation Therapy (SBRT) For Patients With Triple Negative Metastatic Breast Cancer,II,Terminated,University of Texas Southwest Medical Center,Oncology: Breast,HER2 negative; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,United States
A Pilot Study Evaluating Quantitative Volume Contrast Enhanced Ultrasound (VCEUS) Imaging for Determining Early Breast Cancer Response to Neoadjuvant Chemotherapy.,IV,Terminated,"University of Alabama at Birmingham Comprehensive Cancer Center
American Cancer Society",Oncology: Breast,Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
"An Adaptive, Randomized Phase II Trial To Determine Pathologic Complete Response With The Addition Of Carboplatin With And Without Veliparib To Standard Chemotherapy In The Neoadjuvant Treatment Of Triple-Negative Breast Cancer",II,Completed,"Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}
Kimmel Cancer Center-Thomas Jefferson University - Philadelphia, PA",Oncology: Breast,HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Vitamin D3 (Vit D3) Supplementation and T Cell Immunomodulation in Patients With Newly Diagnosed Operative Invasive Ductal Breast Carcinoma Stage I-II,Other,Terminated,Medical University of South Carolina,Oncology: Breast,First line; Stage I; Stage II,"Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast",United States
"NeoPHOEBE: Pi3k Inhibition in Her2 OverExpressing Breast cancEr: A Phase II, Randomized, Parallel Cohort, Two Stage, Double-blind, Placebo-controlled Study of Neoadjuvant Trastuzumab Versus Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive, PIK3CA Wild-type and PIK3CA Mutant Primary Breast Cancer",II,Terminated,"Novartis
(Other Cooperative Group)
Breast International Group
German Breast Group",Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Stage II,Breast Neoplasms,"Australia; Austria; Belgium; Brazil; France; Germany; Italy; New Zealand; Peru; Singapore; Spain; Switzerland; Taiwan, China; United Kingdom; United States"
"A Randomized, Phase II Clinical Trial of a Controlled Diet Prior to Selected Chemotherapy Treatment in Breast and Prostate Cancer to Evaluate the Impact on Toxicity and Efficacy",II,Open,"National Institutes of Health/National Cancer Institute
University of Southern California
Mayo Clinic",Oncology: Breast; Oncology: Prostate; Oncology: Supportive Care,Adjuvant; Cachexia; Emesis; Hormone refractory; Mucositis; Neoadjuvant; Neurotoxicity; Second line; Stage IV,Breast Neoplasms; Cachexia; Mucositis; Palliative Care; Prostatic Neoplasms; Vomiting,United States
Presurgical Phase IIB Trial of Oral CDB-4124 vs. Placebo in Women With Stage I-II Primary Breast Cancer,II,Completed,"Northwestern University
Repros Therapeutics {Zonagen}
Breast Cancer Research Foundation",Oncology: Breast,Neoadjuvant; Stage 0; Stage I; Stage II,Breast Neoplasms,United States
"Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Fulvestrant (Faslodex) Plus Everolimus in Post-Menopausal Patients With Hormone-Receptor Positive Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy",II,Completed,"Novartis
(Other Cooperative Group)",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase IIa Open Label, Randomized Clinical Trial to Study the Safety and Efficacy of Vintafolide and the Combination of Vintafolide and Paclitaxel Compared to Paclitaxel in Subjects With Advanced Triple Negative Breast Cancer Using Etarfolatide (EC20) Subject Selection",II,Terminated,Novartis/Endocyte,Oncology: Breast,Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Brazil; Canada; Denmark; France; Italy; Russia; South Africa; South Korea; Spain; Sweden; United Kingdom; United States
Phase II Trial of Paclitaxel Combined With Trastuzumab and Pertuzumab as Pre-Operative Therapy for Inflammatory Breast Cancer,II,Completed,Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute,Oncology: Breast,Adjuvant; HER2 positive; Maintenance/Consolidation; Neoadjuvant; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting (NALA),III,Completed,Puma Biotechnology,Oncology: Breast,Fourth line or greater; HER2 positive; Stage IV; Third line,Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Brazil; Canada; Czech Republic; Denmark; Finland; France; Germany; Hong Kong, S.A.R., China; Ireland; Israel; Italy; Japan; Netherlands; Portugal; Russia; Singapore; South Korea; Spain; Sweden; Switzerland; Taiwan, China; Turkey; United Kingdom; United States"
A Phase III Randomized Study of Tetrathiomolybdate (TM) For the Treatment of Breast Cancer,III,Terminated,Weill Medical College of Cornell University,Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
"A Three-arm, Randomized, Open Label, Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in the Treatment of Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Prior Letrozole or Anastrozole.",II,Completed,Novartis,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms,Argentina; Australia; Belgium; Brazil; Denmark; Hungary; India; Ireland; Lebanon; Malaysia; Peru; Russia; Spain; Sweden; Thailand; Turkey; United Kingdom; United States
A Phase II Randomized Trial Evaluating the Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Bone Marrow Disseminated Tumor Cells,II,Terminated,"Washington University School of Medicine
Roche/Genentech",Oncology: Breast,Adjuvant; HER2 negative; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
A Phase II Trial of Neoadjuvant MK-2206 in Combination With Either Anastrozole if Postmenopausal or Anastrozole and Goserelin if Premenopausal in Women With Clinical Stage 2 or 3 PIK3CA Mutant Estrogen Receptor Positive and HER2 Negative Invasive Breast Cancer.,II,Terminated,National Institutes of Health/National Cancer Institute,Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
Pilot Study of the Kinetics of High Sensitivity Troponin and Brain Natriuretic Peptide in Breast Cancer Chemotherapy With Adriamycin and Trastuzumab,II,Completed,Mayo Clinic,Oncology: Breast,Adjuvant; Neoadjuvant; Stage IV,Breast Neoplasms,United States
Digoxin as a Novel Inhibitor of Global Hypoxia Inducible Factor-1a (HIF-1a) Expression & Downstream Targets in Breast Cancer: DIG-HIF-1 Pharmacodynamic Trial,II,Completed,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}
US Department of Defense",Oncology: Breast,HER2 negative; HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
NSAID Effects on Clinical and Imaging Breast Biomarkers,II,Completed,"National Institutes of Health/National Cancer Institute
University of Arizona
Stony Brook University Hospital",CNS: Pain (nociceptive); Oncology: Breast,Cancer-related; Estrogen receptor positive; Line of therapy N/A; MSS/pMMR; Progesterone receptor positive; Stage 0; Stage I; Stage II; Stage III,Breast Neoplasms; Cancer pain; Cancer Pain; Inflammation; Nociceptive Pain,United States
A Randomized Placebo-Controlled Phase II Trial Evaluating the Effect of Hedgehog Inhibitor LDE225 on Bone Marrow Disseminated Tumor Cells in Women with Early Stage Estrogen Receptor Negative and HER2 Negative Breast Cancer,II,Terminated,"Novartis
Washington University School of Medicine",Oncology: Breast,First line; HER2 negative; Second line; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
The Relationship of Relative Dose Intensity and Supportive Care to Febrile Neutropenia Rates in Patients with Early Stage Breast Cancer Receiving Chemotherapy: A Prospective Cohort Study of Chemotherapy-Associated Toxicity,II,Completed,"University of Washington
Duke University Medical Center","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Supportive Care",Aggressive; Classical; Indolent; Line of therapy N/A; Neutropenia; Nodular lymphocyte-predominant; Pulmonary; Stage 0; Stage I; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neuroendocrine Tumors; Neutropenia; Ovarian Cancer; Ovarian Neoplasms; Palliative Care; Small Cell Lung Carcinoma",United States
Ixabepilone-Associated Peripheral Neuropathy in Metastatic Breast Cancer Patients and Its Effects on the Ultrastructure of Neurons.,II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast; Oncology: Supportive Care,First line; Fourth line or greater; Neurotoxicity; Second line; Stage IV; Third line,Breast Neoplasms; Palliative Care,United States
A Phase II Study Of Neoadjuvant Chemotherapy With And Without Trastuzumab In Patients With Breast Cancer,II,Closed,"National Institutes of Health/National Cancer Institute
University of Nebraska Medical Center",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Carcinoma,United States
"Phase III, Randomized, open label trial of trastuzumab plus oral BKM 120 vs trastuzumab plus chemotherapy in patients with HER-2 positive breast cancer with progressing brain metastases previously treated with cranial irradiation and lapatinib",III,Terminated,Novartis,Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; HER2 positive; Second line; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
Long-term Anastrozole Versus Tamoxifen Treatment Effects (LATTE),IV,Completed,"AstraZeneca
Cancer Research UK
(Other Hospital/Academic/Medical Center)
American Cancer Society",Oncology: Breast,(N/A); Estrogen receptor positive; Line of therapy N/A; Progesterone receptor positive,Breast Neoplasms,Australia; Belgium; France; Germany; Hungary; Italy; Netherlands; New Zealand; South Africa; Spain; Sweden; United Kingdom; United States
"A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study).",II,Completed,Celldex Therapeutics {CuraGen},Oncology: Breast,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Australia; Belgium; Canada; France; Germany; Italy; Spain; United Kingdom; United States
Meriva for Treatment-induced Inflammation and Fatigue in Women With Breast Cancer,II,Completed,"National Institutes of Health/National Cancer Institute
Winship Cancer Institute of Emory University",Oncology: Breast,(N/A); Adjuvant,Breast Neoplasms,United States
"A Phase II, Randomized Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer",II,Completed,Roche/Genentech,Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,Australia; Austria; Belgium; Czech Republic; South Korea; Spain; United Kingdom; United States
"A Randomized, Multicenter, Double-Blind Phase III Study Of PD-0332991 (Oral CDK 4/6 Inhibitor) Plus Letrozole Versus Placebo Plus Letrozole For The Treatment Of Postmenopausal Women With ER (+), HER2 (-) Breast Cancer Who Have Not Received Any Prior Systemic Anti Cancer Treatment For Advanced Disease.",III,Completed,"Pfizer
UCSF Comprehensive Cancer Center
University of California Los Angeles
British Columbia Cancer Agency
(Other Hospital/Academic/Medical Center)
US Oncology Research",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; PD-1 Positive; Stage III; Stage IV,Breast Neoplasms,"Australia; Belgium; Brazil; Canada; China; Czech Republic; France; Germany; Hungary; Ireland; Italy; Japan; New Zealand; Poland; Russia; South Africa; South Korea; Spain; Taiwan, China; Turkey; Ukraine; United Kingdom; United States"
A Phase II Study of XL184 (Cabozantinib) for Metastatic Triple-Negative Breast Cancer,II,Completed,Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute,Oncology: Breast,First line; Fourth line or greater; HER2 negative; MET Amplification/Alteration; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
A Pilot Phase II Trial of Cabergoline in the Treatment of Metastatic Breast Cancer,II,Completed,"(Other Cooperative Group)
Northwestern University",Oncology: Breast,Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
"Phase II Prospective Open Label Study of Pertuzumab, Trastuzumab, and Nab-Paclitaxel in Patients With HER-2 Positive Advanced Breast Cancer",II,Completed,"Bristol-Myers Squibb
National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center
Roche/Genentech",Oncology: Breast,HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms; Inflammatory Breast Neoplasms,United States
Phase II Study to Evaluate the Development of HER2/Neu (HER2)-Specific Memory T Cells After HER2 Peptide-based Vaccination in Patients With Advanced Stage Her2+ Breast Cancer,II,Terminated,"National Institutes of Health/National Cancer Institute
University of Washington",Oncology: Breast,Estrogen receptor positive; HER2 positive; Line of therapy N/A; Progesterone receptor positive; Stage IV,"Breast Neoplasms; Breast Neoplasms, Male",United States
"A Phase II Trial of Neoadjuvant PD 0332991, a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor, in Combination With Anastrozole in  Women With Clinical Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer",II,Completed,Washington University School of Medicine,Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
A Pilot Study of Vorinostat to Restore Sensitivity to Aromatase Inhibitor Therapy Part B,II,Completed,"National Institutes of Health/National Cancer Institute
University of Washington",Oncology: Breast,Second line; Stage IV,"Breast Neoplasms; Breast Neoplasms, Male",United States
Effect of Targeted Therapy on Circulating Tumor Cells in Patients with Metastatic Breast Cancer.,Other,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Line of therapy N/A; Stage IV,Breast Neoplasms,Italy; United States
A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Chemotherapy Regimens With Weekly Paclitaxel or Eribulin Followed by Doxorubicin and Cyclophosphamide in Women With Locally Advanced HER2-Negative Breast Cancer,II,Completed,"National Surgical Adjuvant Breast and Bowel Project (NSABP)
Eisai",Oncology: Breast,HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,Canada; United States
"A Phase II Randomized, Open Label Study of Ad-RTS-hIL-12 Monotherapy or Combination With Palifosfamide in Subjects With Recurrent/Metastatic Breast Cancer and Accessible Lesions",II,Completed,Alaunos Therapeutics {Ziopharm Oncology},Oncology: Breast,HER2 negative; HER2 positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
COMETI Phase II: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index,Other,Completed,"(Other Cooperative Group)
Johnson & Johnson/Janssen Diagnostics {Veridex {Immunicon}}",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Stage IV,"Breast Neoplasms; Neoplastic Cells, Circulating",Canada; United States
"An Open-label, Phase II, Single-arm Study of Everolimus in Combination With Letrozole in the Treatment of Postmenopausal Women with Estrogen Receptor Positive HER2 Negative Metastatic or Locally Advanced Breast Cancer",II,Completed,Novartis,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Stage III; Stage IV,Breast Neoplasms,Argentina; Austria; Brazil; France; Hungary; Japan; Netherlands; Portugal; South Korea; Spain; Thailand; Turkey; United Kingdom; United States
A Pilot Clinical Trial to Evaluate the Biological Activity of HDAC (Histone Deacetylase Transferases) Inhibition on ER and PR Expression in Triple Negative Invasive Breast Cancer,II,Terminated,"National Institutes of Health/National Cancer Institute
USC/Norris Comprehensive Cancer Center and Hospital",Oncology: Breast,HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Phase II Study of antroquinonol in Stage 0-IV Breast Cancer Patients,II,Completed,Golden Biotechnology,Oncology: Breast,Line of therapy N/A; Stage 0; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,"South Korea; Taiwan, China; United States"
"Phase II Study of Lapatinib and Trastuzumab Followed by Concurrent Lapatinib, Trastuzumab, and Paclitaxel Followed by Surgery for Primary HER2-positive (HER2+) Breast Cancer",II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,Japan; United States
A Pilot Study of GRN1005 for Resectable Brain Metastases in Patients With Breast Cancer and Non-Small Cell Lung Cancer,II,Terminated,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer",CNS mets; HER2 negative; HER2 positive; Line of therapy N/A; Stage IV,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Neoplasms",United States
A Phase II Study of Neratinib Alone and in Combination with Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer.,II,Completed,"Washington University School of Medicine
University Health Network, Toronto/Princess Margaret Cancer Centre {Princess Margaret Hospital}
National Cancer Research Institute
US Department of Defense
Puma Biotechnology",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Second line; Stage IV; Third line,Breast Neoplasms,Canada; New Zealand; United States
"Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy + or - One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer",III,Closed,"Novartis
Southwest Oncology Group
National Institutes of Health/National Cancer Institute
Breast Cancer Research Foundation
Alliance for Clinical Trials in Oncology
NRG Oncology",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,Puerto Rico; United States
"Phase II Study of Dose-Dense TC (Docetaxel + Cyclophosphamide) With Pegfilgrastim Support for Adjuvant Therapy of pN0, pN1 or Nx Breast Cancer",II,Completed,"Amgen
University of Wisconsin",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
A Randomized Phase II Trial of Neoadjuvant Cisplatin vs. Doxorubicin/Cyclophosphamide (AC) in Women with Newly Diagnosed Breast Cancer and Germline BRCA Mutations,II,Completed,Beth Israel Deaconess Medical Center,Oncology: Breast,BRCA; Estrogen receptor positive; First line; HER2 negative; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,Spain; United Kingdom; United States
"An Open-Label Randomized Phase ll Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Estrogen Receptor Positive, Her-2 Negative Advanced Breast Cancer",II,Terminated,Pfizer,Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms,United States
The Effectiveness and Safety of Treating Operable Breast Cancer by the Adjuvant Therapy of Zoledronic Acid and Aromatase Inhibitors and/or Ovarian Function Inhibition,II/III,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,(N/A); Adjuvant,Breast Neoplasms,China; United States
"An Open-Label Multicenter Phase II Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer 

EvaluatiNg Chaperone inhibition by gANetespib in breasT cancer (ENCHANT)",II,Completed,Madrigal Pharmaceuticals {Synta Pharmaceuticals},Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; HER2 positive; Progesterone receptor positive; Stage 0; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Argentina; Belgium; Brazil; Peru; South Korea; Spain; United Kingdom; United States
A Pilot Study to Evaluate the Efficacy of Fosaprepitant and Granisetron Transdermal System for the Prevention of Acute and Delayed Nausea and Vomiting in Breast Cancer Patients and to Identify Predictors of Response,II,Terminated,"National Institutes of Health/National Cancer Institute
University of Southern California",Oncology: Breast; Oncology: Supportive Care,(N/A); Adjuvant; Emesis; Neoadjuvant,Breast Neoplasms; Nausea; Palliative Care; Vomiting,United States
"A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian Cancer",II,Terminated,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Prostate,BRCA; Fourth line or greater; HER2 negative; Hormone refractory; Second line; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Triple Negative Breast Neoplasms",United States
Pilot Study on the Efficacy of an Ondansetron Versus Palonosetron-containing Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC),II,Completed,(Other Academic Cancer Center),"Oncology: Breast; Oncology: Lymphoma, Hodgkin's; Oncology: Supportive Care",Classical; Emesis; First line; Nodular lymphocyte-predominant; Second line; Stage I; Stage II; Stage III,Breast Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Neoplasms; Palliative Care; Vomiting,United States
Gene expression combined with gene set enrichment analysis to identify markers of vinorelbine efficacy in breast cancer patients.,Other,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms,United States
Efficacy and safety of half-dose pegfilgrastim in cancer patients receiving cytotoxic chemotherapy.,III,Completed,(Other Hospital/Academic/Medical Center),"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Supportive Care",(N/A); Line of therapy N/A; Neutropenia,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neutropenia; Palliative Care",United States
A Phase II Study of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced and Metastatic Triple-Negative Breast Cancer,II,Completed,"National Institutes of Health/National Cancer Institute
CASI Pharmaceuticals {EntreMed}
Indiana University Cancer Center
University of Colorado
Alcami {AAIPharma Services Corp. / Cambridge Major Laboratories, Inc. {aaiPharma}}",Oncology: Breast,Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,China; United States
A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.,II,Completed,"Siteman Cancer Center
National Institutes of Health
Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}",Oncology: Breast,Fourth line or greater; HER2 negative; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,Canada; United States
"A Phase III Randomized, Double Blind, Placebo Controlled Study of BKM120 With Fulvestrant, in Postmenopausal Women With Hormone Receptor-positive HER2-negative AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTOR Inhibitor Based Treatment",III,Completed,Novartis,Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,Argentina; Austria; Belgium; Bulgaria; Canada; Colombia; Czech Republic; Denmark; Finland; France; Germany; Greece; Hungary; Italy; Lebanon; Netherlands; Norway; Poland; Russia; South Korea; Spain; Sweden; Thailand; United Kingdom; United States
Metabolizing Enzyme Genotype Versus Exemestane Metabolism Profiles,Other,Completed,Penn State Cancer Institute at Milton S. Hershey Medical Center,Oncology: Breast,(N/A); Estrogen receptor positive; Second line,Breast Neoplasms,United States
A Phase II Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer,II,Completed,"Novartis
(Other Cooperative Group)
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute",Oncology: Breast,First line; HER2 negative; Stage IV; Triple receptor negative,Breast Neoplasms,Spain; United States
"Circulating FGF21 Levels and Efficacy of Exemestane, Everolimus and Metformin in Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer and BMI > or = 25",II,Terminated,"MD Anderson Cancer Center, University of Texas
Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
"Phase II Evaluation of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum",II,Terminated,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Metastatic Cancer; Oncology: Ovarian; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Testicular; Oncology: Thymus",Metastatic; Other mets; Second line; Stage IV; Thymic carcinoma,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Digestive System Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Gastrointestinal Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Mesothelioma; Neoplasm Metastasis; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms; Thymus Neoplasms; Wilms Tumor",United States
"A Phase III, Open-Label, Prospective, Randomized, Multicenter, Neo-adjuvant Study of Chemotherapy Versus Endocrine Therapy in Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer",III,Completed,"AstraZeneca
(Other Cooperative Group)
Asan Medical Center",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,South Korea; United States
A Pilot Pre-operative Window Trial of Black Cohosh in Women With Ductal Carcinoma in Situ,II,Completed,Yale University,Oncology: Breast,Neoadjuvant; Stage 0,"Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Intraductal, Noninfiltrating",United States
Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast Cancer: A Collaborative Study of NRG Oncology and KROG,II,Completed,"(Other Cooperative Group)
Radiation Therapy Oncology Group (RTOG)
National Institutes of Health/National Cancer Institute
NRG Oncology",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; First line; HER2 positive; Second line; Stage IV,Brain Neoplasms; Breast Neoplasms; Carcinoma; Central Nervous System Neoplasms; Neoplasm Metastasis; Neoplasms,Canada; Israel; South Korea; United States
A Phase III Trial of Tesetaxel as Initial Chemotherapy for Women with Metastatic and Advanced Breast Cancer.,III,Terminated,Genta,Oncology: Breast,First line; Stage III; Stage IV,Breast Neoplasms,United States
"Phase II, Open Label Study to Examine Androgen Receptor Status and the Activity of GTx-024 Hormonal Therapy in Women With Estrogen Receptor Positive Metastatic Breast Cancer Who Have Previously Responded to Hormone Therapy",II,Completed,Oncternal Therapeutics {GTx},Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer",II,Completed,Novartis,Oncology: Breast,First line; HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,"Argentina; Australia; Belgium; Brazil; Czech Republic; France; Germany; Ireland; Italy; Russia; South Korea; Spain; Taiwan, China; Turkey; United Kingdom; United States"
"A Randomized, Multicenter, Open-Label, Two-Arm, Phase III Neoadjuvant Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab And Pertuzumab For Patients With HER2-Positive Breast Cancer",III,Completed,Roche {F. Hoffmann-La Roche},Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,"Belgium; Canada; France; Germany; Ireland; Russia; South Korea; Spain; Taiwan, China; Ukraine; United States"
"A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy for Patients with HER2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy.",III,Completed,"National Surgical Adjuvant Breast and Bowel Project (NSABP)
ImmunoGen
Roche {F. Hoffmann-La Roche}
German Breast Group",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Neoadjuvant; PD-L1 High; PD-L1 Positive; Progesterone receptor positive; Stage I; Stage II; Stage III,"Breast Neoplasms; Neoplasm, Residual","Argentina; Austria; Belgium; Brazil; Canada; China; Colombia; Czech Republic; France; Germany; Greece; Guatemala; Hong Kong, S.A.R., China; Ireland; Israel; Italy; Mexico; Panama; Peru; Serbia; South Africa; Spain; Sweden; Switzerland; Taiwan, China; Turkey; United Kingdom; United States"
Preoperative Window of Endocrine Therapy Provides Information to Increase Compliance,II,Completed,University of Utah,Oncology: Breast,Adjuvant; Estrogen receptor positive; First line; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II,Breast Neoplasms,United States
"A Pilot Study of BR-DIM in Women With Stage II-III, Triple Negative, and Androgen Receptor Positive, Invasive Breast Cancer, Who Have Residual Disease Following Surgical Resection After Neoadjuvant Chemotherapy",II,Terminated,"Barbara Ann Karmanos Cancer Institute
National Institutes of Health/National Cancer Institute",Oncology: Breast,First line; HER2 negative; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
Low Dose Metronomic Cyclophosphamide and Methotrexate Chemotherapy in Combination With Aspirin in Patients With Stage II-III Breast Cancer Who Fail to Achieve a Pathologic Complete Response After Neoadjuvant Chemotherapy,II,Completed,"University of Vermont
(Other Hospital/Academic/Medical Center)
Dartmouth-Hitchcock Medical Center",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,United States
"A Phase III Randomized, Double Blind Placebo Controlled Study of BKM120 With Fulvestrant, in  Postmenopausal Women With Hormone Receptor-positive HER2-negative Locally Advanced or  Metastatic Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment",III,Completed,"Novartis
BSP Pharmaceuticals",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; China; Czech Republic; Denmark; France; Germany; Greece; Hong Kong, S.A.R., China; Hungary; Israel; Italy; Japan; Netherlands; New Zealand; Norway; Peru; Poland; Romania; Russia; Singapore; Slovakia; Slovenia; South Africa; South Korea; Spain; Sweden; Switzerland; Taiwan, China; Thailand; Turkey; United Kingdom; United States"
"A Randomized, Phase II Study of Tesetaxel Once Every 3 Weeks Versus Tesetaxel Once Weekly for 3 Weeks Versus Capecitabine Twice Daily for 14 Days as First-line Therapy for Subjects With Locally Advanced or Metastatic Breast Cancer",II,Terminated,Genta,Oncology: Breast,First line; HER2 negative; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"A Randomised, Double-blind, Parallel-group, Multicentre, Phase III Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX) 500 mg With Anastrozole (ARIMIDEX) 1 mg as Hormonal Treatment for Postmenopausal Women With Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Been Treated With Any Hormonal Therapy.

Fulvestrant and AnastrozoLe COmpared in hormonal therapy Naive advanced breast cancer (FALCON)",III,Completed,AstraZeneca,Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,"Argentina; Brazil; Canada; Chile; China; Czech Republic; India; Italy; Japan; Mexico; Peru; Poland; Romania; Russia; Slovakia; Slovenia; South Africa; Spain; Taiwan, China; Turkey; Ukraine; United Kingdom; United States"
Pathologic response rate in HER2-positive locally advanced breast cancers treated with neoadjuvant trastuzumab and concurrent paclitaxel/radiotherapy.,II,Completed,New York University,Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,United States
"A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients",II,Completed,Merck & Co./Merck Sharp & Dohme (MSD),Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Stage III; Stage IV,Breast Neoplasms,"Belgium; Colombia; Czech Republic; Denmark; France; Germany; Israel; Italy; Peru; Portugal; South Korea; Spain; Sweden; Taiwan, China; United States"
64 Cu-DOTA-Trastuzumab Positron Emission Tomography in Women With Advanced HER2 Positive Invasive Breast Cancer,Other,Completed,City of Hope Comprehensive Cancer Center,Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; First line; HER2 negative; HER2 positive; Liver mets; Other mets; Second line; Stage IV,Breast Neoplasms; Liver Neoplasms; Neoplasm Metastasis,United States
"An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Recurrent Glioblastoma, or Metastatic Renal Cell Cancer Treated With Avastin",IV,Completed,Roche/Genentech,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Renal",Adenocarcinoma; Large Cell; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Glioblastoma; Kidney Neoplasms; Renal Cancer; Wilms Tumor",United States
A Phase II Trial Of The JAK-Inhibitor Ruxolitinib (INCB018424) In Combination With Exemestane For Patients With Estrogen Receptor (ER) Positive Advanced Breast Cancer,II,Completed,Abramson Cancer Center at  University of Pennsylvania Medical Center,Oncology: Breast,Estrogen receptor positive; First line; Second line; Stage IV,Breast Neoplasms,United States
A Randomized Phase II Neoadjuvant Study of Sequential Eribulin Followed by FAC/FEC-regimen Compared to Sequential Paclitaxel Followed by FAC/FEC-Regimen in Women With Early Stage Breast Cancer Not Overexpressing HER-2,II,Completed,"MD Anderson Cancer Center, University of Texas
Eisai",Oncology: Breast,HER2 negative; Neoadjuvant; Stage 0; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Phase II, Randomized, Multi-Centre, Open-Label, Active-Controlled, Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy",II,Completed,Evive Biotech {Generon (Shanghai)},Oncology: Breast; Oncology: Supportive Care,Neutropenia; Second line; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms; Neutropenia; Palliative Care,Canada; Russia; Ukraine; United States
"A Multi-center, Open-label, Extension Study to Allow Continued Treatment of Patients Who Have Participated in Allos-sponsored Pralatrexate Studies",II,Terminated,Spectrum Pharmaceuticals {Allos Therapeutics},Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,Hungary; United States
"A Randomized, Double-blind, Placebo Controlled, Phase II/III Study of BKM120 Plus Paclitaxel in  Patients With HER2 Negative Inoperable Locally Advanced or Metastatic Breast Cancer, With or Without  PI3K Pathway Activation",II/III,Completed,Novartis,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,"Australia; Austria; Belgium; Brazil; Canada; Czech Republic; France; Germany; Hong Kong, S.A.R., China; Hungary; Israel; Italy; Japan; Netherlands; Russia; Singapore; South Africa; South Korea; Spain; Taiwan, China; United Kingdom; United States"
Adjuvant breast cancer vaccine improves overall survival of patients with depressed immunity,II,Completed,Theralink Technologies {OncBioMune Pharmaceuticals},Oncology: Breast,Adjuvant; Stage I; Stage II,Breast Neoplasms,United States
Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification.,Other,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,HER2 negative; Line of therapy N/A; Stage 0; Stage I; Stage II,Breast Neoplasms,Netherlands; South Korea; United States
Phase II Study of Ruxolitinib (INCB018424) in Patients With PSTAT3+ Breast Cancer,II,Terminated,Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute,Oncology: Breast,First line; HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer",II,Completed,Roche {F. Hoffmann-La Roche},Oncology: Breast,First line; HER2 positive; Stage III; Stage IV,Breast Neoplasms,Brazil; Denmark; France; Germany; Italy; Spain; United States
"Randomized Phase II Study of Fulvestrant With or Without Ganetespib in Patients With Hormone Receptor-Positive, Metastatic Breast Cancer",II,Completed,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Madrigal Pharmaceuticals {Synta Pharmaceuticals}",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase II Study of Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma",II,Completed,"Memorial Sloan-Kettering Cancer Center
Pfizer
National Comprehensive Cancer Network","Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Adenoid Cystic; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Neoplasms, Unknown Primary",United States
A Phase II Study of Lapatinib in Combination With Trastuzumab in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer,II,Terminated,Washington University School of Medicine,Oncology: Breast,HER2 negative; Second line; Stage IV,Breast Neoplasms,United States
"A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer",III,Completed,"National Surgical Adjuvant Breast and Bowel Project (NSABP)
National Institutes of Health/National Cancer Institute
NRG Oncology",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Stage 0; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,Puerto Rico; United States
Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer,II,Terminated,"Amgen
University of California, San Francisco",Oncology: Breast,First line; Stage I; Stage II; Stage III,Breast Neoplasms,United States
A Phase II Study of ARQ 197 in Metastatic Triple-Negative Breast Cancer,II,Terminated,"National Institutes of Health/National Cancer Institute
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute",Oncology: Breast,Fourth line or greater; HER2 negative; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Carcinoma,United States
"A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy",II,Terminated,Novartis,Oncology: Breast,Estrogen receptor positive; FGFR; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,"Argentina; Austria; Belgium; Brazil; China; Egypt; France; Hungary; Israel; Italy; Netherlands; Peru; Poland; Russia; South Africa; Spain; Taiwan, China; United States"
A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer,II,Completed,"Eisai
(Other Hospital/Academic/Medical Center)",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
Phase II Trial of Neoadjuvant Chemotherapy With Carboplatin and NAB-Paclitaxel in Patients With Locally Advanced and Inflammatory Triple Negative Breast Cancer.,II,Completed,"National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center",Oncology: Breast,BRCA; HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Inflammatory Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Multicenter Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer,II,Completed,PharmaMar {Zeltia/PharmaMar},Oncology: Breast,BRCA; HER2 negative; HER2 positive; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,Spain; United States
Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer.,II,Completed,"Johnson & Johnson/ALZA
Johnson & Johnson/Janssen Therapeutics {J&J/Centocor Ortho Biotech/Tibotec Therapeutics {J&J/Ortho Biotech/Tibotec}}",Oncology: Breast,First line; Stage IV,Breast Neoplasms,United States
"Phase II, Open-Label, Dose-Ranging Study of SPI-2012 (HM10460A) or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen",II,Completed,"Spectrum Pharmaceuticals
Hanmi Pharmaceutical",Oncology: Breast; Oncology: Supportive Care,Adjuvant; Estrogen receptor positive; HER2 positive; Neoadjuvant; Neutropenia; Progesterone receptor positive; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms; Neutropenia; Palliative Care,Australia; Georgia; Hungary; Israel; Poland; United States
"An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers",II,Completed,Roche {F. Hoffmann-La Roche},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Multiple Myeloma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Thyroid",Adenocarcinoma; Anaplastic; BRAF; Large Cell; Recurrent; Second line; Squamous Cell; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gastrointestinal Stromal Tumors; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Multiple Myeloma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",China; France; Germany; Spain; United Kingdom; United States
"A Phase IIIb Multicenter, Open-label Abiraterone Acetate Long-term Safety Study",III,Completed,Johnson & Johnson/Janssen R&D,Oncology: Breast; Oncology: Prostate,Hormone refractory; Line of therapy N/A; Stage IV,Breast Neoplasms; Prostatic Neoplasms,Australia; Austria; Belgium; Germany; Hungary; Italy; Spain; Sweden; United Kingdom; United States
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta,III,Completed,Novartis/Sandoz,Oncology: Breast; Oncology: Supportive Care,(N/A); Adjuvant; Neoadjuvant; Neutropenia,Breast Neoplasms; Neutropenia; Palliative Care,Argentina; Chile; India; Malaysia; Peru; Philippines; Puerto Rico; Russia; Spain; United States
"A Randomized, Double-blind, Parallel-group, Multi-center Phase III Study Comparing the Efficacy and Safety of EP2006 and Neupogen in Breast Cancer Patients Treated With Myelosuppressive Chemotherapy",III,Completed,Novartis/Sandoz,Oncology: Breast; Oncology: Supportive Care,(N/A); Adjuvant; Neoadjuvant; Neutropenia,Breast Neoplasms; Neutropenia; Palliative Care,Czech Republic; Hungary; India; Latvia; Lithuania; Russia; Serbia; Slovakia; Ukraine; United States
"A Randomized, Phase II Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer",II,Completed,AbbVie {Abbott},Oncology: Breast,BRCA; HER2 negative; HER2 positive; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,Argentina; Australia; Belgium; Brazil; Canada; Czech Republic; Denmark; Finland; France; Hungary; Israel; Netherlands; Norway; Poland; Romania; Russia; Slovakia; Spain; Sweden; Ukraine; United States
DCE-MRI and FDG PET with Kinetic Analysis to Monitor Breast Cancer Response to Neoadjuvant Sunitinib and Metronomic Chemotherapy (CC-IRB #6489). A Companion Trial to a Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination with Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide plus GCSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer (CC-IRB #6488),II,Completed,"Fred Hutchinson Cancer Research Center
University of Washington/Seattle Cancer Care Alliance",Oncology: Breast,HER2 negative; Neoadjuvant; Stage III,Breast Neoplasms,United States
"Changes in FDG PET SUV Correlates with Ki-67 Following 2 Weeks of Aromatase Inhibitor Therapy in ER+ Early Stage Breast Cancer, a Pilot Imaging Study",II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage 0; Stage I; Stage II,Breast Neoplasms,United States
Zoledronic Acid Induces an Immune Response in Breast Cancer Patients through Stimulation of Central Memory and Effector Memory gamma/delta T-Cells.,II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Line of therapy N/A; Stage 0; Stage I; Stage II; Stage IV,Breast Neoplasms,United States
MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I,IV,Completed,"(Other Industry Sponsor)
University of South Florida
(Other Hospital/Academic/Medical Center)
University of Miami School of Medicine
University of Oklahoma",Oncology: Breast,HER2 negative; HER2 positive; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
Early Detection of Cardiotoxicity by Advanced Cardiac Imaging and a Novel Biomarker in Breast Cancer Patients Undergoing Chemotherapy.,Other,Completed,University of Connecticut Health Center,Oncology: Breast,First line; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"An Open Label, Phase II Trial of BKM120 in Cancers With PIK3CA Activating Mutations",II,Terminated,"Novartis
Massachusetts General Hospital","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",Second line; Stage II; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
"Phase II Neoadjuvant Trial of Eribulin Followed by Dose Dense Doxorubicin and Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer",II,Terminated,"Winship Cancer Institute of Emory University
Eisai",Oncology: Breast,First line; HER2 negative; Neoadjuvant; Stage III,Breast Neoplasms; Neoplasms,United States
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment,IV,Completed,"Novartis
Southwest Oncology Group
National Institutes of Health/National Cancer Institute
(Other Hospital/Academic/Medical Center)","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer; Oncology: Multiple Myeloma; Oncology: Prostate",Bone mets; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Multiple Myeloma; Neoplasm Metastasis; Neoplasms, Plasma Cell; Osteonecrosis; Plasmacytoma; Prostatic Neoplasms; Unspecified",Mexico; Saudi Arabia; United States
"A Phase II Trial of HKI-272 (Neratinib), Neratinib and Capecitabine, and Ado-Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases",II,Closed,"(Other Cooperative Group)
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Puma Biotechnology",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; First line; Fourth line or greater; HER2 positive; Second line; Stage IV; Third line,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
GCC 0901- A Phase II Study of Letrozole in Combination With Lapatinib Followed by an Addition of Everolimus in Postmenopausal Women With Advanced Endocrine Resistant Breast Cancer.,II,Terminated,"GlaxoSmithKline
Novartis
Marlene and Stewart Greenebaum Cancer Center, University of Maryland",Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Diseases; Breast Neoplasms; Neoplasm Metastasis; Neoplasms,United States
"A Randomized, Two-Arm, Open-Label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab Plus an Aromatase Inhibitor in First Line Patients With HER2-Positive and Hormone Receptor-Positive Advanced (Metastatic or Locally Advanced) Breast Cancer.",II,Completed,Roche {F. Hoffmann-La Roche},Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,Brazil; France; India; Italy; Spain; Switzerland; Turkey; United Kingdom; United States
Combination Immunotherapy with Herceptin and the HER2 Vaccine E75 In Low and Intermediate HER2-Expressing Breast Cancer Patients to Prevent Recurrence,II,Completed,"(Other Industry Sponsor)
SELLAS Life Sciences Group {Galena Biopharma {RXi Pharmaceuticals {Apthera}}}
Roche/Genentech",Oncology: Breast,Adjuvant; HER2 negative; HER2 positive; Maintenance/Consolidation; Neoadjuvant; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
Phase III Randomized Trial of Dose Intensive Neoadjuvant Chemotherapy with or Without G-CSF in Locally Advanced Breast Cancer,III,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Neoadjuvant; Stage III,Breast Neoplasms,United States
Vitamin D and Breast Cancer: Does Weight Make a Difference ?,II,Terminated,Stanford University Medical Center,Oncology: Breast,Neoadjuvant; Stage I; Stage II,Breast Neoplasms,United States
"A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination with Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer",III,Completed,Roche/Chugai Pharmaceutical,Oncology: Breast,First line; HER2 negative; Stage IV,Breast Neoplasms,Argentina; Belgium; Brazil; Bulgaria; Chile; China; Germany; Italy; Japan; Panama; Romania; Russia; South Africa; South Korea; Ukraine; United Kingdom; United States; Vietnam
Low Risk Her-2+ Breast Cancer: Targeted-Only Adjuvant Therapy - Toxicity and Safety (TOATTS),II,Terminated,Southwest Oncology Group,Oncology: Breast,(N/A); Adjuvant; HER2 positive,Breast Neoplasms,United States
Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer,II,Closed,"Bristol-Myers Squibb
MD Anderson Cancer Center, University of Texas
Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}",Oncology: Breast,Adjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib.,II,Completed,"GlaxoSmithKline
Novartis",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
A Feasibility Study of Donepezil in Female Breast Cancer Survivors with Self-Reported Cognitive Dysfunction Following Chemotherapy,II,Completed,"National Institutes of Health/National Cancer Institute
Comprehensive Cancer Center of Wake Forest University",Oncology: Breast; Oncology: Supportive Care,(N/A); Line of therapy N/A; Neurotoxicity,Anxiety Disorders; Breast Neoplasms; Cognition Disorders; Cognitive Dysfunction; Depression; Disease; Fatigue; Palliative Care; Parasomnias; Sleep Wake Disorders,United States
"A Phase II Randomized, Double-Blind, Placebo-Controlled, Study Comparing Tivozanib Hydrochloride in Combination With Paclitaxel v Placebo in Combination With Paclitaxel in Locally Recurrent and/or Metastatic Triple Negative Breast Cancer

BATON (Biomarker Assessment of Tivozanib in ONcology)",II,Terminated,"Astellas Pharma
LG Chem/AVEO Oncology",Oncology: Breast,First line; HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,"Australia; Bahamas; Canada; Germany; Ghana; Italy; Poland; South Africa; South Korea; Spain; Taiwan, China; Thailand; Ukraine; United States"
Efficacy and Tolerability of Nanoparticle Albumin Bound Paclitaxel (Abraxane) in Patients 65 and Older With Metastatic Breast Cancer,II,Completed,"National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center",Oncology: Breast,First line; HER2 negative; HER2 positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma,United States
"A Phase II, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies",II,Completed,Seagen {Seattle Genetics},"Oncology: Anal; Oncology: Breast; Oncology: Colorectal; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Testicular; Oncology: Thyroid",Fourth line or greater; HER2 negative; Pediatric or Adolescent; Pulmonary; RAEB; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Acute Myelocytic Leukemia; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Anus Neoplasms; Breast Neoplasms; Carcinoma, Small Cell; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Colorectal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Liposarcoma; Melanoma; Mesothelioma; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms, Mesothelial; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms; Thyroid Neoplasms",United States
Phase II Study of AT-406 in Metastatic Breast Cancer,II,Terminated,Southwest Oncology Group,Oncology: Breast,Line of therapy N/A; Stage IV,Breast Neoplasms,United States
Phase II Study of The Efficacy And Safety of Chloroquine (C) in Combination With Taxane or Taxane-like (T) Chemo Agents in The Treatment of Patients With Advanced or Metastatic Breast Cancer Who Have Failed Anthracycline Chemo Base Therapy.,II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms; Neoplasms,United States
A Phase II Trial of Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer With Involvement of Bone,II,Completed,"Exelixis
Massachusetts General Hospital",Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Third line,Breast Neoplasms; Neoplasm Metastasis,United States
Lux-Breast 3; Randomized Phase II Study of Afatinib Alone or in Combination With Vinorelbine Versus Investigator's Choice of Treatment in Patients With HER2 Positive Breast Cancer With Progressive Brain Metastases After Trastuzumab and/or Lapatinib Based Therapy,II,Completed,Boehringer Ingelheim,Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; HER2 positive; Second line; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis; Neoplasms,Canada; Finland; France; Germany; Italy; South Korea; Spain; United States
"A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer",II,Completed,Eisai,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Stage I; Stage II,Breast Neoplasms,United States
The Ultrasound Study of Tamoxifen,IV,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Estrogen receptor positive; First line; Stage 0; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Systemic DKK1 During Estrogen Level Changes in Post-menopausal Breast Cancer Patients Treated With Aromatase Inhibitors,Other,Completed,University of Arkansas,Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
A Phase II Study of Low Dose Arsenic Trioxide in Patients With Malignancies as a Potential Chemotherapy Protector,II,Completed,University of Texas Health Science Center at San Antonio,Oncology: Breast; Oncology: Unspecified Cancer,(N/A); Line of therapy N/A,Breast Neoplasms; Neoplasms; Unspecified,United States
A Randomized Study of Lapatinib With Radiation Versus Radiation Alone in Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease,II,Terminated,Virginia Commonwealth University,Oncology: Breast; Oncology: Prostate,Line of therapy N/A; Stage IV,Breast Neoplasms; Neoplasm Metastasis; Prostatic Neoplasms,United States
"A Randomized, Phase II Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer",II,Completed,"Merrimack Pharmaceuticals
Sanofi {Sanofi-Aventis}",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Effect of Vitamin D Replacement on Tumor Response and Survival Parameters for Vitamin D Insufficient Patients With Cancer,II,Open,"National Institutes of Health/National Cancer Institute
Mayo Clinic","Oncology: Breast; Oncology: Colorectal; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lymphoma, Non-Hodgkin's",Aggressive; Cutaneous T-cell lymphoma (CTCL); Diffuse large B-cell lymphoma (DLBCL); First line; Indolent; Other subtype; Peripheral T-cell lymphoma (PTCL); Small lymphocytic lymphoma (SLL); Stage 0; Stage I; Stage II; Stage III; Stage IV; Untreated,"Breast Neoplasms; Chronic Lymphocytic Leukemia; Colorectal Neoplasms; Enteropathy-Associated T-Cell Lymphoma; Immunoblastic Lymphadenopathy; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Panniculitis",United States
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer,III,Terminated,"National Institutes of Health/National Cancer Institute
Syndax
Eddingpharm
ECOG-ACRIN Cancer Research Group",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms; Carcinoma,South Africa; South Korea; United States
A Randomized Phase II Study of LY2523355 Versus Ixabepilone in Patients With Metastatic or Locally Recurrent Breast Cancer Who Have Received Prior Taxane Therapy,II,Completed,Eli Lilly,Oncology: Breast,First line; Second line; Stage III; Stage IV,Breast Neoplasms,United States
Randomized Phase II Study of Docetaxel With or Without Ombrabulin in the First or Second Line Metastatic Breast  Cancer Setting,II,Terminated,North Central Cancer Treatment Group (NCCTG),Oncology: Breast,First line; Second line; Stage IV,Breast Neoplasms,United States
Phase II Trial of AFP-464 in Patients with Metastatic Estrogen Receptor (ER) Positive Breast Cancer,II,Terminated,North Central Cancer Treatment Group (NCCTG),Oncology: Breast,Estrogen receptor positive; Line of therapy N/A; Stage IV,Breast Neoplasms,United States
A Pilot Study of the Impact of a Single Dose of Zoledronic Acid on Biomarkers in Breast Cancer,Other,Terminated,"National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center",Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Stage I; Stage II,"Breast Neoplasms; Carcinoma, Ductal, Breast",United States
Phase II Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy,II,Completed,"Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}
Eisai",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
Fresolimumab and Radiotherapy in Metastatic Breast Cancer,II,Completed,"University of California Los Angeles
New York University
Weill Medical College of Cornell University",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
"A randomized Phase III trial of eribulin compared to physicians choice of paclitaxel, nanoparticle albumin-bound (nabpaclitaxel, or ixabepilone as first or second-line therapy for locally recurrent or metastatic breast cancer",III,Terminated,Cancer and Leukemia Group B (CALGB),Oncology: Breast,First line; Second line; Stage III; Stage IV,Breast Neoplasms,United States
Evaluation of Diindolylmethane Supplementation to Modulate Tamoxifen Efficacy in Breast Cancer The Diindolylmethane Efficacy Study,II/III,Completed,"National Institutes of Health/National Cancer Institute
University of Arizona",Oncology: Breast,Line of therapy N/A; Stage 0; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Phase II Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer.,II,Terminated,"GlaxoSmithKline
National Institutes of Health/National Cancer Institute
University of Arizona",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage II; Stage III,"Breast Neoplasms; Breast Neoplasms, Male",United States
"Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial.",II,Completed,Washington University School of Medicine,Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor.",II,Terminated,New York University,Oncology: Breast,Estrogen receptor positive; Line of therapy N/A; Stage 0,"Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Intraductal, Noninfiltrating",United States
Phase II Neoadjuvant Trial with Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients,II,Completed,"Northwestern University
Eisai",Oncology: Breast,BRCA; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,"Breast Neoplasms; Breast Neoplasms, Male; Triple Negative Breast Neoplasms",United States
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols,II,Completed,LG Chem/AVEO Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Renal",HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Prostatic Neoplasms; Renal Cancer; Unspecified; Wilms Tumor",Belgium; Bulgaria; Canada; Chile; France; Germany; Hungary; India; Italy; Netherlands; Poland; Romania; Russia; Serbia; Spain; Ukraine; United Kingdom; United States
A Multisite International Collaborative Phase II Study of Neoadjuvant Goserelin and a Non-steroidal Aromatase Inhibitor for Premenopausal Women With Estrogen Receptor Positive HER2 Negative Clinical Stage 2 and 3 Breast Cancer,II,Terminated,"National Institutes of Health/National Cancer Institute
Washington University School of Medicine",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,United States
Fulvestrant (F) and letrozole (L) combination in second-line or more for estrogen receptor (ER)-positive (+) metastatic breast cancer (MBC),II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; Fourth line or greater; Progesterone receptor positive; Second line; Stage IV; Third line,Breast Neoplasms,United States
"Phase II trial of biweekly gemcitabine, paclitaxel, and bevacizumab as frontline therapy for metastatic breast cancer (MBC).",II,Terminated,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage IV,Breast Neoplasms,United States
Mutations of the catalytic domain of PI3 kinase and correlation with clinical outcome in trastuzumab-treated metastatic breast cancer (MBC).,Other,Completed,Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation},Oncology: Breast,Line of therapy N/A; Stage IV,Breast Neoplasms,Austria; United States
Radioactive Iodide (131I) Treatment of 124I PET/CT Detected Breast Cancers,II,Terminated,Stanford University Medical Center,Oncology: Breast,Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms,United States
A Phase IIb Confirmatory Trial of Tesetaxel for Breast Cancer,II,Terminated,Genta,Oncology: Breast,(N/A); Second line,Breast Neoplasms,United States
"Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy",II,Completed,Johnson & Johnson/Janssen R&D {Johnson & Johnson/J&JPRD},Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage IV; Third line,Breast Neoplasms,Belgium; France; Italy; Netherlands; Russia; South Korea; Spain; Ukraine; United Kingdom; United States
Efficacy of neoadjuvant cisplatin and oral capecitabine in locally advanced triple-negative breast cancer,II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Adjuvant; HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
Phase II Study of Azacitidine and Entinostat (SNDX-275) in Patients With Advanced Breast Cancer,II,Completed,"(Other Cooperative Group)
National Institutes of Health/National Cancer Institute",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Breast Neoplasms, Male; Carcinoma",Australia; United States
A Phase ll Study of Ganetespib in Trastuzumab-Refractory HER2+ Metistatic Breast Cancer Patients Who Have Progressed on Prior Pertuzumab and T-DM1.,II,Terminated,"Memorial Sloan-Kettering Cancer Center
New York University",Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
"A Phase III Randomized, Multicenter, Two Arm, Open-label Trial to Evaluate the Efficacy of Trastuzumab Emtansine Compared With Treatment of Physician's Choice in Patients With HER2-positive Metastatic Breast Cancer Who Have Received at Least Two Prior Regimens of HER2 Directed Therapy

TH3RESA - TDM1 in 3rd line HER2+ breast cancer",III,Completed,"ImmunoGen
Roche {F. Hoffmann-La Roche}
Roche/Genentech",Oncology: Breast,Fourth line or greater; HER2 positive; Stage III; Stage IV; Third line,Breast Neoplasms,Australia; Belgium; Brazil; Canada; Czech Republic; France; Germany; Hungary; India; Israel; Italy; Norway; Poland; Russia; Slovakia; South Korea; Spain; Sweden; Switzerland; Thailand; United Kingdom; United States
Randomization to Endocrine Therapy Alone Versus Endocrine Therapy Plus RAD-001 in the Neoadjuvant Setting for ER+Breast Cancers Based Upon On-Therapy Biologic Response,II,Terminated,Southwest Oncology Group,Oncology: Breast,(N/A); Estrogen receptor positive; Neoadjuvant,Breast Neoplasms,United States
Randomized Phase II Trial of an Aromatase Inhibitor with and without Metformin in Postmenopausal Obese Women with Hormone Receptor Positive Metastatic Breast Cancer,II,Terminated,Southwest Oncology Group,Oncology: Breast,Estrogen receptor positive; Line of therapy N/A; Progesterone receptor positive; Stage IV,Breast Neoplasms,United States
"A Phase II Randomized, Placebo-Controlled Trial of Exemestane Plus OSI-906 Versus Exemestane Plus Placebo in Postmenopausal Patients with Metastatic Hormone Receptor Positive Breast Cancer",II,Terminated,Southwest Oncology Group,Oncology: Breast,Estrogen receptor positive; Line of therapy N/A; Progesterone receptor positive; Stage IV,Breast Neoplasms,United States
A Multicenter Phase II Study of Enhancement of Immune Reconstitution and Vaccine Responses With Administration of Glyco-Recombinant Human IL-7 in Older Subjects Following Chemotherapy,II,Terminated,National Institutes of Health/National Cancer Institute,Infectious Disease: HBV; Infectious Disease: Respiratory Infections; Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Vaccines (Infectious Disease): Hepatitis Vaccines; Vaccines (Infectious Disease): Influenza Vaccines; Vaccines (Infectious Disease): Respiratory Vaccines,"Estrogen receptor positive; First line; Hepatitis A vaccines; Hepatitis B vaccines; Influenza; Influenza vaccines, seasonal; Pneumococcal vaccines; Progesterone receptor positive; Prophylactic vaccine; Stage II; Stage III","Breast Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Hepatitis; Hepatitis A; Hepatitis B; Influenza, Human; Pneumococcal Infections; Respiratory Tract Infections; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis.,II,Completed,(Other Hospital/Academic/Medical Center),"Oncology: Breast; Oncology: CNS, Medulloblastoma; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Prostate",(N/A); Aggressive; First line; Indolent; Pulmonary; Stage IV; Untreated,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Medulloblastoma; Melanoma; Neuroendocrine Tumors; Prostatic Neoplasms; Small Cell Lung Carcinoma",United States
"A Phase IV, Placebo-controlled Single Sequence Crossover Study to Evaluate the Effect of Repeat Oral Doses of Lapatinib on Cardiac Repolarization in Patients With Advanced Cancer",IV,Completed,"GlaxoSmithKline
Novartis",Oncology: Breast; Oncology: Unspecified Solid Tumor,HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms, Unknown Primary; Unspecified",United States
IDO2 Genetic Status Informs the Neoadjuvant Efficacy of Chloroquine in Brain Metastasis Radiotherapy,Other,Completed,(Other Hospital/Academic/Medical Center),"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer; Oncology: Ovarian",CNS mets; Neoadjuvant; Stage IV,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Neoplasm Metastasis; Ovarian Cancer; Ovarian Neoplasms",United States
"An Open Label, Phase II Trial of Afatinib With or Without Vinorelbine for the Treatment of HER2-overexpressing Inflammatory Breast Cancer",II,Completed,Boehringer Ingelheim,Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms; Inflammatory Breast Neoplasms,"Australia; Hong Kong, S.A.R., China; India; South Korea; Thailand; Tunisia; United Kingdom; United States"
Pre-surgical Evaluation of MK-2206 in Patients With Operable Invasive Breast Cancer.,II,Terminated,National Institutes of Health/National Cancer Institute,Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Multicenter Study in Patients Undergoing Anthracycline-Based Chemotherapy to Assess the Effectiveness of Using Biomarkers to Detect and Identify Cardiotoxicity and Describe Treatment (PREDICT),Other,Closed,"(Other Industry Sponsor)
MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute","Oncology: Breast; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",(N/A); Aggressive; First line; Indolent; Second line,"Acute Myelocytic Leukemia; Breast Neoplasms; Cardiotoxicity; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Ewing Sarcoma; Fibrosarcoma; Leiomyosarcoma; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms, Unknown Primary; Osteosarcoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer,II,Completed,"Sylvester Cancer Center, University of Miami",Oncology: Breast,Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Prospective Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients,Other,Completed,"(Other Industry Sponsor)
(Other Hospital/Academic/Medical Center)",Oncology: Breast,HER2 negative; Neoadjuvant; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Canada; United States
A Phase II Study Evaluating The Efficacy And Tolerability Of Everolimus (RAD001) In Combination With Trastuzumab And Vinorelbine In The Treatment Of Progressive HER2-Positive Breast Cancer Brain Metastases,II,Completed,"Novartis
(Other Cooperative Group)
UNC Lineberger Comprehensive Cancer Center
National Institutes of Health",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; First line; Fourth line or greater; HER2 positive; Second line; Stage I; Stage II; Stage III; Stage IV; Third line,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
A Survey of Clinical Practice of Adjuvant Treatment of Breast Cancer Using Exemestane (Aromasin) in Postmenopausal Hr+ Patients,IV,Terminated,Pfizer,Oncology: Breast,Adjuvant; Estrogen receptor positive; Progesterone receptor positive; Stage 0; Stage I; Stage II,Breast Neoplasms,United States
Obesity-related Mechanisms and Mortality in Breast Cancer Survivors,II,Completed,University of California San Diego,Oncology: Breast,Line of therapy N/A; Stage I; Stage II; Stage III,Breast Neoplasms; Obesity,United States
Prospective Analysis of Changes in Background Parenchymal Enhancement (BPE) and Amount of Fibroglandular Tissue on Breast MRI in Early Stage Breast Cancer Patients on Tamoxifen,Other,Terminated,Memorial Sloan-Kettering Cancer Center,Oncology: Breast,Line of therapy N/A; Stage 0; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"Phase II Randomized Trial of ABT-888 in Combination With Metronomic Oral Cyclophosphamide in Refractory BRCA-Positive Ovarian, Primary Peritoneal, Ovarian High-Grade Serous Carcinoma, Fallopian Tube Cancer, or Triple-Negative Breast Cancer",II,Terminated,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Fallopian Tube; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Primary Peritoneal",BRCA; Cutaneous T-cell lymphoma (CTCL); Extranodal marginal zone B-cell lymphoma (MALT); Follicular lymphoma (FL); Fourth line or greater; HER2 negative; Indolent; Other subtype; Peripheral T-cell lymphoma (PTCL); Second line; Small lymphocytic lymphoma (SLL); Stage IV; Third line; Triple receptor negative; Waldenstrom's macroglobulinemia (WM),"Breast Neoplasms; Carcinoma; Cystadenocarcinoma, Serous; Fallopian Tube Neoplasms; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Triple Negative Breast Neoplasms; Waldenstrom Macroglobulinemia",Canada; United States
A Multi-dose Phase II Trial of Rosuvastatin to Lower Circulating Tissue Factor Bearing Microparticles in Metastatic Breast Cancer,II,Completed,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Beth Israel Deaconess Medical Center
National Institutes of Health
Massachusetts General Hospital",Oncology: Breast,Line of therapy N/A; Stage IV,Breast Neoplasms,United States
Characterization of the Molecular-Genetic Mechanisms Associated with Chemotherapy-Induced Peripheral Neuropathy Progression,Other,Terminated,National Institutes of Health/National Institute of Nursing Research,Oncology: Breast; Oncology: Supportive Care,(N/A); Line of therapy N/A; Neurotoxicity,Breast Neoplasms; Neuralgia; Neurotoxicity Syndromes; Palliative Care,United States
"A Phase II, Multi-center, Open-label Study Evaluating GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases 

GRN1005 Against Brain Metastases - Breast Cancer (GRABM-B).",II,Terminated,"National Institutes of Health/National Cancer Institute
AngioChem",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; HER2 negative; HER2 positive; Line of therapy N/A; Stage IV,"Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis; Neoplasms, Second Primary",Canada; United States
Choosing Neoadjuvant Chemotherapy Versus Hormonal Therapy for Breast Cancer Based on Gene Expression Profile,II,Completed,"National Institutes of Health/National Cancer Institute
Virginia Commonwealth University",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,"Breast Carcinoma In Situ; Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular",Canada; United States
A Pilot Clinical Trial to Evaluate the Biological Activity of 5-azacitidine on ER and PR Expression in Triple Negative Invasive Breast Cancer,II,Terminated,"National Institutes of Health/National Cancer Institute
Bristol-Myers Squibb/Celgene
USC/Norris Comprehensive Cancer Center and Hospital",Oncology: Breast,HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"Safety Profile Assessment of TheraSphere Yttrium-90 Glass Microspheres Used for Treatment of Metastatic Liver Disease From Primary Colorectal, Neuroendocrine, Cholangiocarcinoma, Melanoma, and Breast Cancers Refractory to Chemotherapy: A Pilot Study",II,Completed,"University of California, San Francisco",Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Melanoma; Oncology: Metastatic Cancer,Liver mets; Second line; Stage IV; Unresectable,Bile Duct Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Cholangiocarcinoma; Colorectal Neoplasms; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Neuroendocrine Tumors,United States
"A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Hormone Receptor Positive, HER2 Negative, Metastatic Breast Cancer, With or Without PI3K Activated Pathway",II,Terminated,Novartis,Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,"Argentina; Australia; Belgium; Brazil; Canada; China; Colombia; Czech Republic; France; Germany; Greece; Hong Kong, S.A.R., China; Hungary; Italy; Japan; Netherlands; Peru; Russia; Singapore; South Africa; Spain; Sweden; Taiwan, China; Thailand; Turkey; United Kingdom; United States"
"A Phase II, Multicenter, Open-label, Randomized Trial of Gemcitabine Plus Carboplatin With or Without Iniparib in Patients With Proliferative or Less Proliferative HER2-negative, Hormone Receptor Positive (ER-positive and/or PR-positive) Metastatic Breast Cancer.",II,Terminated,Sanofi {Sanofi-Aventis/BiPar},Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
Phase II Trial of Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer,II,Completed,"GlaxoSmithKline
Novartis
University of Kansas",Oncology: Breast,Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"A Phase II, Single-Arm, Feasibility Study of Dose Dense Doxorubicin and Cyclophosphamide (AC) Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer",II,Completed,Eisai,Oncology: Breast,Adjuvant; HER2 negative; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"Phase II Trial of AKT Inhibitor MK2206 in Patients With Advanced Breast Cancer Who Have Tumors With a PIK3CA Mutation, or an AKT Mutation, and/or PTEN Loss/PTEN Mutation",II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Estrogen receptor positive; HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase III Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine",III,Completed,Nektar Therapeutics,Oncology: Breast,HER2 negative; HER2 positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,Belgium; Canada; China; France; Germany; Hungary; Ireland; Israel; Italy; Netherlands; Poland; Russia; South Korea; Spain; Thailand; Turkey; United Kingdom; United States
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer,II,Completed,"(Other Industry Sponsor)
University of Kansas",Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node- Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer.,III,Completed,"National Surgical Adjuvant Breast and Bowel Project (NSABP)
National Institutes of Health/National Cancer Institute
Roche/Genentech
NRG Oncology",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Stage 0; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,Canada; Ireland; Puerto Rico; United States
"Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer.",II,Completed,"Memorial Sloan-Kettering Cancer Center
University of Pennsylvania
Roche/Genentech",Oncology: Breast,First line; HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
Phase II Trial of Lapatinib in Combination With Everolimus in Triple Negative Metastatic or Locally Advanced Breast Cancer,II,Terminated,Winship Cancer Institute of Emory University,Oncology: Breast,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +or - Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer.",III,Closed,"Southwest Oncology Group
National Institutes of Health/National Cancer Institute
Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}
Breast Cancer Research Foundation",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Stage I; Stage II; Stage III,"Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating",Canada; Colombia; France; Ireland; Mexico; Puerto Rico; Saudi Arabia; South Korea; Spain; United States
"Phase II Trial of a Novel Paclitaxel Schedule As Single-Agent, First-Line Therapy for HER-2/neu-Negative Metastatic Breast Cancer: A Community-Based Study",II,Completed,"Bristol-Myers Squibb
US Oncology Research",Oncology: Breast,First line; HER2 negative; Stage III; Stage IV,Breast Neoplasms,United States
Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer,II,Completed,"GlaxoSmithKline
Novartis
City of Hope Comprehensive Cancer Center",Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"A Phase II, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Positive Breast Cancer",II,Completed,Eisai,Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase II, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer",II,Completed,Eisai,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
Feasibility Study of Biomarkers of Response to Neoadjuvant Paclitaxel in Locally Advanced Breast Cancer,Other,Completed,"National Institutes of Health/National Cancer Institute
University of Wisconsin",Oncology: Breast,HER2 negative; HER2 positive; Neoadjuvant; Stage III; Triple receptor negative,Breast Neoplasms,United States
A Phase II Study of TKI258 (Dovitinib Lactate) as Salvage Therapy in Patients with Stage IV HER2-negative Inflammatory Breast Cancer (IBC) and Local or Distant Relapse,II,Completed,"Novartis
MD Anderson Cancer Center, University of Texas",Oncology: Breast,HER2 negative; Second line; Stage IV,Breast Neoplasms; Inflammatory Breast Neoplasms,United States
"A Randomized Phase II Trial Of AEZS-108 In Chemotherapy Refractory Triple Negative, LHRH-Positive Metastatic Breast Cancer",II,Terminated,Aeterna Zentaris,Oncology: Breast,HER2 negative; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,Germany; United States
"A Randomized Multicenter, Double-blind, Placebo-controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo Versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as Adjuvant Therapy in Patients with Operable HER2-Positive Primary Breast Cancer 

APHINITY (Adjuvant Pertuzumab and Herceptin IN IniTial therapY of breast cancer)",III,Completed,"Breast International Group
Roche/Chugai Pharmaceutical
Roche {F. Hoffmann-La Roche}
Roche/Genentech",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Croatia; Czech Republic; Denmark; El Salvador; France; Germany; Guatemala; Hong Kong, S.A.R., China; Hungary; Ireland; Israel; Italy; Japan; Mexico; Netherlands; New Zealand; Panama; Peru; Philippines; Poland; Romania; Russia; Slovakia; Slovenia; South Africa; South Korea; Spain; Sweden; Switzerland; Taiwan, China; Thailand; Ukraine; United Kingdom; United States"
"A Phase II, Multicenter, Open-label, Randomized Trial of Docetaxel Plus Cyclophosphamide With or Without Iniparib in Patients With Metastatic ER-negative, PR-negative, and HER2-negative Breast Cancer.",II,Terminated,Sanofi {Sanofi-Aventis/BiPar},Oncology: Breast,First line; HER2 negative; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,United States
Modulation of Breast Cancer Risk Biomarkers in Postmenopausal Women by High Dose Omega-3 Fatty Acids,II,Completed,GlaxoSmithKline,Oncology: Breast,(N/A); Estrogen receptor positive; Line of therapy N/A,Breast Neoplasms,United States
Modulation of Breast Cancer Risk Biomarkers in Premenopausal Women by High Dose Omega-3 Fatty Acids.,II,Completed,"University of Kansas
Breast Cancer Research Foundation",Oncology: Breast,(N/A); Estrogen receptor positive; Line of therapy N/A,Breast Neoplasms,United States
"A Phase III Pivotal, Placebo Controlled, Efficacy Study of Orazol in Patients With Breast Cancer As An Adjuvant Treatment.",III,Terminated,Merrion Pharmaceuticals,Oncology: Breast,Adjuvant; Stage II; Stage III,Breast Neoplasms,United States
"An Open-Label, Multi-Center, Expanded Access Program with Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Commercially Available Therapies",III,Completed,Eisai,Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,Belgium; Canada; France; United States
Phase II Trial of MK-2206 (an AKT Inhibitor) in Combination With Endocrine Therapy in Patients With Hormone Receptor Positive Breast Cancer,II,Terminated,Vanderbilt-Ingram Cancer Center,Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
"A Non-Interventional Study With Aromasin As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer Who Are Disease-Free After 2-3 Years Of Initial Adjuvant Tamoxifen Therapy",IV,Terminated,Pfizer,Oncology: Breast,Adjuvant; Estrogen receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,Croatia; Estonia; United States
"An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer",II,Completed,"(Other Cooperative Group)
University of Alabama, Birmingham
Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}
Daiichi Sankyo",Oncology: Breast,First line; HER2 negative; Second line; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Two-Part Adaptive, Randomized Trial of Ridaforolimus in Combination With Dalotuzumab Compared to Exemestane or Compared to Ridaforolimus or Dalotuzumab Monotherapy in Estrogen Receptor Positive Breast Cancer Patients",II,Terminated,Merck & Co./Merck Sharp & Dohme (MSD),Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms,"Belgium; Brazil; Canada; Colombia; Denmark; France; Germany; Ireland; Israel; Italy; Peru; South Korea; Spain; Sweden; Taiwan, China; United Kingdom; United States"
"An Open-Label, Multicenter, Randomized Phase II Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or Icrucumab (IMC-18F1) in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy",II,Completed,Eli Lilly,Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,Canada; United States
A Randomized Phase II Study of AFP464 + or - Faslodex in ER Positive Breast Cancer Patients Who Had Progressed on Aromatase Inhibitor (AI) Therapy,II,Terminated,Kirax Corporation {Tigris Pharmaceuticals},Oncology: Breast,(N/A); Estrogen receptor positive; Second line,Breast Neoplasms,United States
"Phase II Open Label Study of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic, Estrogen Receptor Positive Breast Cancer, After Failure of Tamoxifen and/or Anastrozole and/or Letrozole and/or Fulvestrant and/or Exemestane",IV,Completed,Novartis,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,Israel; United States
"Cyclophosphamide and Docetaxel Every 3 Weeks as Neoadjuvant Therapy in Locally Advanced Breast Cancer, A Collaborative Trial",II,Terminated,(Other Hospital/Academic/Medical Center),Oncology: Breast,First line; HER2 negative; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
"A Phase III Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER 2 - Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer.",III,Completed,AbbVie,Oncology: Breast,BRCA; First line; HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms,"Argentina; Australia; Austria; Belarus; Belgium; Canada; Chile; Colombia; Czech Republic; Denmark; Estonia; Finland; France; Germany; Hungary; Israel; Italy; Japan; Latvia; Lithuania; Mexico; Netherlands; Norway; Poland; Portugal; Puerto Rico; Romania; Russia; Singapore; South Africa; South Korea; Spain; Sweden; Taiwan, China; Turkey; Ukraine; United Kingdom; United States"
"Phase II Clinical Trial of Neoadjuvant Weekly Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer",II,Terminated,"University of Southern California
CTI BioPharma {Cell Therapeutics}",Oncology: Breast,(N/A); Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive,Breast Neoplasms,United States
Vitamin D and Breast Cancer Biomarkers,Other,Completed,"National Institutes of Health/National Cancer Institute
Alliance for Clinical Trials in Oncology",Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
A Phase II Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors.,II,Terminated,"Bristol-Myers Squibb
National Institutes of Health
Mayo Clinic",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Phase II Study of Tesetaxel as First-line Therapy for Subjects With Metastatic Breast Cancer,II,Completed,Genta,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Neoadjuvant; NRAS; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
Double-Blind Randomized 12-Month Soy Intervention Had No Effects On Breast MRI Fibroglandular Tissue Density Or Mammographic Density,II,Completed,"(Other Cooperative Group)
National Institutes of Health/National Cancer Institute
University of Southern California",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; HER2 positive; Progesterone receptor positive; Stage 0; Stage I; Stage II; Stage III,"Breast Carcinoma In Situ; Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular",United States
Subcutaneous Testosterone-Anastrozole Implant Therapy in Breast Cancer Survivors.,II,Completed,(Other Academic Cancer Center),Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
A Phase II Study of Photodynamic Compounds Activated by a Theralase Laser for the Treatment of Cancer,II,Completed,"(Other Hospital/Academic/Medical Center)
Theralase",Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,Canada; United States
A Phase III Randomized Study of CVac in Patients with Advanced Breast Cancer,III,Terminated,Immutep {Prima BioMed},Oncology: Breast,Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms,Australia; United States
"A Phase II Study of Abraxane and Carboplatin as First-line Treatment for ""Triple Negative"" (Demonstrating no Expression for Estrogen, Progesterone, or Human Epidermal Growth Factor Receptor 2 (HER2)Receptors) Metastatic Breast Cancer",II,Terminated,"Bristol-Myers Squibb/Celgene
Duke University Medical Center",Oncology: Breast,First line; HER2 negative; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,China; United States
"A Phase II Trial of Endocrine Therapy in Combination With OSI-906 (an IGF-1R Inhibitor) and Erlotinib (Tarceva, an EGFR Inhibitor) in Patients With Hormone-sensitive Metastatic Breast Cancer",II,Terminated,"Vanderbilt-Ingram Cancer Center
Astellas Pharma {OSI Pharmaceuticals}",Oncology: Breast,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
An Open-Label Study to Evaluate the Effects of Ketoconazole and the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Repeat Doses of Pazopanib in Subjects With Solid Tumor Malignancies,IV,Completed,GlaxoSmithKline,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",(N/A); First line; Locally advanced; Metastatic; Pulmonary; Recurrent; Second line; Stage III; Stage IV; Untreated,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
Randomized Pivotal Trial to Assess the Safety and Efficacy of Preoperative Focused Microwave Thermotherapy Plus Preoperative Chemotherapy Versus Preoperative Chemotherapy Alone for Cytoreduction of Large Breast Cancer in Female Patients With Intact Breast,III,Completed,(Other Industry Sponsor),Oncology: Breast,Adjuvant; Neoadjuvant; Second line; Stage 0; Stage II; Stage III; Stage IV,Breast Neoplasms,Canada; United States
"A Multicenter, Multinational Phase II Study to Assess the Clinical Safety and Feasibility of Trastuzumab Emtansine Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage HER2-positive Breast Cancer",II,Completed,Roche {F. Hoffmann-La Roche},Oncology: Breast,Adjuvant; HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,Belgium; France; Germany; Italy; Poland; Russia; South Korea; Spain; Switzerland; United States
Low-Dose Tamoxifen for Radiation-Induced Breast Cancer Risk Reduction: A Phase IIB Randomized  Placebo-Controlled Trial,II,Completed,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute
Comprehensive Cancer Center of Wake Forest University
University of Chicago Cancer Research Center
St. Jude Children's Research Hospital
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
City of Hope Comprehensive Cancer Center
University of Alabama, Birmingham
University of Washington
Mayo Clinic
(Other Hospital/Academic/Medical Center)
University of Colorado
University Health Network, Toronto
University of Minnesota","Oncology: Breast; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's",Aggressive; Classical; Indolent; Line of therapy N/A; Nodular lymphocyte-predominant; Stage 0,"Breast Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin",Canada; United States
"Phase II Neoadjuvant Trial of Sorafenib in Combination With Cisplatin Followed by Dose Dense Paclitaxel for ER-, PR-, Her2- (Triple Negative) Early-Stage Breast Cancer",II,Terminated,"Bayer AG/Bayer Pharmaceuticals
Winship Cancer Institute of Emory University
Amgen {Onyx Pharmaceuticals}",Oncology: Breast,HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
A Multi-Institutional Phase II Study Evaluating Surrogate Biomarkers of Response to Short Term Oral Vorinostat and Tamoxifen in Women With Newly Diagnosed Breast Cancer,II,Terminated,"Merck & Co.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}",Oncology: Breast,Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Phase II, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2 Negative Primary Tumors and HER2 Positive Circulating Tumor Cells",II,Terminated,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Beth Israel Deaconess Medical Center
Massachusetts General Hospital
Brigham and Womens Hospital
Roche/Genentech",Oncology: Breast,HER2 negative; Second line; Stage IV,Breast Neoplasms,United States
"A Comparative, Multicenter, Open-Label, Randomized, Phase II Study of the Safety and Antitumor Activity of Oral Eniluracil + 5 Fluorouracil + Leucovorin Versus Capecitabine Monotherapy in Subjects With Metastatic Breast Cancer",II,Completed,Fennec Pharmaceuticals {Adherex Technologies},Oncology: Breast,First line; Second line; Stage IV,Breast Neoplasms,Russia; United States
Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors,II,Completed,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}
Yale University",Oncology: Breast; Oncology: Colorectal; Oncology: Metastatic Cancer; Oncology: Neuroendocrine; Oncology: Unspecified Solid Tumor,Liver mets; Metastatic; Second line; Stage IV; Unspecified,"Breast Neoplasms; Colorectal Neoplasms; Liver Neoplasms; Neoplasm Metastasis; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors",United States
"A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab",II,Open,National Institutes of Health/National Cancer Institute,"Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal",Estrogen receptor positive; HER2 negative; Second line; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Colorectal Neoplasms; Endocrine Gland Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Glioblastoma; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasm Metastasis; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase II, Double-Blind, Placebo Controlled, Randomized Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy",II,Completed,Roche/Genentech,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,"Argentina; Australia; Belgium; Brazil; Canada; Chile; Czech Republic; Denmark; France; Germany; Hong Kong, S.A.R., China; Hungary; Israel; Italy; Malaysia; Mexico; New Zealand; Peru; Russia; Singapore; South Korea; Spain; Taiwan, China; Thailand; Ukraine; United Kingdom; United States"
"A Randomized, Phase II, Multicenter, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Onartuzumab (Metmab) And/Or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple Negative Breast Cancer",II,Completed,Roche/Genentech,Oncology: Breast,First line; HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Belgium; Denmark; France; Germany; Spain; United Kingdom; United States
Effect of Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer: Clinical Outcome and Correlation to Biological Parameters,II,Terminated,Washington University School of Medicine,Oncology: Breast,Adjuvant; HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Surgical Cytoreduction Followed by Intraoperative Intrathoracic Hyperthermic Chemotherapy Perfusion for the Management of Disseminated Pleural Malignancies.,II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast; Oncology: Colorectal; Oncology: Metastatic Cancer; Oncology: Ovarian; Oncology: Renal; Oncology: Thymus,Adjuvant; Other mets; Stage IV; Thymic carcinoma,"Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Neoplasm Metastasis; Ovarian Cancer; Ovarian Neoplasms; Pleural Neoplasms; Renal Cancer; Thymus Neoplasms; Uterine Neoplasms; Wilms Tumor",United States
Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D,Other,Completed,(Other Industry Sponsor),Oncology: Breast,Estrogen receptor positive; Second line; Stage 0,Breast Neoplasms,United States
A Phase II Neoadjuvant Study of RAD001 (Everolimus) in Combination With Paclitaxel and Trastuzumab For Operable HER2 Positive Breast Cancer,II,Terminated,"Novartis
University of Kansas",Oncology: Breast,HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Phase III Trial to Compare the Safety and Efficacy of Lapatinib Plus Trastuzumab Plus an Aromatase Inhibitor (AI) vs. Trastuzumab Plus an AI vs. Lapatinib Plus an AI as 1st- or 2nd- Line Therapy in Postmenopausal Subjects With Hormone Receptor+, HER2-positive Metastatic Breast Cancer (MBC) Who Received Prior Trastuzumab and Endocrine Therapies",III,Completed,"GlaxoSmithKline
Novartis",Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,"Argentina; Australia; Belgium; Brazil; Bulgaria; Canada; China; Colombia; Croatia; Denmark; Finland; France; Germany; Greece; Hong Kong, S.A.R., China; Hungary; India; Ireland; Israel; Italy; Japan; Lithuania; Mexico; Norway; Peru; Philippines; Poland; Portugal; Puerto Rico; Romania; Russia; Serbia; Singapore; South Africa; South Korea; Spain; Taiwan, China; Turkey; Ukraine; United Kingdom; United States"
Molecular Triaging of Newly Diagnosed Breast Cancer for Preoperative Therapies,III,Terminated,"MD Anderson Cancer Center, University of Texas",Oncology: Breast,Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Olanzapine versus Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized Phase III Trial.,III,Completed,(Other Hospital/Academic/Medical Center),"Oncology: Bladder; Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Supportive Care",(N/A); Aggressive; Classical; Emesis; First line; Indolent; Nodular lymphocyte-predominant,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Palliative Care; Urethral Neoplasms; Urinary Bladder Neoplasms; Vomiting",United States
Investigation of Pathways Regulating Early Antiangiogenic Response to Bevacizumab Given Prior to Neoadjuvant Breast Cancer Chemotherapy.,II,Completed,Roche/Genentech,Oncology: Breast,Neoadjuvant; Stage III,Breast Neoplasms,United Kingdom; United States
A Pilot Study of Vorinostat to Restore Sensitivity to Aromatase Inhibitor Therapy,II,Completed,"National Institutes of Health/National Cancer Institute
University of Washington",Oncology: Breast,Estrogen receptor positive; Second line; Stage IV,"Breast Neoplasms; Breast Neoplasms, Male",United States
"A Phase II, Randomised, Double-blind, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of AZD8931 In Combination With Anastrozole, Compared to Anastrozole Alone, in Post Menopausal Women With Hormone Receptor Positive, Endocrine Therapy Naive, Locally Advanced or Metastatic Breast Cancer (MINT).",II,Terminated,AstraZeneca,Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms; Neoplasms,"Brazil; Canada; Colombia; Czech Republic; Finland; Hungary; India; Japan; Malaysia; Mexico; Netherlands; Peru; Philippines; Poland; Portugal; Russia; South Africa; South Korea; Taiwan, China; Thailand; Ukraine; United Kingdom; United States"
A Randomized Double-Blind Phase II Trial of Exemestane + or - MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive (ER+) and/or Progesterone Receptor Positive (PR+) Her2 Negative Breast Cancer,II,Completed,Merrimack Pharmaceuticals,Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,Canada; Germany; Russia; Spain; United States
"A Phase II Study of RO4929097 (IND 109291) in Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Carcinoma",II,Terminated,National Institutes of Health/National Cancer Institute,Oncology: Breast,First line; HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Breast Neoplasms, Male; Triple Negative Breast Neoplasms",Canada; United States
A Phase II Study of Anti-CD3 x Anti-HER2/Neu (Her2Bi) Armed Activated T Cells (ATC) After Neoadjuvant Chemo in Patients With HER2/Neu (0-2+)-Negative Stage II-III Breast Cancers,II,Terminated,"Barbara Ann Karmanos Cancer Institute
National Institutes of Health/National Cancer Institute",Oncology: Breast,HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies,II,Completed,Eisai,Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase III Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled, Parallel Group Study of the Efficacy and Safety of Oral Netupitant Administered in Combination With Palonosetron and Dexamethasone Compared to Oral Palonosetron and Dexamethasone for the Prevention of Nausea and Vomiting in Cancer Patients Receiving Moderately Emetogenic Chemotherapy",III,Completed,Helsinn Healthcare,Oncology: Breast; Oncology: Supportive Care,(N/A); Emesis; First line,Breast Neoplasms; Nausea; Palliative Care; Vomiting,Argentina; Belarus; Brazil; Bulgaria; Croatia; Germany; Hungary; India; Italy; Mexico; Poland; Romania; Russia; Switzerland; Ukraine; United States
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer,II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"Open Label Expanded Access for Investigational Use of PV-10 in Patients Who Are Not Eligible for an Existing PV-10 Clinical Trial, for Whom There is no Alternative Therapy, and Whom May Benefit From PV-10 Administration",II,Completed,Provectus Biopharmaceuticals,"Oncology: Breast; Oncology: Head/Neck; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma",First line; Metastatic; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Ewing Sarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms, Basal Cell; Osteosarcoma; Renal Cancer; Unspecified; Wilms Tumor",Australia; United States
"A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer",II,Terminated,GlaxoSmithKline,Oncology: Breast,First line; HER2 positive; Stage IV,Breast Neoplasms,Peru; Russia; United States
A Biomarker Study of Mifepristone in Early Stage Breast Cancer,II,Terminated,University of California San Diego,Oncology: Breast,Neoadjuvant; Stage 0; Stage I; Stage II,"Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Intraductal, Noninfiltrating",United States
Prospective evaluation of megestrol acetate after aromatase inhibitor failure in advanced endocrine responsive breast cancer.,II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,First line; Second line; Stage IV,Breast Neoplasms,Belgium; Brazil; United States
"Phase II Study of Combined Docetaxel, Epirubicin, and Cyclophosphamide as a Neoadjuvant Chemotherapy Regimen in Patients with Locally Advanced Breast Cancer in a Single Institution.",II,Completed,Medical College of Wisconsin Cancer Center,Oncology: Breast,Adjuvant; HER2 positive; Neoadjuvant; Stage III,Breast Neoplasms,United States
The Effect of Aspirin Therapy on Circulating Vascular Endothelial Growth Factor (VEGF) Levels in Tamoxifen-Treated Women.,Other,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Line of therapy N/A; Stage 0; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
"An Open-Label, Expanded Access Protocol of Iniparib in Combination With Gemcitabine/Carboplatin in Patients With ER-, PR-, and HER2-Negative Metastatic Breast Cancer",III,Completed,Sanofi {Sanofi-Aventis/BiPar},Oncology: Breast,First line; HER2 negative; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid and Circulating Tumor Cell Measurements in Patients With HER2-negative Metastatic Breast Cancer Without Bone Metastasis",IV,Completed,Novartis,Oncology: Breast,First line; HER2 negative; Second line; Stage IV,"Bone Marrow Diseases; Bone Neoplasms; Breast Neoplasms; Neoplasm Metastasis; Neoplastic Cells, Circulating",United States
Phase II Trial of RAD001 Plus Carboplatin in Patients With Triple-Negative Metastatic Breast Cancer,II,Completed,"Novartis
New York University",Oncology: Breast,First line; Fourth line or greater; HER2 negative; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
"Neoadjuvant therapy for stage II-III breast cancer with weekly nab-paclitaxel, every-three-week carboplatin, and targeted agents: Interim dose delivery and toxicity data.",II,Completed,Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}},Oncology: Breast,Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
"LUX-Breast 1; An Open Label, Randomised Phase III Trial of BIBW 2992 and Vinorelbine Versus Trastuzumab and Vinorelbine in Patients With Metastatic HER2-overexpressing Breast Cancer Failing One Prior Trastuzumab Treatment",III,Terminated,Boehringer Ingelheim,Oncology: Breast,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,"Argentina; Australia; Austria; Belarus; Belgium; Brazil; Canada; Chile; China; Colombia; Czech Republic; Egypt; Finland; France; Germany; India; Iraq; Ireland; Israel; Italy; Japan; Jordan; Latvia; Lebanon; Lithuania; Mexico; Netherlands; Norway; Peru; Poland; Portugal; Russia; Saudi Arabia; Singapore; Slovakia; Slovenia; South Africa; South Korea; Spain; Sri Lanka; Sweden; Taiwan, China; Turkey; United Arab Emirates; United Kingdom; United States"
A Phase II Prospective Trial Correlating Progression Free Survival With CYP2D6 Activity in Patients With Metastatic Breast Cancer Treated With Single Agent Tamoxifen,II,Completed,"National Institutes of Health/National Cancer Institute
ECOG-ACRIN Cancer Research Group",Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,Canada; Peru; United States
"An Expanded Access, Open-Label Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer",II,Completed,Roche/Genentech,Oncology: Breast,First line; Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
GCC 0845: Pilot and Phase II- Vorinostat and Lapatinib in Patients With Advanced Solid Tumor Malignancies and Women With Recurrent Local-Regional or Metastatic Breast Cancer to Evaluate Response and Biomarkers of EMT and Breast Cancer Stem Cells,II,Terminated,University of Maryland Greenebaum Cancer Center,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Thyroid",Fourth line or greater; HER2 negative; HER2 positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Thyroid Neoplasms",United States
Phase II Study of Pralatrexate in Female Patients With Previously-treated Advanced or Metastatic Breast Cancer,II,Completed,"Spectrum Pharmaceuticals {Allos Therapeutics}
Mundipharma International",Oncology: Breast,HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms,Czech Republic; France; Hungary; United States
"Assessing Response to Neoadjuvant Chemotherapy With Dedicated Breast High Definition PET/CT, Serum Glycomic Markers and Tissue Muc-1 Isoforms",Other,Completed,University of California Davis,Oncology: Breast,Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
A Randomized Trial of Oal melatonin supplementation in breast cancer survivors.,II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Line of therapy N/A; Stage 0; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Phase II Study of Adjuvant Therapy Using a Regimen of Cyclophosphamide, Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Patients",II,Completed,"National Institutes of Health/National Cancer Institute
UNMC Eppley Cancer Center at the University of Nebraska Medical Center",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; HER2 positive; Maintenance/Consolidation; Progesterone receptor positive; Stage I; Stage II; Triple receptor negative,Breast Neoplasms,United States
"Lymphodepleting Chemotherapy and T-Cell Suppression Followed By Allogeneic Natural Killer Cells and IL-2 in Patients With Recurrent Ovarian, Fallopian Tube, Primary Peritoneal Cancer and Advanced Metastatic Breast Cancer (MT2009-30)",II,Terminated,University of Minnesota,Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms; Fallopian Tube Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms,United States
Randomized Open-Label Neo-Adjuvant Phase II Study Comparing Ixabepilone (I) Vs. Ixabepilone Plus Cetuximab (IC) in Triple Negative Breast Cancer Patients,II,Completed,"Bristol-Myers Squibb
(Other Hospital/Academic/Medical Center)",Oncology: Breast,HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Pilot Biomarker Study of the Integrin AlphavBeta3 Antagonist Cilengitide (EMD121974) in Combination With Sunitinib,Other,Terminated,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: CNS, Glioblastoma",Second line; Stage III; Stage IV,Brain Neoplasms; Breast Neoplasms; Glioblastoma; Gliosarcoma; Neoplasms,United States
"A Multicenter, Open-Label, Phase II Study of LEP-ETU for Efficacy and Safety in Patients With Metastatic Breast Cancer",II,Completed,"Insys Therapeutics {NeoPharm, Inc.}",Oncology: Breast,First line; Stage IV,Breast Neoplasms,India; United States
A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer.,II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer,II,Terminated,"North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute
Alliance for Clinical Trials in Oncology",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,Canada; United States
A Phase II Study of High Dose Estradiol in Metastatic Triple Negative Breast Cancer,II,Terminated,University of Wisconsin,Oncology: Breast,First line; Fourth line or greater; HER2 negative; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Phase II Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer,II,Terminated,"Memorial Sloan-Kettering Cancer Center
Madrigal Pharmaceuticals {Synta Pharmaceuticals}",Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer",II,Completed,Celldex Therapeutics {CuraGen},Oncology: Breast,HER2 negative; HER2 positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"A Phase II, Open Label, Non Randomised, Non Comparative, Multicentre Study to Assess the Efficacy and Safety of Olaparib Given Orally Twice Daily in Patients With Advanced Cancers Who Have a Confirmed Genetic BRCA 1 and/or BRCA2 Mutation.",II,Completed,AstraZeneca,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate",(N/A); BRCA; Fourth line or greater; HER2 positive; Hormone refractory; Pulmonary; Second line; Stage II; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Liver Cancer; Liver Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms",Australia; Germany; Israel; Spain; Sweden; United States
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study,II,Completed,"Bristol-Myers Squibb
US Oncology Research",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage I; Stage II; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
"PARP Inhibition After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer or ER/PR +, HER2 Negative With Known BRCA1/2 Mutations: Hoosier Oncology Group BRE09-146",II,Completed,"Hoosier Cancer Research Network {Hoosier Oncology Group}
Pfizer
Clovis Oncology",Oncology: Breast,Adjuvant; BRCA; Estrogen receptor positive; HER2 negative; Maintenance/Consolidation; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole With Lapatinib + Letrozole in Recurrent and Metastatic Breast Cancer Patients Who Are Hormone Receptor Positive Despite HER2 Status And Who Relapsed While Receiving or After Completing Adjuvant Antiendocrine Therapy",II,Completed,Bristol-Myers Squibb,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; HER2 positive; Progesterone receptor positive; Stage IV,Breast Neoplasms,Argentina; Brazil; Germany; Mexico; Peru; Spain; United States
A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ (DCIS),II,Terminated,University of Chicago Cancer Research Center,Oncology: Breast,Neoadjuvant; Stage 0,"Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Intraductal, Noninfiltrating",United States
A Phase II Study of a Fixed Combination of Uracil and Ftorafur (UFT) and Leucovorin Given Orally in a 3-Times-Daily Regimen to Treat Patients with Recurrent Metastatic Breast Cancer,II,Completed,Bristol-Myers Squibb,Oncology: Breast,Estrogen receptor positive; Fourth line or greater; Progesterone receptor positive; Second line; Stage IV; Third line,Breast Neoplasms,United States
"A Randomized, 3 Arm, Multicenter, Phase III Study to Evaluate the Efficacy and the Safety of T-DM1 Combined With Pertuzumab or T-DM1 Combined With Pertuzumab-Placebo (Blinded for Pertuzumab), Versus the Combination of Trastuzumab Plus Taxane, as First Line Treatment in HER2 Positive Progressive or Recurrent Locally Advanced or Metastatic Breast Cancer",III,Completed,"Roche/Chugai Pharmaceutical
ImmunoGen
Roche/Genentech",Oncology: Breast,First line; HER2 positive; PD-L1 High; PD-L1 Positive; Second line; Stage III; Stage IV,Breast Neoplasms,"Argentina; Australia; Austria; Bahamas; Belgium; Bosnia and Herzegovina; Brazil; Bulgaria; Canada; China; Colombia; Costa Rica; Czech Republic; Denmark; France; Germany; Greece; Guatemala; Hungary; Italy; Japan; Latvia; Lithuania; Macedonia; Malaysia; Mexico; New Zealand; Panama; Peru; Philippines; Poland; Portugal; Romania; Russia; South Korea; Spain; Sweden; Switzerland; Taiwan, China; Thailand; Turkey; United Kingdom; United States"
Paclitaxel in Combination with Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma,II,Completed,"Stanford University Medical Center
Roche/Genentech",Oncology: Breast; Oncology: Soft Tissue Sarcoma,(N/A); First line; Locally advanced; Metastatic; Second line; Unresectable,Breast Neoplasms; Fibrosarcoma; Hemangiosarcoma; Leiomyosarcoma; Liposarcoma; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma,United States
Clinical Trial of Vitamin D3 to Reduce Cancer Risk in Postmenopausal Women,III,Completed,"National Institutes of Health
(Other Hospital/Academic/Medical Center)",Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Melanoma; Oncology: Ovarian,(N/A); Line of therapy N/A,"Acute Myelocytic Leukemia; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Colorectal Neoplasms; Endometrial Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Melanoma; Multiple Myeloma; Ovarian Cancer; Ovarian Neoplasms; Unspecified",United States
A Pilot Study Investigating the Feasibility of Using Acupuncture for the Treatment of Taxane-Induced Peripheral Neuropathy,II,Terminated,City of Hope Comprehensive Cancer Center,Oncology: Breast; Oncology: Supportive Care,Neurotoxicity; Second line; Stage I; Stage II; Stage III,Breast Neoplasms; Palliative Care,United States
A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer.,II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Line of therapy N/A; Stage IV,Breast Neoplasms,Canada; United States
Use of the PRO Onc Assay to Assess HER2 Overexpression and Activation in Patients With Metastatic Breast Cancer Whose Tumors Are HER2-Negative by Standard FISH Testing,II,Completed,"Prometheus Biosciences {Precision IBD/Prometheus Laboratories {Nestle Health Science/Prometheus Laboratories}}
Roche/Genentech",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Third line,Breast Neoplasms,United States
Magnetic Resonance Imaging of Tumor Response and Cognitive Impairment in Breast Cancer Patients Undergoing Anthracycline-based Systemic Chemotherapy,Other,Terminated,(Other Hospital/Academic/Medical Center),Oncology: Breast,(N/A); Estrogen receptor positive; Line of therapy N/A; Progesterone receptor positive,Breast Neoplasms; Cognition Disorders,United States
A Phase III Study of HER-2/neu Inhibitor in Patients with Low-to-Intermediate HER-2 Expressing Breast Cancer.,III,Terminated,Generex Biotechnology/NuGenerex Immuno-Oncology {Antigen Express},Oncology: Breast,(N/A); Adjuvant; HER2 negative; Triple receptor negative,Breast Neoplasms,United States
A Randomized Phase II Study Of Imetelstat (GRN163L) In Combination With Paclitaxel (With Or Without Bevacizumab) in Patients With Locally Recurrent Or Metastatic Breast Cancer,II,Terminated,Geron,Oncology: Breast,First line; HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,Canada; United States
I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2),II,Open,"(Other Cooperative Group)
National Institutes of Health/National Cancer Institute
American College of Radiology Imaging Network (ACRIN)",Oncology: Breast,BRCA; Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Hemangiosarcoma; Triple Negative Breast Neoplasms,Canada; United States
The Effect of Metformin on Biomarker Activity in Primary Breast Cancer,II,Completed,"University of Dundee
(Other Hospital/Academic/Medical Center)",Oncology: Breast,Estrogen receptor positive; Neoadjuvant; Stage I; Stage II,Breast Neoplasms,Canada; United Kingdom; United States
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer,II,Completed,"Pfizer
Abramson Cancer Center at  University of Pennsylvania Medical Center",Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Melanoma; Oncology: Ovarian; Oncology: Testicular; Oncology: Unspecified Solid Tumor,BRAF; Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; KRAS; Metastatic; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Adenocarcinoma; Breast Neoplasms; Breast Neoplasms, Male; Colonic Neoplasms; Colorectal Neoplasms; Dermoid Cyst; Esophageal Cancer; Esophageal Neoplasms; Germinoma; Melanoma; Neoplasms, Germ Cell and Embryonal; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Rectal Neoplasms; Seminoma; Stomach Carcinoma; Stomach Neoplasms; Teratoma; Testicular Cancer; Testicular Neoplasms",United States
"A Phase II, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)",II,Terminated,Enzon,Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
"Phase II Study of Panitumumab, Nab-paclitaxel, and Carboplatin for Patients With Primary Inflammatory Breast Cancer (IBC) Without HER2 Overexpression",II,Completed,"Amgen
MD Anderson Cancer Center, University of Texas
Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}}",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Inflammatory Breast Neoplasms,United States
"Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer",II,Completed,"(Other Cooperative Group)
Astellas Pharma",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage IV; Triple receptor negative,Breast Neoplasms,Belgium; Czech Republic; Germany; Ireland; Poland; Russia; United Kingdom; United States
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS),II,Completed,"National Institutes of Health/National Cancer Institute
Alliance for Clinical Trials in Oncology",Oncology: Breast,Estrogen receptor positive; Neoadjuvant; Progesterone receptor positive; Stage 0,"Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Intraductal, Noninfiltrating",United States
"A Multicenter, Phase II Open-Labeled, Single-Arm Clinical and Pharmacology Study of Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer.",II,Terminated,"(Other Cooperative Group)
University of California Los Angeles","Oncology: Breast; Oncology: Lung, Non-Small Cell",Estrogen receptor positive; HER2 positive; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms",United States
Pilot Study to Analyze a Novel Mechanism Underlying Response to Tamoxifen Therapy in Breast Cancer Patients,II,Completed,"National Institutes of Health/National Cancer Institute
Roswell Park Cancer Institute
National Institutes of Health",Oncology: Breast,Estrogen receptor positive; First line; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
"An Open-Label, Multicenter, Randomized, Phase II Study Evaluating the Efficacy and Safety of Ramucirumab (IMC-1121B) Drug Product in Combination With Eribulin Versus Eribulin Monotherapy in Unresectable, Locally-Recurrent or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy",II,Completed,Eli Lilly {ImClone},Oncology: Breast,First line; HER2 negative; HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
"A Phase II Study of Anti-CD3 x Anti-HER2/Neu Armed Activated T Cells for Patients With HER2/Neu (0, 1+ or 2+) Metastatic Breast Cancers.",II,Completed,"Barbara Ann Karmanos Cancer Institute
National Institutes of Health/National Cancer Institute",Oncology: Breast,Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
"A Randomized Phase III Trial of the Steroidal Aromatase Inhibitor, Exemestane, vs. a Combination of Exemestane and the Monocolonal Antibody IGF-1R Inhibitor IMC-A12 in Patients with Metastiatic ER/PgR Positive Breast Cancer.",III,Terminated,Southwest Oncology Group,Oncology: Breast,Estrogen receptor positive; Line of therapy N/A; Progesterone receptor positive; Stage IV,Breast Neoplasms,United States
"A Randomized, Phase III, Double-Blind, Placebo-Controlled Trial of Memantine for Prevention of Cognitive Dysfunction in Patients Receiving Whole-Brain Radiotherapy",III,Completed,"Radiation Therapy Oncology Group (RTOG)
National Institutes of Health/National Cancer Institute
AbbVie/Allergan {Allergan/Actavis/Forest Laboratories {Actavis/Forest Laboratories}}
NRG Oncology","Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Supportive Care",Line of therapy N/A; Neurotoxicity; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasm Metastasis; Neurotoxicity Syndromes; Palliative Care",Canada; United States
Phase II Trial of Sunitinib as Maintenance Therapy After Stereotactic Radiosurgery in Patients With 1-3 Newly Diagnosed Brain Metastases.,II,Terminated,"(Other Academic Cancer Center)
National Institutes of Health/National Cancer Institute
Pfizer","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Renal",CNS mets; Maintenance/Consolidation; Stage IV,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Kidney Neoplasms; Melanoma; Neoplasm Metastasis; Renal Cancer; Wilms Tumor",United States
A Two-Arm Open Label Phase II Study of AFP464 (Aminoflavone Prodrug) in Previously-treated ER-positive or Triple-negative Breast Cancer Patients,II,Terminated,Kirax Corporation {Tigris Pharmaceuticals},Oncology: Breast,(N/A); Estrogen receptor positive; HER2 negative; Second line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase II Trial of Endocrine Therapy in Combination With OSI-906 (an IGF-1R Inhibitor) With or Without Erlotinib (Tarceva, an EGFR Inhibitor) in Patients With Hormone-sensitive Metastatic Breast Cancer.",II,Terminated,"National Institutes of Health/National Cancer Institute
Vanderbilt-Ingram Cancer Center
Astellas Pharma {OSI Pharmaceuticals}",Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
A Phase II Study of MGCD265 in Patients with Breast or Bladder Cancer,II,Terminated,Mirati Therapeutics {MethylGene},Oncology: Bladder; Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms,United States
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer,III,Terminated,"US Department of Defense
Predictive Oncology {Precision Therapeutics}/Helomics {Helomics {Precision Therapeutics}}",Oncology: Breast,Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer,II,Completed,"Southwest Oncology Group
National Institutes of Health/National Cancer Institute",Oncology: Breast,Second line; Stage 0; Stage I; Stage II,Breast Neoplasms,United States
A Phase II Clinical Trial of Weekly Paclitaxel and Carboplatin in Combination With Panitumumab in Metastatic Breast Cancer Patients With Triple Negative Disease,II,Terminated,(Other Academic Cancer Center),Oncology: Breast,First line; HER2 negative; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,United States
A Phase II Study of ABT-888 and Temozolomide for Metastatic Breast Cancer and an Expansion Cohort in BRCA1/2 Mutation Carriers.,II,Completed,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
AbbVie {Abbott}
Beth Israel Deaconess Medical Center
Massachusetts General Hospital",Oncology: Breast,BRCA; Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens With Weekly Paclitaxel Plus Neratinib or Trastuzumab or Neratinib and Trastuzumab Followed by Doxorubicin and Cyclophosphamide With Postoperative Trastuzumab in Women With Locally Advanced HER2-Positive Breast Cancer,II,Completed,"National Surgical Adjuvant Breast and Bowel Project (NSABP)
Puma Biotechnology",Oncology: Breast,Adjuvant; HER2 positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,Canada; France; Italy; Portugal; Puerto Rico; Spain; United States
"A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.

Breast cancer trials of OraL EveROlimus-3 (BOLERO-3) trial",III,Completed,Novartis,Oncology: Breast,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,Argentina; Australia; Belgium; China; Czech Republic; France; Germany; Greece; Hungary; Israel; Italy; Japan; Mexico; Poland; Puerto Rico; Singapore; Slovakia; Spain; Thailand; Turkey; United Kingdom; United States
Pilot Study of Pathologic Complete Response (pCR) in LABC Patients Treated with Dose Dense AC x 4 Followed by Weekly Paclitaxel x 12 Concurrently with Capecitabine,II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage III; Triple receptor negative,Breast Neoplasms,Peru; United States
Sunitinib Malate and Metronomic Cyclophosphamide/Methotrexate (CM) for Patients Who Do Not Achieve a Pathologic Complete Response After Neoadjuvant Chemotherapy: A Toxicity Assessment,II,Completed,"Pfizer
(Other Hospital/Academic/Medical Center)
Breast Cancer Research Foundation",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,United States
"TBCRC 023: A Randomized Multicenter Phase II Neoadjuvant Trial of Lapatinib Pus Trastuzumab, With or Without Endocrine Therapy for 12 Weeks vs. 24 Weeks in Patients With HER2 Overexpressing Breast Cancer",II,Terminated,"GlaxoSmithKline
(Other Cooperative Group)
(Other Academic Cancer Center)",Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage III,Breast Neoplasms,United States
Feasibility of Pre-Surgical Intervention Studies for Evaluating Targeted Therapies for Breast Cancer,II,Completed,"(Other Cooperative Group)
Columbia University Medical Center",Oncology: Breast,Estrogen receptor positive; Neoadjuvant; Progesterone receptor positive; Stage 0; Stage I; Stage II,Breast Neoplasms,United States
Phase II Trial of Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases,II,Completed,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Beth Israel Deaconess Medical Center
Massachusetts General Hospital
Brigham and Womens Hospital
Roche/Genentech",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; HER2 negative; HER2 positive; Second line; Stage IV; Third line,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
"Phase IIa, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor.",II,Completed,Biogen {Biogen Idec},Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,Australia; Belgium; Russia; United States
A Randomized Phase II Trial of Targeted Therapy Alone for Early Stage Small (T1a/b N0) Her2+ Breast Cancer Surgery.,II,Terminated,Southwest Oncology Group,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Stage I,Breast Neoplasms,United States
The Use of Calcium and Magnesium for Prevention of Ixabepilone Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study.,III,Terminated,"National Institutes of Health/National Cancer Institute
Mayo Clinic",Oncology: Breast; Oncology: Supportive Care,First line; Neurotoxicity; Second line; Stage IV,Breast Neoplasms; Palliative Care; Peripheral Nervous System Diseases,United States
A Phase III Study Evaluating the Efficacy of Capecitabine and Dasatinib as Adjuvant Therapy in Patients with Her-2/Neu Negative Breast Cancer and Residual Invasive Disease After Neoadjuvant Anthracycline and Taxane-based Chemotherapy.,III,Terminated,Southwest Oncology Group,Oncology: Breast,Adjuvant; HER2 negative; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
Phase II Trial of Brostallicin and Cisplatin in Patients With Metastatic Triple Negative Breast Cancer,II,Completed,"North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute
Alliance for Clinical Trials in Oncology",Oncology: Breast,First line; Fourth line or greater; HER2 negative; Second line; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug",II,Completed,(Other Industry Sponsor),"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell",Adenocarcinoma; Large Cell; Line of therapy N/A; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Lung Neoplasms",Netherlands; United States
Phase II Study of the Combination of High-dose Methotrexate and Intrathecal Liposomal Cytarabine in Patients With Leptomeningeal Metastases With or Without Parenchymal Brain Involvement,II,Terminated,"National Institutes of Health/National Cancer Institute
Fred Hutchinson Cancer Research Center
University of Washington/Seattle Cancer Care Alliance
(Other Hospital/Academic/Medical Center)",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; First line; Maintenance/Consolidation; Second line; Stage IV,"Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Meningeal Carcinomatosis; Neoplasm Metastasis; Neoplasms, Second Primary",United States
Phase II Evaluation of a Once Every 28 Days Dosing Regimen for LY573636-sodium in Patients With Metastatic Breast Cancer,II,Completed,Eli Lilly,Oncology: Breast,Fourth line or greater; Stage IV; Third line,Breast Neoplasms,United States
"A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study of Denosumab as Adjuvant Treatment for Women With Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE)",III,Terminated,"Amgen
Daiichi Sankyo",Oncology: Breast; Oncology: Metastatic Cancer,Adjuvant; Bone mets; Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Neoplasm Metastasis,"Argentina; Australia; Belgium; Brazil; Bulgaria; Canada; Chile; China; Czech Republic; Denmark; France; Germany; Greece; Hong Kong, S.A.R., China; Hungary; India; Ireland; Israel; Italy; Japan; Latvia; Malaysia; Mexico; Netherlands; Norway; Peru; Philippines; Poland; Portugal; Romania; Russia; Serbia; Slovakia; Slovenia; South Africa; South Korea; Spain; Taiwan, China; Turkey; United Kingdom; United States"
Pilot Study of a MUCI Peptide and Poly-ICLC Vaccine for Triple-Negative Breast Cancer,Other,Completed,"(Other Academic Cancer Center)
National Institutes of Health/National Cancer Institute",Oncology: Breast,First line; HER2 negative; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Inflammatory Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU),II,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Bladder; Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Renal",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Head and Neck Neoplasms; Kidney Neoplasms; Lung Neoplasms; Neoplasms; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
Investigation of Genetic Determinants of Capecitabine Toxicity,Other,Completed,"(Other Cooperative Group)
University of Chicago Cancer Research Center
National Institutes of Health",Oncology: Breast,Estrogen receptor positive; Line of therapy N/A; Stage IV,Breast Neoplasms,United States
Pilot Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer,II,Completed,"(Other Cooperative Group)
Columbia University Medical Center",Oncology: Breast,Second line; Stage 0,Breast Neoplasms,United States
Phase IIa Study of Metastatic Breast Cancer,II,Completed,"National Taiwan University Hospital
Taiwan THL",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,"Taiwan, China; United States"
"A Randomized, Open-Label Comparative Study of Combination Therapy With Cyclophosphamide and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine With or Without Trastuzumab for the Treatment of Metastatic Breast Cancer That Does NOT Over-express HER-2/Neu",II,Completed,"National Institutes of Health/National Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}
Roche/Genentech",Oncology: Breast,First line; HER2 negative; Second line; Stage IV,Breast Neoplasms,United States
"A Double-Blind, Placebo-Controlled, Randomized Phase  IV Study of Epoetin alfa Versus Placebo in Subjects Receiving First Line Chemotherapy for Metastatic Breast Cancer.",IV,Terminated,Amgen,Metabolic/Endocrinology: Anemia; Oncology: Breast; Oncology: Supportive Care,Anemia; Cancer-related; First line; Stage IV,Anemia; Breast Neoplasms; Palliative Care,United States
"A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer",III,Terminated,"GlaxoSmithKline
Novartis",Oncology: Breast,HER2 positive; Maintenance/Consolidation; Stage IV; Third line,Breast Neoplasms; Unspecified,Canada; United States
Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism Using a Limited Pharmacokinetic Sampling Plan,II,Terminated,"MD Anderson Cancer Center, University of Texas
Myrexis {Myriad Pharmaceuticals {Myriad Genetics}}",Oncology: Breast,Line of therapy N/A; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
"A Multi-center, Open Label Phase II Trial of TKI258 in FGFR1 Amplified and Non-amplified Metastatic or Advanced HER2 Negative Breast Cancer.",II,Terminated,Novartis,Oncology: Breast,Estrogen receptor positive; FGFR; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Third line,Breast Neoplasms,"Canada; Finland; France; Italy; Spain; Taiwan, China; United Kingdom; United States"
Pre-surgical Phase IIB Trial of Transdermal 4-Hydroxytamoxifen vs. Oral Tamoxifen in Women With Duct Carcinoma in Situ of the Breast,II,Terminated,"National Institutes of Health/National Cancer Institute
Northwestern University
National Institutes of Health
BHR Pharma",Oncology: Breast,Estrogen receptor positive; Neoadjuvant; Progesterone receptor positive; Stage 0,"Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating",United States
Vaccination with Tetanus Toxoid and Keyhold Limpet Hemocyanin (KLH) to Assess Antigen-Specific Immune Responses.,II,Terminated,University of Minnesota Cancer Center,Oncology: Breast; Oncology: Melanoma; Oncology: Unspecified Hematological Cancer,(N/A); First line; Second line,Breast Neoplasms; Hematologic Neoplasms; Melanoma; Unspecified,United States
A Phase II Study of NK012 in Locally Advanced Non-Resectable and Metastatic Breast Cancer Patients With Triple Negative Phenotype,II,Completed,Nippon Kayaku,Oncology: Breast,HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"Docetaxel, Carboplatin, Trastuzumab and Bevacizumab (TCH+B) For Early-Stage HER-2/Neu(+) Breast Cancer and Bone Marrow Micrometastases",II,Completed,"National Institutes of Health/National Cancer Institute
Case Western Reserve University",Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; First line; HER2 positive; Stage I; Stage II; Stage III,Breast Neoplasms; Neoplasm Metastasis; Neoplasm Micrometastasis,United States
"Radiosensitization of Chemotherapy-Refractory, Locally Advanced or Locally Recurrent Breast Cancer with Trastuzumab: A Phase II Trial.",II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,HER2 positive; Second line; Stage III,Breast Neoplasms,United States
"Thymidilate Synthase (TS), Thymidine Phosphorylase (TP), c Dehydrogenase (DPD), and Dihydrofolate Reductase (DHFR) as Predictive Markers of Capecitabine Efficacy in Breast Cancer Patients.",Other,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms,Canada; Denmark; Poland; United States
Evaluating the Use of Cardiac Biomarkers for Early Detection of Chemotherapy Induced Cardiotoxicity: A Pilot Study in a Minority Population.,Other,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
Evaluation of Ki-67 measured in benign breast tissue acquired from premenopausal women treated with a flaxseed derivative,II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
Evaluation of Antiproliferative Effects of Arimidex in Ductal Lavage Fluid in Patients with Breast Cancer,II,Completed,"MD Anderson Cancer Center, University of Texas",Oncology: Breast,Adjuvant; Stage I; Stage II,Breast Neoplasms,United States
"A Phase II, Open-Label Study to Evaluate Corrected QT Interval Effects of Trastuzumab-MCC-DM1 (T-DM1) in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer and to Evaluate the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression While Receiving T-DM1 Alone.",II,Completed,Roche/Genentech,Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms; Disease Progression,United States
Abraxane and Trastuzumab Followed by Dose Dense Doxorubicin and Cyclophosphamide as Neoadjuvant Therapy in Invasive Breast Cancer With Low HER2 Expression (1+ or 2+ by IHC),II,Completed,"University of Kansas
Bristol-Myers Squibb/Celgene",Oncology: Breast,HER2 negative; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
A Randomized Pilot Study Comparing Aprepitant to Olanzapine for Treatment of Chemotherapy-Induced Nausea and Vomiting.,II,Completed,(Other Hospital/Academic/Medical Center),"Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Soft Tissue Sarcoma; Oncology: Supportive Care",(N/A); Classical; Emesis; First line; Nodular lymphocyte-predominant; Untreated,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Fibrosarcoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Liposarcoma; Palliative Care; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Vomiting",United States
"Randomized, Phase II Trial of Pre-Operative Docetaxel-Cytoxan (TC) or Exemestane in Patients With Hormone Receptor-Positive Breast Cancers With Recurrence Scores Less Than 25 (< or = 24)",II,Completed,"Pfizer
Winship Cancer Institute of Emory University",Oncology: Breast,HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms; Recurrence,United States
Phase II Study of Trastuzumab in Combination with Perifosine in Patients with Her-2 Overexpressing Metastatic Breast Cancer Progressing on Trastuzumab-Based Therapy.,II,Terminated,Akebia Therapeutics {Keryx Biopharmaceuticals},Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
"Phase II Trial Assessing Neoadjuvant Therapy With FEC 100 Followed by Taxotere (Docetaxel) Plus Vectibix (Panitumumab) in Patients With Operable, HR and Her-2 Negative Breast Cancer. TVA Study",II,Completed,"Amgen
(Other Hospital/Academic/Medical Center)",Oncology: Breast,HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,France; United States
"A phase II study of paclitaxel/CBT-1, an MDR modulator.",II,Completed,CBA Pharma,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate; Oncology: Unspecified Cancer",(N/A); First line; Second line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
"A Phase II, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer",II,Terminated,"Bristol-Myers Squibb/Celgene
Merck & Co. {Acceleron Pharma}",Metabolic/Endocrinology: Anemia; Oncology: Breast; Oncology: Supportive Care,Anemia; Cancer-related; Second line; Stage I; Stage II; Stage III; Stage IV,Anemia; Breast Neoplasms; Palliative Care,Russia; Ukraine; United States
"A Phase II Neo-Adjuvant Study of Cisplatin, Paclitaxel with or without RAD001 in Patients with Triple-Negative Locally Advanced Breast Cancer.",II,Completed,"Novartis
National Institutes of Health/National Cancer Institute
Vanderbilt-Ingram Cancer Center",Oncology: Breast,HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
Phase II Pre-Surgical Intervention Study for Evaluating the Effect of Metformin on Breast Cancer Proliferation,II,Completed,"Columbia University Medical Center
Breast Cancer Research Foundation",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage 0; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
Pilot study of fixed-dose bevacizumab (200 mg) for solid malignancies.,II,Completed,(Other Hospital/Academic/Medical Center),"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell",Line of therapy N/A; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms",United States
"A Randomized, Double-Blind, Two-Way Crossover, Bioequivalence Study of SID530 and Taxotere in Study Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Platinum Therapy Failure or Study Participants With Locally Advanced or Metastatic Breast Cancer Who Have Failed At Least One Prior Chemotherapeutic Regimen.",III,Completed,SK Inc. {SK Holdings}/SK Chemicals,"Oncology: Breast; Oncology: Lung, Non-Small Cell",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms",India; United States
"Pilot Biomarker Modulation Study of ZD1839 (IRESSA), in Patients with Ductal Carcinoma in Situ",II,Terminated,AstraZeneca,Oncology: Breast,Line of therapy N/A; Stage 0,Breast Neoplasms,United States
Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients,II,Closed,"MD Anderson Cancer Center, University of Texas",Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; Neoadjuvant; Stage IV,Breast Neoplasms; Neoplasm Metastasis,United States
"A 5-year, Randomized, Double Blind, Placebo Controlled Study of Vitamin D and Fish Oil Supplements in Subjects Who Have Not Previously Had A Heart Attack, Stroke or Cancer (VITAL).",III,Completed,"National Institutes of Health/National Cancer Institute
National Institutes of Health/National Heart, Lung, and Blood Institute
National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health
National Institutes of Health/National Institute of Neurological Disorders and Stroke
Office of Dietary Supplements - ODS
BASF {Pronova BioPharma}
Otsuka Holdings/Otsuka Pharmaceutical/Pharmavite
Brigham and Womens Hospital
(Other government agency)
BASF",Cardiovascular: Coronary Artery Disease; Metabolic/Endocrinology: Diabetic Complications; Metabolic/Endocrinology: Renal Disease; Metabolic/Endocrinology: Type 2 Diabetes; Oncology: Breast; Oncology: Colorectal; Oncology: Prostate; Oncology: Unspecified Cancer,(N/A); Diabetic Nephropathy; Hypertensive Nephropathy; Line of therapy N/A; Primary prevention,"Breast Neoplasms; Cardiovascular Diseases; Colorectal Neoplasms; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Hypertensive Nephropathy; Kidney Diseases; Neoplasms; Prostatic Neoplasms; Renal Insufficiency",United States
"A Randomized, Double-Blind, Controlled Phase III Study of Stimuvax (L-BLP25 or BLP25 Liposome Vaccine) in Combination With Hormonal Treatment Versus Hormonal Treatment Alone for First-Line Therapy of Post-Menopausal Women With Estrogen Receptor (ER)-Positive and/or Progesterone Receptor (PgR)-Positive, Inoperable Locally Advanced, Recurrent, or Metastatic Breast Cancer. 

STRIDE (STimulating immune Response In aDvanced brEast cancer).",III,Terminated,"Seagen {Seattle Genetics/Cascadian Therapeutics {Oncothyreon {Biomira}}}
Merck KGaA/EMD Serono {EMD Pharmaceuticals}",Oncology: Breast,Estrogen receptor positive; First line; Maintenance/Consolidation; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Brazil; Canada; China; Czech Republic; France; Germany; Greece; Hungary; India; Ireland; Israel; Italy; Mexico; Netherlands; Norway; Poland; Portugal; Russia; Slovakia; South Africa; South Korea; Spain; Sweden; Switzerland; Taiwan, China; United Kingdom; United States"
Combined Fulvestrant and Anastrozole as Neo-adjuvant Endocrine Therapy in Postmenopausal Women With Hormone Receptor Positive Invasive Breast Cancer,II,Completed,"AstraZeneca
University of Kansas",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,United States
"A Randomised, Multicenter, Dose-finding Phase II Study Comparing a Single Sub-Cutaneous Injection of Pegfilgrastim to Multiple Daily Sub-Cutaneous Injections of Filgrastim.",II,Completed,Amgen,Oncology: Breast; Oncology: Supportive Care,First line; Neutropenia; Second line; Stage II; Stage III; Stage IV,Breast Neoplasms; Neutropenia; Palliative Care,United States
A Phase II Study of Preoperative Capecitabine and Concomitant Radiation in Women With Advanced Inflammatory or Non-Inflammatory Breast Cancer,II,Terminated,"MD Anderson Cancer Center, University of Texas",Oncology: Breast,HER2 negative; Neoadjuvant; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,Hungary; Norway; Puerto Rico; United States
"Phase II, Randomized, Double-Blind, Placebo-Controlled, Study of the Efficacy of Green Tea Extract on Biomarkers of Breast Cancer Risk in High Risk Women With Differing Catechol-O-Methyl Transferase (COMT) Genotypes",II,Completed,"National Institutes of Health/National Cancer Institute
(Other Hospital/Academic/Medical Center)",Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
"A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab + or - Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)",II,Completed,"Novartis
Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,United States
Randomized Phase II Trial of Trastuzumab or Everolimus in Hormone-refractory Metastatic Breast Cancer,II,Completed,"(Other Hospital/Academic/Medical Center)
Roche/Genentech",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
Statins and Breast Cancer Biomarkers.,II/III,Terminated,"Cancer and Leukemia Group B (CALGB)
University of Vermont
Breast Cancer Research Foundation",Oncology: Breast,BRCA; First line; Second line; Stage 0; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Double-Blind, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim per Cycle versus Daily Filgrastim as an Adjunct to Chemotherapy in Subjects with High-Risk  Stage II or Stage III/IV Breast Cancer.",III,Completed,Amgen,Oncology: Breast; Oncology: Supportive Care,Neutropenia; Second line; Stage II; Stage III; Stage IV,Breast Neoplasms; Neutropenia; Palliative Care,Canada; United States
"An in Vivo Proof of Principle Trial to Determine Whether the Nutritional Supplement Conjugated Linoleic Acid (CLA, Clarinol) Can Modulate the Lipogenic Pathway in Breast Cancer Tissue",Other,Completed,"National Institutes of Health/National Cancer Institute
National Institutes of Health
Dartmouth-Hitchcock Medical Center",Oncology: Breast,Line of therapy N/A; Stage I; Stage II; Stage III,Breast Neoplasms,United States
A Continuation Clinical Trial of Oral Vorinostat (MK0683) in Advanced Cancers.,II,Completed,Merck & Co.,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal",Aggressive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase III, Multi-Center, Open-Label, Randomized Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer",III,Completed,Sanofi {Sanofi-Aventis/BiPar},Oncology: Breast,First line; HER2 negative; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
A Phase II Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer,II,Terminated,Bionovo,Oncology: Breast,Second line; Stage IV; Third line,Breast Neoplasms,United States
Extended Endocrine Therapy for Premenopausal Women with Breast Cancer,II,Terminated,"Novartis
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Beth Israel Deaconess Medical Center",Oncology: Breast,(N/A); Estrogen receptor positive; Line of therapy N/A; Progesterone receptor positive,Breast Neoplasms,United States
EXTENT: Exemestane (AROMASIN) in Combination With Sunitinib (SUTENT) in Hormone Receptor Positive Metastatic Breast Cancer.,II,Terminated,"Pfizer
Baylor College of Medicine",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
The Role of Preoperative Neoadjuvant Cytoreductive Dose-Dense Bevacizumab Plus Docetaxel Followed by Bevacizumab-Doxorubicin-Cyclophosphamide Regimen in Locally Advanced Operable Breast Cancer,II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,HER2 negative; Neoadjuvant; Stage III,Breast Neoplasms,United States
Tamoxifen Resistance in Breast Cancer,Other,Terminated,"National Institutes of Health/National Cancer Institute
Comprehensive Cancer Center of Wake Forest University",Oncology: Breast,Second line; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Safety and effectiveness of dose dense neoadjuvant chemotherapy in patients with stage II/III breast cancer.,II,Completed,University of Alabama at Birmingham Comprehensive Cancer Center,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
"In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-including chemotherapy",Other,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Line of therapy N/A; Stage IV,Breast Neoplasms,Italy; United States
"Phase II Evaluation of Imiquimod, a Topical Toll-like Receptor 7 (TLR7) Agonist in Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases",II,Completed,New York University,Oncology: Breast; Oncology: Metastatic Cancer,Line of therapy N/A; Other mets; Stage IV,Breast Neoplasms; Neoplasm Metastasis,United States
A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6,IV,Completed,Icahn School of Medicine at Mount Sinai {Mount Sinai School of Medicine},Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
DNA Methylation in Serum as a Predictive Marker of Progression and Survival Following Systemic Therapy in Patients With Metastatic Breast Cancer.,Other,Completed,"National Institutes of Health/National Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer,Other,Closed,"Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute",Oncology: Breast,Adjuvant; HER2 positive; Stage IV,Breast Neoplasms,United States
"A Phase II Trial of Panitumumab, Gemcitabine, and Carboplatin in Triple-Negative Metastatic Breast Cancer",II,Completed,"Amgen
Eli Lilly",Oncology: Breast,First line; HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"A Broad Multi-Histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-Small Cell Lung, Head and Neck, Hepatocelluar and Renal Cell Carcinomas and Pheochromocytoma and Thyroid Tumors.",II,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Thyroid",First line; Follicular; Locally advanced; Medullary; Metastatic; Papillary; Second line; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Neoplasms, Basal Cell; Pheochromocytoma; Renal Cancer; Thyroid Neoplasms; Wilms Tumor",United States
"Phase II Study Of Pemetrexed In Patients Pretreated With An Anthracycline, A Taxane, And Capecitabine For Advanced Breast Cancer.",II,Completed,Eli Lilly,Oncology: Breast,Fourth line or greater; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer",III,Completed,"National Surgical Adjuvant Breast and Bowel Project (NSABP)
US Oncology Research
Roche/Genentech",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,Ireland; United States
An Observational Trial of the Effect of Pharmacogenomics Differences in Phase I and II Metabolism of Tamoxifen on Efficacy and Toxicity,IV,Completed,Penn State Cancer Institute at Milton S. Hershey Medical Center,Oncology: Breast,Line of therapy N/A; Stage 0,"Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Intraductal, Noninfiltrating",United States
Clinical Outcomes Following Immunotherapy with a MUC1/CEAVaccine in Patients with Metastatic Breast and Ovarian Cancer.,II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Ovarian,First line; Fourth line or greater; Second line; Stage IV; Third line,Breast Neoplasms; Ovarian Cancer; Ovarian Neoplasms,United States
A Prospective Observational Study of Neutropenia and Anemia Management in Subjects with Solid Tumors Receiving Myelotoxic Chemotherapy,II,Completed,Amgen,"Metabolic/Endocrinology: Anemia; Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Supportive Care",Anemia; Cancer-related; Extensive; Line of therapy N/A; Neutropenia; Pulmonary; Stage III; Stage IV,"Anemia; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Lung Neoplasms; Neuroendocrine Tumors; Neutropenia; Ovarian Cancer; Ovarian Neoplasms; Palliative Care; Small Cell Lung Carcinoma",Australia; Austria; Canada; Czech Republic; Finland; Greece; Italy; Netherlands; Poland; Portugal; Spain; Sweden; Switzerland; United States
"A Phase II Study Evaluating the Role of Sentinel Lymph Node Surgery and Axillary Lymph Node Dissection Following Preoperative Chemotherapy in Women With Node Positive Breast Cancer (T1-4, N1-2, M0) at Initial Diagnosis",II,Completed,"Cancer and Leukemia Group B (CALGB)
Eastern Cooperative Oncology Group (ECOG)
National Institutes of Health/National Cancer Institute
American College of Surgeons Oncology Group (ACOSOG)
Alliance for Clinical Trials in Oncology",Oncology: Breast,Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
A pilot study of GRP78 overexpression and the risk of recurrence in taxane-treated breast cancer patients.,II,Completed,University of Southern California,Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
Elevated pretreatment serum TIMP-1 level predicts reduced PFS and overall survival in trastuzumab-treated metastatic breast cancer patients.,Other,Completed,"(Other Industry Sponsor)
Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}",Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Stage IV,Breast Neoplasms,Austria; United States
"A Phase II, Randomized, Open-Label Study of Bosutinib Administered in Combination with Letrozole vs. Letrozole Alone as First Line Therapy in Post-Menopausal Women with Locally Advanced or Metastatic ER+/PR+/HER2- Breast Cancer",II,Terminated,Pfizer {Wyeth},Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,"Australia; Belgium; Brazil; China; Germany; Hong Kong, S.A.R., China; Hungary; Poland; Singapore; United Kingdom; United States"
"A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer.",II,Completed,Eisai,Oncology: Breast,HER2 negative; HER2 positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
A Phase II Randomized Study of Ixabepilone vs. Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2/Neu-negative Breast Cancer,II,Terminated,"Bristol-Myers Squibb
MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast,Adjuvant; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms; Carcinoma,United States
Predicting Adverse Cardiac Events in Breast Cancer Therapy (PACE in Breast Cancer),IV,Completed,"National Institutes of Health/National Cancer Institute
Vanderbilt University Medical Center",Oncology: Breast,First line; Stage I; Stage II; Stage III,Breast Neoplasms; Cardiotoxicity,United States
"A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer",III,Completed,"National Institutes of Health/National Cancer Institute
Alliance for Clinical Trials in Oncology",CNS: Pain (nociceptive); Oncology: Breast; Oncology: Metastatic Cancer; Oncology: Multiple Myeloma; Oncology: Prostate,Bone mets; Cancer-related; First line; Hormone refractory; Second line; Stage IV,"Adenocarcinoma; Bone Marrow Diseases; Bone Neoplasms; Breast Neoplasms; Cancer pain; Cancer Pain; Multiple Myeloma; Neoplasm Metastasis; Neoplasms; Neoplasms, Plasma Cell; Neoplasms, Second Primary; Nociceptive Pain; Prostatic Neoplasms",United States
Phase II Study of Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER2-Negative Breast Cancer,II,Completed,Bristol-Myers Squibb,Oncology: Breast,HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
"A Randomized, Open-Label, Two-Arm Study Of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel As First-Line Treatment For ErbB-2-Positive Locally Recurrent Or Metastatic Breast Cancer",II,Completed,"Pfizer {Wyeth}
Puma Biotechnology
Excella GmbH",Oncology: Breast,First line; HER2 positive; Stage III; Stage IV,Breast Neoplasms,"Australia; Bahamas; Belarus; Belgium; Bulgaria; Canada; China; Croatia; Denmark; France; Germany; Greece; Hong Kong, S.A.R., China; Hungary; India; Israel; Italy; Japan; Latvia; Lithuania; Malaysia; Malta; Poland; Portugal; Romania; Saudi Arabia; Serbia; Singapore; South Africa; South Korea; Spain; Switzerland; Taiwan, China; Turkey; Ukraine; United Kingdom; United States"
"A Randomized, Double-Blind, Placebo-Controlled Trial Of Neratinib (HKI-272) After Trastuzumab In Women With Early-Stage HER-2/Neu Overexpressed/Amplified Breast Cancer",III,Completed,"Pfizer {Wyeth}
Puma Biotechnology",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,"Argentina; Australia; Austria; Bahamas; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Croatia; Czech Republic; Denmark; France; Germany; Greece; Hong Kong, S.A.R., China; Hungary; Israel; Italy; Japan; Jordan; Lebanon; Lithuania; Macedonia; Malaysia; Malta; Mexico; Netherlands; New Zealand; Peru; Poland; Romania; Saudi Arabia; Serbia; Singapore; Slovakia; South Korea; Spain; Sweden; Switzerland; Taiwan, China; Turkey; United Kingdom; United States"
"A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole


Breast cancer trials of OraL EveROlimus-2 (BOLERO-2)",III,Completed,Novartis,Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,"Australia; Austria; Belgium; Brazil; Canada; Czech Republic; Egypt; France; Germany; Hong Kong, S.A.R., China; Hungary; Italy; Japan; Netherlands; New Zealand; Norway; Poland; South Korea; Spain; Sweden; Thailand; Turkey; United Kingdom; United States"
A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer,III,Completed,"Canadian Cancer Trials Group {NCIC Clinical Trials Group}
National Institutes of Health/National Cancer Institute
Cancer Research UK
Institute of Cancer Research - UK
National Institutes of Health
Breast Cancer Research Foundation
Alliance for Clinical Trials in Oncology",Oncology: Breast,Adjuvant; HER2 negative; HER2 positive; Stage I; Stage II; Stage III,Breast Neoplasms; Fatigue; Parasomnias; Sleep Disorders,Canada; Switzerland; United Kingdom; United States
Effects of High-Dose Vitamin D on Circulating Vitamin D Levels and Breast Density in Postmenopausal Women at High Risk for Breast Cancer Development,II,Completed,"(Other Cooperative Group)
(Other Hospital/Academic/Medical Center)",Oncology: Breast,Line of therapy N/A; Stage 0,Breast Neoplasms,United States
"A Double-blind, Randomized Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic Breast Cancer",II/III,Completed,OBI Pharma,Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Line of therapy N/A; Progesterone receptor positive; Stage IV; Triple receptor negative,Breast Neoplasms,"China; Hong Kong, S.A.R., China; India; Malaysia; Singapore; South Korea; Taiwan, China; United States"
Lapatinib in the Treatment of Ductal Carcinoma in Situ of the Breast.,II,Terminated,"GlaxoSmithKline
Indiana University Cancer Center",Oncology: Breast,EGFR; HER2 positive; Line of therapy N/A; Stage 0,"Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating",United States
A Phase II Trial of Short-Term Everolimus (RAD001) to Predict Response in Women With Operable Breast Cancer.,II,Terminated,"National Institutes of Health/National Cancer Institute
University of Minnesota Cancer Center",Oncology: Breast,Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Phase II Study of Acolbifene in Pre-Menopausal Women at High Risk for Breast Cancer,II,Completed,"National Institutes of Health/National Cancer Institute
University of Wisconsin",Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
Sulforaphane: A Dietary Histone Deacetylase (HDAC) Inhibitor in Ductal Carcinoma in Situ (DCIS),II,Completed,"National Institutes of Health/National Cancer Institute
Oregon Health and Science University",Oncology: Breast,Neoadjuvant; Stage 0,Breast Neoplasms; Carcinoma in Situ; Precancerous Conditions,United States
An Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma,II,Completed,Akebia Therapeutics {Keryx Biopharmaceuticals {Access Oncology/AOI Pharmaceuticals}},"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Multiple Myeloma; Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma",Estrogen receptor positive; Locally advanced; Maintenance/Consolidation; Metastatic; Progesterone receptor positive; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Ewing Sarcoma; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Multiple Myeloma; Osteosarcoma; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women with Locally Advanced Breast Cancer,II,Completed,"GlaxoSmithKline
National Surgical Adjuvant Breast and Bowel Project (NSABP)",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage III; Triple receptor negative,Breast Neoplasms,Canada; United States
"A Safety and Bioactivity Study of Combination Therapy With Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-Secreting Breast Tumor Vaccine for the Treatment of Patients With High Risk/ Metastatic HER-2/Neu- Overexpressing Breast Cancer With No Evidence of Disease",II,Completed,"National Institutes of Health/National Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}",Oncology: Breast,Adjuvant; HER2 positive; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
"Phase II Evaluation of Aprepitant, Dexamethasone, and Palonosetron as Antiemetic Therapy in Breast Cancer Patients Receiving Doxorubicin in Combination with Cyclophosphamide",II,Completed,Eisai {MGI Pharma},Oncology: Breast; Oncology: Supportive Care,(N/A); Emesis; Line of therapy N/A,Breast Neoplasms; Palliative Care; Vomiting,United States
INST 0817: Compassionate Use of mifepristone,IV,Terminated,(Other Cooperative Group),"Metabolic/Endocrinology: Cushing's Syndrome; Oncology: Breast; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Endometrial; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma",Endogenous (Cushing's Disease); Line of therapy N/A; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Central Nervous System Neoplasms; Colorectal Neoplasms; Cushing Syndrome; Endometrial Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Ovarian Cancer; Ovarian Neoplasms; Pituitary ACTH Hypersecretion; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified",United States
Tamoxifen Pharmacogenomics and the Prevention of Recurrent Breast Cancer.,Other,Completed,"(Other Industry Sponsor)
Indiana University School of Medicine
Mayo Clinic
(Other Hospital/Academic/Medical Center)",Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms; Neoplasms,United States
Phase II Trial of Pre-Operative Docetaxel-Cytoxan (TC) in Patients With Hormone Receptor-Positive Cancers With Recurrence Scores > or = 25,II,Terminated,"Winship Cancer Institute of Emory University
Sanofi {Sanofi-Aventis}",Oncology: Breast,Adjuvant; Estrogen receptor positive; First line; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms; Recurrence,United States
Phase II Study of Neoadjuvant Chemotherapy of Breast Cancer,II,Completed,"(Other Academic Cancer Center)
Sanofi {Sanofi-Aventis}",Oncology: Breast,HER2 negative; HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,Puerto Rico; United States
Randomised Phase II Study of Neoadjuvant BIBW 2992 Versus Herceptin Versus Lapatinib in Her2 Positive Breast Cancer Patients,II,Terminated,Boehringer Ingelheim,Oncology: Breast,HER2 positive; Neoadjuvant; Stage III,Breast Neoplasms,Brazil; Chile; Colombia; Mexico; Peru; United States
A Phase II Trial of RAD001 in Triple Negative Metastatic Breast Cancer,II,Terminated,"Novartis
Penn State Cancer Institute at Milton S. Hershey Medical Center",Oncology: Breast,First line; HER2 negative; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,United States
A Phase II Open-label Study of Subcutaneous CPG ODN (PF03512676) in Combination With Trastuzumab in Patients With Metastatic Breast Cancer,II,Terminated,Pfizer,Oncology: Breast,HER2 positive; Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms,United States
Pilot Study to Evaluate the Effect of Sunitinib on Occult Tumor Cells in the Bone Marrow of Patients With High Risk Early Stage Breast Cancer,II,Terminated,"National Institutes of Health/National Cancer Institute
Pfizer
University of California, San Francisco",Oncology: Breast,Adjuvant; Estrogen receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Phase II Study of Topical Imiquimod and Weekly Abraxane for the Treatment of Breast Cancer Cutaneous Metastases,II,Completed,"National Institutes of Health/National Cancer Institute
University of Washington",Oncology: Breast; Oncology: Metastatic Cancer,Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Other mets; Progesterone receptor positive; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Breast Neoplasms, Male; Neoplasm Metastasis",United States
Phase II Study of Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer,II,Completed,"Bristol-Myers Squibb
Roche/Genentech {Genentech}
Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}",Oncology: Breast,Adjuvant; HER2 positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
"A Randomized, Multicentre, Open-Label, Phase III Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Anthracycline- or Taxane-Exposed ErbB2-Positive Metastatic Breast Cancer 

CNS as First Site of Relapse on Lapatinib or trastuzumab Evaluation Trial (CEREBEL)",III,Terminated,"GlaxoSmithKline
Novartis",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; HER2 positive; Second line; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,Belgium; Denmark; France; Germany; Greece; Hungary; Italy; Poland; Russia; Spain; Sweden; Thailand; United Kingdom; United States
Phase II Safety Study of Docetaxel and Carboplatin in Combination With Trastuzumab and Lapatinib in Early Breast Cancer.,II,Completed,"GlaxoSmithKline
North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute
Breast Cancer Research Foundation
Alliance for Clinical Trials in Oncology",Oncology: Breast,Adjuvant; HER2 positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Biologic Efficacy Study of Dasatinib, a Multi-Targeted Tyrosine Kinase, in Locally Advanced Triple-Negative Breast Cancer Patients Developing Effective Therapies for Er-Negative Breast Cancer Using Genomics and Proteomics: Project 3",II,Terminated,"Bristol-Myers Squibb
MD Anderson Cancer Center, University of Texas
Baylor College of Medicine",Oncology: Breast,HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase II Multicenter Study Evaluating the Efficacy and Safety of IPI-504 in Combination With Trastuzumab in Patients With Pretreated, Locally Advanced or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer",II,Terminated,Infinity Pharmaceuticals,Oncology: Breast,Fourth line or greater; HER2 positive; Stage III; Stage IV; Third line,Breast Neoplasms,Spain; United States
A randomized trial of capecitabine dosed for 14 days followed by 7days rest versus 7days dosing followed by a 7 days rest in breast cancer.,II,Terminated,(Other Hospital/Academic/Medical Center),Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
A Phase II Study of NRX4204 in breast cancer patients.,II,Terminated,NuRx Pharmaceuticals,Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
Single Agent Sorafenib in Advanced Solid Tumors: Phase II Evaluation of Dose Re-Escalation Following a Dose Reduction (IST000375).,II,Completed,"Bayer AG/Bayer Pharmaceuticals
Amgen {Onyx Pharmaceuticals}
University of California Davis","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Testicular; Oncology: Thyroid",Fourth line or greater; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Testicular Cancer; Testicular Neoplasms; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Phase II Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer,II,Completed,"Myrexis {Myriad Pharmaceuticals {Myriad Genetics}}
Sanofi {Sanofi-Aventis/BiPar}
Breast Cancer Research Foundation",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Phase II Clinical Study Combining Trastuzumab with Etoposide in Treatment of HER2-Positive Metastatic Breast Cancer.,II,Terminated,"Roche/Genentech {Genentech}
Washington Hospital Center",Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
Prevention of Breast Cancer: As Simple as hCG-A Randomized Clinical Trial in High Risk Women,III,Completed,"New York Presbyterian Hospital
(Other Hospital/Academic/Medical Center)",Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
Intermittent Exemestane Therapy for Metastatic Breast Cancer,II,Completed,"National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center",Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Second line; Stage IV; Third line,Breast Neoplasms,United States
"Expression of ER-a36, a novel variant of estrogen receptor a, and resistance to tamoxifen treatment in breast cancer.",Other,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,China; United States
Safety and Efficacy of Single Agent Adjuvant Trastuzumab (Herceptin) in Older Women With Early-Stage and Locally Advanced Breast Cancer: A Phase II Trial,II,Completed,"National Institutes of Health/National Cancer Institute
Roche/Genentech",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"An Open Label Study to Evaluate the Safety, Tolerability and Effect on Tumor Response of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer",II,Terminated,Roche {F. Hoffmann-La Roche},Oncology: Breast,First line; Stage III; Stage IV,Breast Neoplasms,United States
A Study Evaluating the Effect of Flaxseed on Biomarkers of Breast Cancer Risk,II,Terminated,Roswell Park Cancer Institute,Oncology: Breast,First line; Stage I,Breast Neoplasms; Precancerous Conditions,United States
Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells,II,Completed,"National Institutes of Health/National Cancer Institute
Fred Hutchinson Cancer Research Center","Oncology: Breast; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome; Oncology: Myeloproliferative Neoplasms; Oncology: Ovarian; Oncology: Supportive Care; Oncology: Testicular",Accelerated phase; Aggressive; Blast phase; Classical; Cutaneous T-cell lymphoma (CTCL); Diffuse large B-cell lymphoma (DLBCL); Emesis; Extranodal marginal zone B-cell lymphoma (MALT); Follicular lymphoma (FL); Indolent; Lymphoblastic lymphoma (LBL); Mantle cell lymphoma (MCL); MDS-U; Nodular lymphocyte-predominant; Other subtype; Peripheral T-cell lymphoma (PTCL); Primary Myelofibrosis; Remission; Second line; Small lymphocytic lymphoma (SLL); Stage I; Stage II; Stage III; Stage IV,"Acute Myelocytic Leukemia; Blast Crisis; Breast Neoplasms; Burkitt Lymphoma; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Germinoma; Gestational Trophoblastic Disease; Hodgkin Disease; Hodgkin Lymphoma; Hypereosinophilic Syndrome; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Acute; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Leukemia, Myeloid, Chronic-Phase; Leukemia, Myelomonocytic, Chronic; Leukemia, Neutrophilic, Chronic; Lymphoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Multiple Myeloma; Mycoses; Mycosis Fungoides; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Myeloproliferative Disorders; Neoplasm Metastasis; Neoplasms, Germ Cell and Embryonal; Neoplasms, Glandular and Epithelial; Neoplasms, Plasma Cell; Neuroblastoma; Ovarian Cancer; Ovarian Neoplasms; Palliative Care; Plasmablastic Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Preleukemia; Primary Myelofibrosis; Sezary Syndrome; Syndrome; Testicular Cancer; Testicular Neoplasms; Trophoblastic Neoplasms; Vomiting",United States
"Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients with Triple-Negative Early-Stage Breast Cancer
OR
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer (TITAN)",III,Completed,Bristol-Myers Squibb,Oncology: Breast,Adjuvant; HER2 negative; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,Puerto Rico; United States
"A Phase II, Randomized, Open-Label Study of Bosutinib Administered in Combination with Exemestane Versus Exemestane Alone as Second Line Therapy in Postmenopausal Women with Locally Advanced or Metastatic ER+/PgR+/ErbB2- Breast Cancer.",II,Terminated,Pfizer {Wyeth},Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,"Australia; Belgium; Canada; China; France; Hong Kong, S.A.R., China; Hungary; India; Netherlands; Poland; Serbia; Singapore; South Africa; South Korea; Spain; United States"
A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxel or Ixabepilone with or without Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer.,III,Terminated,"National Institutes of Health/National Cancer Institute
Alliance for Clinical Trials in Oncology",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; HER2 positive; Progesterone receptor positive; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,Puerto Rico; United States
A Phase II Study of Allogeneic Large Multivalent Immunogen (LMI) Vaccine and IL-2 for the Treatment of Stable Metastatic Breast Cancer,II,Terminated,University of Minnesota Cancer Center,Oncology: Breast,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
"An Open-Label, Multicenter Extension Study of Trastuzumab Emtansine Administered as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd-Sponsored Trastuzumab Emtansine Study",II,Open,"Roche/Genentech {Genentech}
Roche/Chugai Pharmaceutical
Roche {F. Hoffmann-La Roche}",Oncology: Breast,First line; HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms; Neoplasm Metastasis,"Argentina; Australia; Austria; Belgium; Bosnia and Herzegovina; Brazil; Bulgaria; Canada; Chile; China; Croatia; Czech Republic; Denmark; Finland; France; Germany; Guatemala; Hong Kong, S.A.R., China; Hungary; Israel; Italy; Japan; Luxembourg; Macedonia; Mexico; New Zealand; Norway; Panama; Peru; Philippines; Poland; Portugal; Russia; Serbia; Singapore; Slovakia; Slovenia; South Korea; Spain; Sweden; Switzerland; Taiwan, China; Thailand; United Kingdom; United States; Venezuela"
Personalized Treatment Selection for Metastatic Breast Cancer,II,Terminated,"AstraZeneca
Bristol-Myers Squibb
MD Anderson Cancer Center, University of Texas",Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; HER2 positive; Liver mets; Other mets; Second line; Stage IV,Breast Neoplasms; Liver Neoplasms; Neoplasm Metastasis,United States
Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin + or - Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer,II,Completed,"National Institutes of Health/National Cancer Institute
Breast Cancer Research Foundation
Roche/Genentech
Alliance for Clinical Trials in Oncology",Oncology: Breast,HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,"Breast Neoplasms; Breast Neoplasms, Male; Carcinoma",United States
Neoadjuvant Weekly Nab-paclitaxel (Abraxane) Plus Carboplatin Followed By Doxorubicin Plus Cyclophosphamide With Bevacizumab Added Concurrently To Chemotherapy For Palpable And Operable Triple Negative Invasive Breast Cancer,II,Terminated,"Roche/Genentech {Genentech}
(Other Academic Cancer Center)
Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}}
National Comprehensive Cancer Network",Oncology: Breast,Adjuvant; HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
A Phase II Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine for the Treatment of ErbB-2 Positive Locally Advanced or Metastatic Breast Cancer,II,Completed,Puma Biotechnology,Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,"Australia; Austria; Belgium; Bulgaria; Canada; Croatia; Czech Republic; Egypt; France; Germany; Greece; Hong Kong, S.A.R., China; Hungary; Italy; Japan; Jordan; Mexico; Netherlands; Poland; Puerto Rico; Romania; Russia; Serbia; Singapore; Slovenia; South Africa; South Korea; Spain; Switzerland; Taiwan, China; Thailand; United Kingdom; United States"
"A Randomized Phase II, Open-Label Multicenter Trial of Panobinostat Monotherapy in Women with HER2 Positive Locally Recurrent or Metastatic Breast Cancer.",II,Terminated,Breast Cancer International Research Group,Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,Belgium; Canada; France; Ireland; United Kingdom; United States
"A Phase II, Open-Label Multicenter Trial of Panobinostat Monotherapy in Women with HER2-Negative Locally Recurrent or Metastatic Breast Cancer",II,Completed,Breast Cancer International Research Group,Oncology: Breast,First line; HER2 negative; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,Belgium; Canada; France; Ireland; United Kingdom; United States
A Phase III Clinical Trial with Acolbifene for the Treatment of Advanced-Stage Breast Cancer in Women who have Previously Failed Current Hormone Therapy.,III,Terminated,Endoceutics,Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,Canada; United States
A Phase II Study of Lonafarnib in Patients With Metastatic Breast Cancer.,II,Terminated,"Merck & Co. {Schering-Plough}
Hoosier Cancer Research Network {Hoosier Oncology Group}",Oncology: Breast,First line; Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"A Randomized, Multicenter, Phase III Open-label Study of the Efficacy and Safety of Trastuzumab MCC-DM1 vs. Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy.",III,Completed,"Roche/Genentech {Genentech}
ImmunoGen
Roche {F. Hoffmann-La Roche}",Oncology: Breast,First line; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,"Bosnia and Herzegovina; Brazil; Bulgaria; Canada; Colombia; Denmark; Finland; France; Germany; Hong Kong, S.A.R., China; India; Italy; Mexico; New Zealand; Philippines; Poland; Portugal; Russia; Singapore; Slovenia; South Korea; Spain; Sweden; Switzerland; Taiwan, China; United Kingdom; United States"
"Multiple investigator-initiated studies of Abraxis BioScience’s anti-cancer drug ABRAXANE for Injectable Suspension in the treatment of breast, non-small cell lung, head and neck, melanoma and ovarian cancers.",III,Terminated,"AstraZeneca
Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}}
National Comprehensive Cancer Network","Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian",(N/A); Line of therapy N/A,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms",United States
A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy,III,Completed,"Roche/Genentech {Genentech}
National Surgical Adjuvant Breast and Bowel Project (NSABP)
National Institutes of Health/National Cancer Institute
NRG Oncology",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Stage 0,"Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating",Canada; Puerto Rico; South Korea; United States
Randomized Phase III Trial of Paclitaxel +Trastuzumab + Lapatinib Versus Paclitaxel + Trastuzumab As Neoadjuvant Treatment Of HER2-Positive Primary Breast Cancer,III,Completed,"Cancer and Leukemia Group B (CALGB)
National Institutes of Health/National Cancer Institute",Oncology: Breast,Adjuvant; HER2 positive; Neoadjuvant; Stage II; Stage III,"Breast Neoplasms; Breast Neoplasms, Male",Puerto Rico; United States
"A Multicenter, Open Label, Randomized Phase II Trial of Presurgical Treatment with Single-Agent Trastuzumab (H) or Lapatinib (Ty) or the Combination of Trastuzumab and Lapatinib (H+Ty), Followed by Six Cycles of Docetaxel (T) and Carboplatin (C) with Trastuzumab (TCH) or Lapatinib (TCTy) or the Combination of Trastuzumab and Lapatinib (TCHTy) in Patients with HER2/Neu-Amplified Operable Breast Cancer",II,Completed,"GlaxoSmithKline
National Institutes of Health/National Cancer Institute
University of California Los Angeles
Sanofi {Sanofi-Aventis}
Translational Oncology Research International",Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Validating CYP2D6 Genotype-Guided Tamoxifen Therapy for a Multiracial U.S. Population,II,Completed,"National Institutes of Health/National Cancer Institute
UNC Lineberger Comprehensive Cancer Center",Oncology: Breast,First line; Second line; Stage 0; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms; Carcinoma in Situ,United States
A Randomized Double-Blind Multicenter Phase III Study of Fixed-Dose Single-Administration Pegfilgrastim versus Daily Filgrastim in Patients Receiving Myelosuppressive Chemotherapy.,III,Completed,Amgen,Oncology: Breast; Oncology: Supportive Care,First line; Neutropenia; Second line; Stage II; Stage III; Stage IV,Breast Neoplasms; Neutropenia; Palliative Care,Australia; Austria; Belgium; Germany; Italy; Netherlands; Spain; United States
Phase II Trial of Lapatinib in Women With Hormone Receptor Positive (Estrogen Receptor [ER] and/or Progesterone Receptor [PR] +) Human Epidermal Growth Factor Receptor 2 (HER-2) Negative Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy,II,Completed,University of Kansas,Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
The Effects of Chemotherapy on Brain Structure and Function,II,Completed,"National Institutes of Health/National Cancer Institute
UCSF Comprehensive Cancer Center
National Institutes of Health
University of California, San Francisco",Oncology: Breast,Adjuvant; Estrogen receptor positive; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms; Fatigue; Neurotoxicity Syndromes,United States
Pilot Study of L-Carnitine Supplementation in the Prevention of Chemotherapy-induced Peripheral Neuropathy in Women With Metastatic Breast Cancer,II,Terminated,(Other Hospital/Academic/Medical Center),Oncology: Breast; Oncology: Supportive Care,Line of therapy N/A; Neurotoxicity; Stage IV,Breast Neoplasms; Neurotoxicity Syndromes; Palliative Care; Peripheral Nervous System Diseases,United States
A Phase II Study of Neoadjuvant Lapatinib Plus Chemotherapy (Sequential FEC75 and Paclitaxel) in Women With Inflammatory Breast Cancer Whose Tumors Overexpress ErbB2 (Her2/Neu),II,Terminated,"GlaxoSmithKline
MD Anderson Cancer Center, University of Texas",Oncology: Breast,HER2 positive; Neoadjuvant; Stage III,Breast Neoplasms; Inflammatory Breast Neoplasms,United States
Phase II Randomized Trial of Fulvestrant with or without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-Positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor.,II,Completed,Bristol-Myers Squibb,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
"Study of Erlotinib, Small Molecule Targeting Epidermal Growth Factor Receptor (EGFR) in Treatment of Patients w/EGFR-Overexpressing 'Triple Receptor-Negative' Metastatic Carcinoma of Breast That Progressed on Anthracyclines and Taxanes",II,Terminated,"MD Anderson Cancer Center, University of Texas
Astellas Pharma {OSI Pharmaceuticals}",Oncology: Breast,HER2 negative; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,United States
A Phase II Study of Chemotherapy Treatment Based on Molecular Profiling Diagnosis for Patients With Carcinoma of Unknown Primary Site,II,Completed,Roche/Genentech {Genentech},"Oncology: Bladder; Oncology: Breast; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Thyroid",First line; Metastatic; Stage IV; Untreated,"Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Mesothelioma; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib,II,Completed,"Roche/Genentech {Genentech}
National Institutes of Health/National Cancer Institute
University of Washington
Johnson & Johnson/Janssen Diagnostics {Veridex {Immunicon}}",Oncology: Breast,First line; HER2 negative; Maintenance/Consolidation; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Randomized Phase ll Study of SCH 727965 in Subjects With Advanced Breast and Non Small Cell Lung (NSCLC) Cancers.,II,Terminated,Merck & Co. {Schering-Plough},"Oncology: Breast; Oncology: Lung, Non-Small Cell",Estrogen receptor positive; HER2 positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung",Canada; United States
"Phase ll Randomized, Multicenter Study of IMCA12 as a Single Agent or in Combination With Antiestrogens in Postmenopausal Women With Hormone Receptor-Positive Advanced or Metastatic Breast Cancer After Progression on Antiestrogen Therapy",II,Completed,Eli Lilly {ImClone},Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
Differential Gene Regulation during Neoadjuvant Therapy Trial of Epirubicin/Cyclophosphamide (EC) vs Docetaxel/Capecitabine (DX) Regimens in Patients with Large ER-positive and ER-negative breast cancers: A Randomized Phase II Trial.,II,Completed,University of Colorado,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage 0; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms; Neoplasms,United States
Prospective Evaluation of Neurotoxicity in Breast Cancer Patients Treated with Adjuvant Paclitaxel,Other,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast; Oncology: Supportive Care,Adjuvant; Neurotoxicity; Stage I; Stage II; Stage III,Breast Neoplasms; Palliative Care,United States
"A Phase II Trial of Oral Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, in Combination with Trastuzumab for Patients with HER2-Positive Trastuzumab-Refractory Metastatic Breast Cancer.",II,Completed,"Merck & Co.
Takeda {Ariad}",Oncology: Breast,Fourth line or greater; HER2 positive; Second line; Stage IV; Third line,Breast Neoplasms,Chile; Czech Republic; France; United States
"A Prospective, Observational, Multicenter, Pharmaco-epidemiological Study of Predictors, Practice Patterns and Effectiveness and Safety Outcomes in Long- Term Treatment (> or = 2) years with Zoledronic Acid in Patients with Solid and Hematological Malignancies.",II,Completed,Novartis,Oncology: Breast; Oncology: Metastatic Cancer; Oncology: Multiple Myeloma; Oncology: Prostate,Bone mets; Second line; Stage IV,Breast Neoplasms; Multiple Myeloma; Neoplasm Metastasis; Prostatic Neoplasms,Belgium; United States
Q3week Carboplatin With Weekly Abraxanea And Avastin + Subsequent Dose-Dense Ac With Avastin As Neoadjuvant Therapy In Resectable And Unresectable (Stage IIa-IIIb) Her2-Negative Breast Cancer,II,Completed,"Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}}
Yale University
Roche/Genentech",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
Combination of Low Dose Antiestrogens With Omega-3 Fatty Acids for Prevention of Hormone-independent Breast Cancer,Other,Completed,"Penn State Cancer Institute at Milton S. Hershey Medical Center
Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}",Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
A Phase II Open-Label Study of Sorafenib Plus Fulvestrant as Salvage Therapy for Hormone Receptor Positive Metastatic Breast Cancer Failing Prior Aromatase Inhibitor Treatment,II,Terminated,"National Institutes of Health/National Cancer Institute
Bayer AG/Bayer Pharmaceuticals
Oregon Health and Science University",Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
Efficacy and Safety of a Combined Treatment Schedule with Fulvestrant and Capecitabine in Elderly Advanced Breast Cancer Patients,II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Second line; Stage IV,Breast Neoplasms,Italy; United States
"Phase II Study of a Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer",II,Terminated,"GlaxoSmithKline
Memorial Sloan-Kettering Cancer Center",Oncology: Breast,First line; HER2 positive; Second line; Stage I; Stage II; Stage IV; Third line,Breast Neoplasms,United States
Inter-ethnic variability of S-1 pharmacokinetics (PK) and correlation with CYP2A6 phenotyping,II,Completed,Otsuka Holdings/Taiho Pharmaceutical,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",Singapore; United States
A 2-Year Phase III Clinical Trial Compare Acolbifene as first-line treatment with an Aromatase Inhibitor in Breast Cancer Patients with Advanced Disease Not Previously Treated with hormones.,III,Terminated,Endoceutics,Oncology: Breast,First line; Stage III; Stage IV,Breast Neoplasms,Canada; United States
Effect of Aromatase Inhibitor Therapy for Breast Cancer on Endothelial Function,Other,Completed,"National Institutes of Health/National Cancer Institute
Mayo Clinic",Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Stage 0,Breast Neoplasms,United States
"A Randomized Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Everolimus in Combination With Trastuzumab and Paclitaxel, as First Line Therapy in Women With HER2 Positive Locally Advanced or Metastatic Breast Cancer

Breast cancer trials of OraL EveROlimus-1 (BOLERO-1)",III,Completed,Novartis,Oncology: Breast,First line; HER2 positive; Stage III; Stage IV,Breast Neoplasms,"Argentina; Australia; Belgium; Brazil; Canada; China; Colombia; Czech Republic; Egypt; France; Germany; Greece; Hong Kong, S.A.R., China; Hungary; Ireland; Italy; Japan; Lebanon; Mexico; Peru; Poland; Puerto Rico; Russia; South Africa; South Korea; Switzerland; Taiwan, China; Turkey; United Kingdom; United States; Venezuela"
Evaluating the Effect of Aprepitant on Cyclophosphamide Pharmacokinetics.,II,Completed,"Merck & Co.
National Institutes of Health/National Cancer Institute
UNC Lineberger Comprehensive Cancer Center",Oncology: Breast; Oncology: Supportive Care,Emesis; Line of therapy N/A; Stage 0; Stage I; Stage II,Breast Neoplasms; Nausea; Palliative Care; Vomiting,United States
"A Phase II, Single-Arm, Multi-Center Study Evaluating the Combination of Vinorelbine and Lapatinib in Women With ErbB2 Overexpressing Metastatic Breast Cancer.",II,Terminated,GlaxoSmithKline,Oncology: Breast,First line; HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
"LPT 111111- A Single-Arm, Multicenter Phase II Study to Evaluate The Combination of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel or ABRAXANE) and Lapatinib (TYKERB) in Women With No More Than One Prior Treatment for ErbB2 Overexpressing Metastatic Breast Cancer",II,Completed,"GlaxoSmithKline
Novartis
Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}",Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Second line; Stage I; Stage II; Stage III; Stage IV; Third line,Breast Neoplasms,United States
Use of total HER2 and HER2 homodimer levels to predict response to trastuzumab.,Other,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,Austria; United States
Phase II Study of Metastatic Cancer That Overexpresses p53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes and Dendritic Cell Vaccination,II,Terminated,"National Institutes of Health/National Cancer Institute
National Institutes of Health",Oncology: Breast; Oncology: Melanoma; Oncology: Renal,Second line; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Kidney Neoplasms; Melanoma; Neoplasm Metastasis; Renal Cancer; Wilms Tumor",United States
Combination Systemic Chemotherapy and Precision Tansarterial Chemoembolization of Metastatic Liver Tumors with Drug Eluting Beads.,II,Completed,(Other Hospital/Academic/Medical Center),"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Metastatic Cancer; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Liver mets; Second line; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Cholangiocarcinoma; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Neoplasms; Neoplasm Metastasis; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Wilms Tumor",United States
Genomic Markers of Breast Cancer Prevention Induced by HCG in Women at High Risk,II,Terminated,"National Institutes of Health/National Cancer Institute
Fox Chase Cancer Center",Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,Austria; United States
"Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic",II,Completed,"Bristol-Myers Squibb
US Oncology Research",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
"ABCDE: A Phase II Randomized Study of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer",II,Terminated,"(Other Cooperative Group)
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Beth Israel Deaconess Medical Center
Brigham and Womens Hospital
Breast Cancer Research Foundation
Roche/Genentech",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
"A Phase II Study: Irinotecan And Etoposide As Treatment For Refractory, Metastatic Breast Cancer",II,Completed,"National Institutes of Health/National Cancer Institute
Pfizer
University of Arizona",Oncology: Breast,First line; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase III Study to Assess the Safety, Tolerability, and Efficacy of MK0822 (Odanacatib) in Reducing the Risk of Bone Metastasis in Women With Breast Cancer",III,Terminated,Merck & Co./Merck Sharp & Dohme (MSD),Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; Estrogen receptor positive; HER2 positive; Line of therapy N/A; Stage I; Stage II; Stage III,Breast Neoplasms; Neoplasm Metastasis,"Belgium; Hong Kong, S.A.R., China; Puerto Rico; Slovakia; Spain; United States"
"A Multicenter, Open-Label, Phase II Study to Evaluate the Safety and Efficacy of NKTR-102 When Given on a Q14 Day or a Q21 Day Schedule in Patients With Metastatic or Locally Advanced Breast Cancer Whose Disease Has Failed Prior Taxane-Based Treatment",II,Completed,Nektar Therapeutics,Oncology: Breast,Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,Belgium; United Kingdom; United States
A Pilot Study Of Estradiol Followed By Exemestane For Post-Menopausal Hormone Receptor Positive Metastatic Breast Cancer After Prior Failed Endocrine Therapy: Reversing Endocrine Resistance,II,Completed,"National Institutes of Health/National Cancer Institute
University of Arizona",Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
Efficacy of neoadjuvant weekly docetaxel in locally advanced or inflammatory breast cancer.,II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
The role of maintenance bevacizumab in patients with metastatic breast cancer treated with chemotherapy and bevacizumab upon achieving complete response or maximal radiologic response with stable disease.,II,Completed,(Other Academic Cancer Center),Oncology: Breast,First line; Maintenance/Consolidation; Second line; Stage IV,Breast Neoplasms,United States
"Markers of bone turnover (ICTP, NTX) and serum matrix metalloproteinase 1 (MMP1) as prognostic markers in breast cancer patients (BC) with bone metastases (BM) treated with bisphosphonates (BP)",Other,Completed,Penn State Cancer Institute at Milton S. Hershey Medical Center,Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; Line of therapy N/A; Stage IV,Breast Neoplasms; Neoplasm Metastasis,United States
"A Cancer Research UK Randomised Phase II Trial of ATN-224 (Copper Binding Agent) in Combination With Exemestane Versus Exemestane Alone in Post-Menopausal Women With Recurrent or Advanced, Oestrogen and/or Progesterone Receptor Positive Breast Cancer.",II,Terminated,"National Institutes of Health/National Cancer Institute
Cancer Research UK",Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,United Kingdom; United States
"Phase II study of primary systemic therapy (PST) with doxorubicin (D) and docetaxel (T), then surgery (S), and radiation (RT), followed by use of non-cross-resistant adjuvant chemotherapy (Adj CT) with CMF based on pathologic response, in patients (pts) with locally advanced breast cancer (LABC): Study ID97-099, M. D. Anderson Cancer Center.",II,Completed,"MD Anderson Cancer Center, University of Texas",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
High-dose chemotherapy and autologous hematopoietic stem cell transplant for women with breast cancer and 10 or more involved axillary lymph nodes: Long-term follow-up.,II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Line of therapy N/A; Stage II; Stage III,Breast Neoplasms,United States
Effect of Dose Intensity and Overexpression of Topoisomerase iia on Survival in Patients with Locally Advanced Breast Cancer Treated with Anthracyclines in Neoadjuvant Setting.,Other,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage III,Breast Neoplasms,United States
Treatment of locally recurrent or high-risk carcinoma of the breast with radiation therapy and weekly docetaxel given as a radiosensitizer.,II,Completed,Sanofi {Sanofi-Aventis},Oncology: Breast,First line; Second line; Stage III,Breast Neoplasms,United States
"A Randomized, Multicenter, Phase II Study of the Efficacy and Safety of Trastuzumab-Mcc-DM1 vs. Trastuzumab (Herceptin) and Docetaxel (Taxotere) in Patients With Metastatic HER2-Positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease",II,Completed,Roche/Genentech {Genentech},Oncology: Breast,First line; HER2 positive; Stage III; Stage IV,Breast Neoplasms; Neoplasm Metastasis,Argentina; Austria; Belgium; Chile; Germany; Hungary; Israel; Italy; Mexico; Spain; Switzerland; United Kingdom; United States
"Adjuvant Doxorubicin, Cyclophosphamide Followed by Avastin Given With Paclitaxel and Gemcitabine for Stage II and III Breast Cancer That Does Not Over-Express HER-2/Neu",II,Terminated,"National Institutes of Health/National Cancer Institute
(Other Hospital/Academic/Medical Center)",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
A Pilot Study of Hypertension in Breast Cancer Patients Receiving Bevacizumab,II,Terminated,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Brigham and Womens Hospital",Oncology: Breast,(N/A); Second line,Breast Neoplasms; Hypertension,United States
"A Phase II, Single-Arm, Open-Label Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients with HER2-Positive Metastatic Breast Cancer",II,Completed,"Roche/Genentech {Genentech}
ImmunoGen",Oncology: Breast,Fourth line or greater; HER2 positive; Stage IV; Third line,Breast Neoplasms,United States
"A Randomized Phase II, Open-Label Study Of CP-751,871 In Combination With Docetaxel And Docetaxel Alone As A First Line Treatment Of Patients With Advanced Breast Cancer",II,Terminated,Pfizer,Oncology: Breast,First line; HER2 negative; Stage III; Stage IV,Breast Neoplasms,United States
Phase II Clinical Trial to Determine if Polyphenon E Inhibits c-Met Signaling and Activation of Pathways Contributing to Breast Cancer Progression,II,Completed,"Columbia University Medical Center
Louisiana State University Health Sciences Center",Oncology: Breast,Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Phase II, Randomized, Double-Blind, Multicenter Study of Exemestane With and Without SNDX-275 in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer, Progressing on Treatment With a Non-Steroidal Aromatase Inhibitor.

ENtinostat Combinations Overcoming REsistance (ENCORE 301)",II,Completed,Syndax,Oncology: Breast,Estrogen receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,Canada; Czech Republic; Hungary; Russia; United States
Phase II Trial of Neoadjuvant Chemotherapy [NCT] With Weekly Nanoparticle Albumin-Bound Paclitaxel [Nab-Paclitaxel; Abraxane] in Combination With Carboplatin and Bevacizumab in Women With Clinical Stages II-III Breast Cancer,II,Completed,"Ohio State University
Roche/Genentech",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
"A Phase II Trial of Gemcitabine and Oxaliplatin for ER-, PR-, HER2NEU- (Triple Negative) Metastatic Breast Cancer",II,Terminated,"Winship Cancer Institute of Emory University
Sanofi {Sanofi-Aventis}",Oncology: Breast,First line; HER2 negative; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"Phase II Study of Bevacizumab in Combination with Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer.",II,Terminated,"Roche/Genentech {Genentech}
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Beth Israel Deaconess Medical Center
Massachusetts General Hospital
(Other Hospital/Academic/Medical Center)
Brigham and Womens Hospital",Oncology: Breast,First line; HER2 positive; Second line; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
Intraductal Therapy of DCIS: A Presurgery Study,II,Completed,(Other Cooperative Group),Oncology: Breast,Neoadjuvant; Stage 0,Breast Neoplasms; Carcinoma in Situ,United States
"A Phase II Study of Carboplatin (CBDCA). Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP).",II,Completed,"North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Adenocarcinoma; First line; Metastatic; Stage IV; Untreated,"Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
Neoadjuvant Therapy and Biomarker Analysis of Stage II and III Breast Cancer with Docetaxel/Capecitabine and Celecoxib Followed by Doxorubicin/Cyclophosphamide and Celecoxib.,II,Terminated,"National Institutes of Health/National Cancer Institute
University of Nebraska Medical Center",Oncology: Breast,Adjuvant; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
A Single Arm Phase II Study of Pharmacologic Dose Estrogen in Postmenopausal Women With Hormone Receptor-Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapies,II,Terminated,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}
Georgetown University Medical Center
U.S. Army Medical Research and Materiel Command",Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
Phase II Trial of Albumin-Bound Paclitaxel in Combination With Gemcitabine and Bevacizumab in Patients With Metastatic Breast Cancer,II,Completed,"North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute",Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Stage IV,Breast Neoplasms,United States
A Phase II Randomized Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ,II,Terminated,Windy Hill Medical,Oncology: Breast,Neoadjuvant; Stage 0,"Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating",United States
IRS Proteins and Trastuzumab Resistance.,Other,Completed,University of Massachusetts Medical Center,Oncology: Breast,HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of Patients With HER2/Neu+ Breast Cancer Who Have Failed Trastuzumab and Chemotherapy Including a Taxane

APRiCOT-B (Apricoxib in Combination Oncology Treatment - Breast)",II,Terminated,Adastra Pharmaceuticals {Tragara Pharmaceuticals},Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
An Exploratory Study of the Biological and Clinical Activity of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer.,II,Completed,"Pfizer
Indiana University School of Medicine
Breast Cancer Research Foundation",Oncology: Breast,Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis",II,Completed,"UNC Lineberger Comprehensive Cancer Center
Sanofi {Sanofi-Aventis/BiPar}",Oncology: Breast; Oncology: Metastatic Cancer,BRCA; CNS mets; HER2 negative; Second line; Stage IV; Triple receptor negative,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis; Triple Negative Breast Neoplasms,Spain; United States
Development of Vitamin D as a Therapy for Breast Cancer - Phase II.,II,Completed,"Stanford University Medical Center
US Department of Defense",Oncology: Breast,First line; Stage 0; Stage I; Stage II,Breast Neoplasms,United States
"A Phase II Study of Carboplatin, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Avastin as the First Line Therapy in Metastatic Breast Cancer.",II,Completed,"Roche/Genentech {Genentech}
Loyola University
Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}}",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; HER2 positive; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"A Phase II Randomized, Placebo-Controlled, Double-Blind Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone as First-line Treatment in Subjects With Locally Recurrent or Metastatic Breast Cancer",II,Completed,"Roche/Genentech {Genentech}
AbbVie {Abbott}",Oncology: Breast,First line; Stage III; Stage IV,Breast Neoplasms,Belgium; Czech Republic; Italy; Mexico; Netherlands; United Kingdom; United States
Feasibility of Dose Titrating Paricalcitol (Zemplar) in Women Receiving Taxanes for Metastatic Breast Cancer.,II,Completed,"National Institutes of Health/National Cancer Institute
Comprehensive Cancer Center of Wake Forest University",Oncology: Breast,HER2 negative; HER2 positive; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,United States
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors,II,Completed,"Bristol-Myers Squibb
Exelixis","CNS: Pain (nociceptive); Oncology: Breast; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate",(N/A); Adenocarcinoma; Bone mets; BRAF; Cancer-related; EGFR; Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; HER2 positive; Hormone refractory; KRAS; Large Cell; Liver mets; MET Amplification/Alteration; Other subtype; Progesterone receptor positive; Pulmonary; Second line; Squamous Cell; Stage II; Stage III; Stage IV; Third line; Triple receptor negative; Untreated,"Breast Neoplasms; Cancer pain; Cancer Pain; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Neuroendocrine Tumors; Nociceptive Pain; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Unspecified","Belgium; Israel; Taiwan, China; United Kingdom; United States"
A Randomized Phase II Trial Evaluating the Performance of Genomic Expression Profiles to Direct the Use of Preoperative Chemotherapy for Early Stage Breast Cancer.,II,Terminated,"Duke University Medical Center
US Department of Defense
U.S. Army Medical Research and Materiel Command",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"Phase II Trial of Primary Systemic Therapy for Locally Advanced Breast Cancer Using Sequential Doxil, Paclitaxel, and Cyclophosphamide With Concurrent Avastin.",II,Completed,"Roche/Genentech {Genentech}
Johnson & Johnson/Janssen Biotech {Centocor Ortho Biotech {J&J/Ortho Biotech}}
University of Alabama, Birmingham",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors,II,Completed,"Bristol-Myers Squibb
(Other Hospital/Academic/Medical Center)","Oncology: Bladder; Oncology: Breast; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",Fourth line or greater; Locally advanced; Metastatic; Second line; Stage II; Stage III; Stage IV; Third line; Unresectable,"Adenocarcinoma; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",Argentina; Belgium; Canada; France; Germany; Netherlands; Poland; United Kingdom; United States
"A Randomized, Double-Blind, Multi-Center Phase II Trial of Exemestane (AromasinA) Plus Dasatinib Versus Exemestane Plus Placebo in Advanced ER+ Breast Cancer After Disease Progression on a Non-Steroidal Aromatase Inhibitor.",II,Completed,Bristol-Myers Squibb,Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,"Czech Republic; France; Ireland; Italy; Norway; Poland; South Korea; Spain; Sweden; Taiwan, China; United Kingdom; United States"
A Phase II Biomarker Trial of Gelatin Encapsulated Extract of American Ginseng Root (LEAG) in Breast Cancer,II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Neoadjuvant; Stage 0; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
Phase II Trial of Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer (With Trastuzumab in HER2 Positive Patients).,II,Completed,"Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}
Bristol-Myers Squibb/Celgene",Oncology: Breast,Adjuvant; HER2 negative; HER2 positive; Maintenance/Consolidation; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
Phase II Study of Ixabepilone in Patients With Metastatic Breast Cancer and a Prospective Evaluation of Its Effects on the Ultrastructure of Neurons,II,Completed,"Bristol-Myers Squibb
Weill Medical College of Cornell University",Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,United States
"Randomized, Open Label, Multicentric Phase III Evaluating the Benefit of a Sequential Regimen Associating FEC 100 and Ixabepilone in Adjuvant Treatment of Non Metastatic, Poor Prognosis Breast Cancer Defined as Triple-Negative Tumor [HER2 Negative - ER Negative - PR Negative] or [HER2 Negative and PR Negative] Tumor; in Node Positive or Node Negative Patients.",III,Terminated,"Amgen
Bristol-Myers Squibb
Federation Nationale des Centres de Lutte contre le Cancer
National Institutes of Health/National Cancer Institute",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,Belgium; France; United States
Omega-3 Fatty Acids and Prevention of DCIS and/or ADH: A Translational Approach,II,Completed,"National Institutes of Health/National Cancer Institute
Oregon Health and Science University",Oncology: Breast,First line; Stage 0; Stage I; Stage II; Stage III,Breast Neoplasms; Carcinoma in Situ; Hyperplasia; Precancerous Conditions,United States
A Biomarker Study of Etodolac in Early Stage Breast Cancer,Other,Completed,Breast Cancer Research Foundation,Oncology: Breast,Line of therapy N/A; Stage 0; Stage I; Stage II,Breast Neoplasms,United States
Phase II Trial of Sorafenib and Paclitaxel for Measurable Metastatic HER2-Negative Breast Cancer,II,Terminated,University of Texas Southwest Medical Center,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"A Phase II, Open-Label, Single-Arm, Multicenter, Multinational Study to Evaluate the Antitumor Activity and Safety of IPI-504, A Novel Small Molecule Inhibitor of Heat Shock Protein 90(HSP90), in Patients With Locally Advanced or Metastatic Human Epidermal Growth Factor Receptor 2-Positive(HER2+) Breast Cancer That Has Progressed Despite Prior Her2=Targeted Therapy.",II,Terminated,AstraZeneca {MedImmune},Oncology: Breast,Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"An International, Randomized, Double-Blind, Placebo-Controlled, Phase II Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer",II,Completed,Amgen,Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms; Neoplasm Metastasis,Australia; Canada; France; Germany; Ireland; Spain; Switzerland; United Kingdom; United States
"A Phase II Trial of Biweekly Gemcitabine, Paclitaxel, and Avastin as Frontline Therapy for Metastatic Breast Cancer.",II,Completed,"Eli Lilly
Roche/Genentech {Genentech}
University of Cincinnati College of Medicine",Oncology: Breast,First line; Stage IV,Breast Neoplasms,United States
"A Phase II Study of Gemcitabine and Bevacizumab as First-Line Treatment in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer Previously Treated With Taxanes",II,Completed,"Eli Lilly
Roche/Genentech {Genentech}",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"A Phase III, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of a Single Dose of Intravenous MK-0517 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Cisplatin Chemotherapy.

Evaluation of fosAprepitant in Single-dose schedulE (Ease-017).",III,Completed,Merck & Co./Merck Sharp & Dohme (MSD),"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Prostate; Oncology: Renal; Oncology: Supportive Care",(N/A); Aggressive; Classical; Emesis; Indolent; Line of therapy N/A; Nodular lymphocyte-predominant,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Nausea; Palliative Care; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Vomiting; Wilms Tumor","Brazil; Canada; Chile; China; Colombia; Denmark; Germany; Guatemala; Hong Kong, S.A.R., China; Hungary; India; Italy; Lithuania; Mexico; Netherlands; New Zealand; Panama; Peru; Poland; Portugal; Romania; Russia; South Africa; South Korea; Spain; Sweden; United States; Venezuela"
"A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting",II,Completed,"National Institutes of Health/National Cancer Institute
National Institutes of Health
University of California Medical Center, Irvine",Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
BrUOG-BR-211B q3week Carboplatin With Weekly Abraxane and Trastuzumab As Neoadjuvant Therapy in Resectable and Unresectable HER2+ (Stage IIa-IIIb) Breast Cancer,II,Completed,"Brown University Oncology Group
Yale University",Oncology: Breast,HER2 positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
A Multi-Institutional Double-Blind Phase II Study Evaluating Response and Surrogate Biomarkers to Carboplatin and Nab-Paclitaxel (CP) With or Without Vorinostat as Preoperative Chemotherapy in HER2-Negative Primary Operable Breast Cancer,II,Completed,"Merck & Co.
National Institutes of Health/National Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
"Pilot Study of Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer.",II,Completed,"Amgen
Memorial Sloan-Kettering Cancer Center",Oncology: Breast,Adjuvant; HER2 negative; Stage I; Stage II,Breast Neoplasms,United States
"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study to Compare the Efficacy and Tolerability of Pazopanib Administered in Combination With Exemestane Versus Exemestane Plus Placebo in Postmenopausal Subjects With Advanced or Metastatic Hormone Receptor Positive Breast Cancer.",II,Terminated,GlaxoSmithKline,Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,Germany; United States
Age-Related Changes in Nanoparticle Albumin Bound (Nab) Paclitaxel Pharmacokinetics and Pharmacodynamics.,II,Completed,"National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center
Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}}",Oncology: Breast,First line; Second line; Stage IV,Breast Neoplasms,United States
"A Phase II Trial of Doxil, Carboplatin and Bevacizumab in Triple Negative Previously Untreated Metastatic Breast Cancer",II,Completed,"National Institutes of Health/National Cancer Institute
Cancer Institute of New Jersey
(Other Hospital/Academic/Medical Center)",Oncology: Breast,First line; HER2 negative; Stage IV; Triple receptor negative,Breast Neoplasms,United States
Effect of Neoadjuvant Cisplatin Based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer: Clinical Outcome and Correlation to Biological Parameters,II,Terminated,Washington University School of Medicine,Oncology: Breast,Adjuvant; HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Pilot Trial of PET Imaging With Cu-64 Labeled Trastuzumab in HER2+ Metastatic Breast Cancer.,Other,Completed,Memorial Sloan-Kettering Cancer Center,Oncology: Breast,HER2 positive; Line of therapy N/A; Stage IV,Breast Neoplasms,United States
Phase II Study of Fulvestrant in Premenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer.,II,Completed,AstraZeneca,Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
Effect of Soy Supplementation on Cellular Markers in Normal and Cancerous Breast Tissue: A Randomized Placebo Controlled Study.,Other,Completed,Memorial Sloan-Kettering Cancer Center,Oncology: Breast,FGFR; HER2 negative; HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
Flaxseed vs. Aromatase Inhibitors: Breast Tumor Characteristics and Prognosis,II,Completed,"AstraZeneca
Roswell Park Cancer Institute
National Institutes of Health/National Center for Complementary and Alternative Medicine",Oncology: Breast,Estrogen receptor positive; Neoadjuvant; Stage I; Stage II,Breast Neoplasms,United States
"A Phase II, Two-arm, Double-blind, Multi-center, Randomized Study of the Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer",II,Completed,"Heidelberg Pharma {WILEX}
U.S. Army Medical Research and Materiel Command",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,Belgium; Brazil; Germany; Israel; Ukraine; United States
A Pilot Study to Determine the Feasibility of Quantifying Apoptosis and Bcl-2 Expression in Circulating Tumor Cells (CTCs) in Women Undergoing Treatment for Metastatic Breast Cancer,II,Completed,"University of Michigan Comprehensive Cancer Center
Johnson & Johnson/Janssen Diagnostics {Veridex {Immunicon}}",Oncology: Breast,Line of therapy N/A; Stage IV,Breast Neoplasms,United States
Phase II Randomized Trial of Weekly and Every 3-Week Ixabepilone in Metastatic Breast Cancer (MBC) Patients.,II,Completed,"Bristol-Myers Squibb
US Oncology Research",Oncology: Breast,First line; HER2 negative; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,United States
High Dose Chemotherapy with Autologous Bone Marrow Transplantation in the Treatment of Metastatic Breast Cancer.,II,Completed,"(Other Hospital/Academic/Medical Center)
University of Oklahoma",Oncology: Breast,Line of therapy N/A; Stage IV,Breast Neoplasms,United States
Serine118 phosphorylation of estrogen receptor: correlation with kinase pathways and evolution after preoperative endocrine therapy.,Other,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Neoadjuvant; Stage II; Stage III,Breast Neoplasms,France; United States
S0715: Randomized Placebo-Controlled Trial of Acetyl-L-Carnitine (ALC) for the Prevention of Taxane Induced Neuropathy Phase III,III,Completed,"Southwest Oncology Group
National Institutes of Health/National Cancer Institute",Oncology: Breast; Oncology: Supportive Care,Adjuvant; Neurotoxicity; Stage I; Stage II; Stage III,Breast Neoplasms; Fatigue; Neurotoxicity Syndromes; Palliative Care; Peripheral Nervous System Diseases,United States
Effects of zoledronic acid on wnt inhibition by dickkopf1 and frizzled-related protein in patients with bone metastases.,Other,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast; Oncology: Metastatic Cancer; Oncology: Prostate,Bone mets; Line of therapy N/A; Stage IV,Breast Neoplasms; Neoplasm Metastasis; Prostatic Neoplasms,United States
Allogeneic (Allo) Non-Myeloablative Stem Cell Transplantation (SCT) Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath-1H,II,Completed,"Duke University Medical Center
Miltenyi Biomedicine","Oncology: Breast; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome; Oncology: Myeloproliferative Neoplasms; Oncology: Renal",Aggressive; Classical; High risk; Indolent; Nodular lymphocyte-predominant; Primary Myelofibrosis; Remission; Second line; Stage IV,"Acute Myelocytic Leukemia; Breast Neoplasms; Carcinoma, Renal Cell; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Multiple Myeloma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Preleukemia; Primary Myelofibrosis; Renal Cancer; Wilms Tumor",United States
HER-2 positive inflammatory breast cancer: high pathological response rate with trastuzumab-based neoadjuvant therapy.,II,Completed,"MD Anderson Cancer Center, University of Texas",Oncology: Breast,HER2 positive; Neoadjuvant; Stage IV,Breast Neoplasms,United States
"Phase II, Multicenter, Open-Label, Clinical Trial of Trabectedin (Yondelis) in Metastatic Breast Cancer Patients With Triple Negative Profile (ER-, PR-, HER2-), HER2 Overexpressing Tumors and BRCA1 or BRCA2 Mutation Carriers",II,Completed,"Johnson & Johnson/Janssen R&D {Johnson & Johnson/J&JPRD}
PharmaMar {Zeltia/PharmaMar}",Oncology: Breast,BRCA; Fourth line or greater; HER2 negative; HER2 positive; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Neoplasms,France; Israel; Italy; Poland; United States
Study of Breast Cancer Prevention by Letrozole in High Risk Women,II,Completed,"Novartis
National Institutes of Health/National Cancer Institute
University of Kansas",Genitourinary: Menopausal Symptoms; Oncology: Breast,(N/A); Line of therapy N/A; VMS - Unspecified or other severity,Breast Neoplasms; Menopause,United States
Circulating immature myeloid cells in breast cancer patients correlate with clinical cancer stage and cyclophosphamide treatment: implications for cancer immunotherapy,Other,Completed,Medical University of South Carolina,Oncology: Breast; Oncology: Unspecified Solid Tumor,Second line; Stage I; Stage II; Stage III; Stage IV,"Breast Neoplasms; Neoplasms, Unknown Primary",United States
Allogeneic Non-Myeloablative Stem Cell Transplantation Utilizing Matched Family Member Stem Cells Purged Using Campath-1H.,II,Completed,"Duke University Medical Center
Miltenyi Biomedicine","Oncology: Breast; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome; Oncology: Myeloproliferative Neoplasms; Oncology: Renal",Aggressive; Classical; High risk; Indolent; Nodular lymphocyte-predominant; Primary Myelofibrosis; Remission; Second line; Stage IV,"Acute Myelocytic Leukemia; Breast Neoplasms; Carcinoma, Renal Cell; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Multiple Myeloma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Preleukemia; Primary Myelofibrosis; Renal Cancer; Wilms Tumor",United States
A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109,II,Terminated,"Roche/Genentech {Genentech}
Amgen {Onyx Pharmaceuticals}
Bayer AG",Oncology: Breast,HER2 negative; HER2 positive; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
"MPA Revisited: A Phase II Study of Anti-Metastatic, Anti-Angiogenic Therapy in Postmenopausal Patients with Hormone Receptor Negative Breast Cancer. A Translational Breast Cancer Research Consortium (TBCRC) Trial",II,Completed,"Indiana University Cancer Center
Breast Cancer Research Foundation",Oncology: Breast,HER2 negative; HER2 positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"Contrast-Enhanced Breast MRI, MRS, And Correlative Science Studies To Characterize Tumor Response In Patients Undergoing Neoadjuvant Treatment For Locally Advanced Breast Cancer.",II,Completed,"(Other Cooperative Group)
Cancer and Leukemia Group B (CALGB)
National Institutes of Health/National Cancer Institute
Breast Cancer Research Foundation
American College of Radiology Imaging Network (ACRIN)",Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,United States
A Phase II Study of Combined Fulvestrant (Faslodex) and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure,II,Completed,Novartis,Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Phase II Study of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer,II,Terminated,"Bayer AG/Bayer Pharmaceuticals
Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}}",Oncology: Breast,First line; HER2 negative; Stage III; Stage IV,Breast Neoplasms,United States
"A phase 2, single arm study to evaluate the safety, efficacy, and pharmacokinetics of bevacizumab as monotherapy in patients with relapsed metastatic breast cancer.",II,Completed,Roche/Genentech {Genentech},Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
"A Phase II Trial of Capecitabine Concomitantly With Whole Brain Radiotherapy (WBRT) Followed by Capecitabine and Sunitinib for Central Nervous System, (CNS) Metastases in Breast Cancer.",II,Terminated,"Pfizer
Baylor College of Medicine",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; First line; HER2 negative; HER2 positive; Stage IV; Triple receptor negative,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
A Phase II Trial of Neoadjuvant Arimidex With or Without Faslodex in Postmenopausal Women With Hormone Receptor Positive Breast Cancer,II,Completed,"AstraZeneca
Baylor College of Medicine",Oncology: Breast,Estrogen receptor positive; Neoadjuvant; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,United States
"Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy",II,Terminated,"Astellas Pharma {OSI Pharmaceuticals}
University of Arkansas",Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
"A Phase II Open-Label Trial to Evaluate the Efficacy and Toxicity of Tarceva (Erlotinib) in Women With Metastatic, Hormone Receptor Negative and Her2-Negative Breast Cancer.",II,Terminated,"Astellas Pharma {OSI Pharmaceuticals}
Rush University Medical Center",Oncology: Breast,First line; HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
A Pilot Safety And Feasibility Study Of Concurrent Capecitabine (Xeloda) And External Beam Irradiation In The Adjuvant Treatment Of High Risk Early Stage Breast Cancer.,II,Completed,"(Other Cooperative Group)
Simmons Cancer Center
Roche {F. Hoffmann-La Roche}",Oncology: Breast,Adjuvant; Neoadjuvant; Stage III,Breast Neoplasms,United States
"A Phase II Study of AZD0530 in Hormone Receptor-Negative, Metastatic or Unresectable, Locally Advanced Breast Cancer.",II,Terminated,"Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute",Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Breast Neoplasms, Male",United States
Activating PIK3CA and AKT mutations in triple-receptor negative breast cancer.,Other,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,(N/A); HER2 negative; Line of therapy N/A; Triple receptor negative,Breast Neoplasms,United States
Pilot Study of Femara Following 1-5 Years of Tamoxifen in Women in Their 40s with Early Stage or Locally Advanced Breast Cancer Who Have Ceased Menstruating with Adjuvant Chemotherapy,II,Completed,US Oncology Research,Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Stage 0; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Aromatase Inhibitors in Premenopausal Breast Cancer Patients with Chemotherapy-Induced Ovarian Failure,II,Terminated,University of Michigan Comprehensive Cancer Center,Oncology: Breast,Line of therapy N/A; Stage I; Stage II; Stage III,"Breast Neoplasms; Menopause, Premature; Primary Ovarian Insufficiency",United States
Randomized Phase II Trial of Capecitabine and Lapatinib With or Without IMC-A12 in Patients With HER2 Positive Breast Cancer Previously Treated With Trastuzumab and an Anthracycline and/or a Taxane,II,Terminated,"GlaxoSmithKline
North Central Cancer Treatment Group (NCCTG)
Southwest Oncology Group
National Institutes of Health/National Cancer Institute
Eli Lilly {ImClone}
Alliance for Clinical Trials in Oncology",Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms; Carcinoma,United States
"A Phase II Clinical Trial of Intermittent Letrozole Therapy in Postmenopausal Women With CA 15-3 Positive (Carcinoma Antigen 15-3), Hormone Receptor Positive, Metastatic Breast Cancer",II,Terminated,"Novartis
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Massachusetts General Hospital",Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Phase II Trial of Lapatinib and Trastuzumab With or Without Endocrine Therapy in Locally Advanced HER2 Overexpressing Breast Cancer Patients.,II,Completed,"GlaxoSmithKline
Baylor College of Medicine",Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
"A Phase II Study of Preoperative Dose-Dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel (T) With Bevacizumab in ER+ and/or PR+, HER2-Negative Operable Breast Cancer.",II,Completed,"Roche/Genentech {Genentech}
(Other Cooperative Group)
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Massachusetts General Hospital
Brigham and Womens Hospital",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
IXTEND: A Randomized Phase II Study to Evaluate the Combination of IXabepilone Plus CapeciTabine or CapEcitabiNe Plus Docetaxel in the Treatment of Metastatic Breast Cancer.,II,Terminated,Bristol-Myers Squibb,Oncology: Breast,First line; HER2 negative; HER2 positive; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,United States
A Phase II Trial of Dasatinib to Treat Women With Stage IV or Inoperable Stage III Advanced Breast Cancer.,II,Terminated,"Bristol-Myers Squibb
Duke University Medical Center",Oncology: Breast,First line; Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
"A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel) (NSC-736631) With or Without Bevacizumab, Either Preceded by or Followed by Q 2 Week Doxorubicin (A)and Cyclophosphamide (C) Plus Pegfilgrastim (PEG-G) as Neoadjuvant Therapy For Inflammatory and Locally Advanced HER-2/NEU Negative Breast Cancer",II,Completed,"Southwest Oncology Group
National Institutes of Health/National Cancer Institute",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,Puerto Rico; United States
Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer,II,Terminated,(Other Academic Cancer Center),Oncology: Breast,HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer,II,Completed,"Roche/Genentech {Genentech}
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Beth Israel Deaconess Medical Center
Massachusetts General Hospital
Brigham and Womens Hospital",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Maintenance/Consolidation; Stage I,Breast Neoplasms,United States
A Pilot Study of Adjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel Plus Sorafenib in Women With Node Positive or High-Risk Early Stage Breast Cancer.,II,Completed,Bayer AG,Oncology: Breast,Adjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Randomized, Double-Blind, Phase II Trial of Paclitaxel Plus Bevacizumab and Enzastaurin Versus Paclitaxel Plus Bevacizumab and Placebo for Locally Recurrent or Metastatic Breast Cancer",II,Terminated,"Eli Lilly
Roche/Genentech {Genentech}",Oncology: Breast,First line; Stage III; Stage IV,Breast Neoplasms,United States
"Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study.",II,Terminated,"Hoosier Cancer Research Network {Hoosier Oncology Group}
Baylor College of Medicine
McGill University Health Centre
Indiana University School of Medicine
US Department of Defense
University of Colorado",Oncology: Breast,First line; Stage III; Stage IV,Breast Neoplasms,United States
Phase IIb study of  VQD-002 in Combination with Herceptin in Breast Cancer.,II,Terminated,VioQuest Pharmaceuticals,Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
Phase II Trial of Capecitabine in Combination With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer.,II,Completed,"AstraZeneca
Roche {F. Hoffmann-La Roche}",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage IV,Breast Neoplasms,United States
"A Phase II, Randomized, Open-Label, Pilot Study to Evaluate the Safety and Effects on Bone Resorption of AZD0530 in Patients With Prostate Cancer or Breast Cancer With Metastatic Bone Disease.",II,Completed,AstraZeneca,Oncology: Breast; Oncology: Metastatic Cancer; Oncology: Prostate,Bone mets; Second line; Stage IV,Bone Diseases; Bone Neoplasms; Breast Neoplasms; Neoplasm Metastasis; Prostatic Neoplasms,Canada; Denmark; Norway; Portugal; Spain; Sweden; United Kingdom; United States
A Humanitarian Device Exemption Compassionate Use Protocol of TheraSphere for Treatment of  Unresectable Metastatic Cancer to the Liver,II,Completed,"National Institutes of Health/National Cancer Institute
Northwestern University","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Small Intestine; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Aggressive; Classical; Indolent; Liver mets; Metastatic; Nodular lymphocyte-predominant; Second line; Stage IV; Unresectable,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Intestinal Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasm Metastasis; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase II, Multi-Center, Open-Label, Randomized Trial of Gemcitabine/ Carboplatin, with or without BSI-201, in Patients with ER, PR and HER2-Negative Metastatic Breast Cancer",II,Completed,"US Oncology Research
Sanofi {Sanofi-Aventis/BiPar}",Oncology: Breast,First line; Fourth line or greater; HER2 negative; Neoadjuvant; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
"A Phase II, Randomized, Open Label Trial of Pre-Operative (Neoadjuvant) Letrozole (Femara) vs. Letrozole in Combination With Avastin in Post Menopausal Women With Newly Diagnosed Operable Breast Cancer.",II,Completed,"Roche/Genentech {Genentech}
University of Alabama, Birmingham
Breast Cancer Research Foundation",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,United States
A Phase II Study of Irinotecan and Temozolomide in Breast Cancer Patients With Brain Metastases That Have Progressed After Stereotactic Radiosurgery or Whole Brain Radiation,II,Completed,"GlaxoSmithKline
Merck & Co.
National Institutes of Health/National Cancer Institute
Pfizer
University of California, San Francisco",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; First line; Fourth line or greater; Second line; Stage IV; Third line,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
"A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients with HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer 

ROSE (Ramucirumab Overall Survival Evaluation)",III,Completed,"Breast Cancer International Research Group
Eli Lilly {ImClone}",Oncology: Breast,First line; HER2 negative; Stage III; Stage IV,Breast Neoplasms,"Australia; Belgium; Brazil; Canada; Croatia; Czech Republic; Egypt; Germany; Greece; Ireland; Israel; Lebanon; New Zealand; Peru; Poland; Russia; Serbia; Slovakia; South Africa; South Korea; Spain; Taiwan, China; United Kingdom; United States"
Cyclophosphamide Pharmacogenetics in Breast Cancer Patients receiving Adjuvant Therapy with Adriamycin and Cyclophosphamide (AC),Other,Completed,Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation},Oncology: Breast,(N/A); Adjuvant,Breast Neoplasms,United States
A Phase II Study of Adding the Multikinase Inhibitor Sorafenib (Nexavar) to Existing Endocrine Therapy in Patients With Advanced Breast Cancer.,II,Terminated,"Amgen {Onyx Pharmaceuticals}
Bayer AG
University of Kentucky",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase II, Multicenter, Exploratory Study, Evaluating the Treatment Effect of Surgery Plus GLIADEL Wafer in Patients With Metastatic Brain Cancer",II,Completed,Eisai {MGI Pharma},"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer",(N/A); CNS mets; Line of therapy N/A,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Melanoma; Neoplasm Metastasis",United States
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor.,II,Terminated,"MD Anderson Cancer Center, University of Texas",Oncology: Breast; Oncology: Ovarian; Oncology: Renal,Line of therapy N/A; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Kidney Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Wilms Tumor",United States
Phase II Study of Neoadjuvant Pegylated Liposomal Doxorubicin and Docetaxel in Locally Advanced Operable Breast Cancer,II,Terminated,"National Institutes of Health/National Cancer Institute
Roswell Park Cancer Institute",Oncology: Breast,Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
Phase II Randomized Trial of Neoadjuvant Trastuzumab and/or Lapatinib Plus Chemotherapy (Sequential FEC75 and Paclitaxel) in Women With ErbB2- (HER2/Neu-) Overexpressing Invasive Breast Cancer,II,Completed,GlaxoSmithKline,Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
Phase II Randomized Study of Sorafenib Compared to Placebo When Administered in Combination With Aromatase Inhibitors for Postmenopausal Women With Metastatic Breast Cancer,II,Terminated,"National Institutes of Health/National Cancer Institute
Mayo Clinic",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
Phase II Study Of The Trifunctional Bispecific Anti-HER-2/Neu x Anti-CD3 Antibody Ertumaxomab In Patients With HER-2/Neu Overexpressing (3+ Or 2+/FISH+) Metastatic Breast Cancer Progressing After Trastuzumab Treatment.,II,Terminated,"Neopharm Group/Neovii Pharmaceuticals/Neovii Biotech {NeoPharm {Neovii Biotech {Fresenius Biotech}}}}
Trion Pharma",Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,Canada; United States
A Phase II Efficacy and Tolerability Study of RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases,II,Terminated,Reata Pharmaceuticals,Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage IV,"Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis; Neoplasms, Second Primary",United States
"A Phase II Study of Pre-Operative Pegylated Liposomal Doxorubicin (PLD), Paclitaxel, and Trastuzumab in Patients With Operable Breast Cancer Over-Expressing Her2-Neu",II,Completed,"Johnson & Johnson/Janssen Biotech {Centocor Ortho Biotech {J&J/Ortho Biotech}}
(Other Cooperative Group)",Oncology: Breast,HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,Australia; United States
Changes in Breast Density and Plasma Hormone Levels After One Year of Aromatase Inhibitor Therapy.,Other,Completed,"North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute
Alliance for Clinical Trials in Oncology",Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Phase II Study of Carboplatin and Bevacizumab (Avastin) Combination Therapy for ER Negative, PR Negative, and HER2/Neu Negative Metastatic Breast Cancer.",II,Terminated,"Roche/Genentech {Genentech}
University of Chicago Medical Center",Oncology: Breast,First line; HER2 negative; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"A Phase III Randomized, Double Blind, Placebo-controlled Trial Comparing Capecitabine Plus Sorafenib Versus Capecitabine Plus Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer (The RESILIENCE Trial).",III,Completed,"Bayer AG/Bayer Pharmaceuticals
Amgen {Onyx Pharmaceuticals}
Karolinska Hospital and Institutet",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Colombia; Czech Republic; Denmark; France; Germany; Greece; Hungary; Ireland; Israel; Italy; Japan; Mexico; New Zealand; Norway; Peru; Poland; Portugal; Puerto Rico; Russia; South Africa; Spain; Sweden; Switzerland; United Kingdom; United States
A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Maleate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer,II,Completed,"National Institutes of Health/National Cancer Institute
Pfizer
University of Washington",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,"Breast Neoplasms; Breast Neoplasms, Male; Inflammatory Breast Neoplasms",United States
Effect of melatonin on taxane-induced neuropathy in breast cancer patients.,II,Completed,University of Cincinnati College of Medicine,Oncology: Breast; Oncology: Supportive Care,Neurotoxicity; Second line; Stage II; Stage III; Stage IV,Breast Neoplasms; Palliative Care,United States
Multimodality Treatment of Primary Breast Cancer Occurring Concomitant With Pregnancy,II,Completed,"MD Anderson Cancer Center, University of Texas",Oncology: Breast,Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Randomized, 4-Arm, Placebo-Controlled Phase II Trial of AMG 386 in Combination with Bevacizumab and Paclitaxel or AMG 386 Plus Paclitaxel as First-Line Therapy in Subjects with HER2-Negative, Metastatic or Locally Recurrent Breast Cancer.",II,Completed,Amgen,Oncology: Breast,First line; HER2 negative; Stage III; Stage IV,Breast Neoplasms,Australia; Austria; Belgium; Denmark; Finland; France; Hungary; India; Netherlands; Poland; Spain; United Kingdom; United States
A Randomized Phase III Trial Comparing a Neoadjuvant Regimen of FEC-75 Followed by Paclitaxel Plus Trastuzumab With a Neoadjuvant Regimen of Paclitaxel Plus Trastuzumab Followed by FEC-75 Plus Trastuzumab in Patients With HER-2 Positive Operable Breast Cancer,III,Completed,"National Institutes of Health/National Cancer Institute
Alliance for Clinical Trials in Oncology",Oncology: Breast,HER2 positive; Neoadjuvant; Stage 0; Stage I; Stage II; Stage III,Breast Neoplasms,Puerto Rico; United States
"A Randomized trial of the effect of celecoxib on the regimen 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) combination, followed by docetaxel.",II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast; Oncology: Supportive Care,HER2 negative; HER2 positive; Neoadjuvant; Neutropenia; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Neutropenia; Palliative Care,"Hong Kong, S.A.R., China; Japan; South Korea; United States"
Effects of letrozole on mammographic density (MD) in post-menopausal (PM) women at high risk for breast cancer (BC),Other,Completed,(Other Academic Cancer Center),Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
A Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer.,II,Terminated,"National Institutes of Health/National Cancer Institute
Takeda/Takeda Oncology {Millennium}
University of Wisconsin",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
Safety of Ovarian Stimulation With Letrozole and Gonadotropins in Breast Cancer Patients Undergoing Embryo or Oocyte Cryopreservation: A Prospective Controlled Follow up Study.,III,Terminated,(Other Hospital/Academic/Medical Center),Oncology: Breast,First line; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Phase II Study of Abraxane, Avastin and Gemcitabine for First Line Metastatic Breast Cancer",II,Completed,"Roche/Genentech {Genentech}
Sylvester Cancer Center, University of Miami",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage IV,Breast Neoplasms,United States
A Pilot Study of the Effect of Erlotinib (Tarceva) on Biomarkers in Estrogen Receptor Negative Breast Cancer Expressing the Epidermal Growth Factor Receptor and Interleukin 1a,II,Terminated,"Roche/Genentech {Genentech}
Barbara Ann Karmanos Cancer Institute
National Institutes of Health/National Cancer Institute",Oncology: Breast,EGFR; HER2 negative; HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Assessment of Circulating Tumor cell (CTC) Patterns Among Disease-Free Breast Cancer Patients Vaccinated with a Preventive HER2/neu E75-Peptide Vaccine.,II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,(N/A); HER2 positive; Line of therapy N/A,Breast Neoplasms,United States
Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane) Followed by Vinorelbine for HER2 Overexpressing Early Stage Breast Cancer.,II,Completed,"Winship Cancer Institute of Emory University
Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}}",Oncology: Breast,HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Phase II Trial of  Vesanoid (Tretinoin, ALL-TRANS Retinoic ACID) and Taxol (Paclitaxel) in Patients with Stage IV Breast Cancer.",II,Completed,Cancer Institute of New Jersey,Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
A Phase II Neo-Adjuvant Study of Letrozole in Combination With Lapatinib in Post -Menopausal Patients With HER2-Positive and Hormone Receptor-Positive Operable Breast Cancer,II,Terminated,"GlaxoSmithKline
National Institutes of Health/National Cancer Institute
Vanderbilt-Ingram Cancer Center",Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Neoadjuvant Intratumoral Injection of Dendritic Cells in Breast Cancer Translation of Biotechnology Into the Clinic.,II,Completed,"National Institutes of Health/National Cancer Institute
University of Nebraska Medical Center",Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
"Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Study of Nab-Paclitaxel (Nanoparticle Albumin Bound-Paclitaxel) in Patients With Advanced Solid Tumors",Other,Terminated,"Eastern Cooperative Oncology Group (ECOG)
National Institutes of Health/National Cancer Institute","Oncology: Bladder; Oncology: Breast; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Testicular",(N/A); Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Double-Blind, Randomized Phase IIB Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Paclitaxel in Patients with Locally Recurrent or Metastatic Breast Cancer",II,Completed,"Amgen
National Institutes of Health/National Cancer Institute
Robert H. Lurie Comprehensive Cancer Center at Northwestern University",Oncology: Breast,First line; HER2 negative; Stage III; Stage IV,Breast Neoplasms,Brazil; India; United States
Open Label Randomized Clinical Trial of Standard Neoadjuvant Chemotherapy (Paclitaxel Followed by FEC) Versus the Combination of Paclitaxel and RAD001 Followed by FEC in Women With Triple Receptor-Negative Breast Cancer (CRAD001C24101),II,Completed,"Novartis
MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast,HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
Phase II Pilot of Aromatase Inhibitor Therapy With Femara (Letrozole) and Ovarian Suppression in Premenopausal Estrogen Receptor Positive Women With Stage IV Carcinoma of the Breast.,II,Terminated,"National Institutes of Health/National Cancer Institute
University of Washington",Oncology: Breast,Estrogen receptor positive; Line of therapy N/A; Progesterone receptor positive; Stage IV,Breast Neoplasms,United States
"Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, As First-Line Therapy in Patients With Metastatic Breast Cancer Previously Treated With Anthracycline Chemotherapy.",II,Completed,Bristol-Myers Squibb,Oncology: Breast,First line; Stage IV,Breast Neoplasms,Canada; France; Italy; United States
Gene Expression Profiles of Breast Cancer Treated with Sequential Adriamycin and Docetaxel in Relation to Tumor Responses,II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,First line; Stage II; Stage III; Stage IV,Breast Neoplasms,Singapore; United States
"An Open-Label, Dose Finding, Prospective, Multi Center, Randomized, Parallel Group Study to Assess the Efficacy and Safety of Three Different Dose Levels of AVI 014 (G-CSF) Compared With a Standard Dose of Neupogen in Breast Cancer Patients at High (>20%) Risk for Chemotherapy Induced Severe Neutropenia",II,Completed,AstraZeneca/Alexion Pharmaceuticals Synageva BioPharma {AviGenics}},Oncology: Breast; Oncology: Supportive Care,First line; HER2 positive; Neoadjuvant; Neutropenia; Stage III; Stage IV,Breast Neoplasms; Neutropenia; Palliative Care,India; United States
A Phase II Study of ZK219477 (ZK-EPO) in Patients with Breast Cancer and Brain Metastases.,II,Terminated,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Beth Israel Deaconess Medical Center
Bayer AG/Bayer Pharmaceuticals
Brigham and Womens Hospital
Breast Cancer Research Foundation",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Second line; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
Phase II Trial of Adjuvant TC (Docetaxel/Cyclophosphamide) Plus Trastuzumab in HER2-Positive Early Stage Breast Cancer Patients,II,Completed,"US Oncology Research
Sanofi {Sanofi-Aventis}",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Phase II Trial of Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in Patients With HER2/Neu-Overexpressing Advanced or Metastatic Breast Cancer.,II,Terminated,"National Institutes of Health/National Cancer Institute
(Other Hospital/Academic/Medical Center)",Oncology: Breast,First line; HER2 positive; Stage III; Stage IV,Breast Neoplasms,United States
Validation of genomic markers that predict distant recurrence risk via FISH assays in women with early stage breast carcinoma.,Other,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; Line of therapy N/A; Progesterone receptor positive; Stage I; Stage II,Breast Neoplasms,United States
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients,III,Completed,"US Oncology Research
Sanofi {Sanofi-Aventis}",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
PET FES measures in vivo pharmacodynamics of endocrine therapy.,Other,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
"Effect of celecoxib, a specific cyclooxygenase 2 inhibitor, on the apoptotic and mitotic indexes of breast cancer in patients with early stage disease.",II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
"Phase II Trial of Neoadjuvant Erlotinib Plus Chemotherapy for Treatment of ER Negative, PgR Negative and HER-2 Negative Primary Breast Cancer.",II,Completed,"Roche/Genentech {Genentech}
University of Kansas",Oncology: Breast,Adjuvant; BRCA; HER2 negative; Maintenance/Consolidation; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
"SOLE, Study of Letrozole Extension, A Phase III Trial Evaluating the Role of Continuous Letrozole Versus Intermittent Letrozole Following 4 to 6 Years of Prior Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone-Receptor Positive, Node Positive Early Stage Breast Cancer.",III,Completed,"Novartis
(Other Cooperative Group)
Breast International Group
European Institute of Oncology
International Breast Cancer Study Group",Oncology: Breast,Adjuvant; Estrogen receptor positive; Progesterone receptor positive; Stage 0; Stage I; Stage II,Breast Neoplasms,Australia; Austria; Belgium; Brazil; Canada; Chile; China; Denmark; Finland; France; Germany; Greece; Hungary; India; Ireland; Italy; Japan; Netherlands; New Zealand; Norway; Pakistan; Peru; Romania; Russia; Slovenia; South Africa; Spain; Sweden; Switzerland; United Kingdom; United States
The Effect of Dexamethasone on Symptoms in Patients With Advanced Cancer,II,Completed,"MD Anderson Cancer Center, University of Texas","CNS: Pain (neuropathic); Oncology: Bladder; Oncology: Breast; Oncology: Endometrial; Oncology: GIST; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma; Oncology: Supportive Care; Oncology: Unspecified Cancer",Cachexia; Cancers-related; Emesis; Second line; Stage III; Stage IV,"Breast Neoplasms; Cachexia; Cancer pain; Cancer Pain; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Ewing Sarcoma; Fibrosarcoma; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasms; Neuralgia; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Palliative Care; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Vomiting",United States
A phase II study of anastrazole and fulvestrant in combination with gefitinib in patients with newly diagnosed ER-positive breast cancer.,II,Terminated,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,United States
"A Randomized, Multicenter, Phase III Study Comparing the Combination of Pazopanib and Lapatinib Versus Lapatinib Monotherapy in Patients With ErbB2 Over-expressing Inflammatory Breast Cancer",III,Completed,GlaxoSmithKline,Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms; Inflammatory Breast Neoplasms,"Algeria; Australia; Belgium; Brazil; Canada; Chile; China; Czech Republic; Egypt; France; Germany; Greece; Hong Kong, S.A.R., China; India; Israel; Italy; Lebanon; Morocco; Pakistan; Peru; Philippines; Romania; Russia; Singapore; South Korea; Spain; Taiwan, China; Thailand; Tunisia; Turkey; United Kingdom; United States; Vietnam"
"A Phase II Open-Label, Non-Comparative, International, Multicentre Study to Assess the Efficacy and Safety of KU 0059436 Given Orally Twice Daily in Patients With Advanced BRCA1 or BRCA2 Associated Breast Cancer",II,Completed,"AstraZeneca {KuDOS Pharmaceuticals}
Myrexis {Myriad Pharmaceuticals {Myriad Genetics}}",Oncology: Breast,BRCA; Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,Australia; Germany; Israel; Spain; Sweden; United Kingdom; United States
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response.,III,Completed,"GlaxoSmithKline
National Surgical Adjuvant Breast and Bowel Project (NSABP)
Roche {F. Hoffmann-La Roche}",Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,Canada; Puerto Rico; United States
A Phase II study of modafinil for treatment of post-chemotherapy impairment of cognitive function.,II,Completed,"National Institutes of Health/National Cancer Institute
Teva {Cephalon}",Oncology: Breast; Oncology: Supportive Care,(N/A); Line of therapy N/A; Neurotoxicity,Breast Neoplasms; Palliative Care,United States
Phase II Study of Dose-Dense Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With Trastuzumab and Lapatinib in HER2/NEU-Overexpressed/Amplified Breast Cancer: Feasibility,II,Terminated,"GlaxoSmithKline
Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute",Oncology: Breast,Adjuvant; HER2 positive; Neoadjuvant; Stage 0; Stage I; Stage II; Stage III,Breast Neoplasms,United States
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response,II,Completed,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Beth Israel Deaconess Medical Center
Massachusetts General Hospital
(Other Hospital/Academic/Medical Center)
Myrexis {Myriad Pharmaceuticals {Myriad Genetics}}",Oncology: Breast,BRCA; First line; HER2 negative; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"A Phase II, Single-Arm, Open-Label Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed While Receiving HER2-Directed Therapy",II,Completed,"Roche/Genentech {Genentech}
ImmunoGen",Oncology: Breast,Fourth line or greater; HER2 positive; Second line; Stage IV; Third line,Breast Neoplasms,United States
Randomized Phase II Trial of Anastrozole Combined With Novel Agent ZD6474 in the Neoadjuvant Treatment of Postmenopausal Patients With Hormone Receptor-Positive Breast Cancer,II,Terminated,"AstraZeneca
Stanford University Medical Center",Oncology: Breast,Estrogen receptor positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
A phase II combination trial of bevacizumab and anti-HER2 therapy in breast cancer,II,Terminated,Memorial Sloan-Kettering Cancer Center,Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
Relationships Between clinical and Biochemical Predictors of Chemotherapy-Related Amenorrhea in Premenopausal Adjuvant Breast Cancer Patients.,IV,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Adjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"An Open-Label, Multi-Centre Study of Lapatinib in Combination with Chemotherapy in Patients with ErbB2 Overexpressing Breast Cancer After Trastuzumab Failure in the Neoadjuvant or Adjuvant Setting",II,Terminated,GlaxoSmithKline,Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Stage IV,Breast Neoplasms,United States
"A Phase II Study of Abraxane, Carboplatin and Bevacizumab in ""Triple Negative"" (Demonstrating no Expression for Estrogen, Progesterone, or Her2 Receptors) Metastatic Breast Cancer.",II,Completed,"Roche/Genentech {Genentech}
Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}}
Duke University Medical Center",Oncology: Breast,First line; HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"A Multicenter, Open-Label, Phase II Study to Determine the Dose, Safety and Efficacy of NKTR-102 (PEG-Irinotecan) in Combination With Cetuximab in Patients With Solid Tumors Refractory to Standard Treatment and to Evaluate the Safety and Efficacy of NKTR-102 or Irinotecan in Combination With Cetuximab in Second Line, Irinotecan and Cetuximab Naïve, Colorectal Cancer Patients With Metastatic or Locally Advanced Disease",II,Completed,Nektar Therapeutics,Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Pancreas,Second line; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms,United States
Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial.,III,Completed,"Merck & Co.
National Institutes of Health/National Cancer Institute",Oncology: Breast; Oncology: Supportive Care,(N/A); Emesis; First line,Breast Neoplasms; Nausea; Palliative Care; Vomiting,United States
A Phase II Safety and Tolerability Study of Avastin When Added to Single-Agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain.,II,Terminated,"Roche/Genentech {Genentech}
Duke University Medical Center",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Line of therapy N/A; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
Celecoxib decreases prostaglandin E2 concentrations in nipple aspirate fluid from high risk postmenopausal women and women with breast cancer.,Other,Completed,US Department of Defense,Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
A Phase II Study of Sunitinib Malate Single Agent For The Treatment of Women with Advanced Breast Cancer,II,Completed,Pfizer,Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Randomized Phase 2 Clinical Trial Of Docetaxel With Or Without PF-3512676 As First-Line Treatment Of Patients With Advanced Breast Cancer.,II,Terminated,Pfizer,Oncology: Breast,First line; HER2 negative; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer",II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,FGFR; First line; HER2 positive; MET Amplification/Alteration; Second line; Stage I; Stage II; Stage III; Stage IV; Third line,Breast Neoplasms,United States
Pilot Study of Immunization of High Risk Breast Cancer Patients With a Sialyl Lewis -Keyhole Limpet Hemocyanin Conjugate Plus the Immunological Adjuvant QS-21,II,Completed,"Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute",Oncology: Breast,Line of therapy N/A; Stage IV,Breast Neoplasms,United States
The Effect of Aspirin on Mammogram Density (TEAM).,II,Completed,"National Institutes of Health/National Cancer Institute
Fred Hutchinson Cancer Research Center
National Institutes of Health
American Cancer Society",Oncology: Breast; Oncology: Ovarian,(N/A); Line of therapy N/A,Breast Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Unspecified,United States
Pegfilgrastim (Neulasta) Versus Filgrastim (Neupogen) in Cancer Patients with Neutropenia: A Randomized Cross-Over Trial.,II,Completed,Northwestern University,"Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Soft Tissue Sarcoma; Oncology: Supportive Care; Oncology: Thyroid",Advanced; Extensive; First line; Limited; Localized; Locally advanced; Metastatic; Neutropenia; Pulmonary; Recurrent; Second line; Stage 0; Stage I; Stage II; Stage III; Stage IV; Untreated,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Medulloblastoma; Melanoma; Mesothelioma; Neoplasms, Basal Cell; Neoplasms, Mesothelial; Neuroendocrine Tumors; Neutropenia; Ovarian Cancer; Ovarian Neoplasms; Palliative Care; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"Bicalutamide for the Treatment of Androgen Receptor Positive (AR(+)), Estrogen Receptor Negative, Progesterone Receptor Negative (ER(-)/PR(-)) Metastatic Breast Cancer Patients: A Phase II Feasibility Study",II,Completed,"AstraZeneca
(Other Cooperative Group)
Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute",Oncology: Breast,First line; HER2 negative; HER2 positive; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
Oral arginine is a potent radiosensitizer for patients with brain metastases.,II,Completed,(Other Hospital/Academic/Medical Center),"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer",CNS mets; Line of therapy N/A; Stage IV,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Melanoma; Neoplasm Metastasis",Argentina; United States
"A Phase II Trial of Bevacizumab and ABI-007 (Abraxane) as Second-Line Therapy in Her-2 Negative, Hormone Receptor Negative Metastatic Breast Cancer",II,Completed,"Roche/Genentech {Genentech}
Abramson Cancer Center at  University of Pennsylvania Medical Center",Oncology: Breast,HER2 negative; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"A Randomized, Open-Label, Phase III Study of Taxane Based Chemotherapy with Lapatinib or Trastuzumab as First-Line Therapy for Patients with HER2/neu Positive Metastatic Breast Cancer",III,Terminated,"GlaxoSmithKline
Canadian Cancer Trials Group {NCIC Clinical Trials Group}",Oncology: Breast,First line; HER2 positive; Maintenance/Consolidation; Stage IV,Breast Neoplasms,"Argentina; Australia; Belgium; Canada; France; Germany; India; Israel; Italy; Japan; Mexico; Netherlands; Poland; Russia; South Korea; Spain; Taiwan, China; Thailand; Ukraine; United Kingdom; United States"
A Phase II Study of Liposomal Doxorubicin (Lipo-Dox) in Patients With Brain Metastasis From Breast Cancer.,II,Terminated,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}
TTY Biopharm",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Second line; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,Singapore; United States
A Phase II Clinical Trial of Epirubicin Plus Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and Bevacizumab Given as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or Given as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer.,II,Completed,"Roche/Genentech {Genentech}
National Surgical Adjuvant Breast and Bowel Project (NSABP)",Oncology: Breast,Adjuvant; HER2 positive; Neoadjuvant; Stage III,Breast Neoplasms,Canada; United States
A Phase II Study of Adjuvant Gemcitabine/Capecitabine and Bevacizumab for Patients Treated Neoadjuvantly Chemotherapy for Early Stage Breast Cancer with High Risk for Relapse.,II,Terminated,"Roche/Genentech {Genentech}
Brown University Oncology Group
University of New Mexico Cancer Research and Treatment Center
Rhode Island Hospital
(Other Hospital/Academic/Medical Center)
Women and Infants Hospital of Rhode Island",Oncology: Breast,Adjuvant; Maintenance/Consolidation; Stage II; Stage III,Breast Neoplasms,United States
Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer.,II,Terminated,"Roche/Genentech {Genentech}
Novartis
Yale University",Oncology: Breast,Estrogen receptor positive; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,United States
"A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients With HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab With Chemotherapy Plus Trastuzumab Plus Bevacizumab. 

Bevacizumab and Trastuzumab Adjuvant Therapy in HER2-positive Breast Cancer (BETH).",III,Terminated,"Roche/Genentech {Genentech}
Breast Cancer International Research Group
National Surgical Adjuvant Breast and Bowel Project (NSABP)
Roche {F. Hoffmann-La Roche}",Oncology: Breast,Adjuvant; HER2 positive; Stage I; Stage II; Stage III,Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Bosnia and Herzegovina; Brazil; Bulgaria; Canada; Chile; China; Colombia; Croatia; Czech Republic; Ecuador; Egypt; Estonia; France; Germany; Greece; Hong Kong, S.A.R., China; Hungary; India; Ireland; Israel; Italy; Latvia; Lebanon; Mexico; Peru; Philippines; Poland; Portugal; Romania; Russia; Serbia; Singapore; Slovenia; South Africa; South Korea; Spain; Sweden; Taiwan, China; Thailand; Tunisia; Turkey; United Kingdom; United States; Uruguay; Venezuela"
"An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in ""Triple Negative"" Breast Cancer.",III,Completed,"Roche/Genentech {Genentech}
Cancer Research UK",Oncology: Breast,Adjuvant; HER2 negative; Stage I; Stage II; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Bosnia and Herzegovina; Brazil; Canada; China; Costa Rica; Czech Republic; Finland; France; Germany; Greece; Hong Kong, S.A.R., China; Israel; Italy; Japan; Macedonia; Malaysia; Mexico; Netherlands; New Zealand; Peru; Philippines; Poland; Portugal; Romania; Russia; Serbia; Singapore; South Africa; South Korea; Spain; Sweden; Switzerland; Taiwan, China; Thailand; United Kingdom; United States"
"Endocrine Therapy With or Without Anti-VEGF Therapy: A Randomized, Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab (NSC 704865) for Women With Hormone Receptor-Positive Advanced Breast Cancer.",III,Completed,"Roche/Genentech {Genentech}
Cancer and Leukemia Group B (CALGB)
Eastern Cooperative Oncology Group (ECOG)
National Institutes of Health/National Cancer Institute
Alliance for Clinical Trials in Oncology",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms; Carcinoma,Puerto Rico; United States
"Double-Blind, Placebo-Controlled, Dose-Finding Study of the Effect of GTx-024 on Muscle Wasting (Cachexia) in Patients With Cancer",II,Completed,"Merck & Co.
Oncternal Therapeutics {GTx}","Oncology: Breast; Oncology: Colorectal; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Supportive Care",Aggressive; Cachexia; First line; Indolent; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Cachexia; Carcinoma, Non-Small-Cell Lung; Chronic Lymphocytic Leukemia; Colorectal Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Muscular Atrophy; Palliative Care",Argentina; Canada; United States
Effect of anastrozole treatment on estrogen and androgen levels in breast fluid.,Other,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Line of therapy N/A; Stage 0; Stage I,Breast Neoplasms,Japan; United States
A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women with Early Stage Breast Cancer.,II,Completed,Bristol-Myers Squibb,Oncology: Breast,HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage 0; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,"Argentina; Austria; France; Germany; India; Italy; Peru; Philippines; Russia; Singapore; South Korea; Spain; Taiwan, China; United Kingdom; United States"
"A Phase II, Double-Blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of AZD2171 in Combination With Fulvestrant vs Fulvestrant Alone in Hormone Sensitive (ER+ve or PgR+ve) Post Menopausal Metastatic Breast Cancer Patients",II,Completed,AstraZeneca,Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,Australia; Brazil; United States
"A Multicenter, Open-Label, Single Arm Phase II Trial Investigating the Efficacy and Tolerability of Vinorelbine, Carboplatin and Trastuzumab for the First-Line Treatment of Metastatic Breast Cancer in Women with HER2+ Disease.",II,Completed,Roche/Genentech {Genentech},Oncology: Breast,First line; HER2 positive; Stage IV,Breast Neoplasms,United States
"A Phase IIa, Open Label, Controlled, Dose Ranging Study of Maxy G34 as an Adjunct to TAC Chemotherapy in High Risk Patients With Stage I, II, or IIIa Breast Cancer.",II,Completed,Maxygen,Oncology: Breast; Oncology: Supportive Care,First line; Neutropenia; Stage I; Stage II; Stage III,Breast Neoplasms; Neutropenia; Palliative Care,Germany; Poland; Romania; Russia; Ukraine; United States
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.,II,Terminated,Pfizer,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Cancer",Line of therapy N/A; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms; Unspecified",Canada; France; Germany; Italy; Spain; United Kingdom; United States
Phase II Trial of Patupilone in Patients With Brain Metastases From Breast Cancer,II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; First line; Second line; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
"A Phase III, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer

CLinical Evaluation Of Pertuzumab And TRAstuzumab (CLEOPATRA)",III,Completed,"Roche/Genentech {Genentech}
Roche {F. Hoffmann-La Roche}",Oncology: Breast,First line; HER2 positive; Stage IV,Breast Neoplasms,"Argentina; Brazil; Canada; Chile; China; Costa Rica; Croatia; Ecuador; Finland; France; Germany; Guatemala; Hong Kong, S.A.R., China; Italy; Japan; Latvia; Macedonia; Mexico; Philippines; Poland; Russia; Singapore; South Korea; Spain; Switzerland; Thailand; United Kingdom; United States"
Phase II Trial of Vinfluinine and Capecitabine in Previously Treated Metastatic Breast Cancer.,II,Terminated,"North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute",Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
Phase II Study of Neoadjuvant Treatment With NOV-002 in Combination With Doxorubicin and Cyclophosphamide Followed by Docetaxel in Patients With Stages IIB-IIIC Breast Cancer,II,Completed,"Sylvester Cancer Center, University of Miami
Cellectar Biosciences {Novelos}",Oncology: Breast,HER2 negative; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
"A Phase II, Open-Label, Multicenter, Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer.",II,Completed,Sanofi {Sanofi-Aventis},Oncology: Breast,Adjuvant; HER2 negative; HER2 positive; Maintenance/Consolidation; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
"A Phase II, Open-Label Study of the Clinical Activity, Safety, and Tolerability of Lapatinib in Combination With Bevacizumab in Subjects With Advanced or Metastatic ErbB2-Overexpressing Breast Cancer",II,Completed,"GlaxoSmithKline
Novartis",Oncology: Breast,First line; HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy.,II,Terminated,GlaxoSmithKline,Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; HER2 positive; Second line; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,Austria; Canada; France; Germany; Greece; Ireland; Israel; Italy; Spain; Sweden; United States
A Multicenter Randomized Open Label Phase III Study in the First Line Treatment of Advanced/Metastatic HER2-Positive Breast Cancer Patients Comparing Trastuzumab Plus Vinflunine (TV) versus Trastuzumab plus Paclitaxel (TP).,III,Terminated,Pierre Fabre,Oncology: Breast,First line; HER2 positive; Stage III; Stage IV,Breast Neoplasms,Belgium; France; United States
Phase II Study of Cardiac Safety and Tolerability of an Adjuvant Chemotherapy Plus Trastuzumab With Lapatinib in Patients With Resected HER2 + Breast Cancer,II,Completed,"GlaxoSmithKline
National Institutes of Health/National Cancer Institute
Mayo Clinic Cancer Center
Breast Cancer Research Foundation",Oncology: Breast,Adjuvant; HER2 positive; Stage 0; Stage I; Stage II; Stage III,Breast Neoplasms; Cardiotoxicity,United States
A Phase II Study of Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Locally Advanced or Primary Metastatic Breast Cancer,II,Terminated,"H. Lee Moffitt Cancer Center and Research Institute
University of California, San Francisco",Oncology: Breast,Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
A Phase II Pilot Study of Sequential High Dose Chemotherapy and CD 34+ Selected Stem Cell Support Without Conventional-Dose Induction Chemotherapy for Women With Metastatic Breast Cancer,II,Completed,"National Institutes of Health/National Cancer Institute
Robert H. Lurie Comprehensive Cancer Center at Northwestern University",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
Menopausal status and estrogen receptor genotypes influenced the severity of hot flashes after tamoxifen treatment.,Other,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
A Double-Blinded Phase II Study of the Expression of Ki-67/MIB-1 in Women with Hyperplasia of the Breast Randomized to Receive Daily Celecoxib 400 mg BID or Placebo,II,Completed,"University of Kansas
Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}",Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
"Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer.",II,Terminated,"National Institutes of Health/National Cancer Institute
Center for Cancer Research
National Institutes of Health",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
"A Randomized, Phase lll Study of Sunitinib In Combination with Capecitabine Compared with Capecitabine In Patients with Previously Treated Breast Cancer",III,Completed,Pfizer,Oncology: Breast,HER2 negative; HER2 positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,Austria; Belgium; Canada; Czech Republic; Denmark; France; Germany; Greece; Ireland; Italy; Netherlands; Norway; Poland; Romania; Russia; Spain; United Kingdom; United States
"A Multicenter, Phase II, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer",II,Terminated,"Roche/Genentech {Genentech}
Pfizer",Oncology: Breast,First line; HER2 negative; Stage IV; Triple receptor negative,Breast Neoplasms,United States
A phase II study of ZD9331 treatment for relapsed or refractory breast cancer,II,Completed,Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center},Oncology: Breast,(N/A); Second line,Breast Neoplasms,United States
"A Multicenter Phase II, Randomized Study Comparing RPR 116258A Administered as a 1-Hour Intravenous Infusion Either Weekly (D1, D8, D15, D22 Every Five Weeks) or Every Three Weeks Versus RPR 109881A as a 1-Hour Intravenous Infusion Every Three Weeks in Taxoid Resistant Metastatic Breast Cancer Patients.",II,Terminated,Sanofi {Sanofi-Aventis {Aventis}},Oncology: Breast,Second line; Stage IV,Breast Neoplasms,Austria; Canada; Germany; Spain; United States
An Open-Label Sunitinib Malate (SU011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment,III,Completed,Pfizer,Oncology: Breast; Oncology: GIST; Oncology: Pancreas; Oncology: Renal,Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Adenoma, Islet Cell; Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Islet Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Gastrointestinal Stromal Tumors; Kidney Neoplasms; Lung Neoplasms; Neoplasms; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Thyroid Neoplasms; Wilms Tumor","Argentina; Australia; Belgium; Brazil; Bulgaria; Canada; Colombia; Denmark; France; Germany; Hong Kong, S.A.R., China; India; Mexico; Netherlands; Philippines; Singapore; South Korea; Spain; Taiwan, China; United Kingdom; United States"
Mini-Allogeneic Peripheral Blood Progenitor Cell Transplantation For Recurrent or Metastatic Breast Cancer,II,Completed,"MD Anderson Cancer Center, University of Texas",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
"A multicenter, phase III randomized trial comparing docetaxel in combination with doxorubicin (A.T.) versus doxorubicin in combination with cyclophosphamide (A.C.) as first line chemotherapy for metastastic breast cancer.",III,Completed,Sanofi {Sanofi-Aventis {Aventis {Rhone Poulenc Rorer SA}}},Oncology: Breast,First line; Stage IV,Breast Neoplasms,Argentina; Australia; Canada; France; Hungary; New Zealand; Poland; South Africa; Spain; United Kingdom; United States
Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Breast,II,Terminated,Burzynski Research Institute,Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
Phase II Study of Purging of Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer Patients.,II,Completed,"MD Anderson Cancer Center, University of Texas",Oncology: Breast,Line of therapy N/A; Stage IV,"Breast Neoplasms; Carcinoma; Neoplastic Cells, Circulating",United States
Phase II Prospective Study of Body Surface Area (BSA) as a Determinant of Paclitaxel Pharmacokinetics in Women With Recurrent Solid Tumors.,II,Completed,"Bristol-Myers Squibb
Cancer and Leukemia Group B (CALGB)
National Institutes of Health/National Cancer Institute","Oncology: Breast; Oncology: Lung, Non-Small Cell",(N/A); Second line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms",United States
Phase III Randomized Study of a Goserelin Acetate for Preservation of Ovarian Function in Patients With Primary Breast Cancer (PBC).,III,Terminated,"MD Anderson Cancer Center, University of Texas",Oncology: Breast,Adjuvant; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,Japan; United States
Phase II Study of 153 Sm-EDTMP Followed by Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases,II,Completed,"MD Anderson Cancer Center, University of Texas
Jazz Pharmaceuticals {Jazz Pharmaceuticals/EUSA Pharma {Cytogen}}",Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; Estrogen receptor positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms; Neoplasm Metastasis,United States
"Phase II Trial of Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients.",II,Completed,"Roche/Genentech {Genentech}
(Other Academic Cancer Center)
University of Pittsburgh",Oncology: Breast,First line; HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
A Phase II Trial of Perillyl Alcohol (NSC 641066) Administered Daily in Patients With Metastatic Breast Cancer.,II,Terminated,"National Institutes of Health/National Cancer Institute
University of Wisconsin",Oncology: Breast,Estrogen receptor positive; Second line; Stage IV,Breast Neoplasms,United States
Phase II Study of Fenretinide and Tamoxifen Prior to Definitive Surgery for Breast Neoplasia,II,Completed,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast,Estrogen receptor positive; Neoadjuvant; Stage 0; Stage I; Stage II,Breast Neoplasms,United States
Phase II Study of Irinotecan in Patients With Metastatic or Recurrent Breast Cancer.,II,Completed,"National Institutes of Health/National Cancer Institute
Robert H. Lurie Comprehensive Cancer Center at Northwestern University",Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Phase II Trial of Delayed Adjuvant Herceptin in Patients With HER-2 Positive Breast Cancer.,II,Terminated,University of California Los Angeles,Oncology: Breast,Adjuvant; HER2 positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
A Pilot Phase II Trial of Temozolomide in Leptomeningeal Metastases,II,Terminated,"National Institutes of Health/National Cancer Institute
Dartmouth-Hitchcock Norris Cotton Cancer Center
Dartmouth-Hitchcock Medical Center","Oncology: Breast; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Neuroendocrine; Oncology: Renal",(N/A); CNS mets; Pulmonary; Second line; Stage IV,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Renal Cell; Carcinoma, Small Cell; Central Nervous System Neoplasms; Kidney Neoplasms; Melanoma; Meningeal Carcinomatosis; Neoplasm Metastasis; Neoplasms; Neoplasms, Second Primary; Nervous System Neoplasms; Neuroendocrine Tumors; Renal Cancer; Small Cell Lung Carcinoma; Wilms Tumor",United States
Phase II Trial of Fulvestrant and Bevacizumab in Patients with Metastatic Breast Cancer Previously Treated with an Aromatase Inhibitor,II,Terminated,"North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute
Alliance for Clinical Trials in Oncology",Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
"A Phase II Trial of Preoperative Cisplatin and Bevacizumab in Estrogen Receptor (ER) Negative, Progesterone (PR) Negative, Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer",II,Completed,"Roche/Genentech {Genentech}
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Beth Israel Deaconess Medical Center
Massachusetts General Hospital
Brigham and Womens Hospital",Oncology: Breast,Adjuvant; HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
"Complete pathologic response in patients receiving neoadjuvant dose dense chemotherapy using doxorubicin or epirubicin, cyclophosphamide and docetaxel.",II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
"A Double-Blind, Randomized Phase IIb Study of Sorafenib Compared to Placebo When Administered in Combination With Chemotherapy for Patients With Locally Advanced or MBC That Has Progressed During or After Bevacizumab Therapy.",II,Completed,"(Other Cooperative Group)
Amgen {Onyx Pharmaceuticals}",Oncology: Breast,First line; HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms,United States
MRI measures of tumor size and pharmacokinetic parameters as early response predictors in breast cancer receiving AC neoadjuvant chemotherapy.,II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,(N/A); Neoadjuvant,Breast Neoplasms,United States
Phase II Study of O6-Benzylguanine in Patients With Surgically Resectable Solid Tumors,II,Completed,"National Institutes of Health/National Cancer Institute
University of Chicago Cancer Research Center",Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Melanoma; Oncology: Renal; Oncology: Soft Tissue Sarcoma,First line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A pilot study of growth factor (GF) omission during paclitaxel (T) for women with early breast carcinoma (BC).,II,Terminated,Memorial Sloan-Kettering Cancer Center,Oncology: Breast,First line; Stage I; Stage II; Stage III,Breast Neoplasms,United States
A Pilot Study of Neoadjuvant Paclitaxel and Concurrent Radiation With Correlative Molecular Studies in Stage II/III Breast Cancer.,Other,Completed,Vanderbilt-Ingram Cancer Center,Oncology: Breast,Adjuvant; Estrogen receptor positive; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,United States
Randomized comparison of early vs. standard intervention with darbepoetin alfa (DA) for chemotherapy induced anemia (CIA) in early stage breast cancer (ESBC),III,Completed,Amgen,Metabolic/Endocrinology: Anemia; Oncology: Breast; Oncology: Supportive Care,Anemia; Cancer-related; Neoadjuvant; Stage 0; Stage I; Stage II,Anemia; Breast Neoplasms; Palliative Care,United States
"Phase II trial of neoadjuvant dose dense chemotherapy for breast cancer with weekly docetaxel and capecitabine, followed by doxorubicin and cyclophosphamide with peg-filgrastim support.",II,Completed,Indiana University Cancer Center,Oncology: Breast,Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
"A Pilot Study of Vitamin D Deficiency and Myalgias, Arthralgias and/or Joint Stiffness Associated With Letrozole (Femara).",II,Completed,"Novartis
National Institutes of Health/National Cancer Institute
University of Washington",Oncology: Breast,Adjuvant; Stage I; Stage II; Stage III,Arthralgia; Breast Neoplasms; Vitamin D Deficiency,United States
Bevacizumab (avastin) and albumin bound paclitaxel (abraxane) treatment in metastatic breast cancer.,II,Completed,Roche/Genentech {Genentech},Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
A phase II study of bi-weekly docetaxel as first-line therapy for metastatic breast cancer.,II,Completed,Sanofi {Sanofi-Aventis},Oncology: Breast,First line; Stage IV,Breast Neoplasms,United States
"Prospective Evaluation of Paclitaxel Versus Combination Chemotherapy with Fluorouracil, Doxorubicin, and Cyclophosphamide as Neoadjuvant Therapy in Patients with Operable Breast Cancer.",III,Completed,"Bristol-Myers Squibb
MD Anderson Cancer Center, University of Texas",Oncology: Breast,Adjuvant; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
An Open-Label Randomized Phase III Study of Capecitabine in Combination with Docetaxel (Taxotere) Versus Docetaxel Monotherapy in Patients with Advanced and/or Metastatic Breast Cancer.,III,Completed,Roche {F. Hoffmann-La Roche},Oncology: Breast,First line; Second line; Stage III; Stage IV,Breast Neoplasms,"Argentina; Australia; Brazil; Canada; France; Germany; Israel; Italy; Mexico; New Zealand; Norway; Russia; Spain; Taiwan, China; United Kingdom; United States"
A North American Fareston versus Tamoxifen Adjuvant trial for Breast Cancer (NAFTA trial) : A Phase II Study of Tamoxifen vs. Fareston as Adjuvant Therapy for Women with Carcinoma of the Breast.,III,Completed,Merck & Co. {Schering-Plough},Oncology: Breast,Adjuvant; Estrogen receptor positive; Progesterone receptor positive; Stage I; Stage II,Breast Neoplasms,United States
Alpha6beta4 integrin expression in node-positive breast carcinoma is associated with HER-2/neu overexpression.,Other,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,HER2 positive; Line of therapy N/A; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study.,II/III,Completed,"Novartis
(Other Cooperative Group)",Oncology: Breast,Estrogen receptor positive; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,Brazil; France; Germany; Japan; Russia; South Africa; Spain; United Kingdom; United States
registHER: An Observational Cohort Study of Patients With HER2 Positive Metastatic Breast Cancer.,IV,Completed,Roche/Genentech {Genentech},Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase II Study of Rapamycin (Rapamune, Sirolimus) and Trastuzumab (Herceptin) for Patients With HER-2 Receptor Positive Metastatic Breast Cancer",II,Terminated,"Roche/Genentech {Genentech}
Yale University",Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
"PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expressions with NeuVax Treatment",III,Terminated,"North Central Cancer Treatment Group (NCCTG)
SELLAS Life Sciences Group {Galena Biopharma {RXi Pharmaceuticals {Apthera}}}",Oncology: Breast,Adjuvant; HER2 negative; Stage II; Stage III,Breast Neoplasms; Recurrence,Bulgaria; Canada; Czech Republic; France; Germany; Hungary; Israel; Poland; Romania; Russia; Singapore; South Korea; Ukraine; United Kingdom; United States
An Evaluation of the Tissue Distribution and the Selective Tumor Trafficking of TNF-Bound Colloidal Gold (CYT-6091) Following Intravenous Administration in Subjects with Primary and Metastatic cancer Undergoing Surgical Resection,Other,Completed,"National Institutes of Health/National Cancer Institute
Center for Cancer Research
CytImmune Sciences",Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Renal; Oncology: Soft Tissue Sarcoma,Metastatic; Neoadjuvant; Stage IV,"Adrenocortical Carcinoma; Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Gastrointestinal Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasm Metastasis; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Wilms Tumor",United States
Phase II Studies of Two Different Schedules of Dasatinib (NSC-732517) in Bone Metastasis Predominant Metastatic Breast Cancer,II,Completed,"Southwest Oncology Group
National Institutes of Health/National Cancer Institute",Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms; Neoplasm Metastasis,United States
Phase II Trial of BIBW 2992 in Patients with HER2-Positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy.,II,Completed,Boehringer Ingelheim,Oncology: Breast,Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United Kingdom; United States
Phase II study of Nexavar in combination with aromatase inhibitors for patients with breast cancer.,II,Terminated,Amgen {Onyx Pharmaceuticals},Oncology: Breast,First line; Second line; Stage IV,Breast Neoplasms,United States
A Phase II Trial of Open-Label Bevacizumab Administered With Anastrozole or Fulvestrant as First-Line Therapy in Postmenopausal Hormone Receptor- Positive Metastatic Breast Cancer (With Trastuzumab in HER2-Positive Patients),II,Completed,"AstraZeneca
Roche/Genentech {Genentech}
Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}",Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,United States
Phase II Trial of Abraxane Administered on a Weekly Schedule in Combination With Bevacizumab in Metastatic Breast Cancer.,II,Completed,"Roche/Genentech {Genentech}
Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}}
Premiere Oncology",Oncology: Breast,First line; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"Phase II Open Label Study of Gemcitabine, Paclitaxel and Bevacizumab Combination as First Line Treatment for Metastatic Breast Cancer.",II,Completed,"Eli Lilly
Roche/Genentech {Genentech}",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage IV,Breast Neoplasms,United States
Phase II Neoadjuvant Chemotherapy Trial in Clinical Stage II/III Her2Neu Positive Breast Cancer With Sequential AC Docetaxel With Concurrent Dual EGFR Kinase Blockade by GW572016 (Lapatinib) Followed by 1 Year Adjuvant Trastuzumab.,II,Completed,"GlaxoSmithKline
Stanford University Medical Center
Sanofi {Sanofi-Aventis}",Oncology: Breast,Adjuvant; HER2 positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients.,II,Completed,Akebia Therapeutics {Keryx Biopharmaceuticals {Access Oncology/AOI Pharmaceuticals}},"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate",Fourth line or greater; Second line; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Neoplasm Metastasis; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms",United States
"Combination Capecitabine (Xeloda) and ABI-007 (Abraxane, Nanoparticle Albumin-Bound Paclitaxel) Chemotherapy as Neoadjuvant Treatment of Locally Advanced, Operable Breast Cancer",II/III,Terminated,Washington Hospital Center,Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
"A Feasibility Study of Combination Therapy With Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for HER-2/Neu-Overexpressing Metastatic Breast Cancer.",II,Completed,"Roche/Genentech {Genentech}
(Other Cooperative Group)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}
US Department of Defense
American Cancer Society
Cancer Treatment Research Foundation (CTRF)",Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Stage IV,Breast Neoplasms,United States
Phase III Randomized Comparison of Postoperative Adjuvant Hormonal Therapy with Tamoxifen vs Tamoxifen/Fluoxymesterone in Postmenopausal Women with ER-Positive Breast Cancer.,III,Completed,"North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute",Oncology: Breast,Adjuvant; Estrogen receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Intrathecal Chemotherapy with Liposomal Cytarabine for Neoplastic Meningitis in Patients with Non-Small Cell Lung Cancer and Breast Cancer.,II,Completed,Memorial Sloan-Kettering Cancer Center,"Oncology: Breast; Oncology: CNS, Other; Oncology: Lung, Non-Small Cell",Second line; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms",United States
A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens.,III,Completed,"Eli Lilly
National Surgical Adjuvant Breast and Bowel Project (NSABP)
National Institutes of Health/National Cancer Institute
Roche/Genentech",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,Canada; Puerto Rico; United States
Analysis of Gene Expression Following Short Term Exposure to Neoadjuvant Endocrine Therapy in Invasive Breast Cancer.,II,Completed,Memorial Sloan-Kettering Cancer Center,Oncology: Breast,Estrogen receptor positive; Neoadjuvant; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
Zoledronic Acid for Treatment of Osteopenia and Osteoporosis in Women With Primary Breast Cancer Undergoing Adjuvant Aromatase Inhibitor (Letrozole) Therapy.,II,Completed,"National Institutes of Health/National Cancer Institute
Mayo Clinic",Metabolic/Endocrinology: Osteoporosis; Oncology: Breast,Adjuvant; Chemotherapy-induced bone loss; Estrogen receptor positive; Neoadjuvant; Osteopenia; Postmenopausal women: treatment; Progesterone receptor positive; Stage I; Stage II; Stage III,"Bone Diseases, Metabolic; Breast Neoplasms; Osteoporosis",United States
A Randomized Phase III Study of Docetaxel In Combination With Sunitinib Versus Docetaxel In The First-Line Treatment Of Advanced Breast Cancer Patients,III,Completed,Pfizer,Oncology: Breast,First line; HER2 negative; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,Argentina; Australia; Austria; Belgium; Canada; Colombia; Czech Republic; Finland; France; Germany; Hungary; Ireland; Italy; Netherlands; Panama; Poland; Portugal; Romania; Russia; Slovakia; South Korea; Spain; Sweden; Turkey; Ukraine; United Kingdom; United States
Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes.,II,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Second line; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Second Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Wilms Tumor",United States
A Phase II Trial of Weekly Administration of ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer.,II,Completed,Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}},Oncology: Breast,First line; HER2 negative; HER2 positive; Stage IV,Breast Neoplasms,United States
Phase II Study of Preoperative Bevacizumab and Trastuzumab Administered With ABI-007 and Carboplatin in HER2 Overexpressing Breast Cancer,II,Completed,"Roche/Genentech {Genentech}
Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}
Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}}",Oncology: Breast,Adjuvant; HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"The ""EMBRACE"" Trial: Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389. A Phase III Open-Label, Randomized, Parallel, Two-Arm, Multi-Center Study of E7389 Versus ""Treatment of Physician's Choice"" in Patients With Locally Recurrent, Metastatic Breast Cancer, Previously Treated With At Least Two and a Maximum of Five Prior Chemotherapy Regimens, Including an Anthracycline and a Taxane",III,Completed,Eisai,Oncology: Breast,Fourth line or greater; HER2 negative; HER2 positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,Argentina; Australia; Austria; Belgium; Brazil; Canada; Croatia; Czech Republic; France; Germany; Hungary; Italy; Japan; Poland; Russia; South Africa; Spain; Switzerland; United Kingdom; United States
"Open Label, Uncontrolled, Study of XRP9881 (Larotaxel) in Combination With Weekly Trastuzumab (Herceptin) in Patients With HER2 Positive Metastatic Breast Cancer (MBC).",II,Terminated,Sanofi {Sanofi-Aventis},Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"Endocrine Therapy with or without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant with or without Lapatinib (GW572016) for Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer.",III,Terminated,"Southwest Oncology Group
National Institutes of Health/National Cancer Institute",Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms; Carcinoma,United States
A Phase II Study of Oral Enzastaurin in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane-Containing Regimen.,II,Terminated,Eli Lilly,Oncology: Breast,Estrogen receptor positive; HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment,III,Completed,"Cancer and Leukemia Group B (CALGB)
Southwest Oncology Group
National Institutes of Health/National Cancer Institute",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; HER2 positive; Maintenance/Consolidation; Progesterone receptor positive; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,Puerto Rico; United States
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer,III,Completed,"Novartis
National Surgical Adjuvant Breast and Bowel Project (NSABP)
National Institutes of Health/National Cancer Institute",Oncology: Breast,Adjuvant; Estrogen receptor positive; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,Canada; Ireland; United States
A Phase II Trial of Amrubicin With or Without Herceptin in the Treatment of Metastatic Breast Cancer.,II,Terminated,Bristol-Myers Squibb/Celgene {Pharmion {Cabrellis}},Oncology: Breast,HER2 negative; HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
"TheraSphere for the Treatment of Liver Metastases: An Open Label Trial of TheraSphere in Patients With Liver Metastases From Primary Colorectal Cancer, Neuroendocrine Cancer or Non-Colorectal/Non-Neuroendocrine Cancer.",II,Completed,"Serb Specialty Pharmaceuticals/BTG Specialty Pharmaceuticals {Boston Scientific/BTG}
Nordion {MDS Nordion}","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal",KRAS; Liver mets; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasm Metastasis; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"Phase II Study of Naltrexone for the Treatment of Hormone-Refractory, Metastatic Breast Cancer",II,Terminated,University of Minnesota,Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
"Adjuvant Therapy for High-Risk Localized Breast Cancer Using Weekly Adriamycin + Daily Oral Cytoxan With Continuous G-CSF Support for 12 Weeks Followed by Weekly Abraxane for 12 Weeks With Concurrent Herceptin for Subjects With HER-2/Neu Positive Disease, Phase II",II,Completed,"National Institutes of Health/National Cancer Institute
Fred Hutchinson Cancer Research Center
Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}}
University of Washington",Oncology: Breast,Adjuvant; HER2 positive; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
A Pilot Study of Bevacizumab With Dose Dense Doxorubicin and Cyclophosphamide (AC) Followed by Dose Dense Nanoparticle Albumin Bound Paclitaxel for the Treatment of Early Stage Breast Cancer,II,Completed,"Roche/Genentech {Genentech}
(Other Cooperative Group)
Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute
Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}}",Oncology: Breast,Adjuvant; HER2 negative; Maintenance/Consolidation; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"An Open-label, Randomized, Comparative Pilot Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer",II,Completed,Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}},Oncology: Breast,Adjuvant; Estrogen receptor positive; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC/TRICOM and Flutamide vs. Flutamide Alone in Men With Androgen Insensitive, Non-Metastatic (D0.5) Prostate Cancer",II,Completed,"National Institutes of Health/National Cancer Institute
Bavarian Nordic/BN ImmunoTherapeutics","Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Prostate",Hormone refractory; Line of therapy N/A; Stage I; Stage II; Stage III,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Liver Cancer; Liver Neoplasms; Prostatic Neoplasms",United States
"A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Adjuvant Lapatinib (GW572016) in Women With Early-Stage ErbB2 Overexpressing Breast Cancer. 

Tykerb Evaluation After Chemotherapy (TEACH).",III,Completed,"GlaxoSmithKline
Massachusetts General Hospital
National Health Service (NHS) - UK",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Stage 0; Stage I; Stage II; Stage III,Breast Neoplasms,"Argentina; Australia; Belgium; Brazil; Canada; Chile; China; Croatia; Czech Republic; Denmark; France; Germany; Greece; Hong Kong, S.A.R., China; Hungary; India; Israel; Italy; Latvia; Lithuania; Mexico; New Zealand; Peru; Philippines; Poland; Russia; Slovakia; South Africa; South Korea; Spain; Ukraine; United Kingdom; United States"
"A Phase II, Randomised, Open-Label, Multicentre Study of AS1402 in Combination With Letrozole as First Line Treatment in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer",II,Terminated,Antisoma,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,Russia; United States
S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623,II,Completed,"Southwest Oncology Group
National Institutes of Health/National Cancer Institute",Oncology: Breast,Adjuvant; Stage II; Stage III,Breast Neoplasms,United States
Dose-Dense Adjuvant Chemotherapy Plus Bevacizumab in Lymph Node Positive Breast Cancer: A Pilot Study.,II,Completed,"Roche/Genentech {Genentech}
Premiere Oncology",Oncology: Breast,Adjuvant; Stage II; Stage III,Breast Neoplasms,United States
"A Two-Arm Randomized Open Label Phase II Study Of CP-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer.",II,Terminated,Pfizer,Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,Argentina; Belgium; Brazil; Canada; Italy; Netherlands; Sweden; United Kingdom; United States
Phase II Study of Dasatinib (BMS-354825) for Advanced 'Triple-Negative' Breast Cancer.,II,Completed,Bristol-Myers Squibb,Oncology: Breast,HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Belgium; France; Italy; Spain; United States
Phase II Study of Dasatinib (BMS-354825) for Advanced Estrogen/Progesterone Receptor-Positive or Her2/Neu-Positive Breast Cancer.,II,Completed,Bristol-Myers Squibb,Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,Argentina; Belgium; France; Italy; Peru; Spain; United States
"Three-arm study of lapatinib in combination with doxorubicin, cyclophosphamide and trastuzumab in the adjuvant setting in HER2+ breast cancer patients.",III,Terminated,North Central Cancer Treatment Group (NCCTG),Oncology: Breast,Adjuvant; HER2 positive; Stage I; Stage II,Breast Neoplasms,Canada; United States
Phase II Trial of High Dose Chemotherapy with Peripheral Stem Cell Infusion in Women with Locally Advanced Breast Cancer.,II,Completed,"(Other Cooperative Group)
Fox Chase Cancer Center",Oncology: Breast,Estrogen receptor positive; First line; Maintenance/Consolidation; Stage III,Breast Neoplasms,United States
"A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab as First Line Therapy for Locally Recurrent or Metastatic Breast Cancer.",II,Completed,Bristol-Myers Squibb,Oncology: Breast,First line; HER2 negative; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,France; Italy; Spain; United Kingdom; United States
Collection of Skin Biopsy With Hair Follicles as Surrogate to Develop Biomarker Assays From Patients With Advanced Solid Tumor Malignancies Receiving Either Single Agent Weekly Irinotecan or Gemcitabine.,Other,Completed,"AstraZeneca
Barbara Ann Karmanos Cancer Institute
National Institutes of Health/National Cancer Institute",Oncology: Breast; Oncology: Colorectal; Oncology: Pancreas,Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms,United Kingdom; United States
"Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain.",III,Completed,"National Institutes of Health/National Cancer Institute
Pfizer
Comprehensive Cancer Center of Wake Forest University
Eisai","Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Metastatic Cancer; Oncology: Prostate; Oncology: Supportive Care",CNS mets; Neurotoxicity; Second line; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Glioblastoma; Medulloblastoma; Neoplasm Metastasis; Palliative Care; Prostatic Neoplasms,United States
Phase II Trial of VEGF Trap in Patients With Metastatic Breast Cancer Previously Treated With Anthracycline and/or Taxane,II,Terminated,"North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute
Regeneron
Sanofi {Sanofi-Aventis}",Oncology: Breast,HER2 positive; Second line; Stage IV; Third line,Breast Neoplasms,United States
"Effects of Soy Isoflavones on the Prostate, Breast and Bone",II,Completed,National Institutes of Health/National Center for Complementary and Alternative Medicine,Oncology: Breast; Oncology: Prostate,(N/A); Neoadjuvant,Breast Neoplasms; Prostatic Neoplasms,United States
Phase II Study of PALA in Combination with 5-FU in Recurrent or Metastatic Breast Cancer.,II,Terminated,Fox Chase Cancer Center,Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
Serum carboxyterminal telopeptide (ICTP) as a prognostic marker in bone metastases (BM) treated with bisphosphonates.,II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast; Oncology: Metastatic Cancer; Oncology: Prostate,Bone mets; Line of therapy N/A; Stage IV,Breast Neoplasms; Neoplasm Metastasis; Prostatic Neoplasms,Portugal; United States
Assessment of circulating tumor cells in breast cancer patients undergoing neoadjuvant chemotherapy.,II,Completed,"(Other Industry Sponsor)
University of Michigan Comprehensive Cancer Center",Oncology: Breast,Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
An Open-Label Phase II Study of Aprepitant for Multi-Day Moderately-High to Highly Emetogenic Chemotherapy Regimens.,II,Completed,"Merck & Co.
NorthWestern Memorial Hospital
University of Illinois at Chicago Health Sciences Center
Johnson & Johnson/Janssen Pharmaceuticals {Johnson & Johnson/Ortho-McNeill}","Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Supportive Care",(N/A); Emesis; Line of therapy N/A,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Nausea; Ovarian Cancer; Ovarian Neoplasms; Palliative Care; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Vomiting",United States
"A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study Of The Safety And Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist, Casopitant (Gw679769) in Combination with Ondansetron and Dexamethasone for the Prevention of Nausea and Vomiting induced by Moderately Emetogenic Chemotherapy",III,Completed,GlaxoSmithKline,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Supportive Care",(N/A); Aggressive; Classical; Emesis; First line; Indolent; Nodular lymphocyte-predominant; Untreated,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Mesothelioma; Nausea; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Palliative Care; Small Cell Lung Carcinoma; Vomiting","Argentina; Austria; Belgium; Bulgaria; Canada; Croatia; Czech Republic; Denmark; Estonia; Germany; Greece; Hong Kong, S.A.R., China; Hungary; India; Ireland; Italy; Latvia; Lithuania; Mexico; Pakistan; Peru; Philippines; Poland; Russia; Slovakia; South Africa; South Korea; Spain; Taiwan, China; Thailand; United Kingdom; United States"
Surrogate Endpoints in Prevention Studies and Ductal Lavage.,II,Completed,"National Institutes of Health/National Cancer Institute
Robert H. Lurie Comprehensive Cancer Center at Northwestern University",Oncology: Breast,Estrogen receptor positive; Line of therapy N/A; Stage 0; Stage I,Breast Neoplasms,United States
Pharmacogenetics of Aromatase Inhibitors.,Other,Completed,"National Institutes of Health/National Cancer Institute
Mayo Clinic",Oncology: Breast,Estrogen receptor positive; Line of therapy N/A; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Impact of Neoadjuvant Chemotherapy With or Without Zometa on Occult Micrometastases and Bone Density in Women With Locally Advanced Breast Cancer.,II,Completed,"Novartis
Pfizer
Washington University School of Medicine",Oncology: Breast; Oncology: Metastatic Cancer,Adjuvant; Bone mets; Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage II; Stage III,Breast Neoplasms; Neoplasm Metastasis,United States
A Phase IV Trial of Cesamet Given With Standard Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting.,IV,Terminated,"Bausch Health Companies {Valeant Pharmaceuticals}
International Oncology Network","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Supportive Care",(N/A); Emesis; Line of therapy N/A,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Nausea; Palliative Care; Vomiting",United States
"Phase II Trial of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) in Combination With Tamoxifen for Patients With Advanced Breast Cancer who Have Failed Prior Anti-hormonal Therapy",II,Completed,"Merck & Co.
H. Lee Moffitt Cancer Center and Research Institute",Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase IIb, Randomized, Multicenter, Noncomparative Pilot Study of the Safety and Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab + or - Trastuzumab for the Adjuvant Treatment of Patients with Node-Positive and High-Risk Node-Negative Breast Cancer",II,Completed,Sanofi {Sanofi-Aventis},Oncology: Breast,Adjuvant; HER2 positive; Maintenance/Consolidation; Stage I; Stage II; Stage III,Breast Neoplasms,United States
The Use of Vitamin E for Prevention of Chemotherapy Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study,III,Completed,"North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Supportive Care; Oncology: Unspecified Cancer",(N/A); Line of therapy N/A; Neurotoxicity,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms; Neurotoxicity Syndromes; Palliative Care; Peripheral Nervous System Diseases",United States
"A Pilot, Phase II, Multicenter, Open-Label, Prospective Evaluation of Docetaxel and Bevacizumab + or - Trastuzumab in the First-Line Treatment of Patients With Metastatic Breast Cancer",II,Completed,Sanofi {Sanofi-Aventis},Oncology: Breast,First line; HER2 positive; Stage IV,Breast Neoplasms,United States
Development of HER-2/Neu (HER2) ICD Memory Immunity After Vaccination With a Plasmid Encoding HER2 ICD in Patients With Advanced Stage HER2 Overexpressing Breast and Ovarian Cancers,Other,Completed,"National Institutes of Health/National Cancer Institute
University of Washington",Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
Early Assessment of Response to Targeted Breast Cancer Therapy.,Other,Completed,"National Institutes of Health/National Cancer Institute
Fred Hutchinson Cancer Research Center
University of Washington/Seattle Cancer Care Alliance",Oncology: Breast,First line; HER2 positive; Stage IV,Breast Neoplasms,United States
"Phase III randomized multicenter trial of surgical resection, BCNU-impregnated wafers, and irradiation versus surgical resection and irradiation alone for treatment of operable, solitary brain metastasis from systemic cancer.",III,Terminated,Sanofi {Sanofi-Aventis {Aventis {Rhone Poulenc Rorer SA}}},"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer",CNS mets; Line of therapy N/A; Stage IV,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Neoplasm Metastasis",United States
Phase II Trial of CCI-779 (Temsirolimus) in Patients with Locally Advanced or Metastatic Breast Cancer.,II,Terminated,"National Institutes of Health/National Cancer Institute
University of Chicago Cancer Research Center",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
A Phase II Study of Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Patients With Carcinoma of Unknown Primary Site.,II,Completed,"Roche/Genentech {Genentech}
Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}",Oncology: Breast; Oncology: Prostate; Oncology: Unspecified Cancer,First line; Maintenance/Consolidation; Stage IV,"Breast Neoplasms; Carcinoma; Neoplasms; Neoplasms, Unknown Primary; Prostatic Neoplasms",United States
A Trial of Carboxypeptidase-G2 (CPDG2) for the Management of Patients With Intrathecal Methotrexate Overdose.,II,Completed,"National Institutes of Health/National Cancer Institute
Children’s Oncology Group","Oncology: Breast; Oncology: Leukemia, Acute Lymphocytic; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Supportive Care",(N/A); Aggressive; Indolent; Line of therapy N/A; Neurotoxicity,"Breast Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neurotoxicity Syndromes; Palliative Care; Precursor Cell Lymphoblastic Leukemia-Lymphoma",Australia; Canada; Switzerland; United States
"Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer.",III,Terminated,"Radiation Therapy Oncology Group (RTOG)
National Institutes of Health/National Cancer Institute
Jazz Pharmaceuticals {Jazz Pharmaceuticals/EUSA Pharma {Cytogen}}
NRG Oncology","CNS: Pain (nociceptive); Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer; Oncology: Prostate",Bone mets; Cancer-related; Line of therapy N/A; Stage IV,"Breast Neoplasms; Cancer pain; Cancer Pain; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Neoplasm Metastasis; Nociceptive Pain; Prostatic Neoplasms",Canada; United States
A Trial Assessing the Effect of Simvastatin on the Pharmacokinetics of Anastrozole,II,Completed,"National Institutes of Health/National Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}",Oncology: Breast,Line of therapy N/A; Stage 0; Stage I; Stage II; Stage III,Breast Neoplasms; Carcinoma in Situ,United States
A Pilot Trial Correlating Metabolic Profile of Tamoxifen With Pharmacogenetic Predictors and Clinical Effects,IV,Completed,"Indiana University School of Medicine
National Institutes of Health/National Institute of General Medical Sciences",Oncology: Breast,(N/A); Adjuvant; Estrogen receptor positive; Progesterone receptor positive,Breast Neoplasms,United States
"Antimetabolite Induction, High-Dose Alkylating Agent Consolidation and Retroviral Transduction of the MDR1 Gene Into Peripheral Blood Progenitor Cells Followed by Intensification Therapy With Sequential Paclitaxel and Doxorubicin for Stage 4 Breast Cancer.",II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,First line; Maintenance/Consolidation; Stage IV,Breast Neoplasms; Multiple Myeloma; Neoplasm Metastasis; Neoplasms,United States
"A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer.",II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Maintenance/Consolidation; Second line; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
"Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells",Other,Open,Washington University School of Medicine,Oncology: Breast,Adjuvant; HER2 positive; Neoadjuvant; Stage II; Stage III; Stage IV,Bone Marrow Neoplasms; Breast Neoplasms,United States
A Pilot Study of Cytochrome P450 Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early Breast Cancer,IV,Terminated,Indiana University School of Medicine,Oncology: Breast,Adjuvant; Stage 0; Stage I; Stage II,Breast Neoplasms,United States
"MINDACT (Microarray In Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy): A Prospective, Randomized Study Comparing the 70-Gene Signature With the Common Clinical-Pathological Criteria in Selecting Patients for Adjuvant Chemotherapy in Breast Cancer With 0 to 3 Positive Nodes.",III,Completed,"Eli Lilly
Novartis
(Other Cooperative Group)
Breast International Group
National Institutes of Health/National Cancer Institute
Cancer Research UK
Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}
National Health Service (NHS) - UK
EORTC Breast Cancer Group
Dutch Cancer Society
Roche {F. Hoffmann-La Roche}
Sanofi {Sanofi-Aventis}
Breast Cancer Research Foundation
Johnson & Johnson/Janssen Diagnostics {Veridex {Immunicon}}",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,Belgium; France; Germany; Ireland; Italy; Netherlands; Poland; Portugal; Slovenia; Spain; Switzerland; United Kingdom; United States
A Multimodality Treatment Approach to Patients With Inflammatory Cancer of the Breast and Locally Advanced Non-Inflammatory Stage III Breast Cancer and Stage IV Breast Cancer,II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Maintenance/Consolidation; Stage III; Stage IV,Breast Neoplasms; Neoplasm Metastasis; Neoplasms,United States
"Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study: A Randomised, Multicenter Open-label Phase III Study of Neoadjuvant Lapatinib, Trastuzumab and Their Combination Plus Paclitaxel in Women With HER2/ErbB2 Positive Primary Breast Cancer",III,Completed,"GlaxoSmithKline
Novartis
Breast International Group
Spanish Breast Cancer Research Group",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; KRAS; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,"Argentina; Belgium; Brazil; Canada; Czech Republic; France; Germany; Hong Kong, S.A.R., China; Hungary; India; Italy; Lithuania; Norway; Peru; Romania; Russia; South Africa; South Korea; Spain; Sweden; Taiwan, China; Ukraine; United Kingdom; United States"
Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast,II,Completed,"Roche/Genentech {Genentech}
MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast,HER2 positive; Neoadjuvant; Stage 0,"Breast Carcinoma In Situ; Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Intraductal, Noninfiltrating",United States
A Phase II Trial of Lovastatin for Modification of Abnormal Breast Duct Cytology and Risk-Associated Biomarkers in Women at High Inherited Risk of Breast Cancer,II,Terminated,"Stanford University Medical Center
Breast Cancer Research Foundation",Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
"A Phase 2, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of SNX-1012 in Reducing the Duration and Severity of Ulcerative Oral Mucositis in Patients Receiving Cytotoxic Chemotherapy for Breast or Lung Cancer.",II,Completed,Coserics,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Supportive Care",First line; Mucositis; Pulmonary; Untreated,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Mucositis; Neuroendocrine Tumors; Palliative Care; Small Cell Lung Carcinoma; Stomatitis",India; United States
A pilot study of physiologic imaging in breast cancer patients treated with SU011248.,II,Completed,Indiana University Cancer Center,Oncology: Breast,(N/A); Second line,Breast Neoplasms,United States
Women’s Health Initiative (WHI),III,Completed,"National Institutes of Health/National Cancer Institute
National Institutes of Health/National Heart, Lung, and Blood Institute
National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Center for Research Resources
National Institutes of Health/National Institute on Aging
(Other government agency)",Genitourinary: Menopausal Symptoms; Metabolic/Endocrinology: Osteoporosis; Oncology: Breast; Oncology: Colorectal,(N/A); Line of therapy N/A; Postmenopausal women: prevention; Postmenopausal women: treatment,Bone Diseases; Breast Neoplasms; Cardiovascular Diseases; Colonic Neoplasms; Colorectal Neoplasms; Coronary Artery Disease; Coronary Disease; Menopause; Myocardial Ischemia; Neoplasms; Osteoporosis,United States
"Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.",II,Completed,"National Institutes of Health/National Cancer Institute
Eisai {MGI Pharma}
(Other Hospital/Academic/Medical Center)",Oncology: Breast; Oncology: Supportive Care,Adjuvant; Emesis; Stage III; Stage IV,Breast Neoplasms; Palliative Care; Vomiting,United States
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases,II,Completed,Novartis,Oncology: Breast; Oncology: Colorectal; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome; Oncology: Myeloproliferative Neoplasms; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Renal; Oncology: Soft Tissue Sarcoma,(N/A); Hypereosinophilic Syndrome; Second line; Systemic Mastocytosis,"Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Hypereosinophilic Syndrome; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Mastocytosis, Systemic; Melanoma; Mesothelioma; Multiple Myeloma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasms, Mesothelial; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Rare Diseases; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",Australia; Belgium; Canada; Finland; Netherlands; Switzerland; United Kingdom; United States
High dose chemotherapy with autologous stem cell rescue as a part of combined modality therapy in stage IIIB inflammatory breast cancer.,II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Estrogen receptor positive; First line; Stage III,Breast Neoplasms,United States
"A Phase II Study to Evaluate the Efficacy, Safety, and Genomic Markers of Response of Capecitabine as NeoAdjuvant Therapy in Women With Newly Diagnosed Locally Advanced Breast Cancer",II,Terminated,"University of Chicago Cancer Research Center
Roche {F. Hoffmann-La Roche}
Breast Cancer Research Foundation",Oncology: Breast,HER2 negative; Neoadjuvant; Stage II; Stage III; Stage IV,Breast Neoplasms,Nigeria; United States
Phase II study of gemcitabine (Gem) + docetaxel (D) in combination with trastuzumab (T) in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC).,II,Terminated,Eli Lilly,Oncology: Breast,First line; HER2 positive; Stage III; Stage IV,Breast Neoplasms,United States
Phase II trial of nanoparticle albumin-bound paclitaxel (ABX) + capecitabine (XEL) in first line treatment of metastatic breast cancer (MBC).,II,Completed,Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}},Oncology: Breast,First line; Stage IV,Breast Neoplasms,United States
"Pharmacogenomic predictor of complete response to preoperative paclitaxel and 5-fluorouracil, doxorubicin, cyclophosphamide chemotherapy in breast cancer in neoadjuvant settings.",Other,Completed,"MD Anderson Cancer Center, University of Texas
Takeda/Takeda Oncology {Millennium}",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,Peru; United States
Long term cardiac tolerability of trastuzumab in HER-2-overexpressing metastatic breast cancer (MBC).,II,Completed,"MD Anderson Cancer Center, University of Texas",Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
Polymorphisms of DNA-repair genes associated with clinical outcome in metastatic breast cancer (MBC) patients treated with gemcitabine/cisplatin (GC) (California Cancer Consortium).,II,Completed,"National Institutes of Health/National Cancer Institute
California Cancer Consortium",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
A Phase II Clinical Trial of Bevacizumab Beginning Concurrently with a Sequential Regimen of Doxorubicin and Cyclophosphamide Followed by Docetaxel and Capecitabine as Neoadjuvant Therapy Followed by Postoperative Bevacizumab Alone for  Women with Locally Advanced Breast Cancer.,II,Completed,"Roche/Genentech {Genentech}
National Surgical Adjuvant Breast and Bowel Project (NSABP)",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage III,Breast Neoplasms,Belgium; Canada; United States
Patient-Tailored Outpatient Chemotherapy Regimens For Advanced Breast Cancer.,II,Completed,Parker Hughes Cancer Center,Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
A Study to Assess HER2-Specific T Cell Responses in Patients Receiving Trastuzumab for Solid Tumor Treatment.,Other,Completed,"Jonsson Comprehensive Cancer Center, UCLA
National Institutes of Health/National Cancer Institute","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate",(N/A); HER2 positive; Line of therapy N/A,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Sarcoma",United States
"An Exploratory Analysis of Molecular Determinants of Response to Neoadjuvant therapy with Lapatinib, a Dual Egfr/Erbb2 Tyrosine Kinase Inhibitor, in Treatment-Naive, Operable Breast Cancer.",II,Terminated,University of Pennsylvania,Oncology: Breast,Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
Efficacy of Palonosetron in the Prevention of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting Following Dose Dense Adriamycin-Cyclophosphamide Chemotherapy in Early Stage Breast Cancer Patients,II,Completed,"National Institutes of Health/National Cancer Institute
Fred Hutchinson Cancer Research Center
Eisai {MGI Pharma}
University of Washington",Oncology: Breast; Oncology: Supportive Care,Emesis; First line; Stage 0; Stage I; Stage II,"Breast Neoplasms; Breast Neoplasms, Male; Nausea; Palliative Care; Vomiting",United States
Phase II Study of a HER-2/Neu (HER2) Intracellular Domain (ICD) Peptide-Based Vaccine Administered to Patients With Locally Advanced or Stage IV HER2 Positive Breast Cancer,II,Completed,"National Institutes of Health/National Cancer Institute
University of Washington",Oncology: Breast,First line; HER2 positive; Maintenance/Consolidation; Stage III; Stage IV,"Breast Neoplasms; Breast Neoplasms, Male",United States
Limited impact of tamoxifen following dose-intensive L-FAC multimodality therapy of breast cancer.,II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,First line; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
Phase II study of sequentially administered mitomycin (MMC) and irinotecan (CPT-11) in patients with metastatic breast cancer (MBC).,II,Completed,"Ohio State University
National Comprehensive Cancer Network",Oncology: Breast,First line; HER2 negative; HER2 positive; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
Phase II clinical trial of ixabepilone in metastatic breast cancer (MBC) patients previously untreated with taxanes.,II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,First line; Second line; Stage IV,Breast Neoplasms,United States
A Phase lll Study of SU011248 in Combination with Paclitaxel Versus Bevacizumab with Paclitaxel in the First-Line Advanced Disease Setting in Patients having Breast Cancer.,III,Terminated,"Pfizer
US Oncology Research",Oncology: Breast,First line; HER2 negative; Stage III; Stage IV,Breast Neoplasms,Germany; Italy; Spain; United States
"A Randomized, Open-label, Multicenter, Phase III Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy",III,Completed,Johnson & Johnson/Janssen R&D {Johnson & Johnson/J&JPRD},Metabolic/Endocrinology: Anemia; Oncology: Breast; Oncology: Supportive Care,Anemia; Cancer-related; First line; HER2 negative; HER2 positive; Second line; Stage IV,Anemia; Breast Neoplasms; Neoplasm Metastasis; Palliative Care,"Argentina; Australia; Brazil; Bulgaria; Chile; Colombia; Ecuador; Georgia; Hong Kong, S.A.R., China; India; Indonesia; Kazakhstan; Macedonia; Malaysia; Mexico; Peru; Philippines; Poland; Romania; Russia; Serbia; South Africa; Taiwan, China; Ukraine; United States"
Blood oxygen level dependent (BOLD) contrast MRI and breast cancer chemotherapy response.,Other,Completed,University of Texas Southwest Medical Center,Oncology: Breast,Line of therapy N/A; Stage III,Breast Neoplasms,United States
Randomized Phase II Biomarker Pilot Trial of Fluvastatin Use in Women With Ductal Carcinoma in Situ (DCIS) or Stage I Breast Cancer.,II,Completed,"Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute
University of California, San Francisco",Oncology: Breast,Estrogen receptor positive; Neoadjuvant; Stage 0; Stage I,"Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating",United States
Neoadjuvant dose-dense (DD) concurrent doxorubicin (A) and docetaxel (T) for stage III breast cancer (BC).,III,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Adjuvant; Neoadjuvant; Stage III,Breast Neoplasms,United States
"A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy (MEC).",III,Completed,Merck & Co.,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Supportive Care",(N/A); Emesis; Line of therapy N/A,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Nausea; Ovarian Cancer; Ovarian Neoplasms; Palliative Care; Vomiting","Australia; Brazil; Canada; Chile; Colombia; France; Germany; Hong Kong, S.A.R., China; Israel; Mexico; Peru; Russia; South Africa; United States"
Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression Profile-Based Test to Select Patients for Preoperative Taxane/Anthracycline Chemotherapy for Stage I-III Breast Cancer.,III,Completed,"MD Anderson Cancer Center, University of Texas
Breast Cancer Research Foundation",Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,France; Mexico; Peru; Spain; United States
"A Phase III Open Label, Randomized Two-Parallel-Arm Multicenter Study of E7389 Versus Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes",III,Completed,Eisai,Oncology: Breast,First line; Fourth line or greater; HER2 negative; HER2 positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,"Argentina; Australia; Belgium; Brazil; Bulgaria; Canada; Croatia; Czech Republic; France; Germany; Greece; Hungary; Israel; Italy; Lithuania; Mexico; Poland; Romania; Russia; Serbia; Singapore; South Africa; Spain; Taiwan, China; Ukraine; United States"
"Split, low-dose docetaxel (D) and low-dose capecitabine (C) is an active regimen in metastatic breast cancer with minimal toxicity.",II,Completed,"Amgen
Sanofi {Sanofi-Aventis}",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage IV; Triple receptor negative,Breast Neoplasms,United States
Phase II Study Evaluating Aprepitant As Salvage Antiemetic Therapy In Breast Cancer Patients Receiving Doxorubicin And Cyclophosphamide.,II,Completed,Merck & Co.,Oncology: Breast; Oncology: Supportive Care,(N/A); Emesis; First line,Breast Neoplasms; Palliative Care; Vomiting,United States
A Phase II Multicenter Study to Evaluate the Efficacy and Safety of 500 mg of Fulvestrant (Faslodex) as a First Line Hormonal Treatment in Postmenopausal Women with Hormonal Receptor Positive Metastatic Breast Cancer,II,Completed,"AstraZeneca
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
University of Colorado Cancer Center at University of Colorado Health Sciences Center
Beth Israel Deaconess Medical Center
University of Maryland Greenebaum Cancer Center
Massachusetts General Hospital
(Other Hospital/Academic/Medical Center)",Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Phase II Study of Fulvestrant (Faslodex) Following Estradiol (Estrace) in Postmenopausal Women with Metastatic Breast Cancer Progressing or Relapsing on Aromatase Inhibitor Therapy.,II,Completed,AstraZeneca,Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
A Randomized Phase II Trial of Docetaxel With or Without Bevacizumab as First-Line Therapy for Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer,II,Completed,"Amgen
Sanofi {Sanofi-Aventis {Aventis}}
Roche/Genentech {Genentech}
Jonsson Comprehensive Cancer Center, UCLA
National Institutes of Health/National Cancer Institute
Translational Oncology Research International",Oncology: Breast,First line; HER2 negative; Stage IV,Breast Neoplasms,United States
A Phase II Study of Simvastatin in Women at High Risk for a New Breast Cancer.,II,Completed,"National Institutes of Health/National Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}",Oncology: Breast,First line; Second line; Stage 0; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"Weekly carboplatin and nab-paclitaxel plus trastuzumab, or plus or minus bevacizumab: Clinical response in patients with breast cancer.",II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,HER2 negative; HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
Randomized phase II trial of two different schedules of carboplatin (C) and paclitaxel (P) + trastuzumab (T) as first line treatment for metastatic breast cancer (MBC).,II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,First line; HER2 negative; HER2 positive; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
An Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Subjects With ErbB2 Overexpressing Locally Advanced or Metastatic Breast Cancer,IV,Completed,"GlaxoSmithKline
Novartis",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,"Australia; Austria; Bahamas; Belgium; Brazil; Bulgaria; Canada; Chile; China; Cyprus; Czech Republic; Denmark; Estonia; Finland; Germany; Greece; Hong Kong, S.A.R., China; Iceland; Indonesia; Ireland; Israel; Italy; Latvia; Luxembourg; Malaysia; Malta; Mexico; Netherlands; New Zealand; Peru; Philippines; Poland; Portugal; Romania; Russia; Singapore; Slovakia; Slovenia; South Korea; Spain; Sweden; Switzerland; Taiwan, China; Thailand; Ukraine; United Kingdom; United States"
Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-Therapeutic Risk Assessment.,IV,Terminated,Novartis,Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,Germany; United States
Pilot Study of Neoadjuvant Dose Dense Docetaxel With Correlative Molecular Studies in Stage II/III Breast Cancer,II,Terminated,"National Institutes of Health/National Cancer Institute
Vanderbilt-Ingram Cancer Center",Oncology: Breast,Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
Pilot Neoadjuvant Trial in Breast Cancer With Combination of ABI-007 (Abraxane) and GW572016 (Lapatinib),II,Completed,"GlaxoSmithKline
Northwestern University
Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}}",Oncology: Breast,First line; HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Androgen Therapy for Management of Estrogen/Progesterone Receptor Negative ER(-)PR(-) Metastatic Breast Cancer: A Phase II Study,II,Terminated,(Other Hospital/Academic/Medical Center),Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
An Open Label Treatment Extension Study of AMG 706,II,Terminated,"Amgen
Takeda","Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",(N/A); Follicular; Locally advanced; Metastatic; Papillary; Pulmonary; Second line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Neuroendocrine Tumors; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Australia; Austria; Belgium; Canada; Denmark; France; Germany; Hungary; Italy; Poland; Sweden; Switzerland; United Kingdom; United States
"Open-label Extension to: A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Moderately Emetogenic Chemotherapy.",III,Completed,Merck & Co.,Oncology: Breast; Oncology: Supportive Care,Emesis; Line of therapy N/A; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms; Nausea; Palliative Care; Vomiting,"Australia; Austria; Canada; Denmark; Germany; Greece; Hong Kong, S.A.R., China; Hungary; Italy; Spain; United Kingdom; United States"
EPREX (Epoetin Alfa) Versus ARANESP (Darbepoetin Alfa): Looking at Outcome of Anemia Treatment and Comparing Cost-Effectiveness (EVALUATE),IV,Completed,Johnson & Johnson/Janssen-Cilag,"Metabolic/Endocrinology: Anemia; Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Supportive Care",(N/A); Aggressive; Anemia; Cancer-related; Classical; Indolent; Line of therapy N/A; Nodular lymphocyte-predominant,"Anemia; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Multiple Myeloma; Palliative Care",Netherlands; United States
A Phase II Randomized Study of Physiological (6 mg Daily) and High Dose (30 mg Daily) Estradiol in the Treatment of Hormone Receptor Positive Metastatic Breast Cancer.,II,Completed,"(Other Cooperative Group)
National Institutes of Health/National Cancer Institute
Washington University School of Medicine",Oncology: Breast,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung",United States
Randomized Phase II Trial of Gemcitabine and Imatinib Mesylate Versus Gemcitabine Alone in Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer,II,Terminated,"Novartis
National Institutes of Health/National Cancer Institute
Cancer Institute of New Jersey",Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
A Phase II Study Of The Efficacy And Safety Of SU-014813 In Patients with Metastatic Breast Cancer.,II,Completed,Pfizer,Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,Germany; Italy; Netherlands; United Kingdom; United States
"A Randomized Phase II Trial of Paclitaxel and Bevacizumab Versus Gemcitabine, Paclitaxel, and Bevacizumab as First Line Treatment for Locally Advanced or Metastatic Breast Cancer.",II,Completed,"Eli Lilly
Roche/Genentech {Genentech}",Oncology: Breast,First line; HER2 negative; HER2 positive; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,Italy; Puerto Rico; United States
"Phase II Study of 852A Administered Subcutaneously in Patients With Metastatic Refractory Breast, Ovarian, Endometrial and Cervical Cancers.",II,Completed,"University of Minnesota Cancer Center
Pfizer {Coley Pharmaceutical Group}",Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal,Estrogen receptor positive; Fourth line or greater; Progesterone receptor positive; Stage IV; Third line,Breast Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Uterine Cervical Neoplasms,United States
Phase II Study of SKI-606 in subjects with advanced or metastatic breast cancer.,II,Completed,Pfizer {Wyeth},Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Neoplasm Metastasis; Neoplasms,"Australia; China; France; Hong Kong, S.A.R., China; Ireland; Italy; Malta; Poland; Russia; Ukraine; United Kingdom; United States"
Prevention of Cisplatin- or Oxaliplatin-Induced Peripheral Neuropathy with Alpha-Lipoic Acid: A Placebo-Controlled Phase III Trial,III,Completed,"(Other Industry Sponsor)
MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute
(Other Hospital/Academic/Medical Center)","CNS: Pain (neuropathic); Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Supportive Care",(N/A); Cancers-related; Line of therapy N/A; Neurotoxicity,"Breast Neoplasms; Cancer pain; Cancer Pain; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasms; Neuralgia; Neurotoxicity Syndromes; Palliative Care; Peripheral Nervous System Diseases; Prostatic Neoplasms",United States
"An Open, Randomized Trial Comparing Combination Chemotherapy (CAF) and Chemohormonal Therapy (CAF + ZOLADEX or CAF + ZOLADEX + Tamoxifen) in Premenopausal Women with Axillary Node-positive, Receptor-positive Breast Cancer (INT0101).",III,Completed,"AstraZeneca
Cancer and Leukemia Group B (CALGB)
Eastern Cooperative Oncology Group (ECOG)
Southwest Oncology Group",Oncology: Breast,Adjuvant; Estrogen receptor positive; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,United States
A Randomized Phase III Double-Blind Placebo-Controlled Trial of First-Line Chemotherapy and Trastuzumab With or Without Bevacizumab for Patients With HER-2/NEU Over-Expressing Metastatic Breast Cancer,III,Terminated,"Roche/Genentech {Genentech}
Cancer and Leukemia Group B (CALGB)
Eastern Cooperative Oncology Group (ECOG)
North Central Cancer Treatment Group (NCCTG)
Southwest Oncology Group
National Institutes of Health/National Cancer Institute",Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Maintenance/Consolidation; Stage IV,Breast Neoplasms; Carcinoma,United States
Telomerase vaccination of metastatic breast cancer patients induces antigen-specific tumor infiltrating lymphocytes and tumor necrosis,II,Completed,Geron,Oncology: Breast,Line of therapy N/A; Stage IV,Breast Neoplasms,United States
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer.,III,Completed,"Roche/Genentech {Genentech}
Cancer and Leukemia Group B (CALGB)
Eastern Cooperative Oncology Group (ECOG)
North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute
National Institutes of Health",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Stage I; Stage II; Stage III,Adenocarcinoma; Breast Neoplasms; Heart Failure; Hypertension; Peripheral Nervous System Diseases,Peru; South Africa; United States
"Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment : The TAILORx Trial

Trial Assigning IndividuaLized Options for Treatment (Rx) - (TAILORx)",III,Completed,"Eastern Cooperative Oncology Group (ECOG)
National Surgical Adjuvant Breast and Bowel Project (NSABP)
Canadian Cancer Trials Group {NCIC Clinical Trials Group}
Southwest Oncology Group
National Institutes of Health/National Cancer Institute
Cancer Trials Ireland {Irish Clinical Oncology Research Group}
Alliance for Clinical Trials in Oncology
ECOG-ACRIN Cancer Research Group
NRG Oncology",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,Australia; Canada; Ireland; New Zealand; Peru; Puerto Rico; United Kingdom; United States
Phase II Study of Oral Antineoplastons A10 and AS2-1 in Women With Advanced Breast Cancer.,II,Terminated,Burzynski Research Institute,Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,United States
Phase II Randomized Study of Methotrexate With or Without Antineoplaston A10 Capsules in Women With Advanced Breast Cancer.,II,Terminated,Burzynski Research Institute,Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,United States
Dose Dense AB1-007 (Abraxane) in Adjuvant Chemotherapy for Breast Cancer: A Feasibility Study.,II,Completed,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Beth Israel Deaconess Medical Center
Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}}
Massachusetts General Hospital",Oncology: Breast,Adjuvant; HER2 positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Phase III Randomized Study of Zoledronate Versus Ibandronate for the Prevention of Skeletal-Related Events in Women With Stage IV Breast Cancer and Bone Metastases.,III,Terminated,"Southwest Oncology Group
National Institutes of Health/National Cancer Institute
Roche",CNS: Pain (nociceptive); Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; Cancer-related; Line of therapy N/A; Stage IV,Breast Neoplasms; Cancer pain; Cancer Pain; Hypercalcemia; Neoplasm Metastasis; Neoplasms; Nociceptive Pain; Paraneoplastic Syndromes,United States
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy,II,Terminated,University of Minnesota,"Oncology: Breast; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome; Oncology: Myeloproliferative Neoplasms; Oncology: Renal",Accelerated phase; Aggressive; Chronic phase; Classical; Cutaneous T-cell lymphoma (CTCL); del(5q); High risk; Indolent; Int-1 risk; Int-2 risk; Low risk; MDS-U; Nodular lymphocyte-predominant; Other subtype; Poor-risk; Primary Myelofibrosis; RA/RARS; RAEB; RAEB-t; RCMD; Second line; Stage IV,"Acute Myelocytic Leukemia; Breast Neoplasms; Carcinoma, Renal Cell; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Multiple Myeloma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasms, Plasma Cell; Plasmacytoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Renal Cancer; Wilms Tumor",United States
"Phase II Study of Doxil and Carboplatin, Plus Herceptin in HER2+ Patients, in Metastatic Breast Cancer.",II,Completed,"Johnson & Johnson/Janssen Therapeutics {J&J/Centocor Ortho Biotech/Tibotec Therapeutics {J&J/Ortho Biotech/Tibotec}}
US Oncology Research",Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
D-Cycloserine in the Management of Chemotherapy-Induced Peripheral Neuropathic Pain,II,Terminated,"National Institutes of Health/National Cancer Institute
Robert H. Lurie Comprehensive Cancer Center at Northwestern University",CNS: Pain (neuropathic); Oncology: Breast; Oncology: Supportive Care,Cancers-related; Chronic pain; Neurotoxicity; Second line; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms; Cancer pain; Cancer Pain; Neuralgia; Neurotoxicity Syndromes; Palliative Care,United States
"A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects With Advanced Breast Cancer.",III,Completed,"Amgen
Daiichi Sankyo",CNS: Pain (nociceptive); Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; Cancer-related; Line of therapy N/A; Stage IV,"Bone Marrow Diseases; Bone Neoplasms; Breast Neoplasms; Cancer pain; Cancer Pain; Neoplasm Metastasis; Neoplasms, Second Primary; Nociceptive Pain",Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; Czech Republic; Denmark; Estonia; France; Germany; Hungary; India; Israel; Italy; Japan; Latvia; Lithuania; Mexico; Netherlands; Panama; Peru; Poland; Romania; Russia; Slovakia; South Africa; Spain; Sweden; Switzerland; Turkey; Ukraine; United Kingdom; United States
Phase II Study of HKI-272 in Subjects With Advanced Breast Cancer,II,Completed,"(Other Industry Sponsor)
Pfizer {Wyeth}
Puma Biotechnology
Excella GmbH",Oncology: Breast,First line; Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms; Neoplasms,Belgium; Brazil; China; France; India; Mexico; Netherlands; Russia; United States
"A Randomized Phase II Trial of Double-Blind, Placebo Controlled AMG 706 in Combination With Paclitaxel, or Open-Label Bevacizumab in Combination With Paclitaxel, as First Line Therapy in Women With HER2 Negative Locally Recurrent or Metastatic Breast Cancer.",II,Completed,"Amgen
Breast Cancer International Research Group
Takeda
ANZ Breast Cancer Trials Group",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage IV,Breast Neoplasms,"Australia; Canada; France; Germany; Hong Kong, S.A.R., China; Hungary; India; Ireland; New Zealand; Poland; Spain; United States"
A Pilot Study of Irradiated HLA-Partially Matched Allogeneic Related Donor Lymphocytes for Patients with Selected Malignancies.,II,Completed,"National Institutes of Health/National Cancer Institute
Cancer Institute of New Jersey","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: GIST; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Testicular",(N/A); Aggressive; APL/M3; Chronic phase; Classical; Cutaneous T-cell lymphoma (CTCL); Diffuse large B-cell lymphoma (DLBCL); Extranodal marginal zone B-cell lymphoma (MALT); Follicular lymphoma (FL); Hormone refractory; Indolent; Mantle cell lymphoma (MCL); Metastatic; Nodular lymphocyte-predominant; Other subtype; Peripheral T-cell lymphoma (PTCL); Post-transplant/ineligible; Pulmonary; Second line; Small lymphocytic lymphoma (SLL); Stage III; Stage IV; Unresectable; Waldenstrom's macroglobulinemia (WM),"Acute Myelocytic Leukemia; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Melanoma; Multiple Myeloma; Myelodysplastic Syndromes; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Waldenstrom Macroglobulinemia; Wilms Tumor",United States
A Pilot Study to Establish a Standardized Protocol for Gene Microarray Analysis in Patients Receiving Neoadjuvant Chemotherapy for Breast Cancer: Identifying Factors Predictive of a Response to Paclitaxel,II,Terminated,"National Institutes of Health/National Cancer Institute
(Other Hospital/Academic/Medical Center)
Georgetown University Medical Center",Oncology: Breast,HER2 negative; HER2 positive; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
"Phase II Trial of 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC100) for 4 cycles followed by Docetaxel with Capecitabine (wTX) with Herceptin (in HER2-positive patients only) administered as preoperative therapy for patients with locally advanced breast cancer. Stages II and III.",II,Completed,"Pfizer
US Oncology Research
Roche {F. Hoffmann-La Roche}
Predictive Oncology {Precision Therapeutics}/Helomics {Helomics {Precision Therapeutics}}",Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,United States
"A Randomized, Multi-Centre, Open-Label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer

ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Trial",III,Completed,"GlaxoSmithKline
(Other Cooperative Group)
Breast International Group
Cancer and Leukemia Group B (CALGB)
Eastern Cooperative Oncology Group (ECOG)
Canadian Cancer Trials Group {NCIC Clinical Trials Group}
North Central Cancer Treatment Group (NCCTG)
Southwest Oncology Group
National Institutes of Health/National Cancer Institute
Cancer Research UK
EORTC Breast Cancer Group
American College of Surgeons Oncology Group (ACOSOG)
Alliance for Clinical Trials in Oncology",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Croatia; Czech Republic; Denmark; Estonia; France; Germany; Greece; Hong Kong, S.A.R., China; Hungary; India; Ireland; Israel; Italy; Japan; Luxembourg; Malaysia; Mexico; Netherlands; New Zealand; Norway; Pakistan; Peru; Philippines; Poland; Portugal; Romania; Russia; Singapore; Slovakia; Slovenia; South Africa; South Korea; Spain; Switzerland; Taiwan, China; Thailand; Ukraine; United Kingdom; United States"
A Randomized Placebo-controlled Trial of Glutamine to Reduce the Signs and Symptoms of Peripheral Neuropathy in Breast Cancer Patients With a Mild Peripheral Neuropathy Receiving Paclitaxel Chemotherapy,III,Completed,Weill Medical College of Cornell University,Oncology: Breast; Oncology: Supportive Care; Oncology: Unspecified Solid Tumor,Line of therapy N/A; Neurotoxicity; Stage I; Stage II; Stage III; Stage IV,"Breast Neoplasms; Neoplasms, Unknown Primary; Palliative Care; Peripheral Nervous System Diseases",United States
A Phase II Trial of Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer,II,Terminated,"Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}
Sanofi {Sanofi-Aventis}",Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
"Randomized Phase II Study of Docetaxel, Adriamycin, and Cytoxan (TAC) Versus Adriamycin/Cytoxan, Followed by Abraxane/Carboplatin (ACAC) +/- Trastuzumab as Neoadjuvant Therapy for Patients With Stage II-III Breast Cancer",II,Completed,"National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center",Oncology: Breast,HER2 positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms; Inflammatory Breast Neoplasms,United States
Pilot Study to Evaluate the Effect of Zoledronic Acid (Zometa) on Occult Malignant Bone Marrow Cells in Patients With High Risk Early Stage Breast Cancer.,II,Completed,"Novartis
University of California, San Francisco",Oncology: Breast; Oncology: Metastatic Cancer,Adjuvant; Bone mets; Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Neoplasm Metastasis,United States
Cancer Risk and Biomarkers of Tamoxifen Chemoprevention,II,Completed,"AstraZeneca
National Institutes of Health/National Cancer Institute
University of Pennsylvania",Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,Italy; United States
"A Phase III Randomized, Controlled Trial of Myocet, Trastuzumab and Paclitaxel Versus Trastuzumab and Paclitaxel for First-Line Therapy of Metastatic Breast Cancer.",III,Completed,Sopherion Therapeutics,Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Stage IV,Breast Neoplasms,Argentina; Canada; Germany; India; Italy; Poland; Portugal; Russia; Spain; United Kingdom; United States
"A Phase II, Open-Label, Randomized, Multicenter Trial of GW786034 (Pazopanib) in Combination With Lapatinib (GW572016) Compared to Lapatinib Alone as First Line Therapy in Subjects With Advanced or Metastatic Breast Cancer With ErbB2 Fluorescence In Situ Hybridization (FISH) Positive Tumors.",II,Completed,GlaxoSmithKline,Oncology: Breast,First line; HER2 positive; Stage III; Stage IV,Breast Neoplasms,Canada; France; Hungary; India; Israel; Malaysia; Mexico; Pakistan; Peru; Poland; Russia; Singapore; South Korea; Thailand; United Kingdom; United States
Phase III Randomized Study of Luteal Phase vs. Follicular Phase Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor-Positive Breast Cancer,III,Completed,"Ohio State University
Breast Cancer Research Foundation",Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Stage IV,Breast Neoplasms,"Bangladesh; China; India; Indonesia; Malaysia; Morocco; Nigeria; Philippines; Taiwan, China; United States; Vietnam"
A Phase III randomized parallel group trial of CoFactor in patients with advanced breast cancer who have completed taxane and doxorubicin treatment.,III,Terminated,Savara {Mast Therapeutics {ADVENTRX}},Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A Pharmacokinetic Interaction and Safety and Efficacy Phase II, Open Label Study with a Safety Lead-In Evaluating Docetaxel Plus Tesmilifene (YMB1002) in Patients with Metastatic Breast Cancer Suitable for Treatment with Docetaxel.",II,Completed,"Gilead Sciences {YM BioSciences}
Sanofi {Sanofi-Aventis}",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,Montenegro; Russia; Serbia; United States
An Exploratory Study to Identify Potential Surrogate Endpoint Biomarkers that are Modulated by Tamoxifen vs. Placebo in Women with an Increased Risk for Breast Cancer.,II,Completed,"National Institutes of Health/National Cancer Institute
Simmons Cancer Center",Oncology: Breast,First line; Stage 0,Breast Neoplasms,United States
"A Prospective, Randomized, Double-blind, Stratified, Multi-center, 2-arm Trial of the Continued Efficacy and Safety of Zoledronic Acid (Every 4 Weeks vs. Every 12 Weeks) in in the 2nd Year of Treatment in Patients With Documented Bone Metastases From Breast Cancer",III,Completed,Novartis,Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; Second line; Stage IV,Breast Neoplasms; Neoplasm Metastasis,Puerto Rico; United States
Phase IIb Trial of G-2535 (Unconjugated Isoflavones-100) in Women at High Risk for Breast Cancer,II,Completed,"National Institutes of Health/National Cancer Institute
Robert H. Lurie Comprehensive Cancer Center at Northwestern University",Oncology: Breast,(N/A); BRCA; Estrogen receptor positive; Line of therapy N/A,Breast Neoplasms,United States
Preservation of Ovarian Function in Young Women Treated With (Neo) Adjuvant Chemotherapy for Breast Cancer: A Randomized Trial Using the GnRH Agonist (Triptorelin) During Chemotherapy.,II,Terminated,"National Institutes of Health/National Cancer Institute
University of South Florida",Oncology: Breast,Adjuvant; Neoadjuvant; Stage I; Stage II,Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions,United States
Phase II Trial of Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer,II,Terminated,"Bristol-Myers Squibb
Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}",Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Stage IV,Breast Neoplasms; Neoplasms,United States
Intermediate Dose Cyclophosphamide Followed by Sequential GM-CSF and G-CSF Produces Efficient and Predictable PBPC Mobilization for Autografting: A Single Center Study of One Hundred and Thirty-Five Patients.,II,Completed,University of California San Diego,"Oncology: Breast; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Testicular",(N/A); Aggressive; Classical; First line; Fourth line or greater; Indolent; Nodular lymphocyte-predominant; Second line; Third line,"Breast Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Multiple Myeloma; Testicular Cancer; Testicular Neoplasms",United States
A Phase II Study of Weekly Versus Every 2-Week Versus Every 3-Week Administration of ABI-007 (Abraxane) in Combination With Bevacizumab in Women With Metastatic Breast Cancer.,II,Completed,Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}},Oncology: Breast,First line; HER2 negative; Stage IV,Breast Neoplasms; Neoplasm Metastasis; Neoplasms,Puerto Rico; United States
"Neoadjuvant Complete Hormonal Blockade Followed by Neoadjuvant Chemotherapy for Resectable Hormone Receptor Positive, HER-2/Neu Negative Breast Cancer, A Phase II Study",II,Terminated,"National Institutes of Health/National Cancer Institute
Fred Hutchinson Cancer Research Center
University of Washington",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Phase III, Multicenter, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy Regimens in Subjects With Previously Treated Metastatic Breast Cancer",III,Completed,Roche/Genentech {Genentech},Oncology: Breast,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,"Australia; Belgium; Bulgaria; Canada; Croatia; Czech Republic; France; Italy; Latvia; Malaysia; Philippines; Romania; Russia; Serbia; Singapore; South Africa; Spain; Taiwan, China; Thailand; Ukraine; United States"
"A 12-Week, Multi-Center, Open-Label, Dose-Response Study to Evaluate the Safety and Efficacy of PTHrp Humanized Monoclonal Antibody in Metastatic Breast Cancer: An Extension of Protocol CAL-03",II,Completed,Roche/Chugai Pharmaceutical,CNS: Pain (nociceptive); Oncology: Breast,Cancer-related; Second line; Stage IV,Breast Neoplasms; Cancer pain; Cancer Pain; Nociceptive Pain,United States
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol,II,Terminated,Pfizer,"Oncology: Breast; Oncology: Colorectal; Oncology: GIST; Oncology: Lung, Non-Small Cell; Oncology: Renal",Second line; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Kidney Neoplasms; Renal Cancer; Unspecified; Wilms Tumor",Australia; Canada; France; Greece; Italy; Netherlands; Singapore; Sweden; Switzerland; United Kingdom; United States
"Phase II Trial of Cetuximab Alone and in Combination with Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancer",II,Completed,"Bristol-Myers Squibb
MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine",Oncology: Breast,EGFR; First line; HER2 negative; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
"A Pilot Study to Evaluate The Effects of Neoadjuvant AZD2171, a VEGF Receptor Tyrosine Kinase Inhibitor With Docetaxel, Doxorubicin, and Cyclophosphamide Chemotherapy in Previously Untreated Locally Advanced Breast Cancer",II,Terminated,National Institutes of Health/National Cancer Institute,Oncology: Breast,HER2 negative; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
Phase II Trial of Concurrent Irinotecan Plus Cetuximab in Patients With Advanced Breast Cancer With Prior Anthracycline and/or Taxane-Containing Therapy,II,Terminated,"North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute",Oncology: Breast,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A Randomized, Open-Label, Parallel-Group, Multicentre, Phase II Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX) 500 mg With Anastrozole (ARIMIDEX) 1 mg as First Line Hormonal Treatment for Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

FIRST (Fulvestrant First-Line Study Comparing Endocrine Treatments).",II,Completed,AstraZeneca,Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,Brazil; Bulgaria; Czech Republic; France; Italy; Poland; Spain; United Kingdom; United States
A Randomized Phase II Study of Weekly or Every 3 Weeks ABI-007 Versus Every 3 Weeks Taxotere as First Line Therapy of Stage IV (Metastatic) Breast Cancer,II,Completed,Bristol-Myers Squibb/Celgene,Oncology: Breast,First line; Stage IV,Breast Neoplasms,Russia; Ukraine; United States
"A Randomised, Active Control, Double-Blind, Double-Dummy, Parallel-Group, Multi-National Study to Assess the Efficacy, Tolerability and Safety of the Granisetron Transdermal Delivery System in Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With the Administration of Moderately or Highly Emetogenic Multi-Day Chemotherapy.",III,Completed,Kyowa Kirin {Kyowa Hakko Kirin}/Kyowa Kirin International {ProStrakan},Oncology: Breast; Oncology: Gastric; Oncology: Supportive Care; Oncology: Unspecified Cancer,Emesis; Line of therapy N/A; Stage IV,Breast Neoplasms; Nausea; Neoplasms; Palliative Care; Stomach Carcinoma; Stomach Neoplasms; Vomiting,Czech Republic; Germany; India; Mexico; United States
Phase II Study of Fixed-Dose Capecitabine in Metastatic Breast Cancer,II,Terminated,"National Institutes of Health/National Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}
Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}
Roche {F. Hoffmann-La Roche}",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; HER2 positive; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
"A Multicenter, Phase III, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy Regimens in Subjects With Previously Untreated Metastatic Breast Cancer",III,Completed,"Roche/Genentech {Genentech}
National Health Service (NHS) - UK",Oncology: Breast,First line; HER2 negative; Stage III; Stage IV,Breast Neoplasms,Brazil; Canada; France; Greece; Netherlands; Russia; Spain; Sweden; Ukraine; United Kingdom; United States
Pilot Trial of Sequential Dose-Dense Neoadjuvant Chemotherapy Plus Herceptin in HER2 Positive Stage II-III Breast Cancer Patients,II,Completed,"Sanofi {Sanofi-Aventis {Aventis}}
(Other Cooperative Group)",Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,United States
A Double Blind Randomization to Letrozole or Placebo for Women Previously Diagnosed with Primary Breast Cancer Completing Five Years of Adjuvant Aromatase Inhibitor Either as Initial Therapy or After Tamoxifen (Including Those in the MA.17 Study),III,Completed,"Novartis
Cancer and Leukemia Group B (CALGB)
Eastern Cooperative Oncology Group (ECOG)
Canadian Cancer Trials Group {NCIC Clinical Trials Group}
North Central Cancer Treatment Group (NCCTG)
Southwest Oncology Group
National Cancer Institute of Canada
Alliance for Clinical Trials in Oncology",Oncology: Breast,Estrogen receptor positive; Line of therapy N/A; Progesterone receptor positive; Stage I; Stage II,Breast Neoplasms,Austria; Belgium; Canada; United Kingdom; United States
A Phase II Study of Oral MKC-1 Administered Twice Daily for 14 Consecutive Days Every 4 Weeks in Patients With Advanced or Metastatic Breast Cancer.,II,Completed,CASI Pharmaceuticals {EntreMed},Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
Open Label Treatment and Survival Continuation Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer.,III,Terminated,Intarcia Therapeutics {BioMedicines},Oncology: Breast,First line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms; Neoplasms, Hormone-Dependent",Canada; Russia; Ukraine; United States
"A prospective randomized trial of adjuvant chemotherapy for patients with stage I-III operable, invasive breast cancer comparing 4 courses of doxorubicin/cyclophosphamide (AC) to 4 courses of docetaxel/cyclophosphamide (TC).",III,Completed,Sanofi {Sanofi-Aventis},Oncology: Breast,Adjuvant; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Neoadjuvant dose dense chemotherapy with sequential doxorubicin/cyclophosphamide followed by taxane yields high pathologic complete response rate in stage II/III breast cancer.,II,Completed,(Other Cooperative Group),Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,United States
Phase II trial of combination therapy with oral capecitabine and weekly paclitaxel for metastatic breast cancer.,II,Completed,Roche,Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
A Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer - preliminary results of the Erasme 3 study.,III,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,First line; Stage IV,Breast Neoplasms,France; United States
Pilot Study Of Biomarker Modulation With A Cox-2 Inhibitor Using Ductal Lavage In Women At High Risk For Breast Cancer,II,Completed,"Pfizer {Pharmacia}
National Institutes of Health/National Cancer Institute",Oncology: Breast,Line of therapy N/A; Stage 0,Breast Neoplasms,United States
"A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Investigate Safety and Efficacy of Tibolone (Org OD14) in Women With Climacteric Symptoms and a History of Breast Cancer

Livial Intervention following Breast cancer: Efficacy, Recurrence, And Tolerability Endpoints (LIBERATE)

(Liberate study- Non Interventional Observational Follow Up Program)",III,Terminated,Organon {Merck & Co./MSD {Schering-Plough/Organon {Akzo Nobel/Organon}}},Genitourinary: Menopausal Symptoms; Oncology: Breast,Cancer or chemotherapy-related; Estrogen receptor positive; Line of therapy N/A; Progesterone receptor positive; Stage I; Stage II; Stage III; VMS - Unspecified or other severity,Breast Neoplasms; Menopause,"Australia; Austria; Belarus; Belgium; Brazil; Chile; Costa Rica; Czech Republic; Estonia; Finland; France; Germany; Hungary; Italy; Latvia; Malaysia; Mexico; Netherlands; Panama; Poland; Romania; Russia; Singapore; Slovakia; South Korea; Spain; Sweden; Taiwan, China; Thailand; Ukraine; United Kingdom; United States"
Pilot Study of Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in High-Risk Breast Cancer: Feasibility in the adjuvant  and neoadjuvant Setting.,II,Completed,"Amgen
Memorial Sloan-Kettering Cancer Center
Pfizer",Oncology: Breast,Adjuvant; Neoadjuvant; Stage I; Stage II; Stage III,Adenocarcinoma; Breast Neoplasms,United States
Phase II study of MT201 in metastatic breast cancer.,II,Terminated,"Amgen {Micromet}
Merck KGaA/Merck Serono {Serono}",Oncology: Breast,Line of therapy N/A; Stage IV,Breast Neoplasms,United States
Phase II Trial Evaluating the Toxicity and Efficacy of a Multiepitope Dendritic Cell Vaccine Given With Trastuzumab and Vinorelbine Ditartrate for the Treatment of Women With Metastatic Breast Cancer That Express HLA-A0201 and Whose Tumors Overexpress HER-2/NEU,II,Completed,"National Institutes of Health/National Cancer Institute
UNC Lineberger Comprehensive Cancer Center",Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
Phase II Trial of CT-2103 (Xyotax) with Capecitabine as First-Line Chemotherapy for Patients with Metastatic Breast Cancer.,II,Terminated,"North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute",Oncology: Breast,First line; HER2 negative; Stage IV,Breast Neoplasms,United States
"A Randomized Phase II/III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg Daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Postmenopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer",II/III,Completed,"Cancer and Leukemia Group B (CALGB)
National Institutes of Health/National Cancer Institute
Pfizer
Cancer Institute of New Jersey
Cancer Trials Support Unit - CTSU/NCI
(Other Hospital/Academic/Medical Center)
Breast Cancer Research Foundation
American College of Surgeons Oncology Group (ACOSOG)",Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Stage 0; Stage I; Stage II; Stage III,Breast Neoplasms,Ireland; United States
Unexpected hepatic toxicity after primary treatment with gefitinib and docetaxel in patients with locally advanced breast cancer.,II,Terminated,"AstraZeneca
Sanofi {Sanofi-Aventis {Aventis}}",Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,Brazil; United States
"Preoperative Therapy With Epirubicin/Cyclophosphamide Followed by Paclitaxel/Trastuzumab and Postoperative Therapy With Trastuzumab in Patients With HER-2 Over Expressed Breast Cancer. 

Taxol-Epirubicin-Cyclophosphamid-Herceptin Neoadjuvant (TECHNO).",II,Completed,"Arbeitsgemeinschaft Gynakologische Onkologie
(Other Hospital/Academic/Medical Center)
German Breast Group",Oncology: Breast,Adjuvant; HER2 positive; Neoadjuvant; Stage II; Stage III; Stage IV,Breast Neoplasms,Germany; United States
"A Multi-Center Randomized Clinical Trial Correlating the Effects of 24 Months of Exemestane or Letrozole on Surrogate Markers of Response with Aromatase Polymorphism.

Exemestane and Letrozole Pharmacogenetics Study.",IV,Completed,"Novartis
Pfizer
University of Michigan Comprehensive Cancer Center
Indiana University School of Medicine
(Other Hospital/Academic/Medical Center)
National Institutes of Health/National Institute of General Medical Sciences",Oncology: Breast,Estrogen receptor positive; Line of therapy N/A; Progesterone receptor positive; Stage 0; Stage I; Stage II; Stage III,Breast Neoplasms,Canada; United States
"A Phase II Study to Evaluate the Efficacy and Safety Using Combined Monoclonal Antibodies, Trastuzumab and Pertuzumab in Subjects with HER-2 Overexpressed Locally Advanced and Metastatic Breast Cancer.",II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Pilot Study Evaluating Surrogates of Response to Short Term Oral Suberoylanilide Hydroxamic Acid (SAHA) in Women With Newly Diagnosed Breast Cancer,II,Completed,"Merck & Co.
National Institutes of Health/National Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}",Oncology: Breast,Estrogen receptor positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,Singapore; United States
Phase II Study of the Combination of PTK787/ZK222584 and Letrozole in Postmenopausal Women With Advanced Hormone Receptor Positive Breast Cancer.,II,Completed,"Novartis
Washington University School of Medicine",Oncology: Breast,Estrogen receptor positive; First line; Maintenance/Consolidation; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A multicenter, open-label, randomized study of three schedules of weekly Taxol induction therapy followed by weekly Taxol maintenance therapy in metastatic breast cancer patients",II,Completed,Bristol-Myers Squibb,Oncology: Breast,First line; Maintenance/Consolidation; Second line; Stage IV,Breast Neoplasms,United States
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-Based Systemic Therapy and Cranial Radiotherapy.,II,Terminated,"GlaxoSmithKline
Novartis",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; HER2 positive; Second line; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,"Australia; Austria; Belgium; Canada; France; Germany; Greece; India; Italy; Japan; Poland; Spain; Sweden; Switzerland; Taiwan, China; United Kingdom; United States"
"A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Study of Lapatinib (GW572016) in Combination With Paclitaxel Versus Paclitaxel Plus Placebo in Subjects With ErbB2 Amplified Metastatic Breast Cancer.",III,Completed,"GlaxoSmithKline
Novartis",Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,"Brazil; China; Hong Kong, S.A.R., China; Norway; Pakistan; Peru; Russia; Thailand; Ukraine; United States"
"A Randomized, Double Blind, Placebo-Controlled, Multicenter, Phase III Study Comparing the Activity of Paclitaxel Plus Trastuzumab Plus Lapatinib to Paclitaxel Plus Trastuzumab Plus Placebo in Women With ErbB2 Overexpressing Metastatic Breast Cancer",III,Terminated,GlaxoSmithKline,Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Stage IV,Breast Neoplasms,Belgium; United States
"A Randomized, Multicenter, Open-Label, Phase III Study of Lapatinib in Combination With Trastuzumab Versus Lapatinib Monotherapy in Subjects With HER2-positive Metastatic Breast Cancer Whose Disease Has Progressed on Trastuzumab-Containing Regimens",III,Completed,GlaxoSmithKline,Oncology: Breast,First line; Fourth line or greater; HER2 positive; Second line; Stage IV; Third line,Breast Neoplasms,Austria; Bulgaria; Canada; Croatia; Czech Republic; Finland; Germany; Greece; Hungary; Italy; Poland; Spain; United Kingdom; United States
A Randomized Study Of The Effect Of Exemestane (Aromasin) Versus Placebo On Breast Density In Postmenopausal Women At Increased Risk For Development Of Breast Cancer,II/III,Completed,"Pfizer {Pharmacia}
Pfizer
National Cancer Institute of Canada",Oncology: Breast,(N/A); First line,Breast Neoplasms,Canada; United States
Phase II Chemoprevention Trial - Anastrozole in the DCIS and Early Invasive Breast Cancer in Postmenopausal Women,II,Completed,"AstraZeneca
University of California Medical Center, Irvine",Oncology: Breast,Estrogen receptor positive; Neoadjuvant; Progesterone receptor positive; Stage 0; Stage I; Stage II,"Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating",United States
"Evaluation of Thymidine Phosphorylase and Other Predictive/Prognostic Factors in Primary Breast Cancer Treated With Docetaxel and Capecitabine.""in the neoadjuvant setting""",II,Completed,"Roche
University of Michigan Comprehensive Cancer Center",Oncology: Breast,Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Neoadjuvant Biweekly Doxorubicin and Cyclophosphamide With GMCSF Followed by Weekly Carboplatin/Nab-paclitaxel Plus or Minus Trastuzumab and Plus or Minus Bevacizumab in Treatment of Large or Inflammatory Breast Cancer-a Phase II Study,II,Completed,"University of California Medical Center, Irvine",Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,United States
Phase II Randomized Study of Arzoxifene Versus Tamoxifen Versus Placebo in Preventing Breast Cancer in Women at High Risk for Breast Cancer.,II,Completed,"National Institutes of Health/National Cancer Institute
Cleveland Clinic Taussig Cancer Center",Oncology: Breast; Oncology: Ovarian,(N/A); Line of therapy N/A,Breast Neoplasms; Ovarian Cancer; Ovarian Neoplasms,United States
A Phase II Trial of Abraxane Given Weekly as a Single Agent in First-Line Treatment of Metastatic Breast Cancer,II,Completed,"Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}}
International Oncology Network",Oncology: Breast,First line; HER2 negative; HER2 positive; Stage III; Stage IV,Breast Neoplasms,United States
Phase II Study to Investigate the Efficacy and Safety of ZK-Epothilone (ZK-Epo; ZK 219477) in Patients With Metastatic Breast Cancer.,II,Completed,Bayer AG/Bayer Pharmaceuticals {Bayer HealthCare {Bayer Schering Pharma {Schering AG/Berlex}}},Oncology: Breast,Fourth line or greater; Second line; Stage IV; Third line,Breast Neoplasms,Canada; United States
Phase II Study of Dose Dense Carboplatin and Taxotere with Herceptin As Primary Systemic Therapy In Breast Cancer in Neoadjuvant Setting.,II,Completed,"Sanofi {Sanofi-Aventis {Aventis}}
Sylvester Cancer Center, University of Miami",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer.,II,Completed,"Bristol-Myers Squibb
Pfizer
US Oncology Research",Oncology: Breast,First line; HER2 negative; HER2 positive; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,United States
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer,III,Completed,Novartis,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,Australia; Austria; Belgium; Canada; China; Denmark; Finland; France; Germany; Ireland; Israel; Italy; Japan; Netherlands; New Zealand; Norway; South Korea; Spain; Sweden; Switzerland; United Kingdom; United States
Phase II of Oral Satraplatin in Patients With Metastatic Breast Cancer (MBC).,II,Completed,"Agennix {GPC Biotech}
Bristol-Myers Squibb/Celgene {Pharmion}",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"A Randomized Phase ll Study of SU011248 versus Standard-of-Care for Patients with Previously Treated, Advanced, Triple Receptor Negative (ER, PR, HER2) Breast Cancer",II,Completed,Pfizer,Oncology: Breast,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,Bulgaria; Canada; Czech Republic; France; Germany; Hungary; Italy; Spain; Turkey; Ukraine; United Kingdom; United States
"A Phase II Open Label Single-Arm Study of E7389 in Patients With Locally Advanced or Metastatic Breast Cancer, Previously Treated With Anthracycline, Taxane, and Capecitabine Therapy, Refractory to the Last Prior Therapy for Their Disease",II,Completed,Eisai,Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,Belgium; Canada; France; Germany; Spain; United Kingdom; United States
Surrogate Markers of Response: A Phase II Study of Changes in Breast Density Among Postmenopausal Women Receiving Adjuvant Anastrozole Therapy.,II,Completed,"National Institutes of Health/National Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}",Oncology: Breast,Adjuvant; Estrogen receptor positive; Progesterone receptor positive; Stage 0; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Phase II Trial of Gemcitabine and Genistein in Metastatic Breast Cancer Patients With Biomarker Assays,II,Terminated,"Barbara Ann Karmanos Cancer Institute
National Institutes of Health/National Cancer Institute",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
A Phase II Efficacy And Safety Study Of SU011248 In Combination With Trastuzumab As Treatment For Metastatic Disease In Patients With Breast Cancer.,II,Completed,Pfizer,Oncology: Breast,First line; HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,Belgium; Canada; France; Spain; United States
The Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Metastatic Breast Cancer Patients Previously Responsive to Hormonal Therapy: A Phase II Trial,II,Completed,"Roche/Genentech {Genentech}
University of Alabama, Birmingham",Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Randomized Feasibility Study of Letrozole in Postmenopausal Women at Increased Risk for Development of Breast Cancer as Evidenced by High Breast Density.,II,Terminated,"Novartis
Canadian Cancer Trials Group {NCIC Clinical Trials Group}
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Beth Israel Deaconess Medical Center
National Cancer Institute of Canada
Massachusetts General Hospital
Brigham and Womens Hospital",Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,Canada; United States
Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility,II,Completed,"Amgen
Roche/Genentech {Genentech}
Memorial Sloan-Kettering Cancer Center",Oncology: Breast,HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Prediction of Response or Resistance to Dose Intensified Pre-Operative Epirubicin Therapy of Operable Breast Cancer,II,Terminated,"National Institutes of Health/National Cancer Institute
Cleveland Clinic Taussig Cancer Center",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
"Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study: Hoosier Oncology Group COE-01.",II,Terminated,"Indiana University School of Medicine
US Department of Defense
Walther Cancer Institute",Oncology: Breast,Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms,Peru; United States
"A Randomised, Double-Blind, Study Comparing ARIMIDEX with NOLVADEX as Neo-Adjuvant and Adjuvant Treatment in Post-Menopausal Women with Large Operable (T2 (>3cm), T3, N0-2, M0) or Potentially-Operable, Locally Advanced (T4b, N0-2, M0), ER+ and/or PR+ Breast Cancer.",III,Completed,AstraZeneca,Oncology: Breast,Adjuvant; Estrogen receptor positive; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,Belgium; Brazil; Canada; Czech Republic; France; Hungary; Italy; Japan; Netherlands; United States
Lapatinib in Endocrine-Resistant Metastatic Breast Cancer,II,Terminated,"GlaxoSmithKline
(Other Hospital/Academic/Medical Center)
University of Colorado
Dartmouth-Hitchcock Medical Center",Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
Phase II Study of Capecitabine and Weekly Docetaxel Followed by Capecitabine Maintenance for Patients With Metastatic Breast Carcinoma.,II,Terminated,(Other Cooperative Group),Oncology: Breast,First line; Maintenance/Consolidation; Second line; Stage IV; Third line,Breast Neoplasms,United States
"Randomized Phase II Trial of Sequential Docetaxel Followed by Capecitabine Versus Concomitant, Dose-Dense Docetaxel/Capecitabine as in Induction Therapy for Early Stage Breast Cancer.",II,Completed,"(Other Academic Cancer Center)
Winship Cancer Institute of Emory University
Sanofi {Sanofi-Aventis}",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
Phase II Study of Goserelin and Anastrozole in Men With Estrogen Receptor- or Progesterone Receptor-Positive Recurrent or Metastatic Breast Cancer.,II,Terminated,"Southwest Oncology Group
National Institutes of Health/National Cancer Institute",Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
A Pilot Study of Taxotere (Docetaxel) Combined With Xeloda (Capecitabine) in the Treatment of Metastatic Breast Cancer,II,Completed,"(Other Cooperative Group)
Roche {F. Hoffmann-La Roche}",Oncology: Breast,First line; Stage III; Stage IV,Breast Neoplasms,United States
Phase II Study of Capecitabine and Pegylated Interferon Alfa-2a in Patients With Recurrent or Progressive Brain Metastases Secondary to Breast Cancer.,II,Terminated,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Second line; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
Phase II Trial of Exemestane (Aromasin) in Combination With Fulvestrant (Faslodex) in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer,II,Completed,"Pfizer
Ohio State University",Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
Phase III Randomized Study of Immediate Versus Luteal Phase Adjuvant Oophorectomy and Tamoxifen in Premenopausal Women With Hormone Receptor-Positive Breast Cancer.,III,Completed,"(Other Cooperative Group)
National Institutes of Health",Oncology: Breast,Adjuvant; Estrogen receptor positive; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,Morocco; Philippines; United States; Vietnam
"A Phase II Trial of Exemestane (Aromasin) in Combination With Celecoxib (Celebrex) as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer.",II,Completed,Ohio State University,Oncology: Breast,Estrogen receptor positive; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
A Randomized Phase II Study of Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients with Metastatic Breast Cancer,II,Completed,Eli Lilly,Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
Phase II Randomized Adjuvant Trial of Dose-Dense Docetaxel Before or After Doxorubicin/Cyclophosphamide (AC) in Axillary Node-Positive Breast Cancer.,II,Completed,"Ohio State University
Sanofi {Sanofi-Aventis}",Oncology: Breast,Adjuvant; Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage III,Breast Neoplasms,United States
Feasibility of A Reduced Dexamethasone Pre-Medication Dose in Elderly Patients Treated with Weekly Docetaxel.,II,Terminated,"Sanofi {Sanofi-Aventis}
Geriatric Oncology Consortium","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine",(N/A); Line of therapy N/A; Pulmonary,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Neuroendocrine Tumors; Small Cell Lung Carcinoma",United States
A Randomized Multicenter Trial Of Neoadjuvant Taxotere (T) And Adriamycin/Cytoxan (AC): A Validation.,II,Completed,Baylor College of Medicine,Oncology: Breast,Adjuvant; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
A Phase II Study Of The Clinical And Biologic Effects Of Docetaxel (Taxotere) In Patients With Locally Advanced Breast Cancer in the neoadjuvant setting.,II,Completed,"Sanofi {Sanofi-Aventis {Aventis}}
Baylor College of Medicine",Oncology: Breast,Adjuvant; Neoadjuvant; Stage III,Breast Neoplasms,United States
"A Neoadjuvant Phase II Trial of ZD1839 (Iressa) and Tamoxifen in Inoperable Locally Advanced HER2-Overexpressing, ER-Positive Breast Cancer Patients: Biologic Correlative Study (AZ #1839US/0303).",II,Terminated,"AstraZeneca
Baylor College of Medicine",Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Stage III,Breast Neoplasms,United States
A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202),II,Completed,"National Institutes of Health/National Cancer Institute
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute",Oncology: Breast,First line; Fourth line or greater; Second line; Stage IV; Third line,"Breast Neoplasms; Breast Neoplasms, Male",United States
Mammographic Density and Soy Isoflavones,II,Completed,"National Institutes of Health/National Cancer Institute
University of Texas
National Center for Research Resources",Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
An Extension Phase II Study of the Clinical and Biologic Effects of Docetaxel (Taxotere) in Patients with Locally Advanced Breast Cancer,II,Terminated,"Baylor College of Medicine
US Department of Defense",Oncology: Breast,Adjuvant; Neoadjuvant; Stage III; Stage IV,Breast Neoplasms,United States
Evaluation of the Efficacy of Esomeprazole in Suppressing Nausea and Vomiting in Patients Undergoing Chemotherapy for Breast Cancer,III,Terminated,"AstraZeneca
Baylor College of Medicine",Oncology: Breast; Oncology: Supportive Care,Adjuvant; Emesis; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms; Nausea; Palliative Care; Vomiting,United States
A Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer at Moderate to High Risk of Recurrence,II,Completed,"Memorial Sloan-Kettering Cancer Center
Weill Medical College of Cornell University",Oncology: Breast,Estrogen receptor positive; HER2 negative; Maintenance/Consolidation; Progesterone receptor positive; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"Arimidex/Faslodex/Iressa Study: A Phase II Trial of Primary Systemic Therapy Using a Combination of Arimidex, Faslodex and Iressa (Gefitinib) in Postmenopausal Women with Hormone Receptor Positive Breast Cancer.",II,Terminated,Baylor College of Medicine,Oncology: Breast,Estrogen receptor positive; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
A Phase II Trial of Capecitabine and Oxaliplatin in Metastatic Breast Cancer.,II,Terminated,"University of Wisconsin
Sanofi {Sanofi-Aventis}",Oncology: Breast,First line; Second line; Stage IV,Breast Neoplasms,United States
"A Study of Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF Followed by Weekly Paclitaxel as Neoadjuvant Therapy for Resectable, Hormone Receptor Negative or Hormone Receptor Positive, HER-2/Neu Positive Breast Cancer Followed by a Novel Regimen of Capecitabine, Methotrexate and Vinorelbine for Patients Who Do Not Have Either a Macroscopic or Microscopic Pathologic Complete Response, a Phase II Study",II,Completed,"National Institutes of Health/National Cancer Institute
University of Washington",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Primary Systemic Therapy Using Sequential Docetaxel/Cyclophosphamide/Bevacizumab Followed by Doxorubicin in Operable/Locally Advanced Breast Cancer.,II,Completed,"Roche/Genentech {Genentech}
University of Arkansas",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
"Adjuvant Therapy for High-Risk Localized Breast Cancer with Weekly Adriamycin +/- Oral Cytoxan with Continuous G-CSF Support for 12 Weeks Followed by Weekly Taxol for 12 Weeks, Phase II.",II,Completed,"Amgen
Bristol-Myers Squibb
University of Washington",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,United States
Taxotere Plus Weekly Navelbine and G-CSF: A Phase II Study in Stage IV Breast Cancer.,II,Completed,"Amgen
Sanofi {Sanofi-Aventis {Aventis {Rhone Poulenc Rorer SA}}}
University of Washington",Oncology: Breast,Second line; Stage IV; Third line,Breast Neoplasms,United States
Weekly Vinorelbine and Oral Capecitabine as Treatment for Stage IV Breast Cancer: A Phase II Trial With Molecular Correlates.,II,Completed,"Pfizer
University of Washington
Roche {F. Hoffmann-La Roche}",Oncology: Breast,First line; Second line; Stage IV,Breast Neoplasms,United States
"Phase II Study of Tandem Cycle Dose-Intense Chemotherapy of Melphalan and Carboplatin, Thiotepa and Cyclophosphamide (STMP V) +or- Trastuzumab Followed by Helical Tomotherapy or Local Regional Radiation Therapy for Stage IV Metastatic and Stage IIIB/C Breast Cancer",II,Completed,"National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center",Oncology: Breast,Adjuvant; First line; Stage III; Stage IV,Breast Neoplasms,United States
A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS).,II,Terminated,"AstraZeneca
USC/Norris Comprehensive Cancer Center and Hospital",Oncology: Breast,First line; Stage 0,"Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating",United States
"A Multicenter, Randomized, Controlled Prospective Trial of the Safety and Efficacy of Ferrlecit in Anemic Cancer Patients Who Are Receiving Acute Chemotherapy and Epoetin as Compared to Oral Iron and No Treatment",IV,Completed,AbbVie/Allergan {Allergan/Actavis {Actavis {Watson Pharmaceuticals}}},"Metabolic/Endocrinology: Anemia; Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Prostate; Oncology: Supportive Care",Aggressive; Anemia; Cancer-related; Indolent; Second line; Stage I; Stage II; Stage III; Stage IV,"Anemia; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Ovarian Cancer; Ovarian Neoplasms; Palliative Care; Prostatic Neoplasms",United States
An open-label study using the MedPulser Electroporation System to Treat Cutaneous and Subcutaneous Foci of Cancer.,IV,Completed,Inovio Pharmaceuticals {Inovio Biomedical},"Oncology: Breast; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Skin, Basal Cell Carcinoma",(N/A); Cutaneous T-cell lymphoma (CTCL); Indolent; Peripheral T-cell lymphoma (PTCL); Second line,"Breast Neoplasms; Carcinoma, Basal Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Melanoma; Neoplasms, Basal Cell; Unspecified",France; Germany; Netherlands; Sweden; United Kingdom; United States
Bone Mineral Density Effects of Zoledronate in Postmenopausal Women with Breast Cancer.,II,Completed,University of Wisconsin,Metabolic/Endocrinology: Osteoporosis; Oncology: Breast,Chemotherapy-induced bone loss; Line of therapy N/A; Stage III,Breast Neoplasms; Osteoporosis,United States
Genomic and Proteonomic Analysis of Docetaxel and Capecitabine as Primary Chemotherapy for Stage II-III Breast Cancer.,II,Completed,"Sanofi {Sanofi-Aventis {Aventis}}
Indiana University School of Medicine",Oncology: Breast,First line; Stage II; Stage III,Breast Neoplasms,United States
Dosing and Outcomes Study of Erythropoietic Stimulating Therapies in Patients With Chemotherpay Induced Anemia (DOSE).,IV,Completed,Johnson & Johnson/Janssen Biotech {Centocor Ortho Biotech {J&J/Ortho Biotech}},"Metabolic/Endocrinology: Anemia; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Supportive Care",(N/A); Anemia; Cancer-related; Line of therapy N/A,"Anemia; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Palliative Care; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
"Phase II Trial of Dose Dense Neo-Adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer",II,Completed,"Eli Lilly
Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}
Bristol-Myers Squibb/Celgene",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Inflammatory Breast Neoplasms,United States
Phase II Trial of Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer.,II,Completed,"Sanofi {Sanofi-Aventis {Aventis}}
Novartis
Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
"Phase II Trial of TAC (Docetaxel, Doxorubicin, Cyclophosphamide) For the Therapy of Patients with Stage I-III Breast Cancer and Bone Marrow Micrometastases.",II,Completed,University of Pittsburgh Cancer Institute,Oncology: Breast; Oncology: Metastatic Cancer,Adjuvant; Bone mets; Other mets; Stage I; Stage II; Stage III,Breast Neoplasms; Neoplasm Metastasis,United States
"A Randomized, Open-Label Study Of Epoetin Alfa (PROCRIT) Initiated At 40,000 Units Every Week Versus 80,000 Units Every Two Weeks In Anemic Patients With Cancer Receiving Chemotherapy",II,Completed,"Johnson & Johnson/Janssen Biotech {Centocor Ortho Biotech {J&J/Ortho Biotech}}
Johnson & Johnson/Janssen R&D {Johnson & Johnson/J&JPRD}","Metabolic/Endocrinology: Anemia; Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Supportive Care",Anemia; Cancer-related; Line of therapy N/A,"Anemia; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Palliative Care; Unspecified",United States
"A Pilot Study to Evaluate the Response Rate of Epoetin Alfa (PROCRIT) at 80,000 Units Every Three Weeks in Anemic Patients with Cancer Not Receiving Chemotherapy or Radiation Therapy",III,Completed,"Johnson & Johnson/Janssen Biotech {Centocor Ortho Biotech {J&J/Ortho Biotech}}
Johnson & Johnson/Janssen R&D {Johnson & Johnson/J&JPRD}",Metabolic/Endocrinology: Anemia; Oncology: Breast; Oncology: Prostate; Oncology: Supportive Care,(N/A); Anemia; Cancer-related; Line of therapy N/A,Anemia; Breast Neoplasms; Neoplasms; Palliative Care; Prostatic Neoplasms,United States
"Phase II Trial of Induction Chemotherapy With Weekly Gemcitabine, Epirubicin, Docetaxel as Primary Treatment of Locally Advanced or Inflammatory Breast Cancer Patients.",II,Completed,"Sanofi {Sanofi-Aventis {Aventis}}
Eli Lilly
Pfizer {Pharmacia}
Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Inflammatory Breast Neoplasms,United States
Allogeneic Natural Killer Cells in Patients With Advanced Metastatic Breast Cancer.,II,Completed,"National Institutes of Health/National Cancer Institute
University of Minnesota Cancer Center",Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms; Fallopian Tube Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms,United States
A Phase II Trial of Sequential Epirubicin/Vinorelbine in Patients With Advanced Breast Cancer,II,Terminated,"National Institutes of Health/National Cancer Institute
(Other Hospital/Academic/Medical Center)",Oncology: Breast,First line; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
A Pilot Study of Aromatase Inhibitors for Women at Increased Risk of Breast Cancer Based on Estradiol Levels.,II,Completed,"Jonsson Comprehensive Cancer Center, UCLA
National Institutes of Health/National Cancer Institute
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute",Genitourinary: Menopausal Symptoms; Oncology: Breast,(N/A); Line of therapy N/A; VMS - Unspecified or other severity,Breast Neoplasms; Menopause,United States
A Feasibility Study of Tamoxifen Prevention of Breast Cancer in Hodgkin's Disease Survivors,II,Completed,"AstraZeneca
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Massachusetts General Hospital
Brigham and Womens Hospital","Oncology: Breast; Oncology: Lymphoma, Hodgkin's",(N/A); Classical; Line of therapy N/A; Nodular lymphocyte-predominant,Breast Neoplasms; Hodgkin Disease; Hodgkin Lymphoma,United States
"A Phase II Trial of Trastuzumab, Neupogen, and Vinorelbine Investigating the Effects on Immune Function and Clinical Outcomes in Patients With Metastatic Breast Cancer Overexpressing Her-2/Neu",II,Completed,"Amgen
Dartmouth-Hitchcock Medical Center",Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
Phase II Study of Mild Whole Body Hyperthermia Combined With 5-Fluorouracil/Interferon-a/Liposomal Doxorubicin in Patients With Advanced Malignancy,II,Completed,University of Texas,Oncology: Breast; Oncology: Endometrial; Oncology: Ovarian,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Fever; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Uterine Cervical Neoplasms",United States
A Randomized Pilot Phase II Study of Docetaxel Alone or in Combination With PANVAC(Trademark)-V (Vaccinia) and PANVAC(Trademark)-F (Fowlpox) in Adults With Metastatic Breast Cancer,II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
A Phase II Open Label Trial of Pre-Operative (Neoadjuvant) Letrozole in Combination with Bevacizumab in Post-Menopausal Women with Newly Diagnosed Operable Breast Cancer.,II,Completed,"Roche/Genentech {Genentech}
University of Alabama, Birmingham",Oncology: Breast,Adjuvant; Estrogen receptor positive; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,United States
"A Phase II Trial of Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer.",II,Completed,"Eli Lilly
Roche/Genentech {Genentech}
Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}",Oncology: Breast,First line; HER2 negative; HER2 positive; Stage III; Stage IV,Breast Neoplasms,United States
A  Phase II Randomized Trial of Gemcitabine Plus Paclitaxel and Gemcitabine plus Docetaxel in Patients with Metastatic Breast Cancer.,II,Terminated,Eli Lilly,Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,United States
Phase II Clinical Trial of Gemcitabine and Oxaliplatin in Recurrent or Metastatic Breast Cancer.,II,Terminated,USC/Norris Comprehensive Cancer Center and Hospital,Oncology: Breast,Second line; Stage IV; Third line,Breast Neoplasms,United States
A Phase II Trial of Doxil and Multiday Vinorelbine in Patients With Metastatic Breast Cancer,II,Completed,"Johnson & Johnson/Janssen Biotech {Centocor Ortho Biotech {J&J/Ortho Biotech}}
Hematology Oncology Consultants",Oncology: Breast,First line; Second line; Stage IV,Breast Neoplasms,United States
Continuation of Treatment and Monitoring of Safety in Patients Treated With LY353381 for Advanced Cancer,IV,Completed,Eli Lilly,Oncology: Breast; Oncology: Endometrial; Oncology: Ovarian,(N/A); Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Ovarian Cancer; Ovarian Neoplasms",United States
"Raloxifene Hydrochloride or Placebo in Postmenopausal Women at Risk for Major Coronary Events

Raloxifene Use for The Heart (RUTH) study",III,Completed,"Eli Lilly
Imperial College",Cardiovascular: Coronary Artery Disease; Oncology: Breast,(N/A); Line of therapy N/A; Secondary prevention,Breast Neoplasms; Cardiovascular Diseases; Coronary Artery Disease,"Argentina; Belgium; Brazil; Canada; Czech Republic; Denmark; Finland; France; Germany; Hungary; Ireland; Israel; Italy; Mexico; Netherlands; Norway; Poland; Russia; Singapore; South Africa; Spain; Sweden; Switzerland; Taiwan, China; United Kingdom; United States"
Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer.,II,Completed,"Sanofi {Sanofi-Aventis {Aventis {Rhone Poulenc Rorer SA}}}
University of Michigan Comprehensive Cancer Center",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
A Phase II Study of Preoperative Capecitabine in Women with Operable Hormone Receptor Positive Breast Cancer,II,Terminated,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Beth Israel Deaconess Medical Center
Roche {F. Hoffmann-La Roche}
Brigham and Womens Hospital",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Phase II Study of CT-2103 in Patients with Metastatic Breast Cancer,II,Terminated,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Beth Israel Deaconess Medical Center
Brigham and Womens Hospital",Oncology: Breast,HER2 negative; Second line; Stage IV,Breast Neoplasms,United States
"A Phase II Trial of Cisplatin in Early Stage ER-, PR-, HER-2 Negative Breast Cancer",II,Completed,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Beth Israel Deaconess Medical Center
National Institutes of Health
Massachusetts General Hospital
Brigham and Womens Hospital
Breast Cancer Research Foundation",Oncology: Breast,Adjuvant; HER2 negative; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
"Preoperative Herceptin and Navelbine in Early Stage, HER-2 Positive Breast Cancer.",II,Completed,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Beth Israel Deaconess Medical Center
Massachusetts General Hospital
Brigham and Womens Hospital",Oncology: Breast,Adjuvant; HER2 positive; Neoadjuvant; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
"A Randomized Phase II Study of Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/ Herceptin in Early Stage, HER-2 Positive Breast Cancer.",II,Completed,"Sanofi {Sanofi-Aventis {Aventis}}
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Beth Israel Deaconess Medical Center
Massachusetts General Hospital
Yale University
Brigham and Womens Hospital",Oncology: Breast,HER2 positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer.,II,Completed,"Roche/Genentech {Genentech}
University of Michigan Comprehensive Cancer Center",Oncology: Breast,First line; HER2 positive; Stage IV,Breast Neoplasms,United States
A Phase II Study of Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer.,II,Completed,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Beth Israel Deaconess Medical Center
Massachusetts General Hospital
(Other Hospital/Academic/Medical Center)
Brigham and Womens Hospital",Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
"A Pilot Study of Cytoxan, Epirubicin, and Capecitabine in Women with Stage I/II/IIIA Breast Cancer.",II,Completed,"Pfizer {Pharmacia}
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Beth Israel Deaconess Medical Center
Massachusetts General Hospital
Brigham and Womens Hospital",Oncology: Breast,First line; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Weekly Trastuzumab (Herceptin) and Irinotecan in Patients with HER-2 Positive Advanced Breast Cancer: A Phase II Trial,II,Completed,"National Institutes of Health/National Cancer Institute
University of California, San Francisco",Oncology: Breast,Fourth line or greater; HER2 positive; Second line; Stage IV; Third line,Breast Neoplasms,United States
An Investigation of the Effect of the Promoter Polymorphism in the Glucuronosyltransferase 2B7 Using Epirubicin Clearance and the Ratios of Epirubicin and Epirubicinol Glucuronide to Epirubicin.,II,Completed,Alberta Cancer Board,Oncology: Breast,Adjuvant; Neoadjuvant; Stage 0; Stage I; Stage II; Stage III,Breast Neoplasms,Canada; United States
A Neoadjuvant Phase II Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients: Biologic Correlative Study.,II,Completed,"GlaxoSmithKline
National Institutes of Health/National Cancer Institute
University of New Mexico Cancer Research and Treatment Center
Baylor College of Medicine",Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
"Phase II Randomized Trial of Faslodex and Herceptin, Alone and Combined, in the First - Line Treatment of Hormone Receptor-Positive, HER-2/Neu-Overexpressing Metastatic Breast Cancer",II,Terminated,"AstraZeneca
Roche/Genentech {Genentech}
University of California Los Angeles
Translational Oncology Research International",Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Stage IV,Breast Neoplasms,United States
Neoadjuvant Therapy with Herceptin and Taxol for Stage II/III Breast Cancer,II,Completed,"Bristol-Myers Squibb
Roche/Genentech {Genentech}
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Beth Israel Deaconess Medical Center
Bayer AG
Massachusetts General Hospital
(Other Hospital/Academic/Medical Center)",Oncology: Breast,Adjuvant; HER2 positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
"A Pivotal Phase III Observer-Blind, Randomized Clinical Trial of the Efficacy and Safety of APF530 Compared to Aloxi For The Prevention of Acute-Onset and Delayed-Onset Chemotherapy-Induced Nausea and Vomiting Following The Administration of Either Moderately or Highly Emetogenic Chemotherapy Regimens.",III,Completed,Heron Therapeutics {A. P. Pharma},"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Supportive Care",(N/A); Emesis; First line; Second line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Nausea; Ovarian Cancer; Ovarian Neoplasms; Palliative Care; Vomiting",India; Poland; United States
A Phase II Study of the Effects of Herceptin in Patients with Locally Advanced HER-2/NEU Overexpressing Breast Cancer,II,Completed,Roche/Genentech {Genentech},Oncology: Breast,Adjuvant; HER2 positive; Neoadjuvant; Stage III; Stage IV,Breast Neoplasms,United States
Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) (NSC 701852) as Salvage Therapy in Metastatic Breast Cancer.,II,Terminated,"National Institutes of Health/National Cancer Institute
California Cancer Consortium",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin (A)/Cyclophosphamide) and/or Weekly Paclitaxel,II,Completed,"National Institutes of Health/National Cancer Institute
Duke Comprehensive Cancer Center",Oncology: Breast,Adjuvant; HER2 positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Phase II Study of High-Dose Estrogen in Postmenopausal Women With Hormone Receptor-Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapies.,II,Terminated,"National Institutes of Health/National Cancer Institute
Robert H. Lurie Comprehensive Cancer Center at Northwestern University",Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
A Phase II Study of XL647 in Subjects with Metastatic Breast Cancer.,II,Terminated,Exelixis,Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
"A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer.",II,Completed,"Roche/Genentech {Genentech}
Jonsson Comprehensive Cancer Center, UCLA
National Institutes of Health/National Cancer Institute
Translational Oncology Research International",Oncology: Breast,HER2 negative; Maintenance/Consolidation; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,Canada; Ireland; United States
"An Open-Label Study of Xeloda Plus Taxotere on Treatment Response in Patients with HER2-Neu-Negative, and the Addition of Herceptin for HER2-Neu-Positive Breast Cancer.",IV,Completed,Roche {F. Hoffmann-La Roche},Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant (Faslodex) in Breast Ductal Carcinoma (DCIS).,II,Completed,"AstraZeneca
Cedars-Sinai Medical Center",Oncology: Breast,Neoadjuvant; Stage 0,"Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating",United States
Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.,III,Completed,"Cancer and Leukemia Group B (CALGB)
Eastern Cooperative Oncology Group (ECOG)
National Surgical Adjuvant Breast and Bowel Project (NSABP)
Canadian Cancer Trials Group {NCIC Clinical Trials Group}
North Central Cancer Treatment Group (NCCTG)
Southwest Oncology Group
National Institutes of Health/National Cancer Institute
Cancer Trials Support Unit - CTSU/NCI",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; HER2 positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,Canada; United States
Patterns of Genetic Expression Associated with Response to Doxorubicin Versus Docetaxel As Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer.,II,Completed,"UNC Lineberger Comprehensive Cancer Center
(Other Hospital/Academic/Medical Center)
Centro Nacional de Investigaciones Oncologicas (CNIO)",Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,Spain; United States
GPX-100 Phase II Breast cancer Combination therapy with herceptin,II,Terminated,Gem Pharmaceuticals,Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
"Phase II, Open Label, Non-Randomized, Efficacy and Safety Study of an Intravenous Formulation of the Anthracycline Analog, GPX-100, in the Treatment of Metastatic Breast Cancer.",II,Terminated,Gem Pharmaceuticals,Oncology: Breast,First line; Stage IV,Breast Neoplasms; Neoplasm Metastasis,Bulgaria; United States
GPX-100 Phase II breast cancer combination therapy with paclitaxel,II,Terminated,Gem Pharmaceuticals,Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
"An Open-Label Study of Xeloda Plus Avastin at Time of Disease Progression in Treatment-naïve Women With HER2-Negative Metastatic Breast Cancer.

XCALIBr (Xeloda in Combination with Avastin as First-Line Treatment for HER2-Negative Metastatic Breast Cancer).",II,Completed,Roche {F. Hoffmann-La Roche},Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Stage III; Stage IV,Breast Neoplasms,United States
Anti-Angiogenesis Treatment After Preoperative Chemotherapy: A Pilot Study in Women with Operable Breast Cancer.,II,Completed,"Roche/Genentech {Genentech}
Beth Israel Deaconess Medical Center
University of California, San Francisco
Indiana University School of Medicine
University of North Carolina",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"An Open-Label, Randomized Phase 2 Study to Validate a Patient Satisfaction Questionnaire for Anemia Treatment in Female Breast Cancer Patients Treated with Darbepoetin Alfa or Recombinant Human Erythropoietin for Anemia due to Chemotherapy",II,Completed,Amgen,Metabolic/Endocrinology: Anemia; Oncology: Breast; Oncology: Supportive Care,(N/A); Anemia; Cancer-related; Line of therapy N/A,Anemia; Breast Neoplasms; Palliative Care,United States
Phase II Feasibility Trial Incorporating Bevacizumab Into Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Patients With Lymph Node Positive Breast Cancer.,II,Completed,"Cancer and Leukemia Group B (CALGB)
Eastern Cooperative Oncology Group (ECOG)
North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute",Oncology: Breast,Adjuvant; Stage II; Stage III,"Breast Neoplasms; Breast Neoplasms, Male",United States
"A Randomized, Open-label, Comparative Study to Estimate the Effect of Darbepoetin Alfa on Hospital Days, Economic Outcomes, and Health-related Quality of Life in Subjects With Nonmyeloid Malignancies and Anemia of Cancer.",II,Terminated,Amgen,"Metabolic/Endocrinology: Anemia; Oncology: Breast; Oncology: Gastric; Oncology: Head/Neck; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Multiple Myeloma; Oncology: Soft Tissue Sarcoma; Oncology: Supportive Care",(N/A); Aggressive; Anemia; Cancer-related; First line; Indolent; Second line; Stage I; Stage II; Stage III; Stage IV; Untreated,"Anemia; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chronic Lymphocytic Leukemia; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Leukemia, Lymphocytic, Chronic, B-Cell; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Multiple Myeloma; Neoplasms; Palliative Care; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma",United States
"A Phase II Trial of Taxotere, Carboplatin and Herceptin in Locally Advanced or Inflammatory Breast Cancer",II,Terminated,"Sanofi {Sanofi-Aventis {Aventis}}
National Institutes of Health/National Cancer Institute
Cancer Institute of New Jersey",Oncology: Breast,Adjuvant; HER2 positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms; Inflammatory Breast Neoplasms,United States
A Phase II Study of GW572016 and Tamoxifen in Patients With Metastatic Breast Cancer Resistant to Single-Agent Tamoxifen,II,Terminated,National Institutes of Health/National Cancer Institute,Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Breast Neoplasms, Male; Carcinoma",United States
"A Multicenter Phase 3, Randomized Comparison of the Safety and Efficacy of Weekly TOCOSOL(R) Paclitaxel Vs. Weekly Paclitaxel Injection in the Treatment of Metastatic Breast Cancer.",III,Terminated,"Achieve Life Sciences {OncoGenex Pharmaceuticals {Sonus Pharmaceuticals}}
Bayer AG/Bayer Pharmaceuticals {Bayer HealthCare {Bayer Schering Pharma {Schering AG}}}
Sorrento Therapeutics/Scilex Pharmaceuticals {Scilex Holding {SCILEX Pharmaceuticals}}",Oncology: Breast,First line; Second line; Stage IV,Breast Neoplasms,Belgium; Hungary; Israel; Italy; Slovakia; South Africa; Spain; United Kingdom; United States
Gemcitabine Plus Vinorelbine as First-line Treatment of Metastatic Breast Cancer.,II,Completed,Eli Lilly,Oncology: Breast,First line; Stage IV,Breast Neoplasms,Turkey; United States
Taxanes in metastatic breast cancer patients with impaired liver function,II,Completed,"MD Anderson Cancer Center, University of Texas",Oncology: Breast,First line; Second line; Stage IV,Breast Neoplasms,United States
High-dose therapy with autologous stem cell rescue in patients with breast cancer at high risk for relapse,II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Line of therapy N/A; Stage II; Stage III,Breast Neoplasms,United States
Toxicity and tolerability of dose dense (q 14 days) docetaxel (T) / doxorubicin (A) / cyclophosphamide (C) (TAC) in stage II - III breast cancer.,II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,First line; Stage II; Stage III,Breast Neoplasms,United States
Phase II Pilot Trial of Dose-Dense Docetaxel Followed by Doxorubicin Plus Cyclophosphamide (T-AC) Given as Adjuvant or Neoadjuvant Treatment for Women with Node Positive or High-Risk Primary Breast Cancer.,II,Completed,"Sanofi {Sanofi-Aventis {Aventis}}
Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}",Oncology: Breast,Adjuvant; Neoadjuvant; Stage III,Breast Neoplasms,United States
Suppression of bone turnover markers by zoledronic acid and correlation with clinical outcome.,IV,Completed,Novartis,Oncology: Breast; Oncology: Multiple Myeloma,Line of therapy N/A; Stage II; Stage III; Stage IV,Breast Neoplasms; Multiple Myeloma,Canada; United Kingdom; United States
A phase II study of docetaxel and gemcitibine as neoadjuvant chemotherapy in stages IIIA & B breast cancer.,II,Completed,Sanofi {Sanofi-Aventis},Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage III,Breast Neoplasms,United States
The effects of sequential chemotherapy on locally advanced breast cancer (LABC) in African-Americans,IV,Completed,(Other Academic Cancer Center),Oncology: Breast,First line; HER2 positive; Stage III,Breast Neoplasms,United States
Cancer therapy with immature monocyte-derived dendritic cells in patients with advanced breast cancer.,II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms,Germany; United States
Prediction of hormone response in breast cancer by microarray analysis of sequential tumour biopsies from patients receiving neoadjuvant therapy with letrozole.,II,Completed,Novartis,Oncology: Breast,Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United Kingdom; United States
"A randomized, double-blind, placebo-controlled trial of oral ibandronate for the treatment of metastatic bone disease in breast cancer.",III,Completed,Roche {F. Hoffmann-La Roche},Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; Line of therapy N/A; Stage IV,Breast Neoplasms; Neoplasm Metastasis,Australia; United States
"Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial.",III,Completed,Roche {F. Hoffmann-La Roche},CNS: Pain (nociceptive); Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; Cancer-related; First line; Second line; Stage IV,Breast Neoplasms; Cancer pain; Cancer Pain; Neoplasm Metastasis; Nociceptive Pain,Australia; Bulgaria; New Zealand; Russia; South Africa; United States
The treatment of pregnant women with breast cancer and the outcomes of the children exposed to chemotherapy in utero.,IV,Completed,"MD Anderson Cancer Center, University of Texas",Oncology: Breast,Adjuvant; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
A Pilot Study to Evaluate the Effects of Omega-3 Fatty Acids on Intermediate Markers of Breast Cancer.,II,Completed,Cedars-Sinai Medical Center,Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
A Multicenter Randomized Double-Blind Trial Of Targretin Capsules Modifying Immunophenotypic Markers Related To Breast Cancer Progression In Breast Tissue From Genetically Identified High Risk Patients.,II,Completed,"National Institutes of Health/National Cancer Institute
Eisai
National Institutes of Health
Baylor College of Medicine
Ligand Pharmaceuticals",Oncology: Breast,(N/A); BRCA; Line of therapy N/A,Breast Neoplasms,United States
"A Randomized, Double Blind, Active-Controlled Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects with Non-Myeloid Malignancy Receiving Multicycle Chemotherapy",III,Completed,Amgen,"Metabolic/Endocrinology: Anemia; Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Supportive Care",(N/A); Anemia; Cancer-related; Line of therapy N/A,"Anemia; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms; Palliative Care",Austria; Belgium; Bulgaria; Czech Republic; Denmark; Estonia; Finland; France; Germany; Hungary; Italy; Latvia; Lithuania; Netherlands; Norway; Poland; Portugal; Romania; Slovakia; Spain; Sweden; Switzerland; Ukraine; United Kingdom; United States
"Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of d-MPH in the Treatment of Fatigue and Neurobehavioral Impairment Related to Chemotherapy in Adult Cancer Patients",II,Completed,Bristol-Myers Squibb/Celgene,Oncology: Breast; Oncology: Ovarian; Oncology: Supportive Care,(N/A); Cachexia; Line of therapy N/A; Neurotoxicity,Breast Neoplasms; Cachexia; Fatigue; Ovarian Cancer; Ovarian Neoplasms; Palliative Care,United States
Phase II study of neoadjuvant therapy with epirubicin and Docetaxel for women with locally advanced breast cancer.,II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Adjuvant; Estrogen receptor positive; Neoadjuvant; Stage III,Breast Neoplasms,United States
"A Phase II Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of Lapatinib in Combination With Paclitaxel as Neoadjuvant Therapy in Patients With Newly Diagnosed Inflammatory Breast Cancer.",II,Completed,GlaxoSmithKline,Oncology: Breast,HER2 negative; HER2 positive; Neoadjuvant; Stage III; Stage IV,Breast Neoplasms; Inflammatory Breast Neoplasms,Australia; Belgium; Canada; France; Israel; New Zealand; Portugal; Spain; Tunisia; United Kingdom; United States
"Phase II Neoadjuvant Trial of Docetaxel (Taxotere), Carboplatin, and Capecitabine (Xeloda) in the Treatment of Early Stage Locally Advanced and Inflammatory Breast Cancer.",II,Completed,"Sanofi {Sanofi-Aventis {Aventis}}
(Other Cooperative Group)",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms; Inflammatory Breast Neoplasms,United States
An Open-Labeled Pilot Study to Evaluate the Effects of High Dose PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Anemic Cancer Patients Receiving Chemotherapy on a Weekly or Every Four Week Regimen.,II,Completed,"Johnson & Johnson/Janssen Biotech {Centocor Ortho Biotech {J&J/Ortho Biotech}}
Johnson & Johnson/Janssen R&D {Johnson & Johnson/J&JPRD}","Metabolic/Endocrinology: Anemia; Oncology: Bladder; Oncology: Breast; Oncology: Endometrial; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Supportive Care; Oncology: Testicular; Oncology: Unspecified Hematological Cancer",Anemia; Cancer-related; Line of therapy N/A; Stage I; Stage II; Stage III; Stage IV,"Anemia; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Endometrial Neoplasms; Hematologic Neoplasms; Kidney Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Palliative Care; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Testicular Cancer; Testicular Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
Phase II trial of neoadjuvant docetaxel in patients with large locally advanced breast cancer.,II,Completed,"Sanofi {Sanofi-Aventis {Aventis}}
Baylor College of Medicine",Oncology: Breast,Neoadjuvant; Stage III,Breast Neoplasms,United States
A study of safety and effectiveness of primary systemic therapy with docetaxel and trastuzumab in HER-2 positive breast cancer in adjuvant setting.,II,Completed,University of Rochester,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Stage II; Stage III,Breast Neoplasms,United States
A Pilot Study of Neoadjuvant Biweekly Doxorubicin and Cyclophosphamide With GMCSF Followed by Weekly Carboplatin/Paclitaxel With Plus and Minus Transtuzumab (TC + or - H) in the Treatment of Breast Cancer,II,Completed,"University of California Medical Center, Irvine",Oncology: Breast,HER2 negative; HER2 positive; Neoadjuvant; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
A Study of Neoadjuvant q4week Carboplatin and Weekly Paclitaxel Plus Trastuzumab in Resectable and Locally Advanced Breast Cancer.,II,Completed,"Bristol-Myers Squibb
Brown University Oncology Group
Roche/Genentech",Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
Phase II trial of gemcitabine plus trastuzumab in minimally pretreated HER2 overexpressing metastatic breast cancer.,II,Completed,"Eli Lilly
Roche/Genentech {Genentech}
Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}",Oncology: Breast,First line; HER2 positive; Second line; Stage IV; Third line,Breast Neoplasms,United States
Phase II Study of GM-CSF to Overcome Herceptin-Resistant HER-2/Neu-Overexpressing Metastatic Breast Cancer,II,Completed,"MD Anderson Cancer Center, University of Texas
Bayer AG/Bayer Pharmaceuticals",Oncology: Breast,Fourth line or greater; HER2 positive; Second line; Stage IV; Third line,Breast Neoplasms,United States
"A Phase ll Study of Neoadjuvant Chemotherapy With Sequential Weekly Nanoparticle Albumin Bound Paclitaxel (Abraxane) Followed by 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) in Locally Advanced Breast Cancer",II,Completed,"National Surgical Adjuvant Breast and Bowel Project (NSABP)
Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}}",Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,Belgium; Canada; United States
A Phase II Trial of Two Schedules of Perifosine in Combination with Endocrine Therapy for Patients with Estrogen Receptor or Progesterone Receptor Positive Metastatic Breast Cancer,II,Completed,Akebia Therapeutics {Keryx Biopharmaceuticals},Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
Phase II Trial of Weekly Nab (Nanoparticle Albumin Bound)-Paclitaxel (Nab-paclitaxel) (Abraxane) in Combination With Gemcitabine in Patients With Metastatic Breast Cancer,II,Completed,"North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute
Mayo Clinic Cancer Center",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"An Open-Label, Multicenter Extension Study of Recombinant Humanized Monoclonal Anti-VEGF Antibody (rhuMAb VEGF, Bevacizumab) in Subjects Treated with rhuMAb VEGF in a Previous Genentech-Sponsored Phase I or Phase II Cancer Study",II,Completed,Roche/Genentech {Genentech},"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Prostate",Line of therapy N/A; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Prostatic Neoplasms; Unspecified",United States
Induction of CD8 T lymphocytes specific for the recognition of a breast cancer-associated polymorphism in the HER2/neu protein in a clinical trial with the HER2 E75-peptide vaccine.,II,Completed,Walter Reed Army Institute of Research - WRAIR,Oncology: Breast,Line of therapy N/A; Stage 0; Stage I; Stage II,Breast Neoplasms,United States
"Continuous Temozolomide (SCH 52365) in Patients with Advanced or Metastatic Soft Tissue Sarcoma or Metastatic Breast Cancer, Phase II",II,Completed,"Merck & Co. {Schering-Plough}
University of Washington",Oncology: Breast; Oncology: Soft Tissue Sarcoma,Metastatic; Second line; Stage IV; Unresectable,Breast Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma,United States
"An Open Label, Pilot Study of Dose-Dense Adriamycin plus Cyclophosphamide (AC) followed by ABI-007 as Adjuvant Therapy for Patients with Breast Cancer.",II,Completed,Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}},Oncology: Breast,Adjuvant; Stage I; Stage II,Breast Neoplasms,United States
"A Phase II, Double-blind, Randomized, Placebo-controlled, Multi-center Study Assessing the Value of Adding Everolimus to Letrozole as Preoperative Therapy of Primary Breast Cancer in Postmenopausal Women.",II,Completed,Novartis,Oncology: Breast,Estrogen receptor positive; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,Austria; Belgium; Canada; France; Germany; Italy; Russia; Spain; United Kingdom; United States
Phase II Trial of Docetaxel and Carboplatin Administered Every Two Weeks as Induction Therapy for Stage II or III Breast Cancer.,II,Completed,"North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute",Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,United States
Phase II Trial of Simple Oral Therapy (Continuous Oral Cyclophosphamide and Capecitabine) in Patients With Metastatic Breast Cancer.,II,Completed,"Southwest Oncology Group
National Institutes of Health/National Cancer Institute",Oncology: Breast,First line; Second line; Stage IV; Third line,Breast Neoplasms,United States
"A Randomized, Open-Label, Phase III Study of RPR109881 IV Every 3 Weeks Versus Capecitabine (Xeloda) Tablets Twice Daily for 2 Weeks in 3-Week Cycles in Patients With Metastatic Breast Cancer Progressing After Taxanes and Anthracycline Therapy",III,Terminated,"Jonsson Comprehensive Cancer Center, UCLA
National Institutes of Health/National Cancer Institute
Sanofi {Sanofi-Aventis}",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; Colombia; Costa Rica; Czech Republic; Finland; France; Germany; Hungary; Ireland; Israel; Italy; Mexico; New Zealand; Norway; Poland; Portugal; Romania; Slovenia; South Africa; South Korea; Spain; Switzerland; Taiwan, China; United Kingdom; United States"
"A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study.",II,Completed,"Eli Lilly
Eisai {MGI Pharma}
Walther Cancer Institute","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Neuroendocrine; Oncology: Supportive Care",(N/A); Aggressive; Emesis; First line; Indolent; Pulmonary; Untreated,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neuroendocrine Tumors; Palliative Care; Small Cell Lung Carcinoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Vomiting",United States
A Pilot Trial Incorporating ZD1839 (IRESSA) into Adjuvant Therapy for Breast Cancer.,II,Completed,Hoosier Cancer Research Network {Hoosier Oncology Group},Oncology: Breast,Adjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Phase II Trial of Capecitabine, Oxaliplatin and Trastuzumab (CAPOX-T) in Patients with Previously Treated HER-2 Positive Metastatic Breast Cancer : Hoosier Oncology Group BRE03-61",II,Terminated,"Walther Cancer Institute
Roche {F. Hoffmann-La Roche}
Sanofi {Sanofi-Aventis}",Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients with Previously Treated Metastatic Breast Cancer : Hoosier Oncology Group BRE03-60.,II,Completed,"Walther Cancer Institute
Roche {F. Hoffmann-La Roche}
Sanofi {Sanofi-Aventis}",Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
"An Open-Label, Randomized Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa (NESP).

Successful Outcomes in Anemia Research (SOAR).",II,Completed,Amgen,"Metabolic/Endocrinology: Anemia; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Supportive Care; Oncology: Unspecified Cancer",Aggressive; Anemia; Cancer-related; Indolent; Line of therapy N/A,"Anemia; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Palliative Care; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms",United States
A Phase II Study of Alimta as First Line Chemotherapy for Advanced or Metastatic Breast Cancer.,II,Terminated,Eli Lilly,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage III; Stage IV,"Breast Neoplasms; Breast Neoplasms, Male; Carcinoma, Ductal",United States
"A Phase II Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Lapatinib in Patients With Relapsed or Refractory Inflammatory Breast Cancer",II,Completed,"GlaxoSmithKline
National Institutes of Health/National Cancer Institute",Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms; Inflammatory Breast Neoplasms,Belgium; Canada; France; Israel; Spain; Tunisia; United Kingdom; United States
"An Open-Label Phase 2a Study in Subjects With N-Cadherin Positive, Advanced or Recurrent Solid Tumors to Investigate the Safety and Efficacy of ADH-1 Administered Intravenously as a Single Agent (Adherex Protocol Number AHX-01-201)",II,Completed,Fennec Pharmaceuticals {Adherex Technologies},"Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Renal",Adenocarcinoma; Large Cell; Second line; Squamous Cell; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Cancer; Esophageal Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",Canada; United States
"A Randomized, Open Label, Active Controlled Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous Bisphosphonates.",III,Completed,Amgen,Oncology: Bladder; Oncology: Breast; Oncology: Metastatic Cancer; Oncology: Multiple Myeloma; Oncology: Prostate; Oncology: Renal,Bone mets; Line of therapy N/A; Stage II; Stage III; Stage IV,"Bone Marrow Diseases; Bone Neoplasms; Breast Neoplasms; Carcinoma, Renal Cell; Kidney Neoplasms; Multiple Myeloma; Neoplasm Metastasis; Neoplasms; Neoplasms, Plasma Cell; Prostatic Neoplasms; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Belgium; Canada; France; Mexico; Poland; United States
Neoadjuvant Trastuzumab Induces Apoptosis in Primary Breast Cancers,II,Completed,"Yale Comprehensive Cancer Center
Baylor College of Medicine",Oncology: Breast,HER2 positive; Neoadjuvant; Stage II,Breast Neoplasms,United States
Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine.,II,Completed,"Amgen
Bristol-Myers Squibb
National Institutes of Health",Oncology: Breast; Oncology: Supportive Care,Line of therapy N/A; Neurotoxicity; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms; Palliative Care,United States
"Randomized Double Blind, Placebo Controlled Trial of Neuroprotective Effects of Epoetin alfa (Procrit) in Patients Receiving Adjuvant Chemotherapy for Breast Cancer 
(DOD/Procrit).",II,Completed,West Virginia University,Oncology: Breast; Oncology: Supportive Care,Adjuvant; Neurotoxicity; Stage I; Stage II; Stage III,Breast Neoplasms; Palliative Care,United States
A Randomized Study of Weekly Vinorelbine (Navelbine®) Alone or in Combination With Trastuzumab (Herceptin®) (NSC-688097) for Patients With HER-2-Positive Metastatic Breast Cancer Whose Tumors Have Progressed After Taxane + Trastuzumab Combination Therapy - Phase III,III,Terminated,"Southwest Oncology Group
National Institutes of Health/National Cancer Institute",Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,Canada; United States
A Randomized Phase II Trial of Three Doses of a study agent in Combination with Trastuzumab (Perifosine 206).,II,Completed,Akebia Therapeutics {Keryx Biopharmaceuticals},Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
A Phase II Multicenter Uncontrolled Trial of BAY43-9006 in Subjects With Metastatic Breast Cancer.,II,Completed,"Bayer AG/Bayer Pharmaceuticals
Amgen {Onyx Pharmaceuticals}",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,Germany; Italy; United States
Phase II Study of Letrozole (Femara) and Celecoxib (Celebrex) in Postmenopausal Women With Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer.,II,Terminated,"National Institutes of Health/National Cancer Institute
Cancer Institute of New Jersey",Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,United States
Phase II Feasibility and Pharmacokinetic Study of Concurrent Administration of Trastuzumab and High-Dose Chemotherapy in Advanced HER2+ Breast Cancer,II,Completed,(Other Academic Cancer Center),Oncology: Breast,Fourth line or greater; HER2 positive; Maintenance/Consolidation; Second line; Stage II; Stage III; Stage IV; Third line,Breast Neoplasms,United States
A Phase II trial of combination therapy with capecitabine (C) and weekly paclitaxel (P) first-line therapy for metastatic breast cancer (MBC) in taxane-naive patients.,II,Completed,Roche,Oncology: Breast,Estrogen receptor positive; First line; Stage IV,Breast Neoplasms,United States
Neoadjuvant Administration of Gemcitabine Plus Doxorubicin Followed by Gemcitabine Plus Cisplatin in Large or Locally Advanced Operable Breast Cancer: A Phase II Study.,II,Completed,Eli Lilly,Oncology: Breast,Neoadjuvant; Stage II; Stage III,Breast Neoplasms,India; United Kingdom; United States
Gemcitabine and docetaxel in metastatic breast cancer  further experience.,II,Completed,"Eli Lilly
Sanofi {Sanofi-Aventis}",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
Phase II trial of weekly docetaxel (DOC) and prolonged capecitabine (C) in metastatic breast cancer (MBC) patients (pts).,II,Completed,"Sanofi {Sanofi-Aventis {Aventis}}
Roche
Ohio State University",Oncology: Breast,First line; HER2 negative; HER2 positive; Second line; Stage IV; Third line,Breast Neoplasms,United States
"A randomized, multicenter phase III trial comparing regimens of doxorubicin + cyclophosphamide followed by paclitaxel or doxorubicin + paclitaxel followed by weekly paclitaxel as adjuvant therapy for patients with high risk breast cancer",III,Completed,Bristol-Myers Squibb,Oncology: Breast,Adjuvant; Estrogen receptor positive; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
A Phase II Study of Pegfilgrastim (Neulasta) and Darbepoetin Alfa (Aranesp) in Support of Dose-Dense Adjuvant Chemotherapy for Breast Cancer.,II,Completed,"Amgen
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Beth Israel Deaconess Medical Center
Massachusetts General Hospital
(Other Hospital/Academic/Medical Center)",Metabolic/Endocrinology: Anemia; Oncology: Breast; Oncology: Supportive Care,Adjuvant; Anemia; Cancer-related; Neoadjuvant; Neutropenia; Stage I; Stage II; Stage III,Anemia; Breast Neoplasms; Neutropenia; Palliative Care,United States
Study of the Effect of Letrozole on Breast Biomarkers of High Risk Postmenopausal Women Receiving Hormone Replacement Therapy.,II,Completed,"Novartis
University of Kansas",Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
A Randomized Open-Labeled Phase II Study of Combretastatin A-4 Phosphate in Combination with Paclitaxel and Carboplatin to Evaluate the Safety and Efficacy in Subjects with Advanced Imageable Malignancies,II,Completed,Oncotelic Therapeutics {Mateon Therapeutics {OXiGENE}},"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Thyroid",First line; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Ovarian Cancer; Ovarian Neoplasms; Thyroid Neoplasms; Unspecified",United States
A single-arm phase II study of gemcitabine and irinotecan in patients with metastatic breast cancer.,II,Completed,"Pfizer
National Comprehensive Cancer Network",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
"A Randomised, Double-Blind, Parallel-group, Multicentre, Phase III Study Comparing the Efficacy and Tolerability of Fulvestrant (FASLODEX) 500 mg With Fulvestrant (FASLODEX) 250 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy. 

COmparisoN of FASLODEX In Recurrent or Metastatic breast cancer (CONFIRM).",III,Completed,AstraZeneca,Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,Belgium; Brazil; Chile; Colombia; Czech Republic; Hungary; India; Italy; Malta; Mexico; Poland; Russia; Slovakia; Spain; Ukraine; United States; Venezuela
Phase II Study of FR901228 in Patients With Metastatic Breast Cancer.,II,Completed,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast,Second line; Stage IV,"Breast Neoplasms; Breast Neoplasms, Male",United States
A Phase 2 Study of GW572016 for Brain Metastases in Patients with HER2-Positive Breast Cancer,II,Completed,"National Institutes of Health/National Cancer Institute
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; HER2 positive; Second line; Stage IV,"Brain Neoplasms; Breast Neoplasms; Breast Neoplasms, Male; Central Nervous System Neoplasms; Neoplasm Metastasis",United States
A Phase II Open Label Study of E7389 (Halichondrin B Analog) in Patients With Advanced/Metastatic Breast Cancer Previously Treated With Chemotherapy Including An Anthracycline and A Taxane,II,Completed,Eisai,Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms; Neoplasms,United States
"Clinical Outcomes in Patients with HER2 Gene-Amplified Metastatic Breast Cancer Treated with First Line Herceptin in Combination with a Taxane: A Phase IV, Prospective, Community Based Study",IV,Completed,Roche/Genentech {Genentech},Oncology: Breast,First line; HER2 positive; Stage IV,Breast Neoplasms,United States
Phase 3 Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer.,III,Terminated,Intarcia Therapeutics {BioMedicines},Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Stage III; Stage IV,"Breast Neoplasms; Neoplasms; Neoplasms, Hormone-Dependent",Bulgaria; Romania; Russia; Ukraine; United States
Phase III Randomized Trial of Gadolinium Texaphyrin (PCI-0120) Injection as a Radiation Sensitizer in Patients Receiving Whole Brain Radiation Therapy for the Treatment of Brain Metastases.,III,Completed,AbbVie/Pharmacyclics,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Supportive Care",Adenocarcinoma; CNS mets; First line; Large Cell; Neurotoxicity; Other subtype; Squamous Cell; Stage IV,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Melanoma; Neoplasm Metastasis; Palliative Care",Canada; France; Netherlands; United Kingdom; United States
"Neoadjuvant Chemotherapy in Palpable Breast Cancer: Evaluation of Physiologic, Radiologic, and Molecular Markers in Predicting Response",II,Completed,"Bristol-Myers Squibb
National Institutes of Health/National Cancer Institute
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute",Oncology: Breast,HER2 negative; HER2 positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
A Phase II Clinical Trial Of 17-Allylamino-17-Demethoxygeldanamycin (17-AAG) In Chemotherapy Refractory Metastatic Breast Cancer,II,Completed,"Barbara Ann Karmanos Cancer Institute
National Institutes of Health/National Cancer Institute
Bristol-Myers Squibb {Kosan Biosciences}",Oncology: Breast,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
A Phase II Trial Of Gemcitabine And Triapine In Refractory Metastatic Breast Cancer,II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,HER2 positive; Second line; Stage IV,"Breast Neoplasms; Breast Neoplasms, Male",United States
A Phase II Trial of Pre-Operative Taxol and Carboplatin in Women With Newly Diagnosed Locally Advanced Operable Breast Cancer.,II,Completed,"Bristol-Myers Squibb
National Institutes of Health/National Cancer Institute
University of Alabama at Birmingham Comprehensive Cancer Center",Oncology: Breast,Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
Phase II Trial of Raf Kinase Inhibitor BAY 43-9006 as Single Agent in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane.,II,Terminated,"North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute",Oncology: Breast,First line; HER2 negative; HER2 positive; Second line; Stage IV,"Breast Neoplasms; Breast Neoplasms, Male",United States
"A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects with Anemia of Cancer.",II,Completed,Amgen,Metabolic/Endocrinology: Anemia; Oncology: Breast; Oncology: Prostate; Oncology: Supportive Care; Oncology: Unspecified Hematological Cancer,(N/A); Anemia; Cancer-related; Line of therapy N/A,Anemia; Breast Neoplasms; Hematologic Neoplasms; Palliative Care; Prostatic Neoplasms,United States
Phase II Study of Thalidomide in Combination With Capecitabine In Patients With Metastatic Breast Cancer,II,Terminated,"Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}
Bristol-Myers Squibb/Celgene",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
A Phase II Randomized Crossover Study Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer,II,Completed,"Sanofi {Sanofi-Aventis {Aventis}}
Johnson & Johnson/Janssen Biotech {Centocor Ortho Biotech {J&J/Ortho Biotech}}
Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}",Oncology: Breast,First line; Stage IV,Breast Neoplasms,United States
A Phase II Trial of Epirubicin/Docetaxel in the First-Line Treatment of Patients with Metastatic Breast Cancer.,II,Terminated,"Sanofi {Sanofi-Aventis {Aventis}}
Pfizer {Pharmacia}
Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}",Oncology: Breast,First line; Stage III; Stage IV,Breast Neoplasms,United States
A Randomized Multicenter Trial Comparing Weekly Docetaxel and CMF in the Adjuvant Treatment of Women with High-Risk Breast Cancer Who Are > 65 Years Old or Are Not Candidates for Anthracycline-Based Adjuvant Therapy,III,Completed,"Sanofi {Sanofi-Aventis {Aventis}}
Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}",Oncology: Breast,Adjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Continuing Outcomes Relevant to Evista: A Study of Raloxifene HCl and Placebo in the Prevention of Invasive Breast Cancer in Postmenopausal Women with Osteoporosis.,III,Completed,Eli Lilly,Oncology: Breast,(N/A); Estrogen receptor positive; Line of therapy N/A,Breast Neoplasms,Argentina; Belgium; France; United Kingdom; United States
"A Randomized, Double-Blind, Phase II Study Evaluating the Safety of same Day versus Next Day Administration of Pegfilgrastim With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) in Women with Breast Cancer.",II,Completed,Amgen,Oncology: Breast; Oncology: Supportive Care,First line; Neutropenia; Stage II; Stage III; Stage IV,Breast Neoplasms; Neutropenia; Palliative Care,United States
A Phase II Study of Letrozole in Combination With Bevacizumab in Patients With Estrogen Receptor- and/or Progesterone Receptor-Positive Unresectable Locally Advanced and/or Metastatic (Stage IV) Breast Cancer.,II,Completed,"Roche/Genentech {Genentech}
Novartis
National Institutes of Health/National Cancer Institute
University of California, San Francisco",Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
Phase III Randomized Study of High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation for Patients With Metastatic Breast Cancer in Complete Response by Standard Treatment,III,Terminated,"MD Anderson Cancer Center, University of Texas",Oncology: Breast,First line; HER2 positive; Stage IV,Breast Neoplasms,United States
A Neo-Adjuvant Study of Sequential Epirubicin and Docetaxel in Combination with Capecitabine in Patients with Locally Advanced Breast Cancer.,II,Completed,"National Institutes of Health/National Cancer Institute
Roche
Pfizer
Mayo Clinic
Sanofi {Sanofi-Aventis}",Oncology: Breast,Neoadjuvant; Stage III,Breast Neoplasms,Ghana; United States
Phase II Trial Of Subcutaneous Amifostine For Reversal Of Persistent Paclitaxel-Induced Peripheral Neuropathy.,II,Terminated,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Ovarian; Oncology: Prostate; Oncology: Supportive Care",Neurotoxicity; Second line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Lung Neoplasms; Neurotoxicity Syndromes; Ovarian Cancer; Ovarian Neoplasms; Palliative Care; Peripheral Nervous System Diseases; Prostatic Neoplasms; Small Cell Lung Carcinoma",United States
Phase II Study of Capecitabine in Combination With Vinorelbine and Trastuzumab for the First- or Second-LineTreatment of HER2+ Metastatic Breast Cancer.,II,Completed,"National Institutes of Health/National Cancer Institute
Alliance for Clinical Trials in Oncology",Oncology: Breast,First line; HER2 positive; Second line; Stage IV,Breast Neoplasms,Canada; United States
"A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed By DD Paclitaxel (DD AC-P); DD AC Followed By DD Paclitaxel Plus Gemcitabine (DD AC-PG)",III,Completed,"Amgen
Eli Lilly
(Other Cooperative Group)
National Surgical Adjuvant Breast and Bowel Project (NSABP)
National Institutes of Health/National Cancer Institute",Oncology: Breast,Adjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,Canada; Ireland; United States
A Phase II Study of Docetaxel and Topotecan Hydrochloride in Patients with Metastatic Breast Cancer.,II,Completed,University of Maryland Greenebaum Cancer Center,Oncology: Breast,Stage IV; Third line,Breast Neoplasms,United States
Effects of Arzoxifene on Vertebral fracture Incidence and on Invasive Breast cancer Incidence in Postmenopausal Women with Osteoporosis or with Low Bone Density. (GENERATION).,III,Completed,Eli Lilly,Metabolic/Endocrinology: Osteoporosis; Oncology: Breast,Line of therapy N/A; Osteopenia; Postmenopausal women: prevention; Postmenopausal women: treatment; Stage I; Stage II; Stage III; Stage IV,"Bone Diseases, Metabolic; Breast Neoplasms; Osteoporosis; Osteoporosis, Postmenopausal",Argentina; Australia; Belgium; Brazil; Bulgaria; Colombia; Denmark; Estonia; Finland; France; Hungary; India; Israel; New Zealand; Norway; Poland; Puerto Rico; Romania; South Africa; South Korea; Spain; Sweden; United States
"A Randomized, Open-Label, Multicenter, Phase II Study Comparing the Effects on Proliferation and the Efficacy and Tolerability of Fulvestrant (FASLODEX) 500 Mg With Fulvestrant (FASLODEX) 250 Mg When Given as Neoadjuvant Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer (T2, 3, 4b, N0-3, M0).",II,Completed,AstraZeneca,Oncology: Breast,Estrogen receptor positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,Austria; Brazil; Germany; India; United Kingdom; United States
A Randomized Active-Controlled Study of AMG 162 in Breast Cancer Subjects With Bone Metastasis Who Have Not Previously Been Treated With Bisphosphonate Therapy.,II,Completed,Amgen,Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; First line; Stage IV,Bone Marrow Diseases; Bone Neoplasms; Breast Neoplasms; Neoplasm Metastasis,Australia; Austria; Belgium; Canada; France; Italy; Mexico; Portugal; Spain; United Kingdom; United States
A Randomized Controlled Study of Docetaxel Monotherapy or Docetaxel and DOXIL for the Treatment of Advanced Breast Cancer.,III,Completed,"Johnson & Johnson/Janssen Biotech {Centocor Ortho Biotech {J&J/Ortho Biotech}}
Johnson & Johnson/Janssen R&D {Johnson & Johnson/J&JPRD}
Johnson & Johnson/Janssen Biotech {{Centocor Ortho Biotech {J&J/Centocor}}",Oncology: Breast,First line; Second line; Stage III; Stage IV,Breast Neoplasms,Austria; Bulgaria; Estonia; France; Germany; Hungary; Israel; Italy; Latvia; Lithuania; Montenegro; Netherlands; Poland; Portugal; Romania; Russia; Serbia; South Africa; Spain; Ukraine; United Kingdom; United States
A Phase II Study of 5T4-Modified Vaccinia Ankara (MVA) Vaccine (TROVAX) in Patients With Advanced Breast Cancer.,II,Terminated,"Southwest Oncology Group
National Institutes of Health/National Cancer Institute",Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A Randomized, Open Label, Multicenter Study of Primary Prophylaxis with Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis as an Adjunct to Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer.",IV,Completed,"Amgen
Geriatric Oncology Consortium","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Supportive Care",Aggressive; Extensive; First line; Indolent; Limited; Neoadjuvant; Neutropenia; Pulmonary; Second line; Stage I; Stage II; Stage III; Stage IV; Untreated,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neuroendocrine Tumors; Neutropenia; Ovarian Cancer; Ovarian Neoplasms; Palliative Care; Small Cell Lung Carcinoma",United States
A phase II randomized study to compare the neoadjuvant administration of docetaxel and vinorelbine or docetaxel followed by adriamycin and cytoxan with all chemotherapy administered in a dose dense fashion to women with stage II and stage III breast cancer.,II,Completed,"Amgen
Sanofi {Sanofi-Aventis {Aventis}}
University of Pittsburgh Cancer Institute",Oncology: Breast,Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors,II,Completed,"MD Anderson Cancer Center, University of Texas",Oncology: Breast; Oncology: Renal,Second line; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Kidney Neoplasms; Renal Cancer; Wilms Tumor",United States
"A Phase II, Open-Label, Randomized, Parallel-Group Multicenter Trial Comparing Two Schedules of GW572016 as First-Line Monotherapy in Patients With Advanced or Metastatic Breast Cancer.",II,Completed,GlaxoSmithKline,Oncology: Breast,First line; HER2 positive; Stage III; Stage IV,Breast Neoplasms,"Chile; China; Hong Kong, S.A.R., China; India; Malaysia; Mexico; Pakistan; Peru; Singapore; Taiwan, China; United States"
"Phase II, Open Label Study of Ispinesib in Subjects with Advanced or Metastatic Breast Cancer.",II,Completed,"GlaxoSmithKline
Cytokinetics",Oncology: Breast,Second line; Stage III; Stage IV; Third line,Breast Neoplasms,Belgium; Malaysia; Singapore; United Kingdom; United States
"A Phase II, Randomized, Double-Blinded Efficacy and Safety Study of Three Doses of TAS-108 Administered Orally in Postmenopausal Patients With Locally Advanced or Locally Recurrent Inoperable or Progressive Metastatic Breast Carcinoma Following Standard First or Second Line Endocrine Therapy.",II,Completed,"Otsuka Holdings/Taiho Pharmaceutical
Mayo Clinic",Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Randomized Study for First-Line Treatment of Known ER/PR+ Metastatic Breast Cancer.,III,Terminated,University of Washington/Seattle Cancer Care Alliance,Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Stage IV,Breast Neoplasms,United States
Phase II Clinical Trial of the Combination of Weekly Taxotere and Herceptin in HER-2 Expressing Metastatic Breast Cancer.,II,Completed,Tufts Medical Center {Tufts-New England Medical Center},Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
Gemcitabine and Capecitabine in advanced breast cancer: A BrUOG phase II study.,II,Completed,"Eli Lilly
Roche
Brown University Oncology Group",Oncology: Breast,Estrogen receptor positive; First line; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A Multicenter, Open-label Phase IV Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy.",IV,Completed,Amgen,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma; Oncology: Supportive Care",(N/A); Aggressive; Classical; First line; Indolent; Neutropenia; Nodular lymphocyte-predominant; Pulmonary; Second line; Stage I; Stage II; Stage III; Stage IV; Untreated,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Fibrosarcoma; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neuroendocrine Tumors; Neutropenia; Ovarian Cancer; Ovarian Neoplasms; Palliative Care; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
SYNCHRONICITY: A Study to Evaluate the Effectiveness of Aranesp at 300 mcg Q3W on Clinical Outcomes in Cancer Patients with Anemia Due to Chemotherapy,IV,Completed,Amgen,"Metabolic/Endocrinology: Anemia; Oncology: Breast; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Neuroendocrine; Oncology: Supportive Care",Aggressive; Anemia; Cancer-related; Indolent; Line of therapy N/A; Pulmonary,"Anemia; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neuroendocrine Tumors; Palliative Care; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms",United States
"Double-blind, Randomized trial Comparing GM-CSF Mouthwash to Placebo in Preventing/Alleviating Chemotherapy Induced Mucositis in Patients Undergoing High Dose Chemotherapy and Stem Cell Transfusion or Bone Marrow Transplantation.",II,Completed,"Herbert Irving Comprehensive Cancer Center at Columbia University
Amgen {Immunex}","Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Other; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Supportive Care",Aggressive; Classical; Indolent; Lymphoblastic lymphoma (LBL); Mucositis; Nodular lymphocyte-predominant; Peripheral T-cell lymphoma (PTCL); Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Central Nervous System Neoplasms; Glioblastoma; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral; Mucositis; Palliative Care",United States
Phase II Evaluation of Liposomal Doxorubicin Combined with Docetaxel in Patients with Metastatic Breast Cancer,II,Completed,"Johnson & Johnson/Janssen Biotech {Centocor Ortho Biotech {J&J/Ortho Biotech}}
Herbert Irving Comprehensive Cancer Center at Columbia University",Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Stage IV,Breast Neoplasms,United States
An open-label study of the effect of intravenous Epothilone D on treatment response in patients with metastatic breast cancer.,II,Completed,"Bristol-Myers Squibb {Kosan Biosciences}
Roche {F. Hoffmann-La Roche}",Oncology: Breast,Second line; Stage IV; Third line,Breast Neoplasms,Canada; United States
"A Randomized, Open-Label, Multicenter, Phase III Trial Comparing Regimens of Adriamycin Plus Cytoxan Followed by Either Taxotere or Taxotere Plus Xeloda as Adjuvant Therapy for Female Patients With High-Risk Breast Cancer Please Note: the Primary Efficacy Endpoint in This Study is Disease Free Survival.",III,Completed,"Sanofi {Sanofi-Aventis {Aventis}}
Roche {F. Hoffmann-La Roche}",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"Phase II Study of Docetaxel, Capecitabine, and Bevacizumab as First-Line Chemotherapy in Patients With Metastatic Breast Cancer.",II,Completed,"North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute",Oncology: Breast,First line; HER2 negative; Stage IV,Breast Neoplasms,United States
Phase II Trial Evaluating the Efficacy of a Multiepitope Dendritic Cell Vaccine Given with Trastuzumab and Vinorelbine for the Treatment of Women with Metastatic Breast Cancer that Express HLA-A0201.,II,Terminated,"National Institutes of Health/National Cancer Institute
UNC Lineberger Comprehensive Cancer Center",Oncology: Breast; Oncology: Metastatic Cancer,HER2 negative; Other mets; Second line; Stage IV,Breast Neoplasms; Neoplasm Metastasis,United States
Randomized Placebo-Controlled Biomarker Modulation Trial Using Celecoxib in Premenopausal Women at High Risk for Breast Cancer.,II,Terminated,"Southwest Oncology Group
National Institutes of Health/National Cancer Institute",Oncology: Breast,Line of therapy N/A; Stage 0,Breast Neoplasms,United States
Phase II Study of Letrozole (Femara) Plus Imatinib Mesylate (Gleevec) for Postmenopausal Patients With ER and/or PR Positive Metastatic Breast Cancer,II,Completed,"Novartis
MD Anderson Cancer Center, University of Texas",Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
A Randomized Multicenter Trial of Neoadjuvant Taxotere and Adriamycin/Cytoxan(AC): A Biologic Correlative Study.,II,Completed,"National Institutes of Health/National Cancer Institute
Baylor College of Medicine
National Health Service (NHS) - UK",Oncology: Breast,Neoadjuvant; Stage II,Breast Neoplasms,United Kingdom; United States
Phase II Trial of Gemzar Plus Paraplatin (Plus Herceptin in HER2+ Patients) in Metastatic Breast Cancer.,II,Completed,Eli Lilly,Oncology: Breast,First line; HER2 negative; HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
Comparison of the Effect of SCH 57050 and Anastrazole in Subjects with Breast Cancer Relapsing After an Initial Response to Tamoxifen or Showing Progression After Tamoxifen given as Adjuvant to Surgery,III,Completed,Merck & Co. {Schering-Plough},Oncology: Breast,Adjuvant; Second line; Stage III; Stage IV,Breast Neoplasms,Spain; United States
"Phase II Multi-Center, Open-Label, Non-Randomized Study of Intravenous RPR109881 Given Every 3 Weeks in Patients With Metastatic Breast Cancer Progressing After Therapy With Anthracyclines, Taxanes and Capecitabine.",II,Completed,Sanofi {Sanofi-Aventis {Aventis}},Oncology: Breast,HER2 negative; HER2 positive; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,Argentina; Belgium; Canada; Colombia; Denmark; France; Germany; Ireland; Italy; Netherlands; South Africa; South Korea; Spain; Switzerland; Turkey; United States
"A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease",II,Completed,"Amgen
Jonsson Comprehensive Cancer Center, UCLA",Metabolic/Endocrinology: Anemia; Oncology: Breast; Oncology: Gastric; Oncology: Supportive Care,Anemia; Cancer-related; Line of therapy N/A,Anemia; Breast Neoplasms; Palliative Care; Stomach Carcinoma; Stomach Neoplasms,United States
"An open-label, randomized, phase III study of capecitabine in combination with docetaxel vs capecitabine followed by docetaxel as first-line treatment for metastatic breast cancer.",IV,Terminated,Roche {F. Hoffmann-La Roche},Oncology: Breast,First line; Stage III; Stage IV,Breast Neoplasms,United States
Phase III comprehensive study of combination treatment with TLCD - 99 liposomal doxorubicin and cyclophospamide vs doxorubicin and cyclophosphamide in metastatic breast cancer,III,Completed,Perrigo Company {Elan {The Liposome Company}},Oncology: Breast,First line; Stage IV,Breast Neoplasms,Canada; India; United States
Phase II evaluation of bi-weekly docetaxel combined with doxorubicin in patients with locally advanced breast cancer.,II,Completed,Columbia University Medical Center,Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage III,Breast Neoplasms,United States
Immunohistochemical tumor markers do not predict response to neoadjuvant doxorubicin and docetaxel in breast cancer.,II,Completed,Sanofi {Sanofi-Aventis {Aventis}},Oncology: Breast,Adjuvant; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
Primary systemic therapy for locally advanced breast cancer using sequential dDoxorubicin followed by dose dense paclitaxel and cyclophosphamide.,II,Completed,"University of Alabama, Birmingham",Oncology: Breast,Adjuvant; Stage III,Breast Neoplasms,United States
Phase II trial of neoadjuvant docetaxel and carboplatin with filgrastim (G-CSF) support in patients with locally advanced breast cancer.,II,Completed,University of Texas,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
"Oral clodronate for adjuvant treatment of operable breast cancer: A randomized, double-blind, placebo-controlled multicenter trial.",III,Completed,Bayer AG/Bayer Pharmaceuticals {Bayer HealthCare {Bayer Schering Pharma {Schering AG}}},Oncology: Breast; Oncology: Metastatic Cancer,Adjuvant; Bone mets; Stage I; Stage II; Stage III,Breast Neoplasms; Neoplasm Metastasis,Canada; Finland; Norway; United Kingdom; United States
Phase II Trial Of Imatinib Mesylate (Gleevec) (NSC-716051) In Combination With Capecitabine (Xeloda) (NSC-712807) In Metastatic Breast Cancer,II,Terminated,National Institutes of Health/National Cancer Institute,Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
A Pilot trial of Zoledronic acid and Calcitriol in Malignancies with Bone Involvement.,II,Completed,(Other Cooperative Group),Oncology: Breast; Oncology: Multiple Myeloma; Oncology: Prostate,Line of therapy N/A; Stage II; Stage III; Stage IV,Breast Neoplasms; Multiple Myeloma; Prostatic Neoplasms,United States
"A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles of 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) To Four Cycles of Adriamycin and Cyclophosphamide (AC) In Patients with Node-Negative Breast Cancer",III,Completed,"National Surgical Adjuvant Breast and Bowel Project (NSABP)
National Institutes of Health/National Cancer Institute",Oncology: Breast,Adjuvant; Stage I; Stage II,Breast Neoplasms,Canada; Puerto Rico; United States
"A Phase III, Randomized, Open-Label, Multicenter Study Comparing GW572016 and Capecitabine (XELODA) Versus Capecitabine in Women With Refractory Advanced or Metastatic Breast Cancer",III,Completed,GlaxoSmithKline,Oncology: Breast,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,"Argentina; Australia; Brazil; Canada; France; Germany; Greece; Hong Kong, S.A.R., China; Ireland; Israel; Italy; Poland; Portugal; Russia; South Africa; Spain; Switzerland; United Kingdom; United States"
Palonosetron plus aprepitant and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting after emetogenic chemotherapy.,II,Completed,Eisai {MGI Pharma},"Oncology: Breast; Oncology: Colorectal; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Supportive Care",Aggressive; Emesis; Indolent; Second line,"Breast Neoplasms; Colorectal Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Palliative Care; Vomiting",United States
Phase III study: AES-14 in patients at risk for mucositis secondary to anthracycline-based chemotherapy.,III,Completed,Eisai {MGI Pharma {Aesgen}},Oncology: Breast; Oncology: Supportive Care,(N/A); Estrogen receptor positive; Line of therapy N/A; Mucositis,Breast Neoplasms; Mucositis; Palliative Care,Russia; United States
"A Randomized, Open-Label Study Of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) To Evaluate Hematologic Response Rate In Anemic Cancer Patients Receiving Chemotherapy.",IV,Completed,Johnson & Johnson/Janssen Biotech {Centocor Ortho Biotech {J&J/Ortho Biotech}},"Metabolic/Endocrinology: Anemia; Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Supportive Care",Anemia; Cancer-related; Line of therapy N/A; Stage I; Stage II; Stage III; Stage IV,"Anemia; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Palliative Care",United States
A phase II study to evaluate the feasibility of bi-weekly docetaxel followed by bi-weekly doxorubicin and cyclophosphamide as adjuvant therapy for operable breast cancer,II,Completed,(Other Academic Cancer Center),Oncology: Breast,Adjuvant; Stage I; Stage II,Breast Neoplasms,United States
5-year survival with dose intensive L-FAC multimodality therapy of breast cancer.,II,Completed,(Other Academic Cancer Center),Oncology: Breast,Neoadjuvant; Stage III; Stage IV,Breast Neoplasms,United States
"Randomized phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer.",III,Completed,"Bristol-Myers Squibb
Roche/Genentech {Genentech}
Roche",Oncology: Breast,First line; HER2 positive; Stage IV,Breast Neoplasms,Canada; United States
"Phase II trial to study the efficacy and toxicity of combined docetaxel, carboplatin, with or without trastuzumab administered weekly in patients with HER-2/neu +/- metastatic breast cancer.",II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,First line; HER2 negative; HER2 positive; Stage IV,Breast Neoplasms,United States
Phase II trial of trastuzumab and paclitaxel or docetaxel administered every 3 weeks to patients receiving a first treatment for HER2+ metastatic breast cancer.,II,Completed,(Other Academic Cancer Center),Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Stage IV,Breast Neoplasms,United States
"Phase II Trial of Weekly Docetaxel, Vinorelbine, and Herceptin in the First-Line Treatment of Patients With Metastatic Breast Cancer and Overexpression of Her-2.",II,Completed,"Sanofi {Sanofi-Aventis {Aventis}}
GlaxoSmithKline
Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}",Oncology: Breast,First line; HER2 positive; Stage IV,Breast Neoplasms,United States
Effect of neoadjuvant chemotherapy on bone marrow micrometastases in women with locally advanced breast cancer.,II,Completed,Washington University,Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; Estrogen receptor positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms; Neoplasm Metastasis,United States
Carboplatin & gemcitabine repeating doublet in recurrent breast cancer.,II,Completed,"Eli Lilly
Rational Therapeutics",Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,United States
An open label phase II trial of glufosfamide: A ß-D-glucose-linked isophosphoramide mustard given as 1-hour infusion in patients with advanced breast cancer.,II,Completed,Molecular Templates {Threshold Pharmaceuticals},Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,Ukraine; United States
A Phase II trial of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP) in patients with metastatic breast cancer.,II,Completed,"Vion Pharmaceuticals
Columbia University College of Physicians and Surgeons Department of Neurology
Weill Cornell Medical College",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
"A pilot, open-label, randomized, comparative study of exemestane versus anastrozole in postmenopausal breast cancer subjects with visceral disease.",III,Completed,Pfizer,Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,Austria; Belgium; Canada; Croatia; France; Greece; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; United Kingdom; United States
A PreSurgical Study to Evaluate Molecular Alterations That Occur in Human Breast Cancer Tissue and Normal Skin After Short Term Exposure to ZD1839 (IRESSA) and to Correlate These Alterations With Pharmacokinetic Parameters,II,Completed,"AstraZeneca
Breast Cancer International Research Group
ANZ Breast Cancer Trials Group",Oncology: Breast,HER2 positive; Neoadjuvant; Stage II; Stage III; Stage IV,Breast Neoplasms,Australia; Canada; France; Germany; Hungary; Ireland; Poland; United Kingdom; United States
A Trial of Exemestane in Postmenopausal Women With DCIS or at High Risk for Invasive Breast Cancer,II,Completed,"National Institutes of Health/National Cancer Institute
Lombardi Cancer Center at Georgetown University Medical Center",Oncology: Breast,First line; Second line; Stage 0,Breast Neoplasms,United States
"A Phase II Trial Of 4 Months Preoperative Letrozole 2.5 mg Daily For Postmenopausal Women With Estrogen Receptor Positive And/Or Progesterone Receptor Positive T2, T3, T4a-c, N0-2, M0 Breast Cancer- Novel Biomarkers for Aromatase Inhibitor Therapy",II,Completed,"National Institutes of Health/National Cancer Institute
Duke Comprehensive Cancer Center
Siteman Cancer Center
Washington University
University of California, San Francisco",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,United States
Phase II Selection Design Trial Of Concurrent Chemotherapy + Cetuximab Vs. Chemotherapy Followed By Cetuximab In Advanced Non-Small Cell Lung Cancer (NSCLC).,II,Completed,"Southwest Oncology Group
National Institutes of Health/National Cancer Institute","Oncology: Breast; Oncology: Lung, Non-Small Cell",Adenocarcinoma; First line; Large Cell; Other subtype; Squamous Cell; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms",United States
"A Phase II Study of Weekly Dose-Dense Nanoparticle Paclitaxel (ABI-007), Carboplatin With Herceptin As First-Line Therapy of Advanced HER-2 Positive Breast Cancer",II,Completed,"Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute
Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}}",Oncology: Breast,First line; HER2 positive; Stage IV,Breast Neoplasms,United States
"A Phase III Randomized, Placebo-Controlled, Double-Blind Study of Oral CCI-779 Administered in Combination With Letrozole Vs. Letrozole Alone as First Line Hormonal Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer",III,Terminated,Pfizer {Wyeth/Wyeth Research},Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms; Neoplasm Metastasis; Neoplasms,"Brazil; Canada; China; Hong Kong, S.A.R., China; Latvia; Lithuania; Poland; Portugal; Slovakia; South Korea; Spain; United Kingdom; United States"
EGFR Pathway Modulation In Patients With Ductal Carcinoma In Situ Of The Breast.,II,Terminated,"National Institutes of Health/National Cancer Institute
Vanderbilt-Ingram Cancer Center",Oncology: Breast,HER2 negative; HER2 positive; Neoadjuvant; Stage 0,"Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating",United States
A Clinical Trial of the Action of Isoflavones in Breast Neoplasia: Administration Prior to Mastectomy or Lumpectomy-A Pilot Study in neoadjuvant setting.,II,Terminated,"National Institutes of Health/National Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute",Oncology: Breast,Neoadjuvant; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
Multicenter phase II study of trastuzumab (herceptin; H) and vinorelbine (navelbine; N) as first-line therapy for HER2 overexpressing metastatic breast cancer (HER2+ MBC).,II,Completed,"Roche/Genentech {Genentech}
GlaxoSmithKline",Oncology: Breast,First line; HER2 positive; Stage III; Stage IV,Breast Neoplasms,United States
"A Prospective, Multicenter, Open-Label Clinical Evaluation of the Effect of IV Zoledronic Acid 4mg on Pain, Quality of Life and Time in Infusion Chair in Breast Cancer, Multiple Myeloma, and Prostate Cancer Patients with Cancer-Related Bone Lesions",IV,Completed,Novartis,CNS: Pain (nociceptive); Oncology: Breast; Oncology: Multiple Myeloma; Oncology: Prostate,Cancer-related; Line of therapy N/A; Stage II; Stage III; Stage IV,"Breast Neoplasms; Cancer pain; Cancer Pain; Multiple Myeloma; Neoplasms, Plasma Cell; Nociceptive Pain; Prostatic Neoplasms",United States
Phase II Study of Pyrazoloacridine in Women With Refractory Metastatic Breast Cancer,II,Terminated,"National Institutes of Health/National Cancer Institute
Richard J. Solove Research Institute
Arthur G. James Cancer Hospital",Oncology: Breast,First line; Second line; Stage IV,Breast Neoplasms,United States
"An Open-label Phase II Study of E7070 in Metastatic Breast Cancer Patients Previously Treated with an Anthracycline, a Taxane, and Capecitabine",II,Terminated,Eisai,Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,Canada; United States
Phase IV Study of Letrozole (Femara) as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer,IV,Completed,"Novartis
National Institutes of Health/National Cancer Institute",Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
Phase II Study of Nitrocamptothecin in Patients With Locally Recurrent or Metastatic Breast Cancer.,II,Completed,Otsuka Holdings/Otsuka Pharmaceutical/Astex Pharmaceuticals {SuperGen},Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Phase II Study of MDX-010 in Patients With Stage IV Adenocarcinoma of the Breast.,II,Completed,"Bristol-Myers Squibb
Bristol-Myers Squibb/Medarex",Oncology: Breast,Second line; Stage IV,Adenocarcinoma; Breast Neoplasms,United States
Metronomic Chemotherapy With Bevacizumab for Advanced Breast Cancer,II,Completed,"National Institutes of Health/National Cancer Institute
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Roche/Genentech",Oncology: Breast,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase II Trial of Tipifarnib (R115777, Zarnestra) in Combination With Fulvestrant (Faslodex) in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients Who Have Progressive Disease After First-Line Endocrine Therapy",II,Terminated,"National Institutes of Health/National Cancer Institute
Albert Einstein Medical College",Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer.

Mammary Prevention 3 (MAP.3)",III,Completed,"Federation Nationale des Centres de Lutte contre le Cancer
Grupo Espanol de investigacion del Cancer de Mama
Canadian Cancer Trials Group {NCIC Clinical Trials Group}
Pfizer",Oncology: Breast,(N/A); Estrogen receptor positive; Line of therapy N/A,Breast Neoplasms; Osteoporosis,Brazil; Canada; France; Puerto Rico; Spain; United States
"A randomized, open-label study of the effect of different dosing regimens of Xeloda in combination with Taxotere on disease progression in patients with locally advanced and/or metastatic breast cancer",II,Completed,Roche {F. Hoffmann-La Roche},Oncology: Breast,HER2 negative; HER2 positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,Argentina; Bosnia and Herzegovina; Brazil; Bulgaria; China; Czech Republic; India; Mexico; Poland; Russia; South Africa; Thailand; United States
A Phase III Study of Novel Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With an Anthracycline and a Taxane.,III,Completed,"Bristol-Myers Squibb
National Health Service (NHS) - UK",Oncology: Breast,Stage III; Stage IV; Third line,Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Croatia; Czech Republic; Denmark; France; Germany; Greece; Ireland; Israel; Italy; Netherlands; Portugal; Russia; Singapore; South Africa; South Korea; Spain; Switzerland; Taiwan, China; Turkey; United Kingdom; United States"
The Use of Ginkgo Biloba For The Prevention Of Chemotherapy-Related Cognitive Dysfunction,III,Completed,"North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute",Oncology: Breast; Oncology: Supportive Care,Adjuvant; Neurotoxicity; Stage I; Stage II; Stage III,Breast Neoplasms; Neurotoxicity Syndromes; Palliative Care,United States
"An Open-Label Study of PROCRIT (Epoetin Alfa) in Women Undergoing Adjuvant Chemotherapy for Stage I, II, or III Breast Cancer.",IV,Completed,"Amgen
Johnson & Johnson/Janssen Biotech {Centocor Ortho Biotech {J&J/Ortho Biotech}}
Jonsson Comprehensive Cancer Center, UCLA
National Institutes of Health/National Cancer Institute",Metabolic/Endocrinology: Anemia; Oncology: Breast; Oncology: Supportive Care,Adjuvant; Anemia; Cancer-related; Stage I; Stage II; Stage III,Anemia; Breast Neoplasms; Fatigue; Palliative Care,United States
"Phase II Study of Novel Epothilone (BMS-247550) in Patients With MBC Who Are Refractory to an Anthracycline, a Taxane, and Capecitabine.",II,Completed,"Bristol-Myers Squibb
Novartis",Oncology: Breast,HER2 positive; Stage III; Stage IV; Third line,Breast Neoplasms,Argentina; Canada; France; Germany; Mexico; Netherlands; Norway; South Africa; Sweden; United States
A Phase III Trial of Novel Epothilone BMS-247550 Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With or Resistant to an Anthracycline and Who Are Taxane Resistant.,III,Completed,"Bristol-Myers Squibb
National Health Service (NHS) - UK",Oncology: Breast,HER2 negative; HER2 positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,"Argentina; Belgium; Brazil; Canada; China; France; Germany; Greece; Hungary; Italy; Malaysia; Mexico; Peru; Philippines; Poland; South Korea; Spain; Sweden; Taiwan, China; Thailand; United Kingdom; United States"
A Randomized Double-Blind Phase ll Study of Anastrozole Plus Lonafarnib (SCH 66336) or Anastrozole Plus Placebo for the Treatment of Subjects With Advanced Breast Cancer,II,Completed,"Merck & Co. {Schering-Plough}
Jonsson Comprehensive Cancer Center, UCLA
National Institutes of Health/National Cancer Institute",Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,"Argentina; Brazil; Canada; Chile; Colombia; Ecuador; France; Germany; Guatemala; Hong Kong, S.A.R., China; Panama; Peru; Puerto Rico; Singapore; South Africa; United States"
"A Randomized, Open-Label Trial Comparing Treatment With Either Pegylated Liposomal Doxorubicin or Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer in Women 60 Years and Older",II/III,Terminated,Johnson & Johnson/Janssen Therapeutics {J&J/Centocor Ortho Biotech/Tibotec Therapeutics {J&J/Ortho Biotech/Tibotec}},Oncology: Breast,First line; Stage III; Stage IV,Breast Neoplasms,United States
"A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Moderately Emetogenic Chemotherapy",IV,Completed,Merck & Co./Merck Sharp & Dohme (MSD),Oncology: Breast; Oncology: Supportive Care,Emesis; First line; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms; Nausea; Palliative Care; Vomiting,"Australia; Austria; Canada; China; Denmark; Germany; Greece; Hong Kong, S.A.R., China; Hungary; Italy; Spain; United Kingdom; United States"
"A Phase II/III Randomized, Controlled Clinical Trial Of Ginger (Zingiber Officinale) For Nausea Caused By Chemotherapy For Cancer",II/III,Completed,"National Institutes of Health/National Cancer Institute
University of Rochester","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Supportive Care",(N/A); Adjuvant; Emesis; Second line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Nausea; Palliative Care; Stomach Carcinoma; Stomach Neoplasms; Vomiting",United States
"A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Phase III Study of Oral GW572016 in Combination With Paclitaxel in Subjects Previously Untreated or Advanced or Metastatic Breast Cancer",III,Completed,GlaxoSmithKline,Oncology: Breast,First line; HER2 negative; Stage III; Stage IV,Breast Neoplasms,Argentina; Australia; Belgium; Brazil; Canada; Chile; Czech Republic; Germany; Hungary; Italy; Latvia; Mexico; Netherlands; New Zealand; Pakistan; Peru; Poland; Russia; Slovakia; South Africa; South Korea; Spain; Turkey; United States
"A Randomized, Open-label, Multicenter Study of Subcutaneous and Intravenous Administration of Darbepoetin alfa (Novel Erythropoiesis Stimulating Protein, NESP) for the Treatment of Anemia in Subjects with Non-myeloid Malignancies Receiving Multicycle Chemotherapy",II,Completed,Amgen,"Metabolic/Endocrinology: Anemia; Oncology: Breast; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Neuroendocrine; Oncology: Supportive Care",(N/A); Aggressive; Anemia; Cancer-related; Indolent; Line of therapy N/A; Pulmonary,"Anemia; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chronic Lymphocytic Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms; Neuroendocrine Tumors; Palliative Care; Small Cell Lung Carcinoma",United States
"A Randomized, Open-Label, Dose-Timing Study of Darbepoetin Alfa Administered Once Every 3 Weeks (Q3W) by Subcutaneous (SC) Injection for Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy.",II,Completed,"Amgen
Jonsson Comprehensive Cancer Center, UCLA
National Institutes of Health/National Cancer Institute",Metabolic/Endocrinology: Anemia; Oncology: Breast; Oncology: Supportive Care; Oncology: Unspecified Solid Tumor,Anemia; Cancer-related; Line of therapy N/A,"Anemia; Breast Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Lung Neoplasms; Multiple Myeloma; Neoplasms; Neoplasms, Plasma Cell; Neoplasms, Unknown Primary; Palliative Care",United States
"A Single Dose, Randomized, Double-Blind, Parallel Group, Multicenter Study of Palonosetron 0.25 mg, 0.50 mg and 0.75 mg Administered by the Oral Route Versus Palonosetron 0.25 mg IV for the Prevention of Moderately Emetogenic Chemotherapy-Induced Nausea and Vomiting in Patients with Cancer.",III,Completed,"Eisai {MGI Pharma}
Helsinn Healthcare","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Supportive Care; Oncology: Unspecified Cancer",(N/A); Emesis; First line; Second line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasms; Palliative Care; Vomiting",Czech Republic; Switzerland; United States
Phase III trial of palonosetron (Aloxi) versus ondansetron for the prevention of chemotherapy-induced nausea and vomiting (CINV).,III,Completed,"Eisai {MGI Pharma}
Helsinn Healthcare","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Supportive Care; Oncology: Unspecified Cancer",(N/A); Emesis; Line of therapy N/A,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms; Palliative Care; Vomiting",Germany; Russia; Switzerland; United States
Phase III trial of palonosetron (Aloxi) versus dolasetron for the prevention of chemotherapy-induced nausea and vomiting (CINV).,III,Completed,"Eisai {MGI Pharma}
Helsinn Healthcare","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Supportive Care",Emesis; Line of therapy N/A; Stage I; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Palliative Care; Vomiting",Mexico; United States
"Biomarkers, Breast Density And Risk Reduction Perspectives In BRCA Carriers",II,Closed,"National Institutes of Health/National Cancer Institute
Hope Cancer Institute",Oncology: Breast,(N/A); BRCA; Line of therapy N/A,Breast Neoplasms,United States
ZD1839 (IRESSA) In Tamoxifen-Resistant Metastatic Breast Cancer,II,Completed,"AstraZeneca
National Institutes of Health/National Cancer Institute
Dartmouth-Hitchcock Norris Cotton Cancer Center",Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
A Pilot Study Assessing Patterns of Response or Resistance to Preoperative Dose Dense Docetaxel in Women With Newly Diagnosed Breast Cancer,II,Terminated,"National Institutes of Health/National Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}",Oncology: Breast,Adjuvant; Estrogen receptor positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Phase II Study of Neoadjuvant and Adjuvant Exemestane in Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer,II,Terminated,"National Institutes of Health/National Cancer Institute
Robert H. Lurie Comprehensive Cancer Center at Northwestern University",Oncology: Breast,Adjuvant; Estrogen receptor positive; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,United States
"Phase II Multicenter, Double-Blind, Randomized Trial Comparing Anastrozole (ZD1033, Arimidex)-Placebo to the Combination Anastrozole-ZD1839 (Gefitinib, IRESSA) in Postmenopausal Patients With Estrogen Receptor (ER) and/or Progesterone Receptor (PgR) Metastatic Breast Cancer",II,Terminated,AstraZeneca,Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Stage IV,Breast Neoplasms,Colombia; Mexico; Puerto Rico; Spain; United States; Venezuela
A randomized phase III/IV clinical study to determine the patient benefit and safety of DepoCyt (cytarabine liposome injection) for the treatment of neoplastic meningitis.,III/IV,Completed,"Pacira BioSciences {Pacira Pharmaceuticals {SkyePharma PLC/SkyePharma, Inc.}}","Oncology: Breast; Oncology: CNS, Other; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine",(N/A); Aggressive; Indolent; Line of therapy N/A; Pulmonary,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Central Nervous System Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Meningeal Carcinomatosis; Meningeal Neoplasms; Meningitis; Neoplasms; Neuroendocrine Tumors; Small Cell Lung Carcinoma",Canada; Germany; United States
Phase II monotherapy ANGIOZYME in late-stage metastatic breast cancer,II,Completed,"Novartis {Chiron}
Alnylam {Merck & Co./Sirna Therapeutics {Ribozyme}}",Oncology: Breast,Fourth line or greater; Second line; Stage IV; Third line,Breast Neoplasms,United States
Phase II Study Of The Efficacy And Safety Of SU011248 In Patients With Anthracycline- And Taxane-Refractory Or Intolerant Metastatic Breast Cancer.,II,Completed,"Jonsson Comprehensive Cancer Center, UCLA
National Institutes of Health/National Cancer Institute
Pfizer",Oncology: Breast,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
"An Open-Label, Multicenter Extension Study of rhuMAb VEGF (Bevacizumab) in Subjects Treated in a Previous Genentech-Sponsored Cancer Study",II/III,Completed,"Roche/Genentech {Genentech}
Jonsson Comprehensive Cancer Center, UCLA
National Institutes of Health/National Cancer Institute",Oncology: Breast; Oncology: Colorectal,First line; Second line; Stage IV,Breast Neoplasms; Colorectal Neoplasms,United States
Phase II study of LY900003(affinitak) in patients with metastatic breast cancer,II,Completed,Ionis Pharmaceuticals {Isis Pharmaceuticals},Oncology: Breast,Line of therapy N/A; Stage IV,Breast Neoplasms,United States
"Phase III, Randomized, Open-label, Comparative Study of Standard Whole Brain Radiation Therapy with Supplemental Oxygen, with or without Concurrent RSR13 (efaproxiral), in Women with Brain Metastases from Breast Cancer 

ENhancing whole brain Radiation therapy In patients with breast Cancer and Hypoxic brain metastases (ENRICH)",III,Completed,"(Other Cooperative Group)
Spectrum Pharmaceuticals {Allos Therapeutics}",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; First line; Stage IV,"Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis; Neoplasms, Second Primary",Canada; France; Italy; United States
Treatment of Stage IV Breast Cancer With Activated T Cells After Peripheral Blood Stem Cell Transplant (Pilot Phase II),II,Terminated,"Barbara Ann Karmanos Cancer Institute
National Institutes of Health/National Cancer Institute",Oncology: Breast,HER2 positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer.,II,Completed,"North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute",Oncology: Breast,First line; Second line; Stage IV; Third line,Breast Neoplasms,United States
A Phase II Study Of Trastuzumab In Combination With BMS-247550 In Women With Metastatic Breast Cancer.,II,Terminated,National Institutes of Health/National Cancer Institute,Oncology: Breast,First line; HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
A Phase III Study of DPPE Combined With Epirubicin and Cyclophosphamide Vs Epirubicin and Cyclophosphamide Alone as First Line Treatment in Metastatic or Recurrent Breast Cancer,III,Terminated,Gilead Sciences {YM BioSciences},Oncology: Breast,First line; Stage III; Stage IV,Breast Neoplasms,Canada; Estonia; United Kingdom; United States
A Phase II Trial of Trastuzumab Plus Weekly Ixabepilone (BMS-247550) And Carboplatin In Patients with HER/Neu-Positive Metastatic Breast Cancer.,II,Completed,"Bristol-Myers Squibb
Eastern Cooperative Oncology Group (ECOG)
North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute",Oncology: Breast,First line; HER2 positive; Maintenance/Consolidation; Stage IV,"Breast Neoplasms; Breast Neoplasms, Male",United States
"A Phase II Trial Of Capecitabine In Combination With The Farnesyltransferase Inhibitor, R115777 (Tipifarnib and /or Zarnestra) In Patients With Metastatic Breast Cancer.",II,Completed,"Eastern Cooperative Oncology Group (ECOG)
North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute",Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,Australia; Peru; Puerto Rico; South Africa; United States
Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women With Metastatic Breast Cancer.,III,Completed,"Cancer and Leukemia Group B (CALGB)
Canadian Cancer Trials Group {NCIC Clinical Trials Group}
Southwest Oncology Group
National Institutes of Health/National Cancer Institute
National Institutes of Health
Cancer Trials Support Unit - CTSU/NCI",Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,Canada; United States
A Pilot Phase II Protocol Of Arsenic Trioxide (TRISENOX) In Subjects With Advanced Carcinoma Of The Breast,II,Terminated,"University of Texas
CTI BioPharma {Cell Therapeutics}",Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Study Comparing GW572016 and Letrozole Versus Letrozole in Subjects With Estrogen/Progesterone Receptor- Positive Advanced or Metastatic Breast Cancer",III,Completed,"GlaxoSmithKline
Novartis",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; HER2 positive; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,Argentina; Australia; Brazil; Bulgaria; Canada; Chile; Colombia; Croatia; Czech Republic; Denmark; France; Germany; Hungary; Ireland; Italy; Mexico; Netherlands; New Zealand; Pakistan; Peru; Poland; Russia; Singapore; South Africa; South Korea; Spain; Tunisia; Turkey; United Kingdom; United States
"Phase II Trial of Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine.",II,Completed,Pfizer {Pharmacia},Oncology: Breast,Fourth line or greater; Stage III; Stage IV,Breast Neoplasms,Argentina; Australia; Colombia; New Zealand; United States
Phase II Treatment of Adults With Brain Metastases With Temodar,II,Completed,"Merck & Co. {Schering-Plough}
National Institutes of Health/National Cancer Institute
Duke Comprehensive Cancer Center","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Ovarian; Oncology: Renal",CNS mets; Extensive; First line; Stage IV; Untreated,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Kidney Neoplasms; Melanoma; Neoplasm Metastasis; Nervous System Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Wilms Tumor",United States
A Phase III Study of Conventional Radiation Therapy Plus Thalidomide (NSC# 66847) Versus Conventional Radiation Therapy For Multiple Brain Metastases.,III,Terminated,"Radiation Therapy Oncology Group (RTOG)
National Institutes of Health/National Cancer Institute
Bristol-Myers Squibb/Celgene","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer",CNS mets; Second line; Stage IV,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Melanoma; Neoplasm Metastasis",Canada; United States
Phase III Randomized Study of Whole Brain Radiotherapy With or Without RSR13 in Patients With Brain Metastases.,III,Completed,Spectrum Pharmaceuticals {Allos Therapeutics},"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer",CNS mets; First line; Stage IV,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Neoplasm Metastasis",Australia; Belgium; Canada; France; Germany; Hungary; Italy; United Kingdom; United States
Phase II Randomized Study of Melatonin and Radiotherapy in Patients With Brain Metastases,II,Completed,"Radiation Therapy Oncology Group (RTOG)
National Institutes of Health/National Cancer Institute","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer",(N/A); Bone mets; CNS mets; First line; Liver mets; Other mets; Second line; Stage IV,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Liver Neoplasms; Melanoma; Neoplasm Metastasis",Canada; United States
A Randomized Clinical Trial Of Adjuvant Chemotherapy For Radically Resected Loco-Regional Relapse Of Breast Cancer,III,Terminated,"Novartis
Breast International Group
Grupo Espanol de investigacion del Cancer de Mama
National Surgical Adjuvant Breast and Bowel Project (NSABP)
International Breast Cancer Study Group
ANZ Breast Cancer Trials Group",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,Australia; Belgium; Canada; Hungary; Netherlands; Nigeria; Peru; Poland; South Africa; Spain; Switzerland; United Kingdom; United States
Phase II Study of Amonafide in Women With Metastatic Breast Cancer Who Have Progressed After Prior Chemotherapy,II,Completed,"Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute
Antisoma {Xanthus}",Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
Phase II Randomized Study of Polyphenon E (Green Tea Extract) and Low-Dose Aspirin in Women at High Risk For Developing Breast Cancer.,II,Completed,"Jonsson Comprehensive Cancer Center, UCLA
National Institutes of Health/National Cancer Institute",Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
Pilot Study of Allogeneic Peripheral Blood Progenitor Cell Transplantation In Patients With Chemotherapy-Refractory Or Poor-Prognosis Metastatic Breast Cancer,II,Terminated,"National Institutes of Health/National Cancer Institute
University of California San Diego",Oncology: Breast,Estrogen receptor positive; Second line; Stage IV,Breast Neoplasms,United States
Pilot Study of Epirubicin and Cyclophosphamide Followed by Paclitaxel at 10-11 Days Interval for Women With Early Breast Carcinoma.,II,Completed,"Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute",Oncology: Breast,Adjuvant; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Randomized Study of the Efficacy of Patient Information in Alleviating Nausea and Emesis in Cancer Patients Receiving Chemotherapy,III,Completed,"National Institutes of Health/National Cancer Institute
University of Rochester","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Supportive Care",(N/A); Emesis; Line of therapy N/A,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Nausea; Palliative Care; Vomiting",United States
Phase III Randomized Study of 3 Regimens For the Prevention of Delayed Nausea After Chemotherapy in Patients With Chemotherapy-Naive Cancer.,III,Completed,"National Institutes of Health/National Cancer Institute
James P. Wilmot Cancer Center","Oncology: Breast; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Supportive Care",Aggressive; Emesis; First line; Indolent,"Breast Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Nausea; Palliative Care; Vomiting",United States
"Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer",III,Completed,"Cancer and Leukemia Group B (CALGB)
Eastern Cooperative Oncology Group (ECOG)
Southwest Oncology Group
National Institutes of Health/National Cancer Institute
International Breast Cancer Study Group",Oncology: Breast,Adjuvant; HER2 negative; Stage I; Stage II; Stage III,Breast Neoplasms; Infertility,Australia; Belgium; Hungary; Italy; New Zealand; Switzerland; United States
"A Phase II Randomised, Double-Blind, Stratified, Multi-Centre Trial Comparing the Nolvadex 20 mg And Placebo Combination To The Nolvadex 20 mg and ZD1839 (IRESSA) 250 mg Combination In Patients with Metastatic Breast Cancer And Estrogen Receptor (ER) and/or Progesterone (PR) Positive Tumours.",II,Completed,AstraZeneca,Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,Argentina; Australia; Belgium; Brazil; Canada; Chile; Denmark; France; Germany; South Africa; Spain; United Kingdom; United States
"A Randomized, Double Blind, Multicenter Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX) vs. Exemestane (AROMASIN) in Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer With Disease Progression After Prior Non-Steroidal Aromatase Inhibitor (AI) Therapy",III,Completed,AstraZeneca,Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,Argentina; Belgium; Brazil; Canada; Denmark; France; Germany; Hungary; Israel; Russia; South Africa; Spain; Sweden; United Kingdom; United States
A Phase II Study of Intravenous Edotecarin (PHA-782615) in Patients With Anthracycline- and Taxane-Refractory or Chemoresistant Metastatic Breast Cancer,II,Terminated,"Pfizer {Pharmacia}
Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute",Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms; Neoplasm Metastasis; Neoplasms,Australia; Belgium; France; United States
"A Randomised, Double-blind Trial Comparing ARIMIDEX Alone with NOLVADEX Alone with ARIMIDEX and NOLVADEX in Combination, as Adjuvant Treatment in Postmenopausal Women with Breast Cancer. ARIMIDEX, Tamoxifen, Alone or in Combination (ATAC)",III,Completed,"AstraZeneca
ANZ Breast Cancer Trials Group",Oncology: Breast,Adjuvant; Estrogen receptor positive; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms; Unspecified,Argentina; Australia; Belgium; Canada; Czech Republic; France; Germany; Hungary; Ireland; Italy; Netherlands; New Zealand; Poland; Portugal; Slovakia; South Africa; Spain; Sweden; Turkey; United Kingdom; United States
"A Double-Blind, Randomized, Multicentre Trial Comparing the Efficacy and Tolerability of 250mg of Faslodex (Long Acting ICI 182,780) With 20mg of Nolvadex (Tamoxifen) in Postmenopausal Women With Advanced Breast Cancer.",III,Completed,AstraZeneca,Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Brazil; Canada; Finland; France; Germany; Hungary; Ireland; Israel; Italy; Japan; Mexico; Netherlands; New Zealand; Poland; Portugal; Russia; South Africa; Spain; Taiwan, China; Turkey; United Kingdom; United States"
"An open, randomised multi-centre parallel group trial to compare the pharmacokinetics and tolerability of single doses of faslodex, given as a 5ml injection or as two 2.5ml injections in post-menopausal women with advanced breast cancer.",III,Completed,AstraZeneca,Oncology: Breast,Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms,Norway; United Kingdom; United States
Phase II Study of GTI-2040 and Capecitabine in Patients With Metastatic Breast Cancer,II,Completed,"National Institutes of Health/National Cancer Institute
Aptose Biosciences {Lorus Therapeutics}
California Cancer Consortium",Oncology: Breast,HER2 positive; Second line; Stage IV,"Breast Neoplasms; Breast Neoplasms, Male",United States
"A Phase III Trial Evaluating the Role of Chemotherapy as Adjuvant Therapy for Premenopausal Women With Endocrine Responsive Breast Cancer Who Receive Endocrine Therapy 

Premenopausal Endocrine Responsive Chemotherapy Trial (PERCHE)",III,Terminated,"Breast International Group
National Institutes of Health/National Cancer Institute
Pfizer
International Breast Cancer Study Group",Oncology: Breast,Adjuvant; Estrogen receptor positive; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,Australia; Brazil; Canada; Germany; Hungary; Italy; Peru; South Africa; Sweden; Switzerland; United States
"A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women With Endocrine Responsive Breast Cancer.

Suppression of Ovarian Function Trial (SOFT)",III,Completed,"(Other Cooperative Group)
Breast International Group
Cancer and Leukemia Group B (CALGB)
National Surgical Adjuvant Breast and Bowel Project (NSABP)
Canadian Cancer Trials Group {NCIC Clinical Trials Group}
North Central Cancer Treatment Group (NCCTG)
Southwest Oncology Group
National Institutes of Health/National Cancer Institute
European Institute of Oncology
Pfizer
International Breast Cancer Study Group
Cancer Research UK
Cancer Trials Ireland {Irish Clinical Oncology Research Group}
National Cancer Institute of Canada
Cancer Trials Support Unit - CTSU/NCI
ANZ Breast Cancer Trials Group
NCRI Breast Clinical Studies Group, United Kingdom
ECOG-ACRIN Cancer Research Group",Genitourinary: Menopausal Symptoms; Oncology: Breast,Adjuvant; Cancer or chemotherapy-related; Estrogen receptor positive; Neoadjuvant; Pre- or perimenopausal; Progesterone receptor positive; Stage 0; Stage I; Stage II; Surgically induced; VMS - Unspecified or other severity,Breast Neoplasms; Menopause,Australia; Belgium; Brazil; Canada; Chile; France; Germany; Hungary; India; Ireland; Israel; Italy; Netherlands; New Zealand; Peru; Poland; Portugal; Serbia; South Africa; Spain; Sweden; Switzerland; Turkey; United Kingdom; United States
"A Phase III Trial Evaluating The Role Of Exemestane Plus GnRH Analogue As Adjuvant Therapy For Premenopausal Women With Endocrine Responsive Breast Cancer

Tamoxifen and Exemestane Trial - TEXT",III,Completed,"Breast International Group
National Institutes of Health/National Cancer Institute
Pfizer
International Breast Cancer Study Group
ANZ Breast Cancer Trials Group",Oncology: Breast,Adjuvant; Estrogen receptor positive; Progesterone receptor positive; Stage 0; Stage I; Stage II; Stage III,Breast Neoplasms; Osteoporosis,Australia; Belgium; Brazil; Canada; Egypt; Germany; Hungary; India; Italy; New Zealand; Peru; Slovenia; South Africa; Sweden; Switzerland; United Kingdom; United States
Phase II Paxoral trial for Breast Cancer,II,Completed,Teva {IVAX},Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,United States
"Phase III Study of the Addition of Octreotide Pamoate (SMS 201-995 pa LAR) to Tamoxifen Alone or to Tamoxifen and Chemotherapy in Women With Axillary Node Negative, Estrogen Receptor Positive, Primary Invasive Breast Cancer",III,Terminated,"National Surgical Adjuvant Breast and Bowel Project (NSABP)
National Institutes of Health/National Cancer Institute",Oncology: Breast,Adjuvant; Estrogen receptor positive; Stage I; Stage II,Breast Neoplasms,Canada; United States
Phase III Study of Idoxifene vs Tamoxifen in Postmenopausal Women with Metastatic Breast Cancer,III,Terminated,GlaxoSmithKline,Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Stage IV,Breast Neoplasms,United States
Phase III Study of Adjuvant Therapy in Pre- and Perimenopausal Women with Node-Negative Breast Cancer: Cyclophosphamide/Methotrexate/Fluorouracil (CMF) vs Goserelin vs Sequential CMF and Goserelin,III,Completed,"National Institutes of Health/National Cancer Institute
International Breast Cancer Study Group
Swiss Group for Clinical Cancer Research - SAKK",Oncology: Breast,Adjuvant; Estrogen receptor positive; Stage I; Stage II,Breast Neoplasms,Australia; Canada; Hungary; Italy; New Zealand; Slovenia; South Africa; Spain; Sweden; Switzerland; United States
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.,II,Completed,"Roche/Genentech {Genentech}
Jonsson Comprehensive Cancer Center, UCLA",Oncology: Breast,First line; HER2 positive; Stage IV,Breast Neoplasms,Canada; United States
"Phase III Randomized, Double-Blind, Placebo-Controlled Study of Low-Dose Gallium Nitrate for Bone Involvement from Breast Cancer",III,Completed,SoloPak Laboratories,CNS: Pain (nociceptive); Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; Cancer-related; First line; Stage IV,Breast Neoplasms; Cancer pain; Cancer Pain; Neoplasm Metastasis; Nociceptive Pain,United States
"A Randomized, Double-blind Trial to Compare the Efficacy and Safety of Anastrozole (ARIMIDEX 1 mg Daily) With Tamoxifen Citrate (20 mg Daily) as First-line Therapy for Advanced Breast Cancer in Postmenopausal Women.",III,Completed,AstraZeneca,Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,Canada; United States
"Double-Blind Randomized Trial of Tamoxifen Versus Placebo in Patients With Node Positive or High Risk Node Negative Breast Cancer Who Have Completed CMF, CEF, or AC Adjuvant Chemotherapy",III,Completed,Canadian Cancer Trials Group {NCIC Clinical Trials Group},Oncology: Breast,Adjuvant; Estrogen receptor positive; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,Canada; United States
Phase III Randomized Study of Quality of Life in Postmenopausal Women with Resectable Stage II/IIIA Breast Cancer Treated with Adjuvant Tamoxifen Alone or in Combination with Cyclophosphamide/Methotrexate/Fluorouracil,III,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Adjuvant; Stage II; Stage III,Breast Neoplasms,United States
Phase III Randomized Study of Paclitaxel vs No Further Chemotherapy Following Doxorubicin/Cyclophosphamide for Resected Node-Positive Breast Cancer.,III,Completed,"National Institutes of Health/National Cancer Institute
Breast Cancer Research Foundation",Oncology: Breast,Adjuvant; Estrogen receptor positive; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,United States
"Phase III Randomized Study of High Dose Chemotherapy, Autologous Bone Marrow Transplantation, and Peripheral Blood Stem Cell Autographs, for Patients with High Risk Primary Breast Cancer",III,Completed,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast,Line of therapy N/A; Stage II; Stage III,Breast Neoplasms,United States
Phase III Study of Adriamycin/Taxotere Versus Adriamycin/Cytoxan for the Adjuvant Treatment of Node Positive or High Risk Node Negative Breast Cancer,III,Completed,"Cancer and Leukemia Group B (CALGB)
Eastern Cooperative Oncology Group (ECOG)
North Central Cancer Treatment Group (NCCTG)
Southwest Oncology Group
National Institutes of Health/National Cancer Institute",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms; Recurrence,United States
Phase III Randomized Study of Doxorubicin With or Without DPPE in Patients With Recurrent or Metastatic Breast Cancer.,III,Completed,"Bristol-Myers Squibb
Canadian Cancer Trials Group {NCIC Clinical Trials Group}
Gilead Sciences {YM BioSciences}",Oncology: Breast,First line; Second line; Stage IV,Breast Neoplasms,Australia; Canada; Poland; Russia; South Africa; United States
Phase III Randomized Study of Adjuvant Tamoxifen with vs without Radiotherapy Following Lumpectomy for Carcinoma of the Breast No Greater Than 2 cm with Clinically Negative Axillary Nodes in Women Age 70 and Over.,III,Completed,"Cancer and Leukemia Group B (CALGB)
Radiation Therapy Oncology Group (RTOG)
National Institutes of Health/National Cancer Institute",Oncology: Breast,Adjuvant; Estrogen receptor positive; Stage I; Stage II,Breast Neoplasms,United States
Phase III Randomized Study of Adjuvant Tamoxifen with vs without Ovarian Ablation in Premenopausal Women with Axillary Node-Negative Receptor-Positive Breast Cancer 3 cm or Less in Diameter.,III,Terminated,"Cancer and Leukemia Group B (CALGB)
Eastern Cooperative Oncology Group (ECOG)
North Central Cancer Treatment Group (NCCTG)
Southwest Oncology Group
National Institutes of Health/National Cancer Institute",Oncology: Breast,Adjuvant; Estrogen receptor positive; Progesterone receptor positive; Stage I; Stage II,Breast Neoplasms,United States
Phase III Randomized Study of Adjuvant Ovarian Ablation and Tamoxifen Maintenance with vs without 4 Courses of Anthracycline/Cyclophosphamide (AC) in Premenopausal Women with Node-Positive Breast Cancer Suitable for Endocrine Therapy Alone,III,Terminated,International Breast Cancer Study Group,Oncology: Breast,Adjuvant; Estrogen receptor positive; Maintenance/Consolidation; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,Australia; Austria; Belgium; Canada; Germany; Italy; Japan; Netherlands; Spain; Switzerland; United Kingdom; United States
Phase III Randomized Double-Blind Study of Tamoxifen/Octreotide Pamoate vs Tamoxifen/Placebo in Women with Locally Recurrent or Metastatic Breast Cancer,III,Terminated,Novartis/Sandoz,Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Stage IV,Breast Neoplasms,Canada; France; Germany; Hungary; Italy; Netherlands; Norway; Turkey; United States
Phase III Open-Label Study of Mitoxantrone/Paclitaxel in Women with Metastatic Breast Cancer,III,Completed,Amgen {Immunex},Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
"Phase III Comparison of Intensive Cyclophosphamide/Doxorubicin (AC) +/- Tamoxifen vs Conventional Cyclophosphamide/Methotrexate/Fluorouracil CMF) +/- Tamoxifen Following Complete Resection of Node-Negative, Estrogen Receptor-Negative Adenocarcinoma of the Breast in the adjuvant setting.

Conventional Compared With Intensive Combination Chemotherapy With or Without Hormone Therapy in Treating Women With Poor Risk Breast Cancer.",III,Completed,"National Surgical Adjuvant Breast and Bowel Project (NSABP)
National Institutes of Health/National Cancer Institute",Oncology: Breast,Adjuvant; Stage I,Breast Neoplasms,Canada; United States
A Randomized Trial of Antiestrogen Therapy Versus Combined Antiestrogen and Octreotide Therapy in the Adjuvant Treatment of Breast Cancer in Post-Menopausal Women,III,Terminated,Canadian Cancer Trials Group {NCIC Clinical Trials Group},Oncology: Breast,Adjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,Canada; United States
"PhaseIII Double-Blind, Placebo-Controlled, Prospective Randomized Comparison Of Adjuvant Therapy With Tamoxifen Vs. Tamoxifen And Fenretinide In Postmenopausal Women With Involved Axillary Lymph Nodes And Positive Receptors.",III,Terminated,"Cancer and Leukemia Group B (CALGB)
Eastern Cooperative Oncology Group (ECOG)
North Central Cancer Treatment Group (NCCTG)
Southwest Oncology Group
National Institutes of Health/National Cancer Institute",Oncology: Breast,Adjuvant; Estrogen receptor positive; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,United States
"Phase III Randomized Study of Adjuvant Cyclophosphamide/Methotrexate/Fluorouracil (CMF) Followed by Tamoxifen vs Tamoxifen Alone in Postmenopausal Women with Operable, Node-Negative Breast Cancer",III,Completed,"International Breast Cancer Study Group
ANZ Breast Cancer Trials Group",Oncology: Breast,Adjuvant; Estrogen receptor positive; Stage I; Stage II,Breast Neoplasms,Australia; Italy; South Africa; Switzerland; United States
"A Phase II, Open-Label, Multi-Center Study to Evaluate the Efficacy of 90Y-SMT 487 Administered Intravenously to Patients With Refractory Small Cell Lung or Advanced Metastatic Breast Cancer Expressing Somatostatin Receptors as Determined by OctreoScan Scintigraphy",II,Completed,"Novartis
National Institutes of Health/National Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute","Oncology: Breast; Oncology: Lung, Small Cell",Second line; Stage IV,"Breast Neoplasms; Carcinoma, Small Cell; Lung Neoplasms; Small Cell Lung Carcinoma",United States
Phase II Study of Twice a Week Paclitaxel During Radiation Therapy for Locally Advanced Breast Cancer,II,Completed,"National Institutes of Health/National Cancer Institute
University of Southern California",Oncology: Breast,First line; Stage II; Stage III,Breast Neoplasms,United States
Phase II Trial of Herceptin Concurrent With External Beam Radiation Following Neoadjuvant Chemotherapy for the Treatment of HER2 Over-Expressing Breast Cancer,II,Completed,"Roche/Genentech {Genentech}
National Institutes of Health/National Cancer Institute
UNC Lineberger Comprehensive Cancer Center",Oncology: Breast,HER2 positive; Neoadjuvant; Stage III; Stage IV,Breast Neoplasms,United States
A Phase II Study Of Topical Ceramide Lipids As Treatment For Cutaneous Breast Cancer,II,Completed,"North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
Phase II Study of Pyrazoloacridine in Women with Metastatic Breast Cancer,II,Completed,"Barbara Ann Karmanos Cancer Institute
National Institutes of Health/National Cancer Institute",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
Phase II Study of PSC 833 plus Doxorubicin in Metastatic Breast Cancer Refractory to Anthracyclines or Anthracenediones,II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
Phase II Study of Paclitaxel plus Carboplatin as First-Line Chemotherapy in Women with Metastatic Breast Cancer,II,Completed,"North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute",Oncology: Breast,First line; Stage IV,Breast Neoplasms,United States
Phase II Study of Weekly 1-Hour Paclitaxel (Taxol) Plus Recombinant Humanized Anti-p185HER2 Monoclonal Antibody (Herceptin) in the Treatment of Patients With Metastatic Breast Cancer.,II,Completed,"Roche/Genentech {Genentech}
Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute",Oncology: Breast,First line; HER2 negative; HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
Phase II Study of Paclitaxel and Carboplatin Combination by 3 Hour Infusion in Patients with Metastatic Breast Carcinoma,II,Completed,Stony Brook University Hospital,Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
Phase II Study of Neoadjuvant Continuous Weekly Doxorubicin/Cyclophosphamide for Locally Advanced and Inflammatory Breast Cancer,II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Neoadjuvant; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
Phase II Study of Multiple Courses of High Dose Chemotherapy Supported with Filgrastim (G-CSF) and Peripheral Blood Progenitor Cells in Patients With Metastatic Breast Cancer.,II,Completed,"National Institutes of Health/National Cancer Institute
UNC Lineberger Comprehensive Cancer Center",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
Phase II Study of Multimodality Therapy for Women with Locally Advanced Breast Cancer: Neoadjuvant Cyclophosphamide/Doxorubicin/Fluorouracil (CAF) Followed by Radiotherapy with Mitomycin Followed by Surgery Followed by Adjuvant CAF or Mitoxantrone/Fluorouracil/Leucovorin,II,Completed,"National Institutes of Health/National Cancer Institute
Yale Comprehensive Cancer Center",Oncology: Breast,Adjuvant; HER2 positive; Neoadjuvant; Stage III; Stage IV,Breast Neoplasms,United States
Phase II Study of Low Dose Infusional Fluorouracil and Biweekly Paclitaxel for Metastatic Breast Cancer (Summary Last Modified 08/2000),II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Estrogen receptor positive; Second line; Stage IV,Breast Neoplasms,United States
Phase II Study of Induction Therapy With Docetaxel and Doxorubicin Followed By Sequential High Dose Chemotherapy and CD34+ Selected Peripheral Blood Stem Cell Support in Women With Metastatic Breast Cancer (Summary Last Modified 06/2000).,II,Completed,"National Institutes of Health/National Cancer Institute
Robert H. Lurie Comprehensive Cancer Center at Northwestern University",Oncology: Breast,Maintenance/Consolidation; Second line; Stage IV,Breast Neoplasms,United States
Management of Metastatic Breast Cancer in Frail Patients,II,Terminated,"National Institutes of Health/National Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute",Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
Phase II Study of Gemcitabine and Cisplatin in Advanced Breast Cancer,II,Completed,"North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute",Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,Canada; United States
Phase II Study of Etoposide and Paclitaxel in Patients with Metastatic Breast Cancer (Summary Last Modified 10/1999),II,Completed,"North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute",Oncology: Breast,First line; Second line; Stage IV; Third line,Breast Neoplasms,United States
Phase II Study of Doxorubicin/Docetaxel for Advanced Breast Cancer (Summary Last Modified 08/97),II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,First line; Stage III; Stage IV,Breast Neoplasms,United States
Phase II Study of Dolastatin 10 in Patients with Previously Treated Advanced Breast Cancer,II,Terminated,"North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute",Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,United States
"Phase II Study of Taxotere, Doxorubicin and Cyclophosphamide (TAC) Primary Therapy in Stage III Breast Cancer",II,Completed,"National Institutes of Health/National Cancer Institute
Robert H. Lurie Comprehensive Cancer Center at Northwestern University",Oncology: Breast,HER2 positive; Neoadjuvant; Stage III,Breast Neoplasms,United States
"Phase II Study of Docetaxel Followed by Surgery, Cyclophosphamide/Doxorubicin (with or without Tamoxifen), and Radiotherapy for Stage III Breast Cancer",II,Completed,Sanofi {Sanofi-Aventis {Aventis}},Oncology: Breast,Adjuvant; Estrogen receptor positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
Phase II Study of Cytoprotection with Amifostine Given with High Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation in Patients with Malignancies.,II,Completed,"Fred Hutchinson Cancer Research Center
AstraZeneca {MedImmune}","Oncology: Breast; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Neuroendocrine; Oncology: Supportive Care",(N/A); Aggressive; Indolent; Mucositis; Pulmonary; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Small Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Mucositis; Multiple Myeloma; Neuroendocrine Tumors; Palliative Care; Small Cell Lung Carcinoma",United States
"Phase II Study of Cyclophosphamide/Thiotepa with Autologous Bone Marrow Rescue as Intensification Therapy Following Low-Dose, Doxorubicin-Based, Adjuvant Chemotherapy for Stage III Breast Cancer at High Risk of Recurrence",II,Completed,"National Institutes of Health/National Cancer Institute
University of Alabama at Birmingham Comprehensive Cancer Center",Oncology: Breast,Adjuvant; Estrogen receptor positive; Stage III,Breast Neoplasms,United States
"Phase II Study of Cyclophosphamide, Thiotepa, and Carboplatin Followed by Autologous Hematopoietic Stem Cell Transplantation in Women With Breast Cancer",II,Completed,"National Institutes of Health/National Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute",Oncology: Breast,Second line; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
Phase II Study of Busulfan/Melphalan/Thiotepa Followed by Autologous or Syngeneic Peripheral Blood Stem Cell Rescue for High-Risk Primary Breast Cancer.,II,Completed,"National Institutes of Health/National Cancer Institute
Fred Hutchinson Cancer Research Center",Oncology: Breast,Estrogen receptor positive; First line; Stage II; Stage III,Breast Neoplasms,United States
"Phase II Study of Busulfan, Cyclophosphamide, Thiotepa, and Allogeneic Bone Marrow Transplantation in Women with Metastatic Breast Cancer.",II,Completed,"National Institutes of Health/National Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}",Oncology: Breast,Line of therapy N/A; Stage IV,Breast Neoplasms,United States
Immunotherapy for Breast Carcinoma - Phase II Trial of Autologous Cancer Antigen Specific Immunotherapy,II,Completed,"Barbara Ann Karmanos Cancer Institute
National Institutes of Health/National Cancer Institute",Oncology: Breast,Adjuvant; Stage III; Stage IV,Breast Neoplasms,United States
Phase II Study of Accelerated Hyperfractionated Radiotherapy Following Lumpectomy and Axillary Lymph Node Dissection in Women with Stage I/II Breast Cancer Receiving Doxorubicin-Based Chemotherapy.,II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Adjuvant; Stage I; Stage II,Breast Neoplasms,United States
Phase II Randomized Study of TNP-470 vs Observation in Women with Metastatic Breast Cancer Who Have Completed CAF or CA Chemotherapy (Summary Last Modified 09/97),II,Completed,"Jonsson Comprehensive Cancer Center, UCLA
National Institutes of Health/National Cancer Institute
Takeda {TAP Pharmaceutical Products (Abbott and Takeda joint venture)}",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
Phase II Randomized Study of Sequential Docetaxel and Doxorubicin/Cyclophosphamide in Patients With Recurrent or Metastatic Breast Cancer (Summary Last Modified 06/1999),II,Completed,"North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
A Phase II Randomized Study of Paclitaxel Versus Paclitaxel + PSC833 for Advanced Breast Cancer (Recurring Less Than 6 Months Since Adjuvant or as Second Line for Advanced Disease,II,Completed,"National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center",Oncology: Breast,Adjuvant; Second line; Stage III; Stage IV,Breast Neoplasms,Canada; Netherlands; United States
Multi-Cycle High-Dose Chemotherapy Versus Optimized Conventionally-Dosed Chemotherapy in Patients With Metastatic Breast Cancer: A Phase II Prospective Randomized Trial,II,Completed,"National Institutes of Health/National Cancer Institute
Herbert Irving Comprehensive Cancer Center at Columbia University",Oncology: Breast,First line; Stage IV,Breast Neoplasms,United States
Phase II Randomized Study of ISIS 5132 or ISIS 3521 in Women With Previously Treated Metastatic Breast Cancer.,II,Completed,"Eastern Cooperative Oncology Group (ECOG)
National Institutes of Health/National Cancer Institute
Ionis Pharmaceuticals {Isis Pharmaceuticals}",Oncology: Breast,Second line; Stage IV; Third line,Breast Neoplasms,United States
Evaluation of Novel Therapeutic Agents Against Breast Cancer: An Innovative Randomized Phase II Trial Design,II,Terminated,"National Institutes of Health/National Cancer Institute
Alliance for Clinical Trials in Oncology",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
"A Phase II, Randomized, Double-Masked, Multicenter Study of Two Dose Levels of ERA-923 for the Treatment of Metastatic Breast Cancer in Postmenopausal Women Who Have Failed Tamoxifen Therapy.",II,Completed,"National Institutes of Health/National Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
Pfizer {Wyeth {Genetics Institute}}
Ligand Pharmaceuticals",Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
Phase II Randomized Study of Doxorubicin/Paclitaxel vs Doxorubicin/Cyclophosphamide in Women with Advanced Breast Cancer (Summary Last Modified 11/97),II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,First line; Stage III; Stage IV,Breast Neoplasms,United States
Phase II Randomized Study of a Chimeric Monoclonal Antibody BR96-Doxorubicin Conjugate (BMS-182248-01) vs Doxorubicin Alone in Metastatic Breast Cancer That Expresses the Lewis y Antigen,II,Completed,Bristol-Myers Squibb,Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
Phase II Randomized Pilot Study of Paclitaxel Plus Trastuzumab (Herceptin) Followed By Adjuvant Chemotherapy in Women With Node Positive Stage II or IIIA Breast Cancer With HER2 Overexpression,II,Completed,"Eastern Cooperative Oncology Group (ECOG)
National Institutes of Health/National Cancer Institute",Oncology: Breast,Adjuvant; HER2 positive; Stage II; Stage III,Breast Neoplasms,South Africa; United States
Phase II Pilot Study of Vaccination with Breast Cancer Mucin Peptide and Keyhole Limpet Hemocyanin plus the Immunologic Adjuvant QS21 for High-Risk Breast Cancer after Definitive Therapy: Stage I/II/IIIA with Rising Tumor Markers and Stage IIIB/IV.,II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Line of therapy N/A; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Phase II Pilot Study of PSC 833 Modulation of Paclitaxel for Recurrent or Metastatic Breast Cancer.,II,Completed,"Eastern Cooperative Oncology Group (ECOG)
National Institutes of Health/National Cancer Institute",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
Phase II Pilot Study of Letrozole plus Tamoxifen in Women with Metastatic Breast Cancer,II,Completed,"North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute
Mayo Clinic",Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United Kingdom; United States
"Phase II Pilot Study of Autologous Peripheral Blood Stem Cell (APBSC) Mobilization with High Dose Cyclophosphamide and Filgrastim (G-CSF) vs G-CSF Alone Followed By High Dose Carboplatin, Ifosfamide, and Thiotepa Followed By APBSC Transplantation and Consolidation Radiotherapy in Patients with Previously Treated Advanced Breast Cancer.",II,Completed,"National Institutes of Health/National Cancer Institute
Robert H. Lurie Comprehensive Cancer Center at Northwestern University",Oncology: Breast,Maintenance/Consolidation; Second line; Stage III; Stage IV,Breast Neoplasms,United States
Allogeneic Transplantation Using Mini-Conditioning for Treatment of Stage IV Breast Cancer,II,Completed,"National Institutes of Health/National Cancer Institute
Ireland Cancer Center",Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
Phase II Pilot Study of Allogeneic Peripheral Blood Stem Cell Transplantation for Patients With Metastatic Recurrent or Refractory Breast Cancer Using a Conditioning Regimen of Busulfan and Cyclophosphamide.,II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
Phase II Pilot Study Comparing Doxorubicin (Adriamycin) and Paclitaxel (Taxol) Induced Locally Advanced Breast Cancer,II,Completed,Lombardi Cancer Center at Georgetown University Medical Center,Oncology: Breast,Neoadjuvant; Stage III,Breast Neoplasms,United States
Phase II Combination Chemotherapy with Continuous Infusion CMF (CTX/MTX/5-FU) in Patients with Measurable Metastatic Breast Cancer Who Have Received No Prior Chemotherapy.,II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,First line; Stage IV,Breast Neoplasms,United States
"NCI HIGH PRIORITY CLINICAL TRIAL --- Phase III Trial of Adjuvant Therapy with Tamoxifen vs Placebo, plus Radiotherapy, in the Management of Patients with Clinically Occult, Invasive, Node-Negative Breast Cancer Treated by Lumpectomy",III,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Adjuvant; Estrogen receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,Canada; United States
NCI HIGH PRIORITY CLINICAL TRIAL --- Phase III Randomized Study of Adjuvant CAF (Cyclophosphamide/Doxorubicin/Fluorouracil) vs Adjuvant CAF Followed by Intensification with High-Dose Cyclophosphamide/Thiotepa plus Autologous Stem Cell Rescue in Women with Stage II/III Breast Cancer At High Risk of Recurrence.,III,Completed,"Eastern Cooperative Oncology Group (ECOG)
Southwest Oncology Group
National Institutes of Health/National Cancer Institute",Oncology: Breast,Adjuvant; Estrogen receptor positive; Stage II; Stage III,Breast Neoplasms,United States
Phase II Open Label Study of CI-958 in Patients with Metastatic Breast Cancer.,II,Completed,Pfizer {Parke-Davis},Oncology: Breast,First line; Second line; Stage IV,Breast Neoplasms,United States
"Phase II Dose Escalation Study of High Dose Mitoxantrone, Thiotepa, and Cyclophosphamide Plus Autologous Blood Cell Rescue and Amifostine (Ethyol) Cytoprotection in Patients with Primary, Locally Advanced, or Stage IV Breast Cancer",II,Completed,"Johnson & Johnson/ALZA
University of Arizona",Oncology: Breast; Oncology: Supportive Care,Mucositis; Second line; Stage III; Stage IV,Breast Neoplasms; Mucositis; Palliative Care,United States
"Phase III Randomized Comparison Study of Letrozole Versus Tamoxifen as First-Line Therapy in Postmenopausal Women with Stage IIIB, Metastatic, or Recurrent Breast Cancer",III,Completed,Novartis,Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Stage II; Stage III; Stage IV,Breast Neoplasms,Argentina; Australia; Austria; Belgium; Canada; Chile; China; Denmark; Egypt; Finland; France; Germany; Greece; Hungary; Iceland; India; Israel; Italy; Netherlands; New Zealand; Poland; Portugal; Russia; South Africa; Spain; United Kingdom; United States; Uruguay
Phase III Randomized Study of Cyclophosphamide/Losoxantrone vs Cyclophosphamide/Doxorubicin in Women with Stage IV Breast Cancer,III,Completed,Merck & Co.,Oncology: Breast,First line; Stage IV,Breast Neoplasms,United States
Vaccination of High Risk Breast Cancer Patients With MUC-1 (Glycosylated) Keyhole Limpet Hemocyanin Conjugates Plus the Immunological Adjuvant QS21,II,Completed,"Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute",Oncology: Breast,Second line; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,Denmark; United States
"A Double-Blind, Randomized, Multi-Center Trial Comparing the Efficacy and Tolerability of 125 and 250mg of Faslodex (Long Acting ICI 182,780) With 1mg Arimidex (Anastrazole) in Postmenopausal Women With Advanced Breast Cancer.",III,Completed,"AstraZeneca
National Institutes of Health/National Cancer Institute",Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,Canada; United States
Phase II Study of Peripheral Blood Stem Cells (PBSC) or Isolated CD34+ Cells from Mobilized Peripheral Stem Cell Collections for Hematolgic Rescue of Advanced Breast Cancer Patients Treated with High Dose Chemotherapy,II,Completed,"National Institutes of Health/National Cancer Institute
Baxter International",Oncology: Breast,Second line; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
Phase II Study of Paclitaxel Administered as a Weekly One Hour Infusion in Women with Metastatic Breast Cancer.,II,Completed,"Bristol-Myers Squibb
Breast Cancer Research Foundation",Oncology: Breast,First line; Second line; Stage IV; Third line,Breast Neoplasms,United States
A Phase II Study of the Combination of Exemestane and Goserelin in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer.,II,Completed,"Pfizer {Pharmacia}
National Institutes of Health/National Cancer Institute
NYU School of Medicines Kaplan Comprehensive Cancer Center",Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
"Phase II Randomized Study of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor (PEG-MGDF) in Patients With High Risk Stage II, III, or IV Breast Cancer Undergoing Autologous Bone Marrow Transplantation Supported by Filgrastim.",II,Completed,Amgen,Oncology: Breast,Line of therapy N/A; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
"A Pilot Study Of Sequential Vaccinations With Recombinant Vaccinia-CEA(6D)-TRICOM, And Recombinant Fowlpox-CEA(6D)-TRICOM (B7.1/ICIAM-1/LFA-3) With Sargramostim (GM-CSF), In Conjunction With Standard Adjuvant Chemotherapy In High Risk Breast Cancer Patients Status Post Surgery With 4+ Or More Lymph Nodes And CEA Expressing Tumors",II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Adjuvant; Stage II; Stage III,Breast Neoplasms,United States
Phase II Randomized Study of Two Dose Levels of LY353381 in Women with Locally Advanced or Metastatic Breast Cancer.,II,Completed,"Eli Lilly
Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute",Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
A randomized 2x2 biomarker trial of low-dose tamoxifen and fenretinide in premenopausal women at-high risk for breast cancer.,II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,First line; Stage 0; Stage I,Breast Neoplasms,Italy; Norway; United Kingdom; United States
Multicenter Phase II Study of VX-710 in Combination with Paclitaxel in Women with Metastatic or Locally Advanced Breast Cancer that is Refractory to Paclitaxel,II,Completed,Vertex Pharmaceuticals,Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,United States
Allogeneic Breast Protocol 1: T-Cell Depleted Allogeneic Blood Stem Cell Transplantation Using an Immunoablative Conditioning Regimen in Metastatic Breast Cancer,II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
A Pilot Study to Evaluate Angiogenesis after Treatment with Bevacizumab (Anti-VEGF Humanized Monoclonal Antibody) in Previously Untreated Patients with Inflammatory Breast Cancer or Locally Advanced Breast Cancer.,II,Completed,"Roche/Genentech {Genentech}
National Institutes of Health/National Cancer Institute",Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Stage II; Stage III; Stage IV,Breast Neoplasms; Inflammatory Breast Neoplasms,United States
A Phase II Study of ABT-751 in Patients With Breast Cancer Refractory to Taxane Regimens.,II,Terminated,AbbVie {Abbott},Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,Canada; Netherlands; United States
Phase II Trial of Alimta (Pemetrexed) and Gemzar (Gemcitabine) in Metastatic Breast Cancer Patients Who Have Received Prior Taxane Therapy.,II,Completed,Eli Lilly,Oncology: Breast,Estrogen receptor positive; HER2 positive; Second line; Stage IV; Third line,Breast Neoplasms,Puerto Rico; United States
"An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 as Single Agent Therapy in Subjects With Advanced or Metastatic Breast Cancer Who Have Progressed While Receiving HERCEPTIN-Containing Regimens.",II,Completed,"GlaxoSmithKline
National Institutes of Health/National Cancer Institute",Oncology: Breast,Fourth line or greater; HER2 negative; HER2 positive; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,Argentina; Australia; Belgium; Canada; France; Germany; Greece; Japan; Spain; United Kingdom; United States
A Phase II Study of OSI-774 (Tarceva) and Gemcitabine for Patients With Metastatic Breast Cancer.,II,Completed,"North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute",Oncology: Breast,First line; HER2 negative; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"Phase II Study of Docetaxel in Older Patients With Metastatic Breast, Lung, or Prostate Cancer",II,Completed,"Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Prostate",Second line; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Prostatic Neoplasms",United States
Vaccine Therapy with Tumor Specific mutated P53 or Ras peptides alone or in combination with cellular immunotherapy with peptide activated lymphocytes (Pal cells) along with subcutaneous IL-2.,II,Completed,"National Institutes of Health/National Cancer Institute
Center for Cancer Research","Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Lung Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Uterine Cervical Neoplasms",United States
Neoadjuvant Treatment and Molecular Characterization of Locally Advanced Breast Cancer.,II,Completed,"Sanofi {Sanofi-Aventis {Aventis}}
Roche/Genentech {Genentech}
Jonsson Comprehensive Cancer Center, UCLA
National Institutes of Health/National Cancer Institute",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,United States
"Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer",III,Terminated,"Amgen
Southwest Oncology Group
National Institutes of Health/National Cancer Institute
Cancer Trials Support Unit - CTSU/NCI",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,Canada; Puerto Rico; United States
Phase III Randomized Study of Zoledronate Versus Pamidronate in Patients With Cancer-Related Bone Lesions Due to Multiple Myeloma or Breast Cancer,III,Completed,Novartis,CNS: Pain (nociceptive); Oncology: Breast; Oncology: Metastatic Cancer; Oncology: Multiple Myeloma,Bone mets; Cancer-related; First line; Second line; Stage III; Stage IV,Breast Neoplasms; Cancer pain; Cancer Pain; Multiple Myeloma; Neoplasm Metastasis; Nociceptive Pain,Canada; South Africa; United Kingdom; United States
"A Randomized, Blinded, Phase II Study of Letrozole Plus the Farnesyl Transferase Inhibitor ZARNESTRA TM (R115777) and Letrozole Plus Placebo in the Treatment of Advanced Breast Cancer After Antiestrogen Therapy.",II,Completed,"National Institutes of Health/National Cancer Institute
Ireland Cancer Center
Johnson & Johnson/Janssen R&D {Johnson & Johnson/J&JPRD}",Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,Belgium; France; Russia; United Kingdom; United States
Phase II Study of Trastuzumab (Herceptin) and Paclitaxel in Patients With HER2-Overexpressing Metastatic Breast Cancer,II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,HER2 positive; Line of therapy N/A; Stage IV,Breast Neoplasms,United States
Phase II Study of Autologous Activated Lymphocytes plus Immunomodulation with High-Dose Cimetidine in Patients with Metastatic Cancer,II,Completed,Cancer Biotherapy Research Group,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Metastatic; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Wilms Tumor",United States
Phase II Randomized Study of High-Dose Paclitaxel with or without Amifostine for Metastatic Breast Cancer.,II,Completed,"Bristol-Myers Squibb
Eli Lilly
Canadian Cancer Trials Group {NCIC Clinical Trials Group}",Oncology: Breast; Oncology: Supportive Care,Neurotoxicity; Second line; Stage IV,Breast Neoplasms; Palliative Care,Canada; United States
"Randomized Phase III Trial of G-CSF Primed Autologous Bone Marrow Versus Peripheral Blood Progenitor Cells (PBPC) as Hematopoietic Support for High-Dose Cyclophosphamide, Thiotepa, and Carboplatin (CTCb) Therapy in Poor Prognosis Breast Cancer",III,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,First line; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
"A Randomized Phase III Trial of Sequential Chemotherapy Using Doxorubicin, Paclitaxel, and Cyclophosphamide or Concurrent Doxorubicin and Cyclophosphamide Followed by Paclitaxel at 14 or 21 Day Intervals in Women With Node Positive Stage II/IIIA Breast Cancer.",III,Completed,"Cancer and Leukemia Group B (CALGB)
Eastern Cooperative Oncology Group (ECOG)
North Central Cancer Treatment Group (NCCTG)
Southwest Oncology Group
National Institutes of Health/National Cancer Institute",Oncology: Breast,Adjuvant; Estrogen receptor positive; Stage II; Stage III,Breast Neoplasms,Canada; United States
Phase III Randomized Study of Preoperative CAF (CTX/DOX/5-FU) vs High-Dose CA (CTX/DOX) with G-CSF in Patients with Large Breast Cancers Not Eligible for Lumpectomy,III,Completed,Hoosier Cancer Research Network {Hoosier Oncology Group},Oncology: Breast,Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
Phase III Randomized Study of PIXY321 vs GM-CSF for Mobilization of Hematopoietic Progenitors in Women with Metastatic Breast Carcinoma,III,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,First line; Maintenance/Consolidation; Stage III; Stage IV,Breast Neoplasms,United States
Phase III Randomized Study of Paclitaxel Administered as a 3-Hour Infusion at Three Different Doses in Women with Recurrent Advanced Breast Cancer.,III,Completed,"Cancer and Leukemia Group B (CALGB)
National Institutes of Health/National Cancer Institute",Oncology: Breast,HER2 negative; HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"Phase III Randomized Study of Hematologic Parameters to Maximize CD34+ Harvest and Initiate Leukapheresis Following Peripheral Blood Stem Cell Mobilization With Cyclophosphamide, Paclitaxel, Filgrastim (G-CSF), and Stem Cell Factor in Patients With Stage II, III, or IV Breast Cancer",III,Completed,"Amgen
National Institutes of Health/National Cancer Institute",Oncology: Breast,Second line; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
Phase III Randomized Study of Autologous Bone Marrow vs G-CSF-Stimulated Peripheral Blood Stem Cell Transplantation for Advanced Breast Carcinoma.,III,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Second line; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
"Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)",III,Completed,"Cancer and Leukemia Group B (CALGB)
Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute",Oncology: Breast,Adjuvant; HER2 negative; HER2 positive; Stage I; Stage II; Triple receptor negative,Breast Neoplasms,United States
"Correlative Studies of ERBB-2/HER-2/NEU and p53 in CALGB Protocol 9344/INT Protocol 0148: Doxorubicin Dose Escalation, With or Without Taxol, as Part of the CA Adjuvant Chemotherapy Regimen For Node Positive Breast Cancer: A Phase III Intergroup Study",III,Completed,"Bristol-Myers Squibb
Cancer and Leukemia Group B (CALGB)
North Central Cancer Treatment Group (NCCTG)
Southwest Oncology Group
National Institutes of Health/National Cancer Institute
National Institutes of Health
Alliance for Clinical Trials in Oncology",Oncology: Breast,Adjuvant; Estrogen receptor positive; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,Canada; South Africa; United States
Phase III Comparison of Preoperative vs Postoperative Fluorouracil/Leucovorin/Doxorubicin/Cyclophosphamide (FLAC) with G-CSF in Women with Stage II Breast Cancer,III,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Metastatic Cancer,Adjuvant; Estrogen receptor positive; Neoadjuvant; Other mets; Stage II,Breast Neoplasms; Neoplasm Metastasis,United States
Phase II/III Randomized Trial of DOX vs TAX vs DOX/TAX/G-CSF in Patients with Metastatic Breast Cancer (Summary Last Modified 02/97),II/III,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,First line; Stage IV,Breast Neoplasms,United States
NCI HIGH PRIORITY CLINICAL TRIAL --- Phase III Randomized Comparison of High-Dose Chemotherapy with Autologous Marrow and Peripheral Stem Cell Support vs Standard-Dose Chemotherapy Following Adjuvant Chemotherapy in Women with Stage II/IIIA Breast Cancer with at Least 10 Positive Axillary Nodes (Summary Last Modified 09/98),III,Completed,"Southwest Oncology Group
National Institutes of Health/National Cancer Institute
National Cancer Institute of Canada",Oncology: Breast,Adjuvant; Estrogen receptor positive; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,Canada; United States
NCI HIGH PRIORITY CLINICAL TRIAL --- Phase III Randomized Comparison of Conventional CMF Maintenance vs High-Dose Combination Chemotherapy plus Autologous Bone Marrow and Peripheral Stem Cell Rescue in Women with Metastatic Breast Cancer Responding to Conventional Induction Chemotherapy,III,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Estrogen receptor positive; First line; Maintenance/Consolidation; Stage IV,Breast Neoplasms,United States
Phase II Study of Interleukin-2 in Patients with Hematologic Malignancies or Solid Tumors Who Have Received Autologous Bone Marrow or Peripheral Blood Progenitor Cell Transplantation.,II,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Unspecified Hematological Cancer; Oncology: Unspecified Solid Tumor",(N/A); Aggressive; Indolent; Line of therapy N/A,"Acute Myelocytic Leukemia; Breast Neoplasms; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Hematologic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms, Unknown Primary",United States
"Phase II Randomized, Double-Blind Study of Zoledronate vs Pamidronate for the Prevention of Skeletal-Related Episodes in Multiple Myeloma or Breast Cancer Patients with Osteolytic Bone Metastases",II,Completed,Novartis,Oncology: Breast; Oncology: Metastatic Cancer; Oncology: Multiple Myeloma,Bone mets; Second line; Stage II; Stage III; Stage IV,Breast Neoplasms; Multiple Myeloma; Neoplasm Metastasis,United States
Autologous Blood and Marrow Transplantation for Hematologic Malignancy and Selected Solid Tumors,II,Completed,"National Institutes of Health/National Cancer Institute
Roswell Park Cancer Institute","Oncology: Breast; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Testicular",Accelerated phase; Aggressive; Blast phase; Chronic phase; Classical; Diffuse large B-cell lymphoma (DLBCL); Follicular lymphoma (FL); Indolent; Lymphoblastic lymphoma (LBL); Mantle cell lymphoma (MCL); Nodular lymphocyte-predominant; Other subtype; Pediatric or Adolescent; Poor-risk; Remission; Second line; Stage IV; Waldenstrom's macroglobulinemia (WM),"Acute Myelocytic Leukemia; Breast Neoplasms; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Hodgkin Disease; Hodgkin Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neoplasms, Plasma Cell; Plasmacytoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Testicular Cancer; Testicular Neoplasms; Waldenstrom Macroglobulinemia",United States
Exploratory Study of Non-Myeloablative Allogeneic Peripheral Blood Stem Cell and Donor Lymphocyte Infusions for Metastatic Neoplasms Refractory to Standard Therapy,II,Terminated,"National Institutes of Health/National Heart, Lung, and Blood Institute",Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma,Hormone refractory; Metastatic; Pediatric or Adolescent; Second line; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Neoplasm Metastasis; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma",United States
"Phase II Study of Gene Therapy with Intralesional Allovectin-7, an HLA-B7 Plasmid DNA-Lipid Complex, for Metastatic Cancer (Summary Last Modified 03/96)",II,Completed,Fresh Tracks Therapeutics {Brickell Biotech {Vical}},"Oncology: Breast; Oncology: Colorectal; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma",Indolent; Second line; Stage IV,"Breast Neoplasms; Colorectal Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma",United States
"A Phase II Randomized Open-Label Study of Letrozole in Combination With Two Dose Levels and Schedules of Oral CCI-779, or Letrozole Alone, in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer",II,Completed,"National Institutes of Health/National Cancer Institute
Ireland Cancer Center
Pfizer {Wyeth/Wyeth Research}",Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms; Neoplasms,Belgium; Denmark; France; Poland; Spain; United Kingdom; United States
A Phase II Trial of Letrozole Plus OSI-774 (Tarceva) in Post-Menopausal Women with ER and/or PR-Positive Metastatic Breast Cancer.,II,Terminated,"Roche/Genentech {Genentech}
Novartis
National Institutes of Health/National Cancer Institute
Vanderbilt-Ingram Cancer Center",Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"Phase II Trial of OSI-774 (Tarceva), a Human Epidermal Growth Factor (HER) (erbB, Also Known as Epidermal Growth Factor Receptor, EGFR) Tyrosine Kinase Inhibitor, in Treatment-Naïve Operable Breast Cancer",II,Completed,"National Institutes of Health/National Cancer Institute
Vanderbilt-Ingram Cancer Center",Oncology: Breast,Neoadjuvant; Stage I; Stage II,Breast Neoplasms,United States
A Phase II Study of Thalidomide as Maintenance Therapy in Patients who Respond to First-Line Chemotherapy for Metastatic Breast Cancer.,II,Completed,Bristol-Myers Squibb/Celgene,Oncology: Breast,Maintenance/Consolidation; Stage IV,Breast Neoplasms,United States
Randomized Trial of Gemcitabine Plus Docetaxel Vs. Docetaxel Plus Capecitabine in Metastatic Breast Cancer in 1st and 2nd line patients.,III,Completed,Eli Lilly,Oncology: Breast,First line; Second line; Stage III; Stage IV,Breast Neoplasms,"Argentina; Australia; Brazil; Mexico; Puerto Rico; South Korea; Taiwan, China; United States"
Phase II Study of Gemcitabine and Trastuzumab Therapy in Patients with HER2 Overexpressing Metastatic Breast Cancer.,II,Terminated,Eli Lilly,Oncology: Breast,First line; HER2 positive; Stage IV,Breast Neoplasms,United States
"Phase II Study of RSR-13 in Patients With Primary Breast, Non-Small Cell Lung, Genitourinary, or Gastrointestinal Carcinoma or Melanoma Receiving Standard Cranial Radiotherapy for Brain Metastases",II,Completed,"National Institutes of Health/National Cancer Institute
Spectrum Pharmaceuticals {Allos Therapeutics}","Oncology: Bladder; Oncology: Breast; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Pancreas; Oncology: Renal",Adenocarcinoma; Adjuvant; CNS mets; Large Cell; Squamous Cell; Stage IV,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Study to Identify Biomarker Modulation by a Cyclooxygenase-2 (COX-2) Inhibitor in Breast Tissue of Premenopausal Women at High Risk for Estrogen Receptor Negative (ERN) Breast Cancer.,II,Completed,"National Institutes of Health/National Cancer Institute
University of Kansas",Oncology: Breast,(N/A); BRCA; Line of therapy N/A,Breast Neoplasms,United States
"An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 as Single Agent Therapy in Subjects With Advanced or Metastatic Breast Cancer Who Have Progressed While Receiving Herceptin Containing Regimens.",II,Completed,"GlaxoSmithKline
National Institutes of Health/National Cancer Institute",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
Phase II Study of Bevacizumab in Combination With Docetaxel in Patients With Advanced Breast Cancer,II,Completed,"Roche/Genentech {Genentech}
National Institutes of Health/National Cancer Institute
Arthur G. James Cancer Hospital
Sanofi {Sanofi-Aventis}",Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A Randomized Phase II Trial of Combination Anastrozole (NSC #719344) Plus ZD1839 (Iressa, NSC #715055, IND #61187) and of Combination Fulvestrant (NSC #719276) Plus ZD1839 in the Treatment of Postmenopausal Women With Hormone Receptor-Positive Metastatic Breast Cancer",II,Completed,"Eastern Cooperative Oncology Group (ECOG)
National Institutes of Health/National Cancer Institute",Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Second line; Stage IV; Third line,Breast Neoplasms,Peru; South Africa; United States
"Phase III Randomized Study of Trastuzumab (Herceptin) With or Without Tamoxifen in Women With Progressive, Stage IV, Estrogen or Progesterone Receptor- and HER2/neu-Positive Breast Cancer",III,Terminated,"Cancer and Leukemia Group B (CALGB)
National Institutes of Health/National Cancer Institute",Oncology: Breast,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
"A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients",II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,Adjuvant; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
"Phase II Study of Herceptin and Exemestane for Treatment of Postmenopausal Women with Metastatic Hormone-Responsive, HER2/NEU Positive Breast Cancer",II,Terminated,"Pfizer {Pharmacia}
National Institutes of Health/National Cancer Institute
Robert H. Lurie Comprehensive Cancer Center at Northwestern University",Oncology: Breast,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase II Evaluation Of The Efficacy And Safety Of R115777 (NSC702818) A Non-Peptidomimetic Farnesyl Transferase Inhibitor, And Trastuzumab In Patients With Advanced Breast Cancer.",II,Terminated,"National Institutes of Health/National Cancer Institute
San Antonio Cancer Institute",Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
A Phase II Study Of OSI-774 In Combination With Bevacizumab In Patients With Stage IV Breast Cancer.,II,Completed,"Roche/Genentech {Genentech}
Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute",Oncology: Breast,HER2 negative; HER2 positive; Maintenance/Consolidation; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
A Phase II Study Of The Weekly Administration Of Docetaxel In Combination With The Epidermal Growth Factor Receptor Inhibitor OSI-774 In Recurrent And/Or Metastatic Breast Cancer,II,Completed,"Roche/Genentech {Genentech}
National Institutes of Health/National Cancer Institute
Case Western Reserve University
Sanofi {Sanofi-Aventis}",Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Stage IV,Breast Neoplasms,United States
"A Phase II, Randomized, Open-Label Study of Single Agent CI-1033 in Patients With Metastatic Breast Cancer.",II,Terminated,Pfizer,Oncology: Breast,HER2 negative; HER2 positive; Second line; Stage IV,Breast Neoplasms,Belgium; Canada; France; Ireland; Italy; Spain; Sweden; United Kingdom; United States
A Phase II study of ET-743 in subjects with advanced breast cancer,II,Completed,"Johnson & Johnson/Janssen R&D {Johnson & Johnson/J&JPRD}
PharmaMar {Zeltia/PharmaMar}",Oncology: Breast,Stage III; Stage IV; Third line,Breast Diseases; Breast Neoplasms; Neoplasms; Neoplasms by Site; Skin Diseases,Russia; United States
Combination Chemotherapy (FLAC) Combined with Granulocyte-Macrophage Colony Stimulating Factor in Locally Advanced and Metastatic Breast Cancer,II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,First line; Stage III; Stage IV,Breast Neoplasms,United States
"A Randomized Three-Arm, Multicenter Comparison of 1 Year and 2 Years of Herceptin Versus No Herceptin in Women With HER2-Positive Primary Breast Cancer Who Have Completed Adjuvant Chemotherapy

HERceptin Adjuvant (HERA) study.",III,Completed,"Breast International Group
Canadian Cancer Trials Group {NCIC Clinical Trials Group}
International Breast Cancer Study Group
Roche/Chugai Pharmaceutical
EORTC Breast Cancer Group
Roche {F. Hoffmann-La Roche}",Oncology: Breast,Adjuvant; HER2 positive; Neoadjuvant; Stage 0; Stage I; Stage II,Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Colombia; Costa Rica; Croatia; Denmark; France; Germany; Greece; Guatemala; Hong Kong, S.A.R., China; Hungary; Ireland; Israel; Italy; Japan; Netherlands; New Zealand; Panama; Poland; Portugal; Russia; Singapore; South Africa; South Korea; Spain; Sweden; Switzerland; Thailand; United Kingdom; United States"
A Clinical Trial Comparing Anastrozole with Tamoxifen in Postmenopausal Patients with Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy with Radiation Therapy,III,Completed,"National Surgical Adjuvant Breast and Bowel Project (NSABP)
North Central Cancer Treatment Group (NCCTG)
Southwest Oncology Group
National Institutes of Health/National Cancer Institute
Cancer Trials Support Unit - CTSU/NCI
American College of Surgeons Oncology Group (ACOSOG)
Alliance for Clinical Trials in Oncology
NRG Oncology",Oncology: Breast,Adjuvant; Stage 0,"Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Intraductal, Noninfiltrating",Canada; Puerto Rico; United States
An International Multi-Centre Study Of Anastrozole Versus Placebo In Postmenopausal Women At Increased Risk Of Breast Cancer,III,Completed,"International Breast Cancer Study Group
Cancer Research UK
Cancer Research UK {Imperial Cancer Research Fund}
National Cancer Research Institute
National Health Service (NHS) - UK
(Other Hospital/Academic/Medical Center)
National Health and Medical Research Council  (NHMRC)",Metabolic/Endocrinology: Osteoporosis; Oncology: Breast,Adjuvant; Chemotherapy-induced bone loss; Estrogen receptor positive; Postmenopausal women: prevention; Postmenopausal women: treatment; Progesterone receptor positive; Stage 0,Breast Neoplasms; Carcinoma in Situ; Osteoporosis,Argentina; Australia; Austria; Belgium; Brazil; Chile; Denmark; Estonia; Finland; France; Germany; Hungary; India; Ireland; Israel; Italy; Japan; Malta; Netherlands; New Zealand; Norway; Peru; Portugal; Russia; South Korea; Spain; Sweden; Switzerland; Turkey; United Kingdom; United States
A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab,II,Completed,National Institutes of Health/National Cancer Institute,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Pancreas",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
"Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen For 2.5- 3 Years Followed By Exemestane (Aromasin) For A Total Of 5 Years As Adjuvant Therapy For Postmenopausal, Receptor Positive, Node Negative or Node Positive Breast Cancer Patients",III,Completed,Pfizer {Pharmacia},Oncology: Breast,Adjuvant; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer.,III,Terminated,"MD Anderson Cancer Center, University of Texas
Roche {F. Hoffmann-La Roche}",Oncology: Breast,Adjuvant; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
"An open-label, multicenter, randomized, controlled study of of IM or Oral Exemestane (Aromasin) in Postmenopausal Women With Advanced Breast Cancer Having Progressed on Tamoxifen.",II,Terminated,Pfizer {Pharmacia},Oncology: Breast,Estrogen receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase II Clinical Trial of ABI-007 (A Cremophor-Free, Protein Stabilized, Nanoparticle Paclitaxel) Administered Weekly in Taxol Resistant Patients with Metastatic Breast Cancer.",II,Completed,Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}},Oncology: Breast,Estrogen receptor positive; Fourth line or greater; Second line; Stage IV; Third line,Breast Neoplasms; Neoplasm Metastasis; Neoplasms,United States
"An Open-Label, Randomized, Multicenter Study to Evaluate the Use of Zoledronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Letrozole as Adjuvant Therapy 

Zometa-Femara Adjuvant Synergy Trial (Z-FAST)",III,Completed,Novartis,Metabolic/Endocrinology: Osteoporosis; Oncology: Breast,Adjuvant; Chemotherapy-induced bone loss; Estrogen receptor positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms; Osteoporosis,Canada; Puerto Rico; United States
"Phase II Study of BMS-247550 in Patients With Incurable, Locally Advanced or Metastatic Breast Cancer",II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast,First line; Fourth line or greater; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes: A 2X2 Factorial Phase III Randomized Study.,III,Terminated,"Cancer and Leukemia Group B (CALGB)
National Institutes of Health/National Cancer Institute
Cancer Trials Support Unit - CTSU/NCI
Alliance for Clinical Trials in Oncology",Oncology: Breast,Adjuvant; HER2 negative; HER2 positive; Stage 0; Stage I; Stage II; Triple receptor negative,Breast Neoplasms,Canada; South Africa; United States
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design,II,Terminated,"National Institutes of Health/National Cancer Institute
Alliance for Clinical Trials in Oncology",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
Phase II Study of Imatinib Mesylate in Patients With Metastatic Breast Cancer.,II,Terminated,"Novartis
MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast,Second line; Stage IV,"Breast Neoplasms; Breast Neoplasms, Male",Italy; United States
Phase III Randomized Study of Hypericum perforatum (St. John's Wort) Combined With Docetaxel in Patients With Unresectable Solid Tumors,III,Terminated,"Cancer and Leukemia Group B (CALGB)
National Institutes of Health/National Cancer Institute","Oncology: Bladder; Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Prostate",Extensive; Pulmonary; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Head and Neck Neoplasms; Neuroendocrine Tumors; Prostatic Neoplasms; Small Cell Lung Carcinoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A multicentre, open-label, non-comparative, non-randomised, 2-cohort Phase II Trial of CT-2103 given every 21 days via a 10 minute Intravenous Infusion in patients with metastatic breast cancer",II,Completed,"Cancer Research UK {Cancer Research Campaign}
CTI BioPharma {Cell Therapeutics {Novuspharma}}
National Health Service (NHS) - UK",Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,United Kingdom; United States
"Docetaxel (NSC-628503) And Vinorelbine (NSC-608210) Plus Filgrastim (NSC-614629) With Weekly Trastuzumab (NSC-688097) For HER-2 Positive, Stage IV Breast Cancer.",II,Terminated,"Southwest Oncology Group
National Institutes of Health/National Cancer Institute",Oncology: Breast,First line; HER2 positive; Stage IV,Breast Neoplasms,United States
"A Phase II, Multi-center Trial of ZD1839 (IRESSA) in Combination With Docetaxel as First-line Treatment in Patients with Advanced Breast Cancer",II,Completed,"AstraZeneca
National Surgical Adjuvant Breast and Bowel Project (NSABP)",Oncology: Breast,First line; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase 2 Study of Neoadjuvant Chemotherapy With Gemcitabine, Epirubicin and Paclitaxel (Taxol)[GET] in Locally Advanced Breast Cancer.",II,Completed,"National Surgical Adjuvant Breast and Bowel Project (NSABP)
National Institutes of Health/National Cancer Institute",Oncology: Breast,Neoadjuvant; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
"Phase II Study of Doxorubicin, Docetaxel, and Cyclophosphamide (ATC) in Patients with Metastatic or Locally Advanced Breast Cancer",II,Completed,"National Surgical Adjuvant Breast and Bowel Project (NSABP)
National Institutes of Health/National Cancer Institute",Oncology: Breast,First line; Stage III; Stage IV,Breast Neoplasms,Canada; United States
"Open-Label, Multicentre, Controlled Study of Exemestane (Aromasin) with Or without Celecoxib (Celebrex) In Postmenopausal Women with Advanced Breast Cancer (ABC) Having Progressed On Tamoxifen",II,Completed,"Pfizer {Pharmacia}
Pfizer",Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,Belgium; Brazil; Canada; Colombia; India; Mexico; Peru; Philippines; United States
A Phase 3 Randomized Double Blind Evaluation of LY353381 Compared With Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.,III,Terminated,Eli Lilly,Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,Argentina; Australia; Brazil; Chile; India; Mexico; Netherlands; Spain; United States
An Uncontrolled Phase II Study Evaluating the Efficacy and Safety of Intravenous BAY 59-8862 in Patients with Taxane-Resistant Metastatic Breast Cancer.,II,Completed,"Bayer AG/Bayer Pharmaceuticals
Spectrum Pharmaceuticals",Oncology: Breast,Second line; Stage IV; Third line,Breast Neoplasms,Germany; Greece; Israel; Italy; Poland; Switzerland; United Kingdom; United States
Phase III Study of Atamestane Plus Toremifene versus Letrozole in Advanced Breast Cancer.,III,Completed,Intarcia Therapeutics {BioMedicines},Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Stage III; Stage IV,"Breast Neoplasms; Neoplasms; Neoplasms, Hormone-Dependent",Canada; Russia; Ukraine; United States
Randomized Discontinuation Study of BAY 43-9006 in Patients With Advanced Refractory Cancer.,II,Completed,"Bayer AG/Bayer Pharmaceuticals
Amgen {Onyx Pharmaceuticals}",Oncology: Breast; Oncology: Colorectal; Oncology: GIST; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid,BRAF; Locally advanced; Metastatic; Second line; Stage I; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Wilms Tumor",United Kingdom; United States
"A Randomized Phase III Study of Trastuzumab (Herceptin) in Combination With Either Vinorelbine (Navelbine), or Taxane-Based Chemotherapy in Patients With HER2 Overexpressing Metastatic Breast Cancer.",III,Terminated,"GlaxoSmithKline
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Massachusetts General Hospital
Brigham and Womens Hospital",Oncology: Breast,First line; HER2 positive; Stage IV,Breast Neoplasms,United States
Effect of Preoperative Chemotherapy on Axillary Lymph Node Metastases in Stage II Breast Cancer: A Prospective Randomized Trial,II,Completed,National Institutes of Health/National Cancer Institute,Oncology: Breast; Oncology: Metastatic Cancer,Adjuvant; Estrogen receptor positive; Neoadjuvant; Other mets; Stage II,Breast Neoplasms; Neoplasm Metastasis; Neoplasms,United States
"Phase II Study of Anastrozole and ZD 1839 in Post-Menopausal Women With Estrogen Receptor-Positive, Hormone Refractory, Metastatic Breast Cancer",II,Terminated,Institute for Drug Development,Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"Phase III, Randomized Study of Epirubicin/Cyclophosphamide Followed by Taxane (Sequential Chemotherapy) versus Epirubicin/Taxane (Concurrent Chemotherapy) as Adjuvant Treatment for Operable, Node-Positive Breast Cancer",III,Completed,"Pfizer {Pharmacia}
Pfizer",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Stage II; Stage III,Adenocarcinoma; Breast Neoplasms,United States
"A Phase II Multicenter, Open-Label, Non-Randomized Study of RPR 109881A Given as a One-Hour Infusion at 90mg/m2 Every 3 Weeks to Female Patients with Metastatic Breast Cancer.",II,Completed,Sanofi {Sanofi-Aventis},Oncology: Breast,Second line; Stage IV,Breast Neoplasms,France; Germany; Lebanon; United States
Phase II Trial of Weekly Docetaxel (Taxotere) Plus Capecitabine (Xeloda) and Trastuzumab (Herceptin) for Patients with HER2/neu Expressing Stage IV Breast Cancer.,II,Completed,"Sanofi {Sanofi-Aventis {Aventis}}
Roche/Genentech {Genentech}
Roche
UCSF Comprehensive Cancer Center",Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
"Phase II Study of Docetaxel, Doxorubicin, and Ad5CMV-p53 Gene Therapy (INGN 201) in Patients With Locally Advanced Breast Cancer",II,Terminated,"Sanofi {Sanofi-Aventis {Aventis}}
MD Anderson Cancer Center, University of Texas
Introgen Therapeutics",Oncology: Breast,First line; Stage III; Stage IV,Breast Neoplasms,United States
A Phase II Study of Neoadjuvant Taxotere/Navelbine plus Herceptin followed by Adjuvant Adriamycin and Cytoxan in Women with HER-2 Overexpressing Locally Advanced Breast Cancer.,II,Completed,University of Pittsburgh Cancer Institute,Oncology: Breast,Adjuvant; HER2 positive; Neoadjuvant; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
"A Controlled Randomized, Phase III, Multicenter, Open Label Study of ABI-007 (a Cremophor Free, Protein Stablized, Nanoparticle Paclitaxel) and Taxol in Patients with Metastatic Breast Cancer.",III,Completed,Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}},Oncology: Breast,First line; Second line; Stage III; Stage IV,Breast Neoplasms; Neoplasm Metastasis; Neoplasms,Canada; Russia; Ukraine; United Kingdom; United States
Phase II Trial of the Combination of Letrozole 2.5 mg Daily and Trastuzumab 2 mg/Kg Weekly in ErbB2 Positive and Estrogen Receptor and/or Progesterone Receptor Positive Metastatic Breast Cancer.,II,Completed,"Roche/Genentech {Genentech}
Novartis
Duke University Medical Center",Oncology: Breast,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,Singapore; United States
Phase II Trial of Gemcitabine and Docetaxel in First and Second Line Metastatic Breast Cancer.,II,Completed,Lombardi Cancer Center at Georgetown University Medical Center,Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
"A Phase II Trial of Arimidex Plus Zoladex in the Treatment of Hormone Receptor Positive, Metastatic Carcinoma of the Breast in Premenopausal Women",II,Completed,"AstraZeneca
Stanford University Medical Center
National Institutes of Health",Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
"An Open-label, Multicenter Phase II Study to Assess the Response of Subjects with Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy With or Without Capecitabine to ZD6474 (100-mg or 300-mg Daily Oral Dose).",II,Completed,AstraZeneca,Oncology: Breast,Fourth line or greater; Stage IV,Breast Neoplasms; Neoplasm Metastasis; Neoplasms,Spain; United States
A Randomized Phase III Trial of Exemestane Versus Anastrozole in Postmenopausal Women with Receptor Positive Primary Breast Cancer,III,Completed,"Pfizer {Pharmacia}
Cancer and Leukemia Group B (CALGB)
Eastern Cooperative Oncology Group (ECOG)
Canadian Cancer Trials Group {NCIC Clinical Trials Group}
North Central Cancer Treatment Group (NCCTG)
Southwest Oncology Group
National Institutes of Health/National Cancer Institute
International Breast Cancer Study Group
Cancer Trials Support Unit - CTSU/NCI
ANZ Breast Cancer Trials Group
Alliance for Clinical Trials in Oncology",Oncology: Breast,Adjuvant; Estrogen receptor positive; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,Australia; Belgium; Canada; Hungary; Italy; South Africa; Switzerland; United States
Phase II Study of Docetaxel in Caucasian and African American Patients With Solid Tumors,II,Completed,"Cancer and Leukemia Group B (CALGB)
National Institutes of Health/National Cancer Institute",Oncology: Bladder; Oncology: Breast; Oncology: Head/Neck,Second line; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms; Head and Neck Neoplasms; Lung Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms,Canada; Puerto Rico; United States
Phase III Study of Atamestane Plus Toremifene in Metastatic Breast Cancer,III,Terminated,Intarcia Therapeutics {BioMedicines},Oncology: Breast,Estrogen receptor positive; First line; Progesterone receptor positive; Stage IV,Breast Neoplasms,United States
"A Phase III Study of High-Dose Chemotherapy Using Busulfan, Melphalan and Thiotepa Versus Cyclophosphamide,Thiotepa, Carboplatin Followed by Autologous Stem Cell Transplantation in Patients With High-Risk Primary Stage II or III (Non-Inflammatory) Breast Cancer",III,Completed,"National Institutes of Health/National Cancer Institute
Fred Hutchinson Cancer Research Center",Oncology: Breast,Estrogen receptor positive; Line of therapy N/A; Stage II; Stage III,Breast Neoplasms,United States
A Phase III Randomized Study of Epoetin Alfa in Anemic Patients with Advanced Cancer Undergoing Chemotherapy.,III,Completed,"North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute","Metabolic/Endocrinology: Anemia; Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Supportive Care; Oncology: Unspecified Hematological Cancer",Advanced; Anemia; Cancer-related; First line; Stage III; Stage IV,"Anemia; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Hematologic Neoplasms; Intestinal Neoplasms; Multiple Myeloma; Myeloproliferative Disorders; Neoplasms, Plasma Cell; Palliative Care; Plasmacytoma; Precancerous Conditions",Canada; United States
Open label Multicentre phase II pilot studies with Herceptin in combination with docetaxel and platinum salts (Cis or Carboplatin) (TCH) as therapy for advanced breast cancer in women with tumors over-expressing the HER2-neu proto-oncogene,II,Completed,"Sanofi {Sanofi-Aventis {Aventis}}
Breast Cancer International Research Group
University of California Los Angeles
Roche {F. Hoffmann-La Roche}",Oncology: Breast,First line; HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,Canada; France; Poland; United States
Phase III Trial Comparing Granulocyte Colony-Stimulating Factor to Leridistim in the Prevention of Neutropenic Complications in Breast Cancer Patients Treated with Docetaxel/Doxorubicin/cyclophosphamide,III,Completed,"Pfizer {Pharmacia}
Pfizer
Pfizer {G D Searle}",Oncology: Breast; Oncology: Supportive Care,First line; Neutropenia; Second line; Stage II; Stage III; Stage IV,Breast Neoplasms; Neutropenia; Palliative Care,Canada; Czech Republic; France; Spain; United States
"A multicenter phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) with TAC followed by high dose chemotherapy with mitoxantrone, cyclophosphamide and vinorelbine (HDCT) with autologous peripheral stem cell transplantation and G-CSF in adjuvant treatment of operable breast cancer with 4 or more positive axillary nodes.",III,Completed,Sanofi {Sanofi-Aventis {Aventis {Rhone Poulenc Rorer SA}}},Oncology: Breast,Adjuvant; Stage I; Stage II,Breast Neoplasms,Canada; United Kingdom; United States
A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination With Doxorubicin and Cyclophosphamide (TAC) Versus 5-fluorouracil in Combination With Doxorubicin and Cyclophosphamide (FAC) as Adjuvant Treatment of Operable Breast Cancer Patients With Positive Axillary Lymph Nodes,III,Completed,"Sanofi {Sanofi-Aventis {Aventis}}
Breast Cancer International Research Group",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II,Breast Neoplasms,Argentina; Austria; Brazil; Canada; Czech Republic; Egypt; France; Germany; Greece; Hungary; Israel; Poland; Portugal; Slovakia; South Africa; Spain; Sweden; United Kingdom; United States; Uruguay
Phase 2 Study of TLK286 in Metastatic Breast Cancer,II,Completed,Mabvax Therapeutics {Telik},Oncology: Breast,Fourth line or greater; Stage IV; Third line,Breast Neoplasms,United States
"A Randomized, Placebo-Controlled Trial of BMS-275291 Given Daily for 12 Months to Women with Stage 1c-IIIA Breast Cancer Receiving Adjuvant Chemotherapy and/or Hormonal Therapy.",II,Terminated,Bristol-Myers Squibb,Oncology: Breast,Adjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A multicenter phase 2 study of CI-1040 in patients with advanced nonsmall-cell lung cancer, breast cancer, colon cancer, or pancreatic cancer",II,Terminated,"National Institutes of Health/National Cancer Institute
Pfizer
University of Alabama, Birmingham","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Pancreas",First line; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Lung Neoplasms; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms",United States
An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Breast Cancer,II,Terminated,Novartis,Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,Canada; Switzerland; United States
Allogeneic Mixed Chimerism Stem Cell Transplantation Utilizing In Vivo and In Vitro Campath for Hemoglobinopathies and Bone Marrow Failure Syndromes,II,Terminated,Duke Comprehensive Cancer Center,"Metabolic/Endocrinology: Paroxysmal Nocturnal Hemoglobinuria; Metabolic/Endocrinology: Sickle Cell Disease; Metabolic/Endocrinology: Thalassemia; Oncology: Breast; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Melanoma; Oncology: Multiple Myeloma; Oncology: Myeloproliferative Neoplasms; Oncology: Renal",Accelerated phase; Adults; Blast phase; Poor-risk; Primary Myelofibrosis; Second line; Stage IV; Transplant - stem cell; Unspecified PNH,"Acute Myelocytic Leukemia; Anemia; Anemia, Aplastic; Anemia, Sickle Cell; Breast Neoplasms; Carcinoma, Renal Cell; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Hemoglobinopathies; Hemoglobinuria; Hemoglobinuria, Paroxysmal; Kidney Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Melanoma; Multiple Myeloma; Myeloproliferative Disorders; Pancytopenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Red-Cell Aplasia, Pure; Renal Cancer; Sickle Cell Anemia; Sickle Cell Trait; Thalassemia; Wilms Tumor",United States
Phase II Randomized Chemoprevention Study of LY353381 Hydrochloride in Women With Fine Needle Aspiration Cytologic Evidence of Hyperplasia and at High Risk for Breast Cancer,II,Completed,"National Institutes of Health/National Cancer Institute
University of Kansas",Oncology: Breast,(N/A); BRCA; Line of therapy N/A,Breast Neoplasms; Hyperplasia,United States
A Phase II Trial Of Exisulind With Docetaxel In Patients With Metastatic Adenocarcinoma Of The Breast,II,Completed,"National Institutes of Health/National Cancer Institute
Fox Chase Cancer Center",Oncology: Breast,First line; Second line; Stage IV,Breast Neoplasms,United States
A Phase II Study of the Proteasome Inhibitor PS-341 (NSC 681 239) in Patients With Metastatic Breast Cancer.,II,Terminated,"National Institutes of Health/National Cancer Institute
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
Takeda/Takeda Oncology {Millennium}",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
Phase II Study of Celecoxib in HER-2/Neu Overexpressing Metastatic Breast Cancer Patients Who Have Failed Recombinant Humanized Anti-p 185HER Monoclonal Antibody Trastuzumab (HERCEPTIN),II,Terminated,"Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute",Oncology: Breast,Fourth line or greater; HER2 positive; Stage IV; Third line,Breast Neoplasms,United States
Phase II Study of Trastuzumab (Herceptin) Plus Interleukin-2 in Patients With HER2-Positive Metastatic Breast Cancer Who Have Failed Prior Trastuzumab.,II,Terminated,"Roche/Genentech {Genentech}
National Institutes of Health/National Cancer Institute
Richard J. Solove Research Institute
Arthur G. James Cancer Hospital
National Institutes of Health",Oncology: Breast,HER2 positive; Second line; Stage IV; Third line,"Breast Neoplasms; Breast Neoplasms, Male",United States
A Randomized Pivotal Clinical Trial To Assess The Efficacy Of Pre-Operative Focused Microwave Thermotherapy Treatment Combined With Pre-Operative Chemotherapy For Cytoreduction Of Advanced Breast Cancer In Intact Breast in the neoadjuvant setting.,II,Completed,Imunon {Celsion},Oncology: Breast,Neoadjuvant; Stage III,Breast Neoplasms,United States
Phase II Study of Fulvestrant (ICI 182780) in Women With Metastatic Breast Cancer Who Have Failed Aromatase Inhibitor Therapy,II,Completed,"North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute
Alliance for Clinical Trials in Oncology",Oncology: Breast,First line; Second line; Stage III; Stage IV,Breast Neoplasms,Canada; United States
Phase II Randomized Study of Soy Isoflavone in Patients With Breast Cancer.,II,Completed,"Jonsson Comprehensive Cancer Center, UCLA
National Institutes of Health/National Cancer Institute",Oncology: Breast,Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"Phase II Randomized Study of Exemestane and Raloxifene in Postmenopausal Women With a History of Stage 0 (Ductal Carcinoma in Situ), I, II, or III Breast Cancer Who Have No Clinical Evidence of Disease.",II,Completed,"Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute",Metabolic/Endocrinology: Osteoporosis; Oncology: Breast,Estrogen receptor positive; Line of therapy N/A; Postmenopausal women: prevention; Progesterone receptor positive; Stage 0; Stage I; Stage II; Stage III,Breast Neoplasms; Osteoporosis,United States
Phase II Trial Of PS-341 In Metastatic Breast Cancer,II,Terminated,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast,Estrogen receptor positive; First line; Second line; Stage IV,Breast Neoplasms,United States
Phase II Study of Irofulven in Patients With Metastatic Breast Cancer,II,Completed,"National Institutes of Health/National Cancer Institute
University of Texas",Oncology: Breast,Fourth line or greater; Second line; Stage IV; Third line,Breast Neoplasms,United States
"A Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Evaluating the Prophylactic Use of Pegfilgrastim on the Incidence of Febrile Neutropenia in Subjects with Advanced Breast Cancer Treated with Single Agent Docetaxel",III,Completed,Amgen,Oncology: Breast; Oncology: Supportive Care,First line; Neutropenia; Second line; Stage III; Stage IV,Breast Neoplasms; Neutropenia; Palliative Care,Mexico; Poland; Russia; United States
Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer.,III,Completed,"Bristol-Myers Squibb
Roche/Genentech {Genentech}
Pfizer {Pharmacia}
MD Anderson Cancer Center, University of Texas",Oncology: Breast,HER2 positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
BNP7787 Vs. Placebo for Prevention of Paclitaxel Neurotoxicity: A Double-Blind Multicenter Randomized Phase 3 Trial in Patients With Metastatic Breast Cancer,III,Completed,"BioNumerik
Lantern Pharma",Oncology: Breast; Oncology: Supportive Care,Emesis; Neurotoxicity; Neutropenia; Second line; Stage IV,Breast Diseases; Breast Neoplasms; Neoplasm Metastasis; Neoplasms; Neurotoxicity Syndromes; Neutropenia; Palliative Care; Vomiting,Russia; Ukraine; United States
"Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen For 2.5- 3 Years Followed By Exemestane (Aromasin) For A Total Of 5 Years As Adjuvant Therapy For Postmenopausal, Receptor Positive, Node Negative or Node Positive Breast Cancer Patients

Tamoxifen, Exemestane, Adjuvant, Multicenter (TEAM) Trial",III,Completed,"Pfizer {Pharmacia}
(Other Cooperative Group)
Cancer Research Campaign Clinical Trials Centre
Cancer Research UK
University of Alabama, Birmingham
National Health Service (NHS) - UK",Oncology: Breast,Adjuvant; Estrogen receptor positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,Belgium; France; Germany; Greece; Ireland; Japan; Netherlands; United Kingdom; United States
Phase III Trial of Tamoxifen Alone vs. Tamoxifen Plus Radiation Therapy for Good Risk Duct Carcinoma In-Situ (DCIS) of the Female Breast,III,Terminated,"Cancer and Leukemia Group B (CALGB)
Canadian Cancer Trials Group {NCIC Clinical Trials Group}
Radiation Therapy Oncology Group (RTOG)
National Institutes of Health/National Cancer Institute
National Cancer Institute of Canada
Cancer Trials Support Unit - CTSU/NCI
NRG Oncology",Oncology: Breast,First line; Stage 0,Breast Neoplasms; Carcinoma; Carcinoma in Situ,Canada; United States
"Reliable Assessment of the Efficacy and Safety of Prolonging the Use of Adjuvant Tamoxifen: A Large, Simple, Randomised Study",III,Completed,"Cancer Research UK
University of Oxford
US Department of Defense
ANZ Breast Cancer Trials Group
National Health and Medical Research Council  (NHMRC)",Oncology: Breast,Adjuvant; Estrogen receptor positive; Second line; Stage I; Stage II; Stage III,Breast Neoplasms,"Argentina; Australia; Belarus; Belgium; Brazil; Chile; China; Colombia; Croatia; Cuba; Czech Republic; Egypt; Estonia; France; Greece; Hong Kong, S.A.R., China; India; Iran; Ireland; Israel; Italy; Japan; Latvia; Lithuania; Mexico; Netherlands; New Zealand; Oman; Paraguay; Poland; Portugal; Russia; South Africa; Spain; Taiwan, China; Tunisia; Turkey; United Kingdom; United States"
Cytokine-Based Immunotherapy Following High-Dose Chemotherapy and Autologous Stem Cell Transplantation,II,Completed,Midwestern Regional Medical Center,"Oncology: Breast; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Ovarian",(N/A); Aggressive; Classical; Cutaneous T-cell lymphoma (CTCL); Diffuse large B-cell lymphoma (DLBCL); Extranodal marginal zone B-cell lymphoma (MALT); Follicular lymphoma (FL); Indolent; Lymphoblastic lymphoma (LBL); Mantle cell lymphoma (MCL); Nodular lymphocyte-predominant; Other subtype; Peripheral T-cell lymphoma (PTCL); Poor-risk; Remission; Second line; Small lymphocytic lymphoma (SLL); Stage III; Stage IV; Waldenstrom's macroglobulinemia (WM),"Acute Myelocytic Leukemia; Breast Neoplasms; Carcinoma, Renal Cell; Chronic Lymphocytic Leukemia; Gestational Trophoblastic Disease; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Multiple Myeloma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neoplasms, Plasma Cell; Neuroblastoma; Ovarian Cancer; Ovarian Neoplasms; Plasmacytoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Preleukemia; Syndrome; Testicular Neoplasms; Trophoblastic Neoplasms; Waldenstrom Macroglobulinemia",United States
"A Phase II, Open-Label, Trial Evaluating the Efficacy of Amifostine in Patients With Cancers Receiving Outpatient Dose-intensive Cyclophosphamide, Etoposide, and Cisplatin (DICEP) Chemotherapy",II,Completed,"Johnson & Johnson/ALZA
Scripps Clinic","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Supportive Care; Oncology: Unspecified Hematological Cancer",(N/A); Aggressive; Classical; Indolent; Line of therapy N/A; Neutropenia; Nodular lymphocyte-predominant; Other,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Hematologic Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Lung Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neutropenia; Ovarian Cancer; Ovarian Neoplasms; Palliative Care",United States
Combination of Interleukin 11 (Neumega) With G-CSF to Mobilize Autologous Peripheral Blood Stem Cells (PBSC),II,Completed,"National Institutes of Health/National Cancer Institute
Fred Hutchinson Cancer Research Center","Oncology: Breast; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Renal",(N/A); Aggressive; Classical; Indolent; Line of therapy N/A; Nodular lymphocyte-predominant,"Breast Neoplasms; Carcinoma, Renal Cell; Gestational Trophoblastic Disease; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Testicular Neoplasms; Trophoblastic Neoplasms; Wilms Tumor",United States
Safety and Immunological Response Rate Study of THERATOPE vaccine in Metastatic Breast Cancer Patients,II,Completed,"Merck KGaA
Seagen {Seattle Genetics/Cascadian Therapeutics {Oncothyreon {Biomira}}}",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
Phase II Study of Preoperative High Dose Chemotherapy with Sequential Doxorubicin and Docetaxel in Women with Stage II-IIIB Breast Cancer,II,Completed,"National Institutes of Health/National Cancer Institute
Ireland Cancer Center",Oncology: Breast,Adjuvant; HER2 negative; HER2 positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
Phase II Study of High Dose Topotecan With Ifosfamide and Etoposide Followed by Autologous Peripheral Blood Stem Cell Rescue in Women With Metastatic Breast Cancer,II,Terminated,"National Institutes of Health/National Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute",Oncology: Breast,First line; Second line; Stage IV,Breast Neoplasms,United States
Phase II Study of Topotecan Administered as a 72-Hour Infusion in Women with Metastatic Breast Cancer,II,Completed,"GlaxoSmithKline
Eastern Cooperative Oncology Group (ECOG)",Oncology: Breast,First line; Stage IV,Breast Neoplasms,United States
An Open-Label Phase II Study of Navelbine (vinorelbine tartrate) and Taxotere (docetaxel) as First-Line Therapy for Metastatic Breast Cancer,II,Completed,(Other Hospital/Academic/Medical Center),Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
"Phase II Study of Sequential High-Dose Cyclophosphamide, Melphalan, and Thiotepa Plus Peripheral Blood Stem Cell Rescue in Patients With Chemotherapy-Sensitive, Metastatic Breast Cancer",II,Completed,"National Institutes of Health/National Cancer Institute
Yale Comprehensive Cancer Center",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
Phase II Evaluation of Docetaxel Combined With Estramustine Phosphate in Patients With Metastatic Breast Cancer.,II,Completed,"Sanofi {Sanofi-Aventis {Aventis}}
Herbert Irving Comprehensive Cancer Center at Columbia University",Oncology: Breast,First line; Second line; Stage IV; Third line,Breast Neoplasms,United States
Treatment of Refractory Stage IV Metastatic Breast Cancer With Weekly Paclitaxel or Weekly Paclitaxel and Herceptin Following Autologous/Syngeneic Stem Cell Transplant.,II,Completed,"Roche/Genentech {Genentech}
National Institutes of Health/National Cancer Institute
Fred Hutchinson Cancer Research Center",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
Phase II Study of Paclitaxel and Capecitabine in Patients With Metastatic Breast Cancer,II,Completed,Roche,Oncology: Breast,First line; Second line; Stage IV,Breast Neoplasms,United States
Orzel (UFT+Leucovorin) as First-Line Therapy for Metastatic Breast Cancer,II,Terminated,"Bristol-Myers Squibb
National Institutes of Health/National Cancer Institute
Robert H. Lurie Comprehensive Cancer Center at Northwestern University",Oncology: Breast,First line; Stage IV,Breast Neoplasms,United States
A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Metastatic Adenocarcinoma of the Breast,II,Completed,Daiichi Sankyo {Daiichi Pharmaceutical},Oncology: Breast,First line; Second line; Stage IV,Breast Neoplasms,United States
Phase II Randomized Study of Subcutaneous Trastuzumab (Herceptin) Plus Paclitaxel in Women With HER2 Overexpressing Metastatic Breast Cancer,II,Completed,"Roche/Genentech {Genentech}
Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute",Oncology: Breast,First line; HER2 positive; Stage IV,Breast Neoplasms,United States
Randomized Phase II Trial of Irinotecan (CPT-11) In Patients With Refractory Metastatic Breast Cancer,II,Completed,"North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute",Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,Canada; United States
Phase II Randomized Study of Bexarotene (LGD1069) in Patients With Advanced Breast Cancer,II,Completed,Ligand Pharmaceuticals,Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"Phase II Study to Evaluate Tariquidar (XR9576), a Selective MDR-1 Inhibitor, in Chemotherapy Resistant Advanced Breast Cancer.",II,Terminated,"Novelion Therapeutics {QLT}
Celtic Pharma {Xenova}",Oncology: Breast,First line; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United Kingdom; United States
Phase II Study of Doxorubicin-Monoclonal Antibody BR96 Immunoconjugate (SGN-15) and Docetaxel in Women With Metastatic or Recurrent Breast Cancer,II,Completed,Seagen {Seattle Genetics},Oncology: Breast,Second line; Stage IV; Third line,Breast Neoplasms,United States
"An Open-Label, Single-Arm, Phase II Study of Liposomal Doxorubicin (Doxil) and Gemcitabine in the Treatment of Women With Metastatic Breast Cancer.",II,Completed,(Other Industry Sponsor),Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
A Phase III Study of Doxorubicin-Cyclophosphamide Therapy Followed by Paclitaxel or Docetaxel Given Weekly or Every 3 Weeks in Patients with Axillary Node-Positive Breast Cancer  in the adjuvant setting.,III,Completed,"Cancer and Leukemia Group B (CALGB)
Eastern Cooperative Oncology Group (ECOG)
North Central Cancer Treatment Group (NCCTG)
Southwest Oncology Group
National Institutes of Health/National Cancer Institute",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
A Pilot Trial Of Two Different Doses Of Capecitabine (XELODA) In Patients With Advanced And/Or Metastatic Breast Cancer.,II,Completed,Roche,Oncology: Breast,Second line; Stage III; Stage IV,Breast Neoplasms,United States
Single Agent Docetaxel for Metastatic Breast Cancer in Patients Aged 70 Years and Older (and in a Cohort of Patients Younger Than 60 Years).,II,Terminated,"Southwest Oncology Group
National Institutes of Health/National Cancer Institute",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,Canada; United States
"Phase II Trial of Oral Vinorelbine for the Treatment of Metastatic Breast Cancer in Patients >65 Years of Age: A Trial of Efficacy, Toxicity, and Patients' Perceived Preference for Oral Therapy",II,Terminated,"North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute",Oncology: Breast,Estrogen receptor positive; First line; Second line; Stage IV,Breast Neoplasms,United States
A Phase II Study of Epothilone B Analog BMS-247550 in Patients With Taxane-Resistant Metastatic Breast Cancer.,II,Completed,"Bristol-Myers Squibb
Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute",Oncology: Breast,Second line; Stage IV; Third line,Breast Neoplasms,France; Italy; Spain; United States
A Phase III Study of Paclitaxel Via Weekly One Hour Infusion Versus Standard Three Hour Infusion Every Three Weeks in the Treatment of Patients With Metastatic Breast Cancer.,III,Completed,"Cancer and Leukemia Group B (CALGB)
National Institutes of Health/National Cancer Institute
Cancer Trials Support Unit - CTSU/NCI",Oncology: Breast,First line; HER2 negative; HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,Puerto Rico; United States
"Phase II Study of Docetaxel, Vinorelbine, and Filgrastim (G-CSF) in Women With HER-2-Negative Stage IV Breast Cancer",II,Completed,"Amgen
GlaxoSmithKline
Southwest Oncology Group
National Institutes of Health/National Cancer Institute
Sanofi {Sanofi-Aventis}",Oncology: Breast,First line; HER2 negative; HER2 positive; Stage IV,Breast Neoplasms,United States
Docetaxel (Taxotere) and 5-Fluorouracil As Second- Or Third-Line Chemotherapy In Women With Metastatic Breast Cancer,II,Completed,"National Institutes of Health/National Cancer Institute
Comprehensive Cancer Center of Wake Forest University",Oncology: Breast,Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
A Phase II Study Of An OutPatient Three Day VIP Regimen With Oral Mesna For Metastatic Breast Cancer,II,Completed,"Bristol-Myers Squibb
National Institutes of Health/National Cancer Institute
Ireland Cancer Center",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
Concurrent Taxol (Paclitaxel) and Definitive Breast Radiation Therapy in Early Stage Breast Cancer Following Four Cycles of Adriamycin/Cytoxan Chemotherapy.,II,Completed,"Bristol-Myers Squibb
National Institutes of Health/National Cancer Institute
Ireland Cancer Center
Case Western Reserve University",Oncology: Breast,Adjuvant; Stage II; Stage III,Breast Neoplasms,United States
"A Nonrandomized Phase II Study of Multimodality Therapy for Stage IIB, IIIA/B, or Initially Presenting Stage IV Breast Cancer With Four Cycles of AC Followed by 12 Weeks of Single Agent Paciltaxel With or Without Herceptin Followed by Local Therapy Followed by Weekly Herceptin or No Additional Therapy",II,Completed,"Bristol-Myers Squibb
Roche/Genentech {Genentech}
National Institutes of Health/National Cancer Institute
UNC Lineberger Comprehensive Cancer Center",Oncology: Breast,Adjuvant; HER2 negative; HER2 positive; Neoadjuvant; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
A Multi-Institutional Phase II Pilot Trial With Weekly Docetaxel and Herceptin as First or Second Line Therapy for HER2/Neu Overexpressing Metastatic Breast Cancer,II,Completed,"Sanofi {Sanofi-Aventis {Aventis}}
National Institutes of Health/National Cancer Institute
Vanderbilt-Ingram Cancer Center",Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
Phase II Study of Docetaxel and Carboplatin as First-Line Therapy in Patients With Metastatic Adenocarcinoma of the Breast,II,Completed,"North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute",Oncology: Breast,First line; Stage IV,Breast Neoplasms,United States
A Safety and Efficacy Study of Doxil and Taxotere +/- Herceptin in Advanced Breast Cancer,II,Completed,"Eastern Cooperative Oncology Group (ECOG)
National Institutes of Health/National Cancer Institute",Oncology: Breast,First line; HER2 negative; HER2 positive; Maintenance/Consolidation; Stage IV,Breast Neoplasms,South Africa; United States
"A Phase II Trial for Patients With Inflammatory (Stage IIIB) and Responsive Metastatic Stage IV Breast Cancer Using Busulfan, Melphalan and Thiotepa Followed by Autologous or Syngeneic PBSC Rescue and 12 Weeks of Post-Engraftment Immunotherapy With Low-Dose IL-2 and GM-CSF",II,Completed,"National Institutes of Health/National Cancer Institute
Fred Hutchinson Cancer Research Center",Oncology: Breast,Second line; Stage III; Stage IV,"Breast Neoplasms; Breast Neoplasms, Male; Inflammatory Breast Neoplasms",United States
"Randomized Phase II Study of Adriamycin/Cytoxan/Taxol (ACT) vs. Cytoxan, Thiotepa, Carboplatin (STAMP V) in Patients With High-Risk Primary Breast Cancer",II,Completed,"National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center",Oncology: Breast; Oncology: Metastatic Cancer,Adjuvant; Bone mets; Neoadjuvant; Stage II; Stage III,Breast Neoplasms; Neoplasm Metastasis,United States
A Randomized Trial Comparing the Safety and Efficacy of Adriamycin and Cyclophosphamide Followed by Taxol (AC-T) to That of Adriamycin and Cyclophosphamide Followed by Taxol Plus Herceptin (AC-T+H) in Node-Positive Breast Cancer Patients Who Have Tumors That Overexpress HER2,III,Completed,"Roche/Genentech {Genentech}
National Surgical Adjuvant Breast and Bowel Project (NSABP)
National Institutes of Health/National Cancer Institute",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,Canada; United States
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer,III,Completed,"AstraZeneca
Eli Lilly
National Surgical Adjuvant Breast and Bowel Project (NSABP)
National Institutes of Health/National Cancer Institute
National Institutes of Health",Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms,Canada; Puerto Rico; United States
A phase III randomized comparison of high dose chemotherapy G-CSF to G-CSF for mobilization of peripheral blood stem cells for autologous transplantation for patients with responsive metastatic breast cancer or high risk stage II-III patients.,III,Completed,"MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast,First line; Second line; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
Phase III comparison of taxotere (docetaxel) and taxol (paclitaxel) in patients with advanced breast cancer,III,Completed,Sanofi {Sanofi-Aventis {Aventis}},Oncology: Breast,First line; Second line; Stage III; Stage IV,Breast Neoplasms,Canada; United States
Phase II Pilot Study of Cyclophosphamide and Active Intralymphatic Immunotherapy With a Vaccine Containing Interferon alfa or Interferon gamma-Treated Tumor Cells Followed By Sargramostim (GM-CSF) in Patients With Advanced Cancer.,II,Completed,St. Vincent Medical Center,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Renal",First line; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Lung Neoplasms; Mesothelioma; Neoplasms, Mesothelial; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Wilms Tumor",United States
Phase II Study of Gemcitabine in the Treatment of Patients With Metastatic Breast Cancer Previously Treated With Adriamycin and Taxol,II,Completed,"Eli Lilly
Memorial Sloan-Kettering Cancer Center
National Institutes of Health/National Cancer Institute",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
Phase II Study of Bryostatin 1 for the Treatment of Stage IV Breast Cancer.,II,Terminated,"National Institutes of Health/National Cancer Institute
University of Colorado Cancer Center at University of Colorado Health Sciences Center",Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
Dose-Intense Chemotherapy and Stem Cell Rescue in the Treatment of Inflammatory Breast Carcinoma in neoadjuvant setting.,II,Completed,"National Institutes of Health/National Cancer Institute
City of Hope Comprehensive Cancer Center",Oncology: Breast,Adjuvant; Neoadjuvant; Stage III,Breast Neoplasms,United States
A Phase III Randomized Double Blind Study of Vorozole Versus Placebo in Women with Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen.,III,Completed,"Novartis
Cancer and Leukemia Group B (CALGB)
Eastern Cooperative Oncology Group (ECOG)
Canadian Cancer Trials Group {NCIC Clinical Trials Group}
North Central Cancer Treatment Group (NCCTG)
Southwest Oncology Group
International Breast Cancer Study Group
National Cancer Institute of Canada
EORTC Breast Cancer Group",Oncology: Breast,Adjuvant; Estrogen receptor positive; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,Belgium; Canada; France; Switzerland; United Kingdom; United States
A Phase II Study Of Safety And Tolerability Of Adjuvant Chemotherapy With Continuous Infusion Paclitaxel And Dose Intense Cyclophosphamide And Hematopoietic Growth Factor Support Followed By Doxorubicin For Stage II-IIIA Breast Cancer Involving Greater Than or Equal to 10 Lymph Nodes,II,Completed,"National Institutes of Health/National Cancer Institute
Case Western Reserve University",Oncology: Breast,Adjuvant; Stage II; Stage III,Breast Neoplasms,United States
Phase II Study of the Predictive Value of the Extreme Drug Resistance Assay in Patients Receiving Paclitaxel for Metastatic Breast Cancer,II,Terminated,Oncotech,Oncology: Breast,Second line; Stage IV,Breast Neoplasms,United States
A Randomized Phase II Study of Bevacizumab in Combination With Docetaxel in Locally Advanced Breast Cancer.,II,Completed,"Sanofi {Sanofi-Aventis {Aventis}}
Roche/Genentech {Genentech}
National Institutes of Health/National Cancer Institute
Ireland Cancer Center",Oncology: Breast,Neoadjuvant; Stage III; Stage IV,Breast Neoplasms,United States
"Phase II Study of Adjuvant Dose Intensive, Sequential Chemotherapy with Doxorubicin, Paclitaxel, and Cyclophosphamide for Resected Stage II/III Breast Cancer",II,Completed,Yale Comprehensive Cancer Center,Oncology: Breast,Adjuvant; Stage II; Stage III,Breast Neoplasms,United States
A Randomized Phase II Study of Rebeccamycin Analog in Advanced Breast Cancer.,II,Completed,"National Institutes of Health/National Cancer Institute
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute",Oncology: Breast,First line; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Breast Neoplasms, Male",United States
Phase II Study of Concurrent Bevacizumab and Vinorelbine in Patients With Stage IV Breast Cancer.,II,Completed,"Roche/Genentech {Genentech}
National Institutes of Health/National Cancer Institute
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Breast Neoplasms, Male",United States
"A Randomized Trial of Adjuvant Chemotherapy With Standard Regimens, Cyclophosphamide, Methotrexate and Fluorouracil - (CMF) or Doxorubicin and Cyclophosphamide - (AC), Versus Capecitabine in Women 65 Years and Older With Node Positive or Node-Negative Breast Cancer.",III,Completed,"Cancer and Leukemia Group B (CALGB)
Eastern Cooperative Oncology Group (ECOG)
Canadian Cancer Trials Group {NCIC Clinical Trials Group}
Southwest Oncology Group
National Institutes of Health/National Cancer Institute
National Cancer Institute of Canada
Alliance for Clinical Trials in Oncology",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,Canada; Peru; United States
Randomized Study of Weekly Vinorelbine plus Trastuzumab for Patients with HER2-positive Breast Cancer Who Have Failed Previous Taxane/Trastuzumab Combination Therapy,III,Terminated,"MD Anderson Cancer Center, University of Texas",Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
"Randomized Double-Blind Trial In Postmenopausal Women With Primary Breast Cancer Who Have Received Adjuvant Tamoxifen For 2-3 Years, Comparing Subsequent Adjuvant Exemestane Treatment With Further Tamoxifen

Intergroup Exemestane Study (IES).",III,Completed,"Pfizer {Pharmacia}
(Other Cooperative Group)
Federation Nationale des Centres de Lutte contre le Cancer
International Collaborative Cancer Group
EORTC Breast Cancer Group",Oncology: Breast,Adjuvant; Estrogen receptor positive; Second line; Stage I; Stage II; Stage III,Breast Neoplasms,"Argentina; Australia; Belgium; Bosnia and Herzegovina; Bulgaria; Croatia; Czech Republic; Denmark; Egypt; Estonia; France; Germany; Greece; Hong Kong, S.A.R., China; Hungary; Ireland; Israel; Italy; Luxembourg; Malta; Montenegro; Netherlands; New Zealand; Norway; Peru; Poland; Portugal; Romania; Russia; Serbia; Slovakia; Slovenia; South Africa; Spain; Sweden; Switzerland; United Kingdom; United States"
A Randomized Phase III Trial of Marimastat Versus Placebo in Patients With Metastatic Breast Cancer Who Have Responding or Stable Disease After Induction Chemotherapy,III,Completed,"Eastern Cooperative Oncology Group (ECOG)
North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute",Oncology: Breast,Maintenance/Consolidation; Stage IV,Breast Neoplasms,United States
High-Dose Chemotherapy Followed By Autologous Hematopoietic Stem Cell Support And One Of Two Regimens Aimed At Modifying Immune Reconstitution In Women With High Risk Stage 2 And Stage 3 Breast Cancer,III,Completed,"National Institutes of Health/National Cancer Institute
Herbert Irving Comprehensive Cancer Center at Columbia University",Oncology: Breast,First line; Stage II; Stage III,Breast Neoplasms,United States
"A randomized comparison of Medroxyprogesterone Acetate (Ma) and observation for prevention of endometrial pathology in postmenopausal breast cancer patients treated with Tamoxifen, Phase III",III,Completed,"Cancer and Leukemia Group B (CALGB)
Southwest Oncology Group
National Institutes of Health/National Cancer Institute",Oncology: Breast,Adjuvant; Estrogen receptor positive; Stage 0; Stage I; Stage II,Breast Neoplasms,United States
"Phase II Study of Paclitaxel, Carboplatin, and Trastuzumab (Herceptin) as First-Line Chemotherapy in Women With Overexpressed HER-2, Metastatic Breast Cancer",II,Completed,"Bristol-Myers Squibb
Roche/Genentech {Genentech}
North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute
Alliance for Clinical Trials in Oncology",Oncology: Breast,First line; HER2 positive; Stage IV,Breast Neoplasms,Canada; United States
A Phase III Study to Evaluate Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women With Receptor (ER and/or PgR) Positive Tumors,III,Completed,"Novartis
Federation Nationale des Centres de Lutte contre le Cancer
National Institutes of Health/National Cancer Institute
International Breast Cancer Study Group
Danish Breast Cancer Cooperative Group
National Cancer Research Institute
ANZ Breast Cancer Trials Group
Swiss Group for Clinical Cancer Research - SAKK",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage 0; Stage I; Stage II; Stage III,Breast Neoplasms; Fatigue; Osteoporosis,Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; Czech Republic; Denmark; France; Germany; Hungary; Iceland; Italy; Netherlands; New Zealand; Peru; Poland; Portugal; Russia; Slovenia; South Africa; Spain; Sweden; Switzerland; Turkey; United Kingdom; United States; Uruguay
"A Multi-Center Phase III Randomized, Controlled Study of Theratope Vaccine for Metastatic Breast Cancer",III,Completed,"Merck KGaA
United Kingdom Coordinating Committee on Cancer Research
Seagen {Seattle Genetics/Cascadian Therapeutics {Oncothyreon {Biomira}}}",Oncology: Breast,Estrogen receptor positive; First line; Stage IV,Breast Neoplasms,Australia; Canada; France; New Zealand; Spain; United Kingdom; United States
A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination With Doxorubicin and Cyclophosphamide Versus Doxorubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment of Operable Breast Cancer HER2neu Negative Patients With Positive Axillary Lymph Nodes,III,Completed,"Sanofi {Sanofi-Aventis {Aventis}}
Breast Cancer International Research Group",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,"Argentina; Australia; Belgium; Bosnia and Herzegovina; Brazil; Bulgaria; Canada; China; Colombia; Croatia; Cyprus; Czech Republic; Egypt; Estonia; France; Germany; Greece; Hong Kong, S.A.R., China; Hungary; Ireland; Israel; Lebanon; Mexico; New Zealand; Poland; Portugal; Romania; Russia; Saudi Arabia; Slovakia; Slovenia; South Africa; South Korea; Spain; Switzerland; Taiwan, China; United States; Uruguay; Venezuela"
"A Multicenter Phase III Randomized Trial Comparing Docetaxel (Taxotere) and Trastuzumab (Herceptin) With Docetaxel (Taxotere), Carboplatin and Trastuzumab (Herceptin) as First Line Chemotherapy for Patients With Advanced Breast Cancer Containing the HER2 Gene Amplification",III,Completed,"Roche/Genentech {Genentech}
(Other Cooperative Group)
Breast Cancer International Research Group
Jonsson Comprehensive Cancer Center, UCLA
National Institutes of Health/National Cancer Institute
Sanofi {Sanofi-Aventis}",Oncology: Breast,First line; HER2 positive; Stage III; Stage IV,Breast Neoplasms,Australia; Belgium; Canada; Croatia; France; Germany; Hungary; Ireland; New Zealand; Poland; Romania; Spain; Switzerland; United States
A Randomized Trial Evaluating The Effect Of Exemestane In Clinical Stage T1-3 N0-1 M0 Postmenopausal Breast Cancer Patients Completing At Least Five Years Of Tamoxifen Therapy.,III,Completed,"Pfizer {Pharmacia}
National Surgical Adjuvant Breast and Bowel Project (NSABP)
National Institutes of Health/National Cancer Institute",Oncology: Breast,Adjuvant; Estrogen receptor positive; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,Canada; Puerto Rico; Spain; United States
A Randomized Trial Comparing Preoperative Doxorubicin (Adriamycin)/Cyclophosphamide (AC) to Preoperative Ac Followed By Preoperative Docetaxel (Taxotere) and to Preoperative AC Followed by Postoperative Docetaxel In Patients with Operable Carcinoma of the Breast,III,Completed,"Sanofi {Sanofi-Aventis {Aventis}}
National Surgical Adjuvant Breast and Bowel Project (NSABP)
National Institutes of Health/National Cancer Institute
National Institutes of Health
Predictive Oncology {Precision Therapeutics}/Helomics {Helomics {Precision Therapeutics}}",Oncology: Breast,Adjuvant; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,Canada; United States
A Comparison of Intensive Sequential Chemotherapy Using Doxorubicin Plus Paclitaxel Plus Cyclophosphamide With High Dose Chemotherapy and Autologous Hematopoietic Progenitor Cell Support for Primary Breast Cancer in Women With 4-9 Involved Axillary Lymph Nodes.,III,Terminated,"Cancer and Leukemia Group B (CALGB)
Eastern Cooperative Oncology Group (ECOG)
Southwest Oncology Group
National Institutes of Health/National Cancer Institute",Oncology: Breast,First line; Stage III; Stage IV,Breast Neoplasms,United States
Phase II Study of Neoadjuvant Sequential Doxorubicin and Docetaxel in Women With Stage III Breast Cancer .,II,Completed,"National Institutes of Health/National Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute",Oncology: Breast,Neoadjuvant; Stage III,Breast Neoplasms,United States
A Clinical Trial Comparing Adjuvant Clodronate Therapy vs Placebo in Early-Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Hormonal Therapy or No Therapy,III,Completed,"National Surgical Adjuvant Breast and Bowel Project (NSABP)
North Central Cancer Treatment Group (NCCTG)
Southwest Oncology Group
National Institutes of Health/National Cancer Institute
Cancer Trials Support Unit - CTSU/NCI",Oncology: Breast; Oncology: Metastatic Cancer,Adjuvant; Bone mets; Estrogen receptor positive; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms; Neoplasm Metastasis,Canada; United States
A Comparative Randomized Study of Standard Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Vs. Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF Followed by Weekly Paclitaxel As Neoadjuvant Therapy For Inflammatory and Locally Advanced Breast Cancer,III,Completed,"Southwest Oncology Group
National Institutes of Health/National Cancer Institute
Cancer Trials Support Unit - CTSU/NCI",Oncology: Breast,HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,United States
A Randomized Phase III Trial of Paclitaxel Versus Paclitaxel Plus Bevacizumab (rhuMAb VEGF) As First-Line Therapy For Locally Recurrent or Metastatic Breast Cancer,III,Completed,"Roche/Genentech {Genentech}
Eastern Cooperative Oncology Group (ECOG)
National Surgical Adjuvant Breast and Bowel Project (NSABP)
Canadian Cancer Trials Group {NCIC Clinical Trials Group}
North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute
National Cancer Institute of Canada",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; HER2 positive; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,Canada; Peru; South Africa; United States
"A Randomized, Phase III Trial of Weekly Taxol (Paclitaxel) Versus Weekly Taxol Plus Paraplatin (Carboplatin) as First-Line Chemotherapy in Patients Age 65 Years or Older With Metastatic Breast Cancer.",III,Completed,Bristol-Myers Squibb,Oncology: Breast,First line; HER2 negative; Stage IV,Breast Neoplasms,United States
"A Three-Arm Randomized Trial to Compare Adjuvant Adriamycin and Cyclophosphamide Followed by Taxotere (AC-T); Adriamycin and Taxotere (AT); and Adriamycin, Taxotere, and Cyclophosphamide (ATC) in Breast Cancer Patients With Positive Axillary Lymph Nodes.",III,Completed,"National Surgical Adjuvant Breast and Bowel Project (NSABP)
National Institutes of Health/National Cancer Institute",Oncology: Breast,Adjuvant; Estrogen receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,Canada; United States
"A Multicenter, Open-Label, Phase III, Randomized, Active-Controlled Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of rhuMAb VEGF (Bevacizumab), in Combination With Capecitabine Chemotherapy, in Subjects With Previously Treated Metastatic Breast Cancer",III,Completed,"Roche/Genentech {Genentech}
National Institutes of Health/National Cancer Institute",Oncology: Breast,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women With HER-2 Over-Expressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer.,III,Completed,"Roche/Genentech {Genentech}
Cancer and Leukemia Group B (CALGB)
Eastern Cooperative Oncology Group (ECOG)
Canadian Cancer Trials Group {NCIC Clinical Trials Group}
North Central Cancer Treatment Group (NCCTG)
Southwest Oncology Group
National Institutes of Health/National Cancer Institute
National Cancer Institute of Canada
Breast Cancer Research Foundation",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,Canada; Peru; South Africa; United States
A 2X2X2 Factorial Randomized Phase III Trial Of Multimodality Therapy Comparing 4 Cycles Of Doxorubicin And Cyclophosphamide With Or Without Dexrazoxane (AC+/-Z) Followed By 12 Weeks Of Weekly Paclitaxel With Or Without Trastuzumab (T+/-H) Followed By Local Therapy Followed By 40 Weeks Of Weekly Trastuzumab Or None In Women With HER-2+ Stage IV Breast Cancer.,III,Completed,"Cancer and Leukemia Group B (CALGB)
National Institutes of Health/National Cancer Institute
Cancer Trials Support Unit - CTSU/NCI",Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms; Inflammatory Breast Neoplasms,United States
A Phase III Adjuvant Trial of Sequenced EC + Filgrastim + Epoetin Alfa Followed By Paclitaxel Versus Sequenced AC Followed By Paclitaxel Versus CEF As Therapy For Premenopausal Women And Early Postmenopausal Women Who Have Had Potentially Curative Surgery For Node Positive Or High Risk Node Negative Breast Cancer,III,Completed,"Amgen
Bristol-Myers Squibb
Johnson & Johnson/Janssen Biotech {Centocor Ortho Biotech {J&J/Ortho Biotech}}
Cancer and Leukemia Group B (CALGB)
Canadian Cancer Trials Group {NCIC Clinical Trials Group}
North Central Cancer Treatment Group (NCCTG)
Southwest Oncology Group
National Institutes of Health/National Cancer Institute
Pfizer
National Cancer Institute of Canada
Cancer Trials Support Unit - CTSU/NCI
Johnson & Johnson/Janssen-Ortho",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; HER2 positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,Canada; United States
"A Phase II, Multicenter, Open-Label Clinical Trial to Evaluate the Efficacy and Safety of OSI-774 in Patients with Advanced or Metastatic Breast Cancer and Disease Progression During or Following Chemotherapy.",II,Completed,"Roche/Genentech {Genentech}
National Institutes of Health/National Cancer Institute",Oncology: Breast,HER2 negative; HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"Multicenter Phase III Randomized Trial Comparing Doxorubicin And Cyclophosphamide Followed By Docetaxel (AC-T) With Doxorubicin And Cyclophosphamide Followed By Docetaxel And Tastuzumab (AC-TH) And With Docetaxel, Platinum Salt And Trastuzumab (TCH) In The Treatment Of Node Positive And High Risk Node Negative Adjuvant Patients With Operable Breast Cancer Containing The HER2NEU Alteration.",III,Completed,"Sanofi {Sanofi-Aventis {Aventis}}
Roche/Genentech {Genentech}
Breast Cancer International Research Group
Jonsson Comprehensive Cancer Center, UCLA
National Institutes of Health/National Cancer Institute",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Bosnia and Herzegovina; Brazil; Bulgaria; Canada; Colombia; Croatia; Cyprus; Czech Republic; Egypt; Estonia; France; Germany; Greece; Hong Kong, S.A.R., China; Hungary; India; Ireland; Israel; Italy; Lebanon; Mexico; New Zealand; Poland; Portugal; Romania; Russia; Saudi Arabia; Singapore; Slovakia; Slovenia; South Africa; South Korea; Spain; Sweden; Switzerland; Taiwan, China; Tunisia; Turkey; United Kingdom; United States; Uruguay; Venezuela"
Phase III Study Comparing the Use of Docetaxel on a Every Three-Week vs. Weekly Schedule in the Treatment of Patients With Metastatic Breast Cancer,III,Terminated,"Sanofi {Sanofi-Aventis {Aventis}}
MD Anderson Cancer Center, University of Texas
National Institutes of Health/National Cancer Institute",Oncology: Breast,First line; HER2 negative; Maintenance/Consolidation; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,United States
A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer.,II,Completed,"Eli Lilly
North Central Cancer Treatment Group (NCCTG)
National Institutes of Health/National Cancer Institute",Oncology: Breast,First line; Second line; Stage IV; Third line,Breast Neoplasms,United States
"Phase III Study of Gemcitabine Plus Paclitaxel Versus Paclitaxel in Patients With Unresectable, Locally Recurrent or Metastatic Breast Cancer.",III,Completed,Eli Lilly,Oncology: Breast,First line; Stage III; Stage IV,Breast Neoplasms,Brazil; Chile; India; Mexico; Poland; South Africa; Spain; United States
"A Randomized, Open-label Study of the Effect of Herceptin Plus Arimidex Compared With Arimidex Alone on Progression-free Survival in Patients With HER2-positive and Hormone-receptor Positive Metastatic Breast Cancer.",III,Completed,Roche/Genentech {Genentech},Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,"Australia; Brazil; Bulgaria; Canada; China; France; Germany; Hungary; India; Israel; Lithuania; Mexico; Poland; Russia; South Africa; Spain; Sweden; Taiwan, China; Turkey; Ukraine; United Kingdom; United States"
Phase III Randomized Study of Shark Cartilage (Benefin) in Patients With Advanced Colorectal or Breast Cancer.,III,Terminated,"Cancer and Leukemia Group B (CALGB)
National Institutes of Health/National Cancer Institute
National Institutes of Health/National Center for Complementary and Alternative Medicine
Lane Labs - USA {Lane Laboratories}",Oncology: Breast; Oncology: Colorectal,Second line; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms,United States